PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kuo, WC; Yang, KT; Hsieh, SL; Lai, MZ				Kuo, W-C; Yang, K-T; Hsieh, S-L; Lai, M-Z			Ezrin is a negative regulator of death receptor-induced apoptosis	ONCOGENE			English	Article						Fas; ezrin; apoptosis; moesin; DISC	ERM PROTEINS; IMMUNOLOGICAL SYNAPSE; ACTIN CYTOSKELETON; T-LYMPHOCYTES; CD95; FAS; MOESIN; PHOSPHORYLATION; ACTIVATION; CELLS	Ezrin links cortical actin filaments with the cell membrane, and has a critical role in many membrane-initiated events. Fas is directly associated with ezrin, but conflicting results have been reported for the involvement of ezrin in Fas-induced cell death. In this study we show that ezrin was associated with Fas in T cells before stimulation and was released shortly after Fas ligand (FasL) engagement. The knockdown of ezrin moderately increased Fas-triggered or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-triggered cell death in normal T lymphocytes and in H9 cells, but had no effect on death receptor-induced apoptosis in type II cells, such as Jurkat and CEM. Expression of a dominant-negative form of ezrin also led to an increased Fas-induced apoptosis in H9 cells. Ezrin deficiency did not affect the internalization of Fas after Fas ligation. Instead, an enhanced formation of death-inducing signaling complex (DISC) was observed in H9 cells with ezrin knockdown, leading to accelerated caspase-8 activation. Together, our results suggest that ezrin has a negative role in the recruitment of Fas into signaling complexes in type I T cells. Loss of ezrin likely removes the constraint imposed by ezrin and facilitates the assembly of death receptor complex in T cells. Oncogene (2010) 29, 1374-1383; doi:10.1038/onc.2009.417; published online 23 November 2009	[Kuo, W-C; Yang, K-T; Lai, M-Z] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; [Kuo, W-C; Hsieh, S-L; Lai, M-Z] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Hsieh, S-L] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lai, M-Z] Natl Taiwan Univ, Inst Immunol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Hsieh, Shie-Liang Edmond/ABA-9184-2021; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803	National Health Research Institute [NHRI-EX96-9527NI]; National Science Council [NSC 95-2320-B001-023]; Academia Sinica, Taiwan, ROC.	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica, Taiwan, ROC.(Academia Sinica - Taiwan)	This work was supported by Grant NHRI-EX96-9527NI from National Health Research Institute, NSC 95-2320-B001-023 from National Science Council and an Academia Sinica Investigator Award from Academia Sinica, Taiwan, ROC. We thank Drs I-Chen Ho, Gina Costa and Garry Nolan for critical reagents, Yamin Lin and FACS Core of Institute of Molecular Biology, Academia Sinica for cell sorting and Dr Harry Wilson for editing this paper.	Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; Chakrabandhu K, 2008, CELL DEATH DIFFER, V15, P1824, DOI 10.1038/cdd.2008.115; Chakrabandhu K, 2007, EMBO J, V26, P209, DOI 10.1038/sj.emboj.7601456; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Feig C, 2007, EMBO J, V26, P221, DOI 10.1038/sj.emboj.7601460; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gupta N, 2006, NAT IMMUNOL, V7, P625, DOI 10.1038/ni1337; Hao JJ, 2009, J CELL BIOL, V184, P451, DOI 10.1083/jcb.200807047; Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963; Ilani T, 2007, J CELL BIOL, V179, P733, DOI 10.1083/jcb.200707199; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Lee KH, 2006, EMBO J, V25, P1009, DOI 10.1038/sj.emboj.7601016; Li YS, 2007, J IMMUNOL, V178, P1938, DOI 10.4049/jimmunol.178.3.1938; Lozupone F, 2004, J BIOL CHEM, V279, P9199, DOI 10.1074/jbc.M305561200; Mrass P, 2008, IMMUNITY, V29, P971, DOI 10.1016/j.immuni.2008.10.015; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137; Ramaswamy M, 2007, J IMMUNOL, V179, P6384, DOI 10.4049/jimmunol.179.10.6384; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shaffer MH, 2009, J IMMUNOL, V182, P1021, DOI 10.4049/jimmunol.182.2.1021; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001	33	20	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1374	1383		10.1038/onc.2009.417	http://dx.doi.org/10.1038/onc.2009.417			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935704				2022-12-28	WOS:000275170600012
J	Koehl, GE; Spitzner, M; Ousingsawat, J; Schreiber, R; Geissler, EK; Kunzelmann, K				Koehl, G. E.; Spitzner, M.; Ousingsawat, J.; Schreiber, R.; Geissler, E. K.; Kunzelmann, K.			Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice	ONCOGENE			English	Article						mTOR; familial adenomatous polyposis; ion channels; APCMin/ plus mice; rapamycin; Sirolimus	GATED POTASSIUM CHANNELS; K+ CHANNELS; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; COLONIC-CARCINOMA; APC GENE; CELLS; PROLIFERATION; MTOR; COMBINATION	The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis. Mice with a heterozygous APC(Min) mutation develop multiple intestinal neoplasia (Min) leading to premature death. Early in colorectal carcinogenesis, APC(Min/+) mice show enhanced Akt-mammalian target of rapamycin (mTOR) signaling, which is paralleled by upregulation of oncogenic K+ channels. In this study, we tested the effect of mTOR inhibition with rapamycin on tumor formation in APC(Min/+) mice and evaluated ion channel regulation. We found that continuous long-term rapamycin treatment of APC(Min/+) mice dramatically inhibits intestinal neoplasia. Moreover, although untreated APC(Min/+) mice lose weight, experience intestinal bleeding and succumb to multiple neoplasia by 22.3 +/- 1.4 weeks of age, mice treated with rapamycin maintain stable weight and survive long term (39.6 +/- 3.4 weeks), with more than 30% surviving > 1 year. Impressively, abnormalities in colonic electrolyte transport typical for APC(Min/+) mice are abolished, along with the suppression of epithelial Na+ channel (ENaC) and oncogenic K+ ion channels BK, Elk1 and Erg1, both functionally and at mRNA levels. These results show that continuous prophylaxis by rapamycin markedly inhibits the development of APC mutation-related polyposis, and suggest a novel contributing mechanism of action through the blockade of intestinal oncogenic ion channels. Oncogene (2010) 29, 1553-1560; doi:10.1038/onc.2009.435; published online 7 December 2009	[Koehl, G. E.; Geissler, E. K.] Univ Regensburg, Univ Hosp Regensburg, Dept Surg, Regensburg, Bavaria, Germany; [Spitzner, M.; Ousingsawat, J.; Schreiber, R.; Kunzelmann, K.] Univ Regensburg, Dept Physiol, Regensburg, Germany	University of Regensburg; University of Regensburg	Koehl, GE (corresponding author), Univ Regensburg, Univ Hosp Regensburg, Dept Surg, Franz Josef Str Allee 11,H4, Regensburg, Bavaria, Germany.	gudrun.koehl@klinik.uni-regensburg.de	Schreiber, Robert/Q-7550-2019; Geissler, Edward/R-4131-2016	Kunzelmann, Karl/0000-0002-4583-7037; Spitzner, Melanie/0000-0002-3673-0625	Deutsche Forschungsgemeinschaft [SCHR 752/2-2, SFB699, KU 756/8-2]; Wilhelm Sander-Stiftung [2005.063.1]; Roche Organ Transplant Research Foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Roche Organ Transplant Research Foundation	We thank Anna Hoehn, Astrid Schwend and Ernestine Tartler for their excellent technical assistance. This study was supported by grants from the Deutsche Forschungsgemeinschaft to RS and KK (SCHR 752/2-2, SFB699, KU 756/8-2), the Wilhelm Sander-Stiftung (2005.063.1; to KK) and the Roche Organ Transplant Research Foundation (to EKG).	Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Gaber AO, 2008, TRANSPLANTATION, V86, P1187, DOI 10.1097/TP.0b013e318187bab0; Guba M, 2005, TRANSPL INT, V18, P89, DOI 10.1111/j.1432-2277.2004.00026.x; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; KOEHL GE, 2005, TRANSPLANT REV, V19, P20; Koehl GE, 2006, TRANSPLANTATION, V82, P741, DOI 10.1097/01.tp.0000233852.75162.74; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Otulakowski G, 2007, AM J RESP CELL MOL, V37, P457, DOI 10.1165/rcmb.2007-0055OC; Ousingsawat J, 2008, PFLUG ARCH EUR J PHY, V456, P847, DOI 10.1007/s00424-008-0451-3; Ousingsawat J, 2007, CLIN CANCER RES, V13, P824, DOI 10.1158/1078-0432.CCR-06-1940; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pillozzi S, 2007, BLOOD, V110, P1238, DOI 10.1182/blood-2006-02-003772; Puntheeranurak S, 2007, CELL PHYSIOL BIOCHEM, V19, P77, DOI 10.1159/000099194; Schreiber R, 2005, J MEMBRANE BIOL, V205, P129, DOI 10.1007/s00232-005-0778-z; Spitzner M, 2008, J BIOL CHEM, V283, P7421, DOI 10.1074/jbc.M703758200; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0; Zhang YQ, 2003, FEBS LETT, V534, P125, DOI 10.1016/S0014-5793(02)03804-8	32	43	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	10					1553	1560		10.1038/onc.2009.435	http://dx.doi.org/10.1038/onc.2009.435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966863				2022-12-28	WOS:000275392400013
J	Hader, C; Marlier, A; Cantley, L				Hader, C.; Marlier, A.; Cantley, L.			Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2	ONCOGENE			English	Article						Foxc2; kidney; E-cadherin; vimentin; migration	FORKHEAD TRANSCRIPTION FACTORS; MARROW-DERIVED CELLS; POSTISCHEMIC KIDNEY; NEPHRON SEGMENTS; EXPRESSION; REPAIR; PROLIFERATION; INSULIN; BOX; MECHANISM	Overexpression of the forkhead family transcription factor Foxc2 has been shown to activate epithelial-mesenchymal transition (EMT) and correlate with tumor metastasis. In this study, we show that both mRNA and protein levels of Foxc2 increase 1 day after kidney ischemia/reperfusion in sublethally injured tubular cells and that the protein is located in the cytoplasm rather than the nucleus of these cells. in vitro studies of cultured tubular cells confirm the cytoplasmic location of Foxc2 and show that increased cytoplasmic expression of Foxc2 correlates with epithelial differentiation rather than dedifferentiation. Silencing of Foxc2 by RNAi in these cells led to EMT and increased cell migration. In contrast, Foxc2 is found in both the nucleus and cytoplasm of cultured fibroblasts, with RNAi leading to increased expression of epithelial markers and impaired cell migration. Consistent with a subcellular localization dependence of Foxc2 function, overexpression of Foxc2 in renal epithelial cells resulted in de novo nuclear expression of the protein and promotion of a mesenchymal/fibroblast phenotype. These results suggest that Foxc2 may have regulatory functions independent of its nuclear transcriptional activity and that upregulation of endogenous Foxc2 in the cytoplasm of injured tubular cells activates epithelial cell redifferentiation rather than dedifferentiation during organ repair. Oncogene (2010) 29, 1031-1040; doi:10.1038/onc.2009.397; published online 23 November 2009	[Hader, C.; Marlier, A.; Cantley, L.] Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Cantley, L (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,POB 208029, New Haven, CT 06520 USA.	lloyd.cantley@yale.edu			NIH [DK65109, DK66216]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, R01DK066216] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH awards to LGC (DK65109 and DK66216). We thank Dr Robert Weinberg for the generous gift of the plasmids for expression of Foxc2, Insa Schmidt for providing the PTEC cells and Dr Jiankan Guo for his experimental assistance.	Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bard JBL, 2008, DEV DYNAM, V237, P2748, DOI 10.1002/dvdy.21652; Berry FB, 2005, HUM MOL GENET, V14, P2619, DOI 10.1093/hmg/ddi295; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Duffield JS, 2005, KIDNEY INT, V68, P1956, DOI 10.1111/j.1523-1755.2005.00629.x; Fujita H, 2006, CIRC RES, V98, P626, DOI 10.1161/01.RES.0000207407.51752.3c; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Ishibe S, 2008, CURR OPIN NEPHROL HY, V17, P379, DOI 10.1097/MNH.0b013e3283046507; Ishibe S, 2006, MOL CELL BIOL, V26, P9232, DOI 10.1128/MCB.01312-06; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Karihaloo A, 2005, MOL CELL BIOL, V25, P7441, DOI 10.1128/MCB.25.17.7441-7448.2005; Lin FM, 2005, J CLIN INVEST, V115, P1756, DOI 10.1172/JCI23015; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; Schwab TS, 2005, APOPTOSIS, V10, P831, DOI 10.1007/s10495-005-0429-y; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	31	64	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1031	1040		10.1038/onc.2009.397	http://dx.doi.org/10.1038/onc.2009.397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935708	Green Accepted			2022-12-28	WOS:000274604400009
J	Treins, C; Warne, PH; Magnuson, MA; Pende, M; Downward, J				Treins, C.; Warne, P. H.; Magnuson, M. A.; Pende, M.; Downward, J.			Rictor is a novel target of p70 S6 kinase-1	ONCOGENE			English	Article						Rictor; S6K; feedback; amino acids; Akt/PKB; mTORC2	CELL-GROWTH CONTROL; MTOR COMPLEX 2; PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; SUBSTRATE-SPECIFICITY; MOTIF PHOSPHORYLATION; MASS-SPECTROMETRY; BINDING PARTNER; TOR COMPLEX-2; AKT	The rapamycin-insensitive companion of mammalian target of rapamycin (mTOR) (Rictor) is a key member of mTOR complex-2 (mTORC2), which phosphorylates the AGC kinases Akt/PKB, PKC and SGK1 at a C-terminal hydrophobic motif. We identified several novel sites on Rictor that are phosphorylated, including Thr1135, which is conserved across all vertebrates. Phosphorylation of this site on Rictor is stimulated by amino acids and growth factors through a rapamycin-sensitive signaling cascade. We demonstrate here that Rictor is a direct target of the ribosomal protein S6 kinase-1 (S6K1). Rictor phosphorylation at Thr1135 does not lead to major changes in mTORC2-kinase activity. However, phosphorylation of this site turns over rapidly and mediates 14-3-3 binding to Rictor and mTORC2, providing possibility for altered interactions of the complex. These findings reveal an unexpected signaling input into mTORC2, which is regulated by amino acids, growth factors and rapamycin. Oncogene (2010) 29, 1003-1016; doi:10.1038/onc.2009.401; published online 23 November 2009	[Treins, C.; Warne, P. H.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; [Magnuson, M. A.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Med Ctr, Nashville, TN 37232 USA; [Magnuson, M. A.] Vanderbilt Univ, Ctr Stem Cell Biol, Med Ctr, Nashville, TN 37232 USA; [Treins, C.; Pende, M.] Paris Descartes Univ, Sch Med, Inserm U845, Lab Cell Growth Control Nutrients, Paris, France	Cancer Research UK; Vanderbilt University; Vanderbilt University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Pende, Mario/AFR-1348-2022; Downward, Julian/A-3251-2012; Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009	Pende, Mario/0000-0002-7864-8937; Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Downward, Julian/0000-0002-2331-4729	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Julie Bastien, Megan Cully, David Hancock and Oliver Pardo for helpful discussions and technical advice. This work was funded by Cancer Research UK.	Akcakanat A, 2007, BIOCHEM BIOPH RES CO, V362, P330, DOI 10.1016/j.bbrc.2007.07.151; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Cantin GT, 2008, J PROTEOME RES, V7, P1346, DOI 10.1021/pr0705441; Dai J, 2007, J PROTEOME RES, V6, P250, DOI 10.1021/pr0604155; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Zanivan S, 2008, J PROTEOME RES, V7, P5314, DOI 10.1021/pr800599n; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	60	119	120	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1003	1016		10.1038/onc.2009.401	http://dx.doi.org/10.1038/onc.2009.401			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935711				2022-12-28	WOS:000274604400007
J	Cockrell, LM; Puckett, MC; Goldman, EH; Khuri, FR; Fu, H				Cockrell, L. M.; Puckett, M. C.; Goldman, E. H.; Khuri, F. R.; Fu, H.			Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome	ONCOGENE			English	Article						ASK1; ASK2; 14-3-3; apoptosis; mitogen-activated protein kinase	KINASE KINASE KINASE; REGULATING KINASE-1; AMPHIPATHIC GROOVE; CELL-DEATH; APOPTOSIS; ACTIVATION; STRESS; 14-3-3-PROTEINS; PHOSPHORYLATION; DISSOCIATION	Faithful and efficient transmission of biological signals through mitogen-activated protein kinase (MAPK) pathways requires engagement of highly regulated cellular machinery in response to diverse environmental cues. Here, we report a novel mechanism controlling signal relay between two MAP3Ks, apoptosis signal-regulating kinase (ASK) 1 and ASK2. We show that ASK2 specifically interacts with 14-3-3 proteins through phosphorylated S964. Although a 14-3-3-binding defective mutant of ASK1 (S967A) has no effect on the ASK2/14-3-3 interaction, both overexpression of the analogous ASK2 (S964A) mutant and knockdown of ASK2 dramatically reduced the amount of ASK1 complexed with 14-3-3. These data suggest a dominant role of ASK2 in 14-3-3 control of ASK1 function. Indeed, ASK2 S964A-induced dissociation of 14-3-3 from ASK1 correlated with enhanced phosphorylation of ASK1 at T838 and increased c-Jun N-terminal kinase phosphorylation, the two biological readouts of ASK1 activation. Our results suggest a model in which upstream signals couple ASK2 S964 phosphorylation to the ASK1 signalosome through dual engagement of 14-3-3. Oncogene (2010) 29, 822-830; doi:10.1038/onc.2009.382; published online 23 November 2009	[Fu, H.] Emory Univ, Dept Pharmacol, Grad Div Biol & Biomed Sci, Program Mol & Syst Pharmacol,Rollins Res Ctr 5111, Atlanta, GA 30322 USA; [Cockrell, L. M.; Puckett, M. C.; Goldman, E. H.; Fu, H.] Emory Univ, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA; [Khuri, F. R.; Fu, H.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, H (corresponding author), Emory Univ, Dept Pharmacol, Grad Div Biol & Biomed Sci, Program Mol & Syst Pharmacol,Rollins Res Ctr 5111, 1510 Clifton Rd, Atlanta, GA 30322 USA.	hfu@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618	National Cancer Institute [5F31CA117057]; National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship [0450303 (I6660663)]; NIH [T32 GM008602, RO1GM53165]; Emory URC; NIH/NCI [PO1CA116676, USAMRMC05075002]; NATIONAL CANCER INSTITUTE [F31CA117057, P01CA116676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165, T32GM008602] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emory URC; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the past and present members of the Fu laboratory for many stimulating discussions, as well as Zhengbin Yao for helpful suggestions. This work was supported by a National Cancer Institute National Research Service Award Grant 5F31CA117057 and a National Science Foundation Facilitating Academic Careers in Engineering and Science Fellowship 0450303 (I6660663) to LMC, an NIH Pharmacological Sciences Training Grant T32 GM008602 to MCP, NIH Grant RO1GM53165 and Emory URC grant to HF, and NIH/NCI Grant PO1CA116676 and USAMRMC05075002 to FRK and HF. HF is a Georgia Research Alliance Distinguished Investigator, and FRK and HF are Georgia Cancer Coalition Distinguished Cancer Scholars.	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imoto K, 2006, DIABETES, V55, P1197, DOI 10.2337/db05-1187; Iriyama T, 2009, EMBO J, V28, P843, DOI 10.1038/emboj.2009.32; Izumiya Y, 2003, CIRC RES, V93, P874, DOI 10.1161/01.RES.0000100665.67510.F5; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Muslin AJ, 2005, CURR TOP DEV BIOL, V65, P211; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Osaka N, 2007, J CELL BIOL, V176, P903, DOI 10.1083/jcb.200611015; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Subramanian RR, 2004, EXP CELL RES, V294, P581, DOI 10.1016/j.yexcr.2003.12.009; Takeda K, 2008, ANNU REV PHARMACOL, V48, P199, DOI 10.1146/annurev.pharmtox.48.113006.094606; Takeda K, 2007, J BIOL CHEM, V282, P7522, DOI 10.1074/jbc.M607177200; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Winter-Vann AM, 2007, J CELL BIOCHEM, V102, P848, DOI 10.1002/jcb.21522; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	34	22	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					822	830		10.1038/onc.2009.382	http://dx.doi.org/10.1038/onc.2009.382			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935702				2022-12-28	WOS:000274397800005
J	Pillaire, MJ; Selves, J; Gordien, K; Gouraud, PA; Gentil, C; Danjoux, M; Do, C; Negre, V; Bieth, A; Guimbaud, R; Trouche, D; Pasero, P; Mechali, M; Hoffmann, JS; Cazaux, C				Pillaire, M-J; Selves, J.; Gordien, K.; Gouraud, P-A; Gentil, C.; Danjoux, M.; Do, C.; Negre, V.; Bieth, A.; Guimbaud, R.; Trouche, D.; Pasero, P.; Mechali, M.; Hoffmann, J-S; Cazaux, C.			A 'DNA replication' signature of progression and negative outcome in colorectal cancer	ONCOGENE			English	Article						DNA replication; S-phase checkpoint; colorectal cancer; genetic instability; prognosis markers	MINICHROMOSOME-MAINTENANCE PROTEIN-7; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; POLYMERASE-LAMBDA; REPAIR; OVEREXPRESSION; PROLIFERATION; MECHANISMS; GEMININ; DAMAGE	Colorectal cancer is one of the most frequent cancers worldwide. As the tumor-node-metastasis (TNM) staging classi. cation does not allow to predict the survival of patients in many cases, additional prognostic factors are needed to better forecast their outcome. Genes involved in DNA replication may represent an underexplored source of such prognostic markers. Indeed, accidents during DNA replication can trigger 'replicative stress', one of the main features of cancer from earlier stages onward. In this study, we assessed the expression of 47 'DNA replication' genes in primary tumors and adjacent normal tissues from a homogeneous series of 74 patients. We found that genes coding for translesional (TLS) DNA polymerases, initiation of DNA replication, S-phase signaling and protection of replication forks were significantly deregulated in tumors. We also observed that the overexpression of either the MCM7 helicase or the TLS DNA polymerase POLQ (if also associated with a concomitant overexpression of. ring genes) was significantly related to poor patient survival. Our data suggest the existence of a 'DNA replication signature' that might represent a source of new prognostic markers. Such a signature could help in understanding the molecular mechanisms underlying tumor progression in colorectal cancer patients. Oncogene (2010) 29, 876-887; doi:10.1038/onc.2009.378; published online 9 November 2009	[Pillaire, M-J; Bieth, A.; Hoffmann, J-S; Cazaux, C.] Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, INSERM, U563, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, Dept Anatomopathol, F-31300 Toulouse 4, Midi Pyrenees, France; [Gouraud, P-A; Gentil, C.; Do, C.] Univ Toulouse 3, Serv Epidemiol, Fac Med, INSERM,U558, F-31300 Toulouse 4, Midi Pyrenees, France; [Negre, V.] INSERM, U868, aCGH GSO Canceropole Platform, Montpellier, France; [Trouche, D.] Univ Toulouse 3, Lab Cellular & Mol Biol Cell Proliferat Control, CNRS, UMR 5099, F-31300 Toulouse 4, Midi Pyrenees, France; [Pasero, P.; Mechali, M.] CNRS, UPR1142, Inst Human Genet, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Cazaux, C (corresponding author), Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, 205 Route Narbonne, F-31300 Toulouse 4, Midi Pyrenees, France.	cazaux@ipbs.fr	Gourraud, Pierre-Antoine FD/O-3024-2015; Selves, Janick/M-7719-2014; Hoffmann, Jean-Sebastien/O-9183-2014; GUIMBAUD, Rosine/M-7503-2014; Pillaire, Marie-Jeanne/P-1579-2014; Pasero, Philippe/O-2340-2018	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Pasero, Philippe/0000-0001-5891-0822; Gourraud, Pierre-Antoine/0000-0003-1131-9554; Trouche, Didier/0000-0003-1398-6481; do, catherine/0000-0002-9796-4345	INCa (Canceropole GSO)	INCa (Canceropole GSO)(Institut National du Cancer (INCA) France)	We thank the 'GSO/3R' Consortium for helpful discussions. We thank B Orsetti for CGH experiments (GSO aCGH platform, CRLCCMontpellier). We also acknowledge JJMaoret (Q-PCR platform, IFR31, Toulouse), as well as F Viala and S Mazeres (IPBS, Toulouse) for iconography and technical assistance, respectively. This study was supported by INCa (Canceropole GSO, grant ACI 'Genetic instability as a negative outcome' 2004/07 and 2008/09 to CC; grants to JS, DT and PP).	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Betous R, 2009, MOL CARCINOGEN, V48, P369, DOI 10.1002/mc.20509; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; Brake T, 2003, CANCER RES, V63, P8173; Brondello JM, 2008, ONCOGENE, V27, P6093, DOI 10.1038/onc.2008.212; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Davies RJ, 2002, LANCET, V359, P1917, DOI 10.1016/S0140-6736(02)08739-1; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Gonzalez MA, 2004, J PATHOL, V204, P121, DOI 10.1002/path.1625; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Hanawalt PC, 2007, MOL CELL, V28, P702, DOI 10.1016/j.molcel.2007.11.014; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kawamura K, 2004, INT J CANCER, V109, P9, DOI 10.1002/ijc.11666; Kunkel TA, 2003, CANCER CELL, V3, P105, DOI 10.1016/S1535-6108(03)00027-8; Lemee F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116; Li JQ, 2003, INT J ONCOL, V23, P1537; Lutzmann M, 2008, MOL CELL, V31, P190, DOI 10.1016/j.molcel.2008.07.001; Lutzmann M, 2006, EMBO J, V25, P5764, DOI 10.1038/sj.emboj.7601436; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Pan QR, 2005, CANCER LETT, V217, P139, DOI 10.1016/j.canlet.2004.07.021; Rey L, 2009, MOL CELL BIOL, V29, P3344, DOI 10.1128/MCB.00115-09; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Shrestha P, 2007, CANCER-AM CANCER SOC, V109, P949, DOI 10.1002/cncr.22474; Sobol RW, 1996, NATURE, V383, P457, DOI 10.1038/383457b0; Sobol RW, 1996, NATURE, V379, P848, DOI 10.1038/379848b0; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07; Wang GL, 2008, JNCI-J NATL CANCER I, V100, P1815, DOI 10.1093/jnci/djn385; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108	47	80	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					876	887		10.1038/onc.2009.378	http://dx.doi.org/10.1038/onc.2009.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901968				2022-12-28	WOS:000274397800010
J	Hao, L; Rizzo, P; Osipo, C; Pannuti, A; Wyatt, D; Cheung, LWK; Sonenshein, G; Osborne, BA; Miele, L				Hao, L.; Rizzo, P.; Osipo, C.; Pannuti, A.; Wyatt, D.; Cheung, L. W-K; Sonenshein, G.; Osborne, B. A.; Miele, L.			Notch-1 activates estrogen receptor-alpha-dependent transcription via IKK alpha in breast cancer cells	ONCOGENE			English	Article						breast cancer; estrogen; ER alpha; IKK alpha; Notch-1	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; CYCLIN D1; INDEPENDENT ACTIVATION; KINASE PATHWAY; C-MYC; GENE; TARGET; BINDING; EXPRESSION	Approximately 80% of breast cancers express the estrogen receptor-alpha (ER alpha) and are treated with anti-estrogens. Resistance to these agents is a major cause of mortality. We have shown that estrogen inhibits Notch, whereas anti-estrogens or estrogen withdrawal activate Notch signaling. Combined inhibition of Notch and estrogen signaling has synergistic effects in ER alpha-positive breast cancer models. However, the mechanisms whereby Notch-1 promotes the growth of ER alpha-positive breast cancer cells are unknown. Here, we demonstrate that Notch-1 increases the transcription of ER alpha-responsive genes in the presence or absence of estrogen via a novel chromatin crosstalk mechanism. Our data support a model in which Notch-1 can activate the transcription of ER alpha-target genes via IKK alpha-dependent cooperative chromatin recruitment of Notch-CSL-MAML1 transcriptional complexes (NTC) and ER alpha, which promotes the recruitment of p300. CSL binding elements frequently occur in close proximity to estrogen-responsive elements (EREs) in the human and mouse genomes. Our observations suggest that a hitherto unknown Notch-1/ER alpha chromatin crosstalk mediates Notch signaling effects in ER alpha-positive breast cancer cells and contributes to regulate the transcriptional functions of ER alpha itself. Oncogene (2010) 29, 201-213; doi:10.1038/onc.2009.323; published online 19 October 2009	[Pannuti, A.; Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA; [Hao, L.; Rizzo, P.; Osipo, C.; Wyatt, D.; Cheung, L. W-K] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Breast Canc Program, Maywood, IL USA; [Cheung, L. W-K] Loyola Univ Chicago, Dept Prevent Med & Bioinformat Core, Maywood, IL USA; [Sonenshein, G.] Boston Univ, Dept Biochem, Boston, MA 02215 USA; [Osborne, B. A.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Mississippi; University of Mississippi Medical Center; Loyola University Chicago; Loyola University Chicago; Boston University; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Guyton 2 Bldg,Suite G751-05, Jackson, MS 39216 USA.	lmiele@ci.umsmed.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674	Schmitt Fellowship Foundation;  [P01AG025531]; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	Schmitt Fellowship Foundation; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by Grant P01AG025531 (LM, BAO) and the Schmitt Fellowship Foundation (LH). We are grateful to Geraldine Weinmaster, Peter Strack and Rafi Kopan for the gift of reagents and cell lines, and to Sarah Bray for helpful discussions.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; DUBIK D, 1992, ONCOGENE, V7, P1587; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hayward P, 2005, DEVELOPMENT, V132, P1819, DOI 10.1242/dev.01724; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; Jehn BM, 1999, J IMMUNOL, V162, P635; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2008, EXPERT REV ANTICANC, V8, P1197, DOI 10.1586/14737140.8.8.1197; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Shen Q, 2008, ONCOGENE, V27, P366, DOI 10.1038/sj.onc.1210643; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu J, 2005, MOL CELL BIOL, V25, P1458, DOI 10.1128/MCB.25.4.1458-1474.2005; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	61	94	98	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					201	213		10.1038/onc.2009.323	http://dx.doi.org/10.1038/onc.2009.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838210	Green Accepted			2022-12-28	WOS:000273650000004
J	Thobe, MN; Gurusamy, D; Pathrose, P; Waltz, SE				Thobe, M. N.; Gurusamy, D.; Pathrose, P.; Waltz, S. E.			The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells	ONCOGENE			English	Article						Ron receptor; prostate cancer; chemokines; receptor tyrosine kinase; Met receptor; angiogenesis	HEPATOCYTE GROWTH-FACTOR; FACTOR-LIKE PROTEIN; CXC-CHEMOKINES; TUMOR-GROWTH; C-MET; ALTERED EXPRESSION; ENHANCES GROWTH; BREAST-CANCER; KAPPA-B; PROGRESSION	Overexpression of the Ron receptor tyrosine kinase has recently been shown in a wide variety of human cancers. However, no studies have examined Ron receptor expression or function during prostate tumorigenesis. In this study we report that Ron is highly expressed in human prostate adenocarcinoma and metastatic lymph nodes when compared with normal prostate or benign prostate hyperplasia. Furthermore, we show that Ron is over-expressed in PC-3 and DU145 prostate cancer cell lines, and that the levels of angiogenic chemokines produced by prostate cancer cells positively correlate with Ron expression. The knockdown of Ron in PC-3 or DU145 cells results in a significant decrease in angiogenic chemokine production and is associated with a decreased activation of the transcription factor nuclear factor-kappa B (NF-kappa B). Moreover, exogenous overexpression of Ron in LNCaP cells is sufficient to induce a significant increase in angiogenic chemokines that can be abrogated by inhibition of NF-kappa B signaling. Given that the function of angiogenic chemokines is important in the development of new blood vessels, we also examined the ability of Ron to modulate endothelial cell migration. Our data show that knockdown of Ron in prostate cancer cells results in significantly less endothelial cell chemotaxis when compared with Ron-expressing cells in vitro as well as in reduced tumor growth and decreased microvessel density after orthotopic transplantation into the prostate in vivo. In total, our data suggest that the Ron receptor is important in modulating prostate tumor growth by modulating angiogenic chemokine production and subsequent endothelial cell recruitment. Oncogene (2010) 29, 214-226; doi:10.1038/onc.2009.331; published online 19 October 2009	[Thobe, M. N.; Gurusamy, D.; Pathrose, P.; Waltz, S. E.] Univ Cincinnati, Dept Canc & Cell Biol, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Waltz, SE (corresponding author), Univ Cincinnati, Dept Canc & Cell Biol, Coll Med, Vontz Bldg Mol Studies,3125 Eden Ave, Cincinnati, OH 45267 USA.	susan.waltz@uc.edu	Gurusamy, Devikala/T-3410-2019	Waltz, Susan/0000-0003-3572-4642; Gurusamy, Devikala/0000-0002-1727-8653	National Institutes of Health [CA-125370]; Department of Defense Congressionally Directed Medical Research Programs [PC060821]; NATIONAL CANCER INSTITUTE [R21CA125370, R01CA125379] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Congressionally Directed Medical Research Programs(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy Schwemberger for her assistance with the flow cytometry experiments as well as Sarah Kader for her technical contributions. This work was supported by Public Health Services Grants CA-125370 (SEW) from the National Institutes of Health, and by grant project no. PC060821 (MNT) from the Department of Defense Congressionally Directed Medical Research Programs.	Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Balbay MD, 1999, CLIN CANCER RES, V5, P783; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Collado B, 2007, PEPTIDES, V28, P1896, DOI 10.1016/j.peptides.2007.04.015; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Greene GF, 1997, AM J PATHOL, V150, P1571; Hepburn PJ, 1997, PROSTATE, V33, P123; Jimenez JA, 2006, UROL ONCOL-SEMIN ORI, V24, P260, DOI 10.1016/j.urolonc.2005.11.022; Keeley EC, 2008, ARTERIOSCL THROM VAS, V28, P1928, DOI 10.1161/ATVBAHA.108.162925; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Li YH, 2003, CANCER BIOTHER RADIO, V18, P829, DOI 10.1089/108497803770418373; Lissbrant IF, 1997, PROSTATE, V33, P38; Loh SA, 2009, PLAST RECONSTR SURG, V123, p65S, DOI 10.1097/PRS.0b013e318191bdf4; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; NIKOLAIDIS NM, 2009, SHOCK IN PRESS; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Puri N, 2007, CANCER RES, V67, P3529, DOI 10.1158/0008-5472.CAN-06-4416; Ren Y, 2005, CLIN CANCER RES, V11, P6190, DOI 10.1158/1078-0432.CCR-04-2553; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Sawa Y, 2008, CELL TISSUE RES, V333, P237, DOI 10.1007/s00441-008-0625-5; Shen H, 2006, FASEB J, V20, P59, DOI 10.1096/fj.05-4764com; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang MH, 2007, J PATHOL, V213, P402, DOI 10.1002/path.2245; Waugh DJJ, 2008, FRONT BIOSCI, V13, P4595, DOI 10.2741/3025; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Wilson C, 2008, J PHARMACOL EXP THER, V327, P746, DOI 10.1124/jpet.108.143826; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	46	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					214	226		10.1038/onc.2009.331	http://dx.doi.org/10.1038/onc.2009.331			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838218	Green Accepted			2022-12-28	WOS:000273650000005
J	Villagra, A; Sotomayor, EM; Seto, E				Villagra, A.; Sotomayor, E. M.; Seto, E.			Histone deacetylases and the immunological network: implications in cancer and inflammation	ONCOGENE			English	Review						HDAC; inflammation; cytokine regulation	NF-KAPPA-B; MHC CLASS-I; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STEROID-RECEPTOR NUR77; GENE-EXPRESSION; MOLECULAR-MECHANISMS; DIFFERENTIAL EXPRESSION; TRANSCRIPTION REPRESSOR; REVERSIBLE ACETYLATION; TUMOR-SUPPRESSOR	The initiation, magnitude and duration of an immune response against antigens are a tightly regulated process involving a dynamic, orchestrated balance of pro- and anti-inflammatory pathways in immune cells. Such a delicate balance is critical for allowing efficient immune response against foreign antigens while preventing autoimmune attack against self-antigens. In recent years, much effort has been devoted to understanding immune evasion by cancer cells. Also, significant advances have been made in mechanistically understanding the role of pro- and anti-inflammatory cytokines in the regulation of immune responses against antigens, including those expressed by tumors. However, we still know very little about the regulation of inflammatory/anti-inflammatory genes in their natural setting, the chromatin substrate. Several mechanisms have been identified to influence chromatin flexibility and allow dynamic changes in gene expression. Among those, chromatin modi. cations induced by acetylation and deacetylation of histone tails have gained wide attention. In this study, we discuss the role of histone deacetylases in the transcriptional regulation of genes involved in the inflammatory response and how these enzymes coordinate the dynamic expression of these genes during an immune response. This emerging knowledge is opening new avenues to better understand epigenetic regulation of inflammatory responses and providing new molecular targets for either amplifying or ameliorating immune responses. Oncogene (2010) 29, 157-173; doi:10.1038/onc.2009.334; published online 26 October 2009	[Villagra, A.; Seto, E.] Univ S Florida, Dept Mol Oncol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Villagra, A.; Sotomayor, E. M.] Univ S Florida, Dept Immunol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Villagra, A.; Sotomayor, E. M.] Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Villagra, A (corresponding author), Univ S Florida, Dept Mol Oncol, H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	alejandro.villagra@moffitt.org; eduardo.sotomayor@moffitt.org; ed.seto@moffitt.org		Villagra, Alejandro/0000-0001-9346-8355	National Institutes of Health (NIH); American Heart Association; Kaul Foundation; NATIONAL CANCER INSTITUTE [R01CA169210, R01CA187040] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Kaul Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work in our laboratories was supported by grants to ES from the National Institutes of Health (NIH), the American Heart Association and the Kaul Foundation, and to EMS from the NIH.	Al-Janadi A, 2008, DRUGS R&D, V9, P369, DOI 10.2165/0126839-200809060-00003; Anderson LA, 2006, CANCER RES, V66, P4975, DOI 10.1158/0008-5472.CAN-05-4253; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Aptsiauri N, 2007, ADV EXP MED BIOL, V601, P123; Asirvatham AJ, 2009, CYTOKINE, V45, P58, DOI 10.1016/j.cyto.2008.11.010; Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019; Aune TM, 2009, IMMUNOLOGY, V126, P299, DOI 10.1111/j.1365-2567.2008.03026.x; Aung HT, 2006, FASEB J, V20, P1315, DOI 10.1096/fj.05-5360com; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barnes PJ, 2005, IMMUNOL ALLERGY CLIN, V25, P451, DOI 10.1016/j.iac.2005.05.003; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bhat KP, 2008, FEBS LETT, V582, P3193, DOI 10.1016/j.febslet.2008.08.010; Bishton M, 2007, EXPERT REV ANTICANC, V7, P1439, DOI 10.1586/14737140.7.10.1439; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bonfils C, 2008, CLIN CANCER RES, V14, P3441, DOI 10.1158/1078-0432.CCR-07-4427; Bowen H, 2008, CLIN EXP ALLERGY, V38, P1422, DOI 10.1111/j.1365-2222.2008.03067.x; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Cabrera T, 2007, TISSUE ANTIGENS, V69, P264, DOI 10.1111/j.1399-0039.2006.00777.x; CALNAN BJ, 1995, IMMUNITY, V3, P273; Cavaillon JM, 2001, CELL MOL BIOL, V47, P695; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chang SJ, 2008, J IMMUNOL, V181, P8372, DOI 10.4049/jimmunol.181.12.8372; Chen GY, 2006, P NATL ACAD SCI USA, V103, P16894, DOI 10.1073/pnas.0607926103; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x; Cohen MC, 1996, AM J CLIN PATHOL, V105, P589; CONNOR ME, 1993, INT J GYNECOL CANCER, V3, P103, DOI 10.1046/j.1525-1438.1993.03020103.x; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; de Visser KE, 2005, CANCER IMMUNOL IMMUN, V54, P1143, DOI 10.1007/s00262-005-0702-5; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duenas-Gonzalez A, 2008, CANCER TREAT REV, V34, P206, DOI 10.1016/j.ctrv.2007.11.003; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ellis L, 2008, CLIN CANCER RES, V14, P4500, DOI 10.1158/1078-0432.CCR-07-4262; Emanuele S, 2008, INT J ONCOL, V33, P637, DOI 10.3892/ijo_00000049; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Enya K, 2008, J LEUKOCYTE BIOL, V83, P190, DOI 10.1189/jlb.0106008; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feng R, 2007, BRIT J HAEMATOL, V139, P385, DOI 10.1111/j.1365-2141.2007.06772.x; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Furumai R, 2002, CANCER RES, V62, P4916; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gesbert F, 1998, J CLIN IMMUNOL, V18, P307, DOI 10.1023/A:1023223614407; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Gimsing P, 2008, EUR J HAEMATOL, V81, P170, DOI 10.1111/j.1600-0609.2008.01102.x; Gimsing P, 2009, EXPERT OPIN INV DRUG, V18, P501, DOI [10.1517/13543780902852560, 10.1517/13543780902852560 ]; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gopal YNV, 2006, CELL CYCLE, V5, P2738, DOI 10.4161/cc.5.23.3522; Gopal YNV, 2006, EMBO REP, V7, P291, DOI 10.1038/sj.embor.7400613; Guo Y, 2002, INT IMMUNOL, V14, P189, DOI 10.1093/intimm/14.2.189; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hallermalm K, 2001, BLOOD, V98, P1108, DOI 10.1182/blood.V98.4.1108; Hartlapp I, 2009, LEUKEMIA RES, V33, P929, DOI 10.1016/j.leukres.2008.12.013; Hauser C, 2002, MOL CELL BIOL, V22, P7820, DOI 10.1128/MCB.22.22.7820-7830.2002; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2001, FASEB J, V15, pA473; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; Kametani Y, 2008, IMMUNOL LETT, V119, P97, DOI 10.1016/j.imlet.2008.05.006; Karpf AR, 2006, EPIGENETICS-US, V1, P116, DOI 10.4161/epi.1.3.2988; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan ANH, 2008, IMMUNOL RES, V40, P164, DOI 10.1007/s12026-007-0085-0; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kuendgen A, 2007, CANCER-AM CANCER SOC, V110, P943, DOI 10.1002/cncr.22891; Le Tourneau C, 2008, EXPERT OPIN INV DRUG, V17, P1247, DOI [10.1517/13543780802256896, 10.1517/13543784.17.8.1247 ]; Lech-Maranda E, 2007, MINI-REV MED CHEM, V7, P1062, DOI 10.2174/138955707782110178; LEDER A, 1975, SCIENCE, V190, P893, DOI 10.1126/science.1059262; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li H, 2006, BIOCHEM BIOPH RES CO, V349, P1315, DOI 10.1016/j.bbrc.2006.08.182; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lu J, 2005, CYTOKINE, V31, P46, DOI 10.1016/j.cyto.2005.03.001; Lucio-Eterovic AK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-243; MA B, 2009, INVES NEW DRUG; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Mann BS, 2007, CLIN CANCER RES, V13, P2318, DOI 10.1158/1078-0432.CCR-06-2672; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; Marquard L, 2009, HISTOPATHOLOGY, V54, P688, DOI 10.1111/j.1365-2559.2009.03290.x; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Minetti GC, 2006, NAT MED, V12, P1147, DOI 10.1038/nm1479; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra N, 2001, P NATL ACAD SCI USA, V98, P2628, DOI 10.1073/pnas.051507098; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morinobu A, 2004, J BIOL CHEM, V279, P40640, DOI 10.1074/jbc.M407576200; Natoli G, 2009, CELL, V136, P19, DOI 10.1016/j.cell.2008.12.034; Nishioka C, 2008, LEUKEMIA, V22, P2159, DOI 10.1038/leu.2008.243; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; ONOZAKI K, 1985, J IMMUNOL, V135, P3962; Osoata GO, 2009, BIOCHEM BIOPH RES CO, V384, P366, DOI 10.1016/j.bbrc.2009.04.128; Ouaissi M, 2008, ANN SURG ONCOL, V15, P2318, DOI 10.1245/s10434-008-9940-z; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pankaj B, 2008, J ALLERGY CLIN IMMUN, V121, P580; Parra M, 2007, GENE DEV, V21, P638, DOI 10.1101/gad.1513107; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Petersson M, 1998, J IMMUNOL, V161, P2099; Poulsen CB, 2005, EUR J HAEMATOL, V74, P453, DOI 10.1111/j.1600-0609.2005.00429.x; Rasheed W, 2008, EXPERT REV ANTICANC, V8, P413, DOI 10.1586/14737140.8.3.413; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Redner RL, 2002, LEUKEMIA, V16, P1927, DOI 10.1038/sj.leu.2402720; Rigas B, 2007, CURR OPIN GASTROEN, V23, P55, DOI 10.1097/MOG.0b013e32801145b0; Rosato RR, 2003, CANCER RES, V63, P3637; Rubenstein RC, 1998, AM J RESP CRIT CARE, V157, P484, DOI 10.1164/ajrccm.157.2.9706088; Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799; SANDRA C, 2005, J NEUROIMMUNOL, V164, P10; Schmeck B, 2008, J IMMUNOL, V181, P940, DOI 10.4049/jimmunol.181.2.940; Scott FL, 2008, J BIOL CHEM, V283, P19499, DOI 10.1074/jbc.M800331200; Seliger B, 2006, INT J CANCER, V118, P129, DOI 10.1002/ijc.21312; Seliger B, 2008, CANCER IMMUNOL IMMUN, V57, P1719, DOI 10.1007/s00262-008-0515-4; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Tao R, 2007, HEPATOB PANCREAT DIS, V6, P348; Togi S, 2009, BIOCHEM BIOPH RES CO, V379, P616, DOI 10.1016/j.bbrc.2008.12.132; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Valapour M, 2002, J ALLERGY CLIN IMMUN, V109, P238, DOI 10.1067/mai.2002.121145; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; van den Elsen PJ, 2003, CLIN IMMUNOL, V109, P46, DOI 10.1016/S1521-6616(03)00200-6; Villagra A, 2009, NAT IMMUNOL, V10, P92, DOI 10.1038/ni.1673; Wang J, 2009, INT IMMUNOL, V21, P227, DOI 10.1093/intimm/dxn143; WANG W, 2009, JPN J CANCER RES, V21, P1439; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, NEOPLASIA, V10, P1021, DOI 10.1593/neo.08474; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Yao YX, 2005, J EXP MED, V201, P1899, DOI 10.1084/jem.20050324; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zeidler R, 1997, BLOOD, V90, P2390; Zhang C, 2009, CANCER IMMUNOL IMMUN, V58, P1275, DOI 10.1007/s00262-008-0645-8; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang X, 2006, J IMMUNOL, V177, P1282, DOI 10.4049/jimmunol.177.2.1282; Zhang YJ, 2008, J IMMUNOL, V180, P402, DOI 10.4049/jimmunol.180.1.402; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou W, 2009, CURR CANCER DRUG TAR, V9, P91, DOI 10.2174/156800909787314039; Zhou WS, 2004, P NATL ACAD SCI USA, V101, P2440, DOI 10.1073/pnas.0306002101; Zika E, 2003, MOL CELL BIOL, V23, P3091, DOI 10.1128/MCB.23.9.3091-3102.2003	181	139	144	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					157	173		10.1038/onc.2009.334	http://dx.doi.org/10.1038/onc.2009.334			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855430				2022-12-28	WOS:000273650000001
J	Wasch, R; Robbins, JA; Cross, FR				Waesch, R.; Robbins, J. A.; Cross, F. R.			The emerging role of APC/C-Cdh1 in controlling differentiation, genomic stability and tumor suppression	ONCOGENE			English	Review						anaphase-promoting complex; ubiquitin; proteasome; differentiation; genomic instability; tumor suppression	ANAPHASE-PROMOTING COMPLEX; APC-DEPENDENT PROTEOLYSIS; XENOPUS EGG EXTRACTS; CELL-CYCLE ARREST; S-PHASE ENTRY; AURORA-A; MITOTIC SPINDLE; UBIQUITIN LIGASE; D-BOX; SACCHAROMYCES-CEREVISIAE	Deregulation of the G1/G0 phase of the cell cycle can lead to cancer. During G1, most cells commit alternatively to DNA replication and division, or to cell-cycle exit and differentiation. The anaphase-promoting complex or cyclosome (APC/C) activated by Cdh1 coordinately eliminates positive cell-cycle regulators as well as inhibitors of differentiation, thereby coupling cell-cycle exit and differentiation. Misregulation of Cdh1 thus has the potential to promote both cell-cycle re-entry and either perturbed differentiation or dedifferentiation. In addition, APC/C-Cdh1 is required to maintain genomic stability. As a result, loss of Cdh1 can contribute to tumorigenesis in the form of proliferation of poorly differentiated and genetically unstable cells.	[Waesch, R.] Univ Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany; [Robbins, J. A.; Cross, F. R.] Rockefeller Univ, Lab Yeast Mol Genet, New York, NY 10021 USA	University of Freiburg; Rockefeller University	Wasch, R (corresponding author), Univ Med Ctr, Dept Hematol & Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Waesch, Ralph/F-6282-2019	Robbins, Jonathan/0000-0001-9690-4976	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047238, T32GM007739] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047238-14, R01 GM047238, R01 GM047238-10, R01 GM047238-05A2, R01 GM047238-09, R01 GM047238-08, R01 GM047238-06, R01 GM047238-07, R01 GM047238-16, T32 GM007739, R01 GM047238-12, R01 GM047238-13, R01 GM047238-15, R01 GM047238-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Benmaamar R, 2005, CELL CYCLE, V4, P1230, DOI 10.4161/cc.4.9.2048; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Castro A, 2002, EMBO REP, V3, P1209, DOI 10.1093/embo-reports/kvf241; Chaudhary J, 2005, BIOL REPROD, V72, P1205, DOI 10.1095/biolreprod.104.035717; Crasta K, 2008, NAT CELL BIOL, V10, P665, DOI 10.1038/ncb1729; Crasta K, 2006, EMBO J, V25, P2551, DOI 10.1038/sj.emboj.7601136; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Cuende J, 2008, ONCOGENE, V27, P3339, DOI 10.1038/sj.onc.1210987; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Enquist-Newman M, 2008, MOL CELL, V30, P437, DOI 10.1016/j.molcel.2008.04.004; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Floyd S, 2008, CURR BIOL, V18, P1649, DOI 10.1016/j.cub.2008.09.058; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Fujita T, 2008, CLIN CANCER RES, V14, P1966, DOI 10.1158/1078-0432.CCR-07-1585; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jacobs HW, 2002, CURR BIOL, V12, P1435, DOI 10.1016/S0960-9822(02)01074-6; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Ji M, 2008, BLOOD, V112, P1068, DOI 10.1182/blood-2008-01-133504; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lehman NL, 2007, AM J PATHOL, V170, P1793, DOI 10.2353/ajpath.2007.060767; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li M, 2008, NAT CELL BIOL, V10, P1083, DOI 10.1038/ncb1768; Li M, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-2; Li WQ, 2007, FASEB J, V21, P3606, DOI 10.1096/fj.07-8159com; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood-2006-11-060350; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Reis A, 2006, EMBO REP, V7, P1040, DOI 10.1038/sj.embor.7400772; Ross KE, 2003, GENETICS, V165, P489; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skotheim JM, 2008, NATURE, V454, P291, DOI 10.1038/nature07118; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stegmuller J, 2008, J NEUROSCI, V28, P1961, DOI 10.1523/JNEUROSCI.3061-07.2008; Stegmuller J, 2006, NEURON, V50, P389, DOI 10.1016/j.neuron.2006.03.034; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stewart S, 2005, MOL CELL BIOL, V25, P10516, DOI 10.1128/MCB.25.23.10516-10527.2005; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Stroschein SL, 2001, GENE DEV, V15, P2822; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suh HC, 2008, ONCOGENE, V27, P5612, DOI 10.1038/onc.2008.175; Sullivan M, 2007, J BIOL CHEM, V282, P19710, DOI 10.1074/jbc.M701507200; Takahashi C, 2006, CANCER RES, V66, P9345, DOI 10.1158/0008-5472.CAN-06-1250; Taylor S, 2008, CURR OPIN CELL BIOL, V20, P77, DOI 10.1016/j.ceb.2007.11.008; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Wu G, 2007, MOL BIOL CELL, V18, P1018, DOI 10.1091/mbc.E06-09-0809; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; Zielke N, 2008, GENE DEV, V22, P1690, DOI 10.1101/gad.469108	100	84	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2010	29	1					1	10		10.1038/onc.2009.325	http://dx.doi.org/10.1038/onc.2009.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19826416	Green Accepted			2022-12-28	WOS:000273373500001
J	Liu, G; Bollig-Fischer, A; Kreike, B; van de Vijver, MJ; Abrams, J; Ethier, SP; Yang, ZQ				Liu, G.; Bollig-Fischer, A.; Kreike, B.; van de Vijver, M. J.; Abrams, J.; Ethier, S. P.; Yang, Z-Q			Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer	ONCOGENE			English	Article						GASC1; gene amplification; histone demethylase	MAMMARY EPITHELIAL-CELLS; ERBB-2 OVEREXPRESSION; STEM/PROGENITOR CELLS; LYSINE METHYLATION; GLAND DEVELOPMENT; SELF-RENEWAL; STEM-CELLS; EXPRESSION; JMJD2C; 9P23-24	Earlier, mapping of the 9p23-24 amplicon in esophageal cancer cell lines led us to the positional cloning of gene amplified in squamous cell carcinoma 1 (GASC1), which encodes a nuclear protein with a Jumonji C domain that catalyzes lysine (K) demethylation of histones. However, the transforming roles of GASC1 in breast cancer remain to be determined. In this study, we identified GASC1 as one of the amplified genes for the 9p23-24 region in breast cancer, particularly in basal-like subtypes. The levels of GASC1 transcript expression were significantly higher in aggressive, basal- like breast cancers compared with nonbasal-like breast cancers. Our in vitro assays demonstrated that GASC1 induces transformed phenotypes, including growth factor-independent proliferation, anchorage-independent growth, altered morphogenesis in Matrigel, and mammosphere forming ability, when overexpressed in immortalized, non-transformed mammary epithelial MCF10A cells. Additionally, GASC1 demethylase activity regulates the expression of genes critical for stem cell self-renewal, including NOTCH1, and may be linked to the stem cell phenotypes in breast cancer. Thus, GASC1 is a driving oncogene in the 9p23-24 amplicon in human breast cancer and targeted inhibition of GASC1 histone demethylase in cancer could provide potential new avenues for therapeutic development. Oncogene (2009) 28, 4491-4500; doi:10.1038/onc.2009.297; published online 28 September 2009	[Liu, G.; Bollig-Fischer, A.; Ethier, S. P.; Yang, Z-Q] Wayne State Univ, Breast Canc Program, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA; [Kreike, B.] Netherlands Canc Inst, Div Radiat Oncol & Expt Therapy, Amsterdam, Netherlands; [van de Vijver, M. J.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Abrams, J.] Wayne State Univ, Dept Internal Med, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Barbara Ann Karmanos Cancer Institute; Wayne State University	Yang, ZQ (corresponding author), Wayne State Univ, Breast Canc Program, Dept Pathol, Karmanos Canc Inst, 4100 John R HWCRC 815, Detroit, MI 48201 USA.	yangz@karmanos.org	LIU, GANG/AAR-4584-2021	LIU, GANG/0000-0001-6620-176X; Bollig-Fischer, Aliccia/0000-0003-4832-9457; Kreike, Bas/0000-0003-0030-8200; van de Vijver, Marc/0000-0002-0385-4787	NCI NIH HHS [R01 CA100724, R01 CA100724-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100724] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2005, J BIOL CHEM, V280, P17732, DOI 10.1074/jbc.M500796200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Geli J, 2005, INT J ONCOL, V26, P1385; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Ignatoski KMW, 2003, MOL CANCER RES, V1, P551; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katoh Y, 2007, INT J MOL MED, V20, P269; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Knuutila S, 1998, AM J PATHOL, V152, P1107; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Moffa AB, 2004, MOL CANCER RES, V2, P643; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pierga JY, 2007, BRIT J CANCER, V96, P341, DOI 10.1038/sj.bjc.6603483; Poetsch M, 2002, ONCOGENE, V21, P3038, DOI 10.1038/sj.onc.1205457; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Savelyeva L, 2001, CANCER RES, V61, P5179; Savelyeva L, 1999, GENE CHROMOSOME CANC, V24, P87, DOI 10.1002/(SICI)1098-2264(199901)24:1<87::AID-GCC13>3.0.CO;2-5; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2001, JPN J CANCER RES, V92, P423, DOI 10.1111/j.1349-7006.2001.tb01112.x; Yang ZQ, 2000, CANCER RES, V60, P4735	47	156	161	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4491	4500		10.1038/onc.2009.297	http://dx.doi.org/10.1038/onc.2009.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19784073	Green Accepted, Bronze			2022-12-28	WOS:000272876500008
J	Chang, YC; Tien, SC; Tien, HF; Zhang, H; Bokoch, GM; Chang, ZF				Chang, Y-C; Tien, S-C; Tien, H-F; Zhang, H.; Bokoch, G. M.; Chang, Z-F			p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1 alpha-directed migration in chronic myeloid leukemia cells	ONCOGENE			English	Article						chronic myeloid leukemia (CML); p210(Bcr-Abl); Cdc42, chemotaxis; stromal-derived factor-1 alpha (SDF-1 alpha)	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; CHEMOTACTIC RESPONSE; BCR-ABL; PHILADELPHIA-CHROMOSOME; PROTOONCOGENE VAV; STRUCTURAL BASIS; ACTIVATION; INDUCTION; BCR/ABL	Chronic myeloid leukemia (CML) is a lethal hematological disorder caused by the p210(Bcr-Abl) oncogene. Previous studies have suggested that p210(Bcr-Abl) transformation contributes to homing and retention defects, typical of immature myeloid cells in CML, by attenuating chemotactic response to stromal-derived factor-1 alpha (SDF-1 alpha). As Rho family GTPases are key regulators of the cytoskeleton and have been previously found to interact with p210(Bcr-Abl), this study aimed to determine whether p210(Bcr-Abl) signaling affects SDF-1 alpha chemotaxis through Rho GTPase signaling. We found that SDF-1 alpha stimulated Cdc42 GTPase activation in myeloid progenitor 32D, but not in p210(BcrAbl)-transformed (32Dp210) cells. In fact, the basal level of active Cdc42 was elevated in 32Dp210 cells and mononuclear cells isolated from bone marrow of CML patients. Inhibition of p210(Bcr-Abl) kinase activity decreased basal Cdc42 activity and restored SDF-1 alpha-induced Cdc42 and migration responses. Transduction of active Tat-Cdc42V12 abolished this reconstituted chemotactic response. As Cdc42 is particularly important in cytoskeletal remodeling and directional sensing, these results suggest that sustained activation of Cdc42 GTPase through p210(Bcr-Abl) tyrosine kinase signaling in CML cells contributes to defects in SDF-1 alpha-chemotactic response due to desensitization of the actin polarization signal required for directional migration. Oncogene (2009) 28, 4105-4115; doi:10.1038/onc.2009.260; published online 31 August 2009	[Chang, Y-C; Tien, S-C; Chang, Z-F] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei, Taiwan; [Tien, H-F] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Zhang, H.; Bokoch, G. M.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Zhang, H.; Bokoch, G. M.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Scripps Research Institute; Scripps Research Institute	Chang, ZF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, 1 Sect,1 Jen Ai Rd, Taipei, Taiwan.	zfchang@ntu.edu.tw		TIEN, HWEI-FANG/0000-0002-1384-5593	National Science Council, Taiwan [NSC 96-3112-B-002-006, NSC 97-3112-B-002-026]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We are grateful to Dr RB Arlinghaus (Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) for providing 32Dp210 and WEHI cells. We thank the staff of the Second Core Lab, Department of Medical Research, National Taiwan University Hospital for technical support during this study. This study is supported by grant NSC 96-3112-B-002-006 and NSC 97-3112-B-002-026 from the National Science Council, Taiwan.	Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bassermann F, 2002, J BIOL CHEM, V277, P12437, DOI 10.1074/jbc.M112397200; Burger JA, 2007, BRIT J HAEMATOL, V137, P288, DOI 10.1111/j.1365-2141.2007.06590.x; Chang YC, 2006, CELL DEATH DIFFER, V13, P2023, DOI 10.1038/sj.cdd.4401901; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Daubon T, 2008, ONCOGENE, V27, P2673, DOI 10.1038/sj.onc.1210933; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; Gottig S, 2006, EUR J IMMUNOL, V36, P180, DOI 10.1002/eji.200525607; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Harnois T, 2003, ONCOGENE, V22, P6445, DOI 10.1038/sj.onc.1206626; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Miletic AV, 2003, CURR OPIN IMMUNOL, V15, P261, DOI 10.1016/S0952-7915(03)00054-2; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Niggli V, 2003, INT J BIOCHEM CELL B, V35, P1619, DOI 10.1016/S1357-2725(03)00144-4; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; ROWLEY JD, 1990, CANCER, V65, P2178, DOI 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-#; Salesse S, 2002, ONCOGENE, V21, P8547, DOI 10.1038/sj.onc.1206082; Salgia R, 1999, BLOOD, V94, P4233; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Stofega Mary, 2006, V332, P269; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Vicente-Manzanares M, 2004, NAT REV IMMUNOL, V4, P110, DOI 10.1038/nri1268; Vicente-Manzanares M, 2005, BLOOD, V105, P3026, DOI 10.1182/blood-2004-07-2925; Volinsky N, 2006, BIOCHEM J, V397, P213, DOI 10.1042/BJ20051655; Wertheim JA, 2002, ONCOGENE, V21, P8612, DOI 10.1038/sj.onc.1206089; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200	36	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	2009	28	46					4105	4115		10.1038/onc.2009.260	http://dx.doi.org/10.1038/onc.2009.260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718053				2022-12-28	WOS:000272560500006
J	Chua, YL; Ito, Y; Pole, JCM; Newman, S; Chin, SF; Stein, RC; Ellis, IO; Caldas, C; O'hare, MJ; Murrell, A; Edwards, PAW				Chua, Y. L.; Ito, Y.; Pole, J. C. M.; Newman, S.; Chin, S-F; Stein, R. C.; Ellis, I. O.; Caldas, C.; O'hare, M. J.; Murrell, A.; Edwards, P. A. W.			The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene	ONCOGENE			English	Article						breast cancer; NRG1; heregulins; DNA methylation; tumour suppressor gene; chromosome rearrangement	DIFFERENTIATION FACTOR NDF; MALIGNANT HUMAN BREAST; MOUSE MAMMARY-GLAND; CELL-LINES; GAMMA-HEREGULIN; GROWTH-FACTOR; CHROMOSOME-TRANSLOCATION; EPITHELIAL-CELLS; DNA METHYLATION; WERNER-SYNDROME	Neuregulin-1 (NRG1) is both a candidate oncogene and a candidate tumour suppressor gene. It not only encodes the heregulins and other mitogenic ligands for the ERBB family, but also causes apoptosis in NRG1-expressing cells. We found that most breast cancer cell lines had reduced or undetectable expression of NRG1. This included cell lines that had translocation breaks in the gene. Similarly, expression in cancers was generally comparable to or less than that in various normal breast samples. Many non-expressing cell lines had extensive methylation of the CpG island at the principal transcription start site at exon 2 of NRG1. Expression was reactivated by demethylation. Many tumours also showed methylation, whereas normal mammary epithelial fragments had none. Lower NRG1 expression correlated with higher methylation. Small interfering RNA (siRNA)-mediated depletion of NRG1 increased net proliferation in a normal breast cell line and a breast cancer cell line that expressed NRG1. The short arm of chromosome 8 is frequently lost in epithelial cancers, and NRG1 is the most centromeric gene that is always affected. NRG1 may therefore be the major tumour suppressor gene postulated to be on 8p: it is in the correct location, is antiproliferative and is silenced in many breast cancers. Oncogene (2009) 28, 4041-4052; doi:10.1038/onc.2009.259; published online 5 October 2009	[Edwards, P. A. W.] Univ Cambridge, Dept Pathol, Hutchison Med Res Council, Res Ctr, Cambridge CB2 0XZ, England; [Ito, Y.; Chin, S-F; Caldas, C.; Murrell, A.] Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0XZ, England; [Stein, R. C.; O'hare, M. J.] UCL, Ludwig Inst Canc Res, Breast Canc Lab, Univ Coll & Middlesex Sch Med, London, England; [Ellis, I. O.] Univ Nottingham Mol Med Sci, Dept Histopathol, City Hosp Nottingham, Nottingham, England	University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Ludwig Institute for Cancer Research; University of London; University College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Edwards, PAW (corresponding author), Univ Cambridge, Dept Pathol, Hutchison Med Res Council, Res Ctr, Cambridge CB2 0XZ, England.	pawe1@cam.ac.uk	Caldas, Carlos/A-7543-2008; Stein, Robert C/N-6679-2015; Newman, Scott/B-4843-2012; Caldas, Carlos/U-7250-2019; Edwards, Paul A/M-8291-2014	Stein, Robert C/0000-0003-2969-0415; Caldas, Carlos/0000-0003-3547-1489; Edwards, Paul A/0000-0002-4789-3374; Ellis, Ian/0000-0001-5292-8474; chin, suet-feung/0000-0001-5697-1082	Breast Cancer Campaign; Cancer Research UK; Hutchison-Whampoa Ltd.; Ludwig Institute for Cancer Research	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Hutchison-Whampoa Ltd.; Ludwig Institute for Cancer Research	We thank Huai-En Huang for some exploratory expression analysis. This study was funded principally by the Breast Cancer Campaign and also by Cancer Research UK, Hutchison-Whampoa Ltd. (who endowed the buildings in which the work was done) and the Ludwig Institute for Cancer Research.	Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amin DN, 2005, EXP CELL RES, V309, P12, DOI 10.1016/j.yexcr.2005.04.034; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; BRADBURY JM, 1993, ONCOGENE, V8, P1551; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Britsch S, 2007, ADV ANAT EMBRYOL CEL, V190, P1; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; Clarke C, 2005, J MAMMARY GLAND BIOL, V10, P273, DOI 10.1007/s10911-005-9587-3; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; Crabbe L, 2007, P NATL ACAD SCI USA, V104, P2205, DOI 10.1073/pnas.0609410104; Deadwyler GD, 2000, GLIA, V32, P304, DOI 10.1002/1098-1136(200012)32:3<304::AID-GLIA90>3.3.CO;2-Q; EDWARDS PAW, 1986, J CELL SCI, V80, P91; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; Hayes NVL, 2008, J MAMMARY GLAND BIOL, V13, P205, DOI 10.1007/s10911-008-9078-4; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Kalirai H, 2006, J PATHOL, V208, P7, DOI 10.1002/path.1881; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	47	56	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4041	4052		10.1038/onc.2009.259	http://dx.doi.org/10.1038/onc.2009.259			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19802002	Green Submitted, Green Accepted			2022-12-28	WOS:000272560500001
J	Gruhne, B; Sompallae, R; Masucci, MG				Gruhne, B.; Sompallae, R.; Masucci, M. G.			Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints	ONCOGENE			English	Article						Epstein-Barr virus; genomic instability; DNA repair; mitotic spindle checkpoint	NUCLEAR ANTIGEN 3C; BURKITTS-LYMPHOMA CELLS; HUMAN EPITHELIAL-CELLS; NASOPHARYNGEAL CARCINOMA; MEMBRANE ANTIGEN; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION; PATHWAY; LINES	Epstein-Barr virus (EBV) has been implicated in the pathogenesis of human malignancies, but its contribution to tumorigenesis is not well understood. EBV carriage is associated with increased genomic instability in Burkitt's lymphoma, suggesting that viral products may induce this tumor phenotype. Using a panel of transfected sublines of the B-lymphoma line BJAB expressing the viral genes associated with latent infection, we show that the EBV nuclear antigens, EBNA-1 and EBNA-3C, and the latent membrane protein 1, LMP-1, independently promote genomic instability, as detected by nonclonal chromosomal aberrations, DNA breaks and phosphorylation of histone H2AX. EBNA-1 promotes the generation of DNA damage by inducing reactive oxygen species (ROS), whereas DNA repair is inhibited in LMP-1-expressing cells through downregulation of the DNA damage-sensing kinase, ataxia telangiectasia mutated (ATM), reduction of phosphorylation of its downstream targets Chk2 and inactivation of the G(2) checkpoint. EBNA-3C enhances the propagation of damaged DNA through inactivation of the mitotic spindle checkpoint and transcriptional downregulation of BubR1. Thus, multiple cellular functions involved in the maintenance of genome integrity seem to be independently targeted by EBV, pointing to the induction of genomic instability as a critical event in viral oncogenesis. Oncogene (2009) 28, 3997-4008; doi:10.1038/onc.2009.258; published online 31 August 2009	[Gruhne, B.; Sompallae, R.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; INCA [LSHC-CT-2005-018704]	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; INCA(Institut National du Cancer (INCA) France)	We thank L Rymo, M Rowe and J Middledorp for the kind gift of transfected cell lines and antibodies and also many colleagues for helpful discussions. This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and Karolinska Institutet, Stockholm, Sweden and by the European Community Integrated Project on Infection and Cancer, INCA, Project No. LSHC-CT-2005-018704.	AMAN P, 1990, INT J CANCER, V45, P77, DOI 10.1002/ijc.2910450115; Bolt J, 2005, ORAL ONCOL, V41, P1013, DOI 10.1016/j.oraloncology.2005.06.003; Bose S, 2007, J PATHOL, V213, P329, DOI 10.1002/path.2232; Bose S, 2009, J PATHOL, V217, P345, DOI 10.1002/path.2487; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen YR, 2008, J VIROL, V82, P8124, DOI 10.1128/JVI.00430-08; Choudhuri T, 2007, J VIROL, V81, P6718, DOI 10.1128/JVI.00053-07; CUOMO L, 1990, EUR J IMMUNOL, V20, P2293, DOI 10.1002/eji.1830201019; Eclache V, 2004, CANCER GENET CYTOGEN, V152, P72, DOI 10.1016/j.cancergencyto.2003.10.010; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Greene LM, 2008, MOL PHARMACOL, V73, P419, DOI 10.1124/mol.107.039024; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Knight JS, 2004, J VIROL, V78, P1981, DOI 10.1128/JVI.78.4.1981-1991.2004; Kulukian A, 2009, DEV CELL, V16, P105, DOI 10.1016/j.devcel.2008.11.005; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Leao M, 2007, J VIROL, V81, P248, DOI 10.1128/JVI.01096-06; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Pan SH, 2009, CARCINOGENESIS, V30, P366, DOI 10.1093/carcin/bgn291; Parish Christopher R, 2009, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0409s84; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Ranjan D, 1998, AM SURGEON, V64, P47; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Raptis S, 2006, EXP SUPPL, V96, P303; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; Saha A, 2009, J VIROL, V83, P4652, DOI 10.1128/JVI.02408-08; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Shea LM, 1996, J IMMUNOL, V157, P3902; Sivachandran N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000170; STOLLMANN B, 1985, BRIT J HAEMATOL, V60, P183, DOI 10.1111/j.1365-2141.1985.tb07399.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	54	103	109	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3997	4008		10.1038/onc.2009.258	http://dx.doi.org/10.1038/onc.2009.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718051				2022-12-28	WOS:000272560300005
J	Klanrit, P; Taebunpakul, P; Flinterman, MB; Odell, EW; Riaz, MA; Melino, G; Salomoni, P; Mymryk, JS; Gaken, J; Farzaneh, F; Tavassoli, M				Klanrit, P.; Taebunpakul, P.; Flinterman, M. B.; Odell, E. W.; Riaz, M. A.; Melino, G.; Salomoni, P.; Mymryk, J. S.; Gaeken, J.; Farzaneh, F.; Tavassoli, M.			PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers	ONCOGENE			English	Article						PML; EGFR; p73; E1A; HNSCC	ACUTE PROMYELOCYTIC LEUKEMIA; SQUAMOUS-CELL CARCINOMAS; FACTOR RECEPTOR PROMOTER; P53 TARGET GENES; RAR-ALPHA; E1A-MEDIATED SUPPRESSION; TRANSCRIPTIONAL ACTIVITY; PREMATURE SENESCENCE; MESSENGER-RNA; P73	Epidermal growth factor receptor (EGFR) tyrosine kinase is commonly overexpressed in human cancers; however, the cellular mechanisms regulating EGFR expression remain unclear. p53, p63 and p73 are transcription factors regulating many cellular targets involved in controlling the cell cycle and apoptosis. p53 activates EGFR expression, whereas TAp63 represses EGFR transcription. The involvement of p73 in the regulation of EGFR has not been reported. Here, a strong correlation between EGFR overexpression and increased levels of the oncogenic Delta Np73 isoform in head and neck squamous cell carcinoma (HNSCC) cell lines was observed. Ectopic expression of TAp73, particularly TAp73 beta, resulted in suppression of the EGFR promoter, significant downregulation of EGFR protein and efficient induction of cell death in all six EGFR-overexpressing HNSCC cell lines. EGFR overexpression from a heterologous LTR promoter protected lung cancer cells from TAp73 beta-induced EGFR suppression and apoptosis. Expression of TAp73 beta efficiently induced promyelocytic leukaemia (PML) protein expression and PML knockdown by shRNA attenuated the downregulation of EGFR and induction of apoptosis by p73 in HNSCC cells. Furthermore, PML was found to be important for E1A-induced suppression of EGFR and subsequent killing of HNSCC cells. Our data therefore suggest a novel pathway involving PML and p73 in the regulation of EGFR expression. Oncogene (2009) 28, 3499-3512; doi: 10.1038/onc.2009.191; published online 13 July 2009	[Klanrit, P.; Taebunpakul, P.; Flinterman, M. B.; Riaz, M. A.; Tavassoli, M.] Kings Coll London, Inst Dent, Head & Neck Oncol Grp, London SE1 9RT, England; [Odell, E. W.] Kings Coll London, Inst Dent, Dept Oral Pathol, London SE1 9RT, England; [Melino, G.; Salomoni, P.] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England; [Mymryk, J. S.] Univ Western Ontario, Dept Oncol, London Reg Canc Program, London, ON, Canada; [Mymryk, J. S.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Gaeken, J.; Farzaneh, F.] Kings Coll London, Dept Hematol & Mol Med, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; University of Leicester; Western University (University of Western Ontario); Western University (University of Western Ontario); University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Inst Dent, Head & Neck Oncol Grp, Guys Hosp Campus,Floor 28 Tower Wing, London SE1 9RT, England.	mahvash.tavassoli@kcl.ac.uk	Klanrit, Poramaporn/X-4784-2019; odell, edward w/E-9920-2012; Farzaneh, Farzin/B-4902-2009; gaken, joop/B-3414-2009	odell, edward w/0000-0001-8435-0048; Farzaneh, Farzin/0000-0002-9275-2415; 	Cancer Research UK [C1116]; Rosetrees Trust; Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; King's College London; Royal Thai Government Scholarship; MRC [MC_U132670601, MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670601, MC_U132670600] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Rosetrees Trust(Rosetrees Trust); Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; King's College London; Royal Thai Government Scholarship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Prof Bert Vogelstein for providing Ad-GFP-p53 and Ad-GFP, Prof Karen Vousden for providing Ad-GFP-TAp73 beta, Prof Alfred Johnson for providing pER1-luc and Associate Prof Kun-Sang Chang for anti-PML clone 3573 antibody. We also thank Prof Alan Lehmann for 1BR3 and 1BR3-LT, Prof Hugh Paterson for 6689, Prof Barry Gusterson for HN5, Prof Kazuya Tominaga for HSC-3 and HSC-3 M3, Prof Fiona Watts for Km3, Prof Andrew Yeudall for HN30 and Prof Stephen Prime for H103 and H357 cell lines. We especially thank Prof Christoph Borner for the critical and helpful reading of this paper. This work was supported by grants from Cancer Research UK, the Rosetrees Trust and Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. Marcella Flinterman was supported by a grant from Cancer Research UK (C1116). Poramaporn Klanrit and Patrayu Taebunpakul were supported by the Royal Thai Government Scholarship.	Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernardi R, 2008, ONCOGENE, V27, P6299, DOI 10.1038/onc.2008.305; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bernassola F, 2005, ONCOGENE, V24, P6982, DOI 10.1038/sj.onc.1208843; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; de Melker AA, 2001, J CELL SCI, V114, P2167; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Denizot A, 2003, THYROID, V13, P867, DOI 10.1089/105072503322401069; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Flinterman MB, 2007, ONCOGENE, V26, P6863, DOI 10.1038/sj.onc.1210497; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; KASTNER P, 1991, CR SOC BIOL, V185, P391; Klanrit P, 2008, CELL CYCLE, V7, P205, DOI 10.4161/cc.7.2.5361; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Racek T, 2005, J BIOL CHEM, V280, P40402, DOI 10.1074/jbc.C500193200; SAKAI E, 1992, ONCOGENE, V7, P927; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Wang ZG, 1998, SCIENCE, V279, P1547; Wu LQ, 2004, ONCOGENE, V23, P4032, DOI 10.1038/sj.onc.1207538; Wu Q, 2009, J BIOL CHEM, V284, P8738, DOI 10.1074/jbc.M807590200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; YAN DH, 1991, ONCOGENE, V6, P343; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu JH, 1998, CANCER RES, V58, P5061	51	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3499	3512		10.1038/onc.2009.191	http://dx.doi.org/10.1038/onc.2009.191			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597475	Green Accepted			2022-12-28	WOS:000270478300007
J	Yuan, BZ; Chapman, J; Reynolds, SH				Yuan, B-Z; Chapman, J.; Reynolds, S. H.			Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage	ONCOGENE			English	Article						proteasome inhibitor; non-small cell lung carcinoma; apoptosis; Mcl-1; positive feedback mechanism; protein cleavage	TRAIL; SENSITIZE; EPIDEMIOLOGY; ACTIVATION; BORTEZOMIB; FLICE; NOXA	Proteasome inhibitors (PIs) are promising new therapeutic agents for treating non-small cell lung carcinoma (NSCLC). To investigate the mechanisms of action of PIs, we analyzed the proapoptotic activities of PIs (MG132 or Bortezomib) in NSCLC cells. We found that both MG132 (>1 mu M) and Bortezomib (>0.025 mu M) induced a significant apoptosis in NCI-H1703, a PI-sensitive NSCLC cell line, through initially activating the intrinsic apoptosis pathway, leading to the activation of a positive feedback mechanism (PFM), which then conveyed apoptosis signaling from the intrinsic pathway to the extrinsic pathway with formation of a signaling loop for maximal caspase activation. Mcl-1 and Noxa were identified to be the major anti-apoptotic and proapoptotic proteins, respectively, in PI-induced apoptosis and mutually exclusive in protein stability. Although the Mcl-1 protein was upregulated by proteasome inhibition, it was also subjected to caspase 3-dependent cleavage governed by the PFM. Moreover, it was revealed that Mcl-1 protein cleavage contributed to PFM-governed apoptosis in following inter-related ways: reducing the anti-apoptotic Mcl-1; generating the truncated proapoptotic Mcl-1(S); and inducing a shift of balance between Mcl-1 and Noxa. It was further manifested that tumor necrosis factor-related apoptosis-inducing ligand boosted MG132's proapoptotic activity through strengthening the PFM in both NCI-H1703 and NCI-H358, a PI-resistant NSCLC cell line. Therefore, this study provides a basis for enhancing the efficacy of PIs in treating NSCLC. Oncogene (2009) 28, 3775-3786; doi:10.1038/onc.2009.240; published online 17 August 2009	[Yuan, B-Z; Chapman, J.; Reynolds, S. H.] NIOSH, Mol Genet Lab, Toxicol & Mol Biol Branch, CDC, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Yuan, BZ (corresponding author), NIOSH, Mol Genet Lab, Toxicol & Mol Biol Branch, CDC, 1095 Willowdale Rd,M-S L-3014, Morgantown, WV 26505 USA.	bby1@cdc.gov						Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Das T, 1999, BIOCHEM BIOPH RES CO, V260, P105, DOI 10.1006/bbrc.1999.0712; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Henderson CJ, 2005, CELL DEATH DIFFER, V12, P1240, DOI 10.1038/sj.cdd.4401729; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Kruyt FAE, 2008, CANCER LETT, V263, P14, DOI 10.1016/j.canlet.2008.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu X, 2006, CANCER RES, V66, P11115, DOI 10.1158/0008-5472.CAN-06-2471; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagy K, 2006, PATHOL ONCOL RES, V12, P133, DOI 10.1007/BF02893359; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saulle E, 2007, APOPTOSIS, V12, P635, DOI 10.1007/s10495-006-0025-9; Steenland K, 1996, AM J IND MED, V30, P495, DOI 10.1002/(SICI)1097-0274(199610)30:4<495::AID-AJIM16>3.3.CO;2-I; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Voortman J, 2007, MOL CANCER THER, V6, P1046, DOI 10.1158/1535-7163.MCT-06-0577; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009; Yuan BZ, 2008, TRANSL ONCOL, V1, P129, DOI 10.1593/tlo.08133; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373	34	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3775	3786		10.1038/onc.2009.240	http://dx.doi.org/10.1038/onc.2009.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684616				2022-12-28	WOS:000271248400002
J	Akita, H; Zheng, Z; Takeda, Y; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Takemasa, I; Nagano, H; Dono, K; Nakamori, S; Monden, M; Mori, M; Doki, Y; Bepler, G				Akita, H.; Zheng, Z.; Takeda, Y.; Kim, C.; Kittaka, N.; Kobayashi, S.; Marubashi, S.; Takemasa, I.; Nagano, H.; Dono, K.; Nakamori, S.; Monden, M.; Mori, M.; Doki, Y.; Bepler, G.			Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; RRM1; ERCC1; AQUA; prognosis; gemcitabine	CELL LUNG-CANCER; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; PHASE-III TRIAL; MESSENGER-RNA LEVELS; FLUOROURACIL CHEMOTHERAPY; GEMCITABINE RESISTANCE; ADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; DNA-SYNTHESIS; SURVIVAL	The identification of molecular markers, useful for therapeutic decisions in pancreatic cancer patients, is crucial for advances in disease management. Gemcitabine, although a cornerstone of current therapy, has limited efficacy. RRM1 is a key molecule for gemcitabine efficacy and is also involved in tumor progression. We determined in situ RRM1 and excision repair cross complementation group 1 (ERCC1) protein levels in 68 pancreatic cancer patients. All had R0 resections without preoperative therapy. Protein levels were determined by automated quantitative analysis (AQUA), a fluorescence-based immunohistochemical method. The relationship between protein expressions and clinical outcomes, including response to gemcitabine at the time of disease recurrence, was determined. Patients with high RRM1 showed significantly better overall survival than patients with low expression (P = 0.0196). There was a trend toward better overall survival for patient with high ERCC1 (P = 0.0552). When both markers were considered together, patients with both high RRM1 and ERCC1 faired the best in terms of overall and disease-free survival (P = 0.0066, P = 0.0127). In addition, treatment benefit from gemcitabine in patients with disease recurrence was observed only in patients with low RRM1. The combination of RRM1 and ERCC1 expression is prognostic in pancreatic cancer patients after a complete resection. On disease recurrence, only patients with low RRM1 derive benefit from gemcitabine. Oncogene (2009) 28, 2903-2909; doi:10.1038/onc.2009.158; published online 22 June 2009	[Akita, H.; Takeda, Y.; Kim, C.; Kittaka, N.; Kobayashi, S.; Marubashi, S.; Takemasa, I.; Nagano, H.; Dono, K.; Monden, M.; Mori, M.; Doki, Y.] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; [Zheng, Z.; Bepler, G.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA; [Nakamori, S.] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan	Osaka University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Osaka National Hospital	Takeda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakeda@gesurg.med.osaka-u.ac.jp			National Institutes of Health (NIH) [R01-CA129343]; Ministry of Culture and Science of Japan; NATIONAL CANCER INSTITUTE [R01CA140314, R01CA129343] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Culture and Science of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by National Institutes of Health (NIH) grant R01-CA129343 to GB and by a grant-in-aid for cancer research from the Ministry of Culture and Science of Japan.	Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bepler G, 2004, J CLIN ONCOL, V22, P1878, DOI 10.1200/JCO.2004.12.002; Bepler G, 2006, J CLIN ONCOL, V24, P4731, DOI 10.1200/JCO.2006.06.1101; Bergman AM, 2005, CANCER RES, V65, P9510, DOI 10.1158/0008-5472.CAN-05-0989; Boeck S, 2008, J CLIN ONCOL, V26, P1178, DOI 10.1200/JCO.2007.15.3304; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Cao MY, 2003, CLIN CANCER RES, V9, P4553; Cascinu S, 2008, LANCET ONCOL, V9, P188, DOI 10.1016/S1470-2045(08)70042-1; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dumontet C, 1999, BRIT J HAEMATOL, V106, P78, DOI 10.1046/j.1365-2141.1999.01509.x; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203; Goan YG, 1999, CANCER RES, V59, P4204; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Jung CP, 2001, CLIN CANCER RES, V7, P2527; KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4; Kim MK, 2008, CLIN CANCER RES, V14, P4225, DOI 10.1158/1078-0432.CCR-07-4848; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li QD, 2000, ANTICANCER RES, V20, P645; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Nakahira S, 2007, INT J CANCER, V120, P1355, DOI 10.1002/ijc.22390; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; NITECKI SS, 1995, ANN SURG, V221, P59, DOI 10.1097/00000658-199501000-00007; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Okusaka T, 2008, CANCER CHEMOTH PHARM, V61, P615, DOI 10.1007/s00280-007-0514-8; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Reardon JT, 1999, CANCER RES, V59, P3968; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Saif MW, 2008, J PANCREAS, V9, P391; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Staley CA, 1996, AM J SURG, V171, P118, DOI 10.1016/S0002-9610(99)80085-3; Ueno H, 2005, ONCOLOGY-BASEL, V68, P171, DOI 10.1159/000086771; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411	48	94	97	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2903	2909		10.1038/onc.2009.158	http://dx.doi.org/10.1038/onc.2009.158			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19543324	Green Accepted			2022-12-28	WOS:000268917100006
J	Plo, I; Lopez, B				Plo, I.; Lopez, B.			AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells	ONCOGENE			English	Article						AKT1; BRCA1; homologous recombination; aneuploidy; centrosome; breast and ovary cancer	STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; MAMMALIAN RAD51; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; CANCER SUSCEPTIBILITY; G1 CHECKPOINT; BRCA1; PHOSPHORYLATION; INSTABILITY	The oncogenic kinase AKT1 is frequently overexpressed or activated in sporadic breast and ovarian cancers. In human breast tumors, we have previously shown that AKT1 represses homologous recombination (HR) induced by one double-strand break (DSB). To further analyze the impact of AKT1 on HR, we ectopically expressed wildtype or mutant forms of AKT1 in a hamster ovary cell line containing an intrachromosomal substrate for monitoring HR. In this cell line, AKT1 repressed HR induced by different genotoxic stresses including ionizing radiation, UV-C and one single DSB introduced into the intrachromosomal substrate. Consistently, AKT1 disrupted RAD51 foci formation, showing that AKT1 specifically affects gene conversion. Concomitantly, AKT1 represses both BRCA1 foci formation and HR stimulation resulting from BRCA1 overexpression, showing that AKT1 affects BRCA1-mediated HR functions, also in another species (hamster) and in another type of cell tissue (ovary cells). Finally, consistent with the HR defects, active AKT1 expression induces supernumerary centrosomes and aneuploidy. In addition to its impact on cell proliferation and apoptosis, the present data propose a novel oncogenic function for AKT1, by producing genomic instability as a consequence of HR repression. Oncogene (2009) 28, 2231-2237; doi: 10.1038/onc.2009.85; published online 27 April 2009	[Plo, I.; Lopez, B.] CEA, CNRS, Inst Radiobiol Cellulaire & Mol, UMR 217, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, B (corresponding author), CEA, CNRS, Inst Radiobiol Cellulaire & Mol, UMR, 18 Route Panorama,BAT 05, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017; Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021	Lopez, Bernard S/0000-0001-5088-0155; Plo, Isabelle/0000-0002-5915-6910; 	La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue; l'Agence Nationale de la Recherche; ARC fellowship	La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue; l'Agence Nationale de la Recherche(French National Research Agency (ANR)); ARC fellowship(Australian Research Council)	We thank Dr Hemmings (Friedrich Miescher Institute, Basel, Switzerland) for providing us the wtAKT1, myrAKT1 and kdAKT1 expression vectors, and Dr Jasin (Sloan-Kettering Institute, NYC, USA) for providing us with the CHO-DRA10 cell line and the I-SceI expression plasmid. This work was supported by La Ligue Nationale contre le Cancer 'Equipes labellisees, La Ligue 2005 and 2008' and by l'Agence Nationale de la Recherche. IP was a recipient of an ARC fellowship.	Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Daboussi F, 2005, ONCOGENE, V24, P3691, DOI 10.1038/sj.onc.1208438; Deans B, 2003, CANCER RES, V63, P8181; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hinton CV, 2007, EXP CELL RES, V313, P1735, DOI 10.1016/j.yexcr.2007.03.008; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Ivanov EL, 1996, GENETICS, V142, P693; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Saintigny Y, 2007, ONCOGENE, V26, P2769, DOI 10.1038/sj.onc.1210075; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yang HL, 2006, CANCER RES, V66, P3096, DOI 10.1158/0008-5472.CAN-05-3620; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	32	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2231	2237		10.1038/onc.2009.85	http://dx.doi.org/10.1038/onc.2009.85			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398948				2022-12-28	WOS:000266640300005
J	Teufel, DP; Bycroft, M; Fersht, AR				Teufel, D. P.; Bycroft, M.; Fersht, A. R.			Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2	ONCOGENE			English	Article						CBP; IHD; Mdm4; fluorescence anisotropy; phospho-peptides; transactivation	ACTIVATION DOMAINS; IN-VIVO; BINDING; PROTEIN; STABILIZATION; TRANSCRIPTION; COACTIVATORS; ACETYLATION; COMPLEX; CBP	The transcriptional activity of the tumour suppressor, p53, requires direct binding between its transactivation domain (TAD, 1-57) and the transcriptional coactivator, p300. We systematically assessed the role of TAD phosphorylation on binding of the p300 domains CH3, Taz1, Kix and IBiD. Thr18 phosphorylation increased the affinity up to sevenfold for CH3 and Taz1, with smaller increases from phosphorylation of Ser20, Ser15, Ser37, Ser33, Ser46 and Thr55. Binding of Kix and IBiD was less sensitive to phosphorylation. Strikingly, hepta-phosphorylation of all Ser and Thr residues increased binding 40- and 80-fold with CH3 and Taz1, respectively, but not with Kix or IBiD. Substitution of all phospho-sites with aspartates partially mimicked the effects of hepta-phosphorylation. Mdm2, the main negative regulator of p53, competes with p300 for binding to TAD. Binding of Mdm2 to TAD was reduced significantly only on phosphorylation of Thr18 (sevenfold) or by hepta-phosphorylation (24-fold). The relative affinities of Mdm2 and p300 for p53 TAD can thus be changed by up to three orders of magnitude by phosphorylation. Accordingly, phosphorylation of Thr18 and hepta-phosphorylation dramatically shifts the balance towards favouring the binding of p300 with p53, and is thus likely to be an important factor in its regulation. Oncogene (2009) 28, 2112-2118; doi:10.1038/onc.2009.71; published online 13 April 2009	[Fersht, A. R.] Univ Cambridge, Ctr Mrc, Dept Chem, MRC Ctr Prot Engn, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Ctr Mrc, Dept Chem, MRC Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, England.	arf25@cam.ac.uk	Bycroft, Mark/D-9446-2017; Fersht, Alan R/B-2189-2008	Bycroft, Mark/0000-0002-0673-2216; Teufel, Daniel/0000-0002-6527-2117	Medical Research Council [MC_U105474168, U.1054.00.012(74168)] Funding Source: Medline; MRC [MC_U105474168] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown CJ, 2008, CELL CYCLE, V7, P608, DOI 10.4161/cc.7.5.5488; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chi SW, 2005, J BIOL CHEM, V280, P38795, DOI 10.1074/jbc.M508578200; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Knights CD, 2003, J BIOL CHEM, V278, P52890, DOI 10.1074/jbc.M300279200; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Legge GB, 2004, J MOL BIOL, V343, P1081, DOI 10.1016/j.jmb.2004.08.087; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Marine JC, 2004, CELL CYCLE, V3, P900; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Polley S, 2008, J MOL BIOL, V376, P8, DOI 10.1016/j.jmb.2007.11.082; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Teufel DP, 2007, P NATL ACAD SCI USA, V104, P7009, DOI 10.1073/pnas.0702010104; Teufel DP, 2003, BIOCHEMISTRY-US, V42, P1451, DOI 10.1021/bi026852o; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Wells M, 2008, P NATL ACAD SCI USA, V105, P5762, DOI 10.1073/pnas.0801353105; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zor T, 2002, J BIOL CHEM, V277, P42241, DOI 10.1074/jbc.M207361200	33	105	108	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2112	2118		10.1038/onc.2009.71	http://dx.doi.org/10.1038/onc.2009.71			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19363523	Green Accepted			2022-12-28	WOS:000266235800005
J	Guo, Y; Schoell, MC; Freeman, RS				Guo, Y.; Schoell, M. C.; Freeman, R. S.			The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIMEL	ONCOGENE			English	Article						VHL; BIMEL; renal cell carcinoma; apoptosis; protein stability	TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLASE; MOLECULAR-BASIS; GENE-PRODUCT; HIF-ALPHA; CANCER; PHOSPHORYLATION; EXPRESSION; COMPLEX; FAMILY	von Hippel-Lindau (VHL) disease is caused by germ-line mutations in the VHL tumor suppressor gene and is the most common cause of inherited renal cell carcinoma (RCC). Mutations in the VHL gene also occur in a large majority of sporadic cases of clear-cell RCC, which have high intrinsic resistance to chemotherapy and radiotherapy. Here we show that VHL-deficient RCC cells express lower levels of the proapoptotic Bcl-2 family protein BIMEL and are more resistant to etoposide and UV radiation-induced death compared to the same cells stably expressing the wild-type VHL protein (pVHL). Reintroducing pVHL into VHL-null cells increased the half-life of BIMEL protein without affecting its mRNA expression, and overexpressing pVHL inhibited BIMEL polyubiquitination. Suppressing pVHL expression with RNA interference resulted in a decrease in BIMEL protein and a corresponding decrease in the sensitivity of RCC cells to apoptotic stimuli. Directly inhibiting BIMEL expression in pVHL-expressing RCC cells caused a similar decrease in cell death. These results demonstrate that pVHL acts to promote BIMEL protein stability in RCC cells, and that destabilization of BIMEL in the absence of pVHL contributes to the increased resistance of VHL-null RCC cells to certain apoptotic stimuli.	[Schoell, M. C.; Freeman, R. S.] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Guo, Y.] Univ Rochester, Sch Med, Interdept Grad Program Neurosci, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Freeman, RS (corresponding author), Univ Rochester, Sch Med, Dept Physiol & Pharmacol, 601 Elmwood Ave,Room 4-6718, Rochester, NY 14642 USA.	robert_freeman@urmc.rochester.edu			National Institutes of Health [NS034400, NS058868]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS034400, R01NS034400, R01NS058868] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr William Kaelin for providing cell lines and Dr Thomas Benzing and Dr Patricia Hinkle for providing plasmids used in this study. This work was supported by grants NS034400 and NS058868 from the National Institutes of Health.	Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; Devarajan P, 2001, J BIOL CHEM, V276, P40599, DOI 10.1074/jbc.M103424200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ewings KE, 2007, CELL CYCLE, V6, P2236, DOI 10.4161/cc.6.18.4728; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Fu J, 2007, J BIOL CHEM, V282, P12410, DOI 10.1074/jbc.M608748200; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kim M, 2004, BIOCHEM BIOPH RES CO, V320, P945, DOI 10.1016/j.bbrc.2004.06.042; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Nyhan MJ, 2008, BIOCHEM SOC T, V36, P472, DOI 10.1042/BST0360472; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Qi H, 2003, CANCER RES, V63, P7076; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; van Houwelingen KP, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-57; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Xie L, 2005, J CELL BIOL, V168, P911, DOI 10.1083/jcb.200407079; YAGODA A, 1995, SEMIN ONCOL, V22, P42; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	42	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1864	1874		10.1038/onc.2009.35	http://dx.doi.org/10.1038/onc.2009.35			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305426	Green Accepted			2022-12-28	WOS:000265640500005
J	Yamazaki, D; Kurisu, S; Takenawa, T				Yamazaki, D.; Kurisu, S.; Takenawa, T.			Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates	ONCOGENE			English	Article						cancer; invasion; migration; mesenchymal; amoeboid; Rac	ACTIN-RELATED PROTEIN-2; PERICELLULAR PROTEOLYSIS; INVASION; MIGRATION; GTPASES; WAVE2; MODES; MECHANISMS; PLASTICITY; MEMBRANE	The motility of cancer cells in 3D matrices is of two types: mesenchymal motility, in which the cells are elongated and amoeboid motility, in which the cells are round. Amoeboid motility is driven by an actomyosin-based contractile force, which is regulated by the Rho/ROCK pathway. However, the molecular mechanisms underlying the motility of elongated cells remain unknown. Here, we show that the motility of elongated cells is regulated by Rac signaling through the WAVE2/Arp2/3-dependent formation of elongated pseudopodia and cell-substrate adhesion in 3D substrates. The involvement of Rac signaling in cell motility was different in cell lines that displayed an elongated morphology in 3D substrates. In U87MG glioblastoma cells, most of which exhibit mesenchymal motility, inhibition of Rac signaling blocked the invasion of these cells in 3D substrates. In HT1080 fibrosarcoma cells, which display mixed cell motility involving both elongated and rounded cells, inhibition of Rac1 signaling not only blocked mesenchymal motility but also caused a mesenchymal-amoeboid transition. Additionally, Rac1 and RhoA signaling regulated the mesenchymal and amoeboid motility in these cells, respectively, and the inhibition of both pathways dramatically decreased cell invasion. Hence, we could conclude that Rac1 and RhoA signaling simultaneously regulate cell invasion in 3D matrices.	[Takenawa, T.] Kobe Univ, Grad Sch Med, Lab Lipid Biochem, Dept Biochem & Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Yamazaki, D.] Kobe Univ, Grad Sch Med, Div Membrane Biol, Dept Biochem & Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; [Kurisu, S.] RIKEN, Brain Sci Inst, Lab Dev Gene Regulat, Brain Sci Inst,Inst Phys Chem Res, Saitama, Japan	Kobe University; Kobe University; RIKEN	Takenawa, T (corresponding author), Kobe Univ, Grad Sch Med, Lab Lipid Biochem, Dept Biochem & Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	takenawa@med.kobe-u.ac.jp	Kurisu, Shusaku/AAB-1799-2022	Kurisu, Shusaku/0000-0002-4876-4419				Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furutani M, 2006, J BIOCHEM, V139, P663, DOI 10.1093/jb/mvj076; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Iwaya K, 2007, CANCER SCI, V98, P992, DOI 10.1111/j.1349-7006.2007.00488.x; Iwaya K, 2007, MODERN PATHOL, V20, P339, DOI 10.1038/modpathol.3800741; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Ohta Y, 2006, NAT CELL BIOL, V8, P803, DOI 10.1038/ncb1437; Paluch E, 2006, TRENDS CELL BIOL, V16, P5, DOI 10.1016/j.tcb.2005.11.003; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Semba S, 2006, CLIN CANCER RES, V12, P2449, DOI 10.1158/1078-0432.CCR-05-2566; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Torka R, 2006, EXP CELL RES, V312, P3857, DOI 10.1016/j.yexcr.2006.08.025; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wilkinson S, 2005, NAT CELL BIOL, V7, P255, DOI 10.1038/ncb1230; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298	41	146	151	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1570	1583		10.1038/onc.2009.2	http://dx.doi.org/10.1038/onc.2009.2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234490				2022-12-28	WOS:000264780500002
J	Rattan, R; Narita, K; Chien, J; Maguire, JL; Shridhar, R; Giri, S; Shridhar, V				Rattan, R.; Narita, K.; Chien, J.; Maguire, J. L.; Shridhar, R.; Giri, S.; Shridhar, V.			TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappa B pathway	ONCOGENE			English	Article						TCEAL7; NF-kappa B; ovarian cancer; tumor suppressor gene	HUMAN OVARIAN-CARCINOMA; RNA-POLYMERASE-II; INDUCED APOPTOSIS; CANCER MODELS; EARLY-STAGE; IN-VITRO; EXPRESSION; CELLS; CHEMORESISTANCE; IDENTIFICATION	We have previously shown that a frequently downregulated gene, transcription elongation factor A-like 7 (TCEAL7), promoted anchorage-independent growth and modulated Myc activity in ovarian surface epithelial cells immortalized with temperature-sensitive large T antigen and human telomerase reverse transcriptase (OSEtsT/hTERT). Analysis of protein/DNA array showed that TCEAL7 downregulation resulted in an approximately twofold increase in nuclear factor (NF)-kappa B binding to its target DNA sequence. In this study we showed that short hairpin RNA (shRNA)-mediated downregulation of TCEAL7 in two different immortalized OSE cells showed higher NF-kappa B activity, as determined using reporter and gel-shift assays. Transient transfection of TCEAL7 inhibited the activation of NF-kappa B in TCEAL7-downregulated clones, IOSE-523 and in other ovarian cancer cell lines (OVCAR8, SKOV3ip and DOV13), suggesting that TCEAL7 negatively regulates NF-kappa B pathway. Consistent with this observation, TCEAL7-downregulated clones showed higher levels of NF-kappa B targets, such as pro-proliferative (cyclin-D1 and cMyc), pro-angiogenic (interleukin (IL)-6, IL-8 and vascular endothelial growth factor (VEGF)), inflammatory (intercellular adhesion molecule 1 (ICAM-1) and cyclooxygenase-2 (Cox-2)) and antiapoptotic (B-cell lymphoma-extra large (Bcl-xl)) genes when compared with vector controls. Inhibition of NF-kappa B by I kappa B kinase (IKK) inhibitor (BMS 345541) attenuated cell survival and proliferation of TCEAL-knockdown clones. Although TCEAL7 inhibited p65 transcriptional activity, it did not modulate the cytoplasmic signaling of the NF-kappa B pathway, by itself or by tumor necrosis factor alpha (TNF-alpha). Chromatin immunoprecipitation (ChIP) assays revealed increased recruitment of p65 and p300 to the promoters of IL-8 and IL-6 in TCEAL7-downregulated clones. Collectively, these results indicate a novel role for TCEAL7 in the negative regulation of NF-kappa B signaling at the basal level by modulating transcriptional activity of NF-kappa B on its target gene promoters, potentially providing a novel mechanism by which NF-kappa B activity may be deregulated in ovarian cancer cells. Oncogene (2010) 29, 1362-1373; doi:10.1038/onc.2009.431; published online 7 December 2009	[Rattan, R.; Chien, J.; Maguire, J. L.; Giri, S.; Shridhar, V.] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN 55905 USA; [Narita, K.] Univ Yamanashi, Fac Med, Dept Anat & Cell Biol, Chuo Ku, Yamanashi, Japan; [Shridhar, R.] Barbara Ann Karmanos Canc Inst, Gershenson Radiat Oncol Ctr, Detroit, MI USA	Mayo Clinic; University of Yamanashi; Barbara Ann Karmanos Cancer Institute	Shridhar, V (corresponding author), Mayo Clin, Coll Med, Dept Lab Med & Expt Pathol, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Narita, Keishi/E-3539-2010; Chien, Jeremy/AID-8939-2022; Seal, Sudipta/A-7698-2012	Narita, Keishi/0000-0002-7602-8523; Chien, Jeremy/0000-0003-4744-8374	Ovarian Cancer Research Fund; Mayo Foundation; Bernard and Edith Waterman Foundation	Ovarian Cancer Research Fund; Mayo Foundation; Bernard and Edith Waterman Foundation	This work was supported by Ovarian Cancer Research Fund to RR as a Program of Excellence grant and with funds from Mayo Foundation and Bernard and Edith Waterman Foundation to VS.	Abdollahi T, 2003, CANCER RES, V63, P4521; Aggarwal BB, 2004, EXPERT OPIN INV DRUG, V13, P1327, DOI 10.1517/13543784.13.10.1327; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Arlt A, 2002, INT J CLIN PHARM TH, V40, P336; Camp ER, 2004, J AM COLL SURGEONS, V199, P249, DOI 10.1016/j.jamcollsurg.2004.04.015; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Chien J, 2005, ONCOGENE, V24, P5089, DOI 10.1038/sj.onc.1208700; Chien J, 2008, ONCOGENE, V27, P7223, DOI 10.1038/onc.2008.360; Collinson FJ, 2008, EXPERT REV ANTICANC, V8, P21, DOI 10.1586/14737140.8.1.21; Ferrandina G, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-182; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIAVAZZI R, 1994, EUR J CANCER, V30A, P1865, DOI 10.1016/0959-8049(94)00345-6; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; Jeon C, 1996, P NATL ACAD SCI USA, V93, P13677, DOI 10.1073/pnas.93.24.13677; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; Kar R, 2007, CANCER BIOL THER, V6, P1101, DOI 10.4161/cbt.6.7.4329; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Mabuchi S, 2004, CLIN CANCER RES, V10, P7645, DOI 10.1158/1078-0432.CCR-04-0958; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mukai J, 2002, J BIOL CHEM, V277, P13973, DOI 10.1074/jbc.M106342200; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nath N, 2009, J IMMUNOL, V182, P8005, DOI 10.4049/jimmunol.0803563; Nilsson MB, 2007, J BIOL CHEM, V282, P29919, DOI 10.1074/jbc.M611539200; Opala T, 2003, EUR J GYNAECOL ONCOL, V24, P255; RAPP G, 1990, DNA CELL BIOL, V9, P479, DOI 10.1089/dna.1990.9.479; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Shridhar V, 2002, CANCER RES, V62, P262; Shridhar V, 2001, CANCER RES, V61, P5895; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Toutirais O, 2003, EUR CYTOKINE NETW, V14, P246; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; YEH CH, 1994, P NATL ACAD SCI USA, V91, P11002, DOI 10.1073/pnas.91.23.11002	35	33	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1362	1373		10.1038/onc.2009.431	http://dx.doi.org/10.1038/onc.2009.431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966855				2022-12-28	WOS:000275170600011
J	Zhang, H; Li, Y; Lai, M				Zhang, H.; Li, Y.; Lai, M.			The microRNA network and tumor metastasis	ONCOGENE			English	Review						microRNA; tumor; metastasis	BREAST-CANCER METASTASIS; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR; SUPPRESSOR GENE; MIR-200 FAMILY; PROSTATE-CANCER; LUNG-CANCER; REDUCED EXPRESSION; MIRNA EXPRESSION; REPRESSORS ZEB1	Metastasis is the most significant process affecting the clinical management of cancer patients and occurs in multiple sequential steps. However, the molecular pathways underlying each step still remain obscure. Recent research has shown that there is a microRNA (miRNA) network that functions as a regulator of tumor metastasis. In this paper, we review the role of miRNAs in tumor metastasis, including control of epithelial-mesenchymal transition, regulation of metastasis-associated genes and epigenetic alterations. More information on miRNAs will promote a better understanding of the molecular mechanism of metastasis. Oncogene (2010) 29, 937-948; doi:10.1038/onc.2009.406; published online 23 November 2009	[Zhang, H.; Li, Y.; Lai, M.] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University	Lai, M (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China.	lmp@zju.edu.cn						Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Albini A, 2008, CANCER METAST REV, V27, P75, DOI 10.1007/s10555-007-9111-x; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bandyopadhyay S, 2004, CANCER RES, V64, P7655, DOI 10.1158/0008-5472.CAN-04-1623; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Hunter Kent W, 2008, Breast Cancer Res, V10 Suppl 1, pS2, DOI 10.1186/bcr1988; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kim YI, 2009, ONCOL REP, V21, P159, DOI 10.3892/or_00000203; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee DY, 2007, P NATL ACAD SCI USA, V104, P20350, DOI 10.1073/pnas.0706901104; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Liu XD, 2009, BIOCHEM BIOPH RES CO, V380, P177, DOI 10.1016/j.bbrc.2009.01.066; Liu Xiqiang, 2009, Cancer Genomics & Proteomics, V6, P131; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lukes L, 2009, CANCER RES, V69, P310, DOI 10.1158/0008-5472.CAN-08-3520; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merkerova M, 2008, EUR J HAEMATOL, V81, P304, DOI 10.1111/j.1600-0609.2008.01111.x; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Neilson JR, 2007, GENE DEV, V21, P578, DOI 10.1101/gad.1522907; Nuyten Dimitry S A, 2006, Breast Dis, V26, P149; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Rinker-Schaeffer CW, 2006, CLIN CANCER RES, V12, P3882, DOI 10.1158/1078-0432.CCR-06-1014; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomida S, 2007, ONCOGENE, V26, P4600, DOI 10.1038/sj.onc.1210242; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tsuchiya S, 2009, NUCLEIC ACIDS RES, V37, P3821, DOI 10.1093/nar/gkp255; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang GF, 2008, FEBS LETT, V582, P3663, DOI 10.1016/j.febslet.2008.09.051; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wickramasinghe NS, 2009, NUCLEIC ACIDS RES, V37, P2584, DOI 10.1093/nar/gkp117; Williams AE, 2007, DEV DYNAM, V236, P572, DOI 10.1002/dvdy.21047; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang K, 2009, INT J CLIN EXP PATHO, V2, P361; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	120	156	177	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					937	948		10.1038/onc.2009.406	http://dx.doi.org/10.1038/onc.2009.406			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935707				2022-12-28	WOS:000274604400001
J	Lenferink, AEG; Cantin, C; Nantel, A; Wang, E; Durocher, Y; Banville, M; Paul-Roc, B; Marcil, A; Wilson, MR; O'Connor-McCourt, MD				Lenferink, A. E. G.; Cantin, C.; Nantel, A.; Wang, E.; Durocher, Y.; Banville, M.; Paul-Roc, B.; Marcil, A.; Wilson, M. R.; O'Connor-McCourt, M. D.			Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies	ONCOGENE			English	Article						TGF-beta; clusterin; EMT; invasion; breast cancer	GROWTH-FACTOR-BETA; BREAST-CANCER METASTASIS; NECROSIS-FACTOR-ALPHA; RENAL-CELL CARCINOMA; MOUSE MAMMARY-TUMOR; RETE TESTIS FLUID; PROSTATE-CANCER; GENE-EXPRESSION; CLUSTERIN/APOLIPOPROTEIN-J; ANTISENSE OLIGONUCLEOTIDE	Transforming growth factor (TGF)-beta plays a dual role in tumorigenesis, switching from acting as a growth inhibitory tumor suppressor early in the process, to a tumor promoter in late-stage disease. Since TGF-beta's prometastatic role may be linked to its ability to induce tumor cell epithelial-to-mesenchymal transition (EMT), we explored TGF-beta's EMT-promoting pathways by analysing the transcriptome changes occurring in BRI-JM01 mammary tumor epithelial cells undergoing a TGF-beta-induced EMT. We found the clusterin gene to be the most highly upregulated throughout most of the TGF-beta time course, and showed that this results in an increase of the secreted form of clusterin. By monitoring several hallmark features of EMT, we demonstrated that antibodies targeting secreted clusterin inhibit the TGF-beta-induced EMT of BRI-JM01 cells, as well as the invasive phenotype of several other breast and prostate tumor cell lines (4T1, NMuMG, MDA-MB231LM2 and PC3), without affecting the proliferation of these cells. These results indicate that secreted clusterin is a functionally important EMT mediator that lies downstream within TGF-beta's EMT-promoting transcriptional cascade, but not within its growth-inhibitory pathways. To further investigate the role played by secreted clusterin in tumor metastasis, we assessed the effect of several anti-clusterin monoclonal antibodies in vivo using a 4T1 syngeneic mouse breast cancer model and found that these antibodies significantly reduce lung metastasis. Taken together, our results reveal a role for secreted clusterin as an important extracellular promoter of EMT, and suggest that antibodies targeting clusterin may inhibit tumor metastasis without reducing the beneficial growth inhibitory effects of TGF-beta. Oncogene (2010) 29, 831-844; doi:10.1038/onc.2009.399; published online 23 November 2009	[Lenferink, A. E. G.; Cantin, C.; Banville, M.; Paul-Roc, B.; O'Connor-McCourt, M. D.] Natl Res Council Canada, Receptor Signaling & Prote Grp, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [Nantel, A.; Marcil, A.] Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, Montreal, PQ H4P 2R2, Canada; [Wang, E.] Natl Res Council Canada, Biotechnol Res Inst, Computat Chem & Biol Grp, Montreal, PQ H4P 2R2, Canada; [Durocher, Y.] Natl Res Council Canada, Biotechnol Res Inst, Anim Cell Culture Technol Grp, Montreal, PQ H4P 2R2, Canada; [Wilson, M. R.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia	National Research Council Canada; National Research Council Canada; National Research Council Canada; National Research Council Canada; University of Wollongong	Lenferink, AEG (corresponding author), Natl Res Council Canada, Receptor Signaling & Prote Grp, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	anne.lenferink@cnrc-nrc.gc.ca	Wilson, Mark R/B-3254-2018; Wang, Edwin/Y-1553-2019; Durocher, Yves/K-8709-2019	Wilson, Mark R/0000-0002-9551-7445; Marcil, Anne/0000-0002-4111-1781				Al Moustafa AE, 1999, BIOTECHNIQUES, V27, P60; Ammar H, 2008, J BIOL CHEM, V283, P12851, DOI 10.1074/jbc.M800403200; Andersen CL, 2007, MOL CELL PROTEOMICS, V6, P1039, DOI 10.1074/mcp.M600261-MCP200; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Chi KN, 2005, J NATL CANCER I, V97, P1287, DOI 10.1093/jnci/dji252; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chou TY, 2009, CELL SIGNAL, V21, P704, DOI 10.1016/j.cellsig.2009.01.008; Cochrane DR, 2007, J BIOL CHEM, V282, P2278, DOI 10.1074/jbc.M608162200; DALAL BI, 1993, AM J PATHOL, V143, P381; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enjalbert B, 2003, MOL BIOL CELL, V14, P1460, DOI 10.1091/mbc.E02-08-0546; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Hunakova L, 2009, NEOPLASMA, V56, P548, DOI 10.4149/neo_2009_06_548; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Lakins JN, 2002, BIOCHEMISTRY-US, V41, P282, DOI 10.1021/bi0157666; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; Lee KB, 2008, BIOCHEM BIOPH RES CO, V366, P905, DOI 10.1016/j.bbrc.2007.12.033; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Lenferink AE, 2004, BREAST CANCER RES, V6, pR514, DOI 10.1186/bcr907; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyake H, 2000, CANCER RES, V60, P2547; Miyake H, 2002, J UROLOGY, V167, P2203, DOI 10.1016/S0022-5347(05)65129-4; Miyake H, 2002, J UROLOGY, V167, P703, DOI 10.1016/S0022-5347(01)69130-4; Moretti RM, 2007, CANCER RES, V67, P10325, DOI 10.1158/0008-5472.CAN-07-0516; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206; Nam JS, 2006, CANCER RES, V66, P6327, DOI 10.1158/0008-5472.CAN-06-0068; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Park DC, 2008, NEOPLASIA, V10, P964, DOI 10.1593/neo.08604; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Santilli G, 2003, J BIOL CHEM, V278, P38214, DOI 10.1074/jbc.C300252200; Scaltriti M, 2004, BRIT J CANCER, V91, P1842, DOI 10.1038/sj.bjc.6602193; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sintich SM, 1999, PROSTATE, V39, P87; So A, 2005, MOL CANCER THER, V4, P1837, DOI 10.1158/1535-7163.MCT-05-0178; So A, 2005, CURR OPIN UROL, V15, P320, DOI 10.1097/01.mou.0000175572.46986.2c; So A, 2005, WORLD J UROL, V23, P1, DOI 10.1007/s00345-004-0473-1; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOM R, 2007, METHODS EXPRESS EXPR, P203; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2005, FREE RADICAL BIO MED, V38, P436, DOI 10.1016/j.freeradbiomed.2004.10.038; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wegrowski Y, 1999, EXP CELL RES, V247, P475, DOI 10.1006/excr.1998.4378; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	87	75	86	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					831	844		10.1038/onc.2009.399	http://dx.doi.org/10.1038/onc.2009.399			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935703				2022-12-28	WOS:000274397800006
J	Davidson, L; Maccario, H; Perera, NM; Yang, X; Spinelli, L; Tibarewal, P; Glancy, B; Gray, A; Weijer, CJ; Downes, CP; Leslie, NR				Davidson, L.; Maccario, H.; Perera, N. M.; Yang, X.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Weijer, C. J.; Downes, C. P.; Leslie, N. R.			Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN	ONCOGENE			English	Article						PTEN; PI3 kinase; phosphoinositide; cancer; TPIP; Akt	TUMOR-SUPPRESSOR; GLIOMA-CELLS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GLIOBLASTOMA CELLS; BINDING MOTIF; NUCLEAR PTEN; GROWTH; ACTIVATION; MIGRATION; EXPRESSION	PTEN is a tumour suppressor with phosphatase activity in vitro against both lipids and proteins and other potential non-enzymatic mechanisms of action. Although the importance of PTEN's lipid phosphatase activity in regulating the PI3K signalling pathway is recognized, the significance of PTEN's other mechanisms of action is currently unclear. In this study, we describe the systematic identification of a PTEN mutant, PTEN Y138L, with activity against lipid, but not soluble substrates. Using this mutant, we provide evidence for the interfacial activation of PTEN against lipid substrates. We also show that when re-expressed at physiological levels in PTEN null U87MG glioblastoma cells, the protein phosphatase activity of PTEN is not required to regulate cellular PtdInsP(3) levels or the downstream protein kinase Akt/PKB. Finally, in three-dimensional Matrigel cultures of U87MG cells similarly re-expressing PTEN mutants, both the protein and lipid phosphatase activities were required to inhibit invasion, but either activity alone significantly inhibited proliferation, albeit only weakly for the protein phosphatase activity. Our data provide a novel tool to address the significance of PTEN's separable lipid and protein phosphatase activities and suggest that both activities suppress proliferation and together suppress invasion. Oncogene (2010) 29, 687-697; doi: 10.1038/onc.2009.384; published online 16 November 2009	[Davidson, L.; Maccario, H.; Perera, N. M.; Spinelli, L.; Tibarewal, P.; Glancy, B.; Gray, A.; Downes, C. P.; Leslie, N. R.] Univ Dundee, Div Mol Physiol, Coll Life Sci, Dundee DD1 5EH, Scotland; [Yang, X.; Weijer, C. J.] Univ Dundee, Div Cell & Dev Biol, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Leslie, NR (corresponding author), Univ Dundee, Div Mol Physiol, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Leslie, Nicholas/D-2699-2009; weijer, cornelis j/I-4538-2012	LESLIE, Nicholas/0000-0001-5131-0541; Tibarewal, Priyanka/0000-0003-3510-8428; Gray, Alexander/0000-0001-9227-0363; Weijer, Cornelis/0000-0003-2192-8150; Spinelli, Laura/0000-0002-5801-6297	Medical Research Council; Association for International Cancer Research; DSTT consortium; MRC [G0801865, G9403619] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [G18071] Funding Source: researchfish; Medical Research Council [G0801865, G9403619] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Association for International Cancer Research; DSTT consortium; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Sam Swift and Paul Appleton from the Dundee Light Microscopy Facility for their help with image acquisition and analysis. We thank Hilary McLauchlan, James Hastie and their staff in the DSTT (University of Dundee) for provision of purified antibodies and recombinant protein kinases and Steven Hubbard for advice regarding data analysis. NL is an RCUK Academic Fellow. Work in the Inositol Lipid Signalling laboratory was funded by the Medical Research Council, the Association for International Cancer Research and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck KGaA and Pfizer).	Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Cheney IW, 1998, CANCER RES, V58, P2331; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Davies MA, 1998, CANCER RES, V58, P5285; de Bouard S, 2002, J NEUROSURG, V97, P169, DOI 10.3171/jns.2002.97.1.0169; Deleu S, 2006, CELL SIGNAL, V18, P488, DOI 10.1016/j.cellsig.2005.05.017; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gil A, 2007, CELL DEATH DIFFER, V14, P395, DOI 10.1038/sj.cdd.4402073; Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599; Goldbrunner RH, 1998, MICROSC RES TECHNIQ, V43, P250, DOI 10.1002/(SICI)1097-0029(19981101)43:3<250::AID-JEMT7>3.0.CO;2-C; Gray A, 2003, ANAL BIOCHEM, V313, P234, DOI 10.1016/S0003-2697(02)00607-3; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hjelmeland AB, 2005, CANCER RES, V65, P11276, DOI 10.1158/0008-5472.CAN-05-3016; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Ikeda Y, 2003, NAT BIOTECHNOL, V21, P569, DOI 10.1038/nbt815; Ji SP, 2006, NAT MED, V12, P324, DOI 10.1038/nm1349; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Lackey J, 2007, ONCOGENE, V26, P7132, DOI 10.1038/sj.onc.1210520; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Mahimainathan L, 2004, J BIOL CHEM, V279, P15258, DOI 10.1074/jbc.M314328200; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ning K, 2006, EMBO J, V25, P2377, DOI 10.1038/sj.emboj.7601118; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Orchiston EA, 2004, J BIOL CHEM, V279, P1116, DOI 10.1074/jbc.M310933200; Park MJ, 2002, CANCER RES, V62, P6318; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tapparel C, 2003, GENE, V323, P189, DOI 10.1016/j.gene.2003.09.038; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; Yang XS, 2002, DEV CELL, V3, P425, DOI 10.1016/S1534-5807(02)00256-3	49	96	100	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					687	697		10.1038/onc.2009.384	http://dx.doi.org/10.1038/onc.2009.384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915616	Green Accepted			2022-12-28	WOS:000274223700006
J	Krishnan, M; Singh, AB; Smith, JJ; Sharma, A; Chen, X; Eschrich, S; Yeatman, TJ; Beauchamp, RD; Dhawan, P				Krishnan, M.; Singh, A. B.; Smith, J. J.; Sharma, A.; Chen, X.; Eschrich, S.; Yeatman, T. J.; Beauchamp, R. D.; Dhawan, P.			HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability	ONCOGENE			English	Article						tight junction; claudin-1; invasion; TSA; HDAC	HISTONE DEACETYLASE INHIBITORS; BREAST-CARCINOMA CELLS; TRICHOSTATIN-A; GENE; TUMORIGENESIS; GROWTH	Expression and cellular distribution of claudin-1, a tight junction protein, is dysregulated in colon cancer and its overexpression in colon cancer cells induced dedifferentiation and increased invasion. However, the molecular mechanism(s) underlying dysregulated claudin-1 expression in colon cancer remains poorly understood. Histone deacetylase (HDAC)-dependent histone acetylation is an important mechanism of the regulation of cancer-related genes and inhibition of HDACs induces epithelial differentiation and decreased invasion. Therefore, in this study, we examined the role of HDAC-dependent epigenetic regulation of claudin-1 in colon cancer. In this study, we show that sodium butyrate and Trichostatin A (TSA), two structurally different and widely used HDAC inhibitors, inhibited claudin-1 expression in multiple colon cancer cell lines. Further studies revealed modulation of claudin-1 mRNA stability by its 3'-UTR as the major mechanism underlying HDAC-dependent claudin-1 expression. In addition, overexpression of claudin-1 abrogated the TSA-induced inhibition of invasion in colon cancer cells suggesting functional crosstalk. Analysis of mRNA expression in colon cancer patients, showed a similar pattern of increase in claudin-1 and HDAC-2 mRNA expression throughout all stages of colon cancer. Inhibition of claudin-1 expression by HDAC-2-specific small interfering RNA further supported the role of HDAC-2 in this regulation. Taken together, we report a novel post-transcriptional regulation of claudin-1 expression in colon cancer cells and further show a functional correlation between claudin-1 expression and TSA-mediated regulation of invasion. As HDAC inhibitors are considered to be promising anticancer drugs, these new findings will have implications in both laboratory and clinical settings. Oncogene (2010) 29, 305-312; doi:10.1038/onc.2009.324; published online 2 November 2009	[Dhawan, P.] Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, Nashville, TN 37240 USA; [Smith, J. J.; Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37240 USA; [Chen, X.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37240 USA; [Eschrich, S.; Yeatman, T. J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Beauchamp, R. D.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37240 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; Vanderbilt University	Dhawan, P (corresponding author), Vanderbilt Univ, Dept Surg, Med Ctr, MCN,Div Surg Oncol, B-2211, Nashville, TN 37240 USA.	punita.dhawan@vanderbilt.edu	Smith, Jesse Joshua/AAN-5440-2020; Sharma, Ashok/AAE-5439-2019; Eschrich, Steven/K-6848-2013	Smith, Jesse Joshua/0000-0003-2538-5456; Sharma, Ashok/0000-0001-7505-6023; Eschrich, Steven/0000-0002-9833-2788; Beauchamp, Robert Daniel/0000-0002-8446-4114	NIH [CA119005, CA124977, DK58404]; AHA [0435471N, 5P50DK044757, P30DK058406]; Society of University Surgeons-Ethicon Scholarship Award [CA112215, DK052334, CA 069457]; GI Cancer SPORE [CA95103]; Vanderbilt-Ingram Cancer Center [P30CA68485]; NATIONAL CANCER INSTITUTE [R01CA124977, P30CA068485, R01CA069457, R21CA119005, R01CA112215, P50CA095103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK044757, P30DK058404, R01DK052334] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHA(American Heart Association); Society of University Surgeons-Ethicon Scholarship Award; GI Cancer SPORE; Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant CA119005, CA124977 (P Dhawan), and AHA Grant 0435471N, 5P50DK044757 and P30DK058406 Pilot project (AB Singh), the Society of University Surgeons-Ethicon Scholarship Award (JJS) CA112215 (TJ Yeatman), DK052334, CA 069457, the GI Cancer SPORE grant CA95103 (RD Beauchamp), the Vanderbilt-Ingram Cancer Center P30CA68485 and the NIH grant supporting the Digestive Diseases Center DK58404. We thank Christian Kis for the help in real-time quantitative reverse transcription-PCR analysis.	Abuazza G, 2006, AM J PHYSIOL-RENAL, V291, pF1132, DOI 10.1152/ajprenal.00063.2006; Chavey C, 2008, MOL PHARMACOL, V74, P1359, DOI 10.1124/mol.108.047332; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Dokmanovic M, 2005, J CELL BIOCHEM, V96, P293, DOI 10.1002/jcb.20532; Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561; Honda H, 2007, CANCER BIOL THER, V6, P1733, DOI 10.4161/cbt.6.11.4832; Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200; Liu PY, 2008, MOL CANCER RES, V6, P1204, DOI 10.1158/1541-7786.MCR-08-0123; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nishikiori N, 2008, JPN J OPHTHALMOL, V52, P195, DOI 10.1007/s10384-008-0524-z; Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x; Osanai M, 2007, CANCER SCI, V98, P1027, DOI 10.1111/j.1349-7006.2007.00494.x; Pesole G, 2001, GENE, V276, P73, DOI 10.1016/S0378-1119(01)00674-6; Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0; Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Wu Y, 2007, REPROD SCI, V14, P374, DOI 10.1177/1933719107302913; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	20	73	74	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					305	312		10.1038/onc.2009.324	http://dx.doi.org/10.1038/onc.2009.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19881542	Green Accepted			2022-12-28	WOS:000273650000013
J	Ming, M; Han, W; Maddox, J; Soltani, K; Shea, CR; Freeman, DM; He, YY				Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y			UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes	ONCOGENE			English	Article						PTEN; UVB; keratinocytes; AKT	NONMELANOMA SKIN-CANCER; TUMOR-SUPPRESSOR; GERMLINE MUTATIONS; GENE; APOPTOSIS; PHOSPHORYLATION; TRANSFORMATION; PROGRESSION; PTEN/MMAC1; EXPRESSION	Ultraviolet (UV) radiation in sunlight is the major environmental cause of skin cancer. PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a proven critical tumor suppressor. We report here that UVB downregulates PTEN in primary human keratinocytes, human HaCaT keratinocytes and mouse skin. As compared with normal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by solar UV. PTEN downregulation is mediated by two mechanisms: (1) PTEN is cleaved by active caspase in apoptotic cells in which AKT activation is reduced; and (2) PTEN transcription is suppressed in surviving cells, and this suppression is independent of caspase activation and occurs in parallel with increased ERK and AKT activation. We report here that the combination of ERK and AKT activation is crucial for PTEN suppression in surviving cells following UVB irradiation. AKT activation is higher in UVB-irradiated surviving cells as compared with unirradiated cells. The ERK and AKT pathways are involved in sustaining PTEN suppression in UVB-exposed cells. Increasing PTEN expression enhances apoptosis of keratinocytes in response to UVB irradiation. Our findings indicate that (1) UVB radiation suppresses PTEN expression in keratinocytes; and (2) the ERK/AKT/PTEN axis may form a positive feedback loop following UVB irradiation. Our identification of PTEN as a critical molecular target of UVB provides new insights into the pathogenesis of skin cancer. Oncogene (2010) 29, 492-502; doi: 10.1038/onc.2009.357; published online 2 November 2009	[Ming, M.; Han, W.; Maddox, J.; Soltani, K.; Shea, C. R.; Freeman, D. M.; He, Y-Y] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago	He, YY (corresponding author), Univ Chicago, Dermatol Sect, Dept Med, 5841 S Maryland Ave,MC5067, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021		Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center [P30 CA014599]; Wendy Will Case Cancer Fund Inc.; CTSA [NIH UL1RR024999]; University of Chicago; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	Department of Medicine and the Section of Dermatology at the University of Chicago; American Skin Association to the University of Chicago Cancer Research Center; Wendy Will Case Cancer Fund Inc.; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago(University of Chicago); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the Department of Medicine and the Section of Dermatology at the University of Chicago, the American Skin Association to the University of Chicago Cancer Research Center (P30 CA014599), the Wendy Will Case Cancer Fund Inc., the CTSA (NIH UL1RR024999), and the University of Chicago 'Friends of Dermatology' Endowment Fund. We thank Terri Li for PTEN immunohistochemistry. We are grateful to Dr Christopher Kontos for the adenoviral PTEN vector and Dr William Sellers for the HA-PTEN plasmid.	Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Birck A, 2000, J INVEST DERMATOL, V114, P277, DOI 10.1046/j.1523-1747.2000.00877.x; BODE AM, 2003, SCI STKE, pRE2; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Byun DS, 2003, INT J CANCER, V104, P318, DOI 10.1002/ijc.10962; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIFFEY BL, 1991, CLIN PHYS PHYSIOL M, V12, P311, DOI 10.1088/0143-0815/12/4/001; DIFFEY BL, 1991, PHYS MED BIOL, V36, P299, DOI 10.1088/0031-9155/36/3/001; Erb P, 2008, ADV EXP MED BIOL, V624, P283, DOI 10.1007/978-0-387-77574-6_22; Grzanka D, 2006, NEOPLASMA, V53, P328; Harima Y, 2001, INT J ONCOL, V18, P493; He YY, 2008, PHOTOCHEM PHOTOBIOL, V84, P69, DOI 10.1111/j.1751-1097.2007.00199.x; He YY, 2008, CANCER RES, V68, P3752, DOI 10.1158/0008-5472.CAN-07-6138; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2004, J INVEST DERMATOL, V122, P533, DOI 10.1046/j.0022-202X.2003.22123.x; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Li G, 2002, DEVELOPMENT, V129, P4159; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Polo SE, 2006, CELL, V127, P481, DOI 10.1016/j.cell.2006.08.049; Ramos J, 2004, CANCER EPIDEM BIOMAR, V13, P2006; Rigel DS, 2008, J AM ACAD DERMATOL, V58, pS129, DOI 10.1016/j.jaad.2007.04.034; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Wong JW, 2000, J INVEST DERMATOL, V115, P427, DOI 10.1046/j.1523-1747.2000.00077.x	33	47	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					492	502		10.1038/onc.2009.357	http://dx.doi.org/10.1038/onc.2009.357			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881543	Green Accepted			2022-12-28	WOS:000274084600003
J	Li, X; Shen, Y; Ichikawa, H; Antes, T; Goldberg, GS				Li, X.; Shen, Y.; Ichikawa, H.; Antes, T.; Goldberg, G. S.			Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration	ONCOGENE			English	Article						Src; contact normalization; cell communication; anchorage independence; migration; cancer	GAP JUNCTIONAL COMMUNICATION; BREAST-CANCER; MICRORNA EXPRESSION; TRANSFORMED-CELLS; HEPATOCELLULAR-CARCINOMA; NONTRANSFORMED CELLS; IN-VIVO; V-CRK; INHIBITION; INVASION	Transformation by the Src tyrosine kinase (Src) promotes nonanchored cell growth and migration. However, non-transformed cells can force Src-transformed cells to assume a normal morphology and phenotype by a process called 'contact normalization'. It has become clear that microRNA (miRNA) can affect tumorigenesis by targeting gene products that direct cell growth and migration. However, the roles of miRNA in Src transformation or contact normalization have not yet been reported. We examined the expression of 95 miRNAs and found 9 of them significantly affected by Src. In this study, we report that miR-218 and miR-224 were most significantly induced by Src, but not affected by contact normalization. In contrast, miR-126 was most significantly suppressed by Src and was induced by contact normalization in transformed cells. Mir-126 targets Crk, a component of the focal adhesion network that participates in events required for tumor cell migration. Accordingly, we show that miR-126 expression correlates inversely with Crk levels, motility and the invasive potential of human mammary carcinoma cells. Moreover, we show that miR-224 expression promotes nonanchored growth of nontransformed cells. These data reveal novel insights into how Src regulates miRNA expression to promote hallmarks of tumor cell growth and invasion, and how nontransformed cells can affect miRNA expression in adjacent tumor cells to inhibit this process. Oncogene (2009) 28, 4272-4283; doi: 10.1038/onc.2009.278; published online 21 September 2009	[Li, X.; Shen, Y.; Goldberg, G. S.] Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ 08084 USA; [Li, X.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Stratford, NJ 08084 USA; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; [Antes, T.] Syst Biosci SBI, Mountain View, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Cancer Center - Japan	Goldberg, GS (corresponding author), Univ Med & Dent New Jersey, Dept Mol Biol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	gary.goldberg@umdnj.edu		Antes, Travis/0000-0002-2294-8797	United States National Institutes of Health [CA88805]; Research Foundation of UMDNJ; Marks and Holzman families; Ministry of Education, Culture, Sports, Science and Technology of Japan; NATIONAL CANCER INSTITUTE [R01CA088805] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Foundation of UMDNJ; Marks and Holzman families; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Xiaofeng Ye and Reuben Lotan (MD Anderson Cancer Center) for helpful suggestions and for the gifts of cells, and Min Han (UMDNJ) for technical assistance. This study was supported by a grant from the United States National Institutes of Health (CA88805), the Research Foundation of UMDNJ, and the Marks and Holzman families to GSG, and by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan to HI.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Alexander DB, 2004, CANCER RES, V64, P1347, DOI 10.1158/0008-5472.CAN-03-2558; Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BIGNAMI M, 1988, ONCOGENE, V2, P509; Blenkiron C, 2007, HUM MOL GENET, V16, pR106, DOI 10.1093/hmg/ddm056; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 1996, ONCOGENE, V12, P2467; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DUBIK D, 1987, CANCER RES, V47, P6517; ENOMOTO T, 1984, CANCER RES, V44, P5200; ESINDUY CB, 1995, CARCINOGENESIS, V16, P915, DOI 10.1093/carcin/16.4.915; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Glick AB, 2005, SEMIN CANCER BIOL, V15, P75, DOI 10.1016/j.semcancer.2004.08.008; GOLDBERG GS, 1994, MOL CARCINOGEN, V11, P106, DOI 10.1002/mc.2940110208; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; GOLDBERG GS, 2008, ENCY CANC; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; HENNINGS H, 1990, CANCER RES, V50, P4794; Holst CR, 2003, CANCER RES, V63, P1596; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jeffrey SS, 2008, NAT BIOTECHNOL, V26, P400, DOI 10.1038/nbt0408-400; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; LIU B, 2009, LUNG CANC IN PRESS, P126; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARTIN W, 1991, CANCER RES, V51, P5348; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; Rubin H, 2006, BIOESSAYS, V28, P515, DOI 10.1002/bies.20403; Rubin H, 2008, ADV CANCER RES, V100, P159, DOI 10.1016/S0065-230X(08)00006-7; Rubin H, 2008, P NATL ACAD SCI USA, V105, P6215, DOI 10.1073/pnas.0800747105; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; STOKER MGP, 1966, J CELL SCI, V1, P297; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Vaccariello M, 1999, J INVEST DERMATOL, V113, P384, DOI 10.1046/j.1523-1747.1999.00701.x; Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985; Valiunas V, 2005, BIOCHEM BIOPH RES CO, V333, P174, DOI 10.1016/j.bbrc.2005.05.104; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x; Widschwendter M, 1997, CANCER RES, V57, P4158; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089	71	38	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4272	4283		10.1038/onc.2009.278	http://dx.doi.org/10.1038/onc.2009.278			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19767772				2022-12-28	WOS:000272876300005
J	Luo, W; Gangwal, K; Sankar, S; Boucher, KM; Thomas, D; Lessnick, SL				Luo, W.; Gangwal, K.; Sankar, S.; Boucher, K. M.; Thomas, D.; Lessnick, S. L.			GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance	ONCOGENE			English	Article						Ewing's sarcoma; EWS/FLI; GSTM4; transformation	GLUTATHIONE-S-TRANSFERASE; CELL-DEATH; GENE; GROWTH; TRANSLOCATION; REPRESSION; PHENOTYPE; FUSION; FAMILY; NKX2.2	Ewing's sarcoma is a malignant bone-associated tumor of children and young adults. Most cases of Ewing's sarcoma express the EWS/FLI fusion protein. EWS/FLI functions as an aberrant ETS-type transcription factor and serves as the master regulator of Ewing's sarcoma-transformed phenotype. We recently showed that EWS/FLI regulates one of its key targets, NR0B1, through a GGAA-microsatellite in its promoter. Whether other critical EWS/FLI targets are also regulated by GGAA-microsatellites was unknown. In this study, we combined transcriptional analysis, whole genome localization data, and RNA interference knockdown to identify glutathione S-transferase M4 (GSTM4) as a critical EWS/FLI target gene in Ewing's sarcoma. We found that EWS/FLI directly binds the GSTM4 promoter, and regulates GSTM4 expression through a GGAA-microsatellite in its promoter. Reduction of GSTM4 levels caused a loss of oncogenic transformation. Furthermore, reduction of GSTM4 resulted in an increased sensitivity of Ewing's sarcoma cells to chemotherapeutic agents, suggesting a role for this protein in drug resistance. Consistent with this hypothesis, patients with Ewing's sarcoma whose tumors had higher levels of GSTM4 expression had worse outcomes than those with lower expression levels. These data show that GSTM4 contributes to the cancerous behavior of Ewing's sarcoma and define a wider role for GGAA-microsatellites in EWS/FLI function than previously appreciated. These data also suggest a novel therapeutic resistance mechanism, in which the central oncogenic abnormality directly regulates a resistance gene. Oncogene (2009) 28, 4126-4132; doi:10.1038/onc.2009.262; published online 31 August 2009	[Luo, W.; Gangwal, K.; Sankar, S.; Lessnick, S. L.] Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Luo, W.; Gangwal, K.; Sankar, S.; Boucher, K. M.; Lessnick, S. L.] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Thomas, D.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu	SANKAR, SAVITA/R-6821-2017	Boucher, Kenneth/0000-0003-2833-0127	Shriver Sarcoma Initiative; Sunbeam Foundation; Huntsman Cancer Institute/Huntsman Cancer Foundation; Alex's Lemonade Stand Foundation; NIH [P30 CA042014]; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	Shriver Sarcoma Initiative; Sunbeam Foundation; Huntsman Cancer Institute/Huntsman Cancer Foundation; Alex's Lemonade Stand Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Andrea Bild and Matt Topham for critical reading of the manuscript; Nikko Ronquillo, Mohan Kaadige and Kym Zumbrennen for technical assistance; and Elizabeth Leibold and members of the Lessnick laboratory for helpful discussions. This work was supported by funds awarded to SLL from the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, the Sunbeam Foundation and Huntsman Cancer Institute/Huntsman Cancer Foundation, and by a grant to WL from the Alex's Lemonade Stand Foundation. We also acknowledge the NIH support to the Huntsman Cancer Institute (P30 CA042014).	ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Camp RL, 2008, J CLIN ONCOL, V26, P5630, DOI 10.1200/JCO.2008.17.3567; COMSTOCK KE, 1993, J BIOL CHEM, V268, P16958; COMSTOCK KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P487, DOI 10.1006/abbi.1994.1266; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DuBois SG, 2009, PEDIATR BLOOD CANCER, V52, P324, DOI 10.1002/pbc.21822; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Liloglou T, 2002, LUNG CANCER-J IASLC, V37, P143, DOI 10.1016/S0169-5002(02)00078-8; Magwere T, 2008, EUR J CANCER, V44, P2276, DOI 10.1016/j.ejca.2008.06.008; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Myatt SS, 2008, ONCOGENE, V27, P985, DOI 10.1038/sj.onc.1210705; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927	24	52	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4126	4132		10.1038/onc.2009.262	http://dx.doi.org/10.1038/onc.2009.262			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718047				2022-12-28	WOS:000272560500008
J	Montano, X				Montano, X.			Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation	ONCOGENE			English	Article						SHP-1; trkA; phosphorylation; cell-cycle arrest; breast-cancer; p53	NERVE GROWTH-FACTOR; ACTIVATION LOOP TYROSINES; FACTOR RECEPTOR; PHOSPHATASE SHP-1; NF-Y; TRANSCRIPTIONAL REPRESSION; SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR; ADAPTER PROTEIN; DNA-DAMAGE	The nerve growth factor (NGF) receptor, trkA, the tumour suppressor p53 and the phosphatase SHP-1 are critical in cell proliferation and differentiation. SHP-1 is a trkA phosphatase that dephosphorylates trkA at tyrosines (Y) 674 and 675. p53 can induce trkA activation and tyrosine phosphorylation in the absence of NGF stimulation. In breast cancer tumours trkA expression is associated with increased patient survival. TrkA protein expression is higher in breast-cancer cell lines than in normal breast epithelia. In cell lines (but not in normal breast epithelia) trkA is functional and can be NGF-stimulated to promote cell proliferation. This study investigates the functional relationship between trkA, p53 and SHP-1 in breast-cancer, and reveals that in wildtype (wt) trkA expressing breast-cancer cells both endogenous wtp53, activated by therapeutic agents, and transfected wtp53 repress expression of SHP-1 through the proximal CCAAT sequence of the SHP-1-P1-promoter and the transcription factor NF-Y. In these cells trkA-Y674/Y675 phosphorylation is detected when SHP-1 protein levels decrease in a wtp53-dependent manner. Proliferation and cell-cycle assays, with cells expressing endogenous or transfected wt-trkA and a temperature-sensitive p53 grown at 32 degrees C (when p53 is in the wt configuration), show suppressed cell proliferation. Suppression is not detected when grown at 37 degrees C (when p53 is in the mutant configuration). A release from suppression is observed when these cells are transiently transfected with wt-SHP-1 and grown at 32 degrees C. Suppression is also detected when, as control, wt-trkA-expressing cells are transiently transfected with SHP-1-siRNA, but not when a dominant-negative (DN) mutant trkA is used to abolish wt-trkA activity. Importantly, suppression is not seen with control trkA-negative breast-cancer cells (expressing wtp53, wt-SHP-1 and undetectable trkA), transfected with Y674F/Y675F mutant-trkA. BrdU-incorporation experiments reveal lack of incorporation in cells expressing wt-trkA and wtp53, or wt-trkA and SHP-1-siRNA. However, BrdU is incorporated in the presence of Y674F/Y675F mutant trkA or DN mutant trkA. These results indicate that p53 repression of SHP-1 expression leads to trkA-Y674/Y675 phosphorylation and trkA-dependent suppression of breast-cancer cell proliferation. These data provide an explanation as to why high trkA levels are associated with favourable prognosis. Oncogene (2009) 28, 3787-3800; doi:10.1038/onc.2009.143; published online 14 September 2009	Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Mol Signalling Grp, London SW7 2AZ, England	Imperial College London	Montano, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Mol Signalling Grp, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.	xmontano@ich.ucl.ac.uk			Breast Cancer Campaign grant	Breast Cancer Campaign grant	Thanks to Tessa Crompton, Sue Outram, Anna Furmanski and Ayad Eddaoudi for helping with FACS analysis; Shanie Budham-Mahadeo for helping with luciferase assays; Ralf Kirschner, KurtEngeland, Finn Werner and David Mann for ChIP and BrdU incorporation protocols; Ben Neel and David Kaplan for wt-SHP-1, Delta-SHP-1 and anti-trk203-antibodies; Alison Sparks for sheep anti-p53-antibodies; Reiner Janicke for MCF7-p53-RNAi cells; Borek Vojtesek for MCF7-p53DD Derek Huntley for bioinformatics and particularly to David Bacon for technical help with photography and graphics. This research was supported by a Breast Cancer Campaign grant awarded to XM.	BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Browes C, 2001, FEBS LETT, V497, P20, DOI 10.1016/S0014-5793(01)02429-2; Brown A, 2000, ONCOGENE, V19, P3032, DOI 10.1038/sj.onc.1203619; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304; Concin N, 2003, BREAST CANCER RES TR, V79, P37, DOI 10.1023/A:1023351717408; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Fraser SP, 2003, J CELL PHYSIOL, V195, P479, DOI 10.1002/jcp.10312; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Horvat A, 2001, J NEUROSCI, V21, P865, DOI 10.1523/JNEUROSCI.21-03-00865.2001; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; JAGJIT SG, 1998, J NEUROONCOL, V40, P19; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marsh HN, 2003, J CELL BIOL, V163, P999, DOI 10.1083/jcb.200309036; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Moll UM, 2004, MOL CANCER RES, V2, P371; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Montano X, 1997, ONCOGENE, V15, P245, DOI 10.1038/sj.onc.1201215; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Olivier Magali, 2004, IARC Sci Publ, P247; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Roccato E, 2005, J BIOL CHEM, V280, P3382, DOI 10.1074/jbc.M407522200; Sakamoto Y, 2001, ONCOL REP, V8, P973; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; Spiesbach K, 2005, INT J CANCER, V114, P555, DOI 10.1002/ijc.20766; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wu CY, 2003, J CELL BIOCHEM, V90, P1026, DOI 10.1002/jcb.10727; Xie P, 2000, LEUKEMIA LYMPHOMA, V36, P595, DOI 10.3109/10428190009148408; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yip SS, 2000, INT J CANCER, V88, P363, DOI 10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677	62	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2009	28	43					3787	3800		10.1038/onc.2009.143	http://dx.doi.org/10.1038/onc.2009.143			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19749791				2022-12-28	WOS:000271248400003
J	Swartling, FJ; Ferletta, M; Kastemar, M; Weiss, WA; Westermark, B				Swartling, F. J.; Ferletta, M.; Kastemar, M.; Weiss, W. A.; Westermark, B.			Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines	ONCOGENE			English	Article						glioma; PDGF; cGMP-dependent protein kinase II; Akt; Sox9; VASP	NITRIC-OXIDE; GROWTH-FACTOR; BRAIN-TUMORS; RECEPTOR GENE; ACTIVATION; MIGRATION; IDENTIFICATION; AMPLIFICATION; PROGRESSION; IMATINIB	Earlier we used a glioma model to identify loci in the mouse genome, which were repeatedly targeted by platelet-derived growth factor (PDGF)-containing Moloney murine leukemia viruses. The gene Prkg2, encoding cyclic guanosine monophosphate (cGMP)-dependent protein kinase II, cGKII, was tagged by retroviral insertions in two brain tumors. The insertions were both situated upstream of the kinase domain and suggested creating a truncated form of the cGKII protein. We transfected different human glioma cell lines with Prkg2 and found an overall reduction in colony formation and cell proliferation compared with controls transfected with truncated Prkg2 (lacking the kinase domain) or empty vector. All glioma cells transfected with the cGKII phosphorylate vasodilator-stimulated phosphoprotein, VASP, after cGMP analog treatment. Glioma cell lines positive for the Sox9 transcription factor showed reduced Sox9 expression when Prkg2 was stably transfected. When cGKII was activated by cGMP analog treatment, Sox9 was phosphorylated, Sox9 protein expression was suppressed and the glioma cell lines displayed loss of cell adhesion, inhibition of Akt phosphorylation and G1 arrest. Sox9 repression by siRNA was similarly shown to reduce glioma cell proliferation. Expression analysis of stem and glial lineage cell markers also suggests that cGKII induces differentiation of glioma cell lines. These findings describe an anti-proliferative role of cGKII in human glioma biology and would further explain the retroviral tagging of the cGKII gene during brain tumor formation in PDGF-induced tumors. Oncogene (2009) 28, 3121-3131; doi: 10.1038/onc.2009.168; published online 22 June 2009	[Westermark, B.] Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; [Swartling, F. J.; Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Uppsala University; Uppsala University Hospital; University of California System; University of California San Francisco	Westermark, B (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjoldsv 20, SE-75185 Uppsala, Sweden.	Bengt.Westermark@genpat.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Westermark, Bengt/0000-0001-7153-5545; Weiss, William/0000-0003-2230-9132	Swedish Cancer Foundation; Children's Cancer Foundation; Swedish Research Council; Swedish Foundation for Strategic Research; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER	Swedish Cancer Foundation; Children's Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Swedish Cancer Foundation, the Children's Cancer Foundation, the Swedish Research Council and the Swedish Foundation for Strategic Research. We acknowledge Lisa Christiansson for skillful technical assistance.	BUTT E, 1994, J BIOL CHEM, V269, P14509; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Chen LH, 2004, ARTERIOSCL THROM VAS, V24, P1403, DOI 10.1161/01.ATV.0000134705.39654.53; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204; Cook ALM, 2004, CELL SIGNAL, V16, P253, DOI 10.1016/S0898-6568(03)00134-7; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Dromard C, 2007, STEM CELLS, V25, P340, DOI 10.1634/stemcells.2005-0556; Finzsch M, 2008, DEVELOPMENT, V135, P637, DOI 10.1242/dev.010454; Gambaryan S, 2002, BIOCHEM BIOPH RES CO, V293, P1438, DOI 10.1016/S0006-291X(02)00412-6; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kordes U, 2006, J NEURO-ONCOL, V80, P151, DOI 10.1007/s11060-006-9180-7; Lahortiga I, 2007, HAEMATOLOGICA, V93, P49, DOI 10.3324/haematol.11836; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; NISTER M, 1988, CANCER RES, V48, P3910; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Swartling FJ, 2008, UPSALA J MED SCI, V113, P1; Tanaka J, 1997, GLIA, V19, P286; Taylor MK, 2002, J BIOL CHEM, V277, P37242, DOI 10.1074/jbc.M202060200; Uhrbom L, 1998, CANCER RES, V58, P5275; Villalobo A, 2006, FEBS J, V273, P2329, DOI 10.1111/j.1742-4658.2006.05250.x; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Walz C, 2007, HAEMATOLOGICA, V92, P163, DOI 10.3324/haematol.10980; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang SI, 1997, CANCER RES, V57, P4183; Yin D, 2008, CLIN CANCER RES, V14, P4002, DOI 10.1158/1078-0432.CCR-07-1826; Yoshioka A, 2000, J NEUROCHEM, V74, P633, DOI 10.1046/j.1471-4159.2000.740633.x	43	80	81	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3121	3131		10.1038/onc.2009.168	http://dx.doi.org/10.1038/onc.2009.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19543319	Green Accepted			2022-12-28	WOS:000269515100004
J	Roovers, K; Wagner, S; Storbeck, CJ; O'Reilly, P; Lo, V; Northey, JJ; Chmielecki, J; Muller, WJ; Siegel, PM; Sabourin, LA				Roovers, K.; Wagner, S.; Storbeck, C. J.; O'Reilly, P.; Lo, V.; Northey, J. J.; Chmielecki, J.; Muller, W. J.; Siegel, P. M.; Sabourin, L. A.			The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility	ONCOGENE			English	Article						cell migration; focal adhesion; Ste20-like kinase; ErbB2; HER2	GROWTH-FACTOR; ERBB RECEPTORS; MAMMARY TUMORIGENESIS; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ADHESION; FAK; TRANSFORMATION; MIGRATION	The Ste20-like kinase, SLK, is involved in the control of cell motility through its effects on actin reorganization and focal adhesion turnover. Here we investigated the role of SLK in chemotaxis downstream of the tyrosine kinase receptor, HER2/ErbB2/Neu, which is frequently over-expressed in human breast cancers. Our results show that SLK is required for the efficient cell migration of human and mouse mammary epithelial cell lines in the presence of the Neu activator, heregulin, as a chemoattractant. SLK activity is stimulated by heregulin treatment or by overexpression of activated Neu. Phosphorylation of tyrosine 1201 or tyrosines 1226/7 on Neu is a key event for SLK activation and cell migration, and cancer cell invasion mediated by these tyrosines is inhibited by kinase-inactive SLK. Signaling pathway inhibitors show that Neu-mediated SLK activation is dependent on MEK, PI3K, PLC gamma and Shc signaling. Furthermore, heregulin-stimulated SLK activity requires signals from the focal adhesion proteins, FAK and src. Finally, phospho-FAK analysis shows that SLK is required for Neu-dependent focal adhesion turnover. Together, these studies de. ne an interaction between Neu and SLK signaling in the regulation of cancer cell motility. Oncogene (2009) 28, 2839-2848; doi:10.1038/onc.2009.146; published online 15 June 2009	[Roovers, K.; Storbeck, C. J.; O'Reilly, P.; Sabourin, L. A.] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Wagner, S.; Lo, V.; Sabourin, L. A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Northey, J. J.; Muller, W. J.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Chmielecki, J.; Muller, W. J.] McGill Univ, Dept Med, Montreal, PQ, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; McGill University; McGill University	Sabourin, LA (corresponding author), Ottawa Reg Canc Ctr, 501 Smyth Rd,Box 926, Ottawa, ON K1H 8L6, Canada.	lsabourin@ohri.ca	Northey, Jason/AAX-6365-2021	Northey, Jason/0000-0003-3115-2560	Canadian Breast Cancer Foundation; Canadian Institute for Health Research; Premier's Research for Excellence Award; OGSST; NSERC; Canadian Heart and Stroke Foundation Fellowship; National Cancer Institute of Canada; CIHR scholar award	Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Premier's Research for Excellence Award; OGSST; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Heart and Stroke Foundation Fellowship(Heart & Stroke Foundation of Canada); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); CIHR scholar award(Canadian Institutes of Health Research (CIHR))	This work was supported by the Canadian Breast Cancer Foundation, the Canadian Institute for Health Research and a Premier's Research for Excellence Award. KR is supported by the Canadian Breast Cancer Foundation, SW is supported by OGSST and NSERC studentships and CJS is the recipient of a Canadian Heart and Stroke Foundation Fellowship. PMS is a research scientist of the National Cancer Institute of Canada and LAS is the recipient of a CIHR scholar award.	BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Burakov AV, 2008, MOL BIOL CELL, V19, P1952, DOI 10.1091/mbc.E06-12-1156; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort D L, 1996, Cancer Treat Res, V83, P71; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hauck CR, 2001, CANCER RES, V61, P7079; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; O'Reilly PG, 2005, J BIOL CHEM, V280, P42383, DOI 10.1074/jbc.M510763200; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; Pytowski B, 1998, ARCH BIOCHEM BIOPHYS, V359, P310, DOI 10.1006/abbi.1998.0907; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Siegel PM, 2000, ADV EXP MED BIOL, V480, P185; Siesser PMF, 2008, CELL MOTIL CYTOSKEL, V65, P25, DOI 10.1002/cm.20241; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wagner S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001868; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Zhang YH, 2002, DEV BRAIN RES, V139, P205, DOI 10.1016/S0165-3806(02)00551-5	42	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2839	2848		10.1038/onc.2009.146	http://dx.doi.org/10.1038/onc.2009.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525980				2022-12-28	WOS:000268684400007
J	Gramatzki, D; Pantazis, G; Schittenhelm, J; Tabatabai, G; Kohle, C; Wick, W; Schwarz, M; Weller, M; Tritschler, I				Gramatzki, D.; Pantazis, G.; Schittenhelm, J.; Tabatabai, G.; Koehle, C.; Wick, W.; Schwarz, M.; Weller, M.; Tritschler, I.			Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells	ONCOGENE			English	Article						AhR; TGF-beta; Smad; LTBP-1; gliomas	GROWTH-FACTOR-BETA; MOUSE EMBRYO FIBROBLASTS; DIOXIN RECEPTOR; GLIOMA-CELLS; IN-VIVO; EXPRESSION; GENE; BINDING; MICE; APOPTOSIS	The dioxin/aryl hydrocarbon receptor (AhR) is a transcription factor, which has been attributed a role in human cancerogenesis, cell cycle progression and transforming growth factor-beta (TGF-beta) signaling. As TGF-beta is an important mediator of the malignant phenotype of human gliomas, we studied AhR expression and function in glioma cells. AhR was not only expressed in glioma cells in vitro, but was also detected in human gliomas in vivo by immunohistochemistry, with a predominantly nuclear staining in glioblastomas. The AhR agonist, 3-methylcholanthrene, induced AhR nuclear translocation and upregulated mRNA levels of the AhR target gene, cytochrome P450 1A1 (CYP1A1). Conversely, pharmacological inhibition of AhR using the novel AhR antagonist, CH-223191, or AhR gene silencing using small interfering RNA showed that constitutive AhR activity positively controls TGF-beta 1, TGF-beta 2 and latent TGF-beta-binding protein-1 protein levels in malignant glioma cells. Moreover, antagonism of AhR reduced clonogenic survival and invasiveness of glioma cells. In contrast, AhR regulates TGF-beta signaling negatively in non-neoplastic astrocytes. Thus, the pathogenesis of glioma formation may involve altered AhR regulation of the TGF-beta/Smad pathway, and AhR may represent a promising target for the treatment of human malignant gliomas and other diseases associated with pathological TGF-beta activity. Oncogene (2009) 28, 2593-2605; doi: 10.1038/onc.2009.104; published online 25 May 2009	[Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Mol Neurooncol Lab, Dept Gen Neurol, Tubingen, Germany; [Gramatzki, D.; Tabatabai, G.; Wick, W.; Weller, M.; Tritschler, I.] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Pantazis, G.; Schittenhelm, J.] Univ Tubingen, Inst Brain Res, Dept Neuropathol, D-7400 Tubingen, Germany; [Koehle, C.; Schwarz, M.] Univ Tubingen, Inst Pharmacol & Toxicol, Dept Toxicol, Tubingen, Germany; [Wick, W.] Univ Heidelberg, Dept Neurooncol, Heidelberg, Germany	University of Zurich; University Zurich Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ruprecht Karls University Heidelberg	Weller, M (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	michael.weller@usz.ch	Tabatabai, Ghazaleh/A-6365-2015; Wick, Wolfgang/AAA-2545-2020	Tabatabai, Ghazaleh/0000-0003-3702-923X; Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X; Tabatabai, Ghazaleh/0000-0002-3542-8782	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)	Jacqueline Seroussi Memorial Foundation for Cancer Research; Swiss National Fund (NCCR Neuro)(Swiss National Science Foundation (SNSF))	We are indebted to Dr Gabrielle Haas for support with confocal microscopy. This study was supported by grants from the Jacqueline Seroussi Memorial Foundation for Cancer Research and the Swiss National Fund (NCCR Neuro) to MW.	Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Carraro G, 2005, MOL CELL PROBE, V19, P181, DOI 10.1016/j.mcp.2004.11.004; Chang XQ, 2007, MOL CELL BIOL, V27, P6127, DOI 10.1128/MCB.00323-07; Corchero J, 2004, INT J EXP PATHOL, V85, P295, DOI 10.1111/j.0959-9673.2004.00397.x; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Elferink Cornelis J, 2003, Prog Cell Cycle Res, V5, P261; Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; Gomez-Duran A, 2006, J CELL BIOCHEM, V97, P380, DOI 10.1002/jcb.20637; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAARMANNSTEMMAN T, 2008, BIOCHEM PHARMACOL, V77, P508; Harper PA, 2006, BIOCHEM PHARMACOL, V72, P267, DOI 10.1016/j.bcp.2006.01.007; HUANG SX, 2004, COMPUTER INTEGRATED, V1, P1; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Kim SH, 2006, MOL PHARMACOL, V69, P1871, DOI 10.1124/mol.105.021832; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier MSV, 2007, NEUROTOXICOLOGY, V28, P594, DOI 10.1016/j.neuro.2007.01.002; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; MASON GGF, 1994, J BIOL CHEM, V269, P4438; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Ohtake F, 2008, BIOCHEM BIOPH RES CO, V370, P541, DOI 10.1016/j.bbrc.2008.03.054; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Schittenhelm J, 2008, BRAIN PATHOL, V18, P344, DOI 10.1111/j.1750-3639.2008.00127.x; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; TRITSCHLER I, 2009, INT J CANC IN PRESS; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Weller M, 1995, BRAIN RES REV, V21, P128, DOI 10.1016/0165-0173(95)00010-0; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wolff S, 2001, MOL PHARMACOL, V59, P716, DOI 10.1124/mol.59.4.716; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024	47	88	101	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2593	2605		10.1038/onc.2009.104	http://dx.doi.org/10.1038/onc.2009.104			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465936				2022-12-28	WOS:000268058900005
J	Dydensborg, AB; Rose, AAN; Wilson, BJ; Grote, D; Paquet, M; Giguere, V; Siegel, PM; Bouchard, M				Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Paquet, M.; Giguere, V.; Siegel, P. M.; Bouchard, M.			GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis	ONCOGENE			English	Article						GATA3; breast cancer; lung metastasis	GENE-EXPRESSION PROFILES; LUMINAL CELL FATE; CARCINOMA IN-SITU; LYMPH-NODE; ESTROGEN-RECEPTOR; LUNG METASTASIS; MAMMARY-GLAND; DIFFERENTIATION; GLYCODELIN; MORPHOGENESIS	The loss of expression of the transcription factor GATA3 in breast tumors has been linked to aggressive tumor development and poor patient survival. In the present work, we address potential roles for GATA3 in breast tumor lung metastasis and progression. Using an aggressive breast cancer cell line, which metastasizes specifically to the lung, we show that GATA3 expression results in reduced tumor outgrowth in the mammary fat pad and lower lung metastatic burden in nude mice. Specifically, GATA3 expression inhibits breast cancer cell expansion inside the lung parenchyma. This phenotype correlates with the ability of GATA3 to negatively regulate the expression of several genes that promote breast cancer lung metastasis (ID1/-3, KRTHB1, LY6E and RARRES3). Conversely, the expression of genes encoding known inhibitors of lung metastasis (DLC1 (deleted in liver cancer 1) and PAEP (progestagen-associated endometrial protein)) is upregulated by GATA3. These data correlate with microarray data from human breast cancer patients, showing a strong correlation between high GATA3 expression and absence of metastases specifically to the lungs. We conclude that GATA3 inhibits primary breast tumor outgrowth and reduces lung metastatic burden by regulating key genes involved in metastatic breast tumor progression. Oncogene (2009) 28, 2634-2642; doi: 10.1038/onc.2009.126; published online 1 June 2009	[Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Giguere, V.; Siegel, P. M.; Bouchard, M.] McGill Univ, Dept Biochem, Goodman Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Paquet, M.] McGill Univ, Comparat Pathol Facil, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Bouchard, M (corresponding author), McGill Univ, Dept Biochem, Goodman Canc Ctr, 1160 Ave Des Pins Ouest, Montreal, PQ H3G 1Y6, Canada.	maxime.bouchard@mcgill.ca	Paquet, Marilene/L-3414-2019; Rose, April/AAR-8222-2020	Paquet, Marilene/0000-0002-3562-4636; Rose, April/0000-0002-9845-4603; Bouchard, Maxime/0000-0002-7619-9680; Giguere, Vincent/0000-0001-9567-3694	Canadian Institutes for Health Research [MOP-84470]; Canderel New Initiative Award; Carlsberg Foundation fellowship [2006_01_0102]; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award; National Cancer Institute of Canada; Fonds de la Recherche en Sante ' du Que ' bec studentship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canderel New Initiative Award; Carlsberg Foundation fellowship; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Fonds de la Recherche en Sante ' du Que ' bec studentship	The authors are grateful to Dr Perou (Division of Cancer Epidemiology and Genetics, the National Cancer Institute, MD 20852-7234, USA) for sharing cDNA constructs. The work was supported by the Canadian Institutes for Health Research grant MOP-84470 and a Canderel New Initiative Award to MB. ABD was supported by a fellowship from the Carlsberg Foundation (2006_01_0102) and a Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award. AANR is supported by a studentship from the Fonds de la Recherche en Sante ' du Que ' bec. PS is a research scientist of the National Cancer Institute of Canada. MB holds a Canada Research Chair in Developmental Genetics of the Urogenital System.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Buess M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r191; de Kok JB, 2005, LAB INVEST, V85, P154, DOI 10.1038/labinvest.3700208; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hautala LC, 2008, INT J CANCER, V123, P2279, DOI 10.1002/ijc.23773; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeschke U, 2005, ONCOL REP, V13, P413; JOHNSTON SRD, 2006, HDB METASTATIC BREAS, P232; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murphy KM, 2005, IMMUNOL RES, V32, P193, DOI 10.1385/IR:32:1-3:193; Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Shabani N, 2005, ANTICANCER RES, V25, P1761; Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Voduc D, 2008, CANCER EPIDEM BIOMAR, V17, P365, DOI 10.1158/1055-9965.EPI-06-1090; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	36	102	105	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2009	28	29					2634	2642		10.1038/onc.2009.126	http://dx.doi.org/10.1038/onc.2009.126			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483726				2022-12-28	WOS:000268211200002
J	Ancot, F; Foveau, B; Lefebvre, J; Leroy, C; Tulasne, D				Ancot, F.; Foveau, B.; Lefebvre, J.; Leroy, C.; Tulasne, D.			Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity	ONCOGENE			English	Review						receptor tyrosine kinase; cleavages; caspase; metalloprotease; gamma-secretase; signalling	GROWTH-FACTOR RECEPTOR; ALPHA-CONVERTING ENZYME; ANAPLASTIC LYMPHOMA KINASE; HUMAN ENDOTHELIAL-CELLS; C-KIT RECEPTOR; GAMMA-SECRETASE; DOWN-REGULATION; INTRACELLULAR DOMAIN; DEPENDENCE RECEPTOR; ECTODOMAIN CLEAVAGE	Receptor tyrosine kinases (RTK) constitute a large family of membrane receptors which, in response to their respective ligand, transmit information into cells. RTK regulate multiple biological responses, and their deregulation is often associated with tumourigenesis. The intracellular signalling pathways initiated by full-length membrane RTK are studied extensively, but many RTK fragments showing unexpected cellular localization have been observed. These fragments are generated by proteolytic cleavages, catalyzed notably by caspases, membrane metalloproteases or gamma-secretase. Interestingly, these cleavages, in addition to regulating membrane receptor levels, generate active fragments that can regulate biological processes, such as transcription or the survival/apoptosis balance. Thus, proteolytic cleavages release RTK from the membrane and extend their functions. Furthermore, the RTK proteolysis are involved in regulating cell transformation, which highlights their potential as attractive targets for therapeutic strategies. Oncogene (2009) 28, 2185-2195; doi: 10.1038/onc.2009.88; published online 4 May 2009	[Ancot, F.; Foveau, B.; Lefebvre, J.; Leroy, C.; Tulasne, D.] Univ Lille 2, Univ Lille 1, CNRS, Inst Biol Lille,Inst Pasteur Lille,UMR 8161, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille 2, Univ Lille 1, CNRS, Inst Biol Lille,Inst Pasteur Lille,UMR 8161, BP 447, F-59021 Lille, France.	david.tulasne@ibl.fr	Tulasne, David/AAR-5287-2020; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; 	CNRS; Institut Pasteur de Lille, and INSERM; Ligue contre le Cancer, comite Nord; Association pour la Recherche sur le Cancer; Fondation Recherche Medicale, Comite Nord-Pas de Calais; Agence Nationale de la Recherche, Young Investigator Program; Institut Pasteur/Region Nord-Pas de Calais' fellowship; French Research and Technology Minister	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille, and INSERM; Ligue contre le Cancer, comite Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation Recherche Medicale, Comite Nord-Pas de Calais; Agence Nationale de la Recherche, Young Investigator Program(French National Research Agency (ANR)); Institut Pasteur/Region Nord-Pas de Calais' fellowship(Region Hauts-de-France); French Research and Technology Minister	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the 'Ligue contre le Cancer, comite Nord', the 'Association pour la Recherche sur le Cancer', the 'Fondation Recherche Medicale, Comite Nord-Pas de Calais' and 'Agence Nationale de la Recherche, Young Investigator Program'. BF was supported by a 'Institut Pasteur/Region Nord-Pas de Calais' fellowship and FA and JL by grants from the French Research and Technology Minister.	Allouche M, 2007, CELL CYCLE, V6, P1533, DOI 10.4161/cc.6.13.4433; Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Athauda G, 2006, CLIN CANCER RES, V12, P4154, DOI 10.1158/1078-0432.CCR-06-0250; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Chen-Konak L, 2003, FASEB J, V17, P2121, DOI 10.1096/fj.02-1151fje; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Christianson TA, 1998, CANCER RES, V58, P5123; Codony-Servat J, 1999, CANCER RES, V59, P1196; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; Dahlen DD, 2001, LEUKEMIA RES, V25, P413, DOI 10.1016/S0145-2126(00)00122-3; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Findley CM, 2007, ARTERIOSCL THROM VAS, V27, P2619, DOI 10.1161/ATVBAHA.107.150482; Foveau B, 2007, CELL DEATH DIFFER, V14, P752, DOI 10.1038/sj.cdd.4402080; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; GALVANI AP, 1995, BIOCHEM PHARMACOL, V50, P959, DOI 10.1016/0006-2952(95)00219-P; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kasuga K, 2007, BIOCHEM BIOPH RES CO, V360, P90, DOI 10.1016/j.bbrc.2007.06.022; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; LEV S, 1992, J BIOL CHEM, V267, P10866; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Liu XD, 2006, CANCER BIOL THER, V5, P648, DOI 10.4161/cbt.5.6.2707; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Marron MB, 2007, J BIOL CHEM, V282, P30509, DOI 10.1074/jbc.M702535200; Mateos S, 2003, ONCOGENE, V22, P740, DOI 10.1038/sj.onc.1206213; McCarthy MJ, 1999, LAB INVEST, V79, P889; McElroy B, 2007, BIOCHEM BIOPH RES CO, V358, P1136, DOI 10.1016/j.bbrc.2007.05.062; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Migliore C, 2008, EUR J CANCER, V44, P641, DOI 10.1016/j.ejca.2008.01.022; Molina MA, 2001, CANCER RES, V61, P4744; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Nagy P, 2005, CANCER RES, V65, P473; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nath D, 2001, J CELL SCI, V114, P1213; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Parks AL, 2007, TRENDS GENET, V23, P140, DOI 10.1016/j.tig.2007.01.008; Perez-Torres M, 2008, EXP CELL RES, V314, P2907, DOI 10.1016/j.yexcr.2008.07.013; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Slack BE, 2006, J CELL BIOCHEM, V98, P672, DOI 10.1002/jcb.20812; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tousseyn Thomas, 2006, Birth Defects Research, V78, P24, DOI 10.1002/bdrc.20066; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; TURNER AM, 1995, BLOOD, V85, P2052, DOI 10.1182/blood.V85.8.2052.bloodjournal8582052; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; Warri AM, 1996, EUR J CANCER, V32A, P134, DOI 10.1016/0959-8049(95)00550-1; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001; Witters L, 2008, CANCER RES, V68, P7083, DOI 10.1158/0008-5472.CAN-08-0739; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	102	37	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2185	2195		10.1038/onc.2009.88	http://dx.doi.org/10.1038/onc.2009.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19421148				2022-12-28	WOS:000266640300001
J	Astanehe, A; Finkbeiner, MR; Hojabrpour, P; To, K; Fotovati, A; Shadeo, A; Stratford, AL; Lam, WL; Berquin, IM; Duronio, V; Dunn, SE				Astanehe, A.; Finkbeiner, M. R.; Hojabrpour, P.; To, K.; Fotovati, A.; Shadeo, A.; Stratford, A. L.; Lam, W. L.; Berquin, I. M.; Duronio, V.; Dunn, S. E.			The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1	ONCOGENE			English	Article						breast cancer; invasion; PI3K; PIK3CA; uPA; YB-1	RIBOSOMAL S6 KINASE; BREAST-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMINOGEN-ACTIVATOR; HEMATOPOIETIC-CELLS; OVARIAN-CANCER; HIGH-FREQUENCY; COPY NUMBER	PIK3CA, which codes for the p110 alpha catalytic subunit of phosphatidylinositol-3-kinase (PI3K), is implicated as an oncogene. Despite importance of PIK3CA in cancer, little is known about what drives up its expression in tumor cells. We recently characterized the PIK3CA promoter and reported that it is transcriptionally silenced by the tumor suppressor protein p53. In the present study, we demonstrate that PIK3CA can be induced by the oncogenic transcription factor Y-box binding protein-1(YB-1). Three YB-1-responsive elements were identified on the PIK3CA promoter using chromatin immunoprecipitation and electrophoretic mobility shift assays. Interestingly, silencing YB-1 with siRNA in models of basal-like breast cancer decreased p110 alpha protein levels regardless of whether PIK3CA was wild type, amplified or mutated. This decrease in p110 alpha led to a reduction in PI3K activity and the downstream signaling primarily through p90 ribosomal S6 kinase and S6 ribosomal protein. Disruption in PIK3CA-dependent signaling suppressed cellular invasion correlative with loss of urokinase plasminogen activator (uPA). Similarly, silencing YB-1 suppressed invasion and uPA production however this was reversible through the introduction of constitutively active PIK3CA. In conclusion, YB-1 is the first reported oncogene to induce the expression of PIK3CA through transcriptional control of its promoter. Oncogene (2009) 28, 2406-2418; doi:10.1038/onc.2009.81; published online 11 May 2009	[Astanehe, A.; Finkbeiner, M. R.; To, K.; Fotovati, A.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Lab Oncogen Res, Dept Pediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Astanehe, A.; Finkbeiner, M. R.; To, K.; Fotovati, A.; Stratford, A. L.; Dunn, S. E.] Univ British Columbia, Dept Expt Med, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Hojabrpour, P.; Duronio, V.] Univ British Columbia, Dept Med, Jack Bell Res Ctr, Vancouver, BC V5Z 4H4, Canada; [Shadeo, A.; Lam, W. L.] Univ British Columbia, Dept Canc Genet & Dev Biol, British Columbia Canc Res Ctr, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27109 USA	Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; Wake Forest University	Dunn, SE (corresponding author), Univ British Columbia, Lab Oncogen Res, Dept Pediat, Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@interchange.ubc.ca		Shadeo, Ashleen/0000-0002-0866-0519	National Cancer Institute of Canada (SED) [RO1 CA114017-01A1]; Canadian Institute of Health Research; Canadian Breast Cancer Research Alliance IDEA; Canadian Institute of Health Research MD/PhD; Michael Smith Foundation for Health Research Studentships.; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	National Cancer Institute of Canada (SED); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance IDEA; Canadian Institute of Health Research MD/PhD(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research Studentships.(Michael Smith Foundation for Health Research); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute of Canada (SED), RO1 CA114017-01A1 (SED and IB), Canadian Institute of Health Research (VD), Canadian Breast Cancer Research Alliance IDEA (WL). AA was supported by the Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research Studentships.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Clark DE, 2005, CANCER RES, V65, P3108; Deleeuw RJ, 2007, GASTROENTEROLOGY, V132, P1902, DOI 10.1053/j.gastro.2007.03.036; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dunn SE, 2001, CANCER RES, V61, P1367; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Horn S, 2008, ONCOGENE, V27, P4096, DOI 10.1038/onc.2008.40; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shadeo A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1370; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Smith JA, 2005, CANCER RES, V65, P1027; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Woo MMM, 2007, IN VITRO CELL DEV-AN, V43, P7, DOI 10.1007/s11626-006-9002-4; Wu GJ, 2005, BREAST CANCER RES, V7, pR609, DOI 10.1186/bcr1262; Wu Joyce, 2007, Transl Oncogenomics, V2, P49; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhao JJ, 2006, P NATL ACAD SCI USA, V103, P16296, DOI 10.1073/pnas.0607899103	44	59	59	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2406	2418		10.1038/onc.2009.81	http://dx.doi.org/10.1038/onc.2009.81			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430491				2022-12-28	WOS:000267342400005
J	Noonan, EJ; Place, RF; Pookot, D; Basak, S; Whitson, JM; Hirata, H; Giardina, C; Dahiya, R				Noonan, E. J.; Place, R. F.; Pookot, D.; Basak, S.; Whitson, J. M.; Hirata, H.; Giardina, C.; Dahiya, R.			miR-449a targets HDAC-1 and induces growth arrest in prostate cancer	ONCOGENE			English	Article						miRNA; miR-449a; miR-34; HDAC-1; HDAC inhibitors; prostate cancer; senescence	HISTONE DEACETYLASE INHIBITORS; MICRORNA EXPRESSION; CLASS-I; VALPROIC ACID; SOLID TUMORS; CELLS; APOPTOSIS; SENESCENCE; MIR-34A; GENE	Histone deacetylases (HDACs) are frequently over-expressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery. In this study, we investigated the expression and functional significance of miR-449a in prostate cancer cells. Using real-time PCR, we found that miR-449a is downregulated in prostate cancer tissues relative to patient-matched control tissue. Introduction of miR-449a into PC-3 prostate cancer cells resulted in cell-cycle arrest, apoptosis and a senescent-like phenotype. In silico analysis of 3'-UTR regions identified a number of genes involved in cell-cycle regulation as putative targets of miR-449a. Using a luciferase 3'-UTR reporter system, we established that HDAC-1 (histone deacetylase 1), a gene that is frequently overexpressed in many types of cancer, is a direct target of miR-449a. Further, our data indicate that miR-449a regulates cell growth and viability in part by repressing the expression of HDAC-1 in prostate cancer cells. Our findings provide new insight into the function of miRNA in regulating HDAC expression in normal versus cancerous tissue.	[Noonan, E. J.; Place, R. F.; Pookot, D.; Basak, S.; Hirata, H.; Dahiya, R.] Vet Affairs Med Ctr, Dept Urol, San Francisco, CA 94121 USA; [Place, R. F.; Whitson, J. M.; Dahiya, R.] Univ Calif San Francisco, Sch Med, Dept Urol, San Francisco, CA 94143 USA; [Giardina, C.] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Connecticut	Noonan, EJ (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.	emily.noonan@gmail.com; Rdahiya@urology.ucsf.edu			Veterans Affairs Research Enhancement Award Program (REAP); National Institutes of Health [RO1CA101844, RO1CA111470s, T32DK007790]; NATIONAL CANCER INSTITUTE [R01CA101844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007790] Funding Source: NIH RePORTER	Veterans Affairs Research Enhancement Award Program (REAP)(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R Erickson for his critical reading and discussion of the paper. This work was supported by the Veterans Affairs Research Enhancement Award Program (REAP), VA Merit Review grant and the National Institutes of Health grants RO1CA101844, RO1CA111470s and T32DK007790 (PI: Rajvir Dahiya).	Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Chen JS, 2005, J CELL PHYSIOL, V202, P87, DOI 10.1002/jcp.20094; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hitomi T, 2003, FEBS LETT, V554, P347, DOI 10.1016/S0014-5793(03)01186-4; Iacomino G, 2008, ANTICANCER RES, V28, P855; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kim HR, 2006, EXP MOL MED, V38, P616, DOI 10.1038/emm.2006.73; Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mehnert JM, 2007, CANCER J, V13, P23, DOI 10.1097/PPO.0b013e31803c72ba; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pan Y, 2001, GENE CHROMOSOME CANC, V30, P187, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1075>3.3.CO;2-8; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Pressman S, 2007, CELL, V130, DOI 10.1016/j.cell.2007.07.042; Qian DZ, 2007, PROSTATE, V67, P1182, DOI 10.1002/pros.20611; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Shabbeer S, 2007, PROSTATE, V67, P1099, DOI 10.1002/pros.20587; Shell S, 2007, P NATL ACAD SCI USA, V104, P11400, DOI 10.1073/pnas.0704372104; Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Tong AW, 2008, CANCER GENE THER, V15, P341, DOI 10.1038/cgt.2008.8; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wagner M, 2001, FEBS LETT, V499, P101, DOI 10.1016/S0014-5793(01)02524-8; Wedel SA, 2008, J CELL MOL MED, V12, P2457, DOI 10.1111/j.1582-4934.2008.00271.x; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Wiklund F, 2003, PROSTATE, V57, P290, DOI 10.1002/pros.10303; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoshikawa M, 2007, J AM SOC NEPHROL, V18, P58, DOI 10.1681/ASN.2005111187; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1	57	306	326	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1714	1724		10.1038/onc.2009.19	http://dx.doi.org/10.1038/onc.2009.19			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252524				2022-12-28	WOS:000265022000006
J	Pinon, JD; Labi, V; Egle, A; Villunger, A				Pinon, J. D.; Labi, V.; Egle, A.; Villunger, A.			Bmf and Bmf in tissue homeostasis and malignant disease	ONCOGENE			English	Review						apoptosis; Bcl2 family; BH3-only proteins; tumorigenesis; drug-response	FAMILY-MEMBER BIM; BH3-ONLY PROTEIN BIM; HISTONE DEACETYLASE INHIBITORS; BCL-X-L; CELL-DEATH; PROAPOPTOTIC PROTEIN; TRANSCRIPTIONAL REGULATION; HOMOZYGOUS DELETIONS; INDUCED APOPTOSIS; LEUKEMIC-CELLS	Among all BH3-only proteins known to date, most information is available on the biological role and function of Bim (Bcl-2 interacting mediator of cell death)/BOD (Bcl-2 related ovarian death agonist), whereas little is still known about its closest relative, Bcl-2 modifying factor (Bmf). Although Bim has been implicated in the regulation of cell death induction in multiple cell types and tissues in response to a large number of stimuli, including growth factor or cytokine deprivation, calcium flux, ligation of antigen receptors on T and B cells, glucocorticoid or loss of adhesion, Bmf seems to play a more restricted role by supporting Bim in some of these cell death processes. This review aims to highlight similarities between Bim and Bmf function in apoptosis signaling and their role in normal development and disease. Oncogene (2009) 27, S41-S52; doi: 10.1038/onc.2009.42	[Labi, V.; Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria; [Pinon, J. D.; Egle, A.] Univ Hosp Salzburg, Lab Immunol & Mol Canc Res, Salzburg, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at	Hofbauer, Josefina Pinon/S-6826-2019; Labi, Verena/V-2766-2019; Egle, Alexander/AAC-3787-2020	Labi, Verena/0000-0001-7538-1520; Egle, Alexander/0000-0003-0648-4416; Pinon Hofbauer, Josefina/0000-0002-8558-9031	Austrian Science Fund (FWF) [Y212-B13 START, P19481-B12, L488-B13]; Doctoral College MCBO [SFB021]; Association for International Cancer Research (AICR) [EU-FP7]; Austrian National Bank (OeNB) [109900]; Tyrolean Science Fund	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Doctoral College MCBO(Austrian Science Fund (FWF)); Association for International Cancer Research (AICR); Austrian National Bank (OeNB); Tyrolean Science Fund	The work in our laboratories is supported by fellowships and grants from the Austrian Science Fund (FWF): Y212-B13 START, P19481-B12, L488-B13, the Doctoral College MCBO, the SFB021, the Association for International Cancer Research (AICR), EU-FP7 (ApopTrain), the Austrian National Bank (OeNB) # 109900 and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited, but was only referred to indirectly through reviews.	Adachi M, 2005, CELL DEATH DIFFER, V12, P192, DOI 10.1038/sj.cdd.4401529; Barron L, 2008, J IMMUNOL, V180, P2762, DOI 10.4049/jimmunol.180.5.2762; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cai BB, 2006, J BIOL CHEM, V281, P25215, DOI 10.1074/jbc.M512627200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Fischer SF, 2007, BLOOD, V110, P3978, DOI 10.1182/blood-2007-05-091306; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hughes PD, 2008, IMMUNITY, V28, P197, DOI 10.1016/j.immuni.2007.12.017; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Inta I, 2006, J NEUROSCI, V26, P12896, DOI 10.1523/JNEUROSCI.3670-06.2006; Jette CA, 2008, CELL DEATH DIFFER, V15, P1063, DOI 10.1038/cdd.2008.42; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Labi V, 2008, J EXP MED, V205, P641, DOI 10.1084/jem.20071658; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Morales AA, 2004, LEUKEMIA, V18, P41, DOI 10.1038/sj.leu.2403183; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oliveira JB, 2007, P NATL ACAD SCI USA, V104, P8953, DOI 10.1073/pnas.0702975104; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Pellegrini M, 2004, J EXP MED, V200, P1189, DOI 10.1084/jem.20041328; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Ponassi R, 2008, CELL CYCLE, V7, P3211, DOI 10.4161/cc.7.20.6830; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Ralston A, 2006, DEV CELL, V10, P275, DOI 10.1016/j.devcel.2006.02.007; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Rodin SN, 2005, DNA CELL BIOL, V24, P529, DOI 10.1089/dna.2005.24.529; Romano S, 2008, HAEMATOL-HEMATOL J, V93, P1039, DOI 10.3324/haematol.12402; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Schmutte C, 1999, CANCER RES, V59, P4564; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weant AE, 2008, IMMUNITY, V28, P218, DOI 10.1016/j.immuni.2007.12.014; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wick W, 1996, ONCOGENE, V12, P973; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wojciechowski S, 2007, J EXP MED, V204, P1665, DOI 10.1084/jem.20070618; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510; Zhang Y, 2006, CELL DEATH DIFFER, V13, P129, DOI 10.1038/sj.cdd.4401686; Zhang YB, 2006, APOPTOSIS, V11, P1349, DOI 10.1007/s10495-006-8266-1; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	96	93	95	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S41	S52		10.1038/onc.2009.42	http://dx.doi.org/10.1038/onc.2009.42			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641506	Green Accepted			2022-12-28	WOS:000268566800004
J	Yu, J; Zhang, L				Yu, J.; Zhang, L.			PUMA, a potent killer with or without p53	ONCOGENE			English	Review						PUMA; BH3 domain; Bcl-2 family; p53; apoptosis	ENDOPLASMIC-RETICULUM STRESS; COLORECTAL-CANCER CELLS; BH3-ONLY PROTEIN PUMA; NF-KAPPA-B; UP-REGULATED MODULATOR; DRUG-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; HUMAN-MELANOMA CELLS; BCL-X-L; DNA-DAMAGE	PUMA (p53 upregulated modulator of apoptosis) is a Bcl2 homology 3 (BH3)-only Bcl-2 family member and a critical mediator of p53-dependent and -independent apoptosis induced by a wide variety of stimuli, including genotoxic stress, deregulated oncogene expression, toxins, altered redox status, growth factor/cytokine withdrawal and infection. It serves as a proximal signaling molecule whose expression is regulated by transcription factors in response to these stimuli. PUMA transduces death signals primarily to the mitochondria, where it acts indirectly on the Bcl-2 family members Bax and/or Bak by relieving the inhibition imposed by antiapoptotic members. It directly binds and antagonizes all known antiapoptotic Bcl-2 family members to induce mitochondrial dysfunction and caspase activation. PUMA ablation or inhibition leads to apoptosis deficiency underlying increased risks for cancer development and therapeutic resistance. Although elevated PUMA expression elicits profound chemo- and radio-sensitization in cancer cells, inhibition of PUMA expression may be useful for curbing excessive cell death associated with tissue injury and degenerative diseases. Therefore, PUMA is a general sensor of cell death stimuli and a promising drug target for cancer therapy and tissue damage. Oncogene (2009) 27, S71-S83; doi: 10.1038/onc.2009.45	[Zhang, L.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Pharmacol & Chem Biol,Sch Med, Pittsburgh, PA 15213 USA; [Yu, J.] Univ Pittsburgh, Inst Canc, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Pharmacol & Chem Biol,Sch Med, UPCI Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu; zhanglx@upmc.edu	Zhang, Lin/A-7389-2009	Zhang, Lin/0000-0003-0018-3903	NIH [CA106348, CA121105]; American Cancer Society [RSG-07-156-01-CNE]; American Lung Association (LZ) [CA129829, P50CA097190]; (Head and Neck Cancer SPORE Career Development Award) [U19A1068021]; University of Pittsburgh Center for Medical Countermeasures Against Radiation Developmental Research Program; Hillman Foundation, Alliance for Cancer Gene Therapy (ACGT); Flight Attendant Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE [R01CA106348, P50CA097190, R01CA121105, R01CA129829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); American Lung Association (LZ); (Head and Neck Cancer SPORE Career Development Award); University of Pittsburgh Center for Medical Countermeasures Against Radiation Developmental Research Program; Hillman Foundation, Alliance for Cancer Gene Therapy (ACGT); Flight Attendant Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Daniel E Johnson, Dr Crissy P Dudgeon and Mr Joshua Jamison for helpful discussion and critical reading. Work in authors' laboratories was supported by the NIH grants CA106348, CA121105, the American Cancer Society grant RSG-07-156-01-CNE, the American Lung Association (LZ), the NIH grant CA129829, P50CA097190 (Head and Neck Cancer SPORE Career Development Award), U19A1068021 (University of Pittsburgh Center for Medical Countermeasures Against Radiation Developmental Research Program) and those from the Hillman Foundation, Alliance for Cancer Gene Therapy (ACGT) and Flight Attendant Medical Research Institute (FAMRI) (JY).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Akhtar RS, 2006, J NEUROSCI, V26, P7257, DOI 10.1523/JNEUROSCI.0196-06.2006; Anding AL, 2007, CANCER RES, V67, P6270, DOI 10.1158/0008-5472.CAN-07-0727; Bauer A, 2006, P NATL ACAD SCI USA, V103, P10979, DOI 10.1073/pnas.0603625103; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castedo M, 2005, BIOCHEM BIOPH RES CO, V331, P701, DOI 10.1016/j.bbrc.2005.03.188; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chang KC, 2007, FASEB J, V21, P708, DOI 10.1096/fj.06-6805com; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen Y, 2007, GYNECOL ONCOL, V107, P505, DOI 10.1016/j.ygyno.2007.08.007; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Concannon CG, 2007, ONCOGENE, V26, P1681, DOI 10.1038/sj.onc.1209974; Cregan SP, 2004, J NEUROSCI, V24, P10003, DOI 10.1523/JNEUROSCI.2114-04.2004; Cumont MC, 2007, CELL DEATH DIFFER, V14, P1747, DOI 10.1038/sj.cdd.4402192; Day CL, 2008, J MOL BIOL, V380, P958, DOI 10.1016/j.jmb.2008.05.071; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Ding WX, 2007, MOL CANCER THER, V6, P1062, DOI 10.1158/1535-7163.MCT-06-0541; Dong F, 2005, INFECT IMMUN, V73, P1861, DOI 10.1128/IAI.73.3.1861-1864.2005; Dvory-Sobol H, 2007, CANCER-AM CANCER SOC, V109, P188, DOI 10.1002/cncr.22416; Ekert PG, 2006, BLOOD, V108, P1461, DOI 10.1182/blood-2006-03-014209; Ekoff M, 2007, BLOOD, V110, P3209, DOI 10.1182/blood-2007-02-073957; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Fei PW, 2002, CANCER RES, V62, P7316; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fischer SE, 2004, J EXP MED, V200, P905, DOI 10.1084/jem.20040402; Fischer SF, 2008, P NATL ACAD SCI USA, V105, P3035, DOI 10.1073/pnas.0706913105; Fujioka S, 2004, J BIOL CHEM, V279, P27549, DOI 10.1074/jbc.M313435200; Futami T, 2005, J BIOL CHEM, V280, P826, DOI 10.1074/jbc.M409948200; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giladi N, 2007, BIOMED PHARMACOTHER, V61, P527, DOI 10.1016/j.biopha.2007.08.010; Gomez-Benito M, 2005, MOL PHARMACOL, V67, P1991, DOI 10.1124/mol.104.007021; Gomez-Benito M, 2007, CELL SIGNAL, V19, P844, DOI 10.1016/j.cellsig.2006.10.009; Gomez-Lazaro M, 2005, EXP NEUROL, V196, P96, DOI 10.1016/j.expneurol.2005.07.011; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hao F, 2007, MAR PETROL GEOL, V24, P1, DOI 10.1016/j.marpetgeo.2006.10.007; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hetz C, 2007, CELL DEATH DIFFER, V14, P1386, DOI 10.1038/sj.cdd.4402166; Hoque MO, 2003, CANCER LETT, V199, P75, DOI 10.1016/S0304-3835(03)00344-6; Horvitz HR, 1999, CANCER RES, V59, p1701S; Ishihara T, 2007, BIOCHEM BIOPH RES CO, V356, P711, DOI 10.1016/j.bbrc.2007.03.034; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jackson JG, 2006, CANCER RES, V66, P8356, DOI 10.1158/0008-5472.CAN-06-1752; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang CC, 2008, CANCER RES, V68, P6708, DOI 10.1158/0008-5472.CAN-08-0349; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kalousek I, 2007, ANTI-CANCER DRUG, V18, P763, DOI 10.1097/CAD.0b013e3280adc905; Karst AM, 2006, CANCER RES, V66, P9221, DOI 10.1158/0008-5472.CAN-05-3633; Karst AM, 2005, ONCOGENE, V24, P1111, DOI 10.1038/sj.onc.1208374; Kieran D, 2007, P NATL ACAD SCI USA, V104, P20606, DOI 10.1073/pnas.0707906105; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim MR, 2007, DIGEST DIS SCI, V52, P2751, DOI 10.1007/s10620-007-9799-z; Klanrit P, 2008, CELL CYCLE, V7, P205, DOI 10.4161/cc.7.2.5361; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee DH, 2008, BIOCHEM PHARMACOL, V75, P2020, DOI 10.1016/j.bcp.2008.02.023; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li YZ, 2008, MOL CELL BIOL, V28, P564, DOI 10.1128/MCB.00738-07; Liu HF, 2008, CHEM-BIOL INTERACT, V176, P48, DOI 10.1016/j.cbi.2008.07.012; Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 2005, CELL DEATH DIFFER, V12, P1310, DOI 10.1038/sj.cdd.4401659; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Middelburg R, 2005, CLIN CANCER RES, V11, P1863, DOI 10.1158/1078-0432.CCR-04-1372; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nardacci R, 2005, AM J PATHOL, V167, P695, DOI 10.1016/S0002-9440(10)62044-5; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; Nickson P, 2007, CARDIOVASC RES, V73, P48, DOI 10.1016/j.cardiores.2006.10.001; Noguchi KK, 2008, CELL DEATH DIFFER, V15, P1582, DOI 10.1038/cdd.2008.97; Nyman U, 2005, J BIOL CHEM, V280, P34159, DOI 10.1074/jbc.M500394200; Patel S, 2008, NUCLEIC ACIDS RES, V36, P5139, DOI 10.1093/nar/gkn490; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Rao RV, 2006, CELL DEATH DIFFER, V13, P415, DOI 10.1038/sj.cdd.4401761; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaltouki A, 2007, APOPTOSIS, V12, P2143, DOI 10.1007/s10495-007-0135-z; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Simoes-Wust AP, 2005, J NEURO-ONCOL, V72, P29, DOI 10.1007/s11060-004-3118-8; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Smits C, 2008, STRUCTURE, V16, P818, DOI 10.1016/j.str.2008.02.009; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Steckley D, 2007, J NEUROSCI, V27, P12989, DOI 10.1523/JNEUROSCI.3400-07.2007; Steele AJ, 2008, BLOOD, V112, P3827, DOI 10.1182/blood-2008-05-156380; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Sun Q, 2007, MOL CANCER THER, V6, P3180, DOI 10.1158/1535-7163.MCT-07-0265; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tategu M, 2008, MOL NUTR FOOD RES, V52, P439, DOI 10.1002/mnfr.200700218; Toth A, 2006, AM J PHYSIOL-HEART C, V291, pH52, DOI 10.1152/ajpheart.01046.2005; Tsuruya K, 2008, LIFE SCI, V83, P550, DOI 10.1016/j.lfs.2008.08.002; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Van Le H, 2005, J BIOL CHEM, V280, P32018, DOI 10.1074/jbc.M504689200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang HJ, 2006, CANCER BIOL THER, V5, P380, DOI 10.4161/cbt.5.4.2477; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; WANG R, 2008, BREAST CANC RES TREA; Wang X, 2008, CANCER BIOL THER, V7, P902, DOI 10.4161/cbt.7.6.5911; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Ward MW, 2004, J BIOENERG BIOMEMBR, V36, P295, DOI 10.1023/B:JOBB.0000041756.23918.11; Webster KA, 2006, AM J PHYSIOL-HEART C, V291, pH20, DOI 10.1152/ajpheart.00111.2006; Wei A, 2008, GASTROENTEROLOGY, V134, P1412, DOI 10.1053/j.gastro.2008.01.072; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Wyttenbach A, 2006, J NEUROCHEM, V96, P1213, DOI 10.1111/j.1471-4159.2005.03676.x; Xu Bo, 2006, Zhongguo Dang Dai Er Ke Za Zhi, V8, P151; Yee KS, 2008, APOPTOSIS, V13, P87, DOI 10.1007/s10495-007-0140-2; Ying SM, 2005, INFECT IMMUN, V73, P1399, DOI 10.1128/IAI.73.3.1399-1403.2005; Yoo NJ, 2007, DIGEST LIVER DIS, V39, P222, DOI 10.1016/j.dld.2006.11.006; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2003, CANCER BIOL THER, V2, P694; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002; Zou CG, 2009, ENDOCRINOLOGY, V150, P277, DOI 10.1210/en.2008-0794	154	424	436	1	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S71	S83		10.1038/onc.2009.45	http://dx.doi.org/10.1038/onc.2009.45			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641508	Green Accepted			2022-12-28	WOS:000268566800006
J	Kim, YH; Kwei, KA; Girard, L; Salari, K; Kao, J; Pacyna-Gengelbach, M; Wang, P; Hernandez-Boussard, T; Gazdar, AF; Petersen, I; Minna, JD; Pollack, JR				Kim, Y. H.; Kwei, K. A.; Girard, L.; Salari, K.; Kao, J.; Pacyna-Gengelbach, M.; Wang, P.; Hernandez-Boussard, T.; Gazdar, A. F.; Petersen, I.; Minna, J. D.; Pollack, J. R.			Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer	ONCOGENE			English	Article						CRKL; lung cancer; DNA amplification; genomic profiling; adapter protein	BRONCHIAL EPITHELIAL-CELLS; HUMAN BREAST-CANCER; ADAPTER PROTEIN; HOMOZYGOUS DELETIONS; TYROSINE KINASE; GENE; MUTATIONS; LINES; MET; AMPLIFICATIONS	DNA amplifications, leading to the overexpression of oncogenes, are a cardinal feature of lung cancer and directly contribute to its pathogenesis. To uncover such novel alterations, we performed an array-based comparative genomic hybridization survey of 128 non-small-cell lung cancer cell lines and tumors. Prominent among our findings, we identified recurrent high-level amplification at cytoband 22q11.21 in 3% of lung cancer specimens, with another 11% of specimens exhibiting low-level gain spanning that locus. The 22q11.21 amplicon core contained eight named genes, only four of which were overexpressed (by transcript pro. ling) when amplified. Among these, CRKL encodes an adapter protein functioning in signal transduction, best known as a substrate of the BCR-ABL kinase in chronic myelogenous leukemia. RNA-interference-mediated knockdown of CRKL in lung cancer cell lines with (but not without) amplification led to significantly decreased cell proliferation, cell-cycle progression, cell survival, and cell motility and invasion. In addition, overexpression of CRKL in immortalized human bronchial epithelial cells led to enhanced growth factor-independent cell growth. Our findings indicate that amplification and resultant overexpression of CRKL contribute to diverse oncogenic phenotypes in lung cancer, with implications for targeted therapy, and highlight a role of adapter proteins as primary genetic drivers of tumorigenesis. Oncogene (2010) 29, 1421-1430; doi:10.1038/onc.2009.437; published online 7 December 2009	[Kim, Y. H.; Kwei, K. A.; Salari, K.; Kao, J.; Pollack, J. R.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Salari, K.; Hernandez-Boussard, T.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Pacyna-Gengelbach, M.] Univ Hosp Charite, Inst Pathol, Berlin, Germany; [Wang, P.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Petersen, I.] Univ Klinikum Jena, Inst Pathol, Jena, Germany	Stanford University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Stanford University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Fred Hutchinson Cancer Center; Friedrich Schiller University of Jena	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, CCSR Bldg,Room 3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu			NIH [R01 CA97139, SPORE P50CA70907, EDRN U01CA084971]; DOD VITAL; Longenbaugh Foundations; TRDRP [17FT-0062]; Deutsche Krebshilfe [108003]; Medical Scientist Training Program; NATIONAL CANCER INSTITUTE [R01CA097139, T32CA009151, U01CA084971, P50CA070907] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD VITAL; Longenbaugh Foundations; TRDRP; Deutsche Krebshilfe(Deutsche Krebshilfe); Medical Scientist Training Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the SFGF for fabrication of microarrays and the SMD for database support. We thank Eon Rios for assistance with flow cytometry analysis. We also thank the members of the Pollack lab for helpful discussion. This work was supported in part by grants from the NIH: R01 CA97139 (JRP), SPORE P50CA70907 (JDM), EDRN U01CA084971 (AFG); DOD VITAL (JDM); Longenbaugh Foundations (JDM); TRDRP (17FT-0062; KAK) and the Deutsche Krebshilfe: 108003 (IP). KS was supported by the Medical Scientist Training Program and is a Paul & Daisy Soros fellow.	Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; DALY RJ, 1994, ONCOGENE, V9, P2723; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Gay B, 1999, INT J CANCER, V83, P235, DOI 10.1002/(SICI)1097-0215(19991008)83:2<235::AID-IJC15>3.0.CO;2-B; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2003, CANCER RES, V63, P6272; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Singer CF, 2006, ONCOL REP, V15, P353; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	33	54	54	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1421	1430		10.1038/onc.2009.437	http://dx.doi.org/10.1038/onc.2009.437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966867	Green Accepted			2022-12-28	WOS:000275392400002
J	Ishikawa, F; Miyoshi, H; Nose, K; Shibanuma, M				Ishikawa, F.; Miyoshi, H.; Nose, K.; Shibanuma, M.			Transcriptional induction of MMP-10 by TGF-beta, mediated by activation of MEF2A and downregulation of class IIa HDACs	ONCOGENE			English	Article						TGF-beta; MMP-10; MEF2A; class IIa HDACs	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASES; MYOGENIC DIFFERENTIATION; CELL CARCINOMA; EXPRESSION; CANCER; PROTEIN; GENE; REPRESSES	Transforming growth factor (TGF)-beta regulates the expression of matrix metalloproteinases (MMPs) and components of the extracellular matrix, thereby profoundly affecting the microenvironment of cells including cancerous ones. We studied MMP-10 induction by TGF-beta in mammary epithelial cells and found that the induction was dependent on the myocyte enhancer factor (MEF)-2 transcription factor. TGF-beta upregulated the gene promoter through the MEF2 site, and knockdown of the MEF2A transcription factor negatively affected MMP-10 induction, whereas its overexpression had a positive effect on the induction. In response to TGF-beta, acetylation and concomitant binding of MEF2A to the promoter region increased, thus suggesting a critical role of MEF2A in transactivation of MMP-10 by TGF-beta. Consistent with the fact that class IIa histone deacetylases (HDACs) interact with MEF2 and suppress transcription, knockdown of HDACs increased and their overexpression inhibited MMP-10 expression. Intriguingly, TGF-beta promoted proteasome-dependent degradation of HDACs. Consistent with this, acetylation of core histones was increased around the MEF2 site of the MMP-10 promoter by TGF-beta and alleviated by overexpression of HDACs. Collectively, it is possible that TGF-beta transcriptionally upregulated MMP-10 through activation of MEF2A, concomitant with acetylation of core histones increasing around the promoter, as a consequence of degradation of the class IIa HDACs. Oncogene (2010) 29, 909-919; doi:10.1038/onc.2009.387; published online 23 November 2009	[Ishikawa, F.; Nose, K.; Shibanuma, M.] Showa Univ, Sch Pharm, Dept Canc Cell Biol, Shinagawa Ku, Tokyo 1428555, Japan; [Miyoshi, H.] RIKEN BioResource Ctr, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki, Japan	Showa University; RIKEN	Shibanuma, M (corresponding author), Showa Univ, Sch Pharm, Dept Canc Cell Biol, Shinagawa Ku, Tokyo 1428555, Japan.	smotoko@pharm.showa-u.ac.jp	Miyoshi, Hiroyuki/G-9808-2013		Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan [19570185]	Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Eric N Olson (University of Texas Southwestern Medical School, Dallas, TX, USA) for his generous gift of the MMP-10 promoter luciferase constructs. We also thank Ms E Kaneko and Ms T Kaneko for contributing to this work as a project for their bachelor's degree. This work was supported in part by a Grant-in-Aid for Scientific Research (C) (19570185) and the High-Technology Research Center Project from the Ministry for Education, Culture Sports, Science and Technology (MEXT) of Japan, and also by the High-Tech Research Centre Project for Private Universities: a matching fund subsidy from MEXT, 2007-2009.	Angelelli C, 2008, NUCLEIC ACIDS RES, V36, P915, DOI 10.1093/nar/gkm1114; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040; Cho NH, 2004, ONCOGENE, V23, P845, DOI 10.1038/sj.onc.1207140; Clark IA, 2008, INT J BIOCHEM CELL B, V40, P1362, DOI 10.1016/j.biocel.2007.12.006; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Gill JH, 2004, NEOPLASIA, V6, P777, DOI 10.1593/neo.04283; Impola U, 2004, J PATHOL, V202, P14, DOI 10.1002/path.1479; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Ishikawa F, 2008, EXP CELL RES, V314, P2131, DOI 10.1016/j.yexcr.2008.03.013; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kanome T, 2007, ONCOGENE, V26, P5991, DOI 10.1038/sj.onc.1210423; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Mathew R, 2002, CANCER DETECT PREV, V26, P222, DOI 10.1016/S0361-090X(02)00035-1; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Miyata Y, 2007, EUR UROL, V52, P791, DOI 10.1016/j.eururo.2006.12.028; Mori K, 2006, J BIOL CHEM, V281, P22048, DOI 10.1074/jbc.M513111200; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nakamura H, 1998, EUR J BIOCHEM, V253, P67, DOI 10.1046/j.1432-1327.1998.2530067.x; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Weeks BH, 2001, CANCER RES, V61, P7435; WINDSOR LJ, 1993, J BIOL CHEM, V268, P17341; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zhao M, 1999, MOL CELL BIOL, V19, P21	45	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					909	919		10.1038/onc.2009.387	http://dx.doi.org/10.1038/onc.2009.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935709				2022-12-28	WOS:000274397800013
J	Jang, GY; Jeon, JH; Cho, SY; Shin, DM; Kim, CW; Jeong, EM; Bae, HC; Kim, TW; Lee, SH; Choi, Y; Lee, DS; Park, SC; Kim, IG				Jang, G-Y; Jeon, J-H; Cho, S-Y; Shin, D-M; Kim, C-W; Jeong, E. M.; Bae, H. C.; Kim, T. W.; Lee, S-H; Choi, Y.; Lee, D-S; Park, S-C; Kim, I-G			Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappa B activity in hypoxic tumor cells	ONCOGENE			English	Article						apoptosis; caspase 3; hypoxia-inducible factor-1; NF-kappa B; transglutaminase 2	TISSUE TRANSGLUTAMINASE; OXIDATIVE STRESS; CANCER-THERAPY; BREAST-CANCER; GENE-EXPRESSION; DRUG-RESISTANT; IDENTIFICATION; ACTIVATION; PROTEIN; ALPHA	The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-kappa B pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an antiapoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy. Oncogene (2010) 29, 356-367; doi:10.1038/onc.2009.342; published online 19 October 2009	[Jang, G-Y; Cho, S-Y; Shin, D-M; Kim, C-W; Jeong, E. M.; Lee, S-H; Choi, Y.; Park, S-C; Kim, I-G] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, AARC, Seoul 110799, South Korea; [Jeon, J-H] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 110799, South Korea; [Bae, H. C.; Kim, T. W.] Korea Univ, Grad Sch Med, Lab Infect & Immunol, Seoul, South Korea; [Lee, D-S] Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU)	Kim, IG (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, AARC, 28 Yongon Dong, Seoul 110799, South Korea.	igkim@plaza.snu.ac.kr	Jeon, Ju-Hong/D-5740-2012; Lee, Dong-Sup/J-2777-2012	Kim, Chai-Wan/0000-0001-5105-2829; Jeong, Eui Man/0000-0003-0692-2033; /0000-0001-8564-2392; Jeon, Ju-Hong/0000-0002-5603-2955	Korea Science and Engineering Foundation [R11-2002-097-09005-0, R01-2005000-10364-0]; Research Program for New Drug Target Discovery [M10748000296-07N4800-29610]; Korea Ministry of Education, Science and Technology	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Research Program for New Drug Target Discovery(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Dr YD Kim for critical comments on this paper. We also thank Dr Shigetaka Kitajima (Tokyo Medical and Dental University, Japan) for providing cIAP2 reporter construct. This work was supported by the grants from Korea Science and Engineering Foundation (R11-2002-097-09005-0 and R01-2005000-10364-0) and also by the Research Program for New Drug Target Discovery (M10748000296-07N4800-29610). GYJ, SYC, EMJ, SHL and YC were supported by the graduate program of BK21, Korea Ministry of Education, Science and Technology.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Antonyak MA, 2006, P NATL ACAD SCI USA, V103, P18609, DOI 10.1073/pnas.0604844103; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brunelle JK, 2002, APOPTOSIS, V7, P475, DOI 10.1023/A:1020668923852; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dirmeier R, 2004, METHOD ENZYMOL, V381, P589; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com; Jeon JH, 2004, EXP MOL MED, V36, P576, DOI 10.1038/emm.2004.74; Jeon JH, 2003, EMBO J, V22, P5273, DOI 10.1093/emboj/cdg495; Jeon JH, 2003, FEBS LETT, V534, P180, DOI 10.1016/S0014-5793(02)03836-X; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kuhlicke J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001364; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006; Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45	45	102	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					356	367		10.1038/onc.2009.342	http://dx.doi.org/10.1038/onc.2009.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838207				2022-12-28	WOS:000273793200005
J	Reed, CA; Mayhew, CN; McClendon, AK; Yang, X; Witkiewicz, A; Knudsen, ES				Reed, C. A.; Mayhew, C. N.; McClendon, A. K.; Yang, X.; Witkiewicz, A.; Knudsen, E. S.			RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1	ONCOGENE			English	Article						retinoblastoma tumor suppressor; aflatoxin B1; carbon tetrachloride; DNA damage; cell cycle; hepatocellular carcinoma	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; HEPATITIS-C; HEPATOCELLULAR CARCINOMAS; PROLIFERATION; GENES; PATHOGENESIS; PROTEINS; CANCER; 13Q	Hepatocellular carcinoma (HCC) is a significant worldwide health concern that is associated with discrete etiological events, encompassing viral infection, metabolic stress and genotoxic compounds. In particular, exposure to the genotoxic hepatocarcinogen aflatoxin B1 (AFB1) is a significant factor in the genesis of human liver cancer. Presumably, genetic events associated with HCC could influence the effect of environmental insults, yielding a predilection for tumor development. The retinoblastoma (RB) tumor suppressor pathway is functionally inactivated in HCC through discrete mechanisms; however, the role of RB in suppressing tumorigenesis in this disease is poorly understood. Therefore, we analysed how RB status affects the response to AFB1 in reference to acute exposures and tumor development reflective of chronic exposure. Liver-specific Rb deletion resulted in an aberrant proliferative response to AFB1. This cell-cycle induction was associated with increased levels of secondary genetic damage and failure in appropriate cell-cycle coupling. This effect of RB loss was unique to AFB1 and involved the induction of a non-canonical proliferative pathway, and was not merely reflective of the overall cell-cycle deregulation or aberrant regenerative responses. The acute responses to AFB1 exposure presaged aberrations in hepatocyte nuclear morphology and ploidy with RB loss. Correspondingly, RB-deficient livers showed significantly enhanced susceptibility to liver tumorigenesis initiated by AFB1. Combined, these studies show that RB has a critical role in mediating checkpoint responses in liver tissue to maintain genome integrity and in suppressing tumorigenesis. Oncogene (2009) 28, 4434-4443; doi:10.1038/onc.2009.303; published online 19 October 2009	[Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Mayhew, C. N.] Cincinnati Childrens Hosp, Res Fdn, Div Dev Biol, Cincinnati, OH USA; [Witkiewicz, A.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org	Mayhew, Christopher N/AGB-4929-2022		NCI NIH HHS [R01 CA127387-05, R01 CA127387] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA127387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azechi H, 2001, ONCOLOGY-BASEL, V60, P346, DOI 10.1159/000058531; Bioulac-Sage P, 2003, HEPATOLOGY, V37, P480, DOI 10.1053/jhep.2003.50058; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; DeGregori J, 2006, CURR MOL MED, V6, P739; Donehower LA, 1997, CANCER SURV, V29, P329; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; FUJIMOTO Y, 1994, CANCER RES, V54, P281; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen ES, 2006, CURR MOL MED, V6, P749; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; LAZAREVA MN, 1981, ONCODEV BIOL MED, V2, P89; Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450; Mayhew CN, 2007, GASTROENTEROLOGY, V133, P976, DOI 10.1053/j.gastro.2007.06.025; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; McGivern DR, 2009, ANNU REV PATHOL-MECH, V4, P399, DOI 10.1146/annurev.pathol.4.110807.092202; Munakata T, 2005, P NATL ACAD SCI USA, V102, P18159, DOI 10.1073/pnas.0505605102; Munakata T, 2007, PLOS PATHOG, V3, P1335, DOI 10.1371/journal.ppat.0030139; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Wikenheiser-Brokamp KA, 2006, CELL MOL LIFE SCI, V63, P767, DOI 10.1007/s00018-005-5487-3; Yang XP, 2003, CANCER RES, V63, P7753; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	30	20	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4434	4443		10.1038/onc.2009.303	http://dx.doi.org/10.1038/onc.2009.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19838213	Green Accepted			2022-12-28	WOS:000272876500003
J	Li, XF; Yan, PJ; Shao, ZM				Li, X-F; Yan, P-J; Shao, Z-M			Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer	ONCOGENE			English	Article						microRNA; breast cancer; metastasis; uPA; mouse xenograft model	MICRORNA TARGETS; MESSENGER-RNA; CELL-MIGRATION; METASTASIS; CARCINOMA; PROGNOSIS; RECEPTOR; SYSTEM; GROWTH; DEMETHYLATION	Emerging evidence suggests the potential involvement of altered regulation of miRNAs in the pathogenesis of cancers, and these miRNAs are thought to be functional as tumor suppressors or oncogenes. Using miRNA arrays, we identified an miRNA differentially expressed between the MDA-MB-231 cell line and its highly metastatic variant. A bioinformatics search revealed a potential target site for miR-193b within the 3'UTR of uPA. Ectopic expression of miR-193b repressed the expression of sensor constructs harboring the 3'UTR of uPA in breast cancer cell lines. Anti-miR-193b treatment led to an increase of uPA protein and increased cell invasion in MDA-MB-231 cells. In contrast, overexpression of miR-193b significantly reduced uPA protein amounts and inhibited cell invasion in MDA-MB-231 and MDA-MB-435 cells. In an immunodeficient mouse model, miR-193b significantly inhibited the growth and dissemination of xenograft tumors. Immunohistochemical staining and real-time PCR assays showed that miR-193b was a negative regulator of the uPA gene in primary breast tumors. Our research reveals that miR-193b is closely associated with clinical metastasis and identifies miR-193b potentially targets uPA transcripts. Perturbation of the miRNA-mRNA pairing may have important roles in the initiation and development of breast cancer. Oncogene (2009) 28, 3937-3948; doi:10.1038/onc.2009.245; published online 24 August 2009	[Li, X-F; Yan, P-J; Shao, Z-M] Fudan Univ, Breast Canc Inst, Dept Breast Surg, Canc Hosp,Canc Inst,Shanghai Med Coll,Inst Biomed, Shanghai 200032, Peoples R China	Fudan University	Shao, ZM (corresponding author), Fudan Univ, Breast Canc Inst, Dept Breast Surg, Canc Hosp,Canc Inst,Shanghai Med Coll,Inst Biomed, 270 Dongan Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com			National Basic Research Program of China [2006CB910501]; National Natural Science Foundation of China [30371580, 30572109]; Shanghai Science and Technology Committee [03J14019, 06DJ14004, 06DZ19504]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee)	This research was supported in part by grants from the National Basic Research Program of China (2006CB910501), National Natural Science Foundation of China (30371580, 30572109) and Shanghai Science and Technology Committee (03J14019, 06DJ14004, 06DZ19504).	ACHBAROU A, 1994, CANCER RES, V54, P2372; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Biermann JC, 2008, INT J MOL MED, V21, P251; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Castello R, 2007, THROMB RES, V120, P753, DOI 10.1016/j.thromres.2006.12.016; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Foekens JA, 2000, CANCER RES, V60, P636; Frandsen TL, 2001, CANCER RES, V61, P532; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li DQ, 2006, PROTEOMICS, V6, P3352, DOI 10.1002/pmic.200500617; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; McSherry EA, 2007, CELL MOL LIFE SCI, V64, P3201, DOI 10.1007/s00018-007-7388-0; Murchison EP, 2004, CURR OPIN CELL BIOL, V16, P223, DOI 10.1016/j.ceb.2004.04.003; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2004, CLIN CANCER RES, V10, P3035, DOI 10.1158/1078-0432.CCR-03-0545; Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751; Rabbani SA, 1998, INT J ONCOL, V12, P911; Rabbani SA, 2007, CANCER METAST REV, V26, P663, DOI 10.1007/s10555-007-9085-8; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; Tetu B, 2001, CANCER, V92, P2957, DOI 10.1002/1097-0142(20011201)92:11<2957::AID-CNCR10112>3.0.CO;2-6; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488	42	142	152	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3937	3948		10.1038/onc.2009.245	http://dx.doi.org/10.1038/onc.2009.245			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19701247				2022-12-28	WOS:000271471900008
J	Dai, J; Peng, L; Fan, K; Wang, H; Wei, R; Ji, G; Cai, J; Lu, B; Li, B; Zhang, D; Kang, Y; Tan, M; Qian, W; Guo, Y				Dai, J.; Peng, L.; Fan, K.; Wang, H.; Wei, R.; Ji, G.; Cai, J.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.			Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells	ONCOGENE			English	Article						osteopontin; angiogenesis; HUVEC; VEGF; signal pathway	BREAST-CANCER CELLS; NF-KAPPA-B; GROWTH-FACTOR; TUMOR PROGRESSION; SURVIVAL FACTOR; PERMEABILITY; MECHANISMS; APOPTOSIS; MIGRATION; KINASE	Angiogenesis is a key step in tumor growth and metastasis. The mechanism by which osteopontin (OPN) induces the angiogenesis of endothelial cells remains unclear. Here, we show that OPN confers cytoprotection through the activation of the PI3K/Akt pathway with subsequent upregulation of Bcl-xL and activation of nuclear factor-kappa B. OPN enhances the expression of vascular endothelial growth factor (VEGF) through the phosphorylation of AKT and extracellular signal-regulated kinase (ERK). In turn, OPN-induced VEGF activates PI3K/AKT and the ERK1/2 pathway as a positive feedback signal. Blocking the feedback signal by anti-VEGF antibody, PI3-kinase inhibitor or ERK inhibitor can partially inhibit the OPN-induced human umbilical vein endothelial cell (HUVEC) motility, proliferation and tube formation, while blocking the signal by anti-OPN or anti-alpha v beta 3 antibody completely abrogates the biological effects of OPN on HUVECs. In addition, blood vessel formation is also investigated in vivo. The antiangiogenesis efficacy of anti-OPN antibody in vivo is more effective than that of anti-VEGF antibody, which only blocks the feedback signals. These data show that OPN enhances angiogenesis directly through PI3K/AKT and ERK-mediated pathways with VEGF acting as a positive feedback signal. The results suggest that OPN might be a valuable target for developing novel antiangiogenesis therapy for treatment of cancer. Oncogene (2009) 28, 3412-3422; doi: 10.1038/onc.2009.189; published online 13 July 2009	[Dai, J.; Peng, L.; Fan, K.; Wang, H.; Ji, G.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China; [Dai, J.; Peng, L.; Fan, K.; Wang, H.; Ji, G.; Lu, B.; Li, B.; Zhang, D.; Kang, Y.; Tan, M.; Qian, W.; Guo, Y.] Second Mil Med Univ, Gen Hosp 301, Ctr Canc, Shanghai 200433, Peoples R China; [Zhang, D.; Tan, M.; Qian, W.; Guo, Y.] Shanghai Jiao Tong Univ, Coll Pharm, Natl Engn Res Ctr Antibody Med, Shanghai 200030, Peoples R China; [Zhang, D.; Tan, M.; Qian, W.; Guo, Y.] Shanghai Jiao Tong Univ, Coll Pharm, Shanghai Key Lab Cell Engn, Shanghai 200030, Peoples R China; [Wei, R.; Cai, J.] Shanghai Changzheng Hosp, Dept Ophthalmol, Shanghai, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University	Guo, Y (corresponding author), Second Mil Med Univ, Int Joint Canc Inst, Adm Bldg 10th 11th Floor,800 Xiang Yin Rd, Shanghai 200433, Peoples R China.	yjguo@smmu.edu.cn		Ji, Guanghui/0000-0003-3763-2311	National Natural Science Foundation of China; Shanghai Commission of Science and Technology; Ministry of Science and Technology of China; Shanghai Commission of Education; Shanghai Pudong Bureau of Science and Technology of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Commission of Science and Technology(Shanghai Science & Technology Committee); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Shanghai Commission of Education; Shanghai Pudong Bureau of Science and Technology of China	This study was supported in part by the grants from the National Natural Science Foundation of China, Shanghai Commission of Science and Technology, Ministry of Science and Technology of China (973 and 863 projects), Shanghai Commission of Education as well as a special grant from Shanghai Pudong Bureau of Science and Technology of China. JX Dai is a recipient of 'Pujiang' Research Scholarship from Shanghai Commission of Education.	ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ASANO M, 1995, CANCER RES, V55, P5296; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Brady H, 2002, CANCER RES, V62, P1439; Cao ZG, 2008, MOL IMMUNOL, V45, P3683, DOI 10.1016/j.molimm.2008.06.008; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1994, J CELL BIOCHEM, V56, P48, DOI 10.1002/jcb.240560109; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Jain S, 2006, CANCER RES, V66, P6638, DOI 10.1158/0008-5472.CAN-06-0661; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; L'Hote CGM, 2005, EXP CELL RES, V304, P417, DOI 10.1016/j.yexcr.2004.11.012; Nishiyama K, 2005, CIRCULATION, V112, P2840, DOI 10.1161/CIRCULATIONAHA.104.516898; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Senger DR, 1996, AM J PATHOL, V149, P293; Shijubo N, 2003, MICROSC RES TECHNIQ, V60, P186, DOI 10.1002/jemt.10257; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Solorzano CC, 2001, CANCER RES, V61, P7048; Standal T, 2004, EXP ONCOL, V26, P179; TOSHIFUMI S, 2003, J BIOL CHEM, V278, P5001; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; WU LW, 2000, J BIOL CHEM, V18; Xu GW, 2005, J CLIN INVEST, V115, P1060	33	220	232	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3412	3422		10.1038/onc.2009.189	http://dx.doi.org/10.1038/onc.2009.189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597469				2022-12-28	WOS:000270103300008
J	Komlodi-Pasztor, E; Trostel, S; Sackett, D; Poruchynsky, M; Fojo, T				Komlodi-Pasztor, E.; Trostel, S.; Sackett, D.; Poruchynsky, M.; Fojo, T.			Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells	ONCOGENE			English	Article						nuclear localization; mutant p53; platinum resistance	WILD-TYPE P53; NUCLEAR-LOCALIZATION SIGNALS; COLORECTAL ADENOCARCINOMA; SUBCELLULAR-LOCALIZATION; N-MYC; PROTEIN; ACCUMULATION; GENE; NEUROBLASTOMA; AMPLIFICATION	Previous studies have described one nuclear localization signal (NLSI) in p53 and speculated on two additional sites termed NLSII and NLSIII. Drug-resistant KB cells selected with cisplatin or oxaliplatin were found to have increased p53 levels and in oxaliplatin-selected cells, a larger p53 predominantly in the cytoplasm. In oxaliplatin-selected cells a single nucleotide deletion in the sequence-encoding amino acid 382, part of NLSIII, resulted in a frame shift and a 420 amino acid protein (p53(420)). We investigated explanations for the cytoplasmic sequestration of p53(420) while assessing the role, if any, of NLSII and NLSIII in p53 nuclear import. We found that neither NLSII nor NLSIII are essential for p53 nuclear localization. Furthermore, we confirmed p53(420) is able to tetramerize, transactivate a p21 promoter, bind dynein and that the reduced nuclear accumulation is not a consequence of increased p53 nuclear export. However, the association of p53(420) with importin-beta, essential for nuclear import, was significantly impaired. We conclude that despite sequence similarity to consensus NLSs neither NLSII nor NLSIII have roles in p53 nuclear transport. We also identified impaired association with importin as a novel mechanism of p53 cytoplasmic sequestration that impairs nuclear transport rendering cells functionally deficient in p53. Oncogene (2009) 28, 3111-3120; doi: 10.1038/onc.2009.166; published online 6 July 2009	[Komlodi-Pasztor, E.; Trostel, S.; Poruchynsky, M.; Fojo, T.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA; [Sackett, D.] NICHHD, Lab Integrat & Med Biophys, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Komlodi-Pasztor, E (corresponding author), NCI, Med Oncol Branch, NIH, 9000 Rockville Pike,B10 R13N260, Bethesda, MD 20892 USA.	komlodie@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010626, ZIABC010625, ZIASC006732] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 CA999999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Becker K, 2007, CELL DEATH DIFFER, V14, P1350, DOI 10.1038/sj.cdd.4402126; BOSARI S, 1995, AM J PATHOL, V147, P790; BOSARI S, 1994, JNCI-J NATL CANCER I, V86, P681, DOI 10.1093/jnci/86.9.681; Bristow RG, 2003, ONCOGENE, V22, P2960, DOI 10.1038/sj.onc.1206405; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1993, CANCER RES, V53, P4053; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; LANE DP, 1992, NATURE, V358, P16; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li Q, 2007, ONCOGENE, V26, P7885, DOI 10.1038/sj.onc.1210597; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; Oggionni M, 2005, ONCOLOGY-BASEL, V69, P154, DOI 10.1159/000087839; Ottaggio L, 2000, CARCINOGENESIS, V21, P1631, DOI 10.1093/carcin/21.9.1631; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scata KA, 2007, ADV EXP MED BIOL, V608, P70; Sembritzki O, 2002, NEURO-ONCOLOGY, V4, P171, DOI 10.1093/neuonc/4.3.171; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH AE, 1985, PROC R SOC SER B-BIO, V226, P43, DOI 10.1098/rspb.1985.0078; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Trostel SY, 2006, CELL CYCLE, V5, P2253, DOI 10.4161/cc.5.19.3291; Utama B, 2006, J CELL SCI, V119, P2457, DOI 10.1242/jcs.02974; WEISS J, 1995, BRIT J DERMATOL, V133, P23; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141	37	16	16	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3111	3120		10.1038/onc.2009.166	http://dx.doi.org/10.1038/onc.2009.166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581934	Green Accepted			2022-12-28	WOS:000269515100003
J	Argast, GM; Croy, CH; Couts, KL; Zhang, Z; Litman, E; Chan, DC; Ahn, NG				Argast, G. M.; Croy, C. H.; Couts, K. L.; Zhang, Z.; Litman, E.; Chan, D. C.; Ahn, N. G.			Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells	ONCOGENE			English	Article						plexin; semaphorin; B-Raf; melanoma; tumor suppressor	GTPASE-ACTIVATING PROTEIN; CONTROLS INVASIVE GROWTH; R-RAS; GENE-EXPRESSION; BRAF MUTATIONS; SEMAPHORIN RECEPTORS; EPITHELIAL-CELLS; AXON GUIDANCE; CANCER; RHO	Human melanomas show oncogenic B-Raf mutations, which activate the B-Raf/MKK/ERK cascade. We screened microarrays to identify cellular targets of this pathway, and found that genes upregulated by B-Raf/MKK/ERK showed highest association with cell-cycle regulators, whereas genes downregulated were most highly associated with axon guidance genes, including plexin-semaphorin family members. Plexin B1 was strongly inhibited by mitogen-activated protein kinase signaling in melanoma cells and melanocytes. In primary melanoma cells, plexin B1 blocked tumorigenesis as measured by growth of colonies in soft agar, spheroids in extracellular matrix and xenograft tumors. Tumor suppression depended on residues in the C-terminal domain of plexin B1, which mediate receptor GTPase activating protein activity, and also correlated with AKT inhibition. Interestingly, the inhibitory response to plexin B1 was reduced or absent in cells from a matched metastatic tumor, suggesting that changes occur in metastatic cells which bypass the tumor-suppressor mechanisms. Plexin B1 also inhibited cell migration, but this was seen in metastatic cells and not in matched primary cells. Thus, plexin B1 has tumor-suppressor function in early-stage cells, although suppressing migration in late-stage cells. Our findings suggest that B-Raf/MKK/ERK provides a permissive environment for melanoma genesis by modulating plexin B1. Oncogene (2009) 28, 2697-2709; doi:10.1038/onc.2009.133; published online 1 June 2009	[Litman, E.; Ahn, N. G.] Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; [Zhang, Z.; Chan, D. C.] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Med Oncol, Aurora, CO USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus	Ahn, NG (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Campus Box 215,Room 76,Cristol Bldg, Boulder, CO 80309 USA.	natalie.ahn@colorado.edu			NIH [R01-CA118972, P50-CA058187, F32-CA105796, ACS-PF-04- 152, T32-GM008759]; NATIONAL CANCER INSTITUTE [R01CA118972, F32CA105796, P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Meenhard Herlyn for providing melanoma cell lines used in this study, and Silvio Gutkind, Kun-liang Guan, Xuedong Liu and Andrey Sorokin for expression plasmids. We also thank Norma Aumen for tumor sectioning, Helen Marshall for microarray analysis and Micah Hamady and Rob Knight for providing access to GO-Getter. This work was supported by NIH awards R01-CA118972 (NGA) and P50-CA058187 ( DC), and fellowship awards F32-CA105796 (GMA), ACS-PF-04- 152 (CHC) and T32-GM008759 (KLC).	Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Basile JR, 2007, J BIOL CHEM, V282, P34888, DOI 10.1074/jbc.M705467200; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bogenrieder T, 2002, CRIT REV ONCOL HEMAT, V44, P1, DOI 10.1016/S1040-8428(01)00196-2; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Brose MS, 2002, CANCER RES, V62, P6997; Charest PG, 2007, BIOCHEM J, V401, P377, DOI 10.1042/BJ20061432; Conrotto P, 2005, BLOOD, V105, P4321, DOI 10.1182/blood-2004-07-2885; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; COX AD, 1994, ONCOGENE, V9, P3281; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Fujisawa H, 2004, J NEUROBIOL, V59, P24, DOI 10.1002/neu.10337; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Ito Y, 2006, EMBO REP, V7, P704, DOI 10.1038/sj.embor.7400737; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Kessler O, 2004, CANCER RES, V64, P1008, DOI 10.1158/0008-5472.CAN-03-3090; Koo HM, 2002, P NATL ACAD SCI USA, V99, P3052, DOI 10.1073/pnas.052707699; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mora N, 2007, CANCER IMMUNOL IMMUN, V56, P535, DOI 10.1007/s00262-006-0205-z; Nakada M, 2005, AM J PATHOL, V167, P565, DOI 10.1016/S0002-9440(10)62998-7; Negishi M, 2005, CELL MOL LIFE SCI, V62, P1363, DOI 10.1007/s00018-005-5018-2; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Oinuma I, 2004, J NEUROSCI, V24, P11473, DOI 10.1523/JNEUROSCI.3257-04.2004; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rincon-Arano H, 2003, CANCER, V97, P575, DOI 10.1002/cncr.11093; Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Shields JM, 2007, CANCER RES, V67, P1502, DOI 10.1158/0008-5472.CAN-06-3311; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tian F, 2003, CANCER RES, V63, P8284; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhuang L, 2005, J CLIN PATHOL, V58, P1163, DOI 10.1136/jcp.2005.025957	54	43	44	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2697	2709		10.1038/onc.2009.133	http://dx.doi.org/10.1038/onc.2009.133			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483722	Green Accepted			2022-12-28	WOS:000268452900001
J	Mestdagh, P; Fredlund, E; Pattyn, F; Schulte, JH; Muth, D; Vermeulen, J; Kumps, C; Schlierf, S; De Preter, K; Van Roy, N; Noguera, R; Laureys, G; Schramm, A; Eggert, A; Westermann, F; Speleman, F; Vandesompele, J				Mestdagh, P.; Fredlund, E.; Pattyn, F.; Schulte, J. H.; Muth, D.; Vermeulen, J.; Kumps, C.; Schlierf, S.; De Preter, K.; Van Roy, N.; Noguera, R.; Laureys, G.; Schramm, A.; Eggert, A.; Westermann, F.; Speleman, F.; Vandesompele, J.			MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors	ONCOGENE			English	Article						MYCN; c-MYC; microRNA; neuroblastoma	B-CELL LYMPHOMAS; C-MYC; N-MYC; TRANSCRIPTIONAL REPRESSION; EXPRESSION SIGNATURES; PATHWAY DEREGULATION; NEUROBLASTOMA; DIFFERENTIATION; TARGET; GROWTH	Increased activity of MYC protein-family members is a common feature in many cancers. Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions. On the basis of an integrated approach including miRNA and messenger RNA (mRNA) gene expression data we show that miRNA activation contributes to widespread mRNA repression, both in c-MYC- and MYCN-activated tumors. c-MYC/MYCN-induced miRNA activation was shown to be dependent on c-MYC/MYCN promoter binding as evidenced by chromatin immunoprecipitation. Finally, we show that pathways, repressed through c-MYC/MYCN miRNA activation, are highly correlated to tumor aggressiveness and are conserved across different tumor entities suggesting that c-MYC/MYCN activate a core set of miRNAs for cooperative repression of common transcriptional programs related to disease aggressiveness. Our results uncover a widespread correlation between miRNA activation and c-MYC/MYCN-mediated coding gene expression modulation and further substantiate the overlapping functions of c-MYC and MYCN in the process of tumorigenesis. Oncogene (2010) 29, 1394-1404; doi:10.1038/onc.2009.429; published online 30 November 2009	[Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, MRB, B-9000 Ghent, Belgium; [Schulte, J. H.; Schlierf, S.; Schramm, A.; Eggert, A.] Univ Childrens Hosp, Essen, Germany; [Muth, D.; Westermann, F.] German Canc Res Ctr, Dept Tumour Genet, D-6900 Heidelberg, Germany; [Noguera, R.] Med Sch Valencia, Valencia, Spain	Ghent University; Ghent University Hospital; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ)	Vandesompele, J (corresponding author), Ghent Univ Hosp, Ctr Med Genet, MRB, Pintelaan 185, B-9000 Ghent, Belgium.	Joke.Vandesompele@UGent.be	Schulte, Johannes H/G-3981-2010; Schulte, Johannes H./V-2474-2018; speleman, frank/AAR-5184-2020; Vandesompele, Jo/W-3411-2018; Westermann, Frank/F-7509-2013; De Preter, Katleen/I-7135-2013; Pattyn, Filip/A-4164-2015; laureys, genevieve/AAG-2390-2021; Eggert, Angelika/AAE-6907-2022; Schramm, Alexander/G-5688-2010	speleman, frank/0000-0002-6628-8559; Vandesompele, Jo/0000-0001-6274-0184; De Preter, Katleen/0000-0002-7726-5096; Pattyn, Filip/0000-0003-0858-6651; Eggert, Angelika/0000-0003-3476-8184; Schramm, Alexander/0000-0001-7670-7529; Mestdagh, Pieter/0000-0001-7821-9684; Schulte, Johannes Hubertus/0000-0003-0671-1201	Gent University [BOF 01D31406, BOF 01F07207, BOF 01Z09407]; Fondation pour la recherche Nuovo-Soldati; RTICC/ISCIII [RD06/0020/0102]; Fund for Scientific Research [G.0198.08, 31511809]; Belgian Kid's Fund; Stichting tegen Kanker; European Community [037260]	Gent University; Fondation pour la recherche Nuovo-Soldati(Fondation pour la Recherche Medicale); RTICC/ISCIII(Instituto de Salud Carlos III); Fund for Scientific Research; Belgian Kid's Fund; Stichting tegen Kanker; European Community(European Commission)	We acknowledge Q Wang and J Maris for providing the neuroblastoma microarray data set. This research was funded by the Gent University Research Fund (BOF 01D31406 to PM, BOF 01F07207 to FP, BOF 01Z09407 to J Vandesompele), the Fondation pour la recherche Nuovo-Soldati (J Vermeulen), RD06/0020/0102 from RTICC/ISCIII to RN, the Fund for Scientific Research (grant number: G.0198.08 and 31511809), the Belgian Kid's Fund and the Stichting tegen Kanker. KDP is a post-doctoral researcher with the Fund for Scientific Research-Flanders. We acknowledge the support of the European Community under the FP6 (project: STREP: EET-pipeline, number: 037260).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chang CC, 2000, AM J CLIN PATHOL, V113, P512, DOI 10.1309/YHFE-R65B-D3LK-3GGV; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Gartel AL, 2006, ONCOGENE, V25, P1989, DOI 10.1038/sj.onc.1209101; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Kramer MHH, 1998, BLOOD, V92, P3152, DOI 10.1182/blood.V92.9.3152.421a07_3152_3162; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Lee Y, 2008, NAT NEUROSCI, V11, P1137, DOI 10.1038/nn.2183; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Liu YC, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r77; Malynn BA, 2000, GENE DEV, V14, P1390; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun Y, 2009, BREAST CANCER RES TR, V118, P185, DOI 10.1007/s10549-008-0171-6; Tan LP, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp715; Van Roy N, 2006, GENE CHROMOSOME CANC, V45, P107, DOI 10.1002/gcc.20272; Vandesompele J, 2003, ONCOGENE, V22, P456, DOI 10.1038/sj.onc.1206148; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Watters JW, 2006, MOL CANCER THER, V5, P2444, DOI 10.1158/1535-7163.MCT-06-0340; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	45	96	98	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1394	1404		10.1038/onc.2009.429	http://dx.doi.org/10.1038/onc.2009.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946337				2022-12-28	WOS:000275170600014
J	Akech, J; Wixted, JJ; Bedard, K; van der Deen, M; Hussain, S; Guise, TA; van Wijnen, AJ; Stein, JL; Languino, LR; Altieri, DC; Pratap, J; Keller, E; Stein, GS; Lian, JB				Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; Guise, T. A.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Keller, E.; Stein, G. S.; Lian, J. B.			Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions	ONCOGENE			English	Article						Runx2; bone metastasis; prostate cancer tissue arrays	MATRIX METALLOPROTEINASES; TRANSCRIPTION FACTORS; TUMOR-CELLS; EXPRESSION; DIFFERENTIATION; INTERLEUKIN-8; SIALOPROTEIN; OSTEOCALCIN; ACTIVATION; PROMOTE	Runx2, a bone-specific transcriptional regulator, is abnormally expressed in highly metastatic prostate cancer cells. Here, we identified the functional activities of Runx2 in facilitating tumor growth and osteolysis. Our studies show that negligible Runx2 is found in normal prostate epithelial and non-metastatic LNCaP prostate cancer cells. In the intra-tibial metastasis model, high Runx2 levels are associated with development of large tumors, increased expression of metastasis-related genes (MMP9, MMP13, VEGF, Osteopontin) and secreted bone-resorbing factors (PTHrP, IL8) promoting osteolytic disease. Runx2 siRNA treatment of PC3 cells decreased cell migration and invasion through Matrigel in vitro, and in vivo shRunx2 expression in PC3 cells blocked their ability to survive in the bone microenvironment. Mechanisms of Runx2 function were identified in co-culture studies showing that PC3 cells promote osteoclastogenesis and inhibit osteoblast activity. The clinical significance of these findings is supported by human tissue microarray studies of prostate tumors at stages of cancer progression, in which Runx2 is expressed in both adenocarcinomas and metastatic tumors. Together these findings indicate that Runx2 is a key regulator of events associated with prostate cancer metastatic bone disease. Oncogene (2010) 29, 811-821; doi:10.1038/onc.2009.389; published online 16 November 2009	[Akech, J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Akech, J.; Wixted, J. J.; Bedard, K.; van der Deen, M.; Hussain, S.; van Wijnen, A. J.; Stein, J. L.; Languino, L. R.; Altieri, D. C.; Pratap, J.; Stein, G. S.; Lian, J. B.] Univ Massachusetts, Sch Med, Ctr Canc, Prostate Canc Discovery & Dev Program, Worcester, MA 01655 USA; [Wixted, J. J.] Univ Massachusetts, Sch Med, Dept Orthoped Surg & Rehabil, Worcester, MA 01655 USA; [Guise, T. A.] Indiana Univ, Sch Med, Dept Internal Med, Indianapolis, IN USA; [Languino, L. R.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA; [Keller, E.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Indiana University System; Indiana University-Purdue University Indianapolis; University of Massachusetts System; University of Massachusetts Worcester; University of Michigan System; University of Michigan	Lian, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	jane.lian@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019; Keller, Evan T/M-1446-2016	van Wijnen, Andre J./0000-0002-4458-0946; Keller, Evan T/0000-0002-7592-7535; Languino, Lucia/0000-0001-9011-7031	NIH [PO1CA082834, RO1CA89720, RO1CA090917, P01CA093900, SPORE P50CA69568, R01CA069158]; Our Danny Cancer Fund post-doctoral fellowship [ODCF 114357]; NATIONAL CANCER INSTITUTE [R01CA069158, P01CA082834, R01CA090917, R01CA089720, P01CA093900, R01CA109874, P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039588, R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Our Danny Cancer Fund post-doctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We acknowledge the following for providing us with prostate cancer cell lines: RWPE, George Barnes (Boston University School of Medicine); PC3-H and C4-2B, Leland Chung (Emory University School of Medicine). This work was supported by NIH Grants PO1CA082834 (GSS); RO1CA89720 (LRL); RO1CA090917 (DCA); P01CA093900 and SPORE P50CA69568 (EK); R01CA069158 (TAG); and Our Danny Cancer Fund post-doctoral fellowship, ODCF 114357 (JA). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.	Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303; Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Armstrong AP, 2008, PROSTATE, V68, P92, DOI 10.1002/pros.20678; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008-5472.CAN-05-2630; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Dai JL, 2004, CANCER RES, V64, P994, DOI 10.1158/0008-5472.CAN-03-1382; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Glinsky GV, 2006, CELL CYCLE, V5, P191, DOI 10.4161/cc.5.2.2320; Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007; Hall CL, 2006, J CELL BIOCHEM, V97, P661, DOI 10.1002/jcb.20735; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Inman CK, 2003, J BIOL CHEM, V278, P48684, DOI 10.1074/jbc.M308001200; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Li ZG, 2008, ONCOGENE, V27, P596, DOI 10.1038/sj.onc.1210694; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z; Morgia G, 2005, UROL RES, V33, P44, DOI 10.1007/s00240-004-0440-8; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Pratap J, 2006, CANCER METAST REV, V25, P589, DOI 10.1007/s10555-006-9032-0; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Pratap J, 2003, CANCER RES, V63, P5357; Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008-5472.CAN-08-1078; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Selvamurugan N, 2006, J CELL BIOCHEM, V99, P545, DOI 10.1002/jcb.20878; Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140; THALMANN GN, 1994, CANCER RES, V54, P2577; Yang QL, 2008, MATRIX BIOL, V27, P589, DOI 10.1016/j.matbio.2008.06.005; Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zaidi SK, 2007, NAT REV CANCER, V7, P454, DOI 10.1038/nrc2149; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200	44	200	207	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					811	821		10.1038/onc.2009.389	http://dx.doi.org/10.1038/onc.2009.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915614	Green Accepted			2022-12-28	WOS:000274397800004
J	Yoo, Y; Ho, HJ; Wang, C; Guan, JL				Yoo, Y.; Ho, H. J.; Wang, C.; Guan, J-L			Tyrosine phosphorylation of cofilin at Y68 by v-Src leads to its degradation through ubiquitin-proteasome pathway	ONCOGENE			English	Article						cofilin; protein phosphorylation; protein degradation; cell spreading	FOCAL ADHESION KINASE; ACTIN DEPOLYMERIZING FACTOR; CELL-MIGRATION; CANCER-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DOWN-REGULATION; N-WASP; ADF/COFILIN; DYNAMICS; MOTILITY	Cofilin is a major regulator of actin dynamics involved in the regulation of cell spreading and migration through its actin depolymerizing and severing activities. v-Src is an activated Src tyrosine kinase and a potent oncogene known to phosphorylate a variety of cellular proteins in cell transformation process including altered cell adhesion, spreading and migration. Recently, it has been suggested that cofilin is a potential substrate of v-Src (Rush et al., 2005). Here, we show direct tyrosine phosphorylation of cofilin by v-Src and identify Y68 as the major phosphorylation site. Cofilin phosphorylation at Y68 did not change its activity per se, but induced increased ubiquitination of cofilin and its degradation through the proteosome pathway. Furthermore, the negative effect of cofilin on cellular F-actin contents was inhibited by coexpression of v-Src, whereas that of cofilin mutant Y68F (Y68 mutated to F) was not affected, suggesting that v-Src-mediated cofilin phosphorylation at Y68 is required for the degradation of cofilin in vivo. Lastly, inhibition of cell spreading by v-Src was rescued partially by coexpression of cofilin, and to a greater extent by the Y68F mutant, which is not subjected to v-Src-induced degradation through phosphorylation, suggesting that v-Src-mediated changes in cell spreading is, at least in part, through inhibiting the function of cofilin through phosphorylating it at Y68. Together, these results suggest a novel mechanism by which cofilin is regulated by v-Src through tyrosine phosphorylation at Y68 that triggers the degradation of cofilin through ubiquitination proteosome pathway and consequently inhibits cofilin activity in reducing cellular F-actin contents and cell spreading. Oncogene (2010) 29, 263-272; doi:10.1038/onc.2009.319; published online 5 October 2009	[Yoo, Y.; Ho, H. J.; Wang, C.; Guan, J-L] Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA; [Guan, J-L] Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, JL (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Mol Med & Genet, Ann Arbor, MI 48109 USA.	jlguan@umich.edu	wang, chenran/N-6629-2013		NIH [GM48050]; NATIONAL CANCER INSTITUTE [R01CA150926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Xiaoyang Wu for discussions during the initial stages of the project. We thank our colleagues Huijun Wei, Ming Luo, Huaping Fan, Fei Liu, Chenran Wang, Richard Liang, Ann Park and Xiaofeng Zhao for their critical reading of the paper and helpful comments. This research was supported by NIH grant GM48050 to J-L Guan.	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Bailly M, 2003, CURR BIOL, V13, pR128, DOI 10.1016/S0960-9822(03)00072-1; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bianchi F, 2006, P NATL ACAD SCI USA, V103, P18981, DOI 10.1073/pnas.0605821103; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chaar Z, 2006, J BIOL CHEM, V281, P28193, DOI 10.1074/jbc.M605665200; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Christopher RA, 2000, INT J MOL MED, V5, P575; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gungabissoon RA, 2003, J HISTOCHEM CYTOCHEM, V51, P411, DOI 10.1177/002215540305100402; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Ichetovkin I, 2002, CURR BIOL, V12, P79, DOI 10.1016/S0960-9822(01)00629-7; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin R, 2006, CELL COMMUN ADHES, V13, P199, DOI 10.1080/15419060600848516; Martinez-Moczygemba M, 2007, J LEUKOCYTE BIOL, V81, P1137, DOI 10.1189/jlb.0706465; Meberg PJ, 2000, MOL NEUROBIOL, V21, P97, DOI 10.1385/MN:21:1-2:097; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ono S, 2003, BIOCHEMISTRY-US, V42, P13363, DOI 10.1021/bi034600x; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Samstag Y, 1996, J IMMUNOL, V156, P4167; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tsumura Y, 2005, BIOCHEM J, V387, P627, DOI 10.1042/BJ20041181; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Wakatsuki T, 2003, J CELL SCI, V116, P1617, DOI 10.1242/jcs.00340; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yan D, 2006, J CELL BIOL, V174, P415, DOI 10.1083/jcb.200511028; Yap CT, 2005, CELL MOTIL CYTOSKEL, V60, P153, DOI 10.1002/cm.20053; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoo YD, 2006, J BIOL CHEM, V281, P15352, DOI 10.1074/jbc.M511825200; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	62	48	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					263	272		10.1038/onc.2009.319	http://dx.doi.org/10.1038/onc.2009.319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802004	Green Accepted			2022-12-28	WOS:000273650000009
J	Konishi, J; Yi, F; Chen, X; Vo, H; Carbone, DP; Dang, TP				Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.			Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim	ONCOGENE			English	Article						Notch3; bim; apoptosis; lung cancer	DOWN-REGULATION; ACTIVATION; CELLS; GROWTH; BCL-2; INHIBITION; EXPRESSION; FAMILY; CANCER	Notch signaling is a highly conserved pathway important for normal embryonic development and cancer. We previously demonstrated a role for Notch3 in lung cancer pathogenesis. Notch3 inhibition resulted in tumor apoptosis and growth suppression. In vitro, these effects were enhanced when the epidermal growth factor receptor (EGFR) pathway was also inhibited, suggesting significant cross-talk between the two pathways. How Notch3 and epidermal growth factor receptor-mitogen-activated protein kinase (EGFR-MAPK) pathways cooperate in modulating apoptosis is not yet known. In this study, we provide evidence that Notch3 regulates Bim, a BH-3-only protein, via MAPK signaling. Furthermore, loss of Bim expression prevents tumor apoptosis induced by Notch3 inhibition. Using c-secretase inhibitor and erlotinib in a xenograft model, Bim induction and tumor inhibition were observed to be enhanced compared with either agent alone, consistent with our previous observation of significant synergism between Notch and EGFR-ras-MAPK signaling. Thus, our data support the hypothesis that Notch3 not only has a crucial role in lung cancer through regulating apoptosis, but also cooperates with the EGFR-MAPK pathway in modulating Bim. Oncogene (2010) 29, 589-596; doi: 10.1038/onc.2009.366; published online 2 November 2009	[Konishi, J.; Yi, F.; Chen, X.; Vo, H.; Carbone, D. P.; Dang, T. P.] Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, Nashville, TN 37232 USA	Vanderbilt University	Dang, TP (corresponding author), Vanderbilt Ingram Canc Ctr, Div Hematol & Med Oncol, 658 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	thao.p.dang@vanderbilt.edu	Nguyen, Phu-Huan Vo/HGF-3643-2022; Sakakibara-Konishi, Jun/G-5941-2012	Nguyen, Phu-Huan Vo/0000-0002-6326-1692; 	 [NCI 1R01 CA115707]; NATIONAL CANCER INSTITUTE [R01CA115707] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Grant NCI 1R01 CA115707.	Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Biswas SC, 2007, J BIOL CHEM, V282, P29368, DOI 10.1074/jbc.M702634200; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Campos AH, 2002, CIRC RES, V91, P999, DOI 10.1161/01.RES.0000044944.99984.25; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Duechler M, 2005, LEUKEMIA, V19, P260, DOI 10.1038/sj.leu.2403592; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Heiser PW, 2004, CELL CYCLE, V3, P270; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Urbich C, 2005, FASEB J, V19, P974, DOI 10.1096/fj.04-2727fje; Wang T, 2007, CELL SIGNAL, V19, P2458, DOI 10.1016/j.cellsig.2007.07.019; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	27	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					589	596		10.1038/onc.2009.366	http://dx.doi.org/10.1038/onc.2009.366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881544	Green Accepted			2022-12-28	WOS:000274084600011
J	Tesniere, A; Schlemmer, F; Boige, V; Kepp, O; Martins, I; Ghiringhelli, F; Aymeric, L; Michaud, M; Apetoh, L; Barault, L; Mendiboure, J; Pignon, JP; Jooste, V; van Endert, P; Ducreux, M; Zitvogel, L; Piard, F; Kroemer, G				Tesniere, A.; Schlemmer, F.; Boige, V.; Kepp, O.; Martins, I.; Ghiringhelli, F.; Aymeric, L.; Michaud, M.; Apetoh, L.; Barault, L.; Mendiboure, J.; Pignon, J-P; Jooste, V.; van Endert, P.; Ducreux, M.; Zitvogel, L.; Piard, F.; Kroemer, G.			Immunogenic death of colon cancer cells treated with oxaliplatin	ONCOGENE			English	Article						apoptosis; dendritic cells; OXP; calreticulin; HMGB1; TLR4	CALRETICULIN EXPOSURE; ANTICANCER CHEMOTHERAPY; COLORECTAL-CANCER; INDUCED APOPTOSIS; IMMUNE-SYSTEM; ANTIGEN; RECEPTOR; POLYMORPHISMS; RADIOTHERAPY; EXPRESSION	Both the pre-apoptotic exposure of calreticulin (CRT) and the post-apoptotic release of high-mobility group box 1 protein (HMGB1) are required for immunogenic cell death elicited by anthracyclins. Here, we show that both oxaliplatin (OXP) and cisplatin (CDDP) were equally efficient in triggering HMGB1 release. However, OXP, but not CDDP, stimulates pre-apoptotic CRT exposure in a series of murine and human colon cancer cell lines. Subcutaneous injection of OXP-treated colorectal cancer (CRC), CT26, cells induced an anticancer immune response that was reduced by short interfering RNA-mediated depletion of CRT or HMGB1. In contrast, CDDP-treated CT26 cells failed to induce anticancer immunity, unless recombinant CRT protein was absorbed into the cells. CT26 tumors implanted in immunocompetent mice responded to OXP treatment in vivo, and this therapeutic response was lost when CRT exposure by CT26 cells was inhibited or when CT26 cells were implanted in immunodeficient mice. The knockout of toll-like receptor 4 (TLR4), the receptor for HMGB1, also resulted in a deficient immune response against OXP-treated CT26 cells. In patients with advanced (stage IV, Duke D) CRC, who received an OXP-based chemotherapeutic regimen, the loss-of-function allele of TLR4 (Asp299Gly in linkage disequilibrium with Thr399Ile, reducing its affinity for HMGB1) was as prevalent as in the general population. However, patients carrying the TLR4 loss-of-function allele exhibited reduced progression-free and overall survival, as compared with patients carrying the normal TLR4 allele. In conclusion, OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients. Oncogene (2010) 29, 482-491; doi: 10.1038/onc.2009.356; published online 2 November 2009	[Tesniere, A.; Schlemmer, F.; Kepp, O.; Martins, I.; Michaud, M.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Tesniere, A.; Schlemmer, F.; Kepp, O.; Martins, I.; Aymeric, L.; Michaud, M.; Apetoh, L.; Ducreux, M.; Zitvogel, L.; Kroemer, G.] Univ Paris 11, Orsay, France; [Boige, V.; Ducreux, M.] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France; [Ghiringhelli, F.] INSERM CRI 866, AVENIR Team, Dijon, France; [Ghiringhelli, F.] Ctr Georges Francois Leclerc, Dijon, France; [Aymeric, L.; Apetoh, L.; Zitvogel, L.] INSERM, U805, Villejuif, France; [Barault, L.; Piard, F.] CHU, Serv Anat Pathol, Dijon, France; [Barault, L.; Piard, F.] INSERM, U866, Dijon, France; [Mendiboure, J.; Pignon, J-P] Inst Gustave Roussy, Serv Biostat & Epidemiol, F-94805 Villejuif, France; [Jooste, V.] Registre Canc Digestifs, Dijon, France; [van Endert, P.] Univ Paris 05, INSERM, U580, Paris, France; [Zitvogel, L.] Inst Gustave Roussy, CIC BT507, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UNICANCER; Gustave Roussy; Institut Agro; AgroSup Dijon; Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1 39,Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Apetoh, Lionel/AIC-2384-2022; Kepp, Oliver/N-2763-2017; Ducreux, Michel/AAG-9415-2019; li, tao/B-2402-2008; Jooste, Valerie/AFW-1362-2022; KROEMER, Guido/B-4263-2013; van Endert, Peter/R-4606-2017; Ducreux, Michel/L-7012-2019; Kroemer, Guido/AAY-9859-2020; Barault, Ludovic/J-2472-2016; Apetoh, Lionel/G-3310-2014; Kepp, Oliver/GPX-8627-2022	Apetoh, Lionel/0000-0002-2774-438X; Kepp, Oliver/0000-0002-6081-9558; Ducreux, Michel/0000-0001-8649-7449; Jooste, Valerie/0000-0002-9902-0700; KROEMER, Guido/0000-0002-9334-4405; van Endert, Peter/0000-0003-3782-0750; Barault, Ludovic/0000-0001-5227-5047; Apetoh, Lionel/0000-0002-2774-438X; Schlemmer, Frederic/0000-0003-2113-7113; Boige, Valerie/0000-0002-7817-4663; ghiringhelli, francois/0000-0002-5465-8305; ZITVOGEL, laurence/0000-0003-1596-0998; PIGNON, Jean-Pierre/0000-0003-2047-1582; Aymeric, Laetitia/0000-0001-7459-7231	INSERM; FRM; Canceropole Ile-de-France; Institut National du Cancer; Fondation de France; Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche; Association for International Cancer Research (AICR); European Commission; La Ligue; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); FRM(Fondation pour la Recherche Medicale); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation de France(Fondation de France); Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche(French National Research Agency (ANR)); Association for International Cancer Research (AICR); European Commission(European CommissionEuropean Commission Joint Research Centre); La Ligue; ARC(Australian Research Council)	We thank all the investigators who participated in the FFCD 2000-05 clinical trial; Pierre Laurent Puig for help with DNA extraction and storage; and Patrick Gonin and IGR animal facility for helping with mouse breeding. This study was supported by INSERM (AT); FRM (FS); Canceropole Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche, Association for International Cancer Research (AICR), and the European Commission (ApoSys, ChemoRes, Death-Train, RIGHT) (GK); la Ligue and FRM (LA); a fellowship from La Ligue (IM); a fellowship from ARC (MM).	Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Blacher NE, 2005, PLOS BIOL, V3, P1070, DOI 10.1371/journal.pbio.0030185; BOUCHE CM, 2007, J CLIN ONCOL, V25, P4069; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Castedo M, 2006, ANN NY ACAD SCI, V1090, P35, DOI 10.1196/annals.1378.004; Ferwerda B, 2007, P NATL ACAD SCI USA, V104, P16645, DOI 10.1073/pnas.0704828104; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Hsu WM, 2005, ANN ONCOL, V16, P314, DOI 10.1093/annonc/mdi062; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; LAANE E, 2009, CELL DEATH DIFFER; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mehta AM, 2008, CANCER IMMUNOL IMMUN, V57, P197, DOI 10.1007/s00262-007-0362-8; Muggia FM, 2004, J CHEMOTHERAPY, V16, P77, DOI 10.1179/joc.2004.16.Supplement-1.77; Netea-Maier RT, 2008, CANCER RES, V68, P1572, DOI 10.1158/0008-5472.CAN-07-5020; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Sancho D, 2008, J CLIN INVEST, V118, P2098, DOI 10.1172/JCI34584; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Toquet C, 2007, ONCOL REP, V17, P1101; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wright CA, 2004, BIOL CHEM, V385, P763, DOI 10.1515/BC.2004.100; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zhang YN, 2006, IMMUNOL RES, V35, P151, DOI 10.1385/IR:35:1:151; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180	35	726	755	10	109	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					482	491		10.1038/onc.2009.356	http://dx.doi.org/10.1038/onc.2009.356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881547				2022-12-28	WOS:000274084600002
J	Said, N; Frierson, HF; Chernauskas, D; Conaway, M; Motamed, K; Theodorescu, D				Said, N.; Frierson, H. F., Jr.; Chernauskas, D.; Conaway, M.; Motamed, K.; Theodorescu, D.			The role of SPARC in the TRAMP model of prostate carcinogenesis and progression	ONCOGENE			English	Article						prostate neoplasms; SPARC/osteonectin; mice; TRAMP	CELL LUNG-CANCER; OVARIAN-CANCER; EXTRACELLULAR-MATRIX; TRANSGENIC MOUSE; CYSTEINE SPARC; POOR-PROGNOSIS; NULL MICE; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; ENHANCED GROWTH	SPARC (Secreted Protein Acidic and Rich in Cysteine), is a matricellular glycoprotein that is produced by tumor and/or neighboring stroma. In human prostate cancer, SPARC immunoreactivity is highest in metastatic lesions but distinct contributions of tumoral and stromal SPARC to tumorigenesis and progression are unclear. To determine the role of SPARC in primary prostate tumorigenesis, we crossed SPARC-null (SP-/-) with TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) mice. TRAMP(+)/SP-/- mice exhibited accelerated cancer development and progression. Compared to their TRAMP(+)/SP-/- counterparts, TRAMP(+)/SP+/+ tumors had fewer proliferating cells, and decreased cyclins A and D1 with increased p21(Cip) and p27(Kip). Similar effects on proliferation and cell-cycle regulators were observed in human prostate cancer cell lines, transiently transfected with pSPARC. TRAMP(+)/SP-/- tumors exhibited decreased stromal collagen, enhanced matrix metalloproteinase activity and increased vascular endothelial growth factor, proinflammatory cytokines. To determine the contribution of stromal SPARC, we evaluated subcutaneous tumor growth of TRAMP cell lines in syngeneic SP+/+ and SP-/- mice. Enhanced growth, decreased stromal collagen and increased proteolysis were noted in SP-/- mice. Our findings demonstrate that both tumor and stromal SPARC are limiting for primary prostate tumorigenesis and progression, through effects on the cell cycle and the creation of a less favorable tumor microenvironment. Oncogene (2009) 28, 3487-3498; doi: 10.1038/onc.2009.205; published online 13 July 2009	[Theodorescu, D.] Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22908 USA; [Said, N.; Chernauskas, D.; Theodorescu, D.] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Frierson, H. F., Jr.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Conaway, M.] Univ Virginia, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA; [Motamed, K.] Univ Virginia, Med Coll Georgia, Vasc Biol Ctr, Charlottesville, VA 22908 USA; [Theodorescu, D.] Univ Virginia, Paul Mellon Urol Canc Inst, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Urol, Box 800422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NIH [CA104106, K01-CA089689]; Georgia Cancer Coalition [GCC0023]; NATIONAL CANCER INSTITUTE [P01CA104106, K01CA089689] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH CA104106 (DT) and Georgia Cancer Coalition grant GCC0023 (KM) and the National Institutes of Health grants K01-CA089689 (KM).	Aycock RL, 2004, J INVEST DERMATOL, V123, P592, DOI 10.1111/j.0022-202X.2004.23316.x; Basu A, 1999, CELL GROWTH DIFFER, V10, P721; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555-007-9109-4; Cheetham S, 2008, BRIT J CANCER, V98, P1810, DOI 10.1038/sj.bjc.6604377; Chen NY, 2007, CANCER RES, V67, P6544, DOI 10.1158/0008-5472.CAN-07-1330; Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608; Chlenski A, 2007, ONCOGENE, V26, P4513, DOI 10.1038/sj.onc.1210247; Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357; Comstock CES, 2007, BRIT J CANCER, V96, P970, DOI 10.1038/sj.bjc.6603615; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Jacob K, 1999, CANCER RES, V59, P4453; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kahn SL, 2008, CANCER CYTOPATHOL, V114, P57, DOI 10.1002/cncr.23258; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kato Y, 2005, INT J MOL MED, V16, P263; Kelloff GJ, 2006, CLIN CANCER RES, V12, P3661, DOI 10.1158/1078-0432.CCR-06-1104; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807; Koukourakis MI, 2003, CANCER RES, V63, P5376; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; MAITLAND N, 2008, METASTASIS PROSTATE, P21; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Pan MR, 2008, EXP BIOL MED, V233, P456, DOI 10.3181/0709-RM-257; Pienta KJ, 2008, PROSTATE, V68, P629, DOI 10.1002/pros.20726; Podhajcer OL, 2008, CANCER METAST REV, V27, P523, DOI 10.1007/s10555-008-9135-x; Puolakkainen PA, 2004, MOL CANCER RES, V2, P215; Rodriguez-Jimenez FJ, 2007, ONCOL REP, V17, P1301; Roy S, 2007, MOL CANCER THER, V6, P2696, DOI 10.1158/1535-7163.MCT-07-0104; SAGE H, 1989, J MOL CELL CARDIOL, V21, P13, DOI 10.1016/0022-2828(89)90833-X; Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2; Said N, 2007, MOL CANCER RES, V5, P1015, DOI 10.1158/1541-7786.MCR-07-0001; Said N, 2007, AM J PATHOL, V170, P1054, DOI 10.2353/ajpath.2007.060903; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; Sansom OJ, 2007, GUT, V56, P1410, DOI 10.1136/gut.2006.116921; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Schultz C, 2002, CANCER RES, V62, P6270; Seraj MJ, 2001, CLIN CANCER RES, V7, P1516; Socha MJ, 2009, NEOPLASIA, V11, P126, DOI 10.1593/neo.81146; Sova P, 2006, CANCER EPIDEM BIOMAR, V15, P114, DOI 10.1158/1055-9965.EPI-05-0323; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Suzuki M, 2005, BRIT J CANCER, V92, P942, DOI 10.1038/sj.bjc.6602376; Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Wang YP, 2005, NEOPLASIA, V7, P748, DOI 10.1593/neo.05289; Wong SY, 2008, CLIN EXP METASTAS, V25, P109, DOI 10.1007/s10585-007-9126-2; Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024; Yamashita K, 2003, CANCER, V97, P2412, DOI 10.1002/cncr.11368; Yang EN, 2007, INT J CANCER, V121, P567, DOI 10.1002/ijc.22706	60	50	53	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3487	3498		10.1038/onc.2009.205	http://dx.doi.org/10.1038/onc.2009.205			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597474				2022-12-28	WOS:000270478300006
J	Ranjan, R; Thompson, EA; Yoon, K; Smart, RC				Ranjan, R.; Thompson, E. A.; Yoon, K.; Smart, R. C.			C/EBP alpha expression is partially regulated by C/EBP beta in response to DNA damage and C/EBP alpha-deficient fibroblasts display an impaired G(1) checkpoint	ONCOGENE			English	Article						C/EBP; DNA damage response; G(1)/S transition; p53	CCAAT/ENHANCER-BINDING-PROTEIN; TERMINAL ADIPOCYTE DIFFERENTIATION; CELL-CYCLE CHECKPOINTS; TRANSCRIPTION FACTORS; GENE PROMOTER; ONCOGENIC RAS; ANTIPROLIFERATIVE ROLE; DOWN-REGULATION; NUCLEAR FACTOR; PROLIFERATION	We observed that CCAAT/enhancer-binding protein (C/EBP)alpha is highly inducible in primary fibroblasts by DNA-damaging agents that induce strand breaks, alkylate and crosslink DNA as well as those that produce bulky DNA lesions. Fibroblasts deficient in C/EBP alpha (C/EBP alpha(-/-)) display an impaired G(1) checkpoint as evidenced by an inappropriate entry into the S-phase in response to DNA damage, and these cells also display an enhanced G(1)/S transition in response to mitogens. The induction of C/EBP alpha by DNA damage in fibroblasts does not require p53. Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts prepared from ultraviolet B (UVB)- and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-treated fibroblasts showed increased binding of C/EBP beta to a C/EBP consensus sequence and chromatin immunoprecipitation (ChIP) analysis also showed increased C/EBP beta binding to the C/EBP alpha promoter. To determine whether C/EBP beta has a function in the regulation of C/EBP alpha, we treated C/EBP beta(-/-) fibroblasts with UVB or MNNG. We observed that C/EBP alpha induction was impaired in both UVB- and MNNG-treated C/EBP beta(-/-) fibroblasts. Our study shows a novel function for C/EBP beta in the regulation of C/EBP alpha in response to DNA damage and provides definitive genetic evidence that C/EBP alpha has a critical role in the DNA damage G(1) checkpoint. Oncogene (2009) 28, 3235-3245; doi: 10.1038/onc.2009.176; published online 6 July 2009	[Ranjan, R.; Thompson, E. A.; Smart, R. C.] N Carolina State Univ, Cell Signaling & Canc Grp, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Yoon, K.] Natl Canc Ctr, Div Common Canc, Lung Canc Branch, Goyang Si, Gyeonggi Do, South Korea	University of North Carolina; North Carolina State University; National Cancer Center - Korea (NCC)	Smart, RC (corresponding author), N Carolina State Univ, Cell Signaling & Canc Grp, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA.	rcsmart@ncsu.edu		Smart, Robert/0000-0002-6767-6756	National Cancer Institute [CA46637]; National Institute of Environmental Health Sciences [ES12473]; NIEHS [ES007046]; NATIONAL CANCER INSTITUTE [R29CA046637, R01CA046637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012473, T32ES007046] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by grants from the National Cancer Institute (CA46637), the National Institute of Environmental Health Sciences (ES12473), and a training grant from the NIEHS (ES007046). We thank Brian Sayers for his technical support with DNA-damaging agents.	AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Berberich-Siebelt F, 2006, J IMMUNOL, V176, P4843, DOI 10.4049/jimmunol.176.8.4843; Cesena TI, 2008, MOL CELL ENDOCRINOL, V289, P94, DOI 10.1016/j.mce.2008.03.009; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; DROUET C, 1991, J IMMUNOL, V147, P1694; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Ewing SJ, 2008, CELL DEATH DIFFER, V15, P1734, DOI 10.1038/cdd.2008.105; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Halmos B, 2002, CANCER RES, V62, P528; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hulla JE, 2001, CARCINOGENESIS, V22, P89, DOI 10.1093/carcin/22.1.89; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Osada S, 1996, J BIOL CHEM, V271, P3891; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tang QQ, 2004, BIOCHEM BIOPH RES CO, V319, P235, DOI 10.1016/j.bbrc.2004.04.176; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Watkins PJ, 1996, CANCER RES, V56, P1063; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xu L, 2001, CANCER RES, V61, P3176; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	65	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3235	3245		10.1038/onc.2009.176	http://dx.doi.org/10.1038/onc.2009.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19581927	Green Accepted			2022-12-28	WOS:000269673400006
J	Peschiaroli, A; Scialpi, F; Bernassola, F; Pagano, M; Melino, G				Peschiaroli, A.; Scialpi, F.; Bernassola, F.; Pagano, M.; Melino, G.			The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73	ONCOGENE			English	Article						ubiquitin; F-box proteins; p73; degradation; proteasome	SCF UBIQUITIN-LIGASE; TRCP-MEDIATED DEGRADATION; KINASE C-ABL; TUMOR-SUPPRESSOR; BETA-TRCP; APOPTOTIC RESPONSE; REGULATES P73; P53; FAMILY; P63	The transcription factor p73, a member of the p53 family, mediates cell-cycle arrest and apoptosis in response to DNA damage-induced cellular stress, acting thus as a proapoptotic gene. Similar to p53, p73 activity is regulated by post-translational modi. cation, including phosphorylation, acetylation and ubiquitylation. In C. elegans, the F-box protein FSN-1 controls germline apoptosis by regulating CEP-1, the single ancestral p53 family member. Here we report that FBXO45, the human ortholog of FSN-1, binds specifically to p73 triggering its proteasome-dependent degradation. Importantly, SCFFBXO45 ubiquitylates p73 both in vivo and in vitro. Moreover, siRNA-mediated depletion of FBXO45 stabilizes p73 and concomitantly induces cell death in a p53-independent manner. All together, these results show that the orphan F-box protein FBXO45 regulates the stability of p73, highlighting a conserved pathway evolved from nematode to human by which the p53 members are regulated by an SCF-dependent mechanism. Oncogene (2009) 28, 3157-3166; doi: 10.1038/onc.2009.177; published online 6 July 2009	[Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; [Pagano, M.] NYU, Sch Med, Dept Pathol, Inst Canc, New York, NY USA; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA; [Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	University of Rome Tor Vergata; New York University; Howard Hughes Medical Institute; New York University; University of Leicester	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS Biochem Lab, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it		PESCHIAROLI, ANGELO/0000-0001-6311-2382; pagano, michele/0000-0003-3210-2442	Medical Research Council, UK; EU [LSHB-CT-019067]; Alleanza contro il Cancro [ACC12]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-20105471]; ISS [N526D5]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon [GGPO4110]; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research Fundation; Philip Morris USA Inc.; Philip Morris International; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R21CA125173, R37CA076584, R21CA161108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EU(European Commission); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); ISS; Italian Human ProteomeNet; Telethon(Fondazione Telethon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research Fundation; Philip Morris USA Inc.; Philip Morris International; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank V De Laurenzi for critically reading the manuscript. This study has been supported by the Medical Research Council, UK; grants from EU EPISTEM (LSHB-CT-019067), 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-20105471), ISS 'Program Italia-USA' N526D5, Italian Human ProteomeNet RBRN07BMCT_007 and Telethon (GGPO4110) to GM; and grants from the National Institutes of Health (R01-GM57587, R37-CA76584 and R21-CA125173) and Multiple Myeloma Research Fundation to MP. Research described in this article was also supported in part by Philip Morris USA Inc. and Philip Morris International to GM. MP is an Investigator with the Howard Hughes Medical Institute.	Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Agami R, 1999, NATURE, V399, P809; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bloom J, 2005, METHOD ENZYMOL, V399, P249, DOI 10.1016/S0076-6879(05)99017-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gao MX, 2008, CELL DEATH DIFFER, V15, P1054, DOI 10.1038/cdd.2008.30; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Hershko A, 2005, ANGEW CHEM INT EDIT, V44, P5932, DOI 10.1002/anie.200501724; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2003, ANN NY ACAD SCI, V1010, P9, DOI 10.1196/annals.1299.002; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Ou HD, 2007, EMBO J, V26, P3463, DOI 10.1038/sj.emboj.7601764; Parry G, 2004, SEMIN CELL DEV BIOL, V15, P221, DOI 10.1016/j.semcdb.2003.12.003; Perez-Losada J, 2005, ONCOGENE, V24, P5521, DOI 10.1038/sj.onc.1208799; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soond SM, 2008, CELL CYCLE, V7, P1214, DOI 10.4161/cc.7.9.5777; Thomas JH, 2006, GENOME RES, V16, P1017, DOI 10.1101/gr.5089806; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Watson IR, 2006, NEOPLASIA, V8, P655, DOI 10.1593/neo.06439; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	54	72	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3157	3166		10.1038/onc.2009.177	http://dx.doi.org/10.1038/onc.2009.177			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581926	Green Accepted			2022-12-28	WOS:000269515100007
J	Ciarapica, R; Annibali, D; Raimondi, L; Savino, M; Nasi, S; Rota, R				Ciarapica, R.; Annibali, D.; Raimondi, L.; Savino, M.; Nasi, S.; Rota, R.			Targeting Id protein interactions by an engineered HLH domain induces human neuroblastoma cell differentiation	ONCOGENE			English	Article						HLH domain; Id proteins; neuroblastoma; differentiation	HELIX-LOOP-HELIX; NEGATIVE AUTOREGULATION; RETINOBLASTOMA PROTEIN; SELF-RENEWAL; CYCLE ARREST; EXPRESSION; CANCER; PROLIFERATION; TRANSCRIPTION; TUMORS	Inhibitor of DNA-binding (Id) proteins prevent cell differentiation, promote growth and sustain tumour development. They do so by binding to E proteins and other transcription factors through the helix-loop-helix (HLH) domain, and inhibiting transcription. This makes HLH-mediated Id protein interactions an appealing therapeutic target. We have used the dominant interfering HLH dimerization mutant 13I to model the impact of Id inhibition in two human neuroblastoma cell lines: LA-N-5, similar to immature neuroblasts, and SH-EP, resembling more immature precursor cells. We have validated 13I as an Id inhibitor by showing that it selectively binds to Ids, impairs complex formation with RB, and relieves repression of E protein-activated transcription. Id inactivation by 13I enhances LA-N-5 neural features and causes SH-EP cells to acquire neuronal morphology, express neuronal proteins such as N-CAMand NF-160, proliferate more slowly, and become responsive to retinoic acid. Concomitantly, 13I augments the cell-cycle inhibitor p27(Kip1) and reduces the angiogenic factor vascular endothelial growth factor. These effects are Id specific, being counteracted by Id overexpression. Furthermore, 13I strongly impairs tumorigenic properties in agar colony formation and cell invasion assays. Targeting Id dimerization may therefore be effective for triggering differentiation and restraining neuroblastoma cell tumorigenicity.	[Ciarapica, R.; Raimondi, L.; Rota, R.] Osped Pediat Bambino Gesu, Angiogenesis Lab, I-00165 Rome, Italy; [Annibali, D.; Savino, M.; Nasi, S.] CNR, Ist Biol & Patol Mol, Rome, Italy	IRCCS Bambino Gesu; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Rota, R (corresponding author), Osped Pediat Bambino Gesu, Angiogenesis Lab, Piazza S Onofrio 4, I-00165 Rome, Italy.	sergio.nasi@uniroma1.it; rota@opbg.net	Raimondi, Lavinia/K-4085-2016; Annibali, Daniela/AAE-3004-2019; Rota, Rossella/AAB-2497-2019; Annibali, Daniela/AAC-5270-2019	Raimondi, Lavinia/0000-0001-9394-2002; Rota, Rossella/0000-0002-9408-7711; Annibali, Daniela/0000-0001-8413-7669				Bai G, 2007, DEV CELL, V13, P283, DOI 10.1016/j.devcel.2007.05.014; Bergmann E, 2001, INT J CANCER, V95, P176, DOI 10.1002/1097-0215(20010520)95:3<176::AID-IJC1030>3.3.CO;2-Q; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chassot AA, 2007, ONCOGENE, V26, P5772, DOI 10.1038/sj.onc.1210386; Ciarapica R, 2003, J BIOL CHEM, V278, P12182, DOI 10.1074/jbc.M211991200; CICCARONE V, 1989, CANCER RES, V49, P219; COHEN PS, 1988, AM J PATHOL, V131, P391; Santos MDL, 2007, MOL CANCER THER, V6, P1425, DOI 10.1158/1535-7163.MCT-06-0623; Farah MH, 2000, DEVELOPMENT, V127, P693; Henke E, 2008, NAT BIOTECHNOL, V26, P91, DOI 10.1038/nbt1366; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Iavarone A, 2006, TRENDS MOL MED, V12, P588, DOI 10.1016/j.molmed.2006.10.007; Jankovic V, 2007, P NATL ACAD SCI USA, V104, P1260, DOI 10.1073/pnas.0607894104; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Kondo M, 2004, CELL DEATH DIFFER, V11, P1092, DOI 10.1038/sj.cdd.4401467; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Li YJ, 2007, J AM SOC NEPHROL, V18, P449, DOI 10.1681/ASN.2006030236; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lofstedt T, 2004, J BIOL CHEM, V279, P39223, DOI 10.1074/jbc.M402904200; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sakurai D, 2004, J IMMUNOL, V173, P5801, DOI 10.4049/jimmunol.173.9.5801; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Tanaka T, 2007, EMBO J, V26, P3250, DOI 10.1038/sj.emboj.7601744; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Vandesompele J, 2003, ONCOGENE, V22, P456, DOI 10.1038/sj.onc.1206148; Voigt A, 2000, CELL ADHES COMMUN, V7, P423, DOI 10.3109/15419060009109023; Wainwright LJ, 2001, P NATL ACAD SCI USA, V98, P9396, DOI 10.1073/pnas.161288698; Wiercinska E, 2006, HEPATOLOGY, V43, P1032, DOI 10.1002/hep.21135; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	41	31	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1881	1891		10.1038/onc.2009.56	http://dx.doi.org/10.1038/onc.2009.56			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330020				2022-12-28	WOS:000265640600001
J	Jang, M; Park, BC; Kang, S; Chi, SW; Cho, S; Chung, SJ; Lee, SC; Bae, KH; Park, SG				Jang, M.; Park, B. C.; Kang, S.; Chi, S-W; Cho, S.; Chung, S. J.; Lee, S. C.; Bae, K-H; Park, S. G.			Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene	ONCOGENE			English	Article						apoptosis; caspase; c-Myc; FBP-1; FUSE	CELL-DEATH; IDENTIFICATION; EXPRESSION; MITOCHONDRIAL; CLEAVAGE; BAX	Far upstream element-binding protein-1 (FBP-1) binds to an upstream element of the c-myc promoter and regulates the c-myc mRNA level. Earlier, FBP-1 was identified as a candidate substrate of caspase-7. Here, we report that FBP-1 is cleaved by executor caspases, both in vitro and during apoptosis. Cleavage occurs at the caspase consensus site (DQPD74) located within the classical bipartite nuclear localization signal sequence. In cells subjected to apoptotic stimuli, the caspase-mediated cleavage of FBP-1 leads to its decreased presence in the nucleus, concomitant with the marked downregulation of c-Myc and its various target proteins. By contrast, cells transfected with a non-cleavable mutant of FBP-1 (D74A) maintain higher levels of c-Myc and are protected from apoptosis. On the basis of these results, we suggest that the oncogenic potential of c-Myc is 'switched off' after apoptosis induction as a consequence of the caspase-mediated cleavage of FBP-1.	[Jang, M.; Park, B. C.; Kang, S.; Chi, S-W; Lee, S. C.; Bae, K-H; Park, S. G.] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon 305806, South Korea; [Cho, S.] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Chung, S. J.] Korea Res Inst Biosci & Biotechnol, BioNano Res Ctr, Taejon 305806, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Bae, KH (corresponding author), Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon 305806, South Korea.	khbae@kribb.re.kr		Bae, Kwang-Hee/0000-0002-5868-2556; Kang, Sunghyun/0000-0003-1542-9750	KRIBB; Korea Science and Engineering Foundation [2008-01050]	KRIBB; Korea Science and Engineering Foundation(Korea Science and Engineering Foundation)	We thank Drs Young Il Yeom, Seung Jun Kim and Do Hee Lee for their helpful advices. This study was supported by a grant sponsored by KRIBB (to K-H Bae) and Korea Science and Engineering Foundation (Basic Research Program no. 2008-01050) (to SG Park).	BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cao XF, 2008, J BIOL CHEM, V283, P14490, DOI 10.1074/jbc.M801107200; Chung HJ, 2005, MOL CELLS, V20, P157; Chung HJ, 2006, MOL CELL BIOL, V26, P6584, DOI 10.1128/MCB.00754-06; Denault JB, 2002, CHEM REV, V102, P4489, DOI 10.1021/cr010183n; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; He LS, 2000, NUCLEIC ACIDS RES, V28, P4558, DOI 10.1093/nar/28.22.4558; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Jang M, 2007, BIOCHEM BIOPH RES CO, V363, P388, DOI 10.1016/j.bbrc.2007.08.183; Krysko DV, 2006, CELL DEATH DIFFER, V13, P2011, DOI 10.1038/sj.cdd.4401900; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lee AY, 2004, PROTEOMICS, V4, P3429, DOI 10.1002/pmic.200400979; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Liu JB, 2007, CANCER CHEMOTH PHARM, V59, P217, DOI 10.1007/s00280-006-0260-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nieminen AI, 2007, CELL CYCLE, V6, P2464, DOI 10.4161/cc.6.20.4917; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Vindigni A, 2001, NUCLEIC ACIDS RES, V29, P1061, DOI 10.1093/nar/29.5.1061; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1	23	43	47	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1529	1536		10.1038/onc.2009.11	http://dx.doi.org/10.1038/onc.2009.11			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19219071				2022-12-28	WOS:000264537400005
J	Nakamura, M; Shimada, K; Konishi, N				Nakamura, M.; Shimada, K.; Konishi, N.			The role of HRK gene in human cancer	ONCOGENE			English	Review						HRK; prostate cancer; glioblastoma; primary central nervous system lymphoma	HUMAN PROSTATE-CANCER; PROMOTER METHYLATION; CELL-DEATH; SECONDARY GLIOBLASTOMAS; PROTEIN EXPRESSION; COLORECTAL-CANCER; DNA METHYLATION; APOPTOTIC INDEX; NERVOUS-SYSTEM; INACTIVATION	Apoptosis regulators play one of the most critical roles in tumorigenesis, and an imbalance between cell proliferation and apoptosis may contribute to tumor progression. HRK was itself originally identified as a proapoptotic gene induced by diminished levels of cytokine in hematopoietic cells and cultured neurons and repressed by the expression of death-repressor proteins. A few analyses of HRK protein expression in primary central nervous system lymphomas have been performed, and little is known about the epigenetic or post-transcriptional mechanisms that may participate in HRK inactivation. Here we show the data on the 5'-CpG methylation status, loss of heterozygosity on 12q13.1 and its association with HRK expression in human malignancies, including prostate cancers, astrocytic tumors and primary central nervous system lymphomas. Aberrant methylation of CpG islands within the promoter is an epigenetic event largely responsible for the silencing of the HRK gene and subsequent low apoptotic counts in our series of malignancies. Inactivation of HRK apparently occurs in a substantial proportion of all tumor phenotypes and, as a potential proapoptotic gene, HRK may contribute to the development and progression of many human cancers. Oncogene (2009) 27, S105-S113; doi: 10.1038/onc.2009.48	[Nakamura, M.; Shimada, K.; Konishi, N.] Nara Med Univ, Dept Pathol, Sch Med, Kashihara, Nara 6348521, Japan	Nara Medical University	Konishi, N (corresponding author), Nara Med Univ, Dept Pathol, Sch Med, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	nkonishi@naramed-u.ac.jp						Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Harris CA, 2001, J BIOL CHEM, V276, P37754; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Higuchi T, 2008, PROSTATE, V68, P105, DOI 10.1002/pros.20600; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kim HS, 2001, CANCER DETECT PREV, V25, P237; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Konishi N, 2005, CLIN CANCER RES, V11, P5090, DOI 10.1158/1078-0432.CCR-05-0195; Konishi N, 2005, PATHOL INT, V55, P531, DOI 10.1111/j.1440-1827.2005.01865.x; Konishi N, 2008, CLIN CANCER RES, V14, P4408, DOI 10.1158/1078-0432.CCR-07-4120; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nakamura M, 2005, ACTA NEUROPATHOL, V110, P402, DOI 10.1007/s00401-005-1065-x; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Nakamura M, 1997, CANCER, V80, P242, DOI 10.1002/(SICI)1097-0142(19970715)80:2<242::AID-CNCR12>3.0.CO;2-U; Nakamura M, 2001, BRAIN PATHOL, V11, P159; Nakamura M, 2006, ONCOLOGY-BASEL, V70, P212, DOI 10.1159/000094322; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Obata T, 2003, CLIN CANCER RES, V9, P6410; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Sanz C, 2000, BLOOD, V95, P2742, DOI 10.1182/blood.V95.9.2742.009k24_2742_2747; Sanz C, 2002, HAEMATOLOGICA, V87, P903; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Shimada K, 2006, HISTOL HISTOPATHOL, V21, P415, DOI 10.14670/HH-21.415; Shimada K, 2005, J PATHOL, V206, P423, DOI 10.1002/path.1791; Shimada K, 2008, CANCER SCI, V99, P39, DOI 10.1111/j.1349-7006.2007.00655.x; Steinbach JP, 2002, BRAIN PATHOL, V12, P12; Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vakkala M, 1999, CLIN CANCER RES, V5, P319; Wistuba II, 2001, CANCER RES, V61, P3795; Zhang GJ, 1998, ANTICANCER RES, V18, P1989; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	42	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S105	S113		10.1038/onc.2009.48	http://dx.doi.org/10.1038/onc.2009.48			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641496				2022-12-28	WOS:000268566800009
J	Roidl, A; Foo, P; Wong, W; Mann, C; Bechtold, S; Berger, HJ; Streit, S; Ruhe, JE; Hart, S; Ullrich, A; Ho, HK				Roidl, A.; Foo, P.; Wong, W.; Mann, C.; Bechtold, S.; Berger, H. J.; Streit, S.; Ruhe, J. E.; Hart, S.; Ullrich, A.; Ho, H. K.			The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells	ONCOGENE			English	Article						cancer; FGFR4; mutation; oncogenesis; proliferation	FACTOR RECEPTOR 4; GROWTH-FACTOR RECEPTOR-3; KINASE GENE FAMILY; PROSTATE-CANCER; ARG388 ALLELE; PROGRESSION; MUTATIONS; EXPRESSION; PROLIFERATION; POLYMORPHISM	Mutational analysis of oncogenes is critical for our understanding of cancer development. Oncogenome screening has identified a fibroblast growth factor receptor 4 (FGFR4) Y367C mutation in the human breast cancer cell line MDA-MB453. Here, we investigate the consequence of this missense mutation in cancer cells. We show that MDA-MB453 cells harbouring the mutation are insensitive to FGFR4-specific ligand stimulation or inhibition with an antagonistic antibody. Furthermore, the FGFR4 mutant elicits constitutive phosphorylation leading to an activation of the mitogen-activated protein kinase cascade as shown by an enhanced Erk1/2 phosphorylation. Cloning and ectopic expression of the FGFR4 Y367C mutant in HEK293 cells revealed high pErk levels and enhanced cell proliferation. Based on these findings, we propose that FGFR4 may be a driver of tumour growth, particularly when highly expressed or stabilized and constitutively activated through genetic alterations. As such, FGFR4 presents an option for further mutational screening in tumours and is an attractive cancer target with the therapeutic potential. Oncogene (2010) 29, 1543-1552; doi:10.1038/onc.2009.432; published online 30 November 2009	[Ho, H. K.] ASTAR, Inst Med Biol, Singapore OncoGenome Programme, Singapore 138648, Singapore; [Roidl, A.; Mann, C.; Bechtold, S.; Berger, H. J.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Max Planck Society	Ho, HK (corresponding author), ASTAR, Inst Med Biol, Singapore OncoGenome Programme, 8A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore.	hankiat.ho@imb.a-star.edu.sg			National Genome Research Network 2/CancerNet [01GS0435]; Agency for Science Technology and Research (A*STAR), Singapore	National Genome Research Network 2/CancerNet; Agency for Science Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR))	We thank Heike Stubbe for excellent technical support and Dr Peter Czernilofsky for critically reading the manuscript. This work was supported by the National Genome Research Network 2/CancerNet, Grant Number: NGFN2/CancerNet no. 01GS0435, and the Agency for Science Technology and Research (A*STAR), Singapore.	Andrea R, 2003, AM J MED GENET A, V121A, P41, DOI 10.1002/ajmg.a.20101; Ansell A, 2009, ORAL ONCOL, V45, P23, DOI 10.1016/j.oraloncology.2008.03.007; Bange J, 2002, CANCER RES, V62, P840; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bignell G, 2006, GENE CHROMOSOME CANC, V45, P42, DOI 10.1002/gcc.20265; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ercolino T, 2008, CLIN ENDOCRINOL, V69, P253, DOI 10.1111/j.1365-2265.2008.03197.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fishman DA, 2001, CANCER RES, V61, P3194; Giri D, 1999, CLIN CANCER RES, V5, P1063; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Ho HK, 2009, J HEPATOL, V50, P118, DOI 10.1016/j.jhep.2008.08.015; Itoh N, 2004, TRENDS GENET, V20, P563, DOI 10.1016/j.tig.2004.08.007; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Ma ZY, 2008, INT J CANCER, V123, P2574, DOI 10.1002/ijc.23578; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roidl A, 2009, CLIN CANCER RES, V15, P2058, DOI 10.1158/1078-0432.CCR-08-0890; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Ruhe JE, 2007, CANCER RES, V67, P11368, DOI 10.1158/0008-5472.CAN-07-2703; Sasaki H, 2008, ONCOL REP, V20, P1125, DOI 10.3892/or_00000119; SHAOUL E, 1995, ONCOGENE, V10, P1553; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Streit S, 2006, BRIT J CANCER, V94, P1879, DOI 10.1038/sj.bjc.6603181; Streit S, 2004, INT J CANCER, V111, P213, DOI 10.1002/ijc.20204; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587; Wang JH, 2008, NEOPLASIA, V10, P847, DOI 10.1593/neo.08450; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; White KE, 2005, AM J HUM GENET, V76, P361, DOI 10.1086/427956; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484	35	49	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1543	1552		10.1038/onc.2009.432	http://dx.doi.org/10.1038/onc.2009.432			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19946327				2022-12-28	WOS:000275392400012
J	Bongiorno-Borbone, L; De Cola, A; Barcaroli, D; Knight, RA; Di Ilio, C; Melino, G; De Laurenzi, V				Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Knight, R. A.; Di Ilio, C.; Melino, G.; De Laurenzi, V.			FLASH degradation in response to UV-C results in histone locus bodies disruption and cell-cycle arrest	ONCOGENE			English	Article						histone locus bodies; Cajal bodies; UV; FLASH	S-PHASE PROGRESSION; DNA-DAMAGE; CAJAL BODIES; GENE-EXPRESSION; E/CDK2 SUBSTRATE; TRANSCRIPTION; P220(NPAT); CHECKPOINT; G(1); BODY	Eucaryotic cell nuclei contain a number of different organelles that are highly dynamic structures and respond to a variety of stimuli. Here we investigated the effect of UV irradiation on a recently identified group of organelles, Histone Locus Bodies. Histone Locus Bodies contain at least two main proteins, FLASH and NPAT, and have been shown to be involved in replication-dependent histone gene transcription. We show that these organelles are disrupted after sublethal irradiation and both FLASH and NPAT are degraded, which in turn results in cell-cycle arrest at the S/G2 transition. The effect on the cell cycle is due to reduced transcription of histone genes and restoring normal histone protein levels by stabilizing histone mRNA allows cells to progress through the cell cycle. This provides a novel mechanism of S-phase arrest in response to DNA damage that potentially allows DNA repair before cells continue into mitosis, and thus prevents transmission of genomic alterations. Oncogene (2010) 29, 802-810; doi:10.1038/onc.2009.388; published online 16 November 2009	[De Laurenzi, V.] Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, I-66100 Chieti, Italy; [Bongiorno-Borbone, L.; De Cola, A.; Barcaroli, D.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Barcaroli, D.; Di Ilio, C.; De Laurenzi, V.] Fdn G DAnnunzio, Ctr Studi SullInvecchiamento, Chieti, Italy; [Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; University of Leicester	De Laurenzi, V (corresponding author), Univ G DAnnunzio, Dipartimento Sci Biomed, CeSI, Via Colle Ara 1, I-66100 Chieti, Italy.	delaurenzi@unich.it	De Laurenzi, Vincenzo/K-7471-2016	De Laurenzi, Vincenzo/0000-0002-7506-1743; De Cola, Antonella/0000-0002-3202-5339	AIRC; MIUR; EU-EPISTEM; MinSan; Telethon and Alleanza Contro il Cancro; FIRC scholarship; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); EU-EPISTEM(European Commission); MinSan; Telethon and Alleanza Contro il Cancro(Fondazione Telethon); FIRC scholarship(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Peter D Adams for the SLBP expression plasmid. The work was supported by grants from AIRC, MIUR to VDL, AIRC, EU-EPISTEM, FIRB, MIUR, MinSan, Telethon and Alleanza Contro il Cancro to GM. DB was supported by an FIRC scholarship.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bongiorno-Borbone L, 2008, CELL CYCLE, V7, P2357, DOI 10.4161/cc.6344; Callegari AJ, 2007, CELL CYCLE, V6, P660, DOI 10.4161/cc.6.6.3984; Cioce M, 2006, J CELL BIOL, V175, P401, DOI 10.1083/jcb.200604099; Dellaire G, 2007, CELL CYCLE, V6, P1864, DOI 10.4161/cc.6.15.4560; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matera AG, 2006, J CELL BIOL, V172, P791, DOI 10.1083/jcb.200602002; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nelson DM, 2002, MOL CELL BIOL, V22, P7459, DOI 10.1128/MCB.22.21.7459-7472.2002; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Wang A, 2004, BIOCHEM BIOPH RES CO, V325, P1509, DOI 10.1016/j.bbrc.2004.10.198; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Ye XF, 2003, CELL CYCLE, V2, P185, DOI 10.4161/cc.2.3.389; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 2004, CELL CYCLE, V3, P695	26	20	21	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					802	810		10.1038/onc.2009.388	http://dx.doi.org/10.1038/onc.2009.388			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915611				2022-12-28	WOS:000274397800003
J	Bommer, UA; Heng, C; Perrin, A; Dash, P; Lobov, S; Elia, A; Clemens, MJ				Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.			Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses	ONCOGENE			English	Article						TCTP; PKR; p53; apoptosis; cell stress	MESSENGER-RNA; ALPHA-SUBUNIT; CALCIUM; ACTIVATION; APOPTOSIS; GENE; INITIATION; FORTILIN; TARGET; GROWTH	Translationally controlled tumour protein (TCTP) is a highly conserved protein present in all eukaryotic organisms. Various cellular functions and molecular interactions have been ascribed to this protein, many related to its growth-promoting and antiapoptotic properties. TCTP levels are highly regulated in response to various cellular stimuli and stresses. We have shown recently that the double-stranded RNA-dependent protein kinase, PKR, is involved in translational regulation of TCTP. Here we extend these studies by demonstrating that TCTP is downregulated in response to various proapoptotic treatments, in particular agents that induce Ca+ (+) stress, in a PKR-dependent manner. This regulation requires phosphorylation of protein synthesis factor eIF2 alpha. Since TCTP has been characterized as an antiapoptotic and Ca+ +- binding protein, we asked whether it is involved in protecting cells from Ca+ (+)- stress-induced apoptosis. Overexpression of TCTP partially protects cells against thapsigargin-induced apoptosis, as measured using caspase-3 activation assays, a nuclear fragmentation assay, using fluorescence-activated cell sorting analysis, and time-lapse video microscopy. TCTP also protects cells against the proapoptotic effects of tunicamycin and etoposide, but not against those of arsenite. Our results imply that cellular TCTP levels influence sensitivity to apoptosis and that PKR may exert its proapoptotic effects at least in part through downregulation of TCTP via eIF2 alpha phosphorylation. Oncogene (2010) 29, 763-773; doi: 10.1038/onc.2009.380; published online 9 November 2009	[Bommer, U-A; Heng, C.; Perrin, A.; Dash, P.; Lobov, S.; Elia, A.; Clemens, M. J.] Univ London, Div Basic Med Sci, London, England	University of London	Bommer, UA (corresponding author), Univ Wollongong, Grad Sch Med, Northfields Ave,Bldg 28, Wollongong, NSW 2522, Australia.	ubommer@uow.edu.au	Lobov, Sergei A/A-8803-2011; Elia, Androulla/AAE-6854-2021	Dash, Phil/0000-0002-6029-4560; Bommer, Ulrich/0000-0003-1110-7615	Wellcome Trust; Cancer Prevention Research Trust; Association for International Cancer Research	Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Prevention Research Trust; Association for International Cancer Research	We thank Drs Charles Weissmann, Randy Kaufman and Donalyn Scheuner for cell lines; Mr Bill Newman for help in performing the initial fluorescence-activated cell sorting analysis experiments; Dr Constantina Constantinou for providing extracts from mouse erythroleukaemia cells and members of Dr Guy Whitley's laboratory for help with the cell-video microscopy facilities. This work was supported by The Wellcome Trust (UAB and MJC), the Cancer Prevention Research Trust (UAB) and the Association for International Cancer Research (MJC).	Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Berkowitz O, 2008, PLANT CELL, V20, P3430, DOI 10.1105/tpc.108.061010; Bommer UA, 2002, RNA, V8, P478, DOI 10.1017/S1355838202022586; Bommer UA, 2004, INT J BIOCHEM CELL B, V36, P379, DOI 10.1016/S1357-2725(03)00213-9; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Chen SH, 2007, MOL BIOL CELL, V18, P2525, DOI 10.1091/mbc.E07-02-0188; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Constantinou C, 2007, CELL DEATH DIFFER, V14, P576, DOI 10.1038/sj.cdd.4402045; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; Efferth T, 2005, DRUG RESIST UPDATE, V8, P85, DOI 10.1016/j.drup.2005.04.003; Feng YG, 2007, ARCH BIOCHEM BIOPHYS, V467, P48, DOI 10.1016/j.abb.2007.08.021; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Gachet Y, 1999, J CELL SCI, V112, P1257; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Gnanasekar M, 2007, PARASITOL RES, V101, P1533, DOI 10.1007/s00436-007-0671-z; Gnanasekar M, 2009, INT J ONCOL, V34, P1241, DOI 10.3892/ijo_00000252; Graidist P, 2007, BIOCHEM J, V408, P181, DOI 10.1042/BJ20070679; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kim JE, 2008, EXP MOL MED, V40, P709, DOI 10.3858/emm.2008.40.6.709; Kim M, 2000, ARCH PHARM RES, V23, P633, DOI 10.1007/BF02975253; Kim MJ, 2008, J MOL CELL CARDIOL, V44, P151, DOI 10.1016/j.yjmcc.2007.09.017; Koziol MJ, 2007, CURR BIOL, V17, P801, DOI 10.1016/j.cub.2007.03.062; Lee ES, 2007, FEBS LETT, V581, P4325, DOI 10.1016/j.febslet.2007.08.001; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MA Q, 2009, J PROTEOME RES; Onuki R, 2004, EMBO J, V23, P959, DOI 10.1038/sj.emboj.7600049; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; Rehmann H, 2008, FEBS LETT, V582, P3005, DOI 10.1016/j.febslet.2008.07.057; Scheuner D, 2006, J BIOL CHEM, V281, P21458, DOI 10.1074/jbc.M603784200; Schmidt I, 2007, FEBS J, V274, P5416, DOI 10.1111/j.1742-4658.2007.06069.x; Singh M, 2009, J MOL BIOL, V385, P457, DOI 10.1016/j.jmb.2008.10.068; Slaby O, 2009, ONCOL REP, V21, P1235, DOI 10.3892/or_00000346; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Tani T, 2007, CLONING STEM CELLS, V9, P267, DOI 10.1089/clo.2006.0072; Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; van de Sande WWJ, 2006, J IMMUNOL, V177, P1997, DOI 10.4049/jimmunol.177.3.1997; Vonakis BM, 2008, BLOOD, V111, P1789, DOI 10.1182/blood-2007-07-104364; Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200; Xiong ZY, 2009, ATHEROSCLEROSIS, V203, P401, DOI 10.1016/j.atherosclerosis.2008.07.041; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200	58	34	40	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					763	773		10.1038/onc.2009.380	http://dx.doi.org/10.1038/onc.2009.380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901967				2022-12-28	WOS:000274223700012
J	Su, F; Pascal, LE; Xiao, W; Wang, Z				Su, F.; Pascal, L. E.; Xiao, W.; Wang, Z.			Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53	ONCOGENE			English	Article						U19/EAF2; prostate cancer; tumor suppressor; TSP-1; p53	HIPPEL-LINDAU PROTEIN; ELONGATION-FACTOR ELL; PROSTATE-CANCER; GENE; ANGIOGENESIS; GROWTH; CELLS; CARCINOMA; APOPTOSIS; TRANSACTIVATION	Inactivation of U19/EAF2 has been shown previously to lead to tumorigenesis in multiple organs; however, the mechanism of U19/EAF2 tumor suppression remains unclear. In this paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prostate and liver of U19/EAF2 knockout mouse. The U19/EAF2 knockout liver displayed increased CD31-positive blood vessels, suggesting that the TSP-1 down-regulation can contribute to increased angiogenesis. TSP-1 is reported to be a p53-target gene and p53 is a known binding partner of ELL, which binds to U19/EAF2. Here, we show that U19/EAF2 can co-localize and co-immunoprecipitate with p53 in transfected cells. In a TSP-1 promoter-driven luciferase reporter assay, p53 transfection suppressed the TSP-1 promoter activity and U19/EAF2 co-transfection blocked the p53 suppression of TSP-1 promoter. However, U19/EAF2 transfection alone had little or no effect on the TSP-1 promoter. The above observations together suggest that U19/EAF2 regulates the expression of TSP-1 via blocking p53 repression of the TSP-1 promoter. Oncogene (2010) 29, 421-431; doi:10.1038/onc.2009.326; published online 12 October 2009	[Su, F.; Pascal, L. E.; Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, Pittsburgh, PA 15232 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Key Lab Biodivers & Conservat Aquat Organisms, Wuhan, Peoples R China; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Urol, 5200 Ctr Ave,Suite G40, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Pascal, Laura E./AAH-5743-2019; Xiao, Wuhan/GLU-7352-2022	Pascal, Laura E./0000-0003-3840-1662; SU, FEI/0000-0001-5834-4074	NIH [R01 CA 120386, R37 DK51993]; Prostate Cancer Specialized Program of Research Excellence (SPORE) [P50 CA90386]; NATIONAL CANCER INSTITUTE [P50CA090386, R01CA120386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK051193] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Specialized Program of Research Excellence (SPORE); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by NIH Grant Number R01 CA 120386, R37 DK51993, and Prostate Cancer Specialized Program of Research Excellence (SPORE), P50 CA90386.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Alvarez AA, 2001, GYNECOL ONCOL, V82, P273, DOI 10.1006/gyno.2001.6287; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Cinatl J, 1999, AM J PATHOL, V155, P285, DOI 10.1016/S0002-9440(10)65122-X; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; Duan X, 2008, INT J RADIAT BIOL, V84, P211, DOI 10.1080/09553000801902117; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; Freitas TMC, 2005, EXP MOL PATHOL, V79, P79, DOI 10.1016/j.yexmp.2005.02.006; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Jiang C, 2004, MOL CANCER THER, V3, P877; Kwak C, 2002, BJU INT, V89, P303, DOI 10.1046/j.1464-4096.2001.01417.x; MAEDA K, 1995, BRIT J CANCER, V72, P319, DOI 10.1038/bjc.1995.331; Mitani K, 2000, BIOCHEM BIOPH RES CO, V279, P563, DOI 10.1006/bbrc.2000.3970; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Reiher FK, 2001, J UROLOGY, V165, P2075, DOI 10.1016/S0022-5347(05)66297-0; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Tokunaga T, 1998, VIRCHOWS ARCH, V433, P415, DOI 10.1007/s004280050268; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Wiederschain D, 2003, MOL CELL BIOL, V23, P4230, DOI 10.1128/MCB.23.12.4230-4246.2003; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2006, PROSTATE, V66, P1, DOI 10.1002/pros.20309; Xiao WH, 2003, CANCER RES, V63, P4698; Xiao WH, 2009, CANCER RES, V69, P2599, DOI 10.1158/0008-5472.CAN-08-2595; Zhou JG, 2009, J BIOL CHEM, V284, P19142, DOI 10.1074/jbc.M109.010439	28	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					421	431		10.1038/onc.2009.326	http://dx.doi.org/10.1038/onc.2009.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19826414	Green Accepted			2022-12-28	WOS:000273793200011
J	Solassol, J; Rouanet, P; Lamy, PJ; Allal, C; Favre, G; Maudelonde, T; Mange, A				Solassol, J.; Rouanet, P.; Lamy, P. J.; Allal, C.; Favre, G.; Maudelonde, T.; Mange, A.			Serum protein signature may improve detection of ductal carcinoma in situ of the breast	ONCOGENE			English	Article						breast; diagnosis; serum; profiling	PLATELET FACTOR-IV; SELDI-TOF-MS; PROTEOMIC ANALYSIS; MASS-SPECTROMETRY; OVARIAN-CANCER; ENDOTHELIAL-CELL; TUMOR-MARKERS; BIOMARKERS; IDENTIFICATION; GROWTH	Ductal carcinoma in situ (DCIS) of the breast is part of a spectrum of preinvasive lesions that originate within normal breast tissue and progress to invasive breast cancer. The detection of DCIS is important for the reduction of mortality from breast cancer, but the diagnosis of preinvasive breast tumors is hampered by the lack of an adequate detection method. To identify the changes in protein expression during the initial stage of tumorigenesis and to identify the presence of new DCIS markers, we analysed serum from 60 patients with breast cancer and 60 normal controls using mass spectrometry. A 23-protein index was generated that correctly distinguishes the DCIS and control groups with sensitivities and specificities in excess of 80% in two independent cohorts. Two candidate peptides were purified and identified as platelet factor 4 (PF-4) and complement C3a(desArg) anaphylatoxin (C3a(desArg)) using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In an independent serum set of 165 patients, PF-4 and C3a(desArg) were significantly upregulated in DCIS compared with non-cancerous controls, as validated using western blot and enzyme-linked immunosorbent assay. We conclude that our serum protein-based test, used in conjunction with image-based screening practices, could improve the sensitivity and specificity of breast cancer detection. Oncogene (2010) 29, 550-560; doi: 10.1038/onc.2009.341; published online 26 October 2009	[Solassol, J.; Maudelonde, T.; Mange, A.] Univ Montpellier I, Montpellier, France; [Solassol, J.; Maudelonde, T.; Mange, A.] CHU Montpellier, Univ Hosp Montpellier, Dept Cellular Biol, Montpellier, France; [Solassol, J.; Maudelonde, T.; Mange, A.] CRLC, Dept Clin Oncoprote, Montpellier, France; [Rouanet, P.] CRLC, Dept Surg Oncol, Montpellier, France; [Lamy, P. J.] CRLC, Dept Biol, Montpellier, France; [Allal, C.; Favre, G.] CPTP, U563, INSERM, Toulouse, France	Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mange, A (corresponding author), Batiment Rech CRLC Val Aurelle,Parc Euromed,208, F-34298 Montpellier 5, France.	alain.mange@univ-montp1.fr	Solassol, Jerome/G-2320-2018; FAVRE, Gilles/K-9189-2014; ALLAL, Ben C/I-8146-2014; Mange, Alain/U-1157-2017; Lamy, Pierre-Jean/I-6077-2015; Lamy, Pierre-Jean/AAZ-1696-2020	Solassol, Jerome/0000-0002-0293-6158; FAVRE, Gilles/0000-0002-2344-1883; ALLAL, Ben C/0000-0002-4207-2219; Mange, Alain/0000-0002-1566-9407; Lamy, Pierre-Jean/0000-0002-5750-159X; Lamy, Pierre-Jean/0000-0002-5750-159X	Comite de l'Herault de la Ligue Contre le Cancer; INSERM [RBM 03-63]	Comite de l'Herault de la Ligue Contre le Cancer; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This work was supported in part by grants from the Comite de l'Herault de la Ligue Contre le Cancer. Serum collection was supported by INSERM (RBM 03-63).	Albrethsen J, 2007, CLIN CHEM, V53, P852, DOI 10.1373/clinchem.2006.082644; Alexander H, 2004, CLIN CANCER RES, V10, P7500, DOI 10.1158/1078-0432.CCR-04-1002; Becker S, 2004, ANN SURG ONCOL, V11, P907, DOI 10.1245/ASO.2004.03.557; Belluco C, 2007, ANN SURG ONCOL, V14, P2470, DOI 10.1245/s10434-007-9354-3; Bijker N, 2006, J CLIN ONCOL, V24, P3381, DOI 10.1200/JCO.2006.06.1366; Bjorge L, 2005, BRIT J CANCER, V92, P895, DOI 10.1038/sj.bjc.6602334; Brozkova K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2101; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cavanaugh PG, 1998, J CELL PHYSIOL, V174, P48, DOI 10.1002/(SICI)1097-4652(199801)174:1<48::AID-JCP6>3.0.CO;2-G; Cavanaugh PG, 1999, BREAST CANCER RES TR, V56, P203; Cervi D, 2008, BLOOD, V111, P1201, DOI 10.1182/blood-2007-04-084798; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-25; Elmore JG, 2005, JAMA-J AM MED ASSOC, V293, P1245, DOI 10.1001/jama.293.10.1245; Esserman LJ, 2007, EXPERT REV MOL DIAGN, V7, P533, DOI 10.1586/14737159.7.5.533; Gast M. C. W., 2006, Cancer Biomarkers, V2, P235; Gast MCW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-389; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Goncalves A, 2006, ONCOGENE, V25, P981, DOI 10.1038/sj.onc.1209131; Greene FL, 2002, CANC STAGING MANUAL; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hagedorn M, 2001, FASEB J, V15, P550; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Hu Y, 2005, BREAST, V14, P250, DOI 10.1016/j.breast.2005.01.008; Jacot W, 2008, J THORAC ONCOL, V3, P840, DOI 10.1097/JTO.0b013e31817e464a; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang XX, 2005, CLIN CHEM, V51, P56, DOI 10.1373/clinchem.2004.032458; Kopczynski Z, 1998, BRIT J CANCER, V78, P466, DOI 10.1038/bjc.1998.516; Kozak KR, 2005, PROTEOMICS, V5, P4589, DOI 10.1002/pmic.200500093; Kramar A, 2001, COMPUT METH PROG BIO, V66, P199, DOI 10.1016/S0169-2607(00)00129-2; Kuerer HM, 2009, J CLIN ONCOL, V27, P279, DOI 10.1200/JCO.2008.18.3103; Lee IN, 2006, PROTEOMICS, V6, P2865, DOI 10.1002/pmic.200500488; Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017; Li JN, 2005, CLIN CHEM, V51, P2229, DOI 10.1373/clinchem.2005.052878; Li JN, 2002, CLIN CHEM, V48, P1296; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mange A, 2008, J CHROMATOGR B, V876, P252, DOI 10.1016/j.jchromb.2008.11.003; Mathelin C, 2006, BREAST CANCER RES TR, V96, P83, DOI 10.1007/s10549-005-9046-2; Miguet L, 2006, J PROTEOME RES, V5, P2258, DOI 10.1021/pr060058y; NICOLSON GL, 1992, J NATL CANCER I MONO, V13, P153; Orel SG, 1999, RADIOLOGY, V211, P845, DOI 10.1148/radiology.211.3.r99jn31845; Pavlakis K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-88; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; Petricoin EF, 2004, CURR OPIN BIOTECH, V15, P24, DOI 10.1016/j.copbio.2004.01.005; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Rai AJ, 2002, ARCH PATHOL LAB MED, V126, P1518; Roesch-Ely M, 2007, ONCOGENE, V26, P54, DOI 10.1038/sj.onc.1209770; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Semmes OJ, 2005, CLIN CHEM, V51, P102, DOI 10.1373/clinchem.2004.038950; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; Solassol J, 2006, EXPERT REV PROTEOMIC, V3, P311, DOI 10.1586/14789450.3.3.311; Solassol K, 2005, ANAL BIOCHEM, V338, P26, DOI 10.1016/j.ab.2004.11.031; Song J, 2006, CLIN CHEM, V52, P1045, DOI 10.1373/clinchem.2005.065722; Timms JF, 2007, CLIN CHEM, V53, P645, DOI 10.1373/clinchem.2006.080101; van der Merwe DE, 2007, ADV CANCER RES, V96, P23, DOI 10.1016/S0065-230X(06)96002-3; Vlahou Antonia, 2003, Clin Breast Cancer, V4, P203, DOI 10.3816/CBC.2003.n.026; Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188	61	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					550	560		10.1038/onc.2009.341	http://dx.doi.org/10.1038/onc.2009.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19855429				2022-12-28	WOS:000274084600008
J	Yang, L; Xie, G; Fan, Q; Xie, J				Yang, L.; Xie, G.; Fan, Q.; Xie, J.			Activation of the hedgehog-signaling pathway in human cancer and the clinical implications	ONCOGENE			English	Review						hedgehog; smoothened; cancer; signal transduction; clinical trials and animal model	BASAL-CELL CARCINOMAS; SMALL-MOLECULE INHIBITOR; GLI-MEDIATED TRANSCRIPTION; SONIC-HEDGEHOG; STEM-CELLS; INTRAFLAGELLAR TRANSPORT; COMBINATION THERAPY; POLARIZING ACTIVITY; KRUPPEL FAMILY; PRIMARY CILIA	The hedgehog pathway, initially discovered by two Nobel laureates Drs E Wieschaus and C Nusslein-Volhard in Drosophila, is a major regulator for cell differentiation, tissue polarity and cell proliferation. Studies from many laboratories reveal activation of this pathway in a variety of human cancer, including basal cell carcinomas (BCCs), medulloblastomas, leukemia, gastrointestinal, lung, ovarian, breast and prostate cancers. It is thus believed that targeted inhibition of hedgehog signaling may be effective in treatment and prevention of human cancer. Even more exciting is the discovery and synthesis of specific signaling antagonists for the hedgehog pathway, which have significant clinical implications in novel cancer therapeutics. In this review, we will summarize major advances in the last 2 years in our understanding of hedgehog signaling activation in human cancer, interactions between hedgehog signaling and other pathways in carcinogenesis, potential antagonists for hedgehog signaling inhibition and their clinical implications for human cancer treatment. Oncogene (2010) 29, 469-481; doi:10.1038/onc.2009.392; published online 23 November 2009	[Xie, J.] Indiana Univ, Dept Pediat, Div Hematol & Oncol, Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, IU Simon Canc Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Xie, J (corresponding author), Indiana Univ, Dept Pediat, Div Hematol & Oncol, Wells Ctr Pediat Res, 980 W Walnut St,R3-520, Indianapolis, IN 46202 USA.	jinxie@iupui.edu	Xie, J/AAR-7259-2020; Liu, Bingya/GMW-5655-2022	Xie, Guorui/0000-0002-2414-1241	National Cancer Institute [CA94160]; Wells Center for Pediatric Research; NATIONAL CANCER INSTITUTE [R01CA094160] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wells Center for Pediatric Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Current research in my laboratory is supported by grants from the National Cancer Institute CA94160 and Wells Center for Pediatric Research.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Baena-Lopez LA, 2008, P NATL ACAD SCI USA, V105, P9645, DOI 10.1073/pnas.0803747105; Allen BL, 2007, GENE DEV, V21, P1244, DOI 10.1101/gad.1543607; Amano K, 2008, J BIOL CHEM, V283, P29513, DOI 10.1074/jbc.M803681200; Arai MA, 2008, BIOORGAN MED CHEM, V16, P9420, DOI 10.1016/j.bmc.2008.09.053; Aszterbaum M, 1999, J INVEST DERM SYMP P, V4, P41, DOI 10.1038/sj.jidsp.5640179; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Athar M, 2004, CANCER RES, V64, P7545, DOI 10.1158/0008-5472.CAN-04-1393; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Barnfield PC, 2005, DIFFERENTIATION, V73, P397, DOI 10.1111/j.1432-0436.2005.00042.x; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Beckett K, 2008, TRENDS CELL BIOL, V18, P360, DOI 10.1016/j.tcb.2008.06.001; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhattacharya R, 2008, CLIN CANCER RES, V14, P7659, DOI 10.1158/1078-0432.CCR-08-1414; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; Brellier F, 2008, ONCOGENE, V27, P6601, DOI 10.1038/onc.2008.260; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Cai QS, 2009, J BIOL CHEM, V284, P2150, DOI 10.1074/jbc.M803235200; Capurro MI, 2008, DEV CELL, V14, P700, DOI 10.1016/j.devcel.2008.03.006; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen MH, 2005, MOL CELL BIOL, V25, P7042, DOI 10.1128/MCB.25.16.7042-7053.2005; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cheung HOL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000405; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Cortellino S, 2009, DEV BIOL, V325, P225, DOI 10.1016/j.ydbio.2008.10.020; Couve-Privat S, 2002, CANCER RES, V62, P7186; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Dierker T, 2009, J BIOL CHEM, V284, P8013, DOI 10.1074/jbc.M806838200; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Endoh-Yamagami S, 2009, CURR BIOL, V19, P1320, DOI 10.1016/j.cub.2009.06.046; Epstein E, 2001, MED PEDIATR ONCOL, V36, P555, DOI 10.1002/mpo.1129; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Evangelista M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1162925; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Feldmann G, 2008, MOL CANCER THER, V7, P2725, DOI 10.1158/1535-7163.MCT-08-0573; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gao J, 2009, CELL STEM CELL, V4, P548, DOI 10.1016/j.stem.2009.03.015; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Hoover AN, 2008, DEVELOPMENT, V135, P4049, DOI 10.1242/dev.029835; Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511; Hu D, 1999, DEVELOPMENT, V126, P4873; Huang SH, 2006, CARCINOGENESIS, V27, P1334, DOI 10.1093/carcin/bgi378; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jia JP, 2009, DEV BIOL, V330, P452, DOI 10.1016/j.ydbio.2009.04.009; Jiang J, 2006, CELL CYCLE, V5, P2457, DOI 10.4161/cc.5.21.3406; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kasperczyk H, 2009, FASEB J, V23, P21, DOI 10.1096/fj.08-111096; Kawakami T, 2002, DEVELOPMENT, V129, P5753, DOI 10.1242/dev.00178; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kise Y, 2009, BIOCHEM BIOPH RES CO, V387, P569, DOI 10.1016/j.bbrc.2009.07.087; Koga K, 2008, ANTICANCER RES, V28, P731; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kovacs JJ, 2008, SCIENCE, V320, P1777, DOI 10.1126/science.1157983; Koziel L, 2004, DEV CELL, V6, P801, DOI 10.1016/j.devcel.2004.05.009; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Ma XL, 2006, INT J CANCER, V118, P139, DOI 10.1002/ijc.21295; Ma XL, 2005, CARCINOGENESIS, V26, P1698, DOI 10.1093/carcin/bgi130; Martinelli DC, 2007, GENE DEV, V21, P1231, DOI 10.1101/gad.1546307; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McLellan JS, 2008, NATURE, V455, P979, DOI 10.1038/nature07358; Merchant M, 2005, MOL CELL BIOL, V25, P7054, DOI 10.1128/MCB.25.16.7054-7068.2005; Mistretta CM, 2003, DEV BIOL, V254, P1, DOI 10.1016/S0012-1606(02)00014-3; Molckovsky A, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-20; Molnar C, 2007, P NATL ACAD SCI USA, V104, P7963, DOI 10.1073/pnas.0702374104; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Nieuwenhuis E, 2006, MOL CELL BIOL, V26, P6609, DOI 10.1128/MCB.00295-06; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ogden SK, 2008, NATURE, V456, P967, DOI 10.1038/nature07459; Okada A, 2006, NATURE, V444, P369, DOI 10.1038/nature05246; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Park HL, 2000, DEVELOPMENT, V127, P1593; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; Philipp M, 2008, MOL BIOL CELL, V19, P5478, DOI 10.1091/mbc.E08-05-0448; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Reifenberger J, 1998, CANCER RES, V58, P1798; Reiter JF, 2006, GENE DEV, V20, P22, DOI 10.1101/gad.1363606; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P12607, DOI 10.1073/pnas.0600880103; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Scholey JM, 2006, CELL, V125, P439, DOI 10.1016/j.cell.2006.04.013; Seppala M, 2007, J CLIN INVEST, V117, P1575, DOI 10.1172/JCI32032; Shaw G, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-3; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; So PL, 2008, MOL CANCER THER, V7, P1275, DOI 10.1158/1535-7163.MCT-07-2043; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stanton BZ, 2009, NAT CHEM BIOL, V5, P154, DOI 10.1038/nchembio.142; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tremblay MR, 2009, J MED CHEM, V52, P4400, DOI 10.1021/jm900305z; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang Y, 2009, P NATL ACAD SCI USA, V106, P2623, DOI 10.1073/pnas.0812110106; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Wilson CW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005182; Wilson CW, 2009, NATURE, V459, P98, DOI 10.1038/nature07883; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; XIE J, 2009, SYSTEM TBOROTUOT, P1; Xie JW, 2008, ACTA BIOCH BIOPH SIN, V40, P670, DOI 10.1111/j.1745-7270.2008.00431.x; Xie JW, 2008, CURR ONCOL REP, V10, P107, DOI 10.1007/s11912-008-0018-7; Xie J, 2008, ADV EXP MED BIOL, V624, P241, DOI 10.1007/978-0-387-77574-6_19; Xie Jingwu, 2005, Future Oncol, V1, P331, DOI 10.1517/14796694.1.3.331; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yanai K, 2008, CANCER LETT, V263, P145, DOI 10.1016/j.canlet.2007.12.030; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yao SQ, 2006, CELL, V125, P343, DOI 10.1016/j.cell.2006.02.040; YAUCH RL, 2009, SCIENCE; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yoshikawa R, 2008, BRIT J CANCER, V98, P1670, DOI 10.1038/sj.bjc.6604361; Yue S, 2009, ONCOGENE, V28, P492, DOI 10.1038/onc.2008.403; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207; Zhang W, 2006, DEV CELL, V10, P657, DOI 10.1016/j.devcel.2006.04.005; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3; Zhang YM, 2009, NEOPLASIA, V11, P96, DOI 10.1593/neo.81264; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao Y, 2007, NATURE, V450, P252, DOI 10.1038/nature06225; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	201	244	265	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					469	481		10.1038/onc.2009.392	http://dx.doi.org/10.1038/onc.2009.392			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19935712				2022-12-28	WOS:000274084600001
J	Mamidipudi, V; Cartwright, CA				Mamidipudi, V.; Cartwright, C. A.			A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways	ONCOGENE			English	Article						RACK1; Src; apoptosis; mitochondrial cell death; intrinsic pathway; Akt cell survival pathway	PROTEIN-KINASE-C; RECEPTOR-INTERACTING PROTEIN; TRANSCRIPTION FACTORS; INHIBITS APOPTOSIS; BCL-2 PROTEINS; CELL-MIGRATION; CANCER-CELLS; GROWTH; ACTIVATION; ADHESION	Earlier we showed that RACK1 regulates growth of human colon cells by suppressing Src activity at G(1) and mitotic checkpoints. Here, we show that RACK1 also induces apoptosis of the cells, partly by inhibiting Src. In the intrinsic pathway, RACK1 inhibits expression of anti-apoptotic Bcl-2 and Bcl-X-L, induces expression of proapoptotic Bim, targets Bim and Bax to the mitochondria, induces oligomerization of Bax (which requires Bim and inhibition of Src), depolarizes mitochondria membranes, releases cytochrome c, and activates caspases-9 and -3 and death substrates. Bax and Bim are required for RACK1-mediated mitochondrial cell death. RACK1-induced oligomerization of Bax is required for staurosporine-mediated cell death. RACK1 also induces apoptosis by blocking Src activation of the Akt cell survival pathway. This leads to activation of the transcription factor FOXO3, a potent inducer of apoptosis and G(1) arrest. Collectively, our results show that RACK1, partly by inhibiting Src, promotes mitochondrial cell death and blocks Akt-mediated cell survival. Thus, RACK1 inhibits growth and induces death of colon cells. Exploitation of these dual functions could lead to novel colon cancer therapies that mimic RACK1 function. Oncogene (2009) 28, 4421-4433; doi:10.1038/onc.2009.293; published online 21 September 2009	[Cartwright, C. A.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, M211 Alway Bldg,MC 5187,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			National Institutes of Health [DK43743]; Broad Medical Research Program [IBD-0068]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Broad Medical Research Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Jenny Cheng and Gayathri Swaminathan for many helpful discussions and critical review of the data and manuscript. This work was supported by a grant from the National Institutes of Health to CAC (DK43743). Preliminary studies were supported by a pilot grant from the Broad Medical Research Program (IBD-0068).	Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Arimoto K, 2008, NAT CELL BIOL, V10, P1324, DOI 10.1038/ncb1791; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Griffiths GJ, 2004, J BIOL CHEM, V279, P46113, DOI 10.1074/jbc.M408550200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Inagaki K, 2006, CARDIOVASC RES, V70, P222, DOI 10.1016/j.cardiores.2006.02.015; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kang BPS, 2003, AM J PHYSIOL-RENAL, V285, pF1013, DOI 10.1152/ajprenal.00209.2003; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Liou JY, 2005, EXP CELL RES, V306, P75, DOI 10.1016/j.yexcr.2005.01.011; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Makin G, 2003, TRENDS MOL MED, V9, P251, DOI 10.1016/S1471-4914(03)00084-4; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2004, FEBS LETT, V567, P321, DOI 10.1016/j.febslet.2004.03.125; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Oberst A, 2008, CELL DEATH DIFFER, V15, P1139, DOI 10.1038/cdd.2008.65; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; SUN Y, 2002, CANCER RES, V21, P6323; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	54	53	57	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4421	4433		10.1038/onc.2009.293	http://dx.doi.org/10.1038/onc.2009.293			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767770				2022-12-28	WOS:000272876500002
J	Leivonen, SK; Makela, R; Ostling, P; Kohonen, P; Haapa-Paananen, S; Kleivi, K; Enerly, E; Aakula, A; Hellstrom, K; Sahlberg, N; Kristensen, VN; Borresen-Dale, AL; Saviranta, P; Perala, M; Kallioniemi, O				Leivonen, S-K; Makela, R.; Ostling, P.; Kohonen, P.; Haapa-Paananen, S.; Kleivi, K.; Enerly, E.; Aakula, A.; Hellstrom, K.; Sahlberg, N.; Kristensen, V. N.; Borresen-Dale, A-L; Saviranta, P.; Perala, M.; Kallioniemi, O.			Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines	ONCOGENE			English	Article						breast cancer; estrogen receptor; miRNA; protein lysate microarray; screening	CYCLE PROGRESSION; MESSENGER-RNAS; EXPRESSION; ALPHA; TARGETS; RESISTANCE; GENES	Predicting the impact of microRNAs (miRNAs) on target proteins is challenging because of their different regulatory effects at the transcriptional and translational levels. In this study, we applied a novel protein lysate microarray (LMA) technology to systematically monitor for target protein levels after high-throughput transfections of 319 pre-miRs into breast cancer cells. We identified 21 miRNAs that downregulated the estrogen receptor-alpha (ER alpha), as validated by western blotting and quantitative real time-PCR, and by demonstrating the inhibition of estrogen-stimulated cell growth. Five potent ER alpha-regulating miRNAs, miR-18a, miR-18b, miR-193b, miR-206 and miR-302c, were confirmed to directly target ER alpha in 3'-untranslated region reporter assays. The gene expression signature that they repressed highly overlapped with that of a small interfering RNA against ER alpha, and across all the signatures tested, was most closely associated with the repression of known estrogen-induced genes. Furthermore, miR-18a and miR-18b showed higher levels of expression in ER alpha-negative as compared with ER alpha-positive clinical tumors. In summary, we present systematic and direct functional evidence of miRNAs inhibiting ER alpha signaling in breast cancer, and demonstrate the high-throughput LMA technology as a novel, powerful technique in determining the relative impact of various miRNAs on key target proteins and associated cellular processes and pathways. Oncogene (2009) 28, 3926-3936; doi:10.1038/onc.2009.241; published online 17 August 2009	[Leivonen, S-K] VTT Tech Res Ctr Finland, VTT Med Biotechnol, FI-20521 Turku, Finland; [Leivonen, S-K; Makela, R.; Ostling, P.; Kohonen, P.; Haapa-Paananen, S.; Kleivi, K.; Aakula, A.; Hellstrom, K.; Sahlberg, N.; Saviranta, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Ctr Biotechnol, Turku, Finland; [Kleivi, K.; Enerly, E.; Kristensen, V. N.; Borresen-Dale, A-L] Univ Hosp, Rikshosp, Norwegian Radiumhosp, Dept Genet,Inst Canc Res, Oslo, Norway; [Enerly, E.; Borresen-Dale, A-L] Univ Oslo, Fac Med, Div Norwegian Radiumhosp, Oslo, Norway; [Kristensen, V. N.] Univ Oslo, Fac Med, Div AHUS, Oslo, Norway; [Kallioniemi, O.] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland	VTT Technical Research Center Finland; University of Turku; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; University of Helsinki	Leivonen, SK (corresponding author), VTT Tech Res Ctr Finland, VTT Med Biotechnol, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	suvi-katri.leivonen@vtt.fi	Haapa-Paananen, Saija/D-3075-2012; Leivonen, Suvi-Katri/AAK-3096-2021; Kohonen, Pekka/F-9596-2011; Kallioniemi, Olli P/H-5111-2011; Enerly, Espen/P-4666-2019	Kohonen, Pekka/0000-0002-7845-3611; Kallioniemi, Olli P/0000-0002-3231-0332; Enerly, Espen/0000-0002-2974-2273; Saviranta, Petri/0000-0002-3289-0621; Ostling, Paivi/0000-0001-5501-466X; Leivonen, Suvi-Katri/0000-0003-3224-0757; Kleivi Sahlberg, Kristine/0000-0002-7281-2759	Academy of Finland Centre of Excellence on Translational Genome-Scale Biology; Academy of Finland postdoctoral researcher's grant; Sigrid Juselius Foundation; Finnish Cancer Society; EU-FP6 [LSHB-CT-2004-005276, LSHG-CT-2004-5033155]; EU-FP7 [HEALTH-F2-2007-201438]	Academy of Finland Centre of Excellence on Translational Genome-Scale Biology(Academy of Finland); Academy of Finland postdoctoral researcher's grant(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Society; EU-FP6(European Commission); EU-FP7(European Commission)	The technical assistance of Pauliina Toivonen is gratefully acknowledged. We thank Agilent Technologies for their support on the miRNA expression arrays, and Hilde Johnsen (Department of Genetics, Norwegian Radium Hospital) for laboratory handling of miRNA expression arrays on tumors. We are grateful to the Department of Pathology, Norwegian Radium Hospital, for providing ER-IHC. This study was supported by the Academy of Finland Centre of Excellence on Translational Genome-Scale Biology, Academy of Finland postdoctoral researcher's grant (to SKL), Sigrid Juselius Foundation, Finnish Cancer Society, EU-FP6 projects RIGHT (LSHB-CT-2004-005276) and Moltools (LSHG-CT-2004-5033155), and EU-FP7 project ProspeR (HEALTH-F2-2007-201438).	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Milano A, 2006, EUR J CANCER, V42, P2692, DOI 10.1016/j.ejca.2006.06.022; Naume B, 2001, CLIN CANCER RES, V7, P4122; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Verghese ET, 2008, J PATHOL, V215, P214, DOI 10.1002/path.2359; Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	31	185	194	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2009	28	44					3926	3936		10.1038/onc.2009.241	http://dx.doi.org/10.1038/onc.2009.241			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19684618				2022-12-28	WOS:000271471900007
J	Simioni, MB; De Thonel, A; Hammann, A; Joly, AL; Bossis, G; Fourmaux, E; Bouchot, A; Landry, J; Piechaczyk, M; Garrido, C				Simioni, M. Brunet; De Thonel, A.; Hammann, A.; Joly, A. L.; Bossis, G.; Fourmaux, E.; Bouchot, A.; Landry, J.; Piechaczyk, M.; Garrido, C.			Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity	ONCOGENE			English	Article						HSP27; SUMOylation; HSF1; transcriptional activity; stress; cancer	NECROSIS-FACTOR-ALPHA; HSP27 OLIGOMERIZATION; MODIFIER SUMO; CELL-DEATH; IN-VIVO; PHOSPHORYLATION; STRESS; SUMOYLATION; HEAT-SHOCK-PROTEIN-27; TUMORIGENICITY	Heat shock protein 27 (HSP27) accumulates in stressed cells and helps them to survive adverse conditions. We have already shown that HSP27 has a function in the ubiquitination process that is modulated by its oligomerization/phosphorylation status. Here, we show that HSP27 is also involved in protein sumoylation, a ubiquitinatio-nrelated process. HSP27 increases the number of cell proteins modified by small ubiquitin-like modi. er (SUMO)-2/3 but this effect shows some selectivity as it neither affects all proteins nor concerns SUMO-1. Moreover, no such alteration in SUMO-2/3 conjugation is achievable by another HSP, such as HSP70. Heat shock factor 1 (HSF1), a transcription factor responsible for HSP expression, is one of the targets of HSP27. In stressed cells, HSP27 enters the nucleus and, in the form of large oligomers, binds to HSF1 and induces its modification by SUMO-2/3 on lysine 298. HSP27-induced HSF1 modification by SUMO-2/3 takes place downstream of the transcription factor phosphorylation on S303 and S307 and does not affect its DNA-binding ability. In contrast, this modi. cation blocks HSF1 transactivation capacity. These data show that HSP27 exerts a feedback inhibition of HSF1 transactivation and enlighten the strictly regulated interplay between HSPs and HSF1. As we also show that HSP27 binds to the SUMO-E2-conjugating enzyme, Ubc9, our study raises the possibility that HSP27 may act as a SUMO-E3 ligase specific for SUMO-2/3. Oncogene (2009) 28, 3332-3344; doi:10.1038/onc.2009.188; published online 13 July 2009	[Garrido, C.] Fac Med, INSERM, U866, F-21000 Dijon, France; [Simioni, M. Brunet; De Thonel, A.; Hammann, A.; Joly, A. L.; Garrido, C.] Univ Burgundy, Fac Med & Pharm, Dijon, France; [Bossis, G.; Piechaczyk, M.] CNRS, Inst Genet Mol, UMR 5535, Montpellier 5, France; [Bossis, G.; Piechaczyk, M.] Univ Montpellier 2, F-34095 Montpellier 5, France; [Bossis, G.; Piechaczyk, M.] Univ Montpellier 1, Montpellier 2, France; [Landry, J.] Univ Laval, Ctr Rech Cancerol, Quebec City, PQ, Canada; [Landry, J.] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Garrido, C.] CHU Dijon, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Laval University; Laval University; CHU Dijon Bourgogne	Garrido, C (corresponding author), Fac Med, INSERM, U866, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, Carolina/GWM-5557-2022; PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012; Garrido, carmen/G-1633-2018	PIECHACZYK, Marc/0000-0003-1367-2597; Garrido, carmen/0000-0003-1368-1493; bossis, guillaume/0000-0002-3349-8250; de Thonel, Aurelie/0000-0003-0405-0745	'Ligue Nationale Contre le Cancer'; 'Nievre'; 'Saone et Loire'; 'L' Association pour la Recherche contre le Cancer'; INCa	'Ligue Nationale Contre le Cancer'(Ligue nationale contre le cancer); 'Nievre'; 'Saone et Loire'; 'L' Association pour la Recherche contre le Cancer'; INCa(Institut National du Cancer (INCA) France)	We thank L Sistonen and J Anckar (Turku Centre for Biotechnology, Finland) for HSF1 and SUMO-2/3 tools, their helpful advices and discussions. We thank M Gaestel and A Vertii for sharing with us HSP27 phosphorylation mutants' constructions. This work was supported by grants from the 'Ligue Nationale Contre le Cancer' and its committees in the 'Nievre' and 'Saone et Loire'. MB and ALJ are recipients of a doctoral fellowship from the 'Ligue Nationale contre le Cancer', ADT has a postdoctoral fellowship from 'L' Association pour la Recherche contre le Cancer', and EF has an INCa financing. CG and MP lead teams 'Labellisees' from the 'Ligue Nationale contre le Cancer'.	Anckar J, 2007, BIOCHEM SOC T, V35, P1409, DOI 10.1042/BST0351409; Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Anckar J, 2007, ADV EXP MED BIOL, V594, P78; Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Blomster HA, 2009, MOL CELL PROTEOMICS, V8, P1382, DOI 10.1074/mcp.M800551-MCP200; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; CAIGNARD A, 1990, INT J CANCER, V46, P633, DOI 10.1002/ijc.2910460414; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Didelot C, 2006, HANDB EXP PHARM, V172, P171; Didelot C, 2007, CURR MED CHEM, V14, P2839, DOI 10.2174/092986707782360079; During RL, 2007, EMBO J, V26, P2240, DOI 10.1038/sj.emboj.7601687; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Guo DH, 2005, BIOCHEM BIOPH RES CO, V337, P1308, DOI 10.1016/j.bbrc.2005.09.191; Gurbuxani S, 2001, ONCOGENE, V20, P7478, DOI 10.1038/sj.onc.1204948; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Lee YJ, 2008, CANCER RES, V68, P7550, DOI 10.1158/0008-5472.CAN-08-0129; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Voellmy R, 2007, ADV EXP MED BIOL, V594, P89; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	43	63	64	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3332	3344		10.1038/onc.2009.188	http://dx.doi.org/10.1038/onc.2009.188			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597476				2022-12-28	WOS:000269893700007
J	Song, H; Zhang, B; Watson, MA; Humphrey, PA; Lim, H; Milbrandt, J				Song, H.; Zhang, B.; Watson, M. A.; Humphrey, P. A.; Lim, H.; Milbrandt, J.			Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis	ONCOGENE			English	Article						prostate cancer; Nkx3.1; pten; Akt; clusterin	PROLIFERATIVE INFLAMMATORY ATROPHY; LASER CAPTURE MICRODISSECTION; TRANSGENIC MOUSE MODEL; INTRAEPITHELIAL NEOPLASIA; SUPPRESSOR GENE; EXPRESSION PROFILES; MOLECULAR-FEATURES; OXIDATIVE DAMAGE; AKT ACTIVATION; PROTEIN NKX3.1	The expression of NKX3.1, a transcriptional regulator and tumor suppressor gene in prostate cancer, is downregulated during early stages of prostate tumorigenesis. However, little is known of the alterations in gene expression that occur as a result of this event. We combined laser capture microdissection and gene expression pro. ling to analyse the molecular consequences of Nkx3.1 loss during prostate cancer initiation using Nkx3.1-deficient mice. This analysis identified a cohort of genes (loss-of-Nkx3.1 signature) that are aberrantly overexpressed during loss-of-Nkx3.1-driven tumor initiation. We studied the expression of these genes in independent loss-of-Pten and c-myc overexpression prostate adenocarcinoma mouse models. Nkx3.1 expression is lost in prostate epithelial proliferation in both of these mouse models. However, Nkx3.1 loss is an early event of tumor development in the loss-of-Pten model, whereas it occurs at later stages in c-myc transgenic mice. A number of genes of the loss-of-Nkx3.1 signature, such as clusterin and quiescin Q6, are highly expressed in prostatic hyperplasia and intraepithelial neoplasia (PIN) lesions that also lack Nkx3.1 in the Pten-deficient prostate, but not in similar lesions in the c-myc transgenic model. Meta-analysis of multiple prostate cancer gene expression data sets, including those from loss-of-Nkx3.1, loss-of-Pten, c-myc overexpression and constitutively active Akt prostate cancer models, further confirmed that genes associated with the loss-of-Nkx3.1 signature integrate with PTEN-AKT signaling pathways, but do not overlap with molecular changes associated with the c-myc signaling pathway. In human prostate tissue samples, loss of NKX3.1 expression and corresponding clusterin overexpression are co-localized at sites of prostatic in. ammatory atrophy, a possible very early stage of human prostate tumorigenesis. Collectively, these results suggest that the molecular consequences of NKX3.1 loss depend on the epithelial proliferative stage at which its expression is lost, and that alterations in the PTEN-AKT-NKX3.1 axis are important for prostate cancer initiation. Oncogene (2009) 28, 3307-3319; doi:10.1038/onc.2009.181; published oline 13 July 2009	[Song, H.; Zhang, B.; Watson, M. A.; Humphrey, P. A.; Milbrandt, J.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; [Lim, H.] Washington Univ, Dept Obstet & Gynecol, Sch Med, St Louis, MO 63110 USA; [Song, H.] Kwandong Univ, Coll Med, Mol Oncol Lab, Cheil Gen Hosp, Seoul, South Korea; [Song, H.] Kwandong Univ, Coll Med, Womens Healthcare Ctr, Seoul, South Korea	Washington University (WUSTL); Washington University (WUSTL); Catholic Kwandong University; Catholic Kwandong University	Milbrandt, J (corresponding author), Washington Univ, Dept Pathol & Immunol, Sch Med, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	jmilbrandt@wustl.edu	Lim, Hyunjung J/D-5343-2011	Lim, Hyunjung J/0000-0003-2191-666X; Song, Haengseok/0000-0002-5027-7310; Milbrandt, Jeffrey/0000-0002-5477-7689	NIH [CA111966]; Washington University; Department of Defense [PC030380]; NATIONAL CANCER INSTITUTE [R01CA111966] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Washington University; Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are deeply indebted to Rakesh Nagarajan for help with bioinformatic analysis and Robert Heuckeroth for careful review of the manuscript and helpful discussions of the data. We thank Amy Strickland, Tatiana Gorodinsky and Nina Panchenko for technical assistance. We are grateful to Hong Wu and Charles Sawyers (UCLA) for Pten conditional and cmyc transgenic mice, respectively. This work was supported by NIH grants CA111966 (to JM) and Washington University Cancer Biology Pathway Fellowship (to BZ). HS was supported by a postdoctoral fellowship from the Department of Defense (PC030380).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Asatiani E, 2005, CANCER RES, V65, P1164, DOI 10.1158/0008-5472.CAN-04-2688; Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Bethel CR, 2007, PROSTATE, V67, P1740, DOI 10.1002/pros.20579; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; BOVA GS, 1993, CANCER RES, V53, P3869; Bowen C, 2000, CANCER RES, V60, P6111; Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; DAS SK, 1994, DEVELOPMENT, V120, P1071; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Ehrig T, 2001, J MOL DIAGN, V3, P22, DOI 10.1016/S1525-1578(10)60645-9; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Eshel R, 2002, SEMIN CANCER BIOL, V12, P139, DOI 10.1006/scbi.2001.0422; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Kim MJ, 2002, CANCER RES, V62, P2999; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Luzzi V, 2003, J MOL DIAGN, V5, P9, DOI 10.1016/S1525-1578(10)60445-X; MACOSKA JA, 1995, CANCER RES, V55, P5390; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Markowski MC, 2008, CANCER RES, V68, P6896, DOI 10.1158/0008-5472.CAN-08-0578; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Oberley TD, 2002, AM J PATHOL, V160, P403, DOI 10.1016/S0002-9440(10)64857-2; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Simard J, 2003, ENDOCR-RELAT CANCER, V10, P225, DOI 10.1677/erc.0.0100225; Simmons SO, 2006, BIOCHEM J, V393, P397, DOI 10.1042/BJ20051030; Song H, 2002, DEVELOPMENT, V129, P2879; Steadman DJ, 2000, NUCLEIC ACIDS RES, V28, P2389, DOI 10.1093/nar/28.12.2389; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tricoli JV, 2004, CLIN CANCER RES, V10, P3943, DOI 10.1158/1078-0432.CCR-03-0200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Zheng SL, 2006, CANCER RES, V66, P69, DOI 10.1158/0008-5472.CAN-05-1550	50	73	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3307	3319		10.1038/onc.2009.181	http://dx.doi.org/10.1038/onc.2009.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597465	Green Accepted			2022-12-28	WOS:000269893700005
J	Li, Y; Zhou, Z; Alimandi, M; Chen, C				Li, Y.; Zhou, Z.; Alimandi, M.; Chen, C.			WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer	ONCOGENE			English	Article						WWP1; ErbB4; PY motif; WW domain; ubiquitination; degradation	ESTROGEN-RECEPTOR; INTRACELLULAR DOMAIN; MITOTIC PROGRESSION; EPITHELIAL-CELLS; EXPRESSION; HER4; GROWTH; DIFFERENTIATION; FAMILY; PHOSPHORYLATION	ErbB4, a member of the epidermal growth factor receptor family, plays a role in normal breast and breast cancer development by regulating mammary epithelial cell proliferation, survival and differentiation. In this study, we show that WWP1, a C2-WW-HECT type E3 ubiquitin ligase, binds, ubiquitinates and destructs ErbB4-CYT1, but much less efficiently for CYT2, isoforms (both JMa and JMb). The protein-protein interaction occurs primarily between the first and third WW domains of WWP1 and the second PY motif of ErbB4. Knockdown of WWP1 by two different small interfering RNAs increases the endogenous ErbB4 protein levels in both MCF7 and T47D breast cancer cell lines. In addition, overexpression of the wild type, but not the catalytic inactive WWP1, dramatically decreases the endogenous ErbB4 protein levels in MCF7. Importantly, we found that WWP1 negatively regulates the heregulin-beta 1-stimulated ErbB4 activity as measured by the serum response element report assay and the BRCA1 mRNA expression. After a systematic screening of all WWP1 family members by small interfering RNA, we found that AIP4/Itch and HECW1/NEDL1 also negatively regulate the ErbB4 protein expression in T47D. Interestingly, the protein expression levels of both WWP1 and ErbB4 are higher in estrogen receptor-alpha-positive than in estrogen receptor-alpha-negative breast cancer cell lines. These data suggest that WWP1 and its family members suppress the ErbB4 expression and function in breast cancer. Oncogene (2009) 28, 2948-2958; doi:10.1038/onc.2009.162; published online 29 June 2009	[Li, Y.; Zhou, Z.; Chen, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Alimandi, M.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Albany Medical College; Sapienza University Rome	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu	Alimandi, Maurizio/AAG-9246-2019	Alimandi, Maurizio/0000-0002-1409-6803	Department of Defense BCRP [W81XWH-08-1-0557]; PCRP IDEA [W81XWH-07-1-0191]; American Cancer Society; Komen for the Cure [BCTR0503705]	Department of Defense BCRP(United States Department of Defense); PCRP IDEA; American Cancer Society(American Cancer Society); Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	This work was supported in part by grants from the Department of Defense BCRP concept award (W81XWH-08-1-0557) and PCRP IDEA award (W81XWH-07-1-0191), a Research Scholar Award from the American Cancer Society and a Grant (BCTR0503705, Chen, C) from Komen for the Cure.	Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chen C, 2007, INT J CANCER, V121, P2834; Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555-007-9091-x; Chen CS, 2009, INT J CANCER, V124, P2829, DOI 10.1002/ijc.24266; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Feng SM, 2007, MOL ENDOCRINOL, V21, P1861, DOI 10.1210/me.2006-0101; Feng SM, 2009, MOL CELL BIOL, V29, P892, DOI 10.1128/MCB.00595-08; Huu NSN, 2008, J PATHOL, V216, P93, DOI 10.1002/path.2385; Jackson-Fisher AJ, 2006, ONCOGENE, V25, P5664, DOI 10.1038/sj.onc.1209574; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Koutras AK, 2008, BRIT J CANCER, V99, P1775, DOI 10.1038/sj.bjc.6604769; Li Y, 2008, CELL DEATH DIFFER, V15, P1941, DOI 10.1038/cdd.2008.134; Li Y, 2008, ONCOGENE, V27, P3700, DOI 10.1038/sj.onc.1211032; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Muraoka-Cook RS, 2008, MOL ENDOCRINOL, V22, P2307, DOI 10.1210/me.2008-0055; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Pitfield SE, 2006, ONCOL RES, V16, P179, DOI 10.3727/000000006783981134; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Strunk KE, 2007, CANCER RES, V67, P6582, DOI 10.1158/0008-5472.CAN-06-4145; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Suo ZH, 2001, VIRCHOWS ARCH, V439, P62, DOI 10.1007/s004280000392; Tang CK, 1999, CANCER RES, V59, P5315; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	38	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2948	2958		10.1038/onc.2009.162	http://dx.doi.org/10.1038/onc.2009.162			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19561640				2022-12-28	WOS:000269142800003
J	Molli, PR; Li, DQ; Murray, BW; Rayala, SK; Kumar, R				Molli, P. R.; Li, D. Q.; Murray, B. W.; Rayala, S. K.; Kumar, R.			PAK signaling in oncogenesis	ONCOGENE			English	Review						PAK; cancer; cytoskeleton; survival; mitosis; knockout mice	KINASE GAMMA-PAK; BREAST-CANCER CELLS; ANCHORAGE-INDEPENDENT GROWTH; P21-ACTIVATED KINASE-1-INTERACTING SUBSTRATE; NUCLEOTIDE EXCHANGE FACTOR; CASPASE-ACTIVATED PAK-2; FAMILY-MEMBER BIM; SERINE/THREONINE KINASE; MENTAL-RETARDATION; PROSTATE-CANCER	The p21-activated kinase (PAK) family of serine/threonine kinases is important in physiological processes including motility, survival, mitosis, transcription and translation. PAKs are evolutionally conserved and widely expressed in a variety of tissues and are often overexpressed in multiple cancer types. Depending on structural and functional similarities, the six members of PAK family are divided into two groups with three members in each group. Group I PAKs are activated by extracellular signals through GTPase-dependent and GTPase-independent mechanisms. In contrast, group II PAKs are constitutively active. Over the years, accumulating data from tissue culture models and human tumors has increased our understanding about the biology of PAK family members. In this review, we have summarized the complex regulation of PAK and its downstream diverse myriads of effectors, which in turn are responsible for the biological effects of PAK family of kinases in cancer cells. Oncogene (2009) 28, 2545-2555; doi: 10.1038/onc.2009.119; published online 25 May 2009	[Molli, P. R.; Li, D. Q.; Rayala, S. K.; Kumar, R.] George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Murray, B. W.] La Jolla Labs, Pfizer Global Res & Dev, San Diego, CA USA	George Washington University; Pfizer	Kumar, R (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, 2300 1 St NW,Suit 530, Washington, DC 20037 USA.	bcmrxk@gwumc.edu	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; murray, brion/0000-0003-1591-2566; Rayala, Suresh/0000-0003-4394-4450	NIH [CA90970, CA098823]; NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in Professor Kumar's laboratory is supported by NIH grants CA90970 and CA098823.	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed S, 1998, J BIOL CHEM, V273, P15693, DOI 10.1074/jbc.273.25.15693; Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bienvenu T, 2000, AM J MED GENET, V93, P294, DOI 10.1002/1096-8628(20000814)93:4<294::AID-AJMG8>3.0.CO;2-F; Block MR, 2008, EUR J CELL BIOL, V87, P491, DOI 10.1016/j.ejcb.2008.02.012; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brecht M, 2005, INT J CANCER, V113, P533, DOI 10.1002/ijc.20626; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Callow MG, 2005, J CELL SCI, V118, P1861, DOI 10.1242/jcs.02313; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chen S, 2003, J BIOL CHEM, V278, P20029, DOI 10.1074/jbc.M300818200; Chen SL, 2008, CANCER BIOL THER, V7, P1793, DOI 10.4161/cbt.7.11.6840; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Cotteret S, 2006, MOL CELL BIOL, V26, P3215, DOI 10.1128/MCB.26.8.3215-3230.2006; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Gedeon AK, 2003, AM J MED GENET A, V120A, P509, DOI 10.1002/ajmg.a.20131; Gnesutta N, 2003, MOL CELL BIOL, V23, P7838, DOI 10.1128/MCB.23.21.7838-7848.2003; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hashimoto S, 2001, J BIOL CHEM, V276, P6037, DOI 10.1074/jbc.M005854200; He H, 2004, CANCER BIOL THER, V3, P96, DOI 10.4161/cbt.3.1.643; Hirokawa Y, 2005, CANCER BIOL THER, V4, P956, DOI 10.4161/cbt.4.9.1911; Hoefen RJ, 2006, J CELL SCI, V119, P1469, DOI 10.1242/jcs.02925; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jung JH, 2005, J BIOL CHEM, V280, P40025, DOI 10.1074/jbc.M509075200; Kaur R, 2008, PROSTATE, V68, P1510, DOI 10.1002/pros.20787; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Koeppel MA, 2004, J BIOL CHEM, V279, P53653, DOI 10.1074/jbc.M410530200; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Kreis P, 2008, J NEUROCHEM, V106, P1184, DOI 10.1111/j.1471-4159.2008.05474.x; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee SR, 2002, MOL ENDOCRINOL, V16, P85, DOI 10.1210/me.16.1.85; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li XF, 2003, MOL CELL BIOL, V23, P7134, DOI 10.1128/MCB.23.20.7134-7142.2003; Ling J, 2005, EMBO J, V24, P4094, DOI 10.1038/sj.emboj.7600868; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Mazumdar A, 2003, FEBS LETT, V535, P6, DOI 10.1016/S0014-5793(02)03846-2; Meng JS, 2005, J NEUROSCI, V25, P6641, DOI 10.1523/JNEUROSCI.0028-05.2005; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Morita T, 2007, J BIOL CHEM, V282, P8454, DOI 10.1074/jbc.M609983200; Nheu T, 2004, CELL CYCLE, V3, P71; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pirruccello M, 2006, J MOL BIOL, V361, P312, DOI 10.1016/j.jmb.2006.06.017; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qu J, 2003, MOL CELL BIOL, V23, P7122, DOI 10.1128/MCB.23.20.7122-7133.2003; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Rousseau V, 2003, J BIOL CHEM, V278, P3912, DOI 10.1074/jbc.M207251200; Schatten H, 2008, HISTOCHEM CELL BIOL, V129, P667, DOI 10.1007/s00418-008-0427-6; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Settleman J, 2007, CELL, V128, P237, DOI 10.1016/j.cell.2007.01.002; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Timm T, 2006, NEURODEGENER DIS, V3, P207, DOI 10.1159/000095258; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Turner CE, 2000, J CELL SCI, V113, P4139; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2004, EMBO REP, V5, P154, DOI 10.1038/sj.embor.7400079; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wang RA, 2003, J CELL BIOL, V161, P583, DOI 10.1083/JCB.200212066; Webb BA, 2006, ARCH BIOCHEM BIOPHYS, V456, P183, DOI 10.1016/j.abb.2006.06.011; Weisz H. M., 2007, BIOCHEM J, V404, P487, DOI DOI 10.1042/BJ20061696; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wu XC, 2006, BIOCHEM BIOPH RES CO, V351, P328, DOI 10.1016/j.bbrc.2006.09.172; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zhan Q, 2003, J IMMUNOL, V171, P3785, DOI 10.4049/jimmunol.171.7.3785; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	104	171	179	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2545	2555		10.1038/onc.2009.119	http://dx.doi.org/10.1038/onc.2009.119			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465939	Green Accepted			2022-12-28	WOS:000268058900001
J	Walter, M; Liang, S; Ghosh, S; Hornsby, PJ; Li, R				Walter, M.; Liang, S.; Ghosh, S.; Hornsby, P. J.; Li, R.			Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells	ONCOGENE			English	Article						adipose stromal cells; cofilin-1; IL-6; breast tumor cells; migration; invasion	BODY-MASS INDEX; CARCINOMA-CELLS; STEM-CELLS; COFILIN PHOSPHORYLATION; MAMMARY-GLAND; TUMOR-GROWTH; OBESITY; TISSUE; INCREASE; DISEASE	Excessive adiposity has long been associated with increased incidence of breast cancer in post-menopausal women, and with increased mortality from breast cancer, regardless of the menopausal status. Although adipose tissue-derived estrogen contributes to obesity-associated risk for estrogen receptor (ER)-positive breast cancer, the estrogen-independent impact of adipose tissue on tumor invasion and progression needs to be elucidated. Here, we show that adipose stromal cells (ASCs) significantly stimulate migration and invasion of ER-negative breast cancer cells in vitro and tumor invasion in a co-transplant xenograft mouse model. Our study also identifies cofilin-1, a known regulator of actin dynamics, as a determinant of the tumor-promoting activity of ASCs. The cofilin-1-dependent pathway affects the production of interleukin 6 (IL-6) in ASCs. Depletion of IL-6 from the ASC-conditioned medium abrogated the stimulatory effect of ASCs on the migration and invasion of breast tumor cells. Thus, our study uncovers a link between a cytoskeleton-based pathway in ASCs and the stromal impact on breast cancer cells. Oncogene (2009) 28, 2745-2755; doi:10.1038/onc.2009.130; published online 1 June 2009	[Walter, M.; Ghosh, S.; Li, R.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; [Liang, S.; Hornsby, P. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Li, R (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	lir3@uthscsa.edu			NCI [CA93506]; DOD [W81XWH-06-1-034]; NIA; Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Owens Medical Research Foundation; Glenn Foundation for Medical Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Adam Katz for ASCs. The work was supported by grants to RL from the NCI (CA93506) and DOD (W81XWH-06-1-034), and by grants to PJH from the NIA, the Owens Medical Research Foundation, and the Glenn Foundation for Medical Research.	Ailhaud G, 2006, CR BIOL, V329, P570, DOI 10.1016/j.crvi.2005.12.012; Amemori Sadahiro, 2007, Am J Physiol Gastrointest Liver Physiol, V292, pG923; Ara T, 2009, CANCER RES, V69, P329, DOI 10.1158/0008-5472.CAN-08-0613; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6; Carmichael AR, 2006, OBES REV, V7, P333, DOI 10.1111/j.1467-789X.2006.00261.x; Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; Cooke PS, 2004, EXP BIOL MED, V229, P1127, DOI 10.1177/153537020422901107; Dawood S, 2008, CLIN CANCER RES, V14, P1718, DOI 10.1158/1078-0432.CCR-07-1479; Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Ghosh S, 2007, AM J PHYSIOL-ENDOC M, V292, pE246, DOI 10.1152/ajpendo.00242.2006; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hjartaker A, 2008, ADV EXP MED BIOL, V630, P72; Hoene M, 2008, OBES REV, V9, P20, DOI 10.1111/j.1467-789X.2007.00410.x; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kilroy GE, 2007, J CELL PHYSIOL, V212, P702, DOI 10.1002/jcp.21068; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; LaVecchia C, 1997, BRIT J CANCER, V75, P441, DOI 10.1038/bjc.1997.73; Li ZP, 2005, SURG CLIN N AM, V85, P681, DOI 10.1016/j.suc.2005.04.006; Lin SY, 2008, EXP CELL RES, V314, P3107, DOI 10.1016/j.yexcr.2008.07.028; Lin YF, 2006, MOL CELL BIOCHEM, V285, P69, DOI 10.1007/s11010-005-9056-8; Liu D, 2007, NEOPLASIA, V9, P418, DOI 10.1593/neo.07205; Liu D, 2007, CANCER RES, V67, P3117, DOI 10.1158/0008-5472.CAN-06-3452; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paduch R, 2005, CELL BIOL TOXICOL, V21, P247, DOI 10.1007/s10565-005-0002-z; Pederson T, 2008, J CELL BIOL, V180, P1061, DOI 10.1083/jcb.200709082; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017; Spalding KL, 2008, NATURE, V453, P783, DOI 10.1038/nature06902; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Tessitore L, 2004, INT J ONCOL, V24, P1529; Tholpady SS, 2006, CLIN PLAST SURG, V33, P55, DOI 10.1016/j.cps.2005.08.004; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Whiteman MK, 2005, CANCER EPIDEM BIOMAR, V14, P2009, DOI 10.1158/1055-9965.EPI-05-0106; Zalesin KC, 2008, ENDOCRIN METAB CLIN, V37, P663, DOI 10.1016/j.ecl.2008.06.004	49	227	231	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2745	2755		10.1038/onc.2009.130	http://dx.doi.org/10.1038/onc.2009.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483720	Green Accepted			2022-12-28	WOS:000268452900005
J	Kumar, C; Purandare, AV; Lee, FY; Lorenzi, MV				Kumar, C.; Purandare, A. V.; Lee, F. Y.; Lorenzi, M. V.			Kinase drug discovery approaches in chronic myeloproliferative disorders	ONCOGENE			English	Review						tyrosine kinase inhibitors; JAK2; BCR-ABL; hematopoeisis	CHRONIC MYELOMONOCYTIC LEUKEMIA; JAK2 EXON-12 MUTATIONS; POLYCYTHEMIA-VERA; TYROSINE KINASE; ESSENTIAL THROMBOCYTHEMIA; PHILADELPHIA-CHROMOSOME; CHRONIC-PHASE; MYELOID METAPLASIA; DASATINIB BMS-354825; IMATINIB RESISTANCE	Myeloproliferative disorders (MPDs) are clonal malignancies that arise from hematopoietic progenitors and characterized by overproduction of mature, functional blood cells. These disorders can be broadly characterized into Philadelphia chromosome-positive (Ph(+)) or negative (Ph(-)) genetic groupings. Chronic myeloid leukemia (CML) is a Ph(+) MPD that is defined on the basis of its molecular lesion, the BCR-ABL fusion gene. Inhibitors directed at the constitutive kinase activity of BCR-ABL have been shown to be disease modifying in CML and have dramatically altered the standard of care for this leukemia. The three main Ph(-) MPDs are polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The key features of these Ph(-) MPDs are an increased red blood cell mass in PV, a high platelet count in ET and bone marrow fibrosis in PMF, respectively. These disorders also share many clinical features such as long clinical course, increased risk for thrombosis, hemorrhage and elevated risk of leukemic transformation. Interest in these disorders has been ignited by the recent discovery of activating mutations in the tyrosine kinase gene, JAK2, in the predominance of Ph(-) MPD patients and has highlighted JAK2 as a therapeutic intervention point for drug discovery efforts with selective kinase inhibitors. This review will focus on the comparison of Ph(+) and Ph(-) MPDs, drug discovery and development efforts targeting these disorders, and will assess the new opportunities for targeted therapies for these diseases. Oncogene (2009) 28, 2305-2313; doi:10.1038/onc.2009.107; published online 4 May 2009	[Lorenzi, M. V.] Bristol Myers Squibb Co, Pharmaceut Res Inst, Oncol Drug Discovery, Res & Dev, Princeton, NJ 08540 USA; [Kumar, C.] SmartAnalyst, New York, NY USA	Bristol-Myers Squibb	Lorenzi, MV (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Oncol Drug Discovery, Res & Dev, POB 4000, Princeton, NJ 08540 USA.	matthew.lorenzi@bms.com						Abdel-Wahab OI, 2009, ANNU REV MED, V60, P233, DOI 10.1146/annurev.med.60.041707.160528; Baccarani M, 2008, HAEMATOL-HEMATOL J, V93, P161, DOI 10.3324/haematol.12588; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cervantes F, 2008, LEUKEMIA, V22, P905, DOI 10.1038/leu.2008.72; CERVANTES F, 1991, ACTA HAEMATOL-BASEL, V85, P124; Cervantes F, 2007, CANCER J, V13, P377, DOI 10.1097/PPO.0b013e31815a7c0a; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; Doesch C, 2008, J THROMB THROMBOLYS, V25, P193, DOI 10.1007/s11239-007-0082-0; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Finazzi G, 2007, BLOOD, V109, P5104, DOI 10.1182/blood-2006-12-038968; Finazzi Guido, 2008, V142, P51; Geron I, 2008, CANCER CELL, V13, P321, DOI 10.1016/j.ccr.2008.02.017; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Goerttler PS, 2005, BRIT J HAEMATOL, V129, P138, DOI 10.1111/j.1365-2141.2005.05416.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9-3-271; Harrison CN, 2005, NEW ENGL J MED, V353, P33, DOI 10.1056/NEJMoa043800; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Johansson P, 2004, J INTERN MED, V256, P161, DOI 10.1111/j.1365-2796.2004.01357.x; Kantarjian H, 2008, BLOOD, V111, P1774, DOI 10.1182/blood-2007-09-110189; Kantarjian HM, 2007, BLOOD, V110, P3540, DOI 10.1182/blood-2007-03-080689; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kutti J, 2001, PATHOL BIOL, V49, P164, DOI 10.1016/S0369-8114(00)00023-7; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; LEE FY, 2005, BLOOD, V106, P1994; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Levine RL, 2006, BLOOD, V107, P4139, DOI 10.1182/blood-2005-09-3900; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Mesa RA, 2008, CURR OPIN HEMATOL, V15, P121, DOI 10.1097/MOH.0b013e3282f3debd; Mesa RA, 2007, CANCER-AM CANCER SOC, V109, P68, DOI 10.1002/cncr.22365; Mesa RA, 2006, BEST PRACT RES CL HA, V19, P495, DOI 10.1016/j.beha.2005.07.008; Morinaga K, 2008, INT J CANCER, V122, P2621, DOI 10.1002/ijc.23435; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Hare T, 2005, CANCER RES, V65, P4500, DOI 10.1158/0008-5472.CAN-05-0259; O'Hare T, 2008, P NATL ACAD SCI USA, V105, P5507, DOI 10.1073/pnas.0800587105; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; Pardanani A, 2007, LEUKEMIA, V21, P1960, DOI 10.1038/sj.leu.2404810; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Quintas-Cardama Alfonso, 2006, Future Oncol, V2, P655, DOI 10.2217/14796694.2.6.655; QUINTASCARDAMA A, 2008, LEUK RES IN PRESS; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; Sawyers CL, 2005, COLD SH Q B, V70, P479, DOI 10.1101/sqb.2005.70.034; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Shah NP, 2007, J CLIN ONCOL, V25; Shah Neil P, 2007, Hematology Am Soc Hematol Educ Program, P371; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Siendones E, 2007, HEMATOL ONCOL, V25, P30, DOI 10.1002/hon.805; Soverini S, 2007, HAEMATOLOGICA, V92, P401, DOI 10.3324/haematol.10822; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Tefferi A, 2008, LEUKEMIA, V22, P1, DOI 10.1038/sj.leu.2404984; Tefferi A, 2005, BRIT J HAEMATOL, V131, P320, DOI 10.1111/j.1365-2141.2005.05776.x; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2008, AM J HEMATOL, V83, P491, DOI 10.1002/ajh.21183; Tefferi A, 2007, BLOOD, V110, P1092, DOI 10.1182/blood-2007-04-083501; Theocharides A, 2007, BLOOD, V110, P375, DOI 10.1182/blood-2006-12-062125; Wang XD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r255; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Werning G, 2008, CANCER CELL, V13, P311, DOI 10.1016/j.ccr.2008.02.009; Wolanskyj AP, 2006, MAYO CLIN PROC, V81, P159, DOI 10.4065/81.2.159; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018	77	26	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2305	2313		10.1038/onc.2009.107	http://dx.doi.org/10.1038/onc.2009.107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421140				2022-12-28	WOS:000267089100001
J	Jones, RA; Campbell, CI; Wood, GA; Petrik, JJ; Moorehead, RA				Jones, R. A.; Campbell, C. I.; Wood, G. A.; Petrik, J. J.; Moorehead, R. A.			Reversibility and recurrence of IGF-IR-induced mammary tumors	ONCOGENE			English	Article						insulin-like growth factor; mammary tumorigenesis; tumor recurrence; epithelial to mesenchymal transition; tumor dormancy	GROWTH-FACTOR-I; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODY; TRANSCRIPTIONAL REPRESSOR; TRANSGENIC MICE; FACTOR RECEPTOR; MESSENGER-RNA; GENE-EXPRESSION; KINASE-ACTIVITY; SOLID TUMORS	The type-I insulin-like growth factor receptor (IGF-IR) is frequently overexpressed in breast cancer and therapeutic agents targeting IGF-IR are currently in development. The ultimate success of anti-IGF-IR therapies will depend on the extent to which established tumors remain dependent upon IGF-IR signaling for sustained growth. To investigate the potential benefits and pitfalls of targeting IGF-IR, we used a doxycycline inducible mouse model of IGF-IR initiated breast cancer. We found that downregulation of IGF-IR results in tumor-size-dependent regression to an undetectable state. Partially regressed tumors almost always resumed growth in the absence of doxycycline and a proportion of tumors that regressed to an undetectable state ultimately recurred. This reemergence of tumor growth in the absence of doxycycline was facilitated by IGF-IR-dependent and IGF-IR-independent mechanisms. Tumor escape from IGF-IR dependence was associated with an epithelial to mesenchymal transition and upregulation of transcriptional repressors of E-cadherin. These results suggest that tumors initiated by IGF-IR have the ability to become independent of this initiating oncogene, and IGF-IR independence is associated with characteristics consistent with an epithelial to mesenchymal transition. Oncogene (2009) 28, 2152-2162; doi: 10.1038/onc.2009.79; published online 20 April 2009	[Jones, R. A.; Campbell, C. I.; Petrik, J. J.; Moorehead, R. A.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; [Wood, G. A.] Univ Guelph, Ontario Vet Coll, Dept Pathobiol, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca	Wood, Geoffrey/ABB-2052-2021	Wood, Geoffrey/0000-0003-1756-8607; , Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301	Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Ontario Graduate Scholarships	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance; Ontario Graduate Scholarships(Ontario Graduate Scholarship)	We thank Katrina Watson, Helen Coates and Michelle Ross for excellent technical assistance. This work was supported by operating grants from the Canadian Institutes of Health Research, the Canadian Breast Cancer Research Alliance, the Cancer Research Society as well as a New Investigator Salary Award from the Canadian Institutes of Health Research (RA Moorehead) and Ontario Graduate Scholarships (RA Jones and CI Campbell).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Burtrum D, 2003, CANCER RES, V63, P8912; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; Divisova J, 2006, BREAST CANCER RES TR, V98, P315, DOI 10.1007/s10549-006-9168-1; Dunn SE, 1998, CANCER RES, V58, P3353; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Feng Y, 2006, MOL CANCER THER, V5, P114, DOI 10.1158/1535-7163.MCT-05-0252; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2008, MOL CANCER RES, V6, P819, DOI 10.1158/1541-7786.MCR-07-2157; Kato M, 2007, P NATL ACAD SCI USA, V104, P3432, DOI 10.1073/pnas.0611192104; Kurebayashi Junichi, 2007, Breast Cancer, V14, P200, DOI 10.2325/jbcs.954; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Linnerth NM, 2005, INT J CANCER, V114, P977, DOI 10.1002/ijc.20814; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nichols KD, 2008, BIOCHEM PHARMACOL, V75, P1230, DOI 10.1016/j.bcp.2007.10.032; PAIK S, 1992, BREAST CANCER RES TR, V22, P31, DOI 10.1007/BF01833331; Parisot JP, 1999, BRIT J CANCER, V79, P693, DOI 10.1038/sj.bjc.6690112; Pattyn F, 2006, NUCLEIC ACIDS RES, V34, pD684, DOI 10.1093/nar/gkj155; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Resnik JL, 1998, CANCER RES, V58, P1159; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; SINGER C, 1995, CANCER RES, V55, P2448; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YEE D, 1988, CANCER RES, V48, P6691; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	52	31	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2152	2162		10.1038/onc.2009.79	http://dx.doi.org/10.1038/onc.2009.79			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19377512				2022-12-28	WOS:000266451300004
J	Nguyen, A; Chang, ACM; Reddel, RR				Nguyen, A.; Chang, A. C. M.; Reddel, R. R.			Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress	ONCOGENE			English	Article						stanniocalcin-1; STC1; ERK1/2; oxidative stress; PD98059; apoptosis	DIFFERENTIAL GENE-EXPRESSION; ELEVATED EXPRESSION; PROTEIN; GROWTH; CELLS; RECEPTOR; OXYGEN; IDENTIFICATION; SENSITIVITY; ACTIVATION	Mammalian Stanniocalcin-1 (STC1) is a glycoprotein that has been implicated in various biological processes including angiogenesis. Aberrant STC1 expression has been reported in breast, ovarian and prostate cancers, but the significance of this is not well understood. Here, we report that oxidative stress caused a 40-fold increase in STC1 levels in mouse embryo. broblasts (MEFs). STC1(-/-) MEFs were resistant to growth inhibition and cell death induced by H2O2 or by 20% O-2 ( which is hyperoxic for most mammalian cells); this is the first phenotype reported for STC1-null cells. STC1(-/-) cells had higher levels of activated MEK and ERK1/2 than their wild-type (WT) counterparts, and these levels were all reduced by stable expression of exogenous STC1 in STC1(-/-) cells. Furthermore, pharmacological inhibition by PD98059 or UO126 of MEK and therefore of ERK1/2 activation restored sensitivity of STC1(-/-) cells to oxidative stress. We also found that H2O2- induced STC1 expression in WT cells was abolished by inhibition of ERK1/2 activation. Thus, the ERK1/2 signaling pathway upregulates STC1 expression, which in turn downregulates the level of activated MEK and consequently ERK1/2 in a novel negative feedback loop. Therefore, STC1 expression downregulates prosurvival ERK1/2 signaling and reduces survival under conditions of oxidative stress. Oncogene (2009) 28, 1982-1992; doi:10.1038/onc.2009.65; published online 6 April 2009	[Nguyen, A.; Chang, A. C. M.; Reddel, R. R.] Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia; [Nguyen, A.; Chang, A. C. M.; Reddel, R. R.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107	Australian Postgraduate Award; Carcinogenesis Fellowship of the Cancer Council NSW; National Health and Medical Research Council of Australia Senior Principal Research Fellowship	Australian Postgraduate Award(Australian Government); Carcinogenesis Fellowship of the Cancer Council NSW(Cancer Council New South Wales); National Health and Medical Research Council of Australia Senior Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by an Australian Postgraduate Award, the Carcinogenesis Fellowship of the Cancer Council NSW and a National Health and Medical Research Council of Australia Senior Principal Research Fellowship.	Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Arrington ED, 2000, FREE RADICAL BIO MED, V29, P1166, DOI 10.1016/S0891-5849(00)00439-1; Bai XC, 2002, BIOCHEM J, V363, P395, DOI 10.1042/0264-6021:3630395; Bell SE, 2001, J CELL SCI, V114, P2755; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Bouras T, 2002, CANCER RES, V62, P1289; Chang ACM, 2005, MOL CELL BIOL, V25, P10604, DOI 10.1128/MCB.25.23.10604-10610.2005; Chang ACM, 2003, ENDOCR-RELAT CANCER, V10, P359, DOI 10.1677/erc.0.0100359; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chang ACM, 1996, MOL CELL ENDOCRINOL, V124, P185, DOI 10.1016/S0303-7207(96)03929-9; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Ellard JP, 2007, MOL CELL ENDOCRINOL, V264, P90, DOI 10.1016/j.mce.2006.10.008; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Ismail RS, 2000, CANCER RES, V60, P6744; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; Jiang WQ, 2000, J ENDOCRINOL, V165, P457, DOI 10.1677/joe.0.1650457; Joensuu K, 2008, CANCER LETT, V265, P76, DOI 10.1016/j.canlet.2008.02.022; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Kanellis J, 2004, AM J PHYSIOL-RENAL, V286, pF356, DOI 10.1152/ajprenal.00138.2003; Koizumi K, 2007, CIRC J, V71, P796, DOI 10.1253/circj.71.796; Lai KP, 2007, BIOCHEM BIOPH RES CO, V356, P968, DOI 10.1016/j.bbrc.2007.03.074; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Long H, 2003, CELL PHYSIOL BIOCHEM, V13, P401, DOI 10.1159/000075128; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; McCudden CR, 2002, J BIOL CHEM, V277, P45249, DOI 10.1074/jbc.M205954200; Okabe H, 2001, CANCER RES, V61, P2129; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Sheikh-Hamad D, 2000, AM J PHYSIOL-RENAL, V278, pF417, DOI 10.1152/ajprenal.2000.278.3.F417; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUNDELL K, 1992, J COMP PHYSIOL B, V162, P489; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; WAGNER GF, 1988, GEN COMP ENDOCR, V72, P237, DOI 10.1016/0016-6480(88)90206-7; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Westberg JA, 2007, AM J PHYSIOL-HEART C, V293, pH1766, DOI 10.1152/ajpheart.00017.2007; Westberg JA, 2007, STROKE, V38, P1025, DOI 10.1161/01.STR.0000258113.67252.fa; Wu SF, 2006, J BIOL CHEM, V281, P5120, DOI 10.1074/jbc.M506667200; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Yeung HY, 2005, ENDOCRINOLOGY, V146, P4951, DOI 10.1210/en.2005-0365; Yeung HY, 2003, ENDOCRINOLOGY, V144, P4446, DOI 10.1210/en.2003-0504; Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003-0130; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	51	48	50	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1982	1992		10.1038/onc.2009.65	http://dx.doi.org/10.1038/onc.2009.65			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347030				2022-12-28	WOS:000265820900005
J	Reisman, D; Glaros, S; Thompson, EA				Reisman, D.; Glaros, S.; Thompson, E. A.			The SWI/SNF complex and cancer	ONCOGENE			English	Review						BRG1; BRM; BAF47; tumor suppressor; chromatin remodeling	CHROMATIN-REMODELING COMPLEX; SWI-SNF COMPLEX; TUMOR-SUPPRESSOR GENE; GLUCOCORTICOID-INDUCED APOPTOSIS; CELL-CYCLE ARREST; LUNG-CANCER; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; ATPASE SUBUNIT; TRANSCRIPTIONAL ACTIVATION	The mammalian SWI/SNF complexes mediate ATP-dependent chromatin remodeling processes that are critical for differentiation and proliferation. Not surprisingly, loss of SWI/SNF function has been associated with malignant transformation, and a substantial body of evidence indicates that several components of the SWI/SNF complexes function as tumor suppressors. This review summarizes the evidence that underlies this conclusion, with particular emphasis upon the two catalytic subunits of the SWI/SNF complexes, BRM, the mammalian ortholog of SWI2/SNF2 in yeast and brahma in Drosophila, and Brahma-related gene-1 (BRG1).	[Reisman, D.] Univ Michigan, Dept Internal Med, Coll Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Thompson, E. A.] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA	University of Michigan System; University of Michigan; Mayo Clinic	Reisman, D (corresponding author), Univ Michigan, Dept Internal Med, Coll Med, Div Hematol Oncol, B-570B MSRBII,Campus Box 0686,1150 Med Ctr Dr, Ann Arbor, MI 48109 USA.	dreisman@med.umich.edu						ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; An HX, 1999, CANCER RES, V59, P3941; Aoyagi S, 2005, VITAM HORM, V70, P281, DOI 10.1016/S0083-6729(05)70009-1; Armstrong JA, 2002, EMBO J, V21, P5245, DOI 10.1093/emboj/cdf517; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Biegel Jaclyn A, 2004, Curr Oncol Rep, V6, P445, DOI 10.1007/s11912-004-0075-5; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Bourachot B, 1999, MOL CELL BIOL, V19, P3931; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Bourdeaut F, 2007, J PATHOL, V211, P323, DOI 10.1002/path.2103; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; Brumby AM, 2002, EMBO J, V21, P3377, DOI 10.1093/emboj/cdf334; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CARLSON M, 1981, GENETICS, V98, P25; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chi TH, 2002, NATURE, V418, P195, DOI 10.1038/nature00876; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Choi EY, 2001, EXP CELL RES, V271, P180, DOI 10.1006/excr.2001.5355; Choi YI, 2001, P NATL ACAD SCI USA, V98, P10267, DOI 10.1073/pnas.181076198; Claudio PP, 2000, CANCER RES, V60, P8; Coisy-Quivy M, 2006, CANCER RES, V66, P5069, DOI 10.1158/0008-5472.CAN-05-0596; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Debril MB, 2004, J BIOL CHEM, V279, P16677, DOI 10.1074/jbc.M312288200; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Eiriksdottir G, 1995, INT J CANCER, V64, P378, DOI 10.1002/ijc.2910640605; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004; Foster KSJ, 2006, ONCOGENE, V25, P4605, DOI 10.1038/sj.onc.1209496; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; Gao CF, 2002, ONCOGENE, V21, P7569, DOI 10.1038/sj.onc.1205933; Gao XL, 2008, P NATL ACAD SCI USA, V105, P6656, DOI 10.1073/pnas.0801802105; Gebuhr TC, 2003, J EXP MED, V198, P1937, DOI 10.1084/jem.20030714; Girard L, 2000, CANCER RES, V60, P4894; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Gong F, 2008, CELL CYCLE, V7, P1067, DOI 10.4161/cc.7.8.5647; GORLOV I, 2005, P 97 ANN AACR M WASH, V3, P41; Grand F, 1999, CANCER RES, V59, P3870; Gunduz E, 2005, INT J ONCOL, V26, P201; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hill DA, 2004, J CELL SCI, V117, P5847, DOI 10.1242/jcs.01502; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Hong CY, 2005, MOL CELL BIOL, V25, P4841, DOI 10.1128/MCB.25.12.4841-4852.2005; Hsiao PW, 2003, MOL CELL BIOL, V23, P6210, DOI 10.1128/MCB.23.17.6210-6220.2003; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Hurlstone AFL, 2002, BIOCHEM J, V364, P255, DOI 10.1042/bj3640255; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Indra AK, 2005, DEVELOPMENT, V132, P4533, DOI 10.1242/dev.02019; INOUE H, 2002, J BIOL CHEM, V27, P27; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jin YT, 1999, ORAL ONCOL, V35, P251, DOI 10.1016/S1368-8375(98)00112-2; Kal AJ, 2000, GENE DEV, V14, P1058; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Ko M, 2004, J BIOL CHEM, V279, P21903, DOI 10.1074/jbc.M402144200; Kozmik Z, 2001, GENOMICS, V73, P140, DOI 10.1006/geno.2001.6477; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lee JH, 2005, MOL CELLS, V19, P289; Lee JH, 2003, MOL CELLS, V16, P78; Lee K, 2007, MOL CELLS, V24, P288; Lee K, 2007, MOL BIOL CELL, V18, P4013, DOI 10.1091/mbc.E07-05-0437; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Manda R, 2000, CANCER LETT, V153, P57, DOI 10.1016/S0304-3835(00)00342-6; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Menoni H, 2007, MOL CELL BIOL, V27, P5949, DOI 10.1128/MCB.00376-07; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Monahan BJ, 2008, NAT STRUCT MOL BIOL, V15, P873, DOI 10.1038/nsmb.1452; Morrison AJ, 2006, RES PRO CEL, V41, P109, DOI 10.1007/008; Morshead KB, 2003, P NATL ACAD SCI USA, V100, P11577, DOI 10.1073/pnas.1932643100; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, GENETICS, V115, P247; NEVILLE EM, 1995, ONCOGENE, V11, P581; Nie ZQ, 2003, MOL CELL BIOL, V23, P2942, DOI 10.1128/MCB.23.8.2942-2952.2003; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Osipovich O, 2007, NAT IMMUNOL, V8, P809, DOI 10.1038/ni1481; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Patenge N, 2004, J BIOL CHEM, V279, P35360, DOI 10.1074/jbc.M405790200; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pottier N, 2007, HUM MOL GENET, V16, P2261, DOI 10.1093/hmg/ddm178; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Ring HZ, 1998, GENOMICS, V51, P140, DOI 10.1006/geno.1998.5343; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; ROY K, 2002, J BIOL CHEM, V8, P8; Sabah M, 2005, VIRCHOWS ARCH, V446, P251, DOI 10.1007/s00428-004-1190-2; Saha A, 2006, RES PRO CEL, V41, P127, DOI 10.1007/005; Sarkar S, 2002, J BIOL CHEM, V277, P36585, DOI 10.1074/jbc.M204244200; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schwartz YB, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-15; Sekine I, 2005, ONCOGENE, V24, P2735, DOI 10.1038/sj.onc.1207694; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Shundrovsky A, 2006, NAT STRUCT MOL BIOL, V13, P549, DOI 10.1038/nsmb1102; Smith CL, 2005, MOL CELL BIOL, V25, P5880, DOI 10.1128/MCB.25.14.5880-5892.2005; Smith CL, 2003, NAT STRUCT BIOL, V10, P141, DOI 10.1038/nsb888; Sohn DH, 2007, J BIOL CHEM, V282, P10614, DOI 10.1074/jbc.M610563200; Spicuglia S, 2002, MOL CELL, V10, P1479, DOI 10.1016/S1097-2765(02)00791-8; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; STROBECK MW, 2002, J BIOL CHEM, V21, P21; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Takeuchi JK, 2007, P NATL ACAD SCI USA, V104, P846, DOI 10.1073/pnas.0608118104; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAMKUN JW, 1995, CURR OPIN GENET DEV, V5, P473, DOI 10.1016/0959-437X(95)90051-H; Tripathi A, 2003, J EXP CLIN CANC RES, V22, P289; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Underhill C, 2000, J BIOL CHEM, V275, P40463, DOI 10.1074/jbc.M007864200; Valdman A, 2003, INT J ONCOL, V22, P1003; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vradii D, 2006, J CELL PHYSIOL, V206, P112, DOI 10.1002/jcp.20432; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang M, 2007, J BIOCHEM, V142, P613, DOI 10.1093/jb/mvm176; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wang XM, 2004, INT J CANCER, V112, P636, DOI 10.1002/ijc.20450; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; WOLFFE AP, 1994, CURR BIOL, V4, P525, DOI 10.1016/S0960-9822(00)00114-7; Wong AKC, 2000, CANCER RES, V60, P6171; Wuebbles RD, 2004, CELL MOL LIFE SCI, V61, P2148, DOI 10.1007/s00018-004-4175-z; Xi QR, 2008, J BIOL CHEM, V283, P1146, DOI 10.1074/jbc.M707479200; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yan Z, 2008, STEM CELLS, V26, P1155, DOI 10.1634/stemcells.2007-0846; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Yuge M, 2000, CANCER GENET CYTOGEN, V122, P37, DOI 10.1016/S0165-4608(00)00274-0; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zraly CB, 2006, J BIOL CHEM, V281, P35305, DOI 10.1074/jbc.M607806200	215	430	449	1	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1653	1668		10.1038/onc.2009.4	http://dx.doi.org/10.1038/onc.2009.4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234488				2022-12-28	WOS:000265022000001
J	Zuo, X; Morris, JS; Broaddus, R; Shureiqi, I				Zuo, X.; Morris, J. S.; Broaddus, R.; Shureiqi, I.			15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells	ONCOGENE			English	Article						15-lipoxygenase-1; colon cancer; NuRD; MTA1	HUMAN COLORECTAL-CARCINOMA; HISTONE DEACETYLASE INHIBITORS; DRUG-INDUCED APOPTOSIS; 15-LIPOXYGENASE-1 EXPRESSION; INDUCE APOPTOSIS; DOWN-REGULATION; PROTEIN-1 MTA1; BREAST-CANCER; IN-VIVO; DIFFERENTIATION	15-Lipoxygenase-1 (15-LOX-1) is transcriptionally silenced in cancer cells, and its transcription reactivation (for example, through histone deacetylase inhibitors (HDACIs)) restores apoptosis to cancer cells. However, the exact mechanism underlying 15-LOX-1 transcription reactivation in cancer cells is still undefined. Therefore, we evaluated the critical mechanisms required for 15-LOX-1 transcription reactivation in colon cancer cells. Specific HDAC1 and HDAC2 inhibition activated 15-LOX-1 transcription. 15-LOX-1 transcription was repressed through transcription repressor complex recruitment in the region of -120 to -391 of the 15-LOX-1 promoter. The nucleosome remodeling and histone deacetylase (NuRD) repression complex was recruited to this region. Depsipeptide significantly reduced the recruitment of NuRD key components (for example, metastasis-associated protein 1 (MTA1) and HDAC1) to the 15-LOX-1 promoter before 15-LOX-1 transcriptional activation. Knock down of NuRD key components (for example, MTA1 and HDAC1) by small interfering RNA (siRNA) activated 15-LOX-1 transcription, as measured by luciferase reporter assays in stably transfected SW480 cells with the 15-LOX-1 promoter construct of the -391, but not the -120 region. Relative to expression in normal tissue, MTA1 expression in colorectal cancer mucosa from colorectal cancer patients was negatively related to 15-LOX-1 expression. Thus, our results show that NuRD contributes to 15-LOX-1 transcription suppression in colon cancer cells and that HDACIs can inhibit NuRD recruitment to a promoter to activate gene transcription, as in the case of 15-LOX-1.	[Zuo, X.; Shureiqi, I.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Morris, J. S.] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; [Broaddus, R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Shureiqi, I.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Shureiqi, Imad/0000-0003-2019-938X; Zuo, Xiangsheng/0000-0002-8593-1132	National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01 [R01 CA106577, R01 CA104278]; Caroline Wiess Law Endowment for Cancer Prevention; Jerry and Maury Rubenstein Foundation; National Colorectal Cancer Research Alliance; NATIONAL CANCER INSTITUTE [R01CA106577, R01CA104278] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Caroline Wiess Law Endowment for Cancer Prevention; Jerry and Maury Rubenstein Foundation; National Colorectal Cancer Research Alliance; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services R01 grants CA106577 and CA104278; the Caroline Wiess Law Endowment for Cancer Prevention; the Jerry and Maury Rubenstein Foundation and the National Colorectal Cancer Research Alliance. We thank Merck and Company Inc., Gloucester Pharmaceuticals and the National Cancer Institute for providing SAHA and depsipeptide. We also thank Ann M. Sutton, Department of Scientific Publications, the University of Texas M D Anderson Cancer Center, for editing the manuscript.	Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BAER AN, 1991, BIOCHEM BIOPH RES CO, V180, P98, DOI 10.1016/S0006-291X(05)81260-4; Balasenthil S, 2006, HUM PATHOL, V37, P656, DOI 10.1016/j.humpath.2006.01.024; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Chen GG, 2003, INT J CANCER, V107, P837, DOI 10.1002/ijc.11447; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Deguchi A, 2005, CANCER RES, V65, P8442, DOI 10.1158/0008-5472.CAN-05-1109; Furumai R, 2002, CANCER RES, V62, P4916; Giannini R, 2005, ANTICANCER RES, V25, P4287; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; GLEASON MM, 1995, AM J PHYSIOL-CELL PH, V268, pC1301; Hennig R, 2007, NEOPLASIA, V9, P917, DOI 10.1593/neo.07565; Heslin MJ, 2005, ANN SURG, V241, P941, DOI 10.1097/01.sla.0000164177.95620.c1; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Hsi LC, 2004, CANCER RES, V64, P8778, DOI 10.1158/0008-5472.CAN-04-1867; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Jiang WG, 2006, PROSTAG LEUKOTR ESS, V74, P235, DOI 10.1016/j.plefa.2006.01.009; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kamitani H, 2000, FEBS LETT, V467, P341, DOI 10.1016/S0014-5793(00)01155-8; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liu C, 2004, EXP CELL RES, V297, P61, DOI 10.1016/j.yexcr.2004.02.014; Manavathi B, 2007, J BIOL CHEM, V282, P1529, DOI 10.1074/jbc.R600029200; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Merchant N, 2005, ANN SURG, V241, P946; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 2000, CANCER RES, V60, P6846; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2005, CANCER RES, V65, P11486, DOI 10.1158/0008-5472.CAN-05-2180; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2002, CANCER RES, V62, P1178; Shureiqi I, 2001, CANCER RES, V61, P4879; Shureiqi I, 2007, FASEB J, V21, P743, DOI 10.1096/fj.06-6830com; Takamitsu S., 2006, VIRCHOWS ARCH, V448, P422; TAKATA S, 1994, J CLIN INVEST, V93, P499, DOI 10.1172/JCI116999; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Wu Y, 2008, MOL THER, V16, P886, DOI 10.1038/mt.2008.44; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zuo X, 2006, ONCOGENE, V25, P1225, DOI 10.1038/sj.onc.1209160; Zuo XS, 2008, FASEB J, V22, P1981, DOI 10.1096/fj.07-098301	50	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1496	1505		10.1038/onc.2008.494	http://dx.doi.org/10.1038/onc.2008.494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198625	Green Accepted			2022-12-28	WOS:000264537400002
J	Bai, J; Zhang, J; Wu, J; Shen, L; Zeng, J; Ding, J; Wu, Y; Gong, Z; Li, A; Xu, S; Zhou, J; Li, G				Bai, J.; Zhang, J.; Wu, J.; Shen, L.; Zeng, J.; Ding, J.; Wu, Y.; Gong, Z.; Li, A.; Xu, S.; Zhou, J.; Li, G.			JWA regulates melanoma metastasis by integrin alpha(V)beta(3) signaling	ONCOGENE			English	Article						JWA; melanoma; metastasis; integrin	V BETA 3; CANCER-CELLS; ALPHA-V-BETA-3 INTEGRIN; VITRONECTIN RECEPTOR; MALIGNANT-MELANOMA; ARSENIC TRIOXIDE; PC12 CELLS; EXPRESSION; PROTEIN; ADHESION	JWA, a newly identified novel microtubule-associated protein (MAP), was recently demonstrated to be indispensable for the rearrangement of actin cytoskeleton and activation of MAPK cascades induced by arsenic trioxide (As2O3) and phorbol ester (PMA). JWA depletion blocked the inhibitory effect of As2O3 on HeLa cell migration, but enhanced cell migration after PMA treatment. As cancer cell migration is a hallmark of tumor metastasis and the functional role of JWA in cancer metastasis is not understood, here we show that JWA has an important role in melanoma metastasis. Our data demonstrated that JWA knockdown increased the adhesion and invasion abilities of melanoma cells. Furthermore, JWA knockdown in B16-F10 and A375 melanoma cells significantly promoted the formation and growth of metastatic colonies in vivo. Moreover, in the tumor biopsies from human melanoma patients, JWA expression was significantly decreased in malignant melanoma compared with normal nevi. In addition, we found that JWA knockdown could intensify tumor integrin alpha(V)beta(3) signaling by regulating nuclear factor Sp1. These findings suggest that JWA suppresses melanoma metastasis and may serve a potential therapeutic target for human melanoma. Oncogene (2010) 29, 1227-1237; doi: 10.1038/onc.2009.408; published online 30 November 2009	[Bai, J.; Zhang, J.; Wu, J.; Shen, L.; Zeng, J.; Ding, J.; Wu, Y.; Gong, Z.; Li, A.; Xu, S.; Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Ctr Canc, Nanjing 210029, Peoples R China; [Bai, J.; Li, G.] Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada; [Zhang, J.] Nantong Canc Hosp, Dept Pathol, Nantong, Jiangsu Prov, Peoples R China	Nanjing Medical University; University of British Columbia; Vancouver Coastal Health Research Institute	Zhou, J (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Ctr Canc, Nanjing 210029, Peoples R China.	jwzhou@njmu.edu.cn	Li, Gang/A-8257-2011	gong, zhenghua/0000-0002-4363-1043	Key Basic Research Project of Department of Education, Jiangsu Province [06KJA33023]; National Natural Science Foundation of China [30771829, 30930080]; Doctoral Training Program of Education Ministry [200803120001]; Jiangsu Provincial Graduate Students Innovation Project [CX08B-181Z]; Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Cancer Research Society; Canadian Dermatology Foundation	Key Basic Research Project of Department of Education, Jiangsu Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Training Program of Education Ministry; Jiangsu Provincial Graduate Students Innovation Project; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Dermatology Foundation	This study was partially supported by the grants of Key Basic Research Project of Department of Education, Jiangsu Province (06KJA33023), the National Natural Science Foundation of China (30771829, 30930080), the Doctoral Training Program of Education Ministry (200803120001) to JZ and the Jiangsu Provincial Graduate Students Innovation Project (CX08B-181Z) to JB; and Canadian Institutes of Health Research (MOP-84559 and MOP-93810), Cancer Research Society and Canadian Dermatology Foundation to GL.	ALBELDA SM, 1990, CANCER RES, V50, P6757; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Becker JC, 2000, CLIN EXP DERMATOL, V25, P503, DOI 10.1046/j.1365-2230.2000.00690.x; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butchbach MER, 2002, GENE, V292, P81, DOI 10.1016/S0378-1119(02)00669-8; Cao HX, 2002, CHINESE SCI BULL, V47, P834, DOI 10.1360/02tb9188; Chen HR, 2007, CELL SIGNAL, V19, P1315, DOI 10.1016/j.cellsig.2007.01.007; Chen HR, 2004, CHINESE SCI BULL, V49, P467, DOI 10.1360/03wc0398; Chen R, 2007, FREE RADICAL BIO MED, V42, P1704, DOI 10.1016/j.freeradbiomed.2007.02.018; Cheng CM, 2009, J BIOL CHEM, V284, P8786, DOI 10.1074/jbc.M806144200; Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Huang S, 2006, BIOCHEM BIOPH RES CO, V341, P440, DOI 10.1016/j.bbrc.2005.12.197; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Li AQ, 2003, CHINESE SCI BULL, V48, P1828, DOI 10.1360/03wc0032; Li XW, 2001, J CELL SCI, V114, P2665; Lossner D, 2009, J CELL PHYSIOL, V220, P367, DOI 10.1002/jcp.21774; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moretti S, 1997, MELANOMA RES, V7, P313, DOI 10.1097/00008390-199708000-00006; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; Pechkovsky DV, 2008, J BIOL CHEM, V283, P12898, DOI 10.1074/jbc.M708226200; REMMELE W, 1987, PATHOLOGE, V8, P138; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Sampsel JW, 2004, NEW ENGL J MED, V351, P2770; Schweneker M, 2005, FEBS LETT, V579, P1751, DOI 10.1016/j.febslet.2005.02.037; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Sinanan ACM, 2008, BIOL CELL, V100, P465, DOI 10.1042/BC20070115; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wang SY, 2009, NUCLEIC ACIDS RES, V37, P1936, DOI 10.1093/nar/gkp054; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zhou JH, 2008, TOXICOL APPL PHARM, V230, P33, DOI 10.1016/j.taap.2008.01.041; Zhou JW, 1999, INVESTIGATION CELL M, P110	42	64	66	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	2010	29	8					1227	1237		10.1038/onc.2009.408	http://dx.doi.org/10.1038/onc.2009.408			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19946336				2022-12-28	WOS:000274912100013
J	Valli, A; Rosner, M; Fuchs, C; Siegel, N; Bishop, CE; Dolznig, H; Madel, U; Feichtinger, W; Atala, A; Hengstschlager, M				Valli, A.; Rosner, M.; Fuchs, C.; Siegel, N.; Bishop, C. E.; Dolznig, H.; Maedel, U.; Feichtinger, W.; Atala, A.; Hengstschlaeger, M.			Embryoid body formation of human amniotic fluid stem cells depends on mTOR	ONCOGENE			English	Article						amniotic fluid; stem cell; EB; mTOR	DIFFERENTIATION; MOUSE; BODIES; ACTIVATION; PLURIPOTENCY; DISRUPTION; GROWTH; RICTOR; OCT-4; GENE	Human amniotic fluid stem cells (hAFSCs) harbor high proliferative capacity and high differentiation potential and do not raise the ethical concerns associated with human embryonic stem cells. The formation of three-dimensional aggregates known as embryoid bodies (EBs) is the principal step in the differentiation of pluripotent embryonic stem cells. Using c-Kit-positive hAFSC lines, we show here that these stem cells harbor the potential to form EBs. As part of the two kinase complexes, mTORC1 and mTORC2, mammalian target of rapamycin (mTOR) is the key component of an important signaling pathway, which is involved in the regulation of cell proliferation, growth, tumor development and differentiation. Blocking intracellular mTOR activity through the inhibitor rapamycin or through specific small interfering RNA approaches revealed hAFSC EB formation to depend on mTORC1 and mTORC2. These findings demonstrate hAFSCs to be a new and powerful biological system to recapitulate the three-dimensional and tissue level contexts of in vivo development and identify the mTOR pathway to be essential for this process. Oncogene (2010) 29, 966-977; doi:10.1038/onc.2009.405; published online 23 November 2009	[Valli, A.; Rosner, M.; Fuchs, C.; Siegel, N.; Dolznig, H.; Hengstschlaeger, M.] Med Univ Vienna, Dept Med Genet, A-1090 Vienna, Austria; [Bishop, C. E.; Atala, A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Urol, Winston Salem, NC 27103 USA; [Bishop, C. E.; Atala, A.] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27103 USA; [Maedel, U.; Feichtinger, W.] Wunschbabyzentrum, Vienna, Austria	Medical University of Vienna; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Hengstschlager, M (corresponding author), Med Univ Vienna, Dept Med Genet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at	Dolznig, Helmut/L-7005-2015	Dolznig, Helmut/0000-0002-6063-3585; Atala, Anthony/0000-0001-8186-2160; Fuchs, Christiane/0000-0002-5052-3198	FWF Austrian Science Fund [P18894-B12]; Herzfelder'sche Familienstiftung; European Community [FP6 036097-2]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD060097] Funding Source: NIH RePORTER	FWF Austrian Science Fund(Austrian Science Fund (FWF)); Herzfelder'sche Familienstiftung; European Community(European Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Research in our laboratory is supported by the FWF Austrian Science Fund (P18894-B12), by the Herzfelder'sche Familienstiftung and by the Research Training Network 'Developing a stem cell based therapy to replace nephrons lost through reflux nephropathy' (http://www.kidstem.org) funded by the European Community as part of the Framework program 6 (FP6 036097-2).	Aboushwareb T, 2008, NAT CLIN PRACT UROL, V5, P621, DOI 10.1038/ncpuro1228; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Blazquez C, 2006, CELL RES, V16, P93, DOI 10.1038/sj.cr.7310012; Bossolasco P, 2006, CELL RES, V16, P329, DOI 10.1038/sj.cr.7310043; Cananzi M, 2009, REPROD BIOMED ONLINE, V18, P17, DOI 10.1016/S1472-6483(10)60111-3; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Ditadi A, 2009, BLOOD, V113, P3953, DOI 10.1182/blood-2008-10-182105; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; GUALANDRIS A, 2008, FASEB J, V23, P1; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hengstschlager M, 2005, AM J MED GENET A, V133A, P48, DOI 10.1002/ajmg.a.30520; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; Itskovitz-Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776; Karlmark KR, 2005, INT J MOL MED, V16, P987; Kim GD, 2008, TOXICOL LETT, V180, P166, DOI 10.1016/j.toxlet.2008.05.023; Kim J, 2007, CELL PROLIFERAT, V40, P75; Koike M, 2007, J BIOSCI BIOENG, V104, P294, DOI 10.1263/jbb.104.294; Kolambkar YM, 2007, J MOL HISTOL, V38, P405, DOI 10.1007/s10735-007-9118-1; Kurosawa H, 2007, J BIOSCI BIOENG, V103, P389, DOI 10.1263/jbb.103.389; Lim SM, 2009, STEM CELLS, V27, P363, DOI 10.1634/stemcells.2008-1008; Maherali N, 2008, COLD SH Q B, V73, P157, DOI 10.1101/sqb.2008.73.017; Narita N, 1997, DEVELOPMENT, V124, P3755; Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Pennings G, 2007, REPROD BIOMED ONLINE, V14, P92, DOI 10.1016/S1472-6483(10)60737-7; Perin L, 2007, CELL PROLIFERAT, V40, P936, DOI 10.1111/j.1365-2184.2007.00478.x; Perin L, 2008, METHOD CELL BIOL, V86, P85, DOI 10.1016/S0091-679X(08)00005-8; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Prusa AR, 2004, AM J OBSTET GYNECOL, V191, P309, DOI 10.1016/j.ajog.2003.12.014; Prusa AR, 2003, HUM REPROD, V18, P1489, DOI 10.1093/humrep/deg279; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Rosner M, 2008, MUTAT RES-REV MUTAT, V659, P284, DOI 10.1016/j.mrrev.2008.06.001; Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192; Rosner M, 2007, HUM MOL GENET, V16, P1541, DOI 10.1093/hmg/ddm103; Sampath P, 2008, CELL STEM CELL, V2, P448, DOI 10.1016/j.stem.2008.03.013; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Siegel N, 2007, STEM CELL REV, V3, P256, DOI 10.1007/s12015-007-9003-z; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Trounson A, 2007, NAT BIOTECHNOL, V25, P62, DOI 10.1038/nbt0107-62; Tsai MS, 2006, BIOL REPROD, V74, P545, DOI 10.1095/biolreprod.105.046029; Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279; Ungrin MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001565; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	50	61	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					966	977		10.1038/onc.2009.405	http://dx.doi.org/10.1038/onc.2009.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935716	Green Accepted			2022-12-28	WOS:000274604400004
J	Zhu, T; Tsuji, T; Chen, C				Zhu, T.; Tsuji, T.; Chen, C.			Roles of PKC isoforms in the induction of apoptosis elicited by aberrant Ras	ONCOGENE			English	Article						PKC isoforms; oncogenic Ras; p73; apoptosis	PROTEIN-KINASE-C; PROTEOLYTIC ACTIVATION; TYROSINE PHOSPHORYLATION; DELTA ACTIVATION; P73; CELLS; GROWTH; ALPHA; TRANSLOCATION; PATHWAY	Emerging evidence indicates that suppression of protein kinase C (PKC) renders the susceptibility of cells expressing mutated ras to apoptosis. Although the effort has been made, the underlying molecular mechanisms are not fully understood. In this study, using small hairpin RNAs (shRNAs) or PKC inhibitor, we show that the concurrent suppression of PKC-alpha and beta induces cells ectopically expressing nu-ras to undergo apoptosis. In this apoptotic process, PKC-delta is upregulated and translocated from the cytosol to the nucleus. The activated PKC-delta associates with and phosphorylates p73 to initiate apoptosis. In this apoptotic process, Akt seems to be downstream of oncogenic Ras. Moreover, overexpression of PKC-delta, without co-suppression of PKC-alpha and beta, is not apoptotic to the cells, suggesting that PKC-delta and PKC-alpha/beta function oppositely to facilitate cells harboring nu-ras to survive. Thus, our study shows that PKC-alpha and beta are necessary for sustaining the homeostasis in cells containing a hyperactive Ras. The abrogation of these two isoforms switches on the p73-regulated apoptotic machinery through the activation of PKC-delta. Oncogene (2010) 29, 1050-1061; doi:10.1038/onc.2009.344; published online 19 October 2009	[Zhu, T.; Tsuji, T.; Chen, C.] Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Chen, C (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, 99 Brookline Ave,RN-325F, Boston, MA 02215 USA.	cchen6@bidmc.harvard.edu			National Institutes of Health [RO1CA100498]; Department of Defense [W81XWH-04-1-0246]; NATIONAL CANCER INSTITUTE [R01CA100498] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Z Luo and Q Yu (Boston University School of Medicine, Boston, MA, USA) for providing various reagents and useful suggestions. This study is supported by the National Institutes of Health (RO1CA100498) and the Department of Defense (W81XWH-04-1-0246).	Aaltonen V, 2007, CANCER LETT, V253, P97, DOI 10.1016/j.canlet.2007.01.011; Agami R, 1999, NATURE, V399, P809; Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Chen EB, 2001, J IRON STEEL RES INT, V8, P12; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Deng X, 2001, J Natl Cancer Inst Monogr, P30; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FUKASAWA K, 1995, ONCOGENE, V10, P1; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gong JG, 1999, NATURE, V399, P806; Gonzalez S, 2003, MOL CELL BIOL, V23, P8161, DOI 10.1128/MCB.23.22.8161-8171.2003; Guo JJ, 2009, J CELL BIOCHEM, V107, P76, DOI 10.1002/jcb.22102; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kheifets V, 2006, J BIOL CHEM, V281, P23218, DOI 10.1074/jbc.M602075200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Mandil R, 2001, CANCER RES, V61, P4612; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; McNeill H, 1999, CURR BIOL, V9, pR176, DOI 10.1016/S0960-9822(99)80107-9; Min BW, 2008, EXP MOL MED, V40, P699, DOI 10.3858/emm.2008.40.6.699; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rusanescu G, 2001, MOL CELL BIOL, V21, P2650, DOI 10.1128/MCB.21.8.2650-2658.2001; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang HG, 1998, BIOFACTORS, V8, P13, DOI 10.1002/biof.5520080103; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zhang XM, 2005, CANCER CHEMOTH PHARM, V55, P251, DOI 10.1007/s00280-004-0863-5	60	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1050	1061		10.1038/onc.2009.344	http://dx.doi.org/10.1038/onc.2009.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19838205	Green Accepted			2022-12-28	WOS:000274604400011
J	Peuhu, E; Rivero-Muller, A; Stykki, H; Torvaldson, E; Holmbom, T; Eklund, P; Unkila, M; Sjoholm, R; Eriksson, JE				Peuhu, E.; Rivero-Muller, A.; Stykki, H.; Torvaldson, E.; Holmbom, T.; Eklund, P.; Unkila, M.; Sjoholm, R.; Eriksson, J. E.			Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						matairesinol; lignans; apoptosis; TRAIL	MAMMALIAN LIGNANS; SECOISOLARICIRESINOL DIGLYCOSIDE; BCL-2 FAMILY; DEATH; RECEPTOR; PROTEIN; LIGAND; GROWTH; LNCAP; RESISTANCE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selectively pro-apoptotic in cancer cells, with minimal toxicity to normal tissues. Although this feature makes TRAIL a promising anticancer agent, not all cancer cell types are sensitive to TRAIL-induced apoptosis despite abundant expression of TRAIL receptors. Thus, combinatorial treatments to sensitize tumor cells to TRAIL-induced apoptosis have been in the focus of extensive research. Dietary lignans have shown cancer preventive and antitumorigenic activity, but the mechanisms behind these effects are poorly known. Here we observed that of the three tested lignan molecules, matairesinol (MAT) was the most effective as a death receptor-sensitizing agent. MAT sensitized the androgen-dependent LNCaP cells to TRAIL-induced apoptosis both in the presence and absence of androgens. Treatment with MAT markedly decreased Akt activity, which has been implicated as a key signaling mechanism in the TRAIL resistance of LNCaP prostate cancer cells. The involvement of the pathway in the MAT-mediated sensitization was shown in rescue experiments using ectopic expression of constitutively active Akt. Owing to the high activity of phosphatidylinositol 3-kinase/Akt signaling in cancer, targeting this survival pathway with MAT could markedly benefit TRAIL-based tumor therapies, including those aimed at prostate cancer. Oncogene (2010) 29, 898-908; doi:10.1038/onc.2009.386; published online 23 November 2009	[Peuhu, E.; Stykki, H.; Torvaldson, E.; Eriksson, J. E.] Abo Akad Univ, Dept Biol, Turku 20520, Finland; [Peuhu, E.; Rivero-Muller, A.; Stykki, H.; Torvaldson, E.; Eriksson, J. E.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Rivero-Muller, A.] Univ Turku, Inst Biomed, Turku, Finland; [Holmbom, T.] Abo Akad Univ, Lab Fiber & Cellulose Technol, Turku 20520, Finland; [Eklund, P.; Sjoholm, R.] Abo Akad Univ, Organ Chem Lab, Turku 20520, Finland; [Unkila, M.] Hormos Med Ltd, Turku, Finland	Abo Akademi University; University of Turku; University of Turku; Abo Akademi University; Abo Akademi University	Eriksson, JE (corresponding author), Abo Akad Univ, Dept Biol, Tykistokatu 6B, Turku 20520, Finland.	john.eriksson@abo.fi	Rivero-Muller, Adolfo/A-5120-2008	Rivero-Muller, Adolfo/0000-0002-9794-802X; Peuhu, Emilia/0000-0003-4945-3046; Torvaldson, Elin/0000-0002-7175-6396	Academy of Finland; Sigrid Juselius Foundation; Research Institute of the Abo Akademi University; Foundation of the Abo Akademi University; K Albin Johansson Foundation; Liv och Halsa Foundation; Magnus Ehrnrooth Foundation	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Research Institute of the Abo Akademi University; Foundation of the Abo Akademi University; K Albin Johansson Foundation; Liv och Halsa Foundation; Magnus Ehrnrooth Foundation	We thank Henning Walczak for providing the recombinant izTRAIL, Julian Downward for the ca-Akt construct and Perttu Terho for technical assistance in flow cytometry. We also thank Cecilia Sahlgren and all the members of our laboratory for critical comments on the paper and technical help during the course of this study. This work was supported by the Academy of Finland, the Sigrid Juselius Foundation, the Research Institute of the Abo Akademi University, the Foundation of the Abo Akademi University, K Albin Johansson Foundation, Liv och Halsa Foundation and Magnus Ehrnrooth Foundation.	ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Adlercreutz H, 2007, CRIT REV CL LAB SCI, V44, P483, DOI 10.1080/10408360701612942; Aslan JE, 2009, MOL CELL, V34, P497, DOI 10.1016/j.molcel.2009.04.011; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; Bucur O, 2006, FRONT BIOSCI-LANDMRK, V11, P1549, DOI 10.2741/1903; Bylund A, 2005, EXP BIOL MED, V230, P217; Chen LH, 2007, MOL CANCER THER, V6, P2581, DOI 10.1158/1535-7163.MCT-07-0220; Chen LH, 2009, J NUTR, V139, P653, DOI 10.3945/jn.108.101832; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fulda S, 2004, CURR OPIN PHARMACOL, V4, P327, DOI 10.1016/j.coph.2004.02.005; Hausott B, 2003, J CANCER RES CLIN, V129, P569, DOI 10.1007/s00432-003-0461-7; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Kim KM, 2005, J BIOL CHEM, V280, P41047, DOI 10.1074/jbc.M503713200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitts DD, 1999, MOL CELL BIOCHEM, V202, P91, DOI 10.1023/A:1007022329660; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Li DH, 1999, CANCER LETT, V142, P91, DOI 10.1016/S0304-3835(99)00158-5; Lin X, 2001, ANTICANCER RES, V21, P3995; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; McCann MJ, 2008, MOL NUTR FOOD RES, V52, P567, DOI 10.1002/mnfr.200700052; McCann MJ, 2005, NUTR CANCER, V52, P1, DOI 10.1207/s15327914nc5201_1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Raja SM, 2008, MOL CANCER THER, V7, P2212, DOI 10.1158/1535-7163.MCT-07-2409; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Rokhlin OW, 2002, CANCER BIOL THER, V1, P631, DOI 10.4161/cbt.311; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Saarinen NM, 2008, INT J CANCER, V123, P1196, DOI 10.1002/ijc.23614; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thompson LU, 1996, NUTR CANCER, V26, P159, DOI 10.1080/01635589609514472; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Yokoyama T, 2003, BIOL PHARM BULL, V26, P371, DOI 10.1248/bpb.26.371	41	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					898	908		10.1038/onc.2009.386	http://dx.doi.org/10.1038/onc.2009.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935713				2022-12-28	WOS:000274397800012
J	Miao, L; Song, Z; Jin, L; Zhu, YM; Wen, LP; Wu, M				Miao, L.; Song, Z.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.			ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation	ONCOGENE			English	Article						p53; Miz-1; p14ARF; protein/protein interaction; transcription	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; GENE-REGULATION; MYC; P53; ASSOCIATION; EXPRESSION; INK4A/ARF; P19(ARF); CANCER	Although Myc-interacting zinc-finger protein-1 (Miz-1) is known to be a poxvirus and zinc-finger (POZ) transcription factor required for Myc transcriptional repression, additional regulatory function of Miz-1 is less well understood. Using a yeast two-hybrid screen, we identified human alternate reading frame (ARF) protein as a novel interaction partner of Miz-1. The zinc-finger domain of Miz-1 is involved in its binding to ARF. In addition, we found that Miz-1 was able to interact with p53 through its DNA-binding domain, thus to diminish the binding of p53 to its target promoter and inhibit p53-mediated gene transcription. Interestingly, the Miz-1-regulated p53 transcriptional suppression does not require the presence of ARF or Mdm2. Importantly, ARF and p53 were found to competitively bind to Miz-1 in regulating p53-mediated transcription, and this conclusion was verified by both in vitro binding assay and competitive chromatin immunoprecipitation assay using a bona fide p53 endogenous Bax and Puma promoters. Thus, our study reveals that Miz-1 acts as a p53 suppressor by interfering with p53 DNA-binding ability, and ARF is able to counteract the suppression of Miz-1 on p53 by direct binding to Miz-1, suggesting that Miz-1 is a novel mediator in the ARF-p53 pathway. Oncogene (2010) 29, 711-722; doi: 10.1038/onc.2009.372; published online 9 November 2009	[Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Miao, L.; Jin, L.; Zhu, Y. M.; Wen, L. P.; Wu, M.] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; [Song, Z.] CALTECH, Div Biol, Pasadena, CA 91125 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; California Institute of Technology	Wu, M (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, 96 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wumian@ustc.edu.cn	Jin, Lei/J-1896-2019; Wu, Mian/H-2494-2018	Jin, Lei/0000-0001-7187-9671; Wen, Longping/0000-0003-0384-4578; Wu, Mian/0000-0002-2714-0500	National Natural Science Foundation of China [30530200, 30728003, 30871290]; Ministry of Science and Technology of China [2006CB933300, 2006CB0N1402, 2006CB910300]; Chinese Academy of Sciences [KSCX1-YW-R-57]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr Nickie Chan for English checking and Dr Ratna B Ray for the plasmid pGL3-13-p53-Luc. This study was supported by grants from the National Natural Science Foundation of China (30530200, 30728003 and 30871290), the Ministry of Science and Technology of China (2006CB933300, 2006CB0N1402, and 2006CB910300) and the Chinese Academy of Sciences (KSCX1-YW-R-57).	Adhikary S, 2003, MOL CELL BIOL, V23, P7648, DOI 10.1128/MCB.23.21.7648-7657.2003; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sakurai T, 2004, J BIOL CHEM, V279, P15505, DOI 10.1074/jbc.M310437200; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Suzuki H, 2005, BIOCHEM BIOPH RES CO, V326, P242, DOI 10.1016/j.bbrc.2004.11.016; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhao NX, 2004, J CELL BIOCHEM, V92, P65, DOI 10.1002/jcb.20025; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	39	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					711	722		10.1038/onc.2009.372	http://dx.doi.org/10.1038/onc.2009.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901969				2022-12-28	WOS:000274223700008
J	Keenen, B; Qi, H; Saladi, SV; Yeung, M; de la Serna, IL				Keenen, B.; Qi, H.; Saladi, S. V.; Yeung, M.; de la Serna, I. L.			Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma	ONCOGENE			English	Article						SWI/SNF; BRG1; MITF; melanoma; chromatin; differentiation	CELL-CYCLE ARREST; LINEAGE-SURVIVAL; RETINOBLASTOMA PROTEIN; MALIGNANT-MELANOMA; MASTER REGULATOR; LUNG-CANCER; IN-VITRO; DIFFERENTIATION; MITF; BRG1	The microphthalmia-associated transcription factor (MITF) promotes melanocyte differentiation and cell-cycle arrest. Paradoxically, MITF also promotes melanoma survival and proliferation, acting like a lineage survival oncogene. Thus, it is critically important to understand the mechanisms that regulate MITF activity in melanoma cells. SWI/SNF chromatin remodeling enzymes are multiprotein complexes composed of one of two related ATPases, BRG1 or BRM, and 9-12-associated factors (BAFs). We previously determined that BRG1 interacts with MITF to promote melanocyte differentiation. However, it was unclear whether SWI/SNF enzymes regulate the expression of different classes of MITF target genes in melanoma. In this study, we characterized SWI/SNF subunit expression in melanoma cells and observed downregulation of BRG1 or BRM, but not concomitant loss of both ATPases. Re-introduction of BRG1 in BRG1-deficient SK-MEL5 cells enhanced expression of differentiation-specific MITF target genes and resistance to cisplatin. Downregulation of the single ATPase, BRM, in SK-MEL5 cells inhibited expression of both differentiation-specific and pro-proliferative MITF target genes and inhibited tumorigenicity in vitro. Our data suggest that heterogeneous SWI/SNF complexes composed of either the BRG1 or BRM subunit promote expression of distinct and overlapping MITF target genes and that at least one ATPase is required for melanoma tumorigenicity.	[Keenen, B.; Qi, H.; Saladi, S. V.; Yeung, M.; de la Serna, I. L.] Univ Toledo, Dept Biochem & Canc Biol, Coll Med, Toledo, OH 43614 USA	University System of Ohio; University of Toledo	de la Serna, IL (corresponding author), Univ Toledo, Dept Biochem & Canc Biol, Coll Med, 3035 Arlington Ave, Toledo, OH 43614 USA.	ivana.delaserna@utoledo.edu	Saladi, SrinivasVinod/AAM-3146-2020	Saladi, SrinivasVinod/0000-0001-8147-4379	National Institute of Environmental Health Sciences; Ohio Cancer Research Associates, American Cancer Society, Ohio Division [5K22ES12981]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES012981] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Ohio Cancer Research Associates, American Cancer Society, Ohio Division(American Cancer Society); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr David Fisher (Dana Farber) for the MITF antibody, Ruth Halaban (Yale Tissue Culture Facility) for melanocytes and melanoma cells, and Stephen Smale (Howard Hughes Medical Institute, UCLA) for shRNA constructs. ILD was supported by the National Institute of Environmental Health Sciences; Grant number: 5K22ES12981, Ohio Cancer Research Associates, American Cancer Society, Ohio Division.	Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x; Becker TM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-4; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2005, MOL CELL BIOL, V25, P3997, DOI 10.1128/MCB.25.10.3997-4009.2005; de la Serna IL, 2006, J BIOL CHEM, V281, P20233, DOI 10.1074/jbc.M512052200; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dynek JN, 2008, CANCER RES, V68, P3124, DOI 10.1158/0008-5472.CAN-07-6622; Eberle J, 1995, PIGM CELL RES, V8, P307, DOI 10.1111/j.1600-0749.1995.tb00679.x; Flowers S, 2009, J BIOL CHEM, V284, P10067, DOI 10.1074/jbc.M808782200; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gong F, 2008, CELL CYCLE, V7, P1067, DOI 10.4161/cc.7.8.5647; Gong F, 2006, NAT STRUCT MOL BIOL, V13, P902, DOI 10.1038/nsmb1152; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Link KA, 2008, CANCER RES, V68, P4551, DOI 10.1158/0008-5472.CAN-07-6392; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Park JH, 2009, DNA REPAIR, V8, P29, DOI 10.1016/j.dnarep.2008.08.011; POLLACK MS, 1981, J NATL CANCER I, V66, P1003, DOI 10.1093/jnci/66.6.1003; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Reisman DN, 2003, CANCER RES, V63, P560; Rosson GB, 2005, J CELL PHYSIOL, V205, P286, DOI 10.1002/jcp.20397; Shen LL, 2007, CANCER RES, V67, P11335, DOI 10.1158/0008-5472.CAN-07-1502; Sif S, 2004, J CELL BIOCHEM, V91, P1087, DOI 10.1002/jcb.20005; Svensson SPS, 2003, PIGM CELL RES, V16, P351, DOI 10.1034/j.1600-0749.2003.00030.x; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VINK J, 1993, LAB INVEST, V68, P192; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601	54	59	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					81	92		10.1038/onc.2009.304	http://dx.doi.org/10.1038/onc.2009.304			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784067	Green Accepted			2022-12-28	WOS:000273373500008
J	Provenzano, PP; Inman, DR; Eliceiri, KW; Keely, PJ				Provenzano, P. P.; Inman, D. R.; Eliceiri, K. W.; Keely, P. J.			Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage	ONCOGENE			English	Article						epithelial morphogenesis; breast cancer; breast tissue density; cell-extracellular matrix interaction; mechanotransduction; 3D matrix/focal adhesion	FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; EPITHELIAL-SPECIFIC DISRUPTION; CARCINOMA IN-SITU; MAMMOGRAPHIC DENSITY; EXTRACELLULAR-MATRIX; CANCER RISK; MALIGNANT PHENOTYPE; GROWTH-FACTORS; STRESS FIBERS	Mammographically dense breast tissue is one of the greatest risk factors for developing breast carcinoma, yet the associated molecular mechanisms remain largely unknown. Importantly, regions of high breast density are associated with increased stromal collagen and epithelial cell content. We set out to determine whether increased collagen-matrix density, in the absence of stromal cells, was sufficient to promote proliferation and invasion characteristic of a malignant phenotype in non-transformed mammary epithelial cells. We demonstrate that increased collagen-matrix density increases matrix stiffness to promote an invasive phenotype. High matrix stiffness resulted in increased formation of activated three-dimensional (3D)-matrix adhesions and a chronically elevated outside-in/inside-out focal adhesion (FA) kinase (FAK)-Rho signaling loop, which was necessary to generate and maintain the invasive phenotype. Moreover, this signaling network resulted in hyperactivation of the Ras-mitogen-activated protein kinase (MAPK) pathway, which promoted growth of mammary epithelial cells in vitro and in vivo and activated a clinically relevant proliferation signature that predicts patient outcome. Hence, the current data provide compelling evidence for the importance of the mechanical features of the microenvironment, and suggest that mechanotransduction in these cells occurs through a FAK-Rho-ERK signaling network with extracellular signal-regulated kinase (ERK) as a bottleneck through which much of the response to mechanical stimuli is regulated. As such, we propose that increased matrix stiffness explains part of the mechanism behind increased epithelial proliferation and cancer risk in human patients with high breast tissue density. Oncogene (2009) 28, 4326-4343; doi: 10.1038/onc.2009.299; published online 12 October 2009	[Provenzano, P. P.; Inman, D. R.; Keely, P. J.] Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; [Provenzano, P. P.; Eliceiri, K. W.; Keely, P. J.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA; [Provenzano, P. P.; Eliceiri, K. W.; Keely, P. J.] Univ Wisconsin, Lab Opt & Computat Instrumentat, Madison, WI USA; [Provenzano, P. P.; Inman, D. R.; Keely, P. J.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Provenzano, PP (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, M5-C119, Seattle, WA 98109 USA.	ppproven@fhcrc.org; pjkeely@wisc.edu	Eliceiri, Kevin/ABD-4516-2020; Peng, Chunwei/F-6788-2010	Eliceiri, Kevin/0000-0001-8678-670X; Provenzano, Paolo/0000-0002-9313-1370	NIH [T32CA009681, CA076537, EB000184]; DOD [W81XWH-04-1-042]; Cancer Soc [RSG-00339CSM]; NATIONAL CANCER INSTITUTE [R29CA076537, R01CA142833, T32CA009681, R01CA114462, R01CA076537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000184] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Cancer Soc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Drs Caroline Alexander and Andreas Friedl for helpful discussions regarding mice and xenograft experiments; Drs Ray Vanderby, Ashish Oza and Wilmot Valhmu for helpful discussions and equipment access for mechanical testing, and Dr John G White for helpful discussions regarding microscopy. This work was supported by an NIH postdoctoral training grant (T32CA009681) to PPP, and grants from the DOD (W81XWH-04-1-042 (PPP)), Am. Cancer Soc. (RSG-00339CSM(PJK)) and NIH (CA076537 (PJK) and EB000184 (KWE)).	Alowami S, 2003, BREAST CANCER RES, V5, pR129, DOI 10.1186/bcr622; Boyd N F, 2001, Curr Oncol Rep, V3, P314, DOI 10.1007/s11912-001-0083-7; Boyd NF, 1998, CANCER EPIDEM BIOMAR, V7, P1133; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gill JK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1507; Guo YP, 2001, CANCER EPIDEM BIOMAR, V10, P243; Habel LA, 2004, JNCI-J NATL CANCER I, V96, P1467, DOI 10.1093/jnci/djh260; KEELY PJ, 1995, J CELL SCI, V108, P595; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Krouskop TA, 1998, ULTRASONIC IMAGING, V20, P260, DOI 10.1177/016173469802000403; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Li T, 2005, CANCER EPIDEM BIOMAR, V14, P343, DOI 10.1158/1055-9965.EPI-04-0490; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin LJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1831; McCormack VA, 2006, CANCER EPIDEM BIOMAR, V15, P1159, DOI 10.1158/1055-9965.EPI-06-0034; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Plewes DB, 2000, PHYS MED BIOL, V45, P1591, DOI 10.1088/0031-9155/45/6/314; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2008, BIOPHYS J, V95, P5374, DOI 10.1529/biophysj.108.133116; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Provenzano PP, 2006, MATRIX BIOL, V25, P71, DOI 10.1016/j.matbio.2005.09.005; Provenzano PP, 2003, J APPL PHYSIOL, V94, P314, DOI 10.1152/japplphysiol.00340.2002; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Roeder BA, 2002, J BIOMECH ENG-T ASME, V124, P214, DOI 10.1115/1.1449904; Samani A, 2001, IEEE T MED IMAGING, V20, P271, DOI 10.1109/42.921476; Sarvazyan A. P., 1995, ACOUST IMAGING, P223, DOI [10.1007/978-1-4615-1943-0_23, DOI 10.1007/978-1-4615-1943-0_23]; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Sniadecki NJ, 2007, P NATL ACAD SCI USA, V104, P14553, DOI 10.1073/pnas.0611613104; Sumi C, 2000, PHYS MED BIOL, V45, P1511, DOI 10.1088/0031-9155/45/6/308; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Ursin G, 2005, BREAST CANCER RES, V7, pR605, DOI 10.1186/bcr1260; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang JG, 2005, LIFE SCI, V76, P2817, DOI 10.1016/j.lfs.2004.10.050; Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	57	451	460	0	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4326	4343		10.1038/onc.2009.299	http://dx.doi.org/10.1038/onc.2009.299			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19826415	Green Accepted			2022-12-28	WOS:000272876400002
J	Arlt, A; Bauer, I; Schafmayer, C; Tepel, J; Muerkoster, SS; Brosch, M; Roder, C; Kalthoff, H; Hampe, J; Moyer, MP; Folsch, UR; Schafer, H				Arlt, A.; Bauer, I.; Schafmayer, C.; Tepel, J.; Mueerkoester, S. Sebens; Brosch, M.; Roeder, C.; Kalthoff, H.; Hampe, J.; Moyer, M. P.; Foelsch, U. R.; Schaefer, H.			Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)	ONCOGENE			English	Article						regulated proteolysis; ubiquitination; gene transcription; oxidative stress; tumorigenesis	NF-KAPPA-B; ANTIOXIDANT RESPONSE ELEMENT; GENE-EXPRESSION; 26S PROTEASOME; BREAST-CANCER; NRF2-DEFICIENT MICE; UBIQUITIN RECEPTORS; ADAPTIVE RESPONSE; 20S PROTEASOME; EMERGING ROLES	An elevated proteasome activity contributes to tumorigenesis, particularly by providing cancer cells with antiapoptotic protection and efficient clearance from irregular proteins. Still, the underlying mechanisms are poorly known. In this study, we report that in colon cancer patients, higher proteasome activity was detected in tumoral tissue compared with surrounding normal tissue, and also that increased levels of proteasomal subunit proteins, such as S5a/PSMD4 and alpha-5/PSMA5, could be detected. Colon tumors showed higher nuclear levels of nuclear factor E2-related factor 2 (Nrf2), a transcription factor supposed to be involved in the control of proteasomal subunit protein expression. The induction or overexpression of Nrf2 led to stronger S5a and alpha-5 expression in the human colon cancer cell lines, Colo320 and Lovo, as well as in NCM460 colonocytes along with higher proteasome activity. The small interfering RNA (siRNA)-mediated Nrf2 knockdown decreased S5a and alpha-5 expression and reduced proteasome activity. Additionally, Nrf2-dependent S5a and alpha-5 expression conferred protection from tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, an effect preceded by an increased nuclear factor (NF)-kappa B activation and higher expression of antiapoptotic NF-kappa B target genes. These findings point to an important role of Nrf2 in the gain of proteasome activity, thereby contributing to colorectal carcinogenesis. Nrf2 may therefore serve as a potential target in anticancer therapy. Oncogene (2009) 28, 3983-3996; doi:10.1038/onc.2009.264; published online 7 September 2009	[Arlt, A.; Bauer, I.; Mueerkoester, S. Sebens; Brosch, M.; Hampe, J.; Foelsch, U. R.; Schaefer, H.] Univ Hosp Schleswig Holstein UKSH, Dept Internal Med, D-24105 Kiel, Germany; [Schafmayer, C.; Tepel, J.; Roeder, C.; Kalthoff, H.] UKSH, Dept Gen & Thorac Surg, Kiel, Germany; [Moyer, M. P.] INCELL Corp LLC, San Antonio, TX USA	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Hosp Schleswig Holstein UKSH, Dept Internal Med, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Sebens, Susanne/C-1222-2010; Roeder, Christian/F-1068-2010; Hampe, Jochen/A-2555-2010; Kalthoff, Holger/B-1618-2010; 高, 雨莉/HGU-8187-2022; Arlt, Alexander/G-7308-2019; Schäfer, Heiner/C-1055-2011	Roeder, Christian/0000-0001-7881-9110; Hampe, Jochen/0000-0002-2421-6127; Arlt, Alexander/0000-0002-6160-1059; Brosch, Mario/0000-0001-8983-6557	German Research Society [DFG/SFB415-A13]; German Cluster of Excellence 'Inflammation at Interfaces'	German Research Society(German Research Foundation (DFG)); German Cluster of Excellence 'Inflammation at Interfaces'	The authors thank Maike Grossmann and Dagmar Leisner for technical support, and the German Research Society (DFG/SFB415-A13) and the German Cluster of Excellence 'Inflammation at Interfaces' for funding.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2007, BIOCHEM J, V402, P367, DOI 10.1042/BJ20061072; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Chen W, 2009, ONCOL REP, V21, P531, DOI 10.3892/or_00000254; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dahlmann B, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S3; Devoy A, 2005, ESSAYS BIOCHEM, V41, P187, DOI 10.1042/EB0410187; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goy A, 2003, BLOOD, V102, p180A; Gudmundsdottir K, 2007, ONCOGENE, V26, P7601, DOI 10.1038/sj.onc.1210579; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kang Y, 2007, J MOL BIOL, V369, P168, DOI 10.1016/j.jmb.2007.03.008; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kepa JK, 2003, BIOCHEM BIOPH RES CO, V311, P446, DOI 10.1016/j.bbrc.2003.10.021; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kwak MK, 2006, BIOCHEM BIOPH RES CO, V345, P1350, DOI 10.1016/j.bbrc.2006.05.043; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Liu CW, 2006, MOL CELL, V24, P39, DOI 10.1016/j.molcel.2006.08.025; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; London MK, 2004, FEBS LETT, V567, P259, DOI 10.1016/j.febslet.2004.04.078; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Muerkoster SS, 2008, ONCOGENE, V27, P1122, DOI 10.1038/sj.onc.1210728; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Orlowski RZ, 2003, BREAST CANCER RES, V5, P1, DOI 10.1186/bcr460; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534; Ren SR, 2000, ONCOGENE, V19, P1419, DOI 10.1038/sj.onc.1203462; Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Smith DM, 2005, MOL CELL, V20, P687, DOI 10.1016/j.molcel.2005.10.019; Sobin, 2009, UICC TNM CLASSIFICAT; Song MY, 2009, TOXICOL APPL PHARM, V235, P57, DOI 10.1016/j.taap.2008.11.007; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; van Tijn P, 2008, PROG NEUROBIOL, V85, P176, DOI 10.1016/j.pneurobio.2008.03.001; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wyke SM, 2004, BRIT J CANCER, V91, P1742, DOI 10.1038/sj.bjc.6602165; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yi JJ, 2007, PHARMACOL REV, V59, P14, DOI 10.1124/pr.59.1.4; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373	68	168	179	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3983	3996		10.1038/onc.2009.264	http://dx.doi.org/10.1038/onc.2009.264			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19734940				2022-12-28	WOS:000272560300004
J	Singh, P; Marikkannu, R; Bitomsky, N; Klempnauer, KH				Singh, P.; Marikkannu, R.; Bitomsky, N.; Klempnauer, K-H			Disruption of the Pdcd4 tumor suppressor gene in chicken DT40 cells reveals its role in the DNA-damage response	ONCOGENE			English	Article						Pdcd4; DT40; DNA damage; UV; tumor suppressor	PROTEIN PDCD4; TRANSLATION INITIATION; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; EXPRESSION; TRANSFORMATION; BINDING; MA-3; TRANSCRIPTION; INHIBITION	The programmed cell death gene 4 (Pdcd4) gene has been implicated as a new tumor suppressor gene in the development of several types of human cancer. Pdcd4 interacts with the translation initiation factor, eIF4A, and is thought to act as a translation inhibitor. Here, we have used the chicken B-cell line DT40 to disrupt the Pdcd4 gene by homologous recombination. Our study shows that cells lacking a functional Pdcd4 gene are viable and have no obvious defects when cultivated under normal growth conditions. However, Pdcd4 knockout cells show an increased sensitivity to agents that cause DNA damage, such as UV light, etoposide or ethyl-methanesulfonate. In summary, our findings show that Pdcd4 has an important function in the cellular response to DNA damage. Low Pdcd4 expression, which is frequently observed in tumor cells, might therefore contribute to tumorigenesis by disturbing the cellular DNA-damage response. Oncogene (2009) 28, 3758-3764; doi: 10.1038/onc.2009.239; published online 17 August 2009	[Singh, P.; Marikkannu, R.; Bitomsky, N.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/GRF-6098-2022; Singh, Priyanka/N-1372-2018	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280	Deutsche Krebshilfe [10-1716]; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank B Berkenfeld for excellent technical assistance. This study was supported by grants from the Deutsche Krebshilfe (10-1716) and the Wilhelm-Sander-Stiftung (2004.088.1). PS and RM were supported by fellowships from the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	32	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3758	3764		10.1038/onc.2009.239	http://dx.doi.org/10.1038/onc.2009.239			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19684621				2022-12-28	WOS:000271023200008
J	Agnihotri, S; Wolf, A; Picard, D; Hawkins, C; Guha, A				Agnihotri, S.; Wolf, A.; Picard, D.; Hawkins, C.; Guha, A.			GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system	ONCOGENE			English	Article						GATA4; astrocyte; proliferation; apoptosis; INK4B; CNS	TRANSCRIPTION FACTOR; GENE-EXPRESSION; CYCLE ARREST; IN-VITRO; MOUSE; P15(INK4B); PATHWAY; FAMILY; CANCER; HYPERMETHYLATION	The GATA transcription factors consist of six family members, which bind to the consensus DNA-binding element, W-GATA-R, and are poorly characterized in the central nervous system (CNS). Using retroviral gene trapping on transgenic mouse glioma models, we identified GATA6 to be a novel tumor suppressor gene in glioblastoma multiforme. We now show GATA4, a family member of GATA6, to be expressed in the neurons and glia of normal murine and human embryonic and adult CNS. Silencing GATA4 in normal astrocytes did not alter their growth properties. In contrast, knockdown of Gata4 in p53 null non-transformed murine astrocytes induced transformation, with increased proliferation and resistance to chemotherapy or radiation-induced apoptosis. Furthermore, GATA4 expression was lost in a panel of human malignant astrocytoma cell lines. GATA4 overexpression in normal human and murine astrocytes resulted in a cell cycle block in G1 phase, with increased apoptosis. Mechanistically, GATA4 was a transcriptional inducer of the cyclin-dependent kinase inhibitor, p15INK4B, leading to the attenuation of cyclin D1. GATA4 expression was also induced by transforming growth factor-beta, leading to the inhibition of astrocyte proliferation. Collectively, we show that GATA4 is expressed in the embryonic and adult CNS and acts as a negative regulator of astrocyte proliferation and growth. Oncogene (2009) 28, 3033-3046; doi:10.1038/onc.2009.159; published online 22 June 2009	[Guha, A.] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Agnihotri, S.; Wolf, A.; Picard, D.; Guha, A.] Univ Toronto, Hosp Sick Children, Res Inst, Arthur & Sonia Labatts Brain Tumor Res Ctr, Toronto, ON M5T 2S8, Canada; [Hawkins, C.] Univ Toronto, Hosp Sick Children, Div Pathol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Guha, A (corresponding author), Univ Toronto, Toronto Western Hosp, Div Neurosurg, Room 4W-446,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	abhijit.guha@uhn.on.ca	Hawkins, Cynthia/M-2571-2019; AGNIHOTRI, SAMEER/HHS-2255-2022	AGNIHOTRI, SAMEER/0000-0001-6584-3795	Hospital for Sick Children and an Ontario Institute of Cancer Research; National Cancer Institute of Canada; Brain Tumor Society; National Brain Tumor Foundation	Hospital for Sick Children and an Ontario Institute of Cancer Research; National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Brain Tumor Society; National Brain Tumor Foundation	SA was supported by a RESTRACOMP studentship award from the Hospital for Sick Children and an Ontario Institute of Cancer Research award. Thanks to Dr Deepak Kamnasaran for technical advice and Jing Ma for technical assistance on IHC. AG was funded for this study by the National Cancer Institute of Canada, Brain Tumor Society and National Brain Tumor Foundation.	Afouda BA, 2005, DEVELOPMENT, V132, P763, DOI 10.1242/dev.01647; Anttonen M, 2006, J MOL ENDOCRINOL, V36, P557, DOI 10.1677/jme.1.01962; Belaguli NS, 2007, AM J PHYSIOL-GASTR L, V292, pG1520, DOI 10.1152/ajpgi.00236.2006; Bogler O, 1999, CELL GROWTH DIFFER, V10, P73; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Guo MZ, 2006, INT J CANCER, V119, P2078, DOI 10.1002/ijc.22092; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Kamnasaran D, 2005, DEV BRAIN RES, V160, P90, DOI 10.1016/j.devbrainres.2005.07.012; Kamnasaran D, 2007, P NATL ACAD SCI USA, V104, P8053, DOI 10.1073/pnas.0611669104; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lawson MA, 1998, MOL CELL ENDOCRINOL, V140, P157, DOI 10.1016/S0303-7207(98)00044-6; Lawson MA, 1998, MOL ENDOCRINOL, V12, P364, DOI 10.1210/me.12.3.364; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; QUELLE DE, 1995, ONCOGENE, V11, P635; Ray A, 2004, CLIN CANCER RES, V10, P7613, DOI 10.1158/1078-0432.CCR-04-0499; Reamon-Buettner SM, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-38; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rempe DA, 2007, J BIOL CHEM, V282, P16187, DOI 10.1074/jbc.M702203200; Rich JN, 1999, J BIOL CHEM, V274, P35053, DOI 10.1074/jbc.274.49.35053; Setogawa T, 2006, BIOCHEM BIOPH RES CO, V343, P1186, DOI 10.1016/j.bbrc.2006.03.077; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sonoda Y, 2001, CANCER RES, V61, P4956; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057	34	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3033	3046		10.1038/onc.2009.159	http://dx.doi.org/10.1038/onc.2009.159			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543315				2022-12-28	WOS:000269319000003
J	Zhou, W; Tu, Y; Simpson, PJ; Kuhajda, FP				Zhou, W.; Tu, Y.; Simpson, P. J.; Kuhajda, F. P.			Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells	ONCOGENE			English	Article						malonyl-CoA decarboxylase; apoptosis; fatty acid metabolism; malonyl-CoA; fatty acid synthase	FATTY-ACID SYNTHASE; 5-AMP-ACTIVATED PROTEIN-KINASE; COENZYME-A; ISCHEMIC-HEART; OXIDATION; APOPTOSIS; DEFICIENCY; EXPRESSION; TISSUE; PHASE	Fatty acid synthase (FAS) inhibition initiates selective apoptosis of cancer cells both in vivo and in vitro, which may involve malonyl-CoA metabolism. These findings have led to the exploration of malonyl-CoA decarboxylase (MCD) as a potential novel target for cancer treatment. MCD regulates the levels of cellular malonyl-CoA through the decarboxylation of malonyl-CoA to acetylCoA. Malonyl-CoA is both a substrate for FAS and an inhibitor of fatty acid oxidation acting as a metabolic switch between anabolic fatty acid synthesis and catabolic fatty acid oxidation. We now report that the treatment of human breast cancer (MCF7) cells with MCD small interference RNA (siRNA) reduces MCD expression and activity, reduces adenosine triphosphate levels, and is cytotoxic to MCF7 cells, but not to human fibroblasts. In addition, we synthesized a small-molecule inhibitor of MCD, 5-{(Morpholine-4-carbonyl)-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-amino}-pentanoic acid methyl ester (MPA). Similar to MCD siRNA, MPA inhibits MCD activity in MCF7 cells, increases cellular malonyl-CoA levels and is cytotoxic to a number of human breast cancer cell lines in vitro. Taken together, these data indicate that MCD-induced cytotoxicity is likely mediated through malonyl-CoA metabolism. These findings support the hypothesis that MCD is a potential therapeutic target for cancer therapy. Oncogene (2009) 28, 2979-2987; doi:10.1038/onc.2009.160; published online 22 June 2009	[Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Pathol, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; [Tu, Y.; Simpson, P. J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21224 USA; [Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21224 USA; [Kuhajda, F. P.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Johns Hopkins Bayview Med Ctr, UMB Res Pk,Bldg 1,4940 Eastern Ave, Baltimore, MD 21224 USA.	fkuhajda@jhmi.edu			Department of Defense Breast Cancer [BC050452]	Department of Defense Breast Cancer(United States Department of Defense)	This study was supported by a grant from the Department of Defense Breast Cancer Grant BC050452 to FPK. We thank FASgen Inc. for the generous gift of MPA.	Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Cheng JF, 2006, J MED CHEM, V49, P1517, DOI 10.1021/jm050109n; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEMOZ A, 1995, J CHROMATOGR B, V667, P148, DOI 10.1016/0378-4347(94)00595-V; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Dyck JRB, 2002, J MOL CELL CARDIOL, V34, P1099, DOI 10.1006/jmcc.2002.2060; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; FitzPatrick DR, 1999, AM J HUM GENET, V65, P318, DOI 10.1086/302492; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; Goodwin GW, 1999, AM J PHYSIOL-ENDOC M, V277, pE772, DOI 10.1152/ajpendo.1999.277.4.E772; KOEPPEN AH, 1987, J NEUROCHEM, V48, P1509, DOI 10.1111/j.1471-4159.1987.tb05693.x; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Menendez JA, 2004, INT J ONCOL, V24, P591; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Pizer ES, 2000, CANCER RES, V60, P213; RILEY KM, 1991, NEUROCHEM RES, V16, P117, DOI 10.1007/BF00965698; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Saha AK, 2003, MOL CELL BIOCHEM, V253, P65, DOI 10.1023/A:1026053302036; Shiu LY, 2008, CELL BIOL TOXICOL, V24, P1, DOI 10.1007/s10565-007-9010-5; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tu YJ, 2005, ENDOCRINOLOGY, V146, P486, DOI 10.1210/en.2004-0976; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Warburg O, 1924, BIOCHEM Z, V152, P319; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; WITTERS LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P413, DOI 10.1006/abbi.1994.1058; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Zhou WB, 2003, CANCER RES, V63, P7330; Zhou WB, 2007, CANCER RES, V67, P2964, DOI 10.1158/0008-5472.CAN-06-3439	33	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2979	2987		10.1038/onc.2009.160	http://dx.doi.org/10.1038/onc.2009.160			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19543323				2022-12-28	WOS:000269142800006
J	Gammoh, N; Isaacson, E; Tomaic, V; Jackson, DJ; Doorbar, J; Banks, L				Gammoh, N.; Isaacson, E.; Tomaic, V.; Jackson, D. J.; Doorbar, J.; Banks, L.			Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2	ONCOGENE			English	Article						HPV; E7; centrosomes; pRb	HUMAN-PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATOR; RETINOBLASTOMA PROTEIN; CENTROSOME DUPLICATION; GENOMIC INSTABILITY; HUMAN KERATINOCYTES; CERVICAL-CANCER; IN-VIVO; E6; ONCOPROTEIN	Human papillomavirus (HPV) E7 is essential in inducing S-phase progression in differentiating epithelial cells. We have previously shown that HPV-16 E7 activity can be controlled by a direct interaction with the viral transcriptional activator E2, thereby inhibiting transforming potential of E7. We have extended these analyses to show that E2 induces a generalized re-localization of E7 within the cell nucleus, one potential consequence of which is the inhibition of E7-induced degradation of pRb. Most importantly, we show that E2 can also inhibit the ability of E7 to induce centrosome abnormalities, thus preventing aberrant mitoses. Taken together, these studies highlight the central importance of E2 in controlling the functions of E7, independently of the ability of E2 to regulate transcription. Oncogene (2009) 28, 2299-2304; doi: 10.1038/onc.2009.78; published online 4 May 2009	[Gammoh, N.; Tomaic, V.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Isaacson, E.; Jackson, D. J.; Doorbar, J.] MRC Natl Inst Med Res, Div Virol, London, England	International Center for Genetic Engineering & Biotechnology (ICGEB); MRC National Institute for Medical Research	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	doorba@nimr.mrc.ac.uk; banks@icgeb.org			Associazione Italiana per la Ricerca sul Cancro; UK Medical Research Council; Medical Research Council [MC_U117584278] Funding Source: researchfish; MRC [MC_U117584278] Funding Source: UKRI	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Daniela Gardiol, David Pim and Miranda Thomas for comments on the paper. We also thank Karl Munger for providing anti-HPV-16 E7 monoclonal antibody. This work was supported in part by a research grant from the Associazione Italiana per la Ricerca sul Cancro. EI, DJ and JD were supported by the UK Medical Research Council.	Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Boyer SN, 1996, CANCER RES, V56, P4620; Donaldson MM, 2007, J VIROL, V81, P4338, DOI 10.1128/JVI.02353-06; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2003, J VIROL, V77, P12331, DOI 10.1128/JVI.77.22.12331-12335.2003; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gammoh N, 2006, J VIROL, V80, P1787, DOI 10.1128/JVI.80.4.1787-1797.2006; Grm HS, 2005, ONCOGENE, V24, P5149, DOI 10.1038/sj.onc.1208701; He WX, 2003, J VIROL, V77, P10566, DOI 10.1128/JVI.77.19.10566-10574.2003; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; Kurg R, 2005, J VIROL, V79, P10528, DOI 10.1128/JVI.79.16.10528-10539.2005; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004	18	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2299	2304		10.1038/onc.2009.78	http://dx.doi.org/10.1038/onc.2009.78			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421149				2022-12-28	WOS:000266886300006
J	Ciechomska, IA; Goemans, GC; Skepper, JN; Tolkovsky, AM				Ciechomska, I. A.; Goemans, G. C.; Skepper, J. N.; Tolkovsky, A. M.			Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function	ONCOGENE			English	Article						apoptosis; autophagy; Bcl-2; Beclin-1; endoplasmic reticulum; mitochondria	CELL-DEATH; REGULATES AUTOPHAGY; MOLECULAR-BASIS; INHIBITION; PROTEINS; CANCER; MITOCHONDRIA; DOMAIN; TUMORIGENESIS; DEGRADATION	The binding of Bcl-2 to Beclin-1 reduces Beclin-1's capacity to induce autophagy. Here, we have tested whether the interaction is reciprocated by loss of Bcl-2's anti-apoptotic function. We targeted Bcl-2 to mitochondria or endoplasmic reticulum (ER) and induced apoptosis using several apoptotic stimuli that initiate ER and/or mitochondrial signaling pathways (UV radiation, TNF and cycloheximide, staurosporine, thapsigargin and tunicamycin). When Beclin-1 and Bcl-2 were expressed together in HeLa cells, Beclin-1 ( but not Beclin-1 lacking the Bcl-2-binding domain) followed Bcl-2 to the appropriate organelle with complete or near-complete overlap ( comprising 60 and 30% of cells, respectively). The interaction between Beclin-1 and Bcl-2 was verified by immunoprecipitation, and a membrane-proximate localization of Beclin-1 was shown by immunoelectron microscopy. Apoptosis was followed by measuring changes in nuclear morphology, caspase-3 activity, poly-ADP-ribose polymerase cleavage or punctation of mRFP-Bax on mitochondria. Binding of Beclin-1 to Bcl-2 did not modify apoptosis irrespective of Bcl-2 concentration, location or apoptotic stimulus. A similar result was obtained in Atg5-/- cells that are autophagy-deficient, arguing against compensation for the loss of protection by Bcl-2 by autophagy-mediated survival induced by Beclin-1. Hence, although Beclin-1 contains a BH3-only motif typical of pro-apoptotic proteins, it is a negligible modulator of Bcl-2's anti-apoptotic function. Oncogene (2009) 28, 2128-2141; doi: 10.1038/onc.2009.60; published online 6 April 2009	[Ciechomska, I. A.; Goemans, G. C.; Tolkovsky, A. M.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Ciechomska, I. A.] M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland; [Skepper, J. N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 1QW, England	University of Cambridge; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; University of Cambridge	Tolkovsky, AM (corresponding author), Univ Cambridge, Dept Biochem, Bldg 0,Downing Site, Cambridge CB2 1QW, England.	amt@mole.bio.cam.ac.uk	Ciechomksa, Iwona/R-4706-2016	Ciechomksa, Iwona/0000-0002-8068-0020	Wellcome Trust [064232]	Wellcome Trust(Wellcome TrustEuropean Commission)	We thank our colleagues Beth Levine, Zenyu Yue, Noboru Mizushima, Said Aoufouchi, Christoph Borner, Goeff Butcher and Eiki Kominami for their generous gifts of reagents. This work was funded by program Grant no. 064232 from the Wellcome Trust.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Annis MG, 2004, BBA-MOL CELL RES, V1644, P115, DOI 10.1016/j.bbamcr.2003.07.001; Arsov I, 2008, CELL DEATH DIFFER, V15, P1385, DOI 10.1038/cdd.2008.59; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Goemans CG, 2008, CELL DEATH DIFFER, V15, P545, DOI 10.1038/sj.cdd.4402290; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Skepper JN, 2000, J MICROSC-OXFORD, V199, P1, DOI 10.1046/j.1365-2818.2000.00704.x; Swerdlow S, 2008, AUTOPHAGY, V4, P612, DOI 10.4161/auto.5920; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	53	128	134	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2128	2141		10.1038/onc.2009.60	http://dx.doi.org/10.1038/onc.2009.60			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19347031				2022-12-28	WOS:000266451300002
J	Giannoni, E; Fiaschi, T; Ramponi, G; Chiarugi, P				Giannoni, E.; Fiaschi, T.; Ramponi, G.; Chiarugi, P.			Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals	ONCOGENE			English	Article						anoikis; prostate cancer cell; EGFR; reactive oxygen species; Src	REACTIVE-OXYGEN; TUMOR PROGRESSION; OXIDATIVE STRESS; GROWTH; ACTIVATION; ADHESION; MECHANISMS; KINASE; CARCINOGENESIS; ANCHORAGE	Resistance to detachment-induced apoptosis, a process commonly referred as anoikis, is emerging as a hallmark of metastatic malignancies, mainly because it can ensure anchorage-independent growth and survival during organ colonization. Besides, a sustained oxidative stress has been associated with several steps of carcinogenesis, including transformation and achievement of a motile mesenchymal phenotype. Here, we demonstrate that metastatic prostate carcinoma cells, undergoing a constitutive deregulated production of reactive oxygen species due to sustained activation of 5-lipoxygenase, lack suicidal pathways in response to lack of matrix contact. These amplified and persistent redox signals in PC3 cells leads to maintenance of Src oxidation and activation in the absence of adhesion, thereby sustaining a ligand-independent phosphorylation of epidermal growth factor receptor. This leads to chronic activation of pro-survival signals, culminating in degradation of the pro-apoptotic protein Bim, thereby promoting cell survival even in the absence of proper adhesion. Anoikis sensitivity of metastatic cells is restored with antioxidant intervention or genetic manipulation of the redox-mediated pro-survival pathway, as well as exposure to a pro-oxidant environment strongly increases anoikis resistance in nontransformed prostate epithelial cells. Hence, our results allow new insight into the aetiology of the molecular mechanisms granting anoikis resistance of metastatic cancers, opening new avenues to pharmacological intervention for antioxidant-sensitive invasive tumours. Oncogene (2009) 28, 2074-2086; doi:10.1038/onc.2009.77; published online 20 April 2009	[Giannoni, E.; Fiaschi, T.] Univ Florence, Dept Biochem Sci, Florence, Italy; [Ramponi, G.; Chiarugi, P.] Univ Florence, Ctr Res Transfer & High Educ, Florence, Italy	University of Florence; University of Florence	Chiarugi, P (corresponding author), Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022	Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098	Italian Association for Cancer Research (AIRC); Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004); Progetto TRESOR (Regione Toscana); Cassa di Risparmio di Firenze; Consorzio Interuniversitario Biotecnologie (CIB)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Progetto TRESOR (Regione Toscana)(Regione Toscana); Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Consorzio Interuniversitario Biotecnologie (CIB)	This work was supported by the Italian Association for Cancer Research (AIRC), by the Ministero della Universitae Ricerca Scientifica e Tecnologica (MIUR-PRIN 2004), by the Progetto TRESOR (Regione Toscana), by the Cassa di Risparmio di Firenze and by the Consorzio Interuniversitario Biotecnologie (CIB).	Bouillet P, 2002, J CELL SCI, V115, P1567; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2007, CELL SIGNAL, V19, P672, DOI 10.1016/j.cellsig.2006.11.009; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Diaz-Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giannoni E, 2008, CELL DEATH DIFFER, V15, P867, DOI 10.1038/cdd.2008.3; Giannoni E, 2005, MOL CELL BIOL, V25, P6391, DOI 10.1128/MCB.25.15.6391-6403.2005; Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420; Haklar G, 2001, CANCER LETT, V165, P219, DOI 10.1016/S0304-3835(01)00421-9; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Kairouz-Wahbe R, 2008, P NATL ACAD SCI USA, V105, P1528, DOI 10.1073/pnas.0711357105; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Mallozzi C, 2001, FREE RADICAL BIO MED, V30, P1108, DOI 10.1016/S0891-5849(01)00509-3; Martinez-Sanchez G, 2007, J EXP CLIN CANC RES, V26, P39; Moldovan L, 2006, CARDIOVASC RES, V71, P236, DOI 10.1016/j.cardiores.2006.05.003; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Quadros MRD, 2004, CANCER RES, V64, P3934, DOI 10.1158/0008-5472.CAN-04-0214; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Taddei ML, 2007, ANTIOXID REDOX SIGN, V9, P469, DOI 10.1089/ars.2006.1392; Toyokuni S, 2006, ANTIOXID REDOX SIGN, V8, P1373, DOI 10.1089/ars.2006.8.1373; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wei L, 2004, ONCOGENE, V23, P9052, DOI 10.1038/sj.onc.1208091; Wu WS, 2008, CANCER METAST REV, V27, P303, DOI 10.1007/s10555-008-9112-4; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; Zhu ZY, 2001, CANCER RES, V61, P1707	46	92	95	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2074	2086		10.1038/onc.2009.77	http://dx.doi.org/10.1038/onc.2009.77			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377510				2022-12-28	WOS:000266235800002
J	Greenow, KR; Clarke, AR; Jones, RH				Greenow, K. R.; Clarke, A. R.; Jones, R. H.			Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation	ONCOGENE			English	Article						Chk1; DNA damage; small intestine; apoptosis; p53	DNA-DAMAGE CHECKPOINT; CELL-DEATH; SERINE 139; CANCER; P53; PHOSPHORYLATION; EXPRESSION; REPLICATION; INHIBITION; INITIATION	Chk1 is a serine/threonine protein kinase that is activated by a wide range of DNA-damaging agents to slow the cell cycle during S phase and G2/M. Abrogation of these cell-cycle checkpoints using Chk1 inhibitors results in hypersensitivity to DNA-damaging agents in vitro and may provide a potential therapeutic tool to sensitize tumour cells in vivo. We have generated a Cre-Lox-based mouse model in which Chk1 can be inducibly deleted from somatic epithelial cells in the adult mouse small intestine and liver. Loss of Chk1 in the liver is tolerated with no apparent phenotype. In contrast, the loss of Chk1 within the small intestine results in immediate DNA damage and high levels of p53-independent apoptosis leading to crypt death. However, the intestine is able to compensate for this death by undergoing complete re-population with Chk1-proficient cells. These data therefore show that Chk1 deficiency is cell lethal, but the intestine can tolerate such lethality at the organ level.	[Greenow, K. R.; Clarke, A. R.; Jones, R. H.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; [Jones, R. H.] Univ Bristol, Dept Cellular & Mol Med, Bristol, Avon, England	Cardiff University; University of Bristol	Jones, RH (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.	jonesrh7@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	Cancer Research UK; MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was supported by Cancer Research UK. We thank Mark Bishop, Lucie Pietzka and Derek Scarborough for technical assistance.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Chen ZH, 2003, MOL CANCER THER, V2, P543; Hapke G, 2001, CANCER METAST REV, V20, P109, DOI 10.1023/A:1013116826788; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kawabe T, 2004, MOL CANCER THER, V3, P513; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Robinson HMR, 2006, ONCOGENE, V25, P5359, DOI 10.1038/sj.onc.1209532; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tse AN, 2007, CLIN CANCER RES, V13, P1955, DOI 10.1158/1078-0432.CCR-06-2793; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	29	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2009	28	11					1443	1453		10.1038/onc.2008.482	http://dx.doi.org/10.1038/onc.2008.482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169280	Green Accepted			2022-12-28	WOS:000264354400005
J	Trang, P; Medina, PP; Wiggins, JF; Ruffino, L; Kelnar, K; Omotola, M; Homer, R; Brown, D; Bader, AG; Weidhaas, JB; Slack, FJ				Trang, P.; Medina, P. P.; Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Homer, R.; Brown, D.; Bader, A. G.; Weidhaas, J. B.; Slack, F. J.			Regression of murine lung tumors by the let-7 microRNA	ONCOGENE			English	Article						let-7; microRNAs; lung cancer; K-ras	MOUSE MODELS; K-RAS; CANCER; EXPRESSION; INHIBITION; FAMILY; GROWTH; CELLS; SIRNA; HMGA2	MicroRNAs (miRNAs) have recently emerged as an important new class of cellular regulators that control various cellular processes and are implicated in human diseases, including cancer. Here, we show that loss of let-7 function enhances lung tumor formation in vivo, strongly supporting the hypothesis that let-7 is a tumor suppressor. Moreover, we report that exogenous delivery of let-7 to established tumors in mouse models of non-small-cell lung cancer (NSCLC) significantly reduces the tumor burden. These results demonstrate the therapeutic potential of let-7 in NSCLC and point to miRNA replacement therapy as a promising approach in cancer treatment. Oncogene (2010) 29, 1580-1587; doi:10.1038/onc.2009.445; published online 7 December 2009	[Wiggins, J. F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Brown, D.; Bader, A. G.] Mirna Therapeut Inc, Austin, TX USA; [Trang, P.; Medina, P. P.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Trang, P.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA; [Homer, R.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Homer, R.] VA Connecticut Healthcare Syst, Dept Pathol & Lab Med Serv, West Haven, CT USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Bader, AG (corresponding author), Mirna Therapeut Inc, 2150 Woodward St, Austin, TX USA.	abader@mirnarx.com; joanne.weidhaas@yale.edu; frank.slack@yale.edu	homer, robert/P-3884-2019; Vico, Pedro Pablo Medina/D-1688-2013	homer, robert/0000-0002-2055-5885; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409	NIH NRSA [F32CA130376]; Ministry of Education and Science of Spain (MEC); Hope Funds for Cancer Research; ASTRO; NIH [CA131301-01A1]; Connecticut Department of Public Health [2006-0913]; NATIONAL CANCER INSTITUTE [F32CA130376, K08CA124484, R01CA131301] Funding Source: NIH RePORTER	NIH NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education and Science of Spain (MEC)(Spanish Government); Hope Funds for Cancer Research; ASTRO; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Connecticut Department of Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Xianping Liang for help with animal husbandry and genotyping, and Paul Lebourgeois for histopathological analyses. PT was supported by an NIH NRSA postdoctoral fellowship (F32CA130376). PM was supported by a postdoctoral fellowship from the Ministry of Education and Science of Spain (MEC) and from the Hope Funds for Cancer Research. JBW was supported by the ASTRO Junior Faculty Career Research Training Award. FJS and JBW were supported by grants from the NIH (CA131301-01A1) and from the Connecticut Department of Public Health (RFP no. 2006-0913).	Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Bitko Vira, 2008, V442, P75, DOI 10.1007/978-1-59745-191-8_6; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esquela-Kerscher A, 2005, DEV DYNAM, V234, P868, DOI 10.1002/dvdy.20572; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Hohla F, 2007, P NATL ACAD SCI USA, V104, P18671, DOI 10.1073/pnas.0709455104; Isobe T, 2005, SEMIN ONCOL, V32, P315, DOI 10.1053/j.seminoncol.2005.02.016; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Levenkova N, 2004, BIOINFORMATICS, V20, P430, DOI 10.1093/bioinformatics/btg437; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sevignani C, 2007, P NATL ACAD SCI USA, V104, P8017, DOI 10.1073/pnas.0702177104; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TAKESHITA F, 2009, MOL THER; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	32	379	402	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1580	1587		10.1038/onc.2009.445	http://dx.doi.org/10.1038/onc.2009.445			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966857	Green Accepted, Green Submitted			2022-12-28	WOS:000275694700003
J	Lin, Z; Yin, P; Reierstad, S; O'Halloran, M; Coon, JS; Pearson, EK; Mutlu, GM; Bulun, SE				Lin, Z.; Yin, P.; Reierstad, S.; O'Halloran, M.; Coon, J. S.; Pearson, E. K.; Mutlu, G. M.; Bulun, S. E.			Adenosine A1 receptor, a target and regulator of estrogen receptor-alpha action, mediates the proliferative effects of estradiol in breast cancer	ONCOGENE			English	Article						Adora1; ER alpha; estradiol; breast cancer; G protein-coupled receptors; cell proliferation	ADENOSINE A(1) RECEPTORS; CELL-PROLIFERATION; ENDOCRINE THERAPY; EXPRESSION; TRANSCRIPTION; ACTIVATION; INHIBITION; REVEALS; BINDING; PHOSPHORYLATION	Estrogen receptor-alpha (ER alpha) and its ligand estradiol (E2) has critical roles in breast cancer growth and are key therapeutic targets. In this study, we report a novel dual role of the adenosine A1 receptor (Adora1) as an E2/ER alpha target and a regulator of ER alpha transcriptional activity. In ER alpha-positive breast cancer cells, E2 upregulated Adora1 messenger RNA (mRNA) and protein levels, an effect that was reversed by the E2 antagonist ICI 182 780. Small interference RNA ablation of Adora1 in ER alpha-positive cells reduced basal and E2-dependent proliferation, whereas Adora1 over-expression in an ER alpha-negative cell line induced proliferation. The selective Adora1 antagonist, DPCPX, reduced proliferation, establishing Adora1 as a mediator of E2/ER alpha-dependent breast cancer growth. Intriguingly, Adora1 ablation decreased both mRNA and protein levels of ER alpha and, consequently, estrogen-responsive element-dependent ER alpha transcriptional activity. Moreover, Adora1 ablation decreased binding activity of ER alpha to the promoter of its target gene TFF1 and led to reduced TFF1 promoter activity and mRNA levels, suggesting that Adora1 is required for full transcriptional activity of ER alpha on E2 stimulation. Taken together, we showed a short feed-forward loop involving E2, ER alpha and Adora1 that favors breast cancer growth. These data suggest that Adora1 may represent an important target for therapeutic intervention in hormone-dependent breast cancer. Oncogene (2010) 29, 1114-1122; doi: 10.1038/onc.2009.409; published online 23 November 2009	[Lin, Z.; Yin, P.; Reierstad, S.; O'Halloran, M.; Coon, J. S.; Pearson, E. K.; Bulun, S. E.] Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA; [Mutlu, G. M.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Dept Obstet & Gynecol, Feinberg Sch Med, Chicago, IL 60611 USA.	s-bulun@northwestern.edu	Mutlu, Gokhan/HIR-2545-2022		NIH [R01CA067167]; AVON Foundation; Lynn Sage Foundation; Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE [R01CA067167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AVON Foundation; Lynn Sage Foundation; Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the NIH (R01CA067167), AVON Foundation, Lynn Sage Foundation, and Northwestern Memorial Foundation. We thank Megha Reddi for expert technical assistance.	AITKEN SC, 1982, CANCER RES, V42, P1727; Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023; Albasanz JL, 2007, EUR J NEUROSCI, V26, P3501, DOI 10.1111/j.1460-9568.2007.05965.x; Altucci L, 1996, ONCOGENE, V12, P2315; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; Brunsden AM, 1999, J PHYSIOL-LONDON, V521, P517, DOI 10.1111/j.1469-7793.1999.00517.x; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Factor P, 2007, P NATL ACAD SCI USA, V104, P4083, DOI 10.1073/pnas.0601117104; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fu HJ, 2006, CANCER BIOL THER, V5, P842, DOI 10.4161/cbt.5.7.2840; HALEEN SJ, 1987, LIFE SCI, V40, P555, DOI 10.1016/0024-3205(87)90369-9; Hayashi S, 2005, CANCER CHEMOTH PHARM, V56, pS27, DOI 10.1007/s00280-005-0096-2; Howell A, 2005, J STEROID BIOCHEM, V93, P237, DOI 10.1016/j.jsbmb.2005.02.004; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Ilie A, 2009, NEUROSCIENCE, V159, P1070, DOI 10.1016/j.neuroscience.2009.01.025; Kenealy MR, 2000, ENDOCRINOLOGY, V141, P2805, DOI 10.1210/en.141.8.2805; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kun Y, 2003, HUM MOL GENET, V12, P3245, DOI 10.1093/hmg/ddg347; Kuske B, 2006, ENDOCR-RELAT CANCER, V13, P1121, DOI 10.1677/erc.1.01257; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Lu J, 2003, CANCER RES, V63, P6413; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2007, J SURG RES, V138, P71, DOI 10.1016/j.jss.2006.07.002; Merighi S, 2003, PHARMACOL THERAPEUT, V100, P31, DOI 10.1016/S0163-7258(03)00084-6; Mirza A, 2005, CANCER BIOL THER, V4, P1355, DOI 10.4161/cbt.4.12.2196; Moosavi SMS, 2009, NEPHROLOGY, V14, P179, DOI 10.1111/j.1440-1797.2008.01024.x; Morrison RR, 2006, AM J PHYSIOL-HEART C, V291, pH1875, DOI 10.1152/ajpheart.00158.2005; Namba R, 2005, BREAST CANCER RES, V7, pR881, DOI 10.1186/bcr1317; Nonclercq D, 2007, J MOL ENDOCRINOL, V39, P105, DOI 10.1677/JME-07-0040; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Reid G, 2002, CELL MOL LIFE SCI, V59, P821, DOI 10.1007/s00018-002-8470-2; Shen Y, 2008, J NATL CANCER I, V100, P1448, DOI 10.1093/jnci/djn320; Snoj N, 2008, CURR OPIN ONCOL, V20, P627, DOI 10.1097/CCO.0b013e3283136770; Wendler CC, 2007, P NATL ACAD SCI USA, V104, P9697, DOI 10.1073/pnas.0703557104	43	44	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1114	1122		10.1038/onc.2009.409	http://dx.doi.org/10.1038/onc.2009.409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935720	Green Accepted			2022-12-28	WOS:000274912100003
J	Merkhofer, EC; Cogswell, P; Baldwin, AS				Merkhofer, E. C.; Cogswell, P.; Baldwin, A. S.			Her2 activates NF-kappa B and induces invasion through the canonical pathway involving IKK alpha	ONCOGENE			English	Article						Her2; IKKalpha; NF-KappaB	HUMAN-BREAST-CANCER; UP-REGULATION; PLASMINOGEN-ACTIVATOR; MONOCLONAL-ANTIBODY; SIGNALING NETWORK; GENE-EXPRESSION; KINASE-ACTIVITY; PHASE-II; CELLS; INHIBITOR	The membrane bound receptor tyrosine kinase Her2 is overexpressed in approximately 30% of human breast cancers, which correlates with poor prognosis. Her2-induced signaling pathways include MAPK and PI3K/Akt, of which the latter has been shown to be critical for Her2(+) breast cancer cell growth and survival. In addition, the NF-kappa B pathway has been shown to be activated downstream of Her2 overexpression; however, the mechanisms leading to this activation are not currently clear. Using Her2(+)/ER- breast cancer cells, we show that Her2 activates NF-kappa B through the canonical pathway which, surprisingly, involves IKK alpha. Knockdown of IKK alpha led to a significant decrease in transcription levels of multiple NF-kappa B-regulated cytokine and chemokine genes. siRNA-mediated knockdown of IKK alpha resulted in a decrease in cancer cell invasion, but had no effect on cell proliferation. Inhibition of the PI3K/Akt pathway had no effect on NF-kappa B activation, but significantly inhibited cell proliferation. Our study suggests different roles for the NF-kappa B and PI3K pathways downstream of Her2, leading to changes in invasion and proliferation of breast cancer cells. In addition this work indicates the importance of IKK alpha as a mediator of Her2-induced tumor progression. Oncogene ( 2010) 29, 1238-1248; doi: 10.1038/onc.2009.410; published online 30 November 2009	[Merkhofer, E. C.; Cogswell, P.; Baldwin, A. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Merkhofer, E. C.; Baldwin, A. S.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	albert_baldwin@med.unc.edu			NIH [RO1CA73756, RO1CA75080]; Department of Defense [BC074027]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA138937, R01CA073756, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank William Comb for his assistance in the preparation of this paper, as well as Dr H Shelton Earp and Dr Carolyn Sartor for generously providing reagents. This work is funded by NIH RO1CA73756 and RO1CA75080, and Department of Defense Grant BC074027. Support is also provided by the Samuel Waxman Cancer Research Foundation.	Arihiro K, 2000, Breast Cancer, V7, P221, DOI 10.1007/BF02967464; Arora P, 2008, ONCOGENE, V27, P4434, DOI 10.1038/onc.2008.84; Baselga J, 1999, SEMIN ONCOL, V26, P78; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Belguise K, 2007, J CLIN INVEST, V117, P4009, DOI 10.1172/JCI32424; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; ETHIER SP, 1993, CANCER RES, V53, P627; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; GUM R, 1995, ANTICANCER RES, V15, P1167; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Klapper LN, 2000, ADV CANCER RES, V77, P25; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Vazquez-Martin A, 2008, ADV EXP MED BIOL, V617, P311, DOI 10.1007/978-0-387-69080-3_29; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Wilson W, 2008, CANCER RES, V68, P8156, DOI 10.1158/0008-5472.CAN-08-1061; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Zhou H, 2004, INT J RADIAT ONCOL, V58, P344, DOI 10.1016/j.ijrobp.2003.09.046	48	105	108	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1238	1248		10.1038/onc.2009.410	http://dx.doi.org/10.1038/onc.2009.410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19946332	Green Submitted, Green Accepted			2022-12-28	WOS:000274912100014
J	Miller, SJ; Lan, ZD; Hardiman, A; Wu, J; Kordich, JJ; Patmore, DM; Hegde, RS; Cripe, TP; Cancelas, JA; Collins, MH; Ratner, N				Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Hegde, R. S.; Cripe, T. P.; Cancelas, J. A.; Collins, M. H.; Ratner, N.			Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis	ONCOGENE			English	Article						EYA4; MPNST; NF1; DACH1; SOX9; Ras	DETERMINATION GENE NETWORK; FATE DETERMINATION FACTOR; NEUROFIBROMATOSIS TYPE-1; SCHWANN-CELLS; SIX1 OVEREXPRESSION; BINDING-PROTEIN; BREAST-CANCER; RAS-GTP; GROWTH; SURVIVAL	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas without effective therapeutics. Bioinformatics was used to identify potential therapeutic targets. Paired Box (PAX), Eyes Absent (EYA), Dachsund (DACH) and Sine Oculis (SIX) genes, which form a regulatory interactive network in Drosophila, were found to be dysregulated in human MPNST cell lines and solid tumors. We identified a decrease in DACH1 expression, and increases in the expressions of PAX6, EYA1, EYA2, EYA4, and SIX1-4 genes. Consistent with the observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to NF1 mutation, we found that exogenous expression of the NF1-GTPase activating protein-related domain normalized DACH1 expression. EYA4 mRNA was elevated more than 100-fold as estimated by quantitative real-time PCR in most MPNST cell lines. In vitro, suppression of EYA4 expression using short hairpin RNA reduced cell adhesion and migration and caused cellular necrosis without affecting cell proliferation or apoptotic cell death. MPNST cells expressing shEYA4 either failed to form tumors in nude mice or formed very small tumors, with extensive necrosis but similar levels of proliferation and apoptosis as control cells. Our findings identify a role of EYA4 and possibly interacting SIX and DACH proteins in MPNSTs and suggest the EYA4 pathway as a rational therapeutic target. Oncogene (2010) 29, 368-379; doi:10.1038/onc.2009.360; published online 9 November 2009	[Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Cancelas, J. A.; Ratner, N.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Hegde, R. S.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Res Fdn, Div Dev Biol,Dept Pediat, Cincinnati, OH 45229 USA; [Cripe, T. P.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Hematol Oncol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Collins, M. H.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Pathol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Ratner, N (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, 3333 Burnet Ave,MLC 7013,Room S7-244, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org	Cancelas, Jose/AAR-9324-2020	RATNER, NANCY/0000-0001-5030-9354	DAMD [DOD W81XWH-04-1-0273]; NINDS Translational Neuroscience Award [K01-NS049191-01A1]; NATIONAL EYE INSTITUTE [R01EY014648, R21EY019125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K01NS049191, R01NS028840] Funding Source: NIH RePORTER	DAMD; NINDS Translational Neuroscience Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Viral vectors were produced by the Viral Vector Core at the Translational Core Laboratories, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, USA. We thank Yonatan Y Mahller for assistance with the xenograft experiments. This study was supported by an award from the DAMD ( DOD W81XWH-04-1-0273) to NR and an NINDS Translational Neuroscience Award K01-NS049191-01A1 to SM.	Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Carli M, 2005, J CLIN ONCOL, V23, P8422, DOI 10.1200/JCO.2005.01.4886; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Casella CTB, 1996, GLIA, V17, P327, DOI 10.1002/(SICI)1098-1136(199608)17:4<327::AID-GLIA7>3.0.CO;2-W; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; DAIMARU Y, 1985, AM J SURG PATHOL, V9, P434, DOI 10.1097/00000478-198506000-00005; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Ferner RE, 2002, CANCER RES, V62, P1573; Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holtkamp N, 2004, BRAIN PATHOL, V14, P258; Hsiao FC, 2001, DEV CELL, V1, P51, DOI 10.1016/S1534-5807(01)00011-9; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; Josephson R, 1998, DEVELOPMENT, V125, P3087; KIM HA, 1995, ONCOGENE, V11, P325; Klose A, 1998, HUM GENET, V102, P367, DOI 10.1007/s004390050706; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Leroy K, 2001, ARCH DERMATOL, V137, P908; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mahller YY, 2007, MOL THER, V15, P279, DOI 10.1038/sj.mt.6300038; Mahller YY, 2006, PEDIATR BLOOD CANCER, V46, P745, DOI 10.1002/pbc.20565; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; MCCONNELL JD, 1995, BRIT J UROL, V76, P5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Ramdas L, 2001, GENOME BIOL, V2; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Silver SJ, 2003, MOL CELL BIOL, V23, P5989, DOI 10.1128/MCB.23.17.5989-5999.2003; Silver SJ, 2005, DEVELOPMENT, V132, P3, DOI 10.1242/dev.01539; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Viskochil David, 1992, Journal of Dermatology (Tokyo), V19, P873; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540; Watson MA, 2004, BRAIN PATHOL, V14, P297; WESTON KM, 1994, CYTOMETRY, V15, P141, DOI 10.1002/cyto.990150207; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06; Wu KM, 2009, CANCER RES, V69, P3347, DOI 10.1158/0008-5472.CAN-08-3821; Xu LZ, 1996, J BIOL CHEM, V271, P24711; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	62	58	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					368	379		10.1038/onc.2009.360	http://dx.doi.org/10.1038/onc.2009.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901965	Green Accepted			2022-12-28	WOS:000273793200006
J	Vlachos, P; Joseph, B				Vlachos, P.; Joseph, B.			The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics	ONCOGENE			English	Article						p57(Kip2); LIMK-1; actin cytoskeleton dynamic; cell mobility	CELL-MIGRATION; PROTEIN-KINASE; PROSTATE-CANCER; FOCAL ADHESIONS; DOWN-REGULATION; STRESS FIBERS; EXPRESSION; PHOSPHORYLATION; ACTIVATION; COFILIN	The cyclin-dependent kinase inhibitor p57(Kip2) gene has been suggested to be a tumor suppressor gene, being inactivated in various cancer types, linked to tumor progression and poor patient outcome. Here, we report that p57(Kip2) interacts with the actin cytoskeleton modifying enzyme, LIM-kinase 1 (LIMK-1) but not LIMK-2. This interaction enhances activity of LIMK-1, independently of its activator Rho-associated kinase. This resulted in an increased phosphorylation and consequent inactivation of the actin depolymerization factor, cofilin. In accordance, selective p57(Kip2) expression promotes actin stress fiber formation in cancer cells. Fluorescence recovery after photobleaching analysis of fluorescent-labeled actin further demonstrated that p57(Kip2) expression results in reduction of actin protein mobile fraction, which affects its turnover rate in cell. Finally, we present evidence that the p57(Kip2) control of LIMK-1 ultimately affects cell mobility negatively. Thus, in addition to its established function in control of proliferation and cell death, these results indicate that p57(Kip2) is critical in the regulation of actin cytoskeleton dynamic and by this means migration ability of cancer cells. Oncogene (2009) 28, 4175-4188; doi: 10.1038/onc.2009.269; published online 7 September 2009	[Vlachos, P.; Joseph, B.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-03, S-17176 Stockholm, Sweden.	Bertrand.Joseph@ki.se			Swedish Research Council; Swedish Cancer Society; Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)(Karolinska Institutet)	We thank Dr Y Xiong (University of North Carolina, USA), Dr S Leibovitch (Centre National de la Recherche Scientifique, France), Dr K Mizuno (Tohoku University, Japan), Dr H Toyoshima (Tsukuba University, Japan), Dr P Hotulainen (University of Helsinki, Finland) and Dr S Okret (Karolinska Institute) for providing us with different DNA constructs and HeLa cell line, respectively. This work was supported by the Swedish Research Council, the Swedish Cancer Society, the Ake Wiberg Foundation, the Swedish Medical Society and the Karolinska Institutet Foundations (KI Cancer).	Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Barbe L, 2008, MOL CELL PROTEOMICS, V7, P499, DOI 10.1074/mcp.M700325-MCP200; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Bozidogan O, 2008, TUMORI J, V94, P556; Chim CS, 2005, AM J HEMATOL, V80, P282, DOI 10.1002/ajh.20503; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Denicourt C, 2004, GENE DEV, V18, P851, DOI 10.1101/gad.1205304; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Fan GK, 2006, ACTA OTO-LARYNGOL, V126, P301, DOI 10.1080/00016480500388851; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Itoh Y, 2007, J BIOL CHEM, V282, P390, DOI 10.1074/jbc.M609944200; Jia JL, 2007, MOL CELL BIOL, V27, P7236, DOI 10.1128/MCB.00780-07; Jin RJ, 2008, CANCER RES, V68, P3601, DOI 10.1158/0008-5472.CAN-08-0073; Joseph B, 2003, P NATL ACAD SCI USA, V100, P15619, DOI 10.1073/pnas.2635658100; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; JOSEPH B, 2009, CELL DEATH IN PRESS; Kobatake T, 2004, ONCOL REP, V12, P1087; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Li JQ, 2003, INT J ONCOL, V23, P1537; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nakai S, 2002, INT J ONCOL, V20, P769; Nan KJ, 2005, WORLD J GASTROENTERO, V11, P1237, DOI 10.3748/wjg.v11.i8.1237; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakai K, 2004, J NEURO-ONCOL, V68, P217, DOI 10.1023/B:NEON.0000033380.08940.c8; Samuelsson MKR, 2002, BIOCHEM BIOPH RES CO, V296, P702, DOI 10.1016/S0006-291X(02)00912-9; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; Sui L, 2002, ANTICANCER RES, V22, P3191; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Vlachos P, 2007, CELL DEATH DIFFER, V14, P1497, DOI 10.1038/sj.cdd.4402158; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	51	40	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4175	4188		10.1038/onc.2009.269	http://dx.doi.org/10.1038/onc.2009.269			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734939				2022-12-28	WOS:000272876100004
J	Zhao, YH; Zhou, M; Liu, H; Ding, Y; Khong, HT; Yu, D; Fodstad, O; Tan, M				Zhao, Y. H.; Zhou, M.; Liu, H.; Ding, Y.; Khong, H. T.; Yu, D.; Fodstad, O.; Tan, M.			Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth	ONCOGENE			English	Article						ErbB2; HSF1; LDH-A; glycolysis; Warburg effect; breast cancer	DNA-BINDING; FACTOR-I; ACTIVATION; METABOLISM; EXPRESSION; TRANSCRIPTION; WARBURG; HYPOXIA; OVEREXPRESSION; DEREGULATION	ErbB2 has been shown to activate signaling molecules that may regulate glucose metabolism. However, there is no evidence reported to directly link ErbB2 to glycolysis, and the mechanism underlying ErbB2-enhanced glycolysis is poorly understood. In this study, we investigated the role and mechanism of ErbB2 in regulating glycolysis. We found that ErbB2-overexpressing cells possessed a significantly higher level of glycolysis when compared to the ErbB2-low-expressing cells, and the downregulation of ErbB2 markedly decreased glycolysis. Overexpression of ErbB2 increased the expression of glycolysis-regulating molecules lactate dehydrogenase A (LDH-A) and heat shock factor 1 (HSF1). ErbB2 activated HSF1, indicated by the increased HSF1 trimer formation, and promoted HSF1 protein synthesis. HSF1 bound to LDH-A promoter and the downregulation of HSF1 reduced the expression of LDH-A and subsequently decreased cancer cell glycolysis and growth. Moreover, the glycolysis inhibitors, 2-deoxyglucose and oxamate, selectively inhibited the growth of ErbB2-overexpressing cells. Taken together, this study shows that in human breast cancer cells, ErbB2 promotes glycolysis at least partially through the HSF1-mediated upregulation of LDH-A. This pathway may have a major role in regulating glucose metabolism in breast cancer cells. These novel findings have important implications for the design of new approaches to target ErbB2-overexpressing breast cancers. Oncogene (2009) 28, 3689-3701; doi: 10.1038/onc.2009.229; published online 10 August 2009	[Tan, M.] Univ S Alabama, Mitchell Canc Inst, Ctr Basic & Translat Canc Res, Mobile, AL 36604 USA; [Zhao, Y. H.] Sichuan Univ, W China Med Ctr, Dept Biochem & Mol Biol, Chengdu 610064, Peoples R China; [Yu, D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Fodstad, O.] Univ Oslo, Norwegian Radium Hosp, Inst Canc Res, Oslo, Norway; [Tan, M.] Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36604 USA	University of South Alabama; Sichuan University; University of Texas System; UTMD Anderson Cancer Center; University of Oslo; University of South Alabama	Tan, M (corresponding author), Univ S Alabama, Mitchell Canc Inst, Ctr Basic & Translat Canc Res, 1660 Spring Hill Ave, Mobile, AL 36604 USA.	mtan@usouthal.edu	Zhao, Yuhua/H-3210-2013; Tan, Ming/ABD-5847-2021	Zhao, Yuhua/0000-0002-4060-631X; Tan, Ming/0000-0003-2007-9898; Yu, Dihua/0000-0001-6231-9381	Jr. Cancer Research Foundation (M Tan) [334003]	Jr. Cancer Research Foundation (M Tan)	We thank Dr Ivor Benjamin for the HSF1 MEFs; Dr Jianrong Lu, Dr Adam Riker and Dr Laurie Owen for reading the article; Ms Amy Brown for editorial assistance; Dr June Ayling, Dr Robert Laush and Ms Judy Miller for assistance with equipments. We are grateful for the support from The Vincent F Kilborn, Jr. Cancer Research Foundation (M Tan) and from the Radiumhospitalets Legater Award Project 334003 (M Tan and O Fodstad).	BALINSKY D, 1983, CANCER RES, V43, P5895; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Gatenby RA, 2007, INT J BIOCHEM CELL B, V39, P1358, DOI 10.1016/j.biocel.2007.03.021; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li YM, 2005, CANCER RES, V65, P3257, DOI 10.1158/0008-5472.CAN-04-1284; Liu HY, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-111; Lu J, 2009, CLIN CANCER RES, V15, P1326, DOI 10.1158/1078-0432.CCR-08-0954; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Nguyen T, 2008, J BIOL CHEM, V283, P29831, DOI 10.1074/jbc.M801642200; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tan M, 2006, ONCOGENE, V25, P3286, DOI 10.1038/sj.onc.1209361; Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; Wadekar SA, 2004, MOL ENDOCRINOL, V18, P500, DOI 10.1210/me.2003-0215; WARBURG O, 1956, SCIENCE, V124, P269; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	39	182	195	5	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3689	3701		10.1038/onc.2009.229	http://dx.doi.org/10.1038/onc.2009.229			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668225				2022-12-28	WOS:000271023200002
J	Lafferty-Whyte, K; Cairney, CJ; Will, MB; Serakinci, N; Daidone, MG; Zaffaroni, N; Bilsland, A; Keith, WN				Lafferty-Whyte, K.; Cairney, C. J.; Will, M. B.; Serakinci, N.; Daidone, M-G; Zaffaroni, N.; Bilsland, A.; Keith, W. N.			A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT	ONCOGENE			English	Article						telomerase; ALT; mesenchymal; microarray; signalling; c-Myc	MAINTENANCE MECHANISMS; IN-VITRO; TRANSFORMATION; SARCOMAS; TUMORS; LIPOSARCOMAS; ASSOCIATION; PROGNOSIS; CULTURE; HTR	Telomere length is maintained by two known mechanisms, the activation of telomerase or alternative lengthening of telomeres (ALT). The molecular mechanisms regulating the ALT phenotype are poorly understood and it is unknown how the decision of which pathway to activate is made at the cellular level. We have shown earlier that active repression of telomerase gene expression by chromatin remodelling of the promoters is one mechanism of regulation; however, other genes and signalling networks are likely to be required to regulate telomerase and maintain the ALT phenotype. Using gene expression profiling, we have uncovered a signature of 1305 genes to distinguish telomerase-positive and ALT cell lines. By combining this with the gene expression profiles of liposarcoma tissue samples, we refined this signature to 297 genes. A network analysis of known interactions between genes within this signature revealed a regulatory signalling network consistent with a model of human telomerase reverse transcriptase (hTERT) repression in ALT cell lines and liposarcomas. This network expands on our existing knowledge of hTERT regulation and provides a platform to understand differential regulation of hTERT in different tumour types and normal tissues. We also show evidence to suggest a novel mesenchymal stem cell origin for ALT immortalization in cell lines and mesenchymal tissues. Oncogene (2009) 28, 3765-3774; doi:10.1038/onc.2009.238; published online 17 August 2009	[Lafferty-Whyte, K.; Cairney, C. J.; Will, M. B.; Bilsland, A.; Keith, W. N.] Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; [Serakinci, N.] So Denmark Univ, Inst Reg Hlth Serv, Telomere & Aging Grp, Vejle, Denmark; [Daidone, M-G; Zaffaroni, N.] Ist Nazl Tumori, Unit 10, Dept Expt Oncol & Labs, Fdn IRCCS, I-20133 Milan, Italy	Beatson Institute; University of Glasgow; University of Southern Denmark; Fondazione IRCCS Istituto Nazionale Tumori Milan	Keith, WN (corresponding author), Univ Glasgow, Ctr Oncol & Appl Pharmacol, Canc Res UK Beatson Labs, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Zaffaroni, Nadia/J-8178-2016; Cairney, Claire/H-6989-2012; Daidone, Maria Grazia/E-9232-2017; Bilsland, Alan/G-2629-2010; Keith, Nicol/D-3325-2009	Zaffaroni, Nadia/0000-0002-4669-0890; Daidone, Maria Grazia/0000-0002-4786-1321; Keith, Nicol/0000-0001-7862-3580; Cairney, Claire/0000-0001-6531-245X; Bilsland, Alan/0000-0003-0957-3908; SERAKINCI, Nedime/0000-0002-1884-0839	Cancer Research UK; European Community [LSHC-CT-2004-502943, LSHC-CT-2005-0018806]; Glasgow University [Health-F2-2007-200950]; Italian Association for Cancer Research	Cancer Research UK(Cancer Research UK); European Community(European Commission); Glasgow University; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Cancer Research UK, European Community Grants LSHC-CT-2004-502943, LSHC-CT-2005-0018806 and Health-F2-2007-200950 Glasgow University and Italian Association for Cancer Research.	Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cairney CJ, 2008, BRIT J CANCER, V98, P1467, DOI 10.1038/sj.bjc.6604328; Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Chen YJ, 2006, CANCER RES, V66, P6473, DOI 10.1158/0008-5472.CAN-06-0910; Costa A, 2006, CANCER RES, V66, P8918, DOI 10.1158/0008-5472.CAN-06-0273; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Hakin-Smith V, 2003, LANCET, V361, P836, DOI 10.1016/S0140-6736(03)12681-5; Hao Huang, 2008, J Exp Clin Cancer Res, V27, P27, DOI 10.1186/1756-9966-27-27; Henson JD, 2005, CLIN CANCER RES, V11, P217; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Huang PR, 2008, BBA-MOL CELL RES, V1783, P193, DOI 10.1016/j.bbamcr.2007.08.006; Jiang WQ, 2007, ONCOGENE, V26, P4635, DOI 10.1038/sj.onc.1210260; Johnson JE, 2005, CLIN CANCER RES, V11, P5347, DOI 10.1158/1078-0432.CCR-05-0684; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Mehle C, 1996, ONCOGENE, V13, P161; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Serakinci N, 2006, REGEN MED, V1, P125, DOI 10.2217/17460751.1.1.125; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Ulaner GA, 2004, GENE CHROMOSOME CANC, V41, P155, DOI 10.1002/gcc.20074; Ulaner GA, 2003, CANCER RES, V63, P1759; Wang Y, 2005, CYTOTHERAPY, V7, P509, DOI 10.1080/14653240500363216; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Yeager TR, 1999, CANCER RES, V59, P4175; Zhao YM, 2008, BIOCHEM BIOPH RES CO, V369, P1114, DOI 10.1016/j.bbrc.2008.03.011; Zhong ZH, 2007, J BIOL CHEM, V282, P29314, DOI 10.1074/jbc.M701413200; Zhou YF, 2006, CANCER RES, V66, P10849, DOI 10.1158/0008-5472.CAN-06-2146; Zimmermann S, 2003, LEUKEMIA, V17, P1146, DOI 10.1038/sj.leu.2402962	32	47	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3765	3774		10.1038/onc.2009.238	http://dx.doi.org/10.1038/onc.2009.238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684619	Green Accepted			2022-12-28	WOS:000271248400001
J	Cooper, WN; Hesson, LB; Matallanas, D; Dallol, A; von Kriegsheim, A; Ward, R; Kolch, W; Latif, F				Cooper, W. N.; Hesson, L. B.; Matallanas, D.; Dallol, A.; von Kriegsheim, A.; Ward, R.; Kolch, W.; Latif, F.			RASSF2 associates with and stabilizes the proapoptotic kinase MST2	ONCOGENE			English	Article						RASSF2; MST2; MST1; proteomics; epigenetics	CASPASE-MEDIATED ACTIVATION; POTENTIAL TUMOR-SUPPRESSOR; STE20-LIKE PROTEIN-KINASE; CHROMATIN CONDENSATION; EPIGENETIC INACTIVATION; APOPTOSIS; PHOSPHORYLATION; PATHWAY; EFFECTOR; GENE	RASSF2 is a tumour suppressor that in common with the rest of the RASSF family contains Ras association and SARAH domains. We identified the proapoptotic kinases, MST1 and MST2, as the most significant binding partners of RASSF2, confirmed the interactions at endogenous levels and showed that RASSF2 immunoprecipitates active MST1/2. We then showed that RASSF2 can be phosphorylated by a co-immunoprecipitating kinase that is likely to be MST1/2. Furthermore, we showed that RASSF2 and MST2 do indeed colocalize, but whereas RASSF2 alone is nuclear, the presence of MST1 or MST2 results in colocalization in the cytoplasm. Expression of RASSF2 (stably in MCF7 or transiently in HEK-293) increases MST2 levels and knockdown of RASSF2 in HEK-293 cells reduces MST2 levels, in addition colorectal tumour cell lines and primary tumours with low RASSF2 levels show decreased MST2 protein levels. This is likely to be mediated by RASSF2-dependent protection of MST2 against proteolytic degradation. Our findings suggest that MST2 and RASSF2 form an active complex in vivo, in which RASSF2 is maintained in a phosphorylated state and protects MST2 from degradation and turnover. Thus, we propose that the frequent loss of RASSF2 in tumours results in the destablization of MST2 and thus decreased apoptotic potential. Oncogene (2009) 28, 2988-2998; doi:10.1038/onc.2009.152; published online 15 June 2009	[Cooper, W. N.; Hesson, L. B.; Dallol, A.; Latif, F.] Univ Birmingham, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Hesson, L. B.] UNSW, Fac Med, Lowy Canc Ctr, Sydney, NSW, Australia; [Hesson, L. B.] UNSW, Fac Med, POW Clin Sch, Sydney, NSW, Australia; [Matallanas, D.; von Kriegsheim, A.; Kolch, W.] Beatson Inst Canc Res, Prote & Signalling Networks Grp, Glasgow G61 1BD, Lanark, Scotland; [Kolch, W.] Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	University of Birmingham; University of New South Wales Sydney; University of New South Wales Sydney; Beatson Institute; University of Glasgow	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Kolch, Walter/ABF-2102-2021; Ward, Robyn L/I-2313-2013; Admin, SBI/HGB-2738-2022; gomez, david/U-9465-2019; Dallol, Ashraf/H-8661-2012; Hesson, Luke/HDM-0311-2022; von Kriegsheim, Alex/C-2371-2016	Ward, Robyn L/0000-0002-6877-8906; gomez, david/0000-0002-2360-3141; Dallol, Ashraf/0000-0002-8803-228X; von Kriegsheim, Alex/0000-0002-4952-8573; Kolch, Walter/0000-0001-5777-5016	Breast Cancer Campaign; Cancer Research UK; Sport Aiding Medical Research for Kids; European Union [LSHG-CT-2003-505520]	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Sport Aiding Medical Research for Kids; European Union(European Commission)	We thank David Sumpton and Willy Bienvenut for the mass spectrometry. This work was supported by Breast Cancer Campaign, Cancer Research UK, Sport Aiding Medical Research for Kids (to FL) and The European Union FP6 project 'Interaction Proteome' (LSHG-CT-2003-505520) and Cancer Research UK (to WK).	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Callus BA, 2006, FEBS J, V273, P4264, DOI 10.1111/j.1742-4658.2006.05427.x; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Cooper WN, 2008, ONCOGENE, V27, P1805, DOI 10.1038/sj.onc.1210805; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hu Y, 2007, CELL DEATH DIFFER, V14, P2035, DOI 10.1038/sj.cdd.4402214; Hwang E, 2007, P NATL ACAD SCI USA, V104, P9236, DOI 10.1073/pnas.0610716104; Imai T, 2008, CANCER SCI, V99, P958, DOI 10.1111/j.1349-7006.2008.00769.x; Kaira K, 2007, INT J ONCOL, V31, P169; Kakeya H, 1998, CANCER RES, V58, P4888; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kurnari G, 2007, J MOL BIOL, V367, P1294, DOI 10.1016/j.jmb.2007.01.026; Kuznetsov S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003997; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Liao XY, 2008, INT J CANCER, V123, P296, DOI 10.1002/ijc.23494; Lin YS, 2002, J BIOL CHEM, V277, P47991, DOI 10.1074/jbc.M202630200; MARUYAMA R, 2008, CARCINOGENESIS; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Ura S, 2007, MOL CELL BIOL, V27, P5514, DOI 10.1128/MCB.00199-07; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; von Kriegsheim A, 2008, METHODS MOL BIOL, V484, P177, DOI 10.1007/978-1-59745-398-1_12; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200	39	64	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2988	2998		10.1038/onc.2009.152	http://dx.doi.org/10.1038/onc.2009.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19525978	Green Accepted			2022-12-28	WOS:000269142800007
J	Zen, K; Yasui, K; Gen, Y; Dohi, O; Wakabayashi, N; Mitsufuji, S; Itoh, Y; Zen, Y; Nakanuma, Y; Taniwaki, M; Okanoue, T; Yoshikawa, T				Zen, K.; Yasui, K.; Gen, Y.; Dohi, O.; Wakabayashi, N.; Mitsufuji, S.; Itoh, Y.; Zen, Y.; Nakanuma, Y.; Taniwaki, M.; Okanoue, T.; Yoshikawa, T.			Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma	ONCOGENE			English	Article						PAR-3; PARD3; esophageal squamous cell carcinoma; homozygous deletion; tight junction; metastasis	TIGHT JUNCTION; CANCER GENOME; COPY NUMBER; IDENTIFICATION; ARRAYS; DNA; AMPLICON; HOMOLOG; ASIP	The partition-defective 3 (PAR-3) protein is implicated in the formation of tight junctions at epithelial cell-cell contacts. We investigated DNA copy number aberrations in human esophageal squamous cell carcinoma (ESCC) cell lines using a high-density oligonucleotide microarray and found a homozygous deletion of PARD3 (the gene encoding PAR-3). Exogenous expression of PARD3 in ESCC cells lacking this gene enhanced the recruitment of zonula occludens 1 (ZO-1), a marker of tight junctions, to sites of cell-cell contact. Conversely, knockdown of PARD3 in ESCC cells expressing this gene caused a disruption of ZO-1 localization at cell-cell borders. A copy number loss of PARD3 was observed in 15% of primary ESCC cells. Expression of PARD3 was significantly reduced in primary ESCC tumors compared with their nontumorous counterparts, and this reduced expression was associated with positive lymph node metastasis and poor differentiation. Our results suggest that deletion and reduced expression of PARD3 may be a novel mechanism that drives the progression of ESCC. Oncogene (2009) 28, 2910-2918; doi:10.1038/onc.2009.148; published online 8 June 2009	[Yasui, K.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, Kyoto 6028566, Japan; [Zen, Y.; Nakanuma, Y.] Kanazawa Univ, Grad Sch Med, Dept Human Pathol, Kanazawa, Ishikawa, Japan; [Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Hematol & Oncol, Kyoto 6028566, Japan; [Okanoue, T.] Saiseikai Suita Hosp, Dept Hepatol, Suita, Osaka, Japan	Kyoto Prefectural University of Medicine; Kanazawa University; Kyoto Prefectural University of Medicine	Yasui, K (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	yasuik@koto.kpu-m.ac.jp	Dohi, Osamu/AAA-1634-2020	Dohi, Osamu/0000-0002-0498-0144	Japan Society for the Program of Science [18390223, 20590408]	Japan Society for the Program of Science	This study was supported by Grants-in-Aid for Scientific Research (18390223 and 20590408) from the Japan Society for the Program of Science (KY).	AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; BERGGREN P, 2003, CLIN CANCER RES, V14, P242; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Fang CM, 2001, CELL RES, V11, P223, DOI 10.1038/sj.cr.7290090; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hirose T, 2006, DEVELOPMENT, V133, P1389, DOI 10.1242/dev.02294; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Inagaki Y, 2008, CANCER GENET CYTOGEN, V180, P30, DOI 10.1016/j.cancergencyto.2007.09.013; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KAMB A, 1994, SCIENCE, V264, P440; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Vizcaino AP, 2002, INT J CANCER, V99, P860, DOI 10.1002/ijc.10427; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Yasui K, 2001, GENE CHROMOSOME CANC, V32, P112, DOI 10.1002/gcc.1172; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zitzelsberger H, 2004, GENE CHROMOSOME CANC, V40, P55, DOI 10.1002/gcc.20024	31	74	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2910	2918		10.1038/onc.2009.148	http://dx.doi.org/10.1038/onc.2009.148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503097				2022-12-28	WOS:000268917100007
J	Burris, HA				Burris, H. A., III			Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs	ONCOGENE			English	Review						NSCLC; non-small-cell lung cancer; EGFR; resistance; dual EGFR/VEGF inhibition; antiangiogenesis	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-III; CHEMOTHERAPY-NAIVE PATIENTS; CISPLATIN PLUS GEMCITABINE; ACQUIRED-RESISTANCE; KRAS MUTATIONS; EGFR MUTATION; TRIAL; CARBOPLATIN	Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Targeted agents are initially effective in certain small subpopulations of patients, but eventually nearly all patients become resistant to further treatment. The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy and safety profiles. This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease. Oncogene (2009) 28, S4-S13; doi:10.1038/onc.2009.196	Sarah Cannon Res Inst, Nashville, TN 37203 USA	Sarah Cannon Research Institute	Burris, HA (corresponding author), Sarah Cannon Res Inst, 250 25th Ave N, Nashville, TN 37203 USA.	howard.burris@scresearch.net			Boehringer Ingelheim Pharmaceuticals	Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim)	The author thanks Johnathan C Maher, PhD, of BlueSpark Healthcare for medical and editorial assistance in this paper. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals.	Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; [Anonymous], 2008, CLIN PRACT GUID NONS; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; Bolonaki I, 2007, J CLIN ONCOL, V25, P2727, DOI 10.1200/JCO.2006.10.3465; Brandes JC, 2006, CANCER INVEST, V24, P283, DOI 10.1080/07357900600629567; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Britten CD, 2004, MOL CANCER THER, V3, P1335; CAMPOS L, 1993, BLOOD, V81, P3091; Carney DN, 2002, NEW ENGL J MED, V346, P126, DOI 10.1056/NEJM200201103460211; Clark GM, 2006, CLIN LUNG CANCER, V7, P389, DOI 10.3816/CLC.2006.n.022; Crawford J, 2004, CANCER-AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882; DOLE M, 1994, CANCER RES, V54, P3253; Dubey Sarita, 2005, J Support Oncol, V3, P149; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; GATZEMEIER U, 2006, J CLIN ONCOL 1, V24; *GEN INC, 2008, AV BEV PRESCR INF; Gendreau SB, 2007, CLIN CANCER RES, V13, P3713, DOI 10.1158/1078-0432.CCR-06-2590; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gridelli C, 2007, ONCOLOGIST, V12, P191, DOI 10.1634/theoncologist.12-2-191; Haber DA, 2005, CELL CYCLE, V4, P1057; Habib AA, 2003, MOL CANCER RES, V1, P219; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Herbst RS, 2007, J THORAC ONCOL, V2, pS335, DOI 10.1097/01.JTO.0000283144.91294.05; Herbst RS, 2004, CLIN CANCER RES, V10, p4245S, DOI 10.1158/1078-0432.CCR-040018; Heymach J, 2007, J CLIN ONCOL, V25; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003; Jackman DM, 2007, J CLIN ONCOL, V25, P760, DOI 10.1200/JCO.2006.07.5754; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Manegold C, 2008, J CLIN ONCOL, V26, P3979, DOI 10.1200/JCO.2007.12.5807; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Metro G, 2006, ANN ONCOL, V17, P42, DOI 10.1093/annonc/mdj920; MILLER VA, 2008, J CLIN ONCOL S, V26; Mita AC, 2006, J CLIN ONCOL, V24, P552, DOI 10.1200/JCO.2004.00.9720; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Mross KB, 2005, J CLIN ONCOL, V23, p199S; NATALE RB, 2006, J CLIN ONCOL S, V24; Nemunaitis J, 2006, MOL THER, V13, pS424, DOI 10.1016/j.ymthe.2006.08.1209; O'Brien MER, 2004, ANN ONCOL, V15, P906, DOI 10.1093/annonc/mdh220; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pirker R, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3; Rao G, 2007, J CLIN ONCOL, V25, P2867, DOI 10.1200/JCO.2007.10.8167; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; RIZVI N, 2007, J THORAC ONCOL, V2, pS737; Rosell R, 2008, ANN ONCOL, V19, P362, DOI 10.1093/annonc/mdm474; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; SCAGLIOTTI G, 2008, J THORAC ONCOL S1, V3, pS9; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217; Socinski MA, 2008, J CLIN ONCOL, V26, P650, DOI 10.1200/JCO.2007.13.9303; Stinchcombe TE, 2008, ONCOLOGIST, V13, P28, DOI 10.1634/theoncologist.13-S1-28; Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; van Zandwijk N, 2007, ANN ONCOL, V18, P99, DOI 10.1093/annonc/mdl323; Von Pawel J, 2007, J CLIN ONCOL, V25; Wang Y, 2007, J CLIN ONCOL, V25; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Wissner A, 2008, ARCH PHARM, V341, P465, DOI 10.1002/ardp.200800009; YANG C, 2008, J CLIN ONCOL, V26; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	78	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S4	S13		10.1038/onc.2009.196	http://dx.doi.org/10.1038/onc.2009.196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680296				2022-12-28	WOS:000269515400002
J	Pulukuri, SM; Gorantla, B; Knost, JA; Rao, JS				Pulukuri, S. M.; Gorantla, B.; Knost, J. A.; Rao, J. S.			Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer	ONCOGENE			English	Article						cystatins; cathepsins; invasion; histone modification; chromatin; prostate cancer	UROKINASE PLASMINOGEN-ACTIVATOR; HISTONE DEACETYLASE INHIBITION; CYSTEINE PROTEINASE-INHIBITOR; ABERRANT DNA METHYLATION; HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CATHEPSIN-B; EPIGENETIC INACTIVATION; INVASION	Cystatin E/M (CST6) is a natural inhibitor of lysosomal cysteine proteases. Recent studies have shown that experimental manipulation of CST6 expression alters the metastatic behavior of human breast cancer cells. However, the association of CST6 with prostate cancer invasion and progression remains unclear. Here, we show that CST6 is robustly expressed in normal human prostate epithelium, whereas its expression is downregulated in metastatic prostate cell lines and prostate tumor tissues. Treatment of metastatic prostate cell lines with the histone deacetylase inhibitor trichostatin A resulted in significant induction of CST6 mRNA levels and increased CST6 protein expression, indicating that epigenetic silencing may play a role in the loss of CST6 expression observed in prostate cancer. CST6 overexpression in human prostate cancer cells significantly reduced in vitro cell proliferation and matrigel invasion. Furthermore, the results from a bioluminescence tumor/metastasis model showed that the overexpression of CST6 significantly inhibits tumor growth and the incidence of lung metastasis. These results suggest that the downregulation of the CST6 gene is associated with promoter histone modi. cations and that this association plays an important role in prostate cancer progression during the invasive and metastatic stages of the disease. Oncogene (2009) 28, 2829-2838; doi:10.1038/onc.2009.134; published online 8 June 2009	[Pulukuri, S. M.; Gorantla, B.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Knost, J. A.] Illinois Canc Care, Peoria, IL USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61605 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu			National Cancer Institute [CA75557, CA92393, CA95058, CA116708, CA138409, NS47699, NS57529, NS61835]; Caterpillar Inc.,; NATIONAL CANCER INSTITUTE [R01CA092393, R01CA075557, R01CA138409, R01CA095058, R01CA116708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057529, R01NS061835, R01NS047699] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Caterpillar Inc.,; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Dr Hnilica of the Department of Pathology at the University of Illinois College of Medicine ( Peoria) for kindly providing normal and tumor human prostate tissues. We thank Shellee Abraham for preparing the paper and Diana Meister and Sushma Jasti for paper review. We also thank Noorjehan Ali and Lavanya Talluri, for technical assistance. This research was supported by National Cancer Institute Grant CA75557, CA92393, CA95058, CA116708, CA138409, N. I. N. D. S. NS47699, NS57529 and NS61835 and Caterpillar Inc., OSF St Francis Inc. Peoria, IL ( to JSR). The contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.	ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Brunner N, 1994, Cancer Treat Res, V71, P299; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Esteller M, 2001, CANCER RES, V61, P3225; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Marks PA, 2001, CLIN CANCER RES, V7, P759; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Ni J, 1997, J BIOL CHEM, V272, P10853; Pulukuri SM, 2007, ONCOGENE, V26, P5229, DOI 10.1038/sj.onc.1210329; Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200; Pulukuri SMK, 2007, CANCER RES, V67, P6637, DOI 10.1158/0008-5472.CAN-07-0751; Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Veena MS, 2008, GENE CHROMOSOME CANC, V47, P740, DOI 10.1002/gcc.20576; Yanamandra N, 2004, ONCOGENE, V23, P2224, DOI 10.1038/sj.onc.1207338; Yoon SO, 2001, J BIOL CHEM, V276, P20085, DOI 10.1074/jbc.M101143200; Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819; Zhong S, 2007, ONCOGENE, V26, P2621, DOI 10.1038/sj.onc.1210041	34	34	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2829	2838		10.1038/onc.2009.134	http://dx.doi.org/10.1038/onc.2009.134			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503093	Green Accepted			2022-12-28	WOS:000268684400006
J	Sun, Q; Ming, L; Thomas, SM; Wang, Y; Chen, ZG; Ferris, RL; Grandis, JR; Zhang, L; Yu, J				Sun, Q.; Ming, L.; Thomas, S. M.; Wang, Y.; Chen, Z. G.; Ferris, R. L.; Grandis, J. R.; Zhang, L.; Yu, J.			PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells	ONCOGENE			English	Article						PUMA; EGFR-TKI; p73; apoptosis; PI3K/AKT; head and neck cancer	BH3-ONLY PROTEINS; CARCINOMA; GROWTH; EXPRESSION; P53; INDUCTION; P63; (-)-GOSSYPOL; GEFITINIB; DISCOVERY	Overexpression of epidermal growth factor receptor (EGFR) is found in over 80% of head and neck squamous cell carcinomas (HNSCC) and associated with poor clinical outcomes. EFGR selective tyrosine kinase inhibitors (TKIs) or antibodies have recently emerged as promising treatments for solid tumors, including HNSCC, though the response rate to these agents is low. p53 upregulated modulator of apoptosis (PUMA), a BH3-only Bcl-2 family protein, is required for apoptosis induced by p53 and various chemotherapeutic agents. In this study, we show that PUMA induction is correlated with EGFR-TKI sensitivity, and is mediated through the p53 family protein p73 beta and inhibition of the PI3K/AKT pathway. In some HNSCC cells, the gefitinib-induced degradation of oncogenic Delta Np63 seems to facilitate p73-mediated PUMA transcription. Inhibiting PUMA expression by small hairpin RNA (shRNA) impairs gefitinib-induced apoptosis. Furthermore, PUMA or BH3 mimetics sensitize HNSCC cells to gefitinib-induced apoptosis. Our results suggest that PUMA induction through p73 represents a new mechanism of EGFR inhibitor-induced apoptosis, and provide potential ways for enhancing and predicting the sensitivity to EGFR-targeted therapies in HNSCC. Oncogene (2009) 28, 2348-2357; doi:10.1038/onc.2009.108; published online 4 May 2009	[Sun, Q.; Ming, L.; Yu, J.] Univ Pittsburgh, Dept Pathol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Thomas, S. M.; Ferris, R. L.; Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Wang, Y.] Univ Pittsburgh, Dept Biostat, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA; [Chen, Z. G.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Grandis, J. R.; Zhang, L.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Dept Pathol, Hillman Canc Ctr, Inst Canc, Suite 2-26H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009; Thomas, Sufi Mary/AFR-1642-2022; Thomas, Sufi/O-1487-2018	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Thomas, Sufi Mary/0000-0001-5370-0842; Thomas, Sufi/0000-0001-5370-0842	NIH [CA129829, P50CA097190, CA106348, CA121105]; American Cancer Society [RSG-07-156-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA121105, R01CA129829, P50CA097190, R01CA106348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank other members of our laboratories for helpful discussion and advice. We also thank Drs Cary Wu, Susanne M Gollin (University of Pittsburgh), Bert Vogelstein (HHMI and Sidney Kimmel Cancer Center at Johns Hopkins), David Sidransky (Sidney Kimmel Cancer Center at Johns Hopkins), and Carol Prives (Columbia University) for reagents. This work is supported in part by NIH grant CA129829, P50CA097190 (Head and Neck SPORE career development award) and those from ACGT and FAMRI (J Yu), and by NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (L Zhang).	Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Choong NW, 2006, CRIT REV ONCOL HEMAT, V57, P25, DOI 10.1016/j.critrevonc.2005.06.002; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Karst AM, 2005, ONCOGENE, V24, P1111, DOI 10.1038/sj.onc.1208374; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Liu B, 2000, BRIT J CANCER, V82, P1991; Matheny KE, 2003, LARYNGOSCOPE, V113, P936, DOI 10.1097/00005537-200306000-00004; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Muller S, 2008, CANCER-AM CANCER SOC, V113, P97, DOI 10.1002/cncr.23557; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sun Q, 2007, MOL CANCER THER, V6, P3180, DOI 10.1158/1535-7163.MCT-07-0265; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang GP, 2006, J MED CHEM, V49, P6139, DOI 10.1021/jm060460o; Wang HJ, 2006, CANCER BIOL THER, V5, P380, DOI 10.4161/cbt.5.4.2477; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wolter KG, 2006, NEOPLASIA, V8, P163, DOI 10.1593/neo.05691; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002	45	55	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2348	2357		10.1038/onc.2009.108	http://dx.doi.org/10.1038/onc.2009.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421143	Green Accepted			2022-12-28	WOS:000267089100005
J	Kang, J; Perry, JK; Pandey, V; Fielder, GC; Mei, B; Qian, PX; Wu, ZS; Zhu, T; Liu, DX; Lobie, PE				Kang, J.; Perry, J. K.; Pandey, V.; Fielder, G. C.; Mei, B.; Qian, P. X.; Wu, Z. S.; Zhu, T.; Liu, D. X.; Lobie, P. E.			Artemin is oncogenic for human mammary carcinoma cells	ONCOGENE			English	Article						artemin; GDNF; mammary; carcinoma; oncogenicity	NEUROTROPHIC FACTOR GDNF; PANCREATIC-CANCER CELLS; HUMAN GROWTH-HORMONE; BREAST-CANCER; STROMAL FIBROBLASTS; NEURONAL CELLS; NUDE-MICE; FAMILY; EXPRESSION; RECEPTOR	We report that artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is oncogenic for human mammary carcinoma. Artemin is expressed in numerous human mammary carcinoma cell lines. Forced expression of artemin in mammary carcinoma cells results in increased anchorage-independent growth, increased colony formation in soft agar and in three-dimensional Matrigel, and also promotes a scattered cell phenotype with enhanced migration and invasion. Moreover, forced expression of artemin increases tumor size in xenograft models and leads to highly proliferative, poorly differentiated and invasive tumors. Expression data in Oncomine indicate that high artemin expression is significantly associated with residual disease after chemotherapy, metastasis, relapse and death. Artemin protein is detectable in 65% of mammary carcinoma and its expression correlates to decreased overall survival in the cohort of patients. Depletion of endogenous artemin with small interfering RNA, or antibody inhibition of artemin, decreases the oncogenicity and invasiveness of mammary carcinoma cells. Artemin is therefore oncogenic for human mammary carcinoma, and targeted therapeutic approaches to inhibit artemin function in mammary carcinoma warrant consideration. Oncogene (2009) 28, 2034-2045; doi:10.1038/onc.2009.66; published online 13 April 2009	[Kang, J.; Perry, J. K.; Pandey, V.; Fielder, G. C.; Liu, D. X.; Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1010, North Island, New Zealand; [Mei, B.; Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Mei, B.; Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Mei, B.] Anhui Med Univ, Inst Basic Med, Hefei, Anhui, Peoples R China; [Wu, Z. S.] Anhui Med Univ, Dept Pathol, Hefei, Anhui, Peoples R China; [Lobie, P. E.] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1010, North Island, New Zealand	University of Auckland; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University; Anhui Medical University; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1010, North Island, New Zealand.	p.lobie@auckland.ac.nz	Pandey, Vijay/P-2767-2016; Qian, Pengxu/B-9376-2016	Perry, Jo/0000-0002-4418-947X; Qian, Pengxu/0000-0001-5636-6704; Kang, Jian/0000-0001-9998-4975	Breast Cancer Research Trust (NZ); Foundation for Research, Science and Technology of New Zealand; Hundred-Talent Scheme of Chinese Academy of Sciences; National Natural Science Foundation of China [2007CB914801, 2007CB914503]; National Basic Research Program of China [30571030]	Breast Cancer Research Trust (NZ); Foundation for Research, Science and Technology of New Zealand(New Zealand Foundation for Research, Science and Technology); Hundred-Talent Scheme of Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	We thank Alan Beedle for critical reading of the manuscript. This work was funded by the Breast Cancer Research Trust (NZ), the Foundation for Research, Science and Technology of New Zealand, the Hundred-Talent Scheme of Chinese Academy of Sciences, the National Natural Science Foundation of China (2007CB914801 & 2007CB914503) and the National Basic Research Program of China (30571030).	Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Bespalov MM, 2007, TRENDS PHARMACOL SCI, V28, P68, DOI 10.1016/j.tips.2006.12.005; BROUTYBOYE D, 1993, ANTICANCER RES, V13, P1087; Ceyhan GO, 2007, GUT, V56, P534, DOI 10.1136/gut.2006.105528; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; CHUNG LWK, 1993, SEMIN CANCER BIOL, V4, P183; Duxbury MS, 2004, ANN SURG, V240, P667, DOI 10.1097/01.sla.0000140755.97224.9a; Enomoto H, 2004, NEURON, V44, P623, DOI 10.1016/j.neuron.2004.10.032; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Hutcheson IR, 2006, ENDOCR-RELAT CANCER, V13, pS89, DOI 10.1677/erc.1.01279; Ichihara M, 2004, CANCER LETT, V204, P197, DOI 10.1016/S0304-3835(03)00456-7; Ito Y, 2005, SURGERY, V138, P788, DOI 10.1016/j.surg.2005.07.007; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu DX, 2007, CELL DEATH DIFFER, V14, P1893, DOI 10.1038/sj.cdd.4402209; Lubaroff D M, 1980, Prog Clin Biol Res, V37, P243; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Meng XJ, 2001, MOL CELL ENDOCRINOL, V184, P33, DOI 10.1016/S0303-7207(01)00649-9; Meng XJ, 2001, CANCER RES, V61, P3267; Okada Y, 1999, INT J CANCER, V81, P67, DOI 10.1002/(SICI)1097-0215(19990331)81:1<67::AID-IJC13>3.0.CO;2-V; Pandey V, 2008, ENDOCRINOLOGY, V149, P3909, DOI 10.1210/en.2008-0286; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Popsueva A, 2003, J CELL BIOL, V161, P119, DOI 10.1083/jcb.200212174; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Saarma M, 1999, MICROSC RES TECHNIQ, V45, P292, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<292::AID-JEMT13>3.0.CO;2-8; Sadlonova A, 2005, BREAST CANCER RES, V7, pR46, DOI 10.1186/bcr949; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Schueler-Furman O, 2006, TRENDS PHARMACOL SCI, V27, P72, DOI 10.1016/j.tips.2005.12.004; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Su G, 2007, J BIOL CHEM, V282, P14906, DOI 10.1074/jbc.M611739200; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Veit C, 2004, CANCER RES, V64, P5291, DOI 10.1158/0008-5472.CAN-04-1112; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje; Zhu T, 2005, CANCER RES, V65, P317; Zhu ZW, 2001, CLIN CANCER RES, V7, P105; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	43	61	71	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2034	2045		10.1038/onc.2009.66	http://dx.doi.org/10.1038/onc.2009.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363524				2022-12-28	WOS:000266023900004
J	Qin, J; Xie, Y; Wang, B; Hoshino, M; Wolff, DW; Zhao, J; Scofield, MA; Dowd, FJ; Lin, MF; Tu, Y				Qin, J.; Xie, Y.; Wang, B.; Hoshino, M.; Wolff, D. W.; Zhao, J.; Scofield, M. A.; Dowd, F. J.; Lin, M-F; Tu, Y.			Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis	ONCOGENE			English	Article						prostate cancer metastasis; P-Rex1; Rac-selective guanine nucleotide exchange factor; G-protein-coupled receptors; receptor tyrosine kinases	PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE 3-KINASE; CELL-MIGRATION; GROWTH-FACTOR; RHO GTPASES; ACTIVATION; PROGRESSION; EXPRESSION; INVASION	Excessive activation of G-protein-coupled receptor (GPCR) and receptor tyrosine kinase (RTK) pathways has been linked to prostate cancer metastasis. Rac activation by guanine nucleotide exchange factors (GEFs) plays an important role in directional cell migration, a critical step of tumor metastasis cascades. We found that the upregulation of P-Rex1, a Rac-selective GEF synergistically activated by Gb gamma freed during GPCR signaling, and PIP3, generated during either RTK or GPCR signaling, strongly correlates with metastatic phenotypes in both prostate cancer cell lines and human prostate cancer specimens. Silencing endogenous P-Rex1 in metastatic prostate cancer PC-3 cells selectively inhibited Rac activity and reduced cell migration and invasion in response to ligands of both epidermal growth factor receptor and G-protein-coupled CXC chemokine receptor 4. Conversely, expression of recombinant P-Rex1, but not its 'GEF-dead' mutant, in non-metastatic prostate cancer cells, such as CWR22Rv1, increased cell migration and invasion through Rac-dependent lamellipodia formation. More importantly, using a mouse xenograft model, we showed that the expression of P-Rex1, but not its mutant, induced lymph node metastasis of CWR22Rv1 cells without an effect on primary tumor growth. Thus, by functioning as a coincidence detector of chemotactic signals from both GPCRs and RTKs, P-Rex1-dependent activation of Rac promotes prostate cancer metastasis.	[Qin, J.; Xie, Y.; Wolff, D. W.; Zhao, J.; Scofield, M. A.; Dowd, F. J.; Tu, Y.] Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; [Wang, B.] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Hoshino, M.] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Biochem & Cellular Biol, Kyoto, Japan; [Zhao, J.; Tu, Y.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China; [Lin, M-F] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	Creighton University; Creighton University; National Center for Neurology & Psychiatry - Japan; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Nebraska System; University of Nebraska Medical Center	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Plaza,Crsis 3, Omaha, NE 68178 USA.	yapingtu@creighton.edu			Nebraska State Grant [LB595]; NIH [1R011CA125661]; Department of Defense Prostate Cancer Research Program [W81XWH-07-1-0189]; National Center for Research Resources [G20RR024001]; NATIONAL CANCER INSTITUTE [R01CA125661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR024001] Funding Source: NIH RePORTER	Nebraska State Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Prostate Cancer Research Program(United States Department of Defense); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported in part by Nebraska State Grant LB595, NIH 1R011CA125661 and by the Department of Defense Prostate Cancer Research Program W81XWH-07-1-0189 (YT). We thank Dr Laura Hansen for helpful comments and discussions; Dr Haihong Jiang, Lyudmila Batalkina, Dr Greg Perry and Lisa Linder-Stephenson for their technical assistance. The project described was also supported by Grant G20RR024001 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Arya Manit, 2004, J Exp Ther Oncol, V4, P291; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Bex A, 1999, PROSTATE CANCER P D, V2, P36, DOI 10.1038/sj.pcan.4500286; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408; CHING KZ, 1993, MOL CELL BIOCHEM, V126, P151, DOI 10.1007/BF00925693; DAAKA Y, 2004, SCI STKE, pRE2; Dada S, 2008, BIOCHEM BIOPH RES CO, V372, P875, DOI 10.1016/j.bbrc.2008.05.154; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jimenez-Sainz MC, 2003, MOL PHARMACOL, V64, P773, DOI 10.1124/mol.64.3.773; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Knight-Krajewski S, 2004, ONCOGENE, V23, P5513, DOI 10.1038/sj.onc.1207708; Kovar JL, 2006, AM J PATHOL, V169, P1415, DOI 10.2353/ajpath.2006.060324; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Lu Y, 2007, J CELL BIOCHEM, V101, P676, DOI 10.1002/jcb.21220; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MENSING H, 1983, EUR J CELL BIOL, V29, P268; Mimeault M, 2006, CARCINOGENESIS, V27, P1, DOI 10.1093/carcin/bgi229; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Schiller MR, 2006, CELL SIGNAL, V18, P1834, DOI 10.1016/j.cellsig.2006.01.022; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Sun D, 2006, DRUG RESIST UPDATE, V9, P274, DOI 10.1016/j.drup.2006.12.001; Wang ZL, 2008, PROSTAG OTH LIPID M, V87, P9, DOI 10.1016/j.prostaglandins.2008.04.001; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005	44	103	105	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1853	1863		10.1038/onc.2009.30	http://dx.doi.org/10.1038/onc.2009.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305425	Green Accepted, Green Submitted			2022-12-28	WOS:000265640500004
J	Busso, CS; Iwakuma, T; Izumi, T				Busso, C. S.; Iwakuma, T.; Izumi, T.			Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway	ONCOGENE			English	Article						APE1; p53; MDM2; DNA repair; DNA damage; ubiquitination	BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; ADENOMATOUS POLYPOSIS-COLI; ABASIC SITE REPAIR; EXTRACELLULAR CALCIUM; PROTEIN APE/REF-1; CELL-DEATH; IN-VIVO; P53; MDM2	APE1/Ref-1 is an essential DNA repair/gene regulatory protein in mammals of which intracellular level significantly affects cellular sensitivity to genotoxicants. The apurinic/apyrimidinic endonuclease 1 (APE1) functions are altered by phosphorylation and acetylation. We here report that APE1 is also modified by ubiquitination. APE1 ubiquitination occurred specifically at Lys residues near the N-terminus, and was markedly enhanced by mouse double minute 2 (MDM2), the major intracellular p53 inhibitor. Moreover, DNA-damaging reagents and nutlin-3, an inhibitor of MDM2-p53 interaction, increased APE1 ubiquitination in the presence of p53. Downmodulation of MDM2 increased APE1 level, suggesting that MDM2-mediated ubiquitination can be a signal for APE1 degradation. In addition, unlike the wild-type APE1, ubiquitin-APE1 fusion proteins were predominantly present in the cytoplasm. Therefore, monoubiquitination not only is a prerequisite for degradation, but may also alter the APE1 activities in cells. These results reveal a novel regulation of APE1 through ubiquitination.	[Izumi, T.] Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Otolaryngol, Hlth Sci Ctr,CSRB, New Orleans, LA 70112 USA; [Iwakuma, T.] Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Genet, Hlth Sci Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Izumi, T (corresponding author), Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Otolaryngol, Hlth Sci Ctr,CSRB, 533 Bolivar St, New Orleans, LA 70112 USA.	tizumi@lsuhsc.edu			NCI [CA98664]; Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE [R01CA098664, R56CA098664] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank KA Kerlec, KM Lane, MWLake, MK Rogoszewicz and C Bulkin for their technical assistance, and Mr Lake for editorial help. We also thank Dr S Desai and Dr A Haas at LSUHSC, New Orleans for their critical discussion and experimental guidance. Dr Davis's excellent editorial help is much appreciated. This research was supported by NCI grant CA98664 (TI) and Louisiana Cancer Research Consortium funding.	ASOU H, 1991, BLOOD, V77, P2031; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Balusu R, 2007, BIOCHEMISTRY-US, V46, P13961, DOI 10.1021/bi701632e; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Di Maso V, 2007, MOL MED, V13, P89, DOI 10.2119/2006-00084.DiMaso; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Guillet M, 2002, EMBO J, V21, P2833, DOI 10.1093/emboj/21.11.2833; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; Jackson EB, 2005, NUCLEIC ACIDS RES, V33, P3303, DOI 10.1093/nar/gki641; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Kakolyris S, 1997, CANCER RES, V57, P1794; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; MCHAFFIE GS, 1995, BONE, V17, P11, DOI 10.1016/8756-3282(95)00131-V; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Meira LB, 2001, CANCER RES, V61, P5552; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yacoub A, 1997, CANCER RES, V57, P5457; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zhao JF, 2008, J BIOL CHEM, V283, P9925, DOI 10.1074/jbc.M708345200; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	57	83	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1616	1625		10.1038/onc.2009.5	http://dx.doi.org/10.1038/onc.2009.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219073	Green Accepted			2022-12-28	WOS:000264780500006
J	De Martino, I; Visone, R; Fedele, M; Petrocca, F; Palmieri, D; Hoyos, JM; Forzati, F; Croce, CM; Fusco, A				De Martino, I.; Visone, R.; Fedele, M.; Petrocca, F.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Croce, C. M.; Fusco, A.			Regulation of microRNA expression by HMGA1 proteins	ONCOGENE			English	Article						HMGA1; microRNA; MEF; ATXN1; STC1; HMGA2	GROUP-A PROTEINS; GENE-EXPRESSION; STANNIOCALCIN-1 EXPRESSION; NEOPLASTIC TRANSFORMATION; MESSENGER-RNA; HUMAN CANCER; CELL LINES; C GENES; HMGI(Y); ATAXIN-1	The High Mobility Group proteins HMGA1 are nuclear architectural factors that play a critical role in a wide range of biological processes. Since recent studies have identified the microRNAs (miRNAs) as important regulators of gene expression, modulating critical cellular functions such as proliferation, apoptosis and differentiation, the aim of our work was to identify the miRNAs that are physiologically regulated by HMGA1 proteins. To this purpose, we have analysed the miRNA expression profile of mouse embryonic fibroblasts (MEFs) carrying two, one or no Hmga1 functional alleles using a microarray (miRNA microarray). By this approach, we found a miRNA expression profile that differentiates Hmga1-null MEFs from the wild-type ones. In particular, a significant decrease in miR-196a-2, miR-101b, miR-331 and miR-29a was detected in homozygous Hmga1-knockout MEFs in comparison with wild-type cells. Consistently, these miRNAs are downregulated in most of the analysed tissues of Hmga1-null mice in comparison with the wild-type mice. ChIP assay shows that HMGA1 is able to bind regions upstream of these miRNAs. Moreover, we identified the HMGA2 gene product as a putative target of miR-196a-2, suggesting that HMGA1 proteins are able to downregulate the expression of the other member of the HMGA family through the regulation of the miR-196a-2 expression. Finally, ATXN1 and STC1 gene products have been identified as targets of miR-101b. Therefore, it is reasonable to hypothesize that HMGA1 proteins are involved in several functions by regulating miRNA expression.	[De Martino, I.; Visone, R.; Fedele, M.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Fusco, A.] Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol Patol Cellulare Mol,Fac Med & C, I-80131 Naples, Italy; [De Martino, I.; Fedele, M.; Fusco, A.] European Sch Mol Med Naples Site, Naples, Italy; [De Martino, I.; Fedele, M.; Fusco, A.] CEINGE, NOGEC, Naples, Italy; [De Martino, I.; Visone, R.; Petrocca, F.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; CEINGE Biotecnologie Avanzate; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	De Martino, I (corresponding author), Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR Gaetano Salvatore, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Young, Richard A/F-6495-2012; Fedele, Monica/C-1417-2015; visone, rosa/K-7910-2016	Young, Richard A/0000-0001-8855-8647; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; VISONE, Rosa/0000-0002-4993-0220; Palmieri, Dario/0000-0002-0797-4268; Martinez Hoyos, Josefina/0000-0002-6909-8259	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR)(Ministry of Education, Universities and Research (MIUR)); NOGEC-Naples Oncogenomic Center; Associazione Partenopea per le Ricerche Oncologiche (APRO)	We thank Professor Stefano Volinia for miRNA microarray data analysis. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and the Ministero dell'Universita e della Ricerca Scientifica e Tecnologica (MIUR). This work was supported from NOGEC-Naples Oncogenomic Center. We thank the Associazione Partenopea per le Ricerche Oncologiche (APRO) for its support.	ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Chang ACM, 2003, ENDOCR-RELAT CANCER, V10, P359, DOI 10.1677/erc.0.0100359; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; Chiappetta G, 1996, ONCOGENE, V13, P2439; De Martino I, 2007, ENDOCR-RELAT CANCER, V14, P875, DOI 10.1677/ERC-07-0036; Eisenhofer G, 2004, ENDOCR-RELAT CANCER, V11, P897, DOI 10.1677/erc.1.00838; Fedele M, 2006, CANCER RES, V66, P2536, DOI 10.1158/0008-5472.CAN-05-1889; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Foti D, 2005, NAT MED, V11, P765, DOI 10.1038/nm1254; Fujiwara Y, 2000, INT J ONCOL, V16, P799; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gerritsen ME, 2002, PHYSIOL GENOMICS, V10, P13, DOI 10.1152/physiolgenomics.00035.2002; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Holmes DIR, 2008, CELL SIGNAL, V20, P569, DOI 10.1016/j.cellsig.2007.11.009; Hoyos JM, 2004, CANCER RES, V64, P5728, DOI 10.1158/0008-5472.CAN-04-1410; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Ishibashi K, 2002, AM J PHYSIOL-RENAL, V282, pF367, DOI 10.1152/ajprenal.00364.2000; Ismail RS, 2000, CANCER RES, V60, P6744; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lai KP, 2007, BIOCHEM BIOPH RES CO, V356, P968, DOI 10.1016/j.bbrc.2007.03.074; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee Y, 2008, NAT NEUROSCI, V11, P1137, DOI 10.1038/nn.2183; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McCudden CR, 2004, MOL CELL ENDOCRINOL, V213, P167, DOI 10.1016/j.mce.2003.10.042; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Okabe H, 2001, CANCER RES, V61, P2129; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; REEVES R, 1990, J BIOL CHEM, V265, P8573; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tsai CC, 2004, P NATL ACAD SCI USA, V101, P4047, DOI 10.1073/pnas.0400615101; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Visone R, 2007, ENDOCR-RELAT CANCER, V14, P791, DOI 10.1677/ERC-07-0129; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; Wascher RA, 2003, CLIN CANCER RES, V9, P1427; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Wong CKC, 2002, J ENDOCRINOL, V173, P199, DOI 10.1677/joe.0.1730199; Yeung HY, 2005, ENDOCRINOLOGY, V146, P4951, DOI 10.1210/en.2005-0365; Yue S, 2001, HUM MOL GENET, V10, P25, DOI 10.1093/hmg/10.1.25; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	64	42	42	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1432	1442		10.1038/onc.2008.495	http://dx.doi.org/10.1038/onc.2008.495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169275				2022-12-28	WOS:000264354400004
J	Danial, NN				Danial, N. N.			BAD: undertaker by night, candyman by day	ONCOGENE			English	Review						BAD; apoptosis; metabolism; survival signaling	BCL-X-L; DEPENDENT PROTEIN-KINASE; HUMAN PANCREATIC-ISLETS; PROMOTES CELL-SURVIVAL; CYTOCHROME-C RELEASE; DEATH AGONIST BAD; GROWTH-FACTOR-II; BH3 DOMAIN; PROAPOPTOTIC BAD; FAMILY-MEMBERS	The BH3-only pro-apoptotic proteins are upstream sensors of cellular damage that selectively respond to specific, proximal death and survival signals. Genetic models and biochemical studies indicate that these molecules are latent killers until activated through transcriptional or post-translational mechanisms in a tissue-restricted and signal-specific manner. The large number of BH3-only proteins, their unique subcellular localization, protein-interaction network and diverse modes of activation suggest specialization of their damage-sensing function, ensuring that the core apoptotic machinery is poised to receive input from a wide range of cellular stress signals. The apoptotic response initiated by the activation of BH3-only proteins ultimately culminates in allosteric activation of pro-apoptotic BAX and BAK, the gateway proteins to the mitochondrial pathway of apoptosis. From activation of BH3-only proteins to oligomerization of BAX and BAK and mitochondrial outer membrane permeabilization, an intricate network of interactions between the pro-and anti-apoptotic members of the BCL-2 family orchestrates the decision to undergo apoptosis. Beyond regulation of apoptosis, multiple BCL-2 proteins have recently emerged as active components of select homeostatic pathways carrying other cellular functions. This review focuses on BAD, which was the first BH3-only protein linked to proximal survival signals through phosphorylation by survival kinases. In addition to findings that delineated the physiological role of BAD in apoptosis and its dynamic regulation by phosphorylation, studies pointing to new roles for this protein in other physiological pathways, such as glucose metabolism, are highlighted. By executing its 'day' and 'night' jobs in metabolism and apoptosis, respectively, BAD helps coordinate mitochondrial fuel metabolism and the apoptotic machinery. Oncogene (2009) 27, S53-S70; doi: 10.1038/onc.2009.44	[Danial, N. N.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Danial, N. N.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Danial, NN (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 3 Blackfan Circle,CLSB 11-143, Boston, MA 02115 USA.	nika_danial@dfci.harvard.edu			National Cancer Institute (NCI, Rockville, MD, USA) [5 K01 CA106596-02]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA) [R01 DK078081-01]; Iacocca Foundation ( Boston, MA, USA); Juvenile Diabetes Research Foundation (JDRF, London, UK); Novartis (Basel, Switzerland); DFCI/Novartis Drug Discovery Program; NATIONAL CANCER INSTITUTE [K01CA106596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078081] Funding Source: NIH RePORTER	National Cancer Institute (NCI, Rockville, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Iacocca Foundation ( Boston, MA, USA); Juvenile Diabetes Research Foundation (JDRF, London, UK)(Juvenile Diabetes Research Foundation); Novartis (Basel, Switzerland); DFCI/Novartis Drug Discovery Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	NN Danial iscurrent ly receiving grant support from the National Cancer Institute (NCI, Rockville, MD, USA) (5 K01 CA106596-02), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA) (R01 DK078081-01), the Iacocca Foundation ( Boston, MA, USA) and the Juvenile Diabetes Research Foundation (JDRF, London, UK). The author is also in receipt of a grant from Novartis ( Basel, Switzerland) as part of the DFCI/Novartis Drug Discovery Program and has a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (Durham, NC, USA). NN Danial is a consultant/an advisor for the Novartis Institute for Biomedical Research (NIBR, Cambridge, MA, USA).	Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arden C, 2006, FEBS LETT, V580, P2065, DOI 10.1016/j.febslet.2006.03.009; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Balasubramanian R, 2007, PLANT PHYSIOL, V145, P1423, DOI 10.1104/pp.107.108704; Beene DL, 2007, CURR OPIN CELL BIOL, V19, P192, DOI 10.1016/j.ceb.2007.02.011; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bose AK, 2005, DIABETES, V54, P146, DOI 10.2337/diabetes.54.1.146; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Cotteret S, 2003, MOL CELL BIOL, V23, P5526, DOI 10.1128/MCB.23.16.5526-5539.2003; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Rasmo D, 2008, CELL SIGNAL, V20, P989, DOI 10.1016/j.cellsig.2008.01.017; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; delPeso L, 1997, SCIENCE, V278, P687; Deng HB, 2008, J BIOL CHEM, V283, P20754, DOI 10.1074/jbc.M800024200; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Djouder N, 2007, MOL CELL, V28, P28, DOI 10.1016/j.molcel.2007.08.010; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Freilinger A, 2006, ONCOGENE, V25, P6467, DOI 10.1038/sj.onc.1209660; FREINKEL N, 1984, DIABETES, V33, P1028, DOI 10.2337/diabetes.33.11.1028; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Giege P, 2003, PLANT CELL, V15, P2140, DOI 10.1105/tpc.012500; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hettiarachchi KD, 2008, EXP TOXICOL PATHOL, V60, P295, DOI 10.1016/j.etp.2008.02.009; Hickman JA, 2008, J NEUROPHYSIOL, V99, P1515, DOI 10.1152/jn.00598.2007; Hill DJ, 2000, ENDOCRINOLOGY, V141, P1151, DOI 10.1210/en.141.3.1151; HOGG J, 1994, J MOL ENDOCRINOL, V13, P49, DOI 10.1677/jme.0.0130049; Houslay M.D., 2006, SCI STKE, V2006, ppe32; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jetton TL, 2005, DIABETES, V54, P2294, DOI 10.2337/diabetes.54.8.2294; Jonas EA, 2003, J NEUROSCI, V23, P8423; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Khor TO, 2004, CANCER LETT, V210, P139, DOI 10.1016/j.canlet.2004.01.017; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim MR, 2007, DIGEST DIS SCI, V52, P2751, DOI 10.1007/s10620-007-9799-z; Kim WH, 2005, DIABETES, V54, P2602, DOI 10.2337/diabetes.54.9.2602; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee JW, 2004, CARCINOGENESIS, V25, P1371, DOI 10.1093/carcin/bgh145; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li WQ, 2004, J BIOL CHEM, V279, P29160, DOI 10.1074/jbc.M401656200; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Liadis N, 2007, DIABETES, V56, P2302, DOI 10.2337/db06-1771; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu WL, 2002, ENDOCRINOLOGY, V143, P3802, DOI 10.1210/en.2002-220058; Livigni A, 2006, MOL BIOL CELL, V17, P263, DOI 10.1091/mbc.e05-09-0827; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Marshall Stephen, 2006, Sci STKE, V2006, pre7; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Matschinsky FM, 2006, DIABETES, V55, P1; Miyawaki T, 2008, P NATL ACAD SCI USA, V105, P4892, DOI 10.1073/pnas.0800628105; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Ness JM, 2006, BRAIN RES, V1099, P150, DOI 10.1016/j.brainres.2006.04.132; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petrik J, 1999, ENDOCRINOLOGY, V140, P2353, DOI 10.1210/en.140.5.2353; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; PIPELEERS D, 1994, DIABETOLOGIA, V37, pS57, DOI 10.1007/BF00400827; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Salomoni P, 2000, BLOOD, V96, P676; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sastry KSR, 2007, J BIOL CHEM, V282, P14094, DOI 10.1074/jbc.M611370200; Sastry KSR, 2006, J BIOL CHEM, V281, P27367, DOI 10.1074/jbc.M511485200; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; Smith WE, 2007, MOL ENDOCRINOL, V21, P1478, DOI 10.1210/me.2006-0356; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; Sone H, 2005, DIABETOLOGIA, V48, P58, DOI 10.1007/s00125-004-1605-2; Sung JY, 2008, P NATL ACAD SCI USA, V105, P3112, DOI 10.1073/pnas.0712180105; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Uzgare AR, 2004, CANCER RES, V64, P6190, DOI 10.1158/0008-5472.CAN-04-0968; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960-9822(00)00702-8; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Waingeh VF, 2006, BIOPHYS J, V90, P1371, DOI 10.1529/biophysj.105.070052; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wiederkehr A, 2006, ENDOCRINOLOGY, V147, P2643, DOI 10.1210/en.2006-0057; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Wikstrom JD, 2007, DIABETES, V56, P2569, DOI 10.2337/db06-0757; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wu L, 2004, J BIOL CHEM, V279, P12126, DOI 10.1074/jbc.M307097200; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	176	186	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S53	S70		10.1038/onc.2009.44	http://dx.doi.org/10.1038/onc.2009.44			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641507				2022-12-28	WOS:000268566800005
J	Qiu, W; Leibowitz, B; Zhang, L; Yu, J				Qiu, W.; Leibowitz, B.; Zhang, L.; Yu, J.			Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis	ONCOGENE			English	Article						PUMA; growth factors; p53; apoptosis; intestinal stem cells; PI3K	GASTROINTESTINAL-TRACT; IONIZING-RADIATION; BH3-ONLY PROTEINS; IN-VIVO; P53; SURVIVAL; GENE; INDUCTION; IDENTIFICATION; EXPRESSION	Gastrointestinal toxicity is the primary limiting factor in abdominal and pelvic radiotherapy, but has no effective treatment currently. We recently showed a critical role of the BH3-only protein p53 upregulated modulator of apoptosis (PUMA) in acute radiation-induced GI damage and GI syndrome in mice. Growth factors such as insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) have been shown to protect against radiation-induced intestinal injury, although the underlying mechanisms remain to be identified. We report here the suppression of PUMA through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/p53 axis in the intestinal stem cells as a novel molecular mechanism of growth factor-mediated intestinal radioprotection. IGF-1 or bFGF impaired radiation-induced apoptosis and the expression of PUMA and p53 in the crypt cells and intestinal stem cells. Using colonic epithelial cells that undergo PUMA-dependent and radiation-induced apoptosis, we found that a PI3K inhibitor, dominant-negative PI3K or Mdm2 antagonist restored the induction of PUMA, p53 and apoptosis in the presence of growth factors. In contrast, overexpression of AKT suppressed the induction of PUMA and p53 by radiation. Furthermore, inhibiting PI3K or activating p53 abrogated growth factor-mediated suppression of apoptosis and PUMA expression in the intestinal crypts and stem cells after radiation. Oncogene (2010) 29, 1622-1632; doi:10.1038/onc.2009.451; published online 7 December 2009	[Yu, J.] Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; [Qiu, W.; Leibowitz, B.; Zhang, L.; Yu, J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhang, L.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Dept Pathol, Sch Med, Suite 2-26H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903	NIH [CA106348, CA121105, CA129829, UO1-DK085570, U19-A1068021]; American Cancer Society [RSG-07-156-01-CNE]; ACGT; FAMRI; NATIONAL CANCER INSTITUTE [R01CA129829, R01CA121105, R01CA106348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); ACGT; FAMRI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank other members of our labs for helpful discussion and advice and Ms Hong Tao Liu for breeding mice. This work is supported in part by NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (L Zhang), and NIH grants CA129829, UO1-DK085570, U19-A1068021 (pilot project), and those from ACGT and FAMRI (J Yu).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Booth D, 2001, J Natl Cancer Inst Monogr, P16; Bouleau S, 2007, APOPTOSIS, V12, P1377, DOI 10.1007/s10495-007-0072-x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; Ch'ang HJ, 2005, NAT MED, V11, P484, DOI 10.1038/nm1237; Clarke AR, 2007, ONCOGENE, V26, P6349, DOI 10.1038/sj.onc.1210457; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; George RJ, 2009, AM J PHYSIOL-GASTR L, V296, pG245, DOI 10.1152/ajpgi.00021.2008; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gu QY, 2004, RADIAT RES, V161, P692, DOI 10.1667/RR3158; Gulati AS, 2008, AM J PHYSIOL-GASTR L, V294, pG286, DOI 10.1152/ajpgi.00416.2007; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; Ishizuka S, 2003, NUCLEIC ACIDS RES, V31, P6198, DOI 10.1093/nar/gkg840; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Katoh M, 2006, INT J ONCOL, V29, P163; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; MERRITT AJ, 1994, CANCER RES, V54, P614; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Potten CS, 2004, RADIAT RES, V161, P123, DOI 10.1667/RR3104; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wilkins HR, 2002, AM J PHYSIOL-GASTR L, V283, pG457, DOI 10.1152/ajpgi.00019.2002; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; Yang JY, 2006, INT J ONCOL, V29, P643; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	51	101	116	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1622	1632		10.1038/onc.2009.451	http://dx.doi.org/10.1038/onc.2009.451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966853	Green Accepted			2022-12-28	WOS:000275694700007
J	Kulkarni, S; Reddy, KB; Esteva, FJ; Moore, HCF; Budd, GT; Tubbs, RR				Kulkarni, S.; Reddy, K. B.; Esteva, F. J.; Moore, H. C. F.; Budd, G. T.; Tubbs, R. R.			Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer	ONCOGENE			English	Article						HER2; AKT1; survival; resistance; calpain	GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; FACTOR-BETA; CELLS; RESISTANCE; KINASE; INTEGRIN; ACTIVATION; ERBB2; HER2	Resistance to anti-HER2 (human epithelial growth factor receptor 2) trastuzumab therapy occurs commonly in HER2-positive breast cancer and involves overactivation of HER2 and/or AKT1. Using the model of trastuzumab-sensitive or trastuzumab-resistant HER2-positive cells with wild-type PTEN, negative regulator of AKT1, we explore the involvement of cysteine protease calpain in mechanisms of trastuzumab resistance. Overexpression of calpain1 or activation of endogenous calpain during adhesion or trastuzumab treatment of trastuzumab-sensitive cells induces cleavage of cytoplasmic domains of HER2/phospho-HER2; cleavage occurs in HER2-positive tumors. Expression of the catalytically inactive mutant of calpain1 reduces the cleavage to enhance the activity of HER2, inactivates PTEN to enhance the activation of AKT1, induces desensitization to trastuzumab and promotes survival of trastuzumab-sensitive cells. In the model of trastuzumab resistance, constitutive overactivation of HER2 and AKT1 correlates with reduced activation of calpain. Moreover, inhibitors of the catalytic site of calpain reduce the increase in constitutive activity of AKT1 and survival of trastuzumab-resistant cells selectively. Together, by regulating the activation of HER2 and PTEN/AKT1, calpain regulates trastuzumab sensitivity and survival, and the deregulation of the activation of calpain promotes trastuzumab resistance. Trastuzumab-resistant cells activate AKT1 in a mechanism dependent on the residual calpain activity, inhibition of which restores trastuzumab sensitivity and rescues resistance. These data identify calpain as a new therapeutic target in HER2-positive breast cancer. Oncogene (2010) 29, 1339-1350; doi:10.1038/onc.2009.422; published online 30 November 2009	[Kulkarni, S.; Tubbs, R. R.] Cleveland Clin, Dept Mol Pathol, Pathol & Lab Med Inst, Cleveland, OH 44195 USA; [Reddy, K. B.] Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44106 USA; [Esteva, F. J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Moore, H. C. F.; Budd, G. T.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Cleveland Clinic Foundation	Kulkarni, S (corresponding author), Cleveland Clin, Dept Mol Pathol, Pathol & Lab Med Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kulkars@ccf.org						Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chan CT, 2005, BREAST CANCER RES TR, V91, P187, DOI 10.1007/s10549-004-7715-1; Clark AS, 2002, MOL CANCER THER, V1, P707; Edelstein CL, 2000, METH MOL B, V144, P233; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lawlor MA, 2001, J CELL SCI, V114, P2903; Libertini SJ, 2007, CANCER RES, V67, P9001, DOI 10.1158/0008-5472.CAN-07-1072; Mlynarczuk-Bialy I, 2006, CANCER RES, V66, P7598, DOI 10.1158/0008-5472.CAN-05-2614; Molina MA, 2001, CANCER RES, V61, P4744; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2004, CANCER CHEMOTH PHARM, V53, P186, DOI 10.1007/s00280-003-0728-3; Perrin BJ, 2006, MOL BIOL CELL, V17, P239, DOI 10.1091/mbc.e05-06-0488; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Raynaud F, 2003, EUR J BIOCHEM, V270, P4662, DOI 10.1046/j.1432-1033.2003.03859.x; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007; Zito CI, 2008, GENE CHROMOSOME CANC, V47, P633, DOI 10.1002/gcc.20566; Zutter MM, 2007, ADV EXP MED BIOL, V608, P87	44	35	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	2010	29	9					1339	1350		10.1038/onc.2009.422	http://dx.doi.org/10.1038/onc.2009.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946330				2022-12-28	WOS:000275170600009
J	Ramakrishnan, V; Timm, M; Haug, JL; Kimlinger, TK; Wellik, LE; Witzig, TE; Rajkumar, SV; Adjei, AA; Kumar, S				Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Adjei, A. A.; Kumar, S.			Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs	ONCOGENE			English	Article						vascular endothelial growth factor; myeloma; angiogenesis; proliferation; apoptosis; microenvironment	BONE-MARROW ANGIOGENESIS; MULTIPLE-MYELOMA; K-RAS; ACTIVATING MUTATIONS; DISEASE PROGRESSION; DOWN-REGULATION; PLASMA-CELLS; TUMOR-CELLS; N-RAS; KINASE	Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF). In addition, the Ras/Raf/MEK/ERK pathway is critical for the proliferation of myeloma cells and is often upregulated. Sorafenib (Nexavar) is a novel multi-kinase inhibitor that acts predominantly through inhibition of Raf-kinase and VEGF receptor 2, offering the potential for targeting two important aspects of disease biology. In in vitro studies, sorafenib-induced cytotoxicity in MM cell lines as well as freshly isolated patient myeloma cells. It retained its activity against MM cells in co-culture with stromal cells or with interleukin-6, VEGF or IGF; conditions mimicking tumor microenvironment. Examination of cellular signaling pathways showed downregulation of Mcl1 as well as decreased phosphorylation of the STAT3 and MEK/ERK, as potential mechanisms of its anti-tumor effect. Sorafenib induces reciprocal upregulation of Akt phosphorylation; and simultaneous inhibition of downstream mTOR with rapamycin leads to synergistic effects. Sorafenib also synergizes with drugs such as proteasome inhibitors and steroids. In a human in vitro angiogenesis assay, sorafenib showed potent anti-angiogenic activity. Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations. Oncogene (2010) 29, 1190-1202; doi: 10.1038/onc.2009.403; published online 23 November 2009	[Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Kumar, S.] Mayo Clin, Div Hematol, Rochester, MN USA; [Adjei, A. A.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Mayo Clinic; Roswell Park Cancer Institute	Kumar, S (corresponding author), Mayo Clin & Mayo Fdn, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA.	kumar.shaji@mayo.edu	Kumar, Shaji K/A-9853-2008; Rajkumar, S. Vincent/AAV-1834-2021	Kumar, Shaji K/0000-0001-5392-9284; Rajkumar, S. Vincent/0000-0002-5862-1833	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals; NATIONAL CANCER INSTITUTE [P50CA097274, R01CA127433] Funding Source: NIH RePORTER	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals(Bayer AG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Roberta DeGoey and Christy Finke for their assistance with processing of tumor cells and all of the patients who provided us with the tumor samples. This work was supported by Mayo Clinic Hematologic Malignancies Program, CR20 Award from Mayo Foundation and Career Development Award from Lymphoma SPORE. Sorafenib was provided through CTEP drug evaluation program by Bayer Pharmaceuticals.	Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; BROWN RD, 1994, LEUKEMIA LYMPHOMA, V16, P147, DOI 10.3109/10428199409114152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; CORRADINI P, 1993, BRIT J HAEMATOL, V83, P672, DOI 10.1111/j.1365-2141.1993.tb04711.x; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Frassanito MA, 2002, BRIT J HAEMATOL, V118, P157, DOI 10.1046/j.1365-2141.2002.03559.x; Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434; Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823; Kumar S, 2005, LEUKEMIA, V19, P1253, DOI 10.1038/sj.leu.2403776; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kumar S, 2004, BONE MARROW TRANSPL, V34, P235, DOI 10.1038/sj.bmt.1704555; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood-2002-08-2383; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Pope B, 1997, LEUKEMIA LYMPHOMA, V25, P545, DOI 10.3109/10428199709039043; PORTIER M, 1992, ONCOGENE, V7, P2539; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281; Rajkumar SV, 2002, CLIN CANCER RES, V8, P2210; Rowley M, 2002, ONCOGENE, V21, P8769, DOI 10.1038/sj.onc.1205387; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Strumberg D, 2005, ONKOLOGIE, V28, P101, DOI 10.1159/000083373; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; UCHIYAMA H, 1993, BLOOD, V82, P3712; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148	43	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1190	1202		10.1038/onc.2009.403	http://dx.doi.org/10.1038/onc.2009.403			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935717	Green Accepted			2022-12-28	WOS:000274912100010
J	Meunier, C; Cai, J; Fortin, A; Kwan, T; Marquis, JF; Turbide, C; Van der Kraak, L; Jothy, S; Beauchemin, N; Gros, P				Meunier, C.; Cai, J.; Fortin, A.; Kwan, T.; Marquis, J-F; Turbide, C.; Van der Kraak, L.; Jothy, S.; Beauchemin, N.; Gros, P.			Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3	ONCOGENE			English	Article						colon cancer; Ccs3; genetics; azoxymethane; gene mapping	GENOME-WIDE ASSOCIATION; COPY NUMBER ANALYSIS; NF-KAPPA-B; COLORECTAL-CANCER; TUMOR SUSCEPTIBILITY; GENETIC-CONTROL; MICE; CARCINOGENESIS; AZOXYMETHANE; COMPLEX	Treatment of mice with the carcinogen azoxymethane (AOM) induces a number of lesions in the colon, including hyperplastic lesions, as well adenomas and carcinomas in situ. Inbred strains of mice show different responses to AOM-induced carcinogenesis. A/J mice are highly susceptible and develop a greater number of hyperplastic lesions and tumors (15-70 tumors per mouse) than resistant C57BL/6J mice (0-6 tumors per mouse). Susceptibility to AOM-induced tumors segregates as a co-dominant trait in (A x B6)F1 hybrids. Using a set of 23 AcB and BcA recombinant congenic mouse strains derived from A/J (susceptible) and B6 (resistant) parents, we observed that the number of hyperplastic lesions and tumors induced by AOM was under different genetic controls in AcB/BcA strains. The multiplicity of AOM-induced tumors is controlled by a major locus that we have mapped on the distal portion of chromosome 3, to which we have given the temporary designation colon cancer susceptibility locus 3 (Ccs3). B6 and A/J alleles at Ccs3 are associated with resistance and susceptibility, respectively. Haplotype analysis in key informative AcB/BcA strains restricts the size of the Ccs3 locus to a 14Mb segment that contains 94 annotated genes. The expression level of all these genes in normal colon has been established by transcript profiling with microarrays, and has led to the identification of a subset of positional candidates that are expressed at high levels in this tissue. The 4q and 1p human chromosomal segments sharing syntenic homology with the mouse Ccs3 segment are known to be associated with inflammatory bowel diseases and colorectal tumors in humans, suggesting that the study of the mouse Ccs3 locus may help further the pathogenesis of these human conditions. Oncogene (2010) 29, 647-661; doi: 10.1038/onc.2009.369; published online 16 November 2009	[Meunier, C.; Cai, J.; Fortin, A.; Marquis, J-F; Van der Kraak, L.; Beauchemin, N.; Gros, P.] McGill Univ, Dept Biochem, Quebec City, PQ H3G 0B1, Canada; [Fortin, A.] Dafra Pharma Int, Turnhout, Belgium; [Kwan, T.] McGill Univ, Genome Quebec Innovat Ctr, Quebec City, PQ H3G 0B1, Canada; [Turbide, C.; Beauchemin, N.; Gros, P.] McGill Univ, Goodman Canc Ctr, Quebec City, PQ H3G 0B1, Canada; [Jothy, S.] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; [Jothy, S.] Univ Toronto, Toronto, ON M5B 1W8, Canada	McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Gros, P (corresponding author), McGill Univ, Dept Biochem, McGill Life Sci Complex,Bellini Pavil,Room 366,36, Quebec City, PQ H3G 0B1, Canada.	philippe.gros@mcgill.ca			National Cancer Institute of Canada; Goodman Cancer Centre	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Goodman Cancer Centre	We thank George Chountalos for his work in the haplotype mapping of the genetic interval of Ccs3 in common mouse strains. This work was supported by research grants to PG and NB from the National Cancer Institute of Canada and the Canderel Initiative Program of the Goodman Cancer Centre. PG is a James McGill professor of biochemistry.	AKAGI K, 2004, NUCLEIC ACIDS RES, V32, pD253; Angel JM, 2000, MOL CARCINOGEN, V27, P47, DOI 10.1002/(SICI)1098-2744(200001)27:1<47::AID-MC7>3.0.CO;2-7; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Cho JH, 1998, P NATL ACAD SCI USA, V95, P7502, DOI 10.1073/pnas.95.13.7502; Cianciulli A, 2004, CANCER GENET CYTOGEN, V151, P52, DOI 10.1016/j.cancergencyto.2003.09.013; Couturier-Turpin MH, 2001, CANCER GENET CYTOGEN, V124, P47, DOI 10.1016/S0165-4608(00)00325-3; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DESCHNER EE, 1988, CANCER, V61, P478, DOI 10.1002/1097-0142(19880201)61:3<478::AID-CNCR2820610312>3.0.CO;2-A; Dragani TA, 2003, CANCER RES, V63, P3011; EVANS JT, 1977, CANCER RES, V37, P134; FIJNEMAN RJA, 1995, CANCER RES, V55, P3179; Fortin A, 2001, GENOMICS, V74, P21, DOI 10.1006/geno.2001.6528; Fortin Anny, 2007, Novartis Found Symp, V281, P141; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gross O, 2008, BLOOD, V112, P2421, DOI 10.1182/blood-2007-11-123513; Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41; Karin M, 2008, CELL RES, V18, P334, DOI 10.1038/cr.2008.30; Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x; LOTHE RA, 1995, GENE CHROMOSOME CANC, V14, P182, DOI 10.1002/gcc.2870140305; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Min-Oo G, 2003, NAT GENET, V35, P357, DOI 10.1038/ng1260; Min-Oo G, 2007, J EXP MED, V204, P511, DOI 10.1084/jem.20061252; Moen CJA, 1996, P NATL ACAD SCI USA, V93, P1082, DOI 10.1073/pnas.93.3.1082; Nambiar PR, 2003, INT J ONCOL, V22, P145; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papanikolaou A, 1998, CANCER LETT, V130, P29, DOI 10.1016/S0304-3835(98)00101-3; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Shih IM, 2001, CANCER RES, V61, P818; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Suzui M, 2002, CANCER LETT, V183, P31, DOI 10.1016/S0304-3835(02)00114-3; Takahashi M, 2004, CANCER SCI, V95, P475, DOI 10.1111/j.1349-7006.2004.tb03235.x; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111; Tuite A, 2005, GENES IMMUN, V6, P672, DOI 10.1038/sj.gene.6364254; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	49	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					647	661		10.1038/onc.2009.369	http://dx.doi.org/10.1038/onc.2009.369			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19915610				2022-12-28	WOS:000274223700003
J	Gu, JJ; Wang, Z; Reeves, R; Magnuson, NS				Gu, J. J.; Wang, Z.; Reeves, R.; Magnuson, N. S.			PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis	ONCOGENE			English	Article						PIM1; phosphorylation; ASK1; kinase activity; apoptosis; cell survival	PROSTATE-CANCER CELLS; KINASE 1 ASK1; ACTIVATION; DEATH; PATHWAY; PROTEIN; STRESS; IDENTIFICATION; DISSOCIATION; THIOREDOXIN	The serine/threonine kinase, PIM1, is involved in promoting cell survival in part by phosphorylation and inhibition of proapoptotic proteins. Apoptosis signaling kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, is involved in the so-called stress-activated pathways that contribute to apoptotic cell death. Here we show that PIM1 phosphorylates ASK1 specifically on serine residue 83 (Ser83) both in vitro and in vivo and that PIM1 binds to ASK1 in cells by co-immunoprecipitation. Using H1299 cells, our results further demonstrate that PIM1 phosphorylation of ASK1 decreases its kinase activity induced by oxidative stress. PIM1 phosphorylation of ASK1 on Ser83 inhibited ASK1-mediated c-Jun N-terminal kinase phosphorylation as well as p38 kinase phosphorylation. Under H2O2-induced stress conditions that normally lead to apoptosis, these phosphorylation events were associated with inhibition of caspase-3 activation and resulted in reduced cell death. Moreover, knockdown of PIM1 in H1299 cells decreased phosphorylation of endogenous Ser83 of ASK1 and was associated with a decrease in cell viability after H2O2 treatment. Taken together, these data reveal a novel mechanism by which PIM1 promotes cell survival that involves negative regulation of the stress-activated kinase, ASK1. Oncogene (2009) 28, 4261-4271; doi: 10.1038/onc.2009.276; published online 14 September 2009	[Gu, J. J.; Wang, Z.; Reeves, R.; Magnuson, N. S.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Magnuson, NS (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	magnuson@wsu.edu			NIH [R01-CA104470, R01-GM071760]; NATIONAL CANCER INSTITUTE [R01CA104470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071760] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grants R01-CA104470 and R01-GM071760. We thank Dr Hidenori Ichijo (Tokyo Medical and Dental University) for providing us the ASK1 constructs (wild type, kinase mutant and deltaN-deleted).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819; CUYPERS HT, 1984, CELL, V37, P141; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Fujii K, 2004, ONCOGENE, V23, P5099, DOI 10.1038/sj.onc.1207668; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katakami N, 2004, J BIOL CHEM, V279, P54742, DOI 10.1074/jbc.M409140200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173; Kumar A, 2005, J MOL BIOL, V348, P183, DOI 10.1016/j.jmb.2005.02.039; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Peng C, 2007, J BIOCHEM, V141, P353, DOI 10.1093/jb/mvm040; Pircher TJ, 2000, ONCOGENE, V19, P3684, DOI 10.1038/sj.onc.1203684; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Shay KP, 2005, MOL CANCER RES, V3, P170; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang Z, 2001, J Vet Sci, V2, P167; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Yan W, 2007, BIOCHEM BIOPH RES CO, V355, P1038, DOI 10.1016/j.bbrc.2007.02.064; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	42	79	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4261	4271		10.1038/onc.2009.276	http://dx.doi.org/10.1038/onc.2009.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749799	Green Accepted			2022-12-28	WOS:000272876300004
J	Jian, Y; Gao, Z; Sun, J; Shen, Q; Feng, F; Jing, Y; Yang, C				Jian, Y.; Gao, Z.; Sun, J.; Shen, Q.; Feng, F.; Jing, Y.; Yang, C.			RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells	ONCOGENE			English	Article						nucleophosmin; RNA aptamer; p14ARF; p53; apoptosis	PROTEIN B23; BINDING; ARF; NUCLEOLI	Nucleophosmin (NPM) is a multifunctional protein involved in both proliferation and apoptosis. Importantly, NPM negatively regulates p53 and is frequently overexpressed in a wide variety of cancers. To identify inhibitory molecules of NPM, we used an in vitro selection method termed systematic evolution of ligands by exponential enrichment (SELEX) to select RNA aptamers that bind to NPM with high affinity and specificity. The selected RNA aptamers bind to the central acidic region of NPM and affect its oligomerization both in vitro and in vivo. Remarkably, expression of NPM-specific aptamers causes mislocalization of NPM in the nucleoplasm rather than in the nucleolus, suggesting that NPM oligomerization is important for its proper localization. Moreover, p14ARF is mislocalized in the nucleoplasm and p53 is upregulated in cells expressing NPM aptamers. In addition, cancer cells expressing NPM aptamers not only undergo apoptosis on their own, but are more susceptible to apoptosis induced by DNA-damaging agents as well. These results suggest that interfering with NPM oligomerization can inhibit NPM function and aptamers targeting NPM can serve as potential lead for developing anticancer drugs. Oncogene (2009) 28, 4201-4211; doi: 10.1038/onc.2009.275; published online 7 September 2009	[Jian, Y.; Gao, Z.; Sun, J.; Shen, Q.; Jing, Y.; Yang, C.] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100101, Peoples R China; [Feng, F.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Yang, C (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Datun Rd, Beijing 100101, Peoples R China.	clyang@genetics.ac.cn			National 863 Program [2006AA02Z147]; National Basic Research Program [2006CB504100, 2007CB947201]; National Natural Science Foundation [30871266]; Chinese Academy of Sciences [KSC1-YW-R-70]; CAS 100-Talents Program	National 863 Program(National High Technology Research and Development Program of China); National Basic Research Program(National Basic Research Program of China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); CAS 100-Talents Program(Chinese Academy of Sciences)	We thank Dr S Luo and Dr D Wu for providing NPM and p14ARF cDNAs; Dr Y Liu for help with protein purification; Dr X Wang for helpful suggestions and critical reading of the paper. This research was supported by grants from National 863 Program (no. 2006AA02Z147), National Basic Research Program (nos. 2006CB504100 and 2007CB947201), National Natural Science Foundation (no. 30871266) and Chinese Academy of Sciences (no. KSC1-YW-R-70). CY was supported by the CAS 100-Talents Program.	Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Apte RS, 2008, EXPERT OPIN PHARMACO, V9, P499, DOI [10.1517/14656566.9.3.499, 10.1517/14656566.9.3.499 ]; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Chu TC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl388; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Enomoto T, 2006, J BIOL CHEM, V281, P18463, DOI 10.1074/jbc.M602788200; Gjerset RA, 2006, CELL CYCLE, V5, P686, DOI 10.4161/cc.5.7.2623; Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Lee HZ, 2005, INT J CANCER, V113, P971, DOI 10.1002/ijc.20676; Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54; Sambrook J., 2001, MOL CLONING LAB MANU; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; WANG DR, 1994, J BIOL CHEM, V269, P30994; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Yang CL, 2006, J BIOL CHEM, V281, P9137, DOI 10.1074/jbc.M511742200; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	49	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4201	4211		10.1038/onc.2009.275	http://dx.doi.org/10.1038/onc.2009.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734942				2022-12-28	WOS:000272876100006
J	Gao, SB; Feng, ZJ; Xu, B; Wu, Y; Yin, P; Yang, Y; Hua, X; Jin, GH				Gao, S-B; Feng, Z-J; Xu, B.; Wu, Y.; Yin, P.; Yang, Y.; Hua, X.; Jin, G-H			Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin	ONCOGENE			English	Article						lung adenocarcinoma; histone H3 lysine 27; Men1; pleiotrophin; Polycomb	ANAPLASTIC LYMPHOMA KINASE; TYROSINE-PHOSPHATASE-BETA/ZETA; EXPRESSION; CANCER; MLL; IDENTIFICATION; RECEPTOR; FIBROBLASTS; METHYLATION; P18(INK4C)	Menin upregulates transcription of cell-cycle inhibitors to suppress endocrine tumors, but it is poorly understood how menin suppresses non-endocrine tumors such as lung cancer. Here, we show that menin inhibits proliferation of human lung cancer cells and growth of lung cancer in mice. The menin-mediated tumor suppression requires repression of growth factor pleiotrophin (PTN), which binds to its cell surface receptor, anaplastic lymphoma kinase (ALK) that is activated in certain lung adenocarcinomas. Menin represses PTN transcription and PTN-induced proliferation of human lung cancer cells, and menin expression is substantially reduced in primary human lung adenocarcinomas. Notably, menin binds the PTN locus and enhances Polycomb gene Enhancer of Zeste homolog 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27m3), a negative mark for gene transcription but does not affect histone H3K4 methylation that is usually upregulated by menin in endocrine cells. Together, our findings indicate that menin suppresses lung cancer partly through increasing Polycomb gene-mediated H3K27 methylation and repressing PTN transcription, unraveling a novel, epigenetically regulated PTN-ALK signaling pathway in suppressing lung cancer. Oncogene (2009) 28, 4095-4104; doi:10.1038/onc.2009.273; published online 14 September 2009	[Yang, Y.; Hua, X.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19096 USA; [Gao, S-B; Feng, Z-J; Xu, B.; Wu, Y.; Hua, X.; Jin, G-H] Xiamen Univ, Coll Med, Dept Basic Med Sci, Xiamen 361005, Fujian, Peoples R China; [Yin, P.] Xiamen Univ, Zhongshan Hosp, Dept Pathol, Xiamen, Peoples R China	University of Pennsylvania; Xiamen University; Xiamen University	Hua, X (corresponding author), Univ Penn, Dept Canc Biol, Room 412,BRB2-3,421 Curie Blvd, Philadelphia, PA 19096 USA.	huax@mail.med.upenn.edu; ghjin@xmu.edu.cn		Feng, Zijie/0000-0002-5633-3686	NFSC [30701003]; Natural Science Foundation of Fujian Province of China [C0710044]; National Cancer Institute Short-Term Scientist Exchange Program; National Cancer Institute [R01CA100912, R01CA113962]; NATIONAL CANCER INSTITUTE [R01CA100912, R01CA113962] Funding Source: NIH RePORTER	NFSC(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province of China(Natural Science Foundation of Fujian Province); National Cancer Institute Short-Term Scientist Exchange Program; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is in partly supported by NFSC Grants (No 30701003, GH Jin), the Natural Science Foundation of Fujian Province of China (No C0710044, GH Jin), National Cancer Institute Short-Term Scientist Exchange Program (GH Jin), and National Cancer Institute Grants (R01CA100912 and R01CA113962, XH). We appreciate the valuable comments from other members of our laboratories.	Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen YX, 2006, P NATL ACAD SCI USA, V103, P1018, DOI 10.1073/pnas.0510347103; Choudhuri R, 1997, CANCER RES, V57, P1814; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jin SH, 2003, CANCER RES, V63, P4204; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Yan JZ, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000047; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632	30	47	50	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4095	4104		10.1038/onc.2009.273	http://dx.doi.org/10.1038/onc.2009.273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19749796	Green Accepted			2022-12-28	WOS:000272560500005
J	Krumschnabel, G; Manzl, C; Villunger, A				Krumschnabel, G.; Manzl, C.; Villunger, A.			Caspase-2: killer, savior and safeguard-emerging versatile roles for an ill-defined caspase	ONCOGENE			English	Review						caspase; apoptosis; DNA repair; tumor suppression	DNA-DAMAGE; APOPTOSIS; ACTIVATION; COMPLEX; DEATH; MICE; DIFFERENTIATION; PIDDOSOME; STRESS	Despite the early discovery of caspase-2, its physiological function has long remained an enigma. A number of recent publications now suggest not just one, but multiple functions, including roles in apoptosis, DNA repair and tumor suppression. How can one enzyme have so many talents? Considering the diversity of interaction partners and the specific mode of pro-apoptotic action proposed in these studies, caspase-2 might in fact represent a primordial protease serving numerous pathways, established before the advent of a more elaborate functionally diversified caspases system. Oncogene (2009) 28, 3093-3096; doi: 10.1038/onc.2009.173; published online 6 July 2009	[Krumschnabel, G.; Manzl, C.; Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	Gerhard.krumschnabel@i-med.ac.at; andreas.villunger@i-med.ac.at	Krumschnabel, Gerhard/E-3694-2010	Krumschnabel, Gerhard/0000-0003-0804-1248	Austrian Science Fund [Y212-B13, SFB021]; EU; Tyrolean Science Fund (TWF)	Austrian Science Fund(Austrian Science Fund (FWF)); EU(European Commission); Tyrolean Science Fund (TWF)	The work in our laboratory is supported by fellowships and grants from the Austrian Science Fund (Y212-B13, SFB021, MCBO), EU-FP6 (ApopTrain) and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited but was only referred to indirectly through reviews.	Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Braga M, 2008, APOPTOSIS, V13, P822, DOI 10.1007/s10495-008-0216-7; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Ditzel M, 2008, MOL CELL, V32, P540, DOI 10.1016/j.molcel.2008.09.025; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Gonzalvez F, 2008, J CELL BIOL, V183, P681, DOI 10.1083/jcb.200803129; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Shi MG, 2009, CELL, V136, P508, DOI 10.1016/j.cell.2008.12.021; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Yi CH, 2009, DEV CELL, V16, P21, DOI 10.1016/j.devcel.2008.12.012; Zhang YP, 2007, MECH AGEING DEV, V128, P213, DOI 10.1016/j.mad.2006.11.030; Zhivotovsky B, 2006, CARCINOGENESIS, V27, P1939, DOI 10.1093/carcin/bgl035	24	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3093	3096		10.1038/onc.2009.173	http://dx.doi.org/10.1038/onc.2009.173			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581929	Green Accepted			2022-12-28	WOS:000269515100001
J	Chitale, D; Gong, Y; Taylor, BS; Broderick, S; Brennan, C; Somwar, R; Golas, B; Wang, L; Motoi, N; Szoke, J; Reinersman, JM; Major, J; Sander, C; Seshan, VE; Zakowski, MF; Rusch, V; Pao, W; Gerald, W; Ladanyi, M				Chitale, D.; Gong, Y.; Taylor, B. S.; Broderick, S.; Brennan, C.; Somwar, R.; Golas, B.; Wang, L.; Motoi, N.; Szoke, J.; Reinersman, J. M.; Major, J.; Sander, C.; Seshan, V. E.; Zakowski, M. F.; Rusch, V.; Pao, W.; Gerald, W.; Ladanyi, M.			An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors	ONCOGENE			English	Article						lung adenocarcinoma; expression profiling; array comparative genomic hybridization; microarray; EGFR; KRAS	SOMATIC MUTATIONS; KRAS MUTATIONS; GENE; ADENOCARCINOMA; GLIOBLASTOMA; PATHWAYS; SPECIFICITY; REGULATORS; SENESCENCE; EXPRESSION	To address the biological heterogeneity of lung cancer, we studied 199 lung adenocarcinomas by integrating genome-wide data on copy number alterations and gene expression with full annotation for major known somatic mutations in this cancer. This showed non-random patterns of copy number alterations significantly linked to EGFR and KRAS mutation status and to distinct clinical outcomes, and led to the discovery of a striking association of EGFR mutations with underexpression of DUSP4, a gene within a broad region of frequent single-copy loss on 8p. DUSP4 is involved in negative feedback control of EGFR signaling, and we provide functional validation for its role as a growth suppressor in EGFR-mutant lung adenocarcinoma. DUSP4 loss also associates with p16/CDKN2A deletion and defines a distinct clinical subset of lung cancer patients. Another novel observation is that of a reciprocal relationship between EGFR and LKB1 mutations. These results highlight the power of integrated genomics to identify candidate driver genes within recurrent broad regions of copy number alteration and to delineate distinct oncogenetic pathways in genetically complex common epithelial cancers. Oncogene (2009) 28, 2773-2783; doi:10.1038/onc.2009.135; published online 15 June 2009	[Chitale, D.; Wang, L.; Motoi, N.; Szoke, J.; Reinersman, J. M.; Zakowski, M. F.; Gerald, W.; Ladanyi, M.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Gong, Y.; Pao, W.; Gerald, W.; Ladanyi, M.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Taylor, B. S.; Major, J.; Sander, C.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA; [Broderick, S.; Golas, B.; Rusch, V.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Brennan, C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [Somwar, R.; Seshan, V. E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Pao, W.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room S-801, New York, NY 10065 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019; Brennan, Cameron/R-7082-2019; Reinersman, Matthew/ABE-3551-2020; Sander, Chris/H-1452-2011; Wang, Lu/N-8128-2018; Motoi, Noriko/AAO-5642-2020; Motoi, Noriko/A-9718-2009	Brennan, Cameron/0000-0003-4064-8891; Reinersman, Matthew/0000-0002-4458-0743; Sander, Chris/0000-0001-6059-6270; Wang, Lu/0000-0002-0073-0666; Motoi, Noriko/0000-0001-7098-3311; Motoi, Noriko/0000-0001-7098-3311; Chitale, Dhananjay/0000-0002-4421-6431; Rusch, Valerie/0000-0003-2345-6900	National Cancer Institute [U01-CA84999, P01-CA129243]; Doris Duke Charitable Foundation; Long Island League to Abolish Cancer; Labrecque Foundation; Lung Cancer Research Foundation; Anbinder Fund; NATIONAL CANCER INSTITUTE [U01CA084999, P01CA129243] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Long Island League to Abolish Cancer; Labrecque Foundation; Lung Cancer Research Foundation; Anbinder Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Agnes Viale and the MSKCC Genomics Core Laboratory personnel for the generation of microarray data; Dr Laetitia Borsu for assistance with Sequenom assays; Drs Hakim Djaballah and Gabriela E. Sanchez of the MSKCC HTS Core Facility for providing GFP siRNAs; Louis Vargas, Yonghong Xiao and the MSKCC Pathology Core personnel for technical assistance; Drs William Travis, Andre Moreira and David Klimstra for providing pathologic diagnoses; Drs John Minna and Adi Gazdar for providing the human bronchial epithelial cell ( HBEC) lines; Drs Alice H Berger, Marasu Niki and Pier Paolo Pandol. for assistance with reagents and related studies; Dr Roman Thomas for sharing unpublished microarray data, and Dr Harold Varmus for support ( to RS). Barry S Taylor is a graduate student in the Department of Physiology and Biophysics, Weill Cornell Graduate School of Medical Sciences. We acknowledge the support of the National Cancer Institute (U01-CA84999 to WG, P01-CA129243to ML), the Doris Duke Charitable Foundation ( to WP), the Long Island League to Abolish Cancer ( to WP), the Labrecque Foundation ( to WG) and the Lung Cancer Research Foundation ( to ML). The MSKCC Sequenom facility is supported by the Anbinder Fund.	Adams J, 2005, CANCER LETT, V220, P137, DOI 10.1016/j.canlet.2004.06.052; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Armes JE, 2004, ONCOGENE, V23, P5697, DOI 10.1038/sj.onc.1207740; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kobayashi S, 2006, CANCER RES, V66, P11389, DOI 10.1158/0008-5472.CAN-06-2318; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lee SH, 1999, CANCER RES, V59, P5683; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Marks JL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000426; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Meyerson M, 2004, SEMIN ONCOL, V31, P4, DOI 10.1053/j.seminoncol.2003.12.009; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Schulze A, 2004, MOL BIOL CELL, V15, P3450, DOI 10.1091/mbc.E03-11-0807; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tresini M, 2007, J BIOL CHEM, V282, P4136, DOI 10.1074/jbc.M604955200; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	38	176	181	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2773	2783		10.1038/onc.2009.135	http://dx.doi.org/10.1038/onc.2009.135			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525976	Green Accepted, Green Submitted			2022-12-28	WOS:000268684400001
J	Kar, R; Singha, PK; Venkatachalam, MA; Saikumar, P				Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.			A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells	ONCOGENE			English	Article						cell death; cytoplasmic vacuolation; LC3; ER stress; MAPK; 15d-PGJ2	15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); OXIDATIVE STRESS; INDUCE APOPTOSIS; DRUG-RESISTANCE; DNA-BINDING; AUTOPHAGY; ACTIVATION; MECHANISMS; PROTEASOME; INHIBITION	Thiol reactive cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2), induced a novel, nonapoptotic and microtubule-associated protein 1 light chain 3 (MAP1 LC3) dependent but nonautophagic form of cell death in colon, breast and prostate cancer cell lines, characterized by extensive cytoplasmic vacuolation with dilatation of endoplasmic reticulum (ER). Disruption of sulfhydryl homeostasis, which resulted in ER stress, accumulation of ubiquitinated proteins and subsequent ER dilation, contributed to peroxisome proliferator-activated receptor gamma (PPAR gamma)-independent cell death by 15d-PGJ2. Absence of intracellular organelles in these vacuoles, shown by electron microscopy and unique fragmentation of lamin B, suggested this form of cell death to be different from autophagy and apoptosis. Cell death induced by 15d-PGJ2 is prevented by cycloheximide and actinomycin D, suggesting a requirement of new protein synthesis for death with cytoplasmic vacuolation. Here, we report for the. first time that upregulation and processing of autophagy marker LC3 is an important event in nonautophagic cytoplasmic vacuolation and cell death. Notably, knockdown of LC3 conferred significant protection against 15d-PGJ2-induced cytoplasmic vacuolation and cell death, suggesting a novel role of LC3 in a death process other than autophagy. Oncogene (2009) 28, 2556-2568; doi: 10.1038/onc.2009.118; published online 18 May 2009	[Kar, R.; Singha, P. K.; Venkatachalam, M. A.; Saikumar, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Saikumar, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	saikumar@uthscsa.edu			National Institutes of Health [DK54472, DK37139]; Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054472, R01DK037139, R37DK037139] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Morrison Trust; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Tamotsu Yoshimori of Osaka University, Japan, for LC3 antibody and GFP-LC3 construct and Drs Anthony J Valente and Robert A Clark of UTHSCSA, TX, for Calreticulin antibody. This work was supported by National Institutes of Health grant DK54472 and Morrison Trust Grant to PS and National Institutes of Health grant DK37139 to MAV.	Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chambers KT, 2007, AM J PHYSIOL-ENDOC M, V292, pE1052, DOI 10.1152/ajpendo.00274.2006; Chen SY, 2002, ANTI-CANCER DRUG, V13, P759, DOI 10.1097/00001813-200208000-00011; Chen YC, 2005, BBA-MOL CELL RES, V1743, P291, DOI 10.1016/j.bbamcr.2004.10.016; Cho WH, 2006, NEUROCHEM RES, V31, P1247, DOI 10.1007/s11064-006-9157-0; Ghribi O, 2001, MOL BRAIN RES, V96, P30, DOI 10.1016/S0169-328X(01)00256-X; Hashimoto K, 2004, PANCREAS, V28, P153, DOI 10.1097/00006676-200403000-00006; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; Ishii T, 2005, BIOCHEMISTRY-US, V44, P13893, DOI 10.1021/bi051336u; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaufmann SH, 2003, ONCOGENE, V22, P7414, DOI 10.1038/sj.onc.1206945; Kimura H, 2008, NEPHROL DIAL TRANSPL, V23, P2496, DOI 10.1093/ndt/gfn139; Li LY, 2001, J BIOL CHEM, V276, P38152; Lin MS, 2007, J DIGEST DIS, V8, P82, DOI 10.1111/j.1443-9573.2007.00290.x; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mimnaugh EG, 2006, MOL CANCER RES, V4, P667, DOI 10.1158/1541-7786.MCR-06-0019; Morosetti R, 2004, INT J ONCOL, V25, P493; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naito M, 2004, CANCER SCI, V95, P361, DOI 10.1111/j.1349-7006.2004.tb03216.x; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392; Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Wang ZY, 2006, J BIOL CHEM, V281, P21377, DOI 10.1074/jbc.M601201200	43	97	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2556	2568		10.1038/onc.2009.118	http://dx.doi.org/10.1038/onc.2009.118			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19448671	Green Accepted			2022-12-28	WOS:000268058900002
J	Thornber, K; Colomba, A; Ceccato, L; Delsol, G; Payrastre, B; Gaits-Iacovoni, F				Thornber, K.; Colomba, A.; Ceccato, L.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.			Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas	ONCOGENE			English	Article						anaplastic large cell lymphomas; NPM-ALK; lipoxygenases; ROS	5-LIPOXYGENASE; KINASE; INHIBITION; ROS	The chimera nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), the tyrosine kinase activity of which is constitutively upregulated, is the causative agent of 75% of the anaplastic large-cell lymphomas (ALCLs). We have demonstrated that NPM-ALK induces the production of reactive oxygen species (ROS) by a pathway involving the arachidonic acid-metabolizing enzymes of the lipoxygenase (LOX) family. The use of the LOX inhibitor nordihydroguaiaretic acid (NDGA) and of the antioxidant N-acetylcysteine (NAC) demonstrated that ROS are important in maintaining the ALK kinase active. Consistent with this, NDGA treatment resulted in the inhibition of key pathways, such as Akt, signal transducer and activator of transcription factor 3 (STAT3) and extracellular signal-regulated kinase (ERK), which are involved in NPM-ALK antiapoptotic and pro-mitogenic functions. Conversely, the stress-activated kinase p38, described in some instances as a mediator of apoptosis, was activated. Interestingly, 5-LOX, an isoform involved in many cancers, was found to be activated in NPM-ALK(+) cells. Functional studies have shown that transforming properties, namely proliferation and resistance to apoptosis, were abrogated by treatment with either NDGA or the 5-LOX inhibitor (N-(3-phenoxycinnamyl)-acetohydroxamic acid) (BW A4C). Together, these data point to the ROS/LOX pathway as a potential new target for therapy in NPM-ALK-positive tumors. Oncogene (2009) 28, 2690-2696; doi: 10.1038/onc.2009.125; published online 8 June 2009	[Gaits-Iacovoni, F.] CHU Purpan, INSERM, U563, Dpt Oncogenese Signalisat & Innovat Therapeut, F-31024 Toulouse 3, France; [Thornber, K.; Colomba, A.; Ceccato, L.; Delsol, G.; Payrastre, B.; Gaits-Iacovoni, F.] Univ Toulouse 3, Ctr Physiopathol Toulouse Purpan, F-31062 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gaits-Iacovoni, F (corresponding author), CHU Purpan, INSERM, U563, Dpt Oncogenese Signalisat & Innovat Therapeut, BP 3028, F-31024 Toulouse 3, France.	frederique.gaits@inserm.fr	Payrastre, Bernard/M-5295-2014	, Bernard/0000-0002-8693-0190; Gaits-Iacovoni, Frederique/0000-0002-9853-0442; , Kelly/0000-0003-0484-8458	INSERM; 'Ministre de la Recherche et de la Technologie; ARC; INCa; La Ligue contre le Cancer; Canceropole GSO; 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); 'Ministre de la Recherche et de la Technologie; ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); La Ligue contre le Cancer(Ligue nationale contre le cancer); Canceropole GSO; 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite	We thank E Espinos for providing pBSK-NPM-ALK, D Ramel and the group 'Signaling and Phosphoinosites in normal and pathologic hematopoietic cells' for helpful discussions. This work was supported by grants from the INSERM, 'Ministre de la Recherche et de la Technologie', ARC, INCa, La Ligue contre le Cancer, Canceropole GSO and the 'Pole de competitivite Cancer-Biosante/Fonds uniques interministeriels des poles de competitivite'.	AGGARWAL BB, 2004, ANTICANCER RES, V26, P503; Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Claesson HE, 2008, FEBS J, V275, P4222, DOI 10.1111/j.1742-4658.2008.06570.x; Colomba A, 2008, ONCOGENE, V27, P2728, DOI 10.1038/sj.onc.1210921; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Furstenberger G, 2006, INT J CANCER, V119, P2247, DOI 10.1002/ijc.22153; Honorat JF, 2006, BLOOD, V107, P4130, DOI 10.1182/blood-2005-06-2421; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Pidgeon GP, 2007, CANCER METAST REV, V26, P503, DOI 10.1007/s10555-007-9098-3; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; TATESON JE, 1988, BRIT J PHARMACOL, V94, P528, DOI 10.1111/j.1476-5381.1988.tb11557.x; Vincent C, 2008, LEUKEMIA RES, V32, P1756, DOI 10.1016/j.leukres.2008.05.005; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Wu XJ, 2007, CANCER BIOL THER, V6, P646, DOI 10.4161/cbt.6.5.4092	19	18	18	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2690	2696		10.1038/onc.2009.125	http://dx.doi.org/10.1038/onc.2009.125			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19503098				2022-12-28	WOS:000268211200007
J	Yuan, J; Yang, BMP; Zhong, ZH; Shats, I; Milyavsky, M; Rotter, V; Lock, RB; Reddel, RR; MacKenzie, KL				Yuan, J.; Yang, B. M-P; Zhong, Z-H; Shats, I.; Milyavsky, M.; Rotter, V.; Lock, R. B.; Reddel, R. R.; MacKenzie, K. L.			Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase	ONCOGENE			English	Article						survivin; telomerase; apoptosis; immortalization; fibroblasts	ANTI-APOPTOSIS GENE; MALIGNANT-TRANSFORMATION; SPINDLE CHECKPOINT; CELL-DIVISION; CORD BLOOD; CANCER; INACTIVATION; INHIBITOR; GROWTH; EXPRESSION	These investigations demonstrate that expression of the inhibitor of apoptosis family member, survivin, is dramatically increased during immortalization of nontransformed human fibroblasts that were transduced with telomerase reverse transcriptase (hTERT). Expression of survivin in immortalized fibroblasts peaked during G(2)/M phase of the cell cycle. However, the upregulation of survivin was dissociated from the rate of proliferation and proportion of G(2)/M cells. Depletion of survivin from immortal flbroblasts increased sensitivity to stress-induced apoptosis and resulted in an accumulation of cells with 4N DNA content. Conversely, overexpression of survivin in mortal. broblasts conferred resistance to apoptosis. In contrast, very low levels of survivin in proliferating parental. broblasts had no bearing on sensitivity to apoptosis. The upregulation of survivin did not appear to be a direct consequence of hTERT transduction. However, repression of hTERT resulted in the rapid downregulation of survivin in telomerase-immortalized. broblasts and tumor cell lines, but not in cells immortalized via an Alternative Lengthening of Telomeres mechanism. These results have important therapeutic implications, as telomerase and survivin are both broadly expressed in human cancers. Selection during the immortalization process for cells expressing high levels of survivin may account for the abundance of survivin in diverse tumor types. Oncogene (2009) 28, 2678-2689; doi: 10.1038/onc.2009.136; published online 1 June 2009	[MacKenzie, K. L.] Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia; [Yuan, J.; Yang, B. M-P; Lock, R. B.; MacKenzie, K. L.] Univ New S Wales, Fac Med, Sydney, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Childrens Med Res Inst, Westmead, NSW, Australia; [Zhong, Z-H; Reddel, R. R.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Shats, I.; Milyavsky, M.; Rotter, V.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Children's Cancer Institute; University of New South Wales Sydney; Children's Medical Research Institute - Australia; University of Sydney; Weizmann Institute of Science	MacKenzie, KL (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Australia Med Res, Level 1,High St,POB 81, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	Reddel, Roger R/A-6635-2014; MacKenzie, Karen/N-5849-2019; Shats, Igor/AAD-8775-2019; Mackenzie, Karen/F-1310-2011; Lock, Richard/G-4253-2013; Milyavsky, Michael/E-8306-2011	Reddel, Roger R/0000-0002-6302-6107; Shats, Igor/0000-0001-6449-5979; Lock, Richard/0000-0002-3436-9071; MacKenzie, Karen/0000-0003-2996-1617				Adida C, 1998, AM J PATHOL, V152, P43; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arora V, 2007, J BIOL CHEM, V282, P26202, DOI 10.1074/jbc.M700776200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Cohen SB, 2007, SCIENCE, V315, P1850, DOI 10.1126/science.1138596; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Colnaghi R, 2006, J BIOL CHEM, V281, P33450, DOI 10.1074/jbc.C600164200; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gurbuxani S, 2005, P NATL ACAD SCI USA, V102, P11480, DOI 10.1073/pnas.0500303102; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Knauer SK, 2006, EMBO REP, V7, P1259, DOI 10.1038/sj.embor.7400824; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Milyavsky M, 2003, CANCER RES, V63, P7147; Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Pennati M, 2007, CARCINOGENESIS, V28, P1133, DOI 10.1093/carcin/bgm047; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Schuller CE, 2007, LEUKEMIA, V21, P983, DOI 10.1038/sj.leu.2404631; Stewart SA, 2006, ANNU REV CELL DEV BI, V22, P531, DOI 10.1146/annurev.cellbio.22.010305.104518; Taylor LM, 2004, J BIOL CHEM, V279, P43634, DOI 10.1074/jbc.M402388200; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verhagen AM, 2001, GENOME BIOL, V2; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; Wang ZX, 2005, CANCER RES, V65, P8224, DOI 10.1158/0008-5472.CAN-05-0303; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Wen VW, 2006, CANCER RES, V66, P10691, DOI 10.1158/0008-5472.CAN-06-0979; Wright WE, 1996, DEV GENET, V18, P173; Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Zhang M, 2006, J EXP CLIN CANC RES, V25, P391	47	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2678	2689		10.1038/onc.2009.136	http://dx.doi.org/10.1038/onc.2009.136			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483728				2022-12-28	WOS:000268211200006
J	Lee, SH; Lee, SJ; Chung, JY; Jung, YS; Choi, SY; Hwang, SH; Choi, D; Ha, NC; Park, BJ				Lee, S-H; Lee, S-J; Chung, J-Y; Jung, Y-S; Choi, S-Y; Hwang, S. H.; Choi, D.; Ha, N-C; Park, B-J			p53, secreted by K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells; implication of target-specific drug delivery and early diagnostic marker	ONCOGENE			English	Article						p53; Snail; secretion; endocytosis; diagnostic marker	COLON-CANCER CELLS; ANTI-P53 ANTIBODIES; NUCLEAR EXPORT; EXPRESSION; MUTATIONS; ACTIVATION; CHOLANGIOCARCINOMAS; RESTORATION; CLEARANCE; ONCOGENE	p53 is eliminated from K-Ras-mutated cancer cells through direct interaction with Snail. However, it is not achieved through proteasome-mediated degradation or transcriptional repression. Here we provide evidence that p53, binding with Snail, is exported from a K-Ras-mutated cell through a vesicle transport-like mechanism, independently using a p53-nuclear-exporting mechanism. Although we can detect p53 in culture media, a majority of p53 might be degraded by extracellular proteases. Thus, we can recover the secreted p53 in culture media by the inhibition of protease and endocytosis. In addition, a considerable amount of p53 is endocytosed by neighboring cells. As p53 resorption occurs in a K-Ras-dependent manner, treatment of recombinant p53 is detected in the whole-cell lysate of K-Ras-mutated cells, but not in that of wild-type cells. Using the property of p53, we can deliver the chemical (propidium iodine) into K-Ras mutated cells selectively. In contrast, Snail, a co-secreted protein with p53 in response to oncogenic K-Ras, shows resistance to endocytosis and protease, and results in remaining in the media. Thus, we can detect an autoantibody against Snail in the serum of a human cancer patient. Our finding can be used for a mutant K-Ras-specific anticancer drug delivery system and for the diagnosis of pancreatic, colon and lung cancers. Oncogene (2009) 28, 2005-2014; doi:10.1038/onc.2009.67; published online 6 April 2009	[Lee, S-H; Lee, S-J; Chung, J-Y; Jung, Y-S; Choi, S-Y; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Hwang, S. H.] Pusan Natl Univ Hosp, Dept Lab Med, Pusan, South Korea; [Choi, D.] Shunchoonhyang Med Ctr, Seoul, South Korea; [Ha, N-C] Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, Pusan 609735, South Korea	Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University	Park, BJ (corresponding author), Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea.	bjpark1219@pusan.ac.kr	Lee, Sang Joon/AAG-2448-2019; Hwang, Sang-Hyun/C-3571-2008; Hwang, Sanghyun/L-5314-2019	Hwang, Sang-Hyun/0000-0003-3201-5728; Hwang, Sanghyun/0000-0003-3201-5728	Research Team for Longevity Life Sciences in Pusan National University; Pusan National University (PNU) [PNU-2008-101-2008-596-000]	Research Team for Longevity Life Sciences in Pusan National University; Pusan National University (PNU)	This work was supported by a research grant from the Research Team for Longevity Life Sciences in Pusan National University and by the Bio-Scientific Research Grant funded by the Pusan National University (PNU, Bio-Scientific Research Grant)(PNU-2008-101-2008-596-000).	Bergqvist M, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-66; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Genschel J, 2000, HUM MUTAT, V16, P451, DOI 10.1002/1098-1004(200012)16:6<451::AID-HUMU1>3.0.CO;2-9; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; LEON M, 1995, ANTICANCER RES, V15, P859; LEVI S, 1991, CANCER RES, V51, P3497; Limpaiboon T, 2004, HEPATO-GASTROENTEROL, V51, P25; Nie LH, 2007, J BIOL CHEM, V282, P14616, DOI 10.1074/jbc.M610515200; Park BJ, 2006, CANCER RES, V66, P6913, DOI 10.1158/0008-5472.CAN-05-3740; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Roy UKB, 2008, MOL CARCINOGEN, V47, P538, DOI 10.1002/mc.20414; Shin J, 2006, CELL PHYSIOL BIOCHEM, V17, P211, DOI 10.1159/000094126; Soussi T, 2000, CANCER RES, V60, P1777; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; TSUDA H, 1992, MOL CARCINOGEN, V6, P266, DOI 10.1002/mc.2940060408; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang GY, 2005, CA-CANCER J CLIN, V55, P352, DOI 10.3322/canjclin.55.6.352	30	28	31	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2005	2014		10.1038/onc.2009.67	http://dx.doi.org/10.1038/onc.2009.67			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19347028				2022-12-28	WOS:000266023900001
J	Samanta, AK; Chakraborty, SN; Wang, Y; Kantarjian, H; Sun, X; Hood, J; Perrotti, D; Arlinghaus, RB				Samanta, A. K.; Chakraborty, S. N.; Wang, Y.; Kantarjian, H.; Sun, X.; Hood, J.; Perrotti, D.; Arlinghaus, R. B.			Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients	ONCOGENE			English	Article						BCR-ABL; Jak2; Lyn; SET; PP2A; drug-resistance	PROTEIN PHOSPHATASE 2A; BCR-ABL; TYROSINE PHOSPHORYLATION; MYELOID-LEUKEMIA; SODIUM STIBOGLUCONATE; SIGNALING PATHWAY; POTENT INHIBITOR; BLAST CRISIS; BCR/ABL; MESYLATE	Chronic myelogenous leukemia (CML) patients treated with imatinib mesylate (IM) become drug resistant by mutations within the kinase domain of Bcr-Abl, and by other changes that cause progression to advanced stage (blast crisis) and increased expression of the Lyn tyrosine kinase, the regulation of which is not understood yet. In Bcr-Abl + cells inhibition of Jak2, a downstream target of Bcr-Abl, by either Jak2 inhibitors or Jak2-specific short interfering RNA (siRNA) reduced the level of the SET protein, and increased PP2A Ser/Thr phosphatase and Shp1 tyrosine phosphatase activities, which led to decreased levels of activated Lyn. Activation of PP2A combined with Jak2 inhibition enhanced the reduction of activated Lyn kinase compared with Jak2 inhibition alone. In contrast, inhibition of either PP2A or Shp1 combined with Jak2 inhibition interfered with the loss of Lyn kinase activation more so than Jak2 inhibition alone, indicating the involvement of PP2A and Shp1 in the inactivation of the Lyn kinase caused by Jak2 inhibition. Inhibition of Jak2 induced apoptosis and reduced colony formation in IM-sensitive and -resistant Bcr-Abl mutant cell lines. Jak2 inhibition also induced apoptosis in CML cells from blast crisis patients but not in normal hematopoietic cells. These results indicate that Lyn is downstream of Jak2, and Jak2 maintains activated Lyn kinase in CML through the SET-PP2A-Shp1 pathway.	[Arlinghaus, R. B.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, Houston, TX 77054 USA; [Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77054 USA; [Sun, X.] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77054 USA; [Hood, J.] TargeGen Inc, San Diego, CA USA; [Perrotti, D.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University	Arlinghaus, RB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Unit 951, 7435 Fannin St, Houston, TX 77054 USA.	rarlingh@mdanderson.org	Perrotti, Danilo/E-3852-2011		DOD [WB1XWH-07-1-0270];  [CA49639];  [CA093792];  [CA095512];  [CA100632]; NATIONAL CANCER INSTITUTE [R01CA093792, P01CA049639, R01CA095512, P50CA100632] Funding Source: NIH RePORTER	DOD(United States Department of Defense); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants CA49639 and CA093792 (RBA), CA095512 and DOD WB1XWH-07-1-0270 (DP), Leukemia Spore grant CA100632 (AKS), and Ladies Leukemia League ( AKS). We thank Santhanam Ramasami, PhD in the Perrotti lab for his help in PP2A assay.	Alvarez RH, 2006, CANCER-AM CANCER SOC, V107, P1918, DOI 10.1002/cncr.22215; Bruno O, 2007, MED CHEM, V3, P127, DOI 10.2174/157340607780059549; Chu S, 2004, BLOOD, V103, P3167, DOI 10.1182/blood-2003-04-1271; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; DONATO NJ, 2004, CANCER RES, V22, P5766; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kantarjian HM, 2003, BLOOD, V101, P97, DOI 10.1182/blood-2002-02-0545; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Nawa M, 2008, CELL SIGNAL, V20, P493, DOI 10.1016/j.cellsig.2007.11.004; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Nimmanapalli R, 2002, CANCER RES, V62, P5761; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Pardanani A, 2008, LEUKEMIA, V22, P23, DOI 10.1038/sj.leu.2404948; Pardanani A, 2007, LEUKEMIA, V21, P1658, DOI 10.1038/sj.leu.2404750; Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391; Perrotti D, 2006, BRIT J CANCER, V95, P775, DOI 10.1038/sj.bjc.6603317; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158/0008-5472.CAN-06-0025; Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Wu J, 2008, BLOOD, V111, P3821, DOI 10.1182/blood-2007-08-109330; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yi TL, 2002, J IMMUNOL, V169, P5978, DOI 10.4049/jimmunol.169.10.5978; Yokota A, 2007, BLOOD, V109, P306, DOI 10.1182/blood-2006-03-013250; Yokoyama N, 2003, ARCH BIOCHEM BIOPHYS, V417, P87, DOI 10.1016/S0003-9861(03)00333-3; Yokoyama N, 2001, J INTERF CYTOK RES, V21, P369, DOI 10.1089/107999001750277844	35	88	94	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1669	1681		10.1038/onc.2009.7	http://dx.doi.org/10.1038/onc.2009.7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234487	Green Accepted			2022-12-28	WOS:000265022000002
J	Robert, I; Aussems, M; Keutgens, A; Zhang, X; Hennuy, B; Viatour, P; Vanstraelen, G; Merville, MP; Chapelle, JP; de Leval, L; Lambert, F; Dejardin, E; Gothot, A; Chariot, A				Robert, I.; Aussems, M.; Keutgens, A.; Zhang, X.; Hennuy, B.; Viatour, P.; Vanstraelen, G.; Merville, M-P; Chapelle, J-P; de Leval, L.; Lambert, F.; Dejardin, E.; Gothot, A.; Chariot, A.			Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappa B2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes	ONCOGENE			English	Article						NF-kappa B; MMP9; H3K4 HMT; p100	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; REED-STERNBERG CELLS; SIGNALING PATHWAYS; SACCHAROMYCES-CEREVISIAE; LYSINE-4 METHYLATION; MULTIPLE-MYELOMA; LYMPHOMA-CELLS; ACTIVE GENES; ALPHA-GENE	Constitutive nuclear factor (NF)-kappa Ba ctivation in haematological malignancies is caused in several cases by loss of function mutations within the coding sequence of NF-kappa B inhibitory molecules such as I kappa B alpha or p100. Hut-78, a truncated form of p100, constitutively generates p52 and contributes to the development of T-cell lymphomas but the molecular mechanism underlying this oncogenic potential remains unclear. We show here that MMP9 gene expression is induced through the alternative NF-kappa B-activating pathway in fibroblasts and also on Hut-78 or p52 overexpression in fibroblasts as well as in lymphoma cells. p52 is critical for Hut-78-mediated MMP9 gene induction as a Hut-78 mutant as well as other truncated NF-kappa B2 proteins that are not processed into p52 failed to induce the expression of this metalloproteinase. Conversely, MMP9 gene expression is impaired in p52-depleted HUT-78 cells. Interestingly, MLL1 and MLL2 H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the I kappa B alpha promoter, and the H3K4 trimethyltransferase activity recruited on the MMP9 promoter is impaired in p52-depleted HUT-78 cells. Moreover, MLL1 and MLL2 are associated with Hut-78 in a native chromatin-enriched extract. Thus, we identified a molecular mechanism by which the recruitment of a H3K4 histone methyltransferase complex on the promoter of a NF-kappa B-dependent gene induces its expression and potentially the invasive potential of lymphoma cells harbouring constitutive activity of the alternative NF-kappa B-activating pathway.	[Chariot, A.] Univ Liege, CHU Sart Tilman, Lab Chem Med,Interdisciplinary Cluster Appl Genop, Unit Signal Transduct,GIGA R,Tour GIGA, B-4000 Liege, Belgium; [Robert, I.; Aussems, M.; Keutgens, A.; Zhang, X.; Viatour, P.; Merville, M-P; Chapelle, J-P; Dejardin, E.; Chariot, A.] Univ Liege, CHU Sart Tilman, GIGA Signal Transduct, B-4000 Liege, Belgium; [Hennuy, B.] Univ Liege, CHU Sart Tilman, GIGA Transcript Facil, B-4000 Liege, Belgium; [Vanstraelen, G.; Gothot, A.] Univ Liege, CHU Sart Tilman, Dept Med Hematol, B-4000 Liege, Belgium; [de Leval, L.] Univ Liege, CHU Sart Tilman, Dept Pathol, B-4000 Liege, Belgium; [Lambert, F.] Univ Liege, CHU Sart Tilman, Lab Human Genet, B-4000 Liege, Belgium; [Dejardin, E.] Univ Liege, CHU Sart Tilman, Lab Virol & Immunol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Chariot, A (corresponding author), Univ Liege, CHU Sart Tilman, Lab Chem Med,Interdisciplinary Cluster Appl Genop, Unit Signal Transduct,GIGA R,Tour GIGA, 2 B34, B-4000 Liege, Belgium.	Alain.chariot@ulg.ac.be	de Leval, Laurence/M-4889-2017; Dejardin, Emmanuel/AAE-9076-2021	de Leval, Laurence/0000-0003-3994-516X; Chariot, Alain/0000-0002-1691-4347	University of Liege (ULg); FNRS; TELEVIE; Belgian Federation against Cancer; Belgian State, Science Policy Office [IAP6/18]	University of Liege (ULg)(University of Liege); FNRS(Fonds de la Recherche Scientifique - FNRS); TELEVIE; Belgian Federation against Cancer; Belgian State, Science Policy Office(Belgian Federal Science Policy Office)	We are gratefulto F Fuks for helpful discussions, to M Pasparakis, Y St-Pierre and R Weil for the gifts of wild-type and NEMO-deficient mouse embryonic fibroblasts, the 164T2 cell line and the anti-NEMO antibody, respectively. We also thank Dr J-H Lee, Dr DG Skalnik and Dr C van Lint for the gift of expression plasmids. M- PM, LdeL and AC are Senior Research Associates whereas ED is Research Associate at the Belgian National fund for Research ('FNRS'). IR and XZ are 'TELEVIE' Research Assistants whereas MA and AK are 'FNRS' Research Assistants. This work was supported by grants from the University of Liege ( ULg), FNRS, TELEVIE, the Belgian Federation against Cancer, the IAP6/18 (funded by the Interuniversity Attraction Poles Programme, initiated by the Belgian State, Science Policy Office), the 'Centre Antireux and Fonds Leon Fredeericq (Faculty of Medicine, ULg).	Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Aoudjit F, 1998, BLOOD, V91, P623, DOI 10.1182/blood.V91.2.623.623_623_629; Aygun O, 2008, P NATL ACAD SCI USA, V105, P8580, DOI 10.1073/pnas.0804424105; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, BIOCHEM BIOPH RES CO, V308, P744, DOI 10.1016/S0006-291X(03)01474-8; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Heissig B, 2003, CURR OPIN HEMATOL, V10, P136, DOI 10.1097/00062752-200303000-00007; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Keutgens A, 2006, BIOCHEM PHARMACOL, V72, P1069, DOI 10.1016/j.bcp.2006.06.011; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Lalancette M, 2000, BLOOD, V95, P314, DOI 10.1182/blood.V95.1.314.001k32_314_319; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; MCKEITHAN TW, 1987, P NATL ACAD SCI USA, V84, P9257, DOI 10.1073/pnas.84.24.9257; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Qing GL, 2007, P NATL ACAD SCI USA, V104, P5324, DOI 10.1073/pnas.0609914104; Redondo-Munoz J, 2006, BLOOD, V108, P3143, DOI 10.1182/blood-2006-03-007294; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635; Sakata K, 2004, CANCER, V100, P356, DOI 10.1002/cncr.11905; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Srivastava AK, 2007, J BIOL CHEM, V282, P35113, DOI 10.1074/jbc.M705329200; THAKUR S, 1994, ONCOGENE, V9, P2335; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Wang Z, 2008, J BIOL CHEM, V283, P10698, DOI 10.1074/jbc.M800806200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; ZHANG JD, 1994, ONCOGENE, V9, P1931	61	31	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1626	1638		10.1038/onc.2009.6	http://dx.doi.org/10.1038/onc.2009.6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219072	Green Published			2022-12-28	WOS:000264780500007
J	Post, SM; Quintas-Cardama, A; Terzian, T; Smith, C; Eischen, CM; Lozano, G				Post, S. M.; Quintas-Cardama, A.; Terzian, T.; Smith, C.; Eischen, C. M.; Lozano, G.			p53-dependent senescence delays E mu-myc-induced B-cell lymphomagenesis	ONCOGENE			English	Article						p53; apoptosis; senescence; lymphoma; mouse model	CYCLIN-DEPENDENT KINASES; IN-VIVO; TUMOR-SUPPRESSOR; HUMAN FIBROBLASTS; ONCOGENIC RAS; P53; P21; P21(CIP1/WAF1); P16(INK4A); INHIBITOR	The effect of p53-dependent cell-cycle arrest and senescence on E mu-myc-induced B-cell lymphoma development remains controversial. To address this question, we crossed E mu-myc mice with the p53(515C) mutant mouse, encoding the mutant p53R172P protein that retains the ability to activate the cell-cycle inhibitor and senescence activator p21. Importantly, this mutant lacks the ability to activate p53-dependent apoptotic genes. Hence, E mu-myc mice that harbor two p53(515C) alleles are completely defective for p53-dependent apoptosis. Both E mu-myc::p53(515C/515C) and E mu-myc::p53(515C/+) mice survive significantly longer than E mu-myc::p53(+/-) mice, indicating the importance of the p53-dependent non-apoptotic pathways in B-cell lymphomagenesis. In addition, the p53(515C) allele is deleted in several E mu-myc::p53(515C/+) lymphomas, further emphasizing the functionality of p53R172P in tumor inhibition. Lymphomas from both E mu-myc:: p53(515C/515C) and E mu-myc::p53(515C/+) mice retain the ability to upregulate p21, resulting in cellular senescence. Senescence-associated beta-galactosidase (SA beta-gal) activity was observed in lymphomas from E mu-myc::p53(+/+), E mu-myc::p53(515C/515C) and E mu-myc::p53(515C /+) mice but not in lymphomas isolated from E mu-myc::p53(+/-) mice. Thus, in the absence of p53-dependent apoptosis, the ability of p53R172P to induce senescence leads to a significant delay in B-cell lymphoma development. Oncogene (2010) 29, 1260-1269; doi:10.1038/onc.2009.423; published online 23 November 2009	[Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, Houston, TX 77030 USA; [Quintas-Cardama, A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Smith, C.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Eischen, C. M.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org			NCI Cancer Center [CA16672]; Ruth L Kirschstein NRSA fellowship [F32CA119616]; Dowdy P Hawn postdoctoral fellowship; NIH [CA82577]; NATIONAL CANCER INSTITUTE [F32CA119616, P30CA016672, R01CA082577] Funding Source: NIH RePORTER	NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L Kirschstein NRSA fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dowdy P Hawn postdoctoral fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tomoo Iwakuma, Arlette Audiffred and Kristina Castro for helpful discussions and technical assistance, and Dr Clifton Stephens for pathological analysis. We thank Drs Jim Jackson and Vinod Pant for review of this paper. Veterinary support and DNA sequencing core facilities were supported by NCI Cancer Center Support Grant CA16672. SMP is supported by a Ruth L Kirschstein NRSA fellowship F32CA119616 and is a recipient of the Dowdy P Hawn postdoctoral fellowship. This study was supported by NIH Grant CA82577 (to GL).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; BEENKEN SW, 1991, NUCLEIC ACIDS RES, V19, P4747, DOI 10.1093/nar/19.17.4747; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; DEIRY WS, 1993, CELL, V75, P817; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HSU B, 1995, ONCOGENE, V11, P175; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; TAHARA H, 1995, ONCOGENE, V10, P835; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	36	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1260	1269		10.1038/onc.2009.423	http://dx.doi.org/10.1038/onc.2009.423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935700	Green Accepted			2022-12-28	WOS:000275170600002
J	Oh, SM; Liu, Z; Okada, M; Jang, SW; Liu, X; Chan, CB; Luo, H; Ye, K				Oh, S-M; Liu, Z.; Okada, M.; Jang, S-W; Liu, X.; Chan, C-B; Luo, H.; Ye, K.			Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity	ONCOGENE			English	Article						Ebp1; TLS/FUS; sumoylation; cell proliferation	HUMAN MYELOID-LEUKEMIA; BINDING-PROTEIN EBP1; ONCOGENIC TRANSFORMATION; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATION; SUBCELLULAR-LOCALIZATION; CELL-PROLIFERATION; GENOMIC STRUCTURE; CHIMERIC PROTEIN	Ebp1, an ErbB3 receptor-binding protein, inhibits cell proliferation and acts as a putative tumor suppressor. Ebp1 translocates into the nucleus and functions as a transcription co-repressor for E2F-1. Here, we show that Ebp1 p42 isoform can be sumoylated on both K93 and K298 residues, which mediate its nuclear translocation and are required for its anti-proliferative activity. We find that translocation in liposarcoma (TLS)/FUS, an RNA-binding nuclear protein that is involved in pre-mRNA processing and nucleocytoplasmic shuttling, has Sumo1 E3 ligase activity for Ebp1 p42. Ebp1 directly binds TLS/FUS, which is regulated by genotoxic stress-triggered phosphorylation on Ebp1. Ebp1 sumoylation facilitates its nucleolar distribution and protein stability. Overexpression of TLS enhances Ebp1 sumoylation, whereas depletion of TLS abolishes Ebp1 sumoylation. Moreover, unsumoylated Ebp1 mutants fail to suppress E2F-1-regulated transcription, resulting in loss of its anti-proliferation activity. Hence, TLS-mediated sumoylation is required for Ebp1 transcriptional repressive activity. Oncogene (2010) 29, 1017-1030; doi:10.1038/onc.2009.411; published online 30 November 2009	[Oh, S-M; Liu, Z.; Okada, M.; Jang, S-W; Liu, X.; Chan, C-B; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Luo, H.] Harvard Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA USA; [Luo, H.] Childrens Hosp, Boston, MA 02115 USA	Emory University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, Sch Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			National Institute of Health [CA127119]; NATIONAL CANCER INSTITUTE [R01CA127119] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from the National Institute of Health (RO1, CA127119) to K Ye. We thank Dr Yang Liu at Medical Research Service (VA Puget Sound Health Care System, Seattle, WA, USA) for TLS constructs.	Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Falini B, 2007, HAEMATOLOGICA, V92, P519, DOI 10.3324/haematol.11007; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huen MS, 2008, CELL RES, V18, P8, DOI 10.1038/cr.2007.109; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Kuroda M, 1997, AM J PATHOL, V151, P735; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; Lee CD, 2008, PROTEIN SCI, V17, P1241, DOI 10.1110/ps.035188.108; Liu X, 2007, P NATL ACAD SCI USA, V104, P9679, DOI 10.1073/pnas.0701806104; Liu ZX, 2006, P NATL ACAD SCI USA, V103, P10917, DOI 10.1073/pnas.0602923103; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Morohoshi F, 1998, GENE, V221, P191, DOI 10.1016/S0378-1119(98)00463-6; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nakagawa K, 1997, J HISTOCHEM CYTOCHEM, V45, P41, DOI 10.1177/002215549704500106; Okada M, 2007, J BIOL CHEM, V282, P36744, DOI 10.1074/jbc.M706169200; PANAKHOVA KG, 1995, BIOL MEMBRANY, V12, P16; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Ron D, 1997, CURR TOP MICROBIOL, V220, P131; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Squatrito M, 2004, ONCOGENE, V23, P4454, DOI 10.1038/sj.onc.1207579; Watts FZ, 2006, DNA REPAIR, V5, P399, DOI 10.1016/j.dnarep.2005.11.002; Wei F, 2007, J BIOL CHEM, V282, P21551, DOI 10.1074/jbc.M611041200; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; Yoo JY, 2000, BRIT J CANCER, V82, P683; Yu YC, 2007, INT J CANCER, V120, P1909, DOI 10.1002/ijc.22541; Zhang YX, 2005, P NATL ACAD SCI USA, V102, P9890, DOI 10.1073/pnas.0503829102; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, ONCOGENE, V14, P451, DOI 10.1038/sj.onc.1200854; Zinszner H, 1997, J CELL SCI, V110, P1741	46	31	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1017	1030		10.1038/onc.2009.411	http://dx.doi.org/10.1038/onc.2009.411			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19946338	Green Accepted, Green Submitted			2022-12-28	WOS:000274604400008
J	Cohen, SB; Ma, W; Valova, VA; Algie, M; Harfoot, R; Woolley, AG; Robinson, PJ; Braithwaite, AW				Cohen, S. B.; Ma, W.; Valova, V. A.; Algie, M.; Harfoot, R.; Woolley, A. G.; Robinson, P. J.; Braithwaite, A. W.			Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing	ONCOGENE			English	Article						YB-1; oncoprotein; proteolysis; nuclear; translocation	BOX-BINDING-PROTEIN; MDR1 GENE-EXPRESSION; COLD SHOCK DOMAIN; P-GLYCOPROTEIN; DISEASE; CELLS; BINDING-PROTEIN-1; PROGRESSION; RESISTANCE; CISPLATIN	Y-box-binding protein 1 (YB-1) is an oncogenic transcription factor whose overexpression and nuclear localization is associated with tumor progression and drug resistance. Transcriptional activation of YB-1 in response to genotoxic stress is believed to occur in the cytoplasm through sequence-specific endoproteolytic cleavage by the 20S Proteasome, followed by nuclear translocation of cleaved YB-1. To study the proteolysis model, we developed a two-step affinity purification of endogenous YB-1 protein species and characterized the products using mass spectrometry. Whereas full-length YB-1 was readily identified, the smaller protein band thought to be activated YB-1 was identified as hnRNP A1. An antibody specific for YB-1 was generated, which revealed only one YB-1 species, even after genotoxic stress-induced nuclear YB-1 translocation. These findings warrant re-evaluation of the mechanism of YB-1 nuclear translocation and transcriptional activation. The relationship between nuclear YB-1 and tumor progression may also have to re-evaluated in some cases. Oncogene (2010) 29, 403-410; doi:10.1038/onc.2009.321; published online 19 October 2009	[Cohen, S. B.; Ma, W.; Braithwaite, A. W.] Childrens Med Res Inst, Cell Transformat Unit, Westmead, NSW 2145, Australia; [Cohen, S. B.; Robinson, P. J.; Braithwaite, A. W.] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Valova, V. A.; Robinson, P. J.] Childrens Med Res Inst, Cell Signalling Unit, Westmead, NSW 2145, Australia; [Algie, M.; Harfoot, R.; Woolley, A. G.; Braithwaite, A. W.] Univ Otago, Dunedin Sch Med, Dept Pathol, Cell Transformat Grp, Dunedin, New Zealand	Children's Medical Research Institute - Australia; University of Sydney; Children's Medical Research Institute - Australia; University of Otago	Braithwaite, AW (corresponding author), Childrens Med Res Inst, Cell Transformat Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	abraithwaite@cmri.org.au	Robinson, Phillip J/G-4008-2011	Robinson, Phillip J/0000-0002-7878-0313; Algie, Michael/0000-0002-0568-331X	National Health & Medical Research Council of Australia [423405, 477100]; Cancer Institute NSW [05/RLP/1-01]; Health Research Council of New Zealand [07/284A]; Children's Medical Research Institute Jeans-for-Genes Campaign	National Health & Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Health Research Council of New Zealand(Health Research Council of New Zealand); Children's Medical Research Institute Jeans-for-Genes Campaign	We thank Professor H-D Royer (CASEAR, Bonn, Germany) for a generous gift of the C-terminal YB-1 antibody. This research was supported by the National Health & Medical Research Council of Australia (SBC, 423405; PJP, 477100), the Cancer Institute NSW (AWB, WM, 05/RLP/1-01), the Health Research Council of New Zealand (AWB, AMW, RH, MA 07/284A) and the Children's Medical Research Institute Jeans-for-Genes Campaign (VAV).	ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Chatterjee M, 2008, BLOOD, V111, P3714, DOI 10.1182/blood-2007-05-089151; Fujita T, 2005, CLIN CANCER RES, V11, P8837, DOI 10.1158/1078-0432.CCR-05-0945; Gimenez-Bonafe P, 2004, PROSTATE, V59, P337, DOI 10.1002/pros.20023; Guay D, 2008, INT J BIOCHEM CELL B, V40, P2492, DOI 10.1016/j.biocel.2008.04.011; HORWITZ EM, 1994, J BIOL CHEM, V269, P14130; Ito Y, 2003, PATHOL INT, V53, P429, DOI 10.1046/j.1440-1827.2003.01494.x; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Lee SM, 2006, NEUROSCI LETT, V401, P188, DOI 10.1016/j.neulet.2006.03.016; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ohga T, 1996, CANCER RES, V56, P4224; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	20	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					403	410		10.1038/onc.2009.321	http://dx.doi.org/10.1038/onc.2009.321			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838214				2022-12-28	WOS:000273793200009
J	Yalcin, A; Clem, B; Makoni, S; Clem, A; Nelson, K; Thornburg, J; Siow, D; Lane, AN; Brock, SE; Goswami, U; Eaton, JW; Telang, S; Chesney, J				Yalcin, A.; Clem, B.; Makoni, S.; Clem, A.; Nelson, K.; Thornburg, J.; Siow, D.; Lane, A. N.; Brock, S. E.; Goswami, U.; Eaton, J. W.; Telang, S.; Chesney, J.			Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling	ONCOGENE			English	Article						ras; phosphatidic acid; phosphocholine	PHOSPHATIDIC-ACID; HUMAN CANCER; PHOSPHOLIPASE-D; BREAST-CANCER; LUNG-CANCER; TUMOR PROGRESSION; DRUG-RESISTANCE; RAS ACTIVATION; EGF RECEPTOR; CELL-LINES	Choline is an essential anabolic substrate for the synthesis of phospholipids. Choline kinase phosphorylates choline to phosphocholine that serves as a precursor for the production of phosphatidylcholine, the major phospholipid constituent of membranes and substrate for the synthesis of lipid signaling molecules. Nuclear magnetic resonance (NMR)-based metabolomic studies of human tumors have identified a marked increase in the intracellular concentration of phosphocholine relative to normal tissues. We postulated that the observed intracellular pooling of phosphocholine may be required to sustain the production of the pleiotropic lipid second messenger, phosphatidic acid. Phosphatidic acid is generated from the cleavage of phosphatidylcholine by phospholipase D2 and is a key activator of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT survival signaling pathways. In this study we show that the steady-state concentration of phosphocholine is increased by the ectopic expression of oncogenic H-Ras(V12) in immortalized human bronchial epithelial cells. We then find that small interfering RNA (siRNA) silencing of choline kinase expression in transformed HeLa cells completely abrogates the high concentration of phosphocholine, which in turn decreases phosphatidylcholine, phosphatidic acid and signaling through the MAPK and PI3K/AKT pathways. This simultaneous reduction in survival signaling markedly decreases the anchorage-independent survival of HeLa cells in soft agar and in athymic mice. Last, we confirm the relative importance of phosphatidic acid for this pro-survival effect as phosphatidic acid supplementation fully restores MAPK signaling and partially rescues HeLa cells from choline kinase inhibition. Taken together, these data indicate that the pooling of phosphocholine in cancer cells may be required to provide a ready supply of phosphatidic acid necessary for the feed-forward amplification of cancer survival signaling pathways.	[Yalcin, A.; Clem, B.; Makoni, S.; Clem, A.; Nelson, K.; Thornburg, J.; Siow, D.; Lane, A. N.; Brock, S. E.; Goswami, U.; Eaton, J. W.; Telang, S.; Chesney, J.] Univ Louisville, Dept Biochem & Mol Biol, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA; [Yalcin, A.] Uludag Univ, Dept Biochem, Sch Vet Med, Bursa, Turkey	University of Louisville; Uludag University	Chesney, J (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, James Graham Brown Canc Ctr, Mol Targets Program, 580 S Preston St,204E, Louisville, KY 40202 USA.	jaches03@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; 	James Graham Brown Cancer Center; NIH [1 R01 CA11642801]; Kentucky Lung Cancer Research Program	James Graham Brown Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kentucky Lung Cancer Research Program	We gratefully acknowledge helpful discussions with Drs Binks Wattenberg, Mary Roth and Otto Grubraw. This work was supported by the James Graham Brown Cancer Center and by the following grants: NIH 1 R01 CA11642801 (JC) and the Kentucky Lung Cancer Research Program (JC).	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264-6021:3630777; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; BOS JL, 1989, CANCER RES, V49, P4682; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031; DEGANI H, 1986, RADIOLOGY, V161, P53, DOI 10.1148/radiology.161.1.3020609; Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; Glunde K, 2006, EXPERT REV MOL DIAGN, V6, P821, DOI 10.1586/14737159.6.6.821; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Ihle NT, 2009, MOL CANCER THER, V8, P1, DOI 10.1158/1535-7163.MCT-08-0801; Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Li GP, 1997, J BIOL CHEM, V272, P10337; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Martinelli Giovanni, 2008, Clin Adv Hematol Oncol, V6, P303; Mazie AR, 2006, J CELL SCI, V119, P1645, DOI 10.1242/jcs.02858; McCubrey JA, 2007, ADV ENZYME REGUL, V47, P64, DOI 10.1016/j.advenzreg.2006.12.013; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Omerovic J, 2008, ONCOGENE, V27, P2754, DOI 10.1038/sj.onc.1210925; ONODERA K, 1986, JPN J CANCER RES, V77, P1201; Pal SK, 2008, CLIN LUNG CANCER, V9, P340, DOI 10.3816/CLC.2008.n.049; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	57	78	86	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					139	149		10.1038/onc.2009.317	http://dx.doi.org/10.1038/onc.2009.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19855431				2022-12-28	WOS:000273373500013
J	Mullenders, J; Bernards, R				Mullenders, J.; Bernards, R.			Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer	ONCOGENE			English	Review						RNAi screen; biomarkers of drug response; cancer therapy	WIDE RNAI SCREEN; PHASE-I; TUMOR SUPPRESSORS; TYROSINE KINASE; SIRNA SCREEN; IDENTIFICATION; INTERFERENCE; PACLITAXEL; CELLS; COMPONENTS	A major impediment to the effective treatment of cancer is the molecular heterogeneity of the disease, which is also reflected in an equally diverse pattern of clinical responses to therapy. Currently, only few drugs are available that can be used safely and effectively to treat cancer. To improve this situation, the development of novel and highly specific targets for therapy is of utmost importance. Possibly even more importantly, we need better tools to predict which patients will respond to specific therapies. Such drug response biomarkers will be instrumental to individualize the therapy of patients having seemingly similar cancers. In this study, we discuss how RNA interference-based genetic screens can be used to address these two pressing needs in the care for cancer patients. Oncogene (2009) 28, 4409-4420; doi:10.1038/onc.2009.295; published online 21 September 2009	[Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Mullenders, Jasper/J-2398-2015	Mullenders, Jasper/0000-0003-3737-6901; Bernards, Rene/0000-0001-8677-3423				Abbas-Terki T, 2002, HUM GENE THER, V13, P2197, DOI 10.1089/104303402320987888; Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bjorklund M, 2006, NATURE, V439, P1009, DOI 10.1038/nature04469; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buchholz F, 2006, NAT METHODS, V3, P696, DOI 10.1038/NMETH912; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Cresta S, 2008, EUR J CANCER, V44, P1829, DOI 10.1016/j.ejca.2008.05.022; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Echeverri CJ, 2006, NAT METHODS, V3, P777, DOI 10.1038/nmeth1006-777; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Gobeil S, 2008, GENE DEV, V22, P2932, DOI 10.1101/gad.1714608; Goff SP, 2008, CELL, V135, P417, DOI 10.1016/j.cell.2008.10.007; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jatoi A, 2008, J THORAC ONCOL, V3, P516, DOI 10.1097/JTO.0b013e31816de276; Ji D, 2007, ONCOL REP, V18, P1499; Jones TR, 2009, P NATL ACAD SCI USA, V106, P1826, DOI 10.1073/pnas.0808843106; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Kittler R, 2007, NAT CELL BIOL, V9, P1401, DOI 10.1038/ncb1659; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Li LM, 2007, RNA, V13, P1765, DOI 10.1261/rna.599107; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma C, 2007, CANCER CHEMOTH PHARM, V59, P207, DOI 10.1007/s00280-006-0259-9; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Moffat J, 2006, NAT REV MOL CELL BIO, V7, P177, DOI 10.1038/nrm1860; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547; Mukherji M, 2006, P NATL ACAD SCI USA, V103, P14819, DOI 10.1073/pnas.0604320103; Neumann B, 2006, NAT METHODS, V3, P385, DOI 10.1038/NMETH876; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Oosterkamp HM, 2006, BRIT J DERMATOL, V155, P182, DOI 10.1111/j.1365-2133.2006.07224.x; Pan XW, 2006, CELL, V124, P1069, DOI 10.1016/j.cell.2005.12.036; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Pepperkok R, 2006, NAT REV MOL CELL BIO, V7, P690, DOI 10.1038/nrm1979; Rines DR, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r44; Rines DR, 2006, METHOD ENZYMOL, V414, P530, DOI 10.1016/S0076-6879(06)14028-8; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rottmann S, 2005, P NATL ACAD SCI USA, V102, P15195, DOI 10.1073/pnas.0505114102; Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560; Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946; Savage P, 2009, NAT CLIN PRACT ONCOL, V6, P43, DOI 10.1038/ncponc1260; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wheeler DB, 2005, NAT GENET, V37, pS25, DOI 10.1038/ng1560; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061	89	60	62	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4409	4420		10.1038/onc.2009.295	http://dx.doi.org/10.1038/onc.2009.295			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767776				2022-12-28	WOS:000272876500001
J	Kaulfuss, S; von Hardenberg, S; Schweyer, S; Herr, AM; Laccone, F; Wolf, S; Burfeind, P				Kaulfuss, S.; von Hardenberg, S.; Schweyer, S.; Herr, A. M.; Laccone, F.; Wolf, S.; Burfeind, P.			Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression	ONCOGENE			English	Article						leupaxin; prostate cancer progression; p120CTN-mediated pathways	CELL-ADHESION PROTEINS; BETA-CATENIN; E-CADHERIN; MATRIX METALLOPROTEINASE-7; ANDROGEN RECEPTOR; FOCAL ADHESIONS; DOWN-REGULATION; ALPHA-CATENIN; LIM PROTEIN; CANCER	Recently, we could show that the focal adhesion protein leupaxin (LPXN) is expressed in human prostate carcinomas (PCa) and induces invasiveness of androgen-independent PCa cells. In this study we show that LPXN enhanced the progression of existing PCa in vivo by breeding transgenic mice with prostate-specific LPXN expression and TRAMP mice (transgenic adenocarcinoma of mouse prostate). Double transgenic LPXN/TRAMP mice showed a significant increase in poorly differentiated PCa and distant metastases as compared with control TRAMP mice. Additional studies on primary PCa cells generated from both transgenic backgrounds confirmed the connection regarding LPXN overexpression and increased motility and invasiveness of PCa cells. One mediator of LPXN-induced invasion was found to be the cell-cell adhesion protein p120catenin (p120CTN). Both in vitro and in vivo experiments revealed that p120CTN expression negatively correlates with LPXN expression, followed by a redistribution of beta-catenin. Downregulation of LPXN using small interfering RNAs (siRNAs) resulted in a membranous localization of beta-catenin, whereas strong nuclear accumulation of beta-catenin was observed in p120CTN knockdown cells leading to enhanced transcription of the beta-catenin target gene matrix metalloprotease-7. In conclusion, the present results indicate that LPXN enhances the progression of PCa through downregulation of p120CTN expression and that LPXN could function as a marker for aggressive PCa in the future. Oncogene (2009) 28, 3971-3982; doi:10.1038/onc.2009.254; published online 24 August 2009	[Kaulfuss, S.; von Hardenberg, S.; Herr, A. M.; Wolf, S.; Burfeind, P.] Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Niedersachsen, Germany; [Schweyer, S.] Univ Gottingen, Dept Pathol, D-37073 Gottingen, Niedersachsen, Germany; [Laccone, F.] Med Univ Vienna, Dept Med Genet, Vienna, Austria	University of Gottingen; University of Gottingen; Medical University of Vienna	Kaulfuss, S (corresponding author), Univ Gottingen, Inst Human Genet, Heinrich Duker Weg 12, D-37073 Gottingen, Niedersachsen, Germany.	svoigt1@gwdg.de	Laccone, Franco A/B-3655-2018	Kaulfuss, Silke/0000-0003-2577-9711	Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen; Deutsche Forschungsgemeinschaft [SK KA 2946/1-1]; Deutsche Krebshilfe [108065]; Horst Muggenburg and Gerhard Muggenburg-Stiftung	Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Horst Muggenburg and Gerhard Muggenburg-Stiftung	We thank R Kampe, B Konig and A Klages for their excellent technical assistance. We also thank M Schindler and H Riedesel for their assistance in generation of transgenic LPXN mice. This project was supported in part by the Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen (to SK), by the Deutsche Forschungsgemeinschaft (to SK KA 2946/1-1), the Deutsche Krebshilfe (to PB and SS, no. 108065) and the Horst Muggenburg and Gerhard Muggenburg-Stiftung (to PB and SS).	ANASTASIADIS PZ, 2006, BIOCHIM BIOPHYS ACTA, V1773, P34; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bidard FC, 2008, CANCER METAST REV, V27, P5, DOI 10.1007/s10555-007-9103-x; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Deakin NO, 2009, J CELL SCI, V122, P1654, DOI 10.1242/jcs.049130; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fuchs SY, 2005, CELL CYCLE, V4, P1522; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Ii M, 2006, EXP BIOL MED, V231, P20; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Jaggi M, 2005, UROL ONCOL-SEMIN ORI, V23, P402, DOI 10.1016/j.urolonc.2005.03.024; Jones LE, 2004, CLIN CANCER RES, V10, P2832, DOI 10.1158/1078-0432.CCR-1157-03; Kallakury BVS, 2001, CANCER, V92, P2786, DOI 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I; Kallakury BVS, 2001, HUM PATHOL, V32, P849, DOI 10.1053/hupa.2001.26463; Kasai M, 2003, CANCER RES, V63, P4927; Kaulfuss S, 2008, MOL ENDOCRINOL, V22, P1606, DOI 10.1210/me.2006-0546; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Millikan RE, 2008, J CLIN ONCOL, V26, P5936, DOI 10.1200/JCO.2007.15.9830; Nong CZ, 2006, WORLD J GASTROENTERO, V12, P1187, DOI 10.3748/wjg.v12.i8.1187; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC581, DOI 10.1152/ajpcell.00636.2005; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; van Oort IM, 2007, PROSTATE, V67, P1432, DOI 10.1002/pros.20626; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wegener KL, 2008, MOL MEMBR BIOL, V25, P376, DOI 10.1080/09687680802269886; Whitaker HC, 2008, PROSTATE, V68, P1196, DOI 10.1002/pros.20780; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007	47	7	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3971	3982		10.1038/onc.2009.254	http://dx.doi.org/10.1038/onc.2009.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19701244				2022-12-28	WOS:000272560300003
J	Enomoto, M; Hayakawa, S; Itsukushima, S; Ren, DY; Matsuo, M; Tamada, K; Oneyama, C; Okada, M; Takumi, T; Nishita, M; Minami, Y				Enomoto, M.; Hayakawa, S.; Itsukushima, S.; Ren, D. Y.; Matsuo, M.; Tamada, K.; Oneyama, C.; Okada, M.; Takumi, T.; Nishita, M.; Minami, Y.			Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling	ONCOGENE			English	Article						Wnt5a; Ror2; MMP-13; invadopodia; osteosarcoma	RECEPTOR TYROSINE KINASE; BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; TUMOR-SUPPRESSOR; INVASION; WNT-5A; ROR2; EXPRESSION; PATHWAY; CANCER	The receptor tyrosine kinase Ror2 regulates cell migration by acting as a receptor or co-receptor for Wnt5a. Although Wnt5a has been implicated in the invasiveness of several types of tumors, the role of Ror2 in tumor invasion remains elusive. Here we show that osteosarcoma cell lines SaOS-2 and U2OS show invasive properties in vitro by activating Wnt5a/Ror2 signaling in a cell-autonomous manner. The suppressed expression of either Wnt5a or Ror2 in osteosarcoma cells inhibits cell invasiveness accompanying decreased invadopodia formation. Gene-expression pro. ling identified matrix metalloproteinase 13 (MMP-13) as one of the genes whose expression is downregulated in SaOS-2 cells following suppression of Ror2 expression. Reduced expression or activity of MMP-13 suppresses invasiveness of SaOS-2 cells. Moreover, expression of MMP-13 and cell invasiveness by Wnt5a/Ror2 signaling can be abrogated by an inhibitor of the Src-family protein tyrosine kinases (SFKs), suggesting the role of the SFKs in MMP-13 expression through Wnt5a/Ror2 signaling. We further show that activation of an SFK is inhibited by the suppressed expression of Ror2. Collectively, these results indicate that Wnt5a/Ror2 signaling involves the activation of a SFK, leading to MMP-13 expression, and that constitutively active Wnt5a/Ror2 signaling confers invasive properties on osteosarcoma cells in a cell-autonomous manner. Oncogene (2009) 28, 3197-3208; doi: 10.1038/onc.2009.175; published online 29 June 2009	[Nishita, M.] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Chuo Ku, Kobe, Hyogo 6500017, Japan; [Enomoto, M.; Matsuo, M.] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Tamada, K.; Takumi, T.] Osaka Biosci Inst, Osaka, Japan; [Oneyama, C.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, Osaka, Japan	Kobe University; Kobe University; Osaka University	Nishita, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nishita@med.kobe-u.ac.jp; minami@kobe-u.ac.jp			a Grant-in-Aid for Scientific Research in Priority Areas (YM); a Grant-in-Aid for Scientific Research (B) (YM); a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM),; Ministry of Education, Culture, Sports, Science, and Technology, Japan; Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN)	a Grant-in-Aid for Scientific Research in Priority Areas (YM)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); a Grant-in-Aid for Scientific Research (B) (YM)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM),(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN)	We thank M Endo for critical reading of the paper. We also thank K Mizuno for pEYFP-Actin. This work was supported by a Grant-in-Aid for Scientific Research in Priority Areas (YM), a Grant-in-Aid for Scientific Research (B) (YM), a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM), a Grant-in-Aid for Young Scientists (B) (MN) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, a Grant from Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN).	Akbarzadeh S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001873; Albini A, 1998, Pathol Oncol Res, V4, P230; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Cortesio CL, 2008, J CELL BIOL, V180, P957, DOI 10.1083/jcb.200708048; Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6; Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999-008-0344-y; He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; IOZZO RV, 1995, CANCER RES, V55, P3495; Kani S, 2004, J BIOL CHEM, V279, P50102, DOI 10.1074/jbc.M409039200; Kodama A, 2004, J CELL BIOL, V167, P203, DOI 10.1083/jcb.200408047; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; Nomachi A, 2008, J BIOL CHEM, V283, P27973, DOI 10.1074/jbc.M802325200; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto S, 2008, DEV CELL, V15, P23, DOI 10.1016/j.devcel.2008.05.007	34	133	140	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3197	3208		10.1038/onc.2009.175	http://dx.doi.org/10.1038/onc.2009.175			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561643	Bronze			2022-12-28	WOS:000269673400003
J	Izumi, H; Matsumoto, Y; Ikeuchi, T; Saya, H; Kajii, T; Matsuura, S				Izumi, H.; Matsumoto, Y.; Ikeuchi, T.; Saya, H.; Kajii, T.; Matsuura, S.			BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells	ONCOGENE			English	Article						centrosome; BubR1; Plk1; chromosome instability syndrome	MOSAIC VARIEGATED ANEUPLOIDY; PREMATURE CHROMATID SEPARATION; POLO-LIKE KINASE-1; MITOTIC-SPINDLE CHECKPOINT; CENTROMERE DIVISION PCD; AURORA-A; CANCER; MUTATIONS; OVEREXPRESSION; PROGRESSION	BubR1 is a critical component of the mitotic checkpoint that delays the onset of anaphase until all chromosomes have established bipolar attachment to the microtubules. We previously reported that mutations of the BUB1B gene ( encoding BubR1) caused premature chromatid separation (PCS) syndrome, a condition characterized by constitutional aneuploidy and a high risk of childhood cancer. We here report that the cells from PCS syndrome patients have loss of regulation of the centrosome duplication machinery, resulting in centrosome amplification and multipolar mitosis. PCS syndrome cells show increased activity of Polo-like kinase 1 (Plk1), whose knockdown suppresses centrosome amplification. BubR1 localizes to centrosomes, physically interacts with Plk1 and inhibits Plk1 phosphorylation and its kinase activity during interphase. These results unravel a crucial role of BubR1 in preventing centrosome reduplication through negative regulation of Plk1 in interphase cells. Oncogene (2009) 28, 2806-2820; doi:10.1038/onc.2009.141; published online 8 June 2009	[Matsuura, S.] Hiroshima Univ, RIRBM, Dept Radiat Biol, Minami Ku, Hiroshima 7348553, Japan; [Ikeuchi, T.] Tokyo Med & Dent Univ, Med Res Inst, Div Mol Cytogenet, Tokyo, Japan; [Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Tokyo, Japan; [Kajii, T.] Hachioji, Tokyo, Japan	Hiroshima University; Tokyo Medical & Dental University (TMDU); Keio University	Matsuura, S (corresponding author), Hiroshima Univ, RIRBM, Dept Radiat Biol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348553, Japan.	shinya@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013; Matsuura, Shinya/U-4182-2017	Matsuura, Shinya/0000-0001-5294-081X; Saya, Hideyuki/0000-0001-6610-1902	Analysis Center of Life Science, Hiroshima University; Japanese Ministry of Education, Science, Sports and Culture; MEXT priority research projects; Haraguchi Memorial Cancer Grant Foundation	Analysis Center of Life Science, Hiroshima University; Japanese Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT priority research projects; Haraguchi Memorial Cancer Grant Foundation	We are grateful to Dr S Tanaka for providing anti- pericentrin antibody and Dr M Ohsugi for providing Flag- Plk1 plasmids. We are also grateful to Dr Y Yamamoto and Dr N Watanabe for technical advice. We thank H Ikeda and H Hatakeyama for technical assistance, and T Jo and A Kamesako for secretarial assistance. We also thank our laboratory members for their continuous encouragement. This work was partly carried out at the Analysis Center of Life Science, Hiroshima University. This work was supported by Grants- in- Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture ( to HI and to SM), MEXT priority research projects ( to HI and to SM) and the Haraguchi Memorial Cancer Grant Foundation ( to HI).	Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bornens M, 1999, METHOD CELL BIOL, V61, P13; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Jacquemont S, 2002, AM J MED GENET, V109, P17, DOI 10.1002/ajmg.10281; Kajii T, 1998, AM J MED GENET, V78, P245, DOI 10.1002/(SICI)1096-8628(19980707)78:3<245::AID-AJMG7>3.0.CO;2-O; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Kawame H, 1999, J HUM GENET, V44, P219, DOI 10.1007/s100380050147; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Loncarek J, 2008, NAT CELL BIOL, V10, P322, DOI 10.1038/ncb1694; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Matsumura S, 2007, J BIOL CHEM, V282, P15217, DOI 10.1074/jbc.M611053200; Matsuura S, 2000, AM J HUM GENET, V67, P483, DOI 10.1086/303022; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Plaja A, 2001, AM J MED GENET, V98, P216, DOI 10.1002/1096-8628(20010122)98:3<216::AID-AJMG1091>3.0.CO;2-0; Rieder CL, 2003, SCIENCE, V300, P91, DOI 10.1126/science.1082177; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	37	36	38	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2806	2820		10.1038/onc.2009.141	http://dx.doi.org/10.1038/onc.2009.141			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503101				2022-12-28	WOS:000268684400004
J	Grover, R; Candeias, MM; Fahraeus, R; Das, S				Grover, R.; Candeias, M. M.; Fahraeus, R.; Das, S.			p53 and little brother p53/47: linking IRES activities with protein functions	ONCOGENE			English	Article						p53; p53/47; IRES; translational control	TRACT BINDING-PROTEIN; RIBOSOME ENTRY SEGMENT; MESSENGER-RNA TRANSLATION; WILD-TYPE P53; SV40-TRANSFORMED CELLS; MEDIATED TRANSLATION; GENE-EXPRESSION; FEEDBACK LOOP; DNA-DAMAGE; ISOFORMS	The tumor suppressor p53 represents a paradigm for gene regulation. Its rapid induction in response to DNA damage conditions has been attributed to both increased half-life of p53 protein and also increased translation of p53 mRNA. Recent advances in our understanding of the post-transcriptional regulation of p53 include the discovery of internal ribosome entry sites (IRESs) within the p53 mRNA. These IRES elements regulate the translation of the full length as well as the N-terminally truncated isoform, p53/47. The p53/47 isoform is generated by alternative initiation at an internal AUG codon present within the p53 ORF. The aim of this review is to summarize the role of translational control mechanisms in regulating p53 functions. We discuss here in detail how diverse cellular stress pathways trigger alterations in the cap-dependent and cap-independent translation of p53 mRNA and how changes in the relative expression levels of p53 isoforms result in more differentiated p53 activity. Oncogene (2009) 28, 2766-2772; doi:10.1038/onc.2009.138; published online 1 June 2009	[Grover, R.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; [Candeias, M. M.; Fahraeus, R.] Hop St Louis, INSERM, Inst Genet Mol, U716, Paris, France; [Candeias, M. M.; Fahraeus, R.] Univ Paris 07, Paris, France	Indian Institute of Science (IISC) - Bangalore; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Das, S (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Sir CV Raman Ave, Bangalore 560012, Karnataka, India.	sdas@mcbl.iisc.ernet.in	fahraeus, robin/K-8726-2014		Council of Scientific and Industrial Research, India	Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	This study is supported by a research grant from the Indo-French (IFCPAR) to SD and RF. RG is supported by predoctoral fellowship from Council of Scientific and Industrial Research, India.	Anensen NA, 2006, LEUKEMIA, V20, P734, DOI 10.1038/sj.leu.2404117; Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldschneider D, 2006, NUCLEIC ACIDS RES, V34, P5603, DOI 10.1093/nar/gkl619; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Halaby MJ, 2007, GENE, V395, P1, DOI 10.1016/j.gene.2007.01.029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hrstka R, 2008, ANTI-CANCER DRUG, V19, P369, DOI 10.1097/CAD.0b013e3282f7f500; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Perry ME, 2004, MOL CANCER RES, V2, P9; Pfingsten JS, 2007, J MOL BIOL, V370, P856, DOI 10.1016/j.jmb.2007.04.076; Pickering BM, 2004, MOL CELL BIOL, V24, P5595, DOI 10.1128/MCB.24.12.5595-5605.2004; Pickering BM, 2003, NUCLEIC ACIDS RES, V31, P639, DOI 10.1093/nar/gkg146; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Scrable H, 2005, INT J BIOCHEM CELL B, V37, P913, DOI 10.1016/j.biocel.2004.11.014; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	54	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2766	2772		10.1038/onc.2009.138	http://dx.doi.org/10.1038/onc.2009.138			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483723				2022-12-28	WOS:000268452900007
J	Zhang, X; Zhu, Y; Geng, L; Wang, H; Legerski, RJ				Zhang, X.; Zhu, Y.; Geng, L.; Wang, H.; Legerski, R. J.			Artemis is a negative regulator of p53 in response to oxidative stress	ONCOGENE			English	Article						Artemis; p53; DNA-PKcs; oxidative stress	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; DNA-DAMAGE; V(D)J RECOMBINATION; TUMOR-SUPPRESSOR; CELL-DEATH; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; MITOCHONDRIA	Artemis is a multifunctional phospho-protein with roles in V(D)J recombination, repair of double-strand breaks by nonhomologous end-joining and regulation of cell-cycle checkpoints after DNA damage. Here, we describe a new function of Artemis as a negative regulator of p53 in response to oxidative stress in both primary cells and cancer cell lines. We show that depletion of Artemis under typical culture conditions (21% oxygen) leads to a spontaneous phosphorylation and stabilization of p53, and resulting cellular G1 arrest and apoptosis. These effects are suppressed by co-depletion of DNA-PKcs, but not ATM, indicating that Artemis is an inhibitor of DNA-PKcs-mediated stabilization of p53. Culturing of cellsat 3% oxygen or treatment with an antioxidant abrogated p53 stabilization, indicating that oxidative stress is the responsible cellular stimulus. Treatment with ionizing radiation or hydrogen peroxide did not cause activation of this signaling pathway, whereas inhibitors of mitochondrial electron transport were effective in reducing its activation. In addition, we show that p53-inducible genes involved in reducing reactive oxygen species are upregulated by Artemis depletion. These findings indicate that Artemis and DNA-PKcs participate in a new, signaling pathway to modulate p53 function in response to oxidative stress produced by mitochondrial respiration. Oncogene (2009) 28, 2196-2204; doi: 10.1038/onc.2009.100; published online 27 April 2009	[Zhang, X.; Zhu, Y.; Geng, L.; Wang, H.; Legerski, R. J.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org			National Cancer Institute [CA096574]; NATIONAL CANCER INSTITUTE [R01CA096574, P01CA097175] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank G Lozano for helpful discussions of the paper. This work was supported by National Cancer Institute grant CA096574 (RJL).	Anwar A, 2003, J BIOL CHEM, V278, P10368, DOI 10.1074/jbc.M211981200; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chen L, 2005, CANCER SCI, V96, P134, DOI 10.1111/j.1349-7006.2005.00019.x; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; Kondoh H, 2005, CANCER RES, V65, P177; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; MONTES DOL, 1995, NATURE, V378, P203; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Poinsignon C, 2004, EUR J IMMUNOL, V34, P3146, DOI 10.1002/eji.200425455; Punj V, 2003, CELL MICROBIOL, V5, P225, DOI 10.1046/j.1462-5822.2003.00269.x; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sohn D, 2006, CANCER RES, V66, P11254, DOI 10.1158/0008-5472.CAN-06-1569; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Tian H, 2000, CANCER RES, V60, P679; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004	39	18	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2196	2204		10.1038/onc.2009.100	http://dx.doi.org/10.1038/onc.2009.100			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398950	Green Accepted			2022-12-28	WOS:000266640300002
J	Akiri, G; Cherian, MM; Vijayakumar, S; Liu, G; Bafico, A; Aaronson, SA				Akiri, G.; Cherian, M. M.; Vijayakumar, S.; Liu, G.; Bafico, A.; Aaronson, S. A.			Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma	ONCOGENE			English	Article						autocrine; lung cancer; wnt	HUMAN CANCER-CELLS; BETA-CATENIN; SIGNALING PATHWAY; STEM-CELLS; EPITHELIAL-CELLS; MUTATIONS; ADENOCARCINOMA; IDENTIFICATION; APC; DIFFERENTIATION	Lung cancer is the most common cause of cancer mortality worldwide. Non-small-cell lung carcinomas (NSCLCs), which represent around 80% of lung tumors, exhibit poor prognosis and are usually refractory to conventional chemotherapy. Elucidating the molecular and cellular mechanisms that are dysregulated in NSCLCs may lead to new possibilities for targeted therapy or enhanced efficacy of current therapies. Here we demonstrate Wnt pathway activation in around 50% of human NSCLC cell lines and primary tumors, through different mechanisms, including autocrine Wnt pathway activation involving upregulation of specific Wnt ligands. Downregulation of activated Wnt signaling inhibited NSCLC proliferation and induced a more differentiated phenotype. Together, our findings establish importance of activated Wnt signaling in human NSCLCs and offer the possibility of targeting upregulated Wnt signaling as a new therapeutic modality for this disease. Oncogene (2009) 28, 2163-2172; doi: 10.1038/onc.2009.82; published online 20 April 2009	[Akiri, G.; Cherian, M. M.; Vijayakumar, S.; Liu, G.; Bafico, A.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu			National Cancer Institute [5R01CA071672]; New York State Department of Health and American Urological Association; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); New York State Department of Health and American Urological Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant number 5R01CA071672 from the National Cancer Institute. SV is supported by consecutive post-doctoral fellowships from New York State Department of Health and American Urological Association. We are grateful to Dr J Minna and Dr A Gazdar (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing us with some NSCLC cell lines. We thank Dr Stefano Rivella (Weill Medical College of Cornell University, New York, NY, USA) for the generous gift of the lentiviral vector, pRRL-SIN-cPPT-PGK-GFP. We also thank Dr Robert Hannigan (Mount Sinai School of Medicine, New York, NY, USA) and Professor Roger Tsien (Howard Hughes Medical Institute, University of California, San Diego, CA, USA) for kindly providing us with the cDNA encoding mOrange. We especially thank Randy Arroyave for excellent technical assistance and Martina Kracikova and Ioana Rus for critical reading of this paper.	Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bernasconi NL, 2000, AM J RESP CELL MOL, V23, P560, DOI 10.1165/ajrcmb.23.4.4233; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GUZMAN J, 1994, EUR RESPIR J, V7, P736, DOI 10.1183/09031936.94.07040736; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Nakamura N, 2006, ONCOGENE, V25, P4245, DOI 10.1038/sj.onc.1209442; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds SD, 2008, STEM CELLS, V26, P1337, DOI 10.1634/stemcells.2008-0053; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; SCHILLER JH, 1992, IN VITRO CELL DEV-AN, V28A, P461; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; VENEMBRE P, 1994, FEBS LETT, V346, P171, DOI 10.1016/0014-5793(94)80695-0; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	33	112	133	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2163	2172		10.1038/onc.2009.82	http://dx.doi.org/10.1038/onc.2009.82			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19377513	Green Accepted			2022-12-28	WOS:000266451300005
J	Tanaka, K; Okamoto, S; Ishikawa, Y; Tamura, H; Hara, T				Tanaka, K.; Okamoto, S.; Ishikawa, Y.; Tamura, H.; Hara, T.			DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes	ONCOGENE			English	Article						DDX1; germ cell tumor; testis; cyclin-D2	MESSENGER-RNA EXPRESSION; DEAD-BOX PROTEINS; CD9 EXPRESSION; CYCLIN D2; TUMORS; PROLIFERATION; NEUROBLASTOMA; TESTIS; MOUSE; DIFFERENTIATION	Cytogenetic analysis has identified 12p gain as the most frequent abnormality in human testicular germ cell tumors (TGCTs). It has been suggested that amplification and overexpression of stem cell-associated genes, including cyclin-D2, on the human chromosome 12p region are involved in germ cell tumorigenesis. By subtractive cDNA analysis, we identified Ddx1, a member of the DEAD-box protein family, as a gene predominantly expressed in the primordial germ cells of mouse embryos. Knockdown of Ddx1 in a mouse spermatogonia-derived cell line, GC-1spg, by short interference RNA repressed the expression of cyclin-D2, CD9 and GDF3 genes. In the mouse cyclin-D2 gene, a genomic DNA region between -348 and -329 was responsible for transcriptional activation by DDX1 based on reporter and gel shift assays. Similarly, DDX1 knockdown in the human TGCT cell line NEC8 repressed the expression of stem cell-associated genes localized on chromosome 12p13.3, including cyclin-D2, CD9 and NANOG. DDX1-knocked-down TGCT cells could not form solid tumors in nude mice. Furthermore, in situ hybridization revealed that DDX1 mRNA was produced in both seminoma and nonseminoma types of human TGCT samples. We conclude that DDX1 is a critical factor for testicular tumorigenesis. Oncogene (2009) 28, 2142-2151; doi: 10.1038/onc.2009.89; published online 27 April 2009	[Hara, T.] Tokyo Metropolitan Org Med Res, Stem Cell Project Grp, Tokyo Metropolitan Inst Med Sci, Setagaya Ku, Tokyo 1568506, Japan; [Ishikawa, Y.] Tokyo Metropolitan Org Med Res, Core Technol & Res Ctr, Tokyo Metropolitan Inst Med Sci, Tokyo 1568506, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Hara, T (corresponding author), Tokyo Metropolitan Org Med Res, Stem Cell Project Grp, Tokyo Metropolitan Inst Med Sci, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	tanaka-ky@igakuken.or.jp; hara-tk@igakuken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527	Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Y Futamata (Nippon Becton Dickinson) for help in the cell sorting experiments. We extend our thanks to all laboratory members for their technical assistance and valuable advice. The anti-SSEA-1 antibody (MC-480) developed by Dr D Solter and Dr BB Knowles was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and was maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	ATKIN NB, 1982, LANCET, V2, P1349; Beumer TL, 2000, BIOL REPROD, V63, P1893, DOI 10.1095/biolreprod63.6.1893; Biermann Katharina, 2007, Cancer Genomics & Proteomics, V4, P359; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chaganti RSK, 1998, APMIS, V106, P80, DOI 10.1111/j.1699-0463.1998.tb01322.x; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; Fujino RS, 2006, MOL ENDOCRINOL, V20, P904, DOI 10.1210/me.2005-0423; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Hori H, 2004, J SURG RES, V117, P208, DOI 10.1016/j.jss.2004.01.014; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Kanatsu-Shinohara M, 2004, BIOL REPROD, V70, P70, DOI 10.1095/biolreprod.103.020867; Kawashima M, 2002, J HISTOCHEM CYTOCHEM, V50, P1195, DOI 10.1177/002215540205000906; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOTOYAMA T, 1987, ACTA PATHOL JAPON, V37, P431; Nakayama H, 1996, DEV GROWTH DIFFER, V38, P141, DOI 10.1046/j.1440-169X.1996.t01-1-00003.x; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; RODRIGUEZ E, 1992, GENE CHROMOSOME CANC, V5, P21, DOI 10.1002/gcc.2870050104; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Sunden Y, 2007, MICROBIOL IMMUNOL, V51, P339, DOI 10.1111/j.1348-0421.2007.tb03907.x; Tanaka K, 2002, DEV BIOL, V246, P466, DOI 10.1006/dbio.2002.0671; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192	37	38	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2142	2151		10.1038/onc.2009.89	http://dx.doi.org/10.1038/onc.2009.89			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398953				2022-12-28	WOS:000266451300003
J	Chen, LC; Liu, HP; Li, HP; Hsueh, C; Yu, JS; Liang, CL; Chang, YS				Chen, L-C; Liu, H-P; Li, H-P; Hsueh, C.; Yu, J-S; Liang, C-L; Chang, Y-S			Thymidine phosphorylase mRNA stability and protein levels are increased through ERK-mediated cytoplasmic accumulation of hnRNP K in nasopharyngeal carcinoma cells	ONCOGENE			English	Article						hnRNP K; thymidine phosphorylase; ERK signaling; nasopharyngeal carcinoma	NUCLEAR RIBONUCLEOPROTEIN-K; HYPOXIA-INDUCED APOPTOSIS; ENDOTHELIAL GROWTH-FACTOR; BINDING-PROTEIN; IN-VITRO; TRANSLATION; EXPRESSION; CANCER; METASTASIS; ACTIVATION	The cytoplasmic level of heterogeneous nuclear ribonucleoprotein K (hnRNP K) is significantly correlated with the elevated expression of thymidine phosphorylase (TP), and high levels of both proteins are predictive of a poor prognosis in nasopharyngeal carcinoma (NPC). We herein show that TP is highly induced by serum deprivation in NPC cells, and that this is due to an increase in the half-life of the TP mRNA, as shown by nuclear run-on and actinomycin D assays. We further show that the CU-rich element of the TP mRNA directly interacts with hnRNP K, as demonstrated by immunoprecipitation RT-PCR assays, and the nucleus-to-cytoplasm translocation of hnRNP K. Blockade of hnRNP K expression reduces TP expression, suggesting that hnRNP K acts in the upregulation of TP. Mechanistically, both MEK inhibitor and the hnRNP K ERK-phosphoacceptor-site mutant decrease cytoplasmic accumulation of hnRNP K, suggesting that ERK-dependent phosphorylation is critical for TP induction. Furthermore, we found that hnRNP K-mediated TP induction allows NPC cells to resist hypoxia-induced apoptosis. Our results collectively establish the regulation and role of ERK-mediated cytoplasmic accumulation of hnRNP K as an upstream modulator of TP, suggesting that hnRNP K may be an attractive candidate as a future therapeutic target for cancer.	[Chen, L-C; Liu, H-P; Hsueh, C.; Yu, J-S; Chang, Y-S] Chang Gung Univ, Chang Gung Mol Med Res Ctr, Tao Yuan 333, Taiwan; [Li, H-P; Yu, J-S; Chang, Y-S] Chang Gung Univ, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan; [Hsueh, C.] Chang Gung Mem Hosp Lin Kou, Dept Pathol, Tao Yuan, Taiwan; [Liang, C-L] Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chung Shan Medical University	Chang, YS (corresponding author), Chang Gung Univ, Chang Gung Mol Med Res Ctr, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	ysc@mail.cgu.edu.tw	Liu, Hao-Ping/AAJ-3038-2020; Li, Hsin-Pai/C-7305-2014	Liu, Hao-Ping/0000-0001-5915-5128; Hsueh, Chuen/0000-0001-7860-5964; Chang, Yu-Sun/0000-0002-6457-3890; Yu, Jau-Song/0000-0002-4295-983X	Ministry of Education, Taiwan (to Chang Gung University); National Science Council, Taiwan [NSC 94-2314-B-182A-188, 94-3112-B-182-005, 95-2320-B-182-001]; Chang Gung Memorial Hospital, Taiwan [CMRPD150961, CMRPG360221]	Ministry of Education, Taiwan (to Chang Gung University)(Ministry of Education, Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital)	Grant support was provided by the Ministry of Education, Taiwan (to Chang Gung University), the National Science Council, Taiwan (grants NSC 94-2314-B-182A-188, 94-3112-B-182-005 and 95-2320-B-182-001 to Y-S Chang) and Chang Gung Memorial Hospital, Taiwan (grants CMRPD150961 and CMRPG360221 to Y-S Chang). Special thanks to Chung Shan Medical University for supporting CL Liang to attend the 12th International EBV Symposium.	Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349; Chen LC, 2008, CLIN CANCER RES, V14, P3807, DOI 10.1158/1078-0432.CCR-08-0155; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Emerald BS, 2007, J BIOL CHEM, V282, P680, DOI 10.1074/jbc.M600224200; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Goto H, 2001, CANCER RES, V61, P469; Griffiths L, 1997, CANCER RES, V57, P570; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Hatakeyama H, 2006, PROTEOMICS, V6, P6300, DOI 10.1002/pmic.200600488; Ikeda R, 2006, BIOCHEM BIOPH RES CO, V342, P280, DOI 10.1016/j.bbrc.2006.01.142; Inoue A, 2007, P NATL ACAD SCI USA, V104, P8983, DOI 10.1073/pnas.0607595104; Katz M, 2007, BBA-MOL CELL RES, V1773, P1161, DOI 10.1016/j.bbamcr.2007.01.002; Kim E, 2006, FEBS J, V273, P793, DOI 10.1111/j.1742-4658.2006.05112.x; Kitazono M, 1998, BIOCHEM BIOPH RES CO, V253, P797, DOI 10.1006/bbrc.1998.9852; LEE AWM, 1992, INT J RADIAT ONCOL, V23, P261, DOI 10.1016/0360-3016(92)90740-9; Lee PT, 2007, MOL BIOL CELL, V18, P5004, DOI 10.1091/mbc.E07-04-0384; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Liekens S, 2007, BIOCHEM PHARMACOL, V74, P1555, DOI 10.1016/j.bcp.2007.05.008; Lin JC, 2007, P NATL ACAD SCI USA, V104, P2235, DOI 10.1073/pnas.0611015104; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Pino I, 2003, LUNG CANCER-J IASLC, V41, P131, DOI 10.1016/S0169-5002(03)00193-4; Roychoudhury P, 2007, BRIT J CANCER, V97, P574, DOI 10.1038/sj.bjc.6603911; Schwartz EL, 1998, CANCER RES, V58, P1551; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Tse KP, 2007, CLIN CANCER RES, V13, P6320, DOI 10.1158/1078-0432.CCR-07-1029; Waggoner SA, 2003, EXP BIOL MED, V228, P387, DOI 10.1177/153537020322800409; Wang SB, 2006, NUCLEIC ACIDS RES, V34, P3044, DOI 10.1093/nar/gkl386; Yao YX, 2005, J NEURO-ONCOL, V72, P217, DOI 10.1007/s11060-004-3012-4; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	35	46	47	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1904	1915		10.1038/onc.2009.55	http://dx.doi.org/10.1038/onc.2009.55			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330019				2022-12-28	WOS:000265640600003
J	Tilman, G; Loriot, A; Van Beneden, A; Arnoult, N; Londono-Vallejo, JA; De Smet, C; Decottignies, A				Tilman, G.; Loriot, A.; Van Beneden, A.; Arnoult, N.; Londono-Vallejo, J. A.; De Smet, C.; Decottignies, A.			Subtelomeric DNA hypomethylation is not required for telomeric sister chromatid exchanges in ALT cells	ONCOGENE			English	Article						telomeres; DNA methylation; T-SCE; ALT; subtelomeric D4Z4 and DNF92	FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; HUMAN-CHROMOSOMES; REVERSE-TRANSCRIPTASE; EPIGENETIC REGULATION; MAMMALIAN TELOMERES; MELANOMA-CELLS; HUMAN CANCER; TUMOR-CELLS; RECOMBINATION; EXPRESSION	Most human tumor cells acquire immortality by activating the expression of telomerase, a ribonucleoprotein that maintains stable telomere lengths at chromosome ends throughout cell divisions. Other tumors use an alternative mechanism of telomere lengthening (ALT), characterized by high frequencies of telomeric sister chromatid exchanges (T-SCEs). Mechanisms of ALT activation are still poorly understood, but recent studies suggest that DNA hypomethylation of chromosome ends might contribute to the process by facilitating T-SCEs. Here, we show that ALT/T-SCEhigh tumor cells display low DNA-methylation levels at the D4Z4 and DNF92 subtelomeric sequences. Surprisingly, however, the same sequences retained high methylation levels in ALT/T-SCEhigh SV40-immortalized fibroblasts. Moreover, T-SCE rates were efficiently reduced by ectopic expression of active telomerase in ALT tumor cells, even though subtelomeric sequences remained hypomethylated. We also show that hypomethylation of subtelomeric sequences in ALT tumor cells is correlated with genome-wide hypomethylation of Alu repeats and pericentromeric Sat2 DNA sequences. Overall, this study suggests that, although subtelomeric DNA hypomethylation is often coincident with the ALT process in human tumor cells, it is not required for T-SCE.	[Tilman, G.; Loriot, A.; Van Beneden, A.; De Smet, C.; Decottignies, A.] Catholic Univ Louvain, de Duve Inst, Genet & Epigenet Alterat Genome Grp, Fac Med, Brussels, Belgium; [Arnoult, N.; Londono-Vallejo, J. A.] Inst Curie, Telomeres & Canc Lab, Paris, France	Universite Catholique Louvain; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Decottignies, A (corresponding author), Catholic Univ Louvain, de Duve Inst, Genet & Epigenet Alterat Genome Grp, Fac Med, 74 Ave Hippocrate,ICP Tower, Brussels, Belgium.	anabelle.decottignies@uclouvain.be	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563; Arnoult, Nausica/0000-0003-2633-0270	Fonds National de la Recherche Scientifique (FNRS), Belgium; Televie/FNRS; ANR; ARC; INCa; La Ligue	Fonds National de la Recherche Scientifique (FNRS), Belgium(Fonds de la Recherche Scientifique - FNRS); Televie/FNRS(Fonds de la Recherche Scientifique - FNRS); ANR(French National Research Agency (ANR)); ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); La Ligue	We are grateful to M Swinarska, F Brasseur, W Wright, F Fuks, J Lingner, F d'Adda di Fagagna, F Journe, H Id Boufker and C Heirman for the generous gifts of cell lines and plasmids. We thank all the members of the GENEPI group for their constant support and help. This study was supported by the Fonds National de la Recherche Scientifique (FNRS), Belgium. GT is supported by a PhD fellowship grant from Televie/FNRS. AL is supported by a post-doctoral grant from the FNRS. Work in the 'Telomere- &Cancer' laboratory is supported by grants from ANR, ARC, INCa and La Ligue.	Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bechter OE, 2004, CELL CYCLE, V3, P547; Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Brock GJR, 1999, GENE, V240, P269, DOI 10.1016/S0378-1119(99)00442-4; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cacurri S, 1998, AM J HUM GENET, V63, P181, DOI 10.1086/301906; Cadieux B, 2006, CANCER RES, V66, P8469, DOI 10.1158/0008-5472.CAN-06-1547; Cerone MA, 2005, ONCOGENE, V24, P7893, DOI 10.1038/sj.onc.1208934; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cornforth MN, 2001, MUTAGENESIS, V16, P85, DOI 10.1093/mutage/16.1.85; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ehrlich M, 2006, CURR TOP MICROBIOL, V310, P251; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Flint J, 1997, HUM MOL GENET, V6, P1305, DOI 10.1093/hmg/6.8.1305; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Kholmanskikh O, 2008, INT J CANCER, V122, P777, DOI 10.1002/ijc.23140; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Londono-Vallejo JA, 2004, CANCER RES, V64, P2324, DOI 10.1158/0008-5472.CAN-03-4035; Loriot A, 2006, J BIOL CHEM, V281, P10118, DOI 10.1074/jbc.M510469200; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Monfouilloux S, 1998, GENOMICS, V51, P165, DOI 10.1006/geno.1998.5358; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Riethman H, 2005, CHROMOSOME RES, V13, P505, DOI 10.1007/s10577-005-0998-1; Riethman H, 2008, ANNU REV GENOM HUM G, V9, P1, DOI 10.1146/annurev.genom.8.021506.172017; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shimojima M, 2004, HEPATOL RES, V29, P31, DOI 10.1016/j.hepres.2004.02.005; Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245; Tilman G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-80; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van Overveld PGM, 2003, NAT GENET, V35, P315, DOI 10.1038/ng1262; Vera E, 2008, ONCOGENE, V27, P6817, DOI 10.1038/onc.2008.289; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Yehezkel S, 2008, HUM MOL GENET, V17, P2776, DOI 10.1093/hmg/ddn177; Young JI, 2003, J BIOL CHEM, V278, P19904, DOI 10.1074/jbc.M301685200	49	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1682	1693		10.1038/onc.2009.23	http://dx.doi.org/10.1038/onc.2009.23			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252523				2022-12-28	WOS:000265022000003
J	Mattera, L; Escaffit, F; Pillaire, MJ; Selves, J; Tyteca, S; Hoffmann, JS; Gourraud, PA; Chevillard-Briet, M; Cazaux, C; Trouche, D				Mattera, L.; Escaffit, F.; Pillaire, M-J; Selves, J.; Tyteca, S.; Hoffmann, J-S; Gourraud, P-A; Chevillard-Briet, M.; Cazaux, C.; Trouche, D.			The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways	ONCOGENE			English	Article						colon cancer; apoptosis; chromatin; p400; Tip60	TIP60 HISTONE ACETYLTRANSFERASE; P53 PATHWAY; ACETYLATION; APOPTOSIS; COMPLEX; P400; HISTONE-DEACETYLASE-3; PROGRESSION; CHROMATIN; REPAIR	The Tip60 histone acetyltransferase belongs to a multi-molecular complex that contains many chromatin remodeling enzymes including the ATPase p400, a protein involved in nucleosomal incorporation of specific histone variants and that can directly or indirectly repress some Tip60-dependent pathways. Tip60 activity is critical for the cellular response to DNA damage and is affected during cancer progression. Here, we found that the ratio between Tip60 and p400 mRNAs is affected in most colorectal carcinoma. Strikingly, reversing the p400/Tip60 imbalance by Tip60 overexpression or the use of siRNAs resulted in increased apoptosis and decreased proliferation of colon-cancer-derived cells, suggesting that this ratio defect is important for cancer progression. Furthermore, we demonstrate that the p400/Tip60 ratio controls the oncogene-induced DNA damage response, a known anticancer barrier. Finally, we found that it is also critical for the response to 5-fluorouracil, a first-line treatment against colon cancer. Together, our data indicate that the p400/Tip60 ratio is critical for colon cancer cells proliferation and response to therapeutic drugs through the control of stress-response pathways.	[Trouche, D.] CNRS, LBCMCP, UMR 5088, F-31062 Toulouse, France; [Mattera, L.; Escaffit, F.; Pillaire, M-J; Selves, J.; Tyteca, S.; Hoffmann, J-S; Gourraud, P-A; Chevillard-Briet, M.; Cazaux, C.; Trouche, D.] Univ Toulouse, UPS, Toulouse, France; [Pillaire, M-J; Hoffmann, J-S; Cazaux, C.] CNRS, IPBS, F-31062 Toulouse, France; [Selves, J.] Fac Med Toulouse, INSERM, CPTP, F-31073 Toulouse, France; [Gourraud, P-A] Hop Toulouse, INSERM, Serv Epidemiol, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Trouche, D (corresponding author), CNRS, LBCMCP, UMR 5088, 118 Route Narbonne, F-31062 Toulouse, France.	dtrouche@cict.fr	Selves, Janick/M-7719-2014; Gourraud, Pierre-Antoine FD/O-3024-2015; Hoffmann, Jean-Sebastien/O-9183-2014; ESCAFFIT, Fabrice/AAE-4832-2021; Pillaire, Marie-Jeanne/P-1579-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Trouche, Didier/0000-0003-1398-6481; Gourraud, Pierre-Antoine/0000-0003-1131-9554	ARC; Institut National du Cancer (INCa); Canceropole Grand Sud-Ouest (ACI 2004/2007); French Ministry of Science; 'Fondation de France'	ARC(Australian Research Council); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Grand Sud-Ouest (ACI 2004/2007)(French National Research Agency (ANR)); French Ministry of Science; 'Fondation de France'(Fondation de France)	We thank Professor JF Beaulieu and K Helin for materials, Professor B Ducommun, Dr G Legube and Dr Y Canitrot for critical reading of the paper. We also acknowledge JJ Maoret, responsible person of the QPCR platform at IFR31 (INSERM), as well as S Mazeres (IPBS) and P Grosclaude (INSERM) for their help to format the data concerning tumor analysis. This work was supported by a grant to DT as a 'subvention libre' from the ARC and the Institut National du Cancer (INCa), Canceropole Grand Sud-Ouest (ACI 2004/2007, to CC). LM and ST were supported by studentships from the French Ministry of Science and the ARC, respectively, whereas FE was supported by a fellowship from the 'Fondation de France'.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lleonart ME, 2006, ONCOL REP, V16, P603; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200	20	72	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1506	1517		10.1038/onc.2008.499	http://dx.doi.org/10.1038/onc.2008.499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19169279				2022-12-28	WOS:000264537400003
J	Pages, F; Galon, J; Dieu-Nosjean, MC; Tartour, E; Sautes-Fridman, C; Fridman, WH				Pages, F.; Galon, J.; Dieu-Nosjean, M-C; Tartour, E.; Sautes-Fridman, C.; Fridman, W-H			Immune infiltration in human tumors: a prognostic factor that should not be ignored	ONCOGENE			English	Review						immune response; prognosis; colorectal cancer	REGULATORY T-CELLS; LYMPHOID-TISSUE IBALT; COLORECTAL-CANCER; IMMUNOSUPPRESSIVE NETWORKS; LYMPHOCYTIC INFILTRATION; B-LYMPHOCYTE; HIGH NUMBERS; SURVIVAL; CARCINOMA; LUNG	The natural history of a tumor includes phases of 'in situ' growth, invasion, extravasation and metastasis. During these phases, tumor cells interact with their microenvironment and are influenced by signals coming from stromal, endothelial, inflammatory and immune cells. Indeed, tumors are often infiltrated by various numbers of lymphocytes, macrophages or mast cells. It is generally believed that the latter produce factors that maintain chronic inflammation and promote tumor growth, whereas lymphocytes may control cancer outcome, as evidenced in mouse models. In this study, we analyze data from large cohorts of human tumors, clearly establishing that infiltration of the primary tumor by memory T cells, particularly of the Th1 and cytotoxic types, is the strongest prognostic factor in terms of freedom from disease and overall survival at all stages of clinical disease. We review data suggesting that tertiary lymphoid structures adjacent to tumors and composed of mature dendritic cells (T and B cells organized as germinal centers) may be the site of an antitumor reaction. We propose an immune scoring based on the type, density and location of lymphocyte infiltrates as a novel prognostic factor for use in addition to tumor node metastasis staging to predict disease-free survival and to aid in decisions regarding adjuvant therapies in early stage human cancers. Oncogene (2010) 29, 1093-1102; doi: 10.1038/onc.2009.416; published online 30 November 2009	[Dieu-Nosjean, M-C; Sautes-Fridman, C.; Fridman, W-H] Ctr Rech Cordeliers, INSERM, U872, Equipe 13, F-75006 Paris, France; [Pages, F.; Tartour, E.; Fridman, W-H] Hop Europe Georges Pompidou, AP HP, Serv Immunol Biol, Paris, France; [Pages, F.; Galon, J.; Dieu-Nosjean, M-C; Sautes-Fridman, C.; Fridman, W-H] Univ Paris 05, UMRS 872, Paris, France; [Pages, F.; Galon, J.; Dieu-Nosjean, M-C; Sautes-Fridman, C.; Fridman, W-H] Univ Paris 06, UMRS872, Paris, France; [Pages, F.; Galon, J.] Ctr Rech Cordeliers, INSERM, U872, Equipe 15, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Fridman, WH (corresponding author), Ctr Rech Cordeliers, INSERM, U872, Equipe 13, 15 Rue Ecole Med, F-75006 Paris, France.	herve.fridman@crc.jussieu.fr	Dieu-Nosjean, Marie-Caroline/N-3736-2017; Dieu-Nosjean, Marie-Caroline/AAD-3695-2022; Galon, Jerome/G-9838-2019; tartour, eric/O-7957-2017	Dieu-Nosjean, Marie-Caroline/0000-0002-1697-8914; Galon, Jerome/0000-0001-9635-1339; fridman, wolf herman/0000-0002-1332-0973; tartour, eric/0000-0002-7323-468X; sautes-fridman, catherine/0000-0003-1735-8722	Association pour la Recherche sur le Cancer (ARC); INSERM; Action Concertee Incitative ACI I MPBio (Universite Paris Descartes); National Cancer Institute (INCa); Canceropole Ile de France; Ville de Paris, Immucan; European Commission [202230]	Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Action Concertee Incitative ACI I MPBio (Universite Paris Descartes); National Cancer Institute (INCa)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)Institut National du Cancer (INCA) France); Canceropole Ile de France(Region Ile-de-France); Ville de Paris, Immucan; European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA), INSERM, Action Concertee Incitative ACI I MPBio (Universite Paris Descartes), the National Cancer Institute (INCa), the Canceropole Ile de France, the Ville de Paris, Immucan and the European Commission (7FP, Geninca Consortium, Grant no. 202230).	Al-Shibli KI, 2008, CLIN CANCER RES, V14, P5220, DOI 10.1158/1078-0432.CCR-08-0133; Badoual C, 2006, CLIN CANCER RES, V12, P465, DOI 10.1158/1078-0432.CCR-05-1886; Badoual C, 2008, CANCER RES, V68, P3907, DOI 10.1158/0008-5472.CAN-07-6842; Badoual C, 2009, J CLIN ONCOL, V27, pE5, DOI 10.1200/JCO.2009.23.0680; Baier PK, 1998, TUMOR BIOL, V19, P205, DOI 10.1159/000030008; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell DC, 1996, CURR BIOL, V6, P1695, DOI 10.1016/S0960-9822(02)70795-1; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Carragher DM, 2008, SEMIN IMMUNOL, V20, P26, DOI 10.1016/j.smim.2007.12.004; Carreras J, 2006, BLOOD, V108, P2957, DOI 10.1182/blood-2006-04-018218; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chaput N, 2009, GUT, V58, P520, DOI 10.1136/gut.2008.158824; Cho Y, 2003, CANCER RES, V63, P1555; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5; Cooley W.B., 1893, AM J MED SCI, V105, P487, DOI [10.1097/00000441-189305000-00001, DOI 10.1097/00000441-189305000-00001]; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dalerba P, 2003, CRIT REV ONCOL HEMAT, V46, P33, DOI 10.1016/S1040-8428(02)00159-2; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; Diederichsen ACP, 2003, CANCER IMMUNOL IMMUN, V52, P423, DOI 10.1007/s00262-003-0388-5; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; Gajewska BU, 2001, J CLIN INVEST, V108, P577, DOI 10.1172/JCI200112627; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806; GAUSE A, 1995, EUR J IMMUNOL, V25, P2775, DOI 10.1002/eji.1830251010; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; GOULD SJ, 1993, J PATHOL, V169, P229, DOI 10.1002/path.1711690209; GRAHAM DM, 1990, MODERN PATHOL, V3, P332; Halama Niels, 2009, Cancer Immun, V9, P1; HALVORSEN TB, 1989, J CLIN PATHOL, V42, P162, DOI 10.1136/jcp.42.2.162; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRISON JC, 1994, HUM PATHOL, V25, P498, DOI 10.1016/0046-8177(94)90122-8; Herr HW, 2008, J UROLOGY, V179, P53, DOI 10.1016/j.juro.2007.08.122; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; HOUSE AK, 1979, GUT, V20, P868, DOI 10.1136/gut.20.10.868; Humby F, 2009, PLOS MED, V6, P59, DOI 10.1371/journal.pmed.0060001; Ito N, 2005, ANTICANCER RES, V25, P2027; JASS JR, 1986, J CLIN PATHOL, V39, P585, DOI 10.1136/jcp.39.6.585; Karja V, 2005, ANTICANCER RES, V25, P4435; Kawai O, 2008, CANCER-AM CANCER SOC, V113, P1387, DOI 10.1002/cncr.23712; Kim R, 2006, CANCER RES, V66, P5527, DOI 10.1158/0008-5472.CAN-05-4128; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Kotlan B, 2003, Hum Antibodies, V12, P113; Le Gouvello S, 2008, GUT, V57, P772, DOI 10.1136/gut.2007.123794; Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5; Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644; MACKENSEN A, 1993, CANCER RES, V53, P3569; Marrogi AJ, 1997, INT J CANCER, V74, P492, DOI 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z; Menegaz RA, 2008, EUR J GYNAECOL ONCOL, V29, P321; Michel S, 2008, BRIT J CANCER, V99, P1867, DOI 10.1038/sj.bjc.6604756; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Moyron-Quiroz JE, 2006, IMMUNITY, V25, P643, DOI 10.1016/j.immuni.2006.08.022; Naito Y, 1998, CANCER RES, V58, P3491; Nakano O, 2001, CANCER RES, V61, P5132; Nielsen HJ, 1999, J PATHOL, V189, P487, DOI 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I; Okazaki T, 2006, TRENDS IMMUNOL, V27, P195, DOI 10.1016/j.it.2006.02.001; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2008, J LEUKOCYTE BIOL, V84, P981, DOI 10.1189/jlb.1107773; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086; Prall F, 2004, HUM PATHOL, V35, P808, DOI 10.1016/j.humpath.2004.01.022; Rangel-Moreno J, 2006, J CLIN INVEST, V116, P3183, DOI 10.1172/JCI28756; Reichert TE, 2001, CANCER, V91, P2136, DOI 10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q; Richardsen E, 2008, HISTOPATHOLOGY, V53, P30, DOI 10.1111/j.1365-2559.2008.03058.x; Ropponen KM, 1997, J PATHOL, V182, P318, DOI 10.1002/(SICI)1096-9896(199707)182:3<318::AID-PATH862>3.0.CO;2-6; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Schumacher K, 2001, CANCER RES, V61, P3932; Schwitalle Y, 2008, GASTROENTEROLOGY, V134, P988, DOI 10.1053/j.gastro.2008.01.015; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Shibuya TY, 2002, CLIN CANCER RES, V8, P745; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; Stolte M, 2002, GUT, V50, P19, DOI 10.1136/gut.50.suppl_3.iii19; SVENNEVIG JL, 1984, BRIT J CANCER, V49, P375, DOI 10.1038/bjc.1984.60; TEFANY FJ, 1991, J INVEST DERMATOL, V97, P197, DOI 10.1111/1523-1747.ep12479662; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Tesar BM, 2004, J IMMUNOL, V173, P4377, DOI 10.4049/jimmunol.173.7.4377; Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007; Thaunat O, 2008, TRANSPLANTATION, V85, P1648, DOI 10.1097/TP.0b013e3181735723; Touitou V, 2007, INVEST OPHTH VIS SCI, V48, P3223, DOI 10.1167/iovs.07-0008; Tschernig T, 2000, PATHOBIOLOGY, V68, P1, DOI 10.1159/000028109; Tzankov A, 2008, HAEMATOLOGICA, V93, P193, DOI 10.3324/haematol.11702; VESALAINEN S, 1994, EUR J CANCER, V30A, P1797, DOI 10.1016/0959-8049(94)E0159-2; Wittekind C, 2002, CANCER-AM CANCER SOC, V94, P2511, DOI 10.1002/cncr.10492; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	99	707	731	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1093	1102		10.1038/onc.2009.416	http://dx.doi.org/10.1038/onc.2009.416			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19946335				2022-12-28	WOS:000274912100001
J	Dean, J; Hashimoto, K; Tsuji, T; Gautier, V; Hall, WW; Sheehy, N				Dean, J.; Hashimoto, K.; Tsuji, T.; Gautier, V.; Hall, W. W.; Sheehy, N.			Functional interaction of HTLV-1 Tax protein with the POZ domain of the transcriptional repressor BCL6	ONCOGENE			English	Article						HTLV-1; BCL6; Tax 1	T-CELL LEUKEMIA; VIRUS TYPE-I; CENTER B-CELLS; FINGER ENCODING GENE; NF-KAPPA-B; LAZ3/BCL6 ONCOPROTEIN; HISTONE DEACETYLASES; DOWN-REGULATION; TYPE-1 HTLV-1; PDCD2 GENE	The Tax protein encoded by human T-cell leukaemia virus type 1 (HTLV-1) has a pivotal role in T-cell transformation by deregulating cellular signalling pathways. Using the yeast two-hybrid system to screen a human leukocyte cDNA library, we identified BCL6 (B-cell lymphoma 6) as a cellular protein, which interacts with Tax 1. The BCL6 gene encodes a sequence-specific transcriptional repressor that contains a conserved N-terminal poxvirus and zinc finger (POZ) repressor domain and a C-terminal Kruppel-like zinc finger DNA binding domain. Using both in vivo and in vitro methods, we demonstrate that the POZ domain of BCL6 is sufficient for its interaction with Tax 1. Using functional assays, we demonstrate that Tax 1 enhanced the repressive activity of BCL6 and increased the levels of apoptosis induced by BCL6 in osteosarcoma cells indicating that both proteins cooperate in vivo to cause a physiological affect. Furthermore, BCL6 recruited Tax 1 into punctate nuclear structures, which suggests that Tax 1 colocalizes with BCL6 in repressor complexes in vivo. BCL6 expression significantly downregulated both basal and Tax-induced nuclear factor-kappa B and long terminal repeat activation. This suggests that the expression of BCL6 in HTLV infected cells may contribute to the silencing of viral gene expression and to the long clinical latency associated with HTLV infection. Oncogene (2009) 28, 3723-3734; doi: 10.1038/onc.2009.230;published online 24 August 2009	[Dean, J.; Hashimoto, K.; Tsuji, T.; Gautier, V.; Hall, W. W.; Sheehy, N.] Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin D4, Ireland; [Hashimoto, K.] Itoh Hosp, Dept Neurol, Ibusuki City, Kagoshima, Japan; [Tsuji, T.] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan	University College Dublin; National Institute of Infectious Diseases (NIID)	Sheehy, N (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Ctr Res Infect Dis, Dublin D4, Ireland.	Noreen.sheehy@ucd.ie	Gautier, virginie/K-4057-2012	Gautier, virginie/0000-0003-1862-2644; Sheehy, Noreen/0000-0001-5004-0228				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baron BW, 2007, P NATL ACAD SCI USA, V104, P7449, DOI 10.1073/pnas.0701770104; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cheng J, 2007, BLOOD, V110, P2110, DOI 10.1182/blood-2006-11-058388; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; GAIDANO G, 1994, BLOOD, V84, P397; GESSAIN A, 1985, LANCET, V2, P407; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hironaka N, 2004, NEOPLASIA, V6, P266, DOI 10.1593/neo.03388; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Hyjek E, 2001, BLOOD, V97, P270, DOI 10.1182/blood.V97.1.270; Ichii H, 2002, NAT IMMUNOL, V3, P558, DOI 10.1038/ni802; Ichii H, 2007, INT IMMUNOL, V19, P427, DOI 10.1093/intimm/dxm007; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Li ZP, 2005, J IMMUNOL, V174, P205, DOI 10.4049/jimmunol.174.1.205; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Mori N, 1999, BLOOD, V93, P2360; Nakayama T, 2008, ONCOGENE, V27, P3221, DOI 10.1038/sj.onc.1210984; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OSAME M, 1986, LANCET, V1, P1031; Perez-Rosado A, 2008, J PATHOL, V214, P498, DOI 10.1002/path.2279; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ranuncolo SM, 2008, J BIOL CHEM, V283, P22565, DOI 10.1074/jbc.M803490200; Ranuncolo SM, 2007, NAT IMMUNOL, V8, P705, DOI 10.1038/ni1478; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Sheehy N, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-20; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tsuji T, 2007, J BIOL CHEM, V282, P13875, DOI 10.1074/jbc.M611629200; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhang H, 2001, BBA-MOL CELL RES, V1540, P188, DOI 10.1016/S0167-4889(01)00128-8; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	64	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3723	3734		10.1038/onc.2009.230	http://dx.doi.org/10.1038/onc.2009.230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19701248				2022-12-28	WOS:000271023200005
J	Ebi, H; Sato, T; Sugito, N; Hosono, Y; Yatabe, Y; Matsuyama, Y; Yamaguchi, T; Osada, H; Suzuki, M; Takahashi, T				Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Yatabe, Y.; Matsuyama, Y.; Yamaguchi, T.; Osada, H.; Suzuki, M.; Takahashi, T.			Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers	ONCOGENE			English	Article						small-cell lung cancer; DNA damage response; miRNA; RB; reactive oxygen species	CHECKPOINT IMPAIRMENT; E2F1; IDENTIFICATION; EXPRESSION; MICRORNAS; APOPTOSIS; PATHWAY; DELETION; MIR-20A; CLUSTER	Small-cell lung cancer (SCLC) is a highly aggressive disease that exhibits rapid growth and genetic instability. We found earlier frequent overexpression of the miR-17-92 microRNA cluster, and showed that SCLC cells were addicted to continued expressions of miR-17-5p and miR-20a, major components of this microRNA cluster. In this study, we identified the frequent presence of constitutively phosphorylated H2AX (gamma-H2AX), which reflects continuing DNA damage, preferentially in SCLC. Knockdown of RB induced gamma-H2AX foci formation in non-small cell lung cancer (NSCLC) cells with wild-type RB, in association with growth inhibition and reactive oxygen species (ROS) generation, which was canceled by overexpression of miR-17-92. Conversely, induction of gamma-H2AX was observed in a miR-17-92-overexpressing SCLC cell line with miR-20a antisense oligonucleotides. These findings suggest that miR-17-92 overexpression may serve as a fine-tuning influence to counterbalance the generation of DNA damage in RB-inactivated SCLC cells, thus reducing excessive DNA damage to a tolerable level and consequently leading to genetic instability. Therefore, miR-17-92 may be an excellent therapeutic target candidate to elicit excessive DNA damage in combination with DNA-damaging chemotherapeutics. Oncogene (2009) 28, 3371-3379; doi: 10.1038/onc.2009.201; published online 13 July 2009	[Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Matsuyama, Y.; Yamaguchi, T.; Suzuki, M.; Takahashi, T.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc,Showa Ku, Nagoya, Aichi 4668550, Japan; [Yatabe, Y.] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diag, Showa Ku, Nagoya, Aichi 464, Japan; [Osada, H.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Showa Ku, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014; Takahashi, Takashi/I-7262-2014; Yamaguchi, Tomoya/AAN-7524-2020; Hosono, Yasuyuki/J-4295-2019; YATABE, Yasushi/J-6461-2014; Ebi, Hiromichi/AAA-7358-2019; Hosono, Yasuyuki/GOP-1342-2022	Suzuki, Motoshi/0000-0003-0682-5006; Takahashi, Takashi/0000-0003-0615-7001; Yamaguchi, Tomoya/0000-0001-6933-543X; YATABE, Yasushi/0000-0003-1788-559X; Ebi, Hiromichi/0000-0003-3155-7576; 	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science; Princess Takamatsu Cancer Research Fund [07-23903]; International Association for the Study of Lung Cancer (IASLC)	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Princess Takamatsu Cancer Research Fund; International Association for the Study of Lung Cancer (IASLC)	This work was financially supported in part by a Grant-in-Aid for Scientific Research on priority areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and a Grant (07-23903) from the Princess Takamatsu Cancer Research Fund. HE was supported by the IASLC fellowship of the International Association for the Study of Lung Cancer (IASLC) during this study.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Ebi H, 2007, CANCER RES, V67, P11158, DOI 10.1158/0008-5472.CAN-07-1749; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Konishi H, 2002, CANCER RES, V62, P271; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Nakagawa T, 2004, CANCER RES, V64, P4826, DOI 10.1158/0008-5472.CAN-04-0871; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pickering MT, 2009, ONCOGENE, V28, P140, DOI 10.1038/onc.2008.372; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	28	76	81	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3371	3379		10.1038/onc.2009.201	http://dx.doi.org/10.1038/onc.2009.201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597473				2022-12-28	WOS:000270103300004
J	Jiang, Y; Luo, W; Howe, PH				Jiang, Y.; Luo, W.; Howe, P. H.			Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions	ONCOGENE			English	Article						Disabled-2 (Dab2); Axin-protein phosphatase 1 (PP1); Wnt-beta-catenin signaling	BETA-CATENIN; DISABLED-2 DAB2; PHOSPHORYLATION; PATHWAY; ENDOCYTOSIS; ACTIVATION; ADAPTER; AP-2; LRP6	Wnt/beta-catenin signaling plays a pivotal role in modulating cellular proliferation, differentiation, tissue organization and embryonic development. Earlier, we found that the endocytic adaptor disabled-2 (Dab2) could attenuate Wnt/beta-catenin signaling by stabilizing Axin and preventing its translocation to the membrane. Recently, protein phosphatase 1 (PP1) has been shown to interact with, and dephosphorylate Axin, leading to its destabilization. Here, we show that Dab2 functions upstream of PP1 to block the interaction between Axin and PP1, inhibiting Axin dephosphorylation and thereby stabilizing its expression, ultimately leading to inhibition of Wnt/beta-catenin. We show that Dab2 acts as a competitive inhibitor of PP1 by binding to the same C-terminal domain of Axin. Both PP1 and Axin bind to the N-terminus of Dab2 and a Dab2 truncation mutant consisting of the N-terminal phosphotyrosine binding domain blocks PP1-Axin interactions and inhibits Wnt signaling. We confirm the inhibitory effect of Dab2 on Wnt/beta-catenin signaling in zebrafish embryos, showing that its ectopic expression phenocopies Axin overexpression resulting in altered dorsoventral patterning. We conclude that Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing PP1 from binding Axin. Oncogene (2009) 28, 2999-3007; doi:10.1038/onc.2009.157; published online 6 July 2009	[Luo, W.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Ctr Children, Salt Lake City, UT USA; [Jiang, Y.; Howe, P. H.] Cleveland Clin, Dept Canc Biol NB4, Lerner Res Inst, Cleveland, OH 44195 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin, Dept Canc Biol, Lerner Res Inst, NB4, Cleveland, OH 44195 USA.	howep@ccf.org			National Cancer Institute [CA55536, CA80095]; NATIONAL CANCER INSTITUTE [R01CA055536, R01CA080095, R29CA055536] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr S Takada for the generous provision of control Wnt-3A-producing mouse L cells and Drs Furuhashi, Wu, Zeng and He for generous provision of the Myc-Axin, Flag-tagged LRP5 plasmids and LRP5/6 antibody, respectively. We also thank Dr David Virshup and Dr Sheng-Cai Lin for generous provision of PP1 and Axin reagents. We are also grateful to Drs Sanjay Pimplikar and Ping Song for all their help with the zebrafish studies. This work was supported by Grant CA55536 and CA80095 from the National Cancer Institute to PHH.	Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Jiang Y, 2008, ONCOGENE, V27, P1865, DOI 10.1038/sj.onc.1210829; Jones WM, 2003, CURR BIOL, V13, pR479, DOI 10.1016/S0960-9822(03)00407-X; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860; Rui YN, 2007, DEV CELL, V13, P268, DOI 10.1016/j.devcel.2007.07.006; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	20	36	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2999	3007		10.1038/onc.2009.157	http://dx.doi.org/10.1038/onc.2009.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19581931	Green Accepted			2022-12-28	WOS:000269142800008
J	Bauer, K; Kretzschmar, AK; Cvijic, H; Blumert, C; Loffler, D; Brocke-Heidrich, K; Schiene-Fischer, C; Fischer, G; Sinz, A; Clevenger, CV; Horn, F				Bauer, K.; Kretzschmar, A. K.; Cvijic, H.; Blumert, C.; Loeffler, D.; Brocke-Heidrich, K.; Schiene-Fischer, C.; Fischer, G.; Sinz, A.; Clevenger, C. V.; Horn, F.			Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells	ONCOGENE			English	Article						Stat3; cyclophilin B; cyclophilin A; cyclosporine A; interleukin-6; multiple myeloma	PROTEIN EXPRESSION PROFILES; RHEUMATOID-ARTHRITIS; CONSTITUTIVE ACTIVATION; MASS-SPECTROMETRY; TRANSDUCER GP130; UP-REGULATION; IN-VIVO; INTERLEUKIN-6; BINDING; TRANSCRIPTION	Signal transducer and activator of transcription 3 (Stat3) is the major mediator of interleukin-6 (IL-6) family cytokines. In addition, Stat3 is known to be involved in the pathophysiology of many malignancies. Here, we show that the cis-trans peptidyl-prolyl isomerase cyclophilin (Cyp) B specifically interacts with Stat3, whereas the highly related CypA does not. CypB knockdown inhibited the IL-6-induced transactivation potential but not the tyrosine phosphorylation of Stat3. Binding of CypB to Stat3 target promoters and alteration of the intranuclear localization of Stat3 on CypB depletion suggested a nuclear function of Stat3/ CypB interaction. By contrast, CypA knockdown inhibited Stat3 IL-6-induced tyrosine phosphorylation and nuclear translocation. The Cyp inhibitor cyclosporine A (CsA) caused similar effects. However, Stat1 activation in response to IL-6 or interferon-gamma was not affected by Cyp silencing or CsA treatment. As a result, Cyp knockdown shifted IL-6 signaling to a Stat1-dominated pathway. Furthermore, Cyp depletion or treatment with CsA induced apoptosis in IL-6-dependent multiple myeloma cells, whereas an IL-6-independent line was not affected. Thus, Cyps support the anti-apoptotic action of Stat3. Taken together, CypA and CypB both play pivotal roles, yet at different signaling levels, for Stat3 activation and function. These data also suggest a novel mechanism of CsA action. Oncogene ( 2009) 28, 2784-2795; doi:10.1038/onc.2009.142; published online 8 June 2009	[Bauer, K.; Kretzschmar, A. K.; Cvijic, H.; Blumert, C.; Loeffler, D.; Brocke-Heidrich, K.; Horn, F.] Univ Leipzig, Inst Clin Immunol & Transfus Med, Fac Med, D-04103 Leipzig, Germany; [Bauer, K.; Loeffler, D.; Brocke-Heidrich, K.; Horn, F.] Univ Leipzig, Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany; [Schiene-Fischer, C.; Fischer, G.] Max Planck Res Unit Enzymol Prot Folding, Halle, Saale, Germany; [Sinz, A.] Univ Halle Wittenberg, Inst Pharm, Dept Pharmaceut Chem & Bioanalyt, Halle, Saale, Germany; [Clevenger, C. V.] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; [Kretzschmar, A. K.; Horn, F.] Fraunhofer Inst Cell Therapy & Immunol, Leipzig, Germany	Leipzig University; Leipzig University; Max Planck Society; Martin Luther University Halle Wittenberg; Northwestern University; Fraunhofer Gesellschaft	Horn, F (corresponding author), Univ Leipzig, Inst Clin Immunol & Transfus Med, Fac Med, Johannisallee 30, D-04103 Leipzig, Germany.	friedemann.horn@medizin.uni-leipzig.de			Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Hans- Georg Krausslich, University Heidelberg, Germany, and Stefan Rose- John, University Kiel, Germany, for CypA vector and recombinant IL- 6, respectively. INA- 6 cells were kindly provided by Renate Burger and Martin Gramatzki, University Kiel, Germany. This work was supported by SFB610 ( project C2) from the Deutsche Forschungsgemeinschaft.	Allain F, 1996, BIOCHEM J, V317, P565, DOI 10.1042/bj3170565; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975; Brazin KN, 2002, P NATL ACAD SCI USA, V99, P1899, DOI 10.1073/pnas.042529199; Brocke-Heidrich K, 2006, ONCOGENE, V25, P7297, DOI 10.1038/sj.onc.1209711; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Cui Y, 2002, J CELL BIOCHEM, V86, P630, DOI 10.1002/jcb.10253; De Ceuninck F, 2003, ARTHRITIS RHEUM, V48, P2197, DOI 10.1002/art.11099; Fang F, 2009, AM J PATHOL, V174, P297, DOI 10.2353/ajpath.2009.080753; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; HODGE DR, 2005, EUR J CANC; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Howard BA, 2004, LUNG CANCER, V46, P313, DOI 10.1016/j.lungcan.2004.05.013; Ihling C, 2003, RAPID COMMUN MASS SP, V17, P1240, DOI 10.1002/rcm.1049; JENSEN ON, 1997, PROTEIN STRUCTURE PR, P48; Kitahara K, 2007, CURR OPIN RHEUMATOL, V19, P238, DOI 10.1097/BOR.0b013e328099af80; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LOFFLER D, 2007, BLOOD; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mariller C, 1996, BBA-PROTEIN STRUCT M, V1293, P31, DOI 10.1016/0167-4838(95)00230-8; Obata Y, 2005, J BIOL CHEM, V280, P18355, DOI 10.1074/jbc.M501684200; Peters M, 1998, J IMMUNOL, V161, P3575; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Rawat R, 2000, BLOOD, V96, P3514; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Syed F, 2003, ENDOCRINE, V20, P83, DOI 10.1385/ENDO:20:1-2:83; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang P, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-226; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yang Y, 2008, RHEUMATOLOGY, V47, P1299, DOI 10.1093/rheumatology/ken225; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng JM, 2008, CANCER RES, V68, P7769, DOI 10.1158/0008-5472.CAN-08-0639	51	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2784	2795		10.1038/onc.2009.142	http://dx.doi.org/10.1038/onc.2009.142			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503092				2022-12-28	WOS:000268684400002
J	Mori, S; Chang, JT; Andrechek, ER; Matsumura, N; Baba, T; Yao, G; Kim, JW; Gatza, M; Murphy, S; Nevins, JR				Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.			Anchorage-independent cell growth signature identifies tumors with metastatic potential	ONCOGENE			English	Article						anchorage-independent cell growth; phenotype; expression signature; metastatic potential; heterogeneity	WIDE EXPRESSION PROFILES; BREAST-CANCER CELLS; SUBCELLULAR-LOCALIZATION; GENES; CARCINOMA; METABOLISM; LINES; TRANSCRIPTION; ENRICHMENT; INCREASES	The oncogenic phenotype is complex, resulting from the accumulation of multiple somatic mutations that lead to the deregulation of growth regulatory and cell fate controlling activities and pathways. The ability to dissect this complexity, so as to reveal discrete aspects of the biology underlying the oncogenic phenotype, is critical to understanding the various mechanisms of disease as well as to reveal opportunities for novel therapeutic strategies. Previous work has characterized the process of anchorage-independent growth of cancer cells in vitro as a key aspect of the tumor phenotype, particularly with respect to metastatic potential. Nevertheless, it remains a major challenge to translate these cell biology findings into the context of human tumors. We previously used DNA microarray assays to develop expression signatures, which have the capacity to identify subtle distinctions in biological states and can be used to connect in vitro and in vivo states. Here we describe the development of a signature of anchorage-independent growth, show that the signature exhibits characteristics of deregulated mitochondrial function and then demonstrate that the signature identifies human tumors with the potential for metastasis. Oncogene ( 2009) 28, 2796-2805; doi:10.1038/onc.2009.139; published online 1 June 2009	[Mori, S.; Chang, J. T.; Andrechek, E. R.; Matsumura, N.; Baba, T.; Yao, G.; Kim, J. W.; Gatza, M.; Murphy, S.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.; Murphy, S.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27708 USA; [Matsumura, N.; Baba, T.] Kyoto Univ, Dept Gynecol & Obstet, Kyoto, Japan	Duke University; Duke University; Kyoto University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, 2123 CIEMAS, Durham, NC 27708 USA.	j.nevins@duke.edu	Murphy, Susan/R-3903-2019	Murphy, Susan/0000-0001-8298-7272; Gatza, Michael/0000-0001-6796-7791; Andrechek, Eran/0000-0002-8680-3423; Matsumura, Noriomi/0000-0002-4512-7975; BABA, Tsukasa/0000-0003-0066-3747; , Guang/0000-0003-0167-777X	NIH/NCI [5U54CA-112952-05]; Uehara Memorial Foundation; NATIONAL CANCER INSTITUTE [U54CA112952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Uehara Memorial Foundation(Uehara Memorial Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank Drs J-T Chi, T Hallstrom, L Kong, R Rempel, J Freedman, M Gatza, Dr B Balakumaran, H Dressman, Y Yokota, S Akiyama, T Inoue, M Oshimura, M Araki, H Saya, Aburatani, A Niida, K Araki, Y Taya and Y Ito for helpful discussions; A Bild, T Kitamura, M Eilers and H Hanafusa for providing materials; L Jakoi for help with experiments; and T Henry and K Culler for assistance with the preparation of the article. This work was supported by a grant (5U54CA-112952-05) from the NIH/NCI to JRN. SM was a research fellow of the Uehara Memorial Foundation	Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Edelman E, 2006, BIOINFORMATICS, V22, pE108, DOI 10.1093/bioinformatics/btl231; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Guda C, 2005, BIOINFORMATICS, V21, P3963, DOI 10.1093/bioinformatics/bti650; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JOHNS ME, 1983, CANCER, V52, P1401, DOI 10.1002/1097-0142(19831015)52:8<1401::AID-CNCR2820520811>3.0.CO;2-7; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kang D, 2005, ANN NY ACAD SCI, V1042, P101, DOI 10.1196/annals.1338.010; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; MATTOX DE, 1980, AM J SURG, V140, P527, DOI 10.1016/0002-9610(80)90205-6; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; NICOLSON GL, 1988, CANCER RES, V48, P399; NOMURA Y, 1989, CANCER RES, V49, P5288; PRICE JE, 1986, J NATL CANCER I, V77, P529; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Scott MS, 2004, GENOME RES, V14, P1957, DOI 10.1101/gr.2650004; SHAFIE SM, 1980, CANCER LETT, V11, P81, DOI 10.1016/0304-3835(80)90097-X; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUTHERLAND CM, 1983, SURGERY, V94, P370; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002; VANSLOOTEN HJ, 1995, BRIT J CANCER, V72, P22, DOI 10.1038/bjc.1995.271; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WARBURG O, 1956, SCIENCE, V124, P269; Weinberg RA, 2007, BIOL CANC; Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100; ZHANG RD, 1991, INVAS METAST, V11, P204; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	43	219	222	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2796	2805		10.1038/onc.2009.139	http://dx.doi.org/10.1038/onc.2009.139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19483725	Green Accepted			2022-12-28	WOS:000268684400003
J	Wu, D; Asiedu, M; Wei, Q				Wu, D.; Asiedu, M.; Wei, Q.			Myosin-interacting guanine exchange factor (MyoGEF) regulates the invasion activity of MDA-MB-231 breast cancer cells through activation of RhoA and RhoC	ONCOGENE			English	Article						MyoGEF; RhoA; RhoC; MDA-MB-231; cell motility; nonmuscle myosin II	BINDING PROTEIN RHO; MIGRATING CELLS; LIVING CELLS; MEMBRANE PROTRUSIONS; ADHESION DYNAMICS; CENTRAL SPINDLE; DISTINCT ROLES; HELA-CELLS; ANTI-RHOA; IN-VIVO	The small guanine triphosphatase (GTPase) proteins RhoA and RhoC are essential for tumor invasion and/or metastasis in breast carcinomas. However, it is poorly understood how RhoA and RhoC are activated in breast cancer cells. Here we describe the role of myosin-interacting guanine nucleotide exchange factor (MyoGEF) in regulating RhoA and RhoC activation as well as cell polarity and invasion in an invasive breast cancer cell line MDA-MB-231. RNA-interference (RNAi)-mediated depletion of MyoGEF in MDA-MB-231 cells not only suppresses the activation of RhoA and RhoC, but also decreases cell polarity and invasion activity. The dominant-negative mutants of RhoA and RhoC, but not Rac1 and Cdc42, dramatically decrease actin polymerization induced by MyoGEF. In addition, MyoGEF colocalizes with nonmuscle myosin IIA (NMIIA) to the front of migrating cells, and depletion of NMIIA by RNAi disrupts the polarized localization of MyoGEF at the cell leading edge, suggesting a role for NMIIA in regulating MyoGEF localization and function. Moreover, MyoGEF protein levels significantly increase in infiltrating ductal carcinomas as well as in invasive breast cancer cell lines. Taken together, our results suggest that MyoGEF cooperates with NMIIA to regulate the polarity and invasion activity of breast cancer cells through activation of RhoA and RhoC. Oncogene (2009) 28, 2219-2230; doi: 10.1038/onc.2009.96; published online 4 May 2009	[Wu, D.; Asiedu, M.; Wei, Q.] Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Wei, Q (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	weiq@ksu.edu			National Institutes of Health (NIH) [P20 RR015563, k22 HL071542]; National Center for Research Resources; Kansas Agricultural Experiment Station, Manhattan, KS, USA [09-136-J]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K22HL071542] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Kansas Agricultural Experiment Station, Manhattan, KS, USA; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Robert S Adelstein and Dr Mary Anne Conti for their criticalreading and comments on the manuscript. We thank Dr Keith Burridge (University of North Carolina at Chapel Hill, Chapel Hill, NC, USA) and Dr Rick Cerione (Cornell University, Ithaca, NY, USA) for providing GSTRBD and GST- PBD plasmids. This publication was made possible by National Institutes of Health (NIH) Grant no. P20 RR015563 from the NationalCenter for Research Resources. This work was also supported by NIH Grant k22 HL071542 (to QW), as well as a fund from Terry C. Johnson Center for Basic Cancer Research (to QW). This is contribution 09-136-J from the Kansas Agricultural Experiment Station, Manhattan, KS, USA.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Ahram M, 2000, EXP CELL RES, V260, P292, DOI 10.1006/excr.2000.5031; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Asiedu M, 2008, J BIOL CHEM, V283, P28392, DOI 10.1074/jbc.M801801200; Asiedu M, 2009, MOL BIOL CELL, V20, P1428, DOI 10.1091/mbc.E08-01-0001; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chang F, 2002, SCIENCE, V297, P531, DOI 10.1126/science.1074649; Cheng L, 2004, J BIOL CHEM, V279, P12786, DOI 10.1074/jbc.M313099200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112; Demou ZN, 2005, CANCER RES, V65, P5674, DOI 10.1158/0008-5472.CAN-04-1682; Wu D, 2006, CELL CYCLE, V5, P1234, DOI 10.4161/cc.5.11.2815; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kleer CG, 2005, BREAST CANCER RES TR, V93, P101, DOI 10.1007/s10549-005-4170-6; Kleer CG, 2004, BREAST CANCER RES, V6, pR110, DOI 10.1186/bcr755; Kolega J, 2006, MOL BIOL CELL, V17, P4435, DOI 10.1091/mbc.E06-05-0431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kurokawa K, 2005, BIOCHEM SOC T, V33, P631, DOI 10.1042/BST0330631; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Kusama T, 2006, INT J ONCOL, V29, P217; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Lo CM, 2004, MOL BIOL CELL, V15, P982, DOI 10.1091/mbc.E03-06-0359; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Meshel AS, 2005, NAT CELL BIOL, V7, P157, DOI 10.1038/ncb1216; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pille JY, 2006, HUM GENE THER, V17, P1019, DOI 10.1089/hum.2006.17.1019; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2007, J CELL BIOL, V176, P35, DOI 10.1083/jcb.200605135; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Sastry SK, 2006, J BIOL CHEM, V281, P11627, DOI 10.1074/jbc.M600897200; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Vicente-Manzanares M, 2007, J CELL BIOL, V176, P573, DOI 10.1083/jcb.200612043; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Wei QZ, 2005, J BIOL CHEM, V280, P37790, DOI 10.1074/jbc.M502974200; Wells CM, 2004, J CELL SCI, V117, P1259, DOI 10.1242/jcs.00997; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	67	46	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2219	2230		10.1038/onc.2009.96	http://dx.doi.org/10.1038/onc.2009.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19421144	Green Accepted			2022-12-28	WOS:000266640300004
J	Jones, DTW; Kocialkowski, S; Liu, L; Pearson, DM; Ichimura, K; Collins, VP				Jones, D. T. W.; Kocialkowski, S.; Liu, L.; Pearson, D. M.; Ichimura, K.; Collins, V. P.			Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma	ONCOGENE			English	Article						RAF1; BRAF; SRGAP3; fusion gene; pilocytic astrocytoma; MAPK	HUMAN CANCER; GENE; REGION; TUMORS	Pilocytic astrocytomas (PAs), WHO malignancy grade I, are the most frequently occurring central nervous system tumour in 5- to 19-year-olds. Recent reports have highlighted the importance of MAPK pathway activation in PAs, particularly through a tandem duplication leading to an oncogenic BRAF fusion gene. Here, we report two alternative mechanisms resulting in MAPK activation in PAs. Firstly, in striking similarity to the common BRAF fusion, tandem duplication at 3p25 was observed, which produces an in-frame oncogenic fusion between SRGAP3 and RAF1. This fusion includes the Raf1 kinase domain, and shows elevated kinase activity when compared with wild-type Raf1. Secondly, a novel 3 bp insertion at codon 598 in BRAF mimics the hotspot V600E mutation to produce a transforming, constitutively active BRaf kinase. Although these two alterations are not common, they bring the number of cases with an identified 'hit' on the Ras/Raf-signalling pathway to 36 from our series of 44 (82%), confirming its central importance to the development of pilocytic astrocytomas. Oncogene (2009) 28, 2119-2123; doi:10.1038/onc.2009.73; published online 13 April 2009	[Jones, D. T. W.; Kocialkowski, S.; Liu, L.; Pearson, D. M.; Ichimura, K.; Collins, V. P.] Univ Cambridge, Dept Pathol, Div Mol Histopathol, Cambridge CB2 0QQ, Cambs, England	University of Cambridge	Jones, DTW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Mol Histopathol, Dept Pathol, Box 231,Level 3 Lab Block,Hills Rd, Cambridge CB2 0QQ, Cambs, England.	davidjones@cantab.net	Jones, David TW/G-9588-2013; Jones, David T. W./Z-1963-2019	Jones, David TW/0000-0002-2036-5141; 	Cancer Research UK; Samantha Dickson Brain Tumour Trust; CAMPOD	Cancer Research UK(Cancer Research UK); Samantha Dickson Brain Tumour Trust; CAMPOD	We thank Dr MG McCabe, Dr M Dimitriadi, Miss S Rigby, Miss F McDuff, Dr S Turner and Professor Y Yuasa for their help and for reagents. We also thank the Mapping and Microarray Facility groups of the Wellcome Trust Sanger Institute, UK and the Centre for Microarray resources in the Department of Pathology, University of Cambridge for technical assistance. This work was supported by grants from Cancer Research UK, the Samantha Dickson Brain Tumour Trust and CAMPOD.	BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; *CENTR BRAIN TUM R, 2005, STAT REP PRIM BRAIN; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dirven CMF, 1997, CHILD NERV SYST, V13, P17, DOI 10.1007/s003810050033; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Endris V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/pnas.162241099; Giannini C, 1997, BRAIN PATHOL, V7, P785, DOI 10.1111/j.1750-3639.1997.tb01064.x; Icking A, 2006, FEBS LETT, V580, P223, DOI 10.1016/j.febslet.2005.11.078; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Listernick R, 1999, AM J MED GENET, V89, P38, DOI 10.1002/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M; Maltzman TH, 1997, CANCER EPIDEM BIOMAR, V6, P239; Moretti S, 2006, ONCOGENE, V25, P4235, DOI 10.1038/sj.onc.1209448; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Sharma MK, 2005, NEUROLOGY, V65, P1335, DOI 10.1212/01.wnl.0000180409.78098.d7; Shimizu K, 1986, Princess Takamatsu Symp, V17, P85; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; The KIDSREEN Group, 2004, KIDSCREEN 52 HLTH QU, P1; The WHO, 2020, CLASSIFICATION TUMOU; TOMLINSON FH, 1994, J CHILD NEUROL, V9, P301, DOI 10.1177/088307389400900317; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Zebisch A, 2006, CELL MOL LIFE SCI, V63, P1314, DOI 10.1007/s00018-006-6005-y	26	228	236	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2119	2123		10.1038/onc.2009.73	http://dx.doi.org/10.1038/onc.2009.73			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19363522	Green Accepted			2022-12-28	WOS:000266235800006
J	Piccirillo, SGM; Combi, R; Cajola, L; Patrizi, A; Redaelli, S; Bentivegna, A; Baronchelli, S; Maira, G; Pollo, B; Mangiola, A; DiMeco, F; Dalpra, L; Vescovi, AL				Piccirillo, S. G. M.; Combi, R.; Cajola, L.; Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Maira, G.; Pollo, B.; Mangiola, A.; DiMeco, F.; Dalpra, L.; Vescovi, A. L.			Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution	ONCOGENE			English	Article						brain tumours; cancer stem-like cells; tumorigenicity	IDENTIFICATION	Glioblastomas (GBMs) contain transformed, self-maintaining, multipotent, tumour-initiating cancer stem cells, whose identification has radically changed our perspective on the physiology of these tumours. Currently, it is unknown whether multiple types of transformed precursors, which display alternative sets of the complement of properties of true cancer stem cells, can be found in a GBM. If different subsets of such cancer stem-like cells (CSCs) do exist, they might represent distinct cell targets, with a differential therapeutic importance, also depending on their characteristics and lineage relationship. Here, we report the presence of two types of CSCs within different regions of the same human GBM. Cytogenetic and molecular analysis shows that the two types of CSCs bear quite diverse tumorigenic potential and distinct genetic anomalies, and, yet, derive from common ancestor cells. This provides critical information to unravel the development of CSCs and the key molecular/genetic components underpinning tumorigenicity in human GBMs.	[Patrizi, A.; Redaelli, S.; Bentivegna, A.; Baronchelli, S.; Dalpra, L.] Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20052 Monza, Mi, Italy; [Piccirillo, S. G. M.; Combi, R.; Vescovi, A. L.] Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; [Piccirillo, S. G. M.; Cajola, L.; Vescovi, A. L.] Univ Milano Bicocca, Unit Canc Stem Cell Biol, I-20126 Milan, Italy; [Maira, G.; Mangiola, A.] Univ Cattolica Sacro Cuore, Dept Neurol Sci, Inst Neurosurg, I-00168 Rome, Italy; [Pollo, B.; DiMeco, F.] Natl Neurol Inst C Besta, Dept Neurosurg, Milan, Italy; [Pollo, B.; DiMeco, F.] Johns Hopkins Med Sch, Dept Neurol Surg, Baltimore, MD USA	University of Milano-Bicocca; University of Milano-Bicocca; University of Milano-Bicocca; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Istituto Neurologico Besta; Johns Hopkins University; Johns Hopkins Medicine	Dalpra, L (corresponding author), Univ Milano Bicocca, Dept Neurosci & Biomed Technol, I-20052 Monza, Mi, Italy.	leda.dalpra@unimib.it; vescovi@tin.it	Combi, Romina/AAC-2944-2020; DiMeco, Francesco/Z-5431-2019; Bentivegna, Angela/J-3478-2018; Vescovi, Angelo Luigi/A-4919-2015; Baronchelli, Simona/G-6771-2016; Pollo, Bianca/K-5347-2018; DiMeco, Francesco/Q-3785-2016	Combi, Romina/0000-0003-1742-6078; Bentivegna, Angela/0000-0001-7535-846X; Vescovi, Angelo Luigi/0000-0002-1742-4112; Baronchelli, Simona/0000-0002-1857-1472; Pollo, Bianca/0000-0002-5523-4256; DiMeco, Francesco/0000-0001-6213-5793; Piccirillo, Sara Grazia Maria/0000-0003-4109-1992	'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy; Brain Tumor Funders Collaborative Initiative, USA	'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy(Fondazione AIRC per la ricerca sul cancro); Brain Tumor Funders Collaborative Initiative, USA	This work was supported by grants of the 'Associazione Italiana per la Ricerca Sul Cancro' AIRC, Italy and the Brain Tumor Funders Collaborative Initiative, USA.	Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Piccirillo SGM, 2007, EXPERT OPIN BIOL TH, V7, P1129, DOI 10.1517/14712598.7.8.1129; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Trent S, 2002, J NEURO-ONCOL, V57, P247, DOI 10.1023/A:1015788814667; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130	14	144	150	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1807	1811		10.1038/onc.2009.27	http://dx.doi.org/10.1038/onc.2009.27			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287454	Bronze			2022-12-28	WOS:000265640400007
J	Lee, CM; Hickey, MM; Sanford, CA; McGuire, CG; Cowey, CL; Simon, MC; Rathmell, WK				Lee, C. M.; Hickey, M. M.; Sanford, C. A.; McGuire, C. G.; Cowey, C. L.; Simon, M. C.; Rathmell, W. K.			VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo	ONCOGENE			English	Article						von Hippel-Lindau; hypoxia inducible factors; renal cell carcinoma	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR; HIPPEL-LINDAU-DISEASE; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; CHUVASH POLYCYTHEMIA; EMBRYONIC LETHALITY; UBIQUITIN LIGASE; VASCULAR TUMORS; BINDING-SITES	Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-alpha regulation. Murine embryonic stem (ES) cells in which the endogenous wildtype Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl(2B/2B)) displayed preserved physiological regulation of both HIF factors with slightly greater normoxic dysregulation of HIF-2 alpha. Differentiated Vhl(2B/2B)-derived teratomas overexpressed joint HIF targets Vegf and EglN3 but not the HIF-1 alpha-specific target Pfk1. Vhl(2B/2B) teratomas additionally displayed a growth advantage over Vhl(-/-)-derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1 alpha and HIF-2 alpha stabilization and cell growth. Vhl(2B/2B) mice displayed mid-gestational embryonic lethality, whereas adult Vhl(2B/+) mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at 12 months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique pro. le of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development and tumor predisposition.	[Lee, C. M.; Sanford, C. A.; McGuire, C. G.; Cowey, C. L.; Rathmell, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Lee, C. M.; Rathmell, W. K.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Hickey, M. M.; Simon, M. C.] Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania	Rathmell, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, 450 W Dr,Room 21-237,Campus Box 7295, Chapel Hill, NC 27599 USA.	rathmell@med.unc.edu	Simon, Celeste/AAG-3941-2021		V Foundation; American Cancer Society; VHL Family Alliance; NCI [K08098410, R01121781]; Howard Hughes Medical Institute; NIEHS [F30015248]; NATIONAL CANCER INSTITUTE [R01CA121781, K08CA098410] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066310] Funding Source: NIH RePORTER	V Foundation; American Cancer Society(American Cancer Society); VHL Family Alliance; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr T Van Dyke and members of her laboratory, Dr I Davis, and Dr WY Kim for many helpful discussions. This work was supported by the V Foundation, the American Cancer Society, the VHL Family Alliance, and the NCI K08098410 and R01121781 (WKR); by the Howard Hughes Medical Institute (MCS, MMH); and by the NIEHS F30015248 (CML).	Alvarez-Silva M, 2003, DEVELOPMENT, V130, P5437, DOI 10.1242/dev.00755; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gallou C, 2004, HUM MUTAT, V24, P215, DOI 10.1002/humu.20082; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hacker KE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003801; Hickey MM, 2007, J CLIN INVEST, V117, P3879, DOI 10.1172/JCI32614; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kobayashi T, 1999, CANCER RES, V59, P1206; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Li LJ, 2007, MOL CELL BIOL, V27, P5381, DOI 10.1128/MCB.00282-07; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Ma WB, 2003, CANCER RES, V63, P5320; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miller MS, 2004, TOXICOL APPL PHARM, V198, P95, DOI 10.1016/j.taap.2003.07.018; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; NEUMANN HPH, 1991, LANCET, V337, P1052, DOI 10.1016/0140-6736(91)91705-Y; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pastore YD, 2003, BLOOD, V101, P1591, DOI 10.1182/blood-2002-06-1843; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Rathmell WK, 2004, CANCER RES, V64, P8595, DOI 10.1158/0008-5472.CAN-04-1430; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Voss AK, 2000, DEVELOPMENT, V127, P1; Williams-Simons L, 1999, TRANSGENIC RES, V8, P253, DOI 10.1023/A:1008994831937; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	65	32	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1694	1705		10.1038/onc.2009.12	http://dx.doi.org/10.1038/onc.2009.12			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19252526	Green Accepted, Green Submitted			2022-12-28	WOS:000265022000004
J	Laner-Plamberger, S; Kaser, A; Paulischta, M; Hauser-Kronberger, C; Eichberger, T; Frischauf, AM				Laner-Plamberger, S.; Kaser, A.; Paulischta, M.; Hauser-Kronberger, C.; Eichberger, T.; Frischauf, A. M.			Cooperation between GLI and JUN enhances transcription of JUN and selected GLI target genes	ONCOGENE			English	Article						GLI1; GLI2; Hedgehog signaling; activated JUN; basal cell carcinoma; keratinocytes	BASAL-CELL CARCINOMAS; HEDGEHOG SIGNALING PATHWAY; SKIN TUMOR-DEVELOPMENT; HUMAN EPIDERMAL-CELLS; C-JUN; TERMINAL PHOSPHORYLATION; HUMAN KERATINOCYTES; PROTEIN-KINASE; AP-1 PROTEINS; HUMAN HOMOLOG	Sustained Hedgehog (HH) signaling is implicated in basal cell carcinoma of the skin and other types of cancer. Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis. Activation of the JUN promoter by GLI is dependent on a GLI-binding site and the AP-1 sites known to be involved in self-activation of JUN. Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein. GLI2act is a more potent activator than GLI1 in these experiments and physical interaction with phosphorylated JUN was only detected for GLI2act. The synergistic effect of GLI and JUN extends to the activation of further GLI target genes as shown by shRNA-mediated knockdown of JUN in human keratinocytes. Some of these cooperatively activated genes are involved in cell-cycle progression, which is consistent with a significant reduction of the proliferative potential of GLI in the absence of JUN. These results suggest a novel connection between HH/GLI pathway activity and JUN, which may contribute to the oncogenic activity of HH/GLI signaling in skin.	[Laner-Plamberger, S.; Kaser, A.; Paulischta, M.; Eichberger, T.; Frischauf, A. M.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Hauser-Kronberger, C.] Paracelsus Med Univ Salzburg, St Johanns Hosp, Dept Pathol, Salzburg, Austria	Salzburg University; Paracelsus Private Medical University	Frischauf, AM (corresponding author), Salzburg Univ, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	annemarie.frischauf@sbg.ac.at	Laner-Plamberger, Sandra/AFP-1191-2022	Laner-Plamberger, Sandra/0000-0002-1416-6023; Kaser-Eichberger, Alexandra/0000-0002-6115-5036	Austrian Genome Project GENAU Ultrasensitive Proteomics; Genomics II; University of Salzburg priority program Biosciences and Health	Austrian Genome Project GENAU Ultrasensitive Proteomics; Genomics II; University of Salzburg priority program Biosciences and Health	We thank Dr Fritz Aberger for stimulating discussions and critical reading of the paper, Mag. Stefan Klingler for advice on propagation ofhuman primary foreskin keratinocytes and Dr Martina Winklmayr for help with co- immunoprecipitations and cloning. We are particularly grateful to Dr Michael J Birrer for providing the JUN expression plasmid and Dr Rune Toftgard for a SUFU expression construct. This work was supported by the Austrian Genome Project GENAU Ultrasensitive Proteomics and Genomics II and the University ofSalzburg priority program Biosciences and Health.	Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eichberger T, 2008, J BIOL CHEM, V283, P12426, DOI 10.1074/jbc.M707117200; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Evangelista M, 2006, CLIN CANCER RES, V12, P5924, DOI 10.1158/1078-0432.CCR-06-1736; Ghali L, 1999, J INVEST DERMATOL, V113, P595, DOI 10.1046/j.1523-1747.1999.00729.x; Giesecke AV, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100053; Ginsberg M, 2007, MOL CELL BIOL, V27, P6300, DOI 10.1128/MCB.00613-07; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Gramigni C, 1998, FEBS LETT, V440, P119, DOI 10.1016/S0014-5793(98)01443-4; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; HERBER B, 1994, ONCOGENE, V9, P1295; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson GL, 2007, BBA-MOL CELL RES, V1773, P1341, DOI 10.1016/j.bbamcr.2006.12.009; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kasper Maria, 2007, V397, P67; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lauth M, 2007, ONCOGENE, V26, P5163, DOI 10.1038/sj.onc.1210321; Maeda S, 2003, CANCER CELL, V3, P102, DOI 10.1016/S1535-6108(03)00025-4; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mimeault M, 2007, MOL CANCER THER, V6, P967, DOI 10.1158/1535-7163.MCT-06-0648; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Panne D, 2008, CURR OPIN STRUC BIOL, V18, P236, DOI 10.1016/j.sbi.2007.12.002; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sheng H, 2002, CANCER RES, V62, P5308; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca Barbara, 2002, J Biol, V1, P9, DOI 10.1186/1475-4924-1-9; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Toualbi K, 2007, ONCOGENE, V26, P3492, DOI 10.1038/sj.onc.1210133; Vezina Chad M, 2007, Curr Urol Rep, V8, P275, DOI 10.1007/s11934-007-0073-x; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yates S, 2002, WOUND REPAIR REGEN, V10, P5, DOI 10.1046/j.1524-475X.2002.10902.x; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726; Zhao M, 2006, MOL CELL BIOL, V26, P6197, DOI 10.1128/MCB.02214-05	83	44	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1639	1651		10.1038/onc.2009.10	http://dx.doi.org/10.1038/onc.2009.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219074				2022-12-28	WOS:000264780500008
J	Nehme, R; Conradt, B				Nehme, R.; Conradt, B.			egl-1: a key activator of apoptotic cell death in C-elegans	ONCOGENE			English	Review						BCL-2 family; BH3-only proteins; apoptosis; C. elegans; EGL-1; CED-13	CAENORHABDITIS-ELEGANS; SEX DETERMINATION; MITOCHONDRIAL DYNAMICS; PHYSICAL INTERACTION; TUMOR-SUPPRESSOR; GENETIC-CONTROL; PROTEIN CEH-30; BCL-2 FAMILY; LIN-35 RB; CED-9	Since the discovery of mammalian BIK and BAD in 1995, BH3-only proteins have emerged as key activators of apoptotic cell death in animals as diverse as the nematode, Caenorhabditis elegans, and humans. BH3-only proteins have also emerged as integrators of cell-death signals that determine the life-versus-death decision and that transduce this decision to the central apoptotic machinery through their physical interaction with 'core' BCL-2 family members, such as BCL-2 or BCL- XL. Currently, eight BH3-only proteins have been identified and characterized in mammals, and there is evidence of functional overlap between them. In contrast, only two BH3-only proteins have so far been identified and characterized in C. elegans, EGL-1 and CED-13, and there seems to be only limited functional overlap between them. Combined with the powerful genetic tools available for the analysis of apoptosis in C. elegans, and the ability to study apoptosis at single-cell resolution in this organism, the absence of extensive functional redundancy makes C. elegans an ideal model for studies on BH3-only proteins. In this study, we will review our current understanding of the role and regulation of EGL-1. We will also briefly summarize studies on CED-13, which was identified more recently. Oncogene (2009) 27, S30-S40; doi: 10.1038/onc.2009.41	[Nehme, R.; Conradt, B.] Norris Cotton Canc Ctr, Dept Genet, Dartmouth Med Sch, Hanover, NH 03755 USA	Dartmouth College; Norris Cotton Cancer Center	Conradt, B (corresponding author), Norris Cotton Canc Ctr, Dept Genet, Dartmouth Med Sch, 7400 Remsen Bldg, Hanover, NH 03755 USA.	conradt@dartmouth.edu	Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308	NIH [GM069950, GM076651]; ACS [RSG-06-110-01-CCG]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069950, R01GM076651] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Angelika Bottger, Eric Lambie and Scott Gerber for comments on the paper and members of the Conradt laboratory for many stimulating discussions. BC is grateful to Bob Horvitz for pointing her towards 'the egl-1 project' and for his encouragement and support, which was critical for the identification of n3082 and for the cloning of egl-1. Research in the Conradt laboratory is funded by the NIH (GM069950, GM076651) and ACS (RSG-06-110-01-CCG).	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Anderson P, 1995, METHOD CELL BIOL, V48, P31; BOYD JM, 1995, ONCOGENE, V11, P1921; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Conradt Barbara, 2005, WormBook, P1; del Peso L, 2000, J BIOL CHEM, V275, P27205; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Doonan R, 2008, MECH DEVELOP, V125, P883, DOI 10.1016/j.mod.2008.06.002; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gartner Anton, 2008, WormBook, P1, DOI 10.1895/wormbook.1.145.1; Grote P, 2006, DEV CELL, V11, P561, DOI 10.1016/j.devcel.2006.07.015; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; Hatzold J, 2008, PLOS BIOL, V6, P771, DOI 10.1371/journal.pbio.0060084; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Herzig S, 2008, CURR MOL MED, V8, P131, DOI 10.2174/156652408783769625; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; Krause M, 1997, DEVELOPMENT, V124, P2179; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Large EE, 2007, TRENDS GENET, V23, P314, DOI 10.1016/j.tig.2007.04.002; Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004; Li SG, 2002, DEVELOPMENT, V129, P3523; Li SG, 2006, DEV DYNAM, V235, P2260, DOI 10.1002/dvdy.20858; Liu HR, 2006, DEVELOPMENT, V133, P641, DOI 10.1242/dev.02234; Liu J, 2000, DEVELOPMENT, V127, P5179; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maurer CW, 2007, DEVELOPMENT, V134, P1357, DOI 10.1242/dev.02818; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offner N, 2005, DEVELOPMENT, V132, P1807, DOI 10.1242/dev.01712; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Peden E, 2007, GENE DEV, V21, P3195, DOI 10.1101/gad.1607807; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Reddien PW, 2007, GENETICS, V175, P1719, DOI 10.1534/genetics.106.068148; Rolland S, 2006, CELL DEATH DIFFER, V13, P1281, DOI 10.1038/sj.cdd.4401980; Schertel C, 2007, DEVELOPMENT, V134, P3691, DOI 10.1242/dev.004606; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Schwartz HT, 2007, GENE DEV, V21, P3181, DOI 10.1101/gad.1607007; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Stergiou L, 2007, CELL DEATH DIFFER, V14, P1129, DOI 10.1038/sj.cdd.4402115; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; TRENT C, 1983, GENETICS, V104, P619; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; Zarkower D, 2006, WORMBOOK, V1, P1, DOI DOI 10.1895/WORMBOOK.1.84.1	91	39	41	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S30	S40		10.1038/onc.2009.41	http://dx.doi.org/10.1038/onc.2009.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641505				2022-12-28	WOS:000268566800003
J	Powers, GL; Ellison-Zelski, SJ; Casa, AJ; Lee, AV; Alarid, ET				Powers, G. L.; Ellison-Zelski, S. J.; Casa, A. J.; Lee, A. V.; Alarid, E. T.			Proteasome inhibition represses ER alpha gene expression in ER plus cells: a new link between proteasome activity and estrogen signaling in breast cancer	ONCOGENE			English	Article						nuclear receptor; proteolysis; hormone-dependent cancer; bortezomib; transcription	RECEPTOR-ALPHA; ANTIESTROGEN ICI-182780; BORTEZOMIB PS-341; PURE ANTIESTROGEN; OVARIAN-CANCER; PHASE-II; PROTEIN; DEGRADATION; THERAPY; GROWTH	Estrogen receptor-alpha (ER alpha) is a major therapeutic target of hormonal therapies in breast cancer, and its expression in tumors is predictive of clinical response. Protein levels of ER alpha are tightly controlled by the 26S proteasome; yet, how the clinical proteasome inhibitor, bortezomib, affects ER alpha regulation has not been studied. Bortezomib selectively inhibits the chymotrypsin-like activity of the proteasome. Unlike other laboratory proteasome inhibitors, bortezomib failed to stabilize ER alpha protein at a dose exceeding 90% inhibition of the chymotrypsin-like activity. Unexpectedly, however, chronic bortezomib exposure caused a reduction of ER alpha levels in multiple ER+ breast cancer cell lines. This response can be explained by the fact that bortezomib induced a dramatic decrease in ER alpha mRNA because of direct transcriptional inhibition and loss of RNA polymerase II recruitment on the ER alpha gene promoter. Bortezomib treatment resulted in promoter-specific changes in estrogen-induced gene transcription that related with occupancy of ER alpha and RNA polymerase II (PolII) on endogenous promoters. In addition, bortezomib inhibited estrogen-dependent growth in soft agar. These results reveal a novel link between proteasome activity and expression of ER alpha in breast cancer and uncover distinct roles of the chymotrypsin-like activity of the proteasome in the regulation of the ER alpha pathway. Oncogene (2010) 29, 1509-1518; doi:10.1038/onc.2009.434; published online 30 November 2009	[Alarid, E. T.] Univ Wisconsin, Dept Oncol, Wisconsin Inst Med Res 6151, Madison, WI 53705 USA; [Casa, A. J.; Lee, A. V.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Casa, A. J.; Lee, A. V.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor College of Medicine	Alarid, ET (corresponding author), Univ Wisconsin, Dept Oncol, Wisconsin Inst Med Res 6151, 1111 Highland Ave, Madison, WI 53705 USA.	alarid@oncology.wisc.edu		Lee, Adrian/0000-0001-9917-514X	NIH [DK64034, DAMD-17-02-1-0286, T32CA009135, T32GM08688, W81XWH-06-1-0714]; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Grants NIH DK64034 (ETA), DAMD-17-02-1-0286 (AVL), T32CA009135 (GLP), T32GM08688 (GLP) and W81XWH-06-1-0714 (AJC). We thank Drs Shigeki Miyamoto and Michael Fritsch for reagents.	Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022; Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Bazzaro M, 2006, CANCER RES, V66, P3754, DOI 10.1158/0008-5472.CAN-05-2321; Bossola M, 2003, ANN SURG, V237, P384, DOI 10.1097/00000658-200303000-00013; Cardoso F, 2006, MOL CANCER THER, V5, P3042, DOI 10.1158/1535-7163.MCT-06-0104; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Clarke RB, 1997, CANCER RES, V57, P4987; Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617; Codony-Servat J, 2006, MOL CANCER THER, V5, P665, DOI 10.1158/1535-7163.MCT-05-0147; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEFRIEND DJ, 1994, BRIT J CANCER, V70, P204, DOI 10.1038/bjc.1994.281; DeNardo DG, 2007, MOL CELL ENDOCRINOL, V277, P13, DOI 10.1016/j.mce.2007.07.006; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; DOWSETT M, 1985, BRIT J CANCER, V52, P31, DOI 10.1038/bjc.1985.144; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Engel RH, 2007, CANCER INVEST, V25, P733, DOI 10.1080/07357900701506573; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Han YQ, 2008, MOL CANCER RES, V6, P1347, DOI 10.1158/1541-7786.MCR-07-2179; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hui R, 2002, CANCER RES, V62, P6916; JORDAN VC, 1976, CANCER TREAT REP, V60, P1409; Khan SA, 1999, CANCER EPIDEM BIOMAR, V8, P867; Kisselev AF, 2006, J BIOL CHEM, V281, P8582, DOI 10.1074/jbc.M509043200; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Lee S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1367; Lee S, 2007, AM J PATHOL, V171, P252, DOI 10.2353/ajpath.2007.061010; Liedtke C, 2009, ANN ONCOL; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Maki CG, 1996, CANCER RES, V56, P2649; Marx C, 2007, MOL PHARMACOL, V71, P1525, DOI 10.1124/mol.107.034090; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NOMURA Y, 1985, CANCER, V55, P546, DOI 10.1002/1097-0142(19850201)55:3<546::AID-CNCR2820550313>3.0.CO;2-V; O'Donnell AJM, 2005, ENDOCR-RELAT CANCER, V12, P851, DOI 10.1677/erc.1.01039; Oesterreich S, 2001, CANCER RES, V61, P5771; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; Qin CH, 2002, MOL ENDOCRINOL, V16, P1793, DOI 10.1210/me.2002-0006; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625; Robertson JFR, 2009, J CLIN ONCOL, V27, P4530, DOI 10.1200/JCO.2008.21.1136; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Shah MH, 2004, CLIN CANCER RES, V10, P6111, DOI 10.1158/1078-0432.CCR-04-0422; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Valley CC, 2008, J MOL ENDOCRINOL, V40, P23, DOI 10.1677/JME-07-0067; Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453; WAKELING AE, 1991, CANCER RES, V51, P3867; Wang XB, 2009, MOL CELL BIOL, V29, P3832, DOI 10.1128/MCB.00032-09; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wong DJ, 2008, CANCER RES, V68, P369, DOI 10.1158/0008-5472.CAN-07-0382; Xu HM, 2008, BREAST CANCER RES TR, V107, P267, DOI 10.1007/s10549-007-9553-4; Yang CH, 2006, ANN ONCOL, V17, P813, DOI 10.1093/annonc/mdj131; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	69	42	47	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1509	1518		10.1038/onc.2009.434	http://dx.doi.org/10.1038/onc.2009.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19946334	Green Accepted			2022-12-28	WOS:000275392400009
J	Fischer, M; Bauer, T; Oberthur, A; Hero, B; Theissen, J; Ehrich, M; Spitz, R; Eils, R; Westermann, F; Brors, B; Konig, R; Berthold, F				Fischer, M.; Bauer, T.; Oberthuer, A.; Hero, B.; Theissen, J.; Ehrich, M.; Spitz, R.; Eils, R.; Westermann, F.; Brors, B.; Koenig, R.; Berthold, F.			Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q	ONCOGENE			English	Article						neuroblastoma; integrative genomics; loss of 11q; gene expression; outcome; cancer	DNA COPY NUMBER; HIGH-RESOLUTION ANALYSIS; GENE-EXPRESSION; MICROARRAY ANALYSIS; 4S NEUROBLASTOMA; CANDIDATE GENES; RISK; PROGRESSION; DELETIONS; TUMORS	Imbalances in chromosome 11q occur in approximately 30% of primary neuroblastoma and are associated with poor outcome. It has been suggested that 11q loss constitutes a distinct clinico-genetic neuroblastoma subgroup by affecting expression levels of corresponding genes. This study analysed the relationship of 11q loss, clinical phenotype and global transcriptomic profiles in four clinico-genetic subgroups (11q alteration/favourable outcome, n = 7; 11q alteration/unfavourable outcome, n 14; no 11q alteration/favourable outcome, n 81; no 11q alteration/unfavourable outcome, n 8; tumours with MYCN amplification and/or 1p loss were excluded). Unsupervised and supervised comparisons of gene expression profiles consistently showed significantly different mRNA patterns between favourable and unfavourable neuroblastomas, both in the subgroups with and without 11q loss. In contrast, favourable tumours with and without 11q loss showed highly similar transcriptomic profiles. Disproportionate downregulation of 11q genes was observed only in unfavourable tumours with 11q loss. The diverging molecular profiles were neither caused by considerable differences in the size of the deleted regions nor by differential methylation patterns of 11q genes. Together, this study shows that neuroblastoma with 11q loss comprises two biological subgroups that differ both in their clinical phenotype and gene expression patterns, indicating that 11q loss is not a primary determinant of neuroblastoma tumour behaviour. Oncogene (2010) 29, 865-875; doi:10.1038/onc.2009.390; published online 9 November 2009	[Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] Univ Childrens Hosp, Dept Paediat Oncol, D-50924 Cologne, NRW, Germany; [Fischer, M.; Oberthuer, A.; Hero, B.; Theissen, J.; Spitz, R.; Berthold, F.] CMMC, Cologne, Germany; [Bauer, T.; Eils, R.; Koenig, R.] Inst Pharm & Mol Biotechnol, Dept Bioinformat & Funct Genom, Heidelberg, Germany; [Bauer, T.; Eils, R.; Brors, B.; Koenig, R.] German Canc Res Ctr, Dept Theoret Bioinformat, Heidelberg, Germany; [Ehrich, M.] SEQUENOM Inc, San Diego, CA USA; [Westermann, F.] German Canc Res Ctr, Dept Tumourbiol, Heidelberg, Germany	University of Cologne; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Cologne; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Sequenom; Helmholtz Association; German Cancer Research Center (DKFZ)	Fischer, M (corresponding author), Univ Childrens Hosp, Dept Paediat Oncol, Kerpener St 62, D-50924 Cologne, NRW, Germany.	matthias.fischer@uk-koeln.de	Westermann, Frank/F-7509-2013; Eils, Roland/B-6121-2009; Brors, Benedikt/E-5620-2013	Eils, Roland/0000-0002-0034-4036; Brors, Benedikt/0000-0001-5940-3101; Bauer, Tobias/0000-0002-4961-3639	Deutsche Krebshilfe [50-2719]; Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2) [01GS0456, 01GR0450]; Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2)(Federal Ministry of Education & Research (BMBF)); Competence Network Paediatric Oncology and Hematology (KPOH); Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	We are grateful to Yvonne Kahlert for excellent technical assistance and to Dr Roman Thomas for critical reading of the paper. This work was supported by grants from the Deutsche Krebshilfe (Grant 50-2719), the Bundesministerium fur Bildung und Forschung (BMBF) through the National Genome Research Network 2 (NGFN2, Grants 01GS0456 and 01GR0450) and the Competence Network Paediatric Oncology and Hematology (KPOH) as well as the Fordergesellschaft Kinderkrebs-Neuroblastom-Forschung e.V.	Alaminos M, 2003, CANCER RES, V63, P4538; Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bilke S, 2005, J CLIN ONCOL, V23, P7322, DOI 10.1200/JCO.2005.03.2821; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411; Classen S, 2007, J IMMUNOL, V178, P6931, DOI 10.4049/jimmunol.178.11.6931; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fischer M, 2008, KLIN PADIATR, V220, P137, DOI 10.1055/s-2008-1065345; Fischer M, 2006, CLIN CANCER RES, V12, P5118, DOI 10.1158/1078-0432.CCR-06-0985; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang J, 2006, FEBS LETT, V580, P3571, DOI 10.1016/j.febslet.2006.05.032; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Lastowska M, 2007, ONCOGENE, V26, P7432, DOI 10.1038/sj.onc.1210552; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McArdle L, 2004, CARCINOGENESIS, V25, P1599, DOI 10.1093/carcin/bgh173; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Oberthuer A, 2008, CLIN CANCER RES, V14, P6590, DOI 10.1158/1078-0432.CCR-07-4377; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potter N, 2008, NEOPLASIA, V10, P757, DOI 10.1593/neo.07914; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Spitz R, 2006, CLIN CANCER RES, V12, P3368, DOI 10.1158/1078-0432.CCR-05-2495; Spitz R, 2003, CLIN CANCER RES, V9, P52; Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376; Stallings RL, 2007, CYTOGENET GENOME RES, V118, P110, DOI 10.1159/000108291; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Yoshimoto T, 2007, J PATHOL, V213, P392, DOI 10.1002/path.2239	40	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					865	875		10.1038/onc.2009.390	http://dx.doi.org/10.1038/onc.2009.390			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901960				2022-12-28	WOS:000274397800009
J	Markova, B; Albers, C; Breitenbuecher, F; Melo, JV; Brummendorf, TH; Heidel, F; Lipka, D; Duyster, J; Huber, C; Fischer, T				Markova, B.; Albers, C.; Breitenbuecher, F.; Melo, J. V.; Bruemmendorf, T. H.; Heidel, F.; Lipka, D.; Duyster, J.; Huber, C.; Fischer, T.			Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma 1-driven activation of mTOR/p70S6-kinase pathway	ONCOGENE			English	Article						Bcr-Abl; CML; PLC-gamma 1; signaling; mTOR; p70S6-kinase	PHOSPHOLIPASE-C-GAMMA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; RIBOSOMAL-PROTEIN S6; MAMMALIAN TARGET; TYROSINE KINASE; POSITIVE CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; IMATINIB MESYLATE	In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway is crucial for survival and proliferation of leukemic cells. Essential downstream molecules involve mammalian target of rapamycin (mTOR) and S6-kinase. Here, we present a comprehensive analysis of the molecular events involved in activation of these key signaling pathways. We provide evidence for a previously unrecognized phospholipase C-gamma 1 (PLC-gamma 1)-controlled mechanism of mTOR/p70S6-kinase activation, which operates in parallel to the classical Akt-dependent machinery. Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6K and S6-protein without inactivation of Akt. Suppression of Akt activity alone did not affect phosphorylation of p70-S6K and S6. These results suggested the existence of an alternative mechanism for mTOR/p70S6-K activation. In Bcr-Abl-expressing cells, we detected strong PLC-gamma 1 activation, which was suppressed by imatinib. Pharmacological inhibition and siRNA knockdown of PLC-gamma 1 blocked p70S6-K and S6 phosphorylation. By inhibiting the Ca-signaling, CaMK and PKCs we demonstrated participation of these molecules in the pathway. Suppression of PLC-gamma 1 led to inhibition of cell proliferation and enhanced apoptosis. The novel pathway proved to be essential for survival and proliferation of leukemic cells and almost complete cell death was observed upon combined PLC-gamma 1 and Bcr-Abl inhibition. The pivotal role of PLC-gamma 1 was further confirmed in a mouse leukemogenesis model. Oncogene (2010) 29, 739-751; doi: 10.1038/onc.2009.374; published online 2 November 2009	[Heidel, F.; Lipka, D.; Fischer, T.] Otto von Guericke Univ, Dept Hematol Oncol, Med Ctr, Magdeburg, Germany; [Markova, B.; Breitenbuecher, F.] Univ Hosp, W German Canc Ctr, Dept Med Canc Res, Essen, Germany; [Albers, C.; Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Melo, J. V.] Inst Med & Vet Sci, Dept Haematol, Adelaide, SA 5000, Australia; [Bruemmendorf, T. H.] UCCH, Dept Oncol & Hematol, Hamburg, Germany; [Markova, B.; Breitenbuecher, F.; Heidel, F.; Lipka, D.; Huber, C.; Fischer, T.] Johannes Gutenberg Univ Mainz, Dept Med 3, Mainz, Germany	Otto von Guericke University; University of Duisburg Essen; Technical University of Munich; University of Munich; Institute Medical & Veterinary Science Australia; University of Hamburg; University Medical Center Hamburg-Eppendorf; Johannes Gutenberg University of Mainz	Fischer, T (corresponding author), Univ Magdeburg, Dept Hematol Oncol, Univ Med Ctr, Leipziger Str 44, D-39120 Magdeburg, Saxony Anhalt, Germany.	thomas.fischer@med.ovgu.de		Heidel, Florian/0000-0003-2438-1955				Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bartolovic K, 2004, BLOOD, V103, P523, DOI 10.1182/blood-2003-05-1535; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Copland M, 2008, BLOOD, V111, P2843, DOI 10.1182/blood-2007-09-112573; Dengler J, 2005, LEUKEMIA, V19, P1835, DOI 10.1038/sj.leu.2403848; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Giles FJ, 2005, CURR MOL MED, V5, P653, DOI 10.2174/156652405774641034; GOTOH A, 1994, LEUKEMIA, V8, P115; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kindler T, 2003, LEUKEMIA, V17, P999, DOI 10.1038/sj.leu.2402940; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; Liao HJ, 2002, J BIOL CHEM, V277, P9335, DOI 10.1074/jbc.M109955200; Ly C, 2003, CANCER RES, V63, P5716; Maffucci T, 2007, BIOCHEM SOC T, V35, P229, DOI 10.1042/BST0350229; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Miething C, 2006, LEUKEMIA, V20, P650, DOI 10.1038/sj.leu.2404151; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Ren SY, 2005, EXP HEMATOL, V33, P1222, DOI 10.1016/j.exphem.2005.06.030; RHEE S, 2000, BIOL PHOSPHOINOSITID, V27; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Saglio G, 2004, CELL MOL LIFE SCI, V61, P2897, DOI 10.1007/s00018-004-4271-0; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Walz C, 2006, CRIT REV ONCOL HEMAT, V57, P145, DOI 10.1016/j.critrevonc.2005.06.007; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Wing LYC, 2005, J BIOL CHEM, V280, P19937, DOI 10.1074/jbc.M411865200; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	46	45	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					739	751		10.1038/onc.2009.374	http://dx.doi.org/10.1038/onc.2009.374			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881535				2022-12-28	WOS:000274223700010
J	Anderson, LR; Sutherland, RL; Butt, AJ				Anderson, L. R.; Sutherland, R. L.; Butt, A. J.			BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activation	ONCOGENE			English	Article						BAG-1; breast cancer; apoptosis; RAF-1; ERK; MCF-10A	HUMAN BREAST-CANCER; PROTEASOME PATHWAY; SIGNALING PATHWAY; PROGNOSTIC VALUE; LUMEN FORMATION; PROTEIN-KINASE; EXPRESSION; GROWTH; BIM; PROLIFERATION	Although the multi-functional, prosurvival protein, Bcl-2-associated anthanogene 1 (BAG-1) is frequently overexpressed in breast cancers, its role in the development or maintenance of the malignant state remains unclear. Here, we have used the established MCF-10A 3-dimensional (3D) model of mammary morphogenesis as a biologically relevant system to determine how BAG-1 expression may influence the development of breast cancer. When cultured in 3D, MCF-10A cells undergo a highly regulated morphogenic program leading to the development of polarized acinar structures containing a central, hollow lumen formed, in part, through the induction of BIM-dependent apoptosis. BAG-1 overexpression resulted in an attenuation of this normal apoptotic program characterized by a significantly increased number of acini with filled lumens-a phenotype commonly observed in ductal carcinoma in situ. BAG-1's effects were associated with an activation of RAF-1-a known binding partner of BAG-1, enhanced signaling through the MAP kinase pathway and a decrease in BIM expression. Reversal of the BAG-1-associated survival phenotype by the mitogen-activated kinase/ERK kinase inhibitor, U0126, implicates the RAF-1-extracellular signal-regulated kinase signaling pathway as a major mediator of BAG-1's effects in this model. As BAG-1 expression is often elevated in preinvasive breast cancers, these findings support a possible role for BAG-1 as an early contributor to the malignant process in the breast. Oncogene (2010) 29, 527-538; doi: 10.1038/onc.2009.362; published online 2 November 2009	[Anderson, L. R.; Sutherland, R. L.; Butt, A. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Sutherland, R. L.; Butt, A. J.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of New South Wales Sydney	Butt, AJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	abutt@garvan.org.au	Sutherland, Robert L/A-8378-2008; Anderson, Luke/D-1780-2012	Anderson, Luke/0000-0003-3654-1258; Butt, Alison/0000-0002-6216-5105	Cancer Institute NSW; Australian Postgraduate Award; National Health and Medical Research Council (Australia) [535903]; RT Hall Trust	Cancer Institute NSW; Australian Postgraduate Award(Australian Government); National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); RT Hall Trust	We gratefully acknowledge the assistance of Drs Will Hughes and James Burchfield (Garvan Institute) with confocal microscopy, and Professor Graham Packham (University of Southampton) for useful discussions. This study was supported by Cancer Institute NSW Postgraduate Scholarship and Australian Postgraduate Award (LRA); Cancer Institute NSW Career Development and Support Fellowship (AJB); National Health and Medical Research Council (Australia) Program Grant 535903; RT Hall Trust.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Caldon CE, 2008, CANCER RES, V68, P3026, DOI 10.1158/0008-5472.CAN-07-3079; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Elliott E, 2009, FEBS LETT, V583, P229, DOI 10.1016/j.febslet.2008.12.009; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris J, 1999, DIS BREAST; Hohfeld J, 1998, BIOL CHEM, V379, P269; Kudoh M, 2002, CANCER RES, V62, P1904; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Meller R, 2006, J BIOL CHEM, V281, P7429, DOI 10.1074/jbc.M512138200; MILLAR EKA, 2008, BRIT J CANCER, V100, P123; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nadler Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1998; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Salh B, 1999, ANTICANCER RES, V19, P731; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Townsend PA, 2003, CANCER RES, V63, P4150; Townsend PA, 2003, BBA-REV CANCER, V1603, P83, DOI 10.1016/S0304-419X(03)00002-7; Townsend PA, 2002, J PATHOL, V197, P51, DOI 10.1002/path.1081; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wang XH, 2009, BRIT J CANCER, V100, P1347, DOI 10.1038/sj.bjc.6604985; Yang XL, 1999, CLIN CANCER RES, V5, P1816; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	45	18	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					527	538		10.1038/onc.2009.362	http://dx.doi.org/10.1038/onc.2009.362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881545				2022-12-28	WOS:000274084600006
J	Jaskelioff, M; Song, W; Xia, J; Liu, C; Kramer, J; Koido, S; Gendler, SJ; Calderwood, SK; Gong, J				Jaskelioff, M.; Song, W.; Xia, J.; Liu, C.; Kramer, J.; Koido, S.; Gendler, S. J.; Calderwood, S. K.; Gong, J.			Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene	ONCOGENE			English	Article						telomerase; telomeres; PyMT; MUC1; mammary carcinoma	LIFE-SPAN; IMMORTAL CELLS; CANCER; MICE; TUMORIGENESIS; EXPRESSION; CARCINOMA; SKIN; P53; TRANSLOCATIONS	Mice transgenic for MUC1 (mucin 1) and polyomavirus middle T (PyMT) develop mammary carcinomas within 15 weeks with 100% penetrance. PyMT-induced mammary tumorigenesis is closely correlated with robust telomerase expression and activity. To assess the role of telomerase activation and telomere maintenance in mammary carcinoma tumorigenesis, we generated mice expressing MUC1 and PyMT (MMT mice) but deficient in the telomerase RNA component, mTerc, on the C57BL/6 background. Successive generational intercrosses of mTerc(-/-)MMT mice produced cohorts with progressively shorter telomeres that were audited for mammary tumor formation. Relative to MMT (N=14) and G0 mTerc(+/-) female controls (G0=14), mTerc(-/-)MMT females (G1=11, G2=15, G3=15 and G4=5) showed decreased tumor volumes and increased tumor latency-MMT=95.6 days; G0 mTerc(+/-) MMT=98.6 days versus G1, G2, G3 and G4 mTerc(-/-)MMT mice with latencies of 122.6, 138.9, 140.7 and 220.9 days, respectively (controls versus G1-G4, P<0.005). The progressive impairment of lung metastasis was also observed with each successive mTerc(-/-)MMT generation. The impairment of tumorigenesis was associated with decreased proliferation of mammary epithelial and tumor cells and increased apoptosis of tumor cells. Together, these results indicate that, in the setting of viral oncoprotein mammary tumorigenesis, telomerase-dependent telomere maintenance facilitates the formation and metastatic progression of mammary tumors. Oncogene (2009) 28, 4225-4236; doi: 10.1038/onc.2009.268; published online 7 September 2009	[Gong, J.] Boston Univ, Sch Med, Dept Med, Med Ctr, Boston, MA 02215 USA; [Jaskelioff, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Koido, S.] Jikei Univ, Sch Med, Dept Internal Med, Tokyo, Japan; [Gendler, S. J.] Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Calderwood, S. K.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA	Boston University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jikei University; Mayo Clinic; Mayo Clinic Phoenix; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gong, J (corresponding author), Boston Univ, Sch Med, Dept Med, Med Ctr, 650 Albany St,Room 309, Boston, MA 02215 USA.	jgong@bu.edu		Gong, Jianlin/0000-0003-0910-014X	Susan G Komen Breast Cancer Foundation [BCTR0503792, PDF060881]; US Department of Defense Breast Cancer Research	Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); US Department of Defense Breast Cancer Research(United States Department of Defense)	This work was supported by the Susan G Komen Breast Cancer Foundation (BCTR0503792 to JG and PDF060881 to MJ) and the US Department of Defense Breast Cancer Research programs (JG). We thank Dr Ronald A DePinho for providing mTerc<SUP>-/-</SUP> mice, advice and comments on the paper.	Argilla D, 2004, CANCER CELL, V6, P373, DOI 10.1016/j.ccr.2004.08.032; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2005, BIOCHEM BIOPH RES CO, V331, P881, DOI 10.1016/j.bbrc.2005.03.211; Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Canela A, 2004, MOL CELL BIOL, V24, P4275, DOI 10.1128/MCB.24.10.4275-4293.2004; Canela Andres, 2007, Methods Mol Biol, V371, P45; Chang S, 2004, NAT GENET, V36, P877, DOI 10.1038/ng1389; Chang S, 2003, GENE DEV, V17, P88, DOI 10.1101/gad.1029903; Chen DS, 2000, BREAST CANCER RES TR, V60, P107, DOI 10.1023/A:1006332009414; Chen DS, 2003, IMMUNOLOGY, V109, P300, DOI 10.1046/j.1365-2567.2003.01656.x; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choudhury AR, 2007, NAT GENET, V39, P99, DOI 10.1038/ng1937; Cosme-Blanco W, 2007, EMBO REP, V8, P497, DOI 10.1038/sj.embor.7400937; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Farazi PA, 2003, CANCER RES, V63, P5021; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Khoo CM, 2007, P NATL ACAD SCI USA, V104, P3931, DOI 10.1073/pnas.0700093104; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Martinez P, 2009, AGING CELL, V8, P2, DOI 10.1111/j.1474-9726.2008.00441.x; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; McClintock B, 1941, GENETICS, V26, P234; Meeker AK, 2004, J MAMMARY GLAND BIOL, V9, P285, DOI 10.1023/B:JOMG.0000048775.04140.92; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Perera SA, 2008, CARCINOGENESIS, V29, P747, DOI 10.1093/carcin/bgn050; Pulaski BA, 1998, CANCER RES, V58, P1486; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Qi L, 2003, CANCER RES, V63, P8188; Rasband W., 2006, IMAGEJ; Rowse GJ, 1998, CANCER RES, V58, P315; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Siegl-Cachedenier I, 2007, GENE DEV, V21, P2234, DOI 10.1101/gad.430107; Sun BC, 2004, CANCER RES, V64, P6144, DOI 10.1158/0008-5472.CAN-04-1376; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Xia JC, 2003, J IMMUNOL, V170, P1980, DOI 10.4049/jimmunol.170.4.1980; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4225	4236		10.1038/onc.2009.268	http://dx.doi.org/10.1038/onc.2009.268			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19734944				2022-12-28	WOS:000272876300001
J	Ueno, S; Tatetsu, H; Hata, H; Iino, T; Niiro, H; Akashi, K; Tenen, DG; Mitsuya, H; Okuno, Y				Ueno, S.; Tatetsu, H.; Hata, H.; Iino, T.; Niiro, H.; Akashi, K.; Tenen, D. G.; Mitsuya, H.; Okuno, Y.			PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL	ONCOGENE			English	Article						myeloma; PU.1; TRAIL; apoptosis; p21	OVERCOMES DRUG-RESISTANCE; TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; REGULATORY ELEMENTS; DISTAL ELEMENTS; LEUKEMIA-CELLS; GENE; EXPRESSION; GROWTH	We earlier reported that PU.1 was downregulated in myeloma cell lines and myeloma cells in a subset of myeloma patients, and that conditional PU.1 expression in PU.1-negative myeloma cell lines, U266 and KMS12PE, induced growth arrest and apoptosis. To elucidate the molecular mechanisms of the growth arrest and apoptosis, we performed DNA microarray analyses to compare the difference in gene expression before and after PU.1 induction in U266 cells. Among cell cycle-related genes, cyclin A2, cyclin B1, CDK2 and CDK4 were downregulated and p21 was upregulated, although among apoptosis-related genes, tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) was found highly upregulated. When TRAIL was knocked down by small interference RNAs, apoptosis of PU-1-expressing cells was inhibited, suggesting that TRAIL has a critical role in PU.1-induced apoptosis in both U266 and KMS12PE myeloma cells. In both U266 and KMS12PE cells expressing PU.1, PU.1 directly bound to a region 30 bp downstream of the transcription start site of the TRAIL gene. Upregulation of PU.1-induced transactivation of the TRAIL promoter in reporter assays, and disruption of the PU.1-binding site in the TRAIL promoter eliminated this transactivation. Therefore, we conclude that PU.1 is capable of inducing apoptosis in certain myeloma cells by direct transactivation of TRAIL. Oncogene (2009) 28, 4116-4125; doi:10.1038/onc.2009.263; published online 14 September 2009	[Ueno, S.; Tatetsu, H.; Hata, H.; Mitsuya, H.; Okuno, Y.] Kumamoto Univ Med, Dept Hematol, Kumamoto 8608556, Japan; [Iino, T.; Niiro, H.; Akashi, K.] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan; [Iino, T.; Akashi, K.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Tenen, D. G.] Harvard Univ, Sch Med, Ctr Life Sci, Boston, MA USA; [Tenen, D. G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore	Kumamoto University; Kyushu University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National University of Singapore	Okuno, Y (corresponding author), Kumamoto Univ Med, Dept Hematol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	yokuno@gpo.kumamoto-u.ac.jp		Tenen, Daniel/0000-0002-6423-3888	International Myeloma Foundation Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER	International Myeloma Foundation Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Award in Aki's Memory from The International Myeloma Foundation Japan (YO) and grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Amaravadi L, 1999, DNA CELL BIOL, V18, P875, DOI 10.1089/104454999314737; Attal M, 2003, NEW ENGL J MED, V349, P2495, DOI 10.1056/NEJMoa032290; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600-065X.2003.00053.x; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kirshner JR, 2005, J VIROL, V79, P9320, DOI 10.1128/JVI.79.14.9320-9324.2005; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Okuno Y, 2002, BLOOD, V100, P4420, DOI 10.1182/blood-2002-03-0788; Okuno Y, 2002, P NATL ACAD SCI USA, V99, P6246, DOI 10.1073/pnas.092027799; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Radomska HS, 2002, BLOOD, V100, P4410, DOI 10.1182/blood-2002-02-0355; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Tatetsu H, 2007, CANCER RES, V67, P5328, DOI 10.1158/0008-5472.CAN-06-4265; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080	33	17	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	2009	28	46					4116	4125		10.1038/onc.2009.263	http://dx.doi.org/10.1038/onc.2009.263			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19749795	Green Accepted			2022-12-28	WOS:000272560500007
J	Seckinger, A; Meissner, T; Moreaux, J; Goldschmidt, H; Fuhler, GM; Benner, A; Hundemer, M; Reme, T; Shaughnessy, JD; Barlogie, B; Bertsch, U; Hillengass, J; Ho, AD; Pantesco, V; Jauch, A; De Vos, J; Rossi, JF; Mohler, T; Klein, B; Hose, D				Seckinger, A.; Meissner, T.; Moreaux, J.; Goldschmidt, H.; Fuhler, G. M.; Benner, A.; Hundemer, M.; Reme, T.; Shaughnessy, J. D., Jr.; Barlogie, B.; Bertsch, U.; Hillengass, J.; Ho, A. D.; Pantesco, V.; Jauch, A.; De Vos, J.; Rossi, J. F.; Moehler, T.; Klein, B.; Hose, D.			Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis	ONCOGENE			English	Article						gene expression profiling; multiple myeloma; angiogenesis; proliferation; survival	MESENCHYMAL STEM-CELLS; MULTIPLE-MYELOMA; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; HEPARAN-SULFATE; PROSTATE-CANCER; GROWTH-FACTOR; UP-REGULATION; B-CELLS; BMP-6	Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance. Bone morphogenic proteins (BMPs) represent possible candidates as they inhibit proliferation, stimulate bone formation and have an effect on the survival of cancer patients. We assessed the expression of BMPs and their receptors by Affymetrix DNA microarrays (n=779) including CD138-purified primary myeloma cell samples (n=635) of previously untreated patients. BMP6 is the only BMP expressed by malignant and normal plasma cells. Its expression is significantly lower in proliferating myeloma cells, myeloma cell lines or plasmablasts. BMP6 significantly inhibits the proliferation of myeloma cell lines, survival of primary myeloma cells and in vitro angiogenesis. A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, beta(2) microglobulin). Oncogene (2009) 28, 3866-3879; doi:10.1038/onc.2009.257; published online 31 August 2009	[Seckinger, A.; Meissner, T.; Goldschmidt, H.; Hundemer, M.; Bertsch, U.; Hillengass, J.; Ho, A. D.; Moehler, T.; Hose, D.] Univ Klinikum Heidelberg, Med Klin 5, D-69120 Heidelberg, Germany; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] Hop St Eloi, Inst Res Biotherapy, CHU Montpellier, Montpellier, France; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] INSERM, U847, Montpellier, France; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] Univ Montpellier, F-34059 Montpellier, France; [Goldschmidt, H.; Moehler, T.; Hose, D.] Natl Ctr Tumorerkrankungen, Heidelberg, Germany; [Fuhler, G. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands; [Benner, A.] Deutsch Krebsforschungszentrum, Biostat Abt, D-6900 Heidelberg, Germany; [Shaughnessy, J. D., Jr.; Barlogie, B.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; [Jauch, A.] Univ Klinikum Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Groningen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Arkansas System; University of Arkansas Medical Sciences; Ruprecht Karls University Heidelberg	Hose, D (corresponding author), Univ Klinikum Heidelberg, Med Klin 5, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	dirk.hose@med.uni-heidelberg.de	J, Moreaux/ABA-2974-2021; De Vos, John/A-5703-2010; moreaux, jerome/HGA-5649-2022	J, Moreaux/0000-0002-5717-3207; De Vos, John/0000-0003-1880-4130; Ho, Anthony D./0000-0002-1656-0833	Hopp-Foundation (Germany); University of Heidelberg (Germany); National Centre for Tumor Diseases (Heidelberg, Germany); Tumorzentrum Heidelberg/Mannheim (Germany); European Community; Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France); Ligue Nationale Contre le Cancer (France)	Hopp-Foundation (Germany); University of Heidelberg (Germany); National Centre for Tumor Diseases (Heidelberg, Germany); Tumorzentrum Heidelberg/Mannheim (Germany); European Community(European Commission); Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France); Ligue Nationale Contre le Cancer (France)(Ligue nationale contre le cancer)	We thank Katrin Heimlich, Maria Dorner and Gabriele Hoock for technical assistance. This work was supported in part by grants from the Hopp-Foundation (Germany), the University of Heidelberg (Germany), the National Centre for Tumor Diseases (Heidelberg, Germany), the Tumorzentrum Heidelberg/Mannheim (Germany), the European Myeloma Stem Cell Network (MSCNET) funded within the 6th framework program of the European Community, Novartis Pharma GmbH (Nuremberg, Germany), the Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France). It is also part of a national program called 'Carte d'Identite des Tumeurs' (CIT) funded by the Ligue Nationale Contre le Cancer (France).	Barlogie B, 2006, BLOOD, V107, P2633, DOI 10.1182/blood-2005-10-4084; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621; Cremer FW, 2005, GENE CHROMOSOME CANC, V44, P194, DOI 10.1002/gcc.20231; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; De Vos J, 2006, IMMUNOL REV, V210, P86, DOI 10.1111/j.0105-2896.2006.00362.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Du J, 2008, J CELL BIOCHEM, V103, P1584, DOI 10.1002/jcb.21547; DURIE BGM, 1986, SEMIN ONCOL, V13, P300; Ebisawa T, 1999, J CELL SCI, V112, P3519; Goldschmidt H, 2003, ANN HEMATOL, V82, P654, DOI 10.1007/s00277-003-0685-2; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Hamdy FC, 1997, CANCER RES, V57, P4427; Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008-5472.CAN-04-2251; Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood-2005-09-3926; Hose D, 2009, BLOOD, V114, P128, DOI 10.1182/blood-2008-10-184226; Hose D, 2009, BLOOD, V113, P4331, DOI 10.1182/blood-2008-09-178350; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jourdan M, 1998, BRIT J HAEMATOL, V100, P637, DOI 10.1046/j.1365-2141.1998.00623.x; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kersten C, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-9; Kersten C, 2006, EXP HEMATOL, V34, P72, DOI 10.1016/j.exphem.2005.09.010; Kim IY, 2003, CLIN CANCER RES, V9, P6046; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Kochanowska I, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-128; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Mahtouk K, 2006, ONCOGENE, V25, P7180, DOI 10.1038/sj.onc.1209699; Mahtouk K, 2005, ONCOGENE, V24, P3512, DOI 10.1038/sj.onc.1208536; Mahtouk K, 2007, BLOOD, V109, P4914, DOI 10.1182/blood-2006-08-043232; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Ren RQ, 2007, BLOOD, V109, P2847, DOI 10.1182/blood-2006-08-039743; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Trojan A, 2006, SWISS MED WKLY, V136, P400; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Witzig TE, 1999, BRIT J HAEMATOL, V104, P131, DOI 10.1046/j.1365-2141.1999.01136.x; Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; ZHANG XG, 1994, BLOOD, V83, P3654	46	64	65	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3866	3879		10.1038/onc.2009.257	http://dx.doi.org/10.1038/onc.2009.257			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718049	Green Submitted, Green Accepted			2022-12-28	WOS:000271471900002
J	Hacker, S; Dittrich, A; Mohr, A; Schweitzer, T; Rutkowski, S; Krauss, J; Debatin, KM; Fulda, S				Haecker, S.; Dittrich, A.; Mohr, A.; Schweitzer, T.; Rutkowski, S.; Krauss, J.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8	ONCOGENE			English	Article						caspase-8; apoptosis; TRAIL; HDACI; medulloblastoma	UP-REGULATING CASPASE-8; DRUG-INDUCED APOPTOSIS; INTERFERON-GAMMA; DEATH RECEPTOR; CELL-DEATH; CHILDHOOD MEDULLOBLASTOMA; PANCREATIC-CARCINOMA; NEUROBLASTOMA-CELLS; EWINGS-SARCOMA; TUMOR CELLS	Evasion of apoptosis can be caused by epigenetic silencing of caspase-8, a key component of the extrinsic apoptosis pathway. Loss of caspase-8 correlates with poor prognosis in medulloblastoma, which highlights the relevance of strategies to upregulate caspase-8 to break apoptosis resistance. Here, we develop a new combinatorial approach, that is treatment using histone deacetylase inhibitors (HDACI) together with interferon (IFN)-gamma, to restore caspase-8 expression and to overcome resistance to the death-receptor ligand TNF-related apoptosis-inducing ligand (TRAIL) in medulloblastoma in vitro and in vivo. HDACI, for example, valproic acid (VA), suberoylanilide hydroxamic acid (SAHA) and MS-275, cooperate with IFN-gamma to upregulate caspase-8 in cancer cells lacking caspase-8, thereby restoring sensitivity to TRAIL-induced apoptosis. Molecular studies show that VA promotes histone acetylation and acts in concert with IFN-gamma to stimulate caspase-8 promoter activity. The resulting increase in caspase-8 mRNA and protein expression leads to enhanced TRAIL-induced activation of caspase-8 at the death-inducing signaling complex, mitochondrial outer-membrane permeabilization and caspase-dependent cell death. Intriguingly, pharmacological or genetic inhibition of caspase-8 also abolishes the VA/IFN-gamma-mediated sensitization for TRAIL-induced apoptosis. It is important to note that VA and IFN-gamma restore caspase-8 expression and sensitivity to TRAIL in primary medulloblastoma samples and significantly potentiate TRAIL-mediated suppression of medulloblastoma growth in vivo. These findings provide the rationale for further (pre)clinical evaluation of VA and IFN-gamma to restore caspase-8 expression and apoptosis sensitivity in cancers with caspase-8 silencing and open new perspectives to overcome TRAIL resistance. Oncogene (2009) 28, 3097-3110; doi: 10.1038/onc.2009.161; published online 13 July 2009	[Haecker, S.; Dittrich, A.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Mohr, A.] Natl Univ Ireland, NCBES, Mol Therapeut Grp, Galway, Ireland; [Schweitzer, T.; Krauss, J.] Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Rutkowski, S.] Univ Wurzburg, Dept Pediat, Wurzburg, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ollscoil na Gaillimhe-University of Galway; University of Wurzburg; University of Wurzburg	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Schweitzer, Tilmann/K-6471-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Mohr, Andrea/0000-0002-4295-0341; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe [IAP6/18]; European Community	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); European Community(European Commission)	We thank R Agami (The Netherlands Cancer Institute, Amsterdam, Netherlands) for providing pRETRO-SUPER vector, CA Schmitt (Berlin, Germany) for mouse Bcl-2 vector, M. Romani (Genova, Italy) for caspase-8 pBL-CAT3 promoter construct, Apoxis (Lausanne, Switzerland) for mega-Fas ligand and F Beguinot (Naples, Italy) for anti-PED antibody. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, IAP6/18 and the European Community (ApopTrain, APOSYS) (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Blaheta RA, 2002, MED RES REV, V22, P492, DOI 10.1002/med.10017; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Fulda S, 2006, ONCOGENE, V25, P5125, DOI 10.1038/sj.onc.1209518; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; FULDA S, 2008, ENCY CANC; FULDA S, 2006, APOPTOSIS CANC THERA, P515; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Guerrini Renzo, 2006, Paediatr Drugs, V8, P113, DOI 10.2165/00148581-200608020-00004; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Jiang MR, 2008, BBA-MOL CELL RES, V1783, P1055, DOI 10.1016/j.bbamcr.2008.02.007; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Li XN, 2005, MOL CANCER THER, V4, P1912, DOI 10.1158/1535-7163.MCT-05-0184; Lissat A, 2007, AM J PATHOL, V170, P1917, DOI 10.2353/ajpath.2007.060993; Meistey N, 2007, EUR J CANCER, V43, P1833, DOI 10.1016/j.ejca.2007.05.028; Merchant MS, 2004, CANCER RES, V64, P8349, DOI 10.1158/0008-5472.CAN-04-1705; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Rutkowski S, 2007, CLIN CANCER RES, V13, P2651, DOI 10.1158/1078-0432.CCR-06-1779; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu Q, 2006, CLIN CANCER RES, V12, P4687, DOI 10.1158/1078-0432.CCR-05-2849; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tekautz TM, 2006, BBA-MOL CELL RES, V1763, P1000, DOI 10.1016/j.bbamcr.2006.06.014; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; van Boxel-Dezaire AHH, 2007, CURR TOP MICROBIOL, V316, P119; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; WEXLER L, 1992, P AN M AM SOC CLIN, V11, P368; Yang XZ, 2003, CANCER RES, V63, P1122	52	87	91	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3097	3110		10.1038/onc.2009.161	http://dx.doi.org/10.1038/onc.2009.161			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19597472				2022-12-28	WOS:000269515100002
J	Akaogi, K; Nakajima, Y; Ito, I; Kawasaki, S; Oie, SH; Murayama, A; Kimura, K; Yanagisawa, J				Akaogi, K.; Nakajima, Y.; Ito, I.; Kawasaki, S.; Oie, S-H; Murayama, A.; Kimura, K.; Yanagisawa, J.			KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ER alpha	ONCOGENE			English	Article						breast cancer; estrogen receptor; KLF4; p53	KRUPPEL-LIKE FACTOR; COLONIC CELL-GROWTH; TUMOR-SUPPRESSOR; NUCLEAR RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; CYCLE ARREST; DNA-DAMAGE; P53; PROMOTER	Kruppel-like factor 4 (KLF4) is a transcription factor that participates in both tumor suppression and oncogenesis. To determine the association of KLF4 with tumorigenesis, we integrated data assembled in the Oncomine database and discovered a decrease in KLF4 gene transcripts in breast cancers. Further analysis of the database also showed a correlation between KLF4 expression and estrogen receptor-alpha (ER alpha) positivity. Knockdown of KLF4 in MCF-7 cells elevated the growth rate of these cells in the presence of estrogen. Therefore, we examined the interaction between KLF4 and ER alpha, and found that KLF4 bound to the DNA-binding region of ER alpha. KLF4 thus inhibits the binding of ER alpha to estrogen response elements in promoter regions, resulting in a reduction in ER alpha target gene transcription. Earlier studies have reported that KLF4 is transcriptionally activated by p53 following DNA damage. We also showed that activation of p53 decreased the transcriptional activity of ER alpha by elevating KLF4 expression. Our studies discovered a novel molecular network between p53, KLF4 and ER alpha. As both p53 and ER alpha are involved in cell growth and apoptosis, these results may explain why KLF4 possesses both tumor suppressive and oncogenic functions in breast cancers. Oncogene (2009) 28, 2894-2902; doi:10.1038/onc.2009.151; published online 8 June 2009	[Akaogi, K.; Nakajima, Y.; Ito, I.; Kawasaki, S.; Oie, S-H; Murayama, A.; Kimura, K.; Yanagisawa, J.] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Murayama, A.; Yanagisawa, J.] Univ Tsukuba, TARA Ctr, Tsukuba, Ibaraki 3058572, Japan; [Murayama, A.] JST, PRESTO, Kawaguchi, Saitama, Japan	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST)	Yanagisawa, J (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.	junny@agbi.tsukuba.ac.jp						Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Blanchon L, 2006, BIOCHEM BIOPH RES CO, V343, P745, DOI 10.1016/j.bbrc.2006.03.032; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; DORGAN JF, 1996, CANCER EPIDEM BIOMAR, V5, P33; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foster KW, 2000, CANCER RES, V60, P6488; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, CANCER RES, V67, P7147, DOI 10.1158/0008-5472.CAN-07-1302; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HENDERSON BE, 1988, CANCER RES, V48, P246; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; Liu WS, 2006, J BIOL CHEM, V281, P9837, DOI 10.1074/jbc.C600001200; Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Oishi Y, 2008, NAT MED, V14, P656, DOI 10.1038/nm1756; Okumura N, 2002, JPN J CANCER RES, V93, P867, DOI 10.1111/j.1349-7006.2002.tb01331.x; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Patel S, 2006, P NATL ACAD SCI USA, V103, P18668, DOI 10.1073/pnas.0608658103; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 1999, GASTROENTEROLOGY, V116, pA520; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Tateishi Y, 2006, MOL CELL BIOL, V26, P7966, DOI 10.1128/MCB.00713-06; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	50	78	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2894	2902		10.1038/onc.2009.151	http://dx.doi.org/10.1038/onc.2009.151			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503094				2022-12-28	WOS:000268917100005
J	Hirsch, FR; Varella-Garcia, M; Cappuzzo, F				Hirsch, F. R.; Varella-Garcia, M.; Cappuzzo, F.			Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer	ONCOGENE			English	Review						non-small-cell lung cancer; EGFR; HER2; biomarker; EGFR TKI	GROWTH-FACTOR-RECEPTOR; GENE COPY NUMBER; MOLECULAR PREDICTORS; GEFITINIB THERAPY; EXPRESSION; MUTATIONS; SENSITIVITY; ERLOTINIB; PROTEIN; RESPONSIVENESS	Epidermal growth factor receptor (EGFR) and HER2 are cell surface receptor tyrosine kinases (TKs) that transduce growth signals through dimerization with HER family receptors. The heterodimerization of EGFR with HER2 induces a more potent activation of EGFR TK than does EGFR homodimerization. When tumor cells overexpress both EGFR and HER2, they exhibit aggressive tumor cell growth, owing to the increased potential for EGFR/HER2 heterodimerization and signaling. Gefitinib and erlotinib are EGFR TK inhibitors (EGFR TKIs) and have antitumor activity in 8-18% of patients with advanced non-small-cell lung cancer (NSCLC). Certain patient subsets are particularly responsive to EGFR TKIs. Analyses of biomarkers from patients in clinical studies of EGFR TKIs show correlations between objective tumor response and EGFR overexpression, as detected by immunohistochemistry and increased gene copy number measured by fluorescence in situ hybridization analysis. Furthermore, NSCLC tumors that overexpress both EGFR and HER2 are more sensitive to EGFR TKIs than are tumors that overexpress EGFR but are HER2 negative. Therefore, the measurement of EGFR and HER2 protein expression and the gene copy number in NSCLC tumors may have a prognostic value in NSCLC and a predictive value for identifying patients likely to benefit from an EGFR TKI. These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC. Oncogene (2009) 28, S32-S37; doi:10.1038/onc.2009.199	[Hirsch, F. R.; Varella-Garcia, M.] Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; [Cappuzzo, F.] IRCCS, Ist Clin Humanitas, Rozzano, Italy	University of Colorado System; University of Colorado Anschutz Medical Campus; IRCCS Humanitas Research Hospital	Hirsch, FR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med Oncol, MS 8117,POB 6511, Aurora, CO 80045 USA.	fred.hirsch@uchsc.edu	Cappuzzo, federico/R-2827-2016	Cappuzzo, federico/0000-0002-6295-6767	Boehringer Ingelheim Pharmaceuticals	Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim)	The authors thank Johnathan C Maher, PhD, of BlueSpark Heathcare Communications for medical and editorial assistance in this paper. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals.	Brabender J, 2001, CLIN CANCER RES, V7, P1850; Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cappuzzo F, 2007, J CLIN ONCOL, V25, P2248, DOI 10.1200/JCO.2006.09.4300; Daniele L, 2007, MOL CANCER THER, V6, P1223, DOI 10.1158/1535-7163.MCT-06-0719; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HERBST RS, 2007, 43 ANN M AM SOC CLIN; Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Hirsch FR, 2002, SEMIN ONCOL, V29, P51, DOI 10.1053/sonc.2002.31523; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Meert AP, 2002, EUR RESPIR J, V20, P975, DOI 10.1183/09031936.02.00296502; Merrick DT, 2006, CLIN CANCER RES, V12, P2281, DOI 10.1158/1078-0432.CCR-05-2291; Onn A, 2004, CLIN CANCER RES, V10, P136, DOI 10.1158/1078-0432.CCR-0373-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; PIRKER R, 2008, J CLIN ONCOL S, V26, pS1006; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Soh J, 2007, INT J CANCER, V121, P1162, DOI 10.1002/ijc.22818; Tokumo M, 2005, CLIN CANCER RES, V11, P1167; Tsai CM, 1996, CANCER RES, V56, P206; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	29	189	200	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S32	S37		10.1038/onc.2009.199	http://dx.doi.org/10.1038/onc.2009.199			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680294				2022-12-28	WOS:000269515400005
J	Pratt, MAC; Tibbo, E; Robertson, SJ; Jansson, D; Hurst, K; Perez-Iratxeta, C; Lau, R; Niu, MY				Pratt, M. A. C.; Tibbo, E.; Robertson, S. J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M. Y.			The canonical NF-kappa B pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population	ONCOGENE			English	Article						NF-kappa B; transgenic mice; mammary cancer; luminal; basal; squamous	BREAST-CANCER; THERAPEUTIC TARGET; TRANSGENIC MICE; EXPRESSION; GROWTH; ALPHA; KINASE; GLAND; IKK; TRANSFORMATION	The role of the canonical NF-kappa B pathway in mammary tumorigenesis was investigated using a transgenic (TG) mouse expressing a dominant-negative inhibitor of kappa B (I kappa B alpha(SR(S32A/S36A))) in the mammary gland under the control of the mouse mammary tumor virus promoter ( MMTV). TG and control mice were subjected to a chemical carcinogenesis protocol. Hyperkeratinized squamous metaplasias ( cytokeratin -6+/p63+) sometimes with a basaloid island component, were found in both TG and control mice whereas luminal (cytokeratin-19+/ MUC1+) ErbB2+ papillary and adenomatous lesions developed almost exclusively in control mice. p65/RelA- and NF-kappa B DNA-binding activity were detected in mammary luminal lesions, but rarely in squamous metaplasias. Analysis of NF-kappa B family proteins and target genes using microarray data from a cohort of human mammary tumors revealed the expression of a canonical NF-kappa B pathway, but not non-canonical pathway proteins in HER2 | luminal cancers. HER2 | tumors also showed differential regulation of specific NF-kappa B target genes relative to basal and ER+ luminal cancers. Isolation of mammary cell populations enriched for stem and progenitor cell characteristics from an NF-kappa B-EGFP reporter mouse by fluorescence-activated cell sorting demonstrated that luminal progenitors contain activated NF-kappa B whereas the mammary stem cell-enriched population, does not. Together these data suggest that the canonical NF-kappa B pathway is active in normal luminal progenitor cells before transformation and is required for the formation of mammary luminal-type epithelial neoplasias. Oncogene (2009) 28, 2710-2722; doi:10.1038/onc.2009.131; published online 1 June 2009	[Pratt, M. A. C.; Tibbo, E.; Jansson, D.; Hurst, K.; Lau, R.; Niu, M. Y.] Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, Ottawa, ON K1H 8M5, Canada; [Robertson, S. J.] Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Perez-Iratxeta, C.] Sprott Ctr Stem Cell Res, Ottawa Hlth Res Inst, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, 451 Smyth Rd,RGN Hall, Ottawa, ON K1H 8M5, Canada.	cpratt@uottawa.ca		Jansson, Deidre/0000-0001-9757-8682; Bone, Kathleen Marie/0000-0002-2690-0934	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance [FRN 79304]; Cancer Research Society Inc.	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance(Canadian Institutes of Health Research (CIHR)); Cancer Research Society Inc.	Our thanks to Jun Wang, Jian Xuan and Jessica Sanguiliano for expert technical assistance. Supported by Grant no. FRN 79304 from the Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance and the Cancer Research Society Inc. to MACP.	Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Grenier J, 2007, ANTICANCER RES, V27, P547; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Tse GM, 2006, PATHOLOGY, V38, P16, DOI 10.1080/00313020500444625; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; WIRAPATI P, 2008, BREAST CANCER RES, V10, P4; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977	37	62	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2710	2722		10.1038/onc.2009.131	http://dx.doi.org/10.1038/onc.2009.131			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483731				2022-12-28	WOS:000268452900002
J	Chin, M; Herscovitch, M; Zhang, N; Waxman, DJ; Gilmore, TD				Chin, M.; Herscovitch, M.; Zhang, N.; Waxman, D. J.; Gilmore, T. D.			Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile	ONCOGENE			English	Article						c-rel; NF-kappa B; malignant transformation; BJAB; lymphoma; microarray	NF-KAPPA-B; EPSTEIN-BARR-VIRUS; TRANSCRIPTION FACTOR REL; TRANSACTIVATION DOMAIN; MOUSE; INDUCTION; CD40; IKK; CHEMOTHERAPY; RESISTANCE	The human REL proto-oncogene encodes a transcription factor in the nuclear factor (NF)-kappa B family. Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown to transform any mammalian lymphoid cell type. In this report, we show that overexpression of a highly transforming mutant of REL (REL Delta TAD1) increases the oncogenic properties of the human B-cell lymphoma BJAB cell line, as shown by increased colony formation in soft agar, tumor formation in SCID (severe combined immunodeficient) mice, and adhesion. BJAB-RELDTAD1 cells also show decreased activation of caspase in response to doxorubicin. BJAB-REL Delta TAD1 cells have increased levels of active nuclear REL protein as determined by immunofluorescence, subcellular fractionation and electrophoretic mobility shift assay. Overexpression of RELDTAD1 in BJAB cells has transformed the gene expression pro. le of BJAB cells from that of a germinal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) (GCB-DLBCL) to that of an activated B-cell subtype (ABC-DLBCL), as evidenced by increased expression of many ABC-defining mRNAs. Upregulated genes in BJAB-RELDTAD1 cells include several NF-kappa B targets that encode proteins previously implicated in B-cell development or oncogenesis, including BCL2, IRF4, CD40 and VCAM1. The cell system we describe here may be valuable for further characterizing the molecular details of REL-induced lymphoma in humans. Oncogene (2009) 28, 2100-2111; doi:10.1038/onc.2009.74; published online 20 April 2009	[Chin, M.; Herscovitch, M.; Zhang, N.; Waxman, D. J.; Gilmore, T. D.] Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu		Waxman, David/0000-0001-7982-9206	Saarland Ministry of Education, Culture and Science; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER	Saarland Ministry of Education, Culture and Science; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Anna-Maria Bohrer for technical assistance and Martina Sester for support in flow cytometry experiments. This work was supported by a grant of the Saarland Ministry of Education, Culture and Science to HU-S.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Clodfelter KH, 2007, PHYSIOL GENOMICS, V31, P63, DOI 10.1152/physiolgenomics.00055.2007; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dierlamm J, 2008, HAEMATOLOGICA, V93, P688, DOI 10.3324/haematol.12057; Enberg I, 1983, INT J CANCER, V31, P163; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; FINKE J, 1992, BLOOD, V80, P459; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2003, VIROLOGY, V316, P9, DOI 10.1016/S0042-6822(03)00562-2; Gupta N, 2008, CANCER RES, V68, P808, DOI 10.1158/0008-5472.CAN-07-3169; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Holloway MG, 2008, MOL ENDOCRINOL, V22, P1274, DOI 10.1210/me.2007-0564; Houldsworth J, 2004, BLOOD, V103, P1862, DOI 10.1182/blood-2003-04-1359; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Leeman JR, 2008, ONCOGENE, V27, P6770, DOI 10.1038/onc.2008.284; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Mainou BA, 2006, J VIROL, V80, P6458, DOI 10.1128/JVI.00135-06; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Pavlidis P, 2003, BIOINFORMATICS, V19, P295, DOI 10.1093/bioinformatics/19.2.295; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Snow AL, 2006, J IMMUNOL, V177, P3283, DOI 10.4049/jimmunol.177.5.3283; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; van Imhoff GW, 2006, J CLIN ONCOL, V24, P4135, DOI 10.1200/JCO.2006.05.5897; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; Voorzanger-Rousselot N, 1998, BLOOD, V92, P3381, DOI 10.1182/blood.V92.9.3381.421k02_3381_3387; WENNBORG A, 1987, INT J CANCER, V40, P202, DOI 10.1002/ijc.2910400213; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	49	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2100	2111		10.1038/onc.2009.74	http://dx.doi.org/10.1038/onc.2009.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377508	Green Accepted			2022-12-28	WOS:000266235800004
J	Laitem, C; Leprivier, G; Choul-Li, S; Begue, A; Monte, D; Larsimont, D; Dumont, P; Duterque-Coquillaud, M; Aumercier, M				Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Larsimont, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.			Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51	ONCOGENE			English	Article						Ets-1; transcriptional regulation; subcellular localization; dominant-negative isoform; alternative splicing	ALTERNATIVELY SPLICED ISOFORMS; MESSENGER-RNA; DNA-BINDING; STROMELYSIN PROMOTER; ENDOTHELIAL-CELLS; EXPRESSION; PROTEIN; GENE; PROTOONCOGENE; CARCINOMA	The transcription factor Ets-1 is implicated in various physiological processes and invasive pathologies. We identified a novel variant of ets-1, ets-1 Delta(III-VI), resulting from the alternative splicing of exons III to VI. This variant encodes a 27 kDa isoform, named Ets-1 p27. Ets-1 p27 lacks the threonine-38 residue, the Pointed domain and the transactivation domain, all of which are required for the transactivation of Ets-1 target genes. Both inhibitory domains surrounding the DNA-binding domain are conserved, suggesting that Ets-1 p27, like the full-length Ets-1 p51 isoform, is autoinhibited for DNA binding. We showed that Ets-1 p27 binds DNA in the same way as Ets-1 p51 does and that it acts both at a transcriptional and a subcellular localization level, thereby constituting a dual-acting dominant negative of Ets-1 p51. Ets-1 p27 blocks Ets-1 p51-mediated transactivation of target genes and induces the translocation of Ets-1 p51 from the nucleus to the cytoplasm. Furthermore, Ets-1 p27 overexpression represses the tumor properties of MDA-MB-231 mammary carcinoma cells in correlation with the known implication of Ets-1 in various cellular mechanisms. Thus the dual-acting dominant-negative function of Ets-1 p27 gives to the Ets-1 p27/Ets-1 p51 ratio a determining effect on cell fate. Oncogene (2009) 28, 2087-2099; doi:10.1038/onc.2009.72; published online 20 April 2009	[Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.] Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8161, F-59021 Lille, France; [Laitem, C.; Leprivier, G.; Choul-Li, S.; Begue, A.; Monte, D.; Dumont, P.; Duterque-Coquillaud, M.; Aumercier, M.] Univ Lille 2, IFR 142, Lille, France; [Larsimont, D.] Inst Jules Bordet, Dept Pathol, B-1000 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Institut Jules Bordet; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Aumercier, M (corresponding author), Univ Lille 1, Inst Pasteur Lille, Inst Biol Lille, CNRS,UMR 8161, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.	marc.aumercier@ibl.fr	CHOUL-LI, Souhaila/ABA-2431-2020	CHOUL-LI, Souhaila/0000-0003-0682-4214; Duterque-Coquillaud, Martine/0000-0003-3943-5629; monte, didier/0000-0002-0613-6203	Centre National de la Recherche Scientifique (CNRS); la Ligue contre le Cancer- Comite du Pas-de-Calais; Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); la Ligue contre le Cancer- Comite du Pas-de-Calais; Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM)(Fondation pour la Recherche Medicale)	We thank Isabelle Roland, Anne-Claire Flourens, Nathalie Tomavo and Arnaud Legrand for technical assistance, and Dr Yvan de Launoit for stimulating discussions. We thank the Microscopy Facility of the Institut Pasteur de Lille Campus. This work was supported by the Centre National de la Recherche Scientifique (CNRS) and by grants from la Ligue contre le Cancer- Comite du Pas-de-Calais and from the Fondation pour la Recherche Medicale-Comite Nord-Pas-de-Calais (FRM). The Ministere de la Recherche et de l'Enseignement Superieur provided a student fellowship to Clelia Laitem. La Ligue contre le Cancer provided a student fellowship to Gabriel Leprivier. The CNRS and the Conseil Regional du Nord-Pas-de-Calais provided a PhD fellowship (BDI) to Souhaila Choul-li.	Alipov G, 2005, HISTOPATHOLOGY, V46, P202, DOI 10.1111/j.1365-2559.2005.02059.x; Araud T, 2007, NUCLEIC ACIDS RES, V35, P4649, DOI 10.1093/nar/gkm482; Baillat D, 2006, ONCOGENE, V25, P5764, DOI 10.1038/sj.onc.1209583; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Baillat D, 2009, BIOCHEM BIOPH RES CO, V378, P213, DOI 10.1016/j.bbrc.2008.11.035; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Cho JY, 2004, J BIOL CHEM, V279, P19512, DOI 10.1074/jbc.M309074200; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Cowley DO, 2000, GENE DEV, V14, P366; De Haro L, 2005, GENOMICS, V85, P493, DOI 10.1016/j.ygeno.2004.12.003; de Nigris F, 2001, CANCER RES, V61, P2267; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; FISHER RJ, 1994, PROTEIN SCI, V3, P257; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Hewett PW, 2001, INT J BIOCHEM CELL B, V33, P347, DOI 10.1016/S1357-2725(01)00022-X; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Higuchi T, 2007, MOL CELL BIOL, V27, P3353, DOI 10.1128/MCB.01871-06; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; John SA, 2008, J BIOL CHEM, V283, P951, DOI 10.1074/jbc.M705262200; JORCYK CL, 1991, ONCOGENE, V6, P523; Katayama S, 2005, HISTOL HISTOPATHOL, V20, P119, DOI 10.14670/HH-20.119; Kherrouche Z, 2006, BIOCHEM J, V396, P547, DOI 10.1042/BJ20051981; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 1999, MODERN PATHOL, V12, P618; KOIZUMI S, 1990, ONCOGENE, V5, P675; Laitem C, 2008, PROTEIN EXPRES PURIF, V62, P53, DOI 10.1016/j.pep.2008.06.010; Lee GM, 2005, J BIOL CHEM, V280, P7088, DOI 10.1074/jbc.M410722200; Lei WL, 2007, AM J PHYSIOL-LUNG C, V293, pL1359, DOI 10.1152/ajplung.00130.2007; Li B, 2007, FRONT BIOSCI-LANDMRK, V12, P2269, DOI 10.2741/2229; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Mylona EE, 2006, CANCER DETECT PREV, V30, P111, DOI 10.1016/j.cdp.2006.03.006; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; O'Leary DA, 2005, GENE, V344, P79, DOI 10.1016/j.gene.2004.09.031; POGNONEC P, 1990, ONCOGENE, V5, P603; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Raffetseder U, 2004, KIDNEY INT, V66, P622, DOI 10.1111/j.1523-1755.2004.00782.x; RayGallet D, 1996, BIOCHEM BIOPH RES CO, V223, P257, DOI 10.1006/bbrc.1996.0881; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; ROWE A, 1992, EXP CELL RES, V202, P199, DOI 10.1016/0014-4827(92)90420-D; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Sasaki A, 2004, BIOCHEM BIOPH RES CO, V317, P1128, DOI 10.1016/j.bbrc.2004.03.172; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Takai N, 2000, CANCER, V89, P2059, DOI 10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3; Takai N, 2006, GYNECOL OBSTET INVES, V61, P15, DOI 10.1159/000087855; Takai N, 2002, INT J MOL MED, V9, P287; Taniguchi H, 2007, INT J CANCER, V121, P1609, DOI 10.1002/ijc.22870; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Valter MM, 1999, CANCER RES, V59, P5608; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	54	31	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2087	2099		10.1038/onc.2009.72	http://dx.doi.org/10.1038/onc.2009.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377509				2022-12-28	WOS:000266235800003
J	Uhlmann-Schiffler, H; Kiermayer, S; Stahl, H				Uhlmann-Schiffler, H.; Kiermayer, S.; Stahl, H.			The DEAD box protein Ddx42p modulates the function of ASPP2, a stimulator of apoptosis	ONCOGENE			English	Article						apoptosis; ASPP2; Ddx42p; p53; ubiquitination	MESSENGER-RNA; KAPPA-B; TUMOR-SUPPRESSOR; P53; HELICASE; 53BP2; EXPRESSION; P68; PROLIFERATION; INHIBITION	Ddx42p is a recently characterized mammalian DEAD box protein with unknown cellular function. We found that in human cells Ddx42p physically interacts with ASPP2, a major apoptosis inducer known to enhance p53 transactivation of proapoptotic genes. The proteins interact via a domain within the carboxy-terminal part of Ddx42p and a mid-amino-terminal sequence as well as the ankyrin-SH3 region of ASPP2. Overexpression of Ddx42p interferes with apoptosis induction by ASPP2, whereas Ddx42p knockdown reduces the survival rate of cultured human cells. In addition, ASPP2 is found in cytoplasm and nucleus at low Ddx42p level, and predominantly in cytoplasm at high concentration of Ddx42p, respectively. Our results show that Ddx42p is capable of modulating ASPP2 function. Oncogene (2009) 28, 2065-2073; doi:10.1038/onc.2009.75; published online 20 April 2009	[Uhlmann-Schiffler, H.; Kiermayer, S.; Stahl, H.] Univ Saarland, Dept Med Biochem & Mol Biol, D-6642 Homburg, Germany	Saarland University	Uhlmann-Schiffler, H (corresponding author), Univ Saarland, Dept Med Biochem & Mol Biol, Kirrberger St Geb 45, D-6642 Homburg, Germany.	heike.uhlmann.schiffler@uniklinikum-saarland.de			Saarland Ministry of Education, Culture and Science	Saarland Ministry of Education, Culture and Science	We thank Anna-Maria Bohrer for technical assistance and Martina Sester for support in flow cytometry experiments. This work was supported by a grant of the Saarland Ministry of Education, Culture and Science to HU-S.	Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Chen YZ, 2003, J NEUROCHEM, V85, P801, DOI 10.1046/j.1471-4159.2003.01727.x; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; Goh PY, 2004, J VIROL, V78, P5288, DOI 10.1128/JVI.78.10.5288-5298.2004; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gutti RK, 2008, J BIOL CHEM, V283, P17055, DOI 10.1074/jbc.M708449200; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058; Katz C, 2008, P NATL ACAD SCI USA, V105, P12277, DOI 10.1073/pnas.0711269105; Kobayashi S, 2005, GENES CELLS, V10, P253, DOI 10.1111/j.1365-2443.2005.00835.x; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lin CW, 2008, VIRUS RES, V137, P49, DOI 10.1016/j.virusres.2008.05.015; Lin F, 2008, CANCER BIOL THER, V7, P1669, DOI 10.4161/cbt.7.10.6660; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Rotem S, 2008, J BIOL CHEM, V283, P18990, DOI 10.1074/jbc.M708717200; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Takahashi N, 2005, GENES CELLS, V10, P803, DOI 10.1111/j.1365-2443.2005.00878.x; Tidow H, 2007, J MOL BIOL, V371, P948, DOI 10.1016/j.jmb.2007.05.024; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Uhlmann-Schiffler H, 2006, NUCLEIC ACIDS RES, V34, P10, DOI 10.1093/nar/gkj403; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhu ZY, 2005, J BIOL CHEM, V280, P34473, DOI 10.1074/jbc.M503736200	35	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2065	2073		10.1038/onc.2009.75	http://dx.doi.org/10.1038/onc.2009.75			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377511				2022-12-28	WOS:000266235800001
J	Senapati, S; Rachagani, S; Chaudhary, K; Johansson, SL; Singh, RK; Batra, SK				Senapati, S.; Rachagani, S.; Chaudhary, K.; Johansson, S. L.; Singh, R. K.; Batra, S. K.			Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway	ONCOGENE			English	Article						MIC-1; prostate; cancer; metastasis	TGF-BETA SUPERFAMILY; FOCAL-ADHESION KINASE; MORPHOGENETIC PROTEIN; BONE METASTASES; GROWTH-FACTOR; WEIGHT-LOSS; EXPRESSION; MEMBER; MIC-1; ACTIVATION	An elevated level of macrophage inhibitory cytokine-1 (MIC-1) is reported in the sera of patients with metastatic prostate cancer compared with that of benign diseases and healthy adults. We investigated the mechanistic role of MIC-1 overexpression in the metastasis of prostate cancer cells. Our study showed a progressive increase in secretory MIC-1 production correlated with the increase in the metastatic potential of PC-3 and LNPCa prostate cancer metastatic variants. Further, the in vitro studies using 'loss-' and 'gain'-of-function approaches showed that ectopic overexpression of MIC-1 (PC-3-MIC-1) and forced downregulation of MIC-1(PC-3M-siMIC-1) enhanced and reduced the motility and invasiveness of these cells, respectively. Supporting our in vitro observations, all the mice orthotopically implanted with PC-3-MIC-1 cells developed metastasis compared with none in the PC-3-vector group. Our results showed that MIC-1 overexpression was associated with apparent changes in actin organization. In addition, an enhanced phosphorylation of focal adhesion kinase (FAK) and guanosine-5'-triphosphate (GTP)-bound RhoA was also seen; however, no significant change was observed in total FAK and RhoA levels in the PC-3-MIC-1 cells. Altogether, our findings show that MIC-1 has a role in prostate cancer metastasis, in part, by promoting the motility of these cells. Activation of the FAK-RhoA signaling pathway is involved in MIC-1-mediated actin reorganization, and thus, leads to an increase in the motility of prostate cancer cells. Oncogene (2010) 29, 1293-1302; doi:10.1038/onc.2009.420; published online 30 November 2009	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA.	sbatra@unmc.edu		Senapati, Shantibhusan/0000-0001-7108-8255	Department of Defense [PC040502, PC074289]; NCI Cancer Center [P30 CA36727]; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA078590] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported, in part, by grants from the Department of Defense (PC040502 and PC074289). We thank Dr Ajay P Singh for reading the paper and for his valuable suggestions. We also thank Erik Moore for his technical assistance and Kristi LW Berger for editing the paper. We also acknowledge the NCI Cancer Center Support Grant (P30 CA36727) to UNMC.	Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Barrack ER, 1997, PROSTATE, V31, P61; Bauskin AR, 2005, CANCER RES, V65, P2330, DOI 10.1158/0008-5472.CAN-04-3827; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; Chen SJ, 2007, PROSTATE, V67, P557, DOI 10.1002/pros.20551; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Hodge JC, 2003, CANCER RES, V63, P1359; Hromas R, 1997, BBA-GENE STRUCT EXPR, V1354, P40, DOI 10.1016/S0167-4781(97)00122-X; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johnen H, 2007, NAT MED, V13, P1333, DOI 10.1038/nm1677; Karan D, 2003, BIOCHEM BIOPH RES CO, V305, P598, DOI 10.1016/S0006-291X(03)00823-4; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Karan D, 2009, CANCER RES, V69, P2, DOI 10.1158/0008-5472.CAN-08-1230; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692; Lawton LN, 1997, GENE, V203, P17, DOI 10.1016/S0378-1119(97)00485-X; Lee DH, 2003, CANCER RES, V63, P4648; Liu T, 2003, CANCER RES, V63, P5034; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Patrikainen L, 2007, EUR J CLIN INVEST, V37, P126, DOI 10.1111/j.1365-2362.2007.01763.x; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Robinson Victoria L, 2004, Cancer Treat Res, V118, P1; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055-9965.EPI-06-0841; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200	35	94	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1293	1302		10.1038/onc.2009.420	http://dx.doi.org/10.1038/onc.2009.420			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946339	Green Accepted			2022-12-28	WOS:000275170600005
J	Bonadies, N; Neururer, C; Steege, A; Vallabhapurapu, S; Pabst, T; Mueller, BU				Bonadies, N.; Neururer, Ch; Steege, A.; Vallabhapurapu, S.; Pabst, T.; Mueller, B. U.			PU.1 is regulated by NF-kappa B through a novel binding site in a 17 kb upstream enhancer element	ONCOGENE			English	Article						NF-kappa B; PU.1; Spi-1; enhancer	TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA BINDS; DNA-BINDING; GENE; EXPRESSION; NEUTROPHILS; DISRUPTION; MECHANISMS; PROMOTER	The majority of patients with acute myeloid leukemia (AML) still die of their disease, and novel therapeutic concepts are needed. Timely expression of the hematopoietic master regulator PU.1 is crucial for normal development of myeloid and lymphoid cells. Targeted disruption of an upstream regulatory element (URE) located several kb upstream in the PU.1 promoter decreases PU.1 expression thereby inducing AML in mice. In addition, suppression of PU.1 has been observed in specific subtypes of human AML. Here, we identified nuclear factor-kappa B (NF-kappa B) to activate PU.1 expression through a novel site within the URE. We found sequence variations of this particular NF-kappa B site in 4 of 120 AML patients. These variant NF-kappa B sequences failed to mediate activation of PU.1. Moreover, the synergistic activation of PU.1 together with CEBPB through these variant sequences was also lost. Finally, AML patients with such variant sequences had suppressed PU.1 mRNA expression. This study suggests that changes of a single base pair in a distal element critically affect the regulation of the tumor suppressor gene PU.1 thereby contributing to the development of AML. Oncogene (2010) 29, 1062-1072; doi:10.1038/onc.2009.371; published online 7 December 2009	[Bonadies, N.; Neururer, Ch; Steege, A.; Vallabhapurapu, S.; Mueller, B. U.] Univ Bern, Univ Hosp Bern, Dept Internal Med & Clin Res, CH-3010 Bern, Switzerland; [Pabst, T.] Univ Bern, Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Mueller, BU (corresponding author), Univ Bern, Univ Hosp Bern, Dept Internal Med & Clin Res, CH-3010 Bern, Switzerland.	beatrice.mueller@insel.ch	Bonadies, Nicolas/F-2388-2017; Steege, Andreas/F-3885-2010	Bonadies, Nicolas/0000-0001-8761-2066; 	Swiss National Science Foundation [SF 310000-113761]; Swiss Cancer League [OCS 01731082005]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League	This work was supported by a grant from the Swiss National Science Foundation SF 310000-113761 (to BUM), and a grant from the Swiss Cancer League, OCS 01731082005 (to BUM).	Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; Friedman AD, 2007, BLOOD CELL MOL DIS, V39, P340, DOI 10.1016/j.bcmd.2007.06.010; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; HROMAS R, 1993, BLOOD, V82, P2998; Huang G, 2008, NAT GENET, V40, P51, DOI 10.1038/ng.2007.7; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; Nijnik A, 2003, NUCLEIC ACIDS RES, V31, P1497, DOI 10.1093/nar/gkg231; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Paz-Priel I, 2005, MOL CANCER RES, V3, P585, DOI 10.1158/1541-7786.MCR-05-0111; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Steidl U, 2007, J CLIN INVEST, V117, P2611, DOI 10.1172/JCI30525; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Suraweera N, 2005, ONCOGENE, V24, P3678, DOI 10.1038/sj.onc.1208422; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; Yeamans C, 2007, BLOOD, V110, P3136, DOI 10.1182/blood-2007-03-080291	39	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1062	1072		10.1038/onc.2009.371	http://dx.doi.org/10.1038/onc.2009.371			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19966852				2022-12-28	WOS:000274604400012
J	Rodriguez-Ubreva, FJ; Cariaga-Martinez, AE; Cortes, MA; Romero-De Pablos, M; Ropero, S; Lopez-Ruiz, P; Colas, B				Rodriguez-Ubreva, F. J.; Cariaga-Martinez, A. E.; Cortes, M. A.; Romero-De Pablos, M.; Ropero, S.; Lopez-Ruiz, P.; Colas, B.			Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery	ONCOGENE			English	Article						prostate cancer; cell cycle; p27; CDK2; SHP-1	GROWTH-FACTOR; DEPENDENT PHOSPHORYLATION; TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; KINASE-ACTIVITY; CDK INHIBITORS; NUCLEAR IMPORT; ACTIVATION; P27(KIP1); DOMAIN	SHP-1, a haematopoietic cell-specific tyrosine phosphatase, is also expressed in human prostate. In this study, we report that SHP-1 depletion in PC-3 cells induced by small interfering RNAs causes G1 phase cell-cycle arrest accompanied by changes in some components of the cell-cycle machinery. SHP-1 knockdown increases p27(Kip1) (p27) protein stability, its nuclear localization and p27 gene transcription. These effects could be mediated by PI3K-AKT pathway as SHP-1 interacts with PI3K regulating its activity and p110 catalytic subunit phosphorylation. The increase in p27 protein stability could also because of reduced cyclin-dependent kinase (CDK2) activity. SHP-1 knockdown decreases the CDK6 levels, inducing retinoblastoma protein hypophosphorylation, downregulation of cyclin E and thereby a decrease in the CDK2 activity. However, the codepletion of SHP-1 and p27 does not produce re-entry into the cycle, implying that p27 is not required to maintain cell-cycle arrest induced by SHP-1 depletion. The maintenance of the PC-3 cell anti-proliferative response after p27 loss could be because of mislocalization of CDK2 induced by SHP-1 knockdown. This study shows that SHP-1 depletion promotes cell-cycle arrest by modulating the activity of cell-cycle regulators and suggests that SHP-1 may be required for the proper functioning of events governing cell-cycle progression. Oncogene (2010) 29, 345-355; doi:10.1038/onc.2009.329; published online 19 October 2009	[Colas, B.] Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, E-28871 Madrid, Spain; [Romero-De Pablos, M.] Univ Alcala de Henares, Dept Fisiol, E-28871 Madrid, Spain	Universidad de Alcala; Universidad de Alcala	Colas, B (corresponding author), Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, Madrid Barcelona Km 33,600, E-28871 Madrid, Spain.	begona.colas@uah.es	Cariaga-Martinez, Ariel Ernesto/M-3619-2018; de Pablos, Montserrat Romero/AAK-3167-2021; Cortés, María Alicia/ABG-3899-2020	Cariaga-Martinez, Ariel Ernesto/0000-0003-1457-995X; de Pablos, Montserrat Romero/0000-0002-2801-6376; Cortés, María Alicia/0000-0001-7765-5302; RODRIGUEZ-UBREVA, JAVIER/0000-0003-4707-4536	Consejeria de Sanidad de Castilla-La Mancha [04077-00]; Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant [PI060109]; FPI fellowship, Comunidad de Madrid; Fundacion Carolina; FPI fellowship Consejeria de Educacion de Castilla-La Mancha	Consejeria de Sanidad de Castilla-La Mancha; Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant(Instituto de Salud Carlos III); FPI fellowship, Comunidad de Madrid(Comunidad de MadridSpanish Government); Fundacion Carolina; FPI fellowship Consejeria de Educacion de Castilla-La Mancha	We are very grateful to Dr T Sakai (Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan) for providing human p27 promoter containing luciferase reporter construct (p27PF) and control empty vector and also to Dr FD Bohmer (Institute of Molecular Cell Biology, Medical Faculty, Friedrich Schiller University, Jena, Germany) for providing GST-SHP-1 wild type. This work was supported by Consejeria de Sanidad de Castilla-La Mancha grant (04077-00); Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant (PI060109); FPI fellowship, Comunidad de Madrid (FJ Rodriguez-Ubreva); Fundacion Carolina and FPI fellowship Consejeria de Educacion de Castilla-La Mancha (AE Cariaga-Martinez).	Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Caron D, 2008, CANCER LETT, V262, P265, DOI 10.1016/j.canlet.2007.12.012; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nakagawa H, 2001, FEBS LETT, V508, P53, DOI 10.1016/S0014-5793(01)03021-6; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Seo DW, 2006, J BIOL CHEM, V281, P3711, DOI 10.1074/jbc.M509932200; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Simoneau M, 2008, J BIOL CHEM, V283, P25544, DOI 10.1074/jbc.M804177200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Valencia AM, 1997, FEBS LETT, V406, P42, DOI 10.1016/S0014-5793(97)00235-4; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zapata PD, 2002, J CLIN ENDOCR METAB, V87, P915, DOI 10.1210/jc.87.2.915; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; 2005, BMC BIOINFORMATICS, V6, P62	44	35	36	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					345	355		10.1038/onc.2009.329	http://dx.doi.org/10.1038/onc.2009.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838216				2022-12-28	WOS:000273793200004
J	Watson, IR; Li, BK; Roche, O; Blanch, A; Ohh, M; Irwin, MS				Watson, I. R.; Li, B. K.; Roche, O.; Blanch, A.; Ohh, M.; Irwin, M. S.			Chemotherapy induces NEDP1-mediated destabilization of MDM2	ONCOGENE			English	Article						chemotherapy; MDM2; NEDD8; NEDP1; p53	DNA-DAMAGE; IN-VIVO; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; COP9 SIGNALOSOME; P53; NEDD8; PROTEINS; PROTEASE; PATHWAY	MDM2 is an E3 ligase that promotes ubiquitin-mediated destruction of p53. Cellular stresses such as DNA damage can lead to p53 activation due in part to MDM2 destabilization. Here, we show that the stability of MDM2 is regulated by an ubiquitin-like NEDD8 pathway and identify NEDP1 as a chemotherapy-induced isopeptidase that deneddylates MDM2, resulting in MDM2 destabilization concomitant with p53 activation. Concordantly, RNAi-mediated knockdown of endogenous NEDP1 blocked diminution of MDM2 levels and increased chemoresistance of tumor cells. These findings unveil the regulation of MDM2 stability through NEDP1 as a common molecular determinant governing chemotherapy-induced p53-dependent cell death. Oncogene (2010) 29, 297-304; doi:10.1038/onc.2009.314; published online 28 September 2009	[Watson, I. R.; Li, B. K.; Roche, O.; Ohh, M.; Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Irwin, M. S.] Hosp Sick Children, Dept Paediat & Cell Biol, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Irwin, M. S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Irwin, MS (corresponding author), Hosp Sick Children, Dept Paediat & Cell Biol, Cell Biol Program, 555 Univ Ave,Black Wing 9th Floor, Toronto, ON M5G 1X8, Canada.	michael.ohh@utoronto.ca; meredith.irwin@sickkids.ca	Roche, UCLM/F-5697-2019; Roche, Olga/K-9342-2014	Roche, UCLM/0000-0003-1884-8256; Watson, Ian/0000-0002-6025-3080; Li, Kincheon/0000-0001-6640-2625	Canadian Cancer Society Research Institute (CCSRI) [018460, 018054]; Hospital for Sick Children Foundation; Canadian Institutes of Health Research (CIHR) Canada	Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Hospital for Sick Children Foundation; Canadian Institutes of Health Research (CIHR) Canada(Canadian Institutes of Health Research (CIHR))	We thank Lynn Cheng, Joanne Lau, Roxana Sufan and Ryan Russell for their technical assistance. We thank Drs Uri Tabori and Loretta Lau for helpful discussions. We thank Drs Stephen Meyn and Paul Bradshaw for providing AT reagents. This work was supported by funds from the Canadian Cancer Society Research Institute (CCSRI 018460 to MO and 018054 to MSI). IRW is a recipient of the Hospital for Sick Children Foundation Student Scholarship and the Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship. OR is a recipient of the CIHR Fellowship. MO and MSI are Canada Research Chairs.	Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chan Y, 2008, J CELL SCI, V121, P3218, DOI 10.1242/jcs.030445; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Hetfeld BKJ, 2008, APOPTOSIS, V13, P187, DOI 10.1007/s10495-007-0164-7; Huang HY, 2008, CLIN CANCER RES, V14, P6023, DOI 10.1158/1078-0432.CCR-08-0252; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Jones J, 2008, J PROTEOME RES, V7, P1274, DOI 10.1021/pr700749v; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Koschny R, 2006, PATHOL RES PRACT, V202, P23, DOI 10.1016/j.prp.2005.10.010; Lau L, 2007, ONCOGENE, V26, P1920, DOI 10.1038/sj.onc.1209981; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Levav-Cohen Y, 2005, GROWTH FACTORS, V23, P183, DOI 10.1080/08977190500196218; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LUNA RMD, 1995, NATURE, V378, P203; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Paunu N, 2002, CANCER RES, V62, P3798; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Suzuki H, 2008, LUNG CANCER, V59, P24, DOI 10.1016/j.lungcan.2007.08.002; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wu JT, 2005, NAT CELL BIOL, V7, P1014, DOI 10.1038/ncb1301; Wu K, 2003, J BIOL CHEM, V278, P28882, DOI 10.1074/jbc.M302888200; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yamoah K, 2005, METHOD ENZYMOL, V398, P509, DOI 10.1016/S0076-6879(05)98042-7; Zhang XC, 2008, J CELL BIOCHEM, V103, P1219, DOI 10.1002/jcb.21504; Zhou LH, 2005, BIOCHEM J, V389, P307, DOI 10.1042/BJ20041991	34	39	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					297	304		10.1038/onc.2009.314	http://dx.doi.org/10.1038/onc.2009.314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19784069				2022-12-28	WOS:000273650000012
J	Nirde, P; Derocq, D; Maynadier, M; Chambon, M; Basile, I; Gary-Bobo, M; Garcia, M				Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.			Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells	ONCOGENE			English	Article						cancer; growth inhibition; Hsc70; secretion; extracellular; cathepsin D	TRANSFECTED CATHEPSIN-D; BREAST-CANCER; TUMOR-CELLS; HSP70-LIKE PROTEIN; CRYSTAL-STRUCTURES; HEAT-SHOCK-PROTEIN-70; EXPRESSION; HSC70; RELEASE; DEGRADATION	Earlier studies indicated that density-arrested cancer cells released an unidentified growth inhibitor whose secretion was prevented by overexpression of the lysosomal protease cathepsin D (cath D). In this study, this growth inhibitor was purified by affinity chromatography and identified as the heat shock cognate 70 protein (hsc70) based on its peptide microsequencing and specific antibody recognition. Among intracellular proteins, including other heat shock proteins, only constitutive hsc70 was secreted in response to the high-cell density. Moreover, hsc70 secretion from cancer cells was generated by serum deprivation, whereas its cellular concentration did not change. Prevention of Hsc70 secretion by cath D overexpression was associated with the formation of multilayer cell cultures, thus indicating a loss of contact inhibition. In addition, we showed that supplementing the culture medium with purified hsc70 inhibited cell proliferation in the nanomolar range. Conversely, removal of this extracellular hsc70 from the medium by either retention on ADP-agarose or competition at the Hsc70 binding site restored cell proliferation. Hsc70 appears active in human breast cancer cells and hypersecreted by direct cath D inhibition. These results suggest a new role of this secreted hsc70 chaperone in cell proliferation that might account for the higher tumor growth of cancer cells overexpressing cath D.	[Garcia, M.] CRLC Val dAurelle Paul Lamarque, IRCM, F-34298 Montpellier 5, France; [Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.] INSERM, U896, Montpellier, France; [Nirde, P.; Derocq, D.; Maynadier, M.; Chambon, M.; Basile, I.; Gary-Bobo, M.; Garcia, M.] Univ Montpellier I, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier	Garcia, M (corresponding author), CRLC Val dAurelle Paul Lamarque, IRCM, 208 Rue Apothicaires, F-34298 Montpellier 5, France.	marcel.garcia@valdorel.fnclcc.fr			Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer; Ligue contre le cancer; Comite de l'Herault; CNRS	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue contre le cancer(Ligue nationale contre le cancer); Comite de l'Herault; CNRS(Centre National de la Recherche Scientifique (CNRS))	We thank Jean Derancourt, (Centre de Recherches de Biochimie Macromoleculaire du CNRS, 1919 Route de Mende, 34293 Montpellier Cedex 5, France) for peptide fragments analysis. The authors thank the Centre Regional d'Imagerie Cellulaire (Montpellier-France) for access to the scanning microscopy facilities. This work was supported by the Institut National de la Sante et de la Recherche Medicale, the Association pour la Recherche sur le Cancer, the Ligue contre le cancer, Comite de l'Herault (fellowship to MM), and CNRS.	ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; ABERCROMBIE M, 1954, EXP CELL RES, V6, P293, DOI 10.1016/0014-4827(54)90176-7; Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; Anagnostopouloua A, 2006, CANCER LETT, V242, P120, DOI 10.1016/j.canlet.2005.10.047; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bossard N, 2003, BREAST CANCER RES TR, V82, P47, DOI 10.1023/B:BREA.0000003919.75055.e8; Brighty DW, 2001, J VIROL, V75, P10472, DOI 10.1128/JVI.75.21.10472-10478.2001; Brocchieri L, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-19; Chen S, 2007, J NEUROSCI RES, V85, P402, DOI 10.1002/jnr.21124; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CIOCCA DR, 1992, CANCER RES, V52, P3648; Ciocca DR, 2003, CELL STRESS CHAPERON, V8, P26, DOI 10.1379/1466-1268(2003)8<26:HAHIRT>2.0.CO;2; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494; COHEN LA, 1974, IN VITRO CELL DEV B, V10, P51, DOI 10.1007/BF02615338; Dressel R, 2003, CANCER RES, V63, P8212; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; ELLEDGE RM, 1994, CANCER RES, V54, P3752; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fouchaq B, 1999, EUR J BIOCHEM, V259, P379, DOI 10.1046/j.1432-1327.1999.00053.x; GARCIA M, 1990, ONCOGENE, V5, P1809; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; Geminard C, 2001, J BIOL CHEM, V276, P9910, DOI 10.1074/jbc.M009641200; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Goldfarb SB, 2006, P NATL ACAD SCI USA, V103, P5817, DOI 10.1073/pnas.0507903103; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Kao RH, 2003, INT J EXP PATHOL, V84, P207, DOI 10.1111/j.1365-2613.2003.00356.x; Lazaris AC, 1997, BREAST CANCER RES TR, V43, P43, DOI 10.1023/A:1005706110275; LIAUDET E, 1995, CELL GROWTH DIFFER, V6, P1045; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marnbula SS, 2007, METHODS, V43, P168, DOI 10.1016/j.ymeth.2007.06.009; Melendez K, 2006, CELL STRESS CHAPERON, V11, P334, DOI 10.1379/CSC-187.1; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Nylandsted J, 2002, CANCER RES, V62, P7139; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; Rohde M, 2005, GENE DEV, V19, P570, DOI 10.1101/gad.305405; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; Saito K, 2005, EXP CELL RES, V310, P229, DOI 10.1016/j.yexcr.2005.07.014; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; Soulier S, 1996, GENE, V172, P285, DOI 10.1016/0378-1119(96)00169-2; Srivastava Pramod K, 2005, Curr Oncol Rep, V7, P104, DOI 10.1007/s11912-005-0035-8; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; Thanner F, 2003, ANTICANCER RES, V23, P1057; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Torronteguy C, 2006, CELL STRESS CHAPERON, V11, P34, DOI 10.1379/CSC-159R.1; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257, DOI 10.1124/mol.58.6.1257; Tsukahara F, 2004, J BIOL CHEM, V279, P8867, DOI 10.1074/jbc.M308848200; Tutar Y, 2006, GENETICS, V172, P851, DOI 10.1534/genetics.105.048926; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Zou N, 2008, AM J PHYSIOL-HEART C, V294, pH2805, DOI 10.1152/ajpheart.00299.2008	61	30	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					117	127		10.1038/onc.2009.311	http://dx.doi.org/10.1038/onc.2009.311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802014	Green Submitted, Green Accepted			2022-12-28	WOS:000273373500011
J	Wolf, I; Laitman, Y; Rubinek, T; Abramovitz, L; Novikov, I; Beeri, R; Kuro-O, M; Koeffler, HP; Catane, R; Freedman, LS; Levy-Lahad, E; Karlan, BY; Friedman, E; Kaufman, B				Wolf, I.; Laitman, Y.; Rubinek, T.; Abramovitz, L.; Novikov, I.; Beeri, R.; Kuro-O, M.; Koeffler, H. P.; Catane, R.; Freedman, L. S.; Levy-Lahad, E.; Karlan, B. Y.; Friedman, E.; Kaufman, B.			Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin	ONCOGENE			English	Article						breast cancer; klotho; BRCA; ovarian cancer; insulin growth factor-1; tumor suppressor	TRANSCRIPTS ENCODING MEMBRANE; MOLECULAR-CLONING; HORMONE KLOTHO; PROTEIN; GENE; SUSCEPTIBILITY; EXPRESSION; ASSOCIATION; PATHWAYS; CLEAVAGE	Klotho is a transmembrane protein that can be shed and act as a circulating hormone and is a putative tumor suppressor in breast cancer. A functional variant of KLOTHO (KL-VS) contains two amino acid substitutions F352V and C370S and shows reduced activity. Germ-line mutations in BRCA1 and BRCA2 substantially increase lifetime risk of breast and ovarian cancers. Yet, penetrance of deleterious BRCA1 and BRCA2 mutations is incomplete even among carriers of identical mutations. We examined the association between KL-VS and cancer risk among 1115 Ashkenazi Jewish women: 236 non-carriers, 631 BRCA1 (185delAG, 5382insC) carriers and 248 BRCA2 (6174delT) carriers. Among BRCA1 carriers, heterozygosity for the KL-VS allele was associated with increased breast and ovarian cancer risk (hazard ratio 1.40, 95% confidence intervals 1.08-1.83, P=0.01) and younger age at breast cancer diagnosis (median age 48 vs 43 P=0.04). KLOTHO and BRCA2 are located on 13q12, and we identified linkage disequilibrium between KL-VS and BRCA2 6174delT mutation. Studies in breast cancer cells showed reduced growth inhibitory activity and reduced secretion of klotho F352V compared with wildtype klotho. These data suggest KL-VS as a breast and ovarian cancer risk modifier among BRCA1 mutation carriers. If validated in additional cohorts, the presence of KL-VS may serve as a predictor of cancer risk among BRCA1 mutation carriers.	[Wolf, I.; Rubinek, T.; Abramovitz, L.; Catane, R.; Kaufman, B.] Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Wolf, I.; Catane, R.; Friedman, E.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Laitman, Y.; Friedman, E.] Chaim Sheba Med Ctr, Susanne Levy Gertner Oncogenet Unit, Inst Human Genet, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Novikov, I.; Freedman, L. S.] Chaim Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, IL-52621 Tel Hashomer, Ramat Gan, Israel; [Beeri, R.; Levy-Lahad, E.] Shaare Zedek Med Ctr, Med Genet Unit, Jerusalem, Israel; [Kuro-O, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Koeffler, H. P.] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Karlan, B. Y.] Cedars Sinai Med Ctr, Womens Canc Res Inst, Los Angeles, CA 90048 USA	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Wolf, I (corresponding author), Chaim Sheba Med Ctr, Inst Oncol, IL-52621 Tel Hashomer, Ramat Gan, Israel.	wolf-i@inter.net.il	Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921; Abramovitz, Lilach/0000-0001-9961-9986	United States-Israel Binational Science Foundation (BSF) [2005150]; Chief Scientist Office of the Ministry of Health, Israel [4055_3]; Koschitzky Family Foundation for Breast Cancer Research; Israel Cancer Association Research Grant; 'Talpiut' Sheba Career Development Award; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv, Israel; Breast Cancer Research Foundation	United States-Israel Binational Science Foundation (BSF)(US-Israel Binational Science Foundation); Chief Scientist Office of the Ministry of Health, Israel; Koschitzky Family Foundation for Breast Cancer Research; Israel Cancer Association Research Grant; 'Talpiut' Sheba Career Development Award; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv, Israel; Breast Cancer Research Foundation	This research was supported by the United States-Israel Binational Science Foundation (BSF) (grant no. 2005150 to IW and HPK); the Chief Scientist Office of the Ministry of Health, Israel (grant no. 4055_3 to IW); the Koschitzky Family Foundation for Breast Cancer Research; the Israel Cancer Association Research Grant; the 'Talpiut' Sheba Career Development Award; the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and the Breast Cancer Research Foundation (to ELL). HPK is a member of the Molecular Biology Institute and Jonsson Comprehensive Cancer Center at UCLA, and holds the endowed Mark Goodson Chair of Oncology Research at Cedars-Sinai Medical Center/UCLA School of Medicine.	Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2005, GENET EPIDEMIOL, V29, P1, DOI 10.1002/gepi.20074; Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008; Antoniou AC, 2007, AM J HUM GENET, V81, P1186, DOI 10.1086/522611; Arking DE, 2005, CIRC RES, V96, P412, DOI 10.1161/01.RES.0000157171.04054.30; Arking DE, 2003, AM J HUM GENET, V72, P1154, DOI 10.1086/375035; Arking DE, 2002, P NATL ACAD SCI USA, V99, P856, DOI 10.1073/pnas.022484299; Begg CB, 2008, JAMA-J AM MED ASSOC, V299, P194, DOI 10.1001/jama.2007.55-a; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Hudelist G, 2007, ENDOCR-RELAT CANCER, V14, P1053, DOI 10.1677/ERC-06-0075; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Ito S, 2000, MECH DEVELOP, V98, P115, DOI 10.1016/S0925-4773(00)00439-1; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535; Maor S, 2007, CANCER LETT, V257, P236, DOI 10.1016/j.canlet.2007.07.019; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Ohyama Y, 1998, BIOCHEM BIOPH RES CO, V251, P920, DOI 10.1006/bbrc.1998.9576; Rohlfs EM, 1997, CLIN CHEM, V43, P24; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; Tomlinson GE, 1998, CANCER RES, V58, P3237; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963	28	42	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2010	29	1					26	33		10.1038/onc.2009.301	http://dx.doi.org/10.1038/onc.2009.301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802015				2022-12-28	WOS:000273373500003
J	Yang, L; Olsson, B; Pfeifer, D; Jonsson, JI; Zhou, ZG; Jiang, X; Fredriksson, BA; Zhang, H; Sun, XF				Yang, L.; Olsson, B.; Pfeifer, D.; Jonsson, J.-I.; Zhou, Z-G; Jiang, X.; Fredriksson, B-A; Zhang, H.; Sun, X-F			Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells	ONCOGENE			English	Article						peroxisome proliferator-activated receptor; colon neoplasm; pathogenesis; RNA interference; differentiation	INTEGRIN-LINKED KINASE; PPAR-DELTA; COLORECTAL-CANCER; EXTRACELLULAR-MATRIX; METABOLIC SYNDROME; SIGNALING PATHWAY; EXPRESSION; CARCINOGENESIS; PROTEIN; GROWTH	The role of peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) in the pathogenesis of colon cancer remains highly controversial. This study specifically silenced the PPAR-beta expression in three colon cancer cell lines with different metastatic potentials. Although PPAR-beta knockdown resulted in more malignant morphological changes, bigger colony sizes and lower carcinoembryonic antigen (CEA) secretion, and enhanced the cell-fibronectin adhesion, cell invasion and migration were unaffected. These effects were stronger in poorly metastatic cell lines compared with highly metastatic ones. Simultaneously, PPAR-beta knockdown decreased the mRNAs encoding adipocyte differentiation-related protein and liver fatty acid binding protein, and increased the mRNA of ILK, whereas the mRNAs encoding integrin-beta 1 and angiopoietin-like 4 were unchanged. Using immunohistochemistry, we determined that the intensity of PPAR-beta expression was stronger in rectal cancers with better differentiation than in those with poor differentiation, and was stronger in early-stage tumors than in advanced ones. Together, these findings consistently indicate that PPAR-beta may facilitate differentiation and inhibit the cell-fibronectin adhesion of colon cancer, having a role as an inhibitor in the carcinogenesis and progression of colorectal cancer. Interestingly, PPAR-beta seems to have a more important role in poorly metastatic cells than in highly metastatic ones. Oncogene (2010) 29, 516-526; doi: 10.1038/onc.2009.370; published online 23 November 2009	[Yang, L.; Olsson, B.; Pfeifer, D.; Sun, X-F] Linkoping Univ, Div Oncol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Jonsson, J.-I.] Linkoping Univ, Div Expt Hematol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Yang, L.; Zhou, Z-G; Jiang, X.] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan Prov, Peoples R China; [Yang, L.; Zhou, Z-G; Jiang, X.] Sichuan Univ, Inst Digest Surg, Chengdu, Sichuan Prov, Peoples R China; [Fredriksson, B-A] Linkoping Univ, Div Expt Pathol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Zhang, H.] Univ Skovde, Div Biomed, Skovde, Sweden	Linkoping University; Linkoping University; Sichuan University; Sichuan University; Linkoping University; University of Skovde	Sun, XF (corresponding author), Linkoping Univ, Div Oncol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden.	xiao-feng.sun@liu.se		Jonsson, Jan-Ingvar/0000-0003-4814-978X; , Zongguang/0000-0002-7616-1199	Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden; Natural Science Foundation of China [30801332]; National Science Foundation [20070421149]	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Health Research Council in the South-East of Sweden; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF))	We thank Petter Hammar (Linkoping University, Sweden) for his help in lentivirus construction, and thank Prof IJ Fidler (Anderson Cancer Center, Houston, TX) for offering KM12 cell lines. This study was financially supported by grants from the Swedish Cancer Foundation, Swedish Research Council and the Health Research Council in the South-East of Sweden, the Natural Science Foundation of China (Grant No. 30801332) and the National Science Foundation for post-doctoral Scientists of China (Grant No. 20070421149).	Alexandrova AY, 2008, BIOCHEMISTRY-MOSCOW+, V73, P733, DOI 10.1134/S0006297908070018; Aung CS, 2006, BIOCHEM BIOPH RES CO, V340, P656, DOI 10.1016/j.bbrc.2005.12.061; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Bordonaro M, 2002, INT J CANCER, V97, P42, DOI 10.1002/ijc.1577; Burdick AD, 2006, CELL SIGNAL, V18, P9, DOI 10.1016/j.cellsig.2005.07.009; Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; DOHERTY UO, 2000, J VIROL, V74, P10074; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Hollingshead HE, 2008, CARCINOGENESIS, V29, P169, DOI 10.1093/carcin/bgm209; JEFFREY MP, 2008, CLIN SCI, V115, P107; Kim DJ, 2006, CELL DEATH DIFFER, V13, P53, DOI 10.1038/sj.cdd.4401713; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lawrie LC, 2004, BRIT J CANCER, V90, P1955, DOI 10.1038/sj.bjc.6601828; MORIKAWA K, 1988, CANCER RES, V48, P6863; Orner GA, 2003, CARCINOGENESIS, V24, P263, DOI 10.1093/carcin/24.2.263; Ouyang N, 2006, CARCINOGENESIS, V27, P232, DOI 10.1093/carcin/bgi221; Park EY, 2005, CANCER RES, V65, P9923, DOI 10.1158/0008-5472.CAN-05-1604; Peraza MA, 2006, TOXICOL SCI, V90, P269, DOI 10.1093/toxsci/kfj062; Piqueras L, 2007, ARTERIOSCL THROM VAS, V27, P63, DOI 10.1161/01.ATV.0000250972.83623.61; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Schmuth M, 2004, J INVEST DERMATOL, V122, P971, DOI 10.1111/j.0022-202X.2004.22412.x; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Shao JY, 2002, CANCER RES, V62, P3282; Takahashi S, 2006, PHARMACOL RES, V53, P501, DOI 10.1016/j.phrs.2006.03.019; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Worth DC, 2008, INT J BIOCHEM CELL B, V40, P2397, DOI 10.1016/j.biocel.2008.04.008; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yang L, 2008, DIS COLON RECTUM, V51, P318, DOI 10.1007/s10350-007-9145-8; Yang L, 2006, EJSO-EUR J SURG ONC, V32, P181, DOI 10.1016/j.ejso.2005.11.005; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246	44	23	25	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					516	526		10.1038/onc.2009.370	http://dx.doi.org/10.1038/onc.2009.370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19935699				2022-12-28	WOS:000274084600005
J	Aylon, Y; Yabuta, N; Besserglick, H; Buganim, Y; Rotter, V; Nojima, H; Oren, M				Aylon, Y.; Yabuta, N.; Besserglick, H.; Buganim, Y.; Rotter, V.; Nojima, H.; Oren, M.			Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation	ONCOGENE			English	Article						Ras; p53; Lats2; apoptosis	MAMMARY EPITHELIAL-CELLS; DOWN-REGULATION; PROMOTER HYPERMETHYLATION; DNA HYPERMETHYLATION; GENOMIC INSTABILITY; INDUCED SENESCENCE; P53; P16(INK4A); MUTATIONS; CANCER	The Lats2 tumor suppressor protein has been implicated earlier in promoting p53 activation in response to mitotic apparatus stress, by preventing Mdm2-driven p53 degradation. We now report that Lats2 also has a role in an ATR-Chk1-mediated stress check point in response to oncogenic H-Ras. Activated mutant H-Ras triggers the translocation of Lats2 from centrosomes into the nucleus, coupled with an increase in Lats2 protein levels. This leads to the induction of p53 activity, upregulation of proapoptotic genes, downregulation of antiapoptotic genes and eventually apoptotic cell death. Many of the cells that survive apoptosis undergo senescence. However, a fraction of the cells escape this checkpoint mechanism, despite maintaining a high mutant H-Ras expression. These escapers display increased genome instability, as evidenced by a substantial fraction of cells with micronuclei and cells with polyploid genomes. Interestingly, such cells show markedly reduced levels of Lats2, in conjunction with enhanced hypermethylation of the Lats2 gene promoter. Our findings suggest that Lats2 might have an important role in quenching H-Ras-induced transformation, whereas silencing of Lats2 expression might serve as a mechanism to enable tumor progression. Oncogene (2009) 28, 4469-4479; doi:10.1038/onc.2009.270; published online 26 October 2009	[Aylon, Y.; Besserglick, H.; Buganim, Y.; Rotter, V.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Yabuta, N.; Nojima, H.] Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Osaka, Japan	Weizmann Institute of Science; Osaka University	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, 300 Herzl St, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Oren, Moshe/0000-0003-4311-7172	National Cancer Institute [R37 CA40099]; EC [LSHC-CT-2004-503576]; Dr Miriam and Sheldon Adelson Medical Research Foundation; Yad Abraham Center for Cancer Diagnosis and Therapy; NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EC(European CommissionEuropean Commission Joint Research Centre); Dr Miriam and Sheldon Adelson Medical Research Foundation; Yad Abraham Center for Cancer Diagnosis and Therapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Doron Ginsberg, Reuven Agami and Scott Lowe for the generous gift or plasmids and the following people for other help: Lior Golomb (beta-gal staining), Efrat Shema (migration assays) and Sylvia Wilder (excellent technical help). We were supported in part by Grant R37 CA40099 from the National Cancer Institute, EC FP6 Grant LSHC-CT-2004-503576, FP7 funding (ONCOMIRS, agreement 201102), the Dr Miriam and Sheldon Adelson Medical Research Foundation and the Yad Abraham Center for Cancer Diagnosis and Therapy. The EC is not liable for any use that may be made of the information contained herein.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bean GR, 2007, CLIN CANCER RES, V13, P6834, DOI 10.1158/1078-0432.CCR-07-0407; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fikaris AJ, 2006, J BIOL CHEM, V281, P34759, DOI 10.1074/jbc.M606737200; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Milyavsky M, 2003, CANCER RES, V63, P7147; Phelps ED, 2006, AM J PHYSIOL-CELL PH, V290, pC352, DOI 10.1152/ajpcell.00050.2005; Ponzio TA, 2007, J NEUROSCI METH, V164, P149, DOI 10.1016/j.jneumeth.2007.04.012; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008; Strazisar M, 2009, LUNG CANCER, V64, P257, DOI 10.1016/j.lungcan.2008.09.011; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yabuta N, 2007, J BIOL CHEM, V282, P19259, DOI 10.1074/jbc.M608562200	36	49	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4469	4479		10.1038/onc.2009.270	http://dx.doi.org/10.1038/onc.2009.270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19855428	Green Accepted			2022-12-28	WOS:000272876500006
J	Mull, BB; Cox, J; Bui, T; Keyomarsi, K				Mull, B. B.; Cox, J.; Bui, T.; Keyomarsi, K.			Post-translational modification and stability of low molecular weight cyclin E	ONCOGENE			English	Article						cyclin E; phosphorylation; low molecular weight form; stability; cell cycle	BREAST-CANCER; UBIQUITIN LIGASE; TRANSGENIC MICE; IN-VIVO; PHOSPHORYLATION; INSTABILITY; CELLS; FORMS; CDK2; TUMORIGENESIS	Our laboratory has previously described the presence of five tumor-specific low molecular weight isoforms of cyclin E in both tumor cell lines and breast cancer patient biopsies. We have also shown that one of these low forms arises from an alternate start site, whereas the other four appear as two sets of doublets following cleavage through an elastase-like enzyme. However, the origin of both sets of doublets was unknown. Here, we demonstrate that the larger isoform of each doublet is the result of phosphorylation at a key degradation site. Through site-directed mutagenesis of different phosphorylation sites within the cyclin E protein, we discovered that phosphorylation of threonine 395 is responsible for generating the larger isoform of each doublet. Because phosphorylation of threonine 395 has been linked to the proteasome-mediated degradation of full length cyclin E, we examined the stability of T395A phospho-mutants in both non-tumorigenic mammary epithelial cells and tumor cells. The results revealed that the low molecular weight isoforms appear to be stable in both a tumor cell line and a non-tumor forming cell line regardless of the presence of this critical phosphorylation site. The stability of low molecular weight cyclin E may have implications for both tumorigenesis and treatment of tumors expressing them. Oncogene (2009) 28, 3167-3176; doi: 10.1038/onc.2009.182; published online 29 June 2009	[Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 0066, Houston, TX 77030 USA; [Mull, B. B.; Keyomarsi, K.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 0066, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Mull, Benjamin/0000-0001-8379-873X	National Institutes of Health [CA87458]; National Cancer Institute [P50CA116199]; Clayton Foundation [W81XWH-05-1-0255 03]; NATIONAL CANCER INSTITUTE [P50CA116199] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clayton Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded in part by the following grants: National Institutes of Health CA87458 (to K Keyomarsi); National Cancer Institute P50CA116199 (project 2 to K Keyomarsi); Clayton Foundation (to K Keyomarsi) Department of Defense W81XWH-05-1-0255 03 (to B Mull).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Bales E, 2005, CANCER RES, V65, P692; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Delk NA, 2009, CANCER RES, V69, P2817, DOI 10.1158/0008-5472.CAN-08-4182; Harwell RM, 2000, CANCER RES, V60, P481; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nguyen HH, 2008, P NATL ACAD SCI USA, V105, P19750, DOI 10.1073/pnas.0806581105; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Wingate H, 2005, J BIOL CHEM, V280, P15148, DOI 10.1074/jbc.M409789200; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464; Wingate H, 2009, CELL CYCLE, V8, P1062, DOI 10.4161/cc.8.7.8119; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200	29	6	7	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3167	3176		10.1038/onc.2009.182	http://dx.doi.org/10.1038/onc.2009.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19561641	Bronze			2022-12-28	WOS:000269515100008
J	Narita, N; Tanemura, A; Murali, R; Scolyer, RA; Huang, S; Arigami, T; Yanagita, S; Chong, KK; Thompson, JF; Morton, DL; Hoon, DS				Narita, N.; Tanemura, A.; Murali, R.; Scolyer, R. A.; Huang, S.; Arigami, T.; Yanagita, S.; Chong, K. K.; Thompson, J. F.; Morton, D. L.; Hoon, D. S.			Functional RET G691S polymorphism in cutaneous malignant melanoma	ONCOGENE			English	Article						RET; polymorphism; mutation; melanoma; desmoplastic; BRAF	DESMOPLASTIC MELANOMA; NEUROTROPHIC FACTOR; TYROSINE KINASE; BRAF MUTATIONS; THYROID-CARCINOMA; CANCER; INHIBITION; CELLS; GENE; PROTOONCOGENE	RET proto-oncogene encodes a receptor tyrosine kinase whose ligand is glial cell line-derived neurotrophic factor (GDNF), and its polymorphism at G691S juxtamembrane region (RETp) is a germline polymorphism. Cutaneous melanomas, particularly the desmoplastic subtype, are highly neurotropic; thus we sought to determine the frequency of RETp in cutaneous melanoma and its functional responsiveness to GDNF. RETp was assessed in 71 non-desmoplastic cutaneous melanomas (non-DMs) and 70 desmoplastic melanomas (DMs). Melanoma cell lines with RETp, RET wild type (RETwt), BRAF V600E mutation (BRAFmt) or BRAF wild type (BRAFwt) were assessed for functional activity. RETp frequency was significantly higher in DMs (61%) than in non-DMs (31%, P<0.001). BRAFmt was detected in only 11% of DMs. GDNF stimulation significantly amplified cell proliferation, migration and invasion in RETp, but not in RETwt melanoma cells. GDNF stimulation of RETp cell lines enhanced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt of the RET-RAS-RAF-ERK and RET-phosphatidylinositol 3-kinase (PI3K)-Akt pathways, respectively. GDNF response of RETp cells in signal transduction and other functional studies were not affected by BRAFmt. The study demonstrates that RETp is frequently found in cutaneous melanoma, particularly desmoplastic subtypes, and responds to GDNF inducing events favorable for tumor progression. Oncogene (2009) 28, 3058-3068; doi:10.1038/onc.2009.164; published online 29 June 2009	[Narita, N.; Tanemura, A.; Huang, S.; Arigami, T.; Yanagita, S.; Chong, K. K.; Hoon, D. S.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; [Murali, R.; Scolyer, R. A.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Anat Pathol, Camperdown, NSW 2050, Australia; [Murali, R.; Scolyer, R. A.; Thompson, J. F.] Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney Melanoma Unit, Camperdown, NSW 2050, Australia; [Morton, D. L.] St Johns Hlth Ctr, John Wayne Canc Inst, Div Surg Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; University of Sydney; Melanoma Institute Australia; University of Sydney; John Wayne Cancer Institute	Hoon, DS (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Scolyer, Richard/AAE-8511-2019; MURALI, RAJMOHAN/A-7960-2008; Narita, Norihiko/AAA-4801-2022; Thompson, John/F-9075-2013; Hoon, Dave SB/C-7146-2018	Scolyer, Richard/0000-0002-8991-0013; MURALI, RAJMOHAN/0000-0001-6988-4295; Narita, Norihiko/0000-0001-9765-9669; Thompson, John/0000-0002-2816-2496; Hoon, Dave SB/0000-0003-1915-3683	National Institutes of Health; National Cancer Institute [P0 CA029605, CA012582]; Ruth and Martin H Weil Foundation; Leslie and Susan Gonda Foundation; Melanoma Foundation of the University of Sydney, Australia; NATIONAL CANCER INSTITUTE [P01CA012582, P01CA029605] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth and Martin H Weil Foundation; Leslie and Susan Gonda Foundation; Melanoma Foundation of the University of Sydney, Australia(University of Sydney); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sandy L Nguyen and Linhda Nguyen for expert editorial assistance and Emily H Liang for technical assistance. This work was supported by the National Institutes of Health, National Cancer Institute (Project II P0 CA029605 and CA012582 grants to DH); Ruth and Martin H Weil Foundation (to DH); the Leslie and Susan Gonda Foundation (to DH) and the Melanoma Foundation of the University of Sydney, Australia (to JT, RS, RM).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bounacer A, 2002, BRIT J CANCER, V86, P1929, DOI 10.1038/sj.bjc.6600371; Busam KJ, 2005, ADV ANAT PATHOL, V12, P92, DOI 10.1097/01.pap.0000155071.86944.a6; Busam KJ, 2005, J INVEST DERMATOL, V124, P412, DOI 10.1111/j.0022-202X.2004.23600.x; Carlomagno F, 2006, JNCI-J NATL CANCER I, V98, P326, DOI 10.1093/jnci/djj069; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davison JM, 2005, CANCER-AM CANCER SOC, V103, P788, DOI 10.1002/cncr.20861; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Elisei R, 2004, J CLIN ENDOCR METAB, V89, P3579, DOI 10.1210/jc.2003-031898; Fujiwara Y, 1999, CANCER RES, V59, P1567; Goto Y, 2006, CANCER RES, V66, P4443, DOI 10.1158/0008-5472.CAN-05-2505; Goto Y, 2008, MOL CANCER THER, V7, P3642, DOI 10.1158/1535-7163.MCT-08-0582; Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102; Gumireddy K, 2007, P NATL ACAD SCI USA, V104, P6696, DOI 10.1073/pnas.0701145104; Hoon DSB, 2001, J INVEST DERMATOL, V117, P375, DOI 10.1046/j.0022-202x.2001.01417.x; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Jaroszewski DE, 2001, AM J SURG, V182, P590, DOI 10.1016/S0002-9610(01)00819-4; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Koyanagi K, 2005, J CLIN ONCOL, V23, P8057, DOI 10.1200/JCO.2005.02.0958; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Livestro DP, 2005, J CLIN ONCOL, V23, P6739, DOI 10.1200/JCO.2005.04.515; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Mologni L, 2006, J MOL ENDOCRINOL, V37, P199, DOI 10.1677/jme.1.01999; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P29230, DOI 10.1074/jbc.M703461200; Quinn MJ, 1998, CANCER-AM CANCER SOC, V83, P1128, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.3.CO;2-Y; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Selek U, 2004, INT J RADIAT ONCOL, V59, P1097, DOI 10.1016/j.ijrobp.2003.12.037; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Shinozaki M, 2007, CLIN CANCER RES, V13, P2068, DOI 10.1158/1078-0432.CCR-06-2120; Stephens LA, 2005, THYROID, V15, P100, DOI 10.1089/thy.2005.15.100; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538; Weber F, 2008, J CLIN ENDOCR METAB, V93, P1097, DOI 10.1210/jc.2008-0212; Zbuk KM, 2007, NAT REV CANCER, V7, P35, DOI 10.1038/nrc2037	42	55	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3058	3068		10.1038/onc.2009.164	http://dx.doi.org/10.1038/onc.2009.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19561646	Green Accepted			2022-12-28	WOS:000269319000005
J	Tanikawa, C; Furukawa, Y; Yoshida, N; Arakawa, H; Nakamura, Y; Matsuda, K				Tanikawa, C.; Furukawa, Y.; Yoshida, N.; Arakawa, H.; Nakamura, Y.; Matsuda, K.			XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway	ONCOGENE			English	Article						XEDAR; P53; FAS; colorectal cancer; anoikis; TNFR	FOCAL-ADHESION KINASE; ECTODERMAL DYSPLASIA RECEPTOR; NF-KAPPA-B; P53-DEPENDENT APOPTOSIS; SOMATIC MUTATIONS; DNA-DAMAGE; P53 GENE; EXPRESSION; ACTIVATION; CANCER	Colorectal cancers with mutations in the p53 gene have an invasive property, but its underlying mechanism is not fully understood. Through the screening of two data sets of the genome-wide expression pro. le, one for p53-introduced cells and the other for the numbers of cancer tissues, we report here X-linked ectodermal dysplasia receptor (XEDAR), a member of the TNFR superfamily, as a novel p53 target that has a crucial role in colorectal carcinogenesis. p53 upregulated XEDAR expression through two p53-binding sites within intron 1 of the XEDAR gene. We also found a significant correlation between decreased XEDAR expressions and p53 gene mutations in breast and lung cancer cell lines (P=0.0043 and P=0.0122, respectively). Furthermore, promoter hypermethylation of the XEDAR gene was detected in 20 of 20 colorectal cancer cell lines (100%) and in 6 of 12 colorectal cancer tissues (50%), respectively. Thus, the XEDAR expression was suppressed to <25% of surrounding normal tissues in 12 of 18 colorectal cancer tissues (66.7%) due to either its epigenetic alterations and/or p53 mutations. We also found that XEDAR interacted with and subsequently caused the accumulation of FAS protein, another member of p53-inducible TNFR. Moreover, XEDAR negatively regulated FAK, a central component of focal adhesion. As a result, inactivation of XEDAR resulted in the enhancement of cell adhesion and spreading, as well as resistance to p53-induced apoptosis. Taken together, our findings showed that XEDAR is a putative tumor suppressor that could prevent malignant transformation and tumor progression by regulating apoptosis and anoikis. Oncogene (2009) 28, 3081-3092; doi:10.1038/onc.2009.154; published online 22 June 2009	[Matsuda, K.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; [Furukawa, Y.] Univ Tokyo, Div Clin Genome Res, Tokyo 1088639, Japan; [Yoshida, N.] Univ Tokyo, Inst Med Sci, Div Gene Express & Regulat, Tokyo 1088639, Japan; [Arakawa, H.] Natl Canc Ctr, Res Inst, Canc Med & Biophys Div, Tokyo 104, Japan	University of Tokyo; University of Tokyo; University of Tokyo; National Cancer Center - Japan	Matsuda, K (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	koichima@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013; Matsuda, Koichi/D-4597-2011	Arakawa, Hirofumi/0000-0001-6077-0638; Matsuda, Koichi/0000-0001-7292-2686; Tanikawa, Chizu/0000-0003-4759-4793	Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan [18687012]	Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Katagiri for helpful discussion and A Takahashi K Makino for her technical assistance. This work was supported partly by grant #18687012 from Japan Society for the Promotion of Science and Ministry of education, culture, sports, science and technology of Japan (to KM). CT is a JSPS Research Fellow.	Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Diez M, 2000, ANTICANCER RES, V20, P3907; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0; Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P373, DOI 10.1002/mc.20395; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kitahara O, 2001, CANCER RES, V61, P3544; Lark AL, 2003, CLIN CANCER RES, V9, P215; Lee SH, 1999, CANCER RES, V59, P5683; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939; Matsuda K, 2002, CANCER RES, V62, P2883; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Newton K, 2004, MOL CELL BIOL, V24, P1608, DOI 10.1128/MCB.24.4.1608-1613.2004; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENS LV, 1995, CANCER RES, V55, P2752; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sinha SK, 2004, J BIOL CHEM, V279, P41873, DOI 10.1074/jbc.M407363200; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Takakuwa T, 2002, ONCOGENE, V21, P4702, DOI 10.1038/sj.onc.1205571; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	39	50	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3081	3092		10.1038/onc.2009.154	http://dx.doi.org/10.1038/onc.2009.154			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543321				2022-12-28	WOS:000269319000007
J	Chen, CH; Chien, CY; Huang, CC; Hwang, CF; Chuang, HC; Fang, FM; Huang, HY; Chen, CM; Liu, HL; Huang, CYF				Chen, C-H; Chien, C-Y; Huang, C-C; Hwang, C-F; Chuang, H-C; Fang, F-M; Huang, H-Y; Chen, C-M; Liu, H-L; Huang, C-Y F.			Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity	ONCOGENE			English	Article						FLJ10540; migration; invasion; FOXM1; MMP-2	MATRIX METALLOPROTEINASE-2 TRANSCRIPTION; GENE-EXPRESSION; CANCER PROGRESSION; IV COLLAGENASE; TUMOR-GROWTH; LUNG-CANCER; ACTIVATION; PROTEIN; HEAD; NECK	Matrix metalloproteinase (MMP)-2 plays critical roles in tumor development and in the metastasis of multiple cancers, including human oral cavity squamous cell carcinoma (OCSCC). One of the upstream regulators of MMP-2 is FOXM1, which is overexpressed in a microarray dataset of OCSCC. It is interesting that FLJ10540 exhibits similar gene expression profiles with MMP-2 and FOXM1, raising the possibility that these molecules might participate in MMP-2-elicited cancer progression and metastasis of OCSCC. To examine this connection, we first showed that FLJ10540 was significantly overexpressed in OCSCC. A strong FLJ10540 expression was significantly correlated with an advanced tumor node metastasis stage and the cumulative 5-year survival rate. Thus, an elevated FLJ10540 expression is an indicator of poor survival. Functionally, FLJ10540 had the abilities to stimulate cell migration and invasion in oral cancer cells through increased FOXM1 and MMP-2 expressions. Conversely, the depletion of the FLJ10540 expression by small interefering RNAs suppressed the FOXM1 and MMP-2 protein expressions. The suppression of either FLJ10540 or FOXM1 could cause significant inhibition on cell migratory and invasive ability in oral cancer cells. Finally, the immunohistochemical and western blotting analyses of human aggressive OCSCC specimens showed a significant positive correlation among FLJ10540, FOXM1 and MMP-2 expressions. These findings suggest that FLJ10540 is not only an important prognostic factor but also a new therapeutic target in the FLJ10540/FOXM1/MMP-2 pathway for OCSCC treatment. Oncogene (2009) 28, 2723-2737; doi:10.1038/onc.2009.128; published online 15 June 2009	[Chen, C-H; Chien, C-Y; Hwang, C-F; Chuang, H-C; Liu, H-L] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Otolaryngol, Kaohsiung 833, Taiwan; [Chen, C-H; Chien, C-Y; Huang, C-C; Hwang, C-F; Chuang, H-C; Fang, F-M; Huang, H-Y; Chen, C-M; Liu, H-L] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Kaohsiung Chang Gung Head & Neck Oncol Grp, Kaohsiung, Taiwan; [Huang, C-C; Huang, H-Y; Chen, C-M] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Pathol, Kaohsiung 833, Taiwan; [Fang, F-M] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Radiat Oncol, Kaohsiung 833, Taiwan; [Huang, C-Y F.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University	Chien, CY (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Otolaryngol, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.	cychien3965@adm.cgmh.org.tw; cyhuang5@ym.edu.tw	Huang, Chi-Ying/AFL-7729-2022; Hwang, Chung-Feng/ABC-1138-2021; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937; Chien, Chih-Yen/0000-0002-6690-6038	Chang Gung Memorial Hospital, Taiwan [CMRPG860512, CMRPG870281, CMRPG870282]; National Science Council [NSC97-2314-B182A-065, NSC97-2627-B-010-011, NSC97-3112-B-010-025-CC1]	Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital); National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by the grants from the Chang Gung Memorial Hospital, Taiwan ( grant numbers CMRPG860512, CMRPG870281, and CMRPG870282), and NSC97-2314-B182A-065 and in part by grants from NSC97-2627-B-010-011, NSC97-3112-B-010-025-CC1 ( National Science Council) and the Program for Promoting Academic Excellence of Universities ( National Yang Ming University) to Chi-Ying F Huang. We thank Dr Wen-Chun Hung, for providing the MMP-2 luciferase plasmids.	BEENKEN SW, 2003, CURRENT SURG DIAGNOS, P282; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chandu A, 2006, J ORAL MAXIL SURG, V64, P495, DOI 10.1016/j.joms.2005.11.028; Chen CH, 2007, ONCOGENE, V26, P4272, DOI 10.1038/sj.onc.1210207; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Gao ZB, 2005, INT J MOL MED, V16, P599; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Hardisson D, 2003, EUR ARCH OTO-RHINO-L, V260, P502, DOI 10.1007/s00405-003-0581-3; Hong SD, 2000, ORAL ONCOL, V36, P207, DOI 10.1016/S1368-8375(99)00088-3; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jezierska A, 2009, MED SCI MONITOR, V15, pRA32; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kamat AA, 2006, CLIN CANCER RES, V12, P1707, DOI 10.1158/1078-0432.CCR-05-2338; Kato Y, 2006, ONCOL REP, V16, P1009; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lev DC, 2004, J CLIN ONCOL, V22, P2092, DOI 10.1200/JCO.2004.11.070; Lo WL, 2003, J ORAL MAXIL SURG, V61, P751, DOI 10.1016/S0278-2391(03)00149-6; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Niehrs C, 1999, NATURE, V402, P483, DOI 10.1038/990025; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Park MJ, 2002, CANCER RES, V62, P6318; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel BP, 2007, HEAD NECK-J SCI SPEC, V29, P564, DOI 10.1002/hed.20561; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ruokolainen H, 2006, MODERN PATHOL, V19, P208, DOI 10.1038/modpathol.3800506; Ruokolainen H, 2004, CLIN CANCER RES, V10, P3110, DOI 10.1158/1078-0432.CCR-03-0530; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Sudbo J, 2005, INT J CANCER, V115, P339, DOI 10.1002/ijc.20896; Werner JA, 2002, CLIN EXP METASTAS, V19, P275, DOI 10.1023/A:1015531319087; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015	44	71	74	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2723	2737		10.1038/onc.2009.128	http://dx.doi.org/10.1038/onc.2009.128			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19525975				2022-12-28	WOS:000268452900003
J	Lee, SG; Jeon, HY; Su, ZZ; Richards, JE; Vozhilla, N; Sarkar, D; Van Maerken, T; Fisher, PB				Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Van Maerken, T.; Fisher, P. B.			Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma	ONCOGENE			English	Article						neuroblastoma; AEG-1; MYCN; PI3K; Akt	RAPID SUBTRACTION HYBRIDIZATION; PHOSPHATIDYLINOSITOL 3-KINASE; N-MYC; C-MYC; CANCER PROGRESSION; TUMOR PROGRESSION; BREAST-CANCER; EXPRESSION; PATHWAY; CELLS	Neuroblastoma, derived from neural crest progenitor cells, is the most common extracranial solid tumor of childhood. Astrocyte elevated gene-1 (AEG-1) is a primary mediator of tumor progression and metastasis in several human cancers. In this study, we investigated the potential contribution of AEG-1 in human neuroblastoma pathogenesis. AEG-1 expression was significantly elevated in neuroblastoma patient-derived samples and neuroblastoma cell lines as compared with normal peripheral nerve tissues, normal astrocytes and immortalized melanocytes. Knockdown of AEG-1 by small interfering RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells. Conversely, over-expression of AEG-1 enhanced proliferation and expression of the transformed state in less aggressive neuroblastoma cells through activation of the phosphatidylinositol 3-kinase-Akt-signaling pathway and stabilization of MYCN. These provocative results indicate that AEG-1 may play a crucial role in the pathogenesis of neuroblastoma and could represent a potential target for therapeutic intervention. Oncogene (2009) 28, 2476-2484; doi:10.1038/onc.2009.93; published online 18 May 2009	[Lee, S-G; Jeon, H-Y; Su, Z-Z; Richards, J. E.; Vozhilla, N.; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Lee, S-G; Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA 23298 USA; [Van Maerken, T.] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Ghent University; Ghent University Hospital; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	sglee@vcu.edu; pbfisher@vcu.edu	Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777	NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA035675] Funding Source: Medline; NINDS NIH HHS [P01 NS31492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Ishola TA, 2007, BBA-GEN SUBJECTS, V1770, P927, DOI 10.1016/j.bbagen.2007.02.002; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Su ZZ, 2003, GENE, V306, P67, DOI 10.1016/S0378-1119(03)00404-9; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Van Maerken T, 2009, J CELL PHYSIOL, V219, P707, DOI 10.1002/jcp.21719; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	35	98	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2476	2484		10.1038/onc.2009.93	http://dx.doi.org/10.1038/onc.2009.93			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448665				2022-12-28	WOS:000267601400006
J	Liao, Y; Wei, Y; Zhou, X; Yang, JY; Dai, C; Chen, YJ; Agarwal, NK; Sarbassov, D; Shi, D; Yu, D; Hung, MC				Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Dai, C.; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Shi, D.; Yu, D.; Hung, M-C			Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation	ONCOGENE			English	Article						PKB/Akt; Pin1; peptidyl-prolyl cis/trans isomerase; breast cancer	PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTORS; BREAST-CANCER; AKT; PATHWAY; AKT/PKB; DISEASE; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION	The serine/threonine protein kinase B (PKB, also known as Akt) plays a pivotal role in diverse cellular functions. Elevated expression of activated Akt has been detected in a wide variety of human cancers; however, the mechanism of Akt protein stability regulation remains unclear. In this study, we showed a strong correlation between the expression levels of an oncogenic peptidyl-prolyl cis/trans isomerase Pin1 and levels of Akt phosphorylation at S473 in multiple cancer types (P<0.0001). Akt-pS473 status combined with Pin1 expression levels predicted a poorer prognosis than did either one alone in patients with breast cancer (P = 0.0052). We further showed that Pin1 regulated Akt stability and phosphorylation on S473 through the phosphorylated Thr-Pro motifs of Akt. These motifs are conserved evolutionary and are required for the maintenance of Akt stability and its interaction with Pin1. In addition, repressing Pin1 expression through either homologue Pin1 knockout or small interfering RNA-mediated knockingdown compromised its ability to protect Akt from degradation. Our results show how Akt protein stability is regulated by the peptidyl-prolyl cis/trans isomerase Pin1 and highlight the importance of this oncogenic network in human disease pathogenesis. Oncogene (2009) 28, 2436-2445; doi: 10.1038/onc.2009.98; published online 18 May 2009	[Liao, Y.; Wei, Y.; Zhou, X.; Yang, J-Y; Chen, Y-J; Agarwal, N. K.; Sarbassov, D.; Yu, D.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Liao, Y.; Dai, C.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Zhou, X.; Shi, D.] Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200433, Peoples R China; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Chen, Y-J; Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Fudan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	yongliao@mdanderson.org; mhung@mdanderson.org	Sarbassov, Dos/AAS-4950-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Sarbassov, Dos/0000-0002-6848-1133; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [P50 CA083639, P01 CA099031, P30 CA016672, P01 CA099031-01, R01 CA109311, P50 CA83639, P50-CA83639-A01, P20 CA101936-05, P50 CA083639-090009, P20 CA101936, P50 CA116199, P50 CA116199-04] Funding Source: Medline; PHS HHS [P01 099031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109311, P50CA083639, P30CA016672, P50CA116199, P01CA099031, P20CA101936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHAN TO, 2001, SCI STKE, pPE1; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2006, MOL CARCINOGEN, V45, P397, DOI 10.1002/mc.20216; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; Takahashi K, 2008, CELL MOL LIFE SCI, V65, P359, DOI 10.1007/s00018-007-7270-0; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tokunaga E, 2008, CURR CANCER DRUG TAR, V8, P27, DOI 10.2174/156800908783497140; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	45	69	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2436	2445		10.1038/onc.2009.98	http://dx.doi.org/10.1038/onc.2009.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448664	Green Accepted			2022-12-28	WOS:000267601400002
J	Boya, P; Kroemer, G				Boya, P.; Kroemer, G.			Beclin 1: a BH3-only protein that fails to induce apoptosis	ONCOGENE			English	Editorial Material						autophagy; apoptosis; Bcl-2; Beclin-1; endoplasmic reticulum; mitochondria	BCL-XL; AUTOPHAGY; COMPLEX; DOMAIN	Beclin 1 has been recently shown to possess a Bcl-2 homology-3 (BH3) domain that mediates its interaction with antiapoptotic multidomain proteins. Unlike other BH3-only proteins, Beclin 1 fails to stimulate apoptosis when it is overexpressed. In this issue of Oncogene, Ciechomska et al. report the intriguing finding that Bcl-2, as it interacts with Beclin 1, does not lose its anti-apoptotic potential. This finding may have far-reaching implications for the comprehension of the cross-talk between apoptosis and autophagy. Oncogene (2009) 28, 2125-2127; doi: 10.1038/onc.2009.83; published online 27 April 2009	[Boya, P.] Consejo Super Invest Cient, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, E-28040 Madrid, Spain; [Kroemer, G.] INSERM, U848, Villejuif, France; [Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, France; [Kroemer, G.] Univ Paris 11, Villejuif, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Boya, P (corresponding author), Consejo Super Invest Cient, Ctr Invest Biol, Lab 3D, Dept Cellular & Mol Physiopathol, Ramiro Maetzu 9, E-28040 Madrid, Spain.	pboya@cib.csic.es; kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Boya, Patricia/P-8345-2019; Boya, Patricia/K-2911-2014	KROEMER, Guido/0000-0002-9334-4405; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X				Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; CIECHOMSKA AI, 2009, ONCOGENE IN PRESS; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Zalckvar E., 2009, EMBO REP, V30, P30	12	27	28	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2009	28	21					2125	2127		10.1038/onc.2009.83	http://dx.doi.org/10.1038/onc.2009.83			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398951				2022-12-28	WOS:000266451300001
J	Nabilsi, NH; Broaddus, RR; Loose, DS				Nabilsi, N. H.; Broaddus, R. R.; Loose, D. S.			DNA methylation inhibits p53-mediated survivin repression	ONCOGENE			English	Article						DNA methylation; endometrium; cancer	WILD-TYPE P53; ENDOMETRIAL CARCINOMA; EXPRESSION; GENE; CANCER; CARCINOGENESIS; APOPTOSIS; DIAGNOSIS; REGION; HTERT	The molecular progression of endometrial cancer is poorly understood, and both genetic and epigenetic factors play a role. Survivin is a member of the inhibitor of apoptosis (IAP) gene family and contains a canonical CpG island that has been described as epigenetically regulated. As survivin is overexpressed in endometrial tumors, we hypothesized that hypomethylation could explain this expression pattern. Surprisingly, methylation-specific PCR and pyrosequencing showed that survivin was hypermethylated in endometrial tumors and correlated with increased survivin expression. We speculated that methylation could inhibit the binding of p53, a repressor of survivin expression. Our data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation. We are the first to report survivin de-repression by DNA methylation. We also present microarray data, which suggest that de-repression by methylation is a general mechanism of p53 regulation. Demethylation induced by decitabine is traditionally thought to be active in tumors by allowing the re-expression of tumor suppressor genes. However, our results indicate that an additional important mechanism is to decrease the expression of oncogenes. Oncogene (2009) 28, 2046-2050; doi:10.1038/onc.2009.62; published online 13 April 2009	[Nabilsi, N. H.; Loose, D. S.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Loose, DS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, 6431 Fannin St,MSB 5-132A, Houston, TX 77030 USA.	david.s.loose@uth.tmc.edu			NIH [1P50CA098258-01]; Rosalie B Hite Graduate Student Fellowship; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rosalie B Hite Graduate Student Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grant NIH 1P50CA098258-01 (SPORE in Endometrial Cancer), and a Rosalie B Hite Graduate Student Fellowship.	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Erkanli S, 2006, INT J GYNECOL CANCER, V16, P1412, DOI 10.1111/j.1525-1438.2006.00541.x; Erkanli S, 2007, GYNECOL ONCOL, V104, P320, DOI 10.1016/j.ygyno.2006.08.044; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Furlan D, 2006, CLIN CANCER RES, V12, P3329, DOI 10.1158/1078-0432.CCR-05-2679; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hopfer O, 2007, EXP HEMATOL, V35, P712, DOI 10.1016/j.exphem.2007.01.054; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Konno R, 2000, MOL HUM REPROD, V6, P529, DOI 10.1093/molehr/6.6.529; Lehner R, 2002, ACTA OBSTET GYN SCAN, V81, P162, DOI 10.1034/j.1600-0412.2002.810213.x; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Meng RD, 1999, INT J ONCOL, V14, P5; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Takai N, 2002, CANCER LETT, V184, P105, DOI 10.1016/S0304-3835(02)00190-8; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Xie R, 2007, MODERN PATHOL, V20, P1045, DOI 10.1038/modpathol.3800940; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828; Zhou XC, 2007, GYNECOL ONCOL, V107, P143, DOI 10.1016/j.ygyno.2007.06.019	26	80	83	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2046	2050		10.1038/onc.2009.62	http://dx.doi.org/10.1038/onc.2009.62			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363521				2022-12-28	WOS:000266023900005
J	Sun, TP; Shieh, SY				Sun, T-P; Shieh, S-Y			Human FEM1B is required for Rad9 recruitment and CHK1 activation in response to replication stress	ONCOGENE			English	Article						CHK1; FEM1B; replication stress	DNA-DAMAGE CHECKPOINTS; SEX-DETERMINATION; STRUCTURAL BASIS; GENE FAMILY; ATR; CLASPIN; PROTEIN; PHOSPHORYLATION; BINDING; P53	Human checkpoint kinase 1 (CHK1) is an essential kinase required to preserve genome stability, and is activated by DNA replication blockage through the ataxia-telangiectasia-mutated-and-Rad3-related (ATR)/ATRIP-signaling pathway. In this report, we show that a novel CHK1-interacting protein, FEM1B ( human homologue of the Caenorhabditis elegans sex determination fem1 protein), identified by a yeast two-hybrid screen, is involved in the activation of CHK1 by replication stress. Depletion of FEM1B by small interfering RNA in cancer cells impairs the activation of CHK1 kinase activity and attenuates the induction of CHK1 Ser345 phosphorylation upon replication interference. It is to be noted that, CHK2 Thr68 phosphorylation is not altered by FEM1B downregulation. By fractionation, we further demonstrated that FEM1B is able to associate with chromatin, and such association facilitates chromatin loading of the Rad9 protein. Consistently, ATR activity is poorly maintained in FEM1B knockdown cells; and FEM1B-ablated cells are as sensitive to replication block as CHK1-depleted cells. Our study has uncovered an adaptor protein FEM1B, which acts as a bridge linking CHK1 and Rad9, thus facilitating checkpoint signaling induced by replication stress. Oncogene (2009) 28, 1971-1981; doi:10.1038/onc.2009.58; published online 30 March 2009	[Sun, T-P; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Sun, T-P] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica, Taiwan	Academia Sinica, Taiwan(Academia Sinica - Taiwan)	We thank Shiaw-Wei Tyan for his assistance with yeast library screening. We are also grateful to Drs Hsiu-Ming Shih for the human testis cDNA library; Victor Yu for pXJ-HA-F1Aa; Carol Prives for GST-Cdc25C<INF>200-256</INF>; Howard Lieberman for Rad9 cDNA; Randal Tibbetts and Robert Abraham for FlagATR. This study was supported by funds from Academia Sinica, Taiwan to S-Y Shieh.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Jamil S, 2008, MOL BIOL CELL, V19, P3212, DOI 10.1091/mbc.E07-11-1171; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Krakow D, 2001, GENE, V279, P213, DOI 10.1016/S0378-1119(01)00756-9; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Lu DY, 2005, MOL CELL BIOL, V25, P6570, DOI 10.1128/MCB.25.15.6570-6577.2005; Machida YJ, 2005, J BIOL CHEM, V280, P6253, DOI 10.1074/jbc.R400037200; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Shieh SY, 2000, GENE DEV, V14, P289; Ventura-Holman T, 2003, GENE, V314, P133, DOI 10.1016/S0378-1119(03)00712-1; Ventura-Holman T, 1998, GENOMICS, V54, P221, DOI 10.1006/geno.1998.5569; Ventura-Holman T, 2000, BIOCHEM BIOPH RES CO, V267, P317, DOI 10.1006/bbrc.1999.1942; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	38	6	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1971	1981		10.1038/onc.2009.58	http://dx.doi.org/10.1038/onc.2009.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19330022				2022-12-28	WOS:000265820900004
J	Levanon, K; Ng, V; Piao, HY; Zhang, Y; Chang, MC; Roh, MH; Kindelberger, DW; Hirsch, MS; Crum, CP; Marto, JA; Drapkin, R				Levanon, K.; Ng, V.; Piao, H. Y.; Zhang, Yi; Chang, M. C.; Roh, M. H.; Kindelberger, D. W.; Hirsch, M. S.; Crum, C. P.; Marto, J. A.; Drapkin, R.			Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis	ONCOGENE			English	Article						ovarian cancer; fallopian tube; primary cell culture; cancer biomarkers; DNA damage and repair	CELL-CYCLE; IN-VITRO; CANCER; DIFFERENTIATION; CARCINOMA; HE-4; PATHOGENESIS; RECEPTOR; OVIDUCT; MARKERS	Recent studies suggest that some serous ovarian carcinomas (SOCs) arise from the fallopian tube (FT) epithelium rather than the ovarian surface epithelium. This hypothesis places emphasis on the FT secretory epithelial cell as a cell-of-origin. Herein, we report the development of a novel ex vivo primary human FT epithelium culture system that faithfully recapitulates the in vivo epithelium, as shown by morphological, ultrastructural and immunophenotypic analyses. Mass spectrometry-based proteomics reveal that these cultures secrete proteins previously identified as biomarkers for ovarian cancer. We also use this culture system to study the response of the FT epithelium to genotoxic stress and find that the secretory cells exhibit a distinct response to DNA damage when compared with neighboring ciliated cells. The secretory cells show a limited ability to resolve the damage over time, potentially leaving them more susceptible to accumulation of additional mutagenic injury. This divergent response is confirmed with in situ studies using tissue samples, further supporting the use of this ex vivo culture system to investigate FT epithelial pathobiology. We anticipate that this novel culture system will facilitate the study of SOC pathogenesis, and propose that similar culture systems could be developed for other organ site-specific epithelia. Oncogene (2010) 29, 1103-1113; doi: 10.1038/onc.2009.402; published online 23 November 2009	[Levanon, K.; Ng, V.; Piao, H. Y.; Drapkin, R.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Zhang, Yi; Marto, J. A.] Dana Farber Canc Inst, Dept Canc Biol, Ctr Prote, Boston, MA 02115 USA; [Chang, M. C.; Roh, M. H.; Kindelberger, D. W.; Hirsch, M. S.; Crum, C. P.; Drapkin, R.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Drapkin, R (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Ctr Mol Oncol Pathol, JF215D,44 Binney St, Boston, MA 02115 USA.	ronny_drapkin@dfci.harvard.edu	Chang, Martin/J-2329-2016; Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Levanon, Keren/0000-0002-5122-064X	National Cancer Institute [P50 CA105009, K08 CA108748, R21 CA124688]; Ovarian Cancer Research Fund; Phi Beta Psi Sorority Charitable Trust; Fannie E. Ripple Foundation; Robert and Deborah First Fund; Randi and Joel Cutler Ovarian Cancer Research Fund; Columbia Hospital for Women Research Foundation; Marsha Rivkin Foundation Scientific Scholar Award; AACR-George and Patricia Sehl Fellowship; American Physicians Fellowship; Emmanuel G Rosenblatt Foundation; NATIONAL CANCER INSTITUTE [P50CA105009, R21CA124688, K08CA108748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ovarian Cancer Research Fund; Phi Beta Psi Sorority Charitable Trust; Fannie E. Ripple Foundation; Robert and Deborah First Fund; Randi and Joel Cutler Ovarian Cancer Research Fund; Columbia Hospital for Women Research Foundation; Marsha Rivkin Foundation Scientific Scholar Award; AACR-George and Patricia Sehl Fellowship; American Physicians Fellowship; Emmanuel G Rosenblatt Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Phil Karp, Thomas Moninger and Drs Paola Vermeer and Joseph Zabner (University of Iowa) for their enthusiastic support and assistance in establishing the FT ex vivo culture system, Drs Steve Cannistra, Glenn Dranoff and David Livingston for thoughtful suggestions and comments on the paper and Drs Tom Benjamin and Dawei Li for the Sall2 antibody. Special thanks goes to the faculty, technicians, residents and fellows of the division of Women's and Perinatal Pathology in the Department of Pathology at the Brigham and Women's Hospital, Boston, MA, for the allocation of tissues. This work was supported by the National Cancer Institute [P50 CA105009, K08 CA108748 and R21 CA124688], Ovarian Cancer Research Fund (Individual Investigator Award and Program Project Development Award), Phi Beta Psi Sorority Charitable Trust, Fannie E. Ripple Foundation, Robert and Deborah First Fund, Randi and Joel Cutler Ovarian Cancer Research Fund, the Columbia Hospital for Women Research Foundation, Marsha Rivkin Foundation Scientific Scholar Award, AACR-George and Patricia Sehl Fellowship for Cancer Genetics Research and the American Physicians Fellowship for Medicine in Israel-Claire and Emmanuel G Rosenblatt Foundation Grant.	Ando H, 2000, HUM REPROD, V15, P1597, DOI 10.1093/humrep/15.7.1597; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bast RC, 2005, INT J GYNECOL CANCER, V15, P274, DOI 10.1111/j.1525-1438.2005.00441.x; Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; Briton-Jones C, 2002, FERTIL STERIL, V77, P576, DOI 10.1016/S0015-0282(01)03216-2; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Comer MT, 1998, HUM REPROD, V13, P3114, DOI 10.1093/humrep/13.11.3114; CROW J, 1994, HUM REPROD, V9, P2224, DOI 10.1093/oxfordjournals.humrep.a138428; Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Folkins AK, 2009, GYNECOL ONCOL, V113, P391, DOI 10.1016/j.ygyno.2009.01.013; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hellstrom I, 2003, CANCER RES, V63, P3695; HENRIKSEN T, 1990, HUM REPROD, V5, P25, DOI 10.1093/oxfordjournals.humrep.a137034; Huang KC, 2006, INT J CANCER, V118, P2433, DOI 10.1002/ijc.21671; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; KERVANCIOGLU ME, 1994, BIOL CELL, V82, P103, DOI 10.1016/S0248-4900(94)80012-X; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kozak KR, 2005, PROTEOMICS, V5, P4589, DOI 10.1002/pmic.200500093; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li DW, 2004, MOL CELL BIOL, V24, P3885, DOI 10.1128/MCB.24.9.3885-3893.2004; Liu H, 2007, PLOS GENET, V3, P996, DOI 10.1371/journal.pgen.0030091; Moore RG, 2009, GYNECOL ONCOL, V112, P40, DOI 10.1016/j.ygyno.2008.08.031; Okada A, 2004, J MOL ENDOCRINOL, V32, P615, DOI 10.1677/jme.0.0320615; Piek JMJ, 2001, HISTOPATHOLOGY, V38, P481, DOI 10.1046/j.1365-2559.2001.1163c.x; Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440; Rajagopal M, 2006, IN VITRO CELL DEV-AN, V42, P248; Rusiniak ME, 2000, CANCER RES, V60, P1824; Saridogan E, 1997, HUM REPROD, V12, P1500, DOI 10.1093/humrep/12.7.1500; Satir P, 2008, HISTOCHEM CELL BIOL, V129, P687, DOI 10.1007/s00418-008-0416-9; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955	39	153	166	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1103	1113		10.1038/onc.2009.402	http://dx.doi.org/10.1038/onc.2009.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935705	Green Accepted			2022-12-28	WOS:000274912100002
J	O'Connell, MP; Fiori, JL; Xu, M; Carter, AD; Frank, BP; Camilli, TC; French, AD; Dissanayake, SK; Indig, FE; Bernier, M; Taub, DD; Hewitt, SM; Weeraratna, AT				O'Connell, M. P.; Fiori, J. L.; Xu, M.; Carter, A. D.; Frank, B. P.; Camilli, T. C.; French, A. D.; Dissanayake, S. K.; Indig, F. E.; Bernier, M.; Taub, D. D.; Hewitt, S. M.; Weeraratna, A. T.			The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma	ONCOGENE			English	Article						Ror2; Wnt5A; melanoma; metastasis; endosome; clathrin	RECESSIVE ROBINOW-SYNDROME; BREAST-CANCER METASTASIS; BRACHYDACTYLY TYPE-B; GENE-EXPRESSION; PROSTATE-CANCER; CELL-MIGRATION; PATHWAY; INHIBITION; ACTIVATION; MOTILITY	Tyrosine kinase receptors represent targets of great interest for cancer therapy. Here we show, for the first time, the importance of the orphan tyrosine kinase receptor, ROR2, in melanoma progression. Using melanoma tissue microarrays, we show that ROR2 is expressed predominantly in metastatic melanoma. As ROR2 has been shown to specifically interact with the non-canonical Wnt ligand, Wnt5A, this corroborates our earlier data implicating Wnt5A as a mediator of melanoma metastasis. We show here that increases in Wnt5A cause increases in ROR2 expression, as well as the PKC-dependent, clathrin-mediated internalization of ROR2. WNT5A knockdown by siRNA decreases ROR2 expression, but silencing of ROR2 has no effect on WNT5A levels. ROR2 knockdown does, however, result in a decrease in signaling downstream of Wnt5A. Using in vitro and in vivo metastasis assays, we show that ROR2 is necessary for the Wnt5A-mediated metastasis of melanoma cells. These data imply that ROR2 may represent a novel target for melanoma therapy.	[Weeraratna, A. T.] NIA, Immunol Lab, NIH, Biomed Res Ctr, Baltimore, MD 21224 USA; [Fiori, J. L.; Bernier, M.] NIA, Clin Invest Lab, NIH, Baltimore, MD 21224 USA; [Indig, F. E.] NIA, Confocal Imaging Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Biomed Res Ctr, 251 Bayview Blvd,Suite 100,Rm 08C226, Baltimore, MD 21224 USA.	prubinstein@nybloodcenter.org	Bernier, Michel/Y-7139-2019; O'Connell, Michael/F-9236-2017; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X; Hewitt, Stephen/0000-0001-8283-1788; O'Connell, Michael/0000-0002-8615-7660	National Institute on Aging, Baltimore, USA [MD 21224]; NATIONAL CANCER INSTITUTE [ZICBC010923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000764, ZICAG000615, ZIAAG000442, ZIAAG000450] Funding Source: NIH RePORTER	National Institute on Aging, Baltimore, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Ms Ana Lustig for assistance with animal experiments. This work was supported by the Intramural Research Program of the National Institute on Aging, Baltimore, MD 21224, USA.	Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Akbarzadeh S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001873; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Da Forno PD, 2008, CLIN CANCER RES, V14, P5825, DOI 10.1158/1078-0432.CCR-07-5104; Desmet CJ, 2006, CELL MOL LIFE SCI, V63, P755, DOI 10.1007/s00018-005-5490-8; Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200; Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008-5472.CAN-08-2149; He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Jonsson M, 1998, BRIT J CANCER, V78, P430, DOI 10.1038/bjc.1998.511; Katoh M, 2005, ONCOL REP, V14, P1583; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Liang ZX, 2005, CANCER RES, V65, P967; Liu Y, 2008, J CELL BIOCHEM, V105, P497, DOI 10.1002/jcb.21848; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; *NAT RES COUNC, 1985, GUID CAR USE LAB AN; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; O'Connell MP, 2009, J BIOL CHEM, V284, P28704, DOI 10.1074/jbc.M109.028498; O'Connell MP, 2009, J INVEST DERMATOL, V129, P1782, DOI 10.1038/jid.2008.433; O'Connell Michael P., 2008, V468, P243, DOI 10.1007/978-1-59745-249-6_19; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Pfeiffer S, 2002, CURR BIOL, V12, P957, DOI 10.1016/S0960-9822(02)00867-9; Romanowska M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005354; Safholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200; Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711; Saldanha J, 1998, PROTEIN SCI, V7, P1632, DOI 10.1002/pro.5560070718; Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529-0131(200104)44:4<772::AID-ANR133>3.0.CO;2-L; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Yamamoto H, 2007, GENES CELLS, V12, P1215, DOI 10.1111/j.1365-2443.2007.01128.x	36	148	154	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					34	44		10.1038/onc.2009.305	http://dx.doi.org/10.1038/onc.2009.305			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802008	Green Accepted			2022-12-28	WOS:000273373500004
J	di Martino, E; L'Hote, CG; Kennedy, W; Tomlinson, DC; Knowles, MA				di Martino, E.; L'Hote, C. G.; Kennedy, W.; Tomlinson, D. C.; Knowles, M. A.			Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner	ONCOGENE			English	Article						fibroblast growth factor; FGFR3; bladder; urothelium; signaling	FGFR3 MUTATIONS; DIFFERENTIAL EXPRESSION; BLADDER; ACTIVATION; DYSPLASIA; PHOSPHORYLATION; CARCINOMA; STAT1; ACHONDROPLASIA; UBIQUITYLATION	Although activating mutations of fibroblast growth factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum. We investigated the phenotypic and signaling consequences of three FGFR3 mutations (S249C, Y375C, and K652E) in immortalized normal human urothelial cells (TERT-NHUC) and mouse fibroblasts (NIH-3T3). In TERT-NHUC, all mutant forms of FGFR3 induced phosphorylation of FRS2 alpha and ERK1/2, but not AKT or SRC. PLC gamma 1 phosphorylation was only observed in TERT-NHUC expressing the common S249C and Y375C mutations, and not the rare K652E mutation. Cells expressing S249C and Y375C FGFR3 displayed an increased saturation density, related to increased proliferation and viability. This effect was significantly dependent on PLC gamma 1 signaling and undetectable in cells expressing K652E FGFR3, which failed to phosphorylate PLC gamma 1. In contrast to TERT-NHUC, expression of mutant FGFR3 in NIH-3T3 resulted in phosphorylation of Src and Akt. In addition, all forms of mutant FGFR3 were able to phosphorylate Plc gamma 1 and induce morphological transformation, cell proliferation, and anchorage-independent growth. Our results indicate that the effects of mutant FGFR3 are both cell type specific and mutation specific. Mutant FGFR3 may confer a selective advantage in the urothelium by overcoming normal contact inhibition of proliferation. Oncogene (2009) 28, 4306-4316; doi: 10.1038/onc.2009.280; published online 14 September 2009	[di Martino, E.; L'Hote, C. G.; Kennedy, W.; Tomlinson, D. C.; Knowles, M. A.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Oncol, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Oncol, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Tomlinson, Darren/0000-0003-4134-7484; di Martino, Erica/0000-0001-6703-1707; Knowles, Margaret/0000-0002-9363-8657	Cancer Research UK [C6228/A5433]	Cancer Research UK(Cancer Research UK)	We acknowledge Dr D Podolsky for donating the FGFR3 IIIb cDNA, and Dr R Agami for the pFB expression vector. This work was funded by a grant from Cancer Research UK (C6228/A5433).	Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Bernard-Pierrot I, 2006, CARCINOGENESIS, V27, P740, DOI 10.1093/carcin/bgi290; Bonaventure J, 2007, FEBS J, V274, P3078, DOI 10.1111/j.1742-4658.2007.05835.x; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Davies-Adetugbo AA, 1998, TROP MED INT HEALTH, V3, P9, DOI 10.1046/j.1365-3156.1998.00162.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Gibbs L, 2007, BBA-MOL CELL RES, V1773, P502, DOI 10.1016/j.bbamcr.2006.12.010; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hafner C, 2006, CELL CYCLE, V5, P2723, DOI 10.4161/cc.5.23.3509; Harada D, 2007, BONE, V41, P273, DOI 10.1016/j.bone.2006.11.030; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Karoui M, 2001, ONCOGENE, V20, P5059, DOI 10.1038/sj.onc.1204651; Korkolopoulou P, 2002, EUR UROL, V41, P274, DOI 10.1016/S0302-2838(02)00003-9; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lievens PMJ, 2006, J MOL BIOL, V357, P783, DOI 10.1016/j.jmb.2006.01.058; Lievens PMJ, 2003, J BIOL CHEM, V278, P17344, DOI 10.1074/jbc.M212710200; Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Murakami M, 2008, CARDIOVASC RES, V78, P223, DOI 10.1093/cvr/cvm086; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ornitz DM, 2001, GENOME BIOL, V2; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sibley K, 2001, ONCOGENE, V20, P4416, DOI 10.1038/sj.onc.1204543; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Tomlinson DC, 2005, CANCER RES, V65, P10441, DOI 10.1158/0008-5472.CAN-05-1718; van Oers JMM, 2006, INT J CANCER, V119, P1212, DOI 10.1002/ijc.21958; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Wallerand H, 2005, CARCINOGENESIS, V26, P177, DOI 10.1093/carcin/bgh275; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Wells A, 2003, CLIN EXP METASTAS, V20, P285, DOI 10.1023/A:1024088922957; YAMAMOTO H, 1995, BRIT J CANCER, V71, P1231, DOI 10.1038/bjc.1995.238	46	77	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4306	4316		10.1038/onc.2009.280	http://dx.doi.org/10.1038/onc.2009.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749790	Green Accepted			2022-12-28	WOS:000272876300008
J	Hoover, AC; Strand, GL; Nowicki, PN; Anderson, ME; Vermeer, PD; Klingelhutz, AJ; Bossler, AD; Pottala, JV; Hendriks, WJAJ; Lee, JH				Hoover, A. C.; Strand, G. L.; Nowicki, P. N.; Anderson, M. E.; Vermeer, P. D.; Klingelhutz, A. J.; Bossler, A. D.; Pottala, J. V.; Hendriks, W. J. A. J.; Lee, J. H.			Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway	ONCOGENE			English	Article						human papilloma virus; HPV E6 oncogene; PTPN13; MAP Kinase; ErbB2	TUMOR-SUPPRESSOR GENE; ANCHORAGE-INDEPENDENT GROWTH; ORAL MEK INHIBITOR; HEPATOCELLULAR-CARCINOMA; HUMAN-PAPILLOMAVIRUS; PROGNOSTIC IMPACT; EPITHELIAL-CELLS; INVASIVE GROWTH; CERVICAL-CANCER; FACTOR RECEPTOR	Human papillomaviruses (HPVs) are a causative factor in over 90% of cervical and 25% of head and neck squamous cell carcinomas (HNSCCs). The C terminus of the high-risk HPV 16 E6 oncoprotein physically associates with and degrades a non-receptor protein tyrosine phosphatase (PTPN13), and PTPN13 loss synergizes with H-Ras(V12) or ErbB2 for invasive growth in vivo. Oral keratinocytes that have lost PTPN13 and express H-Ras(V12) or ErbB2 show enhanced Ras/RAF/MEK/Erk signaling. In co-transfection studies, wild-type PTPN13 inhibited Ras/RAF/MEK/Erk signaling in HEK 293 cells that overexpress ErbB2, EGFR or H-Ras(V12), whereas an enzymatically inactive PTPN13 did not. Twenty percent of HPV-negative HNSCCs had PTPN13 phosphatase mutations that did not inhibit Ras/RAF/MEK/Erk signaling. Inhibition of Ras/RAF/MEK/Erk signaling using MEK inhibitor U0126 blocked anchorage-independent growth in cells lacking PTPN13. These findings show that PTPN13 phosphatase activity has a physiologically significant role in regulating MAP kinase signaling. Oncogene (2009) 28, 3960-3970; doi:10.1038/onc.2009.251; published online 7 September 2009	[Hoover, A. C.; Anderson, M. E.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Strand, G. L.; Bossler, A. D.] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Vermeer, P. D.; Pottala, J. V.; Lee, J. H.] Sanford Res USD, Canc Biol Res Ctr, Sioux Falls, SD USA; [Klingelhutz, A. J.] Univ Iowa, Dept Microbiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Hendriks, W. J. A. J.] Radboud Univ Nijmegen, Med Ctr, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; [Lee, J. H.] Sanford Hlth, Sanford ENT Head & Neck Surg, Sioux Falls, SD USA	University of Iowa; University of Iowa; Sanford Health; University of Iowa; Radboud University Nijmegen; Sanford Health	Lee, JH (corresponding author), Sanford HPV Res Inst, Dept Otolaryngol, 1310 22nd St, Sioux Falls, SD 57105 USA.	leej@sanfordhealth.org	Klingelhutz, Aloysius/L-9081-2018; Hendriks, Wiljan J.A.J./A-5214-2013; Hendriks, Wiljan/Q-4325-2019; Vermeer, Paola D/O-2572-2013	Klingelhutz, Aloysius/0000-0003-4258-5046; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Hendriks, Wiljan/0000-0001-9481-8281; Bossler, Aaron/0000-0002-8748-2510	NIDCR [1R01DE018386-01A1]; HHMI; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018386] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	JHL was supported by an NIDCR 1R01DE018386-01A1 and ACH was supported by an HHMI medical student fellowship. We acknowledge Jan Schepens' technical expertise for completing the phosphatase assays and Catherine Christopherson for manuscript preparation.	Abaan OD, 2008, CANCER METAST REV, V27, P205, DOI 10.1007/s10555-008-9114-2; Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; Dromard M, 2007, CANCER RES, V67, P6806, DOI 10.1158/0008-5472.CAN-07-0513; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Landro ME, 2008, J MED VIROL, V80, P694, DOI 10.1002/jmv.21076; Ford AC, 2003, HEAD NECK-J SCI SPEC, V25, P67, DOI 10.1002/hed.10224; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardisson D, 2003, EUR ARCH OTO-RHINO-L, V260, P502, DOI 10.1007/s00405-003-0581-3; Hopfner M, 2008, WORLD J GASTROENTERO, V14, P1, DOI 10.3748/wjg.14.1; Hoover AC, 2007, ARCH OTOLARYNGOL, V133, P495, DOI 10.1001/archotol.133.5.495; Hsu J. C, 1992, J COMPUTATIONAL STAT, V1, P151, DOI DOI 10.2307/1390839; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Nakahira M, 2007, IMMUNITY, V26, P163, DOI 10.1016/j.immuni.2007.01.010; Perez-Regadera J, 2009, ONCOLOGY-BASEL, V76, P133, DOI 10.1159/000195539; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Spanos WC, 2008, HEAD NECK-J SCI SPEC, V30, P139, DOI 10.1002/hed.20673; Villa F, 2005, J BIOL CHEM, V280, P8180, DOI 10.1074/jbc.M412211200; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wansink DG, 2004, PHYSIOL GENOMICS, V19, P50, DOI 10.1152/physiolgenomics.00079.2004; YARBROUGH WG, 1994, LARYNGOSCOPE, V104, P1337; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	39	55	55	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3960	3970		10.1038/onc.2009.251	http://dx.doi.org/10.1038/onc.2009.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19734941	Green Accepted			2022-12-28	WOS:000272560300002
J	Thirkettle, HJ; Mills, IG; Whitaker, HC; Neal, DE				Thirkettle, H. J.; Mills, I. G.; Whitaker, H. C.; Neal, D. E.			Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression	ONCOGENE			English	Article						LYRIC/AEG-1; PLZF; transcription; repression; nucleus	ASTROCYTE-ELEVATED GENE-1; PROSTATE-CANCER; PROTEIN PLZF; BREAST-CANCER; C-MYC; IDENTIFICATION; METASTASIS; ACTIVATION; PROGRESSION; EXPRESSION	LYRIC/AEG-1 and its altered expression have been linked to carcinogenesis in prostate, brain and melanoma as well as promoting chemoresistance and metastasis in breast cancer. LYRIC/AEG-1 function remains unclear, although LYRIC/AEG-1 is activated by oncogenic HA-RAS, through binding of c-myc to its promoter, which in turn regulates the key components of the PI3-kinase and nuclear factor-kappa B pathways. We have identified the transcriptional repressor PLZF as an interacting protein of LYRIC/AEG through a yeast two-hybrid screen. PLZF regulates the expression of genes involved in cell growth and apoptosis including c-myc. Coexpression of LYRIC/AEG-1 with PLZF leads to a reduction in PLZF-mediated repression by reducing PLZF binding to promoters. We have confirmed that nuclear LYRIC/AEG-1 and PLZF interact in mammalian cells via the N- and C termini of LYRIC/AEG-1 and a region C terminal to the RD2 domain of PLZF. Both proteins colocalize to nuclear bodies containing histone deacetylases, which are known to promote PLZF-mediated repression. Our data suggest one mechanism for cells with altered LYRIC/AEG-1 expression to evade apoptosis and increase cell growth during tumourigenesis through the regulation of PLZF repression. Oncogene (2009) 28, 3663-3670; doi:10.1038/onc.2009.223; published online 3 August 2009	[Whitaker, H. C.] Canc Res UK Cambridge Res Inst, Urooncol Res Grp, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Cancer Research UK; CRUK Cambridge Institute	Whitaker, HC (corresponding author), Canc Res UK Cambridge Res Inst, Urooncol Res Grp, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	Hayley.Whitaker@cancer.org.uk	Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083; Neal, David/0000-0002-6033-5086	Cancer Research UK; Medical Research Council; Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility; MRC [G0500966] Funding Source: UKRI; Medical Research Council [G0500966] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funding for this study was provided by Cancer Research UK (DEN, HCW, IGM) and the Medical Research Council (HJT). We thank Jonathon D Licht for the PLZF reporter construct 4xIL-3R-tkLUC, Zhou Wang (Chicago) for PLZF expression construct, Krishna Chatterjee (Cambridge) for pEF-BOS-b-gal construct. We also thank Wendy Bickmore for LYRIC/AEG-1 antibodies (Edinburgh) and Maria Carmo-Fonseca (Lisbon) for the anti-coilin antibody. We are very grateful to Antonio Ramos-Montoya (Cambridge) for help and advice with ChIP and qRT -PCR. We acknowledge the support of the Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility, The University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited.	Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Bernardo MV, 2007, BIOCHEM BIOPH RES CO, V359, P317, DOI 10.1016/j.bbrc.2007.05.085; Brooke GN, 2008, ONCOGENE, V27, P2941, DOI 10.1038/sj.onc.1210955; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Chao TT, 2007, BIOCHEM BIOPH RES CO, V358, P475, DOI 10.1016/j.bbrc.2007.04.157; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Kikugawa T, 2006, PROSTATE, V66, P1092, DOI 10.1002/pros.20443; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kwong LN, 2009, CANCER CELL, V15, P1, DOI 10.1016/j.ccr.2008.12.007; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Thirkettle HJ, 2009, CLIN CANCER RES, V15, P3003, DOI 10.1158/1078-0432.CCR-08-2046; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Whitaker HC, 2007, PROSTATE, V67, P943, DOI 10.1002/pros.20580	28	56	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3663	3670		10.1038/onc.2009.223	http://dx.doi.org/10.1038/onc.2009.223			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648967				2022-12-28	WOS:000270851800007
J	Bagci, T; Wu, JK; Pfannl, R; Ilag, LL; Jay, DG				Bagci, T.; Wu, J. K.; Pfannl, R.; Ilag, L. L.; Jay, D. G.			Autocrine semaphorin 3A signaling promotes glioblastoma dispersal	ONCOGENE			English	Article						proteomics; glioma; dispersal; semaphorin; neuropilin	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; HUMAN GLIOMA-CELLS; CARCINOMA-CELLS; POOR-PROGNOSIS; TUMOR-CELLS; NEUROPILIN-1; MIGRATION; RECEPTOR; EXPRESSION	Glioblastoma multiforme (GBM) is the most malignant glioma type with diffuse borders due to extensive tumor cell infiltration. Therefore, understanding the mechanism of GBM cell dispersal is critical for developing effective therapies to limit infiltration. We identified neuropilin-1 as a mediator of cancer cell invasion by a functional proteomic screen and showed its role in GBM cells. Neuropilin-1 is a receptor for semaphorin3A (Sema3A), a secreted chemo-repellent that facilitates axon guidance during neural development. Although neuropilin-1 expression in GBMs was previously shown, its role as a Sema3A receptor remained elusive. Using fluorophore-assisted light inactivation and RNA interference, we showed that neuropilin-1 is required for GBM cell migration. We also showed that GBM cells secrete Sema3A endogenously, and RNA interference-mediated downregulation of Sema3A inhibits migration and alters cell morphology that is dependent on Rac1 activity. Sema3A depletion also reduces dispersal, which is recovered by supplying Sema3A exogenously. Extracellular application of Sema3A decreases cell-substrate adhesion in a neuropilin-1-dependent manner. Using immunohistochemistry, we showed that Sema3A is overexpressed in a subset of human GBMs compared with the non-neoplastic brain. Together, these findings implicate Sema3A as an autocrine signal for neuropilin-1 to promote GBM dispersal by modulating substrate adhesion and suggest that targeting Sema3A-neuropilin-1 signaling may limit GBM infiltration. Oncogene (2009) 28, 3537-3550; doi: 10.1038/onc.2009.204; published online 17 August 2009	[Jay, D. G.] Tufts Univ, Dept Physiol, Sch Med, Boston, MA 02111 USA; [Bagci, T.; Jay, D. G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; [Wu, J. K.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [Pfannl, R.] Tufts Univ, Sch Med, Dept Neuropathol, Boston, MA 02111 USA; [Ilag, L. L.] Bio21 Mol Sci & Biotechnol Inst, Patrys Ltd, Parkville, Vic, Australia	Tufts University; Tufts University; Tufts University; Tufts University	Jay, DG (corresponding author), Tufts Univ, Dept Physiol, Sch Med, 136 Harrison Ave,M&V709, Boston, MA 02111 USA.	daniel.jay@tufts.edu	Onder, Tugba Bagci/AAN-1392-2021	Bagci Onder, Tugba/0000-0003-3646-2613	Goldhirsh Foundation; NIH [RO1 CA 116642]; NATIONAL CANCER INSTITUTE [R01CA116642] Funding Source: NIH RePORTER	Goldhirsh Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alex Kolodkin (Johns Hopkins School of Medicine) for kindly providing function blocking anti-Nrp-1 antibody; Jean Stewart, Dean Yimlamai and Jennifer Salluzzo for technical help; Sonya Craig for discussions about the adhesion assay; Brenda Eustace for assistance with the invasion screen; Pat Hibberd for help with the statistical analysis; Laura Liscum, Tamer Onder and Jessica McCready for critically reading the paper. This work was supported by the Goldhirsh Foundation and the NIH, RO1 CA 116642.	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2003, CANCER RES, V63, P5230; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Broholm H, 2004, APMIS, V112, P257, DOI 10.1111/j.1600-0463.2004.apm11204-0505.x; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Castellani V, 2002, EMBO J, V21, P6348, DOI 10.1093/emboj/cdf645; Chen G, 2008, NAT NEUROSCI, V11, P36, DOI 10.1038/nn2018; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; De Wit J, 2005, MOL CELL NEUROSCI, V29, P40, DOI 10.1016/j.mcn.2004.12.009; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Halloran MC, 2006, CURR OPIN CELL BIOL, V18, P533, DOI 10.1016/j.ceb.2006.08.010; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kreuter M, 2006, LEUKEMIA, V20, P1950, DOI 10.1038/sj.leu.2404384; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Mertsch S, 2008, J NEURO-ONCOL, V87, P1, DOI 10.1007/s11060-007-9484-2; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Mueller MW, 2007, INT J CANCER, V121, P2421, DOI 10.1002/ijc.22949; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nakada M, 2006, CANCER RES, V66, P8492, DOI 10.1158/0008-5472.CAN-05-4211; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Okada H, 1996, INT J CANCER, V66, P255, DOI 10.1002/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A; Osada H, 2004, ANTICANCER RES, V24, P547; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; Roche J, 2002, ADV EXP MED BIOL, V515, P103; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Roush W, 1998, SCIENCE, V279, P2042, DOI 10.1126/science.279.5359.2042; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554; Turner LJ, 2004, J BIOL CHEM, V279, P33199, DOI 10.1074/jbc.M402943200; Vales A, 2007, LEUKEMIA LYMPHOMA, V48, P1997, DOI 10.1080/10428190701534424; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	57	86	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3537	3550		10.1038/onc.2009.204	http://dx.doi.org/10.1038/onc.2009.204			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19684614				2022-12-28	WOS:000270851700003
J	Bohm, M; Locke, WJ; Sutherland, RL; Kench, JG; Henshall, SM				Boehm, M.; Locke, W. J.; Sutherland, R. L.; Kench, J. G.; Henshall, S. M.			A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes	ONCOGENE			English	Article						AR; GATA-2; prostate cancer; progression	LIPID MOBILIZING FACTOR; TRANSCRIPTION FACTORS; RECEPTOR; EXPRESSION; CELLS; ADIPOCYTES; EVOLUTION; PATHWAY; MODEL	GATA-2, a member of the GATA family of transcription factors, is involved in androgen receptor (AR) signaling, however, little is known regarding its role in prostate cancer. Here, we report that GATA-2 is expressed in a substantial proportion of prostate cancers and that high expression of GATA-2 is associated with biochemical recurrence and distant metastatic progression in a validation set of 203 cancers. In vitro data show that GATA-2 is directly recruited to the promoter region of the AR upon androgen stimulation of LNCaP prostate cancer cells with 5 alpha-dihydroxytestosterone (DHT) for 24 h. Ectopic GATA-2 expression causes the induction of AR transcript levels under androgen-depleted conditions (P<0.05). The expression of the AR target gene, AZGP1, is induced upon androgen stimulation and this effect is repressed by GATA-2. In contrast, GATA-2 significantly increases transcript levels of KLK2, which increases further in a time-dependent manner on DHT treatment and in the presence of GATA-2. These results indicate that upregulation of GATA-2 may contribute to the progression to aggressive prostate cancer through modulation of expression of AR and key androgen-regulated genes, one of which, AZGP1, is associated with the progression to metastatic disease. Oncogene (2009) 28, 3847-3856; doi:10.1038/onc.2009.243; published online 17 August 2009	[Boehm, M.; Locke, W. J.; Sutherland, R. L.; Kench, J. G.; Henshall, S. M.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Kench, J. G.] Royal Prince Alfred Hosp, Dept Anat Pathol, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of Sydney	Henshall, SM (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	s.henshall@garvan.org.au	Locke, Warwick/G-3152-2017; Sutherland, Robert L/A-8378-2008	Locke, Warwick/0000-0002-9281-0363; Kench, James Geoffrey/0000-0001-8687-4988	Cancer Institute NSW; National Health and Medical Research Council; Prostate Cancer Foundation of Australia; RT Hall Trust	Cancer Institute NSW; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Prostate Cancer Foundation of Australia; RT Hall Trust	This work is supported by grants from the Cancer Institute NSW, the National Health and Medical Research Council, the Prostate Cancer Foundation of Australia and the RT Hall Trust. We thank Professor Liz Musgrove, Dr Ross Laybutt and Dr Liz Caldon for helpful discussion and critical reading of the paper. Furthermore, we thank Ruth PeBenito for technical support.	Bao Y, 2005, FEBS LETT, V579, P41, DOI 10.1016/j.febslet.2004.11.042; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; Borgono CA, 2004, MOL CANCER RES, V2, P257; COX DR, 1972, J R STAT SOC B, V187, P220; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Henshall SM, 2003, CANCER RES, V63, P4196; Henshall SM, 2006, J NATL CANCER I, V98, P1420, DOI 10.1093/jnci/djj378; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kato S, 2004, J STEROID BIOCHEM, V89-90, P627, DOI 10.1016/j.jsbmb.2004.03.099; Lin BY, 1999, CANCER RES, V59, P4180; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Magklara A, 2009, MOL ENDOCRINOL, V23, P61, DOI 10.1210/me.2008-0028; Masuda K, 2005, J MOL BIOL, V353, P763, DOI 10.1016/j.jmb.2005.09.009; Matsuyama M, 2008, PPAR RES, V2008, DOI 10.1155/2008/249849; Minegishi N, 2005, GENES CELLS, V10, P693, DOI 10.1111/j.1365-2443.2005.00864.x; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Oren Aharon, 2005, Saline Syst, V1, P2, DOI 10.1186/1746-1448-1-2; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; Rasiah KK, 2006, CANCER EPIDEM BIOMAR, V15, P711, DOI 10.1158/1055-9965.EPI-05-0752; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Xu Y, 2003, J CELL PHYSIOL, V196, P131, DOI 10.1002/jcp.10281; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	38	62	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3847	3856		10.1038/onc.2009.243	http://dx.doi.org/10.1038/onc.2009.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684615				2022-12-28	WOS:000271248400008
J	Chan, CB; Liu, X; Jang, SW; Hsu, SIH; Williams, I; Kang, S; Chen, J; Ye, K				Chan, C. B.; Liu, X.; Jang, S-W; Hsu, S. I-H; Williams, I.; Kang, S.; Chen, J.; Ye, K.			NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association	ONCOGENE			English	Article						acinus; CtBP2; cyclin A1; gambogic amide; leukemia; NGF	NERVE GROWTH-FACTOR; TERMINAL BINDING-PROTEIN; ACUTE MYELOID-LEUKEMIA; CANCER CELL-LINES; CHROMATIN CONDENSATION; HEMATOPOIETIC-CELLS; COREPRESSOR CTBP; RETINOIC ACID; TRKA RECEPTOR; CO-REPRESSOR	Cyclin A1 is essential for leukemia progression, and its expression is tightly regulated by acinus, a nuclear speckle protein. However, the molecular mechanism of how acinus mediates cyclin A1 expression remains elusive. Here we show that transcription corepressor CtBP2 directly binds acinus, which is regulated by nerve growth factor (NGF), inhibiting its stimulatory effect on cyclin A1, but not cyclin A2, expression in leukemia. NGF, a cognate ligand for the neurotrophic receptor TrkA, promotes the interaction between CtBP2 and acinus through triggering acinus phosphorylation by Akt. Overexpression of CtBP2 diminishes cyclin A1 transcription, whereas depletion of CtBP2 abolishes NGF's suppressive effect on cyclin A1 expression. Strikingly, gambogic amide, a newly identified TrkA agonist, potently represses cyclin A1 expression, thus blocking K562 cell proliferation. Moreover, gambogic amide ameliorates the leukemia progression in K562 cells inoculated nude mice. Hence, NGF downregulates cyclin A1 expression through escalating CtBP2/acinus complex formation, and gambogic amide might be useful for human leukemia treatment. Oncogene (2009) 28, 3825-3836; doi:10.1038/onc.2009.236; published online 10 August 2009	[Chan, C. B.; Liu, X.; Jang, S-W; Williams, I.; Ye, K.] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA; [Hsu, S. I-H] Natl Univ Singapore, Dept Med, Fac Med, Singapore 117548, Singapore; [Kang, S.; Chen, J.] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA 30322 USA	Emory University; National University of Singapore; Emory University	Ye, K (corresponding author), Emory Univ, Dept Pathol & Lab Med, Sch Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			NIH [RO1 NS060680]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS060680] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by a grant from NIH (RO1 NS060680) to K Ye. We thank Dr G Chinnadurai (Saint Louis University Health Sciences Center) for GST-CtBP1 plasmid.	BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chan CB, 2007, CELL DEATH DIFFER, V14, P1688, DOI 10.1038/sj.cdd.4402179; Chen J, 2008, LIFE SCI, V83, P103, DOI 10.1016/j.lfs.2008.05.003; CHEVALIER S, 1994, BLOOD, V83, P1479; DEWECK Z, 1987, BIOCHEMISTRY-US, V26, P4769, DOI 10.1021/bi00389a026; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Guo QL, 2004, ACTA PHARMACOL SIN, V25, P769; Hong EG, 2007, AM J PHYSIOL-ENDOC M, V293, pE1687, DOI 10.1152/ajpendo.00256.2007; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; JACKSON GR, 1992, BRAIN RES, V592, P239, DOI 10.1016/0006-8993(92)91681-4; Jang SW, 2008, CANCER RES, V68, P4559, DOI 10.1158/0008-5472.CAN-08-0021; Jang SW, 2007, P NATL ACAD SCI USA, V104, P16329, DOI 10.1073/pnas.0706662104; Ji P, 2005, ONCOGENE, V24, P2739, DOI 10.1038/sj.onc.1208356; Kaebisch A, 1996, BRIT J HAEMATOL, V95, P102, DOI 10.1046/j.1365-2141.1996.d01-1874.x; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kato T, 2005, J CLIN INVEST, V115, P2716, DOI 10.1172/JCI24280; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Li ZX, 2009, BLOOD, V113, P2028, DOI 10.1182/blood-2008-05-155200; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Liu W, 2005, WORLD J GASTROENTERO, V11, P3655, DOI 10.3748/wjg.v11.i24.3655; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; McLure KG, 2004, MOL CELL BIOL, V24, P9958, DOI 10.1128/MCB.24.22.9958-9967.2004; Meyer J, 2007, LEUKEMIA, V21, P2171, DOI 10.1038/sj.leu.2404882; Miller JP, 2007, CELL CYCLE, V6, P2932, DOI 10.4161/cc.6.23.5042; MISSALE C, 1993, P NATL ACAD SCI USA, V90, P7961, DOI 10.1073/pnas.90.17.7961; Missale C, 1998, P NATL ACAD SCI USA, V95, P5366, DOI 10.1073/pnas.95.9.5366; Nardini M, 2006, PROTEIN SCI, V15, P1042, DOI 10.1110/ps.062115406; Pereda MP, 2000, MOL CELL ENDOCRINOL, V167, P99, DOI 10.1016/S0303-7207(00)00286-0; Qiang L, 2008, BIOCHEM PHARMACOL, V75, P1083, DOI 10.1016/j.bcp.2007.10.033; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; Shu WX, 2008, BASIC CLIN PHARMACOL, V103, P530, DOI 10.1111/j.1742-7843.2008.00292.x; Sigala S, 1999, CLIN CANCER RES, V5, P1211; Skaper SD, 2008, CNS NEUROL DISORD-DR, V7, P46, DOI 10.2174/187152708783885174; Tange TO, 2005, RNA, V11, P1869, DOI 10.1261/rna.2155905; Tao ZJ, 2007, CANCER BIOL THER, V6, P691, DOI 10.4161/cbt.6.5.3960; Thio SSC, 2004, NUCLEIC ACIDS RES, V32, P1836, DOI 10.1093/nar/gkh344; TRIA MA, 1994, EXP NEUROL, V127, P178, DOI 10.1006/exnr.1994.1093; TSUDA T, 1991, BLOOD, V77, P971; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Vucetic Z, 2008, MOL CELL BIOL, V28, P2549, DOI 10.1128/MCB.01199-07; Wolgemuth DJ, 2004, INT J ANDROL, V27, P192, DOI 10.1111/j.1365-2605.2004.00480.x; Xie P, 2000, LEUKEMIA RES, V24, P751, DOI 10.1016/S0145-2126(00)00044-8; Xie P, 1997, NEUROREPORT, V8, P1067, DOI 10.1097/00001756-199703240-00001; Xu XY, 2009, INT J DERMATOL, V48, P186, DOI 10.1111/j.1365-4632.2009.03946.x; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Zhang QH, 2002, SCIENCE, V295, P1895	55	21	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3825	3836		10.1038/onc.2009.236	http://dx.doi.org/10.1038/onc.2009.236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19668232	Green Accepted			2022-12-28	WOS:000271248400006
J	Radpour, R; Kohler, C; Haghighi, MM; Fan, AXC; Holzgreve, W; Zhong, XY				Radpour, R.; Kohler, C.; Haghighi, M. M.; Fan, A. X. C.; Holzgreve, W.; Zhong, X. Y.			Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array	ONCOGENE			English	Article						breast cancer; DNA methylation; MALDI-TOF; mass spectrometry	DNA METHYLATION; PROMOTER METHYLATION; COLORECTAL CANCERS; SERUM; LANDSCAPES; PATTERNS; CLEAVAGE	Alterations of DNA methylation patterns have been suggested as biomarkers for diagnostics and therapy of cancers. Every novel discovery in the epigenetic landscape and every development of an improved approach for accurate analysis of the events may offer new opportunity for the management of patients. Using a novel high-throughput mass spectrometry on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) silico-chips, we determined semiquantitative methylation changes of 22 candidate genes in breast cancer tissues. For the first time we analysed the methylation status of a total of 42 528 CpG dinucleotides on 22 genes in 96 different paraffin-embedded tissues (48 breast cancerous tissues and 48 paired normal tissues). A two-way hierarchical cluster analysis was used to classify methylation profiles. In this study, 10 hypermethylated genes (APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3) were identified to distinguish between cancerous and normal tissues according to the extent of methylation. Individual assessment of the methylation status for each CpG dinucleotide indicated that cytosine hypermethylation in the cancerous tissue samples was mostly located near the consensus sequences of the transcription factor binding sites. These hypermethylated genes may serve as biomarkers for clinical molecular diagnosis and targeted treatments of patients with breast cancer. Oncogene (2009) 28, 2969-2978; doi:10.1038/onc.2009.149; published online 8 June 2009	[Zhong, X. Y.] Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, CH-4031 Basel, Switzerland; [Haghighi, M. M.] E Tehran Branch, IAU, Fac Sci, Dept Biol, Tehran, Iran; [Holzgreve, W.] Univ Med Ctr Freiburg, Freiburg, Germany	University of Basel; University of Freiburg	Zhong, XY (corresponding author), Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, Hebelstr 20,Room 416, CH-4031 Basel, Switzerland.	zhongx@uhbs.ch	Fan, Alex X/I-8247-2014; Radpour, Ramin/J-4949-2014	Fan, Alex X/0000-0003-0433-9864; Radpour, Ramin/0000-0002-5632-7833	Swiss National Science Foundation [320000-119722/1]; Swiss Cancer League; Krebsliga Beider Basel; Dr Hans Altschueler Stiftung	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel; Dr Hans Altschueler Stiftung	We thank Professor Charles Cantor (SEQUENOM) for reading the manuscript and making critical comments, Vivian Kiefer for her excellent assistance and Regan Geissmann for proofreading the text. We are indebted to the patients for their cooperation. This work was supported in part by Swiss National Science Foundation (320000-119722/1) and Swiss Cancer League, Krebsliga Beider Basel and Dr Hans Altschueler Stiftung.	Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117; Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Stanssens P, 2004, GENOME RES, V14, P126; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Trent JM, 2007, SCIENCE, V318, P1079, DOI 10.1126/science.1151428; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900; Zou HZ, 2002, CLIN CANCER RES, V8, P188	20	77	82	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2969	2978		10.1038/onc.2009.149	http://dx.doi.org/10.1038/onc.2009.149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19503099				2022-12-28	WOS:000269142800005
J	Freedman, JA; Chang, JT; Jakoi, L; Nevins, JR				Freedman, J. A.; Chang, J. T.; Jakoi, L.; Nevins, J. R.			A combinatorial mechanism for determining the specificity of E2F activation and repression	ONCOGENE			English	Article						E2F; transcription; gene regulation	TRANSCRIPTION FACTOR; CELL-CYCLE; DNA-REPLICATION; FAMILY-MEMBERS; IN-VIVO; APOPTOSIS; PROLIFERATION; PROMOTER; DISTINCT; BINDING	Various studies have detailed the role of E2F proteins in both transcription activation and repression. Further study has shown that distinct promoter elements, but comprising the same E2F-recognition motif, confer positive or negative E2F control and that this reflects binding of either activator or repressor E2F proteins, respectively. We now show that the specificity of binding of an activator or repressor E2F protein is determined by adjacent sequences that bind a cooperating transcription factor. We propose that the functional E2F element is a module comprising not only the E2F-binding site but also the adjacent site for the cooperating transcription factor. Oncogene (2009) 28, 2873-2881; doi:10.1038/onc.2009.153; published online 22 June 2009	[Freedman, J. A.; Chang, J. T.; Jakoi, L.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, 2123 CIEMAS, Durham, NC 27710 USA.	j.nevins@duke.edu			National Cancer Institute [R01CA104663]; NATIONAL CANCER INSTITUTE [R01CA104663] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We thank the members of the Nevins laboratory for valuable input throughout the course of this study and for comments on the paper. The project described was supported by award number R01CA104663 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or of the National Institutes of Health.	Aparicio Oscar, 2005, Curr Protoc Mol Biol, VChapter 21, DOI 10.1002/0471142727.mb2103s69; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bryne JC, 2008, NUCLEIC ACIDS RES, V36, pD102, DOI 10.1093/nar/gkm955; Christensen J, 2005, NUCLEIC ACIDS RES, V33, P5458, DOI 10.1093/nar/gki855; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Hallstrom TC, 2006, GENE DEV, V20, P613, DOI 10.1101/gad.1345006; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Kong LJ, 2007, ONCOGENE, V26, P321, DOI 10.1038/sj.onc.1209817; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kuhn RM, 2009, NUCLEIC ACIDS RES, V37, pD755, DOI 10.1093/nar/gkn875; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Logan N, 2005, ONCOGENE, V24, P5000, DOI 10.1038/sj.onc.1208703; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M J, 2001, Obes Rev, V2, P15; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wysocka J, 2003, TRENDS BIOCHEM SCI, V28, P294, DOI 10.1016/S0968-0004(03)00088-4; Yamamoto KR, 1998, COLD SPRING HARB SYM, V63, P587, DOI 10.1101/sqb.1998.63.587; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	54	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2873	2881		10.1038/onc.2009.153	http://dx.doi.org/10.1038/onc.2009.153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19543322	Green Accepted			2022-12-28	WOS:000268917100003
J	Flahaut, M; Meier, R; Coulon, A; Nardou, KA; Niggli, FK; Martinet, D; Beckmann, JS; Joseph, JM; Muhlethaler-Mottet, A; Gross, N				Flahaut, M.; Meier, R.; Coulon, A.; Nardou, K. A.; Niggli, F. K.; Martinet, D.; Beckmann, J. S.; Joseph, J-M; Muehlethaler-Mottet, A.; Gross, N.			The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway	ONCOGENE			English	Article						neuroblastoma; chemoresistance; FZD1; MDR1; Wnt signalling	MULTIDRUG-RESISTANCE; GENE-EXPRESSION; BETA-CATENIN; CELL-LINES; INDUCED APOPTOSIS; CYCLIN D1; CANCER; CARCINOMA; TARGET; AMPLIFICATION	The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as neuroblastoma (NB), a particularly aggressive childhood solid tumour. The mechanisms underlying the chemoresistant phenotype in NB were addressed by gene expression profiling of two doxorubicin (DoxR)-resistant vs sensitive parental cell lines. Not surprisingly, the MDR1 gene was included in the identified upregulated genes, although the highest overexpressed transcript in both cell lines was the frizzled-1 Wnt receptor (FZD1) gene, an essential component of the Wnt/beta-catenin pathway. FZD1 upregulation in resistant variants was shown to mediate sustained activation of the Wnt/b-catenin pathway as revealed by nuclear beta-catenin translocation and target genes transactivation. Interestingly, specific micro-adapted short hairpin RNA (shRNAmir)-mediated FZD1 silencing induced parallel strong decrease in the expression of MDR1, another beta-catenin target gene, revealing a complex, Wnt/beta-catenin-mediated implication of FZD1 in chemoresistance. The significant restoration of drug sensitivity in FZD1-silenced cells confirmed the FZD1-associated chemoresistance. RNA samples from 21 patient tumours (diagnosis and postchemotherapy), showed a highly significant FZD1 and/or MDR1 overexpression after treatment, underlining a role for FZD1-mediated Wnt/beta-catenin pathway in clinical chemoresistance. Our data represent the first implication of the Wnt/beta-catenin pathway in NB chemoresistance and identify potential new targets to treat aggressive and resistant NB. Oncogene (2009) 28, 2245-2256; doi:10.1038/onc.2009.80; published online 4 May 2009	[Flahaut, M.; Coulon, A.; Nardou, K. A.; Joseph, J-M; Muehlethaler-Mottet, A.; Gross, N.] Univ Hosp CHUV, Dept Paediat, CH-1011 Lausanne, Switzerland; [Meier, R.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; [Niggli, F. K.] Univ Children Hosp, Dept Paediat, Zurich, Switzerland; [Martinet, D.; Beckmann, J. S.] Univ Hosp CHUV, Med Genet Serv, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University Children's Hospital Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Flahaut, M (corresponding author), Univ Hosp CHUV, Dept Paediat, CH-1011 Lausanne, Switzerland.	Marjorie.Flahaut@chuv.ch	Mühlethaler-Mottet, Annick/H-2848-2019; Beckmann, Jacques S/A-9772-2008; Niggli, Felix/L-6547-2017	Mühlethaler-Mottet, Annick/0000-0001-8274-0907; Beckmann, Jacques S/0000-0002-9741-1900; Niggli, Felix/0000-0002-7553-3712	Schweizer Forschungsstiftung Kind und Krebs; Swiss National Science foundation; FORCE foundation	Schweizer Forschungsstiftung Kind und Krebs; Swiss National Science foundation(Swiss National Science Foundation (SNSF)European Commission); FORCE foundation	We thank M Wicht and N Besuchet Schmutz ( Medical Genetic Service, CHUV) for their skillful help. This study was supported by the Schweizer Forschungsstiftung Kind und Krebs, the Swiss National Science foundation and the FORCE foundation.	Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bedrnicek J, 2005, NEOPLASMA, V52, P415; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Duhem, 1996, Oncologist, V1, P151; Eisenmann David M, 2005, WormBook, P1, DOI 10.1895/wormbook.1.7.1; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Flahaut M, 2006, GENE CHROMOSOME CANC, V45, P495, DOI 10.1002/gcc.20312; Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hopkins-Donaldson S, 2002, ONCOGENE, V21, P6132, DOI 10.1038/sj.onc.1205879; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Johnsson A, 2005, ANTICANCER RES, V25, P2661; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Ludwig JA, 2006, CANCER RES, V66, P4808, DOI 10.1158/0008-5472.CAN-05-3322; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Merle P, 2005, J HEPATOL, V43, P854, DOI 10.1016/j.jhep.2005.05.018; Milovanovic T, 2004, INT J ONCOL, V25, P1337; Modok S, 2006, CURR OPIN PHARMACOL, V6, P350, DOI 10.1016/j.coph.2006.01.009; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; Polakis P, 2000, GENE DEV, V14, P1837; Psarros M, 2005, NUCLEIC ACIDS RES, V33, pW638, DOI 10.1093/nar/gki490; SEEGER RC, 1977, CANCER RES, V37, P1364; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueno K, 2008, NEOPLASIA, V10, P697, DOI 10.1593/neo.08320; Valent A, 1999, CANCER GENET CYTOGEN, V112, P124, DOI 10.1016/S0165-4608(98)00264-7; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yamada T, 2000, CANCER RES, V60, P4761	44	138	146	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2245	2256		10.1038/onc.2009.80	http://dx.doi.org/10.1038/onc.2009.80			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421142				2022-12-28	WOS:000266886300001
J	Boehrer, S; Ades, L; Tajeddine, N; Hofmann, WK; Kriener, S; Bug, G; Ottmann, OG; Ruthardt, M; Galluzzi, L; Fouassier, C; Tailler, M; Olaussen, KA; Gardin, C; Eclache, V; de Botton, S; Thepot, S; Fenaux, P; Kroemer, G				Boehrer, S.; Ades, L.; Tajeddine, N.; Hofmann, W. K.; Kriener, S.; Bug, G.; Ottmann, O. G.; Ruthardt, M.; Galluzzi, L.; Fouassier, C.; Tailler, M.; Olaussen, K. A.; Gardin, C.; Eclache, V.; de Botton, S.; Thepot, S.; Fenaux, P.; Kroemer, G.			Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome	ONCOGENE			English	Article						leukemogenesis; apoptosis; cell cycle; ATM; Chk-1	ATM ACTIVATION; CELL-LINES; CLASSIFICATION; APOPTOSIS; KINASE; CHECKPOINT; PATHWAYS; COMPLEX; BARRIER; TARGET	The molecular mechanisms responsible for the evolution from the preleukemic entities of low-risk myelodysplastic syndrome (MDS) to the less favorable forms of high-risk MDS, as well as those enabling transformation to acute myeloid leukemia (AML), are still incompletely understood. Abundant evidence from solid tumors demonstrates that preneoplastic lesions activate signaling pathways of a DNA damage response (DDR), which functions as an 'anticancer barrier' hindering tumorigenesis. Testing the hypothesis that subgroups of MDS and AML differ with respect to DDR, we first assessed markers of DDR (phosphorylation of ATM, Chk-1, Chk-2 and H2AX) in cell lines representing different entities of MDS (P39, MOLM-13) and AML (MV4-11, KG-1) before and after gamma-irradiation. Although gamma-irradiation induced apoptosis and G(2)/M arrest and a concomitant increase in the phosphorylation of ATM, Chk-1 and H2AX in MDS-derived cell lines, this radiation response was attenuated in the AML-derived cell lines. It is noteworthy that KG-1, but not P39 cells exhibit signs of an endogenous activation of the DDR. Similarly, we found that the frequency of P-ATM(+) cells detectable in bone marrow (BM) biopsies increased in samples from patients with AML as compared with high-risk MDS samples and significantly correlated with the percentage of BM blasts. In contrast, the frequency of gamma-H2AX(+) cells was heterogeneous in all subgroups of AML and MDS. Whereas intermediate-1 MDS samples contained as little P-Chk-1 and P-Chk-2 as healthy controls, staining for both checkpoint kinases increased in intermediate-2 and high-risk MDS, yet declined to near-to-background levels in AML samples. Thus the activation of Chk-1 and Chk-2 behaves in accord with the paradigm established for solid tumors, whereas ATM is activated during and beyond transformation. In conclusion, we demonstrate the heterogeneity of the DDR response in MDS and AML and provide evidence for its selective suppression in AML because of the uncoupling between activated ATM and inactive checkpoint kinases. Oncogene (2009) 28, 2205-2218; doi: 10.1038/onc.2009.69; published online 27 April 2009	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Boehrer, S.; Ades, L.; Tajeddine, N.; Galluzzi, L.; Fouassier, C.; Tailler, M.; Olaussen, K. A.; Fenaux, P.; Kroemer, G.] Univ Paris 11, Paris, France; [Boehrer, S.; Ades, L.; Fouassier, C.; Gardin, C.; Eclache, V.; Thepot, S.; Fenaux, P.] Univ Paris 13, Hop Avicenne, AP HP, Serv Hematol Clin, Bobigny, France; [Hofmann, W. K.] Univ Hosp Benjamin Franklin, Charite, Dept Hematol & Oncol, Berlin, Germany; [Kriener, S.] Goethe Univ Frankfurt, Dept Pathol, Frankfurt, Germany; [Bug, G.; Ottmann, O. G.; Ruthardt, M.] Goethe Univ Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Goethe University Frankfurt	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/AAG-6294-2019; Ades, lionel/T-6882-2019; Bug, Gesine/H-8827-2013; Galluzzi, Lorenzo/AAH-3286-2021; Ottmann, Oliver G/D-5007-2016; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/K-2709-2012	Ottmann, Oliver G/0000-0001-9559-1330; KROEMER, Guido/0000-0002-9334-4405; Galluzzi, Lorenzo/0000-0003-2257-8500; Ruthardt, Martin/0000-0003-1021-3811; Olaussen, Ken/0000-0002-3115-8914	Deutsche Forschungsgemeinschaft; Assistance Publique-Hopitaux de Paris; Caisse Nationale d'Assurance Maladie des Professions Independantes; Canceropole Ile-de-France,; Institut National du Cancer; Fondation de France; Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche; European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT); Gutermuth-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Assistance Publique-Hopitaux de Paris; Caisse Nationale d'Assurance Maladie des Professions Independantes; Canceropole Ile-de-France,(Region Ile-de-France); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation de France(Fondation de France); Association Laurette Fugain; Cent pour Sang la Vie; Agence National de la Recherche(French National Research Agency (ANR)); European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT)(European CommissionEuropean Commission Joint Research Centre); Gutermuth-Stiftung	SB and LA contributed equally to this paper. SB receives a scholarship from the Deutsche Forschungsgemeinschaft, LA receives a scholarship from Assistance Publique-Hopitaux de Paris and Caisse Nationale d'Assurance Maladie des Professions Independantes. GK is supported by Canceropole Ile-de-France, Institut National du Cancer, Fondation de France, Association Laurette Fugain, Cent pour Sang la Vie, Agence National de la Recherche and the European Commission (ApoSys, ChemoRes., Apopt-Train, RIGHT). The project was carried out with the support from the Gutermuth-Stiftung. SB, LA, NT, LG, CF, MT and KAO. performed and analysed the experiments. WKH., SK., GB, OGO., MR, CG, VE, SdeB., ST and PF provided bone marrow biopsies and patient data. SB and GK designed the study and wrote the paper.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2007, ONCOGENE, V26, P7414, DOI 10.1038/sj.onc.1210553; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Braun T, 2006, BLOOD, V107, P1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Coquelle A, 2006, BIOCHEM PHARMACOL, V72, P1396, DOI 10.1016/j.bcp.2006.04.014; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fan C, 2006, BBA-MOL CELL RES, V1763, P1090, DOI 10.1016/j.bbamcr.2006.08.026; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Grimwade D., 2004, Annals of Hematology, V83, pS45; Grimwade D, 2001, BEST PRACT RES CL HA, V14, P497, DOI 10.1053/beha.2001.0152; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Grosjean-Raillard J, 2009, ONCOGENE, V28, P1099, DOI 10.1038/onc.2008.457; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Horibe S, 2007, LEUKEMIA, V21, P2195, DOI 10.1038/sj.leu.2404748; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Klaus M, 2004, CANCER GENET CYTOGEN, V155, P47, DOI 10.1016/j.cancergencyto.2004.03.008; KOEFFLER HP, 1980, BLOOD, V56, P344; LANGE B, 1987, BLOOD, V70, P192; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; NAGAI M, 1984, GANN, V75, P1100; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Parker JE, 2001, INT J HEMATOL, V73, P416, DOI 10.1007/BF02994003; Parker JE, 1998, BRIT J HAEMATOL, V101, P220; Parker JE, 2000, LEUKEMIA LYMPHOMA, V40, P1, DOI 10.3109/10428190009054877; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; ZAMZAMI N, 2003, METH MOL B, V282, P103	42	47	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2205	2218		10.1038/onc.2009.69	http://dx.doi.org/10.1038/onc.2009.69			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398952				2022-12-28	WOS:000266640300003
J	Ngan, S; Stronach, EA; Photiou, A; Waxman, J; Ali, S; Buluwela, L				Ngan, S.; Stronach, E. A.; Photiou, A.; Waxman, J.; Ali, S.; Buluwela, L.			Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells	ONCOGENE			English	Article						prostate cancer; LNCaP cells; androgens; anti-androgens; real-time RT-PCR; microarrays	LIGAND-BINDING DOMAIN; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; RECEPTOR ACTIVATION; RESPONSIVE GENES; TUMOR-SUPPRESSOR; NUCLEAR RECEPTOR; HORMONE-RECEPTOR; GROWTH; EXPRESSION; BETA	The androgen receptor (AR) mediates the growth-stimulatory effects of androgens in prostate cancer cells. Identification of androgen-regulated genes in prostate cancer cells is therefore of considerable importance for de. ning the mechanisms of prostate-cancer development and progression. Although several studies have used microarrays to identify AR-regulated genes in prostate cancer cell lines and in prostate tumours, we present here the results of gene expression microarray profiling of the androgen-responsive LNCaP prostate-cancer cell line treated with R1881 for the identification of androgen-regulated genes. We show that the expression of 319 genes is stimulated by 24h after R1881 addition, with a similar number (300) of genes being significantly repressed. Expression of the upregulated genes, as well as of 60 of the most robustly downregulated genes, was carried out using quantitative RT-PCR (Q-RT-PCR) over a time-course of R1881 treatment from 0 to 72 h. Q-RT-PCR was also carried out following treatment with other AR agonists (dihydrotestosterone, estradiol and medroxyprogesterone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide). This study provides a comprehensive analysis of androgen-regulated gene expression in the LNCaP prostate cancer cell line, and identifies a number of androgen-regulated genes, not described previously, as candidates for mediating androgen responses in prostate cancer cells. Oncogene (2009) 28, 2051-2063; doi:10.1038/onc.2009.68; published online 13 April 2009	[Ngan, S.; Stronach, E. A.; Photiou, A.; Waxman, J.; Ali, S.; Buluwela, L.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W1 0NN, England	Imperial College London	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Du Cane Rd, London W1 0NN, England.	simak.ali@imperial.ac.uk; l.buluwela@imperial.ac.uk	Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100	Joron trust; Hammersmith Hospital trustees; Prostate Cancer Charity; Cancer Research UK	Joron trust; Hammersmith Hospital trustees; Prostate Cancer Charity; Cancer Research UK(Cancer Research UK)	We are grateful to the members of the group for advice and support. Our particular thanks go to Drs Greg Brooke and Charlotte Bevan for discussions, and to Dr Lev Soinov for aiding the analysis of the microarray data. This work was carried out through the support of the Joron trust, Hammersmith Hospital trustees, Prostate Cancer Charity and Cancer Research UK.	Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Agoulnik IU, 2006, J CELL BIOCHEM, V99, P362, DOI 10.1002/jcb.20811; Akashi T, 2006, ONCOL REP, V16, P831; Arnold JT, 2007, PROSTATE, V67, P1152, DOI 10.1002/pros.20585; Brinkmann AO, 1999, J STEROID BIOCHEM, V69, P307, DOI 10.1016/S0960-0760(99)00049-7; Brooke GN, 2008, ONCOGENE, V27, P2941, DOI 10.1038/sj.onc.1210955; Burmester JK, 2004, HUM HERED, V57, P172, DOI 10.1159/000081443; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; CARTER HB, 1990, PROSTATE, V16, P39; Chen H, 2002, CANCER RES, V62, P338; Cheng I, 2006, JNCI-J NATL CANCER I, V98, P123, DOI 10.1093/jnci/djj013; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Furr BJA, 1996, UROLOGY, V47, P13, DOI 10.1016/S0090-4295(96)80003-3; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Guo YP, 1999, CANCER RES, V59, P1366; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Heemers HV, 2006, MOL ENDOCRINOL, V20, P2265, DOI 10.1210/me.2005-0479; Hodgson MC, 2007, CANCER RES, V67, P8388, DOI 10.1158/0008-5472.CAN-07-0617; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kim MJ, 2002, CANCER RES, V62, P2999; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Lau KM, 2000, CANCER RES, V60, P3175; Lee MY, 2009, BIOCHEM J, V417, P313, DOI 10.1042/BJ20080762; Lu NZ, 2006, PHARMACOL REV, V58, P782, DOI 10.1124/pr.58.4.9; Malkowicz SB, 1996, UROLOGY, V47, P29, DOI 10.1016/S0090-4295(96)80005-7; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCCONNELL JD, 1991, UROL CLIN N AM, V18, P1; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Qi W, 2008, BIOCHEM J, V416, P453, DOI 10.1042/BJ20080651; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Simone F, 2003, BLOOD, V101, P2355, DOI 10.1182/blood-2002-06-1664; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Storlazzi CT, 2003, HUM MOL GENET, V12, P2349, DOI 10.1093/hmg/ddg237; Takahashi Y, 2007, MOL CARCINOGEN, V46, P117, DOI 10.1002/mc.20254; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Xiao WH, 2003, CANCER RES, V63, P4698; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yuen HF, 2006, MODERN PATHOL, V19, P931, DOI 10.1038/modpathol.3800602; Zha S, 2005, PROSTATE, V63, P316, DOI 10.1002/pros.20177; Zha S, 2003, CANCER RES, V63, P7365	63	52	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2051	2063		10.1038/onc.2009.68	http://dx.doi.org/10.1038/onc.2009.68			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363526				2022-12-28	WOS:000266023900006
J	Garrison, JB; Samuel, T; Reed, JC				Garrison, J. B.; Samuel, T.; Reed, J. C.			TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappa B	ONCOGENE			English	Article						TRAF2; c-IAP2/MALT1; NF-kappa B; TRAF6; BIR1; B-cell lymphoma	MALT LYMPHOMA; CELL LYMPHOMA; INHIBITOR; APOPTOSIS; GENE; T(11/18)(Q21,Q21); BCL10; UBIQUITINATION; TRANSLOCATION; TRAF2	Marginal zone mucosa-associated lymphoid tissue (MALT) B-cell lymphoma is the most common extranodal non-Hodgkin lymphoma. The t(11;18)(q21;q21) translocation occurs frequently in MALT lymphomas and creates a chimeric NF-kappa B-activating protein containing the baculoviral IAP repeat (BIR) domains of c-IAP2 (inhibitor of apoptosis protein 2) fused with portions of the MALT1 protein. The BIR1 domain of c-IAP2 interacts directly with TRAF2 (TNF alpha-receptor-associated factor-2), but its role in NF-kappa B activation is still unclear. Here, we investigated the role of TRAF2 in c-IAP2/MALT1-induced NF-kappa B activation. We show the BIR1 domain of c-IAP2 is essential for NF-kappa B activation, whereas BIR2 and BIR3 domains are not. Studies of c-IAP2/MALT1 BIR1 mutant (E47A/R48A) that fails to activate NF-kappa B showed loss of TRAF2 binding, but retention of TRAF6 binding, suggesting that interaction of c-IAP2/MALT1 with TRAF6 is insufficient forNF-kappa B induction. In addition, a dominant-negative TRAF2 mutant or down-regulation of TRAF2 achieved by small interfering RNA inhibited NF-kappa B activation by c-IAP2/MALT1 showing that TRAF2 is indispensable. Comparisons of the bioactivity of intact c-IAP2/MALT1 oncoprotein and BIR1 E47A/R48A c-IAP2/MALT1 mutant that cannot bind TRAF2 in a lymphoid cell line provided evidence that TRAF2 interaction is critical for c-IAP2/MALT1mediated increases in the NF-kappa B activity, increased expression of endogenous NF-kappa B target genes (c-FLIP, TRAF1), and resistance to apoptosis.	[Garrison, J. B.; Samuel, T.; Reed, J. C.] Burnham Inst Med Res, Ctr Canc, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, Ctr Canc, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org						Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Morgan JA, 1999, CANCER RES, V59, P6205; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Vega F, 2001, ADV ANAT PATHOL, V8, P313, DOI 10.1097/00125480-200111000-00001; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zucca E, 2000, BLOOD, V96, P410	27	21	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1584	1593		10.1038/onc.2009.17	http://dx.doi.org/10.1038/onc.2009.17			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234489				2022-12-28	WOS:000264780500003
J	Dorn, GW; Kirshenbaum, LA				Dorn, G. W., II; Kirshenbaum, L. A.			Cardiac reanimation: targeting cardiomyocyte death by BNIP3 and NIX/BNIP3L	ONCOGENE			English	Review						apoptosis; autophagy; heart failure; cardiac hypertrophy; myocardial infarction	STAGE HEART-FAILURE; CELL-DEATH; PROTEIN BNIP3; BCL-2 FAMILY; VENTRICULAR MYOCYTES; MYOCARDIAL-INFARCTION; ENDOPLASMIC-RETICULUM; PHYSIOLOGICAL GROWTH; PATHOLOGICAL GENES; PRESSURE-OVERLOAD	Programmed cardiac myocyte death contributes to pathological ventricular remodeling and the progression of myocardial infarction or pressure overload hypertrophy to dilated cardiomyopathy. Recent work has identified importance of stress-mediated transcriptional induction of BNIP3 (BCL2 and 19-kDa interacting protein-3) and NIX/BNIP3L in cardiac remodeling. Here, the regulatory mechanisms for these two factors in the heart and their effects on programmed cardiomyocyte death are reviewed, with a focus on information derived from studies using mouse models of cardiac BNIP3 and NIX/BNIP3L overexpression and gene ablation. Oncogene (2009) 27, S158-S167; doi: 10.1038/onc.2009.53	[Dorn, G. W., II] Washington Univ, Dept Med, Ctr Pharmacogenom, Sch Med, St Louis, MO 63110 USA; [Kirshenbaum, L. A.] Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB, Canada	Washington University (WUSTL); University of Manitoba; Children's Hospital Research Institute of Manitoba	Dorn, GW (corresponding author), Washington Univ, Dept Med, Ctr Pharmacogenom, Sch Med, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.	gdorn@dom.wustl.edu	Kirshenbaum, Lorrie A./F-5742-2014	Ryplanski, Kairee/0000-0002-3737-7181	National Institutes of Health (NIH, Bethesda, MD, USA) [5P50HL077101, 2R01HL059888, 5R01HL080008, 5R01HL087871, 5P50HL077113]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL077101, R01HL059888, R01HL087871, R01HL080008, P50HL077113] Funding Source: NIH RePORTER	National Institutes of Health (NIH, Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	GW Dorn is currently receiving grant support from the National Institutes of Health (NIH, Bethesda, MD, USA) (5P50HL077101; 2R01HL 059888; 5R01H L080008; 5R01HL087871; 5P50HL0771 13). LA Kirschenbaum holds a patent for the NIP3 family of proteins (US patent no. 7, 452,869B2).	Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; BERRY JJ, 1993, J NUCL MED, V34, P39; Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHEN JC, 1997, SOFT COMPUT, V1, P19; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Di Napoli P, 2003, AM HEART J, V146, P1105, DOI 10.1016/S0002-8703(03)00445-9; DIWAN A, 2008, J CLIN INVEST, V118, P3870; Diwan A, 2008, CIRCULATION, V117, P396, DOI 10.1161/CIRCULATIONAHA.107.727073; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Diwan A, 2007, PHYSIOLOGY, V22, P56, DOI 10.1152/physiol.00033.2006; Dorn GW, 2009, CARDIOVASC RES, V81, P465, DOI 10.1093/cvr/cvn243; Dorn GW, 2005, TRENDS CARDIOVAS MED, V15, P185, DOI 10.1016/j.tcm.2005.05.009; Foo RSY, 2007, J BIOL CHEM, V282, P5529, DOI 10.1074/jbc.M609046200; Foo RSY, 2005, J CLIN INVEST, V115, P565, DOI 10.1172/JCI200524569; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Francis GS, 1998, CURR OPIN CARDIOL, V13, P156; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Graham RM, 2007, ANTIOXID REDOX SIGN, V9, P1309, DOI 10.1089/ars.2007.1726; GROSSMAN W, 1975, J CLIN INVEST, V56, P56, DOI 10.1172/JCI108079; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hamacher-Brady A, 2006, AUTOPHAGY, V2, P307, DOI 10.4161/auto.2947; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hayakawa Y, 2003, CIRCULATION, V108, P3036, DOI 10.1161/01.CIR.0000101920.72665.58; Henriquez M, 2008, CURR MOL MED, V8, P187, DOI 10.2174/156652408784221289; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Latif N, 2000, J AM COLL CARDIOL, V35, P1769, DOI 10.1016/S0735-1097(00)00647-1; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Nakayama H, 2007, J CLIN INVEST, V117, P2431, DOI 10.1172/JCI31060; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Narula Jagat, 2001, Cardiology Clinics, V19, P113, DOI 10.1016/S0733-8651(05)70198-3; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; OLIVETTI G, 1990, CIRC RES, V67, P23, DOI 10.1161/01.RES.67.1.23; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Rubart M, 2006, ANNU REV PHYSIOL, V68, P29, DOI 10.1146/annurev.physiol.68.040104.124530; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Siu PM, 2005, J APPL PHYSIOL, V99, P204, DOI 10.1152/japplphysiol.00084.2005; Sowter HM, 2001, CANCER RES, V61, P6669; Stauffer SR, 2007, CURR TOP MED CHEM, V7, P961, DOI 10.2174/156802607780906843; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	76	40	40	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S158	S167		10.1038/onc.2009.53	http://dx.doi.org/10.1038/onc.2009.53			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641501				2022-12-28	WOS:000268566800014
J	Semenza, GL				Semenza, G. L.			Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics	ONCOGENE			English	Review						angiogenesis; chemotherapy; metabolism; oxygen; radiation therapy; transcription	ENDOTHELIAL-GROWTH-FACTOR; SARCOMA-ASSOCIATED HERPESVIRUS; CELL LUNG-CANCER; FACTOR-I-ALPHA; FACTOR 1-ALPHA; UNFAVORABLE PROGNOSIS; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; BREAST-CANCER; DNA-BINDING	Adaptation of cancer cells to their microenvironment is an important driving force in the clonal selection that leads to invasive and metastatic disease. O-2 concentrations are markedly reduced in many human cancers compared with normal tissue, and a major mechanism mediating adaptive responses to reduced O-2 availability (hypoxia) is the regulation of transcription by hypoxia-inducible factor 1 (HIF-1). This review summarizes the current state of knowledge regarding the molecular mechanisms by which HIF-1 contributes to cancer progression, focusing on (1) clinical data associating increased HIF-1 levels with patient mortality; (2) preclinical data linking HIF-1 activity with tumor growth; (3) molecular data linking specific HIF-1 target gene products to critical aspects of cancer biology and (4) pharmacological data showing anticancer effects of HIF-1 inhibitors in mouse models of human cancer. Oncogene (2010) 29, 625-634; doi: 10.1038/onc.2009.441; published online 30 November 2009	[Semenza, G. L.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Vasc Program, Broadway Res Bldg,Suite 671,733 N Broadway, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu			NATIONAL CANCER INSTITUTE [U54CA143868] Funding Source: NIH RePORTER; NCI NIH HHS [U54 CA143868, U54 CA143868-01, T32 CA130840, U54 CA143868-03, T32 CA153952, U54 CA143868-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebersold DM, 2001, CANCER RES, V61, P2911; Akakura N, 2001, CANCER RES, V61, P6548; Bachtiary B, 2003, CLIN CANCER RES, V9, P2234; Barnhart BC, 2007, CANCER METAST REV, V26, P261, DOI 10.1007/s10555-007-9053-3; Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Birner P, 2000, CANCER RES, V60, P4693; Birner P, 2001, CLIN CANCER RES, V7, P1661; Birner P, 2001, CANCER, V92, P165, DOI 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Burri P, 2003, INT J RADIAT ONCOL, V56, P494, DOI 10.1016/S0360-3016(02)04579-0; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371/journal.ppat.0020116; Cai Q, 2007, J VIROL, V81, P10413, DOI 10.1128/JVI.00611-07; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chang Q, 2006, PANCREAS, V32, P297, DOI 10.1097/00006676-200604000-00010; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Cleven AHG, 2007, CELL ONCOL, V29, P229; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Daponte A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-335; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P7972, DOI 10.1158/1078-0432.CCR-04-1068; Giatromanolaki A, 2003, MELANOMA RES, V13, P493, DOI 10.1097/00008390-200310000-00008; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Gillies RJ, 2007, CANCER METAST REV, V26, P311, DOI 10.1007/s10555-007-9065-z; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Griffiths EA, 2007, BRIT J CANCER, V96, P95, DOI 10.1038/sj.bjc.6603524; Hahnfeldt P, 2003, J THEOR BIOL, V220, P545, DOI 10.1006/jtbi.2003.3162; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jiang BH, 1997, CANCER RES, V57, P5328; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaluz S, 2008, BLOOD, V111, P5258, DOI 10.1182/blood-2008-02-140079; Kaluz S, 2006, MOL CELL BIOL, V26, P5895, DOI 10.1128/MCB.00552-06; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Korkolopoulou P, 2004, NEUROPATH APPL NEURO, V30, P267, DOI 10.1111/j.1365-2990.2003.00535.x; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Li LM, 2005, CANCER RES, V65, P7249, DOI 10.1158/0008-5472.CAN-04-4426; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Liu YQ, 2009, MOL THER, V17, P269, DOI 10.1038/mt.2008.266; Lukashev D, 2007, CANCER METAST REV, V26, P273, DOI 10.1007/s10555-007-9054-2; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Makino Y, 2007, J BIOL CHEM, V282, P14073, DOI 10.1074/jbc.M700732200; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Melillo G, 2007, CANCER METAST REV, V26, P341, DOI 10.1007/s10555-007-9059-x; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nakamura M, 2009, VIROLOGY, V387, P442, DOI 10.1016/j.virol.2009.02.036; Nanni S, 2009, J CLIN INVEST, V119, P1093, DOI 10.1172/JCI35079; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Quintero M, 2006, CANCER RES, V66, P770, DOI 10.1158/0008-5472.CAN-05-0333; Rajaganeshan R, 2008, INT J COLORECTAL DIS, V23, P1049, DOI 10.1007/s00384-008-0497-x; Rapisarda A, 2002, CANCER RES, V62, P4316; Rasheed S, 2009, BRIT J CANCER, V100, P1666, DOI 10.1038/sj.bjc.6605026; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schmitz KJ, 2009, INT J COLORECTAL DIS, V24, P1287, DOI 10.1007/s00384-009-0753-8; Schrijivers ML, 2008, INT J RADIAT ONCOL, V72, P161, DOI 10.1016/j.ijrobp.2008.05.025; Schwartz DL, 2009, MOL CANCER THER, V8, P947, DOI 10.1158/1535-7163.MCT-08-0981; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SEMENZA GL, 2009, SYSTEMS BIOL MED, DOI DOI 10.1002/WSBM.69; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Shackelford DB, 2009, P NATL ACAD SCI USA, V106, P11137, DOI 10.1073/pnas.0900465106; Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Sivridis E, 2002, CANCER-AM CANCER SOC, V95, P1055, DOI 10.1002/cncr.10774; Sodhi A, 2000, CANCER RES, V60, P4873; Stoeltzing O, 2004, JNCI-J NATL CANCER I, V96, P946, DOI 10.1093/jnci/djh168; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Sun HC, 2007, INT J ONCOL, V30, P1359; Swietach P, 2007, CANCER METAST REV, V26, P299, DOI 10.1007/s10555-007-9064-0; Swinson DEB, 2004, INT J CANCER, V111, P43, DOI 10.1002/ijc.20052; Takahashi R, 2003, ONCOL REP, V10, P797; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Theodoropoulos VE, 2005, BJU INT, V95, P425, DOI 10.1111/j.1464-410X.2005.05314.x; Theodoropoulos VE, 2004, EUR UROL, V46, P200, DOI 10.1016/j.eururo.2004.04.008; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tomita M, 2007, BIOCHEM J, V406, P317, DOI 10.1042/BJ20070286; Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436; Tzao C, 2008, DIS MARKERS, V25, P141, DOI 10.1155/2008/468323; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang XL, 2009, MOL PHARMACEUT, V6, P738, DOI 10.1021/mp800192d; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	131	1259	1323	6	258	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					625	634		10.1038/onc.2009.441	http://dx.doi.org/10.1038/onc.2009.441			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19946328	Green Accepted			2022-12-28	WOS:000274223700001
J	Lucs, AV; Muller, WJ; Muthuswamy, SK				Lucs, A. V.; Muller, W. J.; Muthuswamy, S. K.			Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity	ONCOGENE			English	Article						ErbB2; apoptosis; 3D culture; taxol; Shc; MCF-10A	HUMAN-BREAST-CANCER; MAMMARY TUMORIGENESIS; ADAPTER PROTEINS; ERBB2; ACTIVATION; RESISTANCE; RECEPTORS; FAMILY; GROWTH; ACTIN	Amplification and overexpression of ErbB2 strongly correlates with aggressive breast cancers. A deeper understanding of pathways downstream of ErbB2 signaling that are required for the transformation of human mammary epithelial cells will identify novel strategies for therapeutic intervention in breast cancer. Using an inducible activation of ErbB2 autophosphorylation qsite mutants and the MCF-10A three-dimensional (3D) culture system, we investigated pathways used by ErbB2 to transform the epithelia. We report that ErbB2 induces cell proliferation and loss of 3D organization by redundant mechanisms, whereas it disrupts apical basal polarity and inhibits apoptosis using Tyr 1201 and Tyr 1226/7, respectively. Signals downstream of Tyr 1226/7 were also sufficient to confer paclitaxel resistance. The Tyr 1226/7 binds Shc, and the knockdown of Shc blocks the ability of ErbB2 to inhibit apoptosis and mediate paclitaxel resistance. Tyr 1226/7 is known to activate the Ras/Erk pathway; however, paclitaxel resistance did not correlate with the activation of Erk or Akt, suggesting the presence of a novel mechanism. Thus, our results show that targeting pathways used by ErbB2 to inhibit cell death is a better option than targeting cell proliferation pathways. Furthermore, we identify a novel function for Shc as a regulator of apoptosis and drug resistance in human mammary epithelial cells transformed by ErbB2. Oncogene (2010) 29, 174-187; doi:10.1038/onc.2009.312; published online 12 October 2009	[Lucs, A. V.; Muthuswamy, S. K.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Muller, W. J.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada; [Lucs, A. V.; Muthuswamy, S. K.] SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA; [Muthuswamy, S. K.] Univ Toronto, Dept Med Biophys, Campbell Family Inst Breast Canc Res, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada	Cold Spring Harbor Laboratory; McGill University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634	NCI [CA098830, CA105388]; DOD [BC075024, DAMD17-03-1-0196]; Rita Allen Foundation; FACT foundation; Lee K Margaret Lau Chair in Breast Cancer Research; NATIONAL CANCER INSTITUTE [R56CA098830, R01CA098830, U01CA105388] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Rita Allen Foundation; FACT foundation; Lee K Margaret Lau Chair in Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Muthuswamy Laboratory for critical discussions and comments on the paper. This work was supported by CA098830 and CA105388 Grants from NCI, DOD BC075024 from DOD Breast Cancer Research Program, Rita Allen Foundation, FACT foundation and Lee K Margaret Lau Chair in Breast Cancer Research to SKM and DAMD17-03-1-0196 from DOD Breast Cancer Research Program to AL.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; JANES PW, 1994, ONCOGENE, V9, P3601; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Leung WH, 2007, J IMMUNOL, V179, P95, DOI 10.4049/jimmunol.179.1.95; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pupa SM, 2005, J CELL PHYSIOL, V205, P10, DOI 10.1002/jcp.20387; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Saucier C, 2004, P NATL ACAD SCI USA, V101, P2345, DOI 10.1073/pnas.0308065101; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	39	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					174	187		10.1038/onc.2009.312	http://dx.doi.org/10.1038/onc.2009.312			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19826412	Green Accepted			2022-12-28	WOS:000273650000002
J	Bettuzzi, S; Davalli, P; Davoli, S; Chayka, O; Rizzi, F; Belloni, L; Pellacani, D; Fregni, G; Astancolle, S; Fassan, M; Corti, A; Baffa, R; Sala, A				Bettuzzi, S.; Davalli, P.; Davoli, S.; Chayka, O.; Rizzi, F.; Belloni, L.; Pellacani, D.; Fregni, G.; Astancolle, S.; Fassan, M.; Corti, A.; Baffa, R.; Sala, A.			Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread	ONCOGENE			English	Article						immunohistochemistry; tumour suppressor gene; cell cycle; NF-kappa B	NF-KAPPA-B; TRANSGENIC MOUSE MODEL; EPITHELIAL-CELLS; CANCER CELLS; CLUSTERIN; EXPRESSION; PROGRESSION; INDUCTION; APOPTOSIS; ACTIVATION	ApoJ/Clusterin (CLU) is a heterodimeric protein localized in the nucleus, cytoplasm or secretory organelles and involved in cell survival and neoplastic transformation. Its function in human cancer is still highly controversial. In this study, we examined the prostate of mice in which CLU has been genetically inactivated. Surprisingly, we observed transformation of the prostate epithelium in the majority of CLU knockout mice. Either PIN (prostate intraepithelial neoplasia) or differentiated carcinoma was observed in 100 and 87% of mice with homozygous or heterozygous deletion of CLU, respectively. Crossing CLU knockout with TRAMP (prostate cancer prone) mice results in a strong enhancement of metastatic spread. Finally, CLU depletion causes tumourigenesis in female TRAMP mice, which are normally cancer free. Mechanistically, deletion of CLU induces activation of nuclear factor-kB, a potentially oncogenic transcription factor important for the proliferation and survival of prostate cells. Oncogene (2009) 28, 4344-4352; doi: 10.1038/onc.2009.286; published online 28 September 2009	[Bettuzzi, S.; Davoli, S.; Rizzi, F.; Belloni, L.] Univ Parma, Dept Expt Med, I-43100 Parma, Italy; [Davalli, P.; Pellacani, D.; Fregni, G.; Astancolle, S.; Corti, A.] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy; [Chayka, O.; Sala, A.] Inst Child Hlth, Mol Haematol & Canc Biol Unit, London, England; [Fassan, M.; Baffa, R.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; [Baffa, R.] MedImmune LLC, Res, Gaithersburg, MD USA	University of Parma; Universita di Modena e Reggio Emilia; University of London; University College London; Jefferson University; AstraZeneca; Medimmune	Bettuzzi, S (corresponding author), Univ Parma, Dept Expt Med, Via Volturno 39, I-43100 Parma, Italy.	saverio.bettuzzi@unipr.it; a.sala@ich.ucl.ac.uk	Fassan, Matteo/F-5152-2012; sala, arturo/C-4959-2008; Bettuzzi, Saverio/B-2609-2009	Fassan, Matteo/0000-0001-6515-5482; Bettuzzi, Saverio/0000-0003-2080-6979; Rizzi, Federica/0000-0002-6670-2588; Sala, Arturo/0000-0002-2841-7866; Davoli, Serena Alba/0000-0002-8731-0305	Worldwide Cancer Research [06-0711] Funding Source: Medline	Worldwide Cancer Research		BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; Caccamo AE, 2005, CELL DEATH DIFFER, V12, P101, DOI 10.1038/sj.cdd.4401491; Caccamo AE, 2003, ANN NY ACAD SCI, V1010, P514, DOI 10.1196/annals.1299.095; Caporali A, 2004, CARCINOGENESIS, V25, P2217, DOI 10.1093/carcin/bgh235; Chayka O, 2009, JNCI-J NATL CANCER I, V101, P663, DOI 10.1093/jnci/djp063; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; July LV, 2002, PROSTATE, V50, P179, DOI 10.1002/pros.10047; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2006, UROLOGY, V68, P609, DOI 10.1016/j.urology.2006.03.017; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nizard P, 2007, TRAFFIC, V8, P554, DOI 10.1111/j.1600-0854.2007.00549.x; Nomura T, 2005, ONCOL REP, V14, P993; Nuutinen T, 2005, NEUROCHEM INT, V47, P528, DOI 10.1016/j.neuint.2005.07.007; Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Santilli G, 2003, J BIOL CHEM, V278, P38214, DOI 10.1074/jbc.C300252200; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Thomas-Tikhonenko A, 2004, CANCER RES, V64, P3126, DOI 10.1158/0008-5472.CAN-03-1953; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291	38	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2009	28	49					4344	4352		10.1038/onc.2009.286	http://dx.doi.org/10.1038/onc.2009.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19784068				2022-12-28	WOS:000272876400003
J	Barsotti, AM; Prives, C				Barsotti, A. M.; Prives, C.			Pro-proliferative FoxM1 is a target of p53-mediated repression	ONCOGENE			English	Article						p53; FoxM1; transcriptional repression; p21; Rb; G2 arrest	M1 TRANSCRIPTION FACTOR; P53 TUMOR-SUPPRESSOR; MOUSE-LIVER REGENERATION; CELL-CYCLE PROGRESSION; WILD-TYPE P53; DNA-DAMAGE; DOWN-REGULATION; C-MYC; FUNCTIONAL DOMAINS; INDUCED SENESCENCE	The p53 tumor suppressor protein acts as a transcription factor to modulate cellular responses to a wide variety of stresses. In this study we show that p53 is required for the downregulation of FoxM1, an essential transcription factor that regulates many G2/M-specific genes and is overexpressed in a multitude of solid tumors. After DNA damage, p53 facilitates the repression of FoxM1 mRNA, which is accompanied by a decrease in FoxM1 protein levels. In cells with reduced p53 expression, FoxM1 is upregulated after DNA damage. Nutlin, a small-molecule activator of p53, suppresses FoxM1 levels in two cell lines in which DNA damage facilitates only mild repression. Mechanistically, p53-mediated inhibition of FoxM1 is partially p21 and retinoblastoma (Rb) family dependent, although in some cases p21-independent repression of FoxM1 was also observed. The importance of FoxM1 to cell fate was indicated by the observation that G2/M arrest follows FoxM1 ablation. Finally, our results indicate a potential contribution of p53-mediated repression of FoxM1 for maintenance of a stable G2 arrest. Oncogene (2009) 28, 4295-4305; doi: 10.1038/onc.2009.282; published online 14 September 2009	[Barsotti, A. M.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, 816 Fairchild, New York, NY 10027 USA.	clp3@columbia.edu			National Institutes of Health [CA77742]; NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Ella Freulich provided expert technical assistance. Members of the Prives laboratory are thanked for their support and encouragement. This work was supported by the National Institutes of Health Grant CA77742.	Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bhonde MR, 2006, J BIOL CHEM, V281, P8675, DOI 10.1074/jbc.M511333200; Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; Das S, 2008, CELL CYCLE, V7, P154, DOI 10.4161/cc.7.2.5236; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1991, CANCER RES, V51, P6304; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Li SKM, 2008, J BIOL CHEM, V283, P16545, DOI 10.1074/jbc.M709604200; Linhart C, 2005, CELL CYCLE, V4, P1788, DOI 10.4161/cc.4.12.2173; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Penzo M, 2009, J CELL PHYSIOL, V218, P215, DOI 10.1002/jcp.21596; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Sax JK, 2003, CANCER BIOL THER, V2, P416, DOI 10.4161/cbt.2.4.477; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Teh MT, 2002, CANCER RES, V62, P4773; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Weymann A, 2009, HEPATOLOGY, V50, P207, DOI 10.1002/hep.22979; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xia LM, 2009, J CELL BIOCHEM, V106, P247, DOI 10.1002/jcb.21996; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	77	109	111	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4295	4305		10.1038/onc.2009.282	http://dx.doi.org/10.1038/onc.2009.282			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749794	Green Accepted			2022-12-28	WOS:000272876300007
J	Atkinson, GP; Nozell, SE; Harrison, DK; Stonecypher, MS; Chen, D; Benveniste, EN				Atkinson, G. P.; Nozell, S. E.; Harrison, D. K.; Stonecypher, M. S.; Chen, D.; Benveniste, E. N.			The prolyl isomerase Pin1 regulates the NF-kappa B signaling pathway and interleukin-8 expression in glioblastoma	ONCOGENE			English	Article						glioblastoma; gene expression; signal transduction; NF-kappa B; Pin1	NECROSIS-FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVITY; CANCER; PHOSPHORYLATION; TARGET; ACTIVATION; APOPTOSIS; TUMORS; GROWTH; STAT3	The brain tumor glioblastoma (GBM) remains one of the most aggressive and devastating tumors despite decades of effort to find more effective treatments. A hallmark of GBM is the constitutive activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signaling pathway, which regulates cell proliferation, in. ammation, migration and apoptosis. The prolyl isomerase, Pin1, has been found to bind directly to the NF-kappa B protein, p65, and cause increases in NF-kappa B promoter activity in a breast cancer model. We now present evidence that this interaction occurs in GBM and that it has important consequences on NF-kappa B signaling. We demonstrate that Pin1 levels are enhanced in primary GBM tissues compared with controls, and that this difference in Pin1 expression affects the migratory capacity of GBM-derived cells. Pin1 knockdown decreases the amount of activated, phosphorylated p65 in the nucleus, resulting in inhibition of the transcriptional program of the IL-8 gene. Through the use of microarray, we also observed changes in the expression levels of other NF-kappa B regulated genes due to Pin1 knockdown. Taken together, these data suggest that Pin1 is an important regulator of NF-kappa B in GBM, and support the notion of using Pin1 as a therapeutic target in the future. Oncogene (2009) 28, 3735-3745; doi: 10.1038/onc.2009.232; published online 10 August 2009	[Atkinson, G. P.; Nozell, S. E.; Stonecypher, M. S.; Benveniste, E. N.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; [Harrison, D. K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Chen, D.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT Room 926A,1900 Univ Blvd, Birmingham, AL 35294 USA.	tika@uab.edu			National Institutes of Health [CA97247, NS-54158, IRG-60-001-47]; American Cancer Society [CA-13148-31]; NCI (SEN); UAB Medical Scientist Training Program; NIH [T32AI0705]; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA158534, R01CA194414, P50CA097247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000705, T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS054158, R01NS045290] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NCI (SEN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UAB Medical Scientist Training Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Michael Crowley in the UAB Comprehensive Cancer Center Gene Expression Shared Facility for his assistance with microarray processing, and Dr Cheryl Ann Palmer (University of Alabama at Birmingham) for providing the brain tumor resections. We also thank Dr Yancey Gillespie, UAB Brain Tumor Tissue Core, for glioma and control tissue samples, and express our appreciation to the laboratory of Dr Dale Benos for assistance with the scratch assay. Finally, many thanks to Dr Rafal Bartoszewski for assistance with the qPCR and to Dr Gerald Fuller for reading the paper. This work was supported in part by National Institutes of Health grants CA97247 (ENB), NS-54158 (ENB and SEN) and IRG-60-001-47 from the American Cancer Society and CA-13148-31 from the NCI (SEN). GPA was supported by the UAB Medical Scientist Training Program, and is currently supported by NIH T32AI0705.	Afra D, 2002, LANCET, V359, P1011; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ayala G, 2003, CANCER RES, V63, P6244; Baker BJ, 2008, GLIA, V56, P1250, DOI 10.1002/glia.20694; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brandes AA, 2008, CRIT REV ONCOL HEMAT, V67, P139, DOI 10.1016/j.critrevonc.2008.02.005; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Chandana SR, 2008, AM FAM PHYSICIAN, V77, P1423; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi YH, 2006, P NATL ACAD SCI USA, V103, P18715, DOI 10.1073/pnas.0604800103; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li ST, 2006, MOL CELL, V24, P497, DOI 10.1016/j.molcel.2006.10.015; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nozell S, 2004, J BIOL CHEM, V279, P38577, DOI 10.1074/jbc.M403738200; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Nozell S, 2006, J IMMUNOL, V177, P822, DOI 10.4049/jimmunol.177.2.822; Pang RW, 2006, J PATHOL, V210, P19, DOI 10.1002/path.2024; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2007, J BIOL CHEM, V282, P36671, DOI 10.1074/jbc.M704145200; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Smith D, 2008, MOL CELL BIOCHEM, V307, P141, DOI 10.1007/s11010-007-9593-4; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Wakabayashi K, 2004, ONCOGENE, V23, P6924, DOI 10.1038/sj.onc.1207778; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xu YX, 2007, GENE DEV, V21, P2950, DOI 10.1101/gad.1592807; Yamamoto M, 2000, ANTICANCER RES, V20, P611; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3735	3745		10.1038/onc.2009.232	http://dx.doi.org/10.1038/onc.2009.232			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668231	Green Accepted			2022-12-28	WOS:000271023200006
J	Fazi, B; Melino, S; De Rubeis, S; Bagni, C; Paci, M; Piacentini, M; Di Sano, F				Fazi, B.; Melino, S.; De Rubeis, S.; Bagni, C.; Paci, M.; Piacentini, M.; Di Sano, F.			Acetylation of RTN-1C regulates the induction of ER stress by the inhibition of HDAC activity in neuroectodermal tumors	ONCOGENE			English	Article						acetylation; ER; RTN-1C; apoptosis	ENDOPLASMIC-RETICULUM; CALRETICULIN EXPOSURE; HISTONE DEACETYLASE; INDUCED APOPTOSIS; CELL-DEATH; PROTEIN; BINDING; FAMILY; CANCER; RNA	Reticulons are a family of highly conserved proteins, localized in the endoplasmic reticulum (ER) and involved in different cellular functions, such as intracellular membrane trafficking, apoptosis and nuclear envelope formation. The reticulon protein family consists of four members, but their specific functions are presently poorly understood. RTN-1C overexpression triggers apoptosis, regulating ER stress versus DNA damage-induced cell death in a mutually exclusive way. The different RTN isoforms share a C-terminal reticulon homology domain containing two hydrophobic segments and a 66-amino acid hydrophilic loop. In the C-terminal region of RTN-1C, a unique consensus sequence (GAKRH) has recently been identified, showing 100% identity with the DNA-binding domain of histone H4. In this study, we show that this sequence is essential for RTN-1C-mediated apoptosis. It is noteworthy that the lysine 204 present in this region is post-translationally modified by acetylation and that this event is associated with a significant decrease in histone deacetylase activity and contributes to RTN-1C binding to DNA. These data demonstrate a molecular mechanism by which RTN-1C controls apoptosis and indicate this protein to be a novel potential target for cancer therapy. Oncogene (2009) 28, 3814-3824; doi:10.1038/onc.2009.233; published online 10 August 2009	[Fazi, B.; De Rubeis, S.; Piacentini, M.; Di Sano, F.] Univ Roma Tor Vergata, Dept Biol, I-133 Rome, Italy; [Melino, S.; Paci, M.] Univ Roma Tor Vergata, Dept Sci & Chem Technol, I-133 Rome, Italy; [De Rubeis, S.; Bagni, C.] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; [De Rubeis, S.; Bagni, C.] Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Louvain, Belgium; [Bagni, C.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-133 Rome, Italy; [Piacentini, M.] Natl Inst Infect Dis IRCCS L Spallanzani, Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; KU Leuven; Flanders Institute for Biotechnology (VIB); University of Rome Tor Vergata; IRCCS Lazzaro Spallanzani	Piacentini, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci 1, I-133 Rome, Italy.	mauro.piacentini@uniroma2.it	De Rubeis, Silvia/E-9852-2013; Piacentini, Mauro/I-2411-2016	De Rubeis, Silvia/0000-0001-9383-6883; Piacentini, Mauro/0000-0003-2919-1296; Di Sano, Federica/0000-0002-5048-3966; Bagni, Claudia/0000-0002-4419-210X; MELINO, SONIA/0000-0001-7694-5279	Ricerca Corrente; Ministero della Salute; AIRC; Telethon Foundation; EU; Cofin; FIRB	Ricerca Corrente(Ministry of Health, ItalyMinistry of Health Italy - Ricerca Corrente (MOH-RC)); Ministero della Salute(Ministry of Health, Italy); AIRC(Fondazione AIRC per la ricerca sul cancro); Telethon Foundation(Fondazione Telethon); EU(European Commission); Cofin; FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB))	This work was partially supported by grants from Ricerca Corrente and Finalizzata from Ministero della Salute, AIRC, Telethon Foundation, EU integrated project 'Apo-sys' and Cofin 2006 to MP, and from COFIN and FIRB to CB.	Anderson DJ, 2007, NAT CELL BIOL, V9, P1160, DOI 10.1038/ncb1636; Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Di Sano F, 2007, J NEUROCHEM, V102, P345, DOI 10.1111/j.1471-4159.2007.04479.x; Eliseeva ED, 2007, MOL CANCER THER, V6, P2391, DOI 10.1158/1535-7163.MCT-07-0159; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gonzenbach RR, 2008, CELL MOL LIFE SCI, V65, P161, DOI 10.1007/s00018-007-7170-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gupta S, 2005, NUCLEIC ACIDS RES, V33, P6972, DOI 10.1093/nar/gki990; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Huber AB, 2002, J NEUROSCI, V22, P3553; Iwahashi J, 2003, Cell Mol Biol (Noisy-le-grand), V49 Online Pub, pOL467; Iwahashi J, 2007, BIOCHEM BIOPH RES CO, V355, P508, DOI 10.1016/j.bbrc.2007.02.001; Kawaguchi Y, 2006, J BIOL CHEM, V281, P1394, DOI 10.1074/jbc.M505772200; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kuang E, 2005, J CELL PHYSIOL, V204, P549, DOI 10.1002/jcp.20340; Lin HY, 2006, MED RES REV, V26, P397, DOI 10.1002/med.20056; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Melino S, 2009, BIOCHEMISTRY-US, V48, P242, DOI 10.1021/bi801407w; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; PUIG OM, 1988, BIOCHIM BIOPHYS ACTA, V1397, P79; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Steiner P, 2004, J NEUROCHEM, V89, P569, DOI 10.1111/j.1471-4159.2004.02345.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Ulbert S, 2006, J CELL BIOL, V173, P469, DOI 10.1083/jcb.200512078; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	39	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3814	3824		10.1038/onc.2009.233	http://dx.doi.org/10.1038/onc.2009.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19668229				2022-12-28	WOS:000271248400005
J	Hoenerhoff, MJ; Chu, I; Barkan, D; Liu, ZY; Datta, S; Dimri, GP; Green, JE				Hoenerhoff, M. J.; Chu, I.; Barkan, D.; Liu, Z-y; Datta, S.; Dimri, G. P.; Green, J. E.			BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases	ONCOGENE			English	Article						BMI1; H-RAS; breast cancer; metastasis	MAMMARY EPITHELIAL-CELLS; STEM-CELLS; CARCINOMA; MYC; TUMORIGENESIS; TRASTUZUMAB; EXPRESSION; APOPTOSIS; THERAPY; RENEWAL	B-lymphoma Moloney murine leukaemia virus insertion region-1 (BMI1) is a member of the polycomb group of transcription repressors, which functions in stem cell maintenance and oncogenesis through the inhibition of the INK4A/ARF tumour suppressor locus. Overexpression of BMI1 is associated with poor prognosis in several human cancers, including breast cancer. We have previously shown that BMI1 collaborates with H-RAS to induce transformation of MCF10A human mammary epithelial cells through dysregulation of multiple growth pathways independent of the INK4A/ARF locus. In this study, we show that BMI1 collaborates with H-RAS to promote increased proliferation, invasion and resistance to apoptosis in vitro, and an increased rate of spontaneous metastases from mammary fat pad xenografts including novel metastases to the brain. Furthermore, in collaboration with H-RAS, BMI1 induced fulminant metastatic disease in the lung using a tail vein model of haematogenous spread through accelerated cellular proliferation and inhibition of apoptosis. Finally, we show that knockdown of BMI1 in several established breast cancer cell lines leads to decreased oncogenic behaviour in vitro and in vivo. In summary, BMI1 collaborates with H-RAS to induce an aggressive and metastatic phenotype with the unusual occurrence of brain metastasis, making it an important target for diagnosis and treatment of aggressive breast cancer. Oncogene (2009) 28, 3022-3032; doi:10.1038/onc.2009.165; published online 22 June 2009	[Hoenerhoff, M. J.; Chu, I.; Barkan, D.; Liu, Z-y; Green, J. E.] NCI, Transgen Oncogenesis Grp, Lab Canc Biol & Genet, NIH, Bethesda, MD 20982 USA; [Datta, S.; Dimri, G. P.] Northwestern Univ, N Shore Univ Hlth Syst Res Inst, Feinberg Sch Med, Div Canc Biol, Evanston, IL USA; [Datta, S.; Dimri, G. P.] Northwestern Univ, N Shore Univ Hlth Syst Res Inst, Feinberg Sch Med, Dept Med, Evanston, IL USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Green, JE (corresponding author), NCI, Transgen Oncogenesis Grp, Lab Canc Biol & Genet, NIH, 37 Convent Dr,Bldg 37,Room 4054, Bethesda, MD 20982 USA.	jegreen@nih.gov	Datta, Sonal/AGI-2356-2022; Dimri, Goberdhan/AAO-4210-2021	, Janet/0000-0001-9020-6982; Datta, Sonal/0000-0002-4924-9355; Barkan, Dalit/0000-0003-4714-0580	NIH; Center for Cancer Research; National Cancer Institute [RO1CA 094150]; NATIONAL CANCER INSTITUTE [ZIABC005740, R01CA094150, ZIABC011229] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Max Wicha for providing the shRNA lentiviral constructs, George Dunn, Asa Dorsey and Gail McMullen for animal care, Zi-ayo Liu for lentiviral transductions and Suresh Arya for advice on lentiviral preparation, and Aleksandra Michalowski and the NIH Biostatisitics Branch for assistance with statistical analysis. This work was supported in part by the Intramural Program of the NIH, Center for Cancer Research, National Cancer Institute and by RO1CA 094150 (GD).	Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Brackstone M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1677; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Dimri GP, 2002, CANCER RES, V62, P4736; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Feng Yan, 2007, Ai Zheng, V26, P154; Fisher B, 2001, J Natl Cancer Inst Monogr, P62; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Glinsky GV, 2005, CELL CYCLE, V4, P1171, DOI 10.4161/cc.4.9.2001; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Huang Kai-hong, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P973; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mihic-Probst D, 2007, INT J CANCER, V121, P1764, DOI 10.1002/ijc.22891; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; TSUKADA Y, 1983, CANCER-AM CANCER SOC, V52, P2349, DOI 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Vernon AE, 2007, REV ENDOCR METAB DIS, V8, P199, DOI 10.1007/s11154-007-9041-5; Wallgren A, 2003, J CLIN ONCOL, V21, P1205, DOI 10.1200/JCO.2003.03.130	31	80	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3022	3032		10.1038/onc.2009.165	http://dx.doi.org/10.1038/onc.2009.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543317	Green Accepted			2022-12-28	WOS:000269319000002
J	Kiessling, A; Hogrefe, C; Erb, S; Bobach, C; Fuessel, S; Wessjohann, L; Seliger, B				Kiessling, A.; Hogrefe, C.; Erb, S.; Bobach, C.; Fuessel, S.; Wessjohann, L.; Seliger, B.			Expression, regulation and function of the ISGylation system in prostate cancer	ONCOGENE			English	Article						ISG15; prostate cancer; androgen receptor; androgen-regulated genes	UBIQUITIN-LIKE PROTEIN; ANDROGEN RECEPTOR EXPRESSION; RESPONSIVE FINGER PROTEIN; RAT VENTRAL PROSTATE; HUMAN BREAST-CANCER; ISG15 E3 LIGASE; NEGATIVE REGULATION; EPITHELIAL-CELLS; GENE-EXPRESSION; LUNG-CANCER	The androgen receptor (AR) plays a crucial role in the modulation of prostate cell proliferation and is involved in the development and progression of prostate cancer (PCa). An understanding of the complex regulation of AR provides novel treatment options for PCa. Here, we show (i) that the ubiquitin-like modifier, interferon-stimulated gene 15 (ISG15), and most enzymes involved in ISG15 conjugation were upregulated in tumor samples versus in non-malignant tissues of PCa patients and (ii) that the expression of these components significantly differed between tumors in patients treated with and without androgen ablation. Using PCa cell lines as in vitro models, the specific androgen-mediated, AR-dependent regulation of the ISGylation components was confirmed. In addition, the ISGylation system controls AR mRNA and protein expressions, as overexpression of Ube1L as a limiting ISGylation factor in the AR(+) androgen-sensitive PCa cell line, LNCaP, results in significant AR upregulation, accompanied by an increased proliferation even under androgen deprivation. Accordingly, Ube1L knockdown decreased the AR expression. Thus, this study describes for the. first time the modulation of AR expression by ISGylation components, which affects the proliferation of PCa cells, thereby providing evidence for a novel function of the ISGylation system in malignant transformation. Oncogene (2009) 28, 2606-2620; doi: 10.1038/onc.2009.115; published online 11 May 2009	[Kiessling, A.; Hogrefe, C.; Erb, S.; Seliger, B.] Univ Halle Wittenberg, Inst Med Immunol, Fac Med, D-06112 Halle, Germany; [Bobach, C.; Wessjohann, L.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Halle, Germany; [Fuessel, S.] Tech Univ Dresden, Dept Urol, Med Fac Carl Gustav Carus, Dresden, Germany	Martin Luther University Halle Wittenberg; Leibniz Institut fur Pflanzenbiochemie; Technische Universitat Dresden; Carl Gustav Carus University Hospital	Seliger, B (corresponding author), Univ Halle Wittenberg, Inst Med Immunol, Fac Med, Magdeburger Str 2, D-06112 Halle, Germany.	Andrea.Kiessling@novartis.com; Barbara.Seliger@medizin.uni-halle.de	Wessjohann, Ludger/AAZ-3838-2021	Wessjohann, Ludger A./0000-0003-2060-8235; Seliger, Barbara/0000-0002-5544-4958				Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Asirvatham AJ, 2006, ENDOCRINOLOGY, V147, P257, DOI 10.1210/en.2005-0942; Basrawala Z, 2006, ONCOGENE, V25, P2812, DOI 10.1038/sj.onc.1209304; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1998, BRIT J CANCER, V78, P1004, DOI 10.1038/bjc.1998.619; Dastur A, 2006, J BIOL CHEM, V281, P4334, DOI 10.1074/jbc.M512830200; Desai KV, 2004, MOL ENDOCRINOL, V18, P2895, DOI 10.1210/me.2004-0033; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2008, MOL CANCER THER, V7, P1430, DOI 10.1158/1535-7163.MCT-07-2345; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; GONG YW, 1995, ENDOCRINOLOGY, V136, P2172, DOI 10.1210/en.136.5.2172; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Ikeda K, 2000, FEBS LETT, V472, P9, DOI 10.1016/S0014-5793(00)01421-6; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jung D, 1999, SCAND J IMMUNOL, V50, P242; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Ko S, 2008, MOL ENDOCRINOL, V22, P273, DOI 10.1210/me.2007-0332; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Li R, 2004, AM J SURG PATHOL, V28, P928, DOI 10.1097/00000478-200407000-00013; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; Liu MJ, 2004, J INTERF CYTOK RES, V24, P647, DOI 10.1089/jir.2004.24.647; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Nakajima A, 2007, BIOCHEM BIOPH RES CO, V357, P245, DOI 10.1016/j.bbrc.2007.03.134; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Okumura F, 2007, GENE DEV, V21, P255, DOI 10.1101/gad.1521607; Olshavsky NA, 2008, ONCOGENE, V27, P3111, DOI 10.1038/sj.onc.1210981; Pitterle DM, 1998, IN VIVO, V12, P643; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Sakuma M, 2005, GYNECOL ONCOL, V99, P664, DOI 10.1016/j.ygyno.2005.07.103; SICA G, 1994, UROL RES, V22, P33, DOI 10.1007/BF00431546; Stanbrough M, 2001, P NATL ACAD SCI USA, V98, P10823, DOI 10.1073/pnas.191235898; Suzuki T, 2005, CLIN CANCER RES, V11, P6148, DOI 10.1158/1078-0432.CCR-05-0040; Takahashi Y, 2007, MOL CARCINOGEN, V46, P117, DOI 10.1002/mc.20254; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Takeuchi T, 2005, BIOCHEM BIOPH RES CO, V336, P9, DOI 10.1016/j.bbrc.2005.08.034; Takeuchi T, 2006, FEBS LETT, V580, P4521, DOI 10.1016/j.febslet.2006.07.032; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Yeap BB, 1999, ENDOCRINOLOGY, V140, P3282, DOI 10.1210/en.140.7.3282; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102; Zou WG, 2007, BIOCHEM BIOPH RES CO, V354, P321, DOI 10.1016/j.bbrc.2006.12.210; Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200	65	45	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2606	2620		10.1038/onc.2009.115	http://dx.doi.org/10.1038/onc.2009.115			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19430494				2022-12-28	WOS:000268058900006
J	Zubia, A; Ropero, S; Otaegui, D; Ballestar, E; Fraga, MF; Boix-Chornet, M; Berdasco, M; Martinez, A; Coll-Mulet, L; Gil, J; Cossio, FP; Esteller, M				Zubia, A.; Ropero, S.; Otaegui, D.; Ballestar, E.; Fraga, M. F.; Boix-Chornet, M.; Berdasco, M.; Martinez, A.; Coll-Mulet, L.; Gil, J.; Cossio, F. P.; Esteller, M.			Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity	ONCOGENE			English	Article						angiogenesis; cancer; computational modeling; epigenetics; histones; histone deacetylase inhibitors	HUMAN HDAC8; MECHANISMS; DISCOVERY; DISEASE; SAHA	Histone deacetylases (HDACs) play a key role in the regulation of gene expression and chromatin structure, and drugs targeting these enzymes might have an important impact in the treatment of human cancer. Herein, we report the characterization of (1H)-pyrroles as a new subfamily of HDAC inhibitors obtained by computational modeling of class-I human HDACs. From a functional standpoint, (1H)-pyrroles are powerful inductors of acetylation of histones H3 and H4, and restore the expression of growth-inhibitory genes. From a cellular view, these compounds cause a marked decrease in the viability of cancer cells in vitro and in vivo, associated with a cell-cycle arrest at G2/M and an inhibition of angiogenesis. Thus, (1H)-pyrroles emerge as a novel group of HDAC inhibitors with promising antitumoral features.	[Zubia, A.; Otaegui, D.; Cossio, F. P.] Univ Pais Vasco Euskal Herriko Unibertsitatea, Sch Chem Quim Kim Fak, Donostia San Sebastian, Euskadi, Spain; [Ropero, S.; Ballestar, E.; Fraga, M. F.; Boix-Chornet, M.; Berdasco, M.; Esteller, M.] Spanish Natl Canc Res Ctr CNIO, Canc Epigenet Lab, Madrid, Spain; [Zubia, A.] IkerChem SL, San Sebastian, Spain; [Ropero, S.; Ballestar, E.; Berdasco, M.; Esteller, M.] Bellvitge Inst Biomed Res IDIBELL, PEBC, Barcelona, Catalonia, Spain; [Ropero, S.; Ballestar, E.; Berdasco, M.; Esteller, M.] ICO, Barcelona, Catalonia, Spain; [Ropero, S.] Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, Madrid, Spain; [Martinez, A.] CSIC, Inst Cajal, Dept Cell Biol & Neuroanat, E-28002 Madrid, Spain; [Coll-Mulet, L.; Gil, J.] Univ Barcelona, IDIBELL, Dept Ciencias Fisiol 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	University of Basque Country; Centro Nacional de Investigaciones Oncologicas (CNIO); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidad de Alcala; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, PEBC, 3rd Floor,Av Gran Via Hosp 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014; Martinez, Alfredo/GQH-5998-2022; Ballestar, Esteban/ABG-8561-2020	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Martinez, Alfredo/0000-0003-4882-4044; Otaegui Ansa, Dorleta/0000-0002-8215-354X; Gil, Joan/0000-0002-3686-3903; ZUBIA OLASCOAGA, AIZPEA/0000-0002-0657-801X; Cossio, Fernando P./0000-0002-4526-2122; Ballestar, Esteban/0000-0002-1400-2440	Consolider [CSD2006-49]; Spanish Association Against Cancer (AECC); SMARTER, Ikerchem Ltd.; Universidad del Pais Vasco-Euskal Herriko Unibertsitatea [UE07/16]; Gobierno Vasco-Eusko Jaurlaritza [9/UPV00170.215-13548]; Spanish Ministerio de Educacion y Ciencia [CTQ2007-67528/BQU];  [SAF2007-00027-65134]; ICREA Funding Source: Custom	Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association Against Cancer (AECC); SMARTER, Ikerchem Ltd.; Universidad del Pais Vasco-Euskal Herriko Unibertsitatea; Gobierno Vasco-Eusko Jaurlaritza(Basque Government); Spanish Ministerio de Educacion y Ciencia(Spanish Government); ; ICREA(ICREA)	This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, the Spanish Association Against Cancer (AECC), FP6 Grant SMARTER, Ikerchem Ltd., The Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (Grant UE07/16), the Gobierno Vasco-Eusko Jaurlaritza (Grant 9/UPV00170.215-13548) and the Spanish Ministerio de Educacion y Ciencia (CTQ2007-67528/BQU). SR is a 'Ramon y Cajal' Researcher. ME is an ICREA Research Professor.	Balakin KV, 2007, ANTI-CANCER AGENT ME, V7, P576, DOI 10.2174/187152007781668698; Chiorazzi N., 2005, NEW ENGL J MED, V352, P804, DOI [10.1056/NEJMra041720, DOI 10.1056/NEJMRA041720, 10.1002/9781444300857.ch36]; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; MAIER T, 2006, Patent No. 2006105979; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Massa S, 2001, J MED CHEM, V44, P2069, DOI 10.1021/jm015515v; Richardson B, 2007, NAT CLIN PRACT RHEUM, V3, P521, DOI 10.1038/ncprheum0573; Sadri-Vakili G, 2006, NAT CLIN PRACT NEURO, V2, P330, DOI 10.1038/ncpneuro0199; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Vivanco S, 2000, J AM CHEM SOC, V122, P6078, DOI 10.1021/ja9945360; Wang DF, 2004, J MED CHEM, V47, P3409, DOI 10.1021/jm0498497	19	19	19	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1477	1484		10.1038/onc.2008.501	http://dx.doi.org/10.1038/onc.2008.501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169274				2022-12-28	WOS:000264354400009
J	Chonghaile, TN; Letai, A				Chonghaile, T. Ni; Letai, A.			Mimicking the BH3 domain to kill cancer cells	ONCOGENE			English	Review						BH3 mimetic; Bcl-2; apoptosis; cancer; drug resistance and ABT-737	OUTER MITOCHONDRIAL-MEMBRANE; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE INHIBITOR; BCL-2 FAMILY PROTEINS; SURVIVAL-PROMOTING PROTEINS; MIMETIC ABT-737; CYTOCHROME-C; X-L; PROAPOPTOTIC ACTIVITY; ANTIAPOPTOTIC BCL-2	Cancer cells show deviant behavior that induces apoptotic signaling. To survive, cancer cells typically acquire changes enabling evasion of death signals. One way they do this is by increasing the expression of anti- apoptotic BCL-2 proteins. Anti-apoptotic BCL-2 family proteins antagonize death signaling by forming heterodimers with pro-death proteins. Heterodimer formation occurs through binding of the pro-apoptotic protein's BH3 domain into the hydrophobic cleft of anti- apoptotic proteins. The BH3 mimetics are small molecule antagonists of the anti- apoptotic BCL-2 members that function as competitive inhibitors by binding to the hydrophobic cleft. Under certain conditions, antagonism of antiapoptotic BCL-2 family proteins can unleash pro-death molecules in cancer cells. Thus, the BH3 mimetics are a new class of cancer drugs that specifically target a mechanism of cancer cell survival to selectively kill cancer cells. Oncogene (2009) 27, S149-S157; doi: 10.1038/onc.2009.52	[Chonghaile, T. Ni; Letai, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Letai, A (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Dana 530B,44 Binney St, Boston, MA 02115 USA.	anthony_letai@dfci.harvard.edu	Chonghaile, Triona Ni/L-9418-2015	Chonghaile, Triona Ni/0000-0002-3041-4031	NATIONAL CANCER INSTITUTE [R01CA129974] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA129974] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Becattini B, 2004, CHEM BIOL, V11, P389, DOI 10.1016/j.chembiol.2004.02.020; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2007, ONCOGENE, V26, P2374, DOI 10.1038/sj.onc.1210028; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER FE, 1994, ONCOGENE, V9, P3049; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Gibson L, 1996, ONCOGENE, V13, P665; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANADA M, 1993, BLOOD, V82, P1820; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee EF, 2007, CELL DEATH DIFFER, V14, P1711, DOI 10.1038/sj.cdd.4402178; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MEIJERINK JPP, 1995, LEUKEMIA, V9, P1828; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIYASHITA T, 1993, BLOOD, V81, P151; Mohammad RM, 2007, CLIN CANCER RES, V13, P2226, DOI 10.1158/1078-0432.CCR-06-1574; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nakashima T, 2000, CANCER RES, V60, P1229; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Brien SM, 2005, J CLIN ONCOL, V23, P7697, DOI 10.1200/JCO.2005.02.4364; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P619; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shoemaker AR, 2008, CLIN CANCER RES, V14, P3268, DOI 10.1158/1078-0432.CCR-07-4622; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Takahashi M, 2003, HEPATOL RES, V25, P192, DOI 10.1016/S1386-6346(02)00244-9; Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951; Trudel S, 2007, CLIN CANCER RES, V13, P621, DOI 10.1158/1078-0432.CCR-06-1526; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogler M, 2008, CELL DEATH DIFFER, V15, P820, DOI 10.1038/cdd.2008.25; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang ZW, 2008, INT J CANCER, V123, P958, DOI 10.1002/ijc.23610; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Wilson WH, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8511; Witham J, 2007, CLIN CANCER RES, V13, P7191, DOI 10.1158/1078-0432.CCR-07-0362; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zhang LZ, 2001, AM J PHYSIOL-CELL PH, V281, pC1642, DOI 10.1152/ajpcell.2001.281.5.C1642; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	93	206	216	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S149	S157		10.1038/onc.2009.52	http://dx.doi.org/10.1038/onc.2009.52			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641500	Green Accepted			2022-12-28	WOS:000268566800013
J	Worthley, DL; Whitehall, VLJ; Buttenshaw, RL; Irahara, N; Greco, SA; Ramsnes, I; Mallitt, KA; Le Leu, RK; Winter, J; Hu, Y; Ogino, S; Young, GP; Leggett, BA				Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Irahara, N.; Greco, S. A.; Ramsnes, I.; Mallitt, K-A; Le Leu, R. K.; Winter, J.; Hu, Y.; Ogino, S.; Young, G. P.; Leggett, B. A.			DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer	ONCOGENE			English	Article						DNA methylation; epigenetics; colorectal cancer; carcinogenesis	NORMAL COLONIC-MUCOSA; MICROSATELLITE INSTABILITY; ULCERATIVE-COLITIS; BRAF MUTATION; CHROMOSOMAL INSTABILITY; PROMOTER METHYLATION; SERRATED ADENOMAS; MOLECULAR-ORIGINS; PHENOTYPE; POLYPS	There are two major molecular pathways to sporadic colorectal cancer, the chromosomal instability (CIN) and the CpG island methylator phenotype (CIMP) pathways. This study recruited 166 patients undergoing colonoscopy. Biopsy samples were collected from the cecum, transverse colon, sigmoid colon and rectum. DNA methylation was quantified at 'type A' (ESR1, GATA5, HIC1, HPP1, SFRP1) and 'type C' markers (MGMT, MLH1, CDKN2A, MINT2, MINT31, IGF2, CACNA1G, NEU-ROG1, SOCS1, RUNX3), and LINE-1. 'Type A' genes are frequently methylated in normal and neoplastic tissues, proportional to tissue age. 'Type C' methylation is more specific for neoplasia. The last five 'type C' markers comprise a CIMP panel. The mean 'type A' and CIMP-panel methylation Z-scores were calculated. In all, 88 patients had adenomatous lesions, 32 had proximal serrated polyps (PSPs) and 50 were normal. Most 'type A' genes showed direct correlations between methylation and age (ESR1, rho = 0.66, P < 0.0001), with higher methylation distally (ESR1, P < 0.0001). On multivariate analysis, 'type A' methylation was inversely associated with colorectal adenomas (odds ratio 0.23, P < 0.001), the precursor to CIN cancers. CIMP-panel methylation was significantly associated with advanced PSPs (odds ratio = 5.1, P = 0.009), the precursor to CIMP cancers. DNA methylation in normal mucosa varied with age and region and was associated with pathway-specific pathology. In the future, the colorectal field could yield important information and potentially inform clinical practice. Oncogene (2010) 29, 1653-1662; doi:10.1038/onc.2009.449; published online 7 December 2009	[Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Greco, S. A.; Ramsnes, I.; Leggett, B. A.] Queensland Inst Med Res, Bancroft Ctr, Conjoint Gastroenterol Lab, Herston, Qld 4029, Australia; [Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Greco, S. A.; Ramsnes, I.; Leggett, B. A.] Royal Brisbane & Womens Hosp, Res Fdn Clin Res Ctr, Brisbane, Qld, Australia; [Irahara, N.; Ogino, S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Mallitt, K-A] Queensland Inst Med Res, Stat Unit, Herston, Qld 4029, Australia; [Le Leu, R. K.; Winter, J.; Hu, Y.; Young, G. P.] Flinders Univ S Australia, Flinders Ctr Canc Prevent & Control, Adelaide, SA, Australia; [Ogino, S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ogino, S.] Harvard Univ, Sch Med, Boston, MA USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; QIMR Berghofer Medical Research Institute; Flinders University South Australia; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Worthley, DL (corresponding author), Queensland Inst Med Res, Bancroft Ctr, Conjoint Gastroenterol Lab, Rm H07,PO RBH, Herston, Qld 4029, Australia.	daniel.worthley@uqconnect.edu.au	Mallitt, Kylie-Ann/E-2240-2011; Whitehall, Vicki L/B-6262-2013; Leggett, Barbara A/D-3579-2011; Mallitt, Kylie-Ann/GPF-9322-2022; Le Leu, Richard K/H-4555-2013; Whitehall, Vicki/E-5414-2019	Mallitt, Kylie-Ann/0000-0002-5722-7287; Whitehall, Vicki L/0000-0002-8285-2391; Mallitt, Kylie-Ann/0000-0002-5722-7287; Le Leu, Richard K/0000-0003-4704-4943; Winter, Jean/0000-0002-2041-8602; Leggett, Barbara/0000-0003-2062-7380; Young, Graeme/0000-0001-9458-8383	National Health and Medical Research Council [442965]; Gastroenterological Society of Australia; Royal Australasian College of Physicians Cottrell Fellowship; Royal Brisbane and Women's Hospital Foundation; Queensland Smart State PhD award	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Gastroenterological Society of Australia; Royal Australasian College of Physicians Cottrell Fellowship; Royal Brisbane and Women's Hospital Foundation; Queensland Smart State PhD award	We thank the gastroenterologists and gastroenterology nurses who helped to collect samples. This study was funded by a National Health and Medical Research Council project grant (442965), a Gastroenterological Society of Australia post-graduate medical scholarship (DLW), the Royal Australasian College of Physicians Cottrell Fellowship (DLW), a Royal Brisbane and Women's Hospital Foundation Research Grant (VLW, DLW, BAL) and a Queensland Smart State PhD award (DLW).	Ahuja N, 1998, CANCER RES, V58, P5489; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Al-Ghnaniem R, 2007, AM J CLIN NUTR, V86, P1064, DOI 10.1093/ajcn/86.4.1064; Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703; Australian Cancer Network Colorectal Cancer Guidelines Revision Committee, 2005, GUID PREV EARL DET M; Belshaw NJ, 2008, BRIT J CANCER, V99, P136, DOI 10.1038/sj.bjc.6604432; Botteri E, 2008, GASTROENTEROLOGY, V134, P388, DOI 10.1053/j.gastro.2007.11.007; Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; East JE, 2008, GASTROENTEROL CLIN N, V37, P25, DOI 10.1016/j.gtc.2007.12.014; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Horii J, 2008, CLIN BIOCHEM, V41, P1440, DOI 10.1016/j.clinbiochem.2008.08.089; Hornsby PJ, 2007, J CLIN ONCOL, V25, P1852, DOI 10.1200/JCO.2006.10.3101; IRAHARA N, 2009, J MOL DIAGN IN PRESS; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kim JY, 2005, P NATL ACAD SCI USA, V102, P17739, DOI 10.1073/pnas.0503976102; Konishi K, 2007, GASTROENTEROLOGY, V132, P1254, DOI 10.1053/j.gastro.2007.01.035; Menigatti M, 2009, ONCOGENE, V28, P899, DOI 10.1038/onc.2008.444; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Nakagawa H, 2001, CANCER RES, V61, P6991; Nuovo GJ, 2006, DIAGN MOL PATHOL, V15, P17, DOI 10.1097/00019606-200603000-00003; Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Preston SL, 2003, CANCER RES, V63, P3819; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sandborn WJ, 1997, ANN INTERN MED, V126, P364, DOI 10.7326/0003-4819-126-5-199703010-00004; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tycko B, 2003, ANN NY ACAD SCI, V983, P43, DOI 10.1111/j.1749-6632.2003.tb05961.x; VANMUNSTER IP, 1994, DIGEST DIS SCI, V39, P834, DOI 10.1007/BF02087431; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Ye CZ, 2006, ONCOL REP, V16, P429; Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298	57	85	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1653	1662		10.1038/onc.2009.449	http://dx.doi.org/10.1038/onc.2009.449			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966864				2022-12-28	WOS:000275694700010
J	Kon, N; Kobayashi, Y; Li, M; Brooks, CL; Ludwig, T; Gu, W				Kon, N.; Kobayashi, Y.; Li, M.; Brooks, C. L.; Ludwig, T.; Gu, W.			Inactivation of HAUSP in vivo modulates p53 function	ONCOGENE			English	Article						hausp; p53; mdm2; deubiquitination; gene knockout; mouse	UBIQUITIN-SPECIFIC PROTEASE; EMBRYONIC LETHALITY; DEUBIQUITINATING ENZYMES; MDM2-DEFICIENT MICE; P53-MDM2 PATHWAY; CONTRIBUTES; USP7/HAUSP; REGULATOR; CARCINOMA; DOMAINS	Hausp is a deubiquitinase that has been shown to regulate the p53-Mdm2 pathway. Cotransfection of p53 and Hausp stabilizes p53 through the removal of ubiquitin moieties from polyubiquitinated p53. Interestingly, knockout or RNA interference-mediated knockdown of Hausp in human cells also resulted in the stabilization of p53 due to the destabilization of Mdm2, suggesting a dynamic role of Hausp in p53 activation. To understand the physiological functions of Hausp, we generated hausp knockout mice. Hausp knockout mice die during early embryonic development between embryonic days E6.5 and E7.5. The hausp knockout embryos showed p53 activation, but no apparent increase in apoptosis. Embryonic lethality was caused by a dramatic reduction in proliferation and termination in development, in part due to p53 activation and/or abrogation of p53-independent functions. Although deletion of p53 did not completely rescue the embryonic lethality of the hausp knockout, embryonic development was extended in both hausp and p53 double knockout embryos. These data show that Hausp has a critical role in regulating the p53-Mdm2 pathway. Oncogene (2010) 29, 1270-1279; doi:10.1038/onc.2009.427; published online 30 November 2009	[Gu, W.] Columbia Univ, Dept Pathol, Inst Canc Genet, New York, NY 10032 USA; [Ludwig, T.] Columbia Univ, Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Dept Pathol, Inst Canc Genet, 1130 St Nicholas Ave Rm 609A, New York, NY 10032 USA.	wg8@columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NIH; NIH/NCI; NATIONAL CANCER INSTITUTE [R01CA129627, P01CA097403] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Qiong Li and Xi Sun for their expert assistance with histology. We also thank Dr Chi-Ming Li for helpful suggestions. This study was supported in part by a post-doctoral fellowship from NIH to NK and grants from NIH/NCI to TL and WG.	Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Becker K, 2008, CELL CYCLE, V7, P1205, DOI 10.4161/cc.7.9.5756; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holowaty MN, 2003, J BIOL CHEM, V278, P47753, DOI 10.1074/jbc.M307200200; Hong S, 2002, MOL CELL NEUROSCI, V20, P298, DOI 10.1006/mcne.2002.1103; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; LUNA RMD, 1995, NATURE, V378, P203; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; PICKART CM, 2004, BIOCHIM BIOPHYS ACTA, V29, P55; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; Wu XS, 2001, P NATL ACAD SCI USA, V98, P3191, DOI 10.1073/pnas.051631598	31	139	145	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1270	1279		10.1038/onc.2009.427	http://dx.doi.org/10.1038/onc.2009.427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946331	Green Accepted			2022-12-28	WOS:000275170600003
J	Madeo, A; Vinciguerra, M; Lappano, R; Galgani, M; Gasperi-Campani, A; Maggiolini, M; Musti, AM				Madeo, A.; Vinciguerra, M.; Lappano, R.; Galgani, M.; Gasperi-Campani, A.; Maggiolini, M.; Musti, A. M.			c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells	ONCOGENE			English	Article						c-Jun; c-Fos; AP-1; JNK; apoptosis; 4-hydroxytamoxifen	COUPLED RECEPTOR GPR30; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; INDUCED APOPTOSIS; OXIDATIVE STRESS; MAP KINASES; C/EBP-BETA; IN-VIVO	The c-Jun N-terminal kinase (JNK) has been shown to mediate tamoxifen-induced apoptosis in breast cancer cells. However, the downstream mediators of the JNK pathway linking tamoxifen to effectors of apoptosis have yet to be identified. In this study, we analysed whether c-Jun, the major nuclear target of JNK, has a role in tamoxifen-induced apoptosis of SkBr3 breast cancer cells. We show that before DNA fragmentation and caspase 3/7 activation, cytotoxic concentrations of 4-hydroxytamoxifen (OHT) induced JNK-dependent phosphorylation of c-Jun at JNK sites earlier shown to regulate c-Jun-mediated apoptosis. In addition, OHT induced ERK-dependent expression of c-Fos and transactivation of an AP-1-responsive promoter. In particular, the ectopic expression of dominant-negative constructs blocking either AP-1 activity or c-Jun N-terminal phosphorylation prevented DNA fragmentation after OHT treatment. Furthermore, both c-Fos expression and c-Jun N-terminal phosphorylation preceded OHT-dependent activation of caspase 3-7 in different types of tamoxifen-sensitive cancer cells, but not in OHT-resistant LNCaP prostate cancer cells. Taken together, our results indicate that the c-Jun/c-Fos AP-1 complex has a pro-apoptotic role in OHT-treated cancer cells and suggest that pharmacological boosts of c-Jun activation may be useful in a combination therapy setting to sensitize cancer cells to tamoxifen-mediated cell death. Oncogene (2010) 29, 978-991; doi:10.1038/onc.2009.400; published online 23 November 2009	[Madeo, A.; Lappano, R.; Maggiolini, M.; Musti, A. M.] Univ Calabria, Dept Pharmacobiol, I-87036 Cosenza, Italy; [Vinciguerra, M.; Galgani, M.] Univ Naples Federico 2, Dept Cellular & Mol Biol & Pathol, Naples, Italy; [Gasperi-Campani, A.] Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy; [Gasperi-Campani, A.] Univ Bologna, Interdepartmental Ctr Res Canc, I-40126 Bologna, Italy	University of Calabria; University of Naples Federico II; University of Bologna; University of Bologna	Maggiolini, M (corresponding author), Univ Calabria, Dept Pharmacobiol, Via P Bucci, I-87036 Cosenza, Italy.	marcellomaggiolini@yahoo.it; ammusti@yahoo.it	Galgani, Mario/AAC-3298-2022; Lappano, Rosamaria/Z-4857-2019; Musti, Anna Maria/M-2520-2019; Maggiolini, Marcello/Z-4729-2019	Maggiolini, Marcello/0000-0002-7485-854X; Galgani, Mario/0000-0001-8414-1676; Lappano, Rosamaria/0000-0002-9374-9701; MUSTI, Anna Maria/0000-0003-1443-2739	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell'Universita' e Ricerca; Regione Calabria	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Universita' e Ricerca(Ministry of Education, Universities and Research (MIUR)); Regione Calabria(Regione Calabria)	We thank Dr Lidia Albanito for continuous helpful experimental assistance. We thank Dr Anna Grazia Recchia for the English revision of the paper. We are grateful to C Vinson, K Nose and H van Dam for gifts of reagents. Funding for this project was provided by the Associazione Italiana Ricerca sul Cancro (AIRC), Ministero dell'Universita' e Ricerca, Regione Calabria.	Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117; Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909; Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033; Bannister AJ, 1995, ONCOGENE, V11, P2509; Basu S, 2004, GLYCOCONJUGATE J, V20, P563; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Friesen C, 2004, CELL DEATH DIFFER, V11, pS73, DOI 10.1038/sj.cdd.4401431; Ham J, 2005, CELL DEATH DIFFER, V12, P1015, DOI 10.1038/sj.cdd.4401689; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Kallio A, 2005, APOPTOSIS, V10, P1395, DOI 10.1007/s10495-005-2137-z; Lagadec C, 2008, ONCOGENE, V27, P1472, DOI 10.1038/sj.onc.1210749; Lee YS, 2000, CELL DEATH DIFFER, V7, P925, DOI 10.1038/sj.cdd.4400717; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; Mabuchi S, 2004, ENDOCRINOLOGY, V145, P1302, DOI 10.1210/en.2003-0709; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Mandlekar S, 2000, CANCER RES, V60, P5995; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Pope R, 2000, CYTOKINE, V12, P1171, DOI 10.1006/cyto.2000.0691; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Prossnitz ER, 2009, MOL CELL ENDOCRINOL, V308, P32, DOI 10.1016/j.mce.2009.03.026; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Recktenwald CV, 2008, CANCER RES, V68, P10086, DOI 10.1158/0008-5472.CAN-08-0360; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shen HM, 1996, FREE RADICAL BIO MED, V21, P139, DOI 10.1016/0891-5849(96)00019-6; Smith WL, 1997, ACAD RADIOL, V4, P657, DOI 10.1016/S1076-6332(05)80273-9; STROBER W, 2001, CURR PROTOC IMMUNO S, V21; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vinciguerr M, 2008, INT J BIOCHEM CELL B, V40, P307, DOI 10.1016/j.biocel.2007.08.001; Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280; Vivacqua A, 2006, MOL PHARMACOL, V70, P1414, DOI 10.1124/mol.106.026344; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Watson A, 1998, J NEUROSCI, V18, P751; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	49	21	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					978	991		10.1038/onc.2009.400	http://dx.doi.org/10.1038/onc.2009.400			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935718				2022-12-28	WOS:000274604400005
J	Allende-Vega, N; Sparks, A; Lane, DP; Saville, MK				Allende-Vega, N.; Sparks, A.; Lane, D. P.; Saville, M. K.			MdmX is a substrate for the deubiquitinating enzyme USP2a	ONCOGENE			English	Article						USP2a; MdmX; Mdm2; p53; ubiquitin; deubiquitinating enzyme	P53 ACTIVATION; DNA-DAMAGE; IN-VIVO; EMBRYONIC LETHALITY; UBIQUITIN LIGASE; PROSTATE-CANCER; TARGETING MDM2; CISPLATIN; CELLS; PATHWAY	It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009	[Allende-Vega, N.; Sparks, A.; Lane, D. P.; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp,Div Mol Med, Dundee DD1 9SY, Scotland	University of Dundee	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp,Div Mol Med, Level 6, Dundee DD1 9SY, Scotland.	m.k.saville@dundee.ac.uk		Allende-Vega, Nerea/0000-0001-5569-6461; Lane, David/0000-0003-0551-3545	Cancer Research UK	Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK. Professor David P Lane is a Gibb fellow of Cancer Research UK.	Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; EVANS GL, 1992, BIOCHEM BIOPH RES CO, V184, P1, DOI 10.1016/0006-291X(92)91149-K; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kruse JJCM, 2007, MUTAT RES-FUND MOL M, V617, P58, DOI 10.1016/j.mrfmmm.2006.12.004; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park KC, 2002, P NATL ACAD SCI USA, V99, P9733, DOI 10.1073/pnas.152011799; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Previati M, 2004, HEARING RES, V196, P8, DOI 10.1016/j.heares.2004.04.009; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656	56	80	86	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					432	441		10.1038/onc.2009.330	http://dx.doi.org/10.1038/onc.2009.330			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838211				2022-12-28	WOS:000273793200012
J	Shaw, A; Gipp, J; Bushman, W				Shaw, A.; Gipp, J.; Bushman, W.			The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts	ONCOGENE			English	Article						Hedgehog; prostate cancer; reactive stroma; myofibroblast; paracrine; tumor microenvironment	GLI TRANSCRIPTION FACTORS; REACTIVE STROMA; CANCER CELLS; ACTIVATION; PROLIFERATION; INHIBITION; NETWORKS; THERAPY	The Hedgehog (Hh) pathway contributes to prostate cancer growth and progression. The presence of robust Sonic Hedgehog (Shh) expression in both normal prostate and localized cancer challenged us to explain the unique growth-promoting effect in cancer. We show here that paracrine Hh signaling exerts a non-cell autonomous effect on xenograft tumor growth and that Hh pathway activation in myofibroblasts alone is sufficient to stimulate tumor growth. Nine genes regulated by Hh in the mesenchyme of the developing prostate were found to be regulated in the stroma of Hh overexpressing xenograft tumors. Correlation analysis of gene expression in matched specimens of benign and malignant human prostate tissue revealed a partial five-gene fingerprint of Hh-regulated expression in stroma of all cancers and the complete nine-gene fingerprint in the subset of tumors exhibiting a reactive stroma. No expression fingerprint was observed in benign tissues. We conclude that changes in the prostate stroma due to association with cancer result in an altered transcriptional response to Hh that mimics the growth-promoting actions of the fetal mesenchyme. Patients with an abundance of myofibroblasts in biopsy tissue may comprise a subgroup that will exhibit a particularly good response to anti-Hh therapy. Oncogene (2009) 28, 4480-4490; doi:10.1038/onc.2009.294; published online 28 September 2009	[Shaw, A.; Gipp, J.; Bushman, W.] Univ Wisconsin, Dept Surg, Div Urol, Madison, WI 53792 USA; [Shaw, A.; Bushman, W.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53792 USA; [Shaw, A.; Gipp, J.; Bushman, W.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bushman, W (corresponding author), Univ Wisconsin, Dept Surg, Div Urol, 600 Highland Ave, Madison, WI 53792 USA.	bushman@surgery.wisc.edu		Shaw, Aubie/0000-0002-5298-801X	Department of Defense [W81XWH-06-1-0060, W81XWH-04-1-0263]; NIDDK [DK056238-06]; Robert and Delores Schnoes Chair in Urologic Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056238] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Robert and Delores Schnoes Chair in Urologic Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Alejandro Munoz, PhD, and Glen Leverson, PhD, for assistance with statistical analysis. The Gli2-mutB expression construct was generously provided by Maximilian Muenke at NIH (Bethesda, MD, USA). This work was supported by the Department of Defense Prostate Cancer Program Graduate Training Award W81XWH-06-1-0060 (AS), Department of Defense Award W81XWH-04-1-0263 (WB), the NIDDK Award DK056238-06 (WB) and the Robert and Delores Schnoes Chair in Urologic Research.	Bai CB, 2002, DEVELOPMENT, V129, P4753; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bierhoff E, 1997, PROSTATE, V31, P234, DOI 10.1002/(SICI)1097-0045(19970601)31:4<234::AID-PROS4>3.0.CO;2-K; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Gustin MP, 2008, PHYSIOL GENOMICS, V34, P34, DOI 10.1152/physiolgenomics.00008.2008; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JANIK P, 1975, CANCER RES, V35, P3698; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kelleher FC, 2006, ACTA ONCOL, V45, P375, DOI 10.1080/02841860600602946; Lauth M, 2007, CURR OPIN INVEST DR, V8, P457; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Levitt RJ, 2007, CANCER LETT, V255, P300, DOI 10.1016/j.canlet.2007.05.006; Lipinski RJ, 2006, EXP CELL RES, V312, P1925, DOI 10.1016/j.yexcr.2006.02.019; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; McCarthy FRK, 2008, BIOCHEM BIOPH RES CO, V373, P109, DOI 10.1016/j.bbrc.2008.05.169; Rhodes DR, 2007, NEOPLASIA, V9, P443, DOI 10.1593/neo.07292; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; SCHIMMANG T, 1993, PROG CLIN BIOL RES, V383, P153; Schwarze SR, 2005, PROSTATE, V64, P67, DOI 10.1002/pros.20215; Shaw A, 2006, PROSTATE, V66, P1347, DOI 10.1002/pros.20357; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Yanagisawa N, 2008, HUM PATHOL, V39, P282, DOI 10.1016/j.humpath.2007.04.025; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yu M, 2009, J BIOL CHEM, V284, P5620, DOI 10.1074/jbc.M809172200; Zhang JX, 2007, J UROLOGY, V177, P1179, DOI 10.1016/j.juro.2006.10.032	33	60	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4480	4490		10.1038/onc.2009.294	http://dx.doi.org/10.1038/onc.2009.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19784071	Green Accepted			2022-12-28	WOS:000272876500007
J	Bailey, JM; Mohr, AM; Hollingsworth, MA				Bailey, J. M.; Mohr, A. M.; Hollingsworth, M. A.			Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; sonic hedgehog; lymphangiogenesis; metastasis	PRIMARY CILIA; N-CADHERIN; EXPRESSION; CELLS; PATHWAY; GROWTH; SHH	Sonic hedgehog (SHH) expression is tightly regulated throughout development. In the adult, aberrant expression of SHH is associated with the onset and progression of pancreatic cancer, as evidenced by increased levels of expression in premalignant and malignant lesions of the pancreas. We investigated the hypothesis that SHH, secreted from pancreatic tumors, functions in a paracrine manner to influence the biological condition of mesenchymal and endothelial cells. Orthotopic implantation of a pancreatic tumor cell line expressing SHH (Capan-2) and a transformed primary cell line that overexpresses SHH (T-HPNE.SHH) were used to show that overexpression of SHH increased primary tumor size and metastasis. Treatment with a neutralizing antibody, 5E1, decreased primary tumor volume and inhibited metastasis. Lyve-1+ vessels and stromal fibroblasts in tumors expressed primary cilium and showed localization of the receptor Smoothened to the primary cilium, providing evidence of active SHH signaling through this pathway. Although primary cilia are present on normal ductal cells of the pancreas, we did not observe primary cilium on the ductal tumor cells, suggesting decreased autocrine signaling through pathways mediated by the primary cilium in pancreatic cancer. These data support the hypothesis that SHH, secreted from pancreatic epithelia, is critical in establishing and regulating the tumor microenvironment and thereby contributes to progression of pancreatic cancer. Oncogene (2009) 28, 3513-3525; doi: 10.1038/onc.2009.220; published online 27 July 2009	[Bailey, J. M.; Mohr, A. M.; Hollingsworth, M. A.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Hollingsworth, MA (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 985950 Nebraska Med Ctr, Omaha, NE 68198 USA.	mahollin@unmc.edu		Bailey-Lundberg, Jennifer/0000-0002-4750-106X	National Institutes of Health [R01CA57362, P30CA36727, U01CA111294]; University of Nebraska [CA09476]; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA057362, T32CA009476, U01CA111294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Nebraska; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kim McDermott for insight, comments and suggestions. We also thank Dr Rick Tempero and Dr Phil Kelley for the gift of HMVEC cells and suggestions related to their use. This work was supported by grants from the National Institutes of Health (R01CA57362, P30CA36727, U01CA111294), training grant awards to JMB and AMM (CA09476) and assistantship awards from the University of Nebraska (JMB).	Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Bailey JM, 2008, CLIN CANCER RES, V14, P5995, DOI 10.1158/1078-0432.CCR-08-0291; Cano DA, 2004, DEVELOPMENT, V131, P3457, DOI 10.1242/dev.01189; Cano DA, 2006, GASTROENTEROLOGY, V131, P1856, DOI 10.1053/j.gastro.2006.10.050; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; HEESCHEN C, 2008, J CLIN INVEST; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Hwang JM, 2008, MOL CELL BIOCHEM, V311, P179, DOI 10.1007/s11010-008-9708-6; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kawahira H, 2005, DEV BIOL, V280, P111, DOI 10.1016/j.ydbio.2005.01.008; Kayed H, 2006, PANCREAS, V32, P119, DOI 10.1097/01.mpa.0000202937.55460.0c; Lee KM, 2003, BIOCHEM BIOPH RES CO, V301, P1038, DOI 10.1016/S0006-291X(03)00086-X; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Lipinski RJ, 2006, EXP CELL RES, V312, P1925, DOI 10.1016/j.yexcr.2006.02.019; Liu MS, 2007, PANCREAS, V34, P340, DOI 10.1097/mpa.0b013e3180333ab5; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nagai S, 2008, CANCER SCI, V99, P1377, DOI 10.1111/j.1349-7006.2008.00822.x; Nagase T, 2008, ANGIOGENESIS, V11, P71, DOI 10.1007/s10456-008-9105-5; Nielsen SK, 2008, DEV DYNAM, V237, P2039, DOI 10.1002/dvdy.21610; Odent S, 1999, HUM MOL GENET, V8, P1683, DOI 10.1093/hmg/8.9.1683; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; SOLER AP, 1995, HUM PATHOL, V26, P1363, DOI 10.1016/0046-8177(95)90302-X; Straface G, 2009, J CELL MOL MED, V13, P2424, DOI 10.1111/j.1582-4934.2008.00440.x; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Tsutsumida H, 2006, CLIN CANCER RES, V12, P2976, DOI 10.1158/1078-0432.CCR-05-1197; Velcheti Vamsidhar, 2007, Med Hypotheses, V69, P948, DOI 10.1016/j.mehy.2007.02.021; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zhang QH, 2005, LAB INVEST, V85, P45, DOI 10.1038/labinvest.3700207	40	207	230	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3513	3525		10.1038/onc.2009.220	http://dx.doi.org/10.1038/onc.2009.220			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633682	Green Accepted			2022-12-28	WOS:000270851700001
J	Westhoff, MA; Kandenwein, JA; Karl, S; Vellanki, SHK; Braun, V; Eramo, A; Antoniadis, G; Debatin, KM; Fulda, S				Westhoff, M-A; Kandenwein, J. A.; Karl, S.; Vellanki, S. H. K.; Braun, V.; Eramo, A.; Antoniadis, G.; Debatin, K-M; Fulda, S.			The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair	ONCOGENE			English	Article						apoptosis; PI3 kinase; GBM	PEGYLATED LIPOSOMAL DOXORUBICIN; DEPENDENT PROTEIN-KINASE; DRUG-INDUCED APOPTOSIS; GROWTH-FACTOR RECEPTOR; HUMAN TUMOR-CELLS; MALIGNANT GLIOMA; STEM-CELLS; CANCER; ACTIVATION; STRAND	The failure of conventional therapies in glioblastoma (GBM) is largely due to an aberrant activity of survival cascades, such as PI3 kinase (PI3K)/Akt-mediated signaling. This study is the first to show that the class I PI3K inhibitor, PI-103, enhances chemotherapy-induced cell death of GBM cells. Concurrent treatment with PI-103 and DNA-damaging drugs, in particular doxorubicin, significantly increases apoptosis and reduces colony formation compared with chemotherapy treatment alone. The underlying molecular mechanism for this chemosensitization was shown by two independent approaches, that is, pharmacological and genetic inhibition of PI3K, DNA-PK and mTOR, to involve inhibition of DNA-PK-mediated DNA repair. Accordingly, blockage of PI3K or DNA-PK, but not of mTOR, significantly delays the resolution of doxorubicin-induced DNA damage and concomitantly increases apoptosis. Importantly, not only are several GBM cell lines chemosensitized by PI-103 but also GBM stem cells. Clinical relevance was further confirmed by the use of primary cultured GBM cells, which also exhibit increased cell death and reduced colony formation on combined treatment with PI-103 and doxorubicin. By identifying class I PI3K inhibitors as powerful agents in enhancing the lethality of DNA-damaging drugs, to which GBMs are usually considered unresponsive, our findings have important implications for the design of rational combination regimens in overcoming the frequent chemoresistance of GBM. Oncogene (2009) 28, 3586-3596; doi: 10.1038/onc.2009.215; published online 27 July 2009	[Westhoff, M-A; Kandenwein, J. A.; Karl, S.; Vellanki, S. H. K.; Antoniadis, G.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, D-89075 Ulm, Germany; [Kandenwein, J. A.] Univ Ulm, Dept Neurosurg, Bezirkskrankenhaus Guenzburg, D-89069 Ulm, Germany; [Braun, V.] Evangel Jung Stilling Krankenhaus, Dept Neurosurg, Siegen, Germany; [Eramo, A.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; Istituto Superiore di Sanita (ISS)	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Westhoff, Mike-Andrew/ABA-9272-2021; Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Eramo, Adriana/K-6694-2016	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Eramo, Adriana/0000-0002-0814-6683; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; European Community; Novartis Stiftung fur therapeutische Forschung; University of Ulm junior research grant;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); European Community(European Commission); Novartis Stiftung fur therapeutische Forschung; University of Ulm junior research grant; 	We thank H Lane (Novartis Institute for BioMedical Research, Oncology Basel, Novartis Pharma AG, Basel, Switzerland) for providing everolimus, R Pallini and R De Maria for glioblastoma-initiating cells and S Piater for expert technical assistance. This work was supported by grants from Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, European Community (ApopTrain, APO-SYS), Novartis Stiftung fur therapeutische Forschung and IAP6/18 (to SF), and the University of Ulm junior research grant (to JAK).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brendler-Schwaab S, 2005, MUTAGENESIS, V20, P245, DOI 10.1093/mutage/gei033; Cavaliere R, 2007, NEUROL CLIN, V25, P1141, DOI 10.1016/j.ncl.2007.07.012; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Chen JS, 2008, MOL CANCER THER, V7, P841, DOI 10.1158/1535-7163.MCT-07-0393; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Colman H, 2008, ARCH NEUROL-CHICAGO, V65, P877, DOI 10.1001/archneur.65.7.877; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fulda S, 1997, CANCER RES, V57, P3823; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Glas M, 2007, ONCOLOGY-BASEL, V72, P302, DOI 10.1159/000113052; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hau P, 2004, CANCER, V100, P1199, DOI 10.1002/cncr.20073; Ihle NT, 2009, MOL CANCER THER, V8, P1, DOI 10.1158/1535-7163.MCT-08-0801; Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200; Koehn H, 2007, ANTI-CANCER DRUG, V18, P419, DOI 10.1097/CAD.0b013e328012a9a0; Kreisl TN, 2009, J NEURO-ONCOL, V92, P99, DOI 10.1007/s11060-008-9741-z; Lees-Miller SP, 2008, CANCER CELL, V13, P379, DOI 10.1016/j.ccr.2008.04.010; Maira SM, 2008, EXPERT OPIN THER TAR, V12, P223, DOI 10.1517/14728222.12.2.223 ; Maira SM, 2009, BIOCHEM SOC T, V37, P265, DOI 10.1042/BST0370265; Newton HB, 2008, CURR TREAT OPTION NE, V10, P285, DOI 10.1007/s11940-008-0031-z; Nitiss John L, 2002, Curr Opin Investig Drugs, V3, P1512; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pawelczak KS, 2008, NUCLEIC ACIDS RES, V36, P4022, DOI 10.1093/nar/gkn344; Prevo R, 2008, CANCER RES, V68, P5915, DOI 10.1158/0008-5472.CAN-08-0757; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Shah NP, 2008, CANCER CELL, V14, P485, DOI 10.1016/j.ccr.2008.11.001; Stupp R, 2006, ONCOLOGIST, V11, P165, DOI 10.1634/theoncologist.11-2-165; TISDALE MJ, 1985, BRIT J CANCER, V52, P789, DOI 10.1038/bjc.1985.259; Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200; Toulany M, 2006, CLIN CANCER RES, V12, P4119, DOI 10.1158/1078-0432.CCR-05-2454; Veuger SJ, 2003, CANCER RES, V63, P6008; Yaneva M, 2005, NUCLEIC ACIDS RES, V33, P5320, DOI 10.1093/nar/gki821; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	53	61	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3586	3596		10.1038/onc.2009.215	http://dx.doi.org/10.1038/onc.2009.215			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633683				2022-12-28	WOS:000270851700007
J	Li, C; Iida, M; Dunn, EF; Ghia, AJ; Wheeler, DL				Li, C.; Iida, M.; Dunn, E. F.; Ghia, A. J.; Wheeler, D. L.			Nuclear EGFR contributes to acquired resistance to cetuximab	ONCOGENE			English	Article						EGFR; nuclear; cetuximab; resistance; src-family kinases; dasatinib	GROWTH-FACTOR RECEPTOR; DEPENDENT PROTEIN-KINASE; PROGNOSTIC VALUE; TYROSINE KINASE; IN-VIVO; CANCER; LOCALIZATION; ACTIVATION; MECHANISMS; EXPRESSION	Epidermal growth factor receptor (EGFR) is a ubiquitously expressed receptor tyrosine kinase involved in the etiology of several human cancers. Cetuximab is an EGFR-blocking antibody that has been approved for the treatment of patients with head and neck squamous cell carcinoma and metastatic colorectal cancer. Previous reports have shown that EGFR translocation to the nucleus is associated with cell proliferation. Here we investigated mechanisms of acquired resistance to cetuximab using a model derived from the non-small cell lung cancer line H226. We demonstrated that cetuximab-resistant cells overexpress HER family ligands including epidermal growth factor (EGF), amphiregulin, heparin-binding EGF and beta-cellulin. Overexpression of these ligands is associated with the nuclear translocation of the EGFR and this process was mediated by the Src family kinases (SFK). Treatment of cetuximab-resistant cells with the SFK inhibitor, dasatinib, resulted in loss of nuclear EGFR, increased membrane expression of the EGFR and resensitization to cetuximab. In addition, expression of a nuclear localization sequence-tagged EGFR in cetuximab-sensitive cells increased resistance to cetuximab both in vitro and in mouse xenografts. Collectively, these data suggest that nuclear expression of EGFR may be an important molecular determinant of resistance to cetuximab therapy and provides a rationale for investigating nuclear EGFR as a biomarker for cetuximab response. Further, these data suggest a rationale for the design of clinical trials that examine the value of treating patients with cetuximab-resistant tumors with inhibitors of SFKs in combination with cetuximab. Oncogene (2009) 28, 3801-3813; doi:10.1038/onc.2009.234; published online 17 August 2009	[Wheeler, D. L.] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, 600 Highland Ave K4-364 CSC, Madison, WI 53792 USA.	dlwheeler@wisc.edu	Li, Chunrong/F-6955-2011; Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA014520-30, P30 CA014520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 2003, J CLIN ONCOL, V21, p289S, DOI 10.1200/JCO.2003.10.523; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bianco R, 2005, ENDOCR-RELAT CANCER, V12, pS159, DOI 10.1677/erc.1.00999; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Camp ER, 2005, CLIN CANCER RES, V11, P397; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Psyrri A, 2008, CANCER EPIDEM BIOMAR, V17, P1486, DOI 10.1158/1055-9965.EPI-07-2684; Rajput A, 2007, CANCER RES, V67, P665, DOI 10.1158/0008-5472.CAN-06-2773; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Viloria-Petit AM, 2004, INT J RADIAT ONCOL, V58, P914, DOI 10.1016/j.ijrobp.2003.09.091; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	42	229	237	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3801	3813		10.1038/onc.2009.234	http://dx.doi.org/10.1038/onc.2009.234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684613	Bronze, Green Accepted			2022-12-28	WOS:000271248400004
J	Lee, KH; Chen, YL; Yeh, SD; Hsiao, M; Lin, JT; Goan, YG; Lu, PJ				Lee, K-H; Chen, Y-L; Yeh, S-D; Hsiao, M.; Lin, J-T; Goan, Y-G; Lu, P-J			MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation	ONCOGENE			English	Article						miR-330; E2F1; Akt; apoptosis; prostate cancer	GASTRIC-CANCER; EXPRESSION; SURVIVAL; PATHWAY; E2F1; GENE; AGGRESSIVENESS; TRANSCRIPTION; SENSITIVITY; CARCINOMA	MicroRNAs (miRNAs) make up a novel class of gene regulators; they function as oncogenes or tumor suppressors by targeting tumor-suppressor genes or oncogenes. A recent study that analysed a large number of human cancer cell lines showed that miR-330 is a potential tumor-suppressor gene. However, the function and molecular mechanism of miR-330 in determining the aggressiveness of human prostate cancer has not been studied. Here, we show that miR-330 is significantly lower expressed in human prostate cancer cell lines than in nontumorigenic prostate epithelial cells. Bioinformatics analyses reveal a conserved target site for miR-330 in the 3'-untranslated region (UTR) of E2F1 at nucleotides 1018-1024. MiR-330 significantly suppressed the activity of a luciferase reporter containing the E2F1-3'-UTR in the cells. This activity could be abolished with the transfection of anti-miR-330 or mutated E2F1-3'-UTR. In addition, the expression level of miR-330 and E2F1 was inversely correlated in cell lines and prostate cancer specimens. After overexpressing of miR-330 in PC-3 cells, cell growth was suppressed by reducing E2F1-mediated Akt phosphorylation and thereby inducing apoptosis. Collectively, this is the first study to show that E2F1 is negatively regulated by miR-330 and also show that miR-330 induces apoptosis in prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene (2009) 28, 3360-3370; doi: 10.1038/onc.2009.192; published online 13 July 2009	[Lu, P-J] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan 704, Taiwan; [Lee, K-H] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Chen, Y-L] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan 70101, Taiwan; [Yeh, S-D] Taipei Med Univ, Dept Urol, Taipei, Taiwan; [Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, J-T] Kaohsiung Vet Gen Hosp, Dept Surg, Div Urol Surg, Kaohsiung, Taiwan; [Goan, Y-G] Natl Yang Ming Univ, Dept Surg, Taipei 112, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; Academia Sinica - Taiwan; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, 138,Sheng Li Rd, Tainan 704, Taiwan.	pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019; Jackson, Benjamin L/C-4297-2012; Chen, Yuh-Ling/AAS-7957-2021	Hsiao, Michael/0000-0001-8529-9213; 	National Cheng Kung University Hospital [NCKUH-9701004]; National Science Council [NSC 97-2311-B-006-003-MY3, NSC-98-3112-B-006-012]	National Cheng Kung University Hospital; National Science Council(Ministry of Science and Technology, Taiwan)	We thank the grant support from National Cheng Kung University Hospital Grant (NCKUH-9701004 to P-J Lu), National Science Council (NSC 97-2311-B-006-003-MY3 to P-J Lu and NSC-98-3112-B-006-012 to Y-L Chen). We also thank Dr Chen in the Department Urology College of Pharmacy and Comprehensive Cancer Center, The Ohio State University, for his generous gifts of Akt plasmid DNA.	ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chaussepied M, 2004, MOL CELL, V16, P831, DOI 10.1016/j.molcel.2004.11.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Guo XM, 2007, CIRC RES, V101, P1113, DOI 10.1161/CIRCRESAHA.107.157644; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson DG, 2006, CURR MOL MED, V6, P731; Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim R, 1999, ANTICANCER RES, V19, P1779; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Leung KW, 2009, ONCOL REP, V21, P1097, DOI 10.3892/or_00000329; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Matos P, 2008, GASTROENTEROLOGY, V135, P899, DOI 10.1053/j.gastro.2008.05.052; Neville PJ, 2003, GENE CHROMOSOME CANC, V36, P332, DOI 10.1002/gcc.10165; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pal P, 2007, HUM GENET, V122, P251, DOI 10.1007/s00439-007-0394-3; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruike Y, 2008, J HUM GENET, V53, P515, DOI 10.1007/s10038-008-0279-x; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Slager SL, 2003, AM J HUM GENET, V72, P759, DOI 10.1086/368230; Stanelle J, 2006, TRENDS MOL MED, V12, P177, DOI 10.1016/j.molmed.2006.02.002; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomas GV, 2004, CLIN CANCER RES, V10, P8351, DOI 10.1158/1078-0432.CCR-04-0130; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Tyagi A, 2003, ONCOGENE, V22, P1302, DOI 10.1038/sj.onc.1206265; Uney JB, 2006, P NATL ACAD SCI USA, V103, P15278, DOI 10.1073/pnas.0607655103; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	43	164	178	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3360	3370		10.1038/onc.2009.192	http://dx.doi.org/10.1038/onc.2009.192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597470				2022-12-28	WOS:000270103300003
J	Palamakumbura, AH; Vora, SR; Nugent, MA; Kirsch, KH; Sonenshein, GE; Trackman, PC				Palamakumbura, A. H.; Vora, S. R.; Nugent, M. A.; Kirsch, K. H.; Sonenshein, G. E.; Trackman, P. C.			Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling	ONCOGENE			English	Article						lysyl oxidase; tumor suppressor; prostate cancer; cell proliferation; fibroblast growth factor; Ras	HEPARAN-SULFATE PROTEOGLYCANS; TUMOR-SUPPRESSOR ACTIVITY; FACTOR RECEPTOR; MESSENGER-RNA; BREAST-CANCER; PHENOTYPIC REVERSION; MEDIATED MECHANISM; ANDROGEN RECEPTOR; IN-VITRO; H-RAS	Enhanced RAS signaling and decreased androgen dependence of prostate cancer cells accompany poor clinical outcomes. Elevated autocrine fibroblast growth factors 2 (FGF-2) signaling promotes prostate cancer cell growth and survival. Expression of lysyl oxidase (LOX) inhibits RAS transforming activity. LOX is secreted as 50 kDa pro-LOX protein and then undergoes extracellular proteolytic processing to form similar to 30 kDa LOX enzyme and similar to 18 kDa propeptide (LOX-PP). We have previously shown that LOX-PP inhibits breast cancer cell transformation and tumor formation, but mechanisms of action of LOX-PP have not been fully elucidated. Here we report that LOX expression is reduced in prostate cancer cell lines and that recombinant LOX-PP protein inhibits serum-stimulated DNA synthesis and MEK/ERK and PI3K/AKT pathways in DU 145 and PC-3 androgen-independent cell lines. In DU 145 cells, treatment with a pharmacologic FGF-receptor inhibitor or a neutralizing anti-FGFR1 antibody mimicked LOX-PP inhibition of serum-stimulated DNA synthesis. FGF-2-stimulated DNA synthesis, ERK1/2, AKT and FRS2 alpha activation were found all to be inhibited by LOX-PP in DU 145 cells. LOX-PP reduced specific binding of FGF-2 to DU 145 cells, suggesting that LOX-PP targets FGF signaling at the receptor. Interestingly, PC-3 cells did not respond to FGF-2, consistent with previous reports. We conclude that LOX-PP inhibits proliferation of DU 145 cells by interfering with FGFR(s) binding and signaling, and that LOX-PP has other mechanisms of action in PC-3 cells. Oncogene (2009) 28, 3390-3400; doi: 10.1038/onc.2009.203; published online 13 July 2009	[Palamakumbura, A. H.; Vora, S. R.; Trackman, P. C.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, Boston, MA 02118 USA; [Nugent, M. A.; Kirsch, K. H.; Sonenshein, G. E.; Trackman, P. C.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Trackman, PC (corresponding author), Boston Univ, Henry M Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Div Oral Biol, 700 Albany St,W-201, Boston, MA 02118 USA.	trackman@bu.edu	Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Nugent, Matthew/0000-0002-8630-4712; Kirsch, Kathrin/0000-0003-1532-1715	NIH/NCI [CA082742]; DOD [W81XWH-08-1-0349]; NIH/NIDCR [DE14066]; NATIONAL CANCER INSTITUTE [R01CA082742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by NIH/NCI CA082742, DOD Award W81XWH-08-1-0349, NIH/NIDCR DE14066. We thank Danielle Stephens and Emilie Vu for expert preparation of rLOX-PP.	Bansal R, 2003, J NEUROSCI RES, V74, P486, DOI 10.1002/jnr.10773; Blanckaert VD, 2002, HYBRIDOMA HYBRIDOM, V21, P153, DOI 10.1089/153685902760173863; Bonaccorsi L, 2004, J CANCER RES CLIN, V130, P604, DOI 10.1007/s00432-004-0581-8; Chu CL, 2004, BIOCHEM J, V379, P331, DOI 10.1042/BJ20031082; Chua CC, 2004, CIRC RES, V94, P316, DOI 10.1161/01.RES.0000112965.70691.AC; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Contente S, 2009, BBA-MOL CELL RES, V1793, P1272, DOI 10.1016/j.bbamcr.2009.04.013; Cronauer MV, 1997, PROSTATE, V31, P223; CULIG Z, 1994, CANCER RES, V54, P5474; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Erlich S, 2006, BIOCHEM PHARMACOL, V72, P427, DOI 10.1016/j.bcp.2006.05.007; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; Forsten-Williams K, 2005, J THEOR BIOL, V233, P483, DOI 10.1016/j.jtbi.2004.10.020; Gioeli D, 2005, CLIN SCI, V108, P293, DOI 10.1042/CS20040329; Gioeli D, 1999, CANCER RES, V59, P279; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Giri D, 1999, CLIN CANCER RES, V5, P1063; Guo Y, 2007, AM J PHYSIOL-CELL PH, V292, pC2095, DOI 10.1152/ajpcell.00613.2006; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Hatziapostolou M, 2006, J BIOL CHEM, V281, P32217, DOI 10.1074/jbc.M607104200; He QM, 2003, J BIOL CHEM, V278, P21831, DOI 10.1074/jbc.M300880200; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Hurtado PA, 2008, BIOCHEM BIOPH RES CO, V366, P156, DOI 10.1016/j.bbrc.2007.11.116; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jones HE, 1997, INT J CANCER, V71, P1010, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1010::AID-IJC17>3.0.CO;2-H; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kominsky SL, 2000, CANCER RES, V60, P3904; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; KUIVANIEMI H, 1986, FEBS LETT, V195, P261, DOI 10.1016/0014-5793(86)80172-7; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; McPherson RA, 2004, PROSTATE, V58, P325, DOI 10.1002/pros.10336; Min CY, 2007, CANCER RES, V67, P1105, DOI 10.1158/0008-5472.CAN-06-3867; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NAKAMOTO T, 1992, CANCER RES, V52, P571; Natke B, 1999, Angiogenesis, V3, P249, DOI 10.1023/A:1009008824246; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Palamakumbura AH, 2004, J BIOL CHEM, V279, P40593, DOI 10.1074/jbc.M406639200; Palamakumbura AH, 2003, J BIOL CHEM, V278, P30781, DOI 10.1074/jbc.M305238200; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Planz B, 2001, J UROLOGY, V166, P678, DOI 10.1016/S0022-5347(05)66042-9; Polnaszek N, 2003, CANCER RES, V63, P5754; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ren CZ, 1998, CANCER RES, V58, P1285; Richardson TP, 1999, J BIOL CHEM, V274, P13534, DOI 10.1074/jbc.274.19.13534; Ropiquet F, 2000, CANCER RES, V60, P4245; Ropiquet F, 1999, J UROLOGY, V162, P595, DOI 10.1016/S0022-5347(05)68632-6; SAMID D, 1993, J CLIN INVEST, V91, P2288, DOI 10.1172/JCI116457; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Shain SA, 2004, MOL CANCER RES, V2, P653; Smith JA, 2001, BIOCHEM PHARMACOL, V62, P469, DOI 10.1016/S0006-2952(01)00690-6; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Weber MJ, 2004, J CELL BIOCHEM, V91, P13, DOI 10.1002/jcb.10683; Wesley UV, 2005, CANCER RES, V65, P1325, DOI 10.1158/0008-5472.CAN-04-1852; Wu M, 2007, CANCER RES, V67, P6278, DOI 10.1158/0008-5472.CAN-07-0776; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426; Zhao YS, 2009, J BIOL CHEM, V284, P1385, DOI 10.1074/jbc.M802612200	70	60	63	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3390	3400		10.1038/onc.2009.203	http://dx.doi.org/10.1038/onc.2009.203			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597471	Green Accepted			2022-12-28	WOS:000270103300006
J	Li, J; Yang, L; Song, L; Xiong, H; Wang, L; Yan, X; Yuan, J; Wu, J; Li, M				Li, J.; Yang, L.; Song, L.; Xiong, H.; Wang, L.; Yan, X.; Yuan, J.; Wu, J.; Li, M.			Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1	ONCOGENE			English	Article						AEG-1; FOXO1; p27(Kip1); p21(Cip1); Akt; breast cancer	TUMOR PROGRESSION; PROSTATE-CANCER; CELL-SURVIVAL; BCCIP-ALPHA; PROTEIN; METASTASIS; DEGRADATION; INTEGRATION; ACTIVATION; EXPRESSION	We have previously reported that astrocyte elevated gene-1 (AEG-1) was upregulated in human breast cancer. However, the biological function of AEG-1 in the development and progression of breast cancer remains to be clarified. In this study, we examined the effect of AEG-1 on cell proliferation and found that AEG-1 upregulation was significantly linked to increased Ki67 (P < 0.001). Ectopic expression of AEG-1 in MCF-7 and MDA-MB-435 breast cancer cells dramatically enhanced cell proliferation and their ability of anchorage-independent growth, whereas silencing endogenous AEG-1 with shRNAs inhibited cell proliferation and colony-forming ability of the cells on soft agar. Furthermore, these proliferative effects were significantly associated with decreases of p27(Kip1) and p21(Cip1) two key cell-cycle inhibitors. Moreover, we further demonstrated that AEG-1 could downregulate the transcriptional activity of FOXO1 by inducing its phosphorylation through the PI3K/Akt signaling pathway. These observations were further confirmed in clinical human primary breast cancer specimens, in which high-level expression of AEG-1 was inversely correlated with the expression of FOXO1. Taken together, our results provide the first demonstration of a novel mechanism by which AEG-1 induces proliferation of breast cancer cell, and our findings suggest that AEG-1 might play an important role in tumorigenesis of breast cancer. Oncogene (2009) 28, 3188-3196; doi: 10.1038/onc.2009.171; published online 27 July 2009	[Yang, L.; Xiong, H.; Wang, L.; Wu, J.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China; [Li, J.; Yan, X.; Yuan, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Li, J.; Yang, L.; Xiong, H.; Wang, L.; Yan, X.; Yuan, J.; Wu, J.; Li, M.] Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China; [Song, L.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, M (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, 74 Zhongshan Rd 2,Her Mu Bldg 9th Floor, Guangzhou 510080, Guangdong, Peoples R China.	limf@mail.sysu.edu.cn	Song, LB/AAL-1968-2020		Ministry of Science and Technology of China [2005CB724605]; Foundation of Ministry of Science and Technology of China [30670803, 30770836, 30771110, 30870963, 30831160517, 30872930]; Program for New Century Excellent Talents in University [NCET-07-0877]; Science and Technology Department of Guangdong Province, China [07001503, 8251008901000006, 2008A030201006]; Foundation of Ministry of Education [(2008) 890, 200805580047]; Science and Technology Department of Guangdong Province, Zhuhai City [PC20071076]; Guangdong Provincial Natural Science Foundation [2006Z3-E4081]; 985-II project	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Foundation of Ministry of Science and Technology of China; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Science and Technology Department of Guangdong Province, China; Foundation of Ministry of Education; Science and Technology Department of Guangdong Province, Zhuhai City; Guangdong Provincial Natural Science Foundation(National Natural Science Foundation of Guangdong Province); 985-II project	This study was supported by grants from the Ministry of Science and Technology of China (Grant (973) 2005CB724605); the Foundation of Ministry of Science and Technology of China (No. 30670803, 30770836, 30771110, 30870963, 30831160517, 30872930); Program for New Century Excellent Talents in University (Grant No. NCET-07-0877); the Science and Technology Department of Guangdong Province, China (No. 07001503, 8251008901000006, 2008A030201006); Foundation of Ministry of Education (No. (2008) 890 and No. 200805580047); the Science and Technology Department of Guangdong Province, Zhuhai City (PC20071076); Guangdong Provincial Natural Science Foundation (Grant 2006Z3-E4081) and a key grant from the 985-II project.	Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Doerfler W, 2001, ANN NY ACAD SCI, V945, P276; Dong XY, 2006, CANCER RES, V66, P6998, DOI 10.1158/0008-5472.CAN-06-0411; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Greene FL PDL, 2002, BREAST CANC AJCC CAN, P255; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Meng X, 2007, ONCOGENE, V26, P6253, DOI 10.1038/sj.onc.1210460; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TRENT RJ, 2006, MOL MED, P93; Ward EC, 2008, ENDOCRINOLOGY, V149, P1942, DOI 10.1210/en.2007-0756	29	111	127	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3188	3196		10.1038/onc.2009.171	http://dx.doi.org/10.1038/onc.2009.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19633686				2022-12-28	WOS:000269673400002
J	Taliaferro-Smith, L; Nagalingam, A; Zhong, D; Zhou, W; Saxena, NK; Sharma, D				Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.			LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells	ONCOGENE			English	Article						adiponectin; LKB1; invasion; migration; breast cancer	FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; BODY-MASS INDEX; TUMOR-SUPPRESSOR; GLOBULAR ADIPONECTIN; THERAPEUTIC TARGET; METABOLIC SYNDROME; SERUM ADIPONECTIN; SIGNALING PATHWAY; SKELETAL-MUSCLE	Adiponectin is widely known as an adipocytokine with therapeutic potential for its markedly protective function in the pathogenesis of obesity-related disorders, metabolic syndrome, systemic insulin resistance, cardiovascular disease and more recently carcinogenesis. In the present study, we show that adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Further analysis of the underlying molecular mechanisms revealed that adiponectin treatment increased AMP-activated protein kinase (AMPK) phosphorylation and activity as evident by increased phosphorylation of downstream target of AMPK, acetyl-coenzyme A carboxylase and inhibition of p70S6 kinase (S6K). Intriguingly, we discovered that adiponectin treatment increases the expression of tumor suppressor gene LKB1 in breast cancer cells. Overexpression of LKB1 in breast cancer cells further increased adiponectin-mediated phosphorylation of AMPK. Using isogenic LKB1 knockdown cell line pair, we found that LKB1 is required for adiponectin-mediated modulation of AMPK -S6K axis and more importantly, inhibition of adhesion, migration and invasion of breast cancer cells. Taken together these data present a novel mechanism involving specific upregulation of tumor suppressor gene LKB1 by which adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Our findings indicate the possibility of using adiponectin analogues to inhibit invasion and migration of breast cancer cells. Oncogene (2009) 28, 2621 -2633; doi: 10.1038/onc.2009.129; published online 1 June 2009	[Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Saxena, N. K.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	Emory University	Sharma, D (corresponding author), Winship Canc Inst, Dept Hematol & Med Oncol, Rm 4010,1701 Uppergate Dr, Atlanta, GA 30322 USA.	nksaxen@emory.edu; dsharma@emory.edu			NATIONAL CANCER INSTITUTE [P01CA116676, R01CA131294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK076742, R03DK089130, K01DK077137] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA131294, 5P01CA116676-030002, R01 CA131294] Funding Source: Medline; NIDDK NIH HHS [K01 DK076742, K01DK076742, R03 DK089130, K01 DK077137-05, K01 DK077137-02, K01 DK077137, K01 DK077137-01A1, R03 DK089130-02, K01 DK077137-04, R03 DK089130-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Arditi JD, 2007, HORM METAB RES, V39, P9, DOI 10.1055/s-2007-956518; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Barb D, 2006, EXPERT OPIN INV DRUG, V15, P917, DOI 10.1517/13543784.15.8.917; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Cacicedo JM, 2004, BIOCHEM BIOPH RES CO, V324, P1204, DOI 10.1016/j.bbrc.2004.09.177; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chen DC, 2006, CANCER LETT, V237, P109, DOI 10.1016/j.canlet.2005.05.047; Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980; Daling JR, 2001, CANCER, V92, P720, DOI 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Dos Santos E, 2008, ONCOL REP, V20, P971, DOI 10.3892/or_00000098; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Jarde T, 2008, HISTOPATHOLOGY, V53, P484, DOI 10.1111/j.1365-2559.2008.03121.x; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051; Korner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858; Liu J, 2008, CARCINOGENESIS, V29, P2195, DOI 10.1093/carcin/bgn194; Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nakayama S, 2008, BREAST CANCER RES TR, V112, P405, DOI 10.1007/s10549-007-9874-3; Petrelli JM, 2002, CANCER CAUSE CONTROL, V13, P325, DOI 10.1023/A:1015288615472; Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008-5472.CAN-08-1952; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029; Takahata C, 2007, CANCER LETT, V250, P229, DOI 10.1016/j.canlet.2006.10.006; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhong DS, 2008, CANCER RES, V68, P7270, DOI 10.1158/0008-5472.CAN-08-1484; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18	71	135	142	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2621	2633		10.1038/onc.2009.129	http://dx.doi.org/10.1038/onc.2009.129			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483724	Green Accepted			2022-12-28	WOS:000268211200001
J	Morrison, BH; Haney, R; Lamarre, E; Drazba, J; Prestwich, GD; Lindner, DJ				Morrison, B. H.; Haney, R.; Lamarre, E.; Drazba, J.; Prestwich, G. D.; Lindner, D. J.			Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma	ONCOGENE			English	Article						inositol hexakisphosphate kinase 2; chemical carcinogenesis; ionizing radiation; proliferation; inositol polyphosphates; apoptosis	DNA-PK; PYROPHOSPHATES; PHOSPHATE; HEAD; 3P; 12P12-13; GROWTH; ASSAY; BETA; KU	Inositol hexakisphosphate kinase 2 (IP6K2), a member of the inositol hexakisphosphate kinase family, functions as a growth suppressive and apoptosis-enhancing kinase during cell stress. We created mice with a targeted deletion of IP6K2; these mice display normal embryogenesis, development, growth and fertility. Chronic exposure to the carcinogen 4-nitroquinoline 1-oxide (4-NQO, a UV-mimetic compound) in drinking water resulted in fourfold increased incidence of invasive squamous cell carcinoma (SCC) formation in the oral cavity and esophagus of the knockout (KO) mice compared to the wild-type (WT) littermates. Paradoxically, KO mice displayed relative resistance to ionizing radiation and exhibit enhanced survival following 8-10 Gy total body irradiation. Primary KO fibroblasts displayed resistance to antiproliferative effects of interferon-beta and increased colony forming units following ionizing radiation. Radioresistance of KO fibroblasts was associated with accelerated DNA repair measured by comet assay. Direct microinjection of 5-PP-Ins(1,2,3,4,6) P-5 (the enzymatic product of IP6K2), but not InsP(6) (the substrate of IP6K2) induced cell death in SCC22A squamous carcinoma cells. Oncogene (2009) 28, 2383-2392; doi:10.1038/onc.2009.113; published online 11 May 2009	[Lindner, D. J.] Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH 44195 USA; [Lamarre, E.] Cleveland Clin, Head & Neck Inst, Cleveland, OH 44195 USA; [Drazba, J.] Cleveland Clin, Res Core Adm, Cleveland, OH 44195 USA; [Prestwich, G. D.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Utah System of Higher Education; University of Utah; Cleveland Clinic Foundation	Lindner, DJ (corresponding author), Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@ccf.org	Lindner, Daniel/ABB-5440-2020		NIH/NCI [CA095020]; NIH [NS29632]; NATIONAL CANCER INSTITUTE [R01CA095020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Philip Sanford, University of Cincinnati, for design of targeting vector and creation of IHPK2 knockout mice. Donna Kusewitt, Ohio State University, Director, Mouse Phenotyping Shared Resource, kusewitt. 1@osu.edu, conducted the phenotyping studies. Judy Drazba, Cleveland Clinic Imaging Core, performed the time-lapse photography of microinjected cells. Dr Yong Xu, Dr Honglu Zhang and Dr Jianxing Zhang performed the synthesis of 5-PP-Ins( 1,2,3,4,6)P<INF>5</INF>. These studies were supported by grants from NIH/NCI (CA095020) to DJL and from NIH (NS29632) to GDP.	Bhandari R, 2008, P NATL ACAD SCI USA, V105, P2349, DOI 10.1073/pnas.0712227105; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Byrum J, 2004, NUCLEIC ACIDS RES, V32, P2776, DOI 10.1093/nar/gkh592; Chakraborty SB, 2003, CANCER GENET CYTOGEN, V146, P130, DOI 10.1016/S0165-4608(03)00127-4; Cheung JCY, 2008, NUCLEIC ACIDS RES, V36, P5713, DOI 10.1093/nar/gkn572; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; Kawata T, 2005, RADIAT RES, V164, P509, DOI 10.1667/RR3382.1; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kibel AS, 2004, INT J CANCER, V109, P668, DOI 10.1002/ijc.20060; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Lu BJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-40; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MA Y, 2002, J BIOL CHEM, V30, P30; MAESTRO R, 1993, CANCER RES, V53, P5775; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; PANIGRAHI GB, 1990, BIOCHEMISTRY-US, V29, P2122, DOI 10.1021/bi00460a023; Pogach MS, 2007, J CELL BIOCHEM, V100, P1415, DOI 10.1002/jcb.21142; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Teng CH, 2007, J BIOL CHEM, V282, P28395, DOI 10.1074/jbc.M705142200; Wojewodzka M, 2002, MUTAT RES-GEN TOX EN, V518, P9, DOI 10.1016/S1383-5718(02)00070-0; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhang HL, 2009, ORG LETT, V11, P1551, DOI 10.1021/ol900149x	37	56	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2383	2392		10.1038/onc.2009.113	http://dx.doi.org/10.1038/onc.2009.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430495	Green Accepted			2022-12-28	WOS:000267342400003
J	Cimmino, F; Schulte, JH; Zollo, M; Koster, J; Versteeg, R; Iolascon, A; Eggert, A; Schramm, A				Cimmino, F.; Schulte, J. H.; Zollo, M.; Koster, J.; Versteeg, R.; Iolascon, A.; Eggert, A.; Schramm, A.			Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness	ONCOGENE			English	Article						neuroblastoma; Galectin-1; TrkB; neurotrophin receptors	NEUROTROPHIC FACTOR; CLASSICAL HODGKIN; TUMOR PROGRESSION; IMMUNE PRIVILEGE; GENE-EXPRESSION; H-RAS; CELLS; CANCER; TARGET; INVASIVENESS	Expression of Trk receptors is an important prognostic factor in neuroblastoma (NB) and other cancers. TrkB and its ligand brain-derived neurotrophic factor (BDNF) are preferentially expressed in NB with poor prognosis, conferring invasive and metastatic potential to the tumor cells as well as enhancing therapy resistance. Galectin-1 (Gal-1) has emerged as an interesting cancer target, as it is involved in modulating cell proliferation, cell death and cell migration, all of which are linked to cancer initiation and progression. We previously identified Gal-1 mRNA to be upregulated in patients with aggressive, relapsing NB and found that Gal-1 protein was upregulated in human SY5Y NB cells on activation of ectopically expressed TrkB (SY5Y-TrkB), but not TrkA (SY5Y-TrkA). Here, we report that Gal-1 mRNA levels positively correlated with TrkB expression and anticorrelated with TrkA expression in a cohort of 102 primary NB. Immunohistochemical analyses of 92 primary NB specimens revealed high Gal-1 expression in stromal septae and in neuroblasts. BDNF-mediated activation of TrkB enhanced invasiveness and migration in vitro, which could be impaired by transient transfection using Gal-1-specific siRNA or a neutralizing antibody directed against Gal-1. The addition of recombinant Gal-1 (rGal-1) in the absence of BDNF partially restored migration and invasive capacity. Using the Trk inhibitor K252a, we could show that the upregulation of Gal-1 protein strictly depended on activated TrkB. Our data suggest that targeting Gal-1 might be a promising strategy for the treatment of aggressive NB. Oncogene (2009) 28, 2015-2023; doi:10.1038/onc.2009.70; published online 13 April 2009	[Cimmino, F.; Zollo, M.; Iolascon, A.] Univ Naples Federico 2, Dipartimento Biochim & Biotecnol Med, Ctr Ingn Genet CEINGE Biotecnol Avanzate, Naples, Italy; [Koster, J.; Versteeg, R.] AMC Amsterdam, Dept Human Genet, Amsterdam, Netherlands; [Cimmino, F.; Schulte, J. H.; Eggert, A.; Schramm, A.] Univ Childrens Hosp Essen, Div Hematol Oncol, Essen, Germany	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen	Schramm, A (corresponding author), Univ Childrens Hosp Essen, Div Hematol Oncol, Hufelandstr 55, D-45122 Essen Nrw, Germany.	alexander.schramm@uni-due.de	Schulte, Johannes H./V-2474-2018; Schulte, Johannes H/G-3981-2010; Schramm, Alexander/G-5688-2010; Versteeg, Rogier/AAQ-1765-2020; Eggert, Angelika/AAE-6907-2022; Koster, Jan/C-5934-2008; Iolascon, Achille/A-4461-2014; Cimmino, Flora/AAA-2378-2020; Cimmino, FLORA/K-6205-2016	Schramm, Alexander/0000-0001-7670-7529; Eggert, Angelika/0000-0003-3476-8184; Koster, Jan/0000-0002-0890-7585; Cimmino, Flora/0000-0003-1538-9285; Cimmino, FLORA/0000-0003-1538-9285; Versteeg, Rogier/0000-0001-7172-0388; iolascon, achille/0000-0002-9558-0356; Schulte, Johannes Hubertus/0000-0003-0671-1201	European Union [037260]	European Union(European Commission)	This study was supported by the 6th framework program of the European Union, Grant no. 037260 (EET-Pipeline).	Belanis L, 2008, MOL BIOL CELL, V19, P1404, DOI 10.1091/mbc.E07-10-1053; Chiang WF, 2008, ORAL ONCOL, V44, P325, DOI 10.1016/j.oraloncology.2007.03.004; Cimmino F, 2007, J PROTEOME RES, V6, P2550, DOI 10.1021/pr060701g; Eggert A, 2001, CANCER RES, V61, P1314; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Ho R, 2002, CANCER RES, V62, P6462; Hughes RC, 2001, BIOCHIMIE, V83, P667; Jaboin J, 2002, CANCER RES, V62, P6756; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Juszczynski P, 2007, P NATL ACAD SCI USA, V104, P13134, DOI 10.1073/pnas.0706017104; Le Mercier M, 2008, J NEUROPATH EXP NEUR, V67, P456, DOI 10.1097/NEN.0b013e318170f892; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Lucarelli E, 1997, EUR J CANCER, V33, P2068, DOI 10.1016/S0959-8049(97)00266-9; Mathieu V, 2007, J INVEST DERMATOL, V127, P2399, DOI 10.1038/sj.jid.5700869; MATSUMOTO K, 1995, CANCER RES, V55, P1798; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Rabinovich GA, 2005, BRIT J CANCER, V92, P1188, DOI 10.1038/sj.bjc.6602493; Rodig SJ, 2008, CLIN CANCER RES, V14, P3338, DOI 10.1158/1078-0432.CCR-07-4709; Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8; Salatino M, 2008, EXPERT OPIN BIOL TH, V8, P45, DOI 10.1517/14712598.8.1.45; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Schulte JH, 2005, ONCOGENE, V24, P165, DOI 10.1038/sj.onc.1208000; Schulte JH, 2008, CANCER LETT, V271, P56, DOI 10.1016/j.canlet.2008.05.039; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sitek B, 2005, MOL CELL PROTEOMICS, V4, P291, DOI 10.1074/mcp.M400188-MCP200; Stephan H, 2008, PEDIATR BLOOD CANCER, V50, P218, DOI 10.1002/pbc.21369; TAPLEY P, 1992, ONCOGENE, V7, P371; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thijssen VLJL, 2007, BLOOD, V110, P2819, DOI 10.1182/blood-2007-03-077792; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2	37	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2015	2023		10.1038/onc.2009.70	http://dx.doi.org/10.1038/onc.2009.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363525				2022-12-28	WOS:000266023900002
J	Rensen, WM; Roscioli, E; Tedeschi, A; Mangiacasale, R; Ciciarello, M; Di Gioia, SA; Lavia, P				Rensen, W. M.; Roscioli, E.; Tedeschi, A.; Mangiacasale, R.; Ciciarello, M.; Di Gioia, S. A.; Lavia, P.			RanBP1 downregulation sensitizes cancer cells to taxol in a caspase-3-dependent manner	ONCOGENE			English	Article						RanBP1; mitotic spindle microtubules; taxol; apoptosis; RanGTPase; caspase-3	INDUCED APOPTOSIS; MITOTIC SPINDLE; BINDING PROTEIN-1; IMPORTIN-BETA; CYCLIN B; MICROTUBULES; GTPASE; CHECKPOINT; MITOSIS; ACTIVATION	Mitotic microtubule (MT)-targeting drugs are widely used to treat cancer. The GTPase Ran regulates multiple processes, including mitotic spindle assembly, spindle pole formation and MT dynamics; Ran activity is therefore essential to formation of a functional mitotic apparatus. The RanBP1 protein, which binds Ran and regulates its interaction with effectors, is overexpressed in many cancer types. Several observations indicate that RanBP1 contributes to regulate the function of the mitotic apparatus: RanBP1 inactivation yields hyperstable MTs and induces apoptosis during mitosis, reminiscent of the effects of the MT-stabilizing drug taxol. Here we have investigated the influence of RanBP1 on spontaneous and taxol-induced apoptosis in transformed cells. We report that RanBP1 downregulation by RNA interference activates apoptosis in several transformed cell lines regardless of their p53 status, but not in the caspase-3-defective MCF-7 breast cancer cell line. Furthermore, RanBP1-interfered cells show an increased apoptotic response to taxol compared to their counterpart with normal or high RanBP1 levels, and this response is caspase-3 dependent. These results indicate that RanBP1 can modulate the outcome of MT-targeting therapeutic protocols.	[Rensen, W. M.; Roscioli, E.; Tedeschi, A.; Mangiacasale, R.; Ciciarello, M.; Di Gioia, S. A.; Lavia, P.] Univ Roma La Sapienza, IBPM Inst Mol Biol & Pathol, CNR Natl Res Council, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Lavia, P (corresponding author), Univ Roma La Sapienza, IBPM Inst Mol Biol & Pathol, CNR Natl Res Council, Via Apuli 4, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it	Lavia, Patrizia/AAL-3982-2021; Ciciarello, Marilena/AAA-7950-2022; Lavia, Patrizia/J-5793-2019; Ciciarello, Marilena/A-4401-2015	Ciciarello, Marilena/0000-0002-4744-507X; Lavia, Patrizia/0000-0003-3310-6701; Tedeschi, Antonio/0000-0001-7276-4550; Di Gioia, Silvio Alessandro/0000-0002-7235-5682	Italian Association for Cancer Research ( AIRC); MIUR-FIRB [RBIN04T7MT]; AIRC; ER; MIUR-FIRB	Italian Association for Cancer Research ( AIRC)(Fondazione AIRC per la ricerca sul cancro); MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); AIRC(Fondazione AIRC per la ricerca sul cancro); ER; MIUR-FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB))	We thank Dr Christopher J Froelich (Northwestern University Medical School, Evanston, IL) for gifting the MCF-7/casp-3 cell line. We also thank Dr Giulia Guarguaglini for discussions and advice. This work was supported by the Italian Association for Cancer Research (AIRC) and by MIUR-FIRB ( grant RBIN04T7MT). WMR and MC were supported by AIRC, ER and RM by MIUR-FIRB research contracts.	Abe H, 2008, INT J CANCER, V122, P2391, DOI 10.1002/ijc.23400; Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Alli E, 2002, CANCER RES, V62, P6864; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Battistoni A, 1997, J CELL SCI, V110, P2345; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bhat KMR, 2007, CLIN CANCER RES, V13, P2849, DOI 10.1158/1078-0432.CCR-06-3040; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BRITO DA, 2008, CELL MOTIL CYTOSKELE; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; Ciciarello M, 2004, J CELL SCI, V117, P6511, DOI 10.1242/jcs.01569; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; De Luca A, 2003, CANCER RES, V63, P1430; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Di Fiore B, 2004, CELL CYCLE, V3, P305; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; DIMATTEO G, 1995, CELL GROWTH DIFFER, V6, P1213; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Giodini A, 2002, CANCER RES, V62, P2462; Gorlich D, 2003, EMBO J, V22, P1088, DOI 10.1093/emboj/cdg113; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Holland AJ, 2008, CANCER CELL, V14, P103, DOI 10.1016/j.ccr.2008.07.010; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Iancu C, 2000, CANCER RES, V60, P3537; Iancu C, 2001, J CELL SCI, V114, P909; Ibrado AM, 1998, LEUKEMIA, V12, P1930, DOI 10.1038/sj.leu.2401218; Impens F, 2008, ONCOGENE, V27, P4580, DOI 10.1038/onc.2008.96; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jiang Y, 2003, ONCOGENE, V22, P8293, DOI 10.1038/sj.onc.1206873; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kurisetty VV, 2008, ONCOGENE, V27, P7139, DOI 10.1038/onc.2008.325; Li HY, 2007, CELL CYCLE, V6, P1886, DOI 10.4161/cc.6.15.4487; Lu KH, 2005, J ORTHOP RES, V23, P988, DOI 10.1016/j.orthres.2005.01.018; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Perez de Castro I, 2007, CARCINOGENESIS, V28, P899, DOI 10.1093/carcin/bgm019; Plafker K, 2000, MOL CELL BIOL, V20, P3510, DOI 10.1128/MCB.20.10.3510-3521.2000; Rensen WM, 2008, FRONT BIOSCI-LANDMRK, V13, P4097, DOI 10.2741/2996; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Spankuch B, 2007, ONCOGENE, V26, P5793, DOI 10.1038/sj.onc.1210355; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Tanaka E, 2007, CLIN CANCER RES, V13, P1331, DOI 10.1158/1078-0432.CCR-06-1192; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wong J, 2006, J CELL BIOL, V173, P879, DOI 10.1083/jcb.200511132; Xia F, 2008, MOL CELL BIOL, V28, P5299, DOI 10.1128/MCB.02039-07; Xia F, 2008, CANCER RES, V68, P1826, DOI 10.1158/0008-5472.CAN-07-5279; Yamada HY, 2006, MOL CANCER THER, V5, P2963, DOI 10.1158/1535-7163.MCT-06-0319; Yang XH, 2001, CANCER RES, V61, P348; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202	70	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1748	1758		10.1038/onc.2009.24	http://dx.doi.org/10.1038/onc.2009.24			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270727	Bronze			2022-12-28	WOS:000265640400002
J	Pradelli, LA; Beneteau, M; Chauvin, C; Jacquin, MA; Marchetti, S; Munoz-Pinedo, C; Auberger, P; Pende, M; Ricci, JE				Pradelli, L. A.; Beneteau, M.; Chauvin, C.; Jacquin, M. A.; Marchetti, S.; Munoz-Pinedo, C.; Auberger, P.; Pende, M.; Ricci, J-E			Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation	ONCOGENE			English	Article						apoptosis; protein translation; glycolysis; AMPK; mTOR; Mcl-1	POSITRON-EMISSION-TOMOGRAPHY; CANCER-THERAPY; GLUCOSE-METABOLISM; EXPRESSION; SURVIVAL; TRAIL; NECROSIS; MTOR; AKT; MODULATION	Most cancer cells exhibit increased glycolysis for generation of their energy supply. This specificity could be used to preferentially kill these cells. In this study, we identified the signaling pathway initiated by glycolysis inhibition that results in sensitization to death receptor (DR)-induced apoptosis. We showed, in several human cancer cell lines (such as Jurkat, HeLa, U937), that glucose removal or the use of nonmetabolizable form of glucose (2-deoxyglucose) dramatically enhances apoptosis induced by Fas or by tumor necrosis factor-related apoptosis-inducing ligand. This sensitization is controlled through the adenosine monophosphate (AMP)-activated protein kinase (AMPK), which is the central energy-sensing system of the cell. We established the fact that AMPK is activated upon glycolysis block resulting in mammalian target of rapamycin (mTOR) inhibition leading to Mcl-1 decrease, but no other Bcl-2 anti-apoptotic members. Interestingly, we determined that, upon glycolysis inhibition, the AMPK-mTOR pathway controlled Mcl-1 levels neither through transcriptional nor through posttranslational mechanism but rather by controlling its translation. Therefore, our results show a novel mechanism for the sensitization to DR-induced apoptosis linking glucose metabolism to Mcl-1 down-expression. In addition, this study provides a rationale for the combined use of DR ligands with AMPK activators or mTOR inhibitors in the treatment of human cancers. Oncogene (2010) 29, 1641-1652; doi:10.1038/onc.2009.448; published online 7 December 2009	[Pradelli, L. A.; Beneteau, M.; Jacquin, M. A.; Ricci, J-E] Fac Med Nice, INSERM, Equipe AVENIR 3, U895,C3M, F-06107 Nice 2, France; [Pradelli, L. A.; Beneteau, M.; Jacquin, M. A.; Marchetti, S.; Auberger, P.; Ricci, J-E] Univ Nice Sophia Antipolis, Nice, France; [Chauvin, C.; Pende, M.] INSERM, U845, Paris, France; [Chauvin, C.; Pende, M.] Univ Paris 05, Fac Med, UMRS 845, Paris, France; [Munoz-Pinedo, C.] Inst Invest Biomed Bellvitge IDIBELL, Ctr Mol Oncol, Barcelona, Spain; [Marchetti, S.; Auberger, P.] Fac Med Nice, INSERM, Equipe 2, U895,C3M, F-06034 Nice, France; [Ricci, J-E] Ctr Hosp Univ Nice, Dept Anesthesie Reanimat, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ricci, JE (corresponding author), Fac Med Nice, INSERM, Equipe AVENIR 3, U895,C3M, 28 Ave Valombrose, F-06107 Nice 2, France.	ricci@unice.fr	AUBERGER, Patrick/G-1491-2013; Pende, Mario/AFR-1348-2022; Munoz-Pinedo, Cristina/B-6118-2008; Ricci, Jean Ehrland/I-7117-2016; Marchetti, Sandrine/P-6479-2016; RICCI, Jean Ehrland/AAS-4379-2020	AUBERGER, Patrick/0000-0002-2481-8275; Pende, Mario/0000-0002-7864-8937; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Ricci, Jean Ehrland/0000-0003-1585-8117; Marchetti, Sandrine/0000-0001-8326-5730; RICCI, Jean Ehrland/0000-0003-1585-8117	Association pour la Recherche sur le Cancer; l'Agence Nationale de la Recherche [ANR-09-JCJC-0003-01]; Conseil regional Provence-Alpes-Cote-d'Azur; La Fondation de France; Fondo de Investigaciones Sanitarias of Spain; INSERM-CHU de Nice	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); l'Agence Nationale de la Recherche(French National Research Agency (ANR)); Conseil regional Provence-Alpes-Cote-d'Azur(Region Provence-Alpes-Cote d'AzurRegion Auvergne-Rhone-Alpes); La Fondation de France(Fondation de France); Fondo de Investigaciones Sanitarias of Spain(Instituto de Salud Carlos III); INSERM-CHU de Nice(Institut National de la Sante et de la Recherche Medicale (Inserm))	We thank Magali Herrant for her input, Audrey Paul and Celine Gracia for their technical assistance, Issam Ben Sahra, Vanessa Lavallard and Drs Anne-Odile Hueber, Frederic Bost, Stephane Rocchi and Marcel Deckert for providing tools and advises, Dr Ulrich Maurer for providing GSK3 inhibitor and Dr DR Green for Bcl-2 overexpressing Jurkat cells. This study was supported by the Association pour la Recherche sur le Cancer and by l'Agence Nationale de la Recherche (ref ANR-09-JCJC-0003-01). LAP and MAJ received a fellowship from the Conseil regional Provence-Alpes-Cote-d'Azur. MB is supported by a fellowship from La Fondation de France, CM-P is supported by the Fondo de Investigaciones Sanitarias of Spain and J-ER is a recipient of a contrat d'interface INSERM-CHU de Nice.	Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; Detterbeck FC, 2004, CHEST, V126, P1656, DOI 10.1378/chest.126.5.1656; Eguchi Y, 1997, CANCER RES, V57, P1835; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; HALICKA HD, 1995, CANCER RES, V55, P444; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Kruyt FAE, 2008, CANCER LETT, V263, P14, DOI 10.1016/j.canlet.2008.02.003; Lavallard VJ, 2009, CANCER RES, V69, P3013, DOI 10.1158/0008-5472.CAN-08-2731; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Marchetti S, 2009, EMBO J, V28, P2449, DOI 10.1038/emboj.2009.183; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VOLLAND S, 1992, INT J CANCER, V52, P384, DOI 10.1002/ijc.2910520310; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	38	105	113	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1641	1652		10.1038/onc.2009.448	http://dx.doi.org/10.1038/onc.2009.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966861				2022-12-28	WOS:000275694700009
J	Guilmeau, S; Flandez, M; Mariadason, JM; Augenlicht, LH				Guilmeau, S.; Flandez, M.; Mariadason, J. M.; Augenlicht, L. H.			Heterogeneity of Jagged1 expression in human and mouse intestinal tumors: implications for targeting Notch signaling	ONCOGENE			English	Article						Jagged1; Notch signaling; colon cancer	PROGENITOR CELLS; CANCER; GENES; LINE; WNT; APC; DIFFERENTIATION; INACTIVATION; REQUIREMENT; SUPPRESSOR	Inhibition of Notch signaling is effective in inhibiting colon tumorigenesis, but targeting specific components of the pathway may provide more effective strategies. Here we show that the expression of Jagged1, a ligand for canonical Notch signaling, was restricted to enteroendocrine cells or undetectable in the mucosa of the human small and large intestine, respectively. In contrast, increased expression characterized half of human colon tumors, although not all tumors with elevated Wnt signaling displayed elevated Jagged1. Increased Jagged1 was also present in intestinal tumors of Apc(1638N/+) and Apc(Min/+) mice, but to a higher level and more frequently in the former, and in 90% of mouse tumors Notch signaling was elevated when Jagged1 was elevated. In the human HT29Cl16E colonic carcinoma cell line, induction of goblet cell differentiation by contact inhibition of growth depended on the loss of Jagged1-mediated Notch activation, with signaling through Notch1 and Notch2 acting redundantly. Therefore, targeting of Jagged1 could be effective in downregulating Notch signaling in a subset of tumors, but may avoid the limiting gastrointestinal toxicity caused by pharmacological inhibition of Notch signaling. Oncogene (2010) 29, 992-1002; doi:10.1038/onc.2009.393; published online 23 November 2009	[Guilmeau, S.; Flandez, M.; Mariadason, J. M.; Augenlicht, L. H.] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Guilmeau, S (corresponding author), INSERM, Dept Endocrinol Canc & Metab, U567, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	sandra.guilmeau@inserm.fr	Mariadason, John/N-2003-2013; Canet, Marta Flández/E-2681-2019; Guilmeau, Sandra/P-2318-2017	Canet, Marta Flández/0000-0002-9096-2267; Mariadason, John/0000-0001-9123-7684; Guilmeau, Sandra/0000-0002-8260-1218	NCI [RO1 CA114265, U54 CA100926]; Philippe Foundation; NATIONAL CANCER INSTITUTE [R01CA114265, U54CA100926] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Philippe Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T Sudo (Toray Industries Inc., Kamakura, Japan) for sharing the Hes1 antibody, and Pamela Stanley (Albert Einstein College Medicine, Bronx, NY, USA) for the TP1-Luc plasmid. We are grateful to A Velcich and L Klampfer for helpful comments. This work was supported by NCI Grants RO1 CA114265 and U54 CA100926 to LH Augenlicht, and by the Philippe Foundation.	Akiyoshi T, 2008, GASTROENTEROLOGY, V134, P131, DOI 10.1053/j.gastro.2007.10.008; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; AUGERON C, 1984, CANCER RES, V44, P3961; Estrach S, 2006, DEVELOPMENT, V133, P4427, DOI 10.1242/dev.02644; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Fre S, 2008, ADV CANCER RES, V100, P85, DOI 10.1016/S0065-230X(08)00003-1; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Ghaleb AM, 2008, MOL CANCER RES, V6, P1920, DOI 10.1158/1541-7786.MCR-08-0224; Guilmeau S, 2008, GASTROENTEROLOGY, V135, P849, DOI 10.1053/j.gastro.2008.05.050; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Katoh M, 2006, INT J MOL MED, V17, P681; LABURTHE M, 1989, AM J PHYSIOL, V256, pG443, DOI 10.1152/ajpgi.1989.256.3.G443; LEVY DB, 1994, CANCER RES, V54, P5953; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MERLIN D, 1994, J MEMBRANE BIOL, V137, P137; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Sander GR, 2004, J HISTOCHEM CYTOCHEM, V52, P509, DOI 10.1177/002215540405200409; Shroyer NF, 2007, GASTROENTEROLOGY, V132, P2478, DOI 10.1053/j.gastro.2007.03.047; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Stanger BZ, 2005, P NATL ACAD SCI USA, V102, P12443, DOI 10.1073/pnas.0505690102; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Velcich A, 2005, EXP CELL RES, V304, P28, DOI 10.1016/j.yexcr.2004.10.014; Wheeler JMD, 2002, GUT, V50, P218, DOI 10.1136/gut.50.2.218; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zheng JL, 2000, DEVELOPMENT, V127, P4551	36	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					992	1002		10.1038/onc.2009.393	http://dx.doi.org/10.1038/onc.2009.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935714				2022-12-28	WOS:000274604400006
J	Scheller, H; Tobollik, S; Kutzera, A; Eder, M; Unterlehberg, J; Pfeil, I; Jungnickel, B				Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.			c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma	ONCOGENE			English	Article						somatic hypermutation; germinal center; Burkitt's lymphoma; c-Myc	INDUCED CYTIDINE DEAMINASE; B-CELL LYMPHOMAS; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN ENHANCERS; ANTIGEN RECEPTOR; ACTIVATION; GENE; EXPRESSION; BCL-6; REGION	The germinal center (GC) reaction has a pivotal function in human B-cell lymphomagenesis. Genetic aberrations occurring during somatic hypermutation and class switch recombination deregulate key factors controlling B-cell physiology and proliferation. Several human lymphoma entities are characterized by a constitutive GC phenotype and ongoing somatic hypermutation, but the molecular basis for this phenomenon is only partly understood. We have investigated the reasons for a constitutive GC-like program in Burkitt's lymphoma cells. Here, overexpression of c-Myc leads to a centroblast phenotype, promotes high constitutive expression of the key GC factors Bcl-6, E2A and activation-induced cytidine deaminase and contributes to proliferation and somatic hypermutation. Our findings elucidate how the activity of a pivotal transcription factor may freeze B-cell lymphoma cells in a constitutive GC-like state that is even maintained at an extrafollicular location. Oncogene (2010) 29, 888-897; doi:10.1038/onc.2009.377; published online 2 November 2009	[Scheller, H.; Tobollik, S.; Kutzera, A.; Eder, M.; Unterlehberg, J.; Pfeil, I.; Jungnickel, B.] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Jungnickel, B (corresponding author), German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol, Marchioninistr 25, D-81377 Munich, Germany.	jungnickel@helmholtz-muenchen.de	Scheller, Henrik/AAH-4770-2020; Jungnickel, Berit/AAU-5297-2021	Scheller, Henrik/0000-0002-6702-3560; 	German Jose Carreras Leukemia Foundation [SP/03/10, R05/10v]; Wilhelm Sander foundation [2003.046.2]; Deutsche Forschungsgemeinschaft [TRR54-TPA4]	German Jose Carreras Leukemia Foundation; Wilhelm Sander foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Sabine Fischer-Burkart for expert technical assistance, Torsten Thiel for contributions to the RNAi system, Maren Mierau and Dirk Eick for discussion and support, and Ursula Zimber-Strobl, Georg Bornkamm and Ralf Kuppers for critical reading of the manuscript. This work was supported by grants from the German Jose Carreras Leukemia Foundation (SP/03/10 and R05/10v), the Wilhelm Sander foundation (2003.046.2) and the Deutsche Forschungsgemeinschaft (TRR54-TPA4).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; Bachl J, 1999, EUR J IMMUNOL, V29, P1383, DOI 10.1002/(SICI)1521-4141(199904)29:04<1383::AID-IMMU1383>3.3.CO;2-O; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chapman CJ, 1998, LEUKEMIA LYMPHOMA, V30, P257, DOI 10.3109/10428199809057539; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; JOHNSTON JM, 1991, BLOOD, V78, P2419; Khuda SE, 2008, J IMMUNOL, V181, P7537, DOI 10.4049/jimmunol.181.11.7537; KLEIN U, 1995, MOL MED, V1, P495, DOI 10.1007/BF03401587; Klein U, 2003, P NATL ACAD SCI USA, V100, P2639, DOI 10.1073/pnas.0437996100; Klein U, 1998, IMMUNOL REV, V162, P261; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Lee SC, 2006, MOL IMMUNOL, V43, P1965, DOI 10.1016/j.molimm.2005.11.017; Liu M, 2008, NATURE, V451, P841, DOI 10.1038/nature06547; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Mierau M, 2008, NUCLEIC ACIDS RES, V36, P5591, DOI 10.1093/nar/gkn542; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Ruckerl F, 2006, MOL IMMUNOL, V43, P1645, DOI 10.1016/j.molimm.2005.09.011; Rutherford MN, 1998, AM J PATHOL, V153, P165, DOI 10.1016/S0002-9440(10)65557-5; Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011; Sayegh CE, 2003, NAT IMMUNOL, V4, P586, DOI 10.1038/ni923; Schoetz U, 2006, J IMMUNOL, V177, P395, DOI 10.4049/jimmunol.177.1.395; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Teng G, 2008, IMMUNITY, V28, P621, DOI 10.1016/j.immuni.2008.03.015; Thorley-Lawson DA, 2008, NAT REV MICROBIOL, V6, P913, DOI 10.1038/nrmicro2015; Toyama H, 2002, IMMUNITY, V17, P329, DOI 10.1016/S1074-7613(02)00387-4; Wagner SD, 2007, LEUKEMIA LYMPHOMA, V48, P1510, DOI 10.1080/10428190701458491; Wang CL, 2005, J IMMUNOL, V174, P5650, DOI 10.4049/jimmunol.174.9.5650; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zhang W, 2001, INT IMMUNOL, V13, P1175, DOI 10.1093/intimm/13.9.1175	51	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					888	897		10.1038/onc.2009.377	http://dx.doi.org/10.1038/onc.2009.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19881537				2022-12-28	WOS:000274397800011
J	Villaronga, MA; Lavery, DN; Bevan, CL; Llanos, S; Belandia, B				Villaronga, M. A.; Lavery, D. N.; Bevan, C. L.; Llanos, S.; Belandia, B.			HEY1 Leu94Met gene polymorphism dramatically modifies its biological functions	ONCOGENE			English	Article						HEY1; androgen receptor; p53; Notch; single-nucleotide polymorphism	MESENCHYMAL TRANSITION; SIGNALING PATHWAYS; PROSTATE-CANCER; NOTCH PATHWAY; TARGET GENES; P53; CELLS; GROWTH; HERP; DIFFERENTIATION	The hairy/enhancer-of-split related with YRPW motif 1 (HEY1) is a member of the basic-helix-loop-helix-Orange (bHLH-O) family of transcriptional repressors that mediate Notch signaling. Several cancer-related pathways also regulate HEY1 expression, and HEY1 itself acts as an indirect positive regulator of the p53 tumor suppressor protein and a negative regulator of androgen receptor activity. In this study we show how a naturally occurring non-synonymous polymorphism at codon 94 of HEY1, which results in a substitution of leucine by methionine (Leu94Met), converts HEY1 from an androgen receptor corepressor to an androgen receptor co-activator without affecting its intrinsic transcriptional repressive domains. The polymorphism Leu94Met also abolishes HEY1-mediated activation of p53 and suppresses the ability of HEY1 to induce p53-dependent cell-cycle arrest and aberrant cell differentiation in human osteosarcoma U2OS cells. Moreover, expression of HEY1, but not of the variant Leu94Met, confers sensitivity to p53-activating chemotherapeutic drugs on U2OS cells. In addition, we have identified motifs in HEY1 that are critical for the regulation of its subcellular localization and analysed how mutations in those motifs affect both HEY1 and HEY1-Leu94Met functions. These findings suggest that the polymorphism Leu94Met in HEY1 radically alters its biological activities and may affect oncogenic processes. Oncogene (2010) 29, 411-420; doi:10.1038/onc.2009.309; published online 5 October 2009	[Villaronga, M. A.; Belandia, B.] Univ Autonoma Madrid, CSIC, Dept Canc Biol, Inst Invest Biomed, Madrid 28029, Spain; [Lavery, D. N.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Oncol, Androgen Signalling Lab, London, England; [Llanos, S.] Spanish Natl Canc Res Ctr CNIO, Tumor Suppress Grp, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London; Centro Nacional de Investigaciones Oncologicas (CNIO)	Belandia, B (corresponding author), Univ Autonoma Madrid, CSIC, Dept Canc Biol, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	sllanos@cnio.es; bbelandia@iib.uam.es	Bevan, Charlotte L/K-2276-2012; Belandia, Borja/H-1509-2015; Lavery, Derek/C-6706-2011; , Susana/AAA-9282-2019; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Belandia, Borja/0000-0003-2448-206X; Llanos, Susana/0000-0002-8555-9326	MICINN [SAF2007-62642, SAF2006-07785]; Fundacion de Investigacion Medica Mutua Madrilena; FIS [RD06/0020/0036]; CRESCENDO [FP-018652]; Cancer Research UK [C11509/A8570]	MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Fundacion de Investigacion Medica Mutua Madrilena; FIS(Instituto de Salud Carlos III); CRESCENDO(European Commission); Cancer Research UK(Cancer Research UK)	We thank Ana Aranda for her continuous support and Linn Markert for technical assistance. This study was supported by the MICINN (SAF2007-62642, SAF2006-07785), the Fundacion de Investigacion Medica Mutua Madrilena, the FIS (RD06/0020/0036), the CRESCENDO (FP-018652) and Cancer Research UK (C11509/A8570).	Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fuke S, 2005, J BIOCHEM, V137, P205, DOI 10.1093/jb/mvi020; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Giovannini C, 2009, J HEPATOL, V50, P969, DOI 10.1016/j.jhep.2008.12.032; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Hulleman E, 2009, J CELL MOL MED, V13, P136, DOI 10.1111/j.1582-4934.2008.00307.x; Hunter KW, 2006, CANCER RES, V66, P1251, DOI 10.1158/0008-5472.CAN-05-3705; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Leong KG, 2008, DIFFERENTIATION, V76, P699, DOI 10.1111/j.1432-0436.2008.00288.x; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pietsch EC, 2006, ONCOGENE, V25, P1602, DOI 10.1038/sj.onc.1209367; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Satow T, 2001, J NEUROSCI, V21, P1265; Sivertsen EA, 2007, EUR J IMMUNOL, V37, P2937, DOI 10.1002/eji.200636759; Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Villaronga MA, 2008, CURR CANCER DRUG TAR, V8, P566, DOI 10.2174/156800908786241096; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang YX, 2006, INT J CANCER, V119, P2071, DOI 10.1002/ijc.22077	36	21	21	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					411	420		10.1038/onc.2009.309	http://dx.doi.org/10.1038/onc.2009.309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19802006	Green Accepted, Green Published			2022-12-28	WOS:000273793200010
J	Monsel, G; Ortonne, N; Bagot, M; Bensussan, A; Dumaz, N				Monsel, G.; Ortonne, N.; Bagot, M.; Bensussan, A.; Dumaz, N.			c-Kit mutants require hypoxia-inducible factor 1 alpha to transform melanocytes	ONCOGENE			English	Article						c-Kit; imatinib; MAPK pathway; melanoma; PI3K/Akt pathway	TYROSINE KINASE; FACTOR-RECEPTOR; MELANOMA-CELLS; INHIBITION; ACTIVATION; IMATINIB; MUTATION; EXPRESSION; ONCOGENE; SURVIVAL	Many studies have highlighted the critical role of c-Kit in normal melanocyte development but its role in melanoma development remains unclear. Although c-Kit expression is often lost during melanoma progression, a subset of melanoma has been found to overexpress c-Kit and mutations activating c-Kit have recently been identified in some acral and mucosal melanoma. To address the role of these c-Kit mutants in the transformation of melanocytes, we characterized the physiological responses of melanocytes expressing the most frequent c-Kit mutants found in melanoma (K642E and L576P) and a novel mutant we identified in an acral melanoma. We analysed signaling pathways activated downstream of c-Kit and showed that all three mutants led to a strong activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway but only weak activation of the Ras/Raf/Mek/Erk pathway, which was not sufficient to promote uncontrolled melanocyte proliferation and transformation. However, in hypoxic conditions or coexpressed with a constitutively active form of hypoxia-inducible factor 1 alpha (HIF-1 alpha), c-Kit mutants activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes. Proliferation of melanocytes transformed by these mutants was specifically inhibited by imatinib. These results show for the first time that melanocytes require a specific epigenetic environment to be transformed by c-Kit mutants and highlight a distinct molecular mechanism of melanocyte transformation. Oncogene (2010) 29, 227-236; doi:10.1038/onc.2009.320; published online 5 October 2009	[Monsel, G.; Ortonne, N.; Bagot, M.; Bensussan, A.; Dumaz, N.] Hop St Louis, INSERM, U976, F-75475 Paris 10, France; [Ortonne, N.] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, Creteil, France; [Bagot, M.; Bensussan, A.] Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Dermatol, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Dumaz, N (corresponding author), Hop St Louis, INSERM, U976, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	nicolas.dumaz@inserm.fr	Dumaz, Nicolas/B-5907-2008; Bensussan, Armand/E-5434-2017	Dumaz, Nicolas/0000-0003-3511-2160; Bensussan, Armand/0000-0002-0409-2497	INSERM; Universite Paris XII, Societe Francaise de Dermatologie; Ligue Contre le Cancer (Comite du Val de Marne); Institut National du Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris XII, Societe Francaise de Dermatologie; Ligue Contre le Cancer (Comite du Val de Marne); Institut National du Cancer(Institut National du Cancer (INCA) France)	We thank Professor Richard Marais for 501mel cells and pMCEF vector, Dr Lars Ronnstrand for a wild-type c-Kit expression vector and Dr Frank Bunn for the vector expressing HIF-1 alpha (401 Delta 603). This work was funded by INSERM, Universite Paris XII, Societe Francaise de Dermatologie, Ligue Contre le Cancer (Comite du Val de Marne) and Institut National du Cancer.	Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Busca R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; LASSAM N, 1992, ONCOGENE, V7, P51; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Muchemwa FC, 2008, BRIT J DERMATOL, V158, P411, DOI 10.1111/j.1365-2133.2007.08292.x; NATALI PG, 1992, CANCER RES, V52, P6139; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200	25	59	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					227	236		10.1038/onc.2009.320	http://dx.doi.org/10.1038/onc.2009.320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802003				2022-12-28	WOS:000273650000006
J	Novakova, Z; Hubackova, S; Kosar, M; Janderova-Rossmeislova, L; Dobrovolna, J; Vasicova, P; Vancurova, M; Horejsi, Z; Hozak, P; Bartek, J; Hodny, Z				Novakova, Z.; Hubackova, S.; Kosar, M.; Janderova-Rossmeislova, L.; Dobrovolna, J.; Vasicova, P.; Vancurova, M.; Horejsi, Z.; Hozak, P.; Bartek, J.; Hodny, Z.			Cytokine expression and signaling in drug-induced cellular senescence	ONCOGENE			English	Article						cytokines; JAK/STAT signaling; interleukins; cellular senescence; 5-bromo-2 '-deoxyuridine; distamycin A	ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE RESPONSE; TUMOR SUPPRESSION; PML PROTEIN; HUMAN-CELLS; HELA-CELLS; CANCER; PATHWAY; STRESS; INDUCTION	Cellular senescence guards against cancer and modulates aging; however, the underlying mechanisms remain poorly understood. Here, we show that genotoxic drugs capable of inducing premature senescence in normal and cancer cells, such as 5-bromo-2'-deoxyuridine (BrdU), distamycin A (DMA), aphidicolin and hydroxyurea, persistently activate Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling and expression of interferon-stimulated genes (ISGs), such as MX1, OAS, ISG15, STAT1, PML, IRF1 and IRF7, in several human cancer cell lines. JAK1/STAT-activating ligands, interleukin 10 (IL10), IL20, IL24, interferon gamma (IFN gamma), IFN beta and IL6, were also expressed by senescent cells, supporting autocrine/paracrine activation of JAK1/STAT. Furthermore, cytokine genes, including proinflammatory IL1, tumor necrosis factor and transforming growth factor families, were highly expressed. The strongest inducer of JAK/STAT signaling, cytokine production and senescence was BrdU combined with DMA. RNA interference-mediated knockdown of JAK1 abolished expression of ISGs, but not DNA damage signaling or senescence. Thus, although DNA damage signaling, p53 and RB activation, and the cytokine/chemokine secretory phenotype are apparently shared by all types of senescence, our data reveal so far unprecedented activation of the IFN beta-STAT1-ISGs axis, and indicate a less prominent causative role of IL6-JAK/STAT signaling in genotoxic drug-induced senescence compared with reports on oncogene-induced or replicative senescence. These results highlight shared and unique features of drug-induced cellular senescence, and implicate induction of cancer secretory phenotype in chemotherapy. Oncogene (2010) 29, 273-284; doi:10.1038/onc.2009.318; published online 5 October 2009	[Novakova, Z.; Hubackova, S.; Kosar, M.; Vancurova, M.; Bartek, J.; Hodny, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Genome Integr, CR-14220 Prague, Czech Republic; [Novakova, Z.; Janderova-Rossmeislova, L.; Dobrovolna, J.; Hozak, P.; Hodny, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Biol Cell Nucleus, CR-14220 Prague, Czech Republic; [Vasicova, P.] Acad Sci Czech Republ, Inst Microbiol, Vvi, Lab Cell Reprod, CR-14220 Prague, Czech Republic; [Horejsi, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Mol Virol, CR-14220 Prague, Czech Republic; [Bartek, J.] Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen O, Denmark; [Bartek, J.] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Res, DK-2100 Copenhagen O, Denmark	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Danish Cancer Society; Danish Cancer Society	Hodny, Z (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Genome Integr, Videnska 1083, CR-14220 Prague, Czech Republic.	jb@cancer.dk; hodny@img.cas.cz	Dobrovolna, Jana/G-5873-2014; Hodny, Zdenek/C-9384-2009; Bartek, Jiri/G-5870-2014; Vasicova, Pavla/I-2010-2014; Hozak, Pavel/AAB-5359-2021; Vasicova, Pavla/AAL-6466-2021; Rossmeislová, Lenka/D-1931-2013; Novakova, Zora/G-8665-2014; Kosar, Martin/B-7143-2018; Hozak, Pavel/J-4182-2014	Hozak, Pavel/0000-0003-1901-1394; Rossmeislová, Lenka/0000-0002-7611-7585; Novakova, Zora/0000-0001-9804-6346; Kosar, Martin/0000-0002-9400-2327; Hozak, Pavel/0000-0003-1901-1394; Vasicova, Pavla/0000-0002-9733-9929; Stemberkova Hubackova, Sona/0000-0002-3454-6840; Dobrovolna, Jana/0000-0003-2412-2080; Licenikova Horejsi, Zuzana/0000-0002-9943-1649	Agency of the Academy of Sciences of the Czech Republic [IAA500390501]; Grant Agency of the Czech Republic [204/08/1418]; European Commission [TRIREME]; Ministry of Education, Youth and Sports of the Czech Republic [LC545]; Institutional Grant [AV0Z5039906]	Agency of the Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); European Commission(European CommissionEuropean Commission Joint Research Centre); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Institutional Grant	We thank Ondrej Horvath and Michal Koc for assistance, and Jan Fric and Ondrej Stanek for help with ELISA. This work was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (Project IAA500390501), the Grant Agency of the Czech Republic (Project 204/08/1418), the European Commission (project TRIREME), Grant LC545 of the Ministry of Education, Youth and Sports of the Czech Republic, and the Institutional Grant (Project AV0Z5039906).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chang BD, 1999, CANCER RES, V59, P3761; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Engstrom JU, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199/8/9; Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Janderovd-Rossmeislova L, 2007, J STRUCT BIOL, V159, P56, DOI 10.1016/j.jsb.2007.02.008; Kaynor C, 2002, J INTERF CYTOK RES, V22, P1089, DOI 10.1089/10799900260442511; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michishita E, 1999, J BIOCHEM-TOKYO, V126, P1052; Minagawa S, 2005, EXP CELL RES, V304, P552, DOI 10.1016/j.yexcr.2004.10.036; Moiseeva O, 2006, MOL BIOL CELL, V17, P1583, DOI 10.1091/mbc.E05-09-0858; Mushinski JF, 2009, J BIOL CHEM, V284, P15206, DOI 10.1074/jbc.M806324200; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Suzuki T, 2002, EXP CELL RES, V276, P174, DOI 10.1006/excr.2002.5524; Suzuki T, 2001, EXP CELL RES, V266, P53, DOI 10.1006/excr.2001.5194; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Toussaint O, 2002, BIOCHEM PHARMACOL, V64, P1007, DOI 10.1016/S0006-2952(02)01170-X; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Yogev O, 2006, J BIOL CHEM, V281, P34475, DOI 10.1074/jbc.M602865200	50	78	82	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					273	284		10.1038/onc.2009.318	http://dx.doi.org/10.1038/onc.2009.318			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802007				2022-12-28	WOS:000273650000010
J	Jacinto, FV; Ballestar, E; Esteller, M				Jacinto, F. V.; Ballestar, E.; Esteller, M.			Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation	ONCOGENE			English	Article						tumor suppressor genes; histone methyltransferase; DNA demethylating agents; CpG island; colon cancer	HUMAN CANCER; DEACETYLASE INHIBITION; COLORECTAL-CANCER; SET DOMAIN; METHYLATION; TRANSCRIPTION; PROTEINS; HYPERMETHYLATION; EPIGENETICS; PATTERNS	Understanding the mechanisms that link changes in DNA methylation with histone modifications is particularly relevant in the case of tumor suppressor genes that undergo transcriptional silencing in cancer cells in association with promoter CpG island hypermethylation. In this study, we show that two histone lysine methylation marks associated with active transcription, dimethylation of H3K79 (H3K79me2) and trimethylation of H3K4 (H3K4me3), are present in all the unmethylated promoters analysed, and both of them are lost when these promoters become hypermethylated. Most importantly, pharmacological and genetic interventions that cause DNA demethylation and partial recovery of gene transcription, result in the restoration of H3K4me3, but not of H3K79me2. We also show that DOT1L, the major H3K79 histone methyltransferase, is no longer recruited to the promoters that are demethylated after 5-azadeoxycytidine treatment or genetic deletion of DNA methyltransferases. Knock-down and transfection experiments for DOT1L show that this enzyme has a direct role in maintaining the euchromatic and active status of these genes when unmethylated. These findings suggest that DNA demethylating interventions alone are not able to restore a complete euchromatic status and a full transcriptional reactivation of the epigenetically silenced tumor suppressor genes, and reinforce the necessity of targeting multiple elements of the epigenetics machinery for a successful treatment of malignancies. Oncogene (2009) 28, 4212-4224; doi: 10.1038/onc.2009.267; published online 7 September 2009	[Jacinto, F. V.; Ballestar, E.; Esteller, M.] Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, Barcelona 8907, Catalonia, Spain; [Jacinto, F. V.] Univ Porto, Grad Program Areas Basic & Appl Biol, P-4100 Oporto, Portugal; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Universidade do Porto; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, 3rd Floor,Avda Gran Via 199-203,08907 Hosp Llobre, Barcelona 8907, Catalonia, Spain.	mesteller@iconcologia.net	Ballestar, Esteban/ABG-8561-2020; Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440	European Union [HEALTH-F2-2007-200620, LSHG-CT-2006-037415, FIS PI08 1345, I + D + I MCYT08-03]; Consolider [MEC09-05]; Departments of the Spanish Government; Health Department of the Catalan Government; Spanish Association Against Cancer (AECC); FCT (Portuguese Foundation for Science and Technology) [SFRH/BD/11757/2003]; ICREA Funding Source: Custom	European Union(European Commission); Consolider(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Departments of the Spanish Government; Health Department of the Catalan Government; Spanish Association Against Cancer (AECC); FCT (Portuguese Foundation for Science and Technology)(Portuguese Foundation for Science and Technology); ICREA(ICREA)	We thank Dr Yi Zhang for providing us with the hDOT1L expression vector for the transfection experiments. Supported by the European Union Grants FP7 CANCERDIP (HEALTH-F2-2007-200620) and SMARTER (LSHG-CT-2006-037415), the Health (FIS PI08 1345) and Education and Science (I + D + I MCYT08-03 and Consolider MEC09-05) Departments of the Spanish Government, the Health Department of the Catalan Government and the Spanish Association Against Cancer (AECC). FVJ is funded by FCT (Portuguese Foundation for Science and Technology) SFRH/BD/11757/2003. ME is an ICREA (Institucio Catalana de Recerca i Estudis Avancats) Research Professor.	Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fahrner JA, 2002, CANCER RES, V62, P7213; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lopez-Serra L, 2008, BRIT J CANCER, V98, P1881, DOI 10.1038/sj.bjc.6604374; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nguyen CT, 2002, CANCER RES, V62, P6456; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010; Paz MF, 2003, CANCER RES, V63, P1114; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	30	28	29	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4212	4224		10.1038/onc.2009.267	http://dx.doi.org/10.1038/onc.2009.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734945				2022-12-28	WOS:000272876100007
J	Ong, DCT; Ho, YM; Rudduck, C; Chin, K; Kuo, WL; Lie, DKH; Chua, CLM; Tan, PH; Eu, KW; Seow-Choen, F; Wong, CY; Hong, GS; Gray, JW; Lee, ASG				Ong, D. C. T.; Ho, Y. M.; Rudduck, C.; Chin, K.; Kuo, W-L; Lie, D. K. H.; Chua, C. L. M.; Tan, P. H.; Eu, K. W.; Seow-Choen, F.; Wong, C. Y.; Hong, G. S.; Gray, J. W.; Lee, A. S. G.			LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer	ONCOGENE			English	Article						LARG; tumor suppressor; breast cancer; colorectal cancer	NUCLEOTIDE-EXCHANGE FACTORS; LEUKEMIA-ASSOCIATED RHOGEF; CELL LUNG-CANCER; PDZ DOMAINS; HETEROZYGOSITY; IDENTIFICATION; CARCINOMA; GENE; PROTEINS; DELETION	Deletion of 11q23-q24 is frequent in a diverse variety of malignancies, including breast and colorectal carcinoma, implicating the presence of a tumor suppressor gene at that chromosomal region. We examined a 6-Mb region on 11q23 by high-resolution deletion mapping, using both loss of heterozygosity analysis and customized microarray comparative genomic hybridization. LARG (leukemia-associated Rho guanine-nucleotide exchange factor) (also called ARHGEF12), identified from the analysed region, is frequently underexpressed in breast and colorectal carcinomas with a reduced expression observed in all breast cancer cell lines (n = 11), in 12 of 38 (32%) primary breast cancers, 5 of 10 (50%) colorectal cell lines and in 20 of 37 (54%) primary colorectal cancers. Underexpression of the LARG transcript was significantly associated with genomic loss (P = 0.00334). Hypermethylation of the LARG promoter was not detected in either breast or colorectal cancer, and treatment of four breast and four colorectal cancer cell lines with 5-aza-2'-deoxycytidine and/or trichostatin A did not result in a reactivation of LARG. Enforced expression of LARG in breast and colorectal cancer cells by stable transfection resulted in reduced cell proliferation and colony formation, as well as in a markedly slower cell migration rate in colorectal cancer cells, providing functional evidence for LARG as a candidate tumor suppressor gene. Oncogene (2009) 28, 4189-4200; doi: 10.1038/onc.2009.266; published online 7 September 2009	[Lee, A. S. G.] Natl Canc Ctr, Div Med Sci, Mol Oncol Lab, Singapore 169610, Singapore; [Rudduck, C.; Tan, P. H.] Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; [Chin, K.; Kuo, W-L; Gray, J. W.] Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Kuo, W-L; Gray, J. W.] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; [Eu, K. W.; Seow-Choen, F.] Singapore Gen Hosp, Dept Colorectal Surg, Singapore 0316, Singapore; [Wong, C. Y.; Hong, G. S.] Singapore Gen Hosp, Dept Gen Surg, Singapore 0316, Singapore; [Lee, A. S. G.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Singapore General Hospital; Singapore General Hospital; National University of Singapore	Lee, ASG (corresponding author), Natl Canc Ctr, Div Med Sci, Mol Oncol Lab, Singapore 169610, Singapore.	dmslsg@nccs.com.sg	Gray, Joe/AAX-9549-2020		National Medical Research Council (NMRC) of Singapore [NMRC/0076/1995, NMRC/0440/2000, NMRC/0570/2001, NMRC/0843/2004]; SingHealth Foundation [SHF/FG235P/2005]; Singapore Cancer Society; SGH Research Fund; Cancer Research Education Fund; NCC and Department of Clinical Research, SGH; US Department of Energy [DE-AC02-05CH11231, USAMRMC BC 061995]; National Institutes of Health, National Cancer Institute [P50 CA 58207, P50 CA 83639, P30 CA 82103, U54 CA 112970, U24 CA 126477, P01 CA 64602]; National Human Genome Research Institute [U24 CA 126551]; SmithKline Beecham Corporation; NATIONAL CANCER INSTITUTE [U24CA126551, P50CA058207, U54CA112970, P30CA082103, U24CA126477, P01CA064602, P50CA083639] Funding Source: NIH RePORTER	National Medical Research Council (NMRC) of Singapore(National Medical Research Council, Singapore); SingHealth Foundation(SingHealth); Singapore Cancer Society; SGH Research Fund; Cancer Research Education Fund; NCC and Department of Clinical Research, SGH; US Department of Energy(United States Department of Energy (DOE)); National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); SmithKline Beecham Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Glenn Koh for assistance with review of case notes; YC Seo, Angela Chang, S Tohari, Irene HK Lim and Gan Yar Chze for excellent technical assistance; and Dr Eric Yap for helpful discussions. This study was supported by Grants from the National Medical Research Council (NMRC) of Singapore (NMRC/0076/1995, NMRC/0440/2000, NMRC/0570/2001, NMRC/0843/2004); SingHealth Foundation (SHF/FG235P/2005); the Singapore Cancer Society, SGH Research Fund, Cancer Research Education Fund, NCC and Department of Clinical Research, SGH, to AL. We gratefully acknowledge the grant support from the US Department of Energy under Contract No. DE-AC02-05CH11231, USAMRMC BC 061995; National Institutes of Health, National Cancer Institute (P50 CA 58207, P50 CA 83639, P30 CA 82103, U54 CA 112970, U24 CA 126477 P01 CA 64602); National Human Genome Research Institute (U24 CA 126551) and SmithKline Beecham Corporation, to JWG.	Baffa R, 1996, CANCER RES, V56, P268; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Gabra H, 1996, CANCER RES, V56, P950; Harris BZ, 2001, J CELL SCI, V114, P3219; Hui ABY, 1996, CANCER RES, V56, P3225; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Koreth J, 1997, ONCOGENE, V14, P431, DOI 10.1038/sj.onc.1200847; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lee ASG, 2000, BRIT J CANCER, V83, P750, DOI 10.1054/bjoc.2000.1366; Lee ASG, 2004, CANCER GENET CYTOGEN, V153, P151, DOI 10.1016/j.cancergencyto.2004.01.007; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Martin B., 2003, ELECT J E GOVT, V1, P11; Massion PP, 2002, CANCER RES, V62, P3636; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; Plass C, 2002, HUM MOL GENET, V11, P2479, DOI 10.1093/hmg/11.20.2479; Pulido HA, 2000, CANCER RES, V60, P6677; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; RASIO D, 1995, CANCER RES, V55, P3988; Rice KL, 2007, ONCOGENE, V26, P6697, DOI 10.1038/sj.onc.1210755; Robertson G, 1996, CANCER RES, V56, P4487; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Smietana K, 2008, ACTA BIOCHIM POL, V55, P269, DOI 10.18388/abp.2008_3074; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424; Tomlinson IPM, 1996, J PATHOL, V180, P38, DOI 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Young Il Lee, 2003, International Journal of Control, Automation, and Systems, V1, P178	42	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4189	4200		10.1038/onc.2009.266	http://dx.doi.org/10.1038/onc.2009.266			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19734946	Green Accepted			2022-12-28	WOS:000272876100005
J	Farina, AR; Tacconelli, A; Cappabianca, L; Cea, G; Chioda, A; Romanelli, A; Pensato, S; Pedone, C; Gulino, A; Mackay, AR				Farina, A. R.; Tacconelli, A.; Cappabianca, L.; Cea, G.; Chioda, A.; Romanelli, A.; Pensato, S.; Pedone, C.; Gulino, A.; Mackay, A. R.			The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells	ONCOGENE			English	Article						neuroblastoma; TrkAI; TrkAIII; Hsp90; geldanamycin	ENDOPLASMIC-RETICULUM STRESS; NERVE GROWTH-FACTOR; CANCER CHEMOTHERAPEUTIC-AGENTS; PHASE-I; SOLID TUMORS; INHIBITOR GELDANAMYCIN; PEDIATRIC-PATIENTS; ADULT PATIENTS; CHAPERONE; RECEPTOR	Hsp90 chaperones stabilize many tyrosine kinases including several oncogenes, which are inhibited or induced to degrade by the Hsp90 inhibitor geldanamycin (GA). As a consequence, GA has been developed for future chemotherapeutic use in several tumour types including neuroblastoma (NB). Alternative splicing of the neurotrophin receptor tyrosine kinase TrkA may have a pivotal function in regulating NB behaviour, with reports suggesting that tumour-suppressing signals from TrkA may be converted to oncogenic signals by stress-regulated alternative TrkAIII splicing. Within this context, it is important to know whether Hsp90 interacts with TrkA variants in NB cells and how GA influences this. Here, we report that both TrkAI and TrkAIII are Hsp90 clients in human NB cells. TrkAI exhibits GA-sensitive interaction with Hsp90 required for receptor endoplasmic reticulum export, maturation, cell surface stabilization and ligand-mediated activation, whereas TrkAIII exhibits GA-sensitive interactions with Hsp90 required for spontaneous activity and to a lesser extent stability. We show that GA inhibits proliferation and induces apoptosis of TrkAI expressing NB cells, whereas TrkAIII reduces the sensitivity of NB cells to GA-induced elimination. Our data suggest that GA-sensitive interactions with Hsp90 are critical for both TrkAI tumour suppressor and TrkAIII oncogenic function in NB and that TrkAIII expression exerts a negative impact on GA-induced NB cell eradication, which can be counteracted by a novel TrkAIII-specific peptide nucleic acid inhibitor. Oncogene (2009) 28, 4075-4094; doi:10.1038/onc.2009.256; published online 7 September 2009	[Mackay, A. R.] Univ Aquila, Dept Expt Med, Sect Mol Pathol, I-67100 Laquila, AQ, Italy; [Romanelli, A.; Pensato, S.; Pedone, C.] Univ Naples Federico 2, Dept Biol Sci, Naples, Italy; [Gulino, A.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy	University of L'Aquila; University of Naples Federico II; Sapienza University Rome	Mackay, AR (corresponding author), Univ Aquila, Dept Expt Med, Sect Mol Pathol, Coppito 2,Via Vetoio, I-67100 Laquila, AQ, Italy.	andrewreay.mackay@univaq.it		ROMANELLI, Alessandra/0000-0002-7609-4061; cappabianca, lucia/0000-0002-9112-1750; FARINA, Antonietta Rosella/0000-0003-0962-6088; Mackay, Andrew Reay/0000-0001-7096-3759	AIRC; Progetto Speciale Ministero Della Sanita; MURST-Cofin; MIUR-CNR-Oncology; Center of Excellence BEMM	AIRC(Fondazione AIRC per la ricerca sul cancro); Progetto Speciale Ministero Della Sanita; MURST-Cofin(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); MIUR-CNR-Oncology(Ministry of Education, Universities and Research (MIUR)); Center of Excellence BEMM	We thank Dr Pyrwes (University of Michigan) for providing the 5xATF6GL3 reporter gene construct, Drs B Cinque, N Di Ianni and M Zani and post-graduate students Paolo Ciufici, Stefania Merolle and Marzia Ragone for technical assistance. This work was supported by AIRC, Progetto Speciale Ministero Della Sanita, MURST-Cofin, MIUR-CNR-Oncology project and Center of Excellence BEMM. We dedicate this work to all the students of L'Aquila University who lost their lives in the earthquake of L'Aquila, 6 April 2009.	Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Bagatell R, 2007, CLIN CANCER RES, V13, P1783, DOI 10.1158/1078-0432.CCR-06-1892; Becker B, 2004, EXP DERMATOL, V13, P27, DOI 10.1111/j.0906-6705.2004.00114.x; Bijlmakers MJJE, 2000, MOL BIOL CELL, V11, P1585, DOI 10.1091/mbc.11.5.1585; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Crevecoeur J, 2008, BIOCHEM PHARMACOL, V75, P2183, DOI 10.1016/j.bcp.2008.03.009; Dai Chengkai, 2005, Future Oncol, V1, P529; Eggert A, 2002, CANCER RES, V62, P1802; Erdmann F, 2007, FEBS LETT, V581, P5709, DOI 10.1016/j.febslet.2007.11.037; Escobar MA, 2005, J PEDIATR SURG, V40, P349, DOI 10.1016/j.jpedsurg.2004.10.032; Frey S, 2007, J BIOL CHEM, V282, P35612, DOI 10.1074/jbc.M704647200; Geetha T, 2008, TRAFFIC, V9, P1146, DOI 10.1111/j.1600-0854.2008.00751.x; Graner MW, 2005, NEURO-ONCOLOGY, V7, P260, DOI 10.1215/S1152851704001188; Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kim S, 2003, INT J CANCER, V103, P352, DOI 10.1002/ijc.10820; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Lopez-Maderuelo MD, 2001, FEBS LETT, V490, P23, DOI 10.1016/S0014-5793(01)02130-5; Lucarelli E, 1997, EUR J CANCER, V33, P2068, DOI 10.1016/S0959-8049(97)00266-9; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; MARCZIN N, 1993, AM J PHYSIOL, V265, P34; Marques C, 2004, FASEB J, V18, P1424, DOI 10.1096/fj.04-1743fje; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Matei D, 2007, J BIOL CHEM, V282, P445, DOI 10.1074/jbc.M607012200; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; Miyata Y, 2005, CURR PHARM DESIGN, V11, P1131, DOI 10.2174/1381612053507585; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nimmanapalli R, 2003, BLOOD, V102, P269, DOI 10.1182/blood-2002-12-3718; Onuoha SC, 2007, J MOL BIOL, V372, P287, DOI 10.1016/j.jmb.2007.06.065; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Pahlman S, 2000, NEUROBLASTOMA, P9; Peng XY, 2005, J BIOL CHEM, V280, P13148, DOI 10.1074/jbc.M410838200; Puyo S, 2008, MOL DIAGN THER, V12, P225, DOI 10.1007/BF03256288; Ramanathan RK, 2007, CLIN CANCER RES, V13, P1769, DOI 10.1158/1078-0432.CCR-06-2233; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Rosser MFN, 2004, BIOCHEMISTRY-US, V43, P8835, DOI 10.1021/bi049539q; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; SHANKOVICH R, 1992, MOL CELL BIOL, V12, P5059; Shen JH, 2007, NEUROSCI LETT, V414, P110, DOI 10.1016/j.neulet.2006.06.050; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Sidera K, 2008, J BIOL CHEM, V283, P2031, DOI 10.1074/jbc.M701803200; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; TACCONELLI A, 2006, ALTERNATIVE SPLICING, P67; Tacconelli Antonella, 2005, Future Oncol, V1, P689, DOI 10.2217/14796694.1.5.689; Theodoraki MA, 2007, EXP CELL RES, V313, P3851, DOI 10.1016/j.yexcr.2007.06.022; Vega VL, 2003, MOL BIOL CELL, V14, P764, DOI 10.1091/mbc.E02-08-0498; Wang Y, 2000, J BIOL CHEM, V275, P27013; Watson FL, 1999, J NEUROBIOL, V39, P323, DOI 10.1002/(SICI)1097-4695(199905)39:2<323::AID-NEU15>3.0.CO;2-4; Weigel BJ, 2007, CLIN CANCER RES, V13, P1789, DOI 10.1158/1078-0432.CCR-06-2270; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yoshimura S, 2001, J CELL SCI, V114, P4105; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	66	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4075	4094		10.1038/onc.2009.256	http://dx.doi.org/10.1038/onc.2009.256			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19734938				2022-12-28	WOS:000272560500004
J	Baritaki, S; Chapman, A; Yeung, K; Spandidos, DA; Palladino, M; Bonavida, B				Baritaki, S.; Chapman, A.; Yeung, K.; Spandidos, D. A.; Palladino, M.; Bonavida, B.			Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction	ONCOGENE			English	Article						metastasis; epithelial to mesenchymal transition; proteasome inhibitor; NF-kappa B; Raf-1 kinase inhibitor protein; Snail	NF-KAPPA-B; RAF KINASE; E-CADHERIN; PROTEIN EXPRESSION; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; TUMOR-CELLS; IN-VITRO; SUPPRESSES	Metastasis is associated with the loss of epithelial features and the acquisition of mesenchymal characteristics and invasive properties by tumor cells, a process known as epithelial to mesenchymal transition (EMT). Snail expression, through nuclear factor (NF)-kappa B activation, is an EMT determinant. The proteasome inhibitor, NPI-0052, induces the metastasis tumor suppressor/immune surveillance cancer gene, Raf kinase inhibitor protein (RKIP), via NF-kappa B inhibition. We hypothesized that NPI-0052 may inhibit Snail expression and, consequently, the metastatic phenotype in DU-145 prostate cancer cells. Cell treatment with NPI-0052 induced E-cadherin and inhibited Snail expression and both tumor cell invasion and migration. Inhibition of Snail inversely correlated with the induction of RKIP. The underlying mechanism of NPI-0052-induced inhibition of the metastatic phenotype was corroborated by: (1) treatment with Snail siRNA in DU-145 inhibited EMT and, in contrast, overexpression of Snail in the nonmetastatic LNCaP cells induced EMT, (2) NPI-0052-induced repression of Snail via inhibition of NF-kappa B was corroborated by the specific NF-kappa B inhibitor DHMEQ and (3) RKIP overexpression mimicked NPI-0052 in the inhibition of Snail and EMT. These findings demonstrate, for the first time, the role of NPI-0052 in the regulation of EMT via inhibition of NF-kappa B and Snail and induction of RKIP. Oncogene (2009) 28, 3573-3585; doi: 10.1038/onc.2009.214; published online 27 July 2009	[Baritaki, S.; Chapman, A.; Bonavida, B.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Yeung, K.] Univ Toledo, Dept Canc Biol & Biochem, Coll Med, Toledo, OH 43606 USA; [Spandidos, D. A.] Univ Crete, Fac Med, Dept Clin Virol, Iraklion, Greece; [Palladino, M.] Nereus Pharmaceut, San Diego, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; University of Toledo; University of Crete	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Baritaki, Voula/AAA-9544-2021	Spandidos, Demetrios/0000-0002-1146-931X	NIH/NCI [CA107023-02S1, CA057152-13S1]; Bodossaki Foundation postdoctoral fellowship; NATIONAL CANCER INSTITUTE [R01CA057152, R01CA107023] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bodossaki Foundation postdoctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the NIH/NCI research supplements CA107023-02S1, CA057152-13S1 and by Bodossaki Foundation postdoctoral fellowship (SB). We thank Chau Tran, Jose A Rodriguez and Haiming Chen for their help in the migration and invasion assays and the immuno. uorescence microscopy. We also thank Dr Kazuo Umezawa for providing us with the NF-kappa B inhibitor DHMEQ. In addition, we thank Tiffany Chin, Katherine Wu and Erica Keng for helping in the preparation of this article.	Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood-2007-04-084996; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Baritaki S, 2008, J IMMUNOL, V180, P6199, DOI 10.4049/jimmunol.180.9.6199; Baritaki S, 2007, J IMMUNOL, V179, P5441, DOI 10.4049/jimmunol.179.8.5441; Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2006, BRIT J CANCER, V95, P961, DOI 10.1038/sj.bjc.6603406; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cusack JC, 2006, CLIN CANCER RES, V12, P6758, DOI 10.1158/1078-0432.CCR-06-1151; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; DEHERREROS AG, 2001, COMMON MOL DEV CARCI; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2006, VIRCHOWS ARCH, V449, P520, DOI 10.1007/s00428-006-0274-6; Fenical W, 2009, BIOORGAN MED CHEM, V17, P2175, DOI 10.1016/j.bmc.2008.10.075; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Katsman A, 2007, DRUG RESIST UPDATE, V10, P1, DOI 10.1016/j.drup.2007.01.002; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Roccaro AM, 2008, BLOOD, V111, P4752, DOI 10.1182/blood-2007-11-120972; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Ruiz S, 2006, MOL CANCER THER, V5, P1836, DOI 10.1158/1535-7163.MCT-06-0066; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Sloss CM, 2008, CLIN CANCER RES, V14, P5116, DOI 10.1158/1078-0432.CCR-07-4506; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI 10.1517/13543784.17.6.879 ; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	115	124	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3573	3585		10.1038/onc.2009.214	http://dx.doi.org/10.1038/onc.2009.214			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633685				2022-12-28	WOS:000270851700006
J	Oh, J; Hur, MW; Lee, CE				Oh, J.; Hur, M-W; Lee, C-E			SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis	ONCOGENE			English	Article						SOCS1; apoptosis; ROS; PTPs; Jaks thioredoxin	TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; CELL-DEATH; REDOX REGULATION; MAPK PATHWAYS; NADPH OXIDASE; ACTIVATION; INHIBITION; INDUCTION; PHOSPHORYLATION	Suppressors of cytokine signaling (SOCS) are negative regulators of cytokine-induced signal transduction, which play multiple roles in cell growth, differentiation and apoptosis. In this study, the regulatory role of SOCS in oxidative stress-induced apoptosis was investigated. In Jurkat T cells and mouse splenocytes, we have found that SOCS1 is induced in response to tumor necrosis factor-alpha or H2O2, concomitant with the activation of Jaks which act as important mediators of reactive oxygen species (ROS)-induced apoptosis upstream of p38 mitogen-activated protein kinase. Using SOCS1 overexpressing or knockdown Jurkat T-cell systems we clearly demonstrate that, SOCS1 inhibits the ROS-mediated apoptosis. The antiapoptotic action of SOCS1 was exerted not only by suppressing Jaks, but also by sustaining protein tyrosine phosphatase (PTP) activities. Notably, SOCS1-transduced cells displayed increase in thioredoxin levels and decrease in ROS generation induced by oxidative stress. In addition, the Jak-inhibiting and PTP-sustaining effect of SOCS1 was significantly reduced on thioredoxin ablation. Moreover, coimmunoprecipitation data revealed molecular interaction of SHP1 or CD45 with thioredoxin, which was promoted in SOCS1-transfected cells. Together, our data strongly suggest that both the protection of PTPs by thioredoxin from ROS attack and the attenuation of Jaks account for the antiapoptotic function of SOCS1 in immune cells under oxidative stress. Oncogene (2009) 28, 3145-3156; doi: 10.1038/onc.2009.169; published online 29 June 2009	[Oh, J.; Lee, C-E] Sungkyunkwan Univ, Dept Biol Sci, Immunol Lab, Inst Basic Sci, Suwon 440746, South Korea; [Hur, M-W] Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Brain Korea Project Med Sci 21, Seoul 120749, South Korea	Institute for Basic Science - Korea (IBS); Sungkyunkwan University (SKKU); Yonsei University	Lee, CE (corresponding author), Sungkyunkwan Univ, Dept Biol Sci, Immunol Lab, Inst Basic Sci, 300 Cheon Cheon Dong, Suwon 440746, South Korea.	celee@skku.edu		Hur, Man-Wook/0000-0002-3416-1334	Brain Korea 21 program; KOSEF [2008-01752]; KRF [314-2008-1: E00030]; MOHW [A084298]; Seoul Graduate Student Scholarship	Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); KOSEF(Korea Science and Engineering Foundation); KRF(National Research Foundation of Korea); MOHW(Ministry of Health & Welfare (MOHW), Republic of Korea); Seoul Graduate Student Scholarship	This work was supported by Brain Korea 21 program and research grants from KOSEF (2008-01752), KRF (314-2008-1: E00030) and MOHW (A084298). J Oh was supported in part by the 2005 Seoul Graduate Student Scholarship.	Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Baetz A, 2008, FASEB J, V22, P4296, DOI 10.1096/fj.08-116079; Barrett DM, 2005, J BIOL CHEM, V280, P14453, DOI 10.1074/jbc.M411523200; Cao Q, 2004, J BIOL CHEM, V279, P4292, DOI 10.1074/jbc.M308351200; Chong MMW, 2002, J BIOL CHEM, V277, P27945, DOI 10.1074/jbc.M110214200; Cuncic C, 1999, J BIOL INORG CHEM, V4, P354, DOI 10.1007/s007750050322; Dang PMC, 2006, J CLIN INVEST, V116, P2033, DOI 10.1172/JCI27544; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Didier C, 2001, FREE RADICAL BIO MED, V31, P585, DOI 10.1016/S0891-5849(01)00617-7; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; Han SI, 2008, BMB REP, V41, P1; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; Hsieh CC, 2006, FASEB J, V20, P259, DOI 10.1096/fj.05-4376com; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jang JY, 2006, CELL IMMUNOL, V241, P14, DOI 10.1016/j.cellimm.2006.07.006; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim SH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-64; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Masuhiro Y, 2008, J BIOL CHEM, V283, P31575, DOI 10.1074/jbc.M800328200; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Odaka C, 2003, J IMMUNOL, V171, P1507, DOI 10.4049/jimmunol.171.3.1507; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Rusanescu G, 2005, EMBO J, V24, P305, DOI 10.1038/sj.emboj.7600522; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; To KF, 2004, BRIT J CANCER, V91, P1335, DOI 10.1038/sj.bjc.6602133; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675	38	35	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3145	3156		10.1038/onc.2009.169	http://dx.doi.org/10.1038/onc.2009.169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19561639				2022-12-28	WOS:000269515100006
J	Su, S; Li, Y; Luo, Y; Sheng, Y; Su, Y; Padia, RN; Pan, ZK; Dong, Z; Huang, S				Su, S.; Li, Y.; Luo, Y.; Sheng, Y.; Su, Y.; Padia, R. N.; Pan, Z. K.; Dong, Z.; Huang, S.			Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration	ONCOGENE			English	Article						PAR2; Src; JNK; paxillin; breast cancer; chemokinesis	N-TERMINAL KINASE; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION; MDA-MB-231 CELLS; COLON-CANCER; FACTOR VIIA; SRC KINASE; PAXILLIN; PROLIFERATION; GROWTH	Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is G(alpha i)-dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of G(alpha i) to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser(178) phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the G(alpha i)-c-Src-JNK-paxillin signaling pathway. Oncogene (2009) 28, 3047-3057; doi:10.1038/onc.2009.163; published online 22 June 2009	[Padia, R. N.; Huang, S.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Su, S.; Li, Y.; Su, Y.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Luo, Y.] Shuguang Hosp, Dept Surg, Shanghai, Peoples R China; [Sheng, Y.] Second Mil Med Univ, Dept Surg, Shanghai, Peoples R China; [Pan, Z. K.] Med Univ Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; [Dong, Z.] Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Shanghai University of Traditional Chinese Medicine; Naval Medical University; University System of Georgia; Augusta University	Huang, S (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	shuang@mcg.edu			MOST of China [2006BAI08B0206]; Shanghai Municipal Science, Technology Commission [06DZ19728]; E-institutes of Shanghai Municipal Education Commission [E 03008]; NIH [CA093926, HL083335]; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	MOST of China(Ministry of Science and Technology, China); Shanghai Municipal Science, Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM)); E-institutes of Shanghai Municipal Education Commission; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by MOST of China (2006BAI08B0206) ( SS), Shanghai Municipal Science, Technology Commission (06DZ19728) (SS), E-institutes of Shanghai Municipal Education Commission (E 03008) (SS), NIH Grant CA093926 and HL083335 (SH).	Abdulrahman M, 2007, ONCOGENE, V26, P1661, DOI 10.1038/sj.onc.1209932; Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Black PC, 2007, PROSTATE, V67, P743, DOI 10.1002/pros.20503; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Ciccarelli M, 2007, CELL SIGNAL, V19, P1949, DOI 10.1016/j.cellsig.2007.05.007; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang Z, 2008, CELL SIGNAL, V20, P2002, DOI 10.1016/j.cellsig.2008.07.014; Kimura K, 2008, INVEST OPHTH VIS SCI, V49, P125, DOI 10.1167/iovs.07-0725; Kozasa Tohru, 2003, V237, P153; Liu Y, 2006, BIOCHEM BIOPH RES CO, V344, P1263, DOI 10.1016/j.bbrc.2006.04.005; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Matej R, 2007, PHYSIOL RES, V56, P475, DOI 10.33549/physiolres.930959; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nishibori M, 2005, J PHARMACOL SCI, V97, P25, DOI 10.1254/jphs.FMJ04005X5; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Ramachandran R, 2008, BRIT J PHARMACOL, V153, pS263, DOI 10.1038/sj.bjp.0707507; Ruf W, 2006, SEMIN THROMB HEMOST, V32, P61, DOI 10.1055/s-2006-939555; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sanchez-Hernandez PE, 2008, GYNECOL ONCOL, V108, P19, DOI 10.1016/j.ygyno.2007.08.083; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Shi XL, 2004, MOL CANCER RES, V2, P395; Soreide K, 2006, J PATHOL, V209, P147, DOI 10.1002/path.1999; Su SB, 2001, CLIN CANCER RES, V7, P1320; Su SB, 2001, CLIN CANCER RES, V7, P309; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; Uusitalo-Jarvinen H, 2007, ARTERIOSCL THROM VAS, V27, P1456, DOI 10.1161/ATVBAHA.107.142539; Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048; Wang H, 2008, J BIOL CHEM, V283, P809, DOI 10.1074/jbc.M703021200; Wilson SR, 2004, PROSTATE, V60, P168, DOI 10.1002/pros.20047; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yada K, 2005, J SURG ONCOL, V89, P79, DOI 10.1002/jso.20197; Yamauchi J, 2002, FEBS LETT, V527, P284, DOI 10.1016/S0014-5793(02)03231-3	48	75	77	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3047	3057		10.1038/onc.2009.163	http://dx.doi.org/10.1038/onc.2009.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543320	Green Accepted			2022-12-28	WOS:000269319000004
J	Morrish, F; Isern, N; Sadilek, M; Jeffrey, M; Hockenbery, DM				Morrish, F.; Isern, N.; Sadilek, M.; Jeffrey, M.; Hockenbery, D. M.			c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry	ONCOGENE			English	Review						NMR; isotopomer; stable isotope labeling; O-linked N-acetylglucosamine; glucose	BETA-N-ACETYLGLUCOSAMINE; PROGRESSION; PROLIFERATION; TRANSCRIPTION; GENES	Cell proliferation requires the coordinated activity of cytosolic and mitochondrial metabolic pathways to provide ATP and building blocks for DNA, RNA and protein synthesis. Many metabolic pathway genes are targets of the c-myc oncogene and cell-cycle regulator. However, the contribution of c-Myc to the activation of cytosolic and mitochondrial metabolic networks during cell-cycle entry is unknown. Here, we report the metabolic fates of [U-C-13] glucose in serum-stimulated myc(-/-) and myc(+/+) fibroblasts by C-13 isotopomer NMR analysis. We demonstrate that endogenous c-myc increased C-13 labeling of ribose sugars, purines and amino acids, indicating partitioning of glucose carbons into C1/folate and pentose phosphate pathways, and increased tricarboxylic acid cycle turnover at the expense of anaplerotic flux. Myc expression also increased global O-linked N-acetylglucosamine protein modi. cation, and inhibition of hexosamine biosynthesis selectively reduced growth of Myc-expressing cells, suggesting its importance in Myc-induced proliferation. These data reveal a central organizing function for the Myc oncogene in the metabolism of cycling cells. The pervasive deregulation of this oncogene in human cancers may be explained by its function in directing metabolic networks required for cell proliferation. Oncogene ( 2009) 28, 2485-2491; doi: 10.1038/onc.2009.112; published online 18 May 2009	[Morrish, F.; Hockenbery, D. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Isern, N.] Pacific NW Natl Lab, High Field NMR Facil, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; [Sadilek, M.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Sadilek, M.] Univ Texas SW, Adv Imaging Res Ctr, Dallas, TX USA	Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-190, Seattle, WA 98109 USA.	dhockenb@fhcrc.org		Isern, Nancy/0000-0001-9571-8864	NIH [R21 DK070297, P41 RR02301]; Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC [RO1CA106650-02]; University of Texas Southwestern Medical Center [H47669-16]; Department of Veterans Affairs Merit Review Award to CR Malloy [RR02584]; NATIONAL CANCER INSTITUTE [R01CA106650] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070297] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC; University of Texas Southwestern Medical Center; Department of Veterans Affairs Merit Review Award to CR Malloy(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank John Sedivy for cell lines. This work utilized the MMC database supported by NIH grants R21 DK070297 and P41 RR02301, the MDL database (www.mdl.imb.liu.se) and the Human Metabolome database (www.hmbd.ca). A portion of this research was performed at EMSL, a national scienti. c user facility sponsored by the Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory. This work was funded by RO1CA106650-02 (DH). Development of the program tca-CALC (University of Texas Southwestern Medical Center) was supported by H47669-16, a Department of Veterans Affairs Merit Review Award to CR Malloy, and RR02584.	Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DEAN M, 1986, J BIOL CHEM, V261, P9161; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hunt AN, 2004, ADV ENZYME REGUL, V44, P173; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Peet AC, 2007, NMR BIOMED, V20, P692, DOI 10.1002/nbm.1181; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; TOLLEFSBOL TO, 1990, BIOCHEM MED METAB B, V44, P282, DOI 10.1016/0885-4505(90)90073-A; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	21	124	132	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2485	2491		10.1038/onc.2009.112	http://dx.doi.org/10.1038/onc.2009.112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448666	Green Accepted			2022-12-28	WOS:000267806800001
J	Yamada, D; Perez-Torrado, R; Filion, G; Caly, M; Jammart, B; Devignot, V; Sasai, N; Ravassard, P; Mallet, J; Sastre-Garau, X; Schmitz, ML; Defossez, PA				Yamada, D.; Perez-Torrado, R.; Filion, G.; Caly, M.; Jammart, B.; Devignot, V.; Sasai, N.; Ravassard, P.; Mallet, J.; Sastre-Garau, X.; Schmitz, M. L.; Defossez, P-A			The human protein kinase HIPK2 phosphorylates and downregulates the methyl-binding transcription factor ZBTB4	ONCOGENE			English	Article						transcription; protein kinase; epigenetics	DNA-DAMAGE; GENE-EXPRESSION; P53 ACTIVITY; APOPTOSIS; CANCER; CELLS; DEGRADATION; ACTIVATION; INTERACTS; SER-46	HIPK2 is a eukaryotic Serine-Threonine kinase that controls cellular proliferation and survival in response to exogenous signals. Here, we show that the human transcription factor ZBTB4 is a new target of HIPK2. The two proteins interact in vitro, colocalize and associate in vivo, and HIPK2 phosphorylates several conserved residues of ZBTB4. Overexpressing HIPK2 causes the degradation of ZBTB4, whereas overexpressing a kinase-deficient mutant of HIPK2 has no effect. The chemical activation of HIPK2 also decreases the amount of ZBTB4 in cells. Conversely, the inhibition of HIPK2 by drugs or by RNA interference causes a large increase in ZBTB4 levels. This negative regulation of ZBTB4 by HIPK2 occurs under normal conditions of cell growth. In addition, the degradation is increased by DNA damage. These findings have two consequences. First, we have recently shown that ZBTB4 inhibits the transcription of p21. Therefore, the activation of p21 by HIPK2 is two-pronged: stimulation of the activator p53, and simultaneous repression of the inhibitor ZBTB4. Second, ZBTB4 is also known to bind methylated DNA and repress methylated sequences. Consequently, our findings raise the possibility that HIPK2 might influence the epigenetic regulation of gene expression at loci that remain to be identified. Oncogene ( 2009) 28, 2535-2544; doi: 10.1038/onc.2009.109; published online 18 May 2009	[Sasai, N.; Defossez, P-A] Univ Paris 07, CNRS, Epigenet & Cell Fate UMR7216, F-75205 Paris 13, France; [Yamada, D.; Perez-Torrado, R.; Filion, G.; Jammart, B.; Devignot, V.; Sasai, N.; Defossez, P-A] Inst Curie, CNRS, UMR218, F-75231 Paris, France; [Caly, M.; Sastre-Garau, X.] Inst Curie, Med Sect, F-75231 Paris, France; [Ravassard, P.; Mallet, J.] Univ Paris 06, CNRS, UMR7091, Paris, France; [Schmitz, M. L.] Univ Giessen, Fac Med, Inst Biochem, Giessen, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Justus Liebig University Giessen	Defossez, PA (corresponding author), Univ Paris 07, CNRS, UMR7216, Batiment Lamarck,Case 7042,35 Rue Helene Brion, F-75205 Paris 13, France.	pierre-antoine.defossez@univ-paris-diderot.fr	Schmitz, M. Lienhard/D-9328-2017; Filion, Guillaume/G-9619-2015; Perez Torrado, Roberto/E-7613-2012	Schmitz, M. Lienhard/0000-0002-6984-7192; Filion, Guillaume/0000-0002-3473-1632; Perez Torrado, Roberto/0000-0002-3118-6755; Defossez, Pierre-Antoine/0000-0002-6463-9263; ravassard, philippe/0000-0002-0393-9262; Sastre-Garau, Xavier/0000-0001-5992-2083	Centre National de la Recherche Scientifique (CNRS); Institut National du Cancer ( ATIP Plus); Association pour la Recherche contre le Cancer [3727, 4859]; Ligue contre le Cancer; Deutsche Forschungsgemeinschaft (DFG)	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer ( ATIP Plus)(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank the following colleagues for reagents: Nelson Dusetti, Roger Tsien, Phillip James, Jacques Camonis, Silvia Soddu. We are especially grateful to Gabriella d'Orazi for the HIPK2 knockdown cells, and to Patricia Le Baccon for her help. DY was supported by postdoctoral fellowships from the Curie Institute, and from Association pour la Recherche contre le Cancer. RPT was supported by a fellowship from Centre National de la Recherche Scientifique (CNRS). The Defossez lab is supported by CNRS ( programme ATIP and programme PICS France-Russie), by Institut National du Cancer ( ATIP Plus), by Association pour la Recherche contre le Cancer ( grants no 3727 and no 4859), and by Ligue contre le Cancer. The work of MLS is supported by the Deutsche Forschungsgemeinschaft (DFG).	Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Clouaire T, 2008, CELL MOL LIFE SCI, V65, P1509, DOI 10.1007/s00018-008-7324-y; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Defossez PA, 2005, J BIOL CHEM, V280, P43017, DOI 10.1074/jbc.M510802200; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Filion GJP, 2006, ANAL BIOCHEM, V357, P156, DOI 10.1016/j.ab.2006.07.021; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; James P, 1996, GENETICS, V144, P1425; KANDURI C, 2002, J BIOL CHEM, V4, P4; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Lee W, 2009, DEVELOPMENT, V136, P241, DOI 10.1242/dev.025460; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ovcharenko D, 2005, RNA, V11, P985, DOI 10.1261/rna.7288405; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Roscic A, 2006, MOL CELL, V24, P77, DOI 10.1016/j.molcel.2006.08.004; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; van Roy FM, 2005, NAT REV CANCER, V5, P956, DOI 10.1038/nrc1752; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102; Zhang QC, 2007, J PROTEOME RES, V6, P4711, DOI 10.1021/pr700571d	40	27	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2535	2544		10.1038/onc.2009.109	http://dx.doi.org/10.1038/onc.2009.109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448668				2022-12-28	WOS:000267806800006
J	Attema, JL; Pronk, CJH; Norddahl, GL; Nygren, JM; Bryder, D				Attema, J. L.; Pronk, C. J. H.; Norddahl, G. L.; Nygren, J. M.; Bryder, D.			Hematopoietic stem cell ageing is uncoupled from p16(INK4A)-mediated senescence	ONCOGENE			English	Article						stem cells; hematopoiesis; ageing; senescence	TUMOR-SUPPRESSOR; BONE-MARROW; PROTEINS; GENE; AGE; PROLIFERATION; METHYLATION; PROGENITORS; POPULATION; EXPRESSION	Somatic stem cells are ultimately responsible for mediating appropriate organ homeostasis and have therefore been proposed to represent a cellular origin of the ageing process-a state often characterized by inappropriate homeostasis. Specifically, it has been suggested that ageing stem cells might succumb to replicative senescence by a mechanism involving the cyclin-dependent kinase inhibitor p16(INK4A). Here, we tested multiple functional and molecular parameters indicative of p16(INK4A) activity in primary aged murine hematopoietic stem cells (HSCs). We found no evidence that replicative senescence accompanies stem cell ageing in vivo, and in line with p16(INK4A) being a critical determinant of such processes, most aged HSCs (>99%) failed to express p16(INK4A) at the mRNA level. Moreover, whereas loss of epigenetically guided repression of the INK4A/ARF locus accompanied replicative senescent murine embryonic fibroblasts, such repression was maintained in aged stem cells. Taken together, these studies indicate that increased senescence as mediated by the p16(INK4A) tumor suppressor has only a minor function as an intrinsic regulator of steady-state HSC ageing in vivo. Oncogene (2009) 28, 2238-2243; doi: 10.1038/onc.2009.94; published online 27 April 2009	[Attema, J. L.; Pronk, C. J. H.; Norddahl, G. L.; Nygren, J. M.; Bryder, D.] Lund Univ, Immunol Unit, Expt Med Res Inst, S-22184 Lund, Sweden	Lund University	Bryder, D (corresponding author), Lund Univ, Immunol Unit, Expt Med Res Inst, BMC D14, S-22184 Lund, Sweden.	David.Bryder@med.lu.se	Bryder, David/Q-6292-2019	Bryder, David/0000-0002-8761-4237; Nygren, Jens M/0000-0002-3576-2393	Swedish Medical Research Council; Swedish Strategic Research Foundation; Swedish Cancer Society; Crafoord foundation and the Medical Faculty at Lund University	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Strategic Research Foundation(Swedish Foundation for Strategic Research); Swedish Cancer Society(Swedish Cancer Society); Crafoord foundation and the Medical Faculty at Lund University	We thank William Agace for critical review of the paper. The expert technical support from Gerd Sten is greatly appreciated. These studies were generously supported by grants to DB from the Swedish Medical Research Council, the Swedish Strategic Research Foundation, The Swedish Cancer Society, The Crafoord foundation and the Medical Faculty at Lund University.	Attema JL, 2007, P NATL ACAD SCI USA, V104, P12371, DOI 10.1073/pnas.0704468104; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bryder D, 2006, AM J PATHOL, V169, P338, DOI 10.2353/ajpath.2006.060312; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nygren JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003710; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Pearce DJ, 2007, STEM CELLS, V25, P828, DOI 10.1634/stemcells.2006-0405; Pronk CJH, 2007, CELL STEM CELL, V1, P428, DOI 10.1016/j.stem.2007.07.005; Randall TD, 1998, STEM CELLS, V16, P38, DOI 10.1002/stem.160038; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Signer RAJ, 2008, GENE DEV, V22, P3115, DOI 10.1101/gad.1715808; Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	26	56	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2009	28	22					2238	2243		10.1038/onc.2009.94	http://dx.doi.org/10.1038/onc.2009.94			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398954				2022-12-28	WOS:000266640300006
J	Greem, DR				Greem, D. R.			April Fish	ONCOGENE			English	Editorial Material													Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2009	28	13					1569	1569		10.1038/onc.2009.28	http://dx.doi.org/10.1038/onc.2009.28			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19339979	Bronze			2022-12-28	WOS:000264780500001
J	Gonzalez, L; Zambrano, A; Lazaro-Trueba, I; Lopez, E; Gonzalez, JJA; Martin-Perez, J; Aranda, A				Gonzalez, L.; Zambrano, A.; Lazaro-Trueba, I.; Lopez, E.; Gonzalez, J. J. A.; Martin-Perez, J.; Aranda, A.			Activation of the unliganded estrogen receptor by prolactin in breast cancer cells	ONCOGENE			English	Article						prolactin; estrogen receptor; transcriptional activation; breast cancer cells	CYCLIN D1; C-MYC; MAMMARY-GLAND; GROWTH-FACTOR; PROGESTERONE-RECEPTOR; ENDOCRINE RESISTANCE; HORMONE RECEPTORS; TYROSINE KINASE; GENE-EXPRESSION; IN-VIVO	Both prolactin (PRL) and estrogen (E2) are involved in the pathogenesis and progression of mammary neoplasia, but the mechanisms by which these hormones interact to exert their effects in breast cancer cells are not well understood. We show here that PRL is able to activate the unliganded estrogen receptor (ER). In breast cancer cells, PRL activates a reporter plasmid containing estrogen response elements (EREs) and induces the ER target gene pS2. These actions are blocked by the antagonist ICI 182,780, showing that ER is required for the PRL-mediated effect. Moreover, PRL leads to phosphorylation of ER alpha in serine-118 (P-ER alpha), a modification related to the potentiation of ligand-independent transcriptional activation. In addition, PRL mimics the effect of E2 on target gene expression by inducing cyclical recruitment of ER alpha and P-ER alpha to ERE-containing promoters, resulting in recruitment of co-activators and acetylation of histone H3. Finally, PRL induces expression of c-Myc and Cyclin D1 and leads to increased cell proliferation, which is specifically antagonized by ICI 182,780 or ERa depletion. These results show that ligand-independent ER alpha activation appears to be an important component of the proliferative and transcriptional actions of PRL in breast cancer cells.	[Martin-Perez, J.; Aranda, A.] CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Martin-Perez, J (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	jmartin@iib.uam.es; aaranda@iib.uam.es	Zambrano, Alberto/A-1580-2013; Aranda, Ana/ABG-8820-2020; Zambrano, Alberto/Q-6188-2019; Martin-Perez, Jorge/A-3522-2008	Zambrano, Alberto/0000-0001-5677-2999; Aranda, Ana/0000-0002-8338-9589; Zambrano, Alberto/0000-0001-5677-2999; Martin-Perez, Jorge/0000-0002-2292-0057; Gonzalez, Lorena/0000-0002-0575-7833	Ministerio de Educacion y Ciencia [SAF2006-00371, BFU2007-62402]; Fondo de Investigaciones Sanitarias [RD06/0020/0036, PIO40682]; Fundacion MMA; CRESCENDO [FP6-018652]	Ministerio de Educacion y Ciencia(Spanish Government); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion MMA; CRESCENDO(European Commission)	This work was supported by grants SAF2006-00371 and BFU2007-62402 from the Ministerio de Educacion y Ciencia, RD06/0020/0036 and PIO40682 from the Fondo de Investigaciones Sanitarias, by a grant from the Fundacion MMA and by the EU Project CRESCENDO (FP6-018652).	Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Carroll JS, 2002, CANCER RES, V62, P3126; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Dong J, 2006, J BIOL CHEM, V281, P18825, DOI 10.1074/jbc.M512826200; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; GINSBURG E, 1995, CANCER RES, V55, P2591; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Likhite VS, 2006, MOL ENDOCRINOL, V20, P3120, DOI 10.1210/me.2006-0068; Lipfert L, 2006, MOL ENDOCRINOL, V20, P516, DOI 10.1210/me.2005-0190; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; McNeil CM, 2006, J STEROID BIOCHEM, V102, P147, DOI 10.1016/j.jsbmb.2006.09.028; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Murphy L, 2004, CLIN CANCER RES, V10, P1354, DOI 10.1158/1078-0432.CCR-03-0112; Murphy LC, 2006, J STEROID BIOCHEM, V102, P139, DOI 10.1016/j.jsbmb.2006.09.021; MURPHY LJ, 1984, CANCER RES, V44, P1963; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Santos MDL, 2007, ENDOCR-RELAT CANCER, V14, P1021, DOI 10.1677/ERC-07-0144; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; SHAFIE S, 1977, CANCER RES, V37, P792; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Wang Y, 2007, CANCER RES, V67, P3698, DOI 10.1158/0008-5472.CAN-06-4000; Weitsman GE, 2006, CANCER RES, V66, P10162, DOI 10.1158/0008-5472.CAN-05-4111; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	57	51	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1298	1308		10.1038/onc.2008.473	http://dx.doi.org/10.1038/onc.2008.473			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169277	Green Submitted			2022-12-28	WOS:000264116000002
J	Morioka, Y; Monypenny, J; Matsuzaki, T; Shi, S; Alexander, DB; Kitayama, H; Noda, M				Morioka, Y.; Monypenny, J.; Matsuzaki, T.; Shi, S.; Alexander, D. B.; Kitayama, H.; Noda, M.			The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts	ONCOGENE			English	Article						cell adhesion; AP polarity; chemotaxis; MMPs; RAS; fibronectin	CELL-MIGRATION; MATRIX-METALLOPROTEINASE; RHO-GTPASES; FIBRONECTIN; BINDING; PROTEIN; FIBRILLOGENESIS; CYTOSKELETON; CHEMOTAXIS; MOTILITY	Accumulating evidence indicates that Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a membrane-anchored matrix metalloproteinase regulator, plays crucial roles in mammalian development and tumor suppression. Its mechanisms of action at the single cell level, however, remain largely unknown. In mouse fibroblasts, RECK is abundant around the perinuclear region, membrane ruffles and cell surface. Cells lacking Reck show decreased spreading, ambiguous anterior-posterior (AP) polarity, and increased speed and decreased directional persistence in migration; these characteristics are also found in transformed fibroblasts and fibrosarcoma cells with low RECK expression. RECK-deficient cells fail to form discrete focal adhesions, have increased levels of GTP-bound Rac1 and Cdc42, and a marked decrease in the level of detyrosinated tubulin, a hallmark of stabilized microtubules. RECK-deficient cells also show elevated gelatinolytic activity and decreased fibronectin fibrils. The phenotype of RECK-deficient cells is largely suppressed when the cells are plated on fibronectin-coated substrates. These findings suggest that RECK regulates pericellular extracellular matrix degradation, thereby allowing the cells to form proper cell-substrate adhesions and to maintain AP polarity during migration; this mechanism is compromised in malignant cells.	[Morioka, Y.; Matsuzaki, T.; Shi, S.; Kitayama, H.; Noda, M.] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; [Monypenny, J.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; [Shi, S.] Harbin Inst Technol, Dept Life Sci & Engn, Harbin 150006, Peoples R China; [Alexander, D. B.] Nagoya City Univ, Grad Sch Med Sci, Dept Mol Toxicol, Mizuho Ku, Nagoya, Aichi, Japan	Kyoto University; Kyoto University; Harbin Institute of Technology; Nagoya City University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp			JSPS; MEXT	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Dr Susan Creig for the GFP-vinculin expression vector, to Drs Shuh Narumiya, Alicia Arroyo and Motoharu Seiki for critical reading of the paper, and to the anonymous reviewer for suggesting the use of GM130 for analysing cell polarity. We also thank Emi Nishimoto, Takashi Kawai, Aiko Nishimoto and Aki Miyazaki for their technical and secretarial assistance, Akira Omura for his technical advice and So-ichiro Noda for his help in data analysis. This work was supported by JSPS Grant-in-Aid for Creative Scientific Research and MEXT Grant-in-Aid on Priority Areas.	Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Arora PD, 2003, EXP CELL RES, V286, P366, DOI 10.1016/S0014-4827(03)00096-X; Auge F, 2003, BIOORG MED CHEM LETT, V13, P1783, DOI 10.1016/S0960-894X(03)00214-2; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; Dunn G A, 1983, Agents Actions Suppl, V12, P14; Echizenya M, 2005, ONCOGENE, V24, P5850, DOI 10.1038/sj.onc.1208733; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Kadler KE, 2008, CURR OPIN CELL BIOL, V20, P495, DOI 10.1016/j.ceb.2008.06.008; Kawashima S, 2008, J NEUROCHEM, V104, P376, DOI 10.1111/j.1471-4159.2007.04977.x; Kondo S, 2007, J CELL SCI, V120, P849, DOI 10.1242/jcs.03388; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; Mellor H, 2004, CURR BIOL, V14, pR434, DOI 10.1016/j.cub.2004.05.038; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sieg DJ, 1999, J CELL SCI, V112, P2677; Simizu S, 2005, CANCER RES, V65, P7455, DOI 10.1158/0008-5472.CAN-04-4446; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takino T, 2006, EXP CELL RES, V312, P1381, DOI 10.1016/j.yexcr.2006.01.008; Wittmann T, 2001, J CELL SCI, V114, P3795; ZICHA D, 1991, J CELL SCI, V99, P769	30	38	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1454	1464		10.1038/onc.2008.486	http://dx.doi.org/10.1038/onc.2008.486			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169281	Green Submitted			2022-12-28	WOS:000264354400006
J	Ragone, G; Bresin, A; Piermarini, F; Lazzeri, C; Picchio, MC; Remotti, D; Kang, SM; Cooper, MD; Croce, CM; Narducci, MG; Russo, G				Ragone, G.; Bresin, A.; Piermarini, F.; Lazzeri, C.; Picchio, M. C.; Remotti, D.; Kang, S-M; Cooper, M. D.; Croce, C. M.; Narducci, M. G.; Russo, G.			The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression	ONCOGENE			English	Article						Tcl1; hair follicle; bulge cells; secondary hair germ cells; stem-cells; transient-amplifying cells	CHRONIC LYMPHOCYTIC-LEUKEMIA; LABEL-RETAINING CELLS; T-CELL; SELF-RENEWAL; COMPREHENSIVE GUIDE; MOUSE; SKIN; GENE; DISTINCT; CLASSIFICATION	Overexpression of the TCL1 gene family plays a role in the onset of T-cell leukemias in mice and in humans. The Tcl1 gene is tightly regulated during early embryogenesis in which it participates in embryonic stem (ES)-cells proliferation and during lymphoid differentiation. Here, we provide evidences that Tcl1 is also important in mouse hair follicle (HF) and skin homeostasis. We found that Tcl1(-/-) adult mice exhibit hair loss, leading to alopecia with extensive skin lesions. By analysing Tcl1 expression in the wild-type (wt) skin through different stages of hair differentiation, we observe high levels in the secondary hair germ (HG) cells and hair bulges, during early anagen and catagen-telogen transition phases. The loss of Tcl1 does not result in apparent skin morphological defects during embryonic development and at birth, but its absence causes a reduction of proliferation in anagen HFs. Importantly, we show the that absence of Tcl1 induces a significant loss of the stem-cell marker CD34 (but not alpha 6-integrin) expression in the bulge cells, which is necessary to maintain stem-cell characteristics. Therefore, our findings indicate that Tcl1 gene(s) might have important roles in hair formation, by its involvement in cycling and self-renewal of transient amplifying (TA) and stem-cell (SC) populations.	[Ragone, G.; Bresin, A.; Piermarini, F.; Lazzeri, C.; Picchio, M. C.; Narducci, M. G.; Russo, G.] Ist Ricovero & Cura Carattere Sci, Ist Dermopat Immacolata, Mol Oncol Lab, I-167 Rome, Italy; [Remotti, D.] Azienda Osped San Camillo Forlanini, Dept Pathol, Rome, Italy; [Kang, S-M] Emory Univ, Sch Med, Dept Microbiol, Atlanta, GA USA; [Kang, S-M] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA; [Cooper, M. D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Croce, C. M.] Ohio State Univ, Coll Med, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet,Human Canc Gen, Columbus, OH 43210 USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Azienda Ospedaliera San Camillo-Forlanini; Emory University; Emory University; Emory University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Russo, G (corresponding author), Ist Ricovero & Cura Carattere Sci, Ist Dermopat Immacolata, Mol Oncol Lab, Via Monti Creta 104, I-167 Rome, Italy.	russo@idi.it	Narducci, Maria Grazia/L-3093-2018; Young, Richard A/F-6495-2012; bresin, antonella/AAG-7189-2020; Russo, Giandomenico/K-9566-2016	Narducci, Maria Grazia/0000-0002-9066-186X; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Narducci, Maria Grazia/0000-0002-8877-4611; BRESIN, antonella/0000-0003-3954-5481	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Ema M, 2008, CELL STEM CELL, V3, P555, DOI 10.1016/j.stem.2008.09.003; French SW, 2007, CANCER LETT, V248, P198, DOI 10.1016/j.canlet.2006.07.006; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Glover CH, 2006, PLOS COMPUT BIOL, V2, P1463, DOI 10.1371/journal.pcbi.0020158; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ito M, 2004, DIFFERENTIATION, V72, P548, DOI 10.1111/j.1432-0436.2004.07209008.x; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Narducci MG, 1997, CANCER RES, V57, P5452; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Narducci MG, 1997, ONCOGENE, V15, P919, DOI 10.1038/sj.onc.1201246; Narducci MG, 2000, CANCER RES, V60, P2095; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Panteleyev AA, 2001, J CELL SCI, V114, P3419; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; PAUS R, 1994, BRIT J DERMATOL, V131, P177; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Tiede S, 2007, EUR J CELL BIOL, V86, P355, DOI 10.1016/j.ejcb.2007.03.006; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Zanesi N, 2006, CANCER RES, V66, P915, DOI 10.1158/0008-5472.CAN-05-3426	46	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1329	1338		10.1038/onc.2008.489	http://dx.doi.org/10.1038/onc.2008.489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169282	Green Published			2022-12-28	WOS:000264116000005
J	Billen, LP; Shamas-Din, A; Andrews, DW				Billen, L. P.; Shamas-Din, A.; Andrews, D. W.			Bid: a Bax-like BH3 protein	ONCOGENE			English	Review						Bid; apoptosis; BH-regions; structural homology; multidomain apoptosis proteins	CYTOCHROME-C RELEASE; BCL-X-L; PRO-APOPTOTIC ACTIVITY; CELL-DEATH MACHINERY; DNA-DAMAGE RESPONSE; CONFORMATIONAL-CHANGE; MEMBRANE PERMEABILIZATION; PEPTIDE COMPLEX; GRANZYME-B; MITOCHONDRIAL LOCALIZATION	Bid, a pro-apoptotic member of the Bcl-2 family, was initially discovered through binding to both pro-apoptotic Bax and anti-apoptotic Bcl-2. During apoptosis, Bid can be cleaved not only by caspase-8 during death receptor apoptotic signaling, but also by other caspases, granzyme B, calpains and cathepsins. Protease-cleaved Bid migrates to mitochondria where it inducespe rmeabilization of the outer mitochondrial membrane that isdependent on the pro-apoptotic proteinsBax and/or Bak, and thus Bid acts as a sentinel for protease-mediated death signals. Although sequence analysis suggests that Bid belongs to the BH3-only subgroup of the Bcl-2 family, structural and phylogenetic analysis suggests that Bid may be more related to multi-BH region proteinss such as pro-apoptotic Bax. Analysis of membrane binding by protease-cleaved Bid reveals mechanistic similarities with the membrane binding of Bax. For both proteins, membrane binding is characterized by relief of N-terminal inhibition of sequences promoting migration to membranes, insertion into the bilayer of the central hydrophobic hairpin helices and exposure of the BH3 region. These findings implicate Bid as a BH3-only protein that is both structurally and functionally related to multi-BH region Bcl-2 family proteins such as Bax. Oncogene (2009) 27, S93-S104; doi: 10.1038/onc.2009.47	[Billen, L. P.; Shamas-Din, A.; Andrews, D. W.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada	McMaster University; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada.	andrewsd@mcmaster.ca		Andrews, David/0000-0002-9266-7157	Canadian Institute of Health Research (CIHR) [FRN12517]; Tier I Canada Research Chair in Membrane Biogenesis	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier I Canada Research Chair in Membrane Biogenesis(Canada Research Chairs)	The work in the author's laboratory was supported by grant FRN12517 from the Canadian Institute of Health Research (CIHR), a Tier I Canada Research Chair in Membrane Biogenesis to DWA and a CIHR Canada Graduate Scholarship to LPB.	Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Arokium H, 2004, J BIOL CHEM, V279, P52566, DOI 10.1074/jbc.M408373200; Arokium H, 2007, J BIOL CHEM, V282, P35104, DOI 10.1074/jbc.M704891200; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Day CL, 2005, J BIOL CHEM, V280, P4738, DOI 10.1074/jbc.M411434200; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, J BIOL CHEM, V278, P15749, DOI 10.1074/jbc.M209208200; Garcia-Saez AJ, 2005, BIOPHYS J, V88, P3976, DOI 10.1529/biophysj.104.058008; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gong XM, 2004, J BIOL CHEM, V279, P28954, DOI 10.1074/jbc.M403490200; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu X, 2003, APOPTOSIS, V8, P277, DOI 10.1023/A:1023676906857; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Klumpp S, 2003, NEUROCHEM INT, V42, P555, DOI 10.1016/S0197-0186(02)00174-2; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kutuk O, 2008, CURR MOL MED, V8, P102; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oh KJ, 2005, J BIOL CHEM, V280, P753, DOI 10.1074/jbc.M405428200; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Peyerl FW, 2007, CELL DEATH DIFFER, V14, P447, DOI 10.1038/sj.cdd.4402025; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smits C, 2008, STRUCTURE, V16, P818, DOI 10.1016/j.str.2008.02.009; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Sutton VR, 2003, IMMUNITY, V18, P319, DOI 10.1016/S1074-7613(03)00050-5; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Uren RT, 2007, J CELL BIOL, V177, P277, DOI 10.1083/jcb.200606065; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xin MG, 2007, J BIOL CHEM, V282, P21268, DOI 10.1074/jbc.M701613200; Xin MG, 2005, J BIOL CHEM, V280, P10781, DOI 10.1074/jbc.M500084200; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	102	191	193	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S93	S104		10.1038/onc.2009.47	http://dx.doi.org/10.1038/onc.2009.47			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641510				2022-12-28	WOS:000268566800008
J	Chinnadurai, G; Vijayalingam, S; Rashmi, R				Chinnadurai, G.; Vijayalingam, S.; Rashmi, R.			BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes	ONCOGENE			English	Review						BIK; BH3-only; apoptosis; ER; cancer; viral pathogenesis	PRO-APOPTOTIC PROTEIN; CYTOCHROME-C RELEASE; ADENOVIRUS-INDUCED APOPTOSIS; BCL-2 FAMILY; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; PROTEASOME INHIBITORS; MITOCHONDRIAL APOPTOSIS; INFECTED CELLS; BH3 DOMAIN	BIK is the founding member of the BH3-only family proapoptotic proteins. BIK is predominantly localized in the ER and induces apoptosis through the mitochondrial pathway by mobilizing calcium from the ER to the mitochondria and remodeling the mitochondrial cristae. BIK-mediated apoptosis is mediated by selective activation of BAX. BIK also induces non-apoptotic cell death in certain cell types by unknown mechanisms. BIK is nonessential for animal development, but appears to be functionally redundant for certain developmental functions with BIM. BIK is implicated in the selection of mature B cells in humans. BIK is a pro-apoptotic tumor suppressor in several human tissues and its expression in cancers is prevented by chromosomal deletions encompassing the Bik locus or by epigenetic silencing. BIK appears to be a critical effector in apoptosis induced by toxins, cytokines and virus infection. Several anti-cancer drugs transcriptionally activate Bik gene expression through transcriptional pathways dependent on factors such as E2F and p53 or by removal of epigenetic marks on the chromatin. BIK appears to be a prominent target for anti-cancer drugs that inhibit proteasomal functions. BIK has also been used as a therapeutic molecule in gene therapy-based approaches to treat difficult cancers. Oncogene (2009) 27, S20-S29; doi: 10.1038/onc.2009.40	[Chinnadurai, G.; Vijayalingam, S.] St Louis Univ, Inst Mol Virol, Doisy Res Ctr, Hlth Sci Ctr, St Louis, MO 63104 USA; [Rashmi, R.] St Louis Univ, Dept Pediat, Doisy Res Ctr, Hlth Sci Ctr, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Inst Mol Virol, Doisy Res Ctr, Hlth Sci Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu	Pillai, Rashmi Ramachandran/B-8130-2012	Pillai, Rashmi Ramachandran/0000-0002-1619-7763	NATIONAL CANCER INSTITUTE [R01CA033616, R01CA073803] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, R01 CA073803, CA-73803, R01 CA073803-09, CA-33616, R01 CA033616-28] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Diallo JS, 2008, BRIT J CANCER, V99, P1613, DOI 10.1038/sj.bjc.6604730; Dong F, 2005, INFECT IMMUN, V73, P1861, DOI 10.1128/IAI.73.3.1861-1864.2005; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Han J, 1996, MOL CELL BIOL, V16, P5857; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Klein U, 2003, ANN NY ACAD SCI, V987, P166, DOI 10.1111/j.1749-6632.2003.tb06045.x; Li CY, 2008, MOL CANCER THER, V7, P1647, DOI 10.1158/1535-7163.MCT-07-2444; Li YM, 2003, CANCER RES, V63, P7630; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mebratu YA, 2008, J CELL BIOL, V183, P429, DOI 10.1083/jcb.200801186; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Nikrad M, 2005, MOL CANCER THER, V4, P443; OLTVAI ZN, 1993, CELL, V74, P619; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; PANARETAKIS T, 2002, J BIOL CHEM, V21, P21; Paquet C, 2004, APOPTOSIS, V9, P815, DOI 10.1023/B:APPT.0000045791.55282.91; Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; SPENDER LC, 2009, CELL DEATH IN PRESS; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Subramanian T, 2007, J VIROL, V81, P10486, DOI 10.1128/JVI.00808-07; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Theodorakis P, 2002, CANCER RES, V62, P3373; Tong Y, 2001, MOL CANCER THER, V1, P95; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wang Y, 2008, CELL MOL LIFE SCI, V65, P3822, DOI 10.1007/s00018-008-8452-0; Warr MR, 2005, FEBS LETT, V579, P5603, DOI 10.1016/j.febslet.2005.09.028; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou YY, 2002, CANCER RES, V62, P8	71	81	82	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S20	S29		10.1038/onc.2009.40	http://dx.doi.org/10.1038/onc.2009.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641504	Green Accepted			2022-12-28	WOS:000268566800002
J	Anastasiadou, E; Boccellato, F; Vincenti, S; Rosato, P; Bozzoni, I; Frati, L; Faggioni, A; Presutti, C; Trivedi, P				Anastasiadou, E.; Boccellato, F.; Vincenti, S.; Rosato, P.; Bozzoni, I.; Frati, L.; Faggioni, A.; Presutti, C.; Trivedi, P.			Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b	ONCOGENE			English	Article						EBV; microRNA; TCL1; LMP1; mir-29b	LATENT MEMBRANE PROTEIN-1; B-CELL LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ENDEMIC BURKITTS-LYMPHOMA; GENE-EXPRESSION; KAPPA-B; DNA METHYLTRANSFERASES; GROWTH TRANSFORMATION; MICRORNA MIR-146A; T-CELLS	Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1) is noted for its transforming potential. Yet, it also acts as a cytostatic and growth-relenting factor in Burkitt's lymphoma (BL) cells. The underlying molecular mechanisms of the growth inhibitory property of LMP1 have remained largely unknown. In this study, we show that LMP1 negatively regulates a major oncogene, TCL1, in diffuse large B-cell lymphoma (DLBCL) and BL cells. MicroRNA (miR) profiling of LMP1 transfectants showed that among others, miR-29b, is upregulated. LMP1 diminished TCL1 by inducing miR-29b through C-terminus activation region 1 (CTAR1) and CTAR2. miR-29b locked nucleic acid (LNA) antisense oligonucleotide transfection into LMP1-expressing cells reduced miR-29b expression and consequently reconstituted TCL1, suggesting that LMP1 negatively regulates TCL1 through miR-29b upregulation. The miR-29b increase by LMP1 was due to an increase in the cluster pri-miR-29b1-a transcription, derived from human chromosome 7. Using pharmacological inhibitors, we found that p38 mitogen-activated protein kinase-activating function of LMP1 is important for this effect. The ability of LMP1 to negatively regulate TCL1 through miR-29b might underlie its B-cell lymphoma growth antagonistic property. As LMP1 is also important for B-cell transformation, we suggest that the functional dichotomy of this viral protein may depend on a combination of levels of its expression, lineage and differentiation of the target cells and regulation of miRs, which then directs the outcome of the cellular response. Oncogene (2010) 29, 1316-1328; doi:10.1038/onc.2009.439; published online 7 December 2009	[Anastasiadou, E.; Boccellato, F.; Rosato, P.; Frati, L.; Faggioni, A.; Trivedi, P.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; [Vincenti, S.; Bozzoni, I.; Presutti, C.] Univ Roma La Sapienza, Dept Genet & Mol Biol, I-00161 Rome, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Trivedi, P (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Ist Pasteur Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	Pankaj.Trivedi@uniroma1.it	Anastasiadou, Eleni/AAI-1845-2020; Frati, Luigi/ABI-7437-2020; ANASTASIADOU, ELENI/AAU-6080-2021; Vincenti, Sara/N-6007-2018	ANASTASIADOU, ELENI/0000-0003-0212-6734; PRESUTTI, Carlo/0000-0003-3837-2275; bozzoni, irene/0000-0002-3485-8537; Vincenti, Sara/0000-0003-3692-1947; Boccellato, Francesco/0000-0001-6013-7154	MIUR; Associazione Italiana per la ricerca sul Cancro (AIRC); Ministero della Salute; Pasteur Cenci-Bolognetti Foundation; Fondazione Italiana per la sclerosi multipla (FISM); European Union [LSHB-CT-2004 005276]; SIROCCO [037900]	MIUR(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Pasteur Cenci-Bolognetti Foundation(Istituto Pasteur Italia Fondazione Cenci Bolognetti); Fondazione Italiana per la sclerosi multipla (FISM)(Fondazione Italiana Sclerosi Multipla (FISM)); European Union(European Commission); SIROCCO	We thank V Licursi, V Del Vescovo and Dr R Negri's group members for help with microarray scanning facility and statistical analysis. We thank Dr Martin Rowe (Birmingham University, UK) for providing mutant LMP1 plasmids and comments. Dr Michael Teitell (UCLA, Los Angeles) and Dr Stefanie Gofflot (University of Liege, Belgium) are acknowledged for supplying TCL1 promoter reporter constructs and SUDH4 DLBCL cell line, respectively. This work was supported by grants from MIUR and Associazione Italiana per la ricerca sul Cancro (AIRC), progetto strategico ISS 9ACF/1 of Ministero della Salute, Pasteur Cenci-Bolognetti Foundation, Fondazione Italiana per la sclerosi multipla (FISM), Sixth Research Framework Programme of the European Union, Project RIGHT (LSHB-CT-2004 005276) and SIROCCO (037900).	ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; Amini RM, 2002, LEUKEMIA LYMPHOMA, V43, P2179, DOI 10.1080/1042819021000032917; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bell AI, 2006, J GEN VIROL, V87, P2885, DOI 10.1099/vir.0.81906-0; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Boccellato F, 2007, J VIROL, V81, P2274, DOI 10.1128/JVI.01822-06; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Cardinaud B, 2009, LEUKEMIA, V23, P2174, DOI 10.1038/leu.2009.125; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; CUOMO L, 1992, INT J CANCER, V51, P949, DOI 10.1002/ijc.2910510619; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Dirmeier U, 2003, CANCER RES, V63, P2982; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kiss C, 2003, P NATL ACAD SCI USA, V100, P4813, DOI 10.1073/pnas.0730710100; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2004, J VIROL, V78, P1657, DOI 10.1128/JVI.78.4.1657-1664.2004; Lam N, 2003, EMBO J, V22, P3027, DOI 10.1093/emboj/cdg284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lay JD, 2003, J BIOMED SCI, V10, P146, DOI 10.1159/000068077; Maruo S, 2001, J GEN VIROL, V82, P2373, DOI 10.1099/0022-1317-82-10-2373; Motsch N, 2007, RNA BIOL, V4, P131, DOI 10.4161/rna.4.3.5206; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; Pajic A, 2001, INT J CANCER, V93, P810, DOI 10.1002/ijc.1404; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Rahadiani N, 2008, BIOCHEM BIOPH RES CO, V377, P579, DOI 10.1016/j.bbrc.2008.10.007; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Said JW, 2001, LAB INVEST, V81, P555, DOI 10.1038/labinvest.3780264; Sandberg ML, 2000, J VIROL, V74, P9755, DOI 10.1128/JVI.74.20.9755-9761.2000; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; Wang S, 1996, CANCER RES, V56, P4610; Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200	59	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1316	1328		10.1038/onc.2009.439	http://dx.doi.org/10.1038/onc.2009.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966860				2022-12-28	WOS:000275170600007
J	Lambert, JMR; Moshfegh, A; Hainaut, P; Wiman, KG; Bykov, VJN				Lambert, J. M. R.; Moshfegh, A.; Hainaut, P.; Wiman, K. G.; Bykov, V. J. N.			Mutant p53 reactivation by PRIMA-1(MET) induces multiple signaling pathways converging on apoptosis	ONCOGENE			English	Article						cancer; mutant p53; apoptosis; novel therapy	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; WILD-TYPE P53; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; TARGET GENES; CANCER-CELLS; CORE DOMAIN; ER STRESS	The low molecular weight compound PRIMA-1(MET) reactivates mutant p53 and triggers mutant p53-dependent apoptosis in human tumor cells. We investigated the effect of PRIMA-1(MET) on global gene expression using microarray analysis of Saos-2 cells expressing His273 mutant p53 and parental p53 null Saos-2 cells. PRIMA-1(MET) affected transcription of a significantly larger number of genes in the mutant p53-expressing cells compared to the p53 null cells. Genes affected by PRIMA-1(MET) in a mutant p53-dependent manner include the cell-cycle regulators GADD45B and 14-3-3 gamma and the pro-apoptotic Noxa. Several of the affected genes are known p53 target genes and/or contain p53 DNA-binding motifs. We also found mutant p53-dependent disruption of the cytoskeleton, as well as transcriptional activation of the XBP1 gene and cleavage of its mRNA, a marker for endoplasmic reticulum stress. Our data show that PRIMA-1(MET) induces apoptosis through multiple transcription-dependent and -independent pathways. Such integral engagement of multiple pathways leading to apoptosis is consistent with restoration of wild-type properties to mutant p53 and is likely to reduce the risk of drug resistance development in clinical applications of PRIMA-1(MET). Oncogene (2010) 29, 1329-1338; doi:10.1038/onc.2009.425; published online 30 November 2009	[Lambert, J. M. R.; Moshfegh, A.; Wiman, K. G.; Bykov, V. J. N.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden; [Lambert, J. M. R.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France	Karolinska Institutet; World Health Organization; International Agency for Research on Cancer (IARC)	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Hainaut, Pierre/B-6018-2012; Wiman, Klas/AAB-8399-2021	Hainaut, Pierre/0000-0002-1303-1610; Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942	Swedish Cancer Society (Cancerfonden); Cancerforeningen; Karolinska Institutet; EU	Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Cancerforeningen; Karolinska Institutet(Karolinska Institutet); EU(European Commission)	We thank Bert Vogelstein, Johns Hopkins Oncology Center, for HCT116 cells. This work was supported by the Swedish Cancer Society (Cancerfonden), Cancerforeningen, Karolinska Institutet and the EU 6th framework program. This publication reflects the author's views and not necessarily those of the EC. The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at his/her sole risk and liability. The Community is not liable for any use that may be made of the information contained herein.	Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; Andersson J, 2005, ANN ONCOL, V16, P743, DOI 10.1093/annonc/mdi150; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Ceribelli M, 2006, CELL CYCLE, V5, P1102, DOI 10.4161/cc.5.10.2777; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Livneh Z, 2006, CELL CYCLE, V5, P1918, DOI 10.4161/cc.5.17.3193; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Rogojina A, 2003, MOL VIS, V9, P482; Rokaeus N, 2007, ONCOGENE, V26, P982, DOI 10.1038/sj.onc.1209858; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang T, 2007, BIOCHEM BIOPH RES CO, V352, P203, DOI 10.1016/j.bbrc.2006.11.006; Westhoff B, 2005, CURR BIOL, V15, P1058, DOI 10.1016/j.cub.2005.04.058; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440	48	82	85	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	2010	29	9					1329	1338		10.1038/onc.2009.425	http://dx.doi.org/10.1038/onc.2009.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946333				2022-12-28	WOS:000275170600008
J	Doronkin, S; Djagaeva, I; Nagle, ME; Reiter, LT; Seagroves, TN				Doronkin, S.; Djagaeva, I.; Nagle, M. E.; Reiter, L. T.; Seagroves, T. N.			Dose-dependent modulation of HIF-1 alpha/sima controls the rate of cell migration and invasion in Drosophila ovary border cells	ONCOGENE			English	Article						hypoxia; metastasis; invasion; HIF-1 alpha; VHL; PHD	GENE DISRUPTION PROJECT; E-CADHERIN; DE-CADHERIN; TRANSCRIPTIONAL ACTIVITY; PROLYL HYDROXYLASE; HYPOXIC RESPONSE; HIF-ALPHA; EXPRESSION; PROTEIN; MECHANISMS	The role of the hypoxic response during metastasis was analysed in migrating border cells of the Drosophila ovary. Acute exposure to 1% O-2 delayed or blocked border cell migration (BCM), whereas prolonged exposure resulted in the first documented accelerated BCM phenotype. Similarly, manipulating the expression levels of sima, the Drosophila hypoxia-inducible factor (HIF)-1 alpha ortholog, revealed that Sima can either block or restore BCM in a dose-dependent manner. In contrast, overexpression of Vhl (Drosophila von Hippel-Lindau) generated a range of phenotypes, including blocked, delayed and accelerated BCM, whereas over-expression of hph (Drosophila HIF prolyl hydroxylase) only accelerated BCM. Mosaic clone analysis of sima or tango (HIF-1 beta ortholog) mutants revealed that cells lacking Hif-1 transcriptional activity were preferentially detected in the leading cell position of the cluster, resulting in either a delay or acceleration of BCM. Moreover, in sima mutant cell clones, there was reduced expression of nuclear slow border cells (Slbo) and basolateral DE-cadherin, proteins essential for proper BCM. These results show that Sima levels de. ne the rate of BCM in part through regulation of Slbo and DE-cadherin, and suggest that dynamic regulation of Hif-1 activity is necessary to maintain invasive potential of migrating epithelial cells. Oncogene (2010) 29, 1123-1134; doi: 10.1038/onc.2009.407; published online 7 December 2009	[Doronkin, S.; Djagaeva, I.; Reiter, L. T.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Nagle, M. E.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN 38163 USA; [Reiter, L. T.] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN 38163 USA; [Seagroves, T. N.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Doronkin, S (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave,Suite 515, Memphis, TN 38163 USA.	sdoronki@utmem.edu	Seagroves, Tiffany/AAE-3278-2019; Reiter, Lawrence/H-4161-2019	Seagroves, Tiffany/0000-0002-6937-943X; Reiter, Lawrence/0000-0002-4100-2630	Medical Student Research Fellowship (MSRF, NIH); Dorothy K Gerwin and the Maston Callison Bowld Cancer Research; UTHSC Molecular Resource Center; UTHSC Clinical and Translational Science Institute; NATIONAL CANCER INSTITUTE [R01CA138488] Funding Source: NIH RePORTER	Medical Student Research Fellowship (MSRF, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dorothy K Gerwin and the Maston Callison Bowld Cancer Research; UTHSC Molecular Resource Center; UTHSC Clinical and Translational Science Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eric Spana of the Duke Model Systems Genomics core facility for generating UAS-Vhl/VHL transgenic fly stocks. Drs Bruce Edgar, Denise Montell and Pernille Rorth generously shared reagents. Several stocks were obtained from the Bloomington Drosophila Stock Center. DE-cadherin antibodies were obtained from the Developmental Studies Hybridoma Bank. MN was supported by a Medical Student Research Fellowship (MSRF, NIH). All work was supported by the Dorothy K Gerwin and the Maston Callison Bowld Cancer Research funds at UTHSC (to TNS), the UTHSC Molecular Resource Center (to LTR) and the UTHSC Clinical and Translational Science Institute.	Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Bianco A, 2007, NATURE, V448, P362, DOI 10.1038/nature05965; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Cameron CM, 2008, EXP BIOL MED, V233, P1044, DOI 10.3181/0709-RM-263; Carthew RW, 2005, CURR OPIN GENET DEV, V15, P358, DOI 10.1016/j.gde.2005.06.002; Centanin L, 2005, EMBO REP, V6, P1070, DOI 10.1038/sj.embor.7400528; Centanin L, 2008, DEV CELL, V14, P547, DOI 10.1016/j.devcel.2008.01.020; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; Janardhan HP, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.143jc2; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lecaudey V, 2006, CURR OPIN CELL BIOL, V18, P102, DOI 10.1016/j.ceb.2005.12.001; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liu GW, 2006, PHYSIOL GENOMICS, V25, P134, DOI 10.1152/physiolgenomics.00262.2005; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.0.CO;2-L; Mathieu J, 2007, GENETICS, V176, P1579, DOI 10.1534/genetics.107.071282; Montell DJ, 2006, CURR OPIN GENET DEV, V16, P374, DOI 10.1016/j.gde.2006.06.010; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Mortimer NT, 2009, DEV BIOL, V329, P294, DOI 10.1016/j.ydbio.2009.03.001; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Oda H, 1997, GENES CELLS, V2, P29, DOI 10.1046/j.1365-2443.1997.d01-284.x; Pacquelet A, 2005, J CELL BIOL, V170, P803, DOI 10.1083/jcb.200506131; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517; Prasad M, 2007, NAT PROTOC, V2, P2467, DOI 10.1038/nprot.2007.363; Prasad M, 2007, DEV CELL, V12, P997, DOI 10.1016/j.devcel.2007.03.021; Rocha S, 2007, TRENDS BIOCHEM SCI, V32, P389, DOI 10.1016/j.tibs.2007.06.005; Rorth P, 2000, MOL CELL, V6, P23; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Russell RC, 2007, CELL CYCLE, V6, P56, DOI 10.4161/cc.6.1.3668; Schober M, 2005, DEVELOPMENT, V132, P3493, DOI 10.1242/dev.01911; Seifeddine R, 2008, CANCER RES, V68, P2158, DOI 10.1158/0008-5472.CAN-07-1190; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Spradling AC, 1999, GENETICS, V153, P135; Starz-Gaiano M, 2004, CURR OPIN GENET DEV, V14, P86, DOI 10.1016/j.gde.2003.12.001; Starz-Gaiano M, 2008, DEV CELL, V14, P726, DOI 10.1016/j.devcel.2008.03.005; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Yang L, 2008, CARCINOGENESIS, V29, P291, DOI 10.1093/carcin/bgm262; Zhong H, 1999, CANCER RES, V59, P5830	59	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1123	1134		10.1038/onc.2009.407	http://dx.doi.org/10.1038/onc.2009.407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19966858				2022-12-28	WOS:000274912100004
J	Humtsoe, JO; Kramer, RH				Humtsoe, J. O.; Kramer, R. H.			Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway	ONCOGENE			English	Article						cell-cell adhesion; EGFR; PI3K/AKT	SQUAMOUS-CELL CARCINOMA; FACTOR EGF RECEPTOR; HYPOXIA-INDUCIBLE FACTOR; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; INTERCELLULAR-ADHESION; TYROSINE KINASE; CYCLIN D1; DEPENDENT REGULATION; CONTACT FORMATION	Tumor cells are capable of surviving loss of nutrients and anchorage in hostile microenvironments. Under these conditions, adapting to specific signaling pathways may shift the balance between growth and cellular dormancy. Here, we report a mechanism by which epidermal growth factor receptor (EGFR) differentially modulates the phosphatidylinositol 30-kinase (PI3K)/AKT pathway in cellular stress conditions. When carcinoma cells were cultured as multicellular aggregates (MCA), cyclin D1 was induced through a serum-dependent EGFR activating pathway, triggering cell proliferation. The expression of cyclin D1 required both EGFR-mediated ERK and AKT activation. In serum-starved MCAs, EGFR activation was associated with active ERK1/2, but not AKT, and failed to induce cyclin D1. Analysis revealed that, under serum-starved conditions, EGFR-Y1086 residue was poorly autophosphorylated and this correlated with failure to phosphorylate Gab1. Accordingly, the EGFR activation failed to induce EGFR/PI3K complex formation or AKT activation, preventing cyclin D1 induction. Furthermore, we show that in serum-starved MCA, expression of constitutively active AKT re-established cyclin D1 expression and induced proliferation in an EGFR-dependent manner. Thus, modulation of the PI3K/AKT pathway by context-dependent EGFR signaling may regulate tumor cell growth and dormancy. Oncogene (2010) 29, 1214-1226; doi: 10.1038/onc.2009.419; published online 23 November 2009	[Humtsoe, J. O.; Kramer, R. H.] Univ Calif San Francisco, Dept Cell & Tissue Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave,Room C-640,Box 0640, San Francisco, CA 94143 USA.	randall.kramer@ucsf.edu			NIH [R01 DE11436]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011436] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr KK Wary (UIC, Chicago) for the insightful discussions and comments, Dr SM Troyanovsky (Washington University, St Louis) for providing the E-cadherin constructs, Dr D Stokoe (UCSF, San Francisco) for the GFP-AKT constructs, L Lee and B Situ for their assistance in preparing the paper. This work was supported by NIH grant R01 DE11436.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alt-Holland A, 2005, SEMIN CANCER BIOL, V15, P84, DOI 10.1016/j.semcancer.2004.08.007; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; BERNARD O, 1987, P NATL ACAD SCI USA, V84, P2125, DOI 10.1073/pnas.84.8.2125; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200; Cabodi S, 2004, BIOCHEM SOC T, V32, P438, DOI 10.1042/BST0320438; Cai WJ, 2006, P NATL ACAD SCI USA, V103, P13801, DOI 10.1073/pnas.0600362103; Chen QM, 2004, BIOCHEM BIOPH RES CO, V315, P850, DOI 10.1016/j.bbrc.2004.01.143; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fournier AK, 2008, J CELL SCI, V121, P226, DOI 10.1242/jcs.017012; Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Humtsoe JO, 2003, EMBO J, V22, P1539, DOI 10.1093/emboj/cdg165; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kawano K, 2001, EXP CELL RES, V262, P180, DOI 10.1006/excr.2000.5083; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lawlor ER, 2002, ONCOGENE, V21, P307, DOI 10.1038/sj.onc.1205053; Lenferink AEG, 2001, CANCER RES, V61, P6583; LeVea CM, 2004, EXP CELL RES, V297, P272, DOI 10.1016/j.yexcr.2004.03.026; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110; Onishi A, 2008, EXP CELL RES, V314, P377, DOI 10.1016/j.yexcr.2007.09.018; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008-5472.CAN-05-3090; Ranganathan AC, 2006, CELL CYCLE, V5, P1799, DOI 10.4161/cc.5.16.3109; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Singh AB, 2007, J BIOL CHEM, V282, P32890, DOI 10.1074/jbc.M702677200; Thelemann A, 2005, MOL CELL PROTEOMICS, V4, P356, DOI 10.1074/mcp.M400118-MCP200; Walker JL, 2005, CANCER METAST REV, V24, P383, DOI 10.1007/s10555-005-5130-7; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	49	48	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1214	1226		10.1038/onc.2009.419	http://dx.doi.org/10.1038/onc.2009.419			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935697	Green Accepted			2022-12-28	WOS:000274912100012
J	Watanabe, Y; Kojima, T; Kagawa, S; Uno, F; Hashimoto, Y; Kyo, S; Mizuguchi, H; Tanaka, N; Kawamura, H; Ichimaru, D; Urata, Y; Fujiwara, T				Watanabe, Y.; Kojima, T.; Kagawa, S.; Uno, F.; Hashimoto, Y.; Kyo, S.; Mizuguchi, H.; Tanaka, N.; Kawamura, H.; Ichimaru, D.; Urata, Y.; Fujiwara, T.			A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy	ONCOGENE			English	Article						telomerase; adenovirus; mesothelioma; heparanase; dual virotherapy	I CLINICAL-TRIAL; GENE-THERAPY; CANCER; REPLICATION; EXPRESSION; INCREASES; P14(ARF); METASTASIS; EFFICACY; IMPROVES	Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-S/hep)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma. Oncogene (2010) 29, 1145-1154; doi: 10.1038/onc.2009.415; published online 23 November 2009	[Fujiwara, T.] Okayama Univ, Ctr Gene & Cell Therapy, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, Okayama 7008558, Japan; [Watanabe, Y.; Kagawa, S.; Uno, F.; Fujiwara, T.] Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama, Japan; [Watanabe, Y.; Hashimoto, Y.; Kawamura, H.; Ichimaru, D.; Urata, Y.] Oncolys BioPharma Inc, Minato Ku, Tokyo, Japan; [Kyo, S.] Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; [Mizuguchi, H.] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biochem & Mol Biol, Osaka, Japan	Okayama University; Okayama University; Oncolys BioPharma; Kanazawa University; Osaka University	Fujiwara, T (corresponding author), Okayama Univ, Ctr Gene & Cell Therapy, Grad Sch Med Dent & Pharmaceut Sci, Dept Surg, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				ALBERTS AS, 1988, J CLIN ONCOL, V6, P527, DOI 10.1200/JCO.1988.6.3.527; BALL DL, 1990, AM J CLIN ONCOL-CANC, V13, P4, DOI 10.1097/00000421-199002000-00002; Blackburn JS, 2007, CANCER RES, V67, P10849, DOI 10.1158/0008-5472.CAN-07-1791; CHAHINIAN AP, 1982, ANN INTERN MED, V96, P746, DOI 10.7326/0003-4819-96-6-746; CHAILLEUX E, 1988, CHEST, V93, P159, DOI 10.1378/chest.93.1.159; Cheng J, 2007, MOL THER, V15, P1982, DOI 10.1038/sj.mt.6300264; CONNELLY RR, 1987, JNCI-J NATL CANCER I, V78, P1053; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Fitzgerald M, 1999, ATHEROSCLEROSIS, V145, P97, DOI 10.1016/S0021-9150(99)00019-2; Fujiwara T, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3572; Ganesh S, 2007, CANCER RES, V67, P4399, DOI 10.1158/0008-5472.CAN-06-4260; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hioki M, 2008, INT J CANCER, V122, P2628, DOI 10.1002/ijc.23438; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Kim JH, 2006, JNCI-J NATL CANCER I, V98, P1482, DOI 10.1093/jnci/djj397; Kishimoto H, 2006, NAT MED, V12, P1213, DOI 10.1038/nm1404; Kishimoto H, 2009, P NATL ACAD SCI USA, V106, P14514, DOI 10.1073/pnas.0906388106; Kuriyama N, 2001, CANCER RES, V61, P1805; McKee TD, 2006, CANCER RES, V66, P2509, DOI 10.1158/0008-5472.CAN-05-2242; McKenzie EA, 2007, BRIT J PHARMACOL, V151, P1, DOI 10.1038/sj.bjp.0707182; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Murayama T, 2006, AM J IND MED, V49, P1, DOI 10.1002/ajim.20246; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; RUFFIE P, 1989, J CLIN ONCOL, V7, P1157, DOI 10.1200/JCO.1989.7.8.1157; RUSCH VW, 1991, J THORAC CARDIOV SUR, V102, P1; Ryan CW, 1998, CHEST, V113, p66S, DOI 10.1378/chest.113.1_Supplement.66S; Sterman DH, 2007, CLIN CANCER RES, V13, P4456, DOI 10.1158/1078-0432.CCR-07-0403; Sterman DH, 2005, CLIN CANCER RES, V11, P7444, DOI 10.1158/1078-0432.CCR-05-0405; Sterman DH, 1998, HUM GENE THER, V9, P1083, DOI 10.1089/hum.1998.9.7-1083; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Tango Y, 2004, CANCER SCI, V95, P459, DOI 10.1111/j.1349-7006.2004.tb03232.x; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; Uno F, 2001, CANCER RES, V61, P7855; Yang CT, 2000, J NATL CANCER I, V92, P636, DOI 10.1093/jnci/92.8.636; Yang CT, 2001, CANCER RES, V61, P5959	36	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1145	1154		10.1038/onc.2009.415	http://dx.doi.org/10.1038/onc.2009.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935710				2022-12-28	WOS:000274912100006
J	Wang, D; DuBois, RN				Wang, D.; DuBois, R. N.			The role of COX-2 in intestinal inflammation and colorectal cancer	ONCOGENE			English	Review						cyclooxygenase; prostaglandins; NSAIDs; inflammation; colorectal cancer	ACTIVATED-RECEPTOR-DELTA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GROWTH-FACTOR RECEPTOR; METASTATIC BREAST-CANCER; HUMAN COLON-CANCER; PHASE-I TRIAL; PROSTAGLANDIN E-2; BOWEL-DISEASE; CYCLOOXYGENASE-2 INHIBITORS; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE	Colorectal cancer (CRC) is a heterogeneous disease, including at least three major forms: hereditary, sporadic and colitis-associated CRC. A large body of evidence indicates that genetic mutations, epigenetic changes, chronic inflammation, diet and lifestyle are the risk factors for CRC. As elevated cyclooxygenase-2 (COX-2) expression was found in most CRC tissue and is associated with worse survival among CRC patients, investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) on CRC. The epidemiological studies, clinical trials and animal experiments indicate that NSAIDs are among the most promising chemopreventive agents for this disease. NSAIDs exert their antiinflammatory and antitumor effects primarily by reducing prostaglandin production by inhibition of COX-2 activity. In this review, we highlight breakthroughs in our understanding of the roles of COX-2 in CRC and inflammatory bowel disease. These recent data provide a rationale for re-evaluating COX-2 as both the prognostic and the predictive marker in a wide variety of malignancies and for renewing the interest in evaluating relative benefits and risk of COXIBs in appropriately selected patients for cancer prevention and treatment. Oncogene (2010) 29, 781-788; doi:10.1038/onc.2009.421; published online 30 November 2009	[DuBois, R. N.] Univ Texas MD Anderson Canc Ctr, Unit 118, Dept Canc Biol & GI Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	DuBois, RN (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 118, Dept Canc Biol & GI Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rdubois@mdanderson.org	DuBois, Raymond N./AAX-8869-2020		National Institutes of Health [RO1DK 62112, P01-CA-77839, R37-DK47297, P30 DK-58404]; National Colorectal Cancer Research Alliance (NCCRA); NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R37DK047297, R01DK062112] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Colorectal Cancer Research Alliance (NCCRA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in part, from the National Institutes of Health Grants RO1DK 62112, P01-CA-77839, R37-DK47297 and P30 DK-58404 (RND). RND (R37-DK47297) is recipient of an NIH MERIT award. We also thank the National Colorectal Cancer Research Alliance (NCCRA) for generous support (RND).	Al-Salihi MA, 2009, CANCER LETT, V273, P225, DOI 10.1016/j.canlet.2008.08.012; Anderson GD, 2009, INFLAMM RES, V58, P109, DOI 10.1007/s00011-009-8149-3; Araujo AMF, 2009, CANCER INVEST, V27, P391, DOI 10.1080/07357900802232756; Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652; Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200; Barry M, 2009, IRISH J MED SCI, V178, P201, DOI 10.1007/s11845-009-0335-3; Bernstein CN, 2002, INFLAMM BOWEL DIS, V8, P356, DOI 10.1097/00054725-200209000-00007; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; Bertagnolli MM, 2009, CANCER PREV RES, V2, P310, DOI 10.1158/1940-6207.CAPR-08-0206; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Buchanan FG, 2007, CANCER RES, V67, P9380, DOI 10.1158/0008-5472.CAN-07-0710; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chan AT, 2008, GASTROENTEROLOGY, V134, P21, DOI 10.1053/j.gastro.2007.09.035; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Chulada PC, 2000, CANCER RES, V60, P4705; Colby JK, 2008, NEOPLASIA, V10, P782, DOI 10.1593/neo.08330; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Davis TW, 2004, CANCER RES, V64, P279, DOI 10.1158/0008-5472.CAN-03-1168; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dudhgaonkar S. P., 2007, Inflammopharmacology, V15, P188, DOI 10.1007/s10787-007-1603-3; Eaden J, 2003, ALIMENT PHARM THER, V18, P15, DOI 10.1046/j.1365-2036.18.s2.3.x; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; El Miedany Y, 2006, AM J GASTROENTEROL, V101, P311, DOI 10.1111/j.1572-0241.2006.00384.x; Fabi A, 2008, CANCER CHEMOTH PHARM, V62, P717, DOI 10.1007/s00280-007-0650-1; Falandry C, 2009, ANN ONCOL, V20, P615, DOI 10.1093/annonc/mdn693; Felder JB, 2000, AM J GASTROENTEROL, V95, P1949; Ferrari V, 2006, CANCER CHEMOTH PHARM, V57, P185, DOI 10.1007/s00280-005-0028-1; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOULD SR, 1981, PROSTAG LEUKOTR ESS, V6, P165, DOI 10.1016/0161-4630(81)90088-4; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Grover JK, 2003, INT J COLORECTAL DIS, V18, P279, DOI 10.1007/s00384-002-0443-2; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Harrington LE, 2006, CURR OPIN IMMUNOL, V18, P349, DOI 10.1016/j.coi.2006.03.017; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Hayslip J, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-221; Izzo AA, 2008, GUT, V57, P1140, DOI 10.1136/gut.2008.148791; JEN J, 1994, CANCER RES, V54, P5523; Jiang GL, 2007, J PHARMACOL EXP THER, V320, P22, DOI 10.1124/jpet.106.111146; Kabashima K, 2002, J CLIN INVEST, V109, P883, DOI 10.1172/JCI14459; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kawamori T, 2003, CARCINOGENESIS, V24, P985, DOI 10.1093/carcin/bgg033; Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kohno H, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-46; Kozak KR, 2002, J BIOL CHEM, V277, P44877, DOI 10.1074/jbc.M206788200; Leung WK, 2008, CARCINOGENESIS, V29, P1648, DOI 10.1093/carcin/bgn156; Lewis JD, 1999, GASTROENTEROL CLIN N, V28, P459, DOI 10.1016/S0889-8553(05)70065-0; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; MACDERMOTT RP, 1994, MED CLIN N AM, V78, P1207, DOI 10.1016/S0025-7125(16)30096-7; Mahadevan U, 2002, AM J GASTROENTEROL, V97, P910; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; Milella M, 2004, CANCER, V101, P133, DOI 10.1002/cncr.20338; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; Morteau O, 2000, J CLIN INVEST, V105, P469, DOI 10.1172/JCI6899; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Mutoh M, 2002, CANCER RES, V62, P28; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Nakanishi M, 2008, CANCER RES, V68, P3251, DOI 10.1158/0008-5472.CAN-07-6100; Narasimha A, 2007, PROSTAG OTH LIPID M, V84, P24, DOI 10.1016/j.prostaglandins.2007.03.004; Ogino S, 2008, CLIN CANCER RES, V14, P8221, DOI 10.1158/1078-0432.CCR-08-1841; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Panigrahy D, 2005, CANCER BIOL THER, V4, P687, DOI 10.4161/cbt.4.7.2014; Patsos HA, 2005, GUT, V54, P1741, DOI 10.1136/gut.2005.073403; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Reckamp KL, 2006, CLIN CANCER RES, V12, P3381, DOI 10.1158/1078-0432.CCR-06-0112; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Rockwell CE, 2008, BIOCHEM PHARMACOL, V76, P353, DOI 10.1016/j.bcp.2008.05.005; Rodriguez DA, 2009, MOL BIOL CELL, V20, P2297, DOI 10.1091/mbc.E08-09-0939; Rostom A, 2007, ANN INTERN MED, V146, P376, DOI 10.7326/0003-4819-146-5-200703060-00010; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheibanie AF, 2007, J IMMUNOL, V178, P8138, DOI 10.4049/jimmunol.178.12.8138; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; SMITH AJ, 1994, CANCER RES, V54, P5527; Solomon SD, 2008, CIRCULATION, V117, P2104, DOI 10.1161/CIRCULATIONAHA.108.764530; Solomon SD, 2006, CIRCULATION, V114, P1028, DOI 10.1161/CIRCULATIONAHA.106.636746; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Strillacci A, 2009, EXP CELL RES, V315, P1439, DOI 10.1016/j.yexcr.2008.12.010; Tachimori A, 2008, ANTICANCER RES, V28, P629; Van Dross RT, 2009, MOL CARCINOGEN, V48, P724, DOI 10.1002/mc.20515; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103; Wang DZ, 2008, PPAR RES, V2008, DOI 10.1155/2008/931074; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Watanabe K, 1999, CANCER RES, V59, P5093; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; Yan M, 2009, P NATL ACAD SCI USA, V106, P9409, DOI 10.1073/pnas.0902367106; Yin YZ, 2005, CANCER RES, V65, P3950, DOI 10.1158/0008-5472.CAN-04-3990; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200; Zhao SP, 2009, CANCER INVEST, V27, P636, DOI 10.1080/07357900802672738; Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078	104	588	612	3	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					781	788		10.1038/onc.2009.421	http://dx.doi.org/10.1038/onc.2009.421			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19946329	Green Accepted			2022-12-28	WOS:000274397800001
J	Hanker, AB; Mitin, N; Wilder, RS; Henske, EP; Tamanoi, F; Cox, AD; Der, CJ				Hanker, A. B.; Mitin, N.; Wilder, R. S.; Henske, E. P.; Tamanoi, F.; Cox, A. D.; Der, C. J.			Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling	ONCOGENE			English	Article						Rheb; mTOR; Ras converting enzyme 1 (Rce1); isoprenylcysteine carboxyl methyltransferase (Icmt); S-trans, trans-farnesylthiosalicylic acid (FTS)	TUBEROUS SCLEROSIS COMPLEX; BREAST-CANCER CELLS; FARNESYLTRANSFERASE INHIBITORS; FARNESYLTHIOSALICYLIC ACID; MAMMALIAN TARGET; MEMBRANE ASSOCIATION; FISSION YEAST; HUMAN-DISEASE; RHO GTPASES; ACTIVE RAS	The Rheb1 and Rheb2 small GTPases and their effector mTOR are aberrantly activated in human cancer and are attractive targets for anti-cancer drug discovery. Rheb is targeted to endomembranes via its C-terminal CAAX (C = cysteine, A = aliphatic, X = terminal amino acid) motif, a substrate for posttranslational modification by a farnesyl isoprenoid. After farnesylation, Rheb undergoes two additional CAAX-signaled processing steps, Ras converting enzyme 1 (Rce1)-catalyzed cleavage of the AAX residues and isoprenylcysteine carboxyl methyltransferase (Icmt)-mediated carboxylmethylation of the farnesylated cysteine. However, whether these postprenylation processing steps are required for Rheb signaling through mTOR is not known. We found that Rheb1 and Rheb2 localize primarily to the endoplasmic reticulum and Golgi apparatus. We determined that Icmt and Rce1 processing is required for Rheb localization, but is dispensable for Rheb-induced activation of the mTOR substrate p70 S6 kinase (S6K). Finally, we evaluated whether farnesylthiosalicylic acid (FTS) blocks Rheb localization and function. Surprisingly, FTS prevented S6K activation induced by a constitutively active mTOR mutant, indicating that FTS inhibits mTOR at a level downstream of Rheb. We conclude that inhibitors of Icmt and Rce1 will not block Rheb function, but FTS could be a promising treatment for Rheb- and mTOR-dependent cancers. Oncogene (2010) 29, 380-391; doi:10.1038/onc.2009.336; published online 19 October 2009	[Mitin, N.; Wilder, R. S.; Cox, A. D.; Der, C. J.] Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Hanker, A. B.; Cox, A. D.; Der, C. J.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Wilder, R. S.; Tamanoi, F.] Univ N Carolina, Dept Radiat Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Tamanoi, F.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90024 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Brigham & Women's Hospital; Harvard Medical School; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, 450 W Dr, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu	Hanker, Ariella/M-7136-2019; Mitin, Natalia/E-8043-2012	Hanker, Ariella/0000-0002-8655-8341; Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454	National Institutes of Health [CA042978, CA109550, CA67771, CA41996]; Department of Defense Breast Cancer Research Program predoctoral fellowship [BC061107]; NATIONAL CANCER INSTITUTE [R01CA041996, R01CA109550, R01CA042978, U19CA067771] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program predoctoral fellowship(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yoel Kloog, Said Sebti, and Andrew Hamilton for inhibitors, Lawrence Quilliam and Mark Philips for providing plasmid constructs, Stephen Young for MEF cell lines deficient in Rce1 and Icmt, and the UNC Michael Hooker Microscopy Facility for imaging assistance. This research was supported by grants from the National Institutes of Health to CJD (CA042978), ADC (CA109550), CJD and ADC (CA67771), and FT (CA41996). ABH was supported by a Department of Defense Breast Cancer Research Program predoctoral fellowship (BC061107).	Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Basso AD, 2005, J BIOL CHEM, V280, P31101, DOI 10.1074/jbc.M503763200; Blum R, 2008, RECENT PAT ANTI-CANC, V3, P31; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chakraborty S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-163; Chenette EJ, 2006, MOL BIOL CELL, V17, P3108, DOI 10.1091/mbc.E05-09-0896; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Gau CL, 2005, MOL CANCER THER, V4, P918, DOI 10.1158/1535-7163.MCT-04-0347; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Heo WD, 2003, CELL, V113, P315; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Kloog Y, 2004, SEMIN CANCER BIOL, V14, P253, DOI 10.1016/j.semcancer.2004.04.004; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Ma DZ, 2008, J BIOL CHEM, V283, P25963, DOI 10.1074/jbc.M802356200; Maehama T, 2008, J BIOL CHEM, V283, P35053, DOI 10.1074/jbc.M805822200; MAROM M, 1995, J BIOL CHEM, V270, P22263, DOI 10.1074/jbc.270.38.22263; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michaelson D, 2005, MOL BIOL CELL, V16, P1606, DOI 10.1091/mbc.e04-11-0960; Nakase Y, 2006, GENETICS, V173, P569, DOI 10.1534/genetics.106.056895; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rotblat B, 2008, METHOD ENZYMOL, V439, P467, DOI 10.1016/S0076-6879(07)00432-6; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sato T, 2008, METHOD ENZYMOL, V438, P307, DOI 10.1016/S0076-6879(07)38021-X; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; Weis B, 1999, ONCOGENE, V18, P2579, DOI 10.1038/sj.onc.1202602; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wienecke R, 1996, ONCOGENE, V13, P913; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yue W, 2005, INT J CANCER, V117, P746, DOI 10.1002/ijc.21222; Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008	54	67	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					380	391		10.1038/onc.2009.336	http://dx.doi.org/10.1038/onc.2009.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838215	Green Submitted, Green Accepted			2022-12-28	WOS:000273793200007
J	Abedini, MR; Muller, EJ; Bergeron, R; Gray, DA; Tsang, BK				Abedini, M. R.; Muller, E. J.; Bergeron, R.; Gray, D. A.; Tsang, B. K.			Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein	ONCOGENE			English	Article						FLIP; Akt; p53; chemoresistance; ovarian cancer	X-LINKED INHIBITOR; FAS-MEDIATED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; DOWN-REGULATION; UP-REGULATION; CELLULAR FLIP; PATHWAY; P53; RESISTANCE	Although Akt is a determinant of cisplatin (cis-diaminedi-chloroplatinum (CDDP)) resistance in ovarian cancer cells, which is related in part to its inhibitory action on p53 activation, precisely how Akt confers CDDP resistance is unclear. In this study, we show that CDDP induced p53-dependent Fas-associated death domain-like interleukin-1 beta-converting enzyme (FLICE)-like inhibitory protein (FLIP) degradation in chemosensitive ovarian cancer cells but not their resistant counterparts. CDDP induced FLIP-p53-Itch interaction, colocalization and FLIP ubiquitination in chemosensitive but not chemoresistant ovarian cancer cells. Moreover, although activated Akt inhibited CDDP-induced FLIP degradation and apoptosis in sensitive cells, these responses were facilitated by dominant-negative Akt expression in chemoresistant cells. Inhibition of Akt function also facilitated p53-FLIP interaction and FLIP ubiquitination, which were attenuated by p53 silencing. These results suggest that Akt confers resistance, in part, by modulating CDDP-induced, p53-dependent FLIP ubiquitination. Understanding the precise etiology of chemoresistance may improve treatment for ovarian cancer.	[Tsang, B. K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1Y 4E9, Canada; [Abedini, M. R.; Muller, E. J.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Cellular, Ottawa, ON, Canada; [Abedini, M. R.; Muller, E. J.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Mol Med, Ottawa, ON, Canada; [Abedini, M. R.] Birjand Univ Med Sci, Dept Physiol & Pharmacol, Birjand, Iran; [Muller, E. J.; Bergeron, R.] Ottawa Hosp Res Inst, Neurosci Program, Ottawa, ON K1Y 4E9, Canada; [Bergeron, R.] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; [Gray, D. A.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Biochem, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Microbiol, Ottawa, ON, Canada; [Gray, D. A.] Univ Ottawa, Dept Immunol, Ottawa, ON, Canada; [Gray, D. A.] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1Y 4E9, Canada; [Tsang, B. K.] Univ Ottawa, Dept Obstet, Ottawa, ON, Canada; [Tsang, B. K.] Univ Ottawa, Dept Gynaecol, Ottawa, ON, Canada; [Tsang, B. K.] Seoul Natl Univ, World Class Univ Major Biomodulat, Dept Agr Biotechnol, Coll Agr & Life Sci, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Seoul National University (SNU)	Tsang, BK (corresponding author), Ottawa Hosp Res Inst, Chron Dis Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	amiri, omolbanin/G-4425-2017; Darmian, Faezeh Vahedi/AAF-7755-2019; /U-3554-2018	amiri, omolbanin/0000-0002-3815-5716; Bergeron, Richard/0000-0002-5632-750X; Tsang, Benjamin K./0000-0003-1213-3946; /0000-0002-8634-4984	Cancer Research Society [11181]; Canadian Institutes of Health Research [MOP-79360]; National Research Foundation of Korea [R31-10056]; Ministry of Health and Medical Education Scholarship, Iran; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA [A2780s-AAkt2, A2780s-PHM6]	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Health and Medical Education Scholarship, Iran; H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA	This work was supported by grants from the Cancer Research Society (# 11181 to BKT) and the Canadian Institutes of Health Research (# MOP-79360 to RB), the WCU (World Class University) program through the Korea Science and Engineering Foundation funded by the National Research Foundation of Korea (R31-10056) and a New Investigator Award to RB. MRA was the recipient of a Ministry of Health and Medical Education Scholarship, Iran. We thank Dr Qiao Li (University of Ottawa, Canada) and Dr Kenneth Walsh (St Elizabeth's Medical Centre, Boston, MA, USA) for providing HA-tagged ubiquitin and adenoviral HA-tagged DN-Akt, respectively. A2780s-AAkt2 and A2780s-PHM6 cells were generously provided by Dr Jin Cheng (H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA).	Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925; Alladina SJ, 2005, J VASC RES, V42, P337, DOI 10.1159/000086599; Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Chandrasekaran Y, 2006, BIOL REPROD, V74, P560, DOI 10.1095/biolreprod.105.045146; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen SZ, 2007, MOL PHARMACOL, V72, P1269, DOI 10.1124/mol.107.037465; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Fraser M, 2003, CANCER RES, V63, P7081; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li JL, 2000, BIOL SIGNAL RECEPT, V9, P122; Mansouri A, 2003, ONCOL RES, V13, P399; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meinander A, 2007, J IMMUNOL, V178, P3944, DOI 10.4049/jimmunol.178.6.3944; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Moriyama H, 2007, IMMUNOL LETT, V109, P36, DOI 10.1016/j.imlet.2006.12.009; Moumen A, 2007, HEPATOLOGY, V45, P1210, DOI 10.1002/hep.21604; Muller E, 2004, EUR J NEUROSCI, V20, P3286, DOI 10.1111/j.1460-9568.2004.03785.x; Nam SY, 2003, CANCER SCI, V94, P1066, DOI 10.1111/j.1349-7006.2003.tb01402.x; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Sasaki H, 2000, CANCER RES, V60, P5659; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shim E, 2007, BIOTECHNOL LETT, V29, P141, DOI 10.1007/s10529-006-9213-5; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Starck L, 2005, EUR J IMMUNOL, V35, P1257, DOI 10.1002/eji.200425686; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zou W, 2007, CANCER BIOL THER, V6, P1614, DOI 10.4161/cbt.6.10.4763	38	95	100	5	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					11	25		10.1038/onc.2009.300	http://dx.doi.org/10.1038/onc.2009.300			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802016				2022-12-28	WOS:000273373500002
J	Szajnik, M; Szczepanski, MJ; Czystowska, M; Elishaev, E; Mandapathil, M; Nowak-Markwitz, E; Spaczynski, M; Whiteside, TL				Szajnik, M.; Szczepanski, M. J.; Czystowska, M.; Elishaev, E.; Mandapathil, M.; Nowak-Markwitz, E.; Spaczynski, M.; Whiteside, T. L.			TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer	ONCOGENE			English	Article						ovarian cancer; paclitaxel; TLR4; MyD88	TOLL-LIKE RECEPTORS; CELL-LINES; EPITHELIAL-CELLS; CARCINOMA; TAXOL; GENE; EXPRESSION; APOPTOSIS; OVEREXPRESSION; INTERLEUKIN-6	Toll-like receptors (TLRs) expressed on immune cells trigger inflammatory responses. TLRs are also expressed on ovarian cancer (OvCa) cells, but the consequences of signaling by the TLR4/MyD88 pathway in these cells are unclear. Here, TLR4 and MyD88 expression in OvCa tissues (n = 20) and cell lines (OVCAR3, SKOV3, AD10, A2780 and CP70) was evaluated by reverse transcriptase-PCR, western blots and immunohistochemistry. Cell growth, apoptosis, nuclear factor-kappa B (NF-kappa B) translocation, IRAK4 and TRIF expression and cJun phosphorylation were measured following tumor cell exposure to the TLR4 ligands, lipopolysaccharide (LPS) or paclitaxel (PTX). Culture supernatants were tested for cytokine levels. TLR4 was expressed in all tumors, tumor cell lines and normal epithelium. MyD88 was detectable in tumor tissues and in 3/5 OvCa lines but not in normal cells. In MyD88(+) SCOV3 cells, LPS or PTX binding to TLR4 induced IRAK4 activation and cJun phosphorylation, activated the NF-kappa B pathway and promoted interleukin (IL)-8, IL-6, vascular endothelial growth factor and monocyte chemotactic protein-1 production and resistance to drug-induced apoptosis. Silencing of TLR4 in SCOV3 cells with small interference RNA resulted in phosphorylated-cJun (p-cJun) downregulation and a loss of PTX resistance. In PTX-sensitive, MyD88(neg) A2780 cells, TLR4 stimulation upregulated TRIF, and TLR4 silencing eliminated this effect. Thus, TLR4/MyD88 signaling supports OvCa progression and chemoresistance, promoting immune escape. Oncogene (2009) 28, 4353-4363; doi: 10.1038/onc.2009.289; published online 12 October 2009	[Whiteside, T. L.] Univ Pittsburgh, Dept Pathol, Inst Canc, Sch Med, Pittsburgh, PA 15232 USA; [Szajnik, M.; Spaczynski, M.] Poznan Univ Med Sci, Dept Gynecol Oncol, Poznan, Poland; [Szczepanski, M. J.; Nowak-Markwitz, E.] Poznan Univ Med Sci, Dept Clin Immunol, Poznan, Poland	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Poznan University of Medical Sciences; Poznan University of Medical Sciences	Whiteside, TL (corresponding author), Univ Pittsburgh, Dept Pathol, Inst Canc, Sch Med, 5117 Ctr Ave,Suite 1-27, Pittsburgh, PA 15232 USA.	whitesidetl@upmc.edu	Mandapathil, Magis/AFL-3260-2022; Czystowska-Kuźmicz, Małgorzata/U-7933-2018; Czystowska-Kuzmicz, Malgorzata/AAC-6989-2020; Czystowska-Kuźmicz, Małgorzata/ABH-3220-2020	Czystowska-Kuźmicz, Małgorzata/0000-0001-9169-6194; Czystowska-Kuźmicz, Małgorzata/0000-0001-9169-6194	NIH [PO1 CA109688, NO1-HB37165]; National Heart Lung and Blood Institute (NHLBI); NATIONAL CANCER INSTITUTE [P01CA109688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart Lung and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B Hilldorfer for technical assistance and the Centre for Biologic Imaging at the University of Pittsburgh for assistance in performing confocal microscopy. This study was supported in part by NIH Grants PO1 CA109688 (TLW) and NO1-HB37165 (TLW) and by Heidi L Browning Ovarian Cancer Research Scholar Fund. Dr Szajnik was supported by the fellowship from the PACT Program of the National Heart Lung and Blood Institute (NHLBI).	Backhed F, 2003, MICROBES INFECT, V5, P951, DOI 10.1016/S1286-4579(03)00189-8; Bayry J, 2004, P NATL ACAD SCI USA, V101, P14210, DOI 10.1073/pnas.0402183101; BEHRENS BC, 1987, CANCER RES, V47, P414; Berek JS, 1999, ANN ONCOL, V10, P87, DOI 10.1023/A:1008323922057; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Brewer MA, 2003, CLIN CANCER RES, V9, P20; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Cimoli G, 2004, BBA-REV CANCER, V1705, P103, DOI 10.1016/j.bbcan.2004.10.001; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Duan ZF, 1999, GENE, V229, P75, DOI 10.1016/S0378-1119(99)00042-6; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Eskan MA, 2008, J IMMUNOL, V180, P1818, DOI 10.4049/jimmunol.180.3.1818; Fitzpatrick FA, 2003, INT IMMUNOPHARMACOL, V3, P1699, DOI 10.1016/j.intimp.2003.08.007; Fukata M, 2008, ONCOGENE, V27, P234, DOI 10.1038/sj.onc.1210908; Gallardo D, 1996, CANCER RES, V56, P4891; Girling JE, 2007, IMMUNOL CELL BIOL, V85, P481, DOI 10.1038/sj.icb.7100086; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Hefler LA, 2003, CANCER RES, V63, P3066; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Huang X, 2005, INVEST OPHTH VIS SCI, V46, P4209, DOI 10.1167/iovs.05-0185; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kassim SK, 2004, CLIN BIOCHEM, V37, P363, DOI 10.1016/j.clinbiochem.2004.01.014; Kawasaki K, 2001, J ENDOTOXIN RES, V7, P232, DOI 10.1177/09680519010070030701; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970; Lauzon NM, 2006, CELL IMMUNOL, V241, P102, DOI 10.1016/j.cellimm.2006.08.004; Lokshin AE, 2006, GYNECOL ONCOL, V102, P244, DOI 10.1016/j.ygyno.2005.12.011; MacRedmond R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-116; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; Molteni M, 2006, CANCER LETT, V235, P75, DOI 10.1016/j.canlet.2005.04.006; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Petty R, 1998, Pathol Oncol Res, V4, P97; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Siervo-Sassi RR, 2003, CANCER LETT, V190, P61, DOI 10.1016/S0304-3835(02)00579-7; Strauss L, 2007, J IMMUNOL, V178, P320, DOI 10.4049/jimmunol.178.1.320; Szczepanski M, 2007, EUR ARCH OTO-RHINO-L, V264, P525, DOI 10.1007/s00405-006-0215-7; Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeda K, 2007, SEMIN IMMUNOL, V19, P24; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tanimura N, 2008, BIOCHEM BIOPH RES CO, V368, P94, DOI 10.1016/j.bbrc.2008.01.061; Taxman DJ, 2003, CANCER RES, V63, P5095; Wang TH, 2006, ONCOGENE, V25, P4857, DOI 10.1038/sj.onc.1209498; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	49	176	199	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4353	4363		10.1038/onc.2009.289	http://dx.doi.org/10.1038/onc.2009.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19826413	Green Accepted			2022-12-28	WOS:000272876400004
J	Wortham, NC; Ahamed, E; Nicol, SM; Thomas, RS; Periyasamy, M; Jiang, J; Ochocka, AM; Shousha, S; Huson, L; Bray, SE; Coombes, RC; Ali, S; Fuller-Pace, FV				Wortham, N. C.; Ahamed, E.; Nicol, S. M.; Thomas, R. S.; Periyasamy, M.; Jiang, J.; Ochocka, A. M.; Shousha, S.; Huson, L.; Bray, S. E.; Coombes, R. C.; Ali, S.; Fuller-Pace, F. V.			The DEAD-box protein p72 regulates ER alpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ER alpha-positive breast cancer	ONCOGENE			English	Article						p68 RNA helicase; p72 RNA helicase; oestrogen receptor-alpha; gene regulation; breast cancer; tamoxifen	ESTROGEN-RECEPTOR-ALPHA; P68 RNA HELICASE; PHOSPHORYLATION; COACTIVATOR; ACTIVATION; TAMOXIFEN; PROMOTER; COMPLEX; DIFFERENTIATION; IDENTIFICATION	The DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have been shown to act as transcriptional co-activators for a diverse range of transcription factors, including oestrogen receptor-alpha (ER alpha). Here, we show that, although both proteins interact with and co-activate ER alpha in reporter gene assays, small interfering RNA-mediated knockdown of p72, but not p68, results in a significant inhibition of oestrogen-dependent transcription of endogenous ER alpha-responsive genes and oestrogen-dependent growth of MCF-7 and ZR75-1 breast cancer cells. Furthermore, immunohistochemical staining of ER alpha-positive primary breast cancers for p68 and p72 indicate that p72 expression is associated with an increased period of relapse-free and overall survival (P = 0.006 and 0.016, respectively), as well as being inversely associated with Her2 expression (P = 0.008). Conversely, p68 shows no association with relapse-free period, or overall survival, but it is associated with an increased expression of Her2 (P = 0.001), AIB-1 (P = 0.001) and higher tumour grade (P = 0.044). Our data thus highlight a crucial role for p72 in ER alpha co-activation and oestrogen-dependent cell growth and provide evidence in support of distinct but important roles for both p68 and p72 in regulating ER alpha activity in breast cancer. Oncogene (2009) 28, 4053-4064; doi:10.1038/onc.2009.261; published online 31 August 2009	[Ahamed, E.; Thomas, R. S.; Periyasamy, M.; Jiang, J.; Ochocka, A. M.; Coombes, R. C.; Ali, S.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 ONN, England; [Wortham, N. C.; Nicol, S. M.; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Scotland; [Jiang, J.; Shousha, S.] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Histopathol, London, England; [Huson, L.] Univ London Imperial Coll Sci Technol & Med, Stat Advisory Serv, London, England; [Bray, S. E.] Univ Dundee, Ninewells Hosp & Med Sch, Tayside Tissue Bank, Dundee DD1 9SY, Scotland	Imperial College London; University of Dundee; Imperial College London; Imperial College London; University of Dundee	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Hammersmith Hosp Campus, London W12 ONN, England.	simak.ali@imperial.ac.uk; f.v.fullerpace@dundee.ac.uk	periyasamy, manikandan/AAB-7924-2020; Thomas, Ross/C-6434-2008; Periyasamy, Manikandan/AAL-6211-2020; Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100; Periyasamy, Manikandan/0000-0001-7626-2531	Breast Cancer Campaign; Association for International Cancer Research; Cancer Research UK; Breast Cancer Research Trust; NIHR Biomedical Research Centre	Breast Cancer Campaign; Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Breast Cancer Research Trust; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	This work was supported by grants from the Breast Cancer Campaign, Association for International Cancer Research, Cancer Research UK and the Breast Cancer Research Trust. We are grateful for support from the NIHR Biomedical Research Centre funding scheme, and thank David Meek, Malcolm Parker and lab members for helpful discussions.	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodman RH, 2000, GENE DEV, V14, P1553; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Jiang J, 2007, CLIN CANCER RES, V13, P5769, DOI 10.1158/1078-0432.CCR-07-0822; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lopez-Garcia J, 2006, NUCLEIC ACIDS RES, V34, P6126, DOI 10.1093/nar/gkl875; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Morris C, 2002, ENDOCR-RELAT CANCER, V9, P267, DOI 10.1677/erc.0.0090267; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shin S, 2007, J CELL BIOCHEM, V101, P1252, DOI 10.1002/jcb.21250; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11	43	86	94	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4053	4064		10.1038/onc.2009.261	http://dx.doi.org/10.1038/onc.2009.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718048	Green Accepted, Green Submitted			2022-12-28	WOS:000272560500002
J	Deng, Z; Wan, M; Cao, P; Rao, A; Cramer, SD; Sui, G				Deng, Z.; Wan, M.; Cao, P.; Rao, A.; Cramer, S. D.; Sui, G.			Yin Yang 1 regulates the transcriptional activity of androgen receptor	ONCOGENE			English	Article						androgen receptor; Yin Yang 1; prostate cancer; PSA promoter; transcription	PROSTATE-SPECIFIC ANTIGEN; GENE-EXPRESSION; CANCER CELLS; FACTOR YY1; FACTOR YIN-YANG-1; RESPONSE ELEMENT; RNAI TECHNOLOGY; IN-VIVO; P53; REPRESSION	The multifunctional protein Yin Yang 1 (YY1) has an important role in epigenetic regulation of gene expression. YY1 is highly expressed in various types of cancers, including prostate cancer. Currently, the mechanism underlying the functional role of YY1 in prostate tumorigenesis remains unclear. In this report, we investigated the functional interplay between YY1 and androgen receptor (AR), and the effect of YY1 on AR-mediated transcription. We found that YY1 physically interacts with AR both in a cell-free system and in cultured cells. YY1 is required for the optimal transcriptional activity of AR in promoting the transcription of the prostate-specific antigen (PSA) promoter. However, ectopic YY1 expression in LNCaP cells did not further enhance the reporter driven by the PSA promoter, suggesting that an optimal level of YY1 is already established in prostate tumor cells. Consistently, YY1 depletion in LNCaP cells reduced endogenous PSA levels, but overexpressed YY1 did not significantly increase PSA expression. We also observed that YY1-AR interaction is essential to YY1-mediated transcription activity of AR and YY1 is a necessary component in the complex binding to the androgen response element. Thus, our study demonstrates that YY1 interacts with AR and regulates its transcriptional activity. Oncogene (2009) 28, 3746-3757; doi: 10.1038/onc.2009.231; published online 10 August 2009	[Sui, G.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sui, G (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 1 Med Ctr Blvd,Hanes 4052, Winston Salem, NC 27157 USA.	gsui@wfubmc.edu	Deng, Zhiyong/D-4656-2012	Sui, Guangchao/0000-0002-8164-5585	Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University; NCI training [5T32CA079448-09]; NATIONAL CANCER INSTITUTE [T32CA079448] Funding Source: NIH RePORTER	Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University; NCI training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Purnima Dubey and Ms Karen Klein for critical reading of the article. We also thank Dr Suzy Torti and Dr Wei Wang for providing the access to some equipment, and Dr Kazushi Inoue for the EMSA protocol. The support for the work came from the grant of American Cancer Society (RSG09-082-01-MGO) and the startup fund from the Department of Cancer Biology and Comprehensive Cancer Center of Wake Forest University to GS. PC is supported by NCI training Grant 5T32CA079448-09.	Bain M, 2005, EUR J CELL BIOL, V84, P543, DOI 10.1016/j.ejcb.2004.12.024; Baritaki S, 2007, INT J ONCOL, V31, P69; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Craft N, 1999, CANCER RES, V59, P5030; de Nigris F, 2006, EUR J CANCER, V42, P2420, DOI 10.1016/j.ejca.2006.06.008; Dehm SM, 2005, EXPERT REV ANTICANC, V5, P63, DOI 10.1586/14737140.5.1.63; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Gross M, 2004, ONCOGENE, V23, P3059, DOI 10.1038/sj.onc.1207443; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hirawat S, 2003, CANCER INVEST, V21, P400, DOI 10.1081/CNV-120018232; Joshi B, 2007, BIOCHEM J, V401, P155, DOI 10.1042/BJ20060364; Koivisto P, 1997, CANCER RES, V57, P314; Lapouge G, 2007, INT J CANCER, V121, P1238, DOI 10.1002/ijc.22830; Rao A, 2003, UROLOGY, V61, P864, DOI 10.1016/S0090-4295(02)02414-7; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Rylski M, 2008, J BIOL CHEM, V283, P35140, DOI 10.1074/jbc.M804540200; Santiago FS, 2007, CIRC RES, V101, P146, DOI 10.1161/CIRCRESAHA.106.145235; Seligson D, 2005, INT J ONCOL, V27, P131; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sui G, 2005, METH MOL B, V309, P205; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Taplin ME, 1999, CANCER RES, V59, P2511; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	43	52	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3746	3757		10.1038/onc.2009.231	http://dx.doi.org/10.1038/onc.2009.231			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668226	Green Accepted			2022-12-28	WOS:000271023200007
J	Komatsu, S; Takenobu, H; Ozaki, T; Ando, K; Koida, N; Suenaga, Y; Ichikawa, T; Hishiki, T; Chiba, T; Iwama, A; Yoshida, H; Ohnuma, N; Nakagawara, A; Kamijo, T				Komatsu, S.; Takenobu, H.; Ozaki, T.; Ando, K.; Koida, N.; Suenaga, Y.; Ichikawa, T.; Hishiki, T.; Chiba, T.; Iwama, A.; Yoshida, H.; Ohnuma, N.; Nakagawara, A.; Kamijo, T.			Plk1 regulates liver tumor cell death by phosphorylation of TAp63	ONCOGENE			English	Article						p63; phosphorylation; Plk1; apoptosis	POLO-LIKE KINASE-1; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; P73-DEPENDENT APOPTOSIS; EPIDERMAL DEVELOPMENT; PHYSICAL INTERACTION; P63 EXPRESSION; P53 HOMOLOG; CANCER; GENE	We previously found that Plk1 inhibited the p53/p73 activity through its direct phosphorylation. In this study, we investigated the functional role of Plk1 in modulating the p53 family member TAp63, resulting in the control of apoptotic cell death in liver tumor cells. Immunoprecipitation and in vitro pull-down assay showed that p63 binds to the kinase domain of Plk1 through its DNA-binding region. in vitro kinase assay indicated that p63 is phosphorylated by Plk1 at Ser-52 of the transactivating (TA) domain. Plk1 decreased the protein stability of TAp63 by its phosphorylation and suppressed TAp63-induced cell death. Furthermore, Plk1 knockdown in p53-mutated liver tumor cells transactivated p53 family downstream effectors, PUMA, p21(Cip1/WAF1) and 14-3-3 sigma, and induced apoptotic cell death. Double knockdown of Plk1/p63 attenuated Plk1 knockdown-induced apoptotic cell death and transactivation. Intriguingly, both Plk1 and p63 are highly expressed in the side population (SP) fraction of liver tumor cells compared to non-SP fraction cells, suggesting the significance of Plk1/TAp63 in the control of cell death in tumor-initiating SP fraction cells. Thus, Plk1 controls TAp63 by its phosphorylation and regulates apoptotic cell death in liver tumor cells. Plk1/TAp63 may be a suitable candidate as a molecular target of liver tumor treatments. Oncogene (2009) 28, 3631-3641; doi: 10.1038/onc.2009.216; published online 10 August 2009	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, Chiba 2608717, Japan; [Komatsu, S.; Hishiki, T.; Yoshida, H.; Ohnuma, N.] Chiba Univ, Grad Sch Med, Dept Pediat Surg, Chiba, Japan; [Chiba, T.; Iwama, A.] Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba, Japan	Chiba Cancer Center; Chiba University; Chiba University	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386; Takenobu, Hisanori/0000-0001-7355-1565	Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai for technical assistance and Daniel Mrozek, Medical English Service, for editorial assistance. This work was supported, in part, by a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer; a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan; and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Blandino G, 2004, CELL CYCLE, V3, P886; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227; Eckerdt F, 2006, CANCER RES, V66, P6895, DOI 10.1158/0008-5472.CAN-06-0358; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Ghioni P, 2005, CELL CYCLE, V4, P183, DOI 10.4161/cc.4.1.1359; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Huang YP, 2004, CELL CYCLE, V3, P1587, DOI 10.4161/cc.3.12.1290; Ichikawa T, 2008, ONCOGENE, V27, P409, DOI 10.1038/sj.onc.1210658; Kato S, 1999, CANCER RES, V59, P5908; Koga F, 2003, CLIN CANCER RES, V9, P5501; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; MacPartlin M, 2008, J BIOL CHEM, V283, P15754, DOI 10.1074/jbc.M801394200; Massion PP, 2003, CANCER RES, V63, P7113; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Yamada S, 2004, ONCOGENE, V23, P5901, DOI 10.1038/sj.onc.1207782; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhou JB, 2008, CELL CYCLE, V7, P1360, DOI 10.4161/cc.7.10.5953	44	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3631	3641		10.1038/onc.2009.216	http://dx.doi.org/10.1038/onc.2009.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19668228				2022-12-28	WOS:000270851800004
J	Chung, S; Furihata, M; Tamura, K; Uemura, M; Daigo, Y; Nasu, Y; Miki, T; Shuin, T; Fujioka, T; Nakamura, Y; Nakagawa, H				Chung, S.; Furihata, M.; Tamura, K.; Uemura, M.; Daigo, Y.; Nasu, Y.; Miki, T.; Shuin, T.; Fujioka, T.; Nakamura, Y.; Nakagawa, H.			Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways	ONCOGENE			English	Article						CRPC; PKIB; protein kinase A; Akt phosphorylation	DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNITS; SIGNAL-TRANSDUCTION; ANDROGEN RECEPTOR; CATALYTIC SUBUNIT; GENE-EXPRESSION; PHOSPHORYLATION; CAMP; MITOXANTRONE; PREDNISONE	Prostate cancer (PC) is the most common malignancy in males. Despite high response rates and clinical benefits, androgen-ablation therapy is ineffective for advanced or relapsed PC because of the emergence of aggressive castration-resistant prostate cancer (CRPC). Through our genome-wide gene expression analysis of PC cells purified from clinical CRPC tissues, we here identified a novel molecular target, PKIB (cAMP-dependent protein kinase inhibitor-beta), which was overexpressed specifically in CRPCs and aggressive PCs. Immunohistochemical analysis confirmed its overexpression in CRPCs and its strong correlation with high Gleason scores of PCs. Knockdown of PKIB by siRNA resulted in drastic growth suppression of PC cells, and, concordantly, exogenous introduction of PKIB into PC cells enhanced their growth and mobility. We found the direct interaction between PKIB and cAMP-dependent protein kinase A catalytic subunit (PKA-C), and showed that knockdown of PKIB in PC cells diminished the nuclear translocation of PKA-C. Knockdown of PKIB also decreased the phosphorylation level of Akt at Ser473 in PC cells, and exogenous PKIB introduction enhanced Akt phosphorylation in PC cells by incorporating with endogenous PKA-C kinase. In vitro kinase assay validated the recombinant PKIB enhanced phosphorylation of Akt at Ser473 by PKA-C kinase. These findings show that PKIB and PKA-C kinase can have critical functions of aggressive phenotype of PCs through Akt phosphorylation and that they should be a promising molecular target for PC treatment. Oncogene (2009) 28, 2849-2859; doi:10.1038/onc.2009.144; published online 1 June 2009	[Nakagawa, H.] RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, Tokyo 1088639, Japan; [Chung, S.; Tamura, K.; Uemura, M.; Daigo, Y.; Nakamura, Y.; Nakagawa, H.] Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome, Tokyo, Japan; [Furihata, M.] Kochi Med Sch, Dept Pathol, Nankoku, Kochi, Japan; [Tamura, K.; Shuin, T.] Kochi Med Sch, Dept Urol, Nankoku, Kochi, Japan; [Nasu, Y.] Okayama Univ, Sch Med, Dept Urol, Okayama 700, Japan; [Miki, T.] Kyoto Prefectural Univ Med, Dept Urol, Kyoto, Japan; [Fujioka, T.] Iwate Med Univ, Dept Urol, Morioka, Iwate 020, Japan	RIKEN; University of Tokyo; Kochi University; Kochi University; Okayama University; Kyoto Prefectural University of Medicine; Iwate Medical University	Nakagawa, H (corresponding author), RIKEN, Ctr Genom Med, Lab Biomarker Dev, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hidewaki@ims.u-tokyo.ac.jp	uemura, motohide/G-6101-2011	Daigo, Yataro/0000-0002-0915-3025	Japan Society for the Promotion of Science [18590323, 00L01402]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We would like to thank Ms Mami U and Ms Hitomi Uchida for their technical assistance, and Dr Ryo Takada at Iwate Medical University for his preparation of prostate cancer tissues. This work was supported by Grant-in-Aid for Scientific Research #18590323 (H Nakagawa) and Research for the Future Program Grants #00L01402 (Y Nakamura) from the Japan Society for the Promotion of Science.	Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Chio CC, 2004, CELL SIGNAL, V16, P565, DOI 10.1016/j.cellsig.2003.10.003; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dalton GD, 2006, NEUROPEPTIDES, V40, P23, DOI 10.1016/j.npep.2005.10.002; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deeble PD, 2007, CANCER RES, V67, P3663, DOI 10.1158/0008-5472.CAN-06-2616; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Filippa N, 1999, MOL CELL BIOL, V19, P4989; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hsing AW, 2001, EPIDEMIOL REV, V23, P3, DOI 10.1093/oxfordjournals.epirev.a000792; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; LALLI E, 1994, J BIOL CHEM, V269, P17359; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Malik SN, 2002, CLIN CANCER RES, V8, P1168; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Miller WR, 2002, ANN NY ACAD SCI, V968, P37, DOI 10.1111/j.1749-6632.2002.tb04325.x; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Orloff MS, 2008, ONCOGENE, V27, P5387, DOI 10.1038/onc.2008.237; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taylor SS, 2005, BBA-PROTEINS PROTEOM, V1754, P25, DOI 10.1016/j.bbapap.2005.08.024; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WEN W, 1994, J BIOL CHEM, V269, P32214; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381	38	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2849	2859		10.1038/onc.2009.144	http://dx.doi.org/10.1038/onc.2009.144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19483721				2022-12-28	WOS:000268917100001
J	Yap, LF; Jenei, V; Robinson, CM; Moutasim, K; Benn, TM; Threadgold, SP; Lopes, V; Wei, W; Thomas, GJ; Paterson, IC				Yap, L. F.; Jenei, V.; Robinson, C. M.; Moutasim, K.; Benn, T. M.; Threadgold, S. P.; Lopes, V.; Wei, W.; Thomas, G. J.; Paterson, I. C.			Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation	ONCOGENE			English	Article						Eps8; oral cancer; integrin; migration; Rac1; invasion	EXTRACAPSULAR SPREAD; CANCER; EXPRESSION; IDENTIFICATION; GROWTH; HEAD; INTEGRIN-ALPHA(V)BETA(6); TRANSFORMATION; PROGRESSION; MOTILITY	Oral squamous cell carcinoma (OSCC) is a lethal disease and early death usually occurs as a result of local invasion and regional lymph node metastases. Current treatment regimens are, to a certain degree, inadequate, with a 5-year mortality rate of around 50% and novel therapeutic targets are urgently required. Using expression microarrays, we identified the eps8 gene as being overexpressed in OSCC cell lines relative to normal oral keratinocytes, and confirmed these findings using RT-PCR and western blotting. In human tissues, we found that Eps8 was upregulated in OSCC (32% of primary tumors) compared with normal oral mucosa, and that expression correlated significantly with lymph node metastasis (P = 0.032), suggesting a disease-promoting effect. Using OSCC cell lines, we assessed the functional role of Eps8 in tumor cells. Although suppression of Eps8 produced no effect on cell proliferation, both cell spreading and migration were markedly inhibited. The latter cell functions may be modulated through the small GTP-ase, Rac1 and we used pull-down assays to investigate the role of Eps8 in Rac1 signaling. We found that alpha v beta 6- and alpha 5 beta 1-integrin-dependent activation of Rac1 was mediated through Eps8. Knockdown of either Eps8 or Rac1, inhibited integrin-dependent cell migration similarly and transient expression of constitutively active Rac1 restored migration of cells in which Eps8 expression had been suppressed. We also showed that knockdown of Eps8 inhibited tumor cell invasion in an organotypic model of OSCC. These data suggest that Eps8 and Rac1 are part of an integrated signaling pathway modulating integrin-dependent tumour cell motility and identify Eps8 as a possible therapeutic target. Oncogene ( 2009) 28, 2524-2534; doi: 10.1038/onc.2009.105; published online 18 May 2009	[Jenei, V.; Moutasim, K.; Thomas, G. J.] Univ Southampton, Sch Med, Canc Sci Div, Southampton, Hants, England; [Yap, L. F.; Benn, T. M.; Threadgold, S. P.; Paterson, I. C.] Univ Bristol, Dept Oral & Dent Sci, Bristol, Avon, England; [Yap, L. F.] Canc Res Initiat Fdn, Kuala Lumpur, Malaysia; [Jenei, V.; Moutasim, K.; Thomas, G. J.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Tumor Biol Ctr, London, England; [Robinson, C. M.] Univ Newcastle, Sch Dent Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Lopes, V.] Univ Edinburgh, Edinburgh Dent Inst, Edinburgh, Midlothian, Scotland; [Wei, W.] Univ Birmingham, Inst Canc Studies, Birmingham, W Midlands, England	University of Southampton; University of Bristol; University of London; Queen Mary University London; Newcastle University - UK; University of Edinburgh; University of Birmingham	Thomas, GJ (corresponding author), Univ Southampton, Sch Med, Canc Sci Div, Tremona Rd, Southampton, Hants, England.	g.thomas@soton.ac.uk	Paterson, Ian/G-8688-2011; Yap, Lee-Fah/M-1065-2016; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Yap, Lee-Fah/0000-0002-6815-3607; Robinson, Max/0000-0003-4491-6865; Wei, Wenbin/0000-0003-1288-6999	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	The Cancer Research Initiatives Foundation, Malaysia and The Health Foundation supported the research.	Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Croce A, 2004, NAT CELL BIOL, V6, P1173, DOI 10.1038/ncb1198; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Inobe M, 1999, BIOCHEM BIOPH RES CO, V266, P216, DOI 10.1006/bbrc.1999.1782; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeon GA, 2004, INT J CANCER, V112, P249, DOI 10.1002/ijc.20399; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Myers JN, 2001, CANCER-AM CANCER SOC, V92, P3030, DOI 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P; Nystrom ML, 2006, CANCER RES, V66, P10833, DOI 10.1158/0008-5472.CAN-06-1640; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Thirthagiri E, 2007, CANCER LETT, V258, P276, DOI 10.1016/j.canlet.2007.09.008; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Woolgar JA, 2003, ORAL ONCOL, V39, P130, DOI 10.1016/S1368-8375(02)00030-1; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yeudall WA, 2005, ORAL ONCOL, V41, P698, DOI 10.1016/j.oraloncology.2005.03.004	38	64	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2524	2534		10.1038/onc.2009.105	http://dx.doi.org/10.1038/onc.2009.105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448673				2022-12-28	WOS:000267806800005
J	Liu, Y; Pixley, R; Fusaro, M; Godoy, G; Kim, E; Bromberg, ME; Colman, RW				Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.			Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway	ONCOGENE			English	Article						Hka; prostate cancer; EGFR; uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; HUMAN CARCINOMA; TUBE FORMATION; TUMOR-GROWTH; IN-VIVO; KALLIKREIN; DORMANCY; PLASMA	Upregulation and activation of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a variety of cancers have been shown to be associated with poor prognosis. High-molecular-weight kininogen can be hydrolysed by plasma kallikrein to bradykinin and cleaved high-molecular-weight kininogen (HKa). HKa and its domain 5 (D5) both have been shown to have potent anti-angiogenic activity. We now show that HKa blocks human prostate cancer cell (DU145) migration by 76.0 +/- 2.4% at 300 nM and invasion by 78.0 +/- 12.9% at 11.1 nM. D5 inhibits tumor migration and invasion in a concentration-dependent manner. Stimulation by basic fibroblast growth factor (bFGF) or vascular endothelial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) on the surface of DU145 cells. The co-localization of uPAR and EGFR is prevented by HKa. Immunoprecipitation suggests that uPAR, EGFR and alpha 5 beta 1 integrin formed a ternary complex. Immunoblotting shows that HKa significantly decreases the bFGF-transactivated phosphorylation of EGFR at Tyr 1173 between 30 min and 4 h. The phosphorylation of extracellular signal-regulated kinase (ERK) and AKT, which are downstream effectors of EGFR, is also inhibited by HKa. These novel data indicate that HKa and D5 inhibit migration and invasion of human prostate cancer cells through an EGFR/uPAR pathway, suggesting the therapeutic potential of HKa and D5 to decrease metastasis of human prostate cancer. Oncogene (2009) 28, 2756-2765; doi:10.1038/onc.2009.132; published online 1 June 2009	[Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu, Y (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St,Room 808 OMS, Philadelphia, PA 19140 USA.	yuchuan@temple.edu	fusaro, maria/R-3386-2016; Fusaro, Maria/AAA-5509-2019	fusaro, maria/0000-0001-9478-4851; Fusaro, Maria/0000-0001-9478-4851	National Institutes of Health [R01 CA83121, R01 AR051713, T32 HL07777]; NATIONAL CANCER INSTITUTE [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051713] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by National Institutes of Health Grants R01 CA83121, R01 AR051713 and T32 HL07777 to RW Colman.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Cao DJ, 2004, CIRC RES, V94, P1227, DOI 10.1161/01.RES.0000126567.75232.46; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; Colman RW, 1998, CLIN REV ALLERG IMMU, V16, P365, DOI 10.1007/BF02737657; Colman RW, 2006, CURR PHARM DESIGN, V12, P2599, DOI 10.2174/138161206777698710; Colman RW, 1999, IMMUNOPHARMACOLOGY, V43, P103, DOI 10.1016/S0162-3109(99)00068-5; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Katkade V, 2005, THROMB HAEMOSTASIS, V94, P606, DOI 10.1160/TH04-12-0834; KIRCHHEIMER JC, 1985, INVAS METAST, V5, P344; Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Liu YC, 2004, J BIOL CHEM, V279, P36142, DOI 10.1074/jbc.M405039200; Liu YC, 2008, AM J PHYSIOL-CELL PH, V295, pC257, DOI 10.1152/ajpcell.00569.2007; Liu Y, 2008, EXP CELL RES, V314, P774, DOI 10.1016/j.yexcr.2007.10.008; Ma Z, 2001, J CELL SCI, V114, P3387; Mahdi F, 2004, J BIOL CHEM, V279, P16621, DOI 10.1074/jbc.M313850200; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Miyake H, 1999, INT J ONCOL, V14, P535; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Pixley RA, 2003, J THROMB HAEMOST, V1, P1791, DOI 10.1046/j.1538-7836.2003.00291.x; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlomm T, 2007, CLIN CANCER RES, V13, P6579, DOI 10.1158/1078-0432.CCR-07-1257; Schmaier AH, 2007, J THROMB HAEMOST, V5, P2323, DOI 10.1111/j.1538-7836.2007.02770.x; Wang XQ, 2005, J INVEST DERMATOL, V124, P839, DOI 10.1111/j.0022-202X.2005.23669.x; Yarden Y, 2001, EUR J CANCER, V37, pS3	31	23	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2756	2765		10.1038/onc.2009.132	http://dx.doi.org/10.1038/onc.2009.132			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483730	Green Accepted			2022-12-28	WOS:000268452900006
J	Lopez-Soto, A; Folgueras, AR; Seto, E; Gonzalez, S				Lopez-Soto, A.; Folgueras, A. R.; Seto, E.; Gonzalez, S.			HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer	ONCOGENE			English	Article						ULBPs; NKG2D; HDAC3; tumour immunosurveillance	HISTONE DEACETYLASE INHIBITORS; I-RELATED CHAIN; NK CELLS; T-CELLS; RECEPTOR; SP3; CYTOTOXICITY; ACTIVATION; PROMOTER; SUSCEPTIBILITY	The expression of the NKG2D ligands on cancer cells leads to their recognition and elimination by host immune responses mediated by natural killer and T cells. UL160-binding proteins (ULBPs) are NKG2D ligands, which are scarcely expressed in epithelial tumours, favouring their evasion from the immune system. Herein, we investigated the epigenetic mechanisms underlying the repression of ULBPs in epithelial cancer cells. We show that ULBP1-3 expression is increased in tumour cells after exposure to the inhibitor of histone deacetylases (HDACs) trichostatin A (TSA), which enhances the natural killer cell-mediated cytotoxicity of HeLa cells. Our experiments showed that the transcription factor Sp3 is crucial in the activation of the ULBP1 promoter by TSA. Furthermore, by small interfering RNA-mediated knockdown and overexpression of HDAC1-3, we showed that HDAC3 is a repressor of ULBPs expression in epithelial cancer cells. Remarkably, TSA treatment caused the complete release of HDAC3 from the ULBP1-3 promoters. HDAC3 is recruited to the ULBP1 promoter through its interaction with Sp3 and TSA treatment interfered with this association. Together, we describe a new mechanism by which cancer cells may evade the immune response through the epigenetic modulation of the ULBPs expression and provide a model in which HDAC inhibitors may favour the elimination of transformed cells by increasing the immunogenicity of epithelial tumours. Oncogene (2009) 28, 2370-2382; doi:10.1038/onc.2009.117; published online 11 May 2009	[Gonzalez, S.] Univ Oviedo, Dept Biol Func, IUOPA, Fac Med, E-33006 Oviedo, Spain; [Folgueras, A. R.] Univ Oviedo, Dept Bioquim & Biol Mol, IUOPA, E-33006 Oviedo, Spain; [Seto, E.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Gonzalez, S (corresponding author), Univ Oviedo, Dept Biol Func, IUOPA, Fac Med, Julian Claveria S-N, E-33006 Oviedo, Spain.	segundog@uniovi.es	Folgueras, Alicia/B-3281-2017; López-Soto, Alejandro/A-9779-2018; Gonzalez, Segundo/AAK-8719-2021	Folgueras, Alicia/0000-0003-3426-9502; López-Soto, Alejandro/0000-0002-6360-5205; Gonzalez, Segundo/0000-0003-4631-9255	Spanish grants of Fondo de Investigaciones Sanitarias [PI-06/0841]; FICYT of Asturias [BP06-99]	Spanish grants of Fondo de Investigaciones Sanitarias; FICYT of Asturias	We thank Dr Spies and Amgen for kindly providing ULBP antibodies, Dr Garcia de Herreros for providing HT-29 M6 cells, Banco de Tumores del Hospital Universitario Central de Asturias for providing human tumour samples, Dr G Gill for providing the pBS/U6-Scrambled plasmid, Dr A Astudillo for histopathological evaluation, Dr C Lopez-Otin for helpful comments and A Vallina and MS Pitiot for technical assistance. This work was supported by the Spanish grants of Fondo de Investigaciones Sanitarias PI-06/0841. ALS holds a predoctoral fellowship from FICYT of Asturias (BP06-99).	Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Andresen L, 2007, J IMMUNOL, V179, P8235, DOI 10.4049/jimmunol.179.12.8235; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Diermayr S, 2008, BLOOD, V111, P1428, DOI 10.1182/blood-2007-07-101311; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gonzalez S, 2008, TRENDS IMMUNOL, V29, P397, DOI 10.1016/j.it.2008.04.007; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Kato N, 2007, LEUKEMIA, V21, P2103, DOI 10.1038/sj.leu.2404862; Knutson SK, 2008, EMBO J, V27, P1017, DOI 10.1038/emboj.2008.51; Kottilil S, 2006, J IMMUNOL, V176, P1107, DOI 10.4049/jimmunol.176.2.1107; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lopez-Larrea C, 2008, TRENDS MOL MED, V14, P179, DOI 10.1016/j.molmed.2008.02.004; Lopez-Soto A, 2006, J BIOL CHEM, V281, P30419, DOI 10.1074/jbc.M604868200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; Pende D, 2002, CANCER RES, V62, P6178; Ropero S, 2008, ONCOGENE, V27, P4008, DOI 10.1038/onc.2008.31; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Sowa Y, 1999, CANCER RES, V59, P4266; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Waldhauer I, 2008, ONCOGENE, V27, P5932, DOI 10.1038/onc.2008.267; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689	45	85	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2370	2382		10.1038/onc.2009.117	http://dx.doi.org/10.1038/onc.2009.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430493				2022-12-28	WOS:000267342400002
J	Piao, C; Jin, M; Kim, HB; Lee, SM; Amatya, PN; Hyun, JW; Chang, IY; You, HJ				Piao, C.; Jin, M.; Kim, H. B.; Lee, S. M.; Amatya, P. N.; Hyun, J-W; Chang, I-Y; You, H. J.			Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2	ONCOGENE			English	Article						p53R2; MEK2; ERK1/2; invasion; transformation	CELL-CYCLE CHECKPOINT; HUMAN CANCER-CELLS; DNA-SYNTHESIS; THYMIDYLATE SYNTHASE; RENAL-FAILURE; R2 COMPONENT; MAP KINASE; DNTP POOLS; PROTEIN; REPAIR	The p53-dependent RR small subunit (p53R2) protein, a newly identified member of the ribonucleotide reductase family, plays a key role in the p53-dependent cellular response to DNA. Several recent studies have suggested that p53R2 also plays an important role in suppressing the invasive potential of human cancer cells. However, the cellular mechanism that regulates invasiveness remains largely unknown. In this study, we show that p53R2 interacts with MEK2 (extracellular signal-regulated kinase (ERK) kinase 2-mitogen-activated protein kinase (MAPK) kinase 2), the molecule immediately upstream of ERK in the Ras-Raf-MAPK signaling cascade. In co-immunoprecipitation and immunofluorescence analyses, we found that p53R2 and MEK2 interact physically in cultured mammalian cells, and that the p53R2 segment comprising amino acids 161-206 is critical for this interaction. Moreover, serum-induced phosphorylation of MEK1/2 and ERK1/2 was greatly augmented in human cancer cells expressing small-interfering RNA against p53R2. On the other hand, phosphorylation of MEK1/2 and ERK1/2 in human cancer cells was markedly attenuated by overexpression of p53R2. Furthermore, MEK2 was required for p53R2 knockdown-induced enhancement of the invasive ability and anchorage-independent growth of human lung cancer H1299 cells. Taken together, these findings show that p53R2 negatively modulates serum-induced MEK-ERK activity and inhibits the MEK-ERK-mediated malignancy potential of human cancer cells. Oncogene (2009) 28, 2173-2184; doi: 10.1038/onc.2009.84; published online 27 April 2009	[Piao, C.; Jin, M.; Kim, H. B.; Lee, S. M.; Amatya, P. N.; Chang, I-Y; You, H. J.] Chosun Univ, DNA Repair Res Ctr, Kwangju 501759, South Korea; [Piao, C.; Kim, H. B.; You, H. J.] Chosun Univ, Dept Pharmacol, Kwangju 501759, South Korea; [Jin, M.] Yanbian Univ, Sch Med, Dept Biochem, Yanji, Jilin, Peoples R China; [Hyun, J-W] Jeju Natl Univ, Coll Med, Dept Biochem, Cheju, Jeju Do, South Korea; [Chang, I-Y] Chosun Univ, Dept Anat, Kwangju 501759, South Korea	Chosun University; Chosun University; Yanbian University; Jeju National University; Chosun University	You, HJ (corresponding author), 2F Chosun Univ, Sch Med, DNA Repair Res Ctr, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@chosun.ac.kr		, Chunmei/0000-0002-2975-7336; You, Ho Jin/0000-0002-0530-4017	Ministry of Science and Technology, the Korean Government [M 1063901, M 20706000032]; Chosun University	Ministry of Science and Technology, the Korean Government(Ministry of Science & Technology (MOST), Republic of Korea); Chosun University	This research was supported by a Grant [ M 1063901] [ M 20706000032] from the Ministry of Science and Technology, the Korean Government and funds from the Chosun University, 2002.	Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Cao MY, 2003, CLIN CANCER RES, V9, P4553; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; Chen M, 2007, ONCOGENE, V26, P4817, DOI 10.1038/sj.onc.1210273; Devlin HL, 2008, MOL CANCER RES, V6, P808, DOI 10.1158/1541-7786.MCR-07-2027; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Fan HZ, 1998, CANCER RES, V58, P1650; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Gautam A, 2003, ONCOGENE, V22, P2135, DOI 10.1038/sj.onc.1206232; Gautam A, 2006, CANCER RES, V66, P6497, DOI 10.1158/0008-5472.CAN-05-4462; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Liu XY, 2007, CLIN COLORECTAL CANC, V6, P374, DOI 10.3816/CCC.2007.n.007; Liu XY, 2006, CLIN CANCER RES, V12, P6337, DOI 10.1158/1078-0432.CCR-06-0799; Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tsai MH, 2006, ONCOGENE, V25, P622, DOI 10.1038/sj.onc.1209082; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873; Xue LJ, 2007, CANCER RES, V67, P16, DOI 10.1158/0008-5472.CAN-06-3200; Xue LJ, 2006, CANCER RES, V66, P1900, DOI 10.1158/0008-5472.CAN-05-2656; Xue LJ, 2003, CANCER RES, V63, P980; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Yoshida T, 2006, INT J CANCER, V118, P1395, DOI 10.1002/ijc.21538; Zheng Z, 2007, NEW ENGL J MED, V356, P800, DOI 10.1056/NEJMoa065411; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	37	28	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2173	2184		10.1038/onc.2009.84	http://dx.doi.org/10.1038/onc.2009.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398949				2022-12-28	WOS:000266451300006
J	Osanai, M; Sawada, N; Lee, GH				Osanai, M.; Sawada, N.; Lee, G-H			Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1	ONCOGENE			English	Article						vitamin A; retinoic acid; CYP26A1; apoptosis; tumorigenesis	VITAMIN-A-DEFICIENCY; HUMAN BREAST; DIFFERENTIATION; EXPRESSION; APOPTOSIS	Vitamin A deficiency (VAD) is associated with increased susceptibility to carcinogenesis in animal models and elevated risk for a number of human cancers. Here, we found that CYP26A1, the gene encoding a cytochrome P450 enzyme specifically involved in metabolic inactivation of retinoic acid (RA), the most active vitamin A derivative, is highly expressed in 42% (27/65) of primary breast cancers. We also showed that enhanced expression of CYP26A1 suppresses cellular responses to anoikis and consequently promotes anchorage-independent growth. This transformed phenotype was sufficient to markedly increase tumorigenic and metastatic potential. Suppression of CYP26A1 significantly reversed the CYP26A1-mediated oncogenic characteristics, suggesting a direct link between intracellular RA status and tumorigenicity. Our observations provide strong evidence for oncogenic and cell survival properties of CYP26A1 in carcinogenesis, and suggest mechanisms whereby VAD might promote cancer development. Oncogene (2010) 29, 1135-1144; doi: 10.1038/onc.2009.414; published online 23 November 2009	[Osanai, M.] Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Kochi 7838505, Japan; [Sawada, N.] Sapporo Med Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido, Japan	Kochi University; Sapporo Medical University	Osanai, M (corresponding author), Kochi Univ, Sch Med, Dept Pathol, Nanko Ku, Oko Cho, Kochi 7838505, Japan.	osanaim@kochi-u.ac.jp			Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This study was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. We thank doctors at the Department of Surgical Pathology for providing archival formalin-fixed, paraffin-embedded tissue specimens and for their pathological diagnoses, and doctors at the Department of Surgical Oncology and Gastroenterological Surgery for scientific cooperation by providing surgically resected materials in patients with breast cancer, as well as the Animal Care Facility (Sapporo Medical University School of Medicine, Sapporo, Japan).	Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang CL, 2008, ONCOGENE, V27, P2951, DOI 10.1038/sj.onc.1210969; ELLIOTT BE, 1988, CANCER RES, V48, P7237; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fenaux P, 1997, NEW ENGL J MED, V337, P1076, DOI 10.1056/NEJM199710093371509; French AL, 2000, J INFECT DIS, V182, P1084, DOI 10.1086/315816; Gozani Or, 2002, Nature Cell Biology, V4, pE159, DOI 10.1038/ncb0602-e159; Kizaki M, 1997, LEUKEMIA LYMPHOMA, V25, P427, DOI 10.3109/10428199709039029; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Loudig O, 2005, BIOCHEM J, V392, P241, DOI 10.1042/BJ20050874; Loudig O, 2000, MOL ENDOCRINOL, V14, P1483, DOI 10.1210/me.14.9.1483; Osanai M, 2005, MOL PHARMACOL, V67, P1808, DOI 10.1124/mol.104.005769; Osanai M, 2006, CANCER RES, V66, P9125, DOI 10.1158/0008-5472.CAN-06-1864; Petkovich PM, 2001, J AM ACAD DERMATOL, V45, pS136, DOI 10.1067/mjd.2001.113715; Shelton DN, 2006, CANCER RES, V66, P7571, DOI 10.1158/0008-5472.CAN-06-1067; Sobin, 2009, UICC TNM CLASSIFICAT; Sonneveld E, 1998, CELL GROWTH DIFFER, V9, P629; Tavassoli FA, 2003, WHO CLASSIFICATION T; Van Heusden J, 1998, BRIT J CANCER, V77, P1229, DOI 10.1038/bjc.1998.207; Wang ZQ, 1999, NAT MED, V5, P418, DOI 10.1038/7417; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753	24	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1135	1144		10.1038/onc.2009.414	http://dx.doi.org/10.1038/onc.2009.414			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935721	Green Submitted			2022-12-28	WOS:000274912100005
J	Xu, X; Ehdaie, B; Ohara, N; Yoshino, T; Deng, CX				Xu, X.; Ehdaie, B.; Ohara, N.; Yoshino, T.; Deng, C-X			Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice	ONCOGENE			English	Article						AKT; mTOR; Notch1; pancreas cancer; transdifferentiation	SQUAMOUS-CELL CARCINOMA; TUMOR; GENE; CANCER; EXPRESSION; INDUCTION; DISRUPTION; NOTCH; KRAS; PANCREATICODUODENECTOMY	Mutations of SMAD4/DPC4 are found in about 60% of human invasive pancreatic ductal adenocarcinomas (PDACs); yet, the manner in which SMAD4 deficiency enhances tumorigenesis remains elusive. Using a Cre-LoxP approach, we generated a mutant mouse carrying a targeted deletion of Smad4 in the pancreas. We showed that the absence of Smad4 alone did not trigger pancreas tumor formation; however, it increased the expression of an inactivated form of Pten, suggesting a role of Pten in preventing Smad4-/- cells from undergoing malignancy. To investigate this, we disrupted both Pten and Smad4. We showed that Pten deficiency initiated widespread premalignant lesions, and a low tumor incidence that was significantly accelerated by Smad4-deficiency. The absence of Smad4 in a Pten-mutant background enhanced cell proliferation and triggered transdifferentiation from acinar, centroacinar and islet cells, accompanied by activation of Notch1 signaling. We showed that all tumors developed in the Smad4/Pten-mutant pancreas exhibited high levels of pAKT and mTOR, and that about 50 and 83% of human pancreatic cancers examined showed increased pAKT and pmTOR, respectively. Besides the similarity in gene expression, the pAKT and/or pmTOR-positive human PDACs and mouse pancreatic tumors also shared some histopathological similarities. These observations indicate that Smad4/Pten-mutant mice mimic the tumor progression of human pancreatic cancers that are driven by activation of the AKT-mTOR pathway, and uncovered a synergistic action of Smad4 and Pten in repressing pancreatic tumorigenesis. Oncogene (2010) 29, 674-686; doi: 10.1038/onc.2009.375; published online 9 November 2009	[Xu, X.; Ehdaie, B.; Deng, C-X] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Ohara, N.; Yoshino, T.] Okayama Univ, Grad Sch Med & Dent, Dept Pathol, Okayama 7008530, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Okayama University	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Rm 9N105, Bethesda, MD 20892 USA.	ChuxiaD@BDG10.NIDDK.NIH.Gov	deng, chuxia/N-6713-2016		National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Douglas Melton for providing Pdx-Cre mice; Dr Hong Wu for Pten conditional mutant mice; and members of the Deng lab for critically reading the paper. This research was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Attri J, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-22; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Farnell MB, 2005, SURGERY, V138, P618, DOI 10.1016/j.surg.2005.06.044; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.3.CO;2-G; Gannon M, 2000, GENESIS, V26, P143, DOI 10.1002/(SICI)1526-968X(200002)26:2<143::AID-GENE13>3.0.CO;2-L; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Hahn SA, 1996, CANCER RES, V56, P490; Hald J, 2003, DEV BIOL, V260, P426, DOI 10.1016/S0012-1606(03)00326-9; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kang YK, 2002, HUM PATHOL, V33, P877, DOI 10.1053/hupa.2002.127444; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Rozenblum E, 1997, CANCER RES, V57, P1731; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Suto T, 2002, ANTICANCER RES, V22, P1529; Takaku K, 1999, CANCER RES, V59, P6113; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEINSTEIN M, 2006, GENETIC DISRUPTIONS, V5; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/00000658-200209000-00012	59	38	40	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					674	686		10.1038/onc.2009.375	http://dx.doi.org/10.1038/onc.2009.375			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901970				2022-12-28	WOS:000274223700005
J	Mira, A; Isella, C; Renzulli, T; Cantarella, D; Martelli, ML; Medico, E				Mira, A.; Isella, C.; Renzulli, T.; Cantarella, D.; Martelli, M. L.; Medico, E.			The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer	ONCOGENE			English	Article						Gab2; anchorage independence; metastasis; microarray; breast cancer	RECEPTOR TYROSINE KINASE; PROGNOSTIC SIGNATURE; EXPRESSION SIGNATURE; HEMATOPOIETIC-CELLS; HISTOLOGIC GRADE; PROTEIN GAB2; GROWTH; SRC; ACTIVATION; INTEGRINS	Acquisition of independence from anchorage to the extracellular matrix is a critical event for onset and progression of solid cancers. To identify and characterize new genes conferring anchorage independence, we transduced MCF10A human normal breast cells with a retroviral cDNA expression library and selected them by growth in suspension. Microarray analysis targeted on library-derived transcripts revealed robust and reproducible enrichment, after selection, of cDNAs encoding the scaffolding adaptor Gab2. Gab2 was confirmed to strongly promote anchorage-independent growth when overexpressed. Interestingly, downregulation by RNA interference of endogenous Gab2 in neoplastic cells did not affect their adherent growth, but abrogated their growth in soft agar. Gab2-driven anchorage independence was found to specifically involve activation of the Src-Stat3 signaling axis. A transcriptional 'signature' of 205 genes was obtained from GAB2-transduced, anchorage-independent MCF10A cells, and found to contain two main functional modules, controlling proliferation and cell adhesion/migration/invasion, respectively. Extensive validation on breast cancer data sets showed that the GAB2 signature provides a robust prognostic classifier for breast cancer metastatic relapse, largely independent from existing clinical and genomic indicators and from estrogen receptor status. This work highlights a pivotal role for GAB2 and its transcriptional targets in anchorage-independent growth and breast cancer metastatic progression. Oncogene (2009) 28, 4444-4455; doi:10.1038/onc.2009.296; published online 19 October 2009	[Medico, E.] Univ Torino, Dept Oncol Sci, Inst Canc Res & Treatment, Sch Med, I-10060 Turin, Italy; Univ Torino, Lab Funct Genom, Inst Canc Res & Treatment, Sch Med, I-10060 Turin, Italy	University of Turin; University of Turin	Medico, E (corresponding author), Univ Torino, Dept Oncol Sci, Inst Canc Res & Treatment, Sch Med, Str Prov 142,Km 3,95, I-10060 Turin, Italy.	enzo.medico@ircc.it	Medico, Enzo/AAC-3185-2021; Isella, Claudio/F-7327-2012	Medico, Enzo/0000-0002-3917-2438; Isella, Claudio/0000-0003-0679-4756; CANTARELLA, DANIELA/0000-0001-6135-2032; Mira, Alessia/0000-0002-8456-8159	AIRC; EC [503438]; CNR-MIUR; FIRB-MIUR; Ministero della Salute, Regione Piemonte; Foundations CRT and 'Compagnia di San Paolo'	AIRC(Fondazione AIRC per la ricerca sul cancro); EC(European CommissionEuropean Commission Joint Research Centre); CNR-MIUR(Ministry of Education, Universities and Research (MIUR)Consiglio Nazionale delle Ricerche (CNR)); FIRB-MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministero della Salute, Regione Piemonte(Regione PiemonteMinistry of Health, Italy); Foundations CRT and 'Compagnia di San Paolo'(Compagnia di San Paolo)	We thank Barbara Martinoglio and Roberta Porporato for technical assistance. We thank Simona Destefanis, Antonella Cignetto and Michela Bruno for secretarial assistance. This research was supported by grants from AIRC, the EC (contract no. 503438 'TRANSFOG'), CNR-MIUR, FIRB-MIUR, Ministero della Salute, Regione Piemonte and the Foundations CRT and 'Compagnia di San Paolo.'	Ariga N, 2001, INT J CANCER, V95, P67, DOI 10.1002/1097-0215(20010120)95:1<67::AID-IJC1012>3.0.CO;2-U; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Bouscary D, 2001, ONCOGENE, V20, P2197, DOI 10.1038/sj.onc.1204317; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Cooley J, 2001, BIOCHEMISTRY-US, V40, P15762, DOI 10.1021/bi0113925; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; ffrench-Constant C, 2004, TRENDS CELL BIOL, V14, P678, DOI 10.1016/j.tcb.2004.10.005; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hess Viviane, 2008, Ther Umsch, V65, P201, DOI 10.1024/0040-5930.65.4.201; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Laird AD, 2003, MOL CANCER THER, V2, P461; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Martelli ML, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-254; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Ni S, 2007, MOL CELL BIOL, V27, P3708, DOI 10.1128/MCB.01838-06; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roux KJ, 2005, MOL BIOL CELL, V16, P1142, DOI 10.1091/mbc.E04-07-0551; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; SOULE HD, 1990, CANCER RES, V50, P6075; TIRESALJ M, 2006, NAT MED, V12, P114; Tsatsanis C, 2004, ANN NY ACAD SCI, V1028, P168, DOI 10.1196/annals.1322.019; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wessels LFA, 2005, BIOINFORMATICS, V21, P3755, DOI 10.1093/bioinformatics/bti429; Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu M, 2006, J BIOL CHEM, V281, P28615, DOI 10.1074/jbc.M603742200; Yuan K, 2008, PATHOL ONCOL RES, V14, P145, DOI 10.1007/s12253-008-9036-x; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang X, 2006, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2005/01/003	51	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	2009	28	50					4444	4455		10.1038/onc.2009.296	http://dx.doi.org/10.1038/onc.2009.296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19838208	Green Submitted			2022-12-28	WOS:000272876500004
J	Eisenmann, KM; Dykema, KJ; Matheson, SF; Kent, NF; DeWard, AD; West, RA; Tibes, R; Furge, KA; Alberts, AS				Eisenmann, K. M.; Dykema, K. J.; Matheson, S. F.; Kent, N. F.; DeWard, A. D.; West, R. A.; Tibes, R.; Furge, K. A.; Alberts, A. S.			5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics	ONCOGENE			English	Review						Rho GTPase; actin assembly; formin; myeloproliferative neoplasms; tumor-suppressor	SERUM RESPONSE FACTOR; DIAPHANOUS-RELATED FORMINS; TRANSCRIPTION FACTOR EGR1; COMMONLY DELETED REGION; FARNESYLTRANSFERASE INHIBITORS; MYELODYSPLASTIC SYNDROMES; ALPHA-CATENIN; HEMATOPOIETIC STEM; CD34(+) CELLS; RHO GTPASE	Complete loss or interstitial deletions of chromosome 5 are the most common karyotypic abnormality in myelodysplastic syndromes (MDSs). Isolated del(5q)/5q- MDS patients have a more favorable prognosis than those with additional karyotypic defects, who tend to develop myeloproliferative neoplasms (MPNs) and acute myeloid leukemia. The frequency of unbalanced chromosome 5 deletions has led to the idea that 5q harbors one or more tumor-suppressor genes that have fundamental roles in the growth control of hematopoietic stem/progenitor cells (HSCs/HPCs). Cytogenetic mapping of commonly deleted regions (CDRs) centered on 5q31 and 5q32 identified candidate tumor-suppressor genes, including the ribosomal subunit RPS14, the transcription factor Egr1/Krox20 and the cytoskeletal remodeling protein, alpha-catenin. Although each acts as a tumor suppressor, alone or in combination, no molecular mechanism accounts for how defects in individual 5q candidates may act as a lesion driving MDS or contributing to malignant progression in MPN. One candidate gene that resides between the conventional del(5q)/5q- MDS-associated CDRs is DIAPH1 (5q31.3). DIAPH1 encodes the mammalian Diaphanous-related formin, mDia1. mDia1 has critical roles in actin remodeling in cell division and in response to adhesive and migratory stimuli. This review examines evidence, with a focus on mouse gene-targeting experiments, that mDia1 acts as a node in a tumor-suppressor network that involves multiple 5q gene products. The network has the potential to sense dynamic changes in actin assembly. At the root of the network is a transcriptional response mechanism mediated by the MADS-box transcription factor, serum response factor (SRF), its actin-binding myocardin family coactivator, MAL, and the SRF-target 5q gene, EGR1, which regulate the expression of PTEN and p53-family tumor-suppressor proteins. We hypothesize that the network provides a homeostatic mechanism balancing HPC/HSC growth control and differentiation decisions in response to microenvironment and other external stimuli. Oncogene (2009) 28, 3429-3441; doi: 10.1038/onc.2009.207; published online 13 July 2009	[Eisenmann, K. M.; Matheson, S. F.; Kent, N. F.; DeWard, A. D.; West, R. A.; Alberts, A. S.] Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA; [Dykema, K. J.; Furge, K. A.] Van Andel Res Inst, Lab Computat Biol, Grand Rapids, MI 49503 USA; [Matheson, S. F.] Calvin Coll, Dept Biol, Grand Rapids, MI 49506 USA; [Tibes, R.] Translat Genom Clin Res Serv, Scottsdale, AZ USA	Van Andel Institute; Van Andel Institute; Calvin University	Alberts, AS (corresponding author), Van Andel Res Inst, Lab Cell Struct & Signal Integrat, 333 Bostwick Ave,NE, Grand Rapids, MI 49503 USA.	art.alberts@vai.org	Tibes, Raoul/AAV-1683-2020	West, Richard/0000-0003-1459-0825; Matheson, Stephen/0000-0003-0561-8152; Tibes, Raoul/0000-0002-1372-8733; Eisenmann, Kathryn/0000-0002-5337-5928	Van Andel Foundation; JP McCarthy Foundation; American Cancer Society [RSG-05-033-01-CSM]	Van Andel Foundation; JP McCarthy Foundation; American Cancer Society(American Cancer Society)	ASA and RAW were supported by the Van Andel Foundation, the JP McCarthy Foundation and the American Cancer Society (RSG-05-033-01-CSM). We are grateful to David Nadziejka for vigilant editing as well as Nick Duesbery, Cindy Miranti and Jeff Mackeigan for their thoughtful discussion.	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; BOULTWOOD J, 1995, LEUKEMIA LYMPHOMA, V17, P71, DOI 10.3109/10428199509051705; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Boultwood J, 2007, BRIT J HAEMATOL, V139, P578, DOI 10.1111/j.1365-2141.2007.06833.x; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Cmejla R, 2007, HUM MUTAT, V28, P1178, DOI 10.1002/humu.20608; Colucci-Guyon E, 2005, CURR BIOL, V15, P2007, DOI 10.1016/j.cub.2005.09.051; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Cortes JE, 2002, SEMIN HEMATOL, V39, P26, DOI 10.1053/shem.2002.35984; Crescenzi B, 2004, HAEMATOLOGICA, V89, P281; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Dent EW, 2007, NAT CELL BIOL, V9, P1347, DOI 10.1038/ncb1654; Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611; Du W, 1999, MOL CELL BIOL, V19, P1831; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Evers C, 2007, GENE CHROMOSOME CANC, V46, P1119, DOI 10.1002/gcc.20498; Farrar JE, 2008, BLOOD, V112, P1582, DOI 10.1182/blood-2008-02-140012; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Giagounidis A A N, 2004, Hematology, V9, P271, DOI 10.1080/10245330410001723824; Giagounidis AAN, 2006, CLIN CANCER RES, V12, P5, DOI 10.1158/1078-0432.CCR-05-1437; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Greer JM, 2000, NATURE, V403, P661, DOI 10.1038/35001077; Guettler S, 2008, MOL CELL BIOL, V28, P732, DOI 10.1128/MCB.01623-07; Gupton SL, 2007, J CELL SCI, V120, P3475, DOI 10.1242/jcs.006049; Herry A, 2007, EUR J HAEMATOL, V78, P457, DOI 10.1111/j.1600-0609.2007.00847.x; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Huang XK, 2003, LEUKEMIA LYMPHOMA, V44, P157, DOI 10.1080/1042819021000040387; Joslin JM, 2007, BLOOD, V110, P719, DOI 10.1182/blood-2007-01-068809; Kamasani U, 2007, CANCER BIOL THER, V6, P1422; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kotsianidis I, 2008, ACTA HAEMATOL-BASEL, V120, P51, DOI 10.1159/000158577; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Kurzrock R, 2002, SEMIN HEMATOL, V39, P18, DOI 10.1053/shem.2002.35981; Kurzrock R, 2002, SEMIN HEMATOL, V39, P20, DOI 10.1053/shem.2002.36925; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lehmann S, 2007, LEUKEMIA, V21, P1931, DOI 10.1038/sj.leu.2404852; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lien WH, 2006, SCIENCE, V311, P1609, DOI 10.1126/science.1121449; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu TX, 2007, NAT MED, V13, P78, DOI 10.1038/nm1512; Malcovati Luca, 2008, Cancer Control, V15 Suppl, P4; Merdek KD, 2008, BIOCHEM BIOPH RES CO, V366, P717, DOI 10.1016/j.bbrc.2007.12.012; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Moseley JB, 2007, J BIOL CHEM, V282, P12661, DOI 10.1074/jbc.M610615200; Neuwirtova R, 1996, LEUKEMIA RES, V20, P717, DOI 10.1016/0145-2126(96)00028-8; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nimer Stephen D, 2008, Hematology Am Soc Hematol Educ Program, P43, DOI 10.1182/asheducation-2008.1.43; Nolte F, 2008, ANN HEMATOL, V87, P777, DOI 10.1007/s00277-008-0502-z; Olney HJ, 2007, LEUKEMIA RES, V31, P427, DOI 10.1016/j.leukres.2006.10.023; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pellagatti A, 2004, BRIT J HAEMATOL, V125, P576, DOI 10.1111/j.1365-2141.2004.04958.x; Pellagatti A, 2008, BRIT J HAEMATOL, V142, P57, DOI 10.1111/j.1365-2141.2008.07178.x; Pellagatti A, 2006, BLOOD, V108, P337, DOI 10.1182/blood-2005-12-4769; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2001, HISTOL HISTOPATHOL, V16, P269, DOI 10.14670/HH-16.269; Qian ZJ, 2008, J EXP MED, V205, P2163, DOI 10.1084/jem.20080578; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Santana-Davila R, 2008, LEUKEMIA RES, V32, P1927, DOI 10.1016/j.leukres.2008.04.022; Shannon KM, 2008, NATURE, V451, P252, DOI 10.1038/451252a; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tefferi A, 2007, CELL CYCLE, V6, P550, DOI 10.4161/cc.6.5.3919; Tibes R, 2008, BRIT J HAEMATOL, V140, P344, DOI 10.1111/j.1365-2141.2007.06920.x; Tominaga T, 2002, J BIOL CHEM, V277, P47686, DOI 10.1074/jbc.M207539200; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Valencia A, 2008, BLOOD, V112, P918, DOI 10.1182/blood-2008-05-159707; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VARDIMAN JW, 2009, BLOOD; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wallar BJ, 2007, EXP CELL RES, V313, P560, DOI 10.1016/j.yexcr.2006.10.033; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	110	63	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3429	3441		10.1038/onc.2009.207	http://dx.doi.org/10.1038/onc.2009.207			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597464				2022-12-28	WOS:000270478300001
J	Sarangi, A; Valadez, JG; Rush, S; Abel, TW; Thompson, RC; Cooper, MK				Sarangi, A.; Valadez, J. G.; Rush, S.; Abel, T. W.; Thompson, R. C.; Cooper, M. K.			Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival	ONCOGENE			English	Article						brain tumor; glioma; Hedgehog; xenotransplantation; cyclopamine	NEURAL STEM-CELLS; MOUSE MODELS; BRAIN-TUMORS; GROWTH; MEDULLOBLASTOMA; CLASSIFICATION; IDENTIFICATION; CYCLOPAMINE; DRIVEN	Hedgehog pathway activity has been demonstrated in malignant glioma. However, its role in tumor growth has not been determined. Here we demonstrate that pharmacological inhibition of the Hedgehog pathway in established orthotopic malignant glioma xenografts confers a survival advantage. Pathway inhibition is measured in transplanted human tumor cells and not in host mouse brain. Correspondingly, survival benefit is observed only in tumors with an operational Hedgehog pathway. These data indicate that Hedgehog signaling regulates the growth of select malignant gliomas. We also demonstrate that Hedgehog pathway component and gene target expression segregate to CD133(+) tumor initiating cells. Treated mice eventually succumb to disease, thus, targeting the Hedgehog pathway in CD133(+) cells produces significant, but incomplete tumor regression. Therefore, our studies suggest that more complete tumor regression may require the inclusion of other therapeutic targets, including CD133(-) cells. Oncogene (2009) 28, 3468-3476; doi: 10.1038/onc.2009.208; published online 20 July 2009	[Sarangi, A.; Valadez, J. G.; Cooper, M. K.] Vanderbilt Univ Sch Med, Dept Neurol, Nashville, TN 37232 USA; [Sarangi, A.; Cooper, M. K.] Vanderbilt Univ Sch Med, Vanderbilt Neurosci Grad Program, Nashville, TN 37232 USA; [Rush, S.] Vanderbilt Univ Sch Med, Dept Pediat, Nashville, TN 37232 USA; [Abel, T. W.] Vanderbilt Univ Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Thompson, R. C.] Vanderbilt Univ Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Thompson, R. C.] Vanderbilt Univ Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Cooper, MK (corresponding author), Vanderbilt Univ Sch Med, Dept Neurol, MRB3,Rm 6160,465 21st Ave S, Nashville, TN 37232 USA.	michael.cooper@vanderbilt.edu	Rush, Sarah/AAA-1701-2020		Vanderbilt Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; MKC from the NINDS [K02 NS053614]; Burroughs Wellcome Fund; Doris Duke Charitable Foundation; VMC development funds; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS053614] Funding Source: NIH RePORTER	Vanderbilt Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; MKC from the NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); VMC development funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Infinity Pharmaceuticals for supplying cyclopamine. Histological services were performed, in part, by the Vanderbilt Medical Center (VMC) Human Tissue Acquisition and Pathology Shared Resource (supported by the Vanderbilt Ingram Cancer Center, P30 CA68485). Flow cytometry experiments were performed in the VMC Flow Cytometry Shared Resource (supported by the Vanderbilt Ingram Cancer Center, P30 CA68485, and the Vanderbilt Digestive Disease Research Center, DK058404). This work was supported by grants to MKC from the NINDS (K02 NS053614), the Burroughs Wellcome Fund and the Doris Duke Charitable Foundation (for human tissues) and VMC development funds (for animal studies).	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Ehtesham M, 2007, ONCOGENE, V26, P5752, DOI 10.1038/sj.onc.1210359; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gutmann David H, 2006, Cancer Res, V66, P10, DOI 10.1158/0008-5472.CAN-05-3180; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Sanchez P, 2005, MECH DEVELOP, V122, P223, DOI 10.1016/j.mod.2004.10.002; Shu Q, 2008, STEM CELLS, V26, P1414, DOI 10.1634/stemcells.2007-1009; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suggitt M, 2005, CLIN CANCER RES, V11, P971; Trowbridge JJ, 2006, P NATL ACAD SCI USA, V103, P14134, DOI 10.1073/pnas.0604568103; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Xu QJ, 2008, STEM CELLS, V26, P3018, DOI 10.1634/stemcells.2008-0459; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	37	45	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3468	3476		10.1038/onc.2009.208	http://dx.doi.org/10.1038/onc.2009.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19617900	Green Accepted			2022-12-28	WOS:000270478300004
J	Cherrier, T; Suzanne, S; Redel, L; Calao, M; Marban, C; Samah, B; Mukerjee, R; Schwartz, C; Gras, G; Sawaya, BE; Zeichner, SL; Aunis, D; Van Lint, C; Rohr, O				Cherrier, T.; Suzanne, S.; Redel, L.; Calao, M.; Marban, C.; Samah, B.; Mukerjee, R.; Schwartz, C.; Gras, G.; Sawaya, B. E.; Zeichner, S. L.; Aunis, D.; Van Lint, C.; Rohr, O.			p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1	ONCOGENE			English	Article						CTIP2; p21(WAF1); SUV39H1; HIV-1	CELL-CYCLE ARREST; HISTONE DEACETYLASE INHIBITORS; MICROGLIAL CELLS; T-LYMPHOCYTES; HIV-1 VPR; TRANSCRIPTIONAL ACTIVATION; P21/WAF1/CIP1 GENE; DNA-REPLICATION; NURD COMPLEX; IN-VIVO	Mainly regulated at the transcriptional level, the cellular cyclin-dependent kinase inhibitor, CDKN1A/p21(WAF1) (p21), is a major cell cycle regulator of the response to DNA damage, senescence and tumor suppression. Here, we report that COUP-TF-interacting protein 2 (CTIP2), recruited to the p21 gene promoter, silenced p21 gene transcription through interactions with histone deacetylases and methyltransferases. Importantly, treatment with the specific SUV39H1 inhibitor, chaetocin, repressed histone H3 lysine 9 trimethylation at the p21 gene promoter, stimulated p21 gene expression and induced cell cycle arrest. In addition, CTIP2 and SUV39H1 were recruited to the silenced p21 gene promoter to cooperatively inhibit p21 gene transcription. Induction of p21(WAF1) gene upon human immunodeficiency virus 1 (HIV-1) infection benefits viral expression in macrophages. Here, we report that CTIP2 further abolishes Vpr-mediated stimulation of p21, thereby indirectly contributing to HIV-1 latency. Altogether, our results suggest that CTIP2 is a constitutive p21 gene suppressor that cooperates with SUV39H1 and histone methylation to silence the p21 gene transcription. Oncogene (2009) 28, 3380-3389; doi: 10.1038/onc.2009.193; published online 6 July 2009	[Cherrier, T.; Suzanne, S.; Redel, L.; Marban, C.; Schwartz, C.; Aunis, D.; Rohr, O.] Univ Strasbourg, INSERM, Inst Virol, U575, F-67000 Strasbourg, France; [Samah, B.; Gras, G.] Serv Neurovirol, CEA, UMRE 01, Fontenay Aux Roses, France; [Mukerjee, R.; Sawaya, B. E.] Temple Univ, Dept Neurol, Sch Med, Mol Virol Lab, Philadelphia, PA 19122 USA; [Zeichner, S. L.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Pediat & Microbiol, Washington, DC USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Immunol, Washington, DC USA; [Zeichner, S. L.] George Washington Univ, Childrens Res Inst, Dept Trop Med, Washington, DC USA; [Calao, M.; Van Lint, C.] Univ Libre Bruxelles, Inst Biol & Med Mol, Mol Virol Lab, Gosselies, Belgium; [Rohr, O.] IUT Louis Pasteur Schiltigheim, Schiltigheim, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CEA; UDICE-French Research Universities; Universite Paris Saclay; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Children's National Health System; George Washington University; George Washington University; George Washington University; Universite Libre de Bruxelles	Rohr, O (corresponding author), Univ Strasbourg, INSERM, Inst Virol, U575, 3 Rue Koeberle, F-67000 Strasbourg, France.	cvlint@ulb.ac.be; olivier.rohr@iutlpa.u-strasbg.fr	Dominique, Aunis/W-1419-2019; CHERRIER, Thomas/F-8727-2018	CHERRIER, Thomas/0000-0002-0707-9204; ROHR, Olivier/0000-0001-8992-2025	Institut National de la Sante et de la Recherche Medicale (INSERM); Agence Nationale de Recherches sur le SIDA (ANRS); Sidaction; French Ministry of Research [ACI JC 5364]; Fonds National de la Recherche Scientifique (FNRS, Belgium); Action de Recherche concertee du Ministere de la Communaute Francaise [04/09-309]; Internationale Brachet Stiftung (IBS); Region Wallonne-Commission Europeenne FEDER; Theyskens-Mineur Foundation; NIH; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059327] Funding Source: NIH RePORTER	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de Recherches sur le SIDA (ANRS)(ANRSFrench National Research Agency (ANR)); Sidaction; French Ministry of Research(Ministry of Research, FranceEuropean Commission); Fonds National de la Recherche Scientifique (FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Action de Recherche concertee du Ministere de la Communaute Francaise; Internationale Brachet Stiftung (IBS); Region Wallonne-Commission Europeenne FEDER; Theyskens-Mineur Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr D Kardassis for providing us with p21-LUC plasmids and Dr Yannick Goumon for his technical support. This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM), by grants from the Agence Nationale de Recherches sur le SIDA (ANRS) to OR and CVL, from Sidaction to OR and TC and from the French Ministry of Research ('ACI JC 5364' to OR and doctoral grant to TC and SS) The work in CVL's laboratory was supported by grants from the 'Fonds National de la Recherche Scientifique' (FNRS, Belgium), the Televie-Program of the FNRS, from the 'Action de Recherche concertee du Ministere de la Communaute Francaise (ULB, ARC program no. 04/09-309), from the Internationale Brachet Stiftung (IBS), from the Region Wallonne-Commission Europeenne FEDER (Intergenes Project, Interreg III program) and from the Theyskens-Mineur Foundation. CVL is 'Directeur de Recherches' of the FNRS. This work was supported by NIH to BES.	Amini S, 2004, J BIOL CHEM, V279, P46046, DOI 10.1074/jbc.M403792200; Anderson MR, 2008, CULT HEALTH SEX, V10, P1, DOI 10.1080/13691050701516363; Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cismasiu VB, 2006, BLOOD, V108, P2695, DOI 10.1182/blood-2006-05-021790; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Grabarczyk P, 2007, ONCOGENE, V26, P3797, DOI 10.1038/sj.onc.1210152; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105; Kamimura K, 2007, ONCOGENE, V26, P5840, DOI 10.1038/sj.onc.1210388; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Le Rouzic E, 2007, CELL CYCLE, V6, P182, DOI 10.4161/cc.6.2.3732; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; Leone C, 2006, GLIA, V54, P183, DOI 10.1002/glia.20372; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; Marban C, 2007, EMBO J, V26, P412, DOI 10.1038/sj.emboj.7601516; Moon HS, 2006, MOL CELLS, V21, P7; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Rohr O, 2003, J VIROL, V77, P5415, DOI 10.1128/JVI.77.9.5415-5427.2003; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schrofelbauer B, 2007, P NATL ACAD SCI USA, V104, P4130, DOI 10.1073/pnas.0610167104; Sowa Y, 1999, CANCER RES, V59, P4266; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Thierry S, 2004, J VIROL, V78, P12198, DOI 10.1128/JVI.78.22.12198-12206.2004; Topark-Ngarm A, 2006, J BIOL CHEM, V281, P32272, DOI 10.1074/jbc.M602776200; Vazquez N, 2005, J VIROL, V79, P4479, DOI 10.1128/JVI.79.7.4479-4491.2005; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Yoshizuka N, 2005, J VIROL, V79, P11366, DOI 10.1128/JVI.79.17.11366-11381.2005; Zhang JL, 2007, J CLIN INVEST, V117, P473, DOI 10.1172/JCI28971	44	91	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3380	3389		10.1038/onc.2009.193	http://dx.doi.org/10.1038/onc.2009.193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19581932	Green Published, Green Accepted			2022-12-28	WOS:000270103300005
J	Li, H; Choi, YJ; Hanes, MA; Marple, T; Vogel, H; Hasty, P				Li, H.; Choi, Y. J.; Hanes, M. A.; Marple, T.; Vogel, H.; Hasty, P.			Deleting Ku70 is milder than deleting Ku80 in p53-mutant mice and cells	ONCOGENE			English	Article						DNA double-strand break; non-homologous end joining; pro-B-cell lymphoma; medulloblastoma; T-cell lymphoma	V(D)J RECOMBINATION; RAG-1-INDUCED DSBS; SPONTANEOUS TUMORS; DNA-DAMAGE; PROTEIN; P53; DEFICIENT; TRANSLOCATION; MECHANISM; BINDING	Ku70 forms a heterodimer with Ku80, called Ku that is well known for repairing DNA double-strand breaks through non-homologous end joining. As a result, deletion of either causes a very similar phenotype in mice that includes hypersensitivity to clastogens and early aging. In addition, deletion of Ku80 along with the cell cycle checkpoint protein, p53, dramatically increases the incidence of pro-B-cell lymphoma. Even though Ku70-p53-mutant mice have not been analysed, a logical assumption is they would exhibit the same cancer phenotype. Here, we test this assumption by comparing p53-mutant littermates deleted for either Ku70 or Ku80 or both. We find this assumption to be incorrect as p53-mutants live significantly longer when deleted for Ku70 rather than Ku80 or Ku70 + Ku80. We also find the former cohort displays much lower levels of pro-B-cell lymphoma than the latter two cohorts. As pro-B-cell lymphoma is caused by a translocation between chromosomes 12 and 15, we tested fibroblasts for DNA repair capacity, and found that p53-mutant fibroblasts are more sensitive to streptonigrin and paraquat when deleted for Ku80 as compared with Ku70. Thus, Ku80 may function outside the Ku heterodimer to influence DNA damage repair presenting the possibility that Ku80 influenced the open coding ends in a manner that suppressed a cancer-causing translocation.	[Li, H.; Choi, Y. J.; Marple, T.; Hasty, P.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78245 USA; [Li, H.; Choi, Y. J.; Marple, T.; Hasty, P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA; [Hanes, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Lab Anim Resources, San Antonio, TX 78245 USA; [Vogel, H.] Stanford Univ, Med Ctr, Dept Pathol, Palo Alto, CA 94304 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University	Hasty, P (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	hastye@uthscsa.edu		Hasty, Paul/0000-0003-3046-0131; Vogel, Otto Hannes/0000-0002-0960-3508	NIH [R01 CA76317-05A1, 3P30 CA054174-16S2, P01 AG17242, UO1 ES11044]; NATIONAL CANCER INSTITUTE [P30CA054174, R01CA076317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the following grants from the NIH: R01 CA76317-05A1, 3P30 CA054174-16S2, P01 AG17242 and UO1 ES11044 to PH.	Bolzan AD, 2001, MUTAT RES-REV MUTAT, V488, P25, DOI 10.1016/S1383-5742(00)00062-4; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; BUS JS, 1974, BIOCHEM BIOPH RES CO, V58, P749, DOI 10.1016/S0006-291X(74)80481-X; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Goedecke W, 1999, NAT GENET, V23, P194, DOI 10.1038/13821; Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Holcomb VB, 2008, CANCER RES, V68, P9497, DOI 10.1158/0008-5472.CAN-08-2085; Holcomb VB, 2007, MECH AGEING DEV, V128, P601, DOI 10.1016/j.mad.2007.08.006; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Koike M, 2000, BIOCHEM BIOPH RES CO, V276, P1105, DOI 10.1006/bbrc.2000.3567; Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785-07; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Lim JW, 2008, INT J BIOCHEM CELL B, V40, P2065, DOI 10.1016/j.biocel.2008.02.015; Marple T, 2004, MUTAT RES-FUND MOL M, V554, P253, DOI 10.1016/j.mrfmmm.2004.05.004; Mazumder S, 2007, MOL CELL BIOL, V27, P3511, DOI 10.1128/MCB.01448-06; Munakata Y, 2005, BLOOD, V106, P3449, DOI 10.1182/blood-2005-02-0536; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Romero F, 1996, MOL CELL BIOL, V16, P37; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Song KY, 2001, J BIOL CHEM, V276, P8321, DOI 10.1074/jbc.M008779200; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu PC, 2006, EMBO REP, V7, P431, DOI 10.1038/sj.embor.7400622	33	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1875	1878		10.1038/onc.2009.57	http://dx.doi.org/10.1038/onc.2009.57			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19330025				2022-12-28	WOS:000265640500006
J	Millar, EKA; Dean, JL; McNeil, CM; O'Toole, SA; Henshall, SM; Tran, T; Lin, J; Quong, A; Comstock, CES; Witkiewicz, A; Musgrove, EA; Rui, H; LeMarchand, L; Setiawan, VW; Haiman, CA; Knudsen, KE; Sutherland, RL; Knudsen, ES				Millar, E. K. A.; Dean, J. L.; McNeil, C. M.; O'Toole, S. A.; Henshall, S. M.; Tran, T.; Lin, J.; Quong, A.; Comstock, C. E. S.; Witkiewicz, A.; Musgrove, E. A.; Rui, H.; LeMarchand, L.; Setiawan, V. W.; Haiman, C. A.; Knudsen, K. E.; Sutherland, R. L.; Knudsen, E. S.			Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome	ONCOGENE			English	Article						cyclin D1b; breast cancer; polymorphism; estrogen receptor; prognosis	SQUAMOUS-CELL CARCINOMA; ADJUVANT TAMOXIFEN; POLYMORPHISM; RISK; AMPLIFICATION; PROGNOSIS; ISOFORM; GENE; VARIANT; ALLELE	Aberrant expression of cyclin D1 protein is a common feature of breast cancer. However, the CCND1 gene encodes two gene products, cyclin D1a and cyclin D1b, which have discrete mechanisms of regulation and impact on cell behavior. A polymorphism at nucleotide 870 in the CCND1 gene, rs603965, influences the relative production of the encoded proteins and can impart increased risk for tumor development. Here, the impact of both the G/A870 polymorphism and cyclin D1b protein production on breast cancer risk, disease phenotype and patient outcome was analysed. In a large multiethnic case-control study, the G/A870 polymorphism conferred no significant risk for breast cancer overall or by stage or estrogen receptor (ER) status. However, the cyclin D1b protein was found to be upregulated in breast cancer, independent of cyclin D1a levels, and exhibited heterogeneous levels in breast cancer specimens. High cyclin D1a expression inversely correlated with the Ki67 proliferation marker and was not associated with clinical outcome. In contrast, elevated cyclin D1b expression was independently associated with adverse outcomes, including recurrence, distant metastasis and decreased survival. Interestingly, cyclin D1b was particularly associated with poor outcome in the context of ER-negative breast cancer. Thus, specific cyclin D1 isoforms are associated with discrete forms of breast cancer and high cyclin D1b protein levels hold prognostic potential.	[Dean, J. L.; Tran, T.; Lin, J.; Quong, A.; Comstock, C. E. S.; Witkiewicz, A.; Rui, H.; Knudsen, K. E.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Millar, E. K. A.; McNeil, C. M.; O'Toole, S. A.; Henshall, S. M.; Musgrove, E. A.; Sutherland, R. L.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia; [Millar, E. K. A.] St George Hosp, Dept Anat Pathol S Eastern Area Lab Serv, Sydney, NSW, Australia; [Dean, J. L.; Tran, T.; Lin, J.; Comstock, C. E. S.; Witkiewicz, A.; Rui, H.; Knudsen, K. E.; Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Witkiewicz, A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [LeMarchand, L.] Canc Res Ctr Hawaii, Program Epidemiol, Honolulu, HI 96813 USA; [Setiawan, V. W.; Haiman, C. A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA	Jefferson University; Garvan Institute of Medical Research; St George Hospital; Jefferson University; Jefferson University; Cancer Research Center of Hawaii; University of Southern California; Jefferson University	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org	Millar, Ewan/ABE-9127-2020; Comstock, Clay/B-6122-2008; Sutherland, Robert L/A-8378-2008; McNeil, Catriona/F-6817-2010	Millar, Ewan/0000-0002-9778-3253; Comstock, Clay/0000-0001-5867-1489; Knudsen, Karen/0000-0002-1301-890X; Setiawan, Veronica/0000-0001-9239-5692	National Health and Medical Research Council of Australia [276408]; Cancer Institute NSW; Petre Foundation; RT Hall Trust; National Institutes of Health [CA104213, CA099996]; NATIONAL CANCER INSTITUTE [R01CA099996, R01CA104213] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Petre Foundation; RT Hall Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all of the laboratory and administrative staff that contributed to the editing and preparation of the manuscript. This work was supported by the following grants: the National Health and Medical Research Council of Australia (Grant no. 276408), the Cancer Institute NSW, the Petre Foundation and the RT Hall Trust, the National Institutes of Health Grant CA104213 (ESK), the National Institutes of Health Grant CA099996 (KEK). We thank Drs Paul Crea and Davendra Segara of St Vincent's Clinic for access to patient material and data.	Arnold A, 2005, J CLIN ONCOL, V23, P4215, DOI 10.1200/JCO.2005.05.064; Bala S, 2001, CANCER RES, V61, P6042; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Batsche E, 2006, NAT STRUCT MOL BIOL, V13, P22, DOI 10.1038/nsmb1030; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Carrere N, 2005, HAEMATOLOGICA, V90, P854; Ceschi M, 2005, CARCINOGENESIS, V26, P1457, DOI 10.1093/carcin/bgi093; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; COMSTOCK CES, 2009, CLIN CANC RES UNPUB; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Gupta VK, 2008, CLIN CANCER RES, V14, P7804, DOI 10.1158/1078-0432.CCR-08-0744; Holley SL, 2005, INT J CANCER, V114, P364, DOI 10.1002/ijc.20750; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Knudsen ES, 2006, EXP BIOL MED, V231, P1271; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Krieger S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-238; Krippl P, 2003, BREAST CANCER RES TR, V82, P165, DOI 10.1023/B:BREA.0000004372.20461.33; Lu FM, 2003, CANCER RES, V63, P7056; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Matthias C, 1998, CLIN CANCER RES, V4, P2411; Naidu R, 2008, NEOPLASMA, V55, P87; Pabalan N, 2008, CANCER EPIDEM BIOMAR, V17, P2773, DOI 10.1158/1055-9965.EPI-08-0169; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Rudas M, 2008, CLIN CANCER RES, V14, P1767, DOI 10.1158/1078-0432.CCR-07-4122; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Shu XO, 2005, CANCER EPIDEM BIOMAR, V14, P91; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spruck C, 2006, CANCER RES, V66, P7355, DOI 10.1158/0008-5472.CAN-05-3240; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang Y, 2008, CANCER RES, V68, P5628, DOI 10.1158/0008-5472.CAN-07-3170; Yu CP, 2008, BREAST CANCER RES TR, V107, P95, DOI 10.1007/s10549-007-9522-y; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	44	67	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1812	1820		10.1038/onc.2009.13	http://dx.doi.org/10.1038/onc.2009.13			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287456	Green Accepted			2022-12-28	WOS:000265640400008
J	Chen, G; Wang, Y; Garate, M; Zhou, J; Li, G				Chen, G.; Wang, Y.; Garate, M.; Zhou, J.; Li, G.			The tumor suppressor ING3 is degraded by SCFSkp2-mediated ubiquitin-proteasome system	ONCOGENE			English	Article						ING3; protein degradation; Skp2; cell cycle; apoptosis	MEDIATED PROTEIN-DEGRADATION; CELL-CYCLE CONTROL; MELANOMA-CELLS; EXPRESSION; CANCER; SKP2; NUCLEAR; P33(ING1B); OVEREXPRESSION; PATHWAY	The inhibitor of growth family member 3 (ING3) has been shown to modulate transcription, cell cycle control and apoptosis. We previously reported that nuclear ING3 expression was remarkably reduced in melanomas, which correlated with a poorer patient survival, suggesting that decreased ING3 expression may be associated with melanoma progression. However, the mechanism of diminished ING3 expression in melanoma is not clear. Here we show that ING3 level was decreased in metastatic melanoma cells because of a rapid degradation. Furthermore, we showed that ING3 undergoes degradation through the ubiquitin proteasome pathway. ING3 physically interacts with subunits of E3 ligase Skp1-Cullin-F-box protein complex (SCF complex). Knockdown of F-box protein S-phase kinase-associated protein 2 (Skp2) reduces the ubiquitination of ING3 and significantly stabilizes ING3 in melanoma cells. In addition, lysine 96 residue is essential for ING3 ubiquitination as its mutation to arginine dramatically abrogated ING3 degradation. Disruption of ING3 degradation stimulated ING3-induced G1 cell-cycle arrest and enhanced ultraviolet-induced apoptosis. Taken together, our data show that ING3 is degraded by the ubiquitin-proteasome pathway through the SCFSkp2 complex and interruption of ING3 degradation enhances the tumor-suppressive function of ING3, which provides a potential cancer therapeutic approach by interfering ING3 degradation. Oncogene (2010) 29, 1498-1508; doi:10.1038/onc.2009.424; published online 23 November 2009	[Chen, G.; Wang, Y.; Garate, M.; Li, G.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Nanjing, Peoples R China	University of British Columbia; Vancouver Coastal Health Research Institute; Nanjing Medical University	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011		Cancer Research Society; Canadian Institutes of Health Research [MOP-93810]; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research; University of British Columbia; National Cancer Institute of Canada	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Dermatology Foundation; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); University of British Columbia; National Cancer Institute of Canada(Canadian Cancer Society (CCS))	We gratefully thank Drs HR Byers, AP Albino, H Silver, R Zhang, M Pagano, S Sun and J Hsieh for kindly providing the materials. This study was supported by Cancer Research Society, the Canadian Institutes of Health Research (MOP-93810) and the Canadian Dermatology Foundation (GL). GC is a recipient of Postdoctoral Trainee Award from Michael Smith Foundation for Health Research. YW is a recipient of Roman M Babicki Fellowship from the University of British Columbia and a research fellow of the Terry Fox Foundation through an award from the National Cancer Institute of Canada.	Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chiappetta G, 2007, ENDOCR-RELAT CANCER, V14, P405, DOI 10.1677/ERC-06-0030; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Fadlelmola FM, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-2; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48; Garate M, 2007, FASEB J, V21, P3705, DOI 10.1096/fj.07-8069com; Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012; Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006; Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; Gunduz M, 2008, CANCER SCI, V99, P531, DOI 10.1111/j.1349-7006.2007.00708.x; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.jdermsci.2005.12.016; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Lu F, 2006, BRIT J CANCER, V95, P80, DOI 10.1038/sj.bjc.6603205; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Masuda T, 2002, CANCER RES, V62, P3819; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nalepa G, 2006, NAT REV DRUG DISCOV, V5, P596, DOI 10.1038/nrd2056; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Newton K, 2007, CANCER INVEST, V25, P502, DOI 10.1080/07357900701508041; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Nouman GS, 2002, HISTOPATHOLOGY, V40, P360, DOI 10.1046/j.1365-2559.2002.01369.x; Schwelchheimer C, 2004, CURR OPIN PLANT BIOL, V7, P677, DOI 10.1016/j.pbi.2004.09.009; Shah Imtiaz M., 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P250, DOI 10.2174/187152907782793572; Sonoda H, 2006, CLIN CANCER RES, V12, P1215, DOI 10.1158/1078-0432.CCR-05-1709; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; Tsai KW, 2008, EXP CELL RES, V314, P3130, DOI 10.1016/j.yexcr.2008.08.002; von Mikecz A, 2006, J CELL SCI, V119, P1977, DOI 10.1242/jcs.03008; Wang YM, 2007, CLIN CANCER RES, V13, P4111, DOI 10.1158/1078-0432.CCR-07-0408; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Woenckhaus C, 2005, HISTOL HISTOPATHOL, V20, P501, DOI 10.14670/HH-20.501; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; Zetter Bruce R, 2005, Future Oncol, V1, P567, DOI 10.2217/14796694.1.5.567	43	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	10					1498	1508		10.1038/onc.2009.424	http://dx.doi.org/10.1038/onc.2009.424			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19935701				2022-12-28	WOS:000275392400008
J	Ahn, BY; Trinh, DLN; Zajchowski, LD; Lee, B; Elwi, AN; Kim, SW				Ahn, B. Y.; Trinh, D. L. N.; Zajchowski, L. D.; Lee, B.; Elwi, A. N.; Kim, S-W			Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer	ONCOGENE			English	Article						p53; Tid1; tumor suppressor; mitochondria; apoptosis	MUTANT P53; MEMBRANE PERMEABILIZATION; MEDIATED APOPTOSIS; DNA-DAMAGE; CELLS; ACTIVATION; BAX; PROTEIN; DEGRADATION; CHAPERONES	The p53 tumor suppressor protein induces apoptosis in response to genotoxic and environmental stresses. Recent studies have revealed the existence of a transcription-independent mitochondrial p53 apoptotic pathway; however, the mechanism that regulates its translocation to the mitochondria has been unknown. In this study, we show that the tumor suppressor Tid1 forms a complex with p53 under hypoxic conditions that directs p53 translocation to the mitochondria and the subsequent initiation of the mitochondrial apoptosis pathway. Loss of Tid1 expression abrogated p53 translocation to the mitochondria and inhibited apoptosis, whereas the over-expression of Tid1 promoted p53 mitochondrial localization and apoptosis. Tid1's mitochondrial signal sequence and DnaJ domain were both required for the movement of the p53-Tid1 complex from the cytosol to the mitochondria. When Tid is over-expressed in cancer cell lines expressing mutant p53 isoforms defective in transcriptional activity, mitochondrial localization and pro-apoptotic activities of the mutant p53 proteins was restored. Our results establish Tid1 as a novel regulator of p53-mediated apoptosis, and suggest that therapies designed to enhance Tid1's function in promoting mitochondrial localization of p53 and apoptosis could be an effective therapy in many cancers. Oncogene (2010) 29, 1155-1166; doi: 10.1038/onc.2009.413; published online 23 November 2009	[Ahn, B. Y.; Trinh, D. L. N.; Lee, B.; Elwi, A. N.; Kim, S-W] Univ Calgary, Dept Biochem, Calgary, AB T2N 4N1, Canada; [Ahn, B. Y.; Trinh, D. L. N.; Lee, B.; Elwi, A. N.; Kim, S-W] Univ Calgary, Dept Mol Biol, Calgary, AB T2N 4N1, Canada; [Kim, S-W] Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Zajchowski, L. D.; Kim, S-W] Univ Calgary, Clark H Smith Brain Tumour Ctr, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kim, SW (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr,HRIC 2A08, Calgary, AB T2N 4N1, Canada.	swkim@ucalgary.ca			Alberta Cancer Research Institute [23123]; Canada Research Chairs Program [950203751]; Canada Institute of Health Research [MOP97962]; Alberta Cancer Board	Alberta Cancer Research Institute; Canada Research Chairs Program(Canada Research Chairs); Canada Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Board	We thank Drs F Jirik, S Robbins, P Forsyth, K Riabowol, S Grewal and X Feng for their invaluable suggestions, critical review of the paper and encouragement. This work was supported in part by grants from the Alberta Cancer Research Institute (23123), the Canada Research Chairs Program (950203751) and the Canada Institute of Health Research (MOP97962) to SWK. BYA and DT were supported by a postdoctoral fellowship and graduate scholarship, respectively, from the Alberta Cancer Board.	Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; Cui Q, 2007, ACTA PHARMACOL SIN, V28, P1057, DOI 10.1111/j.1745-7254.2007.00588.x; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Kim BM, 2007, TOXICOLOGY, V229, P226, DOI 10.1016/j.tox.2006.10.022; Kim SW, 2005, CANCER RES, V65, P8784, DOI 10.1158/0008-5472.CAN-04-4422; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lu B, 2006, J BIOL CHEM, V281, P13150, DOI 10.1074/jbc.M509179200; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mooney LM, 2002, BRIT J CANCER, V87, P909, DOI 10.1038/sj.bjc.6600541; Murphy ME, 2004, CELL CYCLE, V3, P836; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62	37	63	66	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1155	1166		10.1038/onc.2009.413	http://dx.doi.org/10.1038/onc.2009.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935715				2022-12-28	WOS:000274912100007
J	Beck, AH; Lee, CH; Witten, DM; Gleason, BC; Edris, B; Espinosa, I; Zhu, S; Li, R; Montgomery, KD; Marinelli, RJ; Tibshirani, R; Hastie, T; Jablons, DM; Rubin, BP; Fletcher, CD; West, RB; van de Rijn, M				Beck, A. H.; Lee, C-H; Witten, D. M.; Gleason, B. C.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; Marinelli, R. J.; Tibshirani, R.; Hastie, T.; Jablons, D. M.; Rubin, B. P.; Fletcher, C. D.; West, R. B.; van de Rijn, M.			Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling	ONCOGENE			English	Article						sarcoma; leiomyosarcoma; integrative genomics; gene expression profiling; array comparative genomic hybridization; tissue microarrays	SOFT-TISSUE SARCOMAS; GENE-EXPRESSION ANALYSIS; TUMORS; SIGNATURE; PATTERNS; METASTASIS; SUBCLASSES; PROGNOSIS; RELEVANT; REGION	Leiomyosarcoma (LMS) is a soft tissue tumor with a significant degree of morphologic and molecular heterogeneity. We used integrative molecular pro. ling to discover and characterize molecular subtypes of LMS. Gene expression pro. ling was performed on 51 LMS samples. Unsupervised clustering showed three reproducible LMS clusters. Array comparative genomic hybridization (aCGH) was performed on 20 LMS samples and showed that the molecular subtypes defined by gene expression showed distinct genomic changes. Tumors from the 'muscle-enriched' cluster showed significantly increased copy number changes (P = 0.04). A majority of the muscle-enriched cases showed loss at 16q24, which contains Fanconi anemia, complementation group A, known to have an important role in DNA repair, and loss at 1p36, which contains PRDM16, of which loss promotes muscle differentiation. Immunohistochemistry (IHC) was performed on LMS tissue microarrays (n = 377) for five markers with high levels of messenger RNA in the muscle-enriched cluster (ACTG2, CASQ2, SLMAP, CFL2 and MYLK) and showed significantly correlated expression of the five proteins (all pairwise P<0.005). Expression of the five markers was associated with improved disease-specific survival in a multivariate Cox regression analysis (P<0.04). In this analysis that combined gene expression pro. ling, aCGH and IHC, we characterized distinct molecular LMS subtypes, provided insight into their pathogenesis, and identified prognostic biomarkers. Oncogene (2010) 29, 845-854; doi:10.1038/onc.2009.381; published online 9 November 2009	[Beck, A. H.; Edris, B.; Espinosa, I.; Zhu, S.; Li, R.; Montgomery, K. D.; West, R. B.; van de Rijn, M.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Lee, C-H] Vancouver Gen Hosp, Dept Pathol, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada; [Lee, C-H] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Witten, D. M.; Tibshirani, R.; Hastie, T.] Stanford Univ, Med Ctr, Dept Stat, Stanford, CA 94305 USA; [Gleason, B. C.; Fletcher, C. D.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Marinelli, R. J.] Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; [Jablons, D. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Rubin, B. P.] Cleveland Clin, Dept Anat Pathol, Pathol & Lab Med Inst, Cleveland, OH 44106 USA; [Rubin, B. P.] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [West, R. B.] Palo Alto Vet Affairs Hlth Care Syst, Dept Pathol & Lab Serv, Palo Alto, CA USA	Stanford University; University of British Columbia; British Columbia Cancer Agency; Stanford University; Harvard University; Brigham & Women's Hospital; Stanford University; University of California System; University of California San Francisco; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, 300 Pasteur Dr,L235, Stanford, CA 94305 USA.	mrijn@stanford.edu		van de Rijn, Matt/0000-0002-1909-9739; Hastie, Trevor/0000-0002-0164-3142; West, Robert/0000-0002-8330-8283	NIH [CA112270]; National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE [R01CA112270] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Leiomyosarcoma Foundation; Leiomyosarcoma Direct Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support came from NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation. The authors dedicate this paper to the memory of Suzanne Kurtz, LMS patient and founder of LMSdr. This work was supported by NIH grant CA112270, the National Leiomyosarcoma Foundation and the Leiomyosarcoma Direct Research Foundation.	ABBAS AK, 2005, ROBBINS COTRAN PATHO, V15; ACKERMAN L.V, 2004, ROSAI ACKERMANS SURG, V9th; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; BECK AH, 2009, VIRCHOWS ARCH; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Borden EC, 2003, CLIN CANCER RES, V9, P1941; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Espinosa I, 2009, AM J PATHOL, V174, P2347, DOI 10.2353/ajpath.2009.081037; FLETCHER CDM, PATHOLOGY GENETICS T; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Henderson SR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r76; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; JUN HJ, 2009, MED ONCOL; Kapp AV, 2007, BIOSTATISTICS, V8, P9, DOI 10.1093/biostatistics/kxj029; Kattan MW, 2002, J CLIN ONCOL, V20, P791, DOI 10.1200/JCO.2002.20.3.791; Kochetkova M, 2002, CANCER RES, V62, P4599; Lakhani SR, 2001, NAT REV CANCER, V1, P151, DOI 10.1038/35101087; Landis-Piwowar KR, 2008, J CELL BIOCHEM, V105, P514, DOI 10.1002/jcb.21853; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Larramendy ML, 2008, CANCER GENET CYTOGEN, V187, P1, DOI 10.1016/j.cancergencyto.2008.06.005; Lee CH, 2008, CLIN CANCER RES, V14, P1423, DOI 10.1158/1078-0432.CCR-07-1712; Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Meza-Zepeda LA, 2006, CANCER RES, V66, P8984, DOI 10.1158/0008-5472.CAN-06-1972; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Ottone T, 2009, GENE CHROMOSOME CANC, V48, P213, DOI 10.1002/gcc.20633; Perot G, 2009, CANCER RES, V69, P2269, DOI 10.1158/0008-5472.CAN-08-1443; Pervaiz N, 2008, CANCER-AM CANCER SOC, V113, P573, DOI 10.1002/cncr.23592; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Quade BJ, 2004, GENE CHROMOSOME CANC, V40, P97, DOI 10.1002/gcc.20018; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ren BG, 2003, HUM PATHOL, V34, P549, DOI 10.1016/S0046-8177(03)00014-5; RONG S, 1993, CANCER RES, V53, P5355; Sarcoma Meta-analysis Collaboration, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001419, DOI 10.1002/14651858.CD001419]; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; Shmulevich I, 2002, CANCER-AM CANCER SOC, V94, P2069, DOI 10.1002/cncr.10425; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Skubitz KM, 2003, CANCER, V98, P1029, DOI 10.1002/cncr.11586; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2007, NAT REV CANCER, V7, P545, DOI 10.1038/nrc2173; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553; Weigelt B, 2004, CELL CYCLE, V3, P756; Weiss SW, 2008, ENZINGER WEISSS SOFT, P303; Zou H, 2006, J COMPUT GRAPH STAT, V15, P265, DOI 10.1198/106186006X113430	56	91	94	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					845	854		10.1038/onc.2009.381	http://dx.doi.org/10.1038/onc.2009.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901961	Green Submitted, Green Accepted			2022-12-28	WOS:000274397800007
J	Yang, J; Parsons, J; Nicolay, NH; Caporali, S; Harrington, CF; Singh, R; Finch, D; D'Atri, S; Farmer, PB; Johnston, PG; McKenna, WG; Dianov, G; Sharma, RA				Yang, J.; Parsons, J.; Nicolay, N. H.; Caporali, S.; Harrington, C. F.; Singh, R.; Finch, D.; D'Atri, S.; Farmer, P. B.; Johnston, P. G.; McKenna, W. G.; Dianov, G.; Sharma, R. A.			Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy	ONCOGENE			English	Article						DNA repair; colorectal cancer; malignant melanoma	CANCER; LINES; OVEREXPRESSION; EXPRESSION; RESISTANT; CISPLATIN; APOPTOSIS; BREAKAGE; DAMAGE	A significant proportion of human cancers overexpress DNA polymerase beta (Pol beta), the major DNA polymerase involved in base excision repair. The underlying mechanism and biological consequences of overexpression of this protein are unknown. We examined whether Pol beta, expressed at levels found in tumor cells, is involved in the repair of DNA damage induced by oxaliplatin treatment and whether the expression status of this protein alters the sensitivity of cells to oxaliplatin. DNA damage induced by oxaliplatin treatment of HCT116 and HT29 colon cancer cells was observed to be associated with the stabilization of Pol beta protein on chromatin. In comparison with HCT116 colon cancer cells, isogenic oxaliplatin-resistant (HCT-OR) cells were found to have higher constitutive levels of Pol beta protein, faster in vitro repair of a DNA substrate containing a single nucleotide gap and faster repair of 1,2-GG oxaliplatin adduct levels in cells. In HCT-OR cells, small interfering RNA knockdown of Pol beta delayed the repair of oxaliplatin-induced DNA damage. In a different model system, Pol beta-deficient fibroblasts were less able to repair 1,2-GG oxaliplatin adducts and were hypersensitive to oxaliplatin treatment compared with isogenic Pol beta-expressing cells. Consistent with previous studies, Pol beta-deficient mouse fibroblasts were not hypersensitive to cisplatin treatment. These data provide the first link between oxaliplatin sensitivity and DNA repair involving Pol beta. They demonstrate that Pol beta modulates the sensitivity of cells to oxaliplatin treatment. Oncogene (2010) 29, 463-468; doi:10.1038/onc.2009.327; published online 19 October 2009	[Yang, J.; Parsons, J.; Nicolay, N. H.; Finch, D.; McKenna, W. G.; Dianov, G.; Sharma, R. A.] Univ Oxford, Canc Res UK Med Res Council, Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, Oxon, England; [Caporali, S.; D'Atri, S.] IRCCS, Ist Dermopat Immacolata, Oncol Mol Lab, Rome, Italy; [Harrington, C. F.] Univ Surrey, Fac Hlth & Med Sci, Ctr Clin Sci & Measurement, Trace Element Lab, Surrey, England; [Singh, R.; Farmer, P. B.] Univ Leicester, Bioctr, Canc Biomarkers & Prevent Grp, Leicester, Leics, England; [Johnston, P. G.] Queens Univ Belfast, Inst Hlth Sci, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland	Cancer Research UK; University of Oxford; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Surrey; University of Leicester; Queens University Belfast	Sharma, RA (corresponding author), Univ Oxford, Churchill Hosp, Gray Inst Radiat Oncol & Biol, Old Rd Campus Res Bldg, Oxford OX3 7DQ, Oxon, England.	grigory.dianov@rob.ox.ac.uk; ricky.sharma@rob.ox.ac.uk	Singh, Raj/A-5398-2011; Singh, Raj/HDN-1244-2022; D'Atri, Stefania/K-6039-2016; Harrington, Chris F/M-3453-2018	Harrington, Chris F/0000-0003-4101-556X; Parsons, Jason/0000-0002-5052-1125; D'Atri, Stefania/0000-0001-9852-7377	Cancer Research UK; UK Medical Research Council; Higher Education Funding Council for England; UK Biotechnology and Biological Sciences Research Council; NIHR Biomedical Research Centre, Oxford, UK; MRC [G0700730] Funding Source: UKRI; Cancer Research UK [8971] Funding Source: researchfish; Medical Research Council [G0700730] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Higher Education Funding Council for England(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIHR Biomedical Research Centre, Oxford, UK(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Drs Tomas Lindahl and Peter McHugh for comments on the paper. This study was supported by Cancer Research UK, the UK Medical Research Council, the Higher Education Funding Council for England, the Research Equipment Initiative of the UK Biotechnology and Biological Sciences Research Council and the NIHR Biomedical Research Centre, Oxford, UK.	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362; Boyer J, 2006, CANCER RES, V66, P2765, DOI 10.1158/0008-5472.CAN-05-2693; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Horton JK, 2002, DNA REPAIR, V1, P317, DOI 10.1016/S1568-7864(02)00008-3; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Le Pla RC, 2007, CHEM RES TOXICOL, V20, P1177, DOI 10.1021/tx700088j; Ochs K, 2002, CANCER RES, V62, P1524; Ochs K, 1999, CANCER RES, V59, P1544; Parsons JL, 2008, MOL CELL, V29, P477, DOI 10.1016/j.molcel.2007.12.027; Rixe O, 1996, BIOCHEM PHARMACOL, V52, P1855, DOI 10.1016/S0006-2952(97)81490-6; Servant L, 2002, J BIOL CHEM, V277, P50046, DOI 10.1074/jbc.M207101200; Shibuya K, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-37; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Starcevic D, 2004, CELL CYCLE, V3, P998; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	22	44	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					463	468		10.1038/onc.2009.327	http://dx.doi.org/10.1038/onc.2009.327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838217				2022-12-28	WOS:000273793200015
J	Barbash, O; Egan, E; Pontano, LL; Kosak, J; Diehl, JA				Barbash, O.; Egan, E.; Pontano, L. L.; Kosak, J.; Diehl, J. A.			Lysine 269 is essential for cyclin D1 ubiquitylation by the SCFFbx4/alpha B-crystallin ligase and subsequent proteasome-dependent degradation	ONCOGENE			English	Article						cyclin D1; Fbx4; ubiquitin; alpha B crystallin	MEDIATED DEGRADATION; UBIQUITIN LIGASE; PHOSPHORYLATION; PROTEOLYSIS; MUTATIONS; COMPLEX; CANCER; EXPRESSION; BINDING; PROTEIN	Protein ubiquitylation is a complex enzymatic process that results in the covalent attachment of ubiquitin, through Gly-76 of ubiquitin, to an epsilon NH2 group of an internal lysine residue in a given substrate. Although E3 ligases frequently use lysines adjacent to the degron within the substrate, many substrates can be targeted to the proteasome through the polyubiquitylation of any lysine. We have assessed the role of lysine residues proximal to the cyclin D1 phosphodegron for ubiquitylation by the SCFFbx4/alpha B-crystallin ubiquitin ligase and subsequent proteasome-dependent degradation of cyclin D1. The work described herein reveals a requisite role for Lys-269 (K269) for the rapid polyubiquitin-mediated degradation of cyclin D1. Mutation of Lys-269, which is proximal to the phosphodegron sequence surrounding Thr-286 in cyclin D1, not only stabilizes cyclin D1 but also triggers cyclin D1 accumulation within the nucleus, thereby promoting cell transformation. In addition, D1-K269R is resistant to genotoxic stress-induced degradation, similar to non-phosphorylatable D1-T286A, supporting the critical role for the post-translational regulation of cyclin D1 in response to DNA-damaging agents. Strikingly, although mutation of lysine 269 to arginine inhibits cyclin D1 degradation, it does not inhibit cyclin D1 ubiquitylation in vivo, showing that ubiquitylation of a specific lysine can influence substrate targeting to the 26S proteasome. Oncogene (2009) 28, 4317-4325; doi: 10.1038/onc.2009.287; published online 21 September 2009	[Barbash, O.; Egan, E.; Pontano, L. L.; Kosak, J.; Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NIH [CA93237]; NATIONAL CANCER INSTITUTE [P01CA098101, R01CA093237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Serge Fuchs for the plasmids encoding the various ubiquitin lysine-arginine mutants, and Petia Zamfirova and Margarita Romero for their technical assistance. This work was supported by CA93237 (NIH) and a Leukemia & Lymphoma Scholar award (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Feng Q, 2007, ONCOGENE, V26, P5098, DOI 10.1038/sj.onc.1210309; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; KATO J, 1993, GENE DEV, V7, P331; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin J, 2004, SEMIN ONCOL, V31, P476, DOI 10.1053/j.seminoncol.2004.04.019; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Worsley SD, 1996, J CLIN PATHOL-CL MOL, V49, pM46; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	26	24	28	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4317	4325		10.1038/onc.2009.287	http://dx.doi.org/10.1038/onc.2009.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767775	Green Accepted			2022-12-28	WOS:000272876400001
J	Song, B; Wang, Y; Xi, Y; Kudo, K; Bruheim, S; Botchkina, GI; Gavin, E; Wan, Y; Formentini, A; Kornmann, M; Fodstad, O; Ju, J				Song, B.; Wang, Y.; Xi, Y.; Kudo, K.; Bruheim, S.; Botchkina, G. I.; Gavin, E.; Wan, Y.; Formentini, A.; Kornmann, M.; Fodstad, O.; Ju, J.			Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells	ONCOGENE			English	Article						miR-140; chemosensitivity; histone deacetylase 4; cancer stem cells	STEM-CELLS; MICRORNA EXPRESSION; ANIMAL DEVELOPMENT; P53; REPRESSION; TARGETS; CYCLE; INHIBITORS; SIGNATURES; GENE	In this study, high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts. Tumor cells ectopically transfected with miR-140 were more resistant to methotrexate and 5-fluorouracil (5-FU). Overexpression of miR-140 inhibited cell proliferation in both osteosarcoma U-2 OS (wt-p53) and colon cancer HCT 116 (wt-p53) cell lines, but less so in osteosarcoma MG63 (mut-p53) and colon cancer HCT 116 (null-p53) cell lines. miR-140 induced p53 and p21 expression accompanied with G(1) and G(2) phase arrest only in cell lines containing wild type of p53. Histone deacetylase 4 (HDAC4) was confirmed to be one of the important targets of miR-140. The expression of endogenous miR-140 was significantly elevated in CD133(+hi)CD44(+hi) colon cancer stem-like cells that exhibit slow proliferating rate and chemoresistance. Blocking endogenous miR-140 by locked nucleic acid-modified anti-miR partially sensitized resistant colon cancer stem-like cells to 5-FU treatment. Taken together, our findings indicate that miR-140 is involved in the chemoresistance by reduced cell proliferation through G(1) and G(2) phase arrest mediated in part through the suppression of HDAC4. miR-140 may be a candidate target to develop novel therapeutic strategy to overcome drug resistance. Oncogene (2009) 28, 4065-4074; doi:10.1038/onc.2009.274; published online 7 September 2009	[Song, B.; Wang, Y.; Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA; [Wang, Y.; Wan, Y.] Wuhan Univ, Dept Physiol, Wuhan 430072, Peoples R China; [Xi, Y.; Kudo, K.; Gavin, E.] Univ S Alabama, Mitchell Canc Inst, Canc Genom Lab, Mobile, AL 36688 USA; [Bruheim, S.; Fodstad, O.] Univ Hosp, Rikshosp, Norwegian Radium Hosp, Dept Tumor Biol,Inst Canc Res, Oslo, Norway; [Bruheim, S.; Fodstad, O.] Univ Oslo, Norwegian Radium Hosp, Fac Div, Dept Tumor Biol, Oslo, Norway; [Botchkina, G. I.] SUNY Stony Brook, Dept Surg, Stony Brook, NY 11794 USA; [Formentini, A.; Kornmann, M.] Univ Ulm, Dept Visceral & Transplantat Surg, Ulm, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Wuhan University; University of South Alabama; University of Oslo; National Hospital Norway; University of Oslo; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Ulm University	Ju, J (corresponding author), SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA.	jiju@notes.cc.sunysb.edu		Ju, Jingfang/0000-0002-4821-7458; Xi, Yaguang/0000-0003-3681-9352	Stony Brook Translational Research Laboratory; NIH [CA114043, MH075020]; NATIONAL CANCER INSTITUTE [R21CA114043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH075020] Funding Source: NIH RePORTER	Stony Brook Translational Research Laboratory; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We appreciate the critical reading of the paper by Stephanie Burke (Stony Brook University). This work was supported by Stony Brook Translational Research Laboratory Start-up fund and NIH CA114043 (J Ju) and MH075020 (J Ju).	Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Ambros Victor, 2004, Methods Mol Biol, V265, P131; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Botchkina Inna L., 2009, Cancer Genomics & Proteomics, V6, P19; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Bruheim S, 2004, PATHOL ONCOL RES, V10, P133, DOI 10.1007/BF03033741; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; DRESSLER LG, 1988, CANCER, V61, P420, DOI 10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO;2-0; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Izzotti A, 2009, FASEB J, V23, P806, DOI 10.1096/fj.08-121384; Koishi K, 2006, WORLD J GASTROENTERO, V12, P7585, DOI 10.3748/wjg.v12.i47.7585; Kozak M, 2008, GENE, V423, P108, DOI 10.1016/j.gene.2008.07.013; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; Nicolas FE, 2008, RNA, V14, P2513, DOI 10.1261/rna.1221108; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Plasterk RHA, 2006, CELL, V124, P877, DOI 10.1016/j.cell.2006.02.030; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869; Zou GM, 2008, J CELL PHYSIOL, V217, P598, DOI 10.1002/jcp.21541	39	318	349	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4065	4074		10.1038/onc.2009.274	http://dx.doi.org/10.1038/onc.2009.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19734943	Green Accepted, Green Published			2022-12-28	WOS:000272560500003
J	Li, Y; Ye, X; Tan, C; Hongo, JA; Zha, J; Liu, J; Kallop, D; Ludlam, MJC; Pei, L				Li, Y.; Ye, X.; Tan, C.; Hongo, J-A; Zha, J.; Liu, J.; Kallop, D.; Ludlam, M. J. C.; Pei, L.			Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis	ONCOGENE			English	Article						RTK; tumorigenesis; metastasis; angiogenesis; RNAi; therapeutic antibodies	RECEPTOR TYROSINE KINASE; ENDOTHELIAL-CELLS; MYELOID-LEUKEMIA; BREAST-CANCER; TAM RECEPTORS; GAS6; EXPRESSION; FAMILY; MICE; ACTIVATION	Dysregulation of Axl and its ligand growth arrest-specific 6 is implicated in the pathogenesis of several human cancers. In this study, we have used RNAi and monoclonal antibodies to assess further the oncogenic potential of Axl. Here we show that Axl knockdown reduces growth of lung and breast cancer xenograft tumors. Inhibition of Axl expression attenuates breast cancer cell migration and inhibits metastasis to the lung in an orthotopic model, providing the first in vivo evidence that links Axl directly to cancer metastasis. Axl knockdown in endothelial cells impaired tube formation and this effect was additive with anti-vascular endothelial growth factor (VEGF). Further analysis demonstrated that Axl regulates endothelial cell functions by modulation of signaling through angiopoietin/Tie2 and Dickkopf (DKK3) pathways. We have developed and characterized Axl monoclonal antibodies that attenuate non-small cell lung carcinoma xenograft growth by downregulation of receptor expression, reducing tumor cell proliferation and inducing apoptosis. Our data demonstrate that Axl plays multiple roles in tumorigenesis and that therapeutic antibodies against Axl may block Axl functions not only in malignant tumor cells but also in the tumor stroma. The additive effect of Axl inhibition with anti-VEGF suggests that blocking Axl function could be an effective approach for enhancing antiangiogenic therapy. Oncogene (2009) 28, 3442-3455; doi: 10.1038/onc.2009.212; published online 27 July 2009	[Li, Y.; Ye, X.; Pei, L.] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; [Tan, C.; Hongo, J-A] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Zha, J.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; [Liu, J.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; [Kallop, D.] Genentech Inc, Dept Tumor Biol & Angiogenesis, San Francisco, CA 94080 USA; [Ludlam, M. J. C.] Genentech Inc, Dept Cell Regulat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pei, L (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	lpei@gene.com		Liu, Jinfeng/0000-0002-0343-8222				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Angelillo-Scherrer A, 2008, J CLIN INVEST, V118, P583, DOI 10.1172/JCI30375; Berclaz G, 2001, ANN ONCOL, V12, P819, DOI 10.1023/A:1011126330233; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Budagian V, 2005, MOL CELL BIOL, V25, P9324, DOI 10.1128/MCB.25.21.9324-9339.2005; Cao WM, 2001, ARTERIOSCL THROM VAS, V21, P1592, DOI 10.1161/hq1001.097062; Caraux A, 2006, NAT IMMUNOL, V7, P747, DOI 10.1038/ni1353; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; D'Arcangelo D, 2006, CARDIOVASC RES, V71, P754, DOI 10.1016/j.cardiores.2006.06.002; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Gould WR, 2005, J THROMB HAEMOST, V3, P733, DOI 10.1111/j.1538-7836.2005.01186.x; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hasanbasic I, 2005, J THROMB HAEMOST, V3, P2790, DOI 10.1111/j.1538-7836.2005.01662.x; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; Katagiri M, 2001, J BIOL CHEM, V276, P7376, DOI 10.1074/jbc.M007393200; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Korshunov VA, 2006, CIRC RES, V98, P1446, DOI 10.1161/01.RES.0000223322.16149.9a; Korshunov VA, 2007, HYPERTENSION, V50, P1057, DOI 10.1161/HYPERTENSIONAHA.107.096289; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Meric F, 2002, CLIN CANCER RES, V8, P361; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Prasad D, 2006, MOL CELL NEUROSCI, V33, P96, DOI 10.1016/j.mcn.2006.06.011; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Shankar SL, 2006, J NEUROSCI, V26, P5638, DOI 10.1523/JNEUROSCI.5063-05.2006; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Untergasser G, 2008, INT J CANCER, V122, P1539, DOI 10.1002/ijc.23255; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	52	210	257	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3442	3455		10.1038/onc.2009.212	http://dx.doi.org/10.1038/onc.2009.212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19633687				2022-12-28	WOS:000270478300002
J	Baudot, AD; Jeandel, PY; Mouska, X; Maurer, U; Tartare-Deckert, S; Raynaud, SD; Cassuto, JP; Ticchioni, M; Deckert, M				Baudot, A. D.; Jeandel, P. Y.; Mouska, X.; Maurer, U.; Tartare-Deckert, S.; Raynaud, S. D.; Cassuto, J. P.; Ticchioni, M.; Deckert, M.			The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKC delta and proteasome-dependent regulation of Mcl-1 expression	ONCOGENE			English	Article						B-CLL; Syk; survival; PKCdelta; Mcl-1; proteasome	ACUTE LYMPHOBLASTIC-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-TYPE-O; ANTIGEN-RECEPTOR; IN-VITRO; C-DELTA; APOPTOSIS; ACTIVATION; PHOSPHORYLATION; PATHWAY	B-cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of mature monoclonal CD5+ B cells. The disease results mainly from a failure of cells to undergo apoptosis, a process largely influenced by the existence of constitutively activated components of B-cell receptor signaling and the deregulated expression of antiapoptotic molecules. Recent evidence pointing to a critical role of spleen tyrosine kinase (Syk) in ligand-independent BCR signaling prompted us to examine its role in primary B-CLL cell survival. We demonstrate that pharmacological inhibition of constitutive Syk activity and silencing by siRNA led to a dramatic decrease of cell viability in CLL samples (n = 44), regardless of clinical and biological status and induced typical apoptotic cell death with mitochondrial failure followed by caspase 3-dependent cell death. We also provide functional and biochemical evidence that Syk regulated B-CLL cell survival through a novel pathway involving PKC delta and a proteasome-dependent regulation of the anti-apoptotic protein Mcl-1. Together, our observations are consistent with a model wherein PKC delta downstream of Syk stabilizes Mcl-1 through inhibitory phosphorylation of GSK3 by Akt. We conclude that Syk constitutes a key regulator of B-CLL cell survival, emphasizing the clinical utility of Syk inhibition in hematopoietic malignancies. Oncogene (2009) 28, 3261-3273; doi:10.1038/onc.2009.179; published online 6 July 2009	[Baudot, A. D.; Mouska, X.; Ticchioni, M.; Deckert, M.] Hop Archet, INSERM, UMR576, F-06202 Nice 3, France; [Baudot, A. D.; Jeandel, P. Y.; Tartare-Deckert, S.; Deckert, M.] Univ Nice Sophia Antipolis, Nice, France; [Jeandel, P. Y.] CHU Nice, Dept Internal Med, Nice, France; [Maurer, U.] Univ Freiburg, Inst Mol Med & Cell Res, D-7800 Freiburg, Germany; [Tartare-Deckert, S.] INSERM, UMR895, Nice, France; [Raynaud, S. D.] CHU Nice, Genet Lab, Nice, France; [Cassuto, J. P.] CHU Nice, Dept Clin Hematol, Nice, France; [Ticchioni, M.] CHU Nice, Immunol Lab, Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; CHU Nice	Deckert, M (corresponding author), Hop Archet, INSERM, UMR576, 1 Route St Antoine Ginestiere, F-06202 Nice 3, France.	deckert@unice.fr	TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/T-3566-2019; Ticchioni, Michel/P-8095-2016; Deckert, Marcel/M-4998-2016; Jeandel, Pierre-Yves/ABD-6658-2020	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X; Mouska, Xavier/0000-0002-4263-543X	INSERM; ARC [3111]; INCa [PL-06-026]; TxCell (Valbonne, France)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); TxCell (Valbonne, France)	This work was supported by INSERM, ARC (Grant No 3111), and INCa (Grant PL-06-026). ADB is a recipient of an INSERM-Region Provence Alpes Cote d'Azur PhD fellowship in partnership with TxCell (Valbonne, France). M Deckert is a recipient of a Contrat d'Interface Clinique with the Department of Clinical Hematology, CHU de Nice. We thank P Gounon (CCMA, Faculte des Sciences, Nice) for electron microscopy analysis, and M. Ciosi (INRA-CNRS, SophiaAntipolis) for statistical analysis.	Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821; Chiorazzi N, 2003, ANNU REV IMMUNOL, V21, P841, DOI 10.1146/annurev.immunol.21.120601.141018; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Crespo M, 2006, CLIN CANCER RES, V12, P726, DOI 10.1158/1078-0432.CCR-05-1531; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Deglesne PA, 2006, CANCER RES, V66, P7158, DOI 10.1158/0008-5472.CAN-06-0085; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Feldman AL, 2008, LEUKEMIA, V22, P1139, DOI 10.1038/leu.2008.77; Gauld SB, 2005, NAT IMMUNOL, V6, P1160, DOI 10.1038/ni1256; Gobessi S, 2009, LEUKEMIA, V23, P686, DOI 10.1038/leu.2008.346; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Holler C, 2009, BLOOD, V113, P2791, DOI 10.1182/blood-2008-06-160713; Kipps TJ, 2003, CURR OPIN HEMATOL, V10, P312, DOI 10.1097/00062752-200307000-00010; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Monroe JG, 2006, NAT REV IMMUNOL, V6, P283, DOI 10.1038/nri1808; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Muzio M, 2008, BLOOD, V112, P188, DOI 10.1182/blood-2007-09-111344; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Petlickovski A, 2005, BLOOD, V105, P4820, DOI 10.1182/blood-2004-07-2669; Plate JMD, 2004, LEUKEMIA LYMPHOMA, V45, P1519, DOI 10.1080/10428190410001683642; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Semichon M, 1997, LEUKEMIA, V11, P1921, DOI 10.1038/sj.leu.2400832; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stevenson FK, 2004, BLOOD, V103, P4389, DOI 10.1182/blood-2003-12-4312; Ticchioni M, 2007, ONCOGENE, V26, P7081, DOI 10.1038/sj.onc.1210519; TOKER A, 1994, J BIOL CHEM, V269, P32358; Veldurthy A, 2008, BLOOD, V112, P1443, DOI 10.1182/blood-2007-11-123984; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316	48	85	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3261	3273		10.1038/onc.2009.179	http://dx.doi.org/10.1038/onc.2009.179			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581935				2022-12-28	WOS:000269893700001
J	Knight, AS; Notaridou, M; Watson, RJ				Knight, A. S.; Notaridou, M.; Watson, R. J.			A Lin-9 complex is recruited by B-Myb to activate transcription of G(2)/M genes in undifferentiated embryonal carcinoma cells	ONCOGENE			English	Article						cell cycle; mitosis; transcription; B-Myb; Lin-9; LINC	MUVB/DREAM COMPLEX; REPRESSOR COMPLEX; DROSOPHILA MYB; EXPRESSION; PROTEINS; PHOSPHORYLATION; PROGRESSION; DISTINCT; KINASE; CANCER	It has recently been discovered that cell-cycle gene transcription is regulated by a core complex named LINC that switches from a transcriptionally repressive complex in G(0)-G(1) with the p130 or p107 pocket proteins and E2F4 to a transcriptionally active complex in S-G(2) containing B-Myb. We have studied the function of LINC in F9 embryonal carcinoma cells, which are distinguished by a rapid cell cycle resulting from an extremely short G(1) phase. We show that suppressing expression of the LINC component, Lin-9, in F9 cells causes arrest in mitosis, and we have used this system to screen for transcriptional targets. In these cells, B-Myb was found in complexes with Lin-9 and several other LINC constituents, however, the pocket proteins did not associate with LINC unless F9 cells were differentiated. Lin-9 and B-Myb were both required for transcription of G(2)/M genes such as Cyclin B1 and Survivin. Moreover, B-Myb was demonstrated to recruit Lin-9 to the Survivin promoter through multiple Myb-binding sites. The demonstration that a B-Myb/LINC complex is vital for progression through mitosis in cells lacking a G(1)/S checkpoint has implications for both undifferentiated embryonal cells and for cancers in which pocket protein function is compromised.	[Knight, A. S.; Notaridou, M.; Watson, R. J.] Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, London W2 1PG, England	Imperial College London	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, St Marys Campus,Norfolk Pl, London W2 1PG, England.	r.watson@imperial.ac.uk			Association for International Cancer Research [06-030]	Association for International Cancer Research	We thank Stephan Gaubatz and Alexander Brehm for the kind gifts of LINC antibodies and human Lin-9 cDNA, respectively. This work was supported by a project grant from the Association for International Cancer Research (06-030).	Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Georlette D, 2007, GENE DEV, V21, P2880, DOI 10.1101/gad.1600107; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tarasov KV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002478; Tavner F, 2007, ONCOGENE, V26, P2727, DOI 10.1038/sj.onc.1210087; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Wen H, 2008, GENE DEV, V22, P601, DOI 10.1101/gad.1626308; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Yamauchi T, 2008, EMBO J, V27, P1852, DOI 10.1038/emboj.2008.118; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	26	76	77	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	2009	28	15					1737	1747		10.1038/onc.2009.22	http://dx.doi.org/10.1038/onc.2009.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19252525				2022-12-28	WOS:000265640400001
J	Lallet-Daher, H; Roudbaraki, M; Bavencoffe, A; Mariot, P; Gackiere, F; Bidaux, G; Urbain, R; Gosset, P; Delcourt, P; Fleurisse, L; Slomianny, C; Dewailly, E; Mauroy, B; Bonnal, JL; Skryma, R; Prevarskaya, N				Lallet-Daher, H.; Roudbaraki, M.; Bavencoffe, A.; Mariot, P.; Gackiere, F.; Bidaux, G.; Urbain, R.; Gosset, P.; Delcourt, P.; Fleurisse, L.; Slomianny, C.; Dewailly, E.; Mauroy, B.; Bonnal, J. L.; Skryma, R.; Prevarskaya, N.			Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry	ONCOGENE			English	Article						intermediate-conductance potassium channels; TRPV6; prostate cancer; proliferation; capacitative calcium entry; patch clamp	OPERATED CA2+ CURRENT; POTASSIUM CHANNELS; EPITHELIAL-CELLS; UP-REGULATION; EXPRESSION; GROWTH; CYCLE; INVOLVEMENT; PROGRESSION; ACTIVATION	Accumulating data point to K+ channels as relevant players in controlling cell cycle progression and proliferation of human cancer cells, including prostate cancer (PCa) cells. However, the mechanism(s) by which K+ channels control PCa cell proliferation remain illusive. In this study, using the techniques of molecular biology, biochemistry, electrophysiology and calcium imaging, we studied the expression and functionality of intermediate-conductance calcium-activated potassium channels (IKCa1) in human PCa as well as their involvement in cell proliferation. We showed that IKCa1 mRNA and protein were preferentially expressed in human PCa tissues, and inhibition of the IKCa1 potassium channel suppressed PCa cell proliferation. The activation of IKCa1 hyperpolarizes membrane potential and, by promoting the driving force for calcium, induces calcium entry through TRPV6, a cation channel of the TRP (Transient Receptor Potential) family. Thus, the overexpression of the IKCa1 channel is likely to promote carcinogenesis in human prostate tissue.	[Roudbaraki, M.] USTL, Lab Physiol Cellulaire, INSERM U800, Equipe Labellisee Ligue Natl Contre Canc, F-59655 Villeneuve Dascq, Nord, France; [Lallet-Daher, H.; Roudbaraki, M.; Bavencoffe, A.; Mariot, P.; Gackiere, F.; Bidaux, G.; Delcourt, P.; Slomianny, C.; Dewailly, E.; Skryma, R.; Prevarskaya, N.] Univ Sci & Technol Lille, Villeneuve Dascq, France; [Urbain, R.] Inst Rech Pierre Fabre, Paris, France; [Gosset, P.; Fleurisse, L.] Groupement Hosp Inst Catholique Lille, Lab Anat & Cytol Pathol, Fac Libre Med, Lille, France; [Mauroy, B.; Bonnal, J. L.] Hosp St Philibert, Serv Urol, Lomme Les Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite Catholique de Lille	Roudbaraki, M (corresponding author), USTL, Lab Physiol Cellulaire, INSERM U800, Equipe Labellisee Ligue Natl Contre Canc, Batiment SN3,2E Etage, F-59655 Villeneuve Dascq, Nord, France.	morad.roudbaraki@univ-lille1.fr; natacha.prevarskaya@univ-lille1.fr	Slomianny, Christian/L-8285-2018; Bonnal, Jean-Louis JLB/U-9025-2018; Bidaux, Gabriel/F-1294-2016	Prevarskaya, natacha/0000-0003-0316-197X; Morad, Roudbaraki/0000-0001-5751-3323; Bidaux, Gabriel/0000-0002-6162-3223; Bavencoffe, Alexis Guillaume/0000-0001-5659-5988; Mariot, Pascal/0000-0001-7226-9162	INSERM; Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche; La Ligue Nationale Contre le Cancer; Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche; La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We thank Dr Y Shuba (Bogomoletz Institute of Physiology, Kiev, Ukraine) for helpful discussions. This study was supported by grants from INSERM, the Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche, La Ligue Nationale Contre le Cancer. H LalletDaher was supported by the Association pour la Recherche sur les Tumeurs de la Prostate (ARTP). We also thank Dr Mao Xiang Chen ( Laboratory of Gene Expression and Protein Biochemistry, GlaxoSmithKline R&D, UK) for the generous gift of the IK<INF>Ca1</INF> antibodies.	AYUB M, 1990, BIOCHEM PHARMACOL, V40, P1569, DOI 10.1016/0006-2952(90)90456-U; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bloch M, 2007, ONCOGENE, V26, P2525, DOI 10.1038/sj.onc.1210036; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Ducret T, 2002, GLIA, V38, P200, DOI 10.1002/glia.10056; Enomoto N, 1998, J HEPATOL, V28, P221, DOI 10.1016/0168-8278(88)80009-6; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Ghiani CA, 1999, DEVELOPMENT, V126, P1077; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; HAZELTON B, 1979, J CELL BIOL, V83, P487, DOI 10.1083/jcb.83.2.487; Hemmerlein B, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-41; ISAACS JT, 1994, VITAM HORM, V49, P433; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; MagnierGaubil C, 1996, J BIOL CHEM, V271, P27788, DOI 10.1074/jbc.271.44.27788; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; NILIUS B, 1993, AM J PHYSIOL, V265, pC1501, DOI 10.1152/ajpcell.1993.265.6.C1501; Ouadid-Ahidouch H, 2004, BIOCHEM BIOPH RES CO, V316, P244, DOI 10.1016/j.bbrc.2004.02.041; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Pena TL, 2000, J BIOL CHEM, V275, P13677, DOI 10.1074/jbc.275.18.13677; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; Roudbaraki M, 1999, ENDOCRINOLOGY, V140, P4874, DOI 10.1210/en.140.10.4874; Sherbet GV, 1998, ANTICANCER RES, V18, P2415; Si H, 2006, BRIT J PHARMACOL, V148, P909, DOI 10.1038/sj.bjp.0706793; Skryma R, 1999, RECEPTOR CHANNEL, V6, P241; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; TOMITA M, 1987, ENDOCRINOL JAPON, V34, P313; TUPPER JT, 1980, J CELL PHYSIOL, V104, P97, DOI 10.1002/jcp.1041040113; Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943; van de Graaf SFJ, 2006, AM J PHYSIOL-RENAL, V290, pF1295, DOI 10.1152/ajprenal.00443.2005; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1; von Hahn T, 2001, CELL PHYSIOL BIOCHEM, V11, P219, DOI 10.1159/000051936; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; Wulff H, 2004, J IMMUNOL, V173, P776, DOI 10.4049/jimmunol.173.2.776	61	111	120	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1792	1806		10.1038/onc.2009.25	http://dx.doi.org/10.1038/onc.2009.25			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270724	Green Published			2022-12-28	WOS:000265640400006
J	Chinnadurai, G; Vijayalingam, S; Gibson, SB				Chinnadurai, G.; Vijayalingam, S.; Gibson, S. B.			BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions	ONCOGENE			English	Review						BNIP3; BNIP3L; apoptosis; autophagy; cancer; cardiomyopathies	AUTOPHAGIC CELL-DEATH; MALIGNANT GLIOMA-CELLS; CARDIAC MYOCYTE DEATH; BCL-2 FAMILY-MEMBER; BREAST-CANCER CELLS; NF-KAPPA-B; PANCREATIC-CANCER; VENTRICULAR MYOCYTES; UP-REGULATION; BH3 DOMAIN	The BNIP3 subfamily of BH3-only proteins consists of BNIP3 and BNIP3-like (BNIP3L) proteins. These proteins form stable homodimerization complexes that localize to the outer membrane of the mitochondria after cellular stress. This promotes either apoptotic or non-apoptotic cell death such as autophagic cell death. Although the mammalian cells contain both members of this subfamily, the genome of Caenorhabditis elegans codes for a single BNIP3 ortholog, ceBNIP3, which shares homology in the transmembrane (TM) domain and in a conserved region close to the BH3 domain of mammalian BNIP3 protein. The cell death activities of BNIP3 and BNIP3L are determined by either the BH3 domain or the C-terminal TM domain. The TM domain of BNIP3 is unique, as it is capable of autonomous stable dimerization and contributes to mitochondrial localization of BNIP3. In knockout mouse models, BNIP3L was shown to be essential for normal erythrocyte differentiation and hematopoietic homeostasis, whereas BNIP3 plays a role in cellular responses to ischemia/reperfusion injury in the heart. Both BNIP3 and BNIP3L play a role in cellular responses to stress. Under hypoxia, both BNIP3 and BNIP3L expression levels are elevated and contribute to hypoxia-induced cell death. In addition, these proteins play critical roles in disease states. In heart disease, both BNIP3 and BNIP3L play a critical role in cardiomyocyte cell death following ischemic and non-ischemic injuries. In cancer, expression of BNIP3 and BNIP3L is downregulated by promoter hypermethylation or by homozygous deletion of the gene locus in certain cancers, whereas their expression was increased in other cancers. In addition, BNIP3 expression has been correlated with poor prognosis in some cancers. The results reviewed here suggest that BNIP3 and BNIP3L may be novel therapeutic targets for intervention because of their pathological roles in regulating cell death in disease states. Oncogene (2009) 27, S114-S127; doi: 10.1038/onc.2009.49	[Chinnadurai, G.] St Louis Univ, Sch Med, Inst Mol Virol, Doisy Res Ctr,Med Ctr, St Louis, MO 63104 USA; [Gibson, S. B.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada	Saint Louis University; University of Manitoba	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, Doisy Res Ctr,Med Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu		Gibson, Spencer/0000-0003-0119-732X	National Cancer Institute [CA-33616, CA-116262, CA-73803]; Canadian Institutes for Health Research [MOP-64330]; Manitoba Health Research Council; NATIONAL CANCER INSTITUTE [R01CA073803, R21CA116262, R01CA033616] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GC received grant support from the National Cancer Institute (grants CA-33616, CA-116262 and CA-73803). SBG was supported by a grant from the Canadian Institutes for Health Research MOP-64330 and is a Manitoba Research Chair supported by the Manitoba Health Research Council. We thank Lorrie Kirshenbaum for comments on this review and Teralee Burton for assistance in writing the review.	Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1; Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Aerbajinai W, 2003, BLOOD, V102, P712, DOI 10.1182/blood-2002-11-3324; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHEN JC, 1997, SOFT COMPUT, V1, P19; Chen L, 2005, DIFFERENTIATION, V73, P350, DOI 10.1111/j.1432-0436.2005.00038.x; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Diwan A, 2008, APOPTOSIS, V13, P1022, DOI 10.1007/s10495-008-0236-3; Diwan A, 2008, CIRCULATION, V117, P396, DOI 10.1161/CIRCULATIONAHA.107.727073; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642; Farooq M, 2001, EXP MOL MED, V33, P169, DOI 10.1038/emm.2001.29; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625; Galvez AS, 2006, J BIOL CHEM, V281, P1442, DOI 10.1074/jbc.M509056200; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Ha SD, 2007, J BIOL CHEM, V282, P26275, DOI 10.1074/jbc.M703668200; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; Ishida M, 2007, WORLD J GASTROENTERO, V13, P4593, DOI 10.3748/wjg.v13.i34.4593; Itoh T, 2003, J NEUROCHEM, V85, P1500, DOI 10.1046/j.1471-4159.2003.01795.x; Kammouni W, 2007, ARTHRITIS RHEUM, V56, P2854, DOI 10.1002/art.22853; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; KENT G, 1966, AM J PATHOL, V48, P831; Kim JY, 2002, ARCH BIOCHEM BIOPHYS, V398, P147, DOI 10.1006/abbi.2001.2673; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Knowles HJ, 2008, J PATHOL, V215, P56, DOI 10.1002/path.2319; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kubl DA, 2007, BIOCHEM J, V405, P407, DOI 10.1042/BJ20070319; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Liu WN, 2008, NEOPLASIA, V10, P897, DOI 10.1593/neo.08428; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mammucari C, 2008, AUTOPHAGY, V4, P524, DOI 10.4161/auto.5905; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Manka D, 2006, CELL CYCLE, V5, P343, DOI 10.4161/cc.5.4.2474; Manka D, 2005, CANCER RES, V65, P11689, DOI 10.1158/0008-5472.CAN-05-3091; Martin-Rendon E, 2007, STEM CELLS, V25, P1003, DOI 10.1634/stemcells.2006-0398; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0; Metcalf DG, 2007, PROTEINS, V67, P375, DOI 10.1002/prot.21265; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Ohi N, 1999, CELL DEATH DIFFER, V6, P314, DOI 10.1038/sj.cdd.4400493; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Real PJ, 2005, CANCER RES, V65, P8151, DOI 10.1158/0008-5472.CAN-05-1134; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Reynolds TY, 1996, CANCER RES, V56, P5754; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schmidt-Kastner R, 2004, BRAIN RES, V1001, P133, DOI 10.1016/j.brainres.2003.11.065; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Shaw J, 2008, AUTOPHAGY, V4, P427, DOI 10.4161/auto.5901; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Sulistijo ES, 2006, J MOL BIOL, V364, P974, DOI 10.1016/j.jmb.2006.09.065; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; SUN JL, 2004, ZHENG, V23, P8; Syed F, 2004, CIRC RES, V95, P1200, DOI 10.1161/01.RES.0000150366.08972.7f; Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466; Theodorakis P, 1996, ONCOGENE, V12, P1707; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1999, CANCER RES, V59, P533; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang J, 2008, AUTOPHAGY, V4, P354, DOI 10.4161/auto.5552; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhaorigetu S, 2008, AUTOPHAGY, V4, P1079, DOI 10.4161/auto.7066; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	105	136	139	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S114	S127		10.1038/onc.2009.49	http://dx.doi.org/10.1038/onc.2009.49			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641497	Green Accepted			2022-12-28	WOS:000268566800010
J	Ozer, BH; Wiepz, GJ; Bertics, PJ				Ozer, B. H.; Wiepz, G. J.; Bertics, P. J.			Activity and cellular localization of an oncogenic glioblastoma multiforme-associated EGF receptor mutant possessing a duplicated kinase domain	ONCOGENE			English	Article						EGF receptor (EGFR); glioblastoma multiforme; constitutive activity; duplicate kinase domains	EPIDERMAL-GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; TANDEM DUPLICATION; MALIGNANT GLIOMAS; DOWN-REGULATION; BRAIN-TUMORS; ACTIVATION; INTERNALIZATION; PHOSPHORYLATION	A mutation of the epidermal growth factor receptor (EGFR) that results in a tandem kinase domain duplication (TKD-EGFR) has been described in glioblastoma multiforme biopsies and cell lines. Although the TKD-EGFR confers tumorigenicity, little is known about the molecular underpinnings of receptor dysregulation. Therefore, we transfected B82L mouse fibroblast cells devoid of endogenous EGFR to determine the molecular mechanisms of receptor activation when expressed in cells as well as the contribution of each duplicated kinase domain to receptor phosphorylation. The TKD-EGFR displayed chronically elevated basal autophosphorylation at five known phosphotyrosine sites. The chronically phosphorylated TKD-EGFR was also resistant to competitive inhibition of ligand-binding compared with wild-type EGFR (WT-EGFR) and showed undetectable levels of basal dimerization, suggesting the TKD-EGFR escapes known mechanisms of receptor downregulation. Immunofluorescence analyses revealed a substantial portion of the TKD-EGFR resides in the cytosol in an activated state, although surface-localized subsets of the receptor retain ligand responsiveness. Kinase activity-deficient knockouts of the N-terminal or the C-terminal kinase domains generated TKD-EGFRs that recapitulate the autophosphorylation/localization patterns of a constitutively activated receptor versus a WT-like EGFR, respectively. Investigation of the molecular activity of the TKD-EGFR yields evidence for a unique mechanism of constitutive activity and dual kinase domain activation. Oncogene (2010) 29, 855-864; doi:10.1038/onc.2009.385; published online 16 November 2009	[Bertics, P. J.] Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, Med Sci Ctr 571A, 1300 Univ Ave, Madison, WI 53706 USA.	pbertics@wisc.edu			NIH [R33 CA122892, R01 CA108467]; NSF [DMR-0520527]; NATIONAL CANCER INSTITUTE [R33CA122892, R01CA108467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank MJ Ciesielski and RA Fenstermaker for generously providing the pLXIN plasmids of the TKD-EGFR mutant. In addition, we thank CR Peet for her helpful discussions and assistance in reviewing the paper and TL Becker for her advice on statistical analyses. This work was supported in part by grants from the NIH (R33 CA122892, R01 CA108467), and from the NSF (MRSEC Award DMR-0520527).	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Brockmann MA, 2003, NEUROSURGERY, V52, P1391, DOI 10.1227/01.NEU.0000064806.87785.AB; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Ciesielski MJ, 2000, ONCOGENE, V19, P810, DOI 10.1038/sj.onc.1203409; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Edwin Francis, 2006, V327, P1; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Fenstermaker RA, 2007, CURR GENOMICS, V8, P163, DOI 10.2174/138920207780833838; Frederick L, 2000, CANCER RES, V60, P1383; GILL GN, 1984, J BIOL CHEM, V259, P7755; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Jensen RL, 1998, SURG NEUROL, V49, P189, DOI 10.1016/S0090-3019(97)00218-8; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Landau M, 2004, STRUCTURE, V12, P2265, DOI 10.1016/j.str.2004.10.006; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Poppleton HM, 1999, ARCH BIOCHEM BIOPHYS, V363, P227, DOI 10.1006/abbi.1998.1095; Riese DJ, 2007, BIOESSAYS, V29, P558, DOI 10.1002/bies.20582; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Sato J D, 1983, Mol Biol Med, V1, P511; Sihto H, 2005, J MOL MED, V83, P976, DOI 10.1007/s00109-005-0699-4; Smith KJ, 2004, STRUCTURE, V12, P1067, DOI 10.1016/j.str.2004.02.040; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	34	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					855	864		10.1038/onc.2009.385	http://dx.doi.org/10.1038/onc.2009.385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915609	Green Accepted			2022-12-28	WOS:000274397800008
J	Thoennissen, NH; O'Kelly, J; Lu, D; Iwanski, GB; La, DT; Abbassi, S; Leiter, A; Karlan, B; Mehta, R; Koeffler, HP				Thoennissen, N. H.; O'Kelly, J.; Lu, D.; Iwanski, G. B.; La, D. T.; Abbassi, S.; Leiter, A.; Karlan, B.; Mehta, R.; Koeffler, H. P.			Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway	ONCOGENE			English	Article						capsaicin; EGFR/HER-2 pathway; cell-cycle arrest; apoptosis	ACTIVATED PROTEIN-KINASE; RECEPTOR-GAMMA; GROWTH; INDUCTION; RESISTANCE; HER2; PHOSPHORYLATION; DEGRADATION; ANTAGONISTS; INHIBITORS	Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an ingredient of chili peppers with inhibitory effects against cancer cells of different origin. We examined the activity of capsaicin on breast cancer cells in vitro and in vivo. The drug potently inhibited growth of ER-positive (MCF-7, T47D, BT-474) and ER-negative (SKBR-3, MDA-MB231) breast cancer cell lines, which was associated with G(0)/G(1) cell-cycle arrest, increased levels of apoptosis and reduced protein expression of human epidermal growth factor receptor (EGFR), HER-2, activated extracellular-regulated kinase (ERK) and cyclin D1. In contrast, cell-cycle regulator p27(KIP1), caspase activity as well as poly-ADP ribose polymerase (PARP) cleavage were increased. Notably, capsaicin blocked breast cancer cell migration in vitro and decreased by 50% the size of MDA-MB231 breast cancer tumors growing orthotopically in immunodeficient mice without noticeable drug side effects. in vivo activation of ERK was clearly decreased, as well as expression of HER-2 and cyclin D1, whereas caspase activity and PARP cleavage products were increased in tumors of drug-treated mice. Besides, capsaicin potently inhibited the development of preneoplastic breast lesions by up to 80% without evidence of toxicity. Our data indicate that capsaicin is a novel modulator of the EGFR/HER-2 pathway in both ER-positive and-negative breast cancer cells with a potential role in the treatment and prevention of human breast cancer. Oncogene (2010) 29, 285-296; doi:10.1038/onc.2009.335; published online 26 October 2009	[Thoennissen, N. H.; O'Kelly, J.; Lu, D.; Iwanski, G. B.; La, D. T.; Abbassi, S.; Leiter, A.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Karlan, B.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; [Mehta, R.] IIT, Res Inst, Div Carcinogenesis & Chemoprevent, Chicago, IL 60616 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Illinois Institute of Technology	Thoennissen, NH (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, 8700 Beverly Blvd,AC 1069, Los Angeles, CA 90048 USA.	Nils.Thoennissen@cshs.org	Abbassi, Sam/AAF-7646-2021		Deutsche Forschungsgemeinschaft, Bonn, Germany [TH 1438/1-1]; Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA; Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany	Deutsche Forschungsgemeinschaft, Bonn, Germany(German Research Foundation (DFG)); Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA; Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany	NH Thoennissen's work was supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany (TH 1438/1-1); B Karlan by the Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA and GB Iwanski by the Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany. HP Koeffler is the holder of the Mark Goodson endowed Chair in Oncology Research and is a member of the Jonsson Cancer and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.	Athanasiou A, 2007, BIOCHEM BIOPH RES CO, V354, P50, DOI 10.1016/j.bbrc.2006.12.179; Carraway KL, 2006, CANCER CELL, V10, P93, DOI 10.1016/j.ccr.2006.07.015; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; *COUNC EUR, 2001, 48 M STRASB 2 6 APR; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Johnson W, 2007, INT J TOXICOL, V26, P3, DOI 10.1080/10915810601163939; Jung MY, 2001, CANCER LETT, V165, P139, DOI 10.1016/S0304-3835(01)00426-8; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kim CS, 2004, J MED FOOD, V7, P267, DOI 10.1089/jmf.2004.7.267; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lo YC, 2005, WORLD J GASTROENTERO, V11, P6254, DOI 10.3748/wjg.v11.i40.6254; Magkou C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2103; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Mehta RG, 2001, J NATL CANCER I, V93, P1103, DOI 10.1093/jnci/93.14.1103; Menard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MONSEREENUSORN Y, 1982, CRC CR REV TOXICOL, V10, P321, DOI 10.3109/10408448209003371; Montgomery RB, 2005, CANCER RES, V65, P650; Mori A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Morris GJ, 2008, J NATL MED ASSOC, V100, P698, DOI 10.1016/S0027-9684(15)31344-4; Rock E, 2003, J NUTR, V133, p3785S, DOI 10.1093/jn/133.11.3785S; Sanchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schafer JM, 2002, J STEROID BIOCHEM, V83, P75, DOI 10.1016/S0960-0760(02)00251-0; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Solit DB, 2002, CLIN CANCER RES, V8, P986; TAIKKOO Y, 1999, ANN NY ACAD SCI, V889, P157, DOI DOI 10.1111/J.1749-6632.1999.TB08734.X; Tuoya, 2006, LIFE SCI, V78, P1515, DOI 10.1016/j.lfs.2005.07.019	37	113	125	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					285	296		10.1038/onc.2009.335	http://dx.doi.org/10.1038/onc.2009.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855437				2022-12-28	WOS:000273650000011
J	Wang, Q; Sun, ZX; Allgayer, H; Yang, HS				Wang, Q.; Sun, Z-X; Allgayer, H.; Yang, H-S			Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells	ONCOGENE			English	Article						Pdcd4; beta-catenin/Tcf-dependent transcription; E-cadherin; u-PAR; c-Myc; stably knockdown	INITIATION-FACTOR 4A; RECEPTOR U-PAR; SUPPRESSOR PDCD4; C-MYC; TRANSFORMATION SUPPRESSOR; PROGRAMMED CELL-DEATH-4; EUKARYOTIC TRANSLATION; AP-1 TRANSACTIVATION; COLORECTAL-CANCER; TUMOR PROGRESSION	We reported earlier that knockdown of tumor suppressor Pdcd4 (programed cell death 4) downregulates E-cadherin expression and activates beta-catenin/Tcf (T-cell factor)dependent transcription in colon tumor cells. However, the underlying mechanism of these observations remains unknown. In this study, we showed that knockdown of Pdcd4 downregulates E-cadherin expression through elevated protein level of Snail. Over-expression of Pdcd4 upregulates E-cadherin expression and inhibits beta-catenin/Tcf-dependent transcription. We then showed that knockdown of E-cadherin activates beta-catenin/Tcf-dependent transcription. Conversely, over-expression of E-cadherin in Pdcd4 knockdown cells inhibits beta-catenin/Tcf-dependent transcription. In addition, Pdcd4 knockdown stimulates urokinase-type plasminogen activator receptor (u-PAR) and c-Myc expression, whereas u-PAR and c-Myc expression can be reversed by over-expressing E-cadherin in Pdcd4 knockdown cells. Using chromatin immunoprecipitation, we showed that beta-catenin/Tcf4 directly binds to the promoters of u-PAR and c-myc in Pdcd4 knockdown cells. Futhermore, knockdown of u-PAR or c-Myc inhibits invasion in Pdcd4 knockdown cells, suggesting that both u-PAR and c-Myc contribute to invasion induced by Pdcd4 knockdown. Taken together, our data showed that elevated Snail expression by Pdcd4 knockdown leads to downregulation of E-cadherin resulting in activating beta-catenin/Tcf-dependent transcription and stimulating the expression of c-Myc and u-PAR, thus providing molecular explanation of how Pdcd4 suppresses tumor invasion.	[Wang, Q.; Yang, H-S] Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA; [Sun, Z-X] Beijing Univ Chinese Med, Dept Pharmaceut, Sch Chinese Pharm, Beijing, Peoples R China; [Allgayer, H.] Univ Heidelberg, Dept Expt Surg & Mol Oncol Solid Tumors, Med Fac Mannheim, D-6800 Mannheim, Germany; [Allgayer, H.] KDFZ Heidelberg, Mannheim, Germany; [Yang, H-S] Univ Kentucky, Lucille P Markey Canc Ctr, Coll Med, Lexington, KY 40536 USA	University of Kentucky; Beijing University of Chinese Medicine; Ruprecht Karls University Heidelberg; University of Kentucky	Yang, HS (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Coll Med, Lexington, KY 40536 USA.	hyang3@uky.edu	Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036	NCI [R01CA129015]; ACS Institutional Research [IRG-85-001-19]; NCRR CORBE pilot [P20RR020171]; NATIONAL CANCER INSTITUTE [R01CA129015] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS Institutional Research; NCRR CORBE pilot(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Ji Hshiung Chen (Tzu Chi University, Taiwan) for kindly providing E-cadherin promoter and Dr Xiaoling Guo for technical support. This work was supported by NCI Grant R01CA129015, ACS Institutional Research Grant IRG-85-001-19, and NCRR CORBE pilot grant P20RR020171.	Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Fuchs SY, 2005, CELL CYCLE, V4, P1522; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; KARIKO K, 1993, CANCER RES, V53, P3109; Kemler R, 1992, Semin Cell Biol, V3, P149; Laufs S, 2006, CELL CYCLE, V5, P1760; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Memarzedeh S, 2002, P NATL ACAD SCI USA, V99, P10647, DOI 10.1073/pnas.152127499; MIYAKI M, 1994, CANCER RES, V54, P3011; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nestl A, 2001, CANCER RES, V61, P1569; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Ozpolat B, 2007, MOL CANCER RES, V5, P95, DOI 10.1158/1541-7786.MCR-06-0125; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	37	73	79	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					128	138		10.1038/onc.2009.302	http://dx.doi.org/10.1038/onc.2009.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784072	Green Accepted			2022-12-28	WOS:000273373500012
J	Po'uha, ST; Shum, MSY; Goebel, A; Bernard, O; Kavallaris, M				Po'uha, S. T.; Shum, M. S. Y.; Goebel, A.; Bernard, O.; Kavallaris, M.			LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs	ONCOGENE			English	Article						LIM-kinase 2; neuroblastoma; microtubule-destabilizing drugs; mitosis; drug sensitivity	PROTEIN-KINASE; COFILIN PHOSPHORYLATION; CYTOSKELETAL DYNAMICS; CHILDHOOD LEUKEMIA; CELL-MIGRATION; CANCER-CELLS; ACTIVATION; RESISTANCE; SLINGSHOT; TUBULIN	LIM-kinase 2 (LIMK2) belongs to the LIMK family of proteins, which comprises LIMK1 and LIMK2. Both proteins regulate actin polymerization through phosphorylation and inactivation of the actin depolymerizing factor cofilin. In this study, we show that the level of LIMK2 protein is increased in neuroblastoma, BE(2)-C cells, selected for resistance to microtubule-destabilizing agents, vincristine and colchicine. However, the level of phosphorylated LIMK1 and LIMK2 was similar in the resistant and parental BE(2)-C cells. In contrast, the level of phospho-cofilin was greatly increased in the drug-resistant cells. Downregulation of LIMK2 expression increases sensitivity of neuroblastoma SH-EP cells to vincristine and vinblastine but not to microtubule-stabilizing agents, while it's overexpression increased its resistance to vincristine. Its vincristine-induced mitotic arrest was moderately inhibited in the LIMK2 knockdown cells, suggesting that the increased drug sensitivity is through an alternative mechanism other then mitotic arrest and apoptosis. Moreover, downregulation of LIMK2 expression induces formation of abnormal mitotic spindles, an effect enhanced in the presence of microtubule-destabilizing agents. LIMK2 is important for normal mitotic spindle formation and altered LIMK2 expression mediates sensitivity to microtubule destabilizing agents. These findings suggest that inhibition of LIMK2 activity may be used for the treatment of tumors resistant to microtubule-destabilizing drugs. Oncogene (2010) 29, 597-607; doi: 10.1038/onc.2009.367; published online 2 November 2009	[Kavallaris, M.] Childrens Canc Inst Australia Med Res, Pharmacoprote Program, Randwick, NSW 2031, Australia; [Po'uha, S. T.; Shum, M. S. Y.] Univ New S Wales, Sydney, NSW, Australia; [Bernard, O.] St Vincents Inst Med Res, Melbourne, Vic, Australia; [Bernard, O.] St Vincents Hosp, Dept Med, Melbourne, Vic, Australia	Children's Cancer Institute; University of New South Wales Sydney; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne	Kavallaris, M (corresponding author), Childrens Canc Inst Australia Med Res, Pharmacoprote Program, POB 81, Randwick, NSW 2031, Australia.	m.kavallaris@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014		Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council; NHMRC; Endeavour International; Australian Postgraduate Award	Children's Cancer Institute Australia for Medical Research; New South Wales Cancer Council(Cancer Council New South Wales); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Endeavour International; Australian Postgraduate Award(Australian Government)	We thank Professor Kensaku Mizuno, Tohoku University, Japan, for providing the LIMK2 plasmid and Professor Peter Gunning, University of New South Wales, Sydney, Australia, for gamma-actin Ab. This work was supported by the Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and Sydney Children's Hospital, and by grants from the New South Wales Cancer Council (MK). MK is supported by a NHMRC Senior Research Fellowship, STP was supported by an Endeavour International Postgraduate Research Scholarship and MSYS is supported by an Australian Postgraduate Award. OB is a NHMRC Principal Research Fellow.	Acevedo K, 2006, J HISTOCHEM CYTOCHEM, V54, P487, DOI 10.1369/jhc.5C6813.2006; Acevedo K, 2007, EXP CELL RES, V313, P4091, DOI 10.1016/j.yexcr.2007.08.012; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Chakrabarti R, 2007, CELL CYCLE, V6, P2944, DOI 10.4161/cc.6.23.4957; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; Dan C, 2001, J BIOL CHEM, V276, P32115, DOI 10.1074/jbc.M100871200; Dan S, 2002, CANCER RES, V62, P1139; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Deschesnes RG, 2007, J PHARMACOL EXP THER, V320, P853, DOI 10.1124/jpet.106.110957; Don S, 2004, MOL CANCER THER, V3, P1137; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Gorovoy M, 2005, J BIOL CHEM, V280, P26533, DOI 10.1074/jbc.M502921200; Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520; JORDAN MA, 1991, CANCER RES, V51, P2212; Kaji N, 2008, J BIOL CHEM, V283, P4983, DOI 10.1074/jbc.M708644200; Kobayashi M, 2006, EMBO J, V25, P713, DOI 10.1038/sj.emboj.7600973; LAQUAGLIA MP, 1991, J PEDIATR SURG, V26, P1107, DOI 10.1016/0022-3468(91)90684-L; MIZUNO K, 1994, ONCOGENE, V9, P1605; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718; Sarmiere PD, 2004, J NEUROBIOL, V58, P103, DOI 10.1002/neu.10267; Soosairajah J, 2005, EMBO J, V24, P473, DOI 10.1038/sj.emboj.7600543; Sumi T, 2006, EXP CELL RES, V312, P1021, DOI 10.1016/j.yexcr.2005.12.030; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Verrills NM, 2006, PROTEOMICS, V6, P1681, DOI 10.1002/pmic.200500417; Verrills NM, 2005, CURR PHARM DESIGN, V11, P1719, DOI 10.2174/1381612053764706; Verrills NM, 2003, CHEM BIOL, V10, P597, DOI 10.1016/S1074-5521(03)00141-8; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	42	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					597	607		10.1038/onc.2009.367	http://dx.doi.org/10.1038/onc.2009.367			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881550				2022-12-28	WOS:000274084600012
J	Orgaz, JL; Ladhani, O; Hoek, KS; Fernandez-Barral, A; Mihic, D; Aguilera, O; Seftor, EA; Bernad, A; Rodriguez-Peralto, JL; Hendrix, MJC; Volpert, OV; Jimenez, B				Orgaz, J. L.; Ladhani, O.; Hoek, K. S.; Fernandez-Barral, A.; Mihic, D.; Aguilera, O.; Seftor, E. A.; Bernad, A.; Rodriguez-Peralto, J. L.; Hendrix, M. J. C.; Volpert, O. V.; Jimenez, B.			'Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'	ONCOGENE			English	Article						PEDF; melanoma progression; vasculogenic mimicry; anti-angiogenic factors	CEREBELLAR GRANULE NEURONS; DOWN-REGULATION; FACTOR PEDF; NEUROTROPHIC ACTIVITY; RETINOBLASTOMA CELLS; ENDOTHELIAL-CELLS; MOTOR-NEURONS; ANGIOGENESIS; EXPRESSION; IDENTIFICATION	Pigment epithelium-derived factor (PEDF) is a multifunctional secreted glycoprotein that displays broad antitumor activity based on dual targeting of the tumor microenvironment (anti-angiogenic action) and the tumor cells (direct anti-tumor action). Here, we show that PEDF expression is high in melanocytes, but it is lost during malignant progression of human melanoma. Using a high-throughput analysis of the data from microarray studies of molecular profiling of human melanoma, we found that PEDF expression is lost in highly invasive melanomas. In paired cell lines established from the same lesion but representing the high and low extremes of malignant potential, abundant PEDF expression was restricted to the poorly aggressive counterparts. We used RNA interference to directly address the functional consequences of PEDF silencing. PEDF knockdown in poorly aggressive melanoma cell lines augmented migration, invasion and vasculogenic mimicry, which translated into an increased in vivo metastatic potential. PEDF interference also significantly enhanced the migratory and invasive capability of normal melanocytes and moderately increased their proliferative potential. Our results show that loss of PEDF enables melanoma cells to acquire an invasive phenotype and, therefore, modulation of this multifunctional factor could be critical for the malignant progression of human melanoma. Oncogene (2009) 28, 4147-4161; doi: 10.1038/onc.2009.284; published online 21 September 2009	[Orgaz, J. L.; Fernandez-Barral, A.; Aguilera, O.; Jimenez, B.] Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed, CSIC, Madrid 28029, Spain; [Ladhani, O.; Volpert, O. V.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Urol, Feinberg Sch Med, Chicago, IL 60611 USA; [Hoek, K. S.] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Mihic, D.] Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; [Seftor, E. A.; Hendrix, M. J. C.] Northwestern Univ, Childrens Mem Res Ctr, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Bernad, A.] Ctr Nacl Invest Cardiovasc, Dept Regenerat Cardiol, Madrid, Spain; [Rodriguez-Peralto, J. L.] Hosp Univ 12 Octubre Madrid, Dept Pathol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Hospital Universitario 12 de Octubre	Jimenez, B (corresponding author), Univ Autonoma Madrid, Dept Biochem, Inst Invest Biomed, CSIC, Arturo Duperier 4, Madrid 28029, Spain.	bjimenez@iib.uam.es	Fernández-Barral, Asunión/O-8133-2015; Orgaz, Jose L./ABH-1835-2020; Cuenca, Benilde Jimenez/K-9959-2014	Fernández-Barral, Asunión/0000-0002-1278-4645; Orgaz, Jose L./0000-0002-9776-7544; Bernad, Antonio/0000-0003-0620-9668; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Rodriguez-Peralto, Jose Luis/0000-0002-6578-7153	Ministerio de Educacion y Ciencia [SAF2007-62292]; Comunidad de Madrid [SAL-0311-2006]; NIH [RO1 HL68033, CA59702]; NIH/NCI [T32CA009560]; Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship; NATIONAL CANCER INSTITUTE [T32CA009560, R01CA059702, R37CA059702] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068033, R01HL077471] Funding Source: NIH RePORTER	Ministerio de Educacion y Ciencia(Spanish Government); Comunidad de Madrid(Comunidad de Madrid); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We acknowledge with gratitude all researchers that contributed with cell lines: M Herlyn, PF Penas, F Vidal-Vanaclocha, GN Van Muijen, AM Valverde, M Garcia and M del Rio. We also thank P Fernandez for her technical assistance in lentivirus production. Supported by grants: Ministerio de Educacion y Ciencia grant SAF2007-62292 (BJ), Comunidad de Madrid SAL-0311-2006 (BJ), NIH grant RO1 HL68033 (OV), NIH merit grant CA59702 (MJCH). JL Orgaz has been supported by a Ministerio de Educacion y Ciencia fellowship, O Ladhani by an NIH/NCI training grant T32CA009560 and A Fernandez-Barral by a Consejo Superior de Investigaciones Cientificas fellowship.	Abramson LP, 2003, J PEDIATR SURG, V38, P336, DOI 10.1053/jpsu.2003.50104; Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605; Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bilak MM, 2002, J NEUROSCI, V22, P9378; Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870; Ek ETH, 2006, TRENDS MOL MED, V12, P497, DOI 10.1016/j.molmed.2006.08.009; Ek ETH, 2006, MOL CANCER THER, V5, P1641, DOI 10.1158/1535-7163.MCT-06-0107; Fernandez-Garcia NI, 2007, J MOL MED-JMM, V85, P15, DOI 10.1007/s00109-006-0111; Fernandez-Garcia NI, 2005, ONCOGENE, V24, P6533, DOI 10.1038/sj.onc.1208801; Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Guan M, 2003, J CLIN PATHOL, V56, P277, DOI 10.1136/jcp.56.4.277; Halin S, 2004, CANCER RES, V64, P5664, DOI 10.1158/0008-5472.CAN-04-0835; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489; Notari L, 2006, J BIOL CHEM, V281, P38022, DOI 10.1074/jbc.M600353200; Punzon I, 2004, BLOOD, V103, P580, DOI 10.1182/blood-2003-07-2298; Quan GMY, 2005, CALCIFIED TISSUE INT, V76, P146, DOI 10.1007/s00223-004-0068-2; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sato S, 2001, PIGM CELL RES, V14, P428, DOI 10.1034/j.1600-0749.2001.140602.x; Sawant S, 2004, BIOCHEM BIOPH RES CO, V325, P408, DOI 10.1016/j.bbrc.2004.10.041; Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497; SEIGEL GM, 1994, GROWTH FACTORS, V10, P289, DOI 10.3109/08977199409010995; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176; Uehara H, 2004, CANCER RES, V64, P3533, DOI 10.1158/0008-5472.CAN-03-3725; van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200; Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007; Zaichuk TA, 2004, J EXP MED, V199, P1513, DOI 10.1084/jem.20040474	48	59	61	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4147	4161		10.1038/onc.2009.284	http://dx.doi.org/10.1038/onc.2009.284			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19767774	Green Accepted			2022-12-28	WOS:000272876100002
J	Novosyadlyy, R; Vijayakumar, A; Lann, D; Fierz, Y; Kurshan, N; LeRoith, D				Novosyadlyy, R.; Vijayakumar, A.; Lann, D.; Fierz, Y.; Kurshan, N.; LeRoith, D.			Physical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation	ONCOGENE			English	Article						oncogenes; polyoma virus middle T oncogene; insulin receptor; IGF-I receptor; crosstalk	MERKEL CELL POLYOMAVIRUS; EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; TRANSFORMED PHENOTYPE; KAPOSIS-SARCOMA; MAMMARY-TUMORS; SRC KINASE; OVEREXPRESSION; TUMORIGENESIS; PROGRESSION	Polyoma virus middle T antigen (PyVmT) is a powerful viral oncogene; however, the mechanisms of PyVmT activation are poorly understood. The insulin-like growth factor I receptor (IGF-IR) and the insulin receptor (IR) are known to be implicated in the development of many cancers. Furthermore, PyVmT-overexpressing mouse mammary carcinoma Met-1 cells are highly responsive to IGF-I and insulin. Herein, we demonstrate that PyVmT physically interacts with IGF-IR and IR in Met-1 cells. Insulin and IGF-I increase association of the IR and IGF-IR with PyVmT, enhance tyrosine phosphorylation of PyVmT and augment the recruitment of Src and PLC gamma(1) to PyVmT. This is accompanied by robust and sustained phosphorylation of Akt and ERK1/2, which are implicated in both PyVmT and IGF-IR/IR signalling. Both ligands significantly increase proliferation, survival, migration and invasion of Met-1 cells. Furthermore, orthotopic inoculation of Met-1 cells with shRNAmir-mediated knockdown of IR or IGF-IR fails to initiate tumour growth in recipient mice. In conclusion, our data indicate that the physical and functional interaction between PyVmT and cellular receptor tyrosine kinases, including IR and IGF-IR, is critical for PyVmT activation and tumour initiation. These results also provide a novel mechanism for oncogene activation in the host cell. Oncogene (2009) 28, 3477-3486; doi: 10.1038/onc.2009.209; published online 20 July 2009	[Novosyadlyy, R.; Vijayakumar, A.; Lann, D.; Fierz, Y.; Kurshan, N.; LeRoith, D.] Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	LeRoith, D (corresponding author), Mt Sinai Sch Med, Samuel Bronfman Dept Med, Div Endocrinol Diabet & Bone Dis, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA.	derek.leroith@mssm.edu			National Institutes of Health/National Cancer Institute [1RO1CA128799-O1A1, T32 DK007792]; Swiss National Science Foundation [PBBSB-120851]; Novartis Foundation; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007792] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank SD Hurstings (Department of Nutritional Sciences, University of Texas, Austin, TX, USA and Department of Carcinogenesis, University of Texas-MD Anderson Cancer Center, Smithville, TX, USA) and NP Nunez (Department of Nutritional Sciences, University of Texas, Austin, TX, USA) for donating Met-1 cells. This work was funded by National Institutes of Health/National Cancer Institute grant 1RO1CA128799-O1A1. D Lann was supported by National Institutes of Health grant T32 DK007792. Y Fierz was funded by Swiss National Science Foundation grant PBBSB-120851 and Novartis Foundation grant.	Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; Bartucci M, 2001, CANCER RES, V61, P6747; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Foulongne V, 2008, EMERG INFECT DIS, V14, P1491, DOI 10.3201/eid1409.080651; FRITTITTA L, 1995, J CELL BIOCHEM, V57, P666, DOI 10.1002/jcb.240570411; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GROSS L, 1953, P SOC EXP BIOL MED, V83, P414; GROSS L, 1951, P SOC EXP BIOL MED, V76, P27; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Javier RT, 2008, CANCER RES, V68, P7693, DOI 10.1158/0008-5472.CAN-08-3301; Kassem A, 2008, CANCER RES, V68, P5009, DOI 10.1158/0008-5472.CAN-08-0949; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lieskovska J, 2006, J BIOL CHEM, V281, P25041, DOI 10.1074/jbc.M602866200; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; Pisani Paola, 2008, Archives of Physiology and Biochemistry, V114, P63, DOI [10.1080/13813450801954451, 10.1080/13813450801954451 ]; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Rose PP, 2007, ONCOGENE, V26, P1995, DOI 10.1038/sj.onc.1210006; SEGAWA K, 1983, NATURE, V304, P742, DOI 10.1038/304742a0; Shepard CR, 2007, ONCOGENE, V26, P3020, DOI 10.1038/sj.onc.1210115; SOEDA E, 1980, NATURE, V285, P165, DOI 10.1038/285165a0; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; Yakar S, 2005, CYTOKINE GROWTH F R, V16, P407, DOI 10.1016/j.cytogfr.2005.01.010; zur Hausen H, 2008, INT J CANCER, V123, P247, DOI 10.1002/ijc.23620	35	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3477	3486		10.1038/onc.2009.209	http://dx.doi.org/10.1038/onc.2009.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19617901	Green Accepted			2022-12-28	WOS:000270478300005
J	Stylianou, DC; Maur, AAD; Kodack, DP; Henke, RT; Hohn, S; Toretsky, JA; Riegel, AT; Wellstein, A				Stylianou, D. C.; Maur, A. Auf Der; Kodack, D. P.; Henke, R. T.; Hohn, S.; Toretsky, J. A.; Riegel, A. T.; Wellstein, A.			Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor	ONCOGENE			English	Article						ALK; growth factor; PTN; single-chain antibody; tyrosine kinase receptor	TYROSINE-PHOSPHATASE-BETA/ZETA; GROWTH-FACTOR PLEIOTROPHIN; ACTIVATED PROTEIN-KINASE; SULFATE HYBRID CHAINS; NON-HODGKINS-LYMPHOMA; EMBRYONIC PIG BRAIN; MOLECULE HB-GAM; ZETA/RPTP-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; CHONDROITIN/DERMATAN SULFATE	The tyrosine kinase receptor anaplastic lymphoma kinase (ALK) and its ligand, the growth factor pleiotrophin (PTN), are highly expressed during the development of the nervous system and have been implicated in the malignant progression of different tumor types. Here, we describe human single-chain variable fragment (scFv) antibodies that target the ligand-binding domain (LBD) in ALK and show the effect in vitro and in vivo. The ALK LBD was used as a bait in a yeast two-hybdrid system to select human scFv from a library with randomized complementarity-determining region 3 domains. Surface plasmon resonance showed high-affinity binding of the selected scFv. The anti-ALK scFv competed for binding of PTN to ALK in intact cells and inhibited PTN-dependent signal transduction through endogenous ALK. Invasion of an intact endothelial cell monolayer by U87MG human glioblastoma cells was inhibited by the anti-ALK scFv. In addition, the growth of established tumor xenografts in mice was reversed after the induction of the conditional expression of the anti-ALK scFv. In archival malignant brain tumors expression levels of ALK and PTN were found elevated and appear correlated with poor patient survival. This suggests a rate-limiting function of the PTN/ALK interaction that may be exploited therapeutically. Oncogene (2009) 28, 3296-3306; doi:10.1038/onc.2009.184; published online 27 July 2009	[Wellstein, A.] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20057 USA; [Maur, A. Auf Der; Hohn, S.] Esbatech AG, Zurich, Switzerland	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, E315 TRB 3970 Reservoir Rd NW, Washington, DC 20057 USA.	wellstea@georgetown.edu	Stylianou, Dora/AAT-1074-2020; Stylianou, Dora/J-2697-2016	Stylianou, Dora/0000-0003-4167-1380; Stylianou, Dora/0000-0003-4167-1380; Wellstein, Anton/0000-0002-0570-4950	National Institute of Health [RO1 CA108440]; NATIONAL CANCER INSTITUTE [R01CA108440, T32CA009686, R01CA071508, P50CA058185, R01CA101811] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Emma T Bowden, Angera H Kuo and Gerald E Stoica (Georgetown University) for help with some of the experiments as well as discussions and suggestions. This work was supported by RO1 CA108440 from the National Institute of Health (to AW).	Aricescu AR, 2007, SCIENCE, V317, P1217, DOI 10.1126/science.1144646; AUFDERMAUR A, 2002, J BIOL CHEM, V277, P45075; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Chang YC, 2006, BIOCHEM BIOPH RES CO, V351, P336, DOI 10.1016/j.bbrc.2006.09.148; Chen HM, 2007, BLOOD, V110, P287, DOI 10.1182/blood-2006-08-042374; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; der Maur AA, 2001, FEBS LETT, V508, P407, DOI 10.1016/S0014-5793(01)03101-5; der Maur Adrian Auf, 2004, Methods (Amsterdam), V34, P215; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751; Hamma-Kourbali Y, 2008, J CELL PHYSIOL, V214, P250, DOI 10.1002/jcp.21191; Henke RT, 2006, METHODS, V38, P253, DOI 10.1016/j.ymeth.2005.11.013; Ho M, 2006, P NATL ACAD SCI USA, V103, P9637, DOI 10.1073/pnas.0603653103; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Kuo AH, 2007, ONCOGENE, V26, P859, DOI 10.1038/sj.onc.1209840; Li FC, 2007, J BIOL CHEM, V282, P2956, DOI 10.1074/jbc.M609296200; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Mathivet T, 2007, CELL SIGNAL, V19, P2434, DOI 10.1016/j.cellsig.2007.07.011; McCarthy N, 2008, NAT REV CANCER, V8, DOI 10.1038/nrc2305; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Mi RF, 2007, P NATL ACAD SCI USA, V104, P4664, DOI 10.1073/pnas.0603243104; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muramatsu H, 2006, GENES CELLS, V11, P1405, DOI 10.1111/j.1365-2443.2006.01028.x; Owada K, 1999, J NEUROCHEM, V73, P2084; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Perez-Pinera P, 2006, P NATL ACAD SCI USA, V103, P17795, DOI 10.1073/pnas.0607299103; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; Peria FM, 2007, J NEURO-ONCOL, V84, P255, DOI 10.1007/s11060-007-9379-2; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; Schaerer-Brodbeck C, 2004, BIOTECHNIQUES, V37, P202, DOI 10.2144/04372BM05; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tang Y, 2007, J IMMUNOL, V179, P2815, DOI 10.4049/jimmunol.179.5.2815; Weber D, 2000, CANCER RES, V60, P5284; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Zhang N, 1997, J BIOL CHEM, V272, P16733, DOI 10.1074/jbc.272.27.16733; Zou P, 2006, LAB INVEST, V86, P645, DOI 10.1038/labinvest.3700428	63	32	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3296	3306		10.1038/onc.2009.184	http://dx.doi.org/10.1038/onc.2009.184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19633684	Green Accepted			2022-12-28	WOS:000269893700004
J	Dasgupta, S; Wasson, LM; Rauniyar, N; Prokai, L; Borejdo, J; Vishwanatha, JK				Dasgupta, S.; Wasson, L. M.; Rauniyar, N.; Prokai, L.; Borejdo, J.; Vishwanatha, J. K.			Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells	ONCOGENE			English	Article						C17orf37; 17q12; prostate cancer; migration; invasion; NF-kappa B	PLASMINOGEN-ACTIVATOR; PROTEIN PRENYLATION; BREAST-CANCER; NUDE-MICE; ANGIOGENESIS; METASTASIS; PATHWAY; AMPLIFICATION; PROGRESSION; EXPRESSION	C17orf37/MGC14832, a novel gene located on human chromosome 17q12 in the ERBB2 amplicon, is abundantly expressed in breast cancer. C17orf37 expression has been reported to positively correlate with grade and stage of cancer progression; however the functional significance of C17orf37 overexpression in cancer biology is not known. Here, we show that C17orf37 is highly expressed in prostate cancer cell lines and tumors, compared to minimal expression in normal prostate cells and tissues. Cellular localization studies by confocal and total internal reflection fluorescence microscopy revealed predominant expression of C17orf37 in the cytosol with intense staining in the membrane of prostate cancer cells. RNA-interference-mediated downregulation of C17orf37 resulted in decreased migration and invasion of DU-145 prostate cancer cells, and suppressed the DNA-binding activity of nuclear factor-kappa B (NF-kappa B) transcription factor resulting in reduced expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activator and vascular endothelial growth factor. Phosphorylation of PKB/Akt was also reduced upon C17orf37 downregulation, suggesting C17orf37 acts as a signaling molecule that increases invasive potential of prostate cancer cells by NF-kappa B-mediated downstream target genes. Our data strongly suggest C17orf37 overexpression in prostate cancer functionally enhances migration and invasion of tumor cells, and is an important target for cancer therapy. Oncogene (2009) 28, 2860-2872; doi:10.1038/onc.2009.145; published online 8 June 2009	[Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Grad Sch Biomed Sci, Ft Worth, TX 76107 USA; [Dasgupta, S.; Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Dept Biomed Sci, Ft Worth, TX 76107 USA; [Dasgupta, S.; Vishwanatha, J. K.] Univ N Texas, Hlth Sci Ctr, Inst Canc Res, Ft Worth, TX 76107 USA; [Wasson, L. M.] Harris Methodist Ft Worth Hosp, Dept Pathol, Ft Worth, TX USA	University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center; University of North Texas System; University of North Texas Health Science Center	Vishwanatha, JK (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Grad Sch Biomed Sci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	jvishwan@hsc.unt.edu	Dasgupta, Subhamoy/I-6022-2015; Rauniyar, Navin/A-3318-2016	Dasgupta, Subhamoy/0000-0001-7167-908X; Prokai, Laszlo/0000-0002-4559-3458; Vishwanatha, Jamboor/0000-0002-0266-6020	NIH [CA109593, MD 001633]; DOD PCRP Training Award [PC081282]; NCI Cancer Center Support [P30 CA36727]; Nebraska Department of Health Institutional [LB595]; NATIONAL CANCER INSTITUTE [R21CA109593, P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD001633] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD PCRP Training Award; NCI Cancer Center Support(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nebraska Department of Health Institutional; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We thank Dr Linda Cunnighum (UNTHSC) for assistance with immunohistochemistry and Dr Kapil Mehta (MD Anderson Cancer Center, TX) for help with migration assays. The present work is supported by grant nos. CA109593 and MD 001633 (JKV) from NIH and DOD PCRP Training Award PC081282 (SD). UNMC/Eppley Cancer Center Tumor Bank was supported by an NCI Cancer Center Support Grant P30 CA36727 and Nebraska Department of Health Institutional LB595 Grant for Cancer and Smoking Disease Research.	Arya M, 2006, SURG ONCOL, V15, P117, DOI 10.1016/j.suronc.2006.10.002; Axelrod D, 2001, J BIOMED OPT, V6, P6, DOI 10.1117/1.1335689; Banerjee Abhijit G, 2003, Mol Cancer, V2, P34, DOI 10.1186/1476-4598-2-34; Berger R, 2006, CANCER RES, V66, P5723, DOI 10.1158/0008-5472.CAN-05-3928; Burghardt TP, 2006, BIOCHEMISTRY-US, V45, P4058, DOI 10.1021/bi052097d; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Connolly JM, 1998, J UROLOGY, V160, P932, DOI 10.1016/S0022-5347(01)62835-0; Das S, 2007, PROSTATE, V67, P1550, DOI 10.1002/pros.20640; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Evans EE, 2006, MOL CANCER THER, V5, P2919, DOI 10.1158/1535-7163.MCT-06-0389; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kauraniemi P, 2006, ENDOCR-RELAT CANCER, V13, P39, DOI 10.1677/erc.1.01147; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; Maurer-Stroh S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r55; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Pienta Kenneth J, 2005, Clin Prostate Cancer, V4, P24, DOI 10.3816/CGC.2005.n.008; Price JT, 1997, CRIT REV BIOCHEM MOL, V32, P175, DOI 10.3109/10409239709082573; Rothermund CA, 2002, PROSTATE CANCER P D, V5, P236, DOI 10.1038/sj.pcan.4500582; Sheng SJ, 2001, CANCER METAST REV, V20, P287, DOI 10.1023/A:1015539612576; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Sun J, 2008, NAT GENET, V40, P1153, DOI 10.1038/ng.214; THALMANN GN, 1994, CANCER RES, V54, P2577; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Virtanen SS, 2002, CANCER RES, V62, P2708; WILSON MJ, 1993, CELL MOL BIOL RES, V39, P751; Wilson SR, 2004, PROSTATE, V60, P168, DOI 10.1002/pros.20047; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	37	41	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2860	2872		10.1038/onc.2009.145	http://dx.doi.org/10.1038/onc.2009.145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503095	Green Accepted			2022-12-28	WOS:000268917100002
J	Wolyniec, K; Wotton, S; Kilbey, A; Jenkins, A; Terry, A; Peters, G; Stocking, C; Cameron, E; Neil, JC				Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Peters, G.; Stocking, C.; Cameron, E.; Neil, J. C.			RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress	ONCOGENE			English	Article						RUNX1; RUNX1-ETO; premature senescence	ONCOGENE-INDUCED SENESCENCE; ACUTE MYELOID-LEUKEMIA; CELLULAR SENESCENCE; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; MURINE FIBROBLASTS; TUMOR-SUPPRESSOR; PROTEIN-KINASE; RAS; P53	A role for the RUNX genes in cancer fail-safe processes has been suggested by their induction of senescence-like growth arrest in primary murine. broblasts and the failure of RAS-induced senescence in Runx2-deficient cells. We now show that RUNX1 induces senescence in human primary. broblasts. High-affinity DNA binding is necessary but not sufficient, as shown by the functional attenuation of the truncated RUNX1/AML1a isoform and the TEL-RUNX1 fusion oncoprotein. However, a similar phenotype was potently induced by the RUNX1-ETO (AML1-ETO) oncoprotein, despite its dominant-negative potential. A detailed comparison of H-RAS(V12), RUNX1 and RUNX1-ETO senescent phenotypes showed that the RUNX effectors induce earlier growth stasis with only low levels of DNA damage signaling and a lack of chromatin condensation, a marker of irreversible growth arrest. In human. broblasts, all effectors induced p53 in the absence of detectable p14(Arf), whereas only RUNX1-ETO induced senescence in p16(Ink4a)-null cells. Correlation was noted between induction of p53, reactive oxygen species and phospho-p38, whereas p38(MAPK) inhibition rescued cell growth markedly. These findings indicate a role for replication-independent pathways in RUNX and RUNX1-ETO senescence, and show that the context-specific oncogenic activity of RUNX1 fusion proteins is mirrored in their distinctive interactions with fail-safe responses. Oncogene ( 2009) 28, 2502-2512; doi: 10.1038/onc.2009.101; published online 18 May 2009	[Wolyniec, K.; Wotton, S.; Kilbey, A.; Jenkins, A.; Terry, A.; Cameron, E.; Neil, J. C.] Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Glasgow G61 1QH, Lanark, Scotland; [Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; [Peters, G.] London Res Inst, Lincolns Inn Fields Labs, London, England	University of Glasgow; Heinrich Pette Institute; University of Hamburg	Neil, JC (corresponding author), Univ Glasgow, Inst Comparat Med, Fac Vet Med, Oncol Mol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	J.C.Neil@vet.gla.ac.uk			Cancer Research UK; Leukemia Research Fund	Cancer Research UK(Cancer Research UK); Leukemia Research Fund	Primary support for this work was provided by Cancer Research UK and the Leukemia Research Fund. We thank Janice Rowe for excellent technical assistance and Scott Hiebert (Vanderbilt University) for generous supply of reagents and useful discussions.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bernardin F, 2002, CANCER RES, V62, P3904; Blyth K, 2006, CANCER RES, V66, P2195, DOI 10.1158/0008-5472.CAN-05-3558; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Cammenga J, 2007, CANCER RES, V67, P537, DOI 10.1158/0008-5472.CAN-06-1903; Colavitti R, 2005, IUBMB LIFE, V57, P277, DOI 10.1080/15216540500091890; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Kilbey A, 2008, CELL CYCLE, V7, P2333; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Krejci O, 2008, BLOOD, V111, P2190, DOI 10.1182/blood-2007-06-093682; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LENNY N, 1995, ONCOGENE, V11, P1761; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Robinson KA, 1999, J NEUROSCI RES, V55, P724, DOI 10.1002/(SICI)1097-4547(19990315)55:6<724::AID-JNR7>3.3.CO;2-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Swantek D, 2004, DEVELOPMENT, V131, P2281, DOI 10.1242/dev.01109; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tsuzuki S, 2007, PLOS MED, V4, P880, DOI 10.1371/journal.pmed.0040172; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Wotton SF, 2004, ONCOGENE, V23, P5476, DOI 10.1038/sj.onc.1207729; Zaidi SK, 2007, P NATL ACAD SCI USA, V104, P19861, DOI 10.1073/pnas.0709650104; Zhang RG, 2007, MOL CELL BIOL, V27, P2343, DOI 10.1128/MCB.02019-06	40	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2502	2512		10.1038/onc.2009.101	http://dx.doi.org/10.1038/onc.2009.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448675	Green Accepted			2022-12-28	WOS:000267806800003
J	Saito, Y; Suzuki, H; Tsugawa, H; Nakagawa, I; Matsuzaki, J; Kanai, Y; Hibi, T				Saito, Y.; Suzuki, H.; Tsugawa, H.; Nakagawa, I.; Matsuzaki, J.; Kanai, Y.; Hibi, T.			Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells	ONCOGENE			English	Article						miRNA; DNA methylation; histone modification; epigenetic treatment; Alu repeats; gastric cancer	MESSENGER-RNA; METHYLATION; THERAPY; TARGET; FUTURE	Epigenetic therapy using DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors has clinical promise for the treatment of human malignancies. To investigate roles of microRNAs (miRNAs) on epigenetic therapy of gastric cancer, the miRNA expression profile was analysed in human gastric cancer cells treated with 5-aza-2'-deoxycytidine (5-Aza-CdR) and 4-phenylbutyric acid (PBA). miRNA microarray analysis shows that most of miRNAs activated by 5-Aza-CdR and PBA in gastric cancer cells are located at Alu repeats on chromosome 19. Analyses of chromatin modification show that DNA demethylation and HDAC inhibition at Alu repeats activates silenced miR-512-5p by RNA polymerase II. In addition, activation of miR-512-5p by epigenetic treatment induces suppression of Mcl-1, resulting in apoptosis of gastric cancer cells. These results suggest that chromatin remodeling at Alu repeats plays critical roles in the regulation of miRNA expression and that epigenetic activation of silenced Alu-associated miRNAs could be a novel therapeutic approach for gastric cancer. Oncogene (2009) 28, 2738-2744; doi:10.1038/onc.2009.140; published online 8 June 2009	[Saito, Y.; Suzuki, H.; Tsugawa, H.; Nakagawa, I.; Matsuzaki, J.; Hibi, T.] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, Tokyo 1608582, Japan; [Kanai, Y.] Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 104, Japan	Keio University; National Cancer Center - Japan	Suzuki, H (corresponding author), Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hsuzuki@sc.itc.keio.ac.jp	Suzuki, Hidekazu/J-4396-2013; Kanai, Yae/AAE-6987-2019; Tsugawa, Hitoshi/V-9589-2019; Tsugawa, Hitoshi/J-4941-2013; Matsuzaki, Juntaro/S-4107-2019; SUZUKI, HIDEKAZU/S-9376-2019	Tsugawa, Hitoshi/0000-0002-4344-4475; Tsugawa, Hitoshi/0000-0002-4344-4475; Matsuzaki, Juntaro/0000-0002-3204-5049; 	Japan Society for the Promotion of Science (JSPS) [19599024, 19659057]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	The authors are grateful to Dr Robert Roeder at Rockefeller University for providing antibody to Pol III. This work was supported by a Grant-in-Aid for Scientific Research C from the Japan Society for the Promotion of Science (JSPS) ( 19599024, to Y.S.) and a Grant-in-Aid for Exploratory Research from JSPS ( 19659057, to HS).	Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Calin GA, 2006, ONCOGENE, V25, P6202, DOI 10.1038/sj.onc.1209910; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816; Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V149, P1449; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; Maeta Yoshihiko, 2004, Gastric Cancer, V7, P78; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; Oei SL, 2004, GENOMICS, V83, P873, DOI 10.1016/j.ygeno.2003.11.001; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Suzuki H, 1998, AM J PHYSIOL-GASTR L, V275, pG712, DOI 10.1152/ajpgi.1998.275.4.G712; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wacheck V, 2006, CANCER BIOL THER, V5, P1348, DOI 10.4161/cbt.5.10.3224; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zangemeister-Wittke U, 2006, CANCER BIOL THER, V5, P1355, DOI 10.4161/cbt.5.10.3488; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	26	147	161	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2738	2744		10.1038/onc.2009.140	http://dx.doi.org/10.1038/onc.2009.140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19503096				2022-12-28	WOS:000268452900004
J	Chung, BM; Dimri, M; George, M; Reddi, AL; Chen, G; Band, V; Band, H				Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.			The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants	ONCOGENE			English	Article						mutant EGFR; Src; transformation	GROWTH-FACTOR-RECEPTOR; C-SRC; KINASE INHIBITOR; SIGNAL TRANSDUCERS; TYROSINE KINASES; DOWN-REGULATION; MUTATIONS; ACTIVATION; GEFITINIB; SURVIVAL	Non-small cell lung cancer (NSCLC)-associated epidermal growth factor receptor (EGFR) mutants are constitutively active and induce ligand-independent transformation in non-malignant cell lines. We investigated the possibility that the ability of mutant EGFRs to transform cells reflects a constitutive cooperativity with Src using a system in which the overexpression of mutant, but not wild-type, EGFR induced anchorage-independent cell growth. Src was constitutively activated and showed enhanced interaction with mutant EGFRs, suggesting that constitutive EGFR-Src cooperativity may contribute to mutant EGFR-mediated oncogenesis. Indeed, the mutant EGFR-mediated cell transformation was inhibited by Src- as well as EGFR-directed inhibitors. Importantly, a tyrosine to phenylalanine mutation of the major Src phosphorylation site on EGFR, Y845, reduced the constitutive phosphorylation of NSCLC-EGFR mutants, as well as that of STAT3, Akt, Erk and Src, and reduced the mutant EGFR-Src association as well as proliferation, migration and anchorage-independent growth. Reduced anchorage-independent growth and migration were also observed when dominant-negative-Src was expressed in mutant EGFR-expressing cells. Overall, our findings show that mutant EGFR-Src interaction and cooperativity play critical roles in constitutive engagement of the downstream signaling pathways that allow NSCLC-associated EGFR mutants to mediate oncogenesis, and support the rationale to target Src- dependent signaling pathways in mutant EGFR-mediated malignancies.	[Chung, B. M.; George, M.; Band, H.] Univ Nebraska Med Ctr, Eppley Inst Canc & Allied Dis, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, H.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, V.; Band, H.] Univ Nebraska Med Ctr, Coll Med, Dept Genet Cell Biol & Anat, Nebraska Med Ctr, Omaha, NE 68198 USA; [Band, V.; Band, H.] Univ Nebraska Med Ctr, UNMC Eppley Canc Ctr, Nebraska Med Ctr, Omaha, NE 68198 USA; [Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Feinberg Sch Med, Evanston NW Healthcare Res Inst,Dept Med, Evanston, IL USA; [Chung, B. M.; Dimri, M.; George, M.; Reddi, A. L.; Chen, G.; Band, V.; Band, H.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Band, H (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Canc & Allied Dis, Nebraska Med Ctr, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	hband@unmc.edu	Chung, Byung Min/H-6219-2019	Chung, Byung Min/0000-0003-1262-5107	NIH [CA87986, CA105489, CA99900, CA116552, CA99163, CA94143, CA96844, CA81076]; Department of Defense Breast Cancer Research [W81XVVH-08-1-0617, DAMD17-02-1-0508]; NCI Cancer Center of Nanotechnology Excellence [1U54 CA119341-01]; NCI Breast Cancer SPORE and AVON Breast Cancer Fund; H Foundation, Chicago, IL, USA; Jean Ruggles-Romoser Chair of Cancer Research; Duckworth Family Chair of Breast Cancer Research; Malkin Scholarship; NCI Cancer Center Core Grant; NATIONAL CANCER INSTITUTE [R01CA099900, R01CA076118, R01CA099163, R01CA081076, R01CA087986, R01CA094143, R01CA105489, R01CA096844, U54CA119341, R01CA116552] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research(United States Department of Defense); NCI Cancer Center of Nanotechnology Excellence; NCI Breast Cancer SPORE and AVON Breast Cancer Fund; H Foundation, Chicago, IL, USA; Jean Ruggles-Romoser Chair of Cancer Research; Duckworth Family Chair of Breast Cancer Research; Malkin Scholarship; NCI Cancer Center Core Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Band laboratories for helpful suggestions and discussion. This work was supported by: the NIH grants CA87986, CA105489, CA99900, CA116552 and CA99163 to HB, and CA94143, CA96844 and CA81076 to VB; Department of Defense Breast Cancer Research Grants W81XVVH-08-1-0617 (HB) and DAMD17-02-1-0508 (VB); the NCI Cancer Center of Nanotechnology Excellence Grant NCI 1U54 CA119341-01 (HB and VB); the NCI Breast Cancer SPORE and AVON Breast Cancer Fund at Robert H Lurie Cancer Center, Northwestern University; the H Foundation, Chicago, IL, USA; the Jean Ruggles-Romoser Chair of Cancer Research (HB) and the Duckworth Family Chair of Breast Cancer Research (VB); and the Malkin Scholarship (BMC). UNMC-Eppley Cancer Center is supported by an NCI Cancer Center Core Grant.	Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; ANN PAB, 2004, ONCOGENE, V23, P7957; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Golas JM, 2003, CANCER RES, V63, P375; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kazansky AV, 2001, CELL GROWTH DIFFER, V12, P1; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Maeda M, 2006, J BIOL CHEM, V281, P59, DOI 10.1074/jbc.M503304200; Masaki T, 2003, EUR J CANCER, V39, P1447, DOI 10.1016/S0959-8049(03)00276-4; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	40	43	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1821	1832		10.1038/onc.2009.31	http://dx.doi.org/10.1038/onc.2009.31			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305428	Green Accepted			2022-12-28	WOS:000265640500001
J	Bultema, R; Longnecker, R; Swanson-Mungerson, M				Bultema, R.; Longnecker, R.; Swanson-Mungerson, M.			Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis	ONCOGENE			English	Article						Epstein-Barr virus; LMP2A; Burkitt's lymphoma; Bcl; Myc; transgenic models	MEMBRANE-PROTEIN 2A; ENDEMIC BURKITTS-LYMPHOMA; BCL-X-L; B-CELL; C-MYC; GENE-EXPRESSION; IN-VIVO; CONSTITUTIVE ACTIVATION; EBV; PATHWAY	Despite the identification of Epstein-Barr virus (EBV) in tumors of Burkitt's lymphoma (BL) over 40 years ago, the exact contribution of EBV to BL is undefined. EBV encodes for multiple proteins in latent B cells that affect B cell survival and activation. One such protein, latent membrane protein 2A (LMP2A), protects B cells from numerous pro-apoptotic stimuli. Therefore, we tested whether LMP2A protects B cells from apoptosis induced by aberrant c-MYC expression that precedes and dominates BL. We crossed LMP2A-transgenic mice (LMP2A-Tg), in which all B cells express LMP2A, to a transgenic mouse that expresses a BL translocation of myc (lambda-MYC-Tg mice). LMP2A promotes proliferation and protects B cells from MYC-induced apoptosis in lambda-MYC-Tg mice. LMP2A also accelerates the development of lymphoma in LMP2A/lambda-MYC-Tg mice. Finally, LMP2A increases the expression of Bcl-X-L in both pretumor B cells and tumor cells, suggesting a mechanism for LMP2A-mediated B cell survival in the presence of MYC. These results support a hypothesis that EBV LMP2A promotes tumor development by protecting pre-tumor B cells that would normally apoptose after the c-myc translocation.	[Bultema, R.; Longnecker, R.; Swanson-Mungerson, M.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Longnecker, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Ward 6-231,303 E Chicago Ave, Chicago, IL 60611 USA.	r-longnecker@northwestern.edu			Public Health Service [CA62234, CA73507]; NATIONAL CANCER INSTITUTE [R01CA133063, R01CA062234, R01CA073507] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	RL is a John Edward Porter Professor in Biomedical Research and supported by the Public Health Service Grants CA62234 and CA73507 from the NCI. The authors thank Dr Herbert C Morse III, the NIAID, and the NCI for the lambda-MYC transgenic mice.	Anderson LJ, 2008, J GEN VIROL, V89, P1563, DOI 10.1099/vir.0.2008/001461-0; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Bell AI, 2006, J GEN VIROL, V87, P2885, DOI 10.1099/vir.0.81906-0; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Gerbitz A, 1999, ONCOGENE, V18, P1745, DOI 10.1038/sj.onc.1202468; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hsu JL, 2000, CRIT REV ONCOL HEMAT, V34, P27, DOI 10.1016/S1040-8428(00)00046-9; Ikeda A, 2004, J IMMUNOL, V172, P5329, DOI 10.4049/jimmunol.172.9.5329; Kim JS, 2006, J PATHOL, V209, P44, DOI 10.1002/path.1940; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Linden M, 2004, BLOOD, V103, P2779, DOI 10.1182/blood-2003-10-3399; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Newman SC., 2003, BIOSTATISTICAL METHO; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Pan YR, 2008, CELL MICROBIOL, V10, P2447, DOI 10.1111/j.1462-5822.2008.01221.x; Panousis CG, 1997, J VIROL, V71, P4752, DOI 10.1128/JVI.71.6.4752-4760.1997; Park SS, 2005, CANCER RES, V65, P1306, DOI 10.1158/0008-5472.CAN-04-0268; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; RICKINSON AB, 2007, EPSTEINBARR VIRUS; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Swanson-Mungerson MA, 2005, J VIROL, V79, P7355, DOI 10.1128/JVI.79.12.7355-7362.2005; Swanson-Mungerson M, 2006, J VIROL, V80, P6764, DOI 10.1128/JVI.00433-06; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang H, 2006, J IMMUNOL, V177, P2793, DOI 10.4049/jimmunol.177.5.2793; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhu D, 2005, BLOOD, V105, P2135, DOI 10.1182/blood-2004-07-2573	39	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1471	1476		10.1038/onc.2008.492	http://dx.doi.org/10.1038/onc.2008.492			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19182823	Green Accepted			2022-12-28	WOS:000264354400008
J	Kohler, EM; Brauburger, K; Behrens, J; Schneikert, J				Kohler, E. M.; Brauburger, K.; Behrens, J.; Schneikert, J.			Contribution of the 15 amino acid repeats of truncated APC to beta-catenin degradation and selection of APC mutations in colorectal tumours from FAP patients	ONCOGENE			English	Article						adenomatous polyposis coli; APC; beta-catenin; colon cancer; mutation	ADENOMATOUS POLYPOSIS-COLI; SOMATIC MUTATIONS; DESTRUCTION COMPLEX; SUPPRESSOR PROTEIN; CLUSTER REGION; FUNCTIONAL INTERACTION; CRYSTAL-STRUCTURE; STEM-CELLS; IN-VIVO; GENE	The adenomatous polyposis coli (APC) protein is a negative regulator of the mitogenic transcription factor beta-catenin by stimulating its proteasomal degradation. This involves several APC domains, including the binding sites for axin/conductin, the recently described beta-Catenin Inhibitory Domain (CID) and the third 20 amino acid repeat (20R3) that is a beta-catenin-binding site. The four 15 amino acid repeats (15R) and the 20R1 are also beta-catenin-binding sites, but their role in beta-catenin degradation has remained unclear. We show here that binding of beta-catenin to the 15R of APC is necessary and sufficient to target beta-catenin for degradation whereas binding to the 20R1 is neither necessary nor sufficient. The first 15R displays the highest affinity for beta-catenin in the 15R-20R1 module. Biallelic mutations of the APC gene lead to colon cancer in familial adenomatous polyposis coli (FAP) and result in the synthesis of truncated products lacking domains involved in beta-catenin degradation but still having a minimal length. The analysis of the distribution of truncating mutations along the APC sequence in colorectal tumours from FAP patients revealed that the first 15R is one target of the positive selection of mutations that lead to tumour development. Oncogene (2010) 29, 1663-1671; doi:10.1038/onc.2009.447; published online 7 December 2009	[Kohler, E. M.; Brauburger, K.; Behrens, J.; Schneikert, J.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, D-91054 Erlangen, Bayern, Germany	University of Erlangen Nuremberg	Schneikert, J (corresponding author), Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Gluckstr 6, D-91054 Erlangen, Bayern, Germany.	jschneik@molmed.uni-erlangen.de		Wenzel, Eva Maria/0000-0002-5561-3344	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Sander Stiftung	Interdisziplinares Zentrum fur Klinische Forschung (IZKF); Sander Stiftung	We thank G Daum for technical, and A Doebler for secretarial assistances. We thank also I Wacker for critical reading of the paper. This work was supported by grants from the Interdisziplinares Zentrum fur Klinische Forschung (IZKF) and the Sander Stiftung to JB.	Akiyama T, 2006, ONCOGENE, V25, P7538, DOI 10.1038/sj.onc.1210063; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Clarke AR, 2006, ONCOGENE, V25, P7512, DOI 10.1038/sj.onc.1210065; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Ferrarese A, 2007, BIOCHEMISTRY-US, V46, P11902, DOI 10.1021/bi701674z; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; GRODEN J, 1993, AM J HUM GENET, V52, P263; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; Gupta PK, 1997, CANCER RES, V57, P1188; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Hong Y, 2007, MUTAT RES-FUND MOL M, V614, P48, DOI 10.1016/j.mrfmmm.2006.06.006; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kohler EM, 2008, HUM MOL GENET, V17, P1978, DOI 10.1093/hmg/ddn095; Kohler EM, 2009, HUM MOL GENET, V18, P213, DOI 10.1093/hmg/ddn338; Kotiligam D, 2008, HISTOL HISTOPATHOL, V23, P117, DOI 10.14670/HH-23.117; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Latchford A, 2007, HUM MOL GENET, V16, P78, DOI 10.1093/hmg/ddl442; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064; McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001; Menendez M, 2008, GASTROENTEROLOGY, V134, P56, DOI 10.1053/j.gastro.2007.10.009; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyaki M, 2008, INT J CANCER, V122, P2491, DOI 10.1002/ijc.23390; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke I, 2006, NAT REV CANCER, V6, P967, DOI 10.1038/nrc2010; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; Peterson-Nedry W, 2008, DEV BIOL, V320, P226, DOI 10.1016/j.ydbio.2008.05.521; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Schneikert J, 2006, INT J CANCER, V119, P74, DOI 10.1002/ijc.21826; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Taketo MM, 2006, ONCOGENE, V25, P7522, DOI 10.1038/sj.onc.1210058; Tickenbrock L, 2003, J MOL BIOL, V327, P359, DOI 10.1016/S0022-2836(03)00144-X; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603	58	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1663	1671		10.1038/onc.2009.447	http://dx.doi.org/10.1038/onc.2009.447			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966865				2022-12-28	WOS:000275694700011
J	Massip, L; Garand, C; Labbe, A; Perreault, E; Turaga, RVN; Bohr, VA; Lebel, M				Massip, L.; Garand, C.; Labbe, A.; Perreault, E.; Turaga, R. V. N.; Bohr, V. A.; Lebel, M.			Depletion of WRN protein causes RACK1 to activate several protein kinase C isoforms	ONCOGENE			English	Article						Werner syndrome; mass spectrometry; RACK1; PKC activation	WERNER-SYNDROME PROTEIN; OXIDATIVE STRESS; DNA-DAMAGE; FUNCTIONAL INTERACTION; BETA; PHOSPHORYLATION; DELTA; TRANSLOCATION; EPSILON; BREAKS	Werner's syndrome (WS) is a rare autosomal disease characterized by the premature onset of several age-associated pathologies. The protein defective in patients with WS (WRN) is a helicase/exonuclease involved in DNA repair, replication, transcription and telomere maintenance. In this study, we show that a knock down of the WRN protein in normal human fibroblasts induces phosphorylation and activation of several protein kinase C (PKC) enzymes. Using a tandem affinity purification strategy, we found that WRN physically and functionally interacts with receptor for activated C-kinase 1 (RACK1), a highly conserved anchoring protein involved in various biological processes, such as cell growth and proliferation. RACK1 binds strongly to the RQC domain of WRN and weakly to its acidic repeat region. Purified RACK1 has no impact on the helicase activity of WRN, but selectively inhibits WRN exonuclease activity in vitro. Interestingly, knocking down RACK1 increased the cellular frequency of DNA breaks. Depletion of the WRN protein in return caused a fraction of nuclear RACK1 to translocate out of the nucleus to bind and activate PKC delta and PKC beta II in the membrane fraction of cells. In contrast, different DNA-damaging treatments known to activate PKCs did not induce RACK1/PKCs association in cells. Overall, our results indicate that a depletion of the WRN protein in normal fibroblasts causes the activation of several PKCs through translocation and association of RACK1 with such kinases. Oncogene (2010) 29, 1486-1497; doi:10.1038/onc.2009.443; published online 7 December 2009	[Massip, L.; Garand, C.; Labbe, A.; Perreault, E.; Turaga, R. V. N.; Lebel, M.] Univ Laval, Hop Hotel Dieu, Dept Mol Biol Med Biochem & Pathol, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; [Bohr, V. A.] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	Laval University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Lebel, M (corresponding author), Univ Laval, Hop Hotel Dieu, Dept Mol Biol Med Biochem & Pathol, Ctr Rech Cancerol, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.	michel.lebel@crhdq.ulaval.ca	Bohr, Vilhelm/AAP-5931-2020; Perreault, Eric/B-7632-2009	Garand, Chantal/0000-0003-0716-6487	Canadian Institutes of Health Research; National Institute on Aging, NIH; Fonds de la Recherche en Sante du Quebec; NATIONAL INSTITUTE ON AGING [ZIAAG000721] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to Mrs N Roberge for the FACS analyses (Centre de Recherche en Cancerologie, Quebec City, Qc). This study was supported by the Canadian Institutes of Health Research to ML and in part by funds from the intramural Program of the National Institute on Aging, NIH to VAB. ML is a senior scholar from the Fonds de la Recherche en Sante du Quebec.	Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Brosh RM, 2001, EMBO J, V20, P5791; Cheng WH, 2008, MOL BIOL CELL, V19, P3923, DOI 10.1091/mbc.E07-07-0698; Cheng WH, 2007, EXP GERONTOL, V42, P871, DOI 10.1016/j.exger.2007.04.011; Cooper MP, 2000, GENE DEV, V14, P907; Corsini E, 2005, J LEUKOCYTE BIOL, V77, P247, DOI 10.1189/jlb.0504268; Das A, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703343200; Davis T, 2007, ANN NY ACAD SCI, V1100, P455, DOI 10.1196/annals.1395.051; Davis T, 2009, BIOGERONTOLOGY, V10, P253, DOI 10.1007/s10522-008-9179-x; Deschenes F, 2005, HUM MOL GENET, V14, P3293, DOI 10.1093/hmg/ddi362; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Egidy G, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-34; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Indig FE, 2004, J STRUCT BIOL, V146, P251, DOI 10.1016/j.jsb.2003.11.009; Kaneto H, 2005, CURR DIABETES REV, V1, P65, DOI 10.2174/1573399052952613; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Kohda Y, 2005, J PHARMACOL SCI, V98, P49, DOI 10.1254/jphs.FP0040926; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Massip L, 2006, EXP GERONTOL, V41, P157, DOI 10.1016/j.exger.2005.10.011; MASSIP L, 2009, FASEB J; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Melcher R, 2000, CYTOGENET CELL GENET, V91, P180, DOI 10.1159/000056841; Min W, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-8; Nitti M, 2008, MOL ASPECTS MED, V29, P36, DOI 10.1016/j.mam.2007.09.001; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Ottaviani E, 2001, COMP BIOCHEM PHYS C, V129, P295, DOI 10.1016/S1532-0456(01)00211-3; Pagano G, 2005, FREE RADICAL RES, V39, P529, DOI 10.1080/10715760500092683; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sajan MP, 2006, J BIOL CHEM, V281, P17466, DOI 10.1074/jbc.M510803200; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Slager RE, 2008, J HISTOCHEM CYTOCHEM, V56, P7, DOI 10.1369/jhc.7A7249.2007; Stawowy P, 2005, CARDIOVASC RES, V67, P50, DOI 10.1016/j.cardiores.2005.03.002; Szekely AM, 2005, MOL CELL BIOL, V25, P10492, DOI 10.1128/MCB.25.23.10492-10506.2005; Turaga RVN, 2007, AGING CELL, V6, P471, DOI 10.1111/j.1474-9726.2007.00301.x; Turaga RVN, 2009, CELL CYCLE, V8, P2080, DOI 10.4161/cc.8.13.8925; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Wang Z, 2008, MOL CELL PROTEOMICS, V7, P1639, DOI 10.1074/mcp.M700520-MCP200; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134	53	12	12	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1486	1497		10.1038/onc.2009.443	http://dx.doi.org/10.1038/onc.2009.443			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966859	Green Accepted			2022-12-28	WOS:000275392400007
J	Pena, C; Garcia, JM; Larriba, MJ; Barderas, R; Gomez, I; Herrera, M; Garcia, V; Silva, J; Dominguez, G; Rodriguez, R; Cuevas, J; de Herreros, AG; Casal, JI; Munoz, A; Bonilla, F				Pena, C.; Garcia, J. M.; Larriba, M. J.; Barderas, R.; Gomez, I.; Herrera, M.; Garcia, V.; Silva, J.; Dominguez, G.; Rodriguez, R.; Cuevas, J.; de Herreros, A. G.; Casal, J. I.; Munoz, A.; Bonilla, F.			SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue	ONCOGENE			English	Article						colorectal cancer; epithelial-mesenchymal transition; SNAI1; CDH1; normal adjacent tissue	TRANSCRIPTION FACTOR SNAIL; VITAMIN-D-RECEPTOR; CADHERIN GENE-EXPRESSION; TUMOR PROGRESSION; IN-SITU; BREAST; CARCINOMA; CELLS; HETEROZYGOSITY; TRANSITION	SNAI1, ZEB1, E-cadherin (CDH1), and vitamin D receptor (VDR) genes regulate the epithelial-mesenchymal transition (EMT) that initiates the invasion process of many tumor cells. We hypothesized that this process could also affect the behavior of normal cells adjacent to the tumor. To verify this hypothesis, the expression level of these genes was determined by quantitative RT-PCR in tumor, normal adjacent, and normal distant tissues from 32 colorectal cancer (CC) patients. In addition, we extended the study to human HaCaT normal keratinocytes and SW480-ADH colon cancer cells co-cultured with SW480-ADH cells over-expressing the mouse Snai1 gene. Of 18 CC cases with SNAI1 expression in tumor tissue, five also had SNAI1 in normal adjacent tissue (NAT). Expression of SNAI1 in tumor tissue correlated with downregulation of CDH1 and VDR genes in both tumor (P = 0.047 and P = 0.014, respectively) and NAT lacking SNAI1 expression (P = 0.054 and P = 0.003). ZEB1 expression was directly related to VDR expression in tumor tissue (r = 0.39; P = 0.027) and inversely to CDH1 in NAT (r = -0.46; P = 0.010). CDH1 and VDR were also downregulated in SW480-ADH and MaCaT cells, respectively, when they were co-cultured with Snai1-expressing cells. Furthermore, cytokine analysis showed differences in the conditioned media obtained from the two cell types. These results indicate that histologically normal tissue adjacent to tumor tissue expressing the EMT-inducing gene SNAI1 shows alterations in the expression of epithelial differentiation genes such as CDH1 and VDR. Oncogene (2009) 28, 4375-4385; doi: 10.1038/onc.2009.285; published online 5 October 2009	[Pena, C.; Garcia, J. M.; Gomez, I.; Herrera, M.; Garcia, V.; Silva, J.; Dominguez, G.; Bonilla, F.] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, E-28222 Madrid, Spain; [Larriba, M. J.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Barderas, R.; Casal, J. I.] CSIC, CIB, Funct Prote Lab, Madrid, Spain; [Rodriguez, R.] Hosp Virgen Salud, Dept Pathol, Toledo, Spain; [Cuevas, J.] Hosp Gen Univ, Dept Pathol, Guadalajara, Spain; [de Herreros, A. G.] Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona, Spain	Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Complejo Hospitalario de Toledo; Pompeu Fabra University	Bonilla, F (corresponding author), Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, C Joaquin Rodrigo,2 Majadahonda, E-28222 Madrid, Spain.	fbonilla.hpth@salud.madrid.org	de Herreros, A Garcia/H-3104-2014; LARRIBA, MARIA JESUS/O-4652-2014; Barderas, Rodrigo/K-3560-2014; Casal, Ignacio/M-2312-2014; Munoz, Alberto/O-6393-2014	de Herreros, A Garcia/0000-0001-5270-0808; LARRIBA, MARIA JESUS/0000-0001-9035-7414; Barderas, Rodrigo/0000-0003-3539-7469; Casal, Ignacio/0000-0003-1085-2840; Munoz, Alberto/0000-0003-3890-4251; Garcia-Barberan, Vanesa/0000-0002-2531-0203	Accion Transversal del Cancer (ISCIII);  [SAF2007-60431];  [CAM: S-GEN/0266/2006];  [ISCIII-RETIC RD06/0020 and /0009]	Accion Transversal del Cancer (ISCIII)(Instituto de Salud Carlos III); ; ; 	We thank M Eaude for help with the English paper. This study was supported by the grants SAF2007-60431, CAM: S-GEN/0266/2006, ISCIII-RETIC RD06/0020 and /0009, and a grant from the Accion Transversal del Cancer (ISCIII).	Aboseif S, 1999, DIFFERENTIATION, V65, P113, DOI 10.1046/j.1432-0436.1999.6520113.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baulida J, 1999, BIOCHEM J, V344, P565, DOI 10.1042/0264-6021:3440565; Blanco MJ, 2007, DEVELOPMENT, V134, P4073, DOI 10.1242/dev.006858; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; Forsti A, 2001, EUR J CANCER, V37, P1372, DOI 10.1016/S0959-8049(01)00118-6; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzig M, 2002, BBA-REV CANCER, V1602, P97, DOI 10.1016/S0304-419X(02)00039-2; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Lakhani SR, 1999, J PATHOL, V189, P496, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;496::AID-PATH485&gt;3.0.CO;2-D; Larson PS, 1998, AM J PATHOL, V152, P1591; Larson PS, 2002, AM J PATHOL, V161, P283, DOI 10.1016/S0002-9440(10)64180-6; Lazarova DL, 2001, CELL GROWTH DIFFER, V12, P319; Li YW, 2000, DIFFERENTIATION, V66, P126, DOI 10.1046/j.1432-0436.2000.660207.x; Li Z, 2002, CANCER RES, V62, P1000; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Menke A, 2001, CANCER RES, V61, P3508; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nilsson E, 2001, J SOC GYNECOL INVEST, V8, pS17, DOI 10.1016/S1071-5576(00)00099-X; Olumi AF, 1999, CANCER RES, V59, P5002; OTO M, 1993, ANAL BIOCHEM, V213, P19, DOI 10.1006/abio.1993.1379; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2005, HUM MOL GENET, V14, P3361, DOI 10.1093/hmg/ddi366; Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Ren ZP, 1996, ONCOGENE, V12, P765; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SOZZI G, 1991, CANCER RES, V51, P400; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; TOMITA N, 1992, CANCER RES, V52, P6840; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528	50	47	53	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4375	4385		10.1038/onc.2009.285	http://dx.doi.org/10.1038/onc.2009.285			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19802011	Green Submitted			2022-12-28	WOS:000272876400006
J	Careccia, S; Mainardi, S; Pelosi, A; Gurtner, A; Diverio, D; Riccioni, R; Testa, U; Pelosi, E; Piaggio, G; Sacchi, A; Lavorgna, S; Lo-Coco, F; Blandino, G; Levrero, M; Rizzo, MG				Careccia, S.; Mainardi, S.; Pelosi, A.; Gurtner, A.; Diverio, D.; Riccioni, R.; Testa, U.; Pelosi, E.; Piaggio, G.; Sacchi, A.; Lavorgna, S.; Lo-Coco, F.; Blandino, G.; Levrero, M.; Rizzo, M. G.			A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes	ONCOGENE			English	Article						microRNAs; acute promyelocytic leukemia; PML/RAR alpha	HEMATOPOIETIC STEM; RETINOIC ACID; RAR-ALPHA; LEUKEMIA; DIFFERENTIATION; MICRORNAS; EXPRESSION; CELLS; RECEPTORS; GENOMICS	MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. A small set of miRNAs is differentially expressed in hematopoietic cells and seemingly has an important role in granulopoiesis and lineage differentiation. In this study, we analysed, using a quantitative real-time PCR approach, the expression of 12 granulocytic differentiation signature miRNAs in a cohort of acute promyelocytic leukemia (APL) patients. We found nine miRNAs overexpressed and three miRNAs (miR-107, -342 and let-7c) downregulated in APL blasts as compared with normal promyelocytes differentiated in vitro from CD34+ progenitors. Patients successfully treated with all-trans-retinoic acid (ATRA) and chemotherapy showed downregulation of miR-181b and upregulation of miR-15b, -16, -107, -223, -342 and let-7c. We further investigated whether the APL-associated oncogene, promyelocytic leukemia gene (PML)/retinoic acid receptor alpha (RAR alpha), might be involved in the transcriptional repression of miR-107, -342 and let-7c. We found that PML/RAR alpha binds the regulatory sequences of the intragenic miR-342 and let-7c. In addition, we observed, in response to ATRA, the release of PML/RAR alpha paralleled by their transcriptional activation, together with their host genes, EVL and C21orf34 alpha. In conclusion, we show that a small subset of miRNAs is differentially expressed in APL and modulated by ATRA-based treatment. Oncogene (2009) 28, 4034-4040; doi:10.1038/onc.2009.255; published online 14 September 2009	[Careccia, S.; Mainardi, S.; Pelosi, A.; Gurtner, A.; Piaggio, G.; Sacchi, A.; Blandino, G.; Rizzo, M. G.] Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, I-00158 Rome, Italy; [Diverio, D.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy; [Riccioni, R.; Testa, U.; Pelosi, E.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Fdn Santa Lucia, Lab Neurooncoematol, Rome, Italy; [Blandino, G.; Levrero, M.] ROC, Rome, Italy; [Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, Rome, Italy; [Levrero, M.] Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; IRCCS Santa Lucia; Sapienza University Rome	Rizzo, MG (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, Via Messi dOro 156, I-00158 Rome, Italy.	massimo.levrero@uniroma1.it; rizzo@ifo.it	Piaggio, Giulia/AAD-7336-2022; Testa, Ugo/J-6472-2016; lavorgna, serena/O-8490-2016; Careccia, Silvia/K-6475-2016; pelosi, elvira/J-7298-2016; Piaggio, Giulia/J-7214-2018; Rizzo, Maria Giulia/B-2107-2018; gurtner, aymone/AAB-8843-2020; Gurtner, Aymone/J-7217-2018; Pelosi, Andrea/J-9690-2018; riccioni, roberta/AAC-5636-2021; Blandino, Giovanni/B-1137-2013; Levrero, Massimo/G-5680-2016	Testa, Ugo/0000-0001-7900-8942; lavorgna, serena/0000-0001-8812-2325; Careccia, Silvia/0000-0001-7221-8170; pelosi, elvira/0000-0002-3043-6249; Piaggio, Giulia/0000-0003-2114-1892; Rizzo, Maria Giulia/0000-0002-5009-2412; gurtner, aymone/0000-0002-7661-9059; Gurtner, Aymone/0000-0002-7661-9059; Pelosi, Andrea/0000-0003-2308-9215; riccioni, roberta/0000-0002-5766-7717; Blandino, Giovanni/0000-0002-6970-2241; Levrero, Massimo/0000-0002-4978-0875	Associazione Italiana per la Ricerca sul Cancro (AIRC); Ministero della Salute-Italy; European Community (Eu Active p53 Consortium)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute-Italy(Ministry of Health, Italy); European Community (Eu Active p53 Consortium)(European Commission)	We thank Dr WH Miller Jr for kindly providing the NB4 sub-clone MR2 and Dr I Sperduti for his help on statistical analysis. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministero della Salute-Italy and European Community (Eu Active p53 Consortium).	Abramovich C, 2005, CURR OPIN HEMATOL, V12, P210, DOI 10.1097/01.moh.0000160737.52349.aa; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; De Marchis ML, 2009, LEUKEMIA, V23, P856, DOI 10.1038/leu.2008.372; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Mainardi S, 2007, CELL DEATH DIFFER, V14, P1968, DOI 10.1038/sj.cdd.4402210; Mallardo M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-19; Mandelli F, 1997, BLOOD, V90, P1014; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Pasquinelli AE, 2005, CURR OPIN GENET DEV, V15, P200, DOI 10.1016/j.gde.2005.01.002; Peng Y, 2008, MOL CANCER RES, V6, P663, DOI 10.1158/1541-7786.MCR-07-0370; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Saumet A, 2009, BLOOD, V113, P412, DOI 10.1182/blood-2008-05-158139; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391	26	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4034	4040		10.1038/onc.2009.255	http://dx.doi.org/10.1038/onc.2009.255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19749800				2022-12-28	WOS:000272560300008
J	Baum, N; Schiene-Fischer, C; Frost, M; Schumann, M; Sabapathy, K; Ohlenschlager, O; Grosse, F; Schlott, B				Baum, N.; Schiene-Fischer, C.; Frost, M.; Schumann, M.; Sabapathy, K.; Ohlenschlaeger, O.; Grosse, F.; Schlott, B.			The prolyl cis/trans isomerase cyclophilin 18 interacts with the tumor suppressor p53 and modifies its functions in cell cycle regulation and apoptosis	ONCOGENE			English	Article						apoptosis; cell cycle; cyclosporin; genetic polymorphism; peptidyl-prolyl cis/trans isomerization	CIS-TRANS ISOMERASE; DEPENDENT PROLINE ISOMERIZATION; CYCLOSPORINE-A; LUNG-CANCER; POLYMORPHIC VARIANTS; DNA-DAMAGE; WILD-TYPE; PIN1; PROTEIN; CATALYSIS	The functional diversity of the tumor suppressor protein p53 is mainly regulated by protein interactions. In this study, we describe a new interaction with the peptidylprolyl cis/trans isomerase cyclophilin 18 (Cyp18). The interaction reduced the sequence-specific DNA binding of p53 in vitro, whereas the inhibition of the interaction increased p53-reporter gene activity in vivo. The active site of the folding helper enzyme Cyp18 was directly involved in binding. The proline-rich region (amino acids 64-91) of p53 was most likely responsible for the observed binding because a synthetic peptide comprising amino acids 68-81 of p53 inhibited this interaction, and a p53 variant containing a proline residue at position 72 (p53(P72)) interacted with Cyp18 more effectively than the corresponding p53(R72) variant. Impairment of the Cyp18-p53 interaction induced an accumulation of cells in the G2/M phase of the cell cycle, which was more pronounced when p53(P72) was expressed compared with p53(R72) in an otherwise isogenic cellular background. Moreover, p53-dependent apoptosis was elevated in Cyp18 knockout cells, suggesting an antiapoptotic potential of Cyp18-p53 complexes. Functional in vivo data hint to a possible clinical relevance of the p53-Cyp18 interaction observed. Oncogene (2009) 28, 3915-3925; doi:10.1038/onc.2009.248; published online 31 August 2009	[Schlott, B.] Leibniz Inst Age Res, Fritz Lipmann Inst, Biochem Grp, Dept Biochem, D-07745 Jena, Thuringia, Germany; [Schiene-Fischer, C.; Frost, M.; Schumann, M.] Max Planck Res Unit Prot Folding, Halle, Saale, Germany; [Sabapathy, K.] Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore, Singapore; [Ohlenschlaeger, O.] Leibniz Inst Age Res, Dept NMR, D-07745 Jena, Thuringia, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Max Planck Society; National Cancer Centre Singapore (NCCS); Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Schlott, B (corresponding author), Leibniz Inst Age Res, Fritz Lipmann Inst, Biochem Grp, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Thuringia, Germany.	bschlott@fli-leibniz.de		Ohlenschlaeger, Oliver/0000-0002-6428-4423	Deutsche Forschungsgemeinschaft [GK1026, SFB604]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft grant GK1026 (to CS-F) and SFB604 (to Gunter Fischer, Halle, and FG). The technical assistance of Mrs Anita Willitzer is acknowledged. Jurkat cells were kindly provided by J Luban (Columbia University, New York).	Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bauerschmidt C, 2007, GENES CELLS, V12, P745, DOI 10.1111/j.1365-2443.2007.01090.x; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Choi KJ, 2007, CANCER RES, V67, P3654, DOI 10.1158/0008-5472.CAN-06-1759; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Fanghanel J, 2003, ANGEW CHEM INT EDIT, V42, P490, DOI 10.1002/anie.200390149; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; Herman M, 2001, J LAB CLIN MED, V137, P14, DOI 10.1067/mlc.2001.111469; Howard BA, 2005, CANCER RES, V65, P8853, DOI 10.1158/0008-5472.CAN-05-1219; Howard BA, 2004, LUNG CANCER, V46, P313, DOI 10.1016/j.lungcan.2004.05.013; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Jensen P, 1999, J AM ACAD DERMATOL, V40, P177, DOI 10.1016/S0190-9622(99)70185-4; Johnson MD, 1999, J NEUROSCI, V19, P2996; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; LARSSON R, 1991, ANTICANCER RES, V11, P455; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu WF, 2001, FEBS LETT, V496, P105, DOI 10.1016/S0014-5793(01)02411-5; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; MARKS WH, 1991, TRANSPLANTATION, V52, P340, DOI 10.1097/00007890-199108000-00030; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ross HJ, 1997, LUNG CANCER-J IASLC, V18, P189, DOI 10.1016/S0169-5002(97)00061-5; Scheibel T, 1998, BIOCHEM PHARMACOL, V56, P675, DOI 10.1016/S0006-2952(98)00120-8; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Soe K, 2002, ONCOGENE, V21, P6614, DOI 10.1038/sj.onc.1205912; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	52	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3915	3925		10.1038/onc.2009.248	http://dx.doi.org/10.1038/onc.2009.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718045				2022-12-28	WOS:000271471900006
J	Zheng, HQ; Zhou, Z; Huang, J; Chaudhury, L; Dong, JT; Chen, C				Zheng, H-Q; Zhou, Z.; Huang, J.; Chaudhury, L.; Dong, J-T; Chen, C.			Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of broblast growth factor binding protein 1	ONCOGENE			English	Article						KLF5; FGF-BP; proliferation; transcription factor; breast cancer	EPITHELIAL-CELLS; FGF-BP; CANCER-CELLS; SKIN CARCINOGENESIS; TUMOR-GROWTH; LIGASE WWP1; KLF5; EXPRESSION; KRUPPEL-LIKE-FACTOR-5; ACTIVATION	The Kruppel-like factor 5 (KLF5) is a zinc-finger transcription factor promoting cell proliferation, cell-cycle progression and survival. A high expression level of KLF5 mRNA has been shown to be associated with shorter breast cancer patient survival. However, the mechanism of KLF5 action in breast cancer is still not clear. In this study, we found that both KLF5 and its downstream gene. broblast growth factor binding protein 1 (FGF-BP) are co-expressed in breast cell lines and primary tumors. Manipulation of the KLF5 expression can positively regulate the FGF-BP mRNA and protein levels in multiple breast cell lines. In addition, the secreted FGF-BP protein in the conditional medium is also regulated by KLF5. Furthermore, we demonstrated that KLF5 binds and activates the FGF-BP promoter through a GC box by luciferase reporter, oligo pull down and chromatin immunoprecipitation (ChIP) assays. When FGF-BP is depleted by siRNA, KLF5 fails to promote cell proliferation in MCF10A, SW527 and TSU-Pr1. We further demonstrated that overexpression or addition of FGF-BP rescues the KLF5-knockdown-induced growth arrest in MCF10A cells. Finally, KLF5 significantly promotes MCF7 breast cancer cell xenograft growth in athymic nude mice. These findings suggest that KLF5 may promote breast cancer cell proliferation at least partially through directly activating the FGF-BP mRNA transcription. Understanding the mechanism of KLF5 action in breast cancer may result in useful diagnostic and therapeutic targets. Oncogene (2009) 28, 3702-3713; doi: 10.1038/onc.2009.235; published online 10 August 2009	[Zheng, H-Q; Zhou, Z.; Chaudhury, L.; Chen, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Huang, J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dong, J-T] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA USA	Albany Medical College; Baylor College of Medicine; Emory University	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu		Zheng, Hanqiu/0000-0002-8062-1215; Dong, Jin-Tang/0000-0003-2349-5782	Susan G Komen Breast Cancer Foundation [BCTR0503705]; American Cancer Society; Department of Defense [W81XWH-07-1-0191]	Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense)	This work was supported in part by a grant (BCTR0503705) from the Susan G Komen Breast Cancer Foundation, a grant from the American Cancer Society and a grant from the Department of Defense (W81XWH-07-1-0191). We thank Dr Chunhong Yan and Dr Jihe Zhao for providing the pRL-bactin construct and the pBabe-puro retroviral system.	Abuharbeid S, 2006, INT J BIOCHEM CELL B, V38, P1463, DOI 10.1016/j.biocel.2005.10.017; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2007, INT J CANCER, V121, P2834; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Fujiu K, 2005, CIRC RES, V97, P1132, DOI 10.1161/01.RES.0000190613.22565.13; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Kagan BL, 2003, CANCER RES, V63, P1696; Kojima S, 1997, J BIOCHEM, V121, P389; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Kwak MK, 2008, J CANCER RES CLIN, V134, P163, DOI 10.1007/s00432-007-0265-2; Li WM, 2004, CHINESE MED J-PEKING, V117, P621; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Mohsin SK, 2004, MODERN PATHOL, V17, P1545, DOI 10.1038/modpathol.3800229; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Ray PE, 2006, AM J PHYSIOL-REG I, V290, pR105, DOI 10.1152/ajpregu.00492.2005; Ray R, 2003, CANCER RES, V63, P8085; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Sur I, 2006, J CELL SCI, V119, P3593, DOI 10.1242/jcs.03070; Tassi E, 2006, CANCER RES, V66, P1191, DOI 10.1158/0008-5472.CAN-05-2926; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Wan HJ, 2008, DEVELOPMENT, V135, P2563, DOI 10.1242/dev.021964; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; WU DQ, 1991, J BIOL CHEM, V266, P16778; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625	45	79	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3702	3713		10.1038/onc.2009.235	http://dx.doi.org/10.1038/onc.2009.235			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668233				2022-12-28	WOS:000271023200003
J	Brady, SN; Maggi, LB; Winkeler, CL; Toso, EA; Gwinn, AS; Pelletier, CL; Weber, JD				Brady, S. N.; Maggi, L. B., Jr.; Winkeler, C. L.; Toso, E. A.; Gwinn, A. S.; Pelletier, C. L.; Weber, J. D.			Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation	ONCOGENE			English	Article						NPM; ribosome; p19ARF; centrosome	CELL-CYCLE PROGRESSION; NUCLEOLAR PHOSPHOPROTEIN B23; ARF TUMOR-SUPPRESSOR; CENTROSOME DUPLICATION; RIBOSOME BIOGENESIS; DEPENDENT KINASE; NUCLEAR EXPORT; P19(ARF); P53; IDENTIFICATION	Nucleophosmin (NPM), an oligomeric phosphoprotein and nucleolar target of the ARF tumor suppressor, contributes to several critical cellular processes. Previous studies have shown that the human NPM's phosphorylation by cyclin E cyclin-dependent kinase 2 (cdk2) on threonine (Thr) 199 regulates its translocation from the centrosome during cell cycle progression. Given our previous finding that ARF directly binds NPM, impeding its transit to the cytoplasm and arresting cells before S-phase entry, we hypothesized that ARF might also inhibit NPM phosphorylation. However, ARF induction did not impair phosphorylation of the cdk2 target residue in murine NPM, Thr(198). Furthermore, phosphorylation of Thr(198) occurred throughout the cell cycle and was concomitant with increases in overall NPM expression. To investigate the cell's presumed requirement for NPM-Thr(198) phosphorylation in promoting the processes of growth and proliferation, we examined the effects of a non-phosphorylatable NPM mutant, T198A, in a clean cell system in which endogenous NPM had been removed by RNA interference. Here, we show that the T198A mutant is fully capable of executing NPM's described roles in nucleocytoplasmic shuttling, ribosome export and cell cycle progression. Moreover, the proliferative defects observed with stable NPM knockdown were restored by mutant NPM-T198A expression. Thus, we demonstrate that the reduction in NPM protein expression blocks cellular growth and proliferation, whereas phosphorylation of NPM-Thr(198) is not essential for NPM's capacity to drive cell cycle progression and proliferation. Oncogene (2009) 28, 3209-3220; doi: 10.1038/onc.2009.178; published online 29 June 2009	[Weber, J. D.] Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med,Siteman Canc Ctr, St Louis, MO 63110 USA; [Weber, J. D.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Dept Internal Med,Siteman Canc Ctr, 660 S Euclid Ave,Campus Box 8069, St Louis, MO 63110 USA.	jweber@im.wustl.edu	Maggi, Leonard/L-5217-2019	Maggi, Leonard/0000-0003-0138-0984; Weber, Jason/0000-0002-1069-6983	National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research; NATIONAL CANCER INSTITUTE [R01CA120436] Funding Source: NIH RePORTER	National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Sheila Stewart, Gregory Longmore, J Alan Diehl, Martine Roussel, Charles Sherr and Gerard Zambetti for gifts of plasmid constructs, antibodies and primary TKO MEFs. In addition, we would like to thank Sheila Stewart, Helen Piwnica-Worms, Michael Tomasson and John Majors for insightful discussions throughout the course of this study. SNB was supported by the Cancer Biology Pathway. CLP was a trainee in the Lucille P Markey Special Emphasis Pathway in Human Pathobiology. JDW was funded through the National Institutes of Health and Department of Defense Era of Hope Scholar Award in Breast Cancer Research.	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Cha H, 2004, BIOCHEM J, V378, P857, DOI 10.1042/BJ20031173; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Gao H, 2005, J BIOL CHEM, V280, P10988, DOI 10.1074/jbc.M412720200; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Liu HT, 1999, CANCER LETT, V144, P45, DOI 10.1016/S0304-3835(99)00184-6; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Namboodiri VMH, 2004, ACTA CRYSTALLOGR D, V60, P2325, DOI 10.1107/S0907444904023959; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2002, MOL BIOL CELL, V13, P2016, DOI 10.1091/mbc.02-03-0036; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; Zatsepina OV, 1999, J CELL SCI, V112, P455	41	19	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3209	3220		10.1038/onc.2009.178	http://dx.doi.org/10.1038/onc.2009.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561638	Green Accepted			2022-12-28	WOS:000269673400004
J	Steinmann, S; Schulte, K; Beck, K; Chachra, S; Bujnicki, T; Klempnauer, KH				Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H			v-Myc inhibits C/EBP beta activity by preventing C/EBP beta-induced phosphorylation of the co-activator p300	ONCOGENE			English	Article						Myc; C/EBP beta; p300; HIPK2; phosphorylation	BINDING-PROTEIN-BETA; ACUTE MYELOID LEUKEMIAS; C-MYC; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; ALPHA; CELLS; PROLIFERATION; ASSOCIATION	Myc, a key regulator of cellular proliferation, differentiation and apoptosis, exerts its biological functions by activating or suppressing the transcription of specific sets of target genes. C/EBP transcription factors play important roles during differentiation of various cell types and have been identified as critical targets for v-Myc- and c-Myc-dependent suppression of myeloid and fat cell differentiation. Here, we have addressed the mechanism by which v-Myc suppresses the activity of C/EBP beta. We show that v-Myc is recruited to the aminoterminal domain of C/EBP beta and interferes with the cooperation of C/EBP beta and the co-activator p300 by preventing C/EBP beta-induced phosphorylation of p300. We have identified the protein kinase responsible for C/EBP beta-induced phosphorylation of p300 as homeo-domain interacting protein kinase 2 (HIPK2) and show that v-Myc displaces the kinase from the C/EBP beta-p300 complex. Overall, our findings that the modulation of the C/EBP beta-induced phosphorylation of p300 as a new mechanism of transcriptional suppression by v-Myc. Oncogene (2009) 28, 2446-2455; doi:10.1038/onc.2009.90;published online 18 May 2009	[Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de		Bujnicki, Tuyen/0000-0002-7191-8455; Schachtrup, Kristina/0000-0002-9385-8254				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Heath VJ, 2000, EXP CELL RES, V254, P91, DOI 10.1006/excr.1999.4736; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Izumi H, 2001, J CELL SCI, V114, P1533; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Reiter F, 2007, ONCOGENE, V26, P1769, DOI 10.1038/sj.onc.1209975; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tinel M, 2003, J HEPATOL, V39, P171, DOI 10.1016/S0168-8278(03)00238-1; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	57	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2446	2455		10.1038/onc.2009.90	http://dx.doi.org/10.1038/onc.2009.90			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448669				2022-12-28	WOS:000267601400003
J	Goel, VK; Ibrahim, N; Jiang, G; Singhal, M; Fee, S; Flotte, T; Westmoreland, S; Haluska, FS; Hinds, PW; Haluska, FG				Goel, V. K.; Ibrahim, N.; Jiang, G.; Singhal, M.; Fee, S.; Flotte, T.; Westmoreland, S.; Haluska, F. S.; Hinds, P. W.; Haluska, F. G.			Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice	ONCOGENE			English	Article						BRAF; p53; CDKN2A; AKT; melanoma; senescence	BRAF MUTATIONS; TUMOR SUPPRESSION; P53; ACTIVATION; SENESCENCE; INK4A; LOCUS; MDM2; INACTIVATION; INHIBITION	BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in similar to 60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus represents an important therapeutic target in melanoma. In an effort to produce a pre-clinical model of mutant BRAF function in melanoma, we have generated a mouse expressing BRAF V600E targeted to melanocytes. We show that in these transgenic mice, widespread benign melanocytic hyperplasia with histological features of nevi occurs, with biochemical evidence of senescence. Melanocytic hyperplasia progresses to overt melanoma with an incidence dependent on BRAF expression levels. Melanomas show CDKN2A loss, and genetic disruption of the CDKN2A locus greatly enhances melanoma formation, consistent with collaboration between BRAF activation and CDKN2A loss suggested from studies of human melanoma. The development of melanoma also involves activation of the Mapk and Akt signaling pathways and loss of senescence, findings that faithfully recapitulate those seen in human melanomas. This murine model of mutant BRAF-induced melanoma formation thus provides an important tool for identifying further genetic alterations that cooperates with BRAF and that may be useful in enhancing susceptibility to BRAF-targeted therapeutics in melanoma. Oncogene (2009) 28, 2289-2298; doi: 10.1038/onc.2009.95; published online 27 April 2009	[Goel, V. K.; Ibrahim, N.; Jiang, G.; Singhal, M.; Hinds, P. W.; Haluska, F. G.] Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Fee, S.; Flotte, T.; Haluska, F. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Westmoreland, S.] Harvard Univ, Sch Med, New England Primate Res Ctr, Boston, MA USA	Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Goel, VK (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	vkumargoel@gmail.com; frank.haluska@ARIAD.com			NIH [CA095798]; NATIONAL CANCER INSTITUTE [R01CA095798] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA095798 to FGH. We thank Mohammad Miri for technical assistance, Dr Louis Montoliu for the tyrosinase promoter, Dr Lynda Chin for the mouse strains, and Dr Philip Tsichlis, Dr Amit Deshpande and Dr Trevor Pemberton for useful discussions.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Chang DLF, 2007, ONCOGENE, V26, P4627, DOI 10.1038/sj.onc.1210254; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Dhawan P, 2002, CANCER RES, V62, P7335; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hingorani SR, 2003, CANCER RES, V63, P5198; Laud K, 2006, J MED GENET, V43, P39, DOI 10.1136/jmg.2005.033498; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; Tonks ID, 2003, GENESIS, V37, P131, DOI 10.1002/gene.10242; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	112	121	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2289	2298		10.1038/onc.2009.95	http://dx.doi.org/10.1038/onc.2009.95			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19398955	Green Accepted			2022-12-28	WOS:000266886300005
J	Larive, RM; Urbach, S; Poncet, J; Jouin, P; Mascre, G; Sahuquet, A; Mangeat, PH; Coopman, PJ; Bettache, N				Larive, R. M.; Urbach, S.; Poncet, J.; Jouin, P.; Mascre, G.; Sahuquet, A.; Mangeat, P. H.; Coopman, P. J.; Bettache, N.			Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion	ONCOGENE			English	Article						Syk signaling; proteomics; tyrosine kinase; tumor suppressor; cell-cell adhesion	HUMAN BREAST-CANCER; SPLEEN TYROSINE KINASE; ENDOTHELIAL-CELLS; ANTIGEN RECEPTOR; CROSS-LINKING; PROTEIN; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; PROGRESSION	The spleen tyrosine kinase Syk has predominantly been studied in hematopoietic cells in which it is involved in immunoreceptor-mediated signaling. Recently, Syk expression was evidenced in numerous nonhematopoietic cells and shown to be involved in tumor formation and progression. The Syk downstream signaling effectors in nonhematopoietic cells remain, however, to be uncovered, and were investigated using MS-based quantitative phosphoproteomics. Two strategies, based on the inhibition of the Syk catalytic activity and on the loss of Syk expression were employed to identify phosphotyrosine-dependent complexes. Quantitative measurements were obtained on 350 proteins purified with phosphotyrosine affinity columns using the SILAC method. Forty-one proteins are dependent on both Syk expression and catalytic activity and were selected as signaling effectors. They are involved in a variety of biological processes such as signal transduction, cell-cell adhesion and cell polarization. We investigated the functional involvement of Syk in cell-cell adhesion and demonstrated the phosphorylation of E-cadherin and alpha-catenin. In addition, Syk is localized at cell-cell contacts, and Syk-mediated phosphorylation of E-cadherin seems to be important for the proper localization of p120-catenin at adherens junctions. Identification of the biochemical pathways regulated by Syk in human cancer cells will help to uncover its role in tumor formation and progression. Oncogene (2009) 28, 2337-2347; doi:10.1038/onc.2009.99; published online 4 May 2009	[Bettache, N.] Univ Montpellier 2, UMR 5237, CRBM, CNRS, F-34095 Montpellier 5, France; [Larive, R. M.; Mascre, G.; Sahuquet, A.; Mangeat, P. H.; Coopman, P. J.; Bettache, N.] Univ Montpellier 1, UMR 5237, IFR 122, CNRS,CRBM,Equipe Labellisee Ligue Natl Canc 2007, F-34095 Montpellier 5, France; [Urbach, S.; Poncet, J.; Jouin, P.] Univ Montpellier 1, Inst Genom Fonct, UMR 5203, CNRS,INSERM,U661, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Bettache, N (corresponding author), Univ Montpellier 2, UMR 5237, CRBM, CNRS, Cc 107,Pl Eugene Bataillon, F-34095 Montpellier 5, France.	bettache@univ-montp2.fr	; Coopman, Peter/G-7416-2019	Larive, Romain/0000-0001-8479-209X; Bettache, Nadir/0000-0001-5426-7024; Coopman, Peter/0000-0003-3720-523X	Centre National de la Recherche Scientifique; Institut National du Cancer [PL06-111]; Ligue Nationale contre le Cancer; LNCC; Association pour la Recherche sur le Cancer (ARC)	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); LNCC; Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We thank A Morel and M Saen for skilled technical assistance; F Raynaud and C Roy for valuable technical advice; G Freiss for IRS-1 and S Baghdiguian for p65-NF-kappa B antibodies; M Dunach and A Garcia de Herreros for GST constructs; Montpellier RIO Imaging platform for image analysis. MS experiments were performed at the Functional Proteomics Platform located at the IGF. This study was supported by the Centre National de la Recherche Scientifique, the Institut National du Cancer (no. PL06-111 to PJ Coopman) and the Ligue Nationale contre le Cancer (LNCC; Equipe Labellisee Ligue 2007 to PJ Coopman). RM Larive is a recipient of a PhD fellowship funded by the LNCC and the Association pour la Recherche sur le Cancer (ARC).	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200; Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gonzalez-Mariscal L, 2007, PROG HISTOCHEM CYTO, V42, P1, DOI 10.1016/j.proghi.2007.01.001; Hoeller C, 2005, J INVEST DERMATOL, V124, P1293, DOI 10.1111/j.0022-202X.2005.23685.x; Lang ML, 2002, BIOCHEM J, V364, P517, DOI 10.1042/BJ20011696; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Peters JD, 1996, J BIOL CHEM, V271, P4755; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Schymeinsky J, 2006, BLOOD, V108, P3919, DOI 10.1182/blood-2005-12-030387; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; von Willebrand M, 1998, CELL SIGNAL, V10, P407, DOI 10.1016/S0898-6568(97)00139-3; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Xu JW, 2007, MOL ENDOCRINOL, V21, P564, DOI 10.1210/me.2006-0354; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yuan YF, 2001, CANCER RES, V61, P5558; Zolodz MD, 2004, J PROTEOME RES, V3, P743, DOI 10.1021/pr049967i; Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270	33	36	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2337	2347		10.1038/onc.2009.99	http://dx.doi.org/10.1038/onc.2009.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421152				2022-12-28	WOS:000267089100004
J	Olsson, M; Vakifahmetoglu, H; Abruzzo, PM; Hogstrand, K; Grandien, A; Zhivotovsky, B				Olsson, M.; Vakifahmetoglu, H.; Abruzzo, P. M.; Hogstrand, K.; Grandien, A.; Zhivotovsky, B.			DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis	ONCOGENE			English	Article						apoptosis; caspase-2; caspase-8; DISC; DNA damage	CYTOCHROME-C RELEASE; CELL-DEATH; P53-INDUCED PROTEIN; GENOTOXIC STRESS; HCT116 CELLS; PIDD; P53; MITOCHONDRIAL; CLEAVAGE; PATHWAY	The tumor suppressor p53 protein supports growth arrest and is able to induce apoptosis, a signaling cascade regulated by sequential activation of caspases. Mechanisms that lead from p53 to activation of individual initiator caspases are still unclear. The present model for caspase-2 activation includes PIDDosome complex formation. However, in certain experimental models, elimination of complex constituents PIDD or RAIDD did not significantly influence caspase-2 activation, suggesting the existence of an alternative activation platform for caspase-2. Here we have investigated the link between p53 and caspase-2 in further detail and report that the latter is able to utilize the CD95 DISC as an activation platform. The recruitment of caspase-8 to this complex is required for activation of caspase-2. In the experimental system used, the DISC is formed through a distinct, p53-dependent upregulation of CD95. Moreover, we show that caspase-2 and -8 cleave Bid, and that both act simultaneously upstream of mitochondrial cytochrome c release. Finally, a direct interaction between the two caspases and the ability of caspase-8 to cleave caspase-2 are demonstrated. Thus, the observed functional link between caspase-8 and -2 within the DISC represents an alternative mechanism to the PIDDosome for caspase-2 activation in response to DNA damage. Oncogene (2009) 28, 1949-1959; doi:10.1038/onc.2009.36; published online 6 April 2009	[Olsson, M.; Vakifahmetoglu, H.; Abruzzo, P. M.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Hogstrand, K.; Grandien, A.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012; Abruzzo, Provvidenza Maria/G-7009-2015	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423; Abruzzo, Provvidenza Maria/0000-0001-5242-9448	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation; Swedish Society of Medical Research; EC-FP-6; EC-FP-7	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation(European Commission); Swedish Society of Medical Research; EC-FP-6(European CommissionEuropean Commission Joint Research Centre); EC-FP-7(European Commission)	We thank Professor PH Krammer and Dr IN Lavrik (German Cancer Research Center, Heidelberg, Germany) for Abs and Dr GP Nolan (Stanford University, Stanford, CA, USA) for the Phoenix-Ampho packaging cell line. We also thank Professor Sten Orrenius for critical review of the paper and permanent support. This study was supported by grants from the Swedish Science Foundation, the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation and the EC-FP-6 (Oncodeath and Chemores) and EC-FP-7 (APO-SYS). MO is a fellow of the Swedish Society of Medical Research.	Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Borralho PM, 2007, BBA-MOL BASIS DIS, V1772, P40, DOI 10.1016/j.bbadis.2006.09.005; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Dirsch VM, 2003, CANCER RES, V63, P8869; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guerrero AD, 2008, APOPTOSIS, V13, P177, DOI 10.1007/s10495-007-0139-8; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Lamkanfi M, 2005, J BIOL CHEM, V280, P6923, DOI 10.1074/jbc.M411180200; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Park HH, 2007, ANNU REV IMMUNOL, V25, P561, DOI 10.1146/annurev.immunol.25.022106.141656; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Pop C, 2007, BIOCHEMISTRY-US, V46, P4398, DOI 10.1021/bi602623b; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	43	63	66	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1949	1959		10.1038/onc.2009.36	http://dx.doi.org/10.1038/onc.2009.36			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347032				2022-12-28	WOS:000265820900002
J	Shiue, CN; Berkson, RG; Wright, APH				Shiue, C-N; Berkson, R. G.; Wright, A. P. H.			c-Myc induces changes in higher order rDNA structure on stimulation of quiescent cells	ONCOGENE			English	Article						c-Myc; nucleolus; transcription; ribosome biogenesis; RNA polymerase I	RNA-POLYMERASE-I; RIBOSOMAL DNA; SPATIAL-ORGANIZATION; NUCLEAR-MATRIX; TRANSCRIPTION; GENES; VIVO; NUCLEOLAR; UBF; TUMORIGENESIS	c-Myc is an oncogenic transcription factor capable of activating transcription by all three nuclear RNA polymerases, thus acting as a high-level coordinator of protein synthesis capacity and cell growth rate. c-Myc recruits RNA polymerase I-related transcription factors to the rDNA when quiescent cells are stimulated to re-enter the cell cycle. Using a model system of cell lines with variable c-Myc status, we show that on stimulation c-Myc rapidly induces gene loop structures in rDNA chromatin that juxtapose upstream and downstream rDNA sequences. c-Myc activation is both necessary and sufficient for this change in rDNA chromatin conformation. c-Myc activation induces association of TTF-1 with the rDNA, and c-Myc is physically associated with induced rDNA gene loops. The origins of two or more rDNA gene loops are closely juxtaposed, suggesting the possibility that c-Myc induces nucleolar chromatin hubs. Induction of rDNA gene loops may be an early step in the reprogramming of quiescent cells as they re-enter the growth cycle.	[Shiue, C-N; Berkson, R. G.; Wright, A. P. H.] Karolinska Inst, Sch Life Sci, Sodertorns Hogskola & Dept Biosci & Nutr, SE-14189 Huddinge, Sweden	Karolinska Institutet	Wright, APH (corresponding author), Karolinska Inst, Sch Life Sci, Sodertorns Hogskola & Dept Biosci & Nutr, Alfred Nobels Alle 7, SE-14189 Huddinge, Sweden.	anthony.wright@sh.se	Berkson, Rachel/D-3438-2009; Wright, Anthony/J-8187-2015	Wright, Anthony/0000-0003-1029-9969	Taiwan Root Medical Peace Corps; Swedish Cancer Society; Karolinska Institute	Taiwan Root Medical Peace Corps; Swedish Cancer Society(Swedish Cancer Society); Karolinska Institute(Karolinska Institutet)	We thank Lars-Gunnar Larsson for the provision of rat fibroblasts HO15.15, TGR1 and Rat1MycER and Professor Dirk Eick for the generous gift of Smoxi4 cells. This work was supported by a Taiwan Fellowship from the Taiwan Root Medical Peace Corps, the Swedish Cancer Society and the research foundations of the Karolinska Institute.	Ansari A, 2005, GENE DEV, V19, P2969, DOI 10.1101/gad.1362305; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Bukhari MH, 2007, INT J EXP PATHOL, V88, P47, DOI 10.1111/j.1365-2613.2006.00522.x; CASSIDY BG, 1987, MOL CELL BIOL, V7, P2388, DOI 10.1128/MCB.7.7.2388; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; DEAN M, 1986, J BIOL CHEM, V261, P9161; Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735; Friedrich JK, 2005, J BIOL CHEM, V280, P29551, DOI 10.1074/jbc.M501595200; Gomez-Roman N, 2006, BIOCHEM SOC SYMP, V73, P141, DOI 10.1042/bss0730141; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Holzel M, 2001, EMBO REP, V2, P1125, DOI 10.1093/embo-reports/kve251; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; KEPPEL F, 1986, J MOL BIOL, V187, P15, DOI 10.1016/0022-2836(86)90402-X; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nemeth A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; O'Sullivan JM, 2004, NAT GENET, V36, P1014, DOI 10.1038/ng1411; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Shav-Tal Y, 2005, MOL BIOL CELL, V16, P2395, DOI 10.1091/mbc.E04-11-0992; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	36	55	55	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1833	1842		10.1038/onc.2009.21	http://dx.doi.org/10.1038/onc.2009.21			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19270725				2022-12-28	WOS:000265640500002
J	Checquolo, S; Palermo, R; Cialfi, S; Ferrara, G; Oliviero, C; Talora, C; Bellavia, D; Giovenco, A; Grazioli, P; Frati, L; Gulino, A; Screpanti, I				Checquolo, S.; Palermo, R.; Cialfi, S.; Ferrara, G.; Oliviero, C.; Talora, C.; Bellavia, D.; Giovenco, A.; Grazioli, P.; Frati, L.; Gulino, A.; Screpanti, I.			Differential subcellular localization regulates c-Cbl E3 ligase activity upon Notch3 protein in T-cell leukemia	ONCOGENE			English	Article						c-Cbl; E3 ligase; ubiquitinylation; Notch3; pre-TCR; T-cell leukemia	NF-KAPPA-B; PRE-TCR; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; SIGNALING PROMOTES; UBIQUITIN LIGASES; GAMMA-CHAIN; PKC-THETA; RECEPTOR; LEUKEMOGENESIS	Notch3 and pT alpha signaling events are essential for T-cell leukemogenesis and characterize murine and human T-cell acute lymphoblastic leukemia. Genetic ablation of pT alpha expression in Notch3 transgenic mice abrogates tumor development, indicating that pT alpha signaling is crucial to the Notch3-mediated leukemogenesis. Here we report a novel direct interaction between Notch3 and pT alpha. This interaction leads to the recruitment and persistence of the E3 ligase protein c-Cbl to the lipid rafts in Notch3-IC transgenic thymocytes. Conversely, deletion of pT alpha in Notch3 transgenic mice leads to cytoplasmic retention of c-Cbl that targets Notch3 protein to the proteasomal-degradative pathway. It appears that protein kinase C theta (PKC theta), by regulating tyrosine and serine phosphorylation of Cbl, is able to control its function. We report here that the increased Notch3-IC degradation correlates with higher levels of c-Cbl tyrosine phosphorylation in Notch3-IC/pT alpha(-/-) double-mutant thymocytes, which also display a decreased PKC theta activity. Our data indicate that pT alpha/pre-T-cell receptor is able to regulate the different subcellular localization of c-Cbl and, by regulating PKC theta activity, is also able to influence its ubiquitin ligase activity upon Notch3 protein. Oncogene (2010) 29, 1463-1474; doi:10.1038/onc.2009.446; published online 7 December 2009	[Frati, L.; Gulino, A.] Neuromed Inst, Pozzilli, Italy; [Checquolo, S.; Palermo, R.; Cialfi, S.; Ferrara, G.; Oliviero, C.; Talora, C.; Bellavia, D.; Giovenco, A.; Grazioli, P.; Frati, L.; Gulino, A.; Screpanti, I.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy; [Screpanti, I.] Univ Roma La Sapienza, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	IRCCS Neuromed; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Palermo, Rocco/I-5140-2016; Bellavia, Diana/AAO-6348-2021; Talora, Claduio/AIC-4932-2022; Frati, Luigi/ABI-7437-2020	Palermo, Rocco/0000-0003-0134-9370; Talora, Claduio/0000-0002-6973-2184; CHECQUOLO, Saula/0000-0001-5109-8392	Italian Association for Cancer Research (AIRC); Italian Ministry of University and Research (MIUR); PRIN; Italian Ministry of Health; European Union [LHSB-CT-2003-543410]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission)	We thank Dr A Joutel for Notch3 antibodies and Dr R Bei for purification of mouse monoclonal pT alpha antibody, Dr F Grassi for c-Cbl plasmid and Dr M Bouche for PKC theta plasmids. This work was supported by the Italian Association for Cancer Research (AIRC), the Italian Ministry of University and Research (MIUR), PRIN Program, the Italian Ministry of Health and the European Union (Euro-Thymaide FP6 Integrated Project; LHSB-CT-2003-543410).	Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Aifantis L, 1998, IMMUNITY, V9, P649, DOI 10.1016/S1074-7613(00)80662-7; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Benson RA, 2005, EUR J IMMUNOL, V35, P859, DOI 10.1002/eji.200425562; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; Campese AF, 2003, SEMIN CELL DEV BIOL, V14, P151, DOI 10.1016/S1084-9521(02)00184-2; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Gay DL, 2008, IMMUNOL RES, V42, P51, DOI 10.1007/s12026-008-8034-0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Jehn BM, 2002, J BIOL CHEM, V277, P8033, DOI 10.1074/jbc.M108552200; Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Liu YH, 1999, J IMMUNOL, V162, P7095; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rothenberg EV, 2001, NAT IMMUNOL, V2, P189, DOI 10.1038/85231; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Schweisguth F, 1999, P NATL ACAD SCI USA, V96, P11382, DOI 10.1073/pnas.96.20.11382; SPOLSKI R, 1988, EUR J IMMUNOL, V18, P295; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001	41	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1463	1474		10.1038/onc.2009.446	http://dx.doi.org/10.1038/onc.2009.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966856				2022-12-28	WOS:000275392400005
J	Kim, EY; Seo, JM; Cho, KJ; Kim, JH				Kim, E-Y; Seo, J-M; Cho, K-J; Kim, J-H			Ras-induced invasion and metastasis are regulated by a leukotriene B-4 receptor BLT2-linked pathway	ONCOGENE			English	Article						H-Ras; leukotriene B-4 receptor BLT2; ROS; metastasis; MMP-9	NF-KAPPA-B; PANCREATIC-CANCER; ONCOGENIC RAS; H-RAS; EXPRESSION; CYCLOOXYGENASE-2; PROLIFERATION; ACTIVATION; MIGRATION; MECHANISM	Ras signaling pathways are well-recognized for their involvement in cancer cell proliferation; however, considerably less is known regarding their contribution to invasion and metastasis. Here, we demonstrate that a novel BLT2, a low-affinity leukotriene B-4 receptor-linked signaling cascade involving the generation of reactive oxygen species (ROS) via Nox1, NF-kappa B stimulation and subsequent upregulation of matrix metalloproteinase-9 (MMP-9) is a potential mechanism by which Ras promotes invasion and metastasis. We found that inhibition of BLT2 signaling markedly suppressed Ras-evoked metastasis and reduced the associated mortality in mice. Consistent with the proposed role of BLT2 as a key downstream mediator of Ras signaling to metastasis, BLT2 expression alone resulted in the formation of numerous metastatic lung nodules and the nodules formation was significantly attenuated by the inhibition of MMP-9, a downstream component of BLT2. Together, our results reveal the previously unsuspected function of BLT2-linked cascade in driving oncogenic Ras-induced metastasis and would provide a valuable insight into invasion and metastasis. Oncogene (2010) 29, 1167-1178; doi: 10.1038/onc.2009.412; published online 23 November 2009	[Kim, E-Y; Seo, J-M; Cho, K-J; Kim, J-H] Korea Univ, Sch Life Sci & Biotechnol, Inflammatory Signaling Lab, Seoul 136701, South Korea	Korea University	Kim, JH (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Inflammatory Signaling Lab, 5-1 Anam Dong, Seoul 136701, South Korea.	jhongkim@korea.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208	Ministry of Education, Science, and Technology, Korea [M10751050001-08N5105-00110, 20090062880]	Ministry of Education, Science, and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Dr Takao Shimizu (University of Tokyo, Tokyo, Japan) and Dr Takehiko Yokomizo (University of Kyushu, Fukuoka, Japan) for the BLT2 expression plasmids. This work was supported by the Diseases Network Research Program (M10751050001-08N5105-00110), and the SRC-Aging and Apoptosis Research program (20090062880) from the Ministry of Education, Science, and Technology, Korea.	Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; BONDY GP, 1985, CANCER RES, V45, P6005; Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645; Bortuzzo C, 1996, BBA-LIPID LIPID MET, V1300, P240, DOI 10.1016/0005-2760(96)00003-3; BOS JL, 1989, CANCER RES, V49, P4682; Brock TG, 2007, THESCIENTIFICWORLDJO, V7, P1273, DOI 10.1100/tsw.2007.180; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253; Choi JA, 2008, FREE RADICAL BIO MED, V44, P624, DOI 10.1016/j.freeradbiomed.2007.10.041; Choi JA, 2010, CARCINOGENESIS, V31, P543, DOI 10.1093/carcin/bgp203; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ding Xian-Zhong, 2003, Mol Cancer, V2, P10, DOI 10.1186/1476-4598-2-10; Ding XZ, 2005, ANTI-CANCER DRUG, V16, P467, DOI 10.1097/00001813-200506000-00001; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Harris Randall E, 2007, Subcell Biochem, V42, P93; Hennig R, 2008, BRIT J CANCER, V99, P1064, DOI 10.1038/sj.bjc.6604655; Hennig R, 2005, NEOPLASIA, V7, P417, DOI 10.1593/neo.04559; Heukamp I, 2006, PROSTAG LEUKOTR ESS, V74, P223, DOI 10.1016/j.plefa.2006.01.005; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Iizuka Y, 2005, J BIOL CHEM, V280, P24816, DOI 10.1074/jbc.M413257200; Kim GY, 2009, ARTERIOSCL THROM VAS, V29, P915, DOI 10.1161/ATVBAHA.109.185793; Kruger A, 2005, CANCER RES, V65, P3523, DOI 10.1158/0008-5472.CAN-04-3570; KUMAR CC, 1992, CANCER RES, V52, P6877; Lee KW, 2006, INT J CANCER, V119, P1767, DOI 10.1002/ijc.22056; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Nie DT, 2001, CANCER METAST REV, V20, P195, DOI 10.1023/A:1015579209850; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Qiu H, 2006, P NATL ACAD SCI USA, V103, P6913, DOI 10.1073/pnas.0602208103; Rocconi RP, 2008, REPROD SCI, V15, P321, DOI 10.1177/1933719108316390; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Shin EH, 2006, BIOCHEM BIOPH RES CO, V348, P606, DOI 10.1016/j.bbrc.2006.07.084; SU ZZ, 1993, ONCOGENE, V8, P1211; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Tong WG, 2002, CLIN CANCER RES, V8, P3232; Van Putten V, 2001, J BIOL CHEM, V276, P1226, DOI 10.1074/jbc.M003581200; Wang MT, 2007, CANCER METAST REV, V26, P525, DOI 10.1007/s10555-007-9096-5; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Yang JQ, 2001, FREE RADICAL BIO MED, V31, P520, DOI 10.1016/S0891-5849(01)00613-X; YOKOMIZO T, 1995, J LIPID MEDIAT CELL, V12, P321, DOI 10.1016/0929-7855(95)00041-N; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200; Yoo MH, 2004, ONCOGENE, V23, P9259, DOI 10.1038/sj.onc.1208151; Yoo MH, 2001, J BIOL CHEM, V276, P24645, DOI 10.1074/jbc.M101975200; Zampetaki A, 2005, AM J PHYSIOL-HEART C, V288, pH2946, DOI 10.1152/ajpheart.00919.2004	50	44	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1167	1178		10.1038/onc.2009.412	http://dx.doi.org/10.1038/onc.2009.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935719				2022-12-28	WOS:000274912100008
J	Dujka, ME; Puebla-Osorio, N; Tavana, O; Sang, M; Zhu, C				Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.			ATM and p53 are essential in the cell-cycle containment of DNA breaks during V(D)J recombination in vivo	ONCOGENE			English	Article						V(D)J recombination; genomic instability; ATM; cell-cycle control	DOUBLE-STRAND BREAKS; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; CHROMOSOME BREAKS; HISTONE H2AX; C-MYC; DEFICIENT; MICE; RECEPTOR; LOCUS	V(D)J recombination is essential for the maturation of lymphocytes. Because of the involvement of cutting and joining DNA double strands, this recombination activity is strictly contained within the noncycling phases of the cell cycle. Such containment is crucial for the maintenance of genomic integrity. The ataxia telangiectasia mutated (ATM) gene is known to have a central role in sensing general DNA damage and mediating cell-cycle checkpoint. In this study, we investigated the role of ATM and its downstream targets in the cell-cycle control of V(D) J recombination in vivo. Our results revealed the persistence of double-strand breaks (DSBs) throughout the cell cycle in ATM(-/-) and p53(-/-) thymocytes, but the cell-cycle regulation of a V(D) J recombinase, Rag-2, was normal. The histone variant H2AX, which is phosphorylated during normal V(D) J recombination, was dispensable for containing DSBs. H2AX was still phosphorylated at V(D) J loci in the absence of ATM. Therefore, V(D) J recombination, a physiological DNA rearrangement process, activates the ATM/p53 pathway to contain DNA breaks within the noncycling cells and surprisingly this pathway is not important for containing Rag-2 activity. This study shows the dynamic multiple functions of ATM in maintaining genomic stability and preventing tumorigenesis in developing lymphocytes. Oncogene (2010) 29, 957-965; doi:10.1038/onc.2009.394; published online 16 November 2009	[Dujka, M. E.; Puebla-Osorio, N.; Tavana, O.; Sang, M.; Zhu, C.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Dujka, M. E.; Tavana, O.; Zhu, C.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Program Immunol, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Zhu, C (corresponding author), Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd,Unit 901, Houston, TX 77030 USA.	czhu@mdanderson.org		Tavana, Omid/0000-0001-8401-4546; Puebla, Nahum/0000-0001-6498-5230	NIH [CA116933, T32 CA009598-17]; Leukemia Research Foundation; American Cancer Society; NATIONAL CANCER INSTITUTE [T32CA009598, R01CA116933] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge MD Anderson Flow Cytometry Core Facility for cell sorting and the Immune Imaging Core Facility for their assistance with confocal microscopy. This study was financially supported in part by NIH Grant CA116933, the Leukemia Research Foundation, the American Cancer Society-Bonnie Kies Lymphatic System Research Scholar grant (CZ) and NIH Grant T32 CA009598-17 (MED).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Huang CY, 2007, J EXP MED, V204, P1371, DOI 10.1084/jem.20061460; Jankovic M, 2007, NAT IMMUNOL, V8, P801, DOI 10.1038/ni1498; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tsai AG, 2008, CELL, V135, P1130, DOI 10.1016/j.cell.2008.10.035; Vacchio MS, 2007, P NATL ACAD SCI USA, V104, P6323, DOI 10.1073/pnas.0611222104; Widrow RJ, 1997, CYTOMETRY, V27, P250, DOI 10.1002/(SICI)1097-0320(19970301)27:3<250::AID-CYTO6>3.0.CO;2-I; Winrow CJ, 2005, HUM MOL GENET, V14, P2671, DOI 10.1093/hmg/ddi301; Yan MS, 2006, FREE RADICAL BIO MED, V41, P640, DOI 10.1016/j.freeradbiomed.2006.05.008; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	42	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					957	965		10.1038/onc.2009.394	http://dx.doi.org/10.1038/onc.2009.394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915617				2022-12-28	WOS:000274604400003
J	Luo, YP; Zhou, H; Krueger, J; Kaplan, C; Liao, D; Markowitz, D; Liu, C; Chen, T; Chuang, TH; Xiang, R; Reisfeld, RA				Luo, Y. P.; Zhou, H.; Krueger, J.; Kaplan, C.; Liao, D.; Markowitz, D.; Liu, C.; Chen, T.; Chuang, T-H; Xiang, R.; Reisfeld, R. A.			The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression	ONCOGENE			English	Article						tumor-associated macrophages; tumor microenvironment; Fra-1; IL-6/JAK/Stat3 signaling pathway	TRANSCRIPTION FACTORS; ANTITUMOR IMMUNITY; UP-REGULATION; CANCER CELLS; MACROPHAGES; STAT3; ACTIVATION; METASTASIS; EXPRESSION; TARGETS	A growing body of evidence indicates that interactions between neoplastic cells and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) are crucial in promoting tumor cell invasion and progression. Macrophages have an ambiguous role in these processes as this M1 phenotype correlates with tumoricidal capacity, whereas TAMs of M2 phenotype exert tumor-promoting effects. In this study, we provide evidence that interactions between mouse breast tumor cells and TAMs remodel the TME, leading to the upregulation of Fra-1, a member of the FOS family of transcription factor. In turn, this proto-oncogene initiates activation of the IL-6/JAK/Stat3 signaling pathway. This creates a malignant switch in breast tumor cells, leading to increased release of proangiogenic factors MMP-9, vascular endothelial growth factor and transforming growth factor-beta from tumor cells and intensified invasion and progression of breast cancer. Proof of the concept for the crucial role played by transcription factor Fra-1 in regulating these processes was established by specific knockdown of Fra-1 with small interfering RNA, which resulted in a marked suppression of tumor cell invasion, angiogenesis and metastasis in a mouse breast cancer model. Such a strategy could eventually lead to future efficacious treatments of metastatic breast cancer. Oncogene (2010) 29, 662-673; doi: 10.1038/onc.2009.308; published online 7 December 2009	[Luo, Y. P.; Zhou, H.; Krueger, J.; Kaplan, C.; Liao, D.; Markowitz, D.; Liu, C.; Chen, T.; Chuang, T-H; Xiang, R.; Reisfeld, R. A.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA; [Luo, Y. P.; Chen, T.] Chongqing Univ Med Sci, Dept Lab Med, Chongqing, Peoples R China; [Xiang, R.] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China	Scripps Research Institute; Chongqing Medical University; Nankai University	Luo, YP (corresponding author), Scripps Res Inst, Dept Immunol & Microbial Sci, R218,IMM13,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ypluo@scripps.edu; reisfeld@scripps.edu	Chuang, Tsung-Hsien/F-9679-2010	Chen, Tingmei/0000-0003-4250-674X	National Science Foundation of China (NSFC) [30672389, 2007CB914804, 2007AA021010, 30671983]; NIH [CA 115751]; EMD Lexigen Research Center [SFP 1645]; NATIONAL CANCER INSTITUTE [R01CA127535, R01CA115751] Funding Source: NIH RePORTER	National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EMD Lexigen Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank K Cairns for editorial assistance. This work was supported by grants from the National Science Foundation of China (NSFC): Grant 30672389 (to RX), NSFC 973 program Grant 2007CB914804 (to RX), and NSFC 863 program Grant 2007AA021010 (to RX), Grant No. 30671983 from The National Natural Science Foundation of China (to YL); grant from NIH CA 115751 (to RAR); and Grant SFP 1645 from the EMD Lexigen Research Center (to RAR). This is The Scripps Research Institute's manuscript number 19572-IMM.	Adiseshaiah P, 2005, ONCOGENE, V24, P4193, DOI 10.1038/sj.onc.1208583; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Faggioli L, 2004, BBA-MOL CELL RES, V1692, P17, DOI 10.1016/j.bbamcr.2004.03.001; FRASER CC, 1995, BLOOD, V86, P183, DOI 10.1182/blood.V86.1.183.bloodjournal861183; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Guiducci C, 2005, CANCER RES, V65, P3437, DOI 10.1158/0008-5472.CAN-04-4262; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Knudsen E, 2002, EUR J HAEMATOL, V69, P284, DOI 10.1034/j.1600-0609.2002.02657.x; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kortylewski M, 2008, CURR OPIN IMMUNOL, V20, P228, DOI 10.1016/j.coi.2008.03.010; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lewen S, 2008, CANCER IMMUNOL IMMUN, V57, P507, DOI 10.1007/s00262-007-0389-x; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; VAN RN, 1989, J IMMUNOL METHODS, V124, P1; VAN RN, 1994, J IMMUNOL METHODS, V174, P83; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zerbini LF, 2003, CANCER RES, V63, P2206	36	68	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	2010	29	5					662	673		10.1038/onc.2009.308	http://dx.doi.org/10.1038/onc.2009.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19966854	Green Accepted			2022-12-28	WOS:000274223700004
J	Zhang, J; Gonit, M; Salazar, MD; Shatnawi, A; Shemshedini, L; Trumbly, R; Ratnam, M				Zhang, J.; Gonit, M.; Salazar, M. D.; Shatnawi, A.; Shemshedini, L.; Trumbly, R.; Ratnam, M.			C/EBP alpha redirects androgen receptor signaling through a unique bimodal interaction	ONCOGENE			English	Article						androgen receptor; C/EBP alpha; prostate; prostate cancer	CCAAT/ENHANCER-BINDING-PROTEIN; PROSTATE-CANCER CELLS; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL COACTIVATOR; MOLECULAR-MECHANISMS; NUCLEAR RECEPTORS; MYELOID-LEUKEMIA; GENE-EXPRESSION; TERMINAL DOMAIN	Nuclear expression of CCAAT enhancer binding protein-alpha (C/EBP alpha), which supports tissue differentiation through several antiproliferative protein-protein interactions, augurs terminal differentiation of prostate epithelial cells. C/EBP alpha is also a tumor suppressor, but in many tumors its antiproliferative interactions may be attenuated by de-phosphorylation. C/EBP alpha acts as a corepressor of the classical androgen response element (ARE)-mediated gene activation by the androgen receptor (AR), but this is paradoxical as the genotropic actions of AR are crucial not only for the growth of the prostate but also for its maintenance and function. We show that DNA-bound C/EPB alpha recruits AR to activate transcription. C/EBP alpha-dependent trans-activation by AR also overrode suppression of AREs by C/EBP alpha elsewhere in a promoter. This mechanism was remarkable in that its androgen dependence was apparently for nuclear translocation of AR; it was otherwise androgen independent, flutamide insensitive and tolerant to disruption of AR dimerization. Gene response profiles and global chromatin associations in situ supported the direct bimodal regulation of AR transcriptional signaling by C/EBP alpha. This unique mechanism explains the functional coordination between AR and C/EPB alpha in the prostate and also shows that hormone-refractory AR signaling in prostate cancer could occur through receptor tethering. Oncogene (2010) 29, 723-738; doi: 10.1038/onc.2009.373; published online 9 November 2009	[Zhang, J.; Gonit, M.; Salazar, M. D.; Trumbly, R.; Ratnam, M.] Med Univ Ohio, Dept Biochem & Canc Biol, Toledo, OH 43614 USA; [Shatnawi, A.] Duke Univ, Sch Med, Dept Pharmacol & Canc Biol, Durham, NC USA; [Shemshedini, L.] Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; [Trumbly, R.] Med Univ Ohio, Bioinformat & Proteom Genom Core Div, Toledo, OH 43614 USA	Duke University; University System of Ohio; University of Toledo	Ratnam, M (corresponding author), Med Univ Ohio, Dept Biochem & Canc Biol, Block Hlth Sci Bldg,3000 Arlington Ave, Toledo, OH 43614 USA.	manohar.ratnam@utoledo.edu	Westall, Carol A/M-9646-2013; shatnawi, Aymen/AAF-5661-2020; Trumbly, Robert/AAF-6667-2020	Trumbly, Robert/0000-0001-5618-146X	NIH [CA 103964, CA 80183]; NATIONAL CANCER INSTITUTE [R01CA080183, R01CA103964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by NIH R01 grants CA 103964 and CA 80183 to MR.	Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Baron S, 2004, J BIOL CHEM, V279, P14579, DOI 10.1074/jbc.M306143200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Chattopadhyay S, 2006, MOL ENDOCRINOL, V20, P984, DOI 10.1210/me.2005-0240; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Ettwiller L, 2007, NAT METHODS, V4, P563, DOI 10.1038/NMETH1061; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Glass CK, 2000, GENE DEV, V14, P121; Halmos B, 2002, CANCER RES, V62, P528; Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Manolagas SC, 2001, ENDOCRINOLOGY, V142, P2200, DOI 10.1210/en.142.6.2200; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osada S, 1996, J BIOL CHEM, V271, P3891; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paltoo D, 2003, CANCER LETT, V191, P67, DOI 10.1016/S0304-3835(02)00617-1; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Roy AK, 1999, VITAM HORM, V55, P309; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Safe S, 2004, PROG NUCLEIC ACID RE, V77, P1, DOI 10.1016/S0079-6603(04)77001-4; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Schuster MB, 2006, BBA-REV CANCER, V1766, P88, DOI 10.1016/j.bbcan.2006.02.003; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Shatnawi A, 2007, MOL ENDOCRINOL, V21, P635, DOI 10.1210/me.2006-0274; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Thomson AA, 2006, DIFFERENTIATION, V74, P382, DOI 10.1111/j.1432-0436.2006.00101.x; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Vlahopoulos S, 2005, J BIOL CHEM, V280, P7786, DOI 10.1074/JBC.m413992200; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Watkins PJ, 1996, CANCER RES, V56, P1063; Wettenhall JM, 2006, BIOINFORMATICS, V22, P897, DOI 10.1093/bioinformatics/btl025; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang J, 2008, PROSTATE, V68, P1206, DOI 10.1002/pros.20779	68	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					723	738		10.1038/onc.2009.373	http://dx.doi.org/10.1038/onc.2009.373			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901962	Green Accepted			2022-12-28	WOS:000274223700009
J	Lee, Y; Kim, SJ; Park, HD; Park, EH; Huang, SM; Jeon, SB; Kim, JM; Lim, DS; Koh, SS				Lee, Y.; Kim, S. J.; Park, H. D.; Park, E. H.; Huang, S. M.; Jeon, S. B.; Kim, J-M; Lim, D-S; Koh, S. S.			PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression	ONCOGENE			English	Article						PAUF; pancreatic cancer; metastasis; CXCR4; signaling	CHEMOKINE RECEPTOR CXCR4; EPIDERMAL-GROWTH-FACTOR; PROSTATE-CANCER; TUMOR-CELLS; MOUSE MODEL; BREAST; INVASION; CARCINOMA; MIGRATION; INCREASES	Pancreatic cancer is characterized by early metastatic spread, but the process of tumor cell dissemination is largely unknown. In this study we show that the soluble protein pancreatic adenocarcinoma upregulated factor (PAUF) has an important role in the metastasis and progression of the disease. Variations in the level of PAUF, either by overexpression or knockdown, resulted in altered migration, invasion and proliferation capacity of pancreatic cancer cells. Moreover, depletion of PAUF in metastatic cells dramatically abrogated the spread of the cells to distant organs in an orthotopic xenograft mouse model. PAUF elicited the activation of the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and AKT intracellular signaling cascades and consequently their downstream transcription factors in an autocrine manner. Genome-wide expression analysis revealed that C-X-C chemokine receptor type 4 (CXCR4) expression was induced by PAUF overexpression but was repressed by PAUF knockdown. The PAUF-mediated increase in cancer cell motility was attenuated by the CXCR4 inhibitor, AMD3100, or by anti-CXCR4 antibody. Furthermore, immunohistochemical analysis of pancreatic tumor tissues clearly showed a significant positive correlation between PAUF and CXCR4 expression. Collectively, these findings indicate that PAUF enhances the metastatic potential of pancreatic cancer cells, at least in part, by upregulating CXCR4 expression.	[Lee, Y.; Kim, S. J.; Park, E. H.; Koh, S. S.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon 305806, South Korea; [Lee, Y.; Park, H. D.; Lim, D-S] Korea Adv Inst Sci & Technol, Natl Res Lab, Dept Biol Sci, Taejon 305701, South Korea; [Kim, S. J.; Koh, S. S.] Univ Sci & Technol, Sch Sci, Taejon, South Korea; [Park, H. D.; Jeon, S. B.] LG Life Sci Ltd, Taejon, South Korea; [Huang, S. M.; Kim, J-M] Chungnam Natl Univ, Dept Pathol, Canc Res Inst, Coll Med, Taejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); LG Life Sciences Ltd; Chungnam National University	Koh, SS (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, 111 Gwahangno, Taejon 305806, South Korea.	daesiklim@kaist.ac.kr; sskoh@kribb.re.kr	Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	Ministry of Education, Science and Technology, Korea	Ministry of Education, Science and Technology, Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the 21st Century Frontier Functional Human Genome Project of the Ministry of Education, Science and Technology, Korea. We thank CK Jung and MG Kang for statistical analysis, SH Kim for the luciferase reporter plasmids and HJ Hong for critiques of our work.	Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Benovic JL, 2004, CANCER CELL, V6, P429, DOI 10.1016/j.ccr.2004.10.017; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gao RP, 2005, GASTROENTEROLOGY, V129, P1019, DOI 10.1053/j.gastro.2005.06.067; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Koizumi K, 2007, CANCER SCI, V98, P1652, DOI 10.1111/j.1349-7006.2007.00606.x; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Marchesi F, 2004, CANCER RES, V64, P8420, DOI 10.1158/0008-5472.CAN-04-1343; Marshall J, 2006, CANCER-AM CANCER SOC, V107, P1207, DOI 10.1002/cncr.22133; Mashino K, 2002, CANCER RES, V62, P2937; Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Okada Y, 2004, CLIN EXP METASTAS, V21, P285, DOI 10.1023/B:CLIN.0000046131.24625.54; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Saur D, 2005, GASTROENTEROLOGY, V129, P1237, DOI 10.1053/j.gastro.2005.06.056; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sung B, 2008, CANCER RES, V68, P8938, DOI 10.1158/0008-5472.CAN-08-2155; Taichman RS, 2002, CANCER RES, V62, P1832; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; Wang Z, 2008, BRIT J CANCER, V99, P1695, DOI 10.1038/sj.bjc.6604745; Wehler T, 2006, ONCOL REP, V16, P1159; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024	54	51	57	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					56	67		10.1038/onc.2009.298	http://dx.doi.org/10.1038/onc.2009.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19784070				2022-12-28	WOS:000273373500006
J	Gaidarenko, O; Xu, Y				Gaidarenko, O.; Xu, Y.			Transcription activity is required for p53-dependent tumor suppression	ONCOGENE			English	Article						p53; transcription activity; tumor suppression; metastasis	EMBRYONIC STEM-CELLS; LI-FRAUMENI-SYNDROME; MOUSE MODEL; DNA-DAMAGE; P53 GAIN; APOPTOSIS; CANCER; MICE; PHOSPHORYLATION; ACTIVATION	As a transcription factor, the critical tumor suppressor, p53, directly regulates the transcription of hundreds of genes, leading to cell-cycle arrest, apoptosis, cellular senescence and differentiation. Although it has been assumed that p53 transcription activity is critical for tumor suppression, this assumption has been increasingly contested by recent findings of transcription-independent roles of p53 in apoptosis as well as findings that none of the mutant mice lacking important p53 transcription targets are cancer prone. On the basis of previous findings that p53 transcription activity is abolished in p53(QS) (Leu25Trp26 to Gln25Ser26) knock-in mouse cells after DNA damage, to determine the importance of transcription activity of p53 in tumor suppression, we generated knock-in mice that can conditionally express p53QS protein in a Cre-dependent manner. By breeding the knock-in mice with Lck-Cre transgenic mice that specifically express Cre in thymocytes, we show that p53-dependent suppression of thymic lymphomas is abolished in thymocytes expressing high levels of p53QS protein. In addition, p53QS protein is accumulated in some of the thymic tumors. Therefore, p53 transcription activity induced by DNA damage is required for tumor suppression. Together with the findings that the disruption of various p53-dependent functions individually fails to promote cancer, our findings indicate that various transcription-dependent functions of p53 must collaborate to efficiently suppress tumorigenesis. Oncogene (2009) 28, 4397-4401; doi: 10.1038/onc.2009.290; published online 21 September 2009	[Gaidarenko, O.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.du		Xu, Yang/0000-0001-5574-921X; Gaidarenko, Olga/0000-0002-3259-3352	NIH [R01 CA94254]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T Lin and C Chao for their help in constructing the p53QS mice. This work was supported by a NIH grant (R01 CA94254) to YX.	BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Inlay M, 2002, NAT IMMUNOL, V3, P463, DOI 10.1038/ni790; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu Y, 2005, CELL CYCLE, V4, P363, DOI 10.4161/cc.4.3.1529	28	13	13	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4397	4401		10.1038/onc.2009.290	http://dx.doi.org/10.1038/onc.2009.290			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767771	Green Accepted			2022-12-28	WOS:000272876400008
J	Chan, IH; Privalsky, ML				Chan, I. H.; Privalsky, M. L.			Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire	ONCOGENE			English	Article						hepatocellular carcinoma; thyroid hormone receptors; gene expression; mutant; dominant negative	AVIAN ERYTHROBLASTOSIS VIRUS; V-ERBA; NUCLEAR RECEPTORS; MOLECULAR-BASIS; RETINOIC ACID; HIGH-AFFINITY; HUMAN CANCER; HEPG2 CELLS; C-ERBA; RESISTANCE	Thyroid hormone receptors (TRs) are hormone-regulated transcription factors that control multiple aspects of normal physiology and development. Mutations in TRs have been identified at high frequency in certain cancers, including human hepatocellular carcinomas (HCCs). The majority of HCC-TR mutants bear lesions within their DNA recognition domains, and we have hypothesized that these lesions change the mutant receptors' target gene repertoire in a way crucial to their function as oncoproteins. Using stable cell transformants and expression array analysis, we determined that mutant TRs isolated from two different HCCs do, as hypothesized, display a target gene repertoire distinct from that of their normal TR progenitors. Only a subset of genes regulated by wild-type TRs was regulated by the corresponding HCC-TR mutants. More surprisingly, the HCC-TR mutants also gained the ability to regulate additional target genes not recognized by the wild-type receptors, and were not simply restricted to repression, but could also activate a subset of their target genes. We conclude that the TR mutants isolated from HCC have sustained multiple alterations from their normal progenitors that include not only changes in their transcriptional outputs, but also changes in the genes they target; both are likely to contribute to neoplasia. Oncogene (2009) 28, 4162-4174; doi: 10.1038/onc.2009.265; published online 14 September 2009	[Chan, I. H.; Privalsky, M. L.] Univ Calif Davis, Dept Microbiol, Coll Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Dept Microbiol, Coll Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574	Public Health Service/National Cancer Institute [R37-CA53394]; UC Davis Cancer Center Gene Expression Resource [NCI P30-CA93373]; National Institute of General Medical Sciences [T32-GM007377]; NATIONAL CANCER INSTITUTE [P30CA093373, R37CA053394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007377] Funding Source: NIH RePORTER	Public Health Service/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)United States Public Health Service); UC Davis Cancer Center Gene Expression Resource; National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are extremely grateful to Liming Liu for excellent technical assistance, Michael L Goodson for expert assistance in analysis of the array data, and Elsie L Campbell for helpful discussions. This work was supported by the Public Health Service/National Cancer Institute award R37-CA53394 and by the UC Davis Cancer Center Gene Expression Resource (NCI P30-CA93373). IHC was supported in part by a PHS predoctoral training award, T32-GM007377, from the National Institute of General Medical Sciences.	BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Berghagen H, 2002, J BIOL CHEM, V277, P49517, DOI 10.1074/jbc.M209546200; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; Brent G A, 2000, Rev Endocr Metab Disord, V1, P27, DOI 10.1023/A:1010056202122; Buchholz DR, 2006, GEN COMP ENDOCR, V145, P1, DOI 10.1016/j.ygcen.2005.07.009; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chan IH, 2006, ONCOGENE, V25, P3576, DOI 10.1038/sj.onc.1209389; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Cheng SY, 2005, TRENDS ENDOCRIN MET, V16, P176, DOI 10.1016/j.tem.2005.03.008; Cheng SY, 2003, MOL CELL ENDOCRINOL, V213, P23, DOI 10.1016/j.mce.2003.10.051; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARBY IA, 1991, IN VITRO CELL DEV B, V27, P21, DOI 10.1007/BF02630890; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; KATZ RW, 1993, J BIOL CHEM, V268, P19392; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Lin KH, 1997, ENDOCRINOLOGY, V138, P5308, DOI 10.1210/en.138.12.5308; Lin KH, 1996, ENDOCRINOLOGY, V137, P4073, DOI 10.1210/en.137.10.4073; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; Matsushita A, 2007, MOL ENDOCRINOL, V21, P865, DOI 10.1210/me.2006-0208; Meyer T, 1997, J BIOL CHEM, V272, P21090, DOI 10.1074/jbc.272.34.21090; Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549-007-9867-2; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Murata Y, 1998, Nagoya J Med Sci, V61, P103; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; PRIVALSKY ML, 2008, THRYOID HORMONE RECE; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Ricciardelli C, 2009, CANCER METAST REV, V28, P233, DOI 10.1007/s10555-009-9182-y; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Rosen MD, 2009, MOL ENDOCRINOL, V23, P1183, DOI 10.1210/me.2009-0126; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; Tsai CC, 2004, VITAM HORM, V68, P93; Uht Rosalie M, 2004, Nucl Recept, V2, P2, DOI 10.1186/1478-1336-2-2; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Ventura-Holman T, 2008, GENE, V425, P23, DOI 10.1016/j.gene.2008.08.006; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yen PM, 2003, J ENDOCRINOL INVEST, V26, P780, DOI 10.1007/BF03347365; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zhang LP, 2005, CANCER RES, V65, P457	69	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4162	4174		10.1038/onc.2009.265	http://dx.doi.org/10.1038/onc.2009.265			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19749797	Green Accepted			2022-12-28	WOS:000272876100003
J	Mielgo, A; Torres, VA; Clair, K; Barbero, S; Stupack, DG				Mielgo, A.; Torres, V. A.; Clair, K.; Barbero, S.; Stupack, D. G.			Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules	ONCOGENE			English	Article						caspase; microtubule-organizing center; centrosome; cell survival; death effector domain	INDUCED CELL-DEATH; CANCER-CELLS; PROTEASOME INHIBITOR; IN-VIVO; PROTEIN FAMILY; LEUKEMIA-CELLS; LYMPHOID-CELLS; LUNG-CANCER; ACTIVATION; RECEPTOR	Microtubule-perturbing drugs have become front-line chemotherapeutics, inducing cell-cycle crisis as a major mechanism of action. However, these agents show pleiotropic effects on cells and can induce apoptosis through other means. Paclitaxel, a microtubule-stabilizing agent, induces a caspase-dependent apoptosis, although the precise mechanism(s) remain unclear. Here, we used genetic approaches to evaluate the role of caspase 8 in paclitaxel-mediated apoptosis. We observed that caspase 8-expressing cells are more sensitive to paclitaxel than caspase 8-deficient cells. Mechanistically, caspase 8 was found associated with microtubules, and this interaction increased after paclitaxel treatment. The prodomains death effector domains (DEDs) of caspase 8 were sufficient for interaction with microtubules, but the caspase 8 holoprotein was required for apoptosis. DED-only forms of caspase 8 were found in both primary and tumor cell lines, associating with perinuclear microtubules and the centrosome. Microtubule association, and paclitaxel sensitivity, depends on a critical lysine (K156) within a microtubule-binding motif (KLD) in DED-b of caspase 8. The results show an unexpected pathway of apoptosis mediated by caspase 8. Oncogene (2009) 28, 3551-3562; doi: 10.1038/onc.2009.210; published online 10 August 2009	[Stupack, D. G.] Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, Sch Med, La Jolla, CA 92093 USA; [Mielgo, A.; Torres, V. A.; Clair, K.; Barbero, S.; Stupack, D. G.] Univ Calif San Diego, Sch Med, Moores Comprehens Canc Ctr, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Stupack, DG (corresponding author), Univ Calif San Diego, Dept Pathol, Moores Canc Ctr, Sch Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	dstupack@ucsd.edu	Torres, Vicente/I-2437-2013	Torres, Vicente A/0000-0002-5973-7248	NIH/NCI [CA107263]; Swiss National Foundation; Novartis Foundation; Caja Madrid Foundation; NATIONAL CANCER INSTITUTE [R01CA107263] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Foundation(Swiss National Science Foundation (SNSF)); Novartis Foundation(Novartis); Caja Madrid Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the NIH/NCI Grant CA107263 to DGS and by grants from the Swiss National Foundation, the Novartis Foundation and the Caja Madrid Foundation to AM. The authors thank Drs S Zeitlin and M Hogan for helpful comments and Drs Marcus Peter (Ben May Institute), Jill Lahti (St Jude Children's Research Hospital), Mark Ginsberg (UCSD) and Guy Salvesen (The Burnham Institute) for the kind gift of reagents.	Al-Bassam J, 2002, J CELL BIOL, V157, P1187, DOI 10.1083/jcb.200201048; Al-Bassam J, 2003, J CELL BIOL, V163, P743, DOI 10.1083/jcb.200308020; Barbero S, 2008, J BIOL CHEM, V283, P13031, DOI 10.1074/jbc.M800549200; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Bayless KJ, 2004, J BIOL CHEM, V279, P11686, DOI 10.1074/jbc.M308373200; Beisner DR, 2003, J IMMUNOL, V171, P247, DOI 10.4049/jimmunol.171.1.247; Blaineau C, 2007, CURR BIOL, V17, P778, DOI 10.1016/j.cub.2007.03.048; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; Calvaruso G, 2006, MOL CELL BIOCHEM, V287, P13, DOI 10.1007/s11010-005-9016-3; Carrington PE, 2006, MOL CELL, V22, P599, DOI 10.1016/j.molcel.2006.04.018; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Feng GP, 2000, J CLIN INVEST, V105, P329, DOI 10.1172/JCI7398; Garvey TL, 2002, VIROLOGY, V300, P217, DOI 10.1006/viro.2002.1518; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gdynia G, 2007, MOL CANCER RES, V5, P1232, DOI 10.1158/1541-7786.MCR-07-0343; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Hetz CA, 2002, J CELL SCI, V115, P4671, DOI 10.1242/jcs.00153; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kasibhatla S, 2007, CANCER RES, V67, P5865, DOI 10.1158/0008-5472.CAN-07-0127; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kim M, 2008, CANCER RES, V68, P3440, DOI 10.1158/0008-5472.CAN-08-0014; Kretschmar CS, 2004, J CLIN ONCOL, V22, P4119, DOI 10.1200/JCO.2004.08.174; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Mitsui C, 2001, J NEUROSCI RES, V66, P601, DOI 10.1002/jnr.10008; Nimmanapalli R, 2001, CANCER RES, V61, P759; Odoux C, 2002, INT J CANCER, V97, P458, DOI 10.1002/ijc.1640; Odoux C, 2004, VITAM HORM, V67, P385; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Pellegrini M, 2005, BLOOD, V106, P1581, DOI 10.1182/blood-2005-01-0284; Petit I, 2008, BLOOD, V111, P1951, DOI 10.1182/blood-2007-05-089219; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Shikama Y, 2002, BIOCHEM BIOPH RES CO, V291, P484, DOI 10.1006/bbrc.2002.6482; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Singh TR, 2003, CANCER RES, V63, P5390; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200; Teitz T, 2002, ONCOGENE, V21, P1848, DOI 10.1038/sj.onc.1205180; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Torres VA, 2008, J BIOL CHEM, V283, P36280, DOI 10.1074/jbc.M805878200; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Voortman J, 2007, MOL CANCER THER, V6, P2103, DOI 10.1158/1535-7163.MCT-07-0167; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yao Z, 2007, EMBO J, V26, P1068, DOI 10.1038/sj.emboj.7601571; Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007	55	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3551	3562		10.1038/onc.2009.210	http://dx.doi.org/10.1038/onc.2009.210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19668227	Green Accepted			2022-12-28	WOS:000270851700004
J	Switzer, CH; Ridnour, LA; Cheng, RYS; Sparatore, A; Del Soldato, P; Moody, TW; Vitek, MP; Roberts, DD; Wink, DA				Switzer, C. H.; Ridnour, L. A.; Cheng, R. Y. S.; Sparatore, A.; Del Soldato, P.; Moody, T. W.; Vitek, M. P.; Roberts, D. D.; Wink, D. A.			Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity	ONCOGENE			English	Article						dithiolethione; PP2A; Akt; cancer; breast; lung	PROTEIN PHOSPHATASE 2A; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-SUPPRESSOR; HEME OXYGENASE-1; KINASE-B; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNITS; 3T3-L1 ADIPOCYTES; C-MYC; PATHWAY	The chemopreventative effects of dithiolethione compounds are attributed to their activation of antioxidant response elements (AREs) by reacting with the Nrf2/Keap1 protein complex. In this study, we show anti-proliferative effects of the dithiolethione compound ACS1 in human cancer cell lines (A549 and MDA-MB-231) by increasing the activity of the tumor suppressor protein phoshatase 2A (PP2A). ACS-1 inhibited epidermal growth factor (EGF)-induced cellular proliferation in a concentration-and time-dependent manner. Akt activation, as determined by serine-473 phosphorylation, was inhibited by ACS-1 in cells stimulated with either EGF or fibronectin. Furthermore, ACS-1 inhibited mammalian target of rapamycin signaling and decreased c-myc protein levels. ACS-1 did not proximally alter EGF receptor or integrin signaling, but caused a concentration-dependent increase in PP2A activity. The effect of ACS-1 on Akt activation was not observed in the presence of the PP2A inhibitor okadaic acid. ACS-1 effects on PP2A activity were independent of ARE activation and cAMP formation. In addition to ACS-1, other dithiolethione compounds showed similar effects in reducing Akt activation, suggesting that this class of compounds may have other effects beyond chemoprevention. Oncogene (2009) 28, 3837-3846; doi:10.1038/onc.2009.244; published online 24 August 2009	[Switzer, C. H.; Ridnour, L. A.; Cheng, R. Y. S.; Wink, D. A.] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; [Sparatore, A.] Univ Milan, Dipartimento Sci Farmaceut Pietro Pratesi, Milan, Italy; [Del Soldato, P.] Sulfidris, Milan, Italy; [Vitek, M. P.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; [Roberts, D. D.] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; Duke University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wink, DA (corresponding author), NCI, Radiat Biol Branch, NIH, Bldg 10,Room B3-B35, Bethesda, MD 20892 USA.	wink@mail.nih.gov	Switzer, Christopher/D-9203-2013; Roberts, David D./A-9699-2008; Sparatore, Anna/J-8634-2015; Cheng, Robert/E-9799-2013	Roberts, David D./0000-0002-2481-2981; Sparatore, Anna/0000-0003-2135-2649; Azad, Mahan/0000-0002-8633-3513; Cheng, Robert/0000-0003-0287-6439; Wink, David/0000-0002-5652-7480; Vitek, Michael/0000-0001-8140-8048; Ridnour, Lisa A./0000-0001-9446-8349	NATIONAL CANCER INSTITUTE [ZIASC009174, Z01BC010899] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC010899-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Bae EJ, 2007, HEPATOLOGY, V46, P730, DOI 10.1002/hep.21769; Bass SE, 2009, CLIN CANCER RES, V15, P1964, DOI 10.1158/1078-0432.CCR-08-1870; Busserolles J, 2006, INT J BIOCHEM CELL B, V38, P1510, DOI 10.1016/j.biocel.2006.03.013; Cai WJ, 2007, CARDIOVASC RES, V76, P29, DOI 10.1016/j.cardiores.2007.05.026; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Guadagni F, 2007, ANTICANCER RES, V27, P3147; Hamada T, 1999, AM J MED SCI, V318, P146, DOI 10.1097/00000441-199909000-00009; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Isenberg JS, 2007, BRIT J PHARMACOL, V151, P142, DOI 10.1038/sj.bjp.0707198; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim SG, 1998, BIOCHEM PHARMACOL, V55, P1585, DOI 10.1016/S0006-2952(97)00669-2; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lam S, 2002, JNCI-J NATL CANCER I, V94, P1001; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; Martin D, 2004, J BIOL CHEM, V279, P8919, DOI 10.1074/jbc.M309660200; Matsuoka Y, 2003, BRIT J PHARMACOL, V138, P1303, DOI 10.1038/sj.bjp.0705182; Moody TW, 2010, LUNG CANCER, V68, P154, DOI 10.1016/j.lungcan.2009.06.012; Paugh SW, 2006, MOL PHARMACOL, V70, P41, DOI 10.1124/mol.105.020552; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Prickett TD, 2006, J BIOL CHEM, V281, P30503, DOI 10.1074/jbc.M601054200; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sawai H, 2006, ONCOGENE, V25, P3237, DOI 10.1038/sj.onc.1209356; Schmidt A, 2006, MICROVASC RES, V71, P152, DOI 10.1016/j.mvr.2006.01.001; Trotta R, 2007, J EXP MED, V204, P2397, DOI 10.1084/jem.20070419; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Xing YN, 2008, CELL, V133, P154, DOI 10.1016/j.cell.2008.02.041; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang YS, 2008, MOL CANCER THER, V7, P3470, DOI 10.1158/1535-7163.MCT-08-0625	49	39	39	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3837	3846		10.1038/onc.2009.244	http://dx.doi.org/10.1038/onc.2009.244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19701246	Green Accepted			2022-12-28	WOS:000271248400007
J	Hegde, S; Ni, S; He, S; Yoon, D; Feng, GS; Watowich, SS; Paulson, RF; Hankey, PA				Hegde, S.; Ni, S.; He, S.; Yoon, D.; Feng, G. S.; Watowich, S. S.; Paulson, R. F.; Hankey, P. A.			Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation	ONCOGENE			English	Article						Stk; Ron; Gab2; Stat3; Pu.1; leukemia	RECEPTOR TYROSINE KINASE; FRIEND-VIRUS; LEUKEMIA VIRUS; CELLS; MICE; ACTIVATION; GROWTH; GENE; POLYCYTHEMIA; GATA-1	Leukemogenesis requires two classes of mutations, one that promotes proliferation and one that blocks differentiation. The erythroleukemia induced by Friend virus is a multi-stage disease characterized by an early proliferative stage driven by the interaction of the viral glycoprotein, gp55, with Sf-Stk and the EpoR, and a late block to differentiation resulting from retroviral insertion in the Pu.1 locus. We demonstrate here that activation of Stat3 by Sf-Stk in the early stage of disease is essential for the progression of erythroleukemia in the presence of differentiation signals induced by the EpoR, but is dispensable in the late stages of the disease. Furthermore, we identify Pu.1 as a Stat3 target gene in the early stages of erythroleukemia development. Our results support a model whereby the activation of Stat3 in the early stage of disease plays a pivotal role in regulating differentiation through the upregulation of Pu.1, thus inhibiting differentiation and favoring the expansion of infected erythroblasts and enhancing the pool of progenitors available for the acquisition of additional mutations, including insertional activation of Pu.1, resulting in full leukemic transformation. Oncogene (2009) 28, 3349-3359; doi: 10.1038/onc.2009.202; published online 6 July 2009	[Hegde, S.; Ni, S.; He, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Ni, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Grad Program Immunol & Infect Dis, University Pk, PA 16802 USA; [He, S.; Paulson, R. F.; Hankey, P. A.] Penn State Univ, Grad Program Pathobiol, University Pk, PA 16802 USA; [Yoon, D.; Watowich, S. S.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Yoon, D.; Watowich, S. S.] Univ Texas MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA; [Yoon, D.; Watowich, S. S.] Grad Sch Biomed Sci, Program Immunol, Houston, TX USA; [Feng, G. S.] Burnham Inst Med Res, La Jolla, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Hankey, PA (corresponding author), Penn State Univ, Dept Vet & Biomed Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu	he, shihan/N-8067-2014	he, shihan/0000-0001-5806-8583; Watowich, Stephanie/0000-0003-1969-659X	National Institutes of Health [R01 HL066571]; Leukemia and Lymphoma Society; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066571, R01HL066471] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grant R01 HL066571 from the National Institutes of Health and by a scholar award from the Leukemia and Lymphoma Society to P Hankey.	Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; Choe KS, 2003, CANCER RES, V63, P6363; Constantinescu SN, 2003, J BIOL CHEM, V278, P43755, DOI 10.1074/jbc.M302974200; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Ni S, 2007, MOL CELL BIOL, V27, P3708, DOI 10.1128/MCB.01838-06; Panopoulos AD, 2002, J BIOL CHEM, V277, P19001, DOI 10.1074/jbc.M112271200; Papetti M, 2007, MOL CANCER RES, V5, P1053, DOI 10.1158/1541-7786.MCR-07-0145; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Shimizu R, 2004, MOL CELL BIOL, V24, P10814, DOI 10.1128/MCB.24.24.10814-10825.2004; TAMBOURIN PE, 1973, BRIT J HAEMATOL, V24, P511, DOI 10.1111/j.1365-2141.1973.tb01677.x; Teal HE, 2006, ONCOGENE, V25, P2433, DOI 10.1038/sj.onc.1209288; Yang J, 2005, CANCER RES, V65, P939; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang J, 2006, BLOOD, V107, P73, DOI 10.1182/blood-2005-05-1784; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	24	30	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3349	3359		10.1038/onc.2009.202	http://dx.doi.org/10.1038/onc.2009.202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19581930	Green Accepted			2022-12-28	WOS:000270103300002
J	Sporn, JC; Kustatscher, G; Hothorn, T; Collado, M; Serrano, M; Muley, T; Schnabel, P; Ladurner, AG				Sporn, J. C.; Kustatscher, G.; Hothorn, T.; Collado, M.; Serrano, M.; Muley, T.; Schnabel, P.; Ladurner, A. G.			Histone macroH2A isoforms predict the risk of lung cancer recurrence	ONCOGENE			English	Article						Epigenetics; chromatin; metabolism; PARP; proliferation; cancer	ONCOGENE-INDUCED SENESCENCE; CELLULAR SENESCENCE; MARKERS; P53	Lung cancer is the leading cause of cancer deaths. Despite optimal diagnosis and early treatment, many patients die of recurrent disease. There are no sufficiently useful biomarkers to predict the risk of tumor recurrence. Here, we show that expression of histone macroH2A1.1 and macroH2A2 predicts lung cancer recurrence, identifying these histone variants as a novel tool for an improved risk stratification of cancer patients. Moreover, macroH2A isoforms are highly expressed in cells undergoing senescence, a known antitumor mechanism, suggesting macroH2A1.1 may be a useful biomarker for senescent cells in tumors. Oncogene (2009) 28, 3423-3428; doi: 10.1038/onc.2009.26; published online 3 August 2009	[Sporn, J. C.; Kustatscher, G.; Ladurner, A. G.] EMBL, Gene Express Unit, D-69117 Heidelberg, Germany; [Hothorn, T.] Univ Munich, Inst Stat, Munich, Germany; [Collado, M.; Serrano, M.] Spanish Natl Canc Ctr, Madrid, Spain; [Muley, T.] Univ Heidelberg, Thoraxklin, Heidelberg, Germany; [Schnabel, P.] Univ Heidelberg, Dept Pathol, D-6900 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); University of Munich; Centro Nacional de Investigaciones Oncologicas (CNIO); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Ladurner, AG (corresponding author), EMBL, Gene Express Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	ladurner@embl.de	Serrano, Manuel/H-2634-2015; Hothorn, Torsten/A-3639-2010; Collado, Manuel/K-8140-2014	Serrano, Manuel/0000-0001-7177-9312; Hothorn, Torsten/0000-0001-8301-0471; Collado, Manuel/0000-0002-0330-0880; Ladurner, Andreas/0000-0003-3835-232X; Kustatscher, Georg/0000-0001-8955-0866	EMBL; NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity	EMBL; NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity	We thank Dr Esther Herpel for lung cancer tissue microarrays. AGL is supported by the EMBL, the NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity.	Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; D'Amico TA, 2008, ANN THORAC SURG, V85, pS737, DOI 10.1016/j.athoracsur.2007.11.047; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhu CQ, 2006, J CLIN PATHOL, V59, P790, DOI 10.1136/jcp.2005.031351	18	133	139	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3423	3428		10.1038/onc.2009.26	http://dx.doi.org/10.1038/onc.2009.26			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19648962				2022-12-28	WOS:000270103300009
J	Boily, G; He, XH; Pearce, B; Jardine, K; McBurney, MW				Boily, G.; He, X. H.; Pearce, B.; Jardine, K.; McBurney, M. W.			SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol	ONCOGENE			English	Article						oncogenesis; sirtuins; resveratrol	NF-KAPPA-B; PANCREATIC BETA-CELLS; COLON-CANCER GROWTH; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; REGULATES SIRT1; MOUSE SKIN; CELLULAR SENESCENCE; INSULIN-SECRETION	The function of the class III histone deacetylase, Sir2, in promoting lifespan extension is well established in small model organisms. By analogy, SirT1, the mammalian orthologue of Sir2, is a candidate gene to slow down aging and forestall the onset of age-associated diseases. We have used SirT1-null mice to study the function of SirT1 in susceptibility to tumorigenesis. The number of intestinal polyps induced in mice carrying the Apc(min) mutation was unaffected by the SirT1 genotype although the average polyp size was slightly smaller in the SirT1-null animals. Similarly, the presence or absence of SirT1 had no effect on incidence and tumor load of skin papillomas induced by the classical two-stage carcinogenesis protocol. We found that resveratrol topically applied to the skin profoundly reduced tumorigenesis. This chemoprotective effect was significantly reduced but not ablated in SirT1-null mice, suggesting that part of the protection afforded by resveratrol requires the SirT1-encoded protein. Thus, our results suggest that SirT1 does not behave like a classical tumor-suppressor gene but the antitumor activity of resveratrol is mediated at least in part by SirT1. Oncogene (2009) 28, 2882-2893; doi:10.1038/onc.2009.147; published online 8 June 2009	[McBurney, M. W.] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	McBurney, MW (corresponding author), Ottawa Hlth Res Inst, Ctr Canc Therapeut, Box 926,3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mmcburney@ohri.ca			Canadian Institutes of Health Research; Fonds de Recherche en Sante du Quebec (FRSQ)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	We thank Christine Pratt for allowing us to use some of her chemicals. The projects were funded by the Canadian Institutes of Health Research. GB is a recipient of fellowship from the Fonds de Recherche en Sante du Quebec (FRSQ).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Duan CM, 2005, GEN COMP ENDOCR, V142, P44, DOI 10.1016/j.ygcen.2004.12.022; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001710; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kundu JK, 2006, BIOCHEM PHARMACOL, V72, P1506, DOI 10.1016/j.bcp.2006.08.005; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Tiano HF, 2002, CANCER RES, V62, P3395; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; [王福 WANG Fu], 2008, [扬州大学学报. 自然科学版, Journal of Yangzhou University], V11, P20; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu YP, 2002, CANCER RES, V62, P1030; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang QJ, 2008, CARDIOVASC RES, V80, P191, DOI 10.1093/cvr/cvn224	60	110	112	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2882	2893		10.1038/onc.2009.147	http://dx.doi.org/10.1038/onc.2009.147			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503100				2022-12-28	WOS:000268917100004
J	Chen, J; Kobayashi, M; Darmanin, S; Qiao, Y; Gully, C; Zhao, R; Yeung, SC; Lee, MH				Chen, J.; Kobayashi, M.; Darmanin, S.; Qiao, Y.; Gully, C.; Zhao, R.; Yeung, S. C.; Lee, M. H.			Pim-1 plays a pivotal role in hypoxia-induced chemoresistance	ONCOGENE			English	Article						Pim-1; hypoxia; apoptosis; chemoresistance; mitochondrial transmembrane potential	OXYGEN DISTRIBUTION; INHIBITS APOPTOSIS; CANCER-CELLS; HUMAN TUMORS; KINASE; EXPRESSION; PHOSPHORYLATION; ACTIVATION; PROTEIN; DEATH	Hypoxia changes the responses of cancer cells to many chemotherapy agents, resulting in chemoresistance. The underlying molecular mechanism of hypoxia-induced drug resistance remains unclear. Pim-1 is a survival kinase, which phosphorylates Bad at serine 112 to antagonize drug-induced apoptosis. Here we show that hypoxia increases Pim-1 in a hypoxia-inducible factor-1 alpha-independent manner. Inhibition of Pim-1 function by dominant-negative Pim-1 dramatically restores the drug sensitivity to apoptosis induced by chemotherapy under hypoxic conditions in both in vitro and in vivo tumor models. Introduction of siRNAs for Pim-1 also resensitizes cancer cells to chemotherapy drugs under hypoxic conditions, whereas forced overexpression of Pim-1 endows solid tumor cells with resistance to cisplatin, even under normoxia. Dominant-negative Pim-1 prevents a decrease in mitochondrial transmembrane potential in solid tumor cells, which is normally induced by cisplatin (CDDP), followed by the reduced activity of Caspase-3 and Caspase-9, indicating that Pim-1 participates in hypoxia-induced drug resistance through the stabilization of mitochondrial transmembrane potential. Our results demonstrate that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance. Targeting Pim-1 may improve the chemotherapeutic strategy for solid tumors. Oncogene (2009) 28, 2581-2592; doi: 10.1038/onc.2009.124; published online 1 June 2009	[Chen, J.; Qiao, Y.; Gully, C.; Zhao, R.; Lee, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, J.; Darmanin, S.; Qiao, Y.] Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; [Chen, J.] Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; [Kobayashi, M.] Hokkaido Univ, Div Canc Biol, Inst Med Genet, Sapporo, Hokkaido, Japan; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University; Hokkaido University; Hokkaido University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; mhlee@mdanderson.org	Yeung, Sai-Ching/AAI-6178-2021; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Lee, Mong-Hong/0000-0001-8675-8215	NIHRO1CA [089266]; Japan Society for the Promotion of Science (JSPS); Japanese Ministry of Education, Culture, Sports, Science and Technology; US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs [DOD SIDA BC062166]; Cancer Center Core [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA089266, R56CA089266] Funding Source: NIH RePORTER	NIHRO1CA; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs(United States Department of Defense); Cancer Center Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NIHRO1CA (089266 Lee MH), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (Chen J), Grants-in-Aid for Cancer Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Kobayashi M), US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs (DOD SIDA BC062166 Yeung SJ & Lee MH) and Cancer Center Core Grant (CA16672). We thank Dr BQ Vuong for providing the pCDNA3.1-His-SOCS1 plasmid. We thank Mrs Shirley Ware-Gully for her assistance in preparing the article.	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; BANDYOPADHYAY RS, 1995, BBA-GENE STRUCT EXPR, V1264, P72, DOI 10.1016/0167-4781(95)00116-X; Cardenas-Navia LI, 2004, CANCER RES, V64, P6010, DOI 10.1158/0008-5472.CAN-03-0947; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; CHEN J, 2009, AM J PATHOL IN PRESS; Comerford KM, 2002, CANCER RES, V62, P3387; CUYPERS HT, 1984, CELL, V37, P141; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Eichmann A, 2000, ONCOGENE, V19, P1215, DOI 10.1038/sj.onc.1203355; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; KOH WJ, 1992, INT J RADIAT ONCOL, V22, P199, DOI 10.1016/0360-3016(92)91001-4; KOONG AC, 1994, CANCER RES, V54, P1425; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Pierce AC, 2008, J MED CHEM, V51, P1972, DOI 10.1021/jm701248t; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; TEICHER BA, 1981, CANCER RES, V41, P73; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUPEL P, 1991, CANCER RES, V51, P3316; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YOSHIDA A, 1989, J SURG ONCOL, V41, P1, DOI 10.1002/jso.2930410104; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	37	80	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2581	2592		10.1038/onc.2009.124	http://dx.doi.org/10.1038/onc.2009.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19483729	Green Accepted			2022-12-28	WOS:000268058900004
J	Naidu, SR; Love, IM; Imbalzano, AN; Grossman, SR; Androphy, EJ				Naidu, S. R.; Love, I. M.; Imbalzano, A. N.; Grossman, S. R.; Androphy, E. J.			The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells	ONCOGENE			English	Article						chromatin remodeling; p53; proteasomal degradation	CREB-BINDING-PROTEIN; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; RETINOBLASTOMA PROTEIN; CYCLE PROGRESSION; GENE ACTIVATION; RNAI SCREEN; STEM-CELLS; IN-VIVO	The tumor suppressor p53 preserves genome integrity by inducing transcription of genes controlling growth arrest or apoptosis. Transcriptional activation involves nucleosomal perturbation by chromatin remodeling enzymes. Mammalian SWI/SNF remodeling complexes incorporate either the Brahma-related gene 1(BRG1) or Brahma (Brm) as the ATPase subunit. The observation that tumor cell lines harboring wild-type p53 specifically maintain expression of BRG1 and that BRG1 complexes with p53 prompted us to examine the role of BRG1 in regulation of p53. Remarkably, RNAi depletion of BRG1, but not Brm, led to the activation of endogenous wild-type p53 and cell senescence. We found a proline-rich region unique to BRG1 was required for binding to the histone acetyl transferase protein, CBP, as well as to p53. Ectopic expression of a proline-rich region deletion mutant BRG1 that is defective for CBP binding inhibited p53 destabilization. Importantly, RNAi knockdown of BRG1 and CBP reduced p53 poly-ubiquitination in vivo. In support of p53 inactivation by the combined activities of BRG1 and CBP, we show that DNA damage signals promoted disassociation of BRG1 from CBP, thereby allowing p53 accumulation. Our data demonstrate a novel function of the evolutionarily conserved chromatin remodeling subunit BRG1, which cooperates with CBP to constrain p53 activity and permit cancer cell proliferation. Oncogene ( 2009) 28, 2492-2501; doi: 10.1038/onc.2009.121; published online 18 May 2009	[Naidu, S. R.; Love, I. M.; Grossman, S. R.; Androphy, E. J.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; [Imbalzano, A. N.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Grossman, S. R.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Androphy, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, 364 Plantation St,LRB 328, Worcester, MA 01605 USA.	elliot.androphy@umassmed.edu		Naidu, Samisubbu/0000-0001-9411-660X; Androphy, Elliot/0000-0002-8104-0703	SRG [R01 CA107532]; ANI [R01 GM56244]; EJA [R01 CA107394]; NATIONAL CANCER INSTITUTE [R01CA107394, R01CA107532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	SRG; ANI; EJA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Marius Pop and Andrew King for CBP and p300 shRNA, Andrew Turnell for GST-CBP fusion constructs, Yuval Bibi Nitzan for comments and assistance with the figures and Neal Silverman for assistance with baculovirus protein production. R01 CA107532 to SRG, R01 GM56244 to ANI and R01 CA107394 to EJA supported this work.	Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hussain MA, 2006, MOL CELL BIOL, V26, P7747, DOI 10.1128/MCB.02353-05; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; LANE DP, 1992, NATURE, V358, P16; Le Cam L, 2006, CELL, V127, P775, DOI 10.1016/j.cell.2006.09.031; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Papamichos-Chronakis M, 2006, GENE DEV, V20, P2437, DOI 10.1101/gad.1440206; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Szutorisz H, 2006, CELL, V127, P1375, DOI 10.1016/j.cell.2006.10.045; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	88	95	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2492	2501		10.1038/onc.2009.121	http://dx.doi.org/10.1038/onc.2009.121			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448667	Green Accepted			2022-12-28	WOS:000267806800002
J	Gong, Y; Sun, Y; McNutt, MA; Sun, Q; Hou, L; Liu, H; Shen, Q; Ling, Y; Chi, Y; Zhang, B				Gong, Y.; Sun, Y.; McNutt, M. A.; Sun, Q.; Hou, L.; Liu, H.; Shen, Q.; Ling, Y.; Chi, Y.; Zhang, B.			Localization of TEIF in the centrosome and its functional association with centrosome amplification in DNA damage, telomere dysfunction and human cancers	ONCOGENE			English	Article						centrosome; DNA damage; telomere dysfunction; cancer	CHROMOSOMAL INSTABILITY; GENETIC INSTABILITY; TUMOR-VIRUSES; I TAX; PROTEINS; 11Q13; CELLS; MICROTUBULE; ONCOGENE; KINASE	Centrosome amplification and telomere shortening, which are commonly detected in human cancers, have been implicated in the induction of chromosome instability in tumorigenesis. The functions of these two structures are closely related to DNA damage repair machinery, and some factors that operate in the maintenance of telomeres also take part in the regulation of centrosome status, suggesting they are functionally linked. We report that TEIF (telomerase transcriptional elements-interacting factor), a transactivator of the hTERT (human telomerase reverse transcriptase subunit) gene, is distributed in the centrosome throughout the cell cycle, but its transport into the centrosome is increased under some conditions, and its distribution is dependent on its C-terminal domain. Experimental modulation of TEIF expression through overexpression, polypeptide expression or depletion affected centrosome status and increased abnormalities of cell mitosis. Localization of TEIF to the centrosome was also stimulated by treatment with genotoxic agents and experimental telomere dysfunction, accompanying centrosome amplification. Moreover, we demonstrated that the expression level of TEIF is not only closely correlated with centrosome amplification in soft tissue sarcomas but it is also significantly related to tumor histologic grade. Our data confirmed TEIF functions as a centrosome regulator. Its participation in DNA damage response, including telomere dysfunction and tumorigenesis, indicates TEIF is likely to be a factor involved in linking centrosome amplification and telomere dysfunction in cancer development.	[Gong, Y.; Sun, Y.; McNutt, M. A.; Sun, Q.; Hou, L.; Liu, H.; Shen, Q.; Ling, Y.; Chi, Y.; Zhang, B.] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China	Peking University	Zhang, B (corresponding author), Peking Univ, Dept Pathol, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	zhangbo@bjmu.edu.cn			National Natural Science Foundation of China [30570691]; Doctors Program Foundations of Ministry Education [20040001147]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctors Program Foundations of Ministry Education	This research was supported by National Natural Science Foundation of China (no. 30570691), and Doctors Program Foundations of Ministry Education (Grant 20040001147).	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Churikov D, 2006, MOL CELL BIOL, V26, P6971, DOI 10.1128/MCB.01011-06; Dou Z, 2004, FEBS LETT, V572, P51, DOI 10.1016/j.febslet.2004.06.092; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fletcher L, 2006, CANCER LETT, V243, P1, DOI 10.1016/j.canlet.2006.01.006; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gillingham AK, 2000, EMBO REP, V1, P524; Gisselsson D, 2005, CELL CYCLE, V4, P1007, DOI 10.4161/cc.4.8.1884; Gisselsson D, 2005, GENE CHROMOSOME CANC, V42, P22, DOI 10.1002/gcc.20094; Gisselsson D, 2004, BRIT J CANCER, V91, P327, DOI 10.1038/sj.bjc.6601803; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2002, BRIT J CANCER, V87, P202, DOI 10.1038/sj.bjc.6600438; GISSELSSON D, 2001, ATLAS GENETICS CYTOG; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hara T, 2008, CANCER SCI, V99, P1155, DOI 10.1111/j.1349-7006.2008.00798.x; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lou Y, 2004, BIOCHEM BIOPH RES CO, V321, P495, DOI 10.1016/j.bbrc.2004.06.171; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; McPherson JP, 2006, HUM MOL GENET, V15, P831, DOI 10.1093/hmg/ddl002; Momotani K, 2008, BIOCHEM J, V412, P265, DOI 10.1042/BJ20071501; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Ohta T, 2002, J CELL BIOL, V156, P87, DOI 10.1083/jcb.200108088; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Plug-DeMaggio AW, 2004, ONCOGENE, V23, P3561, DOI 10.1038/sj.onc.1207388; Pumfery A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-50; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Slijepcevic P, 2006, DNA REPAIR, V5, P1299, DOI 10.1016/j.dnarep.2006.05.038; Smith S, 1999, J CELL SCI, V112, P3649; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Tang Zhiwei, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P402; Tang ZW, 2004, BIOCHEM BIOPH RES CO, V324, P1324, DOI 10.1016/j.bbrc.2004.09.201; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Wang X, 2007, CELL DEATH DIFFER, V14, P924, DOI 10.1038/sj.cdd.4402105; Wong KF, 1999, CANCER GENET CYTOGEN, V113, P93, DOI 10.1016/S0165-4608(98)00285-4; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481; Zhao YJ, 2005, BIOCHEM BIOPH RES CO, V333, P908, DOI 10.1016/j.bbrc.2005.05.172	48	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1549	1560		10.1038/onc.2008.503	http://dx.doi.org/10.1038/onc.2008.503			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198626				2022-12-28	WOS:000264537400007
J	Gustafson, TL; Wellberg, E; Laffin, B; Schilling, L; Metz, RP; Zahnow, CA; Porter, WW				Gustafson, T. L.; Wellberg, E.; Laffin, B.; Schilling, L.; Metz, R. P.; Zahnow, C. A.; Porter, W. W.			Ha-Ras transformation of MCF10A cells leads to repression of Singleminded-2s through NOTCH and C/EBP beta	ONCOGENE			English	Article						Singleminded-2s; NOTCH; C/EBP-beta; mammary gland	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SINGLE-MINDED GENE; HUMAN-BREAST; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ONCOGENIC RAS; SELF-RENEWAL; MAMMARY; EXPRESSION	We have previously shown that Singleminded-2s (SIM2s), a member of the basic helix-loop-helix Per-Arnt-Sim (bHLH/PAS) family of transcription factors, is downregulated in breast cancer samples and has tumor suppressor activity. However, the mechanism by which SIM2s is repressed in breast cancer cells has not been determined. In this study, we show that transformation of MCF10A cells by Harvey-Ras (Ha-Ras) induces CCAAT/enhance binding protein beta (C/EBP beta) and activates the NOTCH signaling pathway to block SIM2s gene expression. NOTCH-mediated repression acts through a C-repeat binding factor 1 (CBF1)-independent mechanism, as introduction of CBF1 had no effect on SIM2s expression. Consistent with C/ebp beta-dependent inhibition of SIM2s, C/ebp beta(-/-) mouse mammary glands express high levels of SIM2s and reestablishment of C/ebp beta isoforms decreased SIM2s mRNA levels in C/ebp beta immortalized mammary epithelial cell lines. These studies illustrate a novel pathway of tumor suppressor gene silencing in Ha-Ras-transformed breast epithelial cells and identify SIM2s as a target of C/EBP beta and NOTCH signaling.	[Gustafson, T. L.; Wellberg, E.; Laffin, B.; Schilling, L.; Metz, R. P.; Porter, W. W.] Texas A&M Univ, Dept Integrat Biosci, Coll Vet Med, College Stn, TX 77843 USA; [Zahnow, C. A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Dept Oncol, Baltimore, MD USA	Texas A&M University System; Texas A&M University College Station; Johns Hopkins University; Johns Hopkins Medicine	Porter, WW (corresponding author), Texas A&M Univ, Dept Integrat Biosci, Coll Vet Med, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu	Wellberg, Elizabeth/AFQ-6450-2022	Metz, Richard/0000-0002-9876-3385	National Cancer Institute [RO1CA111551, R01CA113795]; Howard Hughes Medical Institute Predoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA113795, R01CA111551] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Howard Hughes Medical Institute Predoctoral Fellowship(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bryan and Alana Welm (Huntsman Cancer Institute, Salt Lake City, UT, USA) for the Ha-Ras parent construct, Jeff Rosen (Baylor College of Medicine, Houston, TX, USA) for providing the C/ebpb<SUP>-/-</SUP> mammary glands and Michael Lewis (Baylor College of Medicine, Houston, TX, USA) for critical reading of the paper. We also thank Keelan Anderson for technical assistance. This work was supported by awards from the National Cancer Institute RO1CA111551 (WWP), R01CA113795 (CAZ) and Howard Hughes Medical Institute Predoctoral Fellowship (TG).	Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Baldwin BR, 2004, MOL CELL BIOL, V24, P3682, DOI 10.1128/MCB.24.9.3682-3691.2004; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; CREWS S, 1992, J EXP ZOOL, V261, P234, DOI 10.1002/jez.1402610303; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Khleif SN, 1999, J IMMUNOTHER, V22, P155, DOI 10.1097/00002371-199903000-00007; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Martinez-Lacaci I, 2000, INT J CANCER, V88, P44, DOI 10.1002/1097-0215(20001001)88:1<44::AID-IJC7>3.0.CO;2-8; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIELSEN LL, 1991, CANCER RES, V51, P3762; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zahnow CA, 2002, BREAST CANCER RES, V4, P109, DOI 10.1186/bcr428; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887; Zahnow CA, 2001, CANCER RES, V61, P261; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	39	21	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1561	1568		10.1038/onc.2008.497	http://dx.doi.org/10.1038/onc.2008.497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19169276	Green Accepted			2022-12-28	WOS:000264537400008
J	Prasad, A; Park, IW; Allen, H; Zhang, X; Reddy, MVR; Boominathan, R; Reddy, EP; Groopman, JE				Prasad, A.; Park, I-W; Allen, H.; Zhang, X.; Reddy, M. V. R.; Boominathan, R.; Reddy, E. P.; Groopman, J. E.			Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells	ONCOGENE			English	Article						mantle cell lymphoma; cell cycle; cytotoxicity; apoptosis; sulfonyl compounds	INITIATION-FACTOR 4E; C-MYC; CASPASE-3 ACTIVATION; HUMAN CANCER; EXPRESSION; APOPTOSIS; PROTEIN; SURVIVAL; PATHWAY; DEATH	Mantle cell lymphoma (MCL) is characterized by the uncontrolled overexpression of cyclin D1. Styryl sulfonyl compounds have shown potent antitumor activity against MCL by inducing cell-cycle arrest and apoptosis. However, the exact molecular mechanism by which these compounds function is yet to be elucidated. Here, we show that the prototypical styryl sulfonyl compound ON 01910.Na decreased cyclin D1 and c-Myc protein levels in MCL cells, whereas mRNA levels of cyclin D1 were minimally affected. Notably, ON 01910.Na suppressed eukaryotic translation initiation factor 4E (eIF4E)-mediated cyclin D1 mRNA translation, decreased levels of phosphorylated Akt, mammalian target of Rapamycin (mTOR) and eIF4E-binding protein (eIF4E-BP), lowered the cap site binding activity of eIF4E and directly inhibited activity of phosphatidylinositol-3 kinase (PI-3K). Analysis of apoptotic signaling pathways revealed that ON 01910.Na induced the release of cytochrome c from mitochondria, altered expression of Bcl-2 family of proteins and stimulated activation of caspases. Taken together, styryl sulfonyls can cause a rapid decrease of cyclin D1 by blocking cyclin D1 mRNA translation through inhibition of the PI-3K/Akt/mTOR/eIF4E-BP signaling pathway and triggering a cytochrome c-dependent apoptotic pathway in MCL cells.	[Groopman, J. E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med,Dept Med, Boston, MA 02215 USA; [Reddy, M. V. R.; Boominathan, R.; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19122 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Groopman, JE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	jgroopma@bidmc.harvard.edu	Reddy, E. Premkumar/F-6233-2011		SBIR [1 R43 CA134108-01A1];  [CA109820]; NATIONAL CANCER INSTITUTE [R01CA109820, R43CA134108] Funding Source: NIH RePORTER	SBIR; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a charitable contribution from Mr and Mrs Henryk and Rochelle Schwarz and SBIR grant # 1 R43 CA134108-01A1. E Premkumar Reddy was supported by grant CA109820. Disclosure: Dr Groopman is a consultant to Onconova Therapeutics, Inc.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Bertoni F, 2006, HEMATOL ONCOL, V24, P22, DOI 10.1002/hon.767; Bertoni F, 2007, INT J BIOCHEM CELL B, V39, P1747, DOI 10.1016/j.biocel.2007.04.026; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brauns SC, 2005, ANTICANCER RES, V25, P4197; Campo E, 1999, SEMIN HEMATOL, V36, P115; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Kawamata N, 2007, BLOOD, V110, P2667, DOI 10.1182/blood-2005-11-026344; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEROUX D, 1991, BRIT J HAEMATOL, V77, P346, DOI 10.1111/j.1365-2141.1991.tb08582.x; Liao D. Joshua, 2007, Critical Reviews in Oncogenesis, V13, P93; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Park IW, 2007, ONCOGENE, V26, P5635, DOI 10.1038/sj.onc.1210350; Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Reddy MVR, 2008, J MED CHEM, V51, P86, DOI 10.1021/jm701077b; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; YODERHILL J, 1993, J BIOL CHEM, V268, P5566; ZUCCA E, 1995, ANN ONCOL, V6, P257, DOI 10.1093/oxfordjournals.annonc.a059155	41	62	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1518	1528		10.1038/onc.2008.502	http://dx.doi.org/10.1038/onc.2008.502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198627				2022-12-28	WOS:000264537400004
J	Ploner, C; Kofler, R; Villunger, A				Ploner, C.; Kofler, R.; Villunger, A.			Noxa: at the tip of the balance between life and death	ONCOGENE			English	Review						apoptosis; BH3-only proteins; p53	BCL-2 FAMILY-MEMBERS; ACUTE LYMPHOBLASTIC-LEUKEMIA; BH3-ONLY PROTEIN NOXA; CELL-DEATH; PROTEASOME INHIBITION; TRIGGERS APOPTOSIS; UP-REGULATION; T-CELLS; PUMA; MCL-1	Among all Bcl2 homology domain 3 (BH3)-only proteins known to date, APR/PMAIP1/Noxa, albeit showing weak proapoptotic potential on its own, appears to be crucial in fine-tuning cell death decisions by targeting the prosurvival molecule Mcl1 for proteasomal degradation. This event appears critical for cell death induction along the mitochondrial Bcl2-regulated apoptosis pathway in response to factor deprivation or DNA damage, presumably by sensitizing the cell toward the action of additional BH3-only protein family members. This review aims to summarize the function of Noxa in normal physiology, stress-induced cell death and tumorigenesis. Oncogene (2009) 27, S84-S92; doi: 10.1038/onc.2009.46	[Villunger, A.] Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria; [Ploner, C.; Kofler, R.] Innsbruck Med Univ, Div Mol Pathophysiol, Bioctr, A-6020 Innsbruck, Austria; [Kofler, R.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Div Dev Immunol, Bioctr, A-6020 Innsbruck, Austria.	andreas.villunger@i-med.ac.at		Ploner, Christian/0000-0002-0313-2960	Austrian Science Fund (FWF) [Y212-B13 START]; Doctoral College MCBO [SFB021, P18747, P18571]; Association for International Cancer Research (AICR) [EU-FP7]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Doctoral College MCBO(Austrian Science Fund (FWF)); Association for International Cancer Research (AICR)	The work in our laboratories was supported by fellowships and grants from the Austrian Science Fund (FWF): Y212-B13 START, the Doctoral College MCBO, the SFB021, projects P18747 and P18571, the Association for International Cancer Research (AICR), EU-FP7 (ApopTrain) and the Tyrolean Science Fund (TWF). We apologize to the many scientists in this field whose excellent research was not cited but was only referred to indirectly through reviews.	Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Bauer A, 2006, P NATL ACAD SCI USA, V103, P10979, DOI 10.1073/pnas.0603625103; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Coultas L, 2002, CELL DEATH DIFFER, V9, P1163, DOI 10.1038/sj.cdd.4401096; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fei PW, 2002, CANCER RES, V62, P7316; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hallaert DYH, 2007, CELL DEATH DIFFER, V14, P1958, DOI 10.1038/sj.cdd.4402211; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Huntington ND, 2007, NAT IMMUNOL, V8, P856, DOI 10.1038/ni1487; Inoue S, 2007, LEUKEMIA, V21, P1773, DOI 10.1038/sj.leu.2404760; Jansson AK, 2003, ONCOGENE, V22, P4675, DOI 10.1038/sj.onc.1206655; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Konopleva M, 2008, CANCER RES, V68, P3413, DOI 10.1158/0008-5472.CAN-07-1919; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Lee SH, 2003, APMIS, V111, P599, DOI 10.1034/j.1600-0463.2003.1110602.x; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mackus WJM, 2005, LEUKEMIA, V19, P427, DOI 10.1038/sj.leu.2403623; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; MICHALAK EM, 2009, CELL DEATH DIFFER; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Ploner C, 2008, LEUKEMIA, V22, P370, DOI 10.1038/sj.leu.2405039; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang Z, 2008, ANTICANCER RES, V28, P1667; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	56	208	215	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S84	S92		10.1038/onc.2009.46	http://dx.doi.org/10.1038/onc.2009.46			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641509	Green Accepted			2022-12-28	WOS:000268566800007
J	Sinha, S; Levine, B				Sinha, S.; Levine, B.			The autophagy effector Beclin 1: a novel BH3-only protein	ONCOGENE			English	Review						Beclin 1; autophagy; BH3-only; apoptosis; Bcl-2; tumor suppressor	PROGRAMMED CELL-DEATH; BCL-2 FAMILY PROTEINS; LIFE-SPAN EXTENSION; TUMOR-SUPPRESSOR; C-ELEGANS; 3-KINASE COMPLEX; PEPTIDE COMPLEX; JNK1-MEDIATED PHOSPHORYLATION; 1-DEPENDENT AUTOPHAGY; REGULATES AUTOPHAGY	BH3 domains were originally discovered in the context of apoptosis regulators and they mediate binding of proapoptotic Bcl-2 family members to antiapoptotic Bcl-2 family members. Yet, recent studies indicate that BH3 domains do not function uniquely in apoptosis regulation; they also function in the regulation of another critical pathway involved in cellular and tissue homeostasis called autophagy. Antiapoptotic Bcl-2 homologs downregulate autophagy through interactions with the essential autophagy effector and haploinsufficient tumor suppressor, Beclin 1. Beclin 1 contains a BH3 domain, similar to that of Bcl-2 proteins, which is necessary and sufficient for binding to antiapoptotic Bcl- 2 homologs and required for Bcl-2-mediated inhibition of autophagy. This review will summarize the evidence that the BH3 domain of Beclin 1 serves as a key structural motif that enables Bcl- 2 to function not only as an antiapoptotic protein, but also as an antiautophagy protein. Oncogene (2009) 27, S137-S148; doi: 10.1038/onc.2009.51	[Sinha, S.] N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Levine, B.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA	North Dakota State University Fargo; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Sinha, S (corresponding author), N Dakota State Univ, Dept Chem Biochem & Mol Biol, Fargo, ND 58105 USA.	Sangita.Sinha@ndsu.edu; beth.levine@utsouthwestern.edu			NIH [R21 AI78108-01, RO1 CA109618, R01 CA084254]; NATIONAL CANCER INSTITUTE [R01CA109618, R01CA084254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The work in the authors' laboratory was funded by NIH Grants R21 AI78108-01 to SS and RO1 CA109618 and R01 CA084254 to BL.	Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Bohensky J, 2007, AUTOPHAGY, V3, P207, DOI 10.4161/auto.3708; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Daniel F, 2006, WORLD J GASTROENTERO, V12, P2895, DOI 10.3748/wjg.v12.i18.2895; Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4; ESCALATINE A, 2009, AUTOPHAGY I IN PRESS; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Fujiki Y, 2007, PLANT PHYSIOL, V143, P1132, DOI 10.1104/pp.106.093864; Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200; FURUYA N, 2005, AUTOPHAGY, P242; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Harada M, 2008, EXP CELL RES, V314, P1753, DOI 10.1016/j.yexcr.2008.01.035; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; He CC, 2008, MOL BIOL CELL, V19, P5506, DOI 10.1091/mbc.E08-05-0544; Huang QL, 2003, J MOL BIOL, V332, P1123, DOI 10.1016/j.jmb.2003.08.007; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080; Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989; Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim HP, 2008, AUTOPHAGY, V4, P887, DOI 10.4161/auto.6767; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Ku B, 2008, AUTOPHAGY, V4, P519, DOI 10.4161/auto.5846; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161; Liang CG, 2008, AUTOPHAGY, V4, P268, DOI 10.4161/auto.5210; Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007; Loh J, 2005, PLOS PATHOG, V1, P80, DOI 10.1371/journal.ppat.0010010; Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352; Obara K, 2008, AUTOPHAGY, V4, P952, DOI 10.4161/auto.6790; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orvedahl A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130; Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patel S, 2008, AUTOPHAGY, V4, P20, DOI 10.4161/auto.5056; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; QU X, 2007, CELL, V128, P833; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ramakrishnan S, 2007, AUTOPHAGY, V3, P512; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schmid D, 2006, J MOL MED-JMM, V84, P194, DOI 10.1007/s00109-005-0014-4; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tannous P, 2008, P NATL ACAD SCI USA, V105, P9745, DOI 10.1073/pnas.0706802105; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730; Toth ML, 2008, AUTOPHAGY, V4, P330, DOI 10.4161/auto.5618; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang JR, 2008, AUTOPHAGY, V4, P947, DOI 10.4161/auto.6787; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Yang C, 2008, AM J PHYSIOL-RENAL, V294, pF777, DOI 10.1152/ajprenal.00590.2007; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	99	298	317	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S137	S148		10.1038/onc.2009.51	http://dx.doi.org/10.1038/onc.2009.51			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641499	Green Accepted			2022-12-28	WOS:000268566800012
J	Ostenfeld, MS; Bramsen, JB; Lamy, P; Villadsen, SB; Fristrup, N; Sorensen, KD; Ulhoi, B; Borre, M; Kjems, J; Dyrskjot, L; Orntoft, TF				Ostenfeld, M. S.; Bramsen, J. B.; Lamy, P.; Villadsen, S. B.; Fristrup, N.; Sorensen, K. D.; Ulhoi, B.; Borre, M.; Kjems, J.; Dyrskjot, L.; Orntoft, T. F.			miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors	ONCOGENE			English	Article						miRNA; bladder cancer; cell death; caspases; microarray	BREAST-CANCER; COLON-CANCER; PROSTATE-CANCER; MICRORNAS; TRANSLATION; DIAGNOSIS; LEUKEMIA; GROWTH; GENES; P53	Downregulation of miR-145 in a variety of cancers suggests a possible tumor suppressor function for this microRNA. Here, we show that miR-145 expression is reduced in bladder cancer and urothelial carcinoma in situ, compared with normal urothelium, using transcription profiling and in situ hybridization. Ectopic expression of miR-145 induced extensive apoptosis in urothelial carcinoma cell lines (T24 and SW780) as characterized by caspase activation, nuclear condensation and fragmentation, cellular shrinkage, and detachment. However, cell death also proceeded upon caspase inhibition by the pharmacological inhibitor zVAD-fmk and ectopic expression of anti-apoptotic Bcl-2, indicating the activation of an alternative caspase-independent death pathway. Microarray analysis of transcript levels in T24 cells, before the onset of cell death, showed destabilization of mRNAs enriched for miR-145 7mer target sites. Among these, direct targeting of CBFB, PPP3CA, and CLINT1 was confirmed by a luciferase reporter assay. Notably, a 22-gene signature targeted on enforced miR-145 expression in T24 cells was significantly (P < 0.00003) upregulated in 55 Ta bladder tumors with concomitant reduction of miR-145. Our data indicate that reduction in miR-145 expression may provide bladder cancer cells with a selective advantage by inhibition of cell death otherwise triggered in malignant cells. Oncogene (2010) 29, 1073-1084; doi:10.1038/onc.2009.395; published online 16 November 2009	[Ostenfeld, M. S.; Lamy, P.; Fristrup, N.; Sorensen, K. D.; Dyrskjot, L.; Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark; [Bramsen, J. B.; Villadsen, S. B.; Kjems, J.] Univ Aarhus, Dept Mol Biol, Aarhus C, Denmark; [Lamy, P.] Univ Aarhus, Bioinformat Res Ctr, BiRC, Aarhus C, Denmark; [Ulhoi, B.] Aarhus Hosp, Inst Pathol NBG, Aarhus, Denmark; [Borre, M.] Aarhus Univ Hosp, Dept Urol, Skejby, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark.	orntoft@ki.au.dk	Kjems, Jorgen/I-3490-2016; Dyrskjot, Lars/H-4922-2012	Kjems, Jorgen/0000-0003-4128-9317; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Borre, Michael/0000-0002-1519-9185	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation; Danish Cancer Society; European Community [201663]	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); European Community(European Commission)	We thank Gitte Hoj, Pamela Celis, Hanne Steen, Inge-Lis Thorsen, Gitte Stougard, and Conni Sorensen for technical assistance. We are grateful to M Jaattela for providing the pCEP4 Bcl-2 vector construct and to Thomas B Hansen for methylation analysis software. We thank the staff at the Departments of Urology, Clinical Biochemistry, and Pathology at Aarhus University Hospital. This work was supported by the Ministry of Technology and Science, The John and Birthe Meyer Foundation, the Lundbeck Foundation, and the Danish Cancer Society, and the European Community's Seventh framework program (FP7/2007-2013) under grant agreement no 201663.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hart SM, 2002, HAEMATOLOGICA, V87, P1307; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kagoshima H, 2007, DEVELOPMENT, V134, P3905, DOI 10.1242/dev.008276; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Litynska A, 2000, ACTA BIOCHIM POL, V47, P427; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mitra AP, 2007, WORLD J UROL, V25, P563, DOI 10.1007/s00345-007-0197-0; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Nuovo GJ, 2008, METHODS, V44, P39, DOI 10.1016/j.ymeth.2007.10.008; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	40	120	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	2010	29	7					1073	1084		10.1038/onc.2009.395	http://dx.doi.org/10.1038/onc.2009.395			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915607				2022-12-28	WOS:000274604400013
J	Chan, PC; Sudhakar, JN; Lai, CC; Chen, HC				Chan, P-C; Sudhakar, J. N.; Lai, C-C; Chen, H-C			Differential phosphorylation of the docking protein Gab1 by c-Src and the hepatocyte growth factor receptor regulates different aspects of cell functions	ONCOGENE			English	Article						Gab1; phosphorylation; Src; Met; Crk; HGF	FACTOR-MEDIATED INTERACTION; KINASE IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; FACTOR STIMULATION; TYROSINE KINASE; MET; ACTIVATION; IDENTIFICATION; CYTOKINE	The docking protein Grb2-associated binder1 (Gab1) has a central role in the integration of the growth-factor signaling. In this study, we aimed to examine the significance of Src-mediated Gab1 phosphorylation in the hepatocyte growth factor (HGF) signaling. Using both mutagenesis and mass spectrometry approaches, Y242, Y259, Y317, Y373 and Y627 of Gab1 were identified to be phosphorylated by c-Src. It is interesting to note that the binding of the tyrosine phosphatase SHP2 to the Y627 antagonized the effect of c-Src on the phosphorylation of the other four tyrosine residues. Moreover, the tyrosine residues predominantly phosphorylated by c-Src were different from those predominantly phosphorylated by the HGF receptor. Gab1 overexpression potentiated both mitogenic and motogenic activities of HGF. However, a Gab1 mutant with substitutions of the Src phosphorylation sites (Y242, Y259, Y317 and Y373) failed to promote HGF-induced DNA synthesis, but retained its ability to facilitate HGF-induced chemotaxis. Taken together, our results not only suggest that the phosphorylation of Gab1 by c-Src is important for HGF-induced DNA synthesis, but also provide an example to illustrate how a docking protein (for example, Gab1) is differentially phosphorylated by c-Src and a receptor tyrosine kinase to emanate full spectrum of signals to the downstream. Oncogene (2010) 29, 698-710; doi: 10.1038/onc.2009.363; published online 2 November 2009	[Chan, P-C; Chen, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Sudhakar, J. N.; Chen, H-C] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan; [Lai, C-C] Natl Chung Hsing Univ, Inst Mol Biol, Taichung 40227, Taiwan	National Chung Hsing University; National Chung Hsing University; National Chung Hsing University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, 250 Kuo Kuang Rd, Taichung 40227, Taiwan.	hcchen@nchu.edu.tw	/AGZ-4617-2022	/0000-0002-7133-8266	National Science Council, Taiwan [NSC97-3112-B-005-001, NSC97-2628-B-005-001-MY3]; National Health Research Institutes, Taiwan [NHRI-EX97-9730BI]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	We are indebted to Dr T Hirano (Osaka University, Osaka, Japan) for Gab1 cDNA and Gab1-null MEFs and Dr DL Wang (Academia Sinica, Taipei, Taiwan) for Flag-tagged SHP2 and its CS mutant. This work is supported by grants NSC97-3112-B-005-001 and NSC97-2628-B-005-001-MY3 from the National Science Council, Taiwan and NHRI-EX97-9730BI from the National Health Research Institutes, Taiwan.	Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200; Chen SY, 2006, MOL CELL BIOL, V26, P5155, DOI 10.1128/MCB.02186-05; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Eulenfeld R, 2009, J CELL SCI, V122, P55, DOI 10.1242/jcs.037226; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Kallin A, 2004, J BIOL CHEM, V279, P17897, DOI 10.1074/jbc.M312996200; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lehr S, 2004, BIOCHEMISTRY-US, V43, P12133, DOI 10.1021/bi049753e; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Machide M, 2000, J BIOL CHEM, V275, P31392, DOI 10.1074/jbc.M002817200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Montagner A, 2005, J BIOL CHEM, V280, P5350, DOI 10.1074/jbc.M410012200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Riordan SM, 2000, BIOCHEM J, V350, P925, DOI 10.1042/0264-6021:3500925; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schaeper U, 2007, P NATL ACAD SCI USA, V104, P15376, DOI 10.1073/pnas.0702555104; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Terry DE, 2004, J AM SOC MASS SPECTR, V15, P784, DOI 10.1016/j.jasms.2004.02.005; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200	31	17	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					698	710		10.1038/onc.2009.363	http://dx.doi.org/10.1038/onc.2009.363			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881549				2022-12-28	WOS:000274223700007
J	Chandarlapaty, S; Scaltriti, M; Angelini, P; Ye, Q; Guzman, M; Hudis, CA; Norton, L; Solit, DB; Arribas, J; Baselga, J; Rosen, N				Chandarlapaty, S.; Scaltriti, M.; Angelini, P.; Ye, Q.; Guzman, M.; Hudis, C. A.; Norton, L.; Solit, D. B.; Arribas, J.; Baselga, J.; Rosen, N.			Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth	ONCOGENE			English	Article						p95-HER2; Trastuzumab; breast cancer; HER2	BREAST-CANCER CELLS; MAMMARY EPITHELIUM; ANTITUMOR-ACTIVITY; FACTOR RECEPTOR; KINASE DOMAIN; NEU ONCOGENE; CYCLIN D1; HER2; EXPRESSION; MICE	The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2-overexpressing breast cancer; resistance, however, invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzumab binding epitope, has been implicated as a mechanism of resistance to the antibody. We utilized an in vivo tumor model that overexpresses p95-HER2 and showed it to be resistant to the signaling and antitumor effects of Trastuzumab. We find that both full-length and p95-HER2 interact with the HSP90 chaperone protein and are degraded in tumor cells exposed to HSP90 inhibitors in tissue culture and in vivo. Loss of expression of p95-HER2 is accompanied by downregulation of the phosphoinositide-3 kinase/AKT and extracellular signal-regulated kinase signaling pathways and inhibition of cell proliferation. Chronic administration of HSP90 inhibitors in vivo results in sustained loss of HER2 and p95-HER2 expression and inhibition of AKT activation, together with induction of apoptosis and complete inhibition of tumor growth in Trastuzumab-resistant, p95-HER2-overexpressing models. Thus, p95-HER2 is an HSP90 client protein, the expression and function of which can be effectively suppressed in vivo by HSP90 inhibitors. HSP90 inhibition is therefore a potentially effective therapeutic strategy for p95-HER2-mediated Trastuzumab-resistant breast cancer. Oncogene (2010) 29, 325-334; doi:10.1038/onc.2009.337; published online 26 October 2009	[Chandarlapaty, S.; Hudis, C. A.; Norton, L.; Solit, D. B.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, Dept Med, New York, NY 10065 USA; [Scaltriti, M.; Guzman, M.; Baselga, J.] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona, Spain; [Angelini, P.; Arribas, J.] Vall dHebron Univ Hosp, Med Oncol Res Program, Barcelona, Spain; [Angelini, P.; Arribas, J.] Autonomous Univ Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Solit, D. B.; Rosen, N.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Arribas, J.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Memorial Sloan Kettering Cancer Center; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Memorial Sloan Kettering Cancer Center; ICREA	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, Dept Med, 1275 York Ave,Room Z-1760, New York, NY 10065 USA.	rosenn@mskcc.org	Arribas, Joaquin/M-4482-2014; Rosen, Neal/ABF-2677-2020; Solit, David B./AAC-5309-2019; Hudis, Clifford/AAW-9482-2021	Arribas, Joaquin/0000-0002-0504-0664; Hudis, Clifford/0000-0001-7144-8791; Norton, Larry/0000-0003-3701-9250	National Institute of Health Program [P01-CA094060]; Breast Cancer Research Foundation; Arlene Taub; ASCO Foundation Young Investigator Award; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; ICREA Funding Source: Custom	National Institute of Health Program; Breast Cancer Research Foundation; Arlene Taub; ASCO Foundation Young Investigator Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ICREA(ICREA)	We thank Gail Lewis Phillips and Mark Sliwkowski for providing the Fo5 tumors for this study. We also thank Elisa DeStanchina and Wai Wong for their assistance with animal studies. This work is supported by the National Institute of Health Program Grant P01-CA094060, the Breast Cancer Research Foundation and the generous support of Arlene Taub. S Chandarlapaty is supported by an ASCO Foundation Young Investigator Award.	Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Baselga J, 1998, CANCER RES, V58, P2825; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Benezra R, 2005, COLD SH Q B, V70, P375, DOI 10.1101/sqb.2005.70.006; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078-0432.CCR-07-1667; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cuello M, 2001, CANCER RES, V61, P4892; Finkle D, 2004, CLIN CANCER RES, V10, P2499, DOI 10.1158/1078-0432.CCR-03-0448; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; MODI S, 2008, ASCO 2008 ANN CHIC I; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Munster PN, 2002, CANCER RES, V62, P3132; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Pegram MD, 2000, SEMIN ONCOL, V27, P21; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; RICE J, 2008, AACR ANN M SAN DIEG; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tikhomirov O, 2003, CANCER RES, V63, P39; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yakes FM, 2002, CANCER RES, V62, P4132; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	42	99	99	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					325	334		10.1038/onc.2009.337	http://dx.doi.org/10.1038/onc.2009.337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19855434	Green Accepted			2022-12-28	WOS:000273793200002
J	DeBerardinis, RJ; Cheng, T				DeBerardinis, R. J.; Cheng, T.			Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer	ONCOGENE			English	Review						glutamine; metabolism; cancer; Warburg effect; cachexia	EHRLICH ASCITES-TUMOR; AMINO-ACID; MESSENGER-RNA; AEROBIC GLYCOLYSIS; C-MYC; MOLECULAR-MECHANISMS; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; GENE-EXPRESSION; HEPATOMA-CELLS	Several decades of research have sought to characterize tumor cell metabolism in the hope that tumor-specific activities can be exploited to treat cancer. Having originated from Warburg's seminal observation of aerobic glycolysis in tumor cells, most of this attention has focused on glucose metabolism. However, since the 1950s cancer biologists have also recognized the importance of glutamine (Q) as a tumor nutrient. Glutamine contributes to essentially every core metabolic task of proliferating tumor cells: it participates in bioenergetics, supports cell defenses against oxidative stress and complements glucose metabolism in the production of macromolecules. The interest in glutamine metabolism has been heightened further by the recent findings that c-myc controls glutamine uptake and degradation, and that glutamine itself exerts influence over a number of signaling pathways that contribute to tumor growth. These observations are stimulating a renewed effort to understand the regulation of glutamine metabolism in tumors and to develop strategies to target glutamine metabolism in cancer. In this study we review the protean roles of glutamine in cancer, both in the direct support of tumor growth and in mediating some of the complex effects on whole-body metabolism that are characteristic of tumor progression. Oncogene (2010) 29, 313-324; doi:10.1038/onc.2009.358; published online 2 November 2009	[DeBerardinis, R. J.; Cheng, T.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [DeBerardinis, R. J.] Univ Texas SW Med Ctr Dallas, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	DeBerardinis, RJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, 5323 Harry Hines Blvd,Room K4-216, Dallas, TX 75390 USA.	ralph.deberardinis@utsouthwestern.edu			National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health [DK072565]; American Cancer Society [ACS-IRG-02-196]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK072565] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Roland Knoblauch and Andrew Mullen for critically reading this paper. RJD is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (DK072565) and the American Cancer Society (ACS-IRG-02-196).	Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Aiken KJ, 2008, J BIOL CHEM, V283, P10252, DOI 10.1074/jbc.M709944200; Arcella A, 2005, NEURO-ONCOLOGY, V7, P236, DOI 10.1215/S1152851704000961; ARDAWI MSM, 1989, BIOCHEM J, V261, P219, DOI 10.1042/bj2610219; Bangsbo J, 1996, AM J PHYSIOL-ENDOC M, V270, pE101, DOI 10.1152/ajpendo.1996.270.1.E101; BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; Brasse-Lagnel C, 2009, FEBS J, V276, P1826, DOI 10.1111/j.1742-4658.2009.06920.x; CHEN MK, 1993, ANN SURG, V217, P655, DOI 10.1097/00000658-199306000-00007; Damink SWMO, 2009, METAB BRAIN DIS, V24, P169, DOI 10.1007/s11011-008-9122-5; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DeBerardinis RJ, 2006, J BIOL CHEM, V281, P37372, DOI 10.1074/jbc.M608372200; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Donadio AC, 2008, J CELL BIOCHEM, V103, P800, DOI 10.1002/jcb.21449; EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501; Eliasen MM, 2006, FRONT BIOSCI-LANDMRK, V11, P3199; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Erbil Y, 2005, LIFE SCI, V78, P376, DOI 10.1016/j.lfs.2005.04.068; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gaunitz F, 2002, BIOCHEM BIOPH RES CO, V296, P1026, DOI 10.1016/S0006-291X(02)02044-2; Guerin PJ, 2006, EUR J CELL BIOL, V85, P355, DOI 10.1016/j.ejcb.2005.11.004; HIATT HH, 1957, CANCER RES, V17, P240; HOLROYDE CP, 1984, CANCER RES, V44, P5910; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; Hubert-Buron A, 2006, J NUTR, V136, P1461, DOI 10.1093/jn/136.6.1461; KANDIL HM, 1995, AM J PHYSIOL-GASTR L, V269, pG591, DOI 10.1152/ajpgi.1995.269.4.G591; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; KLIMBERG VS, 1990, J SURG RES, V48, P319, DOI 10.1016/0022-4804(90)90066-B; KNOX WE, 1969, CANCER RES, V29, P669; Kobayashi S, 2001, J NEUROCHEM, V76, P1935, DOI 10.1046/j.1471-4159.2001.00214.x; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kuhn KS, 1999, AM J CLIN NUTR, V70, P484; KVAMME E, 1960, BIOCHIM BIOPHYS ACTA, V42, P187, DOI 10.1016/0006-3002(60)90779-4; Larson SD, 2007, AM J PHYSIOL-GASTR L, V293, pG1262, DOI 10.1152/ajpgi.00254.2007; LINDERHOROWITZ M, 1969, CANCER RES, V29, P1195; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Lobo C, 2000, BIOCHEM J, V348, P257, DOI 10.1042/0264-6021:3480257; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; MATSUNO T, 1986, INT J BIOCHEM, V18, P187, DOI 10.1016/0020-711X(86)90155-2; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; MEDINA MA, 1992, MOL CELL BIOCHEM, V113, P1; Miller A L, 1999, Altern Med Rev, V4, P239; NEWSHOLME EA, 1985, Q J EXP PHYSIOL CMS, V70, P473, DOI 10.1113/expphysiol.1985.sp002935; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Nicoletti F, 2007, TRENDS PHARMACOL SCI, V28, P206, DOI 10.1016/j.tips.2007.03.008; Ohtani Y, 2008, ONCOGENE, V27, P7162, DOI 10.1038/onc.2008.329; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; PARRYBILLINGS M, 1991, INT J BIOCHEM, V23, P933, DOI 10.1016/0020-711X(91)90082-X; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; QUESADA AR, 1988, CANCER RES, V48, P1551; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; REICHARD GA, 1963, J BIOL CHEM, V238, P495; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943; Roth E, 2007, CLIN NUTR, V26, P535, DOI 10.1016/j.clnu.2007.05.007; SAUER LA, 1982, CANCER RES, V42, P4090; SAUER LA, 1983, CANCER RES, V43, P3497; Segura JA, 2005, CANCER LETT, V218, P91, DOI 10.1016/j.canlet.2004.06.054; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Skerry TM, 2001, TRENDS PHARMACOL SCI, V22, P174, DOI 10.1016/S0165-6147(00)01642-4; Soh H, 2007, J PEDIATR SURG, V42, P608, DOI 10.1016/j.jpedsurg.2006.12.010; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; SOUBA WW, 1993, ANN SURG, V218, P715, DOI 10.1097/00000658-199312000-00004; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Wang YX, 2007, BBA-GEN SUBJECTS, V1770, P594, DOI 10.1016/j.bbagen.2006.11.007; WARBURG O, 1956, SCIENCE, V124, P269; Warburg O, 1925, KLIN WOCHENSCHR, V4, P534, DOI DOI 10.1007/BF01726151; Watatani Y, 2007, LIFE SCI, V80, P879, DOI 10.1016/j.lfs.2006.11.013; Weiner ID, 2007, ANNU REV PHYSIOL, V69, P317, DOI 10.1146/annurev.physiol.69.040705.142215; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yeo JHM, 2006, BIOTECHNOL LETT, V28, P1445, DOI 10.1007/s10529-006-9110-y; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	85	860	889	9	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					313	324		10.1038/onc.2009.358	http://dx.doi.org/10.1038/onc.2009.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19881548	Green Accepted			2022-12-28	WOS:000273793200001
J	Askham, JM; Platt, F; Chambers, PA; Snowden, H; Taylor, CF; Knowles, MA				Askham, J. M.; Platt, F.; Chambers, P. A.; Snowden, H.; Taylor, C. F.; Knowles, M. A.			AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K	ONCOGENE			English	Article						AKT1; mutation; bladder cancer	PLECKSTRIN HOMOLOGY DOMAIN; CELL CARCINOMA; PH DOMAIN; IN-VIVO; KINASE; PROTEIN; ACTIVATION; DOWNSTREAM; AKT/PKB; PATHWAY	The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cancer. Recent reports have identified a transforming mutation of AKT1 in breast, colorectal, ovarian and lung cancers. We report here the occurrence of this mutation in bladder tumours. The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours. Cell lines expressing mutant AKT1 show constitutive AKT1 activation under conditions of growth factor withdrawal. We also detected a novel AKT1 mutation G145A (E49K). This mutation also enhances AKT activation and shows transforming activity in NIH3T3 cells, though activity is weaker than that of E17K. Enhanced activation of AKT1 when E17K and E49K mutations are in tandem suggests that they can co-operate.	[Askham, J. M.; Platt, F.; Knowles, M. A.] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; [Chambers, P. A.; Snowden, H.; Taylor, C. F.] St James Univ Hosp, Canc Res UK Genome Variat Lab, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk	Chambers, Philip/AAK-8549-2020	Chambers, Philip/0000-0002-0926-717X; Knowles, Margaret/0000-0002-9363-8657	Cancer Research UK [C6228/A5433]	Cancer Research UK(Cancer Research UK)	This work was funded by a Programme grant from Cancer Research UK (C6228/A5433).	Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Dong B, 2007, J BIOL CHEM, V282, P25131, DOI 10.1074/jbc.M702123200; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Knowles MA, 2003, CANCER RES, V63, P7652; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Lopez-Knowles E, 2006, CANCER RES, V66, P7401, DOI 10.1158/0008-5472.CAN-06-1182; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; PLATT FM, 2009, CLIN CAN RE IN PRESS; Pymar LS, 2008, HUM MOL GENET, V17, P2006, DOI 10.1093/hmg/ddn098; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tokuda E, 2007, CANCER RES, V67, P9666, DOI 10.1158/0008-5472.CAN-07-1050; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z	27	83	84	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					150	155		10.1038/onc.2009.315	http://dx.doi.org/10.1038/onc.2009.315			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802009				2022-12-28	WOS:000273373500014
J	Shimabe, M; Goyama, S; Watanabe-Okochi, N; Yoshimi, A; Ichikawa, M; Imai, Y; Kurokawa, M				Shimabe, M.; Goyama, S.; Watanabe-Okochi, N.; Yoshimi, A.; Ichikawa, M.; Imai, Y.; Kurokawa, M.			Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells	ONCOGENE			English	Article						Evi-1; Pbx1; leukemogenesis; target gene	MYELOID-TRANSFORMING GENE; DNA-BINDING; STEM-CELLS; PRE-B; TRANSCRIPTION FACTOR-1; TRANSLOCATION PROTEIN; ZINC FINGERS; SELF-RENEWAL; IDENTIFICATION; SEQUENCE	Ecotropic viral integration site-1 (Evi-1) is a nuclear transcription factor, which is essential for the proliferation/maintenance of hematopoietic stem cells (HSCs). Aberrant expression of Evi-1 has been frequently found in myeloid leukemia, and is associated with a poor patient survival. Recently, we reported candidate target genes of Evi-1 shared in HSCs and leukemic cells using gene expression profiling analysis. In this study, we identified Pbx1, a proto-oncogene in hematopoietic malignancy, as a target gene of Evi-1. Overexpression of Evi-1 increased Pbx1 expression in hematopoietic stem/progenitor cells. An analysis of the Pbx1 promoter region revealed that Evi-1 upregulates Pbx1 transcription. Furthermore, reduction of Pbx1 levels through RNAi-mediated knockdown significantly inhibited Evi-1-induced transformation. In contrast, knockdown of Pbx1 did not impair bone marrow transformation by E2A/HLF or AML1/ETO, suggesting that Pbx1 is specifically required for the maintenance of bone marrow transformation mediated by Evi-1. These results indicate that Pbx1 is a target gene of Evi-1 involved in Evi-1-mediated leukemogenesis. Oncogene (2009) 28, 4364-4374; doi: 10.1038/onc.2009.288; published online 21 September 2009	[Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Yoshimi, Akihide/I-3792-2019	Yoshimi, Akihide/0000-0002-0664-7281; Imai, Yoichi/0000-0002-2938-6133	Japan Society for the Promotion of Science; Health and Labour Sciences Research; Ministry of Health, Labour and Welfare; Grants-in-Aid for Scientific Research [19679004] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Health and Labour Sciences Research(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank T Kitamura for Plat-E packaging cells and pMYs-IG retrovirus vector, H Nakauchi and M Onodera for pGCDNsameGFP retroviral vector, T Inaba for E2A/HLF cDNA, SW Hiebert for AML1/ETO cDNA, D Bohmann for c-Jun cDNA, Y Shimamura for expert technical assistance, and KYOWA KIRIN for cytokines. This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and by Health and Labour Sciences Research grants from Ministry of Health, Labour and Welfare.	DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Ficara F, 2008, CELL STEM CELL, V2, P484, DOI 10.1016/j.stem.2008.03.004; FUNABIKI T, 1994, ONCOGENE, V9, P1575; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 2001, ONCOGENE, V20, P5440, DOI 10.1038/sj.onc.1204710; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Laricchia-Robbio L, 2008, BLOOD CELL MOL DIS, V40, P141, DOI 10.1016/j.bcmd.2007.07.012; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lim JH, 2005, HUM MOL GENET, V14, P2027, DOI 10.1093/hmg/ddi207; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Manley NR, 2004, DEV BIOL, V276, P301, DOI 10.1016/j.ydbio.2004.08.030; MANN RS, 1995, BIOESSAYS, V17, P855, DOI 10.1002/bies.950171007; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Nitta E, 2005, ONCOGENE, V24, P6165, DOI 10.1038/sj.onc.1208754; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Ogawa S, 1996, ONCOGENE, V13, P183; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PINTADO T, 1985, CANCER, V55, P535, DOI 10.1002/1097-0142(19850201)55:3<535::AID-CNCR2820550311>3.0.CO;2-4; Qiu Y, 2007, AM J PATHOL, V170, P152, DOI 10.2353/ajpath.2007.060722; Sato T, 2008, CANCER SCI, V99, P1407, DOI 10.1111/j.1349-7006.2008.00842.x; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Schnabel CA, 2003, DEV BIOL, V254, P262, DOI 10.1016/S0012-1606(02)00038-6; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shiraishi K, 2007, ONCOGENE, V26, P339, DOI 10.1038/sj.onc.1209800; Smith KS, 2002, MOL CELL BIOL, V22, P7678, DOI 10.1128/MCB.22.21.7678-7688.2002; SUZUKAWA K, 1994, BLOOD, V84, P2681; Takeshita M, 2008, LEUKEMIA, V22, P1241, DOI 10.1038/leu.2008.53; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Watanabe-Okochi N, 2008, BLOOD, V111, P4297, DOI 10.1182/blood-2007-01-068346; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058; Yatsula B, 2005, J BIOL CHEM, V280, P30712, DOI 10.1074/jbc.M504293200; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679	48	47	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4364	4374		10.1038/onc.2009.288	http://dx.doi.org/10.1038/onc.2009.288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767769				2022-12-28	WOS:000272876400005
J	Shah, KM; Stewart, SE; Wei, W; Woodman, CBJ; O'Neil, JD; Dawson, CW; Young, LS				Shah, K. M.; Stewart, S. E.; Wei, W.; Woodman, C. B. J.; O'Neil, J. D.; Dawson, C. W.; Young, L. S.			The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation	ONCOGENE			English	Article						EBV; NPC; interferon; endosomes; lysosomes	EPSTEIN-BARR-VIRUS; DOWN-REGULATION; CELL-RECEPTOR; 2A; ACTIVATION; CARCINOMA; SUSCEPTIBILITY; PATHOGENESIS; TRAFFICKING; ASSOCIATION	Although frequently expressed in Epstein-Barr virus (EBV)-positive malignancies, the role that latent membrane protein 2A and 2B (LMP2A and LMP2B) have in the oncogenic process remains obscure. Here we show a novel function for these proteins in epithelial cells, namely, their ability to modulate signalling from type I/II interferon receptors (IFNRs). We show that LMP2A- and LMP2B-expressing epithelial cells show decreased responsiveness to interferon (IFN)alpha and IFN gamma, as assessed by STAT1 phosphorylation, ISGF3 and GAF-mediated binding to IFN-stimulated response element and IFN gamma-activated factor sequence elements and luciferase reporter activation. Transcriptional pro. ling highlighted the extent of this modulation, with both viral proteins impacting 'globally' on IFN-stimulated gene expression. Although not affecting the levels of cell-surface IFNRs, LMP2A and LMP2B accelerated the turnover of IFNRs through processes requiring endosome acidification. This function may form part of EBV's strategy to limit anti-viral responses and de. ne a novel function for LMP2A and LMP2B in modulating signalling from receptors that participate in innate immune responses. Oncogene (2009) 28, 3903-3914; doi:10.1038/onc.2009.249; published online 31 August 2009	[Shah, K. M.; Wei, W.; Woodman, C. B. J.; O'Neil, J. D.; Dawson, C. W.; Young, L. S.] Univ Birmingham, Canc Res UK Inst Canc Studies, Sch Med, Birmingham B15 2TT, W Midlands, England; [Stewart, S. E.] Univ Edinburgh, Sch Med, Div Pathway Med, Edinburgh, Midlothian, Scotland	Cancer Research UK; University of Birmingham; University of Edinburgh	Young, LS (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	L.S.Young@bham.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298; Wei, Wenbin/0000-0003-1288-6999	Cancer Research UK; European Commission's FP6 Life Sciences Health Programme [LSHC-CT-.2005-018704]	Cancer Research UK(Cancer Research UK); European Commission's FP6 Life Sciences Health Programme	This work was supported by programme funding from Cancer Research UK and the European Commission's FP6 Life Sciences Health Programme (INCA project LSHC-CT-.2005-018704).	Adachi K, 2007, ARCH VIROL, V152, P2217, DOI 10.1007/s00705-007-1061-7; Allen MD, 2005, J VIROL, V79, P1789, DOI 10.1128/JVI.79.3.1789-1802.2005; Anderson LJ, 2008, VIROLOGY, V371, P257, DOI 10.1016/j.virol.2007.10.009; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cassady KA, 2002, J VIROL, V76, P2029, DOI 10.1128/jvi.76.5.2029-2035.2002; Cho NH, 2006, J VIROL, V80, P108, DOI 10.1128/JVI.80.1.108-118.2006; Claudinon J, 2007, BIOCHIMIE, V89, P735, DOI 10.1016/j.biochi.2007.03.014; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Dawson CW, 2000, VIROLOGY, V272, P204, DOI 10.1006/viro.2000.0344; Dawson CW, 2001, VIROLOGY, V289, P192, DOI 10.1006/viro.2001.1142; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Feys HB, 2008, BLOOD, V112, P102; Ikeda M, 2007, VIROLOGY, V360, P461, DOI 10.1016/j.virol.2006.10.046; Katze MG, 2002, J INTERF CYTOK RES, V22, P283, DOI 10.1089/107999002753675695; Li QL, 2007, J VIROL, V81, P2117, DOI 10.1128/JVI.01961-06; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Longan L, 2000, J GEN VIROL, V81, P2245, DOI 10.1099/0022-1317-81-9-2245; Longnecker R, 2000, ADV CANCER RES, V79, P175, DOI 10.1016/S0065-230X(00)79006-3; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Nanbo A, 2002, REV MED VIROL, V12, P321, DOI 10.1002/rmv.363; Offermann MK, 2007, CURR TOP MICROBIOL, V312, P185; Ogino T, 2007, INT J CANCER, V120, P2401, DOI 10.1002/ijc.22334; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Rechsteiner MP, 2008, J VIROL, V82, P1739, DOI 10.1128/JVI.01723-07; Rechsteiner MP, 2007, J GEN VIROL, V88, P1454, DOI 10.1099/vir.0.82790-0; Rezaee SAR, 2006, J GEN VIROL, V87, P1781, DOI 10.1099/vir.0.81919-0; Rovedo M, 2007, J VIROL, V81, P84, DOI 10.1128/JVI.01302-06; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Stewart S, 2004, P NATL ACAD SCI USA, V101, P15730, DOI 10.1073/pnas.0402135101; Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312; Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	36	70	72	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3903	3914		10.1038/onc.2009.249	http://dx.doi.org/10.1038/onc.2009.249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718044	Green Accepted			2022-12-28	WOS:000271471900005
J	Bui, LC; Tomkiewicz, C; Chevallier, A; Pierre, S; Bats, AS; Mota, S; Raingeaud, J; Pierre, J; Diry, M; Transy, C; Garlatti, M; Barouki, R; Coumoul, X				Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Raingeaud, J.; Pierre, J.; Diry, M.; Transy, C.; Garlatti, M.; Barouki, R.; Coumoul, X.			Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity	ONCOGENE			English	Article						PAHs; cellular plasticity; toxicology; xenobiotics; metastasis marker	DOCKING PROTEIN HEF1; HYDROCARBON RECEPTOR; GENE-EXPRESSION; AH RECEPTOR; CANCER; ACTIVATION; DIOXIN; IDENTIFICATION; METASTASIS; NETWORKS	Aryl hydrocarbon receptor (AhR), or dioxin receptor, is a transcription factor that induces adaptive metabolic pathways in response to environmental pollutants. Recently, other pathways were found to be altered by AhR and its ligands. Indeed, developmental defects elicited by AhR ligands suggest that additional cellular functions may be targeted by this receptor, including cell migration and plasticity. Here, we show that dioxin-mediated activation of Ahr induces Nedd9/Hef1/Cas-L, a member of the Cas protein family recently identified as a metastasis marker. The Hef1 gene induction is mediated by two xenobiotic responsive elements present in this gene promoter. Moreover, using RNA interference, we show that Nedd9/Hef1/Cas-L mediates the dioxin-elicited changes related to cell plasticity, including alterations of cellular adhesion and shape, cytoskeleton reorganization, and increased cell migration. Furthermore, we show that both E-cadherin repression and Jun N-terminal kinases activation by dioxin and AhR also depend on the expression of Nedd9/Hef1/Cas-L. Our study unveils, for the first time, a link between pollutants exposure and the induced expression of a metastasis marker and shows that cellular migration and plasticity markers are regulated by AhR and its toxic ligands. Oncogene (2009) 28, 3642-3651; doi:10.1038/onc.2009.224; published online 3 August 2009	[Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Garlatti, M.; Barouki, R.; Coumoul, X.] INSERM, UMR S 747, Paris, France; [Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Diry, M.; Transy, C.; Garlatti, M.; Barouki, R.; Coumoul, X.] Univ Paris 05, Ctr Univ Saints Peres, Paris, France; [Raingeaud, J.; Pierre, J.] Univ Paris 11, Fac Pharm, INSERM, U461, F-92290 Chatenay Malabry, France; [Diry, M.; Transy, C.] INSERM, U490, Paris, France; [Barouki, R.] Hop Necker Enfants Malad, APHP, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Barouki, R (corresponding author), Univ Paris 05, INSERM, Fac Med Saints Peres, UMR Toxicol Pharmacol & Signalisat Cellulaire S 7, 45 Rue Saints Peres, F-75006 Paris, Ile De France, France.	robert.barouki@univ-paris5.fr; xavier.coumoul@parisdescartes.fr	COUMOUL, Xavier/AAR-3649-2020; Chevallier, Aline/O-5939-2014; Mota, Sandra/AAB-6073-2019	COUMOUL, Xavier/0000-0003-2928-9648; Mota, Sandra/0000-0001-9623-5012; BATS, Anne-Sophie/0000-0001-5333-3296	AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail); ANR (Agence Nationale de la Recherche) [06SEST26]; ARC (Association pour la Recherche sur le Cancer) [3927]; Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui); INSERM (Institut National de la Sante et de la Recherche Medicale); Ligue contre le Cancer; Ministere de l'enseignement superieur et de la recherche; Region Ile de France; Universite Paris Descartes	AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail); ANR (Agence Nationale de la Recherche)(French National Research Agency (ANR)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui)(Fondation pour la Recherche Medicale); INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue contre le Cancer(Ligue nationale contre le cancer); Ministere de l'enseignement superieur et de la recherche; Region Ile de France(Region Ile-de-France); Universite Paris Descartes	This work was supported by AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail; all authors); ANR (Agence Nationale de la Recherche, 06SEST26, Oncopop; all authors); ARC (Association pour la Recherche sur le Cancer, 3927; all authors); Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui); INSERM (Institut National de la Sante et de la Recherche Medicale; all authors); Ligue contre le Cancer (Bourse postdoctorale, Linh-Chi Bui); Ministere de l'enseignement superieur et de la recherche (Bourse doctorale, Aline Chevallier); Region Ile de France (bourse doctorale, Stephane Pierre); Universite Paris Descartes.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Crews ST, 2006, GENE DEV, V20, P2773, DOI 10.1101/gad.1487706; Diry M, 2006, ONCOGENE, V25, P5570, DOI 10.1038/sj.onc.1209553; Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Haas S, 2006, INT J CANCER, V119, P1785, DOI 10.1002/ijc.21915; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2006, CELL CYCLE, V5, P384, DOI 10.4161/cc.5.4.2439; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Qin HT, 2006, DEV BIOL, V298, P606, DOI 10.1016/j.ydbio.2006.07.017; Regelmann AG, 2006, IMMUNITY, V25, P907, DOI 10.1016/j.immuni.2006.09.014; Seo S, 2006, CRIT REV IMMUNOL, V26, P391, DOI 10.1615/CritRevImmunol.v26.i5.20; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wernet MF, 2006, NATURE, V440, P174, DOI 10.1038/nature04615; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	29	63	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3642	3651		10.1038/onc.2009.224	http://dx.doi.org/10.1038/onc.2009.224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648964				2022-12-28	WOS:000270851800005
J	de la Chapelle, A				de la Chapelle, A.			Genetic predisposition to human disease: allele-specific expression and low-penetrance regulatory loci	ONCOGENE			English	Review						allele-specific expression; TGFBR1; APC; DAPK1	TGFBR1	The two alleles of a gene can be expressed at different levels, the extreme example being imprinting, a condition in which one allele is totally suppressed. Recently, subtle differences in the expression of the two alleles have been detected in numerous human genes and in a few cases, have been associated with a genetic predisposition to disease. The underlying mechanisms are largely unexplored. Oncogene (2009) 28, 3345-3348; doi: 10.1038/onc.2009.194; published online 13 July 2009	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	de la Chapelle, A (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 804 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	albert.delachapelle@osumc.edu			NIH [CA67941, CA16058, P01 124570]; NATIONAL CANCER INSTITUTE [R01CA098933, U01CA067941, P01CA124570, T32CA106196, R01CA067941, P30CA016058] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the author's laboratory was supported by NIH grants CA67941, CA16058 and P01 124570.	Carninci P, 2009, NATURE, V457, P974, DOI 10.1038/457974b; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Gimelbrant A, 2007, SCIENCE, V318, P1136, DOI 10.1126/science.1148910; Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119; Guda K, 2009, CANCER RES, V69, P4959, DOI 10.1158/0008-5472.CAN-09-0225; He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Knight JC, 2004, TRENDS GENET, V20, P113, DOI 10.1016/j.tig.2004.01.001; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lynch HT, 2002, AM J MED GENET, V115, P113, DOI 10.1002/ajmg.10686; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Valle L, 2008, SCIENCE, V321, P1361, DOI 10.1126/science.1159397; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Zeng QH, 2009, CANCER RES, V69, P678, DOI 10.1158/0008-5472.CAN-08-3980	17	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3345	3348		10.1038/onc.2009.194	http://dx.doi.org/10.1038/onc.2009.194			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597467	Green Accepted			2022-12-28	WOS:000270103300001
J	Gualberto, A; Pollak, M				Gualberto, A.; Pollak, M.			Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions	ONCOGENE			English	Review						insulin-like growth factor-I receptor inhibitors; clinical trials; targeted therapies	FACTOR-I RECEPTOR; BREAST-CANCER-CELLS; MONOCLONAL-ANTIBODY CP-751,871; SMALL-MOLECULE INHIBITORS; CIRCULATING TUMOR-CELLS; PROSTATE-CANCER; IGF-1 RECEPTOR; PHASE-I; THERAPEUTIC TARGET; HORMONE RECEPTOR	Preclinical evidence that targeting the insulin-like growth factor receptor (IGF-IR) is effective in cancer treatment has been accumulating for almost two decades. Efforts to develop drugs began in the late 1990s, and initial data from clinical trials were reported in 2006. The biological rationale for IGF-IR targeting has potential relevance to many tumor types, and early results have justified expanded programs to evaluate IGF-IR-targeting agents in many areas of clinical need. More than two dozen drug candidates have been developed and clinical trials are underway for at least 12 of these. Early clinical trials reveal an acceptable safety pro. le together with pharmacodynamic evidence that the receptor can be successfully targeted. It is premature to draw conclusions regarding efficacy, but well-documented instances of single-agent activity were noted during phase I evaluations, and recent evidence from a phase II study suggests that co-administration of an anti-IGF-IR antibody with chemotherapy for non-small-cell lung cancer improves objective response rate and progression-free survival. With more than 70 trials involving a variety of drug candidates underway, the IGF-IR is becoming one of the most intensively investigated molecular targets in oncology. Early results justify the continuation of ongoing research across a broad range of cancer indications. Oncogene (2009) 28, 3009-3021; doi:10.1038/onc.2009.172; published online 6 July 2009	[Pollak, M.] McGill Univ, Segal Canc Ctr, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Gualberto, A.] Pfizer Oncol, Clin Dept, New London, CT USA; [Gualberto, A.] Brown Univ, Dept Pathol, Alpert Sch Med, Providence, RI 02912 USA	McGill University; Pfizer; Brown University	Pollak, M (corresponding author), McGill Univ, Segal Canc Ctr, Dept Oncol, 3755 Chemin Cote St Catherine,Room E-763, Montreal, PQ H3T 1E2, Canada.	michael.pollak@mcgill.ca	Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	Pfizer Inc.	Pfizer Inc.(Pfizer)	We thank D Yee and numerous colleagues for constructive criticism and encouragement. Editorial assistance was provided by ACUMED, Tytherington, UK and was funded by Pfizer Inc. This study was supported by funding from Pfizer Inc.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Ahlgren M, 2004, NEW ENGL J MED, V351, P1619, DOI 10.1056/NEJMoa040576; Allen GW, 2007, CANCER RES, V67, P1155, DOI 10.1158/0008-5472.CAN-06-2000; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; Attard G, 2006, J CLIN ONCOL, V24, p126S; Atzori F, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3519; Barr Sharon M., 2007, Proceedings of the American Association for Cancer Research Annual Meeting, V48, P608; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Benini S, 2001, CLIN CANCER RES, V7, P1790; Benyoucef S, 2007, BIOCHEM J, V403, P603, DOI 10.1042/BJ20061709; Best Carolyn J. M., 2006, Proceedings of the American Association for Cancer Research Annual Meeting, V47, P290; BRITTEN C, 2008, 20 EORTC NCI AACR S; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Ceda G P, 2005, J Endocrinol Invest, V28, P96; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; CORTES J, 2008, 50 ASH ANN M EXP SAN; Cox ME, 2009, PROSTATE, V69, P33, DOI 10.1002/pros.20852; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; DEBONO JS, 2008, MOL TARG CANC THER C; del Rincon JP, 2007, DIABETES, V56, P1638, DOI 10.2337/db06-0299; Diorio C, 2005, CANCER EPIDEM BIOMAR, V14, P1065, DOI 10.1158/1055-9965.EPI-04-0706; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; Feng Y, 2008, CURR OPIN DRUG DISC, V11, P178; Gebre-Medhin M, 2001, AM J PATHOL, V158, P1217, DOI 10.1016/S0002-9440(10)64071-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Glait C, 2006, EXP CELL RES, V312, P3899, DOI 10.1016/j.yexcr.2006.08.016; Goodin S, 2008, AM J HEALTH-SYST PH, V65, pS3, DOI 10.2146/ajhp080100; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Gualberto A, 2008, J CLIN ONCOL, V26; Gualberto A, 2008, ANN ONCOL, V19, P62; GUALBERTO A, 2009, CLIN LU IN PRESS JUN; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Hartog H, 2007, EUR J CANCER, V43, P1895, DOI 10.1016/j.ejca.2007.05.021; Hidalgo M, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3520; HIGANO CS, 2007, 2007 PROST CANC S OR; Hochberg Z, 2002, HORM RES, V58, P33, DOI 10.1159/000064764; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Ji QS, 2007, MOL CANCER THER, V6, P2158, DOI 10.1158/1535-7163.MCT-07-0070; Karp DD, 2009, J CLIN ONCOL, V27, P2516, DOI 10.1200/JCO.2008.19.9331; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Kopchick JJ, 2002, ENDOCR REV, V23, P623, DOI 10.1210/er.2001-0022; Lacy MQ, 2008, J CLIN ONCOL, V26, P3196, DOI 10.1200/JCO.2007.15.9319; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; LEONG S, 2007, AACR NCI EORTC MOL T; LINDSAY CR, 2009, J CLIN ONCOL S, V27, pS15; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; Morellec E., 2007, REV FINANC, V11, P1, DOI DOI 10.1093/ROF/RFM001; MORROW LA, 1994, J CLIN ENDOCR METAB, V79, P205, DOI 10.1210/jc.79.1.205; MYAL Y, 1984, CANCER RES, V44, P5486; Natrajan R, 2006, CANCER RES, V66, P11148, DOI 10.1158/0008-5472.CAN-06-1931; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; OLMOS D, 2007, AACR NCI EORTC MOL T; OLMOS D, 2008, J CLIN ONCOL, V26, pS553; Plymate SR, 2007, CLIN CANCER RES, V13, P6429, DOI 10.1158/1078-0432.CCR-07-0648; Pollak M, 2001, BRIT J CANCER, V85, P428, DOI 10.1054/bjoc.2001.1895; POLLAK M, 2007, AACR M; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2008, CURR OPIN PHARMACOL, V8, P384, DOI 10.1016/j.coph.2008.07.004; POLLAK MN, 1987, CANCER LETT, V38, P223, DOI 10.1016/0304-3835(87)90218-7; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; POSTELVINAY S, 2008, 20 EORTC NCI AACR S; RODON J, 2007, J CLIN ONCOL, V25, pS160; Rodon J, 2008, MOL CANCER THER, V7, P2575, DOI 10.1158/1535-7163.MCT-08-0265; ROTHENBERG ML, 2007, AACR NCI EORTC MOL T; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; RYAN PD, 2008, 31 ANN SAN ANT BREAS; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; SARANTOPOULOS J, 2008, J CLIN ONCOL, V26, pS173; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SERAJ J, 2007, AACR NCI EORTC MOL T; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; TABERNERO J, 2008, 33 ESMO C STOCKH SWE; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Tarn C, 2008, P NATL ACAD SCI USA, V105, P8387, DOI 10.1073/pnas.0803383105; TOLCHER AW, 2007, J CLIN ONCOL S, V25, pS118; TOLCHER AW, 2008, J CLIN ONCOL, V26, pS173; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Weroha S, 2008, J MAMMARY GLAND BIOL, V13, P471, DOI 10.1007/s10911-008-9104-6; WISEMAN LR, 1993, EUR J CANCER, V29A, P2256, DOI 10.1016/0959-8049(93)90218-5; WITT K, 2008, OSI PHARM ONCOLOGY P; Wolpin BM, 2009, J CLIN ONCOL, V27, P176, DOI 10.1200/JCO.2008.17.9945; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Wu JD, 2006, CLIN CANCER RES, V12, P6153, DOI 10.1158/1078-0432.CCR-06-0443; Wu YP, 2003, CANCER RES, V63, P4384; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; YIN D, 2008, J CLIN ONCOL, V26, pS118; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zhang H, 2007, CANCER RES, V67, P391, DOI 10.1158/0008-5472.CAN-06-1712; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	103	232	243	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3009	3021		10.1038/onc.2009.172	http://dx.doi.org/10.1038/onc.2009.172			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19581933				2022-12-28	WOS:000269319000001
J	Hirsch, FR				Hirsch, F. R.			The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC INTRODUCTION	ONCOGENE			English	Editorial Material						epidermal growth factor receptor; non-small-cell lung cancer; tyrosine kinase inhibitor	CELL LUNG-CANCER; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; OPEN-LABEL; GEFITINIB; PLUS; CHEMOTHERAPY; MULTICENTER; BEVACIZUMAB; CARBOPLATIN	Lung cancer is the leading cause of cancer deaths worldwide. Non-small-cell lung cancer (NSCLC) is the largest subgroup of the disease and accounts for similar to 80% of lung cancers. Most patients with NSCLC are diagnosed with locally advanced or metastatic disease. The current treatment options for such patients are associated with substantial limitations in efficacy and safety. Targeted therapies have provided some improvement in clinical outcomes. Recent efforts have focused on identifying specific markers that are predictive of response to treatment. A pretreatment detection of such markers could facilitate a more personalized and specific approach to therapy, whereby the most appropriate and efficacious treatment is selected for a specific subset of patients. Such a tailored approach would maximize both the therapeutic index and cost-effectiveness of treatments. In addition, several novel agents are under development, which may have the potential for overcoming acquired resistance to existing treatments. This supplement will review the current and emerging treatments for patients with advanced NSCLC and the molecular predictors of response that may facilitate the future clinical application of personalized medicine. Oncogene (2009) 28, S1-S3; doi:10.1038/onc.2009.195	Univ Colorado, Ctr Canc, Dept Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Hirsch, FR (corresponding author), Univ Colorado, Ctr Canc, Dept Med Oncol, MS 8117,POB 6511, Aurora, CO 80045 USA.	fred.hirsch@uchsc.edu						*AM CANC SOC, 2008, NONSM CELL LUNG CANC; *ASTR ZEN PHARM LP, 2008, ASTRAZENECA FIL MARK; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Carney DN, 2002, NEW ENGL J MED, V346, P126, DOI 10.1056/NEJM200201103460211; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; LEE D, 2008, J CLIN ONCOL, V26, pS430; MOK TS, 2009, N ENGL J ME IN PRESS; *NCCN, 2008, CLIN PRACT GUID NONS; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Ries L MD, 2008, SEER CANC STAT REV 1; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Spigel DR, 2008, CANCER-AM CANCER SOC, V112, P2749, DOI 10.1002/cncr.23490; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; *WHO, 2008, 310 WHO; Wingo PA, 2003, CANCER-AM CANCER SOC, V97, P3133, DOI 10.1002/cncr.11380	19	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2009	28						S1	S3		10.1038/onc.2009.195	http://dx.doi.org/10.1038/onc.2009.195			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680291				2022-12-28	WOS:000269515400001
J	Walker, M; Black, EJ; Oehler, V; Gillespie, DA; Scott, MT				Walker, M.; Black, E. J.; Oehler, V.; Gillespie, D. A.; Scott, M. T.			Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity	ONCOGENE			English	Article						Chk1; ATR; kinase activity	DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND BREAKS; IONIZING-RADIATION; GENOTOXIC STRESS; REQUIRES ATM; S-PHASE; KINASE; REPLICATION; RECRUITMENT; CHROMATIN	Chk1 is phosphorylated within its C-terminal regulatory domain by the upstream ATM/ATR kinases during checkpoint activation; however, how this modulates Chk1 function is poorly understood. Here, we show that Chk1 kinase activity is rapidly stimulated in a cell-cycle phase-specific manner in response to both DNA damage and replication arrest, and that the extent and duration of activation correlates closely with regulatory phosphorylation at serines (S) S317, S345 and S366. Despite their evident co-regulation, substitutions of individual Chk1 regulatory sites with alanine (A) residues have differential effects on checkpoint proficiency and kinase activation. Thus, whereas Chk1 S345 is essential for all functions tested, mutants lacking S317 or S366 retain partial proficiency for G2/M and S/M checkpoint arrests triggered by DNA damage or replication arrest. These phenotypes reflect defects in Chk1 kinase induction, as the mutants are either partially (317A and 366A) or completely (345A) resistant to kinase activation. Importantly, S345 phosphorylation is impaired in Chk1 S317A and S366A mutants, suggesting that modi. cation of adjacent SQ sites promotes this key regulatory event. Finally, we provide biochemical evidence that Chk1 catalytic activity is stimulated by a de-repression mechanism. Oncogene (2009) 28, 2314-2323; doi:10.1038/onc.2009.102; published online 4 May 2009	[Walker, M.; Black, E. J.; Oehler, V.; Gillespie, D. A.; Scott, M. T.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Gillespie, D. A.] Univ Glasgow, Fac Biomed & Life Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow	Scott, MT (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.scott@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Scott, Mary/0000-0002-7177-6960	Cancer Research UK [A3674] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bonilla CY, 2008, MOL CELL, V30, P267, DOI 10.1016/j.molcel.2008.03.023; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cross DAE, 1998, EXP CELL RES, V241, P12, DOI 10.1006/excr.1998.4023; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	36	60	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2314	2323		10.1038/onc.2009.102	http://dx.doi.org/10.1038/onc.2009.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421147	Green Accepted			2022-12-28	WOS:000267089100002
J	Nalbandian, A; Yan, BS; Pichugin, A; Bronson, RT; Kramnik, I				Nalbandian, A.; Yan, B-S; Pichugin, A.; Bronson, R. T.; Kramnik, I.			Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control	ONCOGENE			English	Article						Mycobacterium tuberculosis; sst1; chronic inflammation; squamous cell carcinoma; macrophages; epiregulin	MITOSIS-SPECIFIC PHOSPHORYLATION; GROWTH-FACTOR FAMILY; PULMONARY TUBERCULOSIS; CHRONIC INFLAMMATION; HISTONE H3; CANCER; EPIREGULIN; CARCINOMA; PATHOGENESIS; TUMORS	Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic poses significant challenges for the diagnostic and treatment of both diseases. Although association of chronic inflammation and cancer is well-documented, causal relationship between TB infection and lung cancer are not understood. We present experimental evidence that chronic TB infection induces cell dysplasia and squamous cell carcinoma (SCC) in a lung-specific manner. First, squamous cell aggregates consistently appeared within the lung tissue associated with chronic TB lesions, and in some cases resembled SCCs. A transplantable tumor was established after the transfer of cells isolated from TB lung lesions into syngeneic recipients. Second, the (Mycobacterium tuberculosis) MTB-infected macrophages play a pivotal role in TB-induced carcinogenesis by inducing DNA damage in their vicinity and by the production of a potent epidermal growth factor epiregulin, which may serve as a paracrine survival and growth factor responsible for squamous metaplasia and tumorigenesis. Third, lung carcinogenesis during the course of chronic TB infection was more pronounced in animals with severe lung tissue damage mediated by TB-susceptibility locus sst1. Together, our experimental findings showed a causal link between pulmonary TB and lung tumorigenesis and established a genetic model for further analysis of carcinogenic mechanisms activated by TB infection.	[Nalbandian, A.; Yan, B-S; Pichugin, A.; Kramnik, I.] Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Yan, B-S] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Bronson, R. T.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; National Yang Ming Chiao Tung University; Harvard University; Harvard Medical School	Kramnik, I (corresponding author), Harvard Univ, Sch Med, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ikramnik@hsph.harvard.edu		Yan, Bo-Shiun/0000-0002-9613-4788; Kramnik, Igor/0000-0001-6511-9246; Pichugin, Alexander/0000-0002-2577-7284	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059836] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL059836] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ardies C Murray, 2003, Integr Cancer Ther, V2, P238, DOI 10.1177/1534735403256332; Azad N, 2008, J TOXICOL ENV HEAL B, V11, P1, DOI 10.1080/10937400701436460; Baba I, 2000, CANCER RES, V60, P6886; Bewersdorf J, 2006, P NATL ACAD SCI USA, V103, P18137, DOI 10.1073/pnas.0608709103; CAGLE PT, 1985, CANCER, V56, P2031, DOI 10.1002/1097-0142(19851015)56:8<2031::AID-CNCR2820560824>3.0.CO;2-K; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dacosta N A, 1991, J Postgrad Med, V37, P185; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; GOPALAKRISHNAN P, 1975, AM SURGEON, V41, P405; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Jin DY, 2007, FRONT BIOSCI-LANDMRK, V12, P222, DOI 10.2741/2060; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Klein G, 2005, IMMUNOL LETT, V100, P29, DOI 10.1016/j.imlet.2005.06.024; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197; Kurasawa T, 1998, Nihon Rinsho, V56, P3167; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; Lawrence T, 2007, TRENDS PHARMACOL SCI, V28, P162, DOI 10.1016/j.tips.2007.02.003; Lee D, 2004, MOL CELL BIOL, V24, P8907, DOI 10.1128/MCB.24.20.8907-8916.2004; Melnikova VO, 2005, MUTAT RES-FUND MOL M, V571, P91, DOI 10.1016/j.mrfmmm.2004.11.015; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Naito Y, 2002, FREE RADICAL BIO MED, V33, P323, DOI 10.1016/S0891-5849(02)00868-7; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nussenzweig A, 2006, NATURE, V439, P406, DOI 10.1038/439406a; Oka K, 2005, ACTA BIOCHIM POL, V52, P311; Pastore S, 2006, EUR J DERMATOL, V16, P125; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538; Sakuraba Motoki, 2006, Ann Thorac Cardiovasc Surg, V12, P53; SAKURAI R, 1989, JPN J MED, V28, P471; Saunders BM, 2007, IMMUNOL CELL BIOL, V85, P103, DOI 10.1038/sj.icb.7100027; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Shirasawa S, 2004, P NATL ACAD SCI USA, V101, P13921, DOI 10.1073/pnas.0404217101; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Tan TT, 2007, CURR OPIN IMMUNOL, V19, P209, DOI 10.1016/j.coi.2007.01.001; TING YM, 1976, RADIOLOGY, V119, P307, DOI 10.1148/119.2.307; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906; Ulrichs T, 2004, J PATHOL, V204, P217, DOI 10.1002/path.1628; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang Y, 2004, CANCER RES, V64, P1647, DOI 10.1158/0008-5472.CAN-03-3273	48	84	96	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1928	1938		10.1038/onc.2009.32	http://dx.doi.org/10.1038/onc.2009.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330024				2022-12-28	WOS:000265640600005
J	Hutcheson, J; Perlman, H				Hutcheson, J.; Perlman, H.			BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention	ONCOGENE			English	Review						rheumatoid arthritis; Bim; Bid; BH3-only; BH3 mimetic; apoptosis	BCL-2 FAMILY-MEMBER; CYTOCHROME-C RELEASE; BH3 MIMETIC ABT-737; SYNOVIAL FIBROBLASTS; B-CELLS; INDUCED APOPTOSIS; IN-VIVO; BIM; EXPRESSION; DEATH	Rheumatoid arthritis (RA) is a debilitating disease, resulting in the destruction of bone and cartilage, and in the permanent disfigurement of joints. Although the precise cause of RA is currently unresolved, it has become clear that the damaging effects are a result of the toxic milieu caused by an influx of inflammatory cells and the resulting heightened proinflammatory state within the joint. As the amount of literature suggesting that this preponderance of cells is a result of decreased local apoptosis in the joint continues to increase, in this review, we describe how Bcl-2 family pro-apoptotic BH3-only proteins, particularly Bim and Bid, could act to protect against the development of the disease. We also suggest a role for BH3-mimetic drugs as potential therapeutics in the treatment of RA. Oncogene (2009) 27, S168-S175; doi: 10.1038/onc.2009.54	[Hutcheson, J.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Rheumat Dis, Simmons Arthrit Res Ctr, Dallas, TX 75390 USA; [Perlman, H.] St Louis Univ, Dept Mol Microbiol Immunol, St Louis, MO 63103 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Saint Louis University	Perlman, H (corresponding author), Northwestern Univ, Div Rheumatol, Dept Med, Feinberg Sch Med, 240 E Huron St,McGaw M300, Chicago, IL 60611 USA.	perlmanh@slu.edu		Hutcheson, Jack/0000-0002-6317-2788	National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI067590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002147, R01AR054796, R01AR050250] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	J Hutcheson has declared no conflict of interest. H Perlman is currently receiving grant support from the National Institutes of Health (NIH, Bethesda, MD, USA) and was in receipt of a grant from Reata Pharmaceuticals (Irving, TX, USA) from July 2007 to August 2008.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Alfredsson J, 2005, CELL DEATH DIFFER, V12, P136, DOI 10.1038/sj.cdd.4401537; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brennan F, 2007, CURR OPIN RHEUMATOL, V19, P296, DOI 10.1097/BOR.0b013e32805e87f1; Bugatti S, 2007, AUTOIMMUN REV, V7, P137, DOI 10.1016/j.autrev.2007.02.017; Busteed S, 2006, CLIN RHEUMATOL, V25, P789, DOI 10.1007/s10067-005-0191-0; Cha HS, 2006, ARTHRITIS RHEUM-US, V54, P587, DOI 10.1002/art.21631; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Davey GM, 2002, J EXP MED, V196, P947, DOI 10.1084/jem.20020827; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Enders A, 2003, J EXP MED, V198, P1119, DOI 10.1084/jem.20030411; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fischer SF, 2007, BLOOD, V110, P3978, DOI 10.1182/blood-2007-05-091306; Fujisawa K, 1996, J CLIN INVEST, V98, P271, DOI 10.1172/JCI118789; Harjacek M, 2001, J RHEUMATOL, V28, P1914; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hilbers I, 2003, RHEUMATOL INT, V23, P75, DOI 10.1007/s00296-002-0255-2; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hsu YH, 2006, ARTHRITIS RHEUM-US, V54, P2722, DOI 10.1002/art.22039; Hughes P, 2006, CURR DIRECT AUTOIMMU, V9, P74; Hutcheson J, 2005, J EXP MED, V201, P1949, DOI 10.1084/jem.20041484; Hutcheson J, 2008, IMMUNITY, V28, P206, DOI 10.1016/j.immuni.2007.12.015; Hutcheson J, 2007, IMMUNOBIOLOGY, V212, P629, DOI 10.1016/j.imbio.2007.05.003; Ikeuchi H, 2005, ARTHRITIS RHEUM-US, V52, P1037, DOI 10.1002/art.20965; Kashiwagi H, 2007, ANN SURG ONCOL, V14, P1763, DOI 10.1245/s10434-006-9298-z; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu HT, 2006, ARTHRITIS RHEUM-US, V54, P3174, DOI 10.1002/art.22132; Liu HT, 2005, J IMMUNOL, V175, P8337, DOI 10.4049/jimmunol.175.12.8337; Liu HT, 2004, RHEUM DIS CLIN N AM, V30, P603, DOI 10.1016/j.rdc.2004.04.010; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Matsumoto S, 1996, J RHEUMATOL, V23, P1345; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Mott JL, 2008, MOL CANCER THER, V7, P2339, DOI 10.1158/1535-7163.MCT-08-0285; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; NAKAJIMA T, 1995, ARTHRITIS RHEUM, V38, P485, DOI 10.1002/art.1780380405; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; O'Brien SM, 2009, BLOOD, V113, P299, DOI 10.1182/blood-2008-02-137943; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Perlman H, 2000, J IMMUNOL, V164, P5227, DOI 10.4049/jimmunol.164.10.5227; Perlman H, 2001, ARTHRITIS RHEUM, V44, P21, DOI 10.1002/1529-0131(200101)44:1<21::AID-ANR4>3.0.CO;2-8; Pope RM, 2002, NAT REV IMMUNOL, V2, P527, DOI 10.1038/nri846; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133; Scatizzi JC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2204; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sugiyama M, 1996, ANN RHEUM DIS, V55, P442, DOI 10.1136/ard.55.7.442; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae; Trudel S, 2007, BLOOD, V109, P5430, DOI 10.1182/blood-2006-10-047951; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2004, P NATL ACAD SCI USA, V101, P7052, DOI 10.1073/pnas.0305757101; Wakeyama H, 2007, J BONE MINER RES, V22, P1631, DOI 10.1359/JBMR.070619; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang HD, 1997, J CLIN INVEST, V100, P1951, DOI 10.1172/JCI119726; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	77	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S168	S175		10.1038/onc.2009.54	http://dx.doi.org/10.1038/onc.2009.54			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641502	Green Accepted			2022-12-28	WOS:000268566800015
J	El-Tanani, MK; Jin, D; Campbell, FC; Johnston, PG				El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.			Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression	ONCOGENE			English	Article						osteopontin; INFTM3; interferon; inhibition; breast cancer and metastasis	PROGNOSTIC-SIGNIFICANCE; TRANSCRIPTION FACTOR; METASTASIS; IDENTIFICATION; PROTEIN; GENE; CARCINOMA; FAMILY; CELLS	Osteopontin is a secreted, integrin-binding and phosphorylated acidic glycoprotein, which has an important role in tumour progression. We have shown that Wnt, Ets, AP-1, c-jun and beta-catenin/Lef-1/Tcf-1 stimulates OPN transcription in rat mammary carcinoma cells by binding to a specific promoter sequence. However, co-repressors of OPN have not been identified. In this study, we have used the bacterial two-hybrid system to isolate cDNA-encoding proteins that bind to OPN and modulate its role in malignant transformation. Using this approach we isolated interferon-induced transmembrane protein 3 gene (IFITM3) as a potential protein partner. We show that IFITM3 and OPN interact in vitro and in vivo and that IFITM3 reduces osteopontin (OPN) mRNA expression, possibly by affecting OPN mRNA stability. Stable transfection of IFITM3 inhibits OPN, which mediates anchorage-independent growth, cell adhesion and cell invasion. Northern blot analysis revealed an inverse mRNA expression pattern of IFITM3 and OPN in human mammary cell lines. Inhibition of IFITM3 by antisense RNA promoted OPN protein expression, enhanced cell invasion by parental benign non-invasive Rama 37 cells, indicating that the two proteins interact functionally as well. We also identified an IFITM3 DNA-binding domain, which interacts with OPN, deletion of which abolished its inhibitive effect on OPN. This work has shown for the first time that IFITM3 physically interacts with OPN and reduces OPN mRNA expression, which mediates cell adhesion, cell invasion, colony formation in soft agar and metastasis in a rat model system. Oncogene (2010) 29, 752-762; doi: 10.1038/onc.2009.379; published online 9 November 2009	[El-Tanani, M. K.; Jin, D.; Campbell, F. C.; Johnston, P. G.] Queens Univ Belfast, CCRCB, Belfast BT9 7LB, Antrim, North Ireland	Queens University Belfast	El-Tanani, MK (corresponding author), Queens Univ Belfast, CCRCB, 97 Lisburn Rd, Belfast BT9 7LB, Antrim, North Ireland.	m.el-tanani@qub.ac.uk		El-Tanani, Mohamed/0000-0002-4735-5445	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom	We acknowledge support from Research and Development Office (R&D), Queen's University Belfast, Northern Ireland, United Kingdom.	Andreu P, 2006, CANCER RES, V66, P1949, DOI 10.1158/0008-5472.CAN-05-2731; BEHREND EI, 1994, CANCER RES, V54, P832; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brem R, 2003, CELL MOL LIFE SCI, V60, P1235, DOI 10.1007/s00018-003-3016-9; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; El-Tanani MK, 2006, J BIOL CHEM, V281, P26587, DOI 10.1074/jbc.M604403200; Euer N, 2002, ANTICANCER RES, V22, P733; EVANS SS, 1993, J IMMUNOL, V150, P736; Geissinger E, 2002, CANCER RES, V62, P4820; Green CD, 2007, MOL CANCER RES, V5, P1191, DOI 10.1158/1541-7786.MCR-07-0123; Hsieh YH, 2006, CANCER RES, V66, P7119, DOI 10.1158/0008-5472.CAN-06-1002; Jin DC, 2006, INT J ONCOL, V29, P1591; Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170; Lange U C, 2003, BMC Dev Biol, V3, P1, DOI 10.1186/1471-213X-3-1; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; Liu D, 2002, BRIT J CANCER, V87, P423, DOI 10.1038/sj.bjc.6600456; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; Oates AJ, 1996, ONCOGENE, V13, P97; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Real SM, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-38; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2000, CANCER RES, V60, P1595; Rudland PS, 2002, CANCER RES, V62, P3417; Singhal H, 1997, CLIN CANCER RES, V3, P605; Tanaka SS, 2005, DEV CELL, V9, P745, DOI 10.1016/j.devcel.2005.10.010; Tanaka SS, 2004, DEV DYNAM, V230, P651, DOI 10.1002/dvdy.20085; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Yang HL, 2005, BIOCHEM BIOPH RES CO, V328, P265, DOI 10.1016/j.bbrc.2004.12.159; Yang Y, 2005, CANCER LETT, V221, P191, DOI 10.1016/j.canlet.2004.08.022; Zhang JP, 2009, EXP CELL RES, V315, P304, DOI 10.1016/j.yexcr.2008.10.042	37	19	22	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					752	762		10.1038/onc.2009.379	http://dx.doi.org/10.1038/onc.2009.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901966				2022-12-28	WOS:000274223700011
J	Borbone, E; Berlingieri, MT; De Bellis, F; Nebbioso, A; Chiappetta, G; Mai, A; Altucci, L; Fusco, A				Borbone, E.; Berlingieri, M. T.; De Bellis, F.; Nebbioso, A.; Chiappetta, G.; Mai, A.; Altucci, L.; Fusco, A.			Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation	ONCOGENE			English	Article						HDAC inhibitors; thyroid; carcinomas; apoptosis; TRAIL; proteasome	SUBEROYLANILIDE HYDROXAMIC ACID; REFRACTORY SOLID TUMORS; ACUTE MYELOID-LEUKEMIA; T-CELL LYMPHOMA; HDAC INHIBITORS; CLASS-II; ANTICANCER AGENT; PHASE-I; MALIGNANT PHENOTYPE; LIGAND TRAIL	Anaplastic thyroid carcinoma (ATC) is considered one of the most aggressive malignancies, having a poor prognosis and being refractory to conventional chemotherapy and radiotherapy. Alteration in histone deacetylase (HDAC) activity has been reported in cancer, thus encouraging the development of HDAC inhibitors, whose antitumor action has been shown in both solid and hematological malignancies. However, the molecular basis for their tumor selectivity is unknown. To find an innovative therapy for the treatment of ATCs, we studied the effects of deacetylase inhibitors on thyroid tumorigenesis models. We show that HDACs 1 and 2 are overexpressed in ATCs compared with normal cells or benign tumors and that HDAC inhibitors induce apoptosis selectively in the fully transformed thyroid cells. Our results indicate that these phenomena are mediated by a novel action of HDAC inhibitors that reduces tumor necrosis factor-related apoptosis-inducing ligand protein degradation by affecting the ubiquitin-dependent pathway. Indeed, the combined treatment with HDAC and proteasome inhibitors results in synergistic apoptosis. These results strongly encourage the preclinical application of the combination deacetylase-proteasome inhibitors for the treatment of ATC.	[Fusco, A.] IEOS, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Borbone, E.; Fusco, A.] NOGEC CEINGE, Naples, Italy; [De Bellis, F.; Nebbioso, A.; Altucci, L.] Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; [Chiappetta, G.] Natl Canc Inst G Pascale, Funct Genom Unit, Dept Expt Oncol, Naples, Italy; [Mai, A.] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; Fondazione Cenci Bolognetti; Sapienza University Rome	Fusco, A (corresponding author), IEOS, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	lucia.altucci@unina2.it; alfusco@unina.it	NEBBIOSO, ANGELA/GVS-1294-2022; Altucci, Lucia/S-8031-2019; Mai, Antonello/AAC-2144-2019; NEBBIOSO, Angela/C-3566-2016	altucci, lucia/0000-0002-7312-5387; Fusco, Alfredo/0000-0003-3332-5197; Mai, Antonello/0000-0001-9176-2382; NEBBIOSO, Angela/0000-0001-5374-3527	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU [LSHC-CT2005-518417, HEALTH-F2-2007200620, HEALTH-F4-2007-200767, HEALTH-F4-2009221952]; NOGEC-Naples Oncogenomic Center	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU; NOGEC-Naples Oncogenomic Center	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC), and from the Ministero dell Universita e della Ricerca Scientifica e Tecnologica (MIUR); EU (LSHC-CT2005-518417; HEALTH-F2-2007200620; HEALTH-F4-2007-200767; HEALTH-F4-2009221952) and the NOGEC-Naples Oncogenomic Center. We thank Konstantina Vergadou for revising and editing the article, Mario Berardone for the artwork, and Pollice A for providing some plasmids.	Altucci L, 2005, INT J BIOCHEM CELL B, V37, P1752, DOI 10.1016/j.biocel.2005.04.019; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Altucci L, 2009, INT J BIOCHEM CELL B, V41, P2, DOI 10.1016/j.biocel.2008.09.010; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2; Bontempo P, 2007, INT J BIOCHEM CELL B, V39, P1902, DOI 10.1016/j.biocel.2007.05.010; Chiappetta G, 2008, EUR J CANCER, V44, P1015, DOI 10.1016/j.ejca.2008.02.039; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299; Duvic M, 2007, DRUG TODAY, V43, P585, DOI 10.1358/dot.2007.43.9.1112980; Earel JK, 2006, CANCER RES, V66, P499, DOI 10.1158/0008-5472.CAN-05-3017; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461; Hall MA, 2007, CANCER CELL, V12, P4, DOI 10.1016/j.ccr.2007.06.011; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Iervolino A, 2006, CANCER RES, V66, P6280, DOI 10.1158/0008-5472.CAN-06-0228; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167; Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Macher-Goeppinger S, 2009, CLIN CANCER RES, V15, P650, DOI 10.1158/1078-0432.CCR-08-0284; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; Mai A, 2005, J MED CHEM, V48, P3344, DOI 10.1021/jm049002a; Mai A, 2009, INT J BIOCHEM CELL B, V41, P199, DOI 10.1016/j.biocel.2008.08.020; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Miller CP, 2009, BLOOD, V113, P4289, DOI 10.1182/blood-2008-08-174797; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2005, CLIN CANCER RES, V11, P3958, DOI 10.1158/1078-0432.CCR-03-0776; Nappi TC, 2009, CANCER RES, V69, P1916, DOI 10.1158/0008-5472.CAN-08-1693; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; PORTELLA G, 1989, ONCOGENE, V4, P181; Saltman B, 2006, SURGERY, V140, P899, DOI 10.1016/j.surg.2006.07.027; Scognamiglio A, 2008, BBA-MOL CELL RES, V1783, P2030, DOI 10.1016/j.bbamcr.2008.07.007; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yu C, 2008, NEURO-ONCOLOGY, V10, P309, DOI 10.1215/15228517-2007-063	50	61	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					105	116		10.1038/onc.2009.306	http://dx.doi.org/10.1038/onc.2009.306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802013				2022-12-28	WOS:000273373500010
J	Lacoste, S; Wiechec, E; Silva, AGD; Guffei, A; Williams, G; Lowbeer, M; Benedek, K; Henriksson, M; Klein, G; Mai, S				Lacoste, S.; Wiechec, E.; Silva, A. G. dos Santos; Guffei, A.; Williams, G.; Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.; Mai, S.			Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells	ONCOGENE			English	Article						Epstein-Barr virus; genomic instability; telomere dysfunction; nuclear organization	PROMOTES GENOMIC INSTABILITY; NEGATIVE BURKITTS-LYMPHOMA; STRONG TELOMERASE ACTIVITY; LATENT GENES; GROWTH PHENOTYPE; HODGKINS-DISEASE; TUMOR-CELLS; DNA-DAMAGE; LYMPHOCYTES; LINES	The Epstein-Barr virus (EBV) is carried by more than 90% of the adult world population and has been implicated in several human malignancies. Its ability to induce unlimited in vitro proliferation of B cells is frequently used to generate lymphoblastoid cell lines (LCLs). In this study, we have investigated the evolution of two LCLs up to 25 weeks after EBV infection. LCLs were karyotyped once a month by spectral karyotyping (SKY). LCLs but not mitogen-activated B cells showed evidence of DNA damage and DNA damage response within the first 2 weeks. After 4 weeks, the former, but not the latter, showed a high level of non-clonal structural aberrations, mainly deletions, fragments, dicentric chromosomes and unbalanced translocations. Genomic instability decreased thereafter over time. Nonrandom aneuploidy 12 weeks after infection showed clonal evolution in culture. After 25 weeks post-infection, most cells exhibited karyotypic stability. Chromosomal aberrations were compatible with telomere dysfunction, although in the absence of telomere shortening. The telomere capping protein TRF2 was partially displaced from telomeres in EBV-infected cells, suggesting an EBV-mediated uncapping problem. In conclusion, this study suggests that DNA damage and telomere dysfunction contribute to EBV-related chromosomal instability in early LCLs. Oncogene (2010) 29, 503-515; doi: 10.1038/onc.2009.359; published online 2 November 2009	[Lacoste, S.; Silva, A. G. dos Santos; Guffei, A.; Mai, S.] Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, Winnipeg, MB R3E 0V9, Canada; [Wiechec, E.] Univ Aarhus, Dept Human Genet, Aarhus C, Denmark; [Williams, G.] Hlth Sci Ctr, Hematopathol Lab, Dept Pathol, Winnipeg, MB, Canada; [Lowbeer, M.; Benedek, K.; Henriksson, M.; Klein, G.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden	University of Manitoba; Aarhus University; University of Manitoba; Children's Hospital Research Institute of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Dept Physiol, 675 McDermot Ave,Rm ON6046, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Henriksson, Marie Arsenian/F-5010-2015; Silva, Amanda/G-4992-2010	Mai, Sabine/0000-0002-5797-2201; Arsenian Henriksson, Marie/0000-0001-6376-7792	Canadian Cancer Society; National Cancer Institute of Canada; Swedish Cancer Society; Canadian Institutes of Health; Manitoba Health Research Council	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Swedish Cancer Society(Swedish Cancer Society); Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council	We thank Mary Cheang for statistical analyses, and Ludger Klewes, Brenda Kuschak and Sabine Hombach-Klonisch for technical help. This study was supported by the Canadian Cancer Society and the National Cancer Institute of Canada (SM), the Swedish Cancer Society (GK), the Canadian Institutes of Health Research Strategic Training Program 'Innovative Technologies in Multidisciplinary Health Research Training' fellowships (SL and EW) and by a Manitoba Health Research Council post-doctoral fellowship (SL).	Aubert G, 2008, PHYSIOL REV, V88, P557, DOI 10.1152/physrev.00026.2007; Belfiore MC, 2007, CANCER LETT, V254, P236, DOI 10.1016/j.canlet.2007.03.010; Caporali A, 2007, ONCOGENE, V26, P1398, DOI 10.1038/sj.onc.1209928; Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; CIOBANU N, 1986, MT SINAI J MED, V53, P627; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; De Vos WH, 2009, CYTOM PART A, V75A, P428, DOI 10.1002/cyto.a.20699; Diehl V, 1977, Haematol Blood Transfus, V20, P289; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Gargouri B, 2009, MOL CELL BIOCHEM, V324, P55, DOI 10.1007/s11010-008-9984-1; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; GORDON J, 1986, IMMUNOLOGY, V58, P591; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; GUNVEN P, 1970, NATURE, V228, P1053, DOI 10.1038/2281053a0; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1973, NATL CANCER I MONOGR, P79; HENLE W, 1966, J BACTERIOL, V92, P269, DOI 10.1128/JB.92.1.269-271.1966; HENLE W, 1973, CANCER RES, V33, P1419; Henle W., 1979, EPSTEINBARR VIRUS, P61; Hopwood PA, 2002, TRANSPLANTATION, V74, P194, DOI 10.1097/00007890-200207270-00009; Hu BT, 1999, EUR J IMMUNOL, V29, P3745, DOI 10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Jeon JP, 2007, CANCER GENET CYTOGEN, V173, P122, DOI 10.1016/j.cancergencyto.2006.10.010; JONCAS J, 1974, CAN MED ASSOC J, V110, P33; Jung D, 2001, IMMUNOL INVEST, V30, P157, DOI 10.1081/IMM-100104023; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kim SH, 2004, CYTOGENET GENOME RES, V105, P292, DOI 10.1159/000078201; Knecht H, 2009, LEUKEMIA, V23, P565, DOI 10.1038/leu.2008.314; Konishi A, 2008, GENE DEV, V22, P1221, DOI 10.1101/gad.1634008; Lassoued S, 2008, MOL CELL BIOCHEM, V313, P179, DOI 10.1007/s11010-008-9755-z; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; MAI S, 2002, FISH PRACTICAL APPRO, P55; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; Nagele RG, 2001, J CELL SCI, V114, P377; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; Nilsson K, 1992, Hum Cell, V5, P25; NILSSON K, 1975, INT J CANCER, V15, P321, DOI 10.1002/ijc.2910150217; O'Nions J, 2004, J GEN VIROL, V85, P881, DOI 10.1099/vir.0.19704-0; Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905; OKANO M, 1990, AM J PATHOL, V137, P517; Okubo M, 2001, CANCER GENET CYTOGEN, V129, P30, DOI 10.1016/S0165-4608(01)00420-4; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PURTILO DT, 1980, LANCET, V1, P300; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; ROONEY CM, 1986, BRIT J HAEMATOL, V62, P413, DOI 10.1111/j.1365-2141.1986.tb02952.x; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; STEEL CM, 1977, NATURE, V270, P729, DOI 10.1038/270729a0; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Takahashi T, 2003, DNA CELL BIOL, V22, P727, DOI 10.1089/104454903770946700; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THOMAS JA, 1989, LANCET, V1, P1075; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; WALTER J, 1992, INT J CANCER, V50, P265, DOI 10.1002/ijc.2910500217; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; Weierich C, 2003, CHROMOSOME RES, V11, P485, DOI 10.1023/A:1025016828544; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; YOUNG LS, 1991, LANCET, V337, P1617, DOI 10.1016/0140-6736(91)93322-Z	74	50	50	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					503	515		10.1038/onc.2009.359	http://dx.doi.org/10.1038/onc.2009.359			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881539				2022-12-28	WOS:000274084600004
J	Lai, CPK; Bechberger, JF; Naus, CC				Lai, C. P. K.; Bechberger, J. F.; Naus, C. C.			Pannexin2 as a novel growth regulator in C6 glioma cells	ONCOGENE			English	Article						Panx2; pannexins; gap junction; intercellular communication; C6 glioma	GAP-JUNCTIONS; INTERLEUKIN-1-BETA RELEASE; EXPRESSION; HEMICHANNELS; DEGRADATION; COMMUNICATION; CONNEXIN-43; DELETION; FAMILY; BRAIN	Connexins (Cxs), the gap junction proteins, have been found to be downregulated in many types of cancers including gliomas. By restoring gap junctional communication in cancer cell models, the neoplastic phenotype can be reversed, suggesting Cxs are tumor suppressors. Pannexin2 (Panx2) is a member of the novel gap junction protein family, Panxs, and it has been proposed as a brain-specific protein. Recently, gene array analysis showed an overall reduction of Panx2 in gliomas, and a direct correlation was observed between Panx2 expression and post-diagnosis survival in patients. In this study, we explored the potential inverse correlation between Panx2 and glioma oncogenicity. A decrease or absence of Panx2 expression in a panel of human glioma cell lines was found, whereas an appreciable amount of Panx2 was detected in both human brain and astrocytes. Stable Panx2 expression revealed a flattened morphology and increased cell-cell contacts in rat C6 glioma cells similar to Panx1. However, in contrast to Panx1 and Panx3, Panx2 was predominately detected in the cytoplasm in vesicle-like patterns but not at the plasma membrane. Coexpression of Panx2 and Panx1 did not show colocalization of both Panxs. Strikingly, restoration of Panx2 expression significantly reduced in vitro oncogenicity parameters, including monolayer saturation density and anchorage-independent growth, as well as in vivo tumor growth. This study suggests a role of aberrant Panx2 expression during gliomagenesis, and that Panx2 independently functions as a negative growth regulator without Panx1. Oncogene (2009) 28, 4402-4408; doi: 10.1038/onc.2009.283; published online 14 September 2009	[Lai, C. P. K.; Bechberger, J. F.; Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Naus, CC (corresponding author), Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cnaus@interchange.ubc.ca	Lai, Charles Pin-Kuang/D-5442-2017	Lai, Charles Pin-Kuang/0000-0001-8050-7060	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The research was supported by the Canadian Institutes of Health Research. The authors thank Dr WC Sin for the critical review of the paper, Dr L Matsuuchi for the insightful data discussions, as well as Lynne Bechberger for proofreading the paper. CCN is a recipient of a Canada Research Chair.	Baranova A, 2004, GENOMICS, V83, P706, DOI 10.1016/j.ygeno.2003.09.025; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Berthoud VA, 2004, CARDIOVASC RES, V62, P256, DOI 10.1016/j.cardiores.2003.12.021; Boengler K, 2005, CARDIOVASC RES, V67, P234, DOI 10.1016/j.cardiores.2005.04.014; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; D'Abaco GM, 2007, J CLIN NEUROSCI, V14, P1041, DOI 10.1016/j.jocn.2007.06.019; Das Sarma J, 2005, CELL COMMUN ADHES, V12, P237, DOI 10.1080/15419060500511875; Hu J, 2004, CHINESE MED J-PEKING, V117, P456; Huang YJ, 2007, P NATL ACAD SCI USA, V104, P6436, DOI 10.1073/pnas.0611280104; Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Li H, 2002, AM J PHYSIOL-HEART C, V282, pH2124, DOI 10.1152/ajpheart.01028.2001; Litvin O, 2006, J CELL MOL MED, V10, P613, DOI 10.1111/j.1582-4934.2006.tb00424.x; Locovei S, 2006, P NATL ACAD SCI USA, V103, P7655, DOI 10.1073/pnas.0601037103; LOEWENSTEIN WR, 1987, CELL, V48, P725, DOI 10.1016/0092-8674(87)90067-5; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Naus CC, 2005, GAP JUNCTIONS IN DEVELOPMENT AND DISEASE, P253, DOI 10.1007/3-540-28621-7_12; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Pelegrin P, 2007, J BIOL CHEM, V282, P2386, DOI 10.1074/jbc.M610351200; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Ray A, 2006, CEREBELLUM, V5, P189, DOI 10.1080/14734220500530082; Romanov RA, 2007, EMBO J, V26, P657, DOI 10.1038/sj.emboj.7601526; Schulz R, 2007, HEART FAIL REV, V12, P261, DOI 10.1007/s10741-007-9032-3; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; Thomas T, 2005, J CELL SCI, V118, P4451, DOI 10.1242/jcs.02569; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371; Vogt A, 2005, MOL BRAIN RES, V141, P113, DOI 10.1016/j.molbrainres.2005.08.002; Wang XH, 2009, J COMP NEUROL, V512, P336, DOI 10.1002/cne.21898; Zappala A, 2007, NEUROSCIENCE, V148, P653, DOI 10.1016/j.neuroscience.2007.06.028; Zheng L, 2007, INT J INF SECUR, V6, P67, DOI 10.1007/s10207-007-0019-9	38	53	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4402	4408		10.1038/onc.2009.283	http://dx.doi.org/10.1038/onc.2009.283			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19749789				2022-12-28	WOS:000272876400009
J	Walerych, D; Olszewski, MB; Gutkowska, M; Helwak, A; Zylicz, M; Zylicz, A				Walerych, D.; Olszewski, M. B.; Gutkowska, M.; Helwak, A.; Zylicz, M.; Zylicz, A.			Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions	ONCOGENE			English	Article						p53; molecular chaperones; Hsp70; Hsp90; protein folding	WILD-TYPE P53; HEAT-SHOCK PROTEINS; DNA-BINDING ACTIVITY; MUTANT P53; CORE DOMAIN; HSP90 INHIBITORS; CANCER-THERAPY; IN-VIVO; STABILIZATION; DEGRADATION	p53 as an unstable protein in vitro likely requires stabilizing factors to act as a tumor suppressor in vivo. Here, we show that in human cells transfected with wildtype (WT) p53, Hsp90 and Hsp70 molecular chaperones maintain the p53 native conformation under heat-shock conditions (42 degrees C) as well as assist p53 refolding at 37 degrees C, during the recovery from heat shock. We also show that the interaction of WT p53 with WAF1 promoter in cells is sensitive to Hsp70 and Hsp90 inhibition already at 37 degrees C and further decreased on heat shock. The influence of chaperones on p53 binding to the WAF1 promoter sequence has been confirmed in vitro, using highly purified proteins. Hsp90 stabilizes the binding of p53 to the promoter sequence at 37 degrees C, whereas under heat-shock conditions the requirement for the Hsp70-Hsp40 system and its cooperation with Hsp90 increases. Hop co-chaperone additionally stimulates these reactions. Interestingly, the combined Hsp90 and Hsp70-Hsp40 allow for a limited in vitro restoration of the DNA-binding activity by the p53 oncogenic variant R249S and affect its conformation in cells. Our results indicate for the first time that, especially under stress conditions, not only Hsp90 but also Hsp70 is required for the chaperoning of WT and R249S p53. Oncogene (2009) 28, 4284-4294; doi: 10.1038/onc.2009.281; published online 14 September 2009	[Walerych, D.; Olszewski, M. B.; Gutkowska, M.; Helwak, A.; Zylicz, M.; Zylicz, A.] Int Inst Mol & Cell Biol Warsaw, Dept Mol Biol, PL-02109 Warsaw, Poland; [Gutkowska, M.] Nencki Inst Expt Biol PAS, Warsaw, Poland; [Helwak, A.] Inst Biochem & Biophys PAS, Warsaw, Poland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Zylicz, M (corresponding author), Int Inst Mol & Cell Biol Warsaw, Dept Mol Biol, 4 Ksiecia Trojdena St, PL-02109 Warsaw, Poland.	mzylicz@iimcb.gov.pl; alicja.zylicz@iimcb.gov.pl	Olszewski, Maciej/C-2021-2015; Walerych, Dawid/I-2517-2016; Olszewski, Maciej/G-8396-2016	Olszewski, Maciej/0000-0003-0961-0801; Olszewski, Maciej/0000-0003-0961-0801; Walerych, Dawid/0000-0002-8440-1375; Zylicz, Alicja/0000-0003-4174-3073; Gutkowska, Malgorzata/0000-0001-6584-7964	Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw; Polish Ministry of Science and Higher Education	Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We thank Dr Marcin Klejman for sharing purified Hsp90b proteins; Professor Peter Csermely for the plasmid encoding human Hsp90a; Professor Ted Hupp for plasmid for p53 overexpression; Professor Richard Morimoto for plasmids encoding human Hsp70, Hdj1 and Hop; and Professor Kazutoyo Terada for construct for the Hdj2 overexpression. Dawid Walerych is the recipient of a scholarship from the Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw. This work was supported by a grant from the Polish Ministry of Science and Higher Education.	Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Butler JS, 2006, PROTEIN SCI, V15, P2457, DOI 10.1110/ps.062324206; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI 10.1016/j.febsiet.2007.05.039; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lee DW, 2005, J CELL SCI, V118, P4311, DOI 10.1242/jcs.02548; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller P, 2005, J BIOL CHEM, V280, P6682, DOI 10.1074/jbc.M412767200; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Pacey S, 2006, HANDB EXP PHARM, V172, P331; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sangster TA, 2004, BIOESSAYS, V26, P348, DOI 10.1002/bies.20020; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sreedhar AS, 2004, FEBS LETT, V562, P11; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Wells M, 2008, P NATL ACAD SCI USA, V105, P5762, DOI 10.1073/pnas.0801353105; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	47	58	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4284	4294		10.1038/onc.2009.281	http://dx.doi.org/10.1038/onc.2009.281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749793				2022-12-28	WOS:000272876300006
J	Montanez-Wiscovich, ME; Seachrist, DD; Landis, MD; Visvader, J; Andersen, B; Keri, RA				Montanez-Wiscovich, M. E.; Seachrist, D. D.; Landis, M. D.; Visvader, J.; Andersen, B.; Keri, R. A.			LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression	ONCOGENE			English	Article						breast cancer; cullin-3; ErbB2; HER2; LMO4	MAMMARY EPITHELIAL-CELLS; DOMAIN PROTEIN LMO4; MESSENGER-RNA STABILITY; ADJUVANT CHEMOTHERAPY; TRANSGENIC MICE; ERBB RECEPTORS; IN-VITRO; GENE; EXPRESSION; KINASE	ErbB2/HER2/Neu-overexpressing breast cancers are characterized by poor survival due to high proliferation and metastasis rates and identifying downstream targets of ErbB2 should facilitate developing novel therapies for this disease. Gene expression pro. ling revealed the transcriptional regulator LIM-only protein 4 (LMO4) is upregulated during ErbB2-induced mouse mammary gland tumorigenesis. Although LMO4 is frequently overexpressed in breast cancer and LMO4-overexpressing mice develop mammary epithelial tumors, the mechanisms involved are unknown. In this study, we report that LMO4 is a downstream target of ErbB2 and PI3K in ErbB2-dependent breast cancer cells. Furthermore, LMO4 silencing reduces proliferation of these cells, inducing a G2/M arrest that was associated with decreased cullin-3, an E3-ubiquitin ligase component important for mitosis. Loss of LMO4 subsequently results in reduced Cyclin D1 and Cyclin E. Further supporting a role for LMO4 in modulating proliferation by regulating cullin-3 expression, we found that LMO4 expression oscillates throughout the cell cycle with maximum expression occurring during G2/M and these changes precede oscillations in cullin-3 levels. LMO4 levels are also highest in high-grade/less differentiated breast cancers, which are characteristically highly proliferative. We conclude that LMO4 is a novel cell cycle regulator with a key role in mediating ErbB2-induced proliferation, a hallmark of ErbB2-positive disease. Oncogene (2009) 28, 3608-3618; doi:10.1038/onc.2009.221; published online 3 August 2009	[Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Visvader, J.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Victorian Breast Canc Res Consortium Lab, Parkville, Vic 3050, Australia; [Andersen, B.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; [Andersen, B.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; [Keri, R. A.] Case Western Reserve Univ, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of California System; University of California Irvine; University of California System; University of California Irvine; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	CURE [RO1-CA090398]; NIH [AR44882, T32-GM007250, F31-CA123642]; NATIONAL CANCER INSTITUTE [R01CA090398, F31CA123642, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	CURE; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jonathan Mosley for help with statistical analyses, Meredith Sorenson for technical support and members of the Keri laboratory, especially Gina Bernardo and Emhonta Johnson, for useful discussions. We are grateful for assistance from the Case Comprehensive Cancer Center core facilities (P30 CA43703). This work was supported by: RO1-CA090398 (RAK), CURE supplementary grant to RO1-CA090398 (RAK), NIH AR44882 (BA), T32-GM007250 (MEMW) and F31-CA123642 (MEMW).	Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CAPOROSSI D, 1995, HUM GENET, V96, P269; Chen HH, 2007, BIOCHEM BIOPH RES CO, V357, P56, DOI 10.1016/j.bbrc.2007.03.113; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Ismail IA, 2007, EUR J PHARMACOL, V575, P12, DOI 10.1016/j.ejphar.2007.07.039; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Junaid A, 2007, AM J PHYSIOL-CELL PH, V292, pC919, DOI 10.1152/ajpcell.00477.2006; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; Lewis GD, 1996, CANCER RES, V56, P1457; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mosley JD, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-11; Mousses S, 2002, CANCER RES, V62, P1256; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ribar B, 2007, MOL CELL BIOL, V27, P3211, DOI 10.1128/MCB.00091-07; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Sutherland KD, 2003, INT J CANCER, V107, P155, DOI 10.1002/ijc.11343; Taniwaki M, 2006, INT J ONCOL, V29, P567; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wang N, 2007, ONCOGENE, V26, P6431, DOI 10.1038/sj.onc.1210465; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wittlin S, 2003, GENOMICS, V82, P280, DOI 10.1016/S0888-7543(03)00147-2; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yakes FM, 2002, CANCER RES, V62, P4132; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	53	33	33	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3608	3618		10.1038/onc.2009.221	http://dx.doi.org/10.1038/onc.2009.221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648968	Green Accepted, Green Submitted			2022-12-28	WOS:000270851800002
J	Coulouarn, C; Factor, VM; Andersen, JB; Durkin, ME; Thorgeirsson, SS				Coulouarn, C.; Factor, V. M.; Andersen, J. B.; Durkin, M. E.; Thorgeirsson, S. S.			Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties	ONCOGENE			English	Article						hepatocellular carcinoma; microRNA; differentiation; metastasis; microarray	HUMAN HEPATOCELLULAR-CARCINOMA; C VIRUS-RNA; GENE-EXPRESSION; MICRORNA EXPRESSION; FUNCTIONAL GENOMICS; TUMOR-SUPPRESSOR; CELL-LINES; IN-VIVO; MOUSE; IDENTIFICATION	Growing evidence indicates that microRNAs have a significant role in tumor development and may constitute robust biomarkers for cancer diagnosis and prognosis. In this study, we evaluated the clinical and functional relevance of microRNA-122 (miR-122) expression in human hepatocellular carcinoma (HCC). We report that miR-122 is specifically repressed in a subset of primary tumors that are characterized by poor prognosis. We further show that the loss of miR-122 expression in tumor cells segregates with specific gene expression profiles linked to cancer progression, namely the suppression of hepatic phenotype and the acquisition of invasive properties. We identify liver-enriched transcription factors as central regulatory molecules in the gene networks associated with loss of miR-122, and provide evidence suggesting that miR-122 is under the transcriptional control of HNF1A, HNF3A and HNF3B. We further show that loss of miR-122 results in an increase of cell migration and invasion and that restoration of miR-122 reverses this phenotype. In conclusion, miR-122 is a marker of hepatocyte-specific differentiation and an important determinant in the control of cell migration and invasion. From a clinical point of view, our study emphasizes miR-122 as a diagnostic and prognostic marker for HCC progression. Oncogene (2009) 28, 3526-3536; doi: 10.1038/onc.2009.211; published online 20 July 2009	[Coulouarn, C.; Factor, V. M.; Andersen, J. B.; Durkin, M. E.; Thorgeirsson, S. S.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 4146A, Bethesda, MD 20892 USA.	snorri_s_thorgeirsson@nih.gov	Coulouarn, Cedric/E-5472-2011	Coulouarn, Cedric/0000-0002-5692-9586; Andersen, Jesper B/0000-0003-1760-5244	Intramural Research Program of the Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011173, ZIABC011170] Funding Source: NIH RePORTER	Intramural Research Program of the Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported in part by the Intramural Research Program of the Center for Cancer Research.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Braconi C, 2008, HEPATOLOGY, V47, P1807, DOI 10.1002/hep.22326; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang JH, 2008, J VIROL, V82, P8215, DOI 10.1128/JVI.02575-07; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Coulouarn C, 2006, HEPATOLOGY, V44, P1003, DOI 10.1002/hep.21293; Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Grise F, 2009, BBA-REV CANCER, V1795, P137, DOI 10.1016/j.bbcan.2008.12.003; Henke JI, 2008, EMBO J, V27, P3300, DOI 10.1038/emboj.2008.244; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Kaposi-Novak P, 2006, J CLIN INVEST, V116, P1582, DOI 10.1172/JCI27236; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kutay H, 2006, J CELL BIOCHEM, V99, P671, DOI 10.1002/jcb.20982; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; Li WX, 2008, INT J CANCER, V123, P1616, DOI 10.1002/ijc.23693; Lin CJF, 2008, BIOCHEM BIOPH RES CO, V375, P315, DOI 10.1016/j.bbrc.2008.07.154; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Tang XQ, 2007, RNA, V13, P1803, DOI 10.1261/rna.498607; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tzur G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003726; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Villanueva A, 2007, SEMIN LIVER DIS, V27, P55, DOI 10.1055/s-2006-960171; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; YOSHIOKA K, 1995, FEBS LETT, V372, P25, DOI 10.1016/0014-5793(95)00937-5	46	559	617	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3526	3536		10.1038/onc.2009.211	http://dx.doi.org/10.1038/onc.2009.211			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19617899	Green Accepted			2022-12-28	WOS:000270851700002
J	Helmbold, H; Komm, N; Deppert, W; Bohn, W				Helmbold, H.; Koemm, N.; Deppert, W.; Bohn, W.			Rb2/p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence	ONCOGENE			English	Article						Rb2/p130; p53; DNA-damage; senescence	ONCOGENE-INDUCED SENESCENCE; CELLULAR SENESCENCE; FAMILY-MEMBERS; IN-VIVO; ANTICANCER AGENTS; HUMAN FIBROBLASTS; TUMOR-CELLS; S PHASE; GENE; RETINOBLASTOMA	The different pocket proteins are established as negative cell cycle regulators. With regard to the repressor functions of pocket proteins in cellular senescence, studies so far have mainly focused on pRb/p105. Here, we show that in a broad range of wild-type p53-expressing human tumor cells, and in human diploid fibroblasts, Rb2/p130 is the dominating pocket protein in replicative and in accelerated senescence. Senescent cells are arrested at the transition from late G1- to early S-phase, as indicated by the absence of S- and G2-phase cyclins A and B. Expression of cyclin A and entry into S- phase resumed after RNA interference-mediated knockdown of Rb2/p130. Activation of different upstream pathways by overexpression of either p21 or p16 converged on Rb2/p130 accumulation and induced senescence. In contrast, p53- or p21-negative cells treated with DNA-damaging agents failed to accumulate Rb2/p130 and to enter senescence. Our data suggest that Rb2/p130 is a member of the p53-p21 DNA damage signaling cascade, and represents the essential pocket protein family member needed for the induction of any type of senescence. Oncogene (2009) 28, 3456-3467; doi: 10.1038/onc.2009.222; published online 3 August 2009	[Helmbold, H.; Koemm, N.; Deppert, W.; Bohn, W.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumorvirol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Helmbold, H (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumorvirol, Martinistr 52, D-20251 Hamburg, Germany.	heike.helmbold@hpi.uni-hamburg.de			Deutsche Krebshilfe; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit	Deutsche Krebshilfe(Deutsche Krebshilfe); Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit	This work was supported by a grant from Deutsche Krebshilfe (German Cancer Aid) to WB. The Heinrich-Pette-Institute is financially supported by Freie und Hansestadt Hamburg and Bundesministerium fur Gesundheit.	Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Helmbold H, 2006, ONCOGENE, V25, P5257, DOI 10.1038/sj.onc.1209613; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Li Qiang, 2004, Brain Tumor Pathol, V21, P121, DOI 10.1007/BF02482187; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Takahashi Y, 2000, GENE DEV, V14, P804; te Poele RH, 2002, CANCER RES, V62, P1876; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	40	38	39	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3456	3467		10.1038/onc.2009.222	http://dx.doi.org/10.1038/onc.2009.222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19648966				2022-12-28	WOS:000270478300003
J	Sun, J; Khalid, S; Rozakis-Adcock, M; Fantus, IG; Jin, T				Sun, J.; Khalid, S.; Rozakis-Adcock, M.; Fantus, I. G.; Jin, T.			P-21-activated protein kinase-1 functions as a linker between insulin and Wnt signaling pathways in the intestine	ONCOGENE			English	Article						insulin; beta-catenin; Wnt; PAK-1; c-Myc; ChIP	BETA-CATENIN; P21-ACTIVATED KINASE; COLORECTAL-CANCER; DIABETES-MELLITUS; COLON-CANCER; PHOSPHORYLATION; ACTIVATION; PAK1; RAS; EXPRESSION	Hyperinsulinemia and type II diabetes are associated with an increased risk of developing colorectal tumors. We found previously that in intestinal cells, insulin or insulin-like growth factor-1 stimulates c-Myc and cyclin D1 protein expression through both Akt-dependent and Akt-independent mechanisms. The effect of Akt is attributed to the stimulation of c-Myc translation by mammalian target of rapamycin. However, Akt-independent stimulation was, associated with an increase in beta-catenin (beta-cat) in the nucleus and an increased association between beta-cat and T-cell factor binding sites on the c-Myc promoter, detected by chromatin immunoprecipitation. In this study, we show that insulin stimulated the phosphorylation/activation of p-21-activated protein kinase-1 (PAK-1) in an Akt-independent manner in vitro and in an in vivo hyperinsulinemic mouse model. Significantly, shRNA (small hairpin RNA)-mediated PAK-1 knockdown attenuated both basal and insulin-stimulated c-Myc and cyclin D1 expression, associated with a marked reduction in extracellular signal-regulated kinase activation and beta-cat phosphorylation at Ser675. Furthermore, PAK-1 silencing led to a complete blockade of insulin-stimulated beta-cat binding to the c-Myc promoter and cellular growth. Finally, inhibition of MEK, a downstream target of PAK-1, blocked insulin-stimulated nuclear beta-cat accumulation and c-Myc expression. Our observations suggest that PAK-1 serves as an important linker between insulin and Wnt signaling pathways. Oncogene (2009) 28, 3132-3144; doi: 10.1038/onc.2009.167; published online 6 July 2009	[Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada; [Khalid, S.; Fantus, I. G.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Sun, J.; Rozakis-Adcock, M.; Jin, T.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Sun, J.; Khalid, S.; Fantus, I. G.; Jin, T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto	Jin, T (corresponding author), Univ Hlth Network, Div Cell & Mol Biol, 10-354 Toronto Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	tianru.jin@utoronto.ca			Banting and Best Diabetes Centre (BBDC); Canadian Institutes of Health Research [MOP-89987]; Canadian Breast Cancer Research Alliance/CIHR [016512]	Banting and Best Diabetes Centre (BBDC); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Research Alliance/CIHR(Canadian Institutes of Health Research (CIHR))	We thank Dr Jeffrey Field (University of Pennsylvania) for providing the dominant negative PAK-1 (K299R), constitutively active PAK-1 (T423E) and control plasmids. JS is a recipient of Banting and Best Diabetes Centre (BBDC) Novo Nordisk graduate studentship (2004-2008). This study was supported by an operating grant from Canadian Institutes of Health Research to TJ (MOP-89987) and a Translational Acceleration Research Grant from the Canadian Breast Cancer Research Alliance/CIHR (# 016512) to IGF.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Akinmade D, 2008, BRIT J CANCER, V98, P1132, DOI 10.1038/sj.bjc.6604261; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bustin SA, 2001, TRENDS MOL MED, V7, P447, DOI 10.1016/S1471-4914(01)02104-9; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Clements Wilson M, 2003, Clin Colorectal Cancer, V3, P113, DOI 10.3816/CCC.2003.n.018; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Dong YF, 2006, J CELL PHYSIOL, V208, P77, DOI 10.1002/jcp.20656; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Elwing JE, 2006, AM J GASTROENTEROL, V101, P1866, DOI 10.1111/j.1572-0241.2006.00651.x; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Giovannucci E, 2007, AM J CLIN NUTR, V86, p836S, DOI 10.1093/ajcn/86.3.836S; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lewin HS, 2008, J MED LIBR ASSOC, V96, P155, DOI 10.3163/1536-5050.96.2.155; Li JN, 2005, GASTROENTEROLOGY, V128, P1907, DOI 10.1053/j.gastro.2005.02.067; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu ZY, 2008, J BIOL CHEM, V283, P8723, DOI 10.1074/jbc.M706105200; Ma J, 2004, JNCI-J NATL CANCER I, V96, P546, DOI 10.1093/jnci/djh082; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; OLNES MJ, 1994, BIOTECHNIQUES, V17, P828; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Smith SD, 2008, J CELL SCI, V121, P3729, DOI 10.1242/jcs.027680; Sun J, 2008, CELL SIGNAL, V20, P219, DOI 10.1016/j.cellsig.2007.10.010; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tran TT, 1996, CANCER EPIDEM BIOMAR, V5, P1013; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Wang PX, 2003, BIOCHEM J, V375, P199, DOI 10.1042/BJ20030579; Yi FH, 2008, ENDOCRINOLOGY, V149, P2341, DOI 10.1210/en.2007-1142; Yi FH, 2005, J BIOL CHEM, V280, P1457, DOI 10.1074/jbc.M411487200; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200; Zhou GL, 2004, CANCER BIOL THER, V3, P102, DOI 10.4161/cbt.3.1.691; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	67	49	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3132	3144		10.1038/onc.2009.167	http://dx.doi.org/10.1038/onc.2009.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19581924				2022-12-28	WOS:000269515100005
J	Satyanarayana, A; Kaldis, P				Satyanarayana, A.; Kaldis, P.			Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms	ONCOGENE			English	Review						cell cycle; cyclin; Cdk; DNA damage; meiosis; knockout mouse	RNA-POLYMERASE-II; DEPENDENT KINASES; PROTEIN-KINASE; ACTIVATING KINASE; S-PHASE; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; IN-VIVO; SUBCELLULAR-LOCALIZATION; CENTROSOME DUPLICATION	After a decade of extensive work on gene knockout mouse models of cell-cycle regulators, the classical model of cell-cycle regulation was seriously challenged. Several unexpected compensatory mechanisms were uncovered among cyclins and Cdks in these studies. The most astonishing observation is that Cdk2 is dispensable for the regulation of the mitotic cell cycle with both Cdk4 and Cdk1 covering for Cdk2's functions. Similar to yeast, it was recently discovered that Cdk1 alone can drive the mammalian cell cycle, indicating that the regulation of the mammalian cell cycle is highly conserved. Nevertheless, cell-cycle-independent functions of Cdks and cyclins such as in DNA damage repair are still under investigation. Here we review the compensatory mechanisms among major cyclins and Cdks in mammalian cell-cycle regulation. Oncogene (2009) 28, 2925-2939; doi:10.1038/onc.2009.170; published online 29 June 2009	[Kaldis, P.] IMCB, Lab Cell Div & Canc, Singapore 138673, Singapore; [Satyanarayana, A.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaldis, P (corresponding author), IMCB, Lab Cell Div & Canc, 61 Biopolis Dr,Proteos,3-10B, Singapore 138673, Singapore.	satya@ncifcrf.gov; kaldis@imcb.a-star.edu.sg	Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591	A*STAR of Singapore (PK); NIH; National Cancer Institute; Center for Cancer Research	A*STAR of Singapore (PK)(Agency for Science Technology & Research (A*STAR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kaldis lab members for discussions and support. This research was supported by A*STAR of Singapore (PK) and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (AS).	Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-7; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Argraves WS, 2005, ANAT REC PART A, V286A, P875, DOI 10.1002/ar.a.20232; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheung ZH, 2006, NEURON, V50, P13, DOI 10.1016/j.neuron.2006.02.024; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coverley D, 2000, J CELL SCI, V113, P1929; Cruz JC, 2004, TRENDS MOL MED, V10, P452, DOI 10.1016/j.molmed.2004.07.001; Dhar KK, 1999, BRIT J CANCER, V81, P1174, DOI 10.1038/sj.bjc.6690826; Dhavan R, 2002, J NEUROSCI, V22, P7879; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ericson KK, 2003, MOL CANCER RES, V1, P654; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fischer A, 2005, NEURON, V48, P825, DOI 10.1016/j.neuron.2005.10.033; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fisher RP, 1996, BBA-REV CANCER, V1288, pO7, DOI 10.1016/0304-419X(96)00016-9; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Huang D, 2007, MOL MICROBIOL, V66, P303, DOI 10.1111/j.1365-2958.2007.05914.x; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jablonska B, 2007, J CELL BIOL, V179, P1231, DOI 10.1083/jcb.200702031; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kang MJ, 1997, EXP CELL RES, V234, P27, DOI 10.1006/excr.1997.3590; Kowalczyk A, 2004, J CELL BIOL, V167, P209, DOI 10.1083/jcb.200404181; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Li TY, 2004, MOL CELL BIOL, V24, P3188, DOI 10.1128/MCB.24.8.3188-3197.2004; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Loyer P, 1998, J CELL SCI, V111, P1495; Lozano JC, 2002, BIOCHEM BIOPH RES CO, V291, P406, DOI 10.1006/bbrc.2002.6458; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nguyen TB, 2002, J BIOL CHEM, V277, P41960, DOI 10.1074/jbc.M203951200; Nieduszynski CA, 2002, GENOME BIOL, V3; OConnor PM, 1997, CANCER SURV, V29, P151; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OOKATA K, 1993, J CELL SCI, V105, P873; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013; Parekh V, 2004, MOL CELL BIOL, V24, P7113, DOI 10.1128/MCB.24.16.7113-7129.2004; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Pogoriler J, 2006, DEVELOPMENT, V133, P3929, DOI 10.1242/dev.02556; Qu D, 2007, NEURON, V55, P37, DOI 10.1016/j.neuron.2007.05.033; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ravnik SE, 1999, DEV BIOL, V207, P408, DOI 10.1006/dbio.1998.9156; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2004, DEV CELL, V6, P607, DOI 10.1016/S1534-5807(04)00137-6; Sano M, 2003, CELL CYCLE, V2, P99, DOI 10.4161/cc.2.2.332; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Satyanarayana A, 2008, DEVELOPMENT, V135, P3389, DOI 10.1242/dev.024919; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SOLOMON M, 1988, CELL, V54, P738, DOI 10.1016/S0092-8674(88)90933-6; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Susaki E, 2007, MOL CELL BIOL, V27, P4626, DOI 10.1128/MCB.00862-06; Sweeney C, 1996, DEVELOPMENT, V122, P53; Takaki T, 2005, J BIOCHEM, V137, P381, DOI 10.1093/jb/mvi050; Tetzlaff MT, 2004, MOL CELL BIOL, V24, P2487, DOI 10.1128/MCB.24.6.2487-2498.2004; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Waclaw RR, 2004, ZYGOTE, V12, P19, DOI 10.1017/S0967199404002552; Wang S, 2008, TRENDS PHARMACOL SCI, V29, P302, DOI 10.1016/j.tips.2008.03.003; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	123	513	540	3	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2925	2939		10.1038/onc.2009.170	http://dx.doi.org/10.1038/onc.2009.170			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19561645				2022-12-28	WOS:000269142800001
J	Baras, A; Yu, Y; Filtz, M; Kim, B; Moskaluk, CA				Baras, A.; Yu, Y.; Filtz, M.; Kim, B.; Moskaluk, C. A.			Combined genomic and gene expression microarray profiling identifies ECOP as an upregulated gene in squamous cell carcinomas independent of DNA amplification	ONCOGENE			English	Article						squamous cell carcinoma; tobacco; microarray; ECOP; EGFR	CANCER; MARKERS; NECK; HEAD	To identify dysregulated genes that may play a role in the pathogenesis of tobacco-related human squamous cell carcinoma (SCC), a cohort of SCCs from smokers (29 SCC of the head and neck, 3 SCC of the esophagus and 46 SCC of the lungs) were concomitantly analyzed for gene expression using Affymetrix U133A 2.0 arrays and for genomic variation using Affymetrix Human Mapping 100K set. Gene expression profiling clearly separated benign squamous mucosa (BSM) from SCC and identified several candidate genes relevant to the biology of SCC. The single-nucleotide polymorphism array data adapted for copy number analysis identified two discrete areas of high-level genomic amplification, including 7p11.2 (EGFR (epidermal growth factor receptor)) and 11q13.3 (CCND1 (cyclin D1)). When gene expression measures were correlated with amplification status at 7p11.2 locus, EGFR overexpression in relation to benign tissue was dependent on amplification and occurred in only 9% of cases. However, an adjacent gene (similar to 0.4 Mb), EGFR-co-amplified and overexpressed protein (ECOP), showed strong over-expression in the majority (90%) of SCCs regardless of gene amplification status. This finding was corroborated with quantitative real-time PCR assays and protein immunoblots. Interestingly, small interfering RNA-mediated knockdown of ECOP gene products in a SCC cell line (SCC-9) resulted in increased cell death. The results of these studies identify ECOP as a protein relevant to the biology of SCC. Oncogene (2009) 28, 2919-2924; doi:10.1038/onc.2009.150; published online 15 June 2009	[Baras, A.; Yu, Y.; Filtz, M.; Kim, B.; Moskaluk, C. A.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Moskaluk, C. A.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, 3024 Univ Hosp,POB 800214, Charlottesville, VA 22908 USA.	cam5p@virginia.edu			National Institutes of Health (USA) [T32 GM008715]; Virginia Tobacco Settlement Foundation; University of Virginia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK067629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267, T32GM008715] Funding Source: NIH RePORTER	National Institutes of Health (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Virginia Tobacco Settlement Foundation; University of Virginia; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We wish to thank Ms Angela Miller for her support of the histological techniques required to carry out these studies. We wish to thank Dr Patcharin Pramoonjago for assistance in the creation and evaluation of antibody reagents to the ECOP protein. Alex Baras is a member of the Biotechnology Training Program at The University of Virginia, supported by training grant, T32 GM008715, from the National Institutes of Health (USA). These studies were primarily supported by a grant from the Virginia Tobacco Settlement Foundation. This project was also supported, in part, by a gift provided to the University of Virginia by Philip Morris USA. The review and approval process was overseen by an External Advisory Committee without any affiliation with the University, PM USA, or any other tobacco company. Funding for this project was based upon independent intramural and extramural reviews.	Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Eley GD, 2002, NEURO-ONCOLOGY, V4, P86, DOI 10.1093/neuonc/4.2.86; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Park S, 2005, ONCOGENE, V24, P2495, DOI 10.1038/sj.onc.1208496; Singh B, 2008, J SURG ONCOL, V97, P634, DOI 10.1002/jso.21024; Stewart Sherri L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Toruner GA, 2004, CANCER GENET CYTOGEN, V154, P27, DOI 10.1016/j.cancergencyto.2004.01.026; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176	10	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2919	2924		10.1038/onc.2009.150	http://dx.doi.org/10.1038/onc.2009.150			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19525979				2022-12-28	WOS:000268917100008
J	Hernando, E; Sarmentero-Estrada, J; Koppie, T; Belda-Iniesta, C; de Molina, VR; Cejas, P; Ozu, C; Le, C; Sanchez, JJ; Gonzalez-Baron, M; Koutcher, J; Cordon-Cardo, C; Bochner, BH; Lacal, JC; de Molina, AR				Hernando, E.; Sarmentero-Estrada, J.; Koppie, T.; Belda-Iniesta, C.; de Molina, V. Ramirez; Cejas, P.; Ozu, C.; Le, C.; Sanchez, J. J.; Gonzalez-Baron, M.; Koutcher, J.; Cordon-Cardo, C.; Bochner, B. H.; Lacal, J. C.; de Molina, A. Ramirez			A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas	ONCOGENE			English	Article						bladder cancer; choline kinase; therapeutic target; tumor promoter	TRANSITIONAL-CELL CARCINOMA; ONCOGENE ADDICTION; RADICAL CYSTECTOMY; HUMAN CANCER; INHIBITION; CARCINOGENESIS; PROLIFERATION; MECHANISM; STRATEGY; THERAPY	Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-alpha (ChoK alpha) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoK alpha show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoK alpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoK alpha is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoK alpha potentiate both tumor formation (P <= 0.0001) and aggressiveness of the disease on different end points (P = 0.011). Accordingly, increased levels of ChoK alpha significantly reduce survival of mice with bladder cancer (P = 0.05). Finally, treatment with a ChoK alpha-specific inhibitor resulted in a significant inhibition of tumor growth (P = 0.02) and in a relevant increase in survival (P = 0.03). Oncogene (2009) 28, 2425-2435; doi:10.1038/onc.2009.91; published online 18 May 2009	[Sarmentero-Estrada, J.; Lacal, J. C.; de Molina, A. Ramirez] Natl Biotechnol Ctr, TCD Pharma, Madrid 28049, Spain; [Bochner, B. H.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Belda-Iniesta, C.; Cejas, P.; Gonzalez-Baron, M.] CSIC UAM La Paz, Hosp Univ La Paz, Div Med Oncol, Translat Oncol Unit, Madrid, Spain; [de Molina, V. Ramirez] Hosp Clin San Carlos, Madrid, Spain; [Sanchez, J. J.] Univ Autonoma Madrid, Dept Stat, E-28049 Madrid, Spain; [Lacal, J. C.; de Molina, A. Ramirez] CSIC UAM La Paz, Translat Oncol Unit, Inst Invest Biomed, Madrid, Spain	Memorial Sloan Kettering Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario La Paz; Hospital Clinico San Carlos; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	de Molina, AR (corresponding author), Natl Biotechnol Ctr, TCD Pharma, Darwin 3, Madrid 28049, Spain.	aramirez@cnb.csic.es	estrada, jacinto sarmentero/C-6777-2019; Le, Hongbiao/H-4735-2011; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	estrada, jacinto sarmentero/0000-0002-0118-4919; Bochner, Bernard/0000-0003-0846-0848; Hernando, Eva/0000-0003-1023-0312; Belda Iniesta, Cristobal/0000-0003-3254-7492; Lacal, Juan Carlos/0000-0002-1908-2777	NCI NIH HHS [R24 CA083084, R24 CA083084-08, 1R24CA83084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA083084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; CHIN J, 1991, J UROLOGY, V145, P1297, DOI 10.1016/S0022-5347(17)38618-4; CordonCardo C, 1997, CANCER RES, V57, P1217; Gallego-Ortega D, 2006, INT J ONCOL, V29, P335; GALLEGOORTEGA D, DIFFERENTIAL R UNPUB; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kikuchi E, 2004, CLIN CANCER RES, V10, P1835, DOI 10.1158/1078-0432.CCR-03-0099; Kikuchi E, 2003, J UROLOGY, V170, P1375, DOI 10.1097/01.ju.0000075504.13456.41; Lacal J C, 2001, IDrugs, V4, P419; Lu ML, 2002, CLIN CANCER RES, V8, P171; Mullerad M, 2005, J UROLOGY, V174, P741, DOI 10.1097/01.ju.0000164730.38431.5c; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Oliveira P. A., 2006, Experimental Oncology, V28, P2; Quek ML, 2005, J UROLOGY, V174, P103, DOI 10.1097/01.ju.0000163267.93769.d8; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Rodriguez-Gonzalez A, 2004, ONCOGENE, V23, P8247, DOI 10.1038/sj.onc.1208045; Sanderson KM, 2007, J UROLOGY, V177, P2088, DOI 10.1016/j.juro.2007.01.133; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697	34	52	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2425	2435		10.1038/onc.2009.91	http://dx.doi.org/10.1038/onc.2009.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448670	Green Accepted			2022-12-28	WOS:000267601400001
J	Lindberg, N; Kastemar, M; Olofsson, T; Smits, A; Uhrbom, L				Lindberg, Nanna; Kastemar, M.; Olofsson, T.; Smits, A.; Uhrbom, L.			Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma	ONCOGENE			English	Article						glioma; cell of origin; neural stem cell; oligodendrocyte progenitor cell; glial cell; PDGF	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; PDGF ALPHA-RECEPTOR; IN-VIVO; GENE-TRANSFER; NG2 PROTEOGLYCAN; SONIC HEDGEHOG; NUCLEOTIDE 3'-PHOSPHODIESTERASE; MEDULLOBLASTOMA FORMATION	Gliomas are primary brain tumors mainly affecting adults. The cellular origin is unknown. The recent identification of tumor-initiating cells in glioma, which share many similarities with normal neural stem cells, has suggested the cell of origin to be a transformed neural stem cell. In previous studies, using the RCAS/tv-a mouse model, platelet-derived growth factor B (PDGF-B)induced gliomas have been generated from nestin or glial fibrillary acidic protein-expressing cells, markers of neural stem cells. To investigate if committed glial progenitor cells could be the cell of origin for glioma, we generated the Ctv-a mouse where tumor induction would be restricted to myelinating oligodendrocyte progenitor cells (OPCs) expressing 2',3'-cyclic nucleotide 3'-phosphodiesterase. We showed that PDGF-B transfer to OPCs could induce gliomas with an incidence of 33%. The majority of tumors resembled human WHO grade II oligodendroglioma based on close similarities in histopathology and expression of cellular markers. Thus, with the Ctv-a mouse we have showed that the cell of origin for glioma may be a committed glial progenitor cell. Oncogene (2009) 28, 2266-2275; doi: 10.1038/onc.2009.76; published online 27 April 2009	[Lindberg, Nanna; Kastemar, M.; Olofsson, T.; Uhrbom, L.] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Uppland, Sweden; [Smits, A.] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskoldsvag 20, SE-75185 Uppsala, Uppland, Sweden.	lene.uhrbom@genpat.uu.se	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	Swedish Cancer Society; Swedish Research Council; Association for International Cancer Research; Lars Hiertas Minne; Jeansson's Foundation; Magn. Bergvall's Foundation; Ake Wiberg's Foundation; Department of Genetics and Pathology; Medical Faculty of Uppsala University	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research; Lars Hiertas Minne; Jeansson's Foundation; Magn. Bergvall's Foundation; Ake Wiberg's Foundation; Department of Genetics and Pathology; Medical Faculty of Uppsala University	We thank Michel Gravel for the mouse Cnp promoter DNA and Karin Forsberg-Nilsson for the pTG8 plasmid. This work was supported by grants from The Swedish Cancer Society, The Swedish Research Council, Association for International Cancer Research, Lars Hiertas Minne, Jeansson's Foundation, Magn. Bergvall's Foundation, Ake Wiberg's Foundation, the Department of Genetics and Pathology and the Medical Faculty of Uppsala University.	BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Ferletta M, 2007, MOL CANCER RES, V5, P891, DOI 10.1158/1541-7786.MCR-07-0113; Fults D, 2002, NEOPLASIA, V4, P32, DOI 10.1038/sj.neo.7900200; Gravel M, 1998, J NEUROSCI RES, V53, P393; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; ONeill RC, 1997, J NEUROSCI RES, V50, P248; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; TCHOUGOUNOVA E, 2007, ONCOGENE; Uhrbom L, 2001, J NEURO-ONCOL, V53, P297, DOI 10.1023/A:1012208314436; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; Yuan XQ, 2002, J NEUROSCI RES, V70, P529, DOI 10.1002/jnr.10368	45	127	130	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2266	2275		10.1038/onc.2009.76	http://dx.doi.org/10.1038/onc.2009.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421151				2022-12-28	WOS:000266886300003
J	Kitagawa, K; Hiramatsu, Y; Uchida, C; Isobe, T; Hattori, T; Oda, T; Shibata, K; Nakamura, S; Kikuchi, A; Kitagawa, M				Kitagawa, K.; Hiramatsu, Y.; Uchida, C.; Isobe, T.; Hattori, T.; Oda, T.; Shibata, K.; Nakamura, S.; Kikuchi, A.; Kitagawa, M.			Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb	ONCOGENE			English	Article						c-Myb; ubiquitin-proteasome; Fbw7; phosphorylation; GSK3	F-BOX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; T-CELL LEUKEMIA; CYCLIN-E; TUMOR-SUPPRESSOR; FBXW7 ACTS; DIFFERENTIATION; LIGASE; PROTEOLYSIS	Expression of oncoprotein c-Myb oscillates during hematopoiesis and hematological malignancies. Its quantity is not only regulated through transcriptional control but also through the ubiquitin-proteasome pathway, accompanied by phosphorylation, although the mechanisms are poorly understood. In this report, we tried to identify an E3 ubiquitin ligase, which targets c-Myb for ubiquitin-dependent degradation. We found that an F-box protein, Fbw7, interacted with c-Myb, which is mutated in numerous cancers. Fbw7 facilitated ubiquitylation and degradation of c-Myb in intact cells. Moreover, depletion of Fbw7 by RNA interference delayed turnover and increased the abundance of c-Myb in myeloid leukemia cells concomitantly, and suppressed the transcriptional level of gamma-globin, which receives transcriptional repression from c-Myb. In addition, we analysed sites required for both ubiquitylation and degradation of c-Myb. We found that Thr-572 is critical for Fbw7-mediated ubiquitylation in mouse c-Myb using site-directed mutagenesis. Fbw7 recognized the phosphorylation of Thr-572, which was mediated by glycogen synthase kinase 3 (GSK3). In consequence, the c-Myb protein was markedly stabilized by the substitution of Thr-572 to Ala. These observations suggest that SCFFbw7 ubiquitin ligase regulates phosphorylation-dependent degradation of c-Myb protein. Oncogene (2009) 28, 2393-2405; doi:10.1038/onc.2009.111; published online 4 May 2009	[Kitagawa, K.; Hiramatsu, Y.; Uchida, C.; Isobe, T.; Hattori, T.; Oda, T.; Kitagawa, M.] Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Hiramatsu, Y.] Hamamatsu Univ Sch Med, Dept Surg, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Shibata, K.] Hamamatsu Univ Sch Med, Res Equipment Ctr, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Nakamura, S.] Hamamatsu Univ Sch Med, Dept Internal Med 3, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Kikuchi, A.] Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hiroshima University	Kitagawa, M (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	kitamasa@hama-med.ac.jp		Hiramatsu, Yoshihiro/0000-0003-1448-1610	Ministry of Education, Science, Sports, Culture and Technology of Japan; COE program of Hamamatsu University School of Medicine	Ministry of Education, Science, Sports, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); COE program of Hamamatsu University School of Medicine	We thank Yojiro Kotake, Keiichi I Nakayama, Masaki Matsumoto, Akinobu Matsumoto and Issay Kitabayashi for providing plasmids and useful discussions, and Sayuri Suzuki, Tomomi Abe, Ning Liu, Harumi Shiratori, Daisuke Hiraoka, Daizo Ueno, Yasue Kirita, Tatsuya Kobayashi, Konomi Mizuguchi, Erina Nihashi, Syuhei Iizuka, Daisuke Ichikawa and Naohiro Takamoto for their technical assistance. This study was supported in part by grants from the Ministry of Education, Science, Sports, Culture and Technology of Japan (MK and KK), by a COE program of Hamamatsu University School of Medicine from the Ministry of Education, Science, Sports, Culture and Technology of Japan (MK).	Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bies J, 2001, BLOOD CELL MOL DIS, V27, P422, DOI 10.1006/bcmd.2001.0400; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Corradini F, 2005, J BIOL CHEM, V280, P30254, DOI 10.1074/jbc.M504703200; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Feikova S, 2000, NEOPLASMA, V47, P212; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Goto H, 2007, NAT PROTOC, V2, P2574, DOI 10.1038/nprot.2007.374; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Jiang J, 2006, BLOOD, V108, P1077, DOI 10.1182/blood-2006-01-008912; Kanei-Ishii C, 2004, J BIOL CHEM, V279, P44582, DOI 10.1074/jbc.M407831200; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; Kanei-Ishii C, 2008, J BIOL CHEM, V283, P30540, DOI 10.1074/jbc.M804340200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lahortiga I, 2007, NAT GENET, V39, P593, DOI 10.1038/ng2025; Lieu YK, 2004, P NATL ACAD SCI USA, V101, P14853, DOI 10.1073/pnas.0405338101; Matsumoto A, 2006, BIOCHEM BIOPH RES CO, V350, P114, DOI 10.1016/j.bbrc.2006.09.003; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Onoyama I, 2007, J EXP MED, V204, P2875, DOI 10.1084/jem.20062299; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sharma VM, 2007, CELL CYCLE, V6, P927, DOI 10.4161/cc.6.8.4134; SIEGERT W, 1990, EUR J CANCER, V26, P733, DOI 10.1016/0277-5379(90)90130-L; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamamoto H, 2007, GENES CELLS, V12, P1215, DOI 10.1111/j.1365-2443.2007.01128.x	56	49	52	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2393	2405		10.1038/onc.2009.111	http://dx.doi.org/10.1038/onc.2009.111			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421138				2022-12-28	WOS:000267342400004
J	Kwek, SS; Roy, R; Zhou, H; Climent, J; Martinez-Climent, JA; Fridlyand, J; Albertson, DG				Kwek, S. S.; Roy, R.; Zhou, H.; Climent, J.; Martinez-Climent, J. A.; Fridlyand, J.; Albertson, D. G.			Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis	ONCOGENE			English	Article						gene amplification; array CGH; breast cancer; 8p12; 11q13; CCND1	CANCER CELL-LINES; 8P11-12 AMPLICON; THERAPEUTIC TARGET; DNA AMPLIFICATION; INSTABILITY; FGFR1; COAMPLIFICATION; REARRANGEMENTS; ABERRATIONS	Co-amplification at chromosomes 8p11-8p12 and 11q12-11q14 occurs often in breast tumors, suggesting possible cooperation between genes in these regions in oncogenesis. We used high-resolution array comparative genomic hybridization (array CGH) to map the minimal amplified regions. The 8p and 11q amplicons are complex and consist of at least four amplicon cores at each site. Candidate oncogenes mapping to these regions were identified by combining copy number and RNA and protein expression analyses. These studies also suggested that CCND1 at 11q13 induced expression of ZNF703 mapping at 8p12, which was subsequently shown to be mediated by the Rb/E2F pathway. Nine candidate oncogenes from 8p12 and four from 11q13 were further evaluated for oncogenic function. None of the genes individually promoted colony formation in soft agar or collaborated with each other functionally. On the other hand, FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53. These observations highlight the complexity and functional consequences of the genomic rearrangements that occur in these breast cancer amplicons, including transcriptional cross-talk between genes in the 8p and 11q amplicons, as well as their cooperation with major pathways of tumorigenesis.	[Albertson, D. G.] Univ Calif San Francisco, Canc Res Inst, San Francisco Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Roy, R.; Fridlyand, J.; Albertson, D. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Climent, J.] Hosp Clin, Dept Hematol & Med Oncol, Valencia, Spain; [Martinez-Climent, J. A.] Univ Navarra, Div Oncol, Ctr Appl Med Res CIMA, E-31080 Pamplona, Spain; [Fridlyand, J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Albertson, D. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Navarra; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, San Francisco Comprehens Canc Ctr, 2340 Sutter St,Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu	Martinez-Climent, Jose A/I-9199-2012; Climent, Joan/O-5877-2017	Martinez-Climent, Jose A/0000-0002-7938-3950; Climent, Joan/0000-0002-8927-6614	NIH [CA90421, CA101359]; DOD BCRP [BC021074, DAMD17-03-1-0483]; NATIONAL CANCER INSTITUTE [R01CA101359, R01CA090421] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the UCSF Helen Diller Family Comprehensive Cancer Center Genome Analysis, Informatics, and Microarray Shared Resources for performing the TaqMan assays and printing the custom 8p11q array. This work was supported by NIH Grants CA90421 and CA101359. Serena S Kwek was the recipient of a DOD BCRP fellowship, Grant nos. BC021074, DAMD17-03-1-0483.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Agrawal A, 2006, EXP MOL PATHOL, V81, P115, DOI 10.1016/j.yexmp.2006.07.001; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Climent J, 2007, CANCER RES, V67, P818, DOI 10.1158/0008-5472.CAN-06-3307; Cuny M, 2000, CANCER RES, V60, P1077; ETHIER SP, 1993, CANCER RES, V53, P627; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Kan CE, 2007, CANCER RES, V67, P9862, DOI 10.1158/0008-5472.CAN-07-0259; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Melchor L, 2007, INT J CANCER, V120, P714, DOI 10.1002/ijc.22354; Mineta H, 1997, ORAL ONCOL, V33B, P42, DOI 10.1016/S0964-1955(96)00039-5; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Patel DM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0802030; Paterson AL, 2007, GENE CHROMOSOME CANC, V46, P427, DOI 10.1002/gcc.20424; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Rodriguez C, 2004, CLIN CANCER RES, V10, P5785, DOI 10.1158/1078-0432.CCR-03-0410; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tashiro E, 2003, CANCER RES, V63, P424; Wang B, 1997, ANTICANCER RES, V17, P4387; Willmarth NE, 2004, BREAST CANCER RES, V6, pR531, DOI 10.1186/bcr900; Xian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2007, INT J CANCER, V121, P1265, DOI 10.1002/ijc.22831; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013	46	80	82	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1892	1903		10.1038/onc.2009.34	http://dx.doi.org/10.1038/onc.2009.34			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330026	Green Accepted			2022-12-28	WOS:000265640600002
J	Ito, K; Inoue, K; Bae, SC; Ito, Y				Ito, K.; Inoue, K-i; Bae, S-C; Ito, Y.			Runx3 expression in gastrointestinal tract epithelium: resolving the controversy	ONCOGENE			English	Article						detection of Runx3; immunohistochemistry; gastrointestinal epithelial cells; monoclonal antibody	ROOT GANGLION NEURONS; GASTRIC-CANCER; GROWTH-FACTOR; TUMOR-SUPPRESSOR; REGULATES DEVELOPMENT; CELLS; GENE; ADENOCARCINOMA; METASTASIS; RUNX1/AML1	We reported earlier that RUNX3 is expressed in human and mouse gastrointestinal tract (GIT) epithelium and that it functions as a tumor suppressor in gastric and colorectal tissues. However, there have been conflicting reports describing the absence of Runx3 in GIT epithelial cells. A part of the controversy may be derived from the use of a specific antibody by other groups ( referred to as G-poly). Here, we show further evidence to support our earlier observations and provide a possible explanation for this apparent controversy. We generated multiple anti-RUNX3 monoclonal antibodies and found that RUNX3 antibodies recognizing the RUNX3 N-terminal region (residues 1-234) react with RUNX3 in gastric epithelial cells, whereas those recognizing the C-terminal region (beyond residue 234) did not. G-poly primarily recognizes the region beyond 234 and hence, is unable to detect Runx3 in this tissue.	[Ito, K.; Inoue, K-i; Ito, Y.] Inst Mol & Cell Biol, Singapore 138673, Singapore; [Ito, K.; Ito, Y.] Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; [Bae, S-C] Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju, South Korea; [Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Chungbuk National University; Chungbuk National University	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg						Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Carvalho R, 2005, ONCOGENE, V24, P8252, DOI 10.1038/sj.onc.1208963; Chen AI, 2006, NEURON, V49, P395, DOI 10.1016/j.neuron.2005.12.028; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Katuri V, 2006, ONCOGENE, V25, P1871, DOI 10.1038/sj.onc.1209211; Kramer I, 2006, NEURON, V49, P379, DOI 10.1016/j.neuron.2006.01.008; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Marmigere F, 2006, NAT NEUROSCI, V9, P180, DOI 10.1038/nn1631; Nakamura S, 2008, DEVELOPMENT, V135, P1703, DOI 10.1242/dev.015248; Osaki M, 2004, EUR J CLIN INVEST, V34, P605, DOI 10.1111/j.1365-2362.2004.01401.x; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Usui T, 2006, INT J ONCOL, V29, P779; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zavros Y, 2005, ONCOGENE, V24, P2354, DOI 10.1038/sj.onc.1208407	29	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2009	28	10					1379	1384		10.1038/onc.2008.496	http://dx.doi.org/10.1038/onc.2008.496			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169278				2022-12-28	WOS:000264116000010
J	Joannes, A; Bonnomet, A; Bindels, S; Polette, M; Gilles, C; Burlet, H; Cutrona, J; Zahm, JM; Birembaut, P; Nawrocki-Raby, B				Joannes, A.; Bonnomet, A.; Bindels, S.; Polette, M.; Gilles, C.; Burlet, H.; Cutrona, J.; Zahm, J-M; Birembaut, P.; Nawrocki-Raby, B.			Fhit regulates invasion of lung tumor cells	ONCOGENE			English	Article						Fhit; tumor invasion; epithelial-mesenchymal transition; cell-cell adhesion molecules; matrix metalloproteinases; vimentin	FRAGILE HISTIDINE TRIAD; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; BETA-CATENIN; SUPPRESSES TUMORIGENICITY; ZONULA OCCLUDENS-1; PROTEIN EXPRESSION; GENE; CARCINOMA	In many types of cancers, the fragile histidine triad (Fhit) gene is frequently targeted by genomic alterations leading to a decrease or loss of gene and protein expression. Fhit has been described as a tumor suppressor gene because of its ability to induce apoptosis and to inhibit proliferation of tumor cells. Moreover, several studies have shown a correlation between the lack of Fhit expression and tumor aggressiveness, thus suggesting that Fhit could be involved in tumor progression. In this study, we explored the potential role of Fhit during tumor cell invasion. We first showed that a low Fhit expression is associated with in vivo and in vitro invasiveness of tumor cells. Then, we showed that Fhit overexpression in Fhit-negative highly invasive NCI-H1299 cells by transfection of Fhit cDNA and Fhit inhibition in Fhit-positive poorly invasive HBE4-E6/E7 cells by transfection of Fhit small interfering RNA induce, respectively, a decrease and an increase in migratory/invasive capacities. These changes in cell behavior were associated with a reorganization of tight and adherens junction molecules and a regulation of matrix metalloproteinase and vimentin expression. These results show that Fhit controls the invasive phenotype of lung tumor cells by regulating the expression of genes associated with epithelial-mesenchymal transition. Oncogene (2010) 29, 1203-1213; doi: 10.1038/onc.2009.418; published online 23 November 2009	[Nawrocki-Raby, B.] CHU Maison Blanche, INSERM, U903, UMRS 903, F-51100 Reims, France; [Joannes, A.; Polette, M.; Burlet, H.; Zahm, J-M; Birembaut, P.; Nawrocki-Raby, B.] Univ Reims, IFR53, UMR S903, Reims, France; [Bonnomet, A.; Bindels, S.; Gilles, C.] Univ Liege, CHU Sart Tilman, Lab Biol Tumeurs & Dev, Liege, Belgium; [Polette, M.; Birembaut, P.] Hop Maison Blanche, CHU Reims, Lab Pol Bouin, Reims, France; [Cutrona, J.] Univ Reims, CRESTIC, Reims, France	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne; University of Liege; CHU de Reims; Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne	Nawrocki-Raby, B (corresponding author), CHU Maison Blanche, INSERM, U903, UMRS 903, 45 Rue Cognacq Jay, F-51100 Reims, France.	beatrice.raby@univ-reims.fr	Raby, Beatrice/P-5666-2016; BIREMBAUT, Philippe/P-5210-2016; Cutrona, Jérôme/P-6658-2016; POLETTE, Myriam/P-5147-2016	Raby, Beatrice/0000-0002-3163-8619; BONNOMET, Arnaud/0000-0002-4933-3338; POLETTE, Myriam/0000-0001-8173-3246	Region Champagne-Ardenne; Ligue Contre le Cancer (Comite de la Marne); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante [ACI 2004-2010 INCa]	Region Champagne-Ardenne(Region Grand-Est); Ligue Contre le Cancer (Comite de la Marne); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante	This study was supported by the Region Champagne-Ardenne, the Ligue Contre le Cancer (Comite de la Marne), the Lions Club of Soissons, Un Euro contre le Cancer and the Fond National pour la Sante ACI 2004-2010 INCa (Canceropole Grand-Est project).	Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Campiglio M, 2006, J CELL PHYSIOL, V208, P274, DOI 10.1002/jcp.20633; Cavazzoni A, 2004, ONCOGENE, V23, P8439, DOI 10.1038/sj.onc.1207847; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Gilles C, 2003, CANCER RES, V63, P2658; GILLES C, 1996, BREAST J, V2, P83; Hazgui S, 2005, AM J PHYSIOL-CELL PH, V289, pC1547, DOI 10.1152/ajpcell.00319.2005; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Jayachandran G, 2007, CANCER RES, V67, P10379, DOI 10.1158/0008-5472.CAN-07-0677; Ji L, 1999, CANCER RES, V59, P3333; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Luo J, 1999, CANCER RES, V59, P3552; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Nakagawa Y, 2006, EXP CELL RES, V312, P2433, DOI 10.1016/j.yexcr.2006.04.004; Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870; Nawrocki-Raby B, 2003, AM J PATHOL, V163, P653, DOI 10.1016/S0002-9440(10)63692-9; Negrini M, 1996, CANCER RES, V56, P3173; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Pekarsky Y, 2002, LANCET ONCOL, V3, P748, DOI 10.1016/S1470-2045(02)00931-2; Polette M, 2005, CANCER RES, V65, P7691, DOI 10.1158/0008-5472.CAN-04-4230; Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Pylkkanen L, 2002, INT J ONCOL, V20, P285; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Semba S, 2006, ONCOGENE, V25, P2860, DOI 10.1038/sj.onc.1209323; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Weiske J, 2007, P NATL ACAD SCI USA, V104, P20344, DOI 10.1073/pnas.0703664105; Zahm JM, 1997, CELL MOTIL CYTOSKEL, V37, P33, DOI 10.1002/(SICI)1097-0169(1997)37:1<33::AID-CM4>3.0.CO;2-I	48	33	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1203	1213		10.1038/onc.2009.418	http://dx.doi.org/10.1038/onc.2009.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935706				2022-12-28	WOS:000274912100011
J	Lu, Y; Liu, P; James, M; Vikis, HG; Liu, H; Wen, W; Franklin, A; You, M				Lu, Y.; Liu, P.; James, M.; Vikis, H. G.; Liu, H.; Wen, W.; Franklin, A.; You, M.			Genetic variants cis-regulating Xrn2 expression contribute to the risk of spontaneous lung tumor	ONCOGENE			English	Article						expression; association; lung cancer; mouse	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCUS; SQUAMOUS DIFFERENTIATION; SEQUENCE VARIANTS; CANCER RISK; MOUSE; NONSMOKERS; ADENOCARCINOMAS; DISEASE; CELLS	Gene expression variation is an important mechanism underlying susceptibility to complex disease. In comparison with tobacco-related lung carcinogenesis, lung cancer in nonsmokers may involve important and etiologically distinct causal pathways. In this study, we conducted a genome-wide association study on spontaneous lung tumor incidence in inbred mice and identified a major susceptibility locus on mouse chromosome 2 (rs27328255, P = 6.68 x 10(-7)). We then evaluated the correlations of polymorphisms with the transcription of positional candidate genes in normal lungs. Single-nucleotide polymorphism rs27328255 was consistently and strongly associated (P = 7.42 x 10(-9)) in cis with transcript levels of Xrn2. We further showed that Xrn2 promotes proliferation and inhibits squamous differentiation in human lung epithelial cells and polymorphisms in human homolog XRN2 are associated with human lung cancer (rs2025811, P = 1.90 x 10(-3), OR = 1.20). We conclude that genetic variants regulating Xrn2 expression in cis are determinants of spontaneous lung tumor susceptibility in mice and have genetic equivalents in lung cancer susceptibility in human beings. Identifying Xrn2 as a major candidate for spontaneous lung cancer has important implications for the diagnosis and treatment of lung cancer as well as delineation of the mechanisms underlying the genesis of lung cancer in nonsmokers. Oncogene (2010) 29, 1041-1049; doi:10.1038/onc.2009.396; published online 16 November 2009	[You, M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@wudosis.wustl.edu		James, Michael/0000-0002-8112-1108	US National Institutes of Health [CA099187, CA099147, ES012063, ES013340]; NATIONAL CANCER INSTITUTE [R01CA099147, R01CA139959, R01CA099187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013340, R01ES012063] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the Broad Institute of Harvard/Massachusetts General Hospital and Massachusetts Institute of Technology, the Wellcome Trust Center for Human Genetics at Oxford University, and Perlegen Sciences for releasing inbred laboratory mouse SNP data. We thank the Mouse Phenome Project for collecting mouse SNP data. We thank the International Agency for Research on Cancer (Lyon, France) for releasing lung cancer GWAS data. We also thank investigators for generating spontaneous lung tumor data in inbred mice. The mouse SNP and phenotype data were crucial for the key findings described in this paper. We thank the staff of The Vanderbilt Microarray Shared Resource for microarray processing. MY was supported by grants from the US National Institutes of Health (CA099187, CA099147, ES012063, and ES013340). We thank Dr Jay W Tichelaar for his critical comments on the manuscript.	Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Borczuk Alain C, 2007, Proc Am Thorac Soc, V4, P127, DOI 10.1513/pats.200607-143JG; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Couzin J, 2007, SCIENCE, V316, P820, DOI 10.1126/science.316.5826.820; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; FOLEY JF, 1991, EXP LUNG RES, V17, P157, DOI 10.3109/01902149109064408; Frazer KA, 2007, NATURE, V448, P1050, DOI 10.1038/nature06067; Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kang HM, 2008, GENETICS, V178, P1709, DOI 10.1534/genetics.107.080101; KE Y, 1988, DIFFERENTIATION, V38, P60, DOI 10.1111/j.1432-0436.1988.tb00592.x; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kuntz E, 2006, ARCH BIOCHEM BIOPHYS, V455, P48, DOI 10.1016/j.abb.2006.08.023; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Li JX, 2005, DNA SEQUENCE, V16, P143, DOI 10.1080/10425170500066771; Liu PY, 2008, JNCI-J NATL CANCER I, V100, P1326, DOI 10.1093/jnci/djn268; Liu PY, 2006, NAT GENET, V38, P888, DOI 10.1038/ng1849; Matakidou A, 2005, BRIT J CANCER, V93, P825, DOI 10.1038/sj.bjc.6602769; McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Park MH, 2007, ONCOL REP, V18, P1395; Powell CA, 2003, LUNG CANCER-J IASLC, V39, P23, DOI 10.1016/S0169-5002(02)00384-7; Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296; SAID JW, 1983, LAB INVEST, V49, P563; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tang H, 2008, DEV BIOL, V318, P73, DOI 10.1016/j.ydbio.2008.03.001; Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846; Thun MJ, 2006, JNCI-J NATL CANCER I, V98, P691, DOI 10.1093/jnci/djj187; Tian JM, 2006, CANCER RES, V66, P10399, DOI 10.1158/0008-5472.CAN-06-1564; Wacholder S, 2008, JNCI-J NATL CANCER I, V100, DOI 10.1093/jnci/djn380; WALTS AE, 1985, J PATHOL, V145, P329, DOI 10.1002/path.1711450406; Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wong MP, 2003, CANCER, V97, P1263, DOI 10.1002/cncr.11183; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zeka A, 2006, EPIDEMIOLOGY, V17, P615, DOI 10.1097/01.ede.0000239582.92495.b5	44	18	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1041	1049		10.1038/onc.2009.396	http://dx.doi.org/10.1038/onc.2009.396			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915612	Green Accepted			2022-12-28	WOS:000274604400010
J	Lemjabbar-Alaoui, H; van Zante, A; Singer, MS; Xue, Q; Wang, YQ; Tsay, D; He, B; Jablons, DM; Rosen, SD				Lemjabbar-Alaoui, H.; van Zante, A.; Singer, M. S.; Xue, Q.; Wang, Y-Q; Tsay, D.; He, B.; Jablons, D. M.; Rosen, S. D.			Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis	ONCOGENE			English	Article						lung cancer; Sulf-2; sulfatase; heparan sulfate proteoglycans	WNT SIGNALING PATHWAY; CANCER-CELLS; HUMAN BREAST; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; WNT/BETA-CATENIN; IN-VIVO; GROWTH; ACTIVATION; BINDING	Heparan sulfate (HS) proteoglycans (HSPGs) bind to multiple growth factors/morphogens and regulate their signaling. 6-O-sulfation (6S) of glucosamine within HS chains is critical for many of these ligand interactions. Sulf-1 and Sulf-2, which are extracellular neutral-pH sulfatases, provide a novel post-synthetic mechanism for regulation of HSPG function by removing 6S from intact HS chains. The Sulfs can thereby modulate several signaling pathways, including the promotion of Wnt signaling. We found induction of SULF2 transcripts and Sulf-2 protein in human lung adenocarcinoma and squamous cell carcinoma, the two major classes of nonsmall-cell lung carcinomas (NSCLCs). We confirmed widespread Sulf-2 protein expression in tumor cells of 10/10 surgical specimens of human lung squamous carcinomas. We studied five Sulf-2(+) NSCLC cell lines, including two, which were derived by cigarette-smoke transformation of bronchial epithelial cells. shRNA-mediated Sulf-2 knockdown in these lines caused an increase in 6S on their cell surface and in parallel reversed their transformed phenotype in vitro, eliminated autocrine Wnt signaling and strongly blunted xenograft tumor formation in nude mice. Conversely, forced Sulf-2 expression in non-malignant bronchial epithelial cells produced a partially transformed phenotype. Our findings support an essential role for Sulf-2 in lung cancer, the leading cancer killer. Oncogene (2010) 29, 635-646; doi: 10.1038/onc.2009.365; published online 26 October 2009	[Lemjabbar-Alaoui, H.; Singer, M. S.; Xue, Q.; Wang, Y-Q; Tsay, D.; Rosen, S. D.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [van Zante, A.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [He, B.; Jablons, D. M.] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,Box 0452, San Francisco, CA 94143 USA.	steven.rosen@ucsf.edu		Rosen, Steven/0000-0002-6245-701X	University of California [17RT-0216, NIH P01 AI053194, NIH R21 CA122025]; Susan Komen Breast Cancer Foundation [PDF0402844, NIH RO1 HL075602]; NIH [RO1 HL075602, R01CA125030]; The Larry Hall and Zygielbaum Memorial Trust; The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation; NATIONAL CANCER INSTITUTE [R01CA125030, R21CA122025] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER	University of California(University of California System); Susan Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Larry Hall and Zygielbaum Memorial Trust; The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	RB4CD12 was a kind gift from Drs Guido Jenniskens and Toin van Kuppevelt of Nijmegen Medical Center. We thank Dr Roman Nawroth for preliminary work with lung cancer cell lines. We thank Drs Zena Werb, Joanna Phillips and Inna Maltseva for comments on the paper. This work was performed with support from the Tobacco-Related Disease Research Program of the University of California Grant 17RT-0216, NIH P01 AI053194 and NIH R21 CA122025; Susan Komen Breast Cancer Foundation PDF0402844 to SDR; NIH RO1 HL075602 to Dr Zena Werb; The Larry Hall and Zygielbaum Memorial Trust, and The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation to DMJ and NIH R01CA125030 to BH.	Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Ai XB, 2007, DEVELOPMENT, V134, P3327, DOI 10.1242/dev.007674; Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Castro NP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2157; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Danesin C, 2006, J NEUROSCI, V26, P5037, DOI 10.1523/JNEUROSCI.0715-06.2006; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Freeman SD, 2008, DEV BIOL, V320, P436, DOI 10.1016/j.ydbio.2008.05.554; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Habuchi H, 2007, J BIOL CHEM, V282, P15578, DOI 10.1074/jbc.M607434200; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Holst CR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000575; HOSSAIN MM, 2009, GLYCOBIOLOGY; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; HUGUET EL, 1994, CANCER RES, V54, P2615; Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim J, 2007, J THORAC CARDIOV SUR, V133, P733, DOI 10.1016/j.jtcvs.2006.09.053; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008-5472.CAN-05-4540; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lamanna WC, 2008, J BIOL CHEM, V283, P27724, DOI 10.1074/jbc.M802130200; Langsdorf A, 2007, DEV BIOL, V311, P464, DOI 10.1016/j.ydbio.2007.08.053; Lemjabbar-Alaoui H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000093; Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lum DH, 2007, MOL CELL BIOL, V27, P678, DOI 10.1128/MCB.01279-06; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-53; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nakashima T, 2008, ONCOL REP, V19, P203; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Ratzka A, 2008, DEV DYNAM, V237, P339, DOI 10.1002/dvdy.21423; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tang RH, 2009, J BIOL CHEM, V284, P21505, DOI 10.1074/jbc.M109.028472; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844	70	103	107	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					635	646		10.1038/onc.2009.365	http://dx.doi.org/10.1038/onc.2009.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19855436	Green Accepted, Green Submitted			2022-12-28	WOS:000274223700002
J	Shiota, M; Yokomizo, A; Tada, Y; Inokuchi, J; Kashiwagi, E; Masubuchi, D; Eto, M; Uchiumi, T; Naito, S				Shiota, M.; Yokomizo, A.; Tada, Y.; Inokuchi, J.; Kashiwagi, E.; Masubuchi, D.; Eto, M.; Uchiumi, T.; Naito, S.			Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression	ONCOGENE			English	Article						AR; CRPC; oxidative stress; prostate cancer; ROS; Twist1	ANTIOXIDANT ENZYMES; EXPRESSION; DAMAGE; GENE; MUTATIONS; RADIATION; PROTEIN; AGE	There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmented androgen/androgen receptor (AR) signaling pathway, for most of which AR overexpression has been observed. In this study, Twist1, a member of basic helix-loop-helix transcription factors as well as AR was upregulated in response to hydrogen peroxide, and the response to which was abolished by an addition of N-acetyl-L-cysteine and Twist1 knockdown. In addition, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives exhibited a similar phenotype to each other. Then, both castration and AR knockdown increased intracellular reactive oxygen species level. Moreover, Twist1 was shown to regulate AR expression through binding to E-boxes in AR promoter region. Silencing of Twist1 suppressed cell growth of AR-expressing LNCaP cells as well as castration-resistant LNCaP derivatives by inducing cell-cycle arrest at G1 phase and cellular apoptosis. These findings indicated that castration-induced oxidative stress may promote AR overexpression through Twist1 overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twist1/AR signaling might be a useful strategy for developing a novel therapeutics in prostate cancer, even in CRPC, which remains dependent on AR signaling by overexpressing AR. Oncogene (2010) 29, 237-250; doi:10.1038/onc.2009.322; published online 5 October 2009	[Shiota, M.; Yokomizo, A.; Tada, Y.; Inokuchi, J.; Kashiwagi, E.; Masubuchi, D.; Naito, S.] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, Fukuoka 8128252, Japan; [Uchiumi, T.] Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Fukuoka 8128252, Japan; [Eto, M.] Kumamoto Univ, Grad Sch Med, Dept Urol, Kumamoto, Japan	Kyushu University; Kyushu University; Kumamoto University	Yokomizo, A (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Urol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128252, Japan.	yokoa@uro.med.kyushu-u.ac.jp	Shiota, Masaki/Q-9387-2019; Inokuchi, Junichi/AAO-3297-2020	Inokuchi, Junichi/0000-0002-6791-905X; Shiota, Masaki/0000-0002-3306-4858	Ministry of Health, Labor and Welfare, Japan [016]; Japanese Urological Association, Japan	Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Japanese Urological Association, Japan	This work was supported in part by Health Sciences Research Grants for Clinical Research for evidence-based medicine and grants-in-aid for Cancer Research (016), from the Ministry of Health, Labor and Welfare, Japan, Young Researcher Promotion Grant from the Japanese Urological Association, Japan. We are grateful to Dr Chawnshang Chang for providing the pCMV-AR plasmid. We would like to thank Dr Dongchon Kang (Kyushu University, Fukuoka, Japan) for helping with quantitative real-time PCR and flow cytometry, and Noriko Hakoda, Hitomi Matoba and Seiko Kamori for their technical assistances.	Benz CC, 2008, NAT REV CANCER, V8, P875, DOI 10.1038/nrc2522; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; BILLIS A, 1996, J UROL PATHOL, V5, P1; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Castanon I, 2001, DEVELOPMENT, V128, P3145; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304-3835(02)00413-5; Ghatak S, 1996, BIOCHEM BIOPH RES CO, V222, P362, DOI 10.1006/bbrc.1996.0749; Gregory CW, 1998, CANCER RES, V58, P5718; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Hakimian P, 2008, BJU INT, V102, P1509, DOI 10.1111/j.1464-410X.2008.07933.x; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Hsing AW, 2001, EPIDEMIOL REV, V23, P3, DOI 10.1093/oxfordjournals.epirev.a000792; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Linja MJ, 2001, CANCER RES, V61, P3550; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Maynard S, 2009, CARCINOGENESIS, V30, P2, DOI 10.1093/carcin/bgn250; Mitsiades N, 2008, SEMIN ONCOL, V35, P569, DOI 10.1053/j.seminoncol.2008.08.002; Oberley TD, 2000, PROSTATE, V44, P144, DOI 10.1002/1097-0045(20000701)44:2<144::AID-PROS7>3.0.CO;2-G; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pang ST, 2002, ENDOCRINOLOGY, V143, P4897, DOI 10.1210/en.2002-220327; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Pathak S, 2008, CANCER LETT, V261, P74, DOI 10.1016/j.canlet.2007.11.015; Pinthus JH, 2007, NEOPLASIA, V9, P68, DOI 10.1593/neo.06739; Reddy GPV, 2006, J CELL BIOCHEM, V98, P1408, DOI 10.1002/jcb.20927; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sakr WA, 1996, EUR UROL, V30, P138; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Shiota M, 2009, CANCER RES, V69, P3148, DOI 10.1158/0008-5472.CAN-08-2334; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; Tso CL, 2000, CANCER J, V6, P220; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; van Doorn R, 2004, CANCER RES, V64, P5578, DOI 10.1158/0008-5472.CAN-04-1253; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	45	98	99	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					237	250		10.1038/onc.2009.322	http://dx.doi.org/10.1038/onc.2009.322			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802001				2022-12-28	WOS:000273650000007
J	van Amerongen, R; Nawijn, MC; Lambooij, JP; Proost, N; Jonkers, J; Berns, A				van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Jonkers, J.; Berns, A.			Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways	ONCOGENE			English	Article						Frat; Gsk3-binding protein; lymphoma-genesis; Diversin; Wnt-signal transduction; planar cell polarity	KINASE-I-EPSILON; CELL POLARITY; PLANAR POLARITY; BETA-CATENIN; AXIN; ACTIVATION; BINDING; LEADS; OVEREXPRESSION; PROTOONCOGENE	Wnt-signal transduction is critical for development and tissue homeostasis in a wide range of animal species and is frequently deregulated in human cancers. Members of the Frat/GBP family of glycogen synthase kinase 3 beta (Gsk3b)binding oncoproteins are recognized as potent activators of the Wnt/beta-catenin pathway in vertebrates. Here, we reveal a novel, Gsk3b-independent function of Frat converging on the activation of JNK and AP-1. Both these have been used as readouts for the noncanonical Frizzled/PCP pathway, which controls polarized cell movements and the establishment of tissue polarity. We find that Frat synergizes with Diversin, the mammalian homolog of the Drosophila PCP protein diego, in the activation of JNK/AP-1 signaling. Importantly, Frat mutants deficient for binding to Gsk3b retain oncogenic activity in vivo, suggesting that Wnt/beta-catenin-independent events contribute to Frat-induced malignant transformation. The observed activities of Frat are reminiscent of the dual function of Dishevelled in the Wnt/beta-catenin and Frizzled/PCP pathways and suggest that Frat may also function to bridge canonical and noncanonical Wnt pathways.	[van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Berns, A.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [van Amerongen, R.; Nawijn, M. C.; Lambooij, J-P; Proost, N.; Berns, A.] Ctr Biomed Genet, Amsterdam, Netherlands; [Jonkers, J.] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Berns, A.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl	van Amerongen, Renee/G-2945-2017; van Amerongen, Renee/N-6645-2019; Jonkers, Jos/AAG-3246-2019	van Amerongen, Renee/0000-0002-8808-2092; van Amerongen, Renee/0000-0002-8808-2092; Jonkers, Jos/0000-0002-9264-9792; Nawijn, Martijn/0000-0003-3372-6521	Centre of Biomedical Genetics (CBG)	Centre of Biomedical Genetics (CBG)	We thank Dr Walter Birchmeier, Dr Hans Clevers, Dr Gerald Crabtree, Dr Trevor Dale, Dr Jolita Hendriksen, Dr Rob Michalides, and Dr Rob Wolthuis for providing constructs and reagents and Dr Ping Chen for advice on cochlear dissections. We thank Fina van de Ahe, Sjaak Greven, Loes Rijswijk, and Maaike Voetel for tail vein injections, Hanneke van de Gulden for generating the Frat1<SUP>IAQA</SUP> mutant, and Dr Joaquim Calbo-Angrill for reading of an early version of the manuscript. This work received financial support from the Centre of Biomedical Genetics (CBG).	Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Etheridge SL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000259; Fanto M, 2004, J CELL SCI, V117, P527, DOI 10.1242/jcs.00973; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hongisto V, 2003, MOL CELL BIOL, V23, P6027, DOI 10.1128/MCB.23.17.6027-6036.2003; Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Jonkers J, 1999, MECH DEVELOP, V88, P183, DOI 10.1016/S0925-4773(99)00187-2; Jonkers J, 1999, ONCOGENE, V18, P5982, DOI 10.1038/sj.onc.1202995; Klein TJ, 2006, CURR BIOL, V16, P1337, DOI 10.1016/j.cub.2006.06.030; Klein TJ, 2005, ANNU REV CELL DEV BI, V21, P155, DOI 10.1146/annurev.cellbio.21.012704.132806; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Moeller H, 2006, P NATL ACAD SCI USA, V103, P15900, DOI 10.1073/pnas.0603808103; Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011; Saitoh T, 2001, INT J ONCOL, V19, P311; Sakanaka C, 2000, RECENT PROG HORM RES, V55, P225; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Strutt H, 2006, CURR BIOL, V16, P1329, DOI 10.1016/j.cub.2006.04.041; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2005, CELL CYCLE, V4, pE89; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; van Amerongen R, 2004, J BIOL CHEM, V279, P26967, DOI 10.1074/jbc.M400439200; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang JB, 2006, DEVELOPMENT, V133, P1767, DOI 10.1242/dev.02347; Wang Y, 2006, BRIT J CANCER, V94, P686, DOI 10.1038/sj.bjc.6602988; Wang YS, 2007, DEVELOPMENT, V134, P647, DOI 10.1242/dev.02772; Wang YH, 2006, J NEUROSCI, V26, P2147, DOI 10.1523/JNEUROSCI.4698-05.2005; Wang YH, 2008, INT J CANCER, V123, P561, DOI 10.1002/ijc.23600; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	47	32	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					93	104		10.1038/onc.2009.310	http://dx.doi.org/10.1038/onc.2009.310			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802005				2022-12-28	WOS:000273373500009
J	Olaussen, KA; Commo, F; Tailler, M; Lacroix, L; Vitale, I; Raza, SQ; Richon, C; Dessen, P; Lazar, V; Soria, JC; Kroemer, G				Olaussen, K. A.; Commo, F.; Tailler, M.; Lacroix, L.; Vitale, I.; Raza, S. Q.; Richon, C.; Dessen, P.; Lazar, V.; Soria, J-C; Kroemer, G.			Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines	ONCOGENE			English	Article						pazopanib; lapatinib; TKIs; apoptosis; kinome; transcriptome	EPIDERMAL-GROWTH-FACTOR; TUMOR-CELLS; FACTOR RECEPTOR-1; DUAL INHIBITION; MESSENGER-RNA; RIBOSOMAL-RNA; DRUG INSIGHT; C-MET; CANCER; EXPRESSION	Pazopanib and lapatinib are two tyrosine kinase inhibitors that have been designed to inhibit the VEGF tyrosine kinase receptors 1, 2 and 3 (pazopanib), and the HER1 and HER2 receptors in a dual manner (lapatinib). Pazopanib has also been reported to mediate inhibitory effect on a selected panel of additional tyrosine kinases such as PDGFR and c-kit. Here, we report that pazopanib and lapatinib act synergistically to induce apoptosis of A549 non-small-cell lung cancer cells. Systematic assessment of the kinome revealed that both pazopanib and lapatinib inhibited dozens of different tyrosine kinases and that their combination could suppress the activity of some tyrosine kinases (such as c-Met) that were not or only partially affected by either of the two agents alone. We also found that pazopanib and lapatinib induced selective changes in the transcriptome of A549 cells, some of which were specific for the combination of both agents. Analysis of a panel of unrelated human carcinoma cell lines revealed a signature of 52 genes whose up- or downregulation reflected the combined action of pazopanib and lapatinib. Indeed, pazopanib and lapatinib exerted synergistic cytotoxic effects on several distinct non-small-cell lung cancer cells as well as on unrelated carcinomas. Altogether, these results support the contention that combinations of tyrosine kinase inhibitors should be evaluated for synergistic antitumor effects. Such combinations may lead to a 'collapse' of pro-survival signal transduction pathways that leads to apoptotic cell death. Oncogene (2009) 28, 4249-4260; doi: 10.1038/onc.2009.277; published online 14 September 2009	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Olaussen, K. A.; Commo, F.; Lacroix, L.; Soria, J-C] Inst Gustave Roussy, Lab Rech Translat, F-94805 Villejuif, France; [Olaussen, K. A.; Tailler, M.; Vitale, I.; Raza, S. Q.; Soria, J-C; Kroemer, G.] Univ Paris 11, Paris, France; [Richon, C.; Dessen, P.; Lazar, V.] Inst Gustave Roussy, Unite Genom Fonct & Bioinformat, F-94805 Villejuif, France; [Soria, J-C] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Lazar, Vladimir/AAV-2087-2020; Kroemer, Guido/AAY-9859-2020; Raza, Syed/G-3158-2016; Vitale, Ilio/M-3960-2017; Soria, Jean-Charles/F-3619-2014; KROEMER, Guido/B-4263-2013; Lazar, Vladimir/AAQ-2086-2020	Raza, Syed/0000-0003-3536-6611; Vitale, Ilio/0000-0002-5918-1841; KROEMER, Guido/0000-0002-9334-4405; RICHON, Catherine/0000-0002-3556-3941; Olaussen, Ken/0000-0002-3115-8914	Ligue Nationale contre le Cancer; Agence Nationale de Recherche; Institut National contre le Cancer; Canceropole Ile-de France; European Union; Fondation pour la Recherche Medicale	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de Recherche(French National Research Agency (ANR)); Institut National contre le Cancer; Canceropole Ile-de France(Region Ile-de-France); European Union(European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	GK received grants from Ligue Nationale contre le Cancer (equipe labellisee), Agence Nationale de Recherche, Institut National contre le Cancer, Canceropole Ile-de France, European Union (Active p53, ApoSys, ChemoRes, DeathTrain, RIGHT, TransDeath) and Fondation pour la Recherche Medicale.	Barnes CJ, 2003, CANCER METAST REV, V22, P301, DOI 10.1023/A:1023726827771; Bianco R, 2008, CLIN CANCER RES, V14, P5069, DOI 10.1158/1078-0432.CCR-07-4905; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Bozec A, 2007, BRIT J CANCER, V97, P65, DOI 10.1038/sj.bjc.6603791; Calandrella N, 2007, J EXP CLIN CANC RES, V26, P405; Cameron DA, 2008, NAT CLIN PRACT ONCOL, V5, P512, DOI 10.1038/ncponc1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chien AJ, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3595; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Danilov AV, 2005, BRIT J HAEMATOL, V128, P472, DOI 10.1111/j.1365-2141.2004.05346.x; Donnem T, 2007, CLIN CANCER RES, V13, P6649, DOI 10.1158/1078-0432.CCR-07-0414; DRUKER BJ, 2001, NEW ENGL J MED, V344, P1037; Edinger AL, 2007, BIOCHEM J, V406, P1, DOI 10.1042/BJ20070490; Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Fransson A, 2003, J BIOL CHEM, V278, P6495, DOI 10.1074/jbc.M208609200; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Harris PA, 2008, J MED CHEM, V51, P4632, DOI 10.1021/jm800566m; Hayashida N, 2006, EMBO J, V25, P4773, DOI 10.1038/sj.emboj.7601370; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Hulit J, 2002, BIOCHEM PHARMACOL, V64, P827, DOI 10.1016/S0006-2952(02)01145-0; Hurwitz HI, 2009, CLIN CANCER RES, V15, P4220, DOI 10.1158/1078-0432.CCR-08-2740; Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731; Joo JH, 2007, CANCER RES, V67, P7929, DOI 10.1158/0008-5472.CAN-07-0931; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; KLAWITTER J, 2009, BIOMED CHROMATOGR; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Oberst MD, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-189; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Petit AMV, 1997, AM J PATHOL, V151, P1523; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103; Press MF, 2008, CLIN CANCER RES, V14, P7861, DOI 10.1158/1078-0432.CCR-08-1056; Puri N, 2007, CANCER RES, V67, P3529, DOI 10.1158/0008-5472.CAN-06-4416; Puri Neelu, 2008, J Carcinog, V7, P9; Riely GJ, 2009, J CLIN ONCOL, V27, P264, DOI 10.1200/JCO.2008.17.4656; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Sini P, 2008, CANCER RES, V68, P1581, DOI 10.1158/0008-5472.CAN-06-4685; Sleijfer S, 2008, NAT CLIN PRACT ONCOL, V5, P102, DOI 10.1038/ncponc1037; Sloan B, 2008, CURR OPIN INVEST DR, V9, P1324; Sonpavde G, 2008, EXPERT OPIN INV DRUG, V17, P253, DOI 10.1517/13543784.17.2.253; Storey John D, 2003, Methods Mol Biol, V224, P149; Storniolo AM, 2008, J CLIN ONCOL, V26, P3317, DOI 10.1200/JCO.2007.13.5202; Thompson HJ, 2004, CANCER RES, V64, P1541, DOI 10.1158/0008-5472.CAN-03-3108; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Wu BL, 2006, BIOINFORMATICS, V22, P472, DOI 10.1093/bioinformatics/bti827; ZAMZAMI N, 2003, METH MOL B, V282, P103	64	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4249	4260		10.1038/onc.2009.277	http://dx.doi.org/10.1038/onc.2009.277			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749798				2022-12-28	WOS:000272876300003
J	van Zijl, F; Mair, M; Csiszar, A; Schneller, D; Zulehner, G; Huber, H; Eferl, R; Beug, H; Dolznig, H; Mikulits, W				van Zijl, F.; Mair, M.; Csiszar, A.; Schneller, D.; Zulehner, G.; Huber, H.; Eferl, R.; Beug, H.; Dolznig, H.; Mikulits, W.			Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge	ONCOGENE			English	Article						TGF-beta; PDGF; tumor-stroma interaction; epithelial to mesenchymal transition; spheroid	GROWTH-FACTOR; TGF-BETA; STELLATE CELLS; LIVER FIBROSIS; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION; RAT-LIVER; PROGRESSION; HEPATOCYTES; MYOFIBROBLASTS	The tumor-stroma crosstalk is a dynamic process fundamental in tumor development. In hepatocellular carcinoma (HCC), the progression of malignant hepatocytes frequently depends on transforming growth factor (TGF)-beta provided by stromal cells. TGF-beta induces an epithelial to mesenchymal transition (EMT) of oncogenic Ras-transformed hepatocytes and an upregulation of platelet-derived growth factor (PDGF) signaling. To analyse the influence of the hepatic tumor-stroma crosstalk onto tumor growth and progression, we co-injected malignant hepatocytes and myofibroblasts (MFBs). For this, we either used in vitro-activated p19(ARF) MFBs or in vivo-activated MFBs derived from physiologically inflamed livers of Mdr2/p19(ARF) double-null mice. We show that co-transplantation of MFBs with Ras-transformed hepatocytes strongly enhances tumor growth. Genetic interference with the PDGF signaling decreases tumor cell growth and maintains plasma membrane-located E-cadherin and beta-catenin at the tumor-host border, indicating a blockade of hepatocellular EMT. We further generated a collagen gel-based three dimensional HCC model in vitro to monitor the MFB-induced invasion of micro-organoid HCC spheroids. This invasion was diminished after inhibition of TGF-beta or PDGF signaling. These data suggest that the TGF-beta/PDGF axis is crucial during hepatic tumor-stroma crosstalk, regulating both tumor growth and cancer progression. Oncogene (2009) 28, 4022-4033; doi:10.1038/onc.2009.253; published online 31 August 2009	[van Zijl, F.; Schneller, D.; Zulehner, G.; Huber, H.; Mikulits, W.] Med Univ Vienna, Div Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria; [Mair, M.; Eferl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Csiszar, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Dolznig, H.] Med Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria	Medical University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna	Mikulits, W (corresponding author), Med Univ Vienna, Div Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Csiszar, Agnes/I-2747-2019; Mikulits, Wolfgang/AAH-4043-2021; Dolznig, Helmut/L-7005-2015	Csiszar, Agnes/0000-0001-7911-3427; Dolznig, Helmut/0000-0002-6063-3585; Mikulits, Wolfgang/0000-0003-4612-7106; Eferl, Robert/0000-0002-6074-7144	FWF [P19598-B13, SFB F28]; 'Hochschuljubilaumsstiftung der Stadt Wien'; Herzfelder Family Foundation; European Union [HEALTH-F4-2008-202047]	FWF(Austrian Science Fund (FWF)); 'Hochschuljubilaumsstiftung der Stadt Wien'; Herzfelder Family Foundation; European Union(European Commission)	Mdr2 null mice were kindly provided by Dr Ilan Stein. We thank Dr Takako Sasaki for the fibulin-2 antibody. This work was supported by the Austrian Science Fund, FWF, grant numbers P19598-B13 (to WM) and SFB F28 (to RE, HB and WM), the 'Hochschuljubilaumsstiftung der Stadt Wien' (to WM), the Herzfelder Family Foundation (to WM), and the European Union, FP7 Health Research, project number HEALTH-F4-2008-202047 (to WM).	Amann T, 2009, CANCER SCI, V100, P646, DOI 10.1111/j.1349-7006.2009.01087.x; Benckert C, 2003, CANCER RES, V63, P1083; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Campbell JS, 2007, DIFFERENTIATION, V75, P843, DOI 10.1111/j.1432-0436.2007.00235.x; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Dooley S, 2008, GASTROENTEROLOGY, V135, P642, DOI 10.1053/j.gastro.2008.04.038; Fickert P, 2004, GASTROENTEROLOGY, V127, P261, DOI 10.1053/j.gastro.2004.04.009; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Forbes SJ, 2004, GASTROENTEROLOGY, V126, P955, DOI 10.1053/j.gastro.2004.02.025; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Ikegami T, 2007, CELLS TISSUES ORGANS, V185, P213, DOI 10.1159/000101322; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Kisseleva T, 2006, J HEPATOL, V45, P429, DOI 10.1016/j.jhep.2006.04.014; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N; Lahsnig C, 2009, ONCOGENE, V28, P638, DOI 10.1038/onc.2008.418; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee JS, 2005, SEMIN LIVER DIS, V25, P125, DOI 10.1055/s-2005-871192; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Magness ST, 2004, HEPATOLOGY, V40, P1151, DOI 10.1002/hep.20427; Marra F, 2002, FRONT BIOSCI, V7, pD1899, DOI 10.2741/marra; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Morini Sergio, 2005, Italian Journal of Anatomy and Embryology, V110, P193; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nitta T, 2008, HEPATOLOGY, V48, P909, DOI 10.1002/hep.22397; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pinzani M, 1996, AM J PATHOL, V148, P785; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; Roderfeld M, 2006, FASEB J, V20, P444, DOI 10.1096/fj.05-4828com; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Russo FP, 2006, GASTROENTEROLOGY, V130, P1807, DOI 10.1053/j.gastro.2006.01.036; Sasaki T, 1996, J CELL SCI, V109, P2895; Sherman M, 2005, SEMIN LIVER DIS, V25, P143, DOI 10.1055/s-2005-871194; Sprenger H, 1999, J HEPATOL, V30, P88, DOI 10.1016/S0168-8278(99)80011-7; Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Witz IP, 2008, CANCER RES, V68, P9, DOI 10.1158/0008-5472.CAN-07-2917; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	59	130	131	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4022	4033		10.1038/onc.2009.253	http://dx.doi.org/10.1038/onc.2009.253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718050	Green Accepted			2022-12-28	WOS:000272560300007
J	John, T; Liu, G; Tsao, MS				John, T.; Liu, G.; Tsao, M-S			Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors	ONCOGENE			English	Review						erlotinib; gefitinib; polymerase chain reaction; biomarker; survival	GROWTH-FACTOR-RECEPTOR; IN-SITU HYBRIDIZATION; DINUCLEOTIDE REPEAT POLYMORPHISM; RESOLUTION MELTING ANALYSIS; GEFITINIB SENSITIVITY; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; MESSENGER-RNA; PROGNOSTIC INDICATORS; JAPANESE PATIENTS	Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease. Current treatment paradigms are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. As patient responses to these therapies vary, predictive biomarkers will be an important facet of a patient's diagnostic workup in personalized medicine, as there is accumulating evidence that they may enable the prognostication and prediction of therapeutic response. Potential biomarkers for the selection of patients with NSCLC most likely to benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, include mutations, gene copy number increase and single-nucleotide polymorphisms of the EGFR gene, EGFR protein expression and oncogenic mutation on the KRAS gene. Many techniques are available to assay for these biomarkers. In this review, we present the current weight of evidence for using these methods as biomarkers for anti-EGFR therapy in patients with NSCLC. Oncogene (2009) 28, S14-S23; doi:10.1038/onc.2009.197	[John, T.; Liu, G.; Tsao, M-S] Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tsao, MS (corresponding author), Room 7-611,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; John, Thomas/0000-0003-3399-5342; Liu, Geoffrey/0000-0002-2603-7296	Boehringer Ingelheim Pharmaceuticals Inc.	Boehringer Ingelheim Pharmaceuticals Inc.(Boehringer Ingelheim)	This article was funded by Boehringer Ingelheim Pharmaceuticals Inc. Dr John is an International Association for Study of Lung Cancer (IASLC) Translational Fellow in Lung Cancer Research. Dr Liu is the Alan B Brown Chair in Molecular Genomics, and Dr Tsao is the M Qasim Choksi Chair in Lung Cancer Translational Research.	Atkins D, 2004, J HISTOCHEM CYTOCHEM, V52, P893, DOI 10.1369/jhc.3A6195.2004; Aviel-Ronen S, 2006, CLIN LUNG CANCER, V8, P30, DOI 10.3816/CLC.2006.n.030; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Bhargava R, 2006, CANCER-AM CANCER SOC, V106, P1857, DOI 10.1002/cncr.21782; Buckley AF, 2007, APPL IMMUNOHISTO M M, V15, P305, DOI 10.1097/01.pai.0000213141.47277.bf; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Chang JWC, 2008, LUNG CANCER, V61, P328, DOI 10.1016/j.lungcan.2008.01.009; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Cheng TL, 2005, CHEST, V128, P1453, DOI 10.1378/chest.128.3.1453; Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Cusatis G, 2006, J NATL CANCER I, V98, P1739, DOI 10.1093/jnci/djj469; Daniele L, 2007, MOL CANCER THER, V6, P1223, DOI 10.1158/1535-7163.MCT-06-0719; Dei Tos AP, 2005, EUR J CANCER, V41, P1383, DOI 10.1016/j.ejca.2005.03.018; Dubey S, 2006, J THORAC ONCOL, V1, P406, DOI 10.1097/01243894-200606000-00005; Dziadziuszko R, 2007, ANN ONCOL, V18, P447, DOI 10.1093/annonc/mdl407; Dziadziuszko R, 2006, CLIN CANCER RES, V12, P3078, DOI 10.1158/1078-0432.CCR-06-0106; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; Etienne-Grimaldi MC, 2005, ANN ONCOL, V16, P934, DOI 10.1093/annonc/mdi189; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fukui T, 2008, CLIN CANCER RES, V14, P4751, DOI 10.1158/1078-0432.CCR-07-5207; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; GARDAR AF, 2009, ONCOGENE S1, V28, pS24; Gebhardt F, 1999, J BIOL CHEM, V274, P13176, DOI 10.1074/jbc.274.19.13176; Gregorc V, 2008, CLIN PHARMACOL THER, V83, P477, DOI 10.1038/sj.clpt.6100320; HALEY JD, 1991, J BIOL CHEM, V266, P1746; Han SW, 2007, PHARMACOGENET GENOM, V17, P313, DOI 10.1097/FPC.0b013e328011abc0; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hirsch FR, 2008, J CLIN ONCOL, V26, P3351, DOI 10.1200/JCO.2007.14.0111; Hirsch FR, 2008, CANCER-AM CANCER SOC, V112, P1114, DOI 10.1002/cncr.23282; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Hsieh ETK, 2000, LUNG CANCER, V29, P151, DOI 10.1016/S0169-5002(00)00116-1; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Ichihara S, 2007, INT J CANCER, V120, P1239, DOI 10.1002/ijc.22513; Janne PA, 2006, CLIN CANCER RES, V12, P751, DOI 10.1158/1078-0432.CCR-05-2047; Kim KS, 2005, CLIN CANCER RES, V11, P2244, DOI 10.1158/1078-0432.CCR-04-2081; Kimura H, 2007, BRIT J CANCER, V97, P778, DOI 10.1038/sj.bjc.6603949; Kimura H, 2006, CLIN CANCER RES, V12, P3915, DOI 10.1158/1078-0432.CCR-05-2324; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kondo M, 2005, LUNG CANCER, V50, P385, DOI 10.1016/j.lungcan.2005.06.008; Kosaka T, 2007, J CLIN ONCOL, V25; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Li AR, 2008, J MOL DIAGN, V10, P242, DOI 10.2353/jmoldx.2008.070178; Li J, 2007, CANCER BIOL THER, V6, P432, DOI 10.4161/cbt.6.3.3763; Liu G, 2008, PHARMACOGENOMICS J, V8, P129, DOI 10.1038/sj.tpj.6500444; Liu WQ, 2005, CANCER RES, V65, P46; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Miller VA, 2008, J CLIN ONCOL, V26, P1472, DOI 10.1200/JCO.2007.13.0062; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok T, 2008, ANN ONCOL, V19, P1; Molina JR, 2006, J THORAC ONCOL, V1, P7, DOI 10.1097/01243894-200601000-00004; Mu XL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-51; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Nie Q, 2007, EUR J PHARMACOL, V570, P175, DOI 10.1016/j.ejphar.2007.05.015; Nomoto K, 2006, AM J CLIN PATHOL, V126, P608, DOI 10.1309/N5PQNGW2QKMX09X7; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Penault-Llorca F, 2006, ONCOL REP, V16, P1173; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Rossi G, 2005, J CLIN ONCOL, V23, P8774, DOI 10.1200/JCO.2005.02.8233; Rudin CM, 2008, J CLIN ONCOL, V26, P1119, DOI 10.1200/JCO.2007.13.1128; Ruiz MIG, 2007, HISTOPATHOLOGY, V51, P631, DOI 10.1111/j.1365-2559.2007.02854.x; Rusch V, 1997, CLIN CANCER RES, V3, P515; Sakurada A, 2006, CLIN LUNG CANCER, V7, pS138, DOI 10.3816/CLC.2006.s.005; Sasaki H, 2006, INT J CANCER, V118, P180, DOI 10.1002/ijc.21301; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shih JY, 2006, INT J CANCER, V118, P963, DOI 10.1002/ijc.21458; Sholl LM, 2007, MODERN PATHOL, V20, P1028, DOI 10.1038/modpathol.3800946; Sone T, 2007, CANCER-AM CANCER SOC, V109, P1836, DOI 10.1002/cncr.22593; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Tokumo M, 2005, CLIN CANCER RES, V11, P1167; Tomizawa Y, 2005, CLIN CANCER RES, V11, P6816, DOI 10.1158/1078-0432.CCR-05-0441; TRASK B, 1985, SCIENCE, V230, P1401, DOI 10.1126/science.2416058; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Uramoto H, 2006, LUNG CANCER, V51, P71, DOI 10.1016/j.lungcan.2005.08.006; Varella-Garcia M, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-19; Whitcombe D, 1999, NAT BIOTECHNOL, V17, P804, DOI 10.1038/11751; Willmore-Payne C, 2006, HUM PATHOL, V37, P755, DOI 10.1016/j.humpath.2006.02.004; Yoshida K, 2007, J THORAC ONCOL, V2, P22, DOI 10.1097/01243894-200701000-00006; Zhang XT, 2005, ANN ONCOL, V16, P1334, DOI 10.1093/annonc/mdi340; Zhou QY, 2006, CANCER BIOL THER, V5, P1445, DOI 10.4161/cbt.5.11.3457; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	107	167	173	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S14	S23		10.1038/onc.2009.197	http://dx.doi.org/10.1038/onc.2009.197			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680292				2022-12-28	WOS:000269515400003
J	Hu, XT; Zhang, FB; Fan, YC; Shu, XS; Wong, AHY; Zhou, W; Shi, QL; Tang, HM; Fu, L; Guan, XY; Rha, SY; Tao, Q; He, C				Hu, X-T; Zhang, F-B; Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Zhou, W.; Shi, Q-L; Tang, H-M; Fu, L.; Guan, X-Y; Rha, S. Y.; Tao, Q.; He, C.			Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer	ONCOGENE			English	Article						Phospholipase C delta 1; tumor suppressor gene; methylation; 3p22; gastric cancer	ACTIN-DEPOLYMERIZING FACTOR; GTPASE-ACTIVATING PROTEIN; MATRIX METALLOPROTEINASE-7; BINDING PROTEIN; EXPRESSION; GENE; ESOPHAGEAL; MATRILYSIN; CELLS; NASOPHARYNGEAL	Located at the important tumor suppressor locus, 3p22, PLCD1 encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movements. We identified PLCD1 as a downregulated gene in aerodigestive carcinomas through expression pro. ling and epigenetic characterization. We found that PLCD1 was expressed in all normal adult tissues but low or silenced in 84% (16/19) gastric cancer cell lines, well correlated with its CpG island (CGI) methylation status. Methylation was further detected in 62% (61/98) gastric primary tumors, but none of normal gastric mucosa tissues. PLCD1 methylation was significantly correlated with tumor high stage. Detailed methylation analysis of 37 CpG sites at the PLCD1 CGI by bisulfite genomic sequencing confirmed its methylation. PLCD1 silencing could be reversed by pharmacological demethylation with 5-aza-2'-deoxycytidine, indicating a direct epigenetic silencing. Ectopic expression of PLCD1 in silenced gastric tumor cells dramatically inhibited their clonogenicity and migration, possibly through downregulating MMP7 expression and hampering the reorganization of cytoskeleton through cofilin inactivation by phosphorylation. Thus, epigenetic inactivation of PLCD1 is common and tumor-specific in gastric cancer, and PLCD1 acts as a functional tumor suppressor involved in gastric carcinogenesis. Oncogene (2009) 28, 2466-2475; doi: 10.1038/onc.2009.92; published online 18 May 2009	[Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Hong Kong Canc Inst, Canc Epigenet Lab,Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Zhou, W.; He, C.] Zhejiang Univ, Dept Colorectal Surg, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Rha, S. Y.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Zhejiang University; Yonsei University; Yonsei University Health System	He, C (corresponding author), Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.	qtao@clo.cuhk.edu.hk; drhe_srrsh@sina.com	Hu, Xiao-tong/K-5820-2019; Tao, Qian/T-4743-2018; Fu, Li/F-7182-2010; Guan, Xin-Yuan/A-3639-2009	Tao, Qian/0000-0001-5383-4808; Fu, Li/0000-0003-2643-6278; Rha, Sun Young/0000-0002-2512-4531; Guan, Xin-Yuan/0000-0002-4485-6017	Chinese University of Hong Kong; National Natural Science Foundation of China [30770920/C03030202]; Natural Science Foundation of Zhejiang Province [Y206090]	Chinese University of Hong Kong(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This study was supported by a grant from the Chinese University of Hong Kong, a grant from National Natural Science Foundation of China ( Grant no. 30770920/C03030202) and a grant from Natural Science Foundation of Zhejiang Province ( Grant no. Y206090).	Adachi Y, 1998, INT J ONCOL, V13, P1031; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carvou N, 2007, CELL SIGNAL, V19, P42, DOI 10.1016/j.cellsig.2006.05.023; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Irino Y, 2004, BIOCHEM BIOPH RES CO, V320, P537, DOI 10.1016/j.bbrc.2004.05.206; Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156; Kaminishi M, 2005, ONCOLOGY-BASEL, V69, P1, DOI 10.1159/000086624; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kitoh T, 2004, J GASTROENTEROL, V39, P434, DOI 10.1007/s00535-003-1316-3; Liu XP, 2002, JPN J CANCER RES, V93, P291, DOI 10.1111/j.1349-7006.2002.tb02171.x; Maehara Y, 2000, BRIT J SURG, V87, P353, DOI 10.1046/j.1365-2168.2000.01358.x; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Nakahara M, 2005, J BIOL CHEM, V280, P29128, DOI 10.1074/jbc.M503817200; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; Panani AD, 2008, CANCER LETT, V266, P99, DOI 10.1016/j.canlet.2008.02.053; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Qiu GH, 2008, J HEPATOL, V48, P433, DOI 10.1016/j.jhep.2007.11.015; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sako A, 2004, CANCER RES, V64, P3624, DOI 10.1158/0008-5472.CAN-04-0304; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Senota A, 1998, CLIN EXP METASTAS, V16, P313; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; TAKAISHI K, 1994, ONCOGENE, V9, P273; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Yonemura Y, 2001, CLIN CANCER RES, V7, P1647; Yonemura Yutaka, 2000, Gastric Cancer, V3, P63, DOI 10.1007/PL00011698	43	57	60	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2466	2475		10.1038/onc.2009.92	http://dx.doi.org/10.1038/onc.2009.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448674				2022-12-28	WOS:000267601400005
J	Spinello, I; Quaranta, MT; Pasquini, L; Pelosi, E; Petrucci, E; Pagliuca, A; Castelli, G; Mariani, G; Diverio, D; Foa, R; Testa, U; Labbaye, C				Spinello, I.; Quaranta, M. T.; Pasquini, L.; Pelosi, E.; Petrucci, E.; Pagliuca, A.; Castelli, G.; Mariani, G.; Diverio, D.; Foa, R.; Testa, U.; Labbaye, C.			PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis	ONCOGENE			English	Article						PLZF; c-kit; hematopoietic progenitor cells; erythropoiesis	RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTORS; GERM-CELLS; STEM-CELLS; PROTEIN; CD117; DIFFERENTIATION; IDENTIFICATION	The promyelocytic leukemia zinc-finger protein (PLZF) is a transcription factor and c-kit is a receptor tyrosine kinase associated with human disease, particularly in hematopoietic cells. MicroRNAs (miRs) are post-transcriptional regulators of gene expression, and c-kit has been described as a target of miRs-221 and -222 in erythropoiesis. In the present study, we identified c-kit as a target of PLZF in normal and leukemic cells. Particularly, in erythropoietic (E) culture of CD34(+) progenitors, PLZF is downregulated, whereas c-kit expression at both the mRNA and protein levels inversely increases during the first days of E differentiation. In functional experiments, PLZF transfection induces c-kit downregulation, inhibits E proliferation and delays differentiation, whereas PLZF knockdown induces opposite effects, independently of miRs-221 and -222 expression. The inverse correlation between PLZF and c-kit expression was found in normal CD34(+)38(+/-) hematopoietic progenitor/stem cells and in acute myeloid leukemias of M0/M1 French-American-British subtypes, suggesting that the control of PLZF on c-kit expression may be crucial at the level of the stem cell/progenitor compartment. Altogether, our data indicate a new mechanism of regulation of c-kit expression that involves a transcriptional control by PLZF in CD34(+) cells and early erythropoiesis. Oncogene (2009) 28, 2276-2288; doi: 10.1038/onc.2009.87; published online 4 May 2009	[Spinello, I.; Quaranta, M. T.; Pasquini, L.; Pelosi, E.; Petrucci, E.; Pagliuca, A.; Castelli, G.; Mariani, G.; Testa, U.; Labbaye, C.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Diverio, D.; Foa, R.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Div Hematol, Rome, Italy	Istituto Superiore di Sanita (ISS); Sapienza University Rome	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	catherine.labbaye@iss.it	pagliuca, alfredo/J-3107-2012; Pagliuca, Alfredo/AAI-3689-2020; pelosi, elvira/J-7298-2016; Testa, Ugo/J-6472-2016; Quaranta, Maria Teresa/AAC-2134-2019; PETRUCCI, ELEONORA/J-8778-2016; Labbaye, Catherine/J-9930-2016; SPINELLO, ISABELLA/J-8779-2016; pasquini, luca/J-8319-2016; castelli, germana/J-7244-2016	pagliuca, alfredo/0000-0002-8703-2077; pelosi, elvira/0000-0002-3043-6249; Testa, Ugo/0000-0001-7900-8942; Quaranta, Maria Teresa/0000-0002-5886-507X; PETRUCCI, ELEONORA/0000-0001-6459-490X; pasquini, luca/0000-0002-3484-6288; Labbaye, Catherine/0000-0003-1255-4396; castelli, germana/0000-0002-3593-1230	Italian Ministry of Health; Associazione Italiana per la Ricerca sul Cancro (AIRC); 'Fondazione Roma', Rome, Italy	Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); 'Fondazione Roma', Rome, Italy(Fondazione Roma)	We thank Dr F Spadaro, from the Department of Cell Biology and Neuroscience, for her help with confocal microscopy and G Loreto for graphics. This work was supported by institutional grants from the Italian Ministry of Health to UT and CL, from Associazione Italiana per la Ricerca sul Cancro ( AIRC) to RF, and from 'Fondazione Roma', Rome, Italy to UT.	Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Bene MC, 1998, BLOOD, V92, P596, DOI 10.1182/blood.V92.2.596.414k05_596_599; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Cascavilla N, 1998, HAEMATOLOGICA, V83, P392; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Edling CE, 2007, INT J BIOCHEM CELL B, V39, P1995, DOI 10.1016/j.biocel.2006.12.005; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07; Gabbianelli M, 2000, BLOOD, V95, P3555, DOI 10.1182/blood.V95.11.3555.011k16_3555_3561; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Isken F, 2008, BRIT J HAEMATOL, V140, P153, DOI 10.1111/j.1365-2141.2007.06915.x; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Jing HI, 2008, MOL CELL, V29, P232, DOI 10.1016/j.molcel.2007.11.020; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Munugalavadla V, 2005, CRIT REV ONCOL HEMAT, V54, P63, DOI 10.1016/j.critrevonc.2004.11.005; MUTA K, 1995, BLOOD, V86, P572, DOI 10.1182/blood.V86.2.572.bloodjournal862572; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Patnaik MM, 2007, CURR CANCER DRUG TAR, V7, P492; Quaranta MT, 2006, ONCOGENE, V25, P399, DOI 10.1038/sj.onc.1209060; Scolnik MP, 2002, LEUKEMIA RES, V26, P615, DOI 10.1016/S0145-2126(01)00182-5; Sperling C, 1997, HAEMATOLOGICA, V82, P617; Tsuzuki S, 2002, BLOOD, V99, P3404, DOI 10.1182/blood.V99.9.3404; Wessely O, 1997, CELL GROWTH DIFFER, V8, P481; YAMAMOTO K, 1993, JPN J CANCER RES, V84, P1136, DOI 10.1111/j.1349-7006.1993.tb02813.x	33	25	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	2009	28	23					2276	2288		10.1038/onc.2009.87	http://dx.doi.org/10.1038/onc.2009.87			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421145				2022-12-28	WOS:000266886300004
J	Kato, M; Paranjape, T; Ullrich, R; Nallur, S; Gillespie, E; Keane, K; Esquela-Kerscher, A; Weidhaas, JB; Slack, FJ				Kato, M.; Paranjape, T.; Ullrich, R.; Nallur, S.; Gillespie, E.; Keane, K.; Esquela-Kerscher, A.; Weidhaas, J. B.; Slack, F. J.			The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells	ONCOGENE			English	Article						miRNA; DNA damage response; radiation; cancer; C. elegans	P53 NETWORK; RESISTANCE; APOPTOSIS	MicroRNAs (miRNAs) are important regulators of cell fate determination and homeostasis. Expression of these small RNA genes is tightly regulated during development and in normal tissues, but they are often misregulated in cancer. MiRNA expression is also affected by DNA damaging agents, such as radiation. In particular, mammalian miR-34 is upregulated by p53 in response to radiation, but little is known about the role of this miRNA in vivo. Here we show that Caenorhabditis elegans with loss-of-function mutations in the mir-34 gene have an abnormal cellular survival response to radiation; these animals are highly radiosensitive in the soma and radioresistant in the germline. These findings show a role for mir-34 in both apoptotic and non-apoptotic cell death in vivo, much like that of cep-1, the C. elegans p53 homolog. These results have been additionally validated in vitro in breast cancer cells, wherein exogenous addition of miR-34 alters cell survival post-radiation. These observations confirm that mir-34 is required for a normal cellular response to DNA damage in vivo resulting in altered cellular survival post-irradiation, and point to a potential therapeutic use for anti-miR-34 as a radio-sensitizing agent in p53-mutant breast cancer. Oncogene (2009) 28, 2419-2424; doi:10.1038/onc.2009.106; published online 4 May 2009	[Kato, M.; Esquela-Kerscher, A.; Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Paranjape, T.; Ullrich, R.; Nallur, S.; Gillespie, E.; Keane, K.; Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA	Yale University; Yale University	Slack, FJ (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, KBT 936,POB 208103,266 Whitney Ave, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu; frank.slack@yale.edu	Paranjape, Trupti/E-4338-2012; Gillespie, Erin/AAZ-8543-2021	Gillespie, Erin/0000-0002-1386-1542; Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409	Uehara Life Science Foundation; Breast Cancer Alliance; NIH [CA124484, CA131301-01A1]; American Cancer Society Institutional Research; ASTRO Junior Faculty Career Research Training Award; Ellison Medical Foundation; NATIONAL CANCER INSTITUTE [R01CA131301, K08CA124484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071157] Funding Source: NIH RePORTER	Uehara Life Science Foundation; Breast Cancer Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Institutional Research(American Cancer Society); ASTRO Junior Faculty Career Research Training Award; Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the CGC for strains. MK was supported by a postdoctoral fellowship from the Uehara Life Science Foundation. JW was supported by the Breast Cancer Alliance and a K08 grant (CA124484) from the NIH and by an American Cancer Society Institutional Research Grant to the Yale Cancer Center and by the ASTRO Junior Faculty Career Research Training Award. FS was supported by a grant from the Ellison Medical Foundation. FS and JW were supported by a grant from the NIH (CA131301-01A1).	Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hui L, 2006, ONCOGENE, V25, P7305, DOI 10.1038/sj.onc.1209735; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Salter KH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001908; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weidhaas JB, 2006, P NATL ACAD SCI USA, V103, P9946, DOI 10.1073/pnas.0603791103; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858	17	179	191	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2419	2424		10.1038/onc.2009.106	http://dx.doi.org/10.1038/onc.2009.106			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421141	Green Accepted			2022-12-28	WOS:000267342400006
J	Martin, V; Xu, J; Pabbisetty, SK; Alonso, MM; Liu, D; Lee, OH; Gumin, J; Bhat, KP; Colman, H; Lang, FF; Fueyo, J; Gomez-Manzano, C				Martin, V.; Xu, J.; Pabbisetty, S. K.; Alonso, M. M.; Liu, D.; Lee, O-H; Gumin, J.; Bhat, K. P.; Colman, H.; Lang, F. F.; Fueyo, J.; Gomez-Manzano, C.			Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters	ONCOGENE			English	Article						Tie2; gliomas; chemoresistance; ABC transporters; brain tumor stem cells	TUMOR STEM-CELLS; DRUG-RESISTANCE; EXPRESSION; CANCER; CHEMORESISTANCE; GLIOBLASTOMA; RECEPTOR; GENES; TIE2	Resistance and relapse are still primary causes that result in poor effectiveness of chemotherapy in malignant gliomas. Therefore, development of new therapeutic strategies requires the identification of key molecular pathways regulating chemoresistance. We previously found that abnormal high expression of the Tie2 receptor in gliomas was associated with tumor malignancy. Here, we studied the role of Tie2 activation in drug resistance by testing the cytotoxicity of several chemotherapeutic drugs in a panel of human glioma cell lines and brain tumor stem cells and found that Tie2 activation was significantly related to chemoresistance. The essential role of Tie2 in this phenotype was illustrated by silencing Tie2 using specific siRNA, and the subsequent abrogation of the angiopoietin 1 (Ang1)-mediated chemoresistance. Using quantitative real-time PCR and functional drug efflux studies, we observed that Tie2 activation resulted in increased expression of ATP-binding cassette (ABC) transporters. Consistent with these results, downmodulation of ABCG2 or ABCC2 resulted in the inability of Tie2 activation to induce a chemoresistant phenotype. Our results indicate that Tie2 activation may be important in modifying the evolution of gliomas during conventional chemotherapy regimens, and open new avenues for the search of more effective therapies to avoid the inevitable brain tumor recurrence. Oncogene (2009) 28, 2358-2363; doi:10.1038/onc.2009.103; published online 4 May 2009	[Gomez-Manzano, C.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Bhat, K. P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Gomez-Manzano, C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gomez-Manzano, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cmanzano@mdanderson.org	Alonso, Marta M/AAI-9457-2020; Pabbisetty, Sudheer Kumar/H-3338-2019; MARTIN, VANESA/A-7312-2012; Colman, Howard/L-5433-2019	Alonso, Marta M/0000-0002-7520-7351; Pabbisetty, Sudheer Kumar/0000-0001-7490-1352; MARTIN, VANESA/0000-0001-6923-2529; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	Department of Education and Science, Spain; American Brain Tumor Association; Elsa U Pardee Foundation; NIH/Developmental Research Program [P50CA127001]; NATIONAL CANCER INSTITUTE [P50CA127001] Funding Source: NIH RePORTER	Department of Education and Science, Spain; American Brain Tumor Association; Elsa U Pardee Foundation; NIH/Developmental Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alyson Todd (Department of Scientific Publications, The University of Texas MD Anderson Cancer Center) for editorial assistance. This work was supported by a postdoctoral fellowship from the Department of Education and Science, Spain (to VM), an American Brain Tumor Association postdoctoral fellowship (to DL), Elsa U Pardee Foundation Award (to CGM), and an NIH/Developmental Research Program P50CA127001 (to CGM).	Alonso MM, 2007, CANCER RES, V67, P11499, DOI 10.1158/0008-5472.CAN-07-5312; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bredel M, 2001, BRAIN RES REV, V35, P161, DOI 10.1016/S0165-0173(01)00045-5; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Decleves X, 2006, CURR CANCER DRUG TAR, V6, P433, DOI 10.2174/156800906777723930; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Jin F, 2008, NEUROSCIENCE, V154, P541, DOI 10.1016/j.neuroscience.2008.03.054; Lee OH, 2008, ONCOGENE, V27, P1310, DOI 10.1038/sj.onc.1210731; Lee OH, 2006, MOL CANCER RES, V4, P915, DOI 10.1158/1541-7786.MCR-06-0184; Lu C, 2008, MOL CELL BIOCHEM, V312, P71, DOI 10.1007/s11010-008-9722-8; Martin V, 2008, HISTOL HISTOPATHOL, V23, P773, DOI 10.14670/HH-23.773; Shervington A, 2008, CANCER INVEST, V26, P535, DOI 10.1080/07357900801904140; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Zadeh G, 2004, AM J PATHOL, V164, P467, DOI 10.1016/S0002-9440(10)63137-9; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	17	36	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2358	2363		10.1038/onc.2009.103	http://dx.doi.org/10.1038/onc.2009.103			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421150	Green Accepted			2022-12-28	WOS:000267089100006
J	Lau, LMS; Wolter, JK; Lau, JTML; Cheng, LS; Smith, KM; Hansford, LM; Zhang, L; Baruchel, S; Robinson, F; Irwin, MS				Lau, L. M. S.; Wolter, J. K.; Lau, J. T. M. L.; Cheng, L. S.; Smith, K. M.; Hansford, L. M.; Zhang, L.; Baruchel, S.; Robinson, F.; Irwin, M. S.			Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; COX inhibitor; celecoxib; p73; E2F-1	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IN-VIVO; UP-REGULATION; HUMAN TUMORS; P53 FAMILY; APOPTOSIS; CELECOXIB; CANCER; EXPRESSION; CELL	p73 encodes multiple functionally distinct isoforms. Proapoptotic TAp73 isoforms contain a transactivation (TA) domain, and like p53, have tumor suppressor properties and are activated by chemotherapies to induce cell death. In contrast, antiapoptotic Delta Np73 isoforms lack the TA domain and are dominant-negative inhibitors of p53 and TAp73. Delta Np73 proteins are overexpressed in a variety of tumors including neuroblastoma. Thus, identification of drugs that upregulate TAp73 and/or downregulate Delta Np73 represents a potential therapeutic strategy. Here, we report that cyclooxygenase (COX) inhibitors induce apoptosis independent of p53, and differentially modulate endogenous p73 isoforms in neuroblastoma and other tumors. COX inhibitor-mediated apoptosis is associated with the induction of TAp73 beta and its target genes. COX inhibitors also downregulate the alternative-spliced Delta Np73(AS) isoforms, Delta exon2 and Delta exon2/3. Furthermore, forced expression of Delta Np73(AS) results in diminished apoptosis in response to the selective COX-2 inhibitor celecoxib. Celecoxib-mediated downregulation of DNp73AS is associated with decreased E2F1 levels and diminished E2F1 activation of the p73 promoter. These results provide the first evidence that COX inhibitors differentially modulate p73 isoforms leading to enhanced apoptosis, and support the potential use of COX inhibitors as novel regulators of p73 to enhance chemosensitivity in tumors with deregulated E2F1 and in those with wild-type (wt) or mutant p53. Oncogene (2009) 28, 2024-2033; doi:10.1038/onc.2009.59; published online 13 April 2009	[Irwin, M. S.] Univ Toronto, MARS Ctr, Div Haematol Oncol, Hosp Sick Children, Toronto, ON M5G 1L7, Canada; [Lau, L. M. S.; Wolter, J. K.; Lau, J. T. M. L.; Cheng, L. S.; Smith, K. M.; Hansford, L. M.; Robinson, F.; Irwin, M. S.] Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Zhang, L.; Baruchel, S.] Hosp Sick Children, Res Inst, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Pediat, Inst Med Sci & Lab Med & Pathobiol, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Irwin, MS (corresponding author), Univ Toronto, MARS Ctr, Div Haematol Oncol, Hosp Sick Children, Toronto Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970; Zhang, Libo/0000-0001-7072-4408; Smith, Kristen/0000-0003-0960-0937	Canadian Cancer Society; National Cancer Institute of Canada (CCS) [019274]; James Fund for Neuroblastoma Research at SickKids Foundation; Lloyd Carr-Harris Foundation; Terry Fox Foundation	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Cancer Institute of Canada (CCS); James Fund for Neuroblastoma Research at SickKids Foundation; Lloyd Carr-Harris Foundation; Terry Fox Foundation	This study was supported by the Canadian Cancer Society and the National Cancer Institute of Canada (CCS Grant no. 019274, MS Irwin), the James Fund for Neuroblastoma Research at SickKids Foundation and Lloyd Carr-Harris Foundation. MS Irwin is a Canada Research Chair in Cancer Biology. L Lau was supported by the Terry Fox Foundation Clinical Research Fellowship (National Cancer Institute of Canada).	Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bock JM, 2007, CANCER RES, V67, P3801, DOI 10.1158/0008-5472.CAN-06-3780; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Johnson AJ, 2005, BLOOD, V105, P2504, DOI 10.1182/blood-2004-05-1957; Kashfi K, 2005, BIOCHEM PHARMACOL, V70, P969, DOI 10.1016/j.bcp.2005.05.004; Lau L, 2007, ONCOGENE, V26, P1920, DOI 10.1038/sj.onc.1209981; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Stempak D, 2002, CLIN PHARMACOL THER, V72, P490, DOI 10.1067/mcp.2002.129322; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063	34	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2024	2033		10.1038/onc.2009.59	http://dx.doi.org/10.1038/onc.2009.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363520				2022-12-28	WOS:000266023900003
J	Lagadec, C; Meignan, S; Adriaenssens, E; Foveau, B; Vanhecke, E; Romon, R; Toillon, RA; Oxombre, B; Hondermarck, H; Le Bourhis, X				Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke, E.; Romon, R.; Toillon, R-A; Oxombre, B.; Hondermarck, H.; Le Bourhis, X.			TrkA overexpression enhances growth and metastasis of breast cancer cells	ONCOGENE			English	Article						neurotrophins; tyrosine kinase receptors; anoikis	FACTOR RECEPTOR; NEUROTROPHIN RECEPTORS; SIGNALING PATHWAYS; FACTOR EXPRESSION; PROSTATE-CANCER; SINGLE-AGENT; CARCINOMA; SURVIVAL; ANOIKIS; ACTIVATION	The Trk family of neurotrophin tyrosine kinase receptors is emerging as an important player in carcinogenic progression in non-neuronal tissues. Here, we show that breast tumors present high levels of TrkA and phospho-TrkA compared to normal breast tissues. To further evaluate the precise functions of TrkA overexpression in breast cancer development, we have performed a series of biological tests using breast cancer cells that stablyov erexpress TrkA. We show that ( 1) TrkA overexpression promoted cell growth, migration and invasion in vitro; ( 2) overexpression of TrkA per se conferred constitutive activation of its tyrosine kinase activity; ( 3) signal pathways including PI3K-Akt and ERK/p38 MAP kinases were activated byTrkA overexpression and were required for the maintenance of a more aggressive cellular phenotype; and ( 4) TrkA overexpression enhanced tumor growth, angiogenesis and metastasis of xenografted breast cancer cells in immunode efficient mice. Moreover, recovered metastatic cells from the lungs exhibited enhanced anoikis resistance that was abolished by the pharmacological inhibitor K252a, suggesting that TrkA-promoted breast tumor metastasis could be mediated at least in part by enhancing anoikis resistance. Together, these results provide the first direct evidence that TrkA overexpression enhances the tumorigenic properties of breast cancer cells and point to TrkA as a potential target in breast cancer therapy. Oncogene ( 2009) 28, 1960-1970; doi:10.1038/onc.2009.61; published online 30 March 2009	[Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke, E.; Romon, R.; Toillon, R-A; Oxombre, B.; Hondermarck, H.; Le Bourhis, X.] Univ Lille 1, INSERM, U908, IFR 147, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Lille 1, INSERM, U908, IFR 147, Batiment SN3, F-59655 Villeneuve Dascq, France.	xuefen.lebourhis@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021; Lagadec, chann/E-4250-2010; Toillon, Robert-Alain/Q-2286-2018; Meignan, Samuel/E-9628-2017	Lagadec, chann/0000-0002-5182-2069; Toillon, Robert-Alain/0000-0001-5483-2118; 	la Ligue Nationale Contre le Cancer; INSERM; le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais	la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais(Region Hauts-de-France)	We acknowledge the excellent technical assistance of Isabelle Lefebvre. This work was supported by la Ligue Nationale Contre le Cancer ( Equipe Labellisee 2009), INSERM, le Ministere de l'Education Nationale and la Region Nord/Pas-de-Calais plus the FEDER.	Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Aragona M, 2001, CANCER INVEST, V19, P692, DOI 10.1081/CNV-100106144; Campos X, 2007, GYNECOL ONCOL, V104, P168, DOI 10.1016/j.ygyno.2006.07.007; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; Chiarenza A, 2001, CANCER RES, V61, P3002; Davidson B, 2004, BREAST CANCER RES TR, V83, P119, DOI 10.1023/B:BREA.0000010704.17479.8a; Davidson B, 2003, CLIN CANCER RES, V9, P2248; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dolle L, 2003, ONCOGENE, V22, P5592, DOI 10.1038/sj.onc.1206805; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Hedley BD, 2008, CLIN EXP METASTAS, V25, P727, DOI 10.1007/s10585-008-9184-0; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; McGregor LM, 1999, P NATL ACAD SCI USA, V96, P4540, DOI 10.1073/pnas.96.8.4540; Mercurio AM, 2005, J MAMMARY GLAND BIOL, V10, P283, DOI 10.1007/s10911-006-9001-9; Muka J, 2003, VITAM HORM, V66, P385, DOI 10.1016/S0083-6729(03)01011-2; Nakanishi K, 2002, CANCER RES, V62, P2971; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rennebeck G, 2005, CANCER RES, V65, P11230, DOI 10.1158/0008-5472.CAN-05-2763; Ricci A, 2001, AM J RESP CELL MOL, V25, P439, DOI 10.1165/ajrcmb.25.4.4470; Sawaki M, 2004, TUMORI J, V90, P40, DOI 10.1177/030089160409000110; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Zhu ZW, 1999, J CLIN ONCOL, V17, P2419, DOI 10.1200/JCO.1999.17.8.2419	31	154	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1960	1970		10.1038/onc.2009.61	http://dx.doi.org/10.1038/onc.2009.61			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19330021				2022-12-28	WOS:000265820900003
J	Oh, H; Irvine, KD				Oh, H.; Irvine, K. D.			In vivo analysis of Yorkie phosphorylation sites	ONCOGENE			English	Article						Warts; hippo; yorkie; Drosophila; tumor; phosphorylation	CELL CONTACT INHIBITION; YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; TEAD/TEF FAMILY; GROWTH-CONTROL; HIPPO PATHWAY; DROSOPHILA; YAP; APOPTOSIS; MECHANISM	The co-activator Yorkie (Yki) mediates transcriptional regulation effectedby the Drosophila Fat-Warts (Wts) Hippo (Hpo) pathways. Yki is inhibitedby Wts-mediated phosphorylation, and a Wts phosphorylation site at Ser168 has been identified. Here we identify two additional Wts phosphorylation sites on Yki, and examine the respective contribution of all three sites to Yki nuclear localization and activity. Our results show that although Ser168 is the most critical site, all three phosphorylation sites influence Yki localization and activity in vivo, and can be sites of regulation by Wts. Thus, investigations of the role of Yki and its mammalian homolog Yes-associated protein (YAP) in development and oncogenesis should include evaluations of additional sites. The WW domains of Yki are not required for its phosphorylation, but instead are positively required for its activity. We also identify two potential sites of phosphorylation by an unknown kinase, which could influence phosphorylation of Ser168 by Wts, suggesting that there are additional mechanisms for regulating Yki/YAP activity.	[Oh, H.; Irvine, K. D.] Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08855 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Howard Hughes Med Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08855 USA.	irvine@waksman.rutgers.edu			Howard Hughes Medical Institute; NIH [1F32GM079817]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM079817] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P Beachy, D Pan, J Jiang, G Halder and the Bloomington Drosophila Stock Center for antibodies, plasmids and Drosophila stocks, and C Rauskolb for comments on the paper. This research was supported by the Howard Hughes Medical Institute and NIH post-doctoral fellowship 1F32GM079817 to HO.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	20	134	140	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1916	1927		10.1038/onc.2009.43	http://dx.doi.org/10.1038/onc.2009.43			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330023	Green Accepted			2022-12-28	WOS:000265640600004
J	Nikkila, J; Coleman, KA; Morrissey, D; Pylkas, K; Erkko, H; Messick, TE; Karppinen, SM; Amelina, A; Winqvist, R; Greenberg, RA				Nikkila, J.; Coleman, K. A.; Morrissey, D.; Pylkas, K.; Erkko, H.; Messick, T. E.; Karppinen, S-M; Amelina, A.; Winqvist, R.; Greenberg, R. A.			Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function	ONCOGENE			English	Article						RAP80; breast cancer; BRCA1; ubiquitin	DOUBLE-STRAND BREAKS; TARGETS BRCA1; STROMAL CELLS; PROTEIN; MUTATIONS; SUSCEPTIBILITY; REPAIR; COMPLEX; GENES; RNF8	Germline mutations in two major susceptibility genes, BRCA1 and BRCA2, account for nearly 20% of familial breast cancers. A majority of the remaining genetic factors involved in heritable breast cancer susceptibility are, however, unknown. Recently, a new BRCA1-interacting protein, receptor associated protein 80 (RAP80), was identified. RAP80 plays an important role in BRCA1-mediated DNA damage responses (DDRs) by recruiting BRCA1 to DNA double-strand breaks (DSBs). A comprehensive screening of DNA from affected index cases of 112 BRCA1/BRCA2 mutation-negative Finnish breast cancer families revealed altogether 10 alterations in RAP80, one of which, c.241-243delGAA, resulted in a single glutamic acid deletion at residue 81 in a highly conserved region of ubiquitin interaction motif 1. The resultant delE81 protein product displayed significantly reduced ubiquitin binding and DSB localization. Expression of the RAP80 delE81 allele impaired both BRCA1 and ABRA1 DSB recruitment, thus compromising BRCA1-mediated DDR signaling. Compared with wildtype RAP80, expression of the delE81 allele was associated with a significant increase in cytogenetically detectable chromosomal aberrations, particularly chromatid breaks. Although evidently quite rare, these results suggest that critical constitutional mutations in RAP80 abrogate DDR function and may be involved in genetic predisposition to cancer.	[Coleman, K. A.; Morrissey, D.; Messick, T. E.; Greenberg, R. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Nikkila, J.; Pylkas, K.; Erkko, H.; Karppinen, S-M; Amelina, A.; Winqvist, R.] Univ Oulu, Oulu Univ Hosp, Dept Clin Genet, Canc Genet Lab, Oulu, Finland; [Nikkila, J.; Pylkas, K.; Erkko, H.; Karppinen, S-M; Amelina, A.; Winqvist, R.] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Oulu, Finland; [Greenberg, R. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Oulu; University of Oulu; University of Pennsylvania; Pennsylvania Medicine	Greenberg, RA (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd,BRB 2-3 Rm 513, Philadelphia, PA 19104 USA.	robert.winqvist@oulu.fi; rogergr@mail.med.upenn.edu		Pylkas, Katri/0000-0002-2449-0521; Karppinen, Sanna/0000-0001-6233-9075; Winqvist, Robert/0000-0003-0932-9104; Messick, Troy/0000-0001-7914-1524	Finnish Breast Cancer Group; Cancer Foundation of Northern Finland; Orion-Farmos Research Foundation; Academy of Finland; Finnish Cancer Society; Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation; NIH [T32-GM-007229]; National Cancer Institute [1K08CA106597-01]; Sidney Kimmel Foundation Scholar Award; Mary Kay Ash Charitable Foundation Cancer Research; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE [K08CA106597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	Finnish Breast Cancer Group; Cancer Foundation of Northern Finland; Orion-Farmos Research Foundation; Academy of Finland(Academy of Finland); Finnish Cancer Society; Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sidney Kimmel Foundation Scholar Award; Mary Kay Ash Charitable Foundation Cancer Research; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Dr Aki Mustonen, Dr Jaakko Ignatius, Dr Ylermi Soini, Dr Mervi Grip and Dr Arja Jukkola-Vuorinen for their contribution, and nurses Kari Mononen and Outi Kajula for their help in patient contacts and Ms Helmi Konola for technical assistance. We also gratefully acknowledge Dr Junjie Chen for the antibodies to ABRA1, and Dr David Livingston for critical discussion of the manuscript before submission. The Finnish Breast Cancer Group, the Cancer Foundation of Northern Finland, the Orion-Farmos Research Foundation, the Academy of Finland, the Finnish Cancer Society, the Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation to RW, the NIH training grant T32-GM-007229 to KAC and the National Cancer Institute K08 award 1K08CA106597-01, the Sidney Kimmel Foundation Scholar Award, the Mary Kay Ash Charitable Foundation Cancer Research Grant and funds from the Abramson Family Cancer Research Institute to RAG financially supported this study.	Akbari MR, 2009, BREAST CANCER RES TR, V113, P377, DOI 10.1007/s10549-008-9938-z; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Greenberg RA, 2008, CHROMOSOMA, V117, P305, DOI 10.1007/s00412-008-0154-8; Greenberger JS, 2006, EXP HEMATOL, V34, P46; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heikkinen K, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.12.e131; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Huusko P, 1998, AM J HUM GENET, V62, P1544, DOI 10.1086/301880; ISOLA J, 1994, AM J PATHOL, V145, P1301; Karppinen SM, 2006, EUR J CANCER, V42, P2647, DOI 10.1016/j.ejca.2006.05.030; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; Liu ZX, 2007, NAT STRUCT MOL BIOL, V14, P716, DOI 10.1038/nsmb1279; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Novak DJ, 2009, BREAST CANCER RES TR, V117, P453, DOI 10.1007/s10549-008-0134-y; Osorio A, 2009, BREAST CANCER RES TR, V113, P371, DOI 10.1007/s10549-008-9933-4; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rapakko K, 2001, BRIT J CANCER, V84, P116, DOI 10.1054/bjoc.2000.1530; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Schwab M, 2002, CANCER LETT, V175, P1, DOI 10.1016/S0304-3835(01)00752-2; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan J, 2008, CANCER LETT, V271, P179, DOI 10.1016/j.canlet.2008.04.046; Yan J, 2007, CANCER RES, V67, P6647, DOI 10.1158/0008-5472.CAN-07-0924; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	51	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1843	1852		10.1038/onc.2009.33	http://dx.doi.org/10.1038/onc.2009.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305427	Green Accepted			2022-12-28	WOS:000265640500003
J	Al-Ahmadi, W; Al-Haj, L; Al-Mohanna, FA; Silverman, RH; Khabar, KSA				Al-Ahmadi, W.; al-Haj, L.; Al-Mohanna, F. A.; Silverman, R. H.; Khabar, K. S. A.			RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth	ONCOGENE			English	Article						3 ' untranslated regions; RNase L; HuR; RNA-binding proteins; cell growth	DOUBLE-STRANDED-RNA; MESSENGER-RNA; PROGNOSTIC-FACTOR; PROSTATE-CANCER; RIBONUCLEASE-L; 3'-UNTRANSLATED REGION; INTERFERON RESPONSE; CELLS; EXPRESSION; KINASE	Ribonuclease L (RNase L) is an intracellular enzyme that is vital in innate immunity, but also is a tumor suppressor candidate. Here, we show that overexpression of RNase L decreases cellular growth and downmodulates the RNA-binding protein, HuR, a regulator of cell-cycle progression and tumorigenesis. The effect is temporal, occurring in specific cell-cycle phases and correlated with the cytoplasmic localization of RNase L. Both cellular growth and HuR were increased in RNASEL-null mouse fibroblast lines when compared to wild-type cells. Moreover, the stability of HuR mRNA was enhanced in RNASEL-null cells. The HuR 30 untranslated region (UTR), which harbors U-rich and adenylate-uridylate-rich elements, was potently responsive to RNase L when compared to control 30 UTR. Our results may offer a new explanation to the tumor suppressor function of RNase L.	[Al-Ahmadi, W.; al-Haj, L.; Al-Mohanna, F. A.; Khabar, K. S. A.] King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, Riyadh 11211, Saudi Arabia; [Silverman, R. H.; Khabar, K. S. A.] Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	King Faisal Specialist Hospital & Research Center; Cleveland Clinic Foundation	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, P3354,MBC 03,Takhasusi Rd, Riyadh 11211, Saudi Arabia.	khabar@kfshrc.edu.sa	Khabar, Khalid/A-4772-2011; Khabar, Khalid/AAG-3487-2019	Khabar, Khalid/0000-0003-1003-9788; Khabar, Khalid/0000-0003-1003-9788	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA044059-26, R01 CA044059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoghaibi F, 2007, GENE, V391, P130, DOI 10.1016/j.gene.2006.12.013; Andersen JB, 2007, ONCOGENE, V26, P3081, DOI 10.1038/sj.onc.1210111; Atasoy U, 1998, J CELL SCI, V111, P3145; BAYARD BA, 1993, BIOCHEM J, V296, P155, DOI 10.1042/bj2960155; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Castelli JC, 1998, CELL DEATH DIFFER, V5, P313, DOI 10.1038/sj.cdd.4400352; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Dormoy-Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113-07; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KHABAR K, 1999, J INTERFERON CYTOKIN, V19, P68; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Khabar KSA, 2004, J MOL BIOL, V342, P833, DOI 10.1016/j.jmb.2004.07.065; Khabar KSA, 2003, J BIOL CHEM, V278, P20124, DOI 10.1074/jbc.M208766200; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Li XL, 2007, J BIOL CHEM, V282, P7950, DOI 10.1074/jbc.M607939200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; Liu W, 2007, EUR J CANCER, V43, P202, DOI 10.1016/j.ejca.2006.08.024; Malathi K, 2007, NATURE, V448, P816, DOI 10.1038/nature06042; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Molinaro RJ, 2006, NUCLEIC ACIDS RES, V34, P6684, DOI 10.1093/nar/gkl968; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; SUBBARAMAIAH K, 2003, J BIOL CHEM, V25, P25; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Urisman A, 2006, PLOS PATHOG, V2, P211, DOI 10.1371/journal.ppat.0020025; van der Giessen K, 2003, J BIOL CHEM, V278, P47119, DOI 10.1074/jbc.M308889200; Wang QQ, 2004, MICROBIOL MOL BIOL R, V68, P432, DOI 10.1128/MMBR.68.3.432-452.2004; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; Xiang Y, 2003, CANCER RES, V63, P6795; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhu J, 2006, J IMMUNOL METHODS, V309, P25, DOI 10.1016/j.jim.2005.10.018	48	33	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1782	1791		10.1038/onc.2009.16	http://dx.doi.org/10.1038/onc.2009.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19252527	Green Accepted			2022-12-28	WOS:000265640400005
J	Scholl, FA; Dumesic, PA; Barragan, DI; Charron, J; Khavari, PA				Scholl, F. A.; Dumesic, P. A.; Barragan, D. I.; Charron, J.; Khavari, P. A.			Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin	ONCOGENE			English	Article						MAP kinase; Mek; Ras; cancer; apoptosis	EPIDERMAL HYPERPLASIA; TRANSGENIC MICE; MAP KINASE; MOUSE SKIN; ACTIVATION; PATHWAY; MUTATION; GROWTH; CANCER; DIFFERENTIATION	Ras genes are commonly mutated in human cancers of the skin and other tissues. Oncogenic Ras signals through multiple effector pathways, including the Erk1/2 mitogen-activated protein kinase (MAPK), phosphatidylinositol-3 kinase (PI3K) and the Ral guanine nucleotide exchange factor (RalGEF) cascades. In epidermis, the activation of oncogenic Ras induces hyperplasia and inhibits differentiation, features characteristic of squamous cell carcinoma. The downstream effector pathways required for oncogenic Ras effects in epidermis, however, are undefined. In this study, we investigated the direct contribution of Mek1 and Mek2 MAPKKs to oncogenic Ras signaling. The response of murine epidermis to conditionally active oncogenic Ras was unimpaired by deletion of either Mek1 or Mek2 MAPKKs individually. In contrast, Ras effects were entirely abolished by combined deletion of all Mek1/2 alleles, whereas epidermis retaining only one allele of either Mek1 or Mek2 showed intermediate responsiveness. Thus, the effects of oncogenic Ras on proliferation and differentiation in skin show a gene dosage-dependent requirement for the Erk1/2 MAPK cascade at the level of Mek1/2 MAPKKs.	[Scholl, F. A.; Dumesic, P. A.; Barragan, D. I.; Khavari, P. A.] Stanford Univ, Dept Dermatol, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; [Charron, J.] Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, CHUQ, Quebec City, PQ, Canada; [Khavari, P. A.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA	Stanford University; Laval University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Khavari, PA (corresponding author), Stanford Univ, Dept Dermatol, Sch Med, Program Epithelial Biol, CCSR Bldg,Room 2145,269 Campus Dr, Stanford, CA 94305 USA.	khavari@stanford.edu	Charron, Jean/A-9792-2013	Charron, Jean/0000-0002-5133-0056	US VA Office of Research and Development; NIAMS/NIH [AR49737]; Swiss cancer foundation [BIL SKL-01236-02-2002]; CIHR [MOP-67208]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049737] Funding Source: NIH RePORTER	US VA Office of Research and Development; NIAMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Swiss cancer foundation; CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank A Truong and K Jameson for critical reading of the manuscript, E Fuchs for K14-Cre mice, P Chambon for K14-CreER mice, C Enrile for histological work, H Bernstein, P Bernstein and N Griffiths for support. This study was supported by the US VA Office of Research and Development and by AR49737 from NIAMS/NIH to PAK, the Swiss cancer foundation Grant BIL SKL-01236-02-2002 to FAS and MOP-67208 from CIHR to JC.	[Anonymous], 2007, NATURE, V449, P378; Aoki Y, 2008, HUM MUTAT, V29, P992, DOI 10.1002/humu.20748; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bissonauth V, 2006, DEVELOPMENT, V133, P3429, DOI 10.1242/dev.02526; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Castro AF, 2005, METHODS, V37, P190, DOI 10.1016/j.ymeth.2005.05.015; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Denley A, 2008, METHOD ENZYMOL, V438, P291, DOI 10.1016/S0076-6879(07)38020-8; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Estep AL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001279; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Kratz CP, 2007, J MOL MED-JMM, V85, P223, DOI 10.1007/s00109-006-0135-4; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Marks JL, 2008, CANCER RES, V68, P5524, DOI 10.1158/0008-5472.CAN-08-0099; McCubrey JA, 2008, CURR OPIN INVEST DR, V9, P614; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Naiche LA, 2007, GENESIS, V45, P768, DOI 10.1002/dvg.20353; Oh WJ, 2007, CARCINOGENESIS, V28, P2244, DOI 10.1093/carcin/bgm127; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Schmidt-Supprian M, 2007, NAT IMMUNOL, V8, P665, DOI 10.1038/ni0707-665; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Sturgill TW, 2008, BIOCHEM BIOPH RES CO, V371, P1, DOI 10.1016/j.bbrc.2008.04.002; Sun BC, 2008, CELL CYCLE, V7, P934, DOI 10.4161/cc.7.7.5622; Tarutani M, 2003, CANCER RES, V63, P319; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wallace EM, 2005, CURR TOP MED CHEM, V5, P215, DOI 10.2174/1568026053507723; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	39	20	21	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1485	1495		10.1038/onc.2008.459	http://dx.doi.org/10.1038/onc.2008.459			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198628	Green Accepted			2022-12-28	WOS:000264537400001
J	Lewis, DA; Travers, JB; Somani, AK; Spandau, DF				Lewis, D. A.; Travers, J. B.; Somani, A-K; Spandau, D. F.			The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer	ONCOGENE			English	Article						aging; IGF-1R; skin cancer; keratinocytes; fibroblasts; UVB	GROWTH-FACTOR-I; HUMAN KERATINOCYTES; INSULIN; RECEPTOR; FIBROBLASTS; APOPTOSIS; LINK	The appropriate response of human keratinocytes to ultraviolet-B (UVB) is dependent on the activation status of the insulin-like growth factor 1 (IGF-1) receptor. Keratinocytes grown in conditions in which the IGF-1 receptor is inactive inappropriately replicate in the presence of UVB-induced DNA damage. In human skin, epidermal keratinocytes do not express IGF-1, and hence the IGF-1 receptor on keratinocytes is activated by IGF-1 secreted from dermal fibroblasts. We now show that the IGF-1 produced by human fibroblasts is essential for the appropriate UVB response of keratinocytes. Furthermore, the expression of IGF-1 is silenced in senescent fibroblasts in vitro. Using quantitative reverse transcriptase-PCR and immunohistochemisty, we can show that IGF-1 expression is also silenced in geriatric dermis in vivo. The diminished IGF-1 expression in geriatric skin correlates with an inappropriate UVB response in geriatric volunteers. Finally, the appropriate UVB response is restored in geriatric skin in vivo through pretreatment with exogenous IGF-1. These studies provide further evidence for a role of the IGF-1 receptor (IGF-1R) in suppressing UVB-induced carcinogenesis, suggest that fibroblasts have a critical role in maintaining appropriate activation of the keratinocyte IGF-1R, and imply that reduced expression of IGF-1 in geriatric skin could be an important component in the development of aging-related non-melanoma skin cancer. Oncogene (2010) 29, 1475-1485; doi:10.1038/onc.2009.440; published online 7 December 2009	[Lewis, D. A.; Travers, J. B.; Somani, A-K; Spandau, D. F.] Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; [Travers, J. B.] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Travers, J. B.] Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Travers, J. B.] Univ Sch Med, Richard L Roudebush VA Med Ctr, Indianapolis, IN USA; [Spandau, D. F.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis	Spandau, DF (corresponding author), Indiana Univ, Sch Med, Dept Dermatol, 975 W Walnut St,Room 349, Indianapolis, IN 46202 USA.	dspanda@iupui.edu	Somani, ally-khan/AAA-9656-2020	Somani, Ally-Khan/0000-0003-2166-4896; Travers, Jeffrey/0000-0001-7232-1039	National Institutes of Health [R01ES11155, R21CA131901, R01HL062996, U19A1070448]; VA Merit Award; NATIONAL CANCER INSTITUTE [R21CA131901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011155] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit Award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We are grateful to Dr Raymond Konger for his valuable suggestions. The recombinant human IGF-1 was generously provided by Tercica, Inc. This work was supported by grants from the National Institutes of Health (R01ES11155 and R21CA131901 to DFS; R01HL062996 and U19A1070448 to JBT) and VA Merit Award (JBT).	Chuang TY, 2005, BRIT J DERMATOL, V153, P552, DOI 10.1111/j.1365-2133.2005.06738.x; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Donovan EA, 2008, CRIT REV ONCOL HEMAT, V66, P91, DOI 10.1016/j.critrevonc.2007.09.003; Dziadziuszko R, 2008, J THORAC ONCOL, V3, P815, DOI 10.1097/JTO.0b013e31818180f5; FERBER A, 1993, J BIOL CHEM, V268, P17883; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lann D, 2008, J MAMMARY GLAND BIOL, V13, P371, DOI 10.1007/s10911-008-9100-x; Lewis DA, 2003, EXP CELL RES, V284, P316, DOI 10.1016/S0014-4827(02)00043-5; Lewis DA, 2003, J INVEST DERMATOL, V120, P483, DOI 10.1046/j.1523-1747.2003.12060.x; LEWIS DA, 2007, J INVEST DERMATOL, V128, P1022; Lewis DA, 2008, MOL BIOL CELL, V19, P1346, DOI 10.1091/mbc.E07-10-1041; Lewis DA, 2009, J INVEST DERMATOL, V129, P787, DOI 10.1038/jid.2008.293; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928	20	91	94	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1475	1485		10.1038/onc.2009.440	http://dx.doi.org/10.1038/onc.2009.440			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966862	Green Accepted			2022-12-28	WOS:000275392400006
J	Sachdev, D; Zhang, X; Matise, I; Gaillard-Kelly, M; Yee, D				Sachdev, D.; Zhang, X.; Matise, I.; Gaillard-Kelly, M.; Yee, D.			The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival	ONCOGENE			English	Article						cancer metastasis; type I IGF receptor; antibodies against IGF1R; invasion; circulating tumor cells; survival	BREAST-CANCER; MONOCLONAL-ANTIBODY; CELLS; VIVO; EXPRESSION; INHIBITOR; COMBINATION; INVOLVEMENT; ACTIVATION; THERAPY	The type I insulin-like growth factor receptor (IGF1R) regulates multiple aspects of malignancy and is the target of several drugs currently in clinical trials. Although the function of IGF1R in proliferation and survival is well studied, the regulation of metastasis by IGF1R is not as clearly delineated. Previous work showed that disruption of IGF1R signaling by overexpression of a dominant-negative IGF1R inhibited metastasis. To establish a clinically applicable approach to inhibition of metastasis by targeting IGF1R, we examined the effect of an inhibitory antibody against IGF1R, EM164 and its humanized version, AVE1642, on metastasis of cancer cells. EM164 and AVE1642 did not affect primary tumor growth of MDA-435A/LCC6 cells but inhibited metastasis of these cells. Consistent with this inhibition in the formation of metastatic nodules, disruption of IGF1R also resulted in a decreased number of circulating tumor cells in blood of tumor-bearing mice. Disruption of IGF1R with a dominant-negative construct or antibody inhibited invasion across Matrigel in vitro. When tumor cells were directly injected into the circulation through the lateral tail vein of mice, IGF1R disruption also resulted in significant reduction of pulmonary nodules, suggesting that regulation of invasion is not the only function of IGF1R signaling. Further, disruption of IGF1R rendered cells more susceptible to anoikis. Thus, IGF1R regulated metastasis independently of tumor growth. The multiple phenotypes regulated by IGF1R must be considered during development of this therapeutic strategy as inhibition of metastasis independent of inhibition of tumor growth is not easily assessed in phase II clinical trials. Oncogene (2010) 29, 251-262; doi:10.1038/onc.2009.316; published online 19 October 2009	[Sachdev, D.; Zhang, X.; Matise, I.; Yee, D.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA; [Sachdev, D.; Yee, D.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Matise, I.] Univ Minnesota, Dept Vet Clin Sci, St Paul, MN 55108 USA; [Gaillard-Kelly, M.] Sanofi Aventis, Antony, France	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Sanofi-Aventis	Sachdev, D (corresponding author), Univ Minnesota, Mason Canc Ctr, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	sachd003@umn.edu		Yee, Douglas/0000-0002-3387-4009	NIH [R01 CA074285, P30 CA077598PHS]; National Cancer Institute [P30 CA77398]; Prospect Creek Foundation; NATIONAL CANCER INSTITUTE [R01CA077398, P30CA077598, R01CA074285] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prospect Creek Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge ImmunoGen Inc. for providing us with EM164 and the isotype-matched control antibody (anti-CD20), sanofi-aventis for AVE1642 (the humanized version of EM164), and the National Cell Culture Center (NCCC), a division of Biovest International, Fridley, MN, USA, for producing supernatant containing scFv-Fc from NSO 3b1Fc 1F12 cells in spinner cultures. We thank Nicole Kirchoff and the staff of the Comparative Pathology Shared Resource of the Masonic Cancer Center, University of Minnesota. We thank Sarah Thuriot and Alissa Pelzer for assistance with the care of the mice. We also thank Michael Franklin for editorial assistance. This work was supported by NIH R01 CA074285 (D Yee), NIH P30 CA077598PHS Cancer Center Support Grant P30 CA77398 from the National Cancer Institute and the Prospect Creek Foundation.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Burtrum D, 2003, CANCER RES, V63, P8912; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; Dunn SE, 1998, CANCER RES, V58, P3353; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Higano CS, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.08.8146; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karp DD, 2007, J CLIN ONCOL, V25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Maloney EK, 2003, CANCER RES, V63, P5073; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagle JA, 2004, MOL CELL BIOL, V24, P9726, DOI 10.1128/MCB.24.22.9726-9735.2004; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Radisky ES, 2007, REV ENDOCR METAB DIS, V8, P279, DOI 10.1007/s11154-007-9037-1; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2003, CANCER RES, V63, P627; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Tolcher AW, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3582; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008-5472.CAN-05-1448; Wu JD, 2006, CLIN CANCER RES, V12, P6153, DOI 10.1158/1078-0432.CCR-06-0443; Wu YP, 2003, CANCER RES, V63, P4384; Wu YP, 2002, CANCER RES, V62, P1030; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zhang XH, 2002, CANCER RES, V62, P4369	52	75	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					251	262		10.1038/onc.2009.316	http://dx.doi.org/10.1038/onc.2009.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838209	Green Accepted			2022-12-28	WOS:000273650000008
J	Lee, JJ; Lee, JH; Ko, YG; Hong, SI; Lee, JS				Lee, J-J; Lee, J-H; Ko, Y-G; Hong, S. I.; Lee, J-S			Prevention of premature senescence requires JNK regulation of Bcl-2 and reactive oxygen species	ONCOGENE			English	Article						premature senescence; JNK; Bcl-2; ROS; DNA damage	CELL-CYCLE PROGRESSION; PROTEIN-KINASE; KAPPA-B; PHOSPHORYLATION; APOPTOSIS; INHIBITION; CANCER; ACTIVATION; INDUCTION; ARREST	Premature senescence is considered as a cellular defense mechanism to prevent tumorigenesis. Although recent evidences show that c-Jun N-terminal kinase (JNK) is involved in the senescence process, the mechanism for this regulation is not fully understood. Here, we examined the role of JNK in premature senescence of tumor cells. Treatment of cells with the JNK-specific inhibitor SP600125 caused phenotypical changes of senescence and triggered a rapid increase in mitochondrial reactive oxygen species (ROS) production and DNA-damage response (DDR) in MCF7 breast carcinoma cells. ROS generation was attributed to the suppression of B-cell lymphoma-2 (Bcl-2) phosphorylation, and resulted in DNA damage and p53 activation. Bax did not change their localization to the mitochondria, which is required for apoptosis. The essential roles of JNK and phosphorylated Bcl-2 in preventing premature senescence were confirmed using RNA interference and ectopic expression of mutants of Bcl-2, including phosphomimetic and nonphosphorylatable forms. These findings were evidenced in H460 lung carcinoma cells and primary human embryonic fibroblasts. Altogether, our results showed that loss of JNK activity triggers a Bcl-2/ROS/DDR signaling cascade that ultimately leads to premature senescence, indicating that basal JNK activity is essential in preventing premature senescence. Oncogene (2010) 29, 561-575; doi: 10.1038/onc.2009.355; published online 26 October 2009	[Lee, J-J; Lee, J-S] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul 139706, South Korea; [Lee, J-J; Ko, Y-G] Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul, South Korea; [Lee, J-H] Catholic Univ, Coll Med, Dept Biochem, Seoul, South Korea; [Hong, S. I.] Korea Inst Radiol & Med Sci, Dept Lab Med & Clin Pathol, Seoul 139706, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Catholic University of Korea; Korea Institute of Radiological & Medical Sciences	Lee, JS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Res, 75 Nowongil, Seoul 139706, South Korea.	jaeslee@kcch.re.kr			Korean government (MEST)	Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	We thank Professor WS May of the University of Florida, USA for the kind gift of Bcl-2 mutant constructs and Professor J-Y Lee of the Hallym University, Korea for the kind supply of HEF cells. This work was supported by the Nuclear Research & Development Program of the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean government (MEST).	Autret A, 2007, J VIROL, V81, P7504, DOI 10.1128/JVI.02690-06; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bihani T, 2007, J BIOL CHEM, V282, P2666, DOI 10.1074/jbc.M608127200; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Bulgin D, 2006, THYROID, V16, P217, DOI 10.1089/thy.2006.16.217; Byun HO, 2009, CANCER RES, V69, P4638, DOI 10.1158/0008-5472.CAN-08-4042; Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Chan SHH, 2006, FREE RADICAL BIO MED, V40, P2028, DOI 10.1016/j.freeradbiomed.2006.01.032; Crescenzi E, 2003, BIOCHEM J, V375, P263, DOI 10.1042/BJ20030868; Das M, 2007, P NATL ACAD SCI USA, V104, P15759, DOI 10.1073/pnas.0707782104; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2003, BLOOD, V102, P3179, DOI 10.1182/blood-2003-04-1027; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Du LH, 2005, ONCOGENE, V24, P107, DOI 10.1038/sj.onc.1208189; Du LH, 2004, J BIOL CHEM, V279, P11957, DOI 10.1074/jbc.M304935200; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GEWIRTZ DA, 2008, BIOCHEM PHARMACOL, V76, P957; GOLETZ TJ, 1994, COLD SPRING HARB SYM, V59, P59, DOI 10.1101/SQB.1994.059.01.009; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Huang STJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0852com; Jones KR, 2005, INT J RADIAT BIOL, V81, P445, DOI 10.1080/09553000500168549; Kerr LE, 2007, ONCOGENE, V26, P2554, DOI 10.1038/sj.onc.1210044; Kim HS, 2005, MECH AGEING DEV, V126, P1255, DOI 10.1016/j.mad.2005.07.002; Kramer DL, 2001, CANCER RES, V61, P7754; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Mates J M, 1999, Front Biosci, V4, pD339; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Muller IM, 2005, MOL PHARMACOL, V67, P1684, DOI 10.1124/mol.104.004234; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Schmitt Estelle, 2007, Journal of Zhejiang University-Science B, V8, P377, DOI 10.1631/jzus.2007.B0377; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tombor B, 2003, BIOCHEM BIOPH RES CO, V303, P800, DOI 10.1016/S0006-291X(03)00402-9; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Turjanski AG, 2007, ONCOGENE, V26, P3240, DOI 10.1038/sj.onc.1210415; Vigneron A, 2005, CANCER RES, V65, P8927, DOI 10.1158/0008-5472.CAN-05-0461; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Xia HHX, 2006, CANCER LETT, V241, P268, DOI 10.1016/j.canlet.2005.10.031; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang P, 2006, ONCOGENE, V25, P7758, DOI 10.1038/sj.onc.1209744; Zimmermann AK, 2007, J BIOL CHEM, V282, P29296, DOI 10.1074/jbc.M702853200	67	45	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					561	575		10.1038/onc.2009.355	http://dx.doi.org/10.1038/onc.2009.355			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19855432				2022-12-28	WOS:000274084600009
J	Tennant, DA; Frezza, C; MacKenzie, ED; Nguyen, QD; Zheng, L; Selak, MA; Roberts, DL; Dive, C; Watson, DG; Aboagye, EO; Gottlieb, E				Tennant, D. A.; Frezza, C.; MacKenzie, E. D.; Nguyen, Q. D.; Zheng, L.; Selak, M. A.; Roberts, D. L.; Dive, C.; Watson, D. G.; Aboagye, E. O.; Gottlieb, E.			Reactivating HIF prolyl hydroxylases under hypoxia results in metabolic catastrophe and cell death	ONCOGENE			English	Article						cancer; metabolism; prolyl hydroxylase; hypoxia; alpha-ketoglutarate; HIF	INDUCIBLE FACTORS HIF-1-ALPHA; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; FACTOR-1-ALPHA; INHIBITION; DISEASE; FAMILY; PHD1; OVEREXPRESSION	Cells exposed to low-oxygen conditions (hypoxia) alter their metabolism to survive. This response, although vital during development and high-altitude survival, is now known to be a major factor in the selection of cells with a transformed metabolic phenotype during tumorigenesis. It is thought that hypoxia-selected cells have increased invasive capacity and resistance to both chemo-and radiotherapies, and therefore represent an attractive target for antitumor therapy. Hypoxia inducible factors (HIFs) are responsible for the majority of gene expression changes under hypoxia, and are themselves controlled by the oxygen-sensing HIF prolyl hydroxylases (PHDs). It was previously shown that mutations in succinate dehydrogenase lead to the inactivation PHDs under normoxic conditions, which can be overcome by treatment with alpha-ketoglutarate derivatives. Given that solid tumors contain large regions of hypoxia, the reactivation of PHDs in these conditions could induce metabolic catastrophe and therefore prove an effective antitumor therapy. In this report we demonstrate that derivatized alpha-ketoglutarate can be used as a strategy for maintaining PHD activity under hypoxia. By increasing intracellular alpha-ketoglutarate and activating PHDs we trigger PHD-dependent reversal of HIF1 activation, and PHD-dependent hypoxic cell death. We also show that derivatized alpha-ketoglutarate can permeate multiple layers of cells, reducing HIF1 alpha levels and its target genes in vivo. Oncogene (2009) 28, 4009-4021; doi:10.1038/onc.2009.250; published online 31 August 2009	[Tennant, D. A.; Frezza, C.; MacKenzie, E. D.; Selak, M. A.; Gottlieb, E.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Nguyen, Q. D.; Aboagye, E. O.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Comprehens Canc Imaging Ctr, London, England; [Zheng, L.; Watson, D. G.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland; [Roberts, D. L.; Dive, C.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England	Beatson Institute; Imperial College London; University of Strathclyde; Paterson Institute for Cancer Research; University of Manchester	Gottlieb, E (corresponding author), Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	e.gottlieb@beatson.gla.ac.uk	Frezza, Christian/G-2174-2010; Gottlieb, Eyal/G-6450-2010; Tennant, Daniel/ABE-8145-2021	Frezza, Christian/0000-0002-3293-7397; Gottlieb, Eyal/0000-0002-9770-0956; Tennant, Daniel/0000-0003-0499-2732; ABOAGYE, Eric/0000-0003-2276-6771; Dive, Caroline/0000-0002-1726-8850; Zheng, Liang/0000-0002-5346-4111; Roberts, Darren/0000-0001-7175-7754	Cancer Research UK; Association for International Cancer Research; Cancer Research UK [10337] Funding Source: researchfish; Medical Research Council [MC_U120081322] Funding Source: researchfish; MRC [MC_U120081322] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by Cancer Research UK and the Association for International Cancer Research. We thank Tom Hamilton and Derek Miller for their invaluable assistance with the in vivo work, Colin Nixon and Mairi Macdonald for helping with the histology, Margaret O'Prey for help with the microscopy, Celeste Simon for generously providing us with the HIF1 alpha-expressing plasmid and Ayala King for her excellent editorial work.	Aebersold DM, 2001, CANCER RES, V61, P2911; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Birner P, 2001, CLIN CANCER RES, V7, P1661; Bishop T, 2008, MOL CELL BIOL, V28, P3386, DOI 10.1128/MCB.02041-07; Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y; Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2008, CELL DEATH DIFFER, V15, P619, DOI 10.1038/cdd.2008.11; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; GOLDBERG MA, 1991, BLOOD, V77, P271; Hewitson KS, 2007, J BIOL CHEM, V282, P3293, DOI 10.1074/jbc.M608337200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Ikeda E, 2005, PATHOL INT, V55, P603, DOI 10.1111/j.1440-1827.2005.01877.x; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Khatua S, 2003, CANCER RES, V63, P1865; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Knowles HJ, 2003, CANCER RES, V63, P1764; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Rofstad EK, 2000, INT J RADIAT BIOL, V76, P589, DOI 10.1080/095530000138259; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; To KKW, 2005, CELL CYCLE, V4, P881, DOI 10.4161/cc.4.7.1839; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williamson J R, 1979, Methods Enzymol, V55, P200; Yoon D, 2006, J BIOL CHEM, V281, P25703, DOI 10.1074/jbc.M602329200	50	87	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4009	4021		10.1038/onc.2009.250	http://dx.doi.org/10.1038/onc.2009.250			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718054				2022-12-28	WOS:000272560300006
J	Justilien, V; Fields, AP				Justilien, V.; Fields, A. P.			Ect2 links the PKC iota-Par6 alpha complex to Rac1 activation and cellular transformation	ONCOGENE			English	Article						gene amplification; anchorage-independent growth; invasion; Rac1; Mek-Erk signaling; cytokinesis	CYTOKINESIS REGULATOR ECT2; EXCHANGE FACTOR ECT2; KINASE-C-IOTA; DETECTS FREQUENT; LUNG-CANCER; G2/M PHASE; PROTEIN; CARCINOMAS; AMPLIFICATION; HYBRIDIZATION	Protein kinase C iota (PKC iota) promotes non-small cell lung cancer (NSCLC) by binding to Par6 alpha and activating a Rac1-Pak-Mek1,2-Erk1,2 signaling cascade. The mechanism by which the PKC iota-Par6 alpha complex regulates Rac1 is unknown. Here we show that epithelial cell transforming sequence 2 (Ect2), a guanine nucleotide exchange factor for Rho family GTPases, is coordinately amplified and overexpressed with PKC iota in NSCLC tumors. RNA interference-mediated knockdown of Ect2 inhibits Rac1 activity and blocks transformed growth, invasion and tumorigenicity of NSCLC cells. Expression of constitutively active Rac1 (RacV12) restores transformation to Ect2-deficient cells. Interestingly, the role of Ect2 in transformation is distinct from its well-established role in cytokinesis. In NSCLC cells, Ect2 is mislocalized to the cytoplasm where it binds the PKC iota-Par6 alpha complex. RNA interference-mediated knockdown of either PKC iota or Par6 alpha causes Ect2 to redistribute to the nucleus, indicating that the PKC iota-Par6 alpha complex regulates the cytoplasmic localization of Ect2. Our data indicate that Ect2 and PKC iota are genetically and functionally linked in NSCLC, acting to coordinately drive tumor cell proliferation and invasion through formation of an oncogenic PKC iota-Par6 alpha-Ect2 complex. Oncogene (2009) 28, 3597-3607; doi:10.1038/onc.2009.217; published online 20 July 2009	[Justilien, V.; Fields, A. P.] Mayo Clin, Coll Med, Dept Canc Biol, Jacksonville, FL 32224 USA	Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu			National Institutes of Health [CA081436]; V Foundation for Cancer Research; Mayo Foundation; NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; Mayo Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Roderick P Regala for assistance with the ectopic tumor studies, Dr Andras Khoor and Capella Weems for analysis of primary NSCLC tumors, Pam Kreinest and Brandy Eden. eld for immunohistochemistry, Dr Lee Jamieson and Alyssa Kunz for technical assistance, and Drs E Aubrey Thompson and Nicole R Murray for critical review of the paper. This work was supported in part by grants from the National Institutes of Health (CA081436), The V Foundation for Cancer Research and The Mayo Foundation to APF.	Balsara BR, 1997, CANCER RES, V57, P2116; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; FREDERICK LA, 2008, ONCOGENE; Hara T, 2006, ONCOGENE, V25, P566, DOI 10.1038/sj.onc.1209078; Hirata D, 2009, CLIN CANCER RES, V15, P256, DOI 10.1158/1078-0432.CCR-08-1672; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Kanada M, 2008, MOL BIOL CELL, V19, P8, DOI 10.1091/mbc.E07-04-0370; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Liu XF, 2004, MOL CELL BIOL, V24, P6665, DOI 10.1128/mcb.24.15.6665-6675.2004; Liu XF, 2006, CELL SIGNAL, V18, P1604, DOI 10.1016/j.cellsig.2006.01.007; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Niiya F, 2006, ONCOGENE, V25, P827, DOI 10.1038/sj.onc.1209124; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sano M, 2006, ONCOL REP, V16, P1093; Snaddon J, 2001, BRIT J CANCER, V84, P1630, DOI 10.1054/bjoc.2001.1848; Solski PA, 2004, J BIOL CHEM, V279, P25226, DOI 10.1074/jbc.M313792200; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; TAKAI S, 1995, GENOMICS, V27, P220, DOI 10.1006/geno.1995.1033; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200; Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P533	27	94	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3597	3607		10.1038/onc.2009.217	http://dx.doi.org/10.1038/onc.2009.217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19617897	Green Accepted			2022-12-28	WOS:000270851800001
J	Kelly-Spratt, KS; Philipp-Staheli, J; Gurley, KE; Hoon-Kim, K; Knoblaugh, S; Kemp, CJ				Kelly-Spratt, K. S.; Philipp-Staheli, J.; Gurley, K. E.; Hoon-Kim, K.; Knoblaugh, S.; Kemp, C. J.			Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer	ONCOGENE			English	Article						kras; p27; Akt; lung cancer; tumor suppressor	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; TUMOR SUPPRESSION; BREAST-CANCER; MICE LACKING; P53 RESTORATION; P27; PHOSPHORYLATION; GROWTH; DEGRADATION	Reduced expression of the CDK inhibitor p27(Kip1) (p27) in human lung cancer correlates with tumor aggressiveness and poor prognosis. However, the regulation of p27 expression and the role of p27 during lung cancer are poorly understood. Urethane-induced lung tumors in mice frequently harbor mutations in the Kras oncogene, and in this study, we use this model to address the regulation of p27 during tumorigenesis. The Ras effector Akt is known to regulate p27 mRNA abundance by phosphorylating and inactivating the FOXO transcription factors. Phosphorylated Akt and FOXO proteins were both increased in lung tumors, correlating with a reduction in p27 mRNA transcript. Akt also directly phosphorylates p27 and regulates its nuclear/cytoplasmic localization. Tumors showed a reduced nuclear/cytoplasmic ratio of p27 protein, together with an increase in phosphorylated Thr197 p27 in the cytoplasmic pool. Treatment of lung tumor-bearing mice with the phosphoinositol-3 kinase inhibitor LY294002 induced a rapid decrease in phosphorylated Akt and phosphorylated p27, concomitant with an increase in nuclear p27. Germline p27 deficiency accelerated both the growth and malignant progression of urethane-induced lung tumors, and did so in a cell autonomous manner, confirming a causal role of p27 in tumor suppression. These results show that p27 is a potent barrier to the growth and malignant progression of Kras-initiated lung tumors. Further, the reduction of nuclear p27 in tumors is mediated by oncogene signaling pathways, which can be reversed by pharmacological agents. Oncogene (2009) 28, 3652-3662; doi:10.1038/onc.2009.226; published online 3 August 2009	[Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, C1-015,1100 Fairview Ave N, Seattle, WA 98109 USA.	cjkemp@fhcrc.org			NIH [T32 CA8046, R01]; ACS; NATIONAL CANCER INSTITUTE [R01CA099517] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by a NIH T32 CA8046 Interdisciplinary Training Grant in Cancer Research (KSK-S), and an ACS Research Scholar Award and a NIH R01 Research Grant (CJK).	Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Catzavelos C, 1999, CANCER RES, V59, P684; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malkinson AM, 2001, LUNG CANCER, V32, P265, DOI 10.1016/S0169-5002(00)00232-4; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Motti ML, 2004, CELL CYCLE, V3, P1074; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661; Susaki E, 2007, CELL CYCLE, V6, P3015, DOI 10.4161/cc.6.24.5087; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Yuan YH, 2007, CANCER RES, V67, P8032, DOI 10.1158/0008-5472.CAN-07-0083; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462	55	37	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	2009	28	41					3652	3662		10.1038/onc.2009.226	http://dx.doi.org/10.1038/onc.2009.226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648963	Green Accepted			2022-12-28	WOS:000270851800006
J	Neel, BD; Lopez, J; Chabadel, A; Gillet, G				Neel, B. D.; Lopez, J.; Chabadel, A.; Gillet, G.			Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases	ONCOGENE			English	Article						lithium; Src tyrosine kinase; PTPases; cell migration; glutathione	GLYCOGEN-SYNTHASE KINASE-3; ROUS-SARCOMA VIRUS; GENE-EXPRESSION; TYROSINE KINASE; NEURORETINAL CELLS; ENDOTHELIAL-CELLS; BIPOLAR DISORDER; FAMILY KINASES; CANCER CELLS; IN-VIVO	Lithium has long been used for the treatment and prophylaxis of bipolar mood disorder. However, nerve cells are not the sole targets of lithium. Indeed, lithium was reported to target numerous cell types, and affect cell proliferation, differentiation and death. Thus, the idea has been raised that lithium may act on signaling pathways involved in neoplastic transformation. Indeed, the effect of lithium on tumor progression is currently being tested in a limited number of clinical trials. However, the molecular mechanisms by which lithium affects neoplastic transformation remain to be characterized. Here, using mouse fibroblasts transformed by the v-src oncogene as a model, we show that lithium drastically inhibits cell motility and compromises the invasive phenotype of v-src-transformed cells. In addition, we show that this effect is mediated by the activation of phosphotyrosine phosphatases, but not by the direct inhibition of the v-Src tyrosine kinase. Finally, we show that lithium activates phosphotyrosine phosphatases by the modulation of the redox status of the cell, independently of the Wnt and the inositol phosphate canonical pathways. Thus, this study supports the idea that lithium, acting similar to an antioxydizer, may have antimetastatic properties in vivo. Oncogene (2009) 28, 3246-3260; doi: 10.1038/onc.2009.190; published online 13 July 2009	[Neel, B. D.; Lopez, J.; Gillet, G.] Univ Lyon 1, Inst Biol & Chim Prot, UMR 5086, CNRS,IFR 128, F-69367 Lyon 07, France; [Chabadel, A.] Univ Lyon, Lab Biol Mol Cellule, UMR 5239, CNRS,Ecole Normale Super Lyon,IFR 128, Lyon 07, France; [Lopez, J.] Hop Croix Rousse, Hosp Civils Lyon, F-69317 Lyon 04, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CHU Lyon	Gillet, G (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, UMR 5086, CNRS,IFR 128, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	gillet, germain/A-9095-2013	LOPEZ, Jonathan/0000-0003-3768-2378; GILLET, Germain/0000-0002-1514-327X	Association pour la Recherche sur le Cancer (ARC); the Ligue Nationale contre le Cancer; Region Rhone Alpes; Ministere de la Recherche; ARC	Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); the Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Region Rhone Alpes(Region Auvergne-Rhone-Alpes); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); ARC(Australian Research Council)	We thank Pierre Jurdic and Philippe Gonzalo for helpfull discussions and critical reading of the paper. We acknowledge Aurelie Cornut for skillfull technical assistance. This work was supported by the Association pour la Recherche sur le Cancer (ARC), the Ligue Nationale contre le Cancer and the Region Rhone Alpes. BDN is a recipient of fellowships from the Ministere de la Recherche and the ARC.	Aghdam SY, 2007, CURR ALZHEIMER RES, V4, P21; Almeida CG, 2003, NEUROSCI LETT, V339, P127, DOI 10.1016/S0304-3940(02)01478-7; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Beaulieu JM, 2008, CELL, V132, P125, DOI 10.1016/j.cell.2007.11.041; Benati D, 2008, CURR MED CHEM, V15, P1154, DOI 10.2174/092986708784310404; CAMPAGNE MMV, 1988, DEV GENET, V9, P589, DOI 10.1002/dvg.1020090435; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; Cui J, 2007, NEUROSCIENCE, V144, P1447, DOI 10.1016/j.neuroscience.2006.11.010; D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje; Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood-2007-03-077685; GILLET G, 1993, ONCOGENE, V8, P565; Gould TD, 2005, NEUROPSYCHOPHARMACOL, V30, P1223, DOI 10.1038/sj.npp.1300731; Gould TD, 2004, MOL PSYCHIATR, V9, P734, DOI 10.1038/sj.mp.4001518; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; Karlovic D, 2007, CELL BIOL TOXICOL, V23, P83, DOI 10.1007/s10565-006-0126-9; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Markova B, 2005, METHODS, V35, P22, DOI 10.1016/j.ymeth.2004.07.004; MARONEY AC, 1992, ONCOGENE, V7, P1207; Mathew S, 2008, J BIOL CHEM, V283, P22709, DOI 10.1074/jbc.M801319200; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Moldovan L, 2006, CARDIOVASC RES, V71, P236, DOI 10.1016/j.cardiores.2006.05.003; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Pao LI, 2007, ANNU REV IMMUNOL, V25, P473, DOI 10.1146/annurev.immunol.23.021704.115647; Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIZARRO JG, 2008, J CELL MOL MED; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ronziere MC, 2003, BIOMATERIALS, V24, P851, DOI 10.1016/S0142-9612(02)00418-0; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Seelan RS, 2008, NEUROSCIENCE, V151, P1184, DOI 10.1016/j.neuroscience.2007.10.045; Severus WE, 2008, BIPOLAR DISORD, V10, P231, DOI 10.1111/j.1399-5618.2007.00475.x; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Song L, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-20; Stump RJW, 2006, J PATHOL, V210, P249, DOI 10.1002/path.2049; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X; WELSHONS WV, 1995, J CELL PHYSIOL, V165, P134, DOI 10.1002/jcp.1041650116; Yang B, 2003, CANCER RES, V63, P1520; Zhang WV, 2005, APOPTOSIS, V10, P75, DOI 10.1007/s10495-005-6063-x; Zhen XC, 2002, PSYCHOPHARMACOLOGY, V162, P379, DOI 10.1007/s00213-002-1126-y	52	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3246	3260		10.1038/onc.2009.190	http://dx.doi.org/10.1038/onc.2009.190			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19597466				2022-12-28	WOS:000269673400007
J	Reis-Sobreiro, M; Gajate, C; Mollinedo, F				Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F.			Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions	ONCOGENE			English	Article						lipid rafts; Fas/CD95 signaling; mitochondrial transmembrane potential; multiple myeloma; T-cell leukemia; resveratrol	DEATH-RECEPTOR; MULTIPLE-MYELOMA; SELECTIVE APOPTOSIS; CANCER; FAS; CELLS; EDELFOSINE; COMPLEX; REDISTRIBUTION; ACTIVATION	We have found that resveratrol (trans-3,4',5-trihydroxystilbene) induced apoptosis in multiple myeloma (MM) and T-cell leukemia cells through coclustering of Fas/CD95 death receptor and lipid rafts, whereas normal lymphocytes were spared. Tumor necrosis factor-related apoptosis-inducing ligand receptors, Fas-associated death domain-containing protein (FADD), procaspase-8, procaspase-10, c-Jun amino-terminal kinase and Bid were also recruited into lipid rafts on resveratrol incubation with MM and T-cell leukemia cells. Raft disruption inhibited resveratrol-induced apoptosis. Bcl-X-L overexpression prevented resveratrol-induced disruption of mitochondrial transmembrane potential (Delta Psi(m)) and apoptosis. A FADD dominant-negative mutant, that blocked Fas/CD95 downstream signaling, precluded resveratrol-induced Delta Psi(m) loss and apoptosis, indicating a sequence of Fas/CD95 signaling -> mitochondrion in the apoptotic response triggered by resveratrol. Cells deficient in Fas/CD95 did not undergo resveratrol-induced apoptosis. Pretreatment of MM cells with interferon-gamma upregulated Fas/CD95 and caspase-8, and potentiated resveratrol-induced apoptosis. Our data indicate that recruitment of Fas/CD95 death receptor and downstream signaling molecules into lipid rafts, followed by Delta Psi(m) disruption, underlies the apoptotic action of resveratrol in MM and T-cell leukemic cells. Combination of resveratrol with perifosine or bortezomib potentiated the apoptotic response induced by each single drug. These results also highlight the role of recruitment of Fas/CD95 signaling in lipid rafts in antimyeloma and antileukemia chemotherapy. Oncogene (2009) 28, 3221-3234; doi: 10.1038/onc.2009.183; published online 29 June 2009	[Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F.] Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca	Mollinedo, F (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.	fmollin@usal.es	2009, Secribsal/A-1266-2012	Gajate, Consuelo/0000-0003-0604-6459; Reis Sobreiro, Mariana/0000-0003-0286-0824	Ministerio de Ciencia e Innovacion [SAF2008-02251, SAF2005-04293, RD06/0020/1037]; Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III; Fondo de Investigacion Sanitaria and European Commission [FIS-FEDER 06/0813, 04/0843]; Junta de Castilla y Leon [CSI01A08, SAN673/SA32/08]; Experimental Therapeutics and Translational Oncology Program [GR15]; Fundacion de Investigacion Medica Mutua Madrilena (FMM); Fundacion 'la Caixa' [BM05-30-0]; Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal); Ministerio de Ciencia e Innovacion of Spain	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III(Instituto de Salud Carlos III); Fondo de Investigacion Sanitaria and European Commission(Instituto de Salud Carlos III); Junta de Castilla y Leon(Junta de Castilla y Leon); Experimental Therapeutics and Translational Oncology Program; Fundacion de Investigacion Medica Mutua Madrilena (FMM); Fundacion 'la Caixa'(La Caixa Foundation); Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal)(Portuguese Foundation for Science and Technology); Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from Ministerio de Ciencia e Innovacion (SAF2008-02251, SAF2005-04293, RD06/0020/1037-Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER 06/0813, 04/0843), Junta de Castilla y Leon (CSI01A08, SAN673/SA32/08, and GR15-Experimental Therapeutics and Translational Oncology Program), Fundacion de Investigacion Medica Mutua Madrilena (FMM) and Fundacion 'la Caixa' (BM05-30-0). MRS is recipient of a predoctoral fellowship from the Fundacao para a Ciencia e Tecnologia (Ministerio da Ciencia, Tecnologia e Ensino Superior of Portugal). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain. We thank Lienhard Schmitz (University of Bern, Switzerland) for providing the stably transfected Jurkat FADD-DN cell line.	Ashkenazi A, 2008, J CLIN ONCOL, V26, P3621, DOI 10.1200/JCO.2007.15.7198; Aziz MH, 2003, INT J ONCOL, V23, P17; Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248; Barjot C, 2007, LIFE SCI, V81, P1565, DOI 10.1016/j.lfs.2007.08.047; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Christian AE, 1997, J LIPID RES, V38, P2264; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Fulda S, 2005, EUR J CANCER, V41, P786, DOI 10.1016/j.ejca.2004.12.020; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2005, J BIOL CHEM, V280, P11641, DOI 10.1074/jbc.M411781200; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2000, INT J CANCER, V86, P208, DOI 10.1002/(SICI)1097-0215(20000415)86:2<208::AID-IJC10>3.0.CO;2-E; Gajate C, 2003, CLIN CANCER RES, V9, P1535; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Gill C, 2007, PROSTATE, V67, P1641, DOI 10.1002/pros.20653; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Lonial S, 2007, CLIN LYMPHOMA MYELOM, V8, pS18, DOI 10.3816/CLM.2007.s.029; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MOLLINEDO F, 1992, J IMMUNOL, V149, P323; Mollinedo F, 2007, EXPERT OPIN THER PAT, V17, P385, DOI 10.1517/13543776.17.4.385; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo Faustino, 2006, P13; Nieto-Miguel T, 2008, ONCOGENE, V27, P1779, DOI 10.1038/sj.onc.1210816; Nieto-Miguel T, 2006, J BIOL CHEM, V281, P14833, DOI 10.1074/jbc.M511251200; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; WESTENDORF JJ, 1995, BLOOD, V85, P3566, DOI 10.1182/blood.V85.12.3566.bloodjournal85123566	36	72	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3221	3234		10.1038/onc.2009.183	http://dx.doi.org/10.1038/onc.2009.183			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561642				2022-12-28	WOS:000269673400005
J	Mateo, F; Vidal-Laliena, M; Canela, N; Busino, L; Martinez-Balbas, MA; Pagano, M; Agell, N; Bachs, O				Mateo, F.; Vidal-Laliena, M.; Canela, N.; Busino, L.; Martinez-Balbas, M. A.; Pagano, M.; Agell, N.; Bachs, O.			Degradation of cyclin A is regulated by acetylation	ONCOGENE			English	Article						acetylation; cyclin A; degradation; P/CAF; ubiquitylation	SPINDLE ASSEMBLY CHECKPOINT; DEPENDENT KINASES; DNA-DAMAGE; CELL-CYCLE; S-PHASE; MITOSIS; CDC20; UBIQUITINATION; DESTRUCTION; COMPLEX	Cyclin A accumulates at the onset of S phase, remains high during G(2) and early mitosis and is degraded at prometaphase. Here, we report that the acetyltransferase P/CAF directly interacts with cyclin A that as a consequence becomes acetylated at lysines 54,68, 95 and 112. Maximal acetylation occurs simultaneously to ubiquitylation at mitosis, indicating importance of acetylation on cyclin A stability. This was further confirmed by the observation that the pseudoacetylated cyclin A mutant can be ubiquitylated whereas the nonacetylatable mutant cannot. The nonacetylatable mutant is more stable than cyclin A WT (cycA WT) and arrests cell cycle at mitosis. Moreover, in cells treated with histone deacetylase inhibitors cyclin A acetylation increases and its stability decreases, thus supporting the function of acetylation on cyclin A degradation. Although the nonacetylatable mutant cannot be ubiquitylated, it interacts with the proteins needed for its degradation (cdks, Cks, Cdc 20, Cdh1 and APC/C). In fact, its association with cdks is increased and its complexes with these kinases display higher activity than control cycA WT-cdk complexes. All these results indicate that cyclin A acetylation at specific lysines is crucial for cyclin A stability and also has a function in the regulation of cycA-cdk activity. Oncogene (2009) 28, 2654-2666; doi: 10.1038/onc.2009.127; published online 1 June 2009	[Mateo, F.; Vidal-Laliena, M.; Canela, N.; Agell, N.; Bachs, O.] Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, E-08036 Barcelona, Spain; [Busino, L.; Pagano, M.] NYU, Sch Med, Dept Pathol, NYU Canc Inst,Smilow Res Ctr, New York, NY USA; [Martinez-Balbas, M. A.] CSIC, Inst Biol Mol Barcelona, Barcelona, Spain; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA	University of Barcelona; New York University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Howard Hughes Medical Institute; New York University	Bachs, O (corresponding author), Univ Barcelona, Dept Pathol & Cell Biol, Fac Med, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Mateo, Francesca/K-7746-2015; Agell, Neus/E-9640-2016; Canela, Núria/I-5401-2015	Mateo, Francesca/0000-0002-2342-7010; Agell, Neus/0000-0002-1205-6074; Canela, Núria/0000-0003-0261-2396; Martinez-Balbas, Marian/0000-0003-0173-0964; pagano, michele/0000-0003-3210-2442	Ministerio de Educacion y Ciencia of Spain [SAF2006-05212, SAF2007-60491]; RETICS [RD06/0020/0010]; Instituto de Salud Carlos III; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R21CA125173, R21CA161108, R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Ministerio de Educacion y Ciencia of Spain(Spanish Government); RETICS; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research foundation to Michele Pagano; Michele Pagano is an Investigator with the Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by grants SAF2006-05212 and SAF2007-60491 from the Ministerio de Educacion y Ciencia of Spain and RETICS RD06/0020/0010 from the Instituto de Salud Carlos III. It was also supported by grants from the National Institutes of Health (R01-GM57587, R37-CA76584, and R21-CA125173) and the Multiple Myeloma Research foundation to Michele Pagano. Michele Pagano is an Investigator with the Howard Hughes Medical Institute.	Abramova MV, 2006, J BIOL CHEM, V281, P21040, DOI 10.1074/jbc.M511059200; Baek SY, 2006, NEUROSCI LETT, V396, P230, DOI 10.1016/j.neulet.2005.11.041; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Canela N, 2006, J BIOL CHEM, V281, P35942, DOI 10.1074/jbc.M603511200; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; PAGANO M, 1991, Progress in Growth Factor Research, V3, P267, DOI 10.1016/0955-2235(91)90004-N; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Ramachandran V, 2007, CELL CYCLE, V6, P171, DOI 10.4161/cc.6.2.3716; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Sadoul K, 2008, BIOCHIMIE, V90, P306, DOI 10.1016/j.biochi.2007.06.009; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimazu T, 2006, ONCOGENE, V25, P7391, DOI 10.1038/sj.onc.1209731; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027	42	45	48	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2654	2666		10.1038/onc.2009.127	http://dx.doi.org/10.1038/onc.2009.127			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483727	Green Submitted, Green Accepted			2022-12-28	WOS:000268211200004
J	Kelber, JA; Panopoulos, AD; Shani, G; Booker, EC; Belmonte, JC; Vale, WW; Gray, PC				Kelber, J. A.; Panopoulos, A. D.; Shani, G.; Booker, E. C.; Belmonte, J. C.; Vale, W. W.; Gray, P. C.			Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways	ONCOGENE			English	Article						Cripto; GRP78; TGF-beta; MAPK; Akt; stem cell; cancer	MAMMARY EPITHELIAL-CELLS; CANCER-CELLS; TGF-BETA; TYROSINE PHOSPHORYLATION; CHAPERONE GRP78/BIP; ACTIVIN RECEPTOR; GROWTH; IDENTIFICATION; PROLIFERATION; SUPPRESSES	Cripto is a developmental oncoprotein that signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Smad2/3 pathways. However, the molecular basis for Cripto coupling to these pathways during embryogenesis and tumorigenesis is not fully understood. In this regard, we recently demonstrated that Cripto forms a cell surface complex with the HSP70 family member glucose-regulated protein-78 (GRP78). Here, we provide novel functional evidence demonstrating that cell surface GRP78 is a necessary mediator of Cripto signaling in human tumor, mammary epithelial and embryonic stem cells. We show that targeted disruption of the cell surface Cripto/GRP78 complex using shRNAs or GRP78 immunoneutralization precludes Cripto activation of MAPK/PI3K pathways and modulation of activin-A, activin-B, Nodal and transforming growth factor-beta 1 signaling. We further demonstrate that blockade of Cripto binding to cell surface GRP78 prevents Cripto from increasing cellular proliferation, downregulating E-Cadherin, decreasing cell adhesion and promoting proproliferative responses to activin-A and Nodal. Thus, disrupting the Cripto/GRP78 binding interface blocks oncogenic Cripto signaling and may have important therapeutic value in the treatment of cancer. Oncogene (2009) 28, 2324-2336; doi:10.1038/onc.2009.97; published online 4 May 2009	[Gray, P. C.] Salk Inst Biol Studies, Vale Lab, Clayton Fdn Labs Peptide Biol, PBL, La Jolla, CA 92037 USA; [Kelber, J. A.] Univ San Diego, Dept Chem & Biochem, La Jolla, CA USA; [Panopoulos, A. D.; Belmonte, J. C.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Shani, G.] Burnham Inst Med Res, Tumor Microenvironm Program, La Jolla, CA USA; [Booker, E. C.] Univ San Diego, Dept Biol, La Jolla, CA USA	Salk Institute; University of San Diego; Salk Institute; Sanford Burnham Prebys Medical Discovery Institute; University of San Diego	Gray, PC (corresponding author), Salk Inst Biol Studies, Vale Lab, Clayton Fdn Labs Peptide Biol, PBL, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gray@salk.edu		Panopoulos, Athanasia/0000-0002-9610-2604; Kelber, Jonathan/0000-0002-4606-1445	NCI, National Institutes of Health [R01CA107420]; Foundation for Medical research, Inc.; Robert J Jr and Helen Kleberg Foundaton; NIH [T32 CA009370]; G Harold and Leila Y Mathers Charitable Foundation; Foundation for Medical Research, Inc; NATIONAL CANCER INSTITUTE [R01CA107420, T32CA009370] Funding Source: NIH RePORTER	NCI, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Foundation for Medical research, Inc.; Robert J Jr and Helen Kleberg Foundaton; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); G Harold and Leila Y Mathers Charitable Foundation; Foundation for Medical Research, Inc; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI, National Institutes of Health, Grant R01CA107420, the Foundation for Medical research, Inc., and the Robert J Jr and Helen Kleberg Foundaton. A portion of this work was also supported by an NIH training grant T32 CA009370 (to ADP) and the G Harold and Leila Y Mathers Charitable Foundation (to JCIB). Wylie W Vale is a senior investigator of the Foundation for Medical Research, Inc. and is a cofounder, consultant, equity holder and member of the Board of Directors of Neurocrine Biosciences and Acceleron Pharma. We thank Dr Travis Berggren and Margaret Lutz of The Salk Institute Stem Cell Core for valuable technical assistance.	Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bianco C, 1999, J BIOL CHEM, V274, P8624, DOI 10.1074/jbc.274.13.8624; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gonzalez-Gronow M, 2006, CANCER RES, V66, P11424, DOI 10.1158/0008-5472.CAN-06-1721; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gray PC, 2006, MOL CELL BIOL, V26, P9268, DOI 10.1128/MCB.01168-06; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Jakobsen CG, 2007, CANCER RES, V67, P9507, DOI 10.1158/0008-5472.CAN-06-4686; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kelber JA, 2008, J BIOL CHEM, V283, P4490, DOI 10.1074/jbc.M704960200; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j; Minchiotti G, 2005, ONCOGENE, V24, P5668, DOI 10.1038/sj.onc.1208917; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Misra UK, 2004, CELL SIGNAL, V16, P929, DOI 10.1016/j.cellsig.2004.01.003; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Philippova M, 2008, MOL CELL BIOL, V28, P4004, DOI 10.1128/MCB.00157-08; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Rahimi RA, 2007, J CELL BIOCHEM, V102, P593, DOI 10.1002/jcb.21501; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07; Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shukla A, 2008, MOL CANCER RES, V6, P509, DOI 10.1158/1541-7786.MCR-07-0396; Strizzi L, 2005, ONCOGENE, V24, P5731, DOI 10.1038/sj.onc.1208918; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Wechselberger C, 2005, ONCOGENE, V24, P4094, DOI 10.1038/sj.onc.1208417; Xing PX, 2004, CANCER RES, V64, P4018, DOI 10.1158/0008-5472.CAN-03-3888; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0	39	139	144	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2324	2336		10.1038/onc.2009.97	http://dx.doi.org/10.1038/onc.2009.97			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421146	Green Accepted			2022-12-28	WOS:000267089100003
J	Li, JJ; Liu, DP; Liu, GT; Xie, D				Li, J-J; Liu, D-P; Liu, G-T; Xie, D.			EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor	ONCOGENE			English	Article						ephrinA5; EGFR; c-Cbl; glioma	C-CBL; EPH RECEPTORS; TYROSINE KINASES; GENE-EXPRESSION; CANCER CELLS; T-CELLS; PHOSPHORYLATION; BINDING; LIGAND; TUMORIGENICITY	Eph receptors, the largest subfamily of receptor tyrosine kinases, and their ephrin ligands play important roles in nervous system development. Recently, they have been implicated in tumorigenesis of different cancers. In this study, we showed that the expression of ephrinA5 was dramatically downregulated in primary gliomas compared with normal tissues. Forced expression of ephrinA5 reduced tumorigenicity of human glioma U373 cells. Epidermal growth factor receptor (EGFR), which frequently acts as an oncoprotein in glioma, was greatly decreased in ephrinA5-transfected glioma cells, and the two molecules exhibited a mutually exclusive expression pattern in primary glioma samples. We found that ephrinA5 enhanced c-Cbl binding to EGFR, thus promoted ubiquitylation and degradation of the receptor. Either ephrinA5-Fc or EphA2-Fc treatment simulating bidirectional signaling of Eph/ephrin system resulted in EGFR decrease. This study discovered that ephrinA5 acted as a tumor suppressor in glioma, and its negative regulation of EGFR contributed to the suppressive effects. In addition to identifying a novel mechanism underlying tumor suppressor activity of ephrinA5, we also showed cross-talk between different receptor tyrosine kinase families in glioma. These.ndings may improve therapeutic strategies for glioma.	[Xie, D.] Chinese Acad Sci, Mol Oncol Lab, Inst Nutr Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; [Li, J-J] Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; [Liu, G-T] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Cedars Sinai Medical Center	Xie, D (corresponding author), Chinese Acad Sci, Mol Oncol Lab, Inst Nutr Sci, Shanghai Inst Biol Sci, 294 Tai Yuan Rd, Shanghai 200031, Peoples R China.	dxie@sibs.ac.cn		Xie, Dong/0000-0002-1150-8657				Bolz J, 2004, J NEUROBIOL, V59, P82, DOI 10.1002/neu.10346; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Finne EF, 2004, BIOCHEM J, V379, P39, DOI 10.1042/BJ20031619; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grossmann AH, 2004, FEBS LETT, V577, P555, DOI 10.1016/j.febslet.2004.10.054; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Halatsch ME, 2006, CANCER TREAT REV, V32, P74, DOI 10.1016/j.ctrv.2006.01.003; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Huberman AD, 2005, NAT NEUROSCI, V8, P1013, DOI 10.1038/nn1505; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Larsen AB, 2007, MOL CANCER RES, V5, P283, DOI 10.1158/1541-7786.MCR-06-0321; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li ZB, 2007, PLOS BIOL, V5, P212, DOI 10.1371/journal.pbio.0050035; Liu DP, 2007, INT J ONCOL, V30, P865; Liu XW, 2000, J BIOL CHEM, V275, P7280, DOI 10.1074/jbc.275.10.7280; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Nicholas MK, 2006, CLIN CANCER RES, V12, P7261, DOI 10.1158/1078-0432.CCR-06-0874; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Otal R, 2006, NEUROSCIENCE, V141, P109, DOI 10.1016/j.neuroscience.2006.03.052; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Varelias A, 2002, CANCER, V95, P862, DOI 10.1002/cncr.10749; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; XU J, 1993, J BIOL CHEM, V268, P16065; Yarden RI, 2001, J CELL BIOCHEM, P232	36	51	55	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1759	1768		10.1038/onc.2009.15	http://dx.doi.org/10.1038/onc.2009.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270726				2022-12-28	WOS:000265640400003
J	Wicovsky, A; Henkler, F; Salzmann, S; Scheurich, P; Kneitz, C; Wajant, H				Wicovsky, A.; Henkler, F.; Salzmann, S.; Scheurich, P.; Kneitz, C.; Wajant, H.			Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation	ONCOGENE			English	Article						apoptosis; NF-kappa B; TNF; TNFR1; TNFR2; TRAF1	NF-KAPPA-B; FACTOR-ALPHA; CELL-DEATH; SUPEROXIDE-DISMUTASE; INDUCED APOPTOSIS; FACTOR (TRAF)-1; T-LYMPHOCYTES; LIPID RAFTS; ACTIVATION; TRAF2	It has been shown that tumor necrosis factor receptor-2 (TNFR2) stimulation leads to degradation of TNF receptor associated factor-2 (TRAF2) and inhibition of TNFR1-induced activation of NF kappa B and JNK. Here, we show that TRAF1 inhibits TNFR2-induced proteasomal degradation of TRAF2 and relieves TNFR1-induced activation of NF kappa B from the inhibitory effect of TNFR2. TRAF1 co-recruited with TRAF2 to both TNF receptors. Despite lackingan amino-terminal RING/zinc-finger domain, TRAF1 did not interfere with TNFR1-induced activation of JNK and NF kappa B. It is noted that physiological expression levels of TRAF1 enhanced NF kappa B activation and interleukin-8 (IL8) production induced by TNFR2. Thus, TRAF1 shifts the quality of integrated TNFR1-TNFR2 signaling from apoptosis induction to proinflammatory NF kappa B signaling.	[Wicovsky, A.; Henkler, F.; Salzmann, S.; Kneitz, C.; Wajant, H.] Univ Hosp Wurzburg, Div Mol Internal Med, Dept Internal Med 2, D-97070 Wurzburg, Germany; [Scheurich, P.] Univ Stuttgart, Inst Cell Biol & Immunol, Stuttgart, Germany	University of Wurzburg; University of Stuttgart	Wajant, H (corresponding author), Univ Hosp Wurzburg, Div Mol Internal Med, Dept Internal Med 2, Roentgenring 11, D-97070 Wurzburg, Germany.	harald.wajant@mail.uni-wuerzburg.de	Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949	Deutsche Forschungsgemeinschaft [B7, HE 5275/2-1, Wa1025/8-1]; IZKF Wurzburg [A-49]; Weyth Biopharma	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IZKF Wurzburg; Weyth Biopharma	The project was supported by Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 487, project B7, HE 5275/2-1 and Wa1025/8-1), IZKF Wurzburg (project A-49) and Weyth Biopharma (Forschungspreis Rheumatologie 2007).	Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Baxter GT, 1999, J BIOL CHEM, V274, P9539, DOI 10.1074/jbc.274.14.9539; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Declercq W, 1998, J IMMUNOL, V161, P390; Dietz AB, 2006, TRANSFUSION, V46, P2083, DOI 10.1111/j.1537-2995.2006.01033.x; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Henkler F, 2003, J BIOL CHEM, V278, P29216, DOI 10.1074/jbc.M211090200; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Krippner-Heidenreich A, 2008, J IMMUNOL, V180, P8176, DOI 10.4049/jimmunol.180.12.8176; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Speiser DE, 1996, EUR J IMMUNOL, V26, P3055, DOI 10.1002/eji.1830261235; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VERCAMMEN D, 1995, CYTOKINE, V7, P463, DOI 10.1006/cyto.1995.0063; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weingartner M, 2002, J BIOL CHEM, V277, P34853, DOI 10.1074/jbc.M205149200; Weiss T, 1997, J IMMUNOL, V158, P2398; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	43	57	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1769	1781		10.1038/onc.2009.29	http://dx.doi.org/10.1038/onc.2009.29			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287455				2022-12-28	WOS:000265640400004
J	Endo, K; Kondo, S; Shackleford, J; Horikawa, T; Kitagawa, N; Yoshizaki, T; Furukawa, M; Zen, Y; Pagano, JS				Endo, K.; Kondo, S.; Shackleford, J.; Horikawa, T.; Kitagawa, N.; Yoshizaki, T.; Furukawa, M.; Zen, Y.; Pagano, J. S.			Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration	ONCOGENE			English	Article						latent membrane protein 1; ezrin; nasopharyngeal carcinoma; cell migration	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; EPITHELIAL-CELLS; ERM PROTEINS; KINASE-C; MEMBRANE-PROTEIN-1; GROWTH; EXPRESSION; INDUCTION; CYTOSKELETON; MOTILITY	Tumor metastasis is a complex phenomenon that is the culmination of effects of numerous cellular factors. We have shown that the Epstein-Barr virus (EBV) oncoprotein, latent membrane protein 1(LMP1), is capable of inducing a wide range of such factors in cell culture, expression of which is also elevated in the LMP1-expressing tumor, nasopharyngeal carcinoma (NPC), a highly invasive neoplasm. Recently, the membrane crosslinker protein, ezrin, has been implicated in tumor cell metastasis and malignant progression. In this study, we evaluated the possible role of LMP1 and ezrin in the pathophysiology of NPC. We show that C-terminal phosphorylation of ezrin is increased by the expression of LMP1 in nasopharyngeal (NP) cells through a protein kinase C (PKC) pathway. LMP1 enhances the organization of a ternary complex of CD44, ezrin and F-actin, which is a prerequisite for ezrin phosphorylation. In NPC tissues, the expression of phosphoezrin and LMP1 is directly correlated. Silencing of endogenously expressed ezrin suppresses LMP1-induced cell motility and invasiveness. Moreover, the inhibition of ezrin phosphorylation by PKC inhibitor suppresses migration and invasion of NP cells. These data show that the phosphorylation of ezrin and its recruitment to the cell membrane linked to F-actin and CD44 is a process required for LMP1-stimulated cell motility and invasion of NP cells.	[Pagano, J. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Pagano, J. S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Endo, K.; Kondo, S.; Horikawa, T.; Kitagawa, N.; Yoshizaki, T.; Furukawa, M.] Kanazawa Univ, Grad Sch Med, Div Otolaryngol, Kanazawa, Ishikawa, Japan; [Zen, Y.] Kanazawa Univ Hosp, Div Pathol, Kanazawa, Ishikawa, Japan	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kanazawa University; Kanazawa University	Pagano, JS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, West Dr, Chapel Hill, NC 27599 USA.	joseph_pagano@med.unc.edu			NCI [CA 19014]; Nakayama Foundation for Human Science (Tokyo, Japan); NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042371] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nakayama Foundation for Human Science (Tokyo, Japan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Sai Wah Tsao and Erik K Flemington for the NP69SV40T cell line and the Ad-AH cell line, respectively. We thank Drs Yojiro Kotake and Yuki Okada for helpful advice. This work was supported by NCI (CA 19014) (JSP) and the Nakayama Foundation for Human Science (Tokyo, Japan) (KE).	Auvinen E, 2007, EXP CELL RES, V313, P824, DOI 10.1016/j.yexcr.2006.12.002; Baumgartner M, 2006, P NATL ACAD SCI USA, V103, P13391, DOI 10.1073/pnas.0605950103; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; CONTRERASBRODIN BA, 1991, J GEN VIROL, V72, P3025, DOI 10.1099/0022-1317-72-12-3025; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Fais S, 2004, TRENDS MOL MED, V10, P249, DOI 10.1016/j.molmed.2004.04.005; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Hiscox S, 1999, J CELL SCI, V112, P3081; Hopkins AM, 2007, AM J PHYSIOL-GASTR L, V292, pG806, DOI 10.1152/ajpgi.00333.2006; Horikawa T, 2001, AM J PATHOL, V159, P27, DOI 10.1016/S0002-9440(10)61669-0; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kondo S, 2005, INT J CANCER, V115, P368, DOI 10.1002/ijc.20849; Kondo S, 2007, J VIROL, V81, P1554, DOI 10.1128/JVI.02222-06; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Larsson C, 2006, CELL SIGNAL, V18, P276, DOI 10.1016/j.cellsig.2005.07.010; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Park JH, 2002, VIROLOGY, V303, P345, DOI 10.1006/viro.2002.1638; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; RAAB-TRAUB N, 1987, Journal of Experimental Pathology (New York), V3, P449; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; TAKIMOTO T, 1988, LARYNGOSCOPE, V98, P1334; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wakisaka N, 2002, CANCER RES, V62, P6337; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; WALTER J, 1995, INT J CANCER, V61, P363, DOI 10.1002/ijc.2910610315; Yan GR, 2007, CELL SIGNAL, V19, P341, DOI 10.1016/j.cellsig.2006.07.019; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Yoshizaki T, 2005, EPSTEIN-BARR VIRUS, P171; Zhang Y, 2006, J CANCER RES CLIN, V132, P685, DOI 10.1007/s00432-006-0117-5	43	61	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1725	1735		10.1038/onc.2009.20	http://dx.doi.org/10.1038/onc.2009.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234486	Green Accepted, Green Submitted			2022-12-28	WOS:000265022000007
J	Giam, M; Huang, DCS; Bouillet, P				Giam, M.; Huang, D. C. S.; Bouillet, P.			BH3-only proteins and their roles in programmed cell death	ONCOGENE			English	Review						Bcl-2 family; BH3-only proteins; Bax/Bak activation; direct/indirect models; mitochondria; cytochrome c release	MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BCL-2 FAMILY; CONFORMATIONAL-CHANGE; TRIGGER APOPTOSIS; INDUCE APOPTOSIS; DEFICIENT MICE; CYTOCHROME-C; BH3 DOMAINS; T-CELL; BAX	The Bcl-2 family of proteins controls the mitochondrial pathway to apoptosis. It consists of pro-survival and proapoptotic members, and their interactions decide whether apoptogenic factor confined to the mitochondrial intermembrane space can leak to the cytosol. Despite the intense efforts to understand the molecular mechanisms that lead to the permeabilization of the mitochondrial membrane, this particular issue remains a matter of intense controversy. It is well accepted that pro-apoptotic Bax and Bak are directly responsible for the damage to the mitochondria, but pro-survival family members prevent them from doing so. It is also accepted that stress signals activate selected Bcl-2 homology (BH) 3-only proteins. But do these BH3-only proteins bind and activate Bax and Bak directly, or do they inhibit the pro-survival family members? Oncogene (2009) 27, S128-S136; doi: 10.1038/onc.2009.50	[Giam, M.; Huang, D. C. S.; Bouillet, P.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; [Giam, M.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Bouillet, P (corresponding author), Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Parkville, Vic 3050, Australia.	bouillet@wehi.edu.au	Bouillet, Philippe/E-1241-2013; Huang, David C. S./C-7586-2013	Bouillet, Philippe/0000-0002-9012-6058; Huang, David C. S./0000-0002-3101-4873	NHMRC; Charles and Sylvia Viertel Charitable Foundation	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Charles and Sylvia Viertel Charitable Foundation	This work was supported by the NHMRC (Program Grant, Fellowship, Career Development Award and Project Grant) and the Charles and Sylvia Viertel Charitable Foundation. We are grateful to our colleagues at WEHI for stimulating discussions and insightful comments. We apologize to the authors whose contributions have not been cited owing to space limitations.	Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cai BB, 2008, APOPTOSIS, V13, P803, DOI 10.1007/s10495-008-0218-5; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2008, NATURE, V455, P1047, DOI 10.1038/4551047a; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Khoury CM, 2008, BBA-MOL CELL RES, V1783, P1449, DOI 10.1016/j.bbamcr.2007.12.013; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Oh KJ, 2006, J BIOL CHEM, V281, P36999, DOI 10.1074/jbc.M602341200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rinkenberger JL, 2000, GENE DEV, V14, P23; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorilas A, 2001, GENOMICS, V72, P217, DOI 10.1006/geno.2000.6455; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Strasser A, 2008, IMMUNOL CELL BIOL, V86, P57, DOI 10.1038/sj.icb.7100141; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Theodorakis P, 2002, CANCER RES, V62, P3373; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	59	145	150	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S128	S136		10.1038/onc.2009.50	http://dx.doi.org/10.1038/onc.2009.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641498				2022-12-28	WOS:000268566800011
J	Liang, MC; Ma, J; Chen, L; Kozlowski, P; Qin, W; Li, D; Goto, J; Shimamura, T; Hayes, DN; Meyerson, M; Kwiatkowski, DJ; Wong, KK				Liang, M-C; Ma, J.; Chen, L.; Kozlowski, P.; Qin, W.; Li, D.; Goto, J.; Shimamura, T.; Hayes, D. N.; Meyerson, M.; Kwiatkowski, D. J.; Wong, K-K			TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity	ONCOGENE			English	Article						lung cancer; TSC1; KRAS; TSC2; mTOR	TUBEROUS SCLEROSIS COMPLEX; PEUTZ-JEGHERS-SYNDROME; ONCOGENIC K-RAS; TSC1-TSC2 COMPLEX; MAMMALIAN TARGET; MTOR INHIBITORS; BLADDER-CANCER; GENE TSC1; MODEL; LKB1	Germline TSC1 or TSC2 mutations cause tuberous sclerosis complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice in which Tsc1 loss and KrasG12D expression occur in a small fraction of lung epithelial cells were generated. Mice with a combined Tsc1-KrasG12D mutation had dramatically reduced tumor latency (median survival: 11.6-15.6 weeks) in comparison with KrasG12D alone mutant mice (median survival: 27.5 weeks). Tsc1-KrasG12D tumors showed consistent activation of mTOR (mammalian target of rapamycin) C1 and responded to treatment with rapamycin, leading to significantly improved survival, whereas rapamycin had minor effects on cancers in KrasG12D alone mice. Loss of heterozygosity for TSC1 or TSC2 was found in 22% of 86 human lung cancer specimens. However, none of the 80 lung cancer lines studied showed evidence of the lack of expression of either TSC1 or TSC2 or a signaling pattern corresponding to complete loss. These data indicate that Tsc1 loss synergizes with the Kras mutation to enhance lung tumorigenesis in the mouse, but that this is a rare event in human lung cancer. Rapamycin may have unique benefit for patients with lung cancer, for whom the TSC1/TSC2 function is limited. Oncogene (2010) 29, 1588-1597; doi:10.1038/onc.2009.452; published online 7 December 2009	[Ma, J.; Kozlowski, P.; Qin, W.; Goto, J.; Kwiatkowski, D. J.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA; [Liang, M-C; Chen, L.; Li, D.; Wong, K-K] Harvard Canc Ctr, Ludwig Ctr Dana Farber, Boston, MA USA; [Liang, M-C; Chen, L.; Li, D.; Shimamura, T.; Meyerson, M.; Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hayes, D. N.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC USA; [Meyerson, M.] MIT, Cambridge, MA 02139 USA; [Meyerson, M.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Translat Med, 1 Blackfan Circle,Room 6-216, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Meyerson, Matthew L/E-7123-2012; Kozlowski, Piotr/I-1860-2019	Kozlowski, Piotr/0000-0003-3770-7715; Liang, Mei-Chih/0000-0002-7389-2455; Goto, June/0000-0002-4000-9750; Chen, Liang/0000-0001-7300-6604; Hayes, D. Neil/0000-0001-6203-7771	NIH [R01 AG2400401, R01 CA122794, K08 AG024004, P01 CA120964]; Sidney Kimmel Foundation for Cancer Research; Joan Scarangello Foundation to Conquer Lung Cancer; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE [P01CA120964, R01CA122794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sidney Kimmel Foundation for Cancer Research; Joan Scarangello Foundation to Conquer Lung Cancer; Flight Attendant Medical Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Kate McNamara and Sara Zaghlul (Dana-Farber Cancer Institute, Boston), Christine Lam, Iza Malinowska-Kolodziej and Mei Zheng (Brigham and Women's Hospital, Boston) for their technical assistance and Roderick T. Bronson (Harvard Medical School, Boston) and Robert Padera and Lucian Chirieac (Brigham and Women's Hospital, Boston) for assistance with pathology review. This study was supported in part by the NIH Grant nos R01 AG2400401 (K-KW), R01 CA122794 (K-KW), K08 AG024004 (K-KW), P01 CA120964 (DJK), the Sidney Kimmel Foundation for Cancer Research (K-KW), the Joan Scarangello Foundation to Conquer Lung Cancer (K-KW and DJK) and the Flight Attendant Medical Research Institute (K-KW).	Adachi H, 2003, J UROLOGY, V170, P601, DOI 10.1097/01.ju.0000074621.74361.10; Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Gridelli C, 2008, ONCOLOGIST, V13, P139, DOI 10.1634/theoncologist.2007-0171; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Henske EP, 1996, AM J HUM GENET, V59, P400; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kozlowski P, 2007, HUM GENET, V121, P389, DOI 10.1007/s00439-006-0308-9; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; McCormack FX, 2008, CHEST, V133, P507, DOI 10.1378/chest.07-0898; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Milton DT, 2007, CANCER-AM CANCER SOC, V110, P599, DOI 10.1002/cncr.22816; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Muir TE, 1998, AM J SURG PATHOL, V22, P465, DOI 10.1097/00000478-199804000-00012; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Pollizzi K, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-38; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Smilenov LB, 2006, CANCER LETT, V240, P17, DOI 10.1016/j.canlet.2005.08.015; Takamochi K, 2001, AM J PATHOL, V159, P1941, DOI 10.1016/S0002-9440(10)63041-6; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	41	43	44	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1588	1597		10.1038/onc.2009.452	http://dx.doi.org/10.1038/onc.2009.452			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966866	Green Submitted, Green Accepted			2022-12-28	WOS:000275694700004
J	Cowling, VH				Cowling, V. H.			Enhanced mRNA cap methylation increases Cyclin D1 expression and promotes cell transformation	ONCOGENE			English	Article						Cyclin D1; cell transformation; mRNA cap methylation; mRNA translation	C-MYC; CANCER; METHYLTRANSFERASE; TRANSLATION; RECRUITMENT; REPRESSION; APOPTOSIS; BINDING; EIF4E; GENE	Cap-dependent mRNA translation requires the methylation of the mRNA guanosine cap by RNA guanine-7-methyltransferase (RNMT). mRNA cap methylation was recently described to be rate-limiting for a subset of mRNAs, and to be enhanced by expression of c-Myc and E2F1, although the biological significance of this finding was not investigated. Here, it is reported that increased RNMT expression enhances cellular mRNA cap methyltransferase activity, promotes mammary epithelial cell transformation and cooperates with H-RasV12 or c-Myc to promote fibroblast cell transformation. Cyclin D1 is a prominent oncogene in epithelial tumours. A signi. cant fraction of Cyclin D1 mRNA was found to be unmethylated on the mRNA cap and thus dormant in mammary epithelial cells. Cyclin D1 expression was increased by enhanced mRNA cap methylation. In summary, this report shows that mRNA cap methylation is rate-limiting for expression of an oncogene and cell transformation. Oncogene (2010) 29, 930-936; doi:10.1038/onc.2009.368; published online 16 November 2009	Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Cowling, VH (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Biol & Immunol, Dow St, Dundee DD1 5EH, Scotland.	v.h.cowling@dundee.ac.uk		Cowling, Victoria/0000-0001-7638-4870	MRC; Tenovus Scotland Project; Medical Research Council [G0700240] Funding Source: researchfish; MRC [G0700240] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tenovus Scotland Project; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	I thank Mike Cole for the generous gift of the anti-m7G antibodies, Aaron Shatkin for providing the RNMT-GFP construct, Julian Downward for providing the H-RasV12 construct and James DiRenzo for providing IMEC. I also thank all of the above and the Cowling lab for advice. This work was funded by an MRC Career Development Award and a Tenovus Scotland Project Grant.	Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Chu C, 2008, MOL CELL BIOL, V28, P5829, DOI 10.1128/MCB.00021-08; Cole MD, 2009, ONCOGENE, V28, P1169, DOI 10.1038/onc.2008.463; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; DiRenzo J, 2002, CANCER RES, V62, P89; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Goy A, 2006, CANCER CYTOPATHOL, V108, P10, DOI 10.1002/cncr.21500; MAO XD, 1995, MOL CELL BIOL, V15, P4167; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Shafer B, 2005, MOL CELL BIOL, V25, P2644, DOI 10.1128/MCB.25.7.2644-2649.2005; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; Tsai YP, 2008, FEBS LETT, V582, P4083, DOI 10.1016/j.febslet.2008.11.004; Vallat LD, 2007, BLOOD, V109, P3989, DOI 10.1182/blood-2006-09-045377; Wen YX, 2000, GENE DEV, V14, P2944, DOI 10.1101/gad.848200; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White RJ, 2008, TRENDS GENET, V24, P622, DOI 10.1016/j.tig.2008.10.003	26	31	31	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					930	936		10.1038/onc.2009.368	http://dx.doi.org/10.1038/onc.2009.368			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915615	Green Accepted, Bronze			2022-12-28	WOS:000274397800015
J	Robinson, JP; VanBrocklin, MW; Guilbeault, AR; Signorelli, DL; Brandner, S; Holmen, SL				Robinson, J. P.; VanBrocklin, M. W.; Guilbeault, A. R.; Signorelli, D. L.; Brandner, S.; Holmen, S. L.			Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation	ONCOGENE			English	Article						glioma; BRAF; KRas; Akt; Ink4a; Arf	SPINDLE-CELL GLIOBLASTOMA; LEUKOSIS-SARCOMA VIRUSES; CENTRAL-NERVOUS-SYSTEM; B-RAF GENE; PROTEIN-KINASE; NEGATIVE REGULATION; PATHWAY ACTIVATION; NEURAL PROGENITORS; TUMOR SUPPRESSION; CYCLE ARREST	Mutations in receptor tyrosine kinase (RTK) growth factor receptors (epidermal growth factor receptor, platelet-derived growth factor receptor, MET and ERBB2), which result in downstream activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway and PI(3)K/Akt pathway, are found in almost all high-grade gliomas and MAPK signaling is necessary for continued glioma maintenance. In addition, BRAF is mutated in the majority of low-grade gliomas and its expression and activity is significantly increased in the majority of high-grade gliomas. Although the importance of RTKs and RAS signaling in glioma development has been shown, the role of BRAF has yet to be characterized. We evaluated the effect of activated BRAF in glioma formation using the retroviral replication-competent avian leukosis virus long terminal repeat, splice acceptor (RCAS)/TVA system to transfer genes encoding activated forms of BRAF, KRas, Akt and Cre to nestin-expressing neural progenitor cells in Ink4a/Arf(lox/lox) mice in vivo. Although expression of activated BRAF alone is not sufficient for tumorigenesis, the combination of activated BRAF and Akt or BRAF with Ink4a/Arf loss is transforming. Interestingly, activated BRAF generates gliomas with characteristics similar to activated KRas in the context of Akt but not Ink4a/Arf loss. Our studies show a role for BRAF activation and signaling in glioma development and as potential target for glioma therapy. Oncogene (2010) 29, 335-344; doi:10.1038/onc.2009.333; published online 26 October 2009	[Robinson, J. P.; VanBrocklin, M. W.; Guilbeault, A. R.; Signorelli, D. L.; Holmen, S. L.] Nevada Canc Inst, Drug Dev Dept, Las Vegas, NV 89135 USA; [Brandner, S.] UCL, Inst Neurol, Dept Neurogenerat Dis, Div Neuropathol, London, England	University of California System; University of California San Diego; University of London; University College London	Holmen, SL (corresponding author), Nevada Canc Inst, Drug Dev Dept, 1 Breakthrough Way,Lab 3, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org	Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Robinson, James/0000-0002-6585-0116	Nevada Cancer Institute; National Brain Tumor Foundation; American Cancer Society [RSG-06-198-01-TBE]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Nevada Cancer Institute(University of California System); National Brain Tumor Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Nevada Cancer Institute, the National Brain Tumor Foundation, and RSG-06-198-01-TBE from the American Cancer Society. We thank Nick Henderson and Robert Kirsh for animal husbandry. We also thank Eric Holland, Martin McMahon, and Ronald DePinho for the reagents. SLH designed the research; JPR, MWV and SLH performed the research; SB performed the pathological analysis; DLS and ARG provided technical support; JPR and SLH prepared the images and wrote the paper.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Basto D, 2005, ACTA NEUROPATHOL, V109, P207, DOI 10.1007/s00401-004-0936-x; Bromberg-White JL, 2004, J VIROL, V78, P4914, DOI 10.1128/JVI.78.9.4914-4916.2004; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; Dai CK, 2005, NEOPLASIA, V7, P397, DOI 10.1593/neo.04691; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Guan KL, 2000, J BIOL CHEM, V275, P27354; HAMEL W, 1993, J NEURO-ONCOL, V16, P159, DOI 10.1007/BF01324703; Hill JR, 1999, ARCH NEUROL-CHICAGO, V56, P439, DOI 10.1001/archneur.56.4.439; Hmitou I, 2007, MOL CELL BIOL, V27, P31, DOI 10.1128/MCB.01265-06; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holmen SL, 1999, J VIROL, V73, P10051, DOI 10.1128/JVI.73.12.10051-10060.1999; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Jeuken J, 2007, ACTA NEUROPATHOL, V114, P121, DOI 10.1007/s00401-007-0239-0; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; JONES H, 1991, NEUROPATH APPL NEURO, V17, P177, DOI 10.1111/j.1365-2990.1991.tb00713.x; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Marino S, 2000, GENE DEV, V14, P994; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; PAULUS W, 1992, NEUROPATH APPL NEURO, V18, P207; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; QUELLE DE, 1995, CELL, V83, P993; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SMITH EJ, 1979, AVIAN DIS, V23, P698, DOI 10.2307/1589746; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7	51	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					335	344		10.1038/onc.2009.333	http://dx.doi.org/10.1038/onc.2009.333			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19855433	Green Accepted			2022-12-28	WOS:000273793200003
J	Dean, JL; McClendon, AK; Stengel, KR; Knudsen, ES				Dean, J. L.; McClendon, A. K.; Stengel, K. R.; Knudsen, E. S.			Modeling the effect of the RB tumor suppressor on disease progression: dependence on oncogene network and cellular context	ONCOGENE			English	Article						retinoblastoma tumor suppressor (RB); Ras; c-Myc; chemotherapeutics; cell cycle checkpoints	PRB-DEFICIENT EPIDERMIS; CYCLE CONTROL; RETINOBLASTOMA PROTEIN; C-MYC; SKIN CARCINOGENESIS; INDUCED APOPTOSIS; RAS; CANCER; P53; FIBROBLASTS	The retinoblastoma tumor suppressor, RB, is a key regulator of cellular proliferation that is functionally inactivated at high frequency in human cancer. Although RB has been extensively studied with regard to tumor etiology, loss of tumor-suppressor function often occurs relatively late in tumor progression. Therefore, inactivation of RB could have a profound impact on the behavior of tumors driven by discrete oncogenes. Here, collaboration between Ras or c-Myc deregulation and RB functional state was investigated in a model of conditional genetic deletion to decipher the effects related to disease progression. These studies showed that RB loss had a robust impact on mitogen dependence, anchorage dependence and overall survival, which was significantly modified by oncogene activation. Specifically, RB deficiency predisposed c-Myc-expressing cells to cell death and reduced overall tumorigenic proliferation. In contrast, RB deficiency exacerbated the tumorigenic behavior of Ras-transformed cells in both the model system and human tumor cell lines. As these tumors exhibited highly aggressive behavior, the possibility of exploiting the intrinsic sensitivity to cell death with RB loss was evaluated. Particularly, although Ras-transformed, RB-deficient cells bypassed the G1-checkpoint elicited by pharmacological activation of the p53 pathway, they were also highly sensitized to cell death. Altogether, these data suggest that the impact of RB deletion is dependent on the oncogene milieu, and can directly contribute to transformed phenotypes and response to therapeutic intervention.	[Dean, J. L.; McClendon, A. K.; Knudsen, E. S.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Dean, J. L.; McClendon, A. K.; Knudsen, E. S.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Stengel, K. R.] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH USA	Jefferson University; Jefferson University; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, BLSB Room 1002,233 S 10th St, Philadelphia, PA 19107 USA.	eknudsen@kimmelcancercenter.org		Stengel, Kristy/0000-0002-8330-5744				Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Alkarain A, 2004, BREAST CANCER RES, V6, P13, DOI 10.1186/bcr722; Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; BOS JL, 1989, CANCER RES, V49, P4682; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DeGregori J, 2006, MOL CELL BIOL, V26, P1165, DOI 10.1128/MCB.26.4.1165-1169.2006; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FILMUS J, 1994, ONCOGENE, V9, P3627; Groth A, 2000, J BIOL CHEM, V275, P27473; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ho VM, 2009, ONCOGENE, V28, P1393, DOI 10.1038/onc.2008.491; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Kharitonova MA, 2007, CELL BIOL INT, V31, P220, DOI 10.1016/j.cellbi.2006.10.008; Kitagawa M, 2008, ONCOGENE, V27, P5303, DOI 10.1038/onc.2008.164; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Lara MF, 2008, MOL CARCINOGEN, V47, P105, DOI 10.1002/mc.20367; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2007, EMBO J, V26, P784, DOI 10.1038/sj.emboj.7601515; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Marino S, 2000, GENE DEV, V14, P994; Markey MP, 2007, ONCOGENE, V26, P6307, DOI 10.1038/sj.onc.1210450; Markey MP, 2002, CANCER RES, V62, P6587; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Rogoff HA, 2004, CELL CYCLE, V3, P845; Ruiz S, 2005, CANCER RES, V65, P9678, DOI 10.1158/0008-5472.CAN-05-1853; Santos M, 2008, MOL CARCINOGEN, V47, P815, DOI 10.1002/mc.20426; Seeley SL, 2007, CANCER LETT, V245, P205, DOI 10.1016/j.canlet.2006.01.028; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Stengel KR, 2008, CELL CYCLE, V7, DOI 10.4161/cc.7.8.5737; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Williams JP, 2006, MOL CELL BIOL, V26, P1170, DOI 10.1128/MCB.26.4.1170-1182.2006; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	54	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					68	80		10.1038/onc.2009.313	http://dx.doi.org/10.1038/onc.2009.313			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802012				2022-12-28	WOS:000273373500007
J	Lakshmikuttyamma, A; Scott, SA; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Scott, S. A.; DeCoteau, J. F.; Geyer, C. R.			Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition	ONCOGENE			English	Article						p15INK4B; SUV39H1; chaetocin; histone methylation; DNA methylation	HISTONE METHYLTRANSFERASE SUV39H1; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; DEACETYLASE INHIBITION; CPG ISLAND; E-CADHERIN; HETEROCHROMATIN FORMATION; LYSINE-9 METHYLATION; POOR-PROGNOSIS; PROMOTER DNA	Reexpression of hypermethylated tumor suppressor genes using DNA methyltransferase (DNMT) and histone deacetylase inhibitors occurs by a mechanism whereby promoter demethylation is the dominant event. In support of this model, we found in acute myeloid leukemia cells with hypermethylated p15INK4B and E-cadherin promoters that the DNMT inhibitor, 5-aza-20-deoxycytidine, induced p15INK4B and E-cadherin expression, and decreased levels of DNA methylation, histone H3 lysine 9 (H3K9) methylation and SUV39H1 associated with p15INK4B and E-cadherin promoters. On the basis of these observations, we examined whether promoter demethylation was dominant to H3K9 demethylation in p15INK4B and E-cadherin reexpression. We observed that SUV39H1 short hairpin RNA and chaetocin, a SUV39H1 inhibitor, induced p15INK4B and E-cadherin expression and H3K9 demethylation without promoter demethylation. Reexpression of hypermethylated p15INK4B and E-cadherin required histone H3K9 demethylation that was achieved directly by inhibiting SUV39H1 expression or activity, or indirectly by decreasing the amount of SUV39H1 associated with the p15INK4B and E-cadherin promoters using 5-aza-20-deoxycytidine. The results from this study highlight the potential of H3K9 methyltransferases as therapeutic targets for reactivating expression of hypermethylated genes. Oncogene (2010) 29, 576-588; doi: 10.1038/onc.2009.361; published online 2 November 2009	[Geyer, C. R.] Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, Saskatoon, SK S7N 4H4, Canada; [Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan; University of Saskatchewan	Geyer, CR (corresponding author), Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855; Scott, Stuart/0000-0001-5720-1864	Canadian Institutes of Health Research; Canada Foundation for Innovation; Saskatchewan Health Research Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Saskatchewan Health Research Foundation	This work was supported by grants from the Canadian Institutes of Health Research, Canada Foundation for Innovation, and the Saskatchewan Health Research Foundation. CRG is a CIHR-RPP New Investigator. AL is a Rethink Breast Cancer PDF.	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845; Fahrner JA, 2002, CANCER RES, V62, P7213; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gore Steven D, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS30, DOI 10.1038/ncponc0346; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Guldberg P, 2002, METHODS, V27, P121, DOI 10.1016/S1046-2023(02)00063-4; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa Jean-Pierre, 2003, Current Opinion in Oncology, V15, P446, DOI 10.1097/00001622-200311000-00007; Jang H, 2007, J BIOL CHEM, V282, P11172, DOI 10.1074/jbc.M611199200; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mal AK, 2006, EMBO J, V25, P3323, DOI 10.1038/sj.emboj.7601229; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nguyen CT, 2002, CANCER RES, V62, P6456; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa M, 2007, LEUKEMIA RES, V31, P611, DOI 10.1016/j.leukres.2006.09.023; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Preisler HD, 2001, LEUKEMIA, V15, P1589, DOI 10.1038/sj.leu.2402211; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; Shimamoto T, 2005, LEUKEMIA RES, V29, P653, DOI 10.1016/j.leukres.2004.11.014; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Teofili L, 2003, LEUKEMIA, V17, P919, DOI 10.1038/sj.leu.2402907; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	72	84	92	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					576	588		10.1038/onc.2009.361	http://dx.doi.org/10.1038/onc.2009.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881540				2022-12-28	WOS:000274084600010
J	Shao, R; Hamel, K; Petersen, L; Cao, QJ; Arenas, RB; Bigelow, C; Bentley, B; Yan, W				Shao, R.; Hamel, K.; Petersen, L.; Cao, Q. J.; Arenas, R. B.; Bigelow, C.; Bentley, B.; Yan, W.			YKL-40, a secreted glycoprotein, promotes tumor angiogenesis	ONCOGENE			English	Article						tumor angiogenesis; vascular endothelial cells; YKL-40 (human cartilage-glycoprotein 39 or Chitinase 3-like 1); signal transduction; heparin-binding protein; breast cancer	HUMAN CARTILAGE GLYCOPROTEIN-39; CHITINASE PROTEIN FAMILY; GROWTH-FACTOR; SERUM YKL-40; INTEGRIN ACTIVITY; CARCINOMA CELLS; SYNOVIAL-CELLS; SHORT SURVIVAL; BREAST-CANCER; IN-VIVO	Tumor angiogenesis is of paramount importance in solid tumor development. Elevated serum levels of YKL-40, which is a secreted heparin-binding glycoprotein, have been associated with a worse prognosis from various advanced human cancers. Yet the role of YKL-40 activity in these cancers is still missing. In this study, we showed that ectopic expression of YKL-40 in MDA-MB-231 breast cancer cells and in HCT-116 colon cancer cells led to larger tumor formation with an extensive angiogenic phenotype than did control cancer cells in mice. Affinity-purified recombinant YKL-40 protein promoted vascular endothelial cell angiogenesis in vitro, the effects of which are similar to the activities observed using MDA-MB-231 and HCT-116 cell-conditioned medium after transfection with YKL-40. Furthermore, YKL-40 was found to induce coordination of membrane-bound receptor syndecan-1 and integrin alpha(v)beta(3) and to activate an intracellular signaling cascade, including focal adhesion kinase and mitogen-activated protein kinase extracellular signal-related kinase1/2 in endothelial cells. Moreover, blockade of YKL-40 using small-interfering RNA gene knockdown suppressed tumor angiogenesis in vitro and in vivo. Immunohistochemical analysis of human breast cancer showed a correlation between YKL-40 expression and blood vessel density. These findings provide novel insights into angiogenic activities and molecular mechanisms of YKL-40 in cancer development. Oncogene (2009) 28, 4456-4468; doi:10.1038/onc.2009.292; published online 21 September 2009	[Shao, R.] Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Baystate Med Ctr, Springfield, MA 01199 USA; [Shao, R.; Hamel, K.; Petersen, L.] Univ Massachusetts, Mol & Cellular Biol Program, Morrill Sci Ctr, Amherst, MA 01003 USA; [Shao, R.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Cao, Q. J.] Baystate Med Ctr, Dept Pathol, Springfield, MA USA; [Arenas, R. B.] Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA; [Bigelow, C.] Univ Massachusetts, Dept Biostat & Epidemiol, Amherst, MA 01003 USA	Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Baystate Medical Center; Baystate Medical Center; University of Massachusetts System; University of Massachusetts Amherst	Shao, R (corresponding author), Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Baystate Med Ctr, 3601 Main St, Springfield, MA 01199 USA.	rong.shao@bhs.org			NCI [R01 CA120659]; DOD [W81XWH-06-1-0563]; Collaborative Biomedical Research Program; Baystate Medical Center/University of Massachusetts at Amherst; Rays of Hope, Baystate Medical Center; NATIONAL CANCER INSTITUTE [R01CA120659] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Collaborative Biomedical Research Program; Baystate Medical Center/University of Massachusetts at Amherst; Rays of Hope, Baystate Medical Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs A Schneyer, S Schneider and S Scully for their critical comments. This work was supported by NCI R01 CA120659 and DOD W81XWH-06-1-0563 (RS), Collaborative Biomedical Research Program, Baystate Medical Center/University of Massachusetts at Amherst (RS, QJC and RBA) and Rays of Hope, Baystate Medical Center (QJC and RS).	Albini A, 1996, ONCOGENE, V12, P289; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bergmann OJ, 2005, CLIN CANCER RES, V11, P8644, DOI 10.1158/1078-0432.CCR-05-1317; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brasso K, 2006, PROSTATE, V66, P503, DOI 10.1002/pros.20311; Cintin C, 2002, CANCER-AM CANCER SOC, V95, P267, DOI 10.1002/cncr.10644; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hogdall EVS, 2003, ONCOL REP, V10, P1535; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hormigo A, 2006, CLIN CANCER RES, V12, P5698, DOI 10.1158/1078-0432.CCR-06-0181; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Jendraschak E, 1996, SEMIN CANCER BIOL, V7, P139, DOI 10.1006/scbi.1996.0019; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Kim H, 2007, J KOREAN ASTRON SOC, V40, P17, DOI 10.5303/JKAS.2007.40.1.017; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lal A, 1999, CANCER RES, V59, P5403; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; MAGLIONE D, 1993, ONCOGENE, V8, P925; McQuade KJ, 2006, J CELL SCI, V119, P2445, DOI 10.1242/jcs.02970; Millauer B, 1996, CANCER RES, V56, P1615; Naruse T, 2006, CARCINOGENESIS, V27, P584, DOI 10.1093/carcin/bgi240; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Pelloski CE, 2005, CLIN CANCER RES, V11, P3326, DOI 10.1158/1078-0432.CCR-04-1765; Polnaszek N, 2003, CANCER RES, V63, P5754; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Roslind A, 2008, BREAST CANCER RES TR, V112, P275, DOI 10.1007/s10549-007-9870-7; Schmidt H, 2006, CANCER-AM CANCER SOC, V106, P1130, DOI 10.1002/cncr.21678; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sharif M, 2006, RHEUMATOLOGY, V45, P522, DOI 10.1093/rheumatology/kei216; Yan W, 2008, MOL BIOL CELL, V19, P2278, DOI 10.1091/mbc.E07-10-1068; Yan W, 2006, J BIOL CHEM, V281, P19700, DOI 10.1074/jbc.M601856200; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	43	201	217	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	2009	28	50					4456	4468		10.1038/onc.2009.292	http://dx.doi.org/10.1038/onc.2009.292			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DU	19767768	Green Accepted			2022-12-28	WOS:000272876500005
J	Najdi, R; Syed, A; Arce, L; Theisen, H; Ting, JHT; Atcha, F; Nguyen, AV; Martinez, M; Holcombe, RF; Edwards, RA; Marsh, JL; Waterman, ML				Najdi, R.; Syed, A.; Arce, L.; Theisen, H.; Ting, J-H T.; Atcha, F.; Nguyen, A. V.; Martinez, M.; Holcombe, R. F.; Edwards, R. A.; Marsh, J. L.; Waterman, M. L.			A Wnt kinase network alters nuclear localization of TCF-1 in colon cancer	ONCOGENE			English	Article						CaMKII; colon cancer; export; TCF-1; Wnt	COLORECTAL-CANCER; BETA-CATENIN; TRANSCRIPTION FACTORS; CELLS; PATHWAY; DISEASE; EXPORT; PHOSPHORYLATION; PROTEINS; ISOFORMS	Constitutive activation of the Wnt/beta-catenin pathway has been implicated as the primary cause of colon cancer. However, the major transducers of Wnt signaling in the intestine, T-cell factor 1 (TCF-1) and TCF-4, have opposing functions. Knockout of TCF-4 suppresses growth and maintenance of crypt stem cells, whereas knockout of TCF-1 leads to adenomas. These phenotypes suggest that TCF-4 is Wnt-promoting, whereas TCF-1 acts like a tumor suppressor. Our study of TCF expression in human colon crypts reveals a mechanistic basis for this paradox. In normal colon cells, a dominant-negative isoform of TCF-1 (dnTCF-1) is expressed that is equally distributed between nuclear and cytoplasmic compartments. In colon cancer cells, TCF-1 is predominantly cytoplasmic. Localization is because of active nuclear export and is directed by an autocrine-acting Wnt ligand that requires Ca2+/calmodulin-dependent kinase II (CaMKII) activity for secretion and a downstream step in the export pathway. TCF-4 remains nuclear; its unopposed activity is accompanied by downregulation of dnTCF-1 and increased expression of full-length isoforms. Thus, the dnTCF-1 and TCF-4 balance is corrupted in cancer by two mechanisms, a Wnt/CaMKII kinase signal for nuclear export and decreased dnTCF-1 expression. We propose that dnTCF-1 provides homeostatic regulation of Wnt signaling and growth in normal colon, and the alterations in nuclear export and promoter usage contribute to aberrant Wnt activity in colon cancer. Oncogene (2009) 28, 4133-4146; doi: 10.1038/onc.2009.271; published online 14 September 2009	[Syed, A.; Theisen, H.; Marsh, J. L.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; [Najdi, R.; Arce, L.; Ting, J-H T.; Atcha, F.; Waterman, M. L.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; [Syed, A.; Theisen, H.; Marsh, J. L.] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; [Nguyen, A. V.; Martinez, M.; Holcombe, R. F.] Univ Calif Irvine, Div Hematol Oncol, Dept Med, Irvine, CA 92697 USA; [Edwards, R. A.; Marsh, J. L.] Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Marsh, JL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	jlmarsh@uci.edu; mlwaterm@uci.edu			NIH [RO1 HD36081, RO1 HD36049, T32 CA113265, CA096878, CA108697, R21 DK071591, CA-82450]; Cancer Center Support Grant at the University of California, Irvine [CA-62203]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036049, R01HD036081] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K24CA082450, R01CA096878, T32CA113265, P30CA062203, R01CA108697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071591] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant at the University of California, Irvine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We specially thank Didi Mwengela, Amanda Chamberlain, Candice Solomon and David Hernandez for help in cloning and sequencing TCF-1 cDNA. We also thank Eric J Stanbridge for critical reading of the manuscript, Michelle Digman for help with confocal imaging, Tohru Ishitani, Bang Hoang and Randall T Moon for reagents and advice. This work was supported by NIH grants RO1 HD36081 and RO1 HD36049 to JLM, NIH T32 CA113265, CA096878 and CA108697 to MLW, R21 DK071591 to RAE and NIH grant CA-82450 to RFH. This work was made possible, in part, through access to the confocal facility of the Optical Biology Shared Resource of the Cancer Center Support Grant (CA-62203) at the University of California, Irvine.	Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056; Atcha FA, 2007, MOL CELL BIOL, V27, P8352, DOI 10.1128/MCB.02132-06; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Chang MV, 2008, CURR BIOL, V18, P1877, DOI 10.1016/j.cub.2008.10.047; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Griffith LC, 2008, CELL, V133, P397, DOI 10.1016/j.cell.2008.04.018; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sievers S, 2006, BIOMARKERS, V11, P270, DOI 10.1080/13547500600633954; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Yamada M, 2006, J BIOL CHEM, V281, P20749, DOI 10.1074/jbc.M602089200	30	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2009	28	47					4133	4146		10.1038/onc.2009.271	http://dx.doi.org/10.1038/onc.2009.271			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DQ	19749792	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000272876100001
J	Kaler, P; Augenlicht, L; Klampfer, L				Kaler, P.; Augenlicht, L.; Klampfer, L.			Macrophage-derived IL-1 beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D-3	ONCOGENE			English	Article						Wnt; IL-1; colon cancer; STAT1; macrophages; vitamin D	TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; BETA-CATENIN; COLORECTAL-CANCER; ACTIVATED MACROPHAGES; D-RECEPTOR; INHIBITION; EXPRESSION; MICROENVIRONMENT; TRANSCRIPTION	Tumor-associated macrophages mediate the link between inflammation and cancer progression. Here, we showed that macrophage-derived soluble factors induce canonical Wnt signaling in colon cancer cells and promote their growth. Tumor cells induced the release of interleukin (IL)-1 beta from macrophages, which induced phosphorylation of GSK3 beta, stabilized beta-catenin, enhanced T-cell factor (TCF)-dependent gene activation and induced the expression of Wnt target genes in tumor cells. Neutralization experiments using anti-IL-1 beta-specific antibodies, or silencing of IL-1 beta in THP1 macrophages, showed that IL-1 beta was required for macrophages to induce Wnt signaling and to support the growth of tumor cells. Constitutive activation of signal transducer and activator of transcription (STAT) 1 in THP1 macrophages was essential for the induction of IL-1 beta and thus for the activation of beta-catenin signaling in tumor cells. Vitamin D-3, an effective chemopreventive agent, interrupted this crosstalk by blocking the constitutive activation of STAT1 and the production of IL-1 beta in macrophages, and therefore-in a vitamin D receptor-dependent manner-inhibited the ability of macrophages to activate Wnt signaling in colon carcinoma cells. Our data therefore established that vitamin D-3 exerts its chemopreventive activity by interrupting a crosstalk between tumor epithelial cells and the tumor microenvironment. Oncogene (2009) 28, 3892-3902; doi:10.1038/onc.2009.247; published online 24 August 2009	[Kaler, P.; Augenlicht, L.; Klampfer, L.] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Med, 111 E 210th St,Room 316, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NCI [CA 111361, U54 CA 100926, P30-13330]; NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Paolo Norio for reading the paper. This work was supported by CA 111361 (to LK), U54 CA 100926 (to LA) and P30-13330 from NCI.	Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Etoh T, 2000, CLIN CANCER RES, V6, P3545; Fichera A, 2007, J SURG RES, V142, P239, DOI 10.1016/j.jss.2007.02.038; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gunter MJ, 2006, CANCER EPIDEM BIOMAR, V15, P1126, DOI 10.1158/1055-9965.EPI-06-0042; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Kampman E, 2000, CANCER CAUSE CONTROL, V11, P459, DOI 10.1023/A:1008914108739; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Klampfer L, 2007, CANCER RES, V67, P8477, DOI 10.1158/0008-5472.CAN-07-0210; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Kusmartsev S, 2005, J IMMUNOL, V174, P4880, DOI 10.4049/jimmunol.174.8.4880; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lee C, 2006, MOL PHARMACOL, V69, P1041, DOI 10.1124/mol.105.018481; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lipkin M, 2006, J MED FOOD, V9, P135, DOI 10.1089/jmf.2006.9.135; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NEWMARK HL, 1992, CANCER RES, V52, pS2067; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Oosterling SJ, 2005, J PATHOL, V207, P147, DOI 10.1002/path.1830; Oyama T, 2008, CARCINOGENESIS, V29, P666, DOI 10.1093/carcin/bgn001; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pendas-Franco N, 2008, ANTICANCER RES, V28, P2613; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Robsahm TE, 2004, CANCER CAUSE CONTROL, V15, P149, DOI 10.1023/B:CACO.0000019494.34403.09; Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SIZIOPIKOU KP, 1991, CANCER, V68, P1035, DOI 10.1002/1097-0142(19910901)68:5<1035::AID-CNCR2820680522>3.0.CO;2-D; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Tsukada J, 1996, MOL CELL BIOL, V16, P2183; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036	51	189	196	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3892	3902		10.1038/onc.2009.247	http://dx.doi.org/10.1038/onc.2009.247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19701245	Green Accepted			2022-12-28	WOS:000271471900004
J	Wan, X; Kim, SY; Guenther, LM; Mendoza, A; Briggs, J; Yeung, C; Currier, D; Zhang, H; Mackall, C; Li, WJ; Tuan, RS; Deyrup, AT; Khanna, C; Helman, L				Wan, X.; Kim, S. Y.; Guenther, L. M.; Mendoza, A.; Briggs, J.; Yeung, C.; Currier, D.; Zhang, H.; Mackall, C.; Li, W-J; Tuan, R. S.; Deyrup, A. T.; Khanna, C.; Helman, L.			Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin	ONCOGENE			English	Article						beta 4 integrin; osteosarcoma; metastases; ezrin; interaction	ALPHA-6-BETA-4 INTEGRIN; DOMAIN INTERACTIONS; BINDING; KINASE; EXPRESSION; TRANSDUCTION; INVASION; PATHWAY	The development of pulmonary metastasis is the major cause of death in osteosarcoma, and its molecular basis is poorly understood. In this study, we show that beta 4 integrin is highly expressed in human osteosarcoma cell lines and tumor samples. Furthermore, highly metastatic MNNG-HOS cells have increased levels of beta 4 integrin. Suppression of beta 4 integrin expression by shRNA and disruption of beta 4 integrin function by transfection of dominant-negative beta 4 integrin was sufficient to revert this highly metastatic phenotype in the MNNG-HOS model without significantly affecting primary tumor growth. These findings suggest a role for beta 4 integrin expression in the metastatic phenotype in human osteosarcoma cells. In addition, we identified a previously uncharacterized interaction between beta 4 integrin and ezrin, a membrane-cytoskeletal linker protein that is implicated in the metastatic behavior of osteosarcoma. The beta 4 integrin-ezrin interaction appears to be critical for maintenance of beta 4 integrin expression. These data begin to integrate ezrin and beta 4 integrin expression into a model of action for the mechanism of osteosarcoma metastases. Oncogene (2009) 28, 3401-3411; doi: 10.1038/onc.2009.206; published online 13 July 2009	[Wan, X.] NCI, Mol Oncol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Li, W-J; Tuan, R. S.] NIAMSD, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA; [Deyrup, A. T.] Emory Univ, Dept Pathol, Atlanta, GA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Emory University	Wan, X (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, Ctr Canc Res,NIH, Bldg 10,Rm CRC-1W-3750, Bethesda, MD 20892 USA.	xiaolinw@mail.nih.gov			NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011074, ZIABC011024, ZIASC006892, ZIABC010566, ZIASC006891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr AM Mercurio for providing empty vector and beta 4 mutant (Y1494F), Dr L Trusolino for providing control-shRNA and beta 4-shRNA, Dr M Arpin for providing GST and GST-ezrin-CT, Dr R Nguyen for providing BSA and ezrinNT. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	ANDREOLI C, 1994, J CELL SCI, V107, P2509; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Bertotti A, 2005, CANCER RES, V65, P10674, DOI 10.1158/0008-5472.CAN-05-2827; Bertotti A, 2006, J CELL BIOL, V175, P993, DOI 10.1083/jcb.200605114; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; GAFFNEY R, 2006, HUM PATHOL, V244, P799; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossman HB, 2000, ONCOL REP, V7, P13; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harris MB, 1998, J CLIN ONCOL, V16, P3641, DOI 10.1200/JCO.1998.16.11.3641; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim SY, 2008, CLIN EXP METASTAS, V25, P201, DOI 10.1007/s10585-007-9133-3; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LIU S, 2002, J CELL SCI, V113, P3563; Liu XF, 2000, CANCER RES, V60, P4752; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nguyen R, 2001, J BIOL CHEM, V276, P7621, DOI 10.1074/jbc.M006708200; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878	39	54	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3401	3411		10.1038/onc.2009.206	http://dx.doi.org/10.1038/onc.2009.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597468	Green Accepted			2022-12-28	WOS:000270103300007
J	Balamurugan, K; Luu, VD; Kaufmann, MR; Hofmann, VS; Boysen, G; Barth, S; Bordoli, MR; Stiehl, DP; Moch, H; Schraml, P; Wenger, RH; Camenisch, G				Balamurugan, K.; Luu, V-D; Kaufmann, M. R.; Hofmann, V. S.; Boysen, G.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Moch, H.; Schraml, P.; Wenger, R. H.; Camenisch, G.			Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response	ONCOGENE			English	Article						renal cell carcinoma; tumor immunity; paraneoplastic cerebellar degeneration; oxygen sensing	TRANSCRIPTIONAL ACTIVITY; SPONTANEOUS REGRESSION; TUMOR-IMMUNITY; HIF; HIF-1-ALPHA; ACTIVATION; PROTEIN; ALPHA; DOMAIN; HYDROXYLATION	The onconeuronal cerebellar degeneration-related antigen Cdr2 is associated with paraneoplastic syndromes. Neoplastic expression of Cdr2 in ovary and breast tumors triggers an autoimmune response that suppresses tumor growth by developing tumor immunity, but culminates in cerebellar degeneration when Cdr2-specific immune cells recognize neuronal Cdr2. We identified Cdr2 as a novel interactor of the hypoxia-inducible factor (HIF) prolyl-4-hydroxylase PHD1 and provide evidence that Cdr2 might represent a novel important tumor antigen in renal cancer. Strong Cdr2 protein expression was observed in 54.2% of papillary renal cell carcinoma (pRCC) compared with 7.8% of clear-cell RCC and no staining was observed in chromophobe RCC or oncocytoma. High Cdr2 protein levels correlated with attenuated HIF target gene expression in these solid tumors, and Cdr2 overexpression in tumor cell lines reduced HIF-dependent transcriptional regulation. This effect was because of both attenuation of hypoxic protein accumulation and suppression of the transactivation activity of HIF-1 alpha. pRCC is known for its tendency to avascularity, usually associated with a lower pathological stage and higher survival rates. We provide evidence that Cdr2 protein strongly accumulates in pRCC, attenuates the HIF response to tumor hypoxia and may become of diagnostic importance as novel renal tumor marker. Oncogene (2009) 28, 3274-3285; doi:10.1038/onc.2009.186; published online 6 July 2009	[Balamurugan, K.; Kaufmann, M. R.; Hofmann, V. S.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Wenger, R. H.; Camenisch, G.] Univ Zurich UZH, Inst Physiol, Zurich, Switzerland; [Balamurugan, K.; Kaufmann, M. R.; Hofmann, V. S.; Barth, S.; Bordoli, M. R.; Stiehl, D. P.; Wenger, R. H.; Camenisch, G.] Univ Zurich UZH, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland; [Luu, V-D; Boysen, G.; Moch, H.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, Inst Surg Pathol, CH-8091 Zurich, Switzerland	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital	Camenisch, G (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	gieri.camenisch@access.uzh.ch	Stiehl, Daniel/A-3622-2008; Kuppusamy, Balamurugan/AAC-6020-2022; Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Bordoli, Mattia/0000-0001-6917-8753; Stiehl, Daniel/0000-0002-0076-4874; Boysen, Gunther/0000-0002-7610-6085	SNF [3100AO-116047/1]; Sassella Stiftung; Krebsliga des Kantons Zurich; UZH University Research Priority; European Commission EUROXY [LSHCCT-2003-502932, SBF03.0647-2]	SNF; Sassella Stiftung; Krebsliga des Kantons Zurich; UZH University Research Priority; European Commission EUROXY	We would like to thank R Fischer and C Ruber (ETH Zurich, Switzerland) for the generation of monoclonal anti-Cdr2 antibodies, DM Katschinski (Georg August University Gottingen, Germany) for providing the custom-made mouse testis cDNA library, J Nesper (University of Konstanz, Germany) and MO Hottiger (University of Zurich, Switzerland) for help with the yeast two-hybrid screenings, DJ Peet (University of Adelaide, Australia) and N Sang (Thomas Jefferson University, PA, USA) for gifts of plasmids, P Carmeliet and M Schneider (Katholieke Universiteit Leuven and Flanders Institute for Biotechnology, Belgium) for Phd1 MEFs, I Flamme and F Oehme (Bayer HealthCare, Germany) for helpful discussions and P Spielmann, M Storz and S Behnke for excellent technical assistance. This work was supported by SNF 3100AO-116047/1 (RHW and GC), Sassella Stiftung (GC, KB and SB), Krebsliga des Kantons Zurich (GC),UZH University Research Priority Program 'Integrative Human Physiology' and the 6th Framework Programme of the European Commission EUROXY LSHCCT-2003-502932/SBF03.0647-2 (RHW).	Albert ML, 2004, NAT REV CANCER, V4, P36, DOI 10.1038/nrc1255; Albert ML, 2000, ANN NEUROL, V47, P9; Barth S, 2007, MOL CELL BIOL, V27, P3758, DOI 10.1128/MCB.01324-06; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Coleman ML, 2007, J BIOL CHEM, V282, P24027, DOI 10.1074/jbc.M704102200; Corradi JP, 1997, J NEUROSCI, V17, P1406; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; Darnell JC, 2000, CANCER RES, V60, P2136; Darnell RB, 2003, NAT IMMUNOL, V4, P201, DOI 10.1038/ni0303-201; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Eble J, 2004, WHO CLASSIFICATION T; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2003, CANCER RES, V63, P8777; Ferguson JE, 2007, MOL CELL BIOL, V27, P6407, DOI 10.1128/MCB.00511-07; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Koditz J, 2007, BLOOD, V110, P3610, DOI 10.1182/blood-2007-06-094441; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KOSARY CL, 1993, NIH PUBLICATION; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martin F, 2005, BLOOD, V105, P4613, DOI 10.1182/blood-2004-10-3980; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moch H, 2002, VIRCHOWS ARCH, V441, P320, DOI 10.1007/s00428-002-0685-y; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; OLIVER RTD, 1989, BRIT J UROL, V63, P128, DOI 10.1111/j.1464-410X.1989.tb05147.x; Onishi Tetsuro, 2002, Int J Clin Oncol, V7, P159, DOI 10.1007/s101470200023; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; PETERSON K, 1992, NEUROLOGY, V42, P1931, DOI 10.1212/wnl.42.10.1931; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Santomasso BD, 2007, P NATL ACAD SCI USA, V104, P19073, DOI 10.1073/pnas.0704336104; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Shin DH, 2008, ONCOGENE, V27, P1939, DOI 10.1038/sj.onc.1210826; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; VOGELZANG NJ, 1992, J UROLOGY, V148, P1247, DOI 10.1016/S0022-5347(17)36874-X; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12	47	20	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3274	3285		10.1038/onc.2009.186	http://dx.doi.org/10.1038/onc.2009.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581925				2022-12-28	WOS:000269893700002
J	Feng, X; Lu, X; Man, X; Zhou, W; Jiang, LQ; Knyazev, P; Lei, L; Huang, Q; Ullrich, A; Zhang, Z; Chen, Z				Feng, X.; Lu, X.; Man, X.; Zhou, W.; Jiang, L. Q.; Knyazev, P.; Lei, L.; Huang, Q.; Ullrich, A.; Zhang, Z.; Chen, Z.			Overexpression of Csk-binding protein contributes to renal cell carcinogenesis	ONCOGENE			English	Article						Csk-binding protein; renal cell carcinoma; carcinogenesis; RhoA; PDZ-binding motif	TRANSMEMBRANE ADAPTER PROTEIN; FAMILY TYROSINE KINASES; LIPID RAFTS; DOWN-REGULATION; CARCINOMA; SRC; ACTIVATION; PHOSPHOPROTEIN; CYTOSKELETON; EXPRESSION	C-terminal Src kinase (Csk)-binding protein (Cbp) is a transmembrane adaptor protein that localizes exclusively in lipid rafts, where it regulates Src family kinase (SFK) activities through recruitment of Csk. Although SFKs are well known for their involvement in cancer, the function of Cbp in carcinogenesis remains largely unknown. In this study, we reported overexpression of Cbp in more than 70% of renal cell carcinoma (RCC) specimens and in the majority of tested RCC cell lines. Depletion of Cbp in RCC cells by RNA interference led to remarkable inhibition of cell proliferation, migration, anchorage-independent growth as well as tumorigenicity in nude mice. Strikingly, silencing of Cbp negatively affected the sustaining of Erk1/2 activation but not c-Src activation induced by serum. Besides, the RhoA activity in RCC cells was remarkably impaired when Cbp was knocked down. Overexpression of wild-type Cbp, but not its mutant Cbp/Delta CP lacking C-terminal PDZ-binding motif, significantly enhanced RhoA activation and cell migration of RCC cells. These results provided new insights into the function of Cbp in modulating RhoA activation, by which Cbp might contribute to renal cell carcinogenesis. Oncogene (2009) 28, 3320-3331; doi:10.1038/onc.2009.185; published online 6 July 2009	[Feng, X.; Lu, X.; Zhou, W.; Jiang, L. Q.; Lei, L.; Huang, Q.; Zhang, Z.; Chen, Z.] Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; [Feng, X.; Lu, X.; Zhou, W.; Lei, L.; Huang, Q.] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China; [Man, X.] Second Mil Med Univ, Int Cooperat Lab Signal Transduct, Eastern Hepotabiliary Surg Inst, Shanghai, Peoples R China; [Knyazev, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Naval Medical University; Max Planck Society	Chen, Z (corresponding author), Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci, State Key Lab Mol Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zhangzhe@sibs.ac.cn; zjchen@sibs.ac.cn			National Natural Science Foundation of China [30730055, 30623002]; National Key Scientific Program of China [2007CB914504]; Chinese Academy of Sciences [KSCX1-YW-R-67, KSCX2-YW-R108]; Program of Shanghai Subject Chief Scientist [08XD14051]; National High Technology Research and Development Programme of China [2006AA02A308]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Scientific Program of China; Chinese Academy of Sciences(Chinese Academy of Sciences); Program of Shanghai Subject Chief Scientist; National High Technology Research and Development Programme of China(National High Technology Research and Development Program of China)	We thank Dr Vaclav Horejsi (Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Videnska 1083, 14220 Prague 4, Czech Republic) for kindly and generously giving us the monoclonal antibody against Cbp. This work was supported by grants from National Natural Science Foundation of China (30730055 and 30623002), National Key Scientific Program of China (2007CB914504), the Chinese Academy of Sciences (KSCX1-YW-R-67, KSCX2-YW-R108), Program of Shanghai Subject Chief Scientist (08XD14051) and the National High Technology Research and Development Programme of China (2006AA02A308).	Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Bratslavsky G, 2007, CLIN CANCER RES, V13, P4667, DOI 10.1158/1078-0432.CCR-06-2510; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brdickova N, 2001, FEBS LETT, V507, P133, DOI 10.1016/S0014-5793(01)02955-6; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; D'Angelo R, 2007, MOL BIOL CELL, V18, P4780, DOI 10.1091/mbc.E06-12-1144; D'Hondt V, 2005, EUR J CANCER, V41, P1246, DOI 10.1016/j.ejca.2004.11.025; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; Hayashi M, 2005, J CLIN ENDOCR METAB, V90, P1712, DOI 10.1210/jc.2004-1547; Ingley E, 2006, J BIOL CHEM, V281, P31920, DOI 10.1074/jbc.M602637200; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klatte T, 2007, CLIN CANCER RES, V13, P7388, DOI 10.1158/1078-0432.CCR-07-0411; Lam JS, 2005, UROLOGY, V66, P1, DOI 10.1016/j.urology.2005.06.112; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Mathivanan S, 2008, NAT BIOTECHNOL, V26, P164, DOI 10.1038/nbt0208-164; Matsuoka H, 2004, J BIOL CHEM, V279, P5975, DOI 10.1074/jbc.M311278200; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005; Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071; Rathmell WK, 2008, EXPERT REV ANTICANC, V8, P63, DOI 10.1586/14737140.8.1.63; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Shima T, 2003, P NATL ACAD SCI USA, V100, P14897, DOI 10.1073/pnas.2432139100; Solheim SA, 2008, J BIOL CHEM, V283, P2773, DOI 10.1074/jbc.M705215200; Svec A, 2005, IMMUNOL LETT, V100, P94, DOI 10.1016/j.imlet.2005.05.002; Svec A, 2007, PATHOL RES PRACT, V203, P193, DOI 10.1016/j.prp.2007.01.005; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tauzin S, 2008, BLOOD, V111, P2310, DOI 10.1182/blood-2007-05-090985; Tedoldi S, 2006, BLOOD, V107, P213, DOI 10.1182/blood-2005-06-2273; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	40	15	20	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3320	3331		10.1038/onc.2009.185	http://dx.doi.org/10.1038/onc.2009.185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581936	Bronze			2022-12-28	WOS:000269893700006
J	Confalonieri, S; Quarto, M; Goisis, G; Nuciforo, P; Donzelli, M; Jodice, G; Pelosi, G; Viale, G; Pece, S; Di Fiore, PP				Confalonieri, S.; Quarto, M.; Goisis, G.; Nuciforo, P.; Donzelli, M.; Jodice, G.; Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.			Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor	ONCOGENE			English	Article						ubiquitin; ubiquitin E3 ligase; cancer; in situ hybridization; tissue microarrays	SQUAMOUS-CELL CARCINOMA; CYCLIN B1; HECT-DOMAIN; BREAST-CANCER; PROTEIN; OVEREXPRESSION; DEGRADATION; CDC6; P53; SUPPRESSOR	Protein ubiquitination is critical for many cellular processes, through its ability to regulate protein degradation and various signaling mechanisms. In the ubiquitin (Ub) system, substrate specificity is achieved through the E3 family of Ub ligases. Because alterations of the ubiquitination machinery have been reported in human cancers, the selective interference with Ub ligases might represent a powerful therapeutic tool. Here, we report the first wide survey of misregulation of Ub ligases in cancer. We analysed 82 Ub ligases in nine types of cancer by in situ hybridization on tissue microarrays. We found 27 instances in which an Ub ligase was altered in a given type of tumor, when compared with normal tissues: 21 cases of overexpression and 6 cases of underexpression. We further analysed selected Ub ligases in large cohorts of breast and non-small-cell lung carcinomas. In five, of six, of these extended analyses (HUWE1, CCNB1IP1, SIAH1 and SIAH2 in breast cancer and CCNB1IP1 in lung cancer), we found that the levels of Ub ligases correlated significantly with relevant prognostic factors, and with clinical outcome. Our findings show that the alteration of Ub ligases is a frequent event in cancer and identify candidate targets for molecular therapies. Oncogene (2009) 28, 2959-2968; doi:10.1038/onc.2009.156; published online 22 June 2009	[Confalonieri, S.; Quarto, M.; Nuciforo, P.; Jodice, G.; Pece, S.; Di Fiore, P. P.] IFOM, Fdn Ist FIRC Oncol Mol, I-20139 Milan, Italy; [Goisis, G.; Donzelli, M.; Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.] Ist Europeo Oncol, Milan, Italy; [Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.] Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan	Confalonieri, S (corresponding author), IFOM, Fdn Ist FIRC Oncol Mol, Via Adamello 16, I-20139 Milan, Italy.	stefano.confalonieri@ifom-ieo-campus.it; pierpaolo.difiore@ifom-ieo-campus.it	Nuciforo, Paolo/Q-2885-2019; Confalonieri, Stefano/AAQ-6786-2020; Viale, Giuseppe/AAE-8921-2019; Donzelli, Maddalena/ABD-3774-2020; Di Fiore, Pier Paolo/K-2130-2012; Pece, Salvatore/B-9609-2013; Pelosi, Giuseppe/F-5073-2012	Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Pece, Salvatore/0000-0003-1764-3929; Pelosi, Giuseppe/0000-0003-4725-4692; Nuciforo, Paolo/0000-0003-1380-0990; DONZELLI, MADDALENA/0000-0002-4045-0802; Iodice, Maria Giovanna/0000-0002-6173-1080	AIRC (Associazione Italiana per la Ricerca sul Cancro); AIRC and MIUR; European Community (VI Framework); Ferrari Foundation; Monzino Foundation; CARIPLO Foundation; G Vollaro Foundation	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AIRC and MIUR(Fondazione AIRC per la ricerca sul cancroMinistry of Education, Universities and Research (MIUR)); European Community (VI Framework)(European Commission); Ferrari Foundation; Monzino Foundation; CARIPLO Foundation(Fondazione Cariplo); G Vollaro Foundation	We thank Maria Capra and Maria Tuttoilmondo for TMA database development and TMA analysis, and Sara Volorio for excellent technical assistance. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) to SC, and from AIRC and MIUR to SP and PPDF; from the European Community (VI Framework), the Ferrari Foundation, the Monzino Foundation and the CARIPLO Foundation to PPDF; and from the G Vollaro Foundation to SP. PN was supported by an AIRC fellowship.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Ciechanover A, 2003, BIOCHEM SOC T, V31, P474, DOI 10.1042/BST0310474; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Dong YY, 2002, CANCER LETT, V177, P13, DOI 10.1016/S0304-3835(01)00770-4; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Hassan KA, 2002, CANCER RES, V62, P6414; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; Kallijarvi J, 2005, EXP CELL RES, V308, P146, DOI 10.1016/j.yexcr.2005.04.001; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nicassio F, 2005, J CLIN INVEST, V115, P3015, DOI 10.1172/JCI24862; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Pelizon C, 2003, TRENDS CELL BIOL, V13, P110, DOI 10.1016/S0962-8924(03)00024-2; Scarafia LE, 2000, PHYSIOL GENOMICS, V4, P147, DOI 10.1152/physiolgenomics.2000.4.2.147; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Soria JC, 2000, CANCER RES, V60, P4000; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Ward JO, 2007, PLOS GENET, V3, P1550, DOI 10.1371/journal.pgen.0030139; Weiss A, 2007, FEBS LETT, V581, P5131, DOI 10.1016/j.febslet.2007.09.062; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Yasuda M, 2002, J CANCER RES CLIN, V128, P412, DOI 10.1007/s00432-002-0359-9; Yoon SY, 2005, BIOCHEM BIOPH RES CO, V326, P7, DOI 10.1016/j.bbrc.2004.11.004; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	45	80	87	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	2009	28	33					2959	2968		10.1038/onc.2009.156	http://dx.doi.org/10.1038/onc.2009.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19543318				2022-12-28	WOS:000269142800004
J	Zhu, C; Qin, YR; Xie, D; Chua, DTT; Fung, JM; Chen, L; Fu, L; Hu, L; Guan, XY				Zhu, C.; Qin, Y-R; Xie, D.; Chua, D. T. T.; Fung, J. M.; Chen, L.; Fu, L.; Hu, L.; Guan, X-Y			Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma	ONCOGENE			English	Article						esophageal squamous cell carcinoma; PCAF; tumor suppressor gene; loss of heterozygosity; methylation	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL-ABERRATIONS; CYCLIN D1; GENE; EXPRESSION; PCAF; HYPERMETHYLATION; REVEALS; CANCER; BETA	Deletion of 3p is one of the most frequent genetic alterations in many tumors, including esophageal squamous cell carcinoma (ESCC). In our recent study, deletion of 3p24 was frequently detected in ESCC and one candidate tumor suppressor gene (TSG), p300/CBP-associated factor ( PCAF), was identified within the region. In this study, downregulation of PCAF was detected in 23/40 (57.5%) of primary ESCCs and 4/9 (44.4%) of the ESCC cell lines. A further study found that downregulation of PCAF was also associated with hypermethylation of the promoter region of PCAF gene. Methylation-specific PCR found that promoter methylation was detected in 28/40 (70%) of primary ESCCs and 5/9 (55.6%) of ESCC cell lines. In addition, the expression of PCAF could be reactivated in ESCC cell line KYSE510 after demethylation treatment with 5-aza-dC. Functional studies showed that PCAF was able to suppress tumorigenicity of ESCC cells both in vitro and in vivo, including foci formation, colony formation in soft agar and tumor formation in nude mice. Molecular study found that the tumor suppressive mechanism of PCAF was associated with its role in cell cycle arrest at the G1/S checkpoint by the downregulation of CDK2 and upregulation of p21(waf1/Cip1), Smad4, Rb and p27(Kip1). In conclusion, PCAF might be the target TSG responsible for the 3p24 deletion event, which has an important role in the development and progression of ESCC. Oncogene ( 2009) 28, 2821-2828; doi:10.1038/onc.2009.137; published online 15 June 2009	[Zhu, C.; Chua, D. T. T.; Fung, J. M.; Chen, L.; Fu, L.; Hu, L.; Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Qin, Y-R] Zhengzhou Univ, Dept Clin Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Xie, D.; Guan, X-Y] Sun Yat Sen Univ, State Key Lab Oncol So China, Guangzhou, Peoples R China; [Xie, D.; Guan, X-Y] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China	University of Hong Kong; Zhengzhou University; Sun Yat Sen University; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room L10-56,Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Fu, Li/F-7182-2010; Chen, Leilei/F-7668-2011; Guan, Xin-Yuan/A-3639-2009	Fu, Li/0000-0003-2643-6278; Guan, Xin-Yuan/0000-0002-4485-6017	Research Grant Council Central Allocation [HKUST 2/06C]; Sun Yat-Sen University 'Hundred Talents Program' [85000-3171311]; Major State Basic Research Program of China [2006CB910104]; National Natural Science Foundation of China [30772475]	Research Grant Council Central Allocation; Sun Yat-Sen University 'Hundred Talents Program'; Major State Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Research Grant Council Central Allocation ( HKUST 2/06C), Sun Yat-Sen University 'Hundred Talents Program' (85000-3171311), a grant from the Major State Basic Research Program of China (2006CB910104) and a grant from the National Natural Science Foundation of China ( 30772475).	ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chiao PJ, 1999, ANN NY ACAD SCI, V880, P31, DOI 10.1111/j.1749-6632.1999.tb09507.x; de Jong JS, 1998, J CLIN PATHOL-MOL PA, V51, P30, DOI 10.1136/mp.51.1.30; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Guan XY, 2001, CANCER RES, V61, P3806; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kuroki T, 2003, CANCER RES, V63, P3724; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Offner FA, 2000, PATHOLOGE, V21, P349, DOI 10.1007/s002920000414; OGASAWARA S, 1995, CANCER RES, V55, P891; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tanaka H, 1996, INT J CANCER, V65, P372, DOI 10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.3.CO;2-3; Ullmannova V, 2003, LEUKEMIA RES, V27, P1115, DOI 10.1016/S0145-2126(03)00103-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang X, 2008, ONCOGENE, V27, P1894, DOI 10.1038/sj.onc.1210821; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M; Zhang CS, 2007, J CLIN PATHOL, V60, P1249, DOI 10.1136/jcp.2006.044099; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916	31	37	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2821	2828		10.1038/onc.2009.137	http://dx.doi.org/10.1038/onc.2009.137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525977				2022-12-28	WOS:000268684400005
J	Kashima, L; Toyota, M; Mita, H; Suzuki, H; Idogawa, M; Ogi, K; Sasaki, Y; Tokino, T				Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.			CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappa B	ONCOGENE			English	Article						CHFR; NF-kappa B; IL-8; tumor suppressor; angiogenesis	MITOTIC CHECKPOINT PROTEIN; NECROSIS-FACTOR-ALPHA; CANCER-CELL-LINES; GENE-EXPRESSION; GASTRIC-CANCER; EPIGENETIC INACTIVATION; MICROTUBULE INHIBITORS; TRANSCRIPTION FACTORS; BREAST CANCERS; NUCLEAR-FACTOR	The mitotic checkpoint gene CHFR (checkpoint with forkhead and ring finger domains) is silenced in various human cancers by promoter hypermethylation, suggesting that CHFR is a tumor suppressor. Here, we show that CHFR functions as a negative regulator of the nuclear factor-kappa B (NF-kappa B) pathway. Expression of CHFR inhibited NF-kappa B reporter activity, whereas knockdown of CHFR activated reporter activity. These activities are independent of its RING finger domain. Furthermore, we found that CHFR physically interacts with p65 in cells. Electrophoretic mobility shift assays (EMSAs) and ELISA-based NF-kappa B-binding assays showed that CHFR negatively regulated transcriptional activity of p65. In addition, our data show that interleukin (IL)-8 is significantly downregulated by CHFR, and that the migration of human endothelial cells is suppressed in culture medium conditioned from CHFR-expressing cancer cells. Using a xenograft model, we show that neovascularization is suppressed by adenovirus-mediated transfer of CHFR. These results indicate that expression of CHFR markedly reduces the expression of IL-8 through the inhibition of NF-kappa B. As the NF-kappa B signaling pathway plays a critical role in the development and progression of cancer, our findings show the functional relationship between epigenetic alteration and inflammation/angiogenesis in human cancer cells, thereby showing several potential targets for therapeutic intervention. Oncogene (2009) 28, 2643 -2653; doi: 10.1038/onc.2009.123; published online 18 May 2009	[Kashima, L.; Toyota, M.; Mita, H.; Suzuki, H.; Idogawa, M.; Ogi, K.; Sasaki, Y.; Tokino, T.] Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; [Toyota, M.; Suzuki, H.] Sapporo Med Univ, Dept Internal Med, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University	Tokino, T (corresponding author), Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Idogawa, Masashi/B-5208-2008; Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Idogawa, Masashi/0000-0002-8507-1726; Sasaki, Yasushi/0000-0002-3500-8059	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) [pcDNA3-Flag-p65]	Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This research was supported by a grant to TT (KAKENHI (20390519)) from the Grants-in-Aid for Scienti. c Research (B) program of the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). We thank Dr Toshiharu Suzuki (Hokkaido University, Japan) for the pcDNA3-Flag-p65 construct.	AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Cuenca R E, 1992, Surg Oncol, V1, P323, DOI 10.1016/0960-7404(92)90094-2; Daniels MJ, 2004, NAT STRUCT MOL BIOL, V11, P1114, DOI 10.1038/nsmb837; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fukuda T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001776; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kang Dongmin, 2004, Methods Mol Biol, V280, P229; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kawai N, 2005, DEV BIOL, V277, P80, DOI 10.1016/j.ydbio.2004.09.007; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kontermann RE, 2008, J IMMUNOTHER, V31, P225, DOI 10.1097/CJI.0b013e31816a88f9; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lee KH, 2004, ONCOLOGY-BASEL, V66, P210, DOI 10.1159/000077997; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mumm JB, 2008, ONCOGENE, V27, P5913, DOI 10.1038/onc.2008.275; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Ogi K, 2005, CANCER BIOL THER, V4, P773, DOI 10.4161/cbt.4.7.1896; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Privette LM, 2008, TRANSL ONCOL, V1, P57, DOI 10.1593/tlo.08109; Rakitina TV, 2003, CANCER RES, V63, P8600; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Sathe SS, 2004, P NATL ACAD SCI USA, V101, P192, DOI 10.1073/pnas.0306812101; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Williams JL, 2008, CARCINOGENESIS, V29, P390, DOI 10.1093/carcin/bgm275; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Yuan A, 2005, FRONT BIOSCI-LANDMRK, V10, P853, DOI 10.2741/1579	48	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2643	2653		10.1038/onc.2009.123	http://dx.doi.org/10.1038/onc.2009.123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19448676				2022-12-28	WOS:000268211200003
J	Kopanja, D; Stoyanova, T; Okur, MN; Huang, E; Bagchi, S; Raychaudhuri, P				Kopanja, D.; Stoyanova, T.; Okur, M. N.; Huang, E.; Bagchi, S.; Raychaudhuri, P.			Proliferation defects and genome instability in cells lacking Cul4A	ONCOGENE			English	Article						Cul4A; proliferation; genome instability; p53	PROTEOLYSIS; PROTEIN; DDB1; AMPLIFICATION; DEGRADATION; TARGETS; MOUSE; GENE; P53; STABILITY	The Cul4A gene, which encodes a core component of a cullin-based E3 ubiquitin ligase complex, is overexpressed in breast and hepatocellular cancers. In breast cancers, overexpression of Cul4A strongly correlates with poor prognosis. In addition, Cul4A is required for early embryonic development. The early lethality of mouse embryos prevented a detailed analysis of the functions of Cul4A. Here, we used a strain of mice carrying floxed alleles of Cul4A to study its role in cell division, in vitro and in vivo. Embryonic fibroblasts (MEFs) show a severe deficiency in cell proliferation after deletion of Cul4A. We observed that the Cul4A protein is abundantly expressed in the brain, liver and the mammary tissue of pregnant mice. Deletion of Cul4A in the liver impairs hepatocyte proliferation during regeneration after carbon tetrachloride (CCl4)-induced injury. The Cul4A-deleted cells are slow in entering the S phase, and are deficient in progressing through the early M phase. Several cell-cycle regulators, including p53 and p27Kip1, are deregulated in the Cul4A-deleted cells. Expression of a dominant negative mutant of p53 causes significant reversal of the proliferation defects in Cul4A-deleted cells. The Cul4A-deleted cells show an aberrant number of centrosome, multipolar spindles and micronuclei formation. Furthermore, those cells are sensitive to UV irradiation and show reduced levels of unscheduled DNA synthesis (UDS). Together, our observations indicate that Cul4A is required for efficient cell proliferation, control of centrosome amplification and genome stability. Oncogene (2009) 28, 2456-2465; doi:10.1038/onc.2009.86; published online 11 May 2009	[Kopanja, D.; Stoyanova, T.; Okur, M. N.; Huang, E.; Raychaudhuri, P.] Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA; [Bagchi, S.] Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 699, Coll Med, 900 S Ashland Ave,2302 MBRB, Chicago, IL 60607 USA.	sbagchi@uic.edu; pradip@uic.edu			National Institute of Health [CA 77637, AG 02413]; NATIONAL CANCER INSTITUTE [R01CA077637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024138] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Cul4A fl/fl mouse strain was generated in collaboration with Xenogen Biosciences, NJ, USA. The work was supported by grants from the National Institute of Health (CA 77637 to PR and AG 02413 to PR and SB).	Abba MC, 2007, CANCER RES, V67, P4104, DOI 10.1158/0008-5472.CAN-06-4672; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Belzile JP, 2007, PLOS PATHOG, V3, P882, DOI 10.1371/journal.ppat.0030085; Bergametti F, 2002, J VIROL, V76, P6495, DOI 10.1128/JVI.76.13.6495-6501.2002; Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006; Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chen LC, 1998, CANCER RES, V58, P3677; El-Mahdy MA, 2006, J BIOL CHEM, V281, P13404, DOI 10.1074/jbc.M511834200; FAUSTO N, 1996, HEPATOLOGY TXB LIVER, P32; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Kim Y, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-18; Li BH, 2002, MOL CELL BIOL, V22, P4997, DOI 10.1128/MCB.22.14.4997-5005.2002; Li BH, 2006, BLOOD, V107, P4291, DOI 10.1182/blood-2005-08-3349; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Schindl M, 2007, ANTICANCER RES, V27, P949; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Shinmura K, 2007, ONCOGENE, V26, P2939, DOI 10.1038/sj.onc.1210085; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; Waning DL, 2008, BLOOD, V112, P320, DOI 10.1182/blood-2007-11-126300; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yasui K, 2002, HEPATOLOGY, V35, P1476, DOI 10.1053/jhep.2002.33683; Zhang Y, 2003, EMBO J, V22, P6057, DOI 10.1093/emboj/cdg577	29	33	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2456	2465		10.1038/onc.2009.86	http://dx.doi.org/10.1038/onc.2009.86			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19430492	Green Accepted			2022-12-28	WOS:000267601400004
J	Morioka, S; Omori, E; Kajino, T; Kajino-Sakamoto, R; Matsumoto, K; Ninomiya-Tsuji, J				Morioka, S.; Omori, E.; Kajino, T.; Kajino-Sakamoto, R.; Matsumoto, K.; Ninomiya-Tsuji, J.			TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP	ONCOGENE			English	Article						TAK1; TRAIL; reactive oxygen species; cIAP; apoptosis	NF-KAPPA-B; APOPTOSIS-INDUCING LIGAND; HUMAN CANCER-CELLS; INDUCED DEATH; CASPASE-8 ACTIVATION; SIGNALING PATHWAYS; DECOY RECEPTORS; TARGETING DEATH; JNK ACTIVATION; UP-REGULATION	TNF-related apoptosis-inducing ligand (TRAIL) is a potent inducer of cell death in several cancer cells, but many cells are resistant to TRAIL. The mechanism that determines sensitivity to TRAIL-killing is still elusive. Here we report that deletion of TAK1 kinase greatly increased activation of caspase-3 and cell death after TRAIL stimulation in keratinocytes, fibroblasts and cancer cells. Although TAK1 kinase is involved in NF-kappa B pathway, ablation of NF-kappa B did not alter sensitivity to TRAIL. We found that TRAIL could induce accumulation of reactive oxygen species (ROS) when TAK1 was deleted. Furthermore, we found that TAK1 deletion induced TRAIL-dependent downregulation of cIAP, which enhanced activation of caspase-3. These results show that TAK1 deletion facilitates TRAIL-induced cell death by activating caspase through ROS and downregulation of cIAP. Thus, inhibition of TAK1 can be an effective approach to increase TRAIL sensitivity. Oncogene (2009) 28, 2257-2265; doi: 10.1038/onc.2009.110; published online 4 May 2009	[Morioka, S.; Omori, E.; Kajino-Sakamoto, R.; Ninomiya-Tsuji, J.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Morioka, S.; Kajino, T.; Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648601, Japan; [Matsumoto, K.] Japan Sci & Technol Agcy, SORST, Tokyo, Japan	University of North Carolina; North Carolina State University; Nagoya University; Japan Science & Technology Agency (JST)	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Morioka, Sho/I-2074-2019	Morioka, Sho/0000-0002-1153-4919; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NIH [GM068812]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Akira, Karin, Ballard and Wang for materials. This work was supported by a grant ( GM068812) from NIH to JN-T.	Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Choo MK, 2006, MOL CANCER THER, V5, P2970, DOI 10.1158/1535-7163.MCT-06-0379; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; Kajino T, 2007, J BIOL CHEM, V282, P9475, DOI 10.1074/jbc.M700875200; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Rudolph D, 2000, GENE DEV, V14, P854; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200	40	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2257	2265		10.1038/onc.2009.110	http://dx.doi.org/10.1038/onc.2009.110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421137	Green Accepted			2022-12-28	WOS:000266886300002
J	Jinawath, N; Vasoontara, C; Yap, KL; Thiaville, MM; Nakayama, K; Wang, TL; Shih, IM				Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Nakayama, K.; Wang, T-L; Shih, I-M			NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway	ONCOGENE			English	Article						ovarian; NAC-1; chemoresistance; paclitaxel	CHROMATIN-REMODELING GENE; KAPPA-B; POZ/BTB PROTEIN; C-MYC; TUMOR-SUPPRESSOR; TAXOL-RESISTANCE; IN-VITRO; CARCINOMA; EXPRESSION; SURVIVAL	Nucleus accumbens-1 (Nac1 or NAC-1) belongs to the BTB/POZ (Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad complex) transcription factor family and is a novel protein that potentially participates in self-renewal and pluripotency in embryonic stem cells. In human cancer, NAC-1 is upregulated in several types of neoplasms, but particularly in recurrent chemoresistant ovarian carcinomas, suggesting a biological role for NAC-1 in the development of drug resistance in ovarian cancer. We have assessed this possibility and shown a correlation between NAC-1 expression and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines. We found that expression of Gadd45-gamma-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells. Ectopic expression of NAC-1 or knockdown of Gadd45gip1 conferred paclitaxel resistance, whereas NAC-1 knockdown or ectopic expression of Gadd45gip1 increased paclitaxel sensitivity. Furthermore, silencing NAC-1 expression or disrupting NAC-1 homodimerization by a dominant negative NAC-1 protein that contained only the BTB/POZ domain induced the expression of Gadd45 gamma, which interacted with Gadd45gip1. Reducing Gadd45 gamma expression by small hairpin RNAs partially enhanced paclitaxel resistance. Thus, this study provides new evidence that NAC-1 upregulation and homodimerization contribute to tumor recurrence by equipping ovarian cancer cells with the paclitaxel-resistant phenotype through negative regulation of the Gadd45 pathway. Oncogene (2009) 28, 1941-1948; doi:10.1038/onc.2009.37; published online 23 March 2009	[Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; [Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA; [Jinawath, N.; Vasoontara, C.; Yap, K-L; Thiaville, M. M.; Wang, T-L; Shih, I-M] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21231 USA; [Nakayama, K.] Shimane Univ, Dept Gynecol & Obstet, Izumo, Shimane, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Shimane University	Shih, IM (corresponding author), Johns Hopkins Med Inst, Dept Pathol, CRB 2,Room 306,1550 Orleans St, Baltimore, MD 21231 USA.	ishih@jhmi.edu	sdsd, shihieih/ABE-6190-2020	Yap, Kai Lee/0000-0003-4496-5464	NIH [RO1CA103937, RO1CA129080]; HERA women's cancer foundation; NATIONAL CANCER INSTITUTE [R01CA103937, R01CA129080] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HERA women's cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is in memory of Ms Sean Patrick, the founder of HERA women's cancer foundation who has fought courageously with recurrent ovarian cancer. The authors appreciate the valuable comments from members in our laboratory. This work is supported by NIH RO1CA103937 (IMS), NIH RO1CA129080 ( IMS) and the HERA women's cancer foundation OSB1 (NJ, USA).	Abeysinghe HR, 1999, CANCER GENET CYTOGEN, V114, P136, DOI 10.1016/S0165-4608(99)00064-3; Abhiman S, 2008, BIOINFORMATICS, V24, P458, DOI 10.1093/bioinformatics/btn007; BAKER VV, 1990, GYNECOL ONCOL, V38, P340, DOI 10.1016/0090-8258(90)90069-W; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cha XY, 1997, J NEUROSCI, V17, P6864; Chung HK, 2003, J BIOL CHEM, V278, P28079, DOI 10.1074/jbc.M212835200; Davidson B, 2007, HUM PATHOL, V38, P1030, DOI 10.1016/j.humpath.2006.12.009; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Dimova I, 2006, EUR J CANCER, V42, P674, DOI 10.1016/j.ejca.2005.11.022; Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078-0432.CCR-06-0861; Holloway RW, 2002, GYNECOL ONCOL, V87, P8, DOI 10.1006/gyno.2002.6797; Ishibashi M, 2008, CLIN CANCER RES, V14, P3149, DOI 10.1158/1078-0432.CCR-07-4358; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kalivas PW, 1999, SYNAPSE, V33, P153, DOI 10.1002/(SICI)1098-2396(199908)33:2<153::AID-SYN5>3.0.CO;2-N; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; Korutla L, 2005, J NEUROCHEM, V94, P786, DOI 10.1111/j.1471-4159.2005.03206.x; Korutla L, 2007, J NEUROCHEM, V101, P611, DOI 10.1111/j.1471-4159.2006.04387.x; Liu GH, 2006, INT J GYNECOL CANCER, V16, P1777, DOI 10.1111/j.1525-1438.2006.00652.x; Loizzi V, 2003, AM J OBSTET GYNECOL, V189, P1301, DOI 10.1067/S0002-9378(03)00629-X; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000; Mackler S, 2008, BEHAV BRAIN RES, V187, P48, DOI 10.1016/j.bbr.2007.08.036; Mao TL, 2006, HUM PATHOL, V37, P1169, DOI 10.1016/j.humpath.2006.04.008; Materna V, 2007, VIRCHOWS ARCH, V450, P187, DOI 10.1007/s00428-006-0346-7; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Qiu WH, 2004, AM J PATHOL, V165, P1689, DOI 10.1016/S0002-9440(10)63425-6; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yeasmin S, 2008, CLIN CANCER RES, V14, P1686, DOI 10.1158/1078-0432.CCR-07-4085; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zerbini LF, 2005, CLIN CANCER RES, V11, P6409, DOI 10.1158/1078-0432.CCR-05-1475; Zerbini LF, 2005, CELL CYCLE, V4, P18, DOI 10.4161/cc.4.1.1363; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	44	67	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1941	1948		10.1038/onc.2009.37	http://dx.doi.org/10.1038/onc.2009.37			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19305429	Green Accepted			2022-12-28	WOS:000265820900001
J	Fox, BP; Kandpal, RP				Fox, B. P.; Kandpal, R. P.			EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells	ONCOGENE			English	Article						breast cancer; EphB6; Eph receptors; ephrin ligands; invasiveness; growth rate	GENE-EXPRESSION; MATRIX METALLOPROTEINASES; CANCER METASTASIS; ESTROGEN-RECEPTOR; TYROSINE KINASES; TISSUE INHIBITOR; ASSOCIATION; APOPTOSIS; TUMORIGENICITY; IDENTIFICATION	Breast cancer mortality in women is largely attributed to the metastasis of primary breast tumors. We have analysed the function of EphB6, a kinase-deficient receptor, in the invasive phenotype of breast cancer cell lines. We have demonstrated the loss of EphB6 protein in invasive breast carcinoma cell lines and absence of EphB6 transcript in a metastatic breast tumor specimen. The function of EphB6 in invasiveness was confirmed by the ability of EphB6 protein to decrease the in vitro invasiveness of MDA-MB-231, MDA-MB-435 and BT549 cells transfected with an EphB6 expression construct. In MDA-MB-231 cells, the decreased invasiveness appeared to be mediated by decreased transcript levels of matrix metalloproteinase (MMP)7 and MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2. In addition to affecting invasiveness phenotype, EphB6 overexpression was also responsible for altering the growth rate and colony-forming efficiency of MCF-7 and MDA-MB-231 cells in a cell-line-specific manner. We suggest that the significant decrease in the invasiveness of MDA-MB-231 and other cell lines transfected with EphB6 is likely occurring by the ability of EphB6 to transduce signals to the nucleus and altering relevant gene expression.	[Fox, B. P.; Kandpal, R. P.] Western Univ Hlth Sci, Dept Basic Med Sci, Pomona, CA 91766 USA	Western University of Health Sciences	Kandpal, RP (corresponding author), Western Univ Hlth Sci, Dept Basic Med Sci, 309 E 2nd St, Pomona, CA 91766 USA.	rkandpal@westernu.edu						Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Bashyam MD, 2002, CANCER, V94, P1821, DOI 10.1002/cncr.10362; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Campbell TN, 2008, CURR ISSUES MOL BIOL, V10, P61; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Freywald A, 2003, J BIOL CHEM, V278, P10150, DOI 10.1074/jbc.M208179200; Hafner C, 2003, INT J ONCOL, V23, P1553; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Holmberg J, 2000, NATURE, V408, P203, DOI 10.1038/35041577; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kagara N, 2007, CANCER SCI, V98, P692, DOI 10.1111/j.1349-7006.2007.00446.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lai KO, 2004, J BIOL CHEM, V279, P13383, DOI 10.1074/jbc.M313356200; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; MADSEN MW, 1990, EUR J CANCER, V26, P793, DOI 10.1016/0277-5379(90)90154-L; Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; Matsuoka H, 2005, J BIOL CHEM, V280, P29355, DOI 10.1074/jbc.M500010200; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Muller-Tidow C, 2005, CANCER RES, V65, P1778, DOI 10.1158/0008-5472.CAN-04-3388; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Nakamoto M, 2000, INT J BIOCHEM CELL B, V32, P7, DOI 10.1016/S1357-2725(99)00096-5; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pratt RL, 2003, MOL CANCER RES, V1, P1070; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; Tanaka M, 2007, J CELL SCI, V120, P2179, DOI 10.1242/jcs.008607; Tang XX, 2004, CLIN CANCER RES, V10, P5837, DOI 10.1158/1078-0432.CCR-04-0395; Tang XX, 2001, MED PEDIATR ONCOL, V36, P80, DOI 10.1002/1096-911X(20010101)36:1<80::AID-MPO1019>3.0.CO;2-N; Tang XX, 2000, MED PEDIATR ONCOL, V35, P656, DOI 10.1002/1096-911X(20001201)35:6<656::AID-MPO37>3.0.CO;2-A; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tong D, 1999, BREAST CANCER RES TR, V56, P91, DOI 10.1023/A:1006262501062; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	53	54	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2009	28	14					1706	1713		10.1038/onc.2009.18	http://dx.doi.org/10.1038/onc.2009.18			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430WQ	19234485				2022-12-28	WOS:000265022000005
J	Hartman, TR; Nicolas, E; Klein-Szanto, A; Al-Saleem, T; Cash, TP; Simon, MC; Henske, EP				Hartman, T. R.; Nicolas, E.; Klein-Szanto, A.; Al-Saleem, T.; Cash, T. P.; Simon, M. C.; Henske, E. P.			The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis	ONCOGENE			English	Article						BHD; mTOR; folliculin; renal carcinoma; oncocytoma	TUBEROUS SCLEROSIS COMPLEX; RIBOSOMAL S6 KINASE; NIHON RAT MODEL; BHD GENE; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; TUBEROUS-SCLEROSIS-COMPLEX-2 TSC2; SPONTANEOUS PNEUMOTHORAX; EMBRYONIC LETHALITY; NATURAL-HISTORY; CELL CARCINOMA	Birt-Hogg-Dube (BHD) syndrome is a tumor-suppressor gene disorder characterized by skin tumors, cystic lung disease and renal cell carcinoma. Very little is known about the molecular pathogenesis of BHD. Clinical similarities between BHD and tuberous sclerosis complex (TSC) suggest that the BHD and TSC proteins may function within a common pathway. The TSC proteins inhibit the activity of the mammalian target of rapamycin complex 1 (TORC1), and in Schizosaccharomyces pombe, Bhd and Tsc1/Tsc2 have opposing roles in the regulation of amino-acid homeostasis. We report here that in mammalian cells, downregulation of BHD reduces the phosphorylation of ribosomal protein S6, an indicator of TORC1 activity. To determine whether folliculin, the product of the BHD gene, regulates mammalian target of rapamycin activity in vivo, we generated a mouse with targeted inactivation of the Bhd gene. The mice developed spontaneous oncocytic cysts and tumors composed of cells that resemble the renal cell carcinomas in BHD patients. The cysts and tumors had low levels of phospho-S6. Taken together, these data indicate that folliculin regulates the activity of TORC1, and suggest a new paradigm in which both inappropriately high and inappropriately low levels of TORC1 activity can be associated with renal tumorigenesis.	[Henske, E. P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Hartman, T. R.; Henske, E. P.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Nicolas, E.] Fox Chase Canc Ctr, Genom Core Facil, Philadelphia, PA 19111 USA; [Klein-Szanto, A.; Al-Saleem, T.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Cash, T. P.; Simon, M. C.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Simon, M. C.] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; [Simon, M. C.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Henske, EP (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care Med, 1 Blackfan Circle, Boston, MA 02115 USA.	Ehenske@partners.org	Simon, Celeste/AAG-3941-2021; Klein-Szanto, A./E-6218-2010		NIH [RO1 (DK51052), F32 (DK076443-01)]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051052, R29DK051052, F32DK076443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Victoria Robb for critical reading of this paper. We also thank Dr Laura Schmidt for the FLCN mAb, Dr Samuel Litwin for statistical analysis and the Fox Chase Cancer Center Lab Animal Facility for technical assistance with the development and maintenance of the Bhd mutant mice. This work was supported by NIH RO1 (DK51052). Dr Hartman was supported by NIH F32 (DK076443-01).	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103; Babbitt JT, 2000, CARCINOGENESIS, V21, P1379, DOI 10.1093/carcin/21.7.1379; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; BARBOUR G L, 1978, Urology, V12, P694, DOI 10.1016/0090-4295(78)90434-X; BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chen JD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003581; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; HINO O, 1993, CANCER RES, V53, P5856; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kouchi M, 2006, VIRCHOWS ARCH, V448, P463, DOI 10.1007/s00428-005-0142-9; Leter EM, 2008, J INVEST DERMATOL, V128, P45, DOI 10.1038/sj.jid.5700959; Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mohr U, 1996, PATHOBIOLOGY AGING M, V1; Murakami T, 2007, J PATHOL, V211, P524, DOI 10.1002/path.2139; Nagy A, 2004, INT J CANCER, V109, P472, DOI 10.1002/ijc.11694; NELLIST M, 1993, CELL, V75, P1305; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; O'Callaghan FJK, 1998, LANCET, V351, P1490, DOI 10.1016/S0140-6736(05)78872-3; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Painter JN, 2005, AM J HUM GENET, V76, P522, DOI 10.1086/428455; Pavlovich CP, 2005, J UROLOGY, V173, P1482, DOI 10.1097/01.ju.0000154629.45832.30; Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Rolfe M, 2005, BIOCHEM J, V388, P973, DOI 10.1042/BJ20041888; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stutman O, 1975, Adv Cancer Res, V22, P261; Takagi Y, 2008, ONCOGENE, V27, P5339, DOI 10.1038/onc.2008.261; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; Urban T, 1999, MEDICINE, V78, P321, DOI 10.1097/00005792-199909000-00004; van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154; Warren MB, 2004, MODERN PATHOL, V17, P998, DOI 10.1038/modpathol.3800152; Yang Y, 2008, CANCER GENET CYTOGEN, V180, P100, DOI 10.1016/j.cancergencyto.2007.10.010; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	58	152	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1594	1604		10.1038/onc.2009.14	http://dx.doi.org/10.1038/onc.2009.14			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234517	Green Accepted			2022-12-28	WOS:000264780500004
J	Reeves, CV; Dufraine, J; Young, JAT; Kitajewski, J				Reeves, C. V.; Dufraine, J.; Young, J. A. T.; Kitajewski, J.			Anthrax toxin receptor 2 is expressed in murine and tumor vasculature and functions in endothelial proliferation and morphogenesis	ONCOGENE			English	Article						ANTXR2; CMG2; angiogenesis; endothelial cells	CAPILLARY MORPHOGENESIS; ANGIOGENESIS; PROTEIN-2; CELLS; IDENTIFICATION; COLLAGEN; MARKERS; CANCER; DOMAIN	The Capillary Morphogenesis Gene 2 (CMG2) gene encodes an Anthrax toxin receptor (ANTXR2), but the normal physiological function is not known. ANTXR2/CMG2 was originally identified as a result of up-regulation during capillary morphogenesis of endothelial cells (ECs) cultured in vitro. We explored the hypothesis that key steps of the angiogenic process are either dependent or are influenced by ANTXR2/CMG2 activity. We describe the expression pattern of ANTXR2/CMG2 in several murine tissues and in normal breast and breast tumors. Endothelial expression was found in all of the tissues analyzed, in cultured ECs and in breast tumor vessels; however, ANTXR2/CMG2 expression was not restricted to this cell type. To assess potential angiogenic function, we used RNA interference to achieve significant reduction of ANTXR2/CMG2 expression in cultured human umbilical venous endothelial cells (HUVECs). Reduced ANTXR2/CMG2 expression resulted in significant inhibition of proliferation and reduced capacity of ECs to form capillary-like networks in vitro, whereas overexpression of ANTXR2/CMG2 in HUVEC increased proliferation and capillary-like network formation. Little change in migration of ECs was observed on knockdown or overexpression. We conclude that ANTXR2/CMG2 functions to promote endothelial proliferation and morphogenesis during sprouting angiogenesis, consistent with the endothelial expression of ANTXR2/CMG2 in several vascular beds. Oncogene (2010) 29, 789-801; doi:10.1038/onc.2009.383; published online 9 November 2009	[Kitajewski, J.] Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, New York, NY 10035 USA; [Reeves, C. V.; Dufraine, J.; Kitajewski, J.] Columbia Univ, Med Ctr, OB GYN, New York, NY 10035 USA; [Young, J. A. T.] Salk Inst Biol Studies, Infect Dis Lab, La Jolla, CA 92037 USA; [Kitajewski, J.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY 10035 USA	Columbia University; Columbia University; Salk Institute; Columbia University	Kitajewski, J (corresponding author), Columbia Univ, Med Ctr, Dept Pathol, Off 926,Irving Canc Res Ctr, 1130 St Nicholas Ave, New York, NY 10035 USA.	jkk9@columbia.edu		Young, John/0000-0003-1824-2561	NIH [RO1 HL62454, RO1 AI064654, DK07328, AI48489]; DOD Breast Cancer Program [X81WH-06-1-0355]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064654, R01AI048489, R01AI076852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007328] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Program(United States Department of Defense); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH RO1 HL62454 (JKK) and NIH RO1 AI064654 (JKK). CVR was supported by endocrinology training grant DK07328 and by a fellowship from the DOD Breast Cancer Program X81WH-06-1-0355. JY was supported by NIH grant AI48489. We thank Dr Yasuhiro Funahashi, Ayelet Spitzer, and Eunice Kim for technical support, Dr David Owens for the gift of the antibodies and critical reading of the paper, and Dr Darrell Yamashiro for help with preparation of the figures.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Bell SE, 2001, J CELL SCI, V114, P2755; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Hanks S, 2003, AM J HUM GENET, V73, P791, DOI 10.1086/378418; Hotchkiss KA, 2005, EXP CELL RES, V305, P133, DOI 10.1016/j.yexcr.2004.12.025; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Liu SL, 2009, P NATL ACAD SCI USA, V106, P12424, DOI 10.1073/pnas.0905409106; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rmali KA, 2005, BIOCHEM BIOPH RES CO, V334, P231, DOI 10.1016/j.bbrc.2005.06.085; Rogers MS, 2007, CANCER RES, V67, P9980, DOI 10.1158/0008-5472.CAN-07-0829; Scobie HM, 2006, PLOS PATHOG, V2, P949, DOI 10.1371/journal.ppat.0020111; Scobie HM, 2005, J INFECT DIS, V192, P1047, DOI 10.1086/432731; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; St Croix B, 2000, SCIENCE, V289, P1197; Tung JJ, 2009, ANGIOGENESIS, V12, P209, DOI 10.1007/s10456-009-9139-3; Xu QF, 2007, MICROB PATHOGENESIS, V43, P37, DOI 10.1016/j.micpath.2007.03.002	25	46	47	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					789	801		10.1038/onc.2009.383	http://dx.doi.org/10.1038/onc.2009.383			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901963	Green Accepted			2022-12-28	WOS:000274397800002
J	Ribeiro, AS; Albergaria, A; Sousa, B; Correia, AL; Bracke, M; Seruca, R; Schmitt, FC; Paredes, J				Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Bracke, M.; Seruca, R.; Schmitt, F. C.; Paredes, J.			Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells	ONCOGENE			English	Article						P-cadherin; migration; invasion; MMPs; sP-cad	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE-1; GASTRIC-CANCER; EXPRESSION; ADHESION; LINES; CARCINOMA; MOTILITY; METASTASIS; PHENOTYPE	Cell-cell adhesion is an elementary process in normal epithelial cellular architecture. Several studies have shown the role mediated by cadherins in this process, besides their role in the maintenance of cell polarity, differentiation and cell growth. However, during tumour progression, these molecules are frequently altered. In breast cancer, tumours that overexpress P-cadherin usually present a high histological grade, show decreased cell polarity and are associated with worse patient survival. However, little is known about how this protein dictates the very aggressive behaviour of these tumours. To achieve this goal, we set up two breast cancer cell models, where P-cadherin expression was differently modulated and analysed in terms of cell invasion, motility and migration. We show that P-cadherin overexpression, in breast cancer cells with wild-type E-cadherin, promotes cell invasion, motility and migration. Moreover, we found that the overexpression of P-cadherin induces the secretion of matrix metalloproteases, specifically MMP-1 and MMP-2, which then lead to P-cadherin ectodomain cleavage. Further, we showed that soluble P-cadherin fragment is able to induce in vitro invasion of breast cancer cells. Overall, our results contribute to elucidate the mechanism underlying the invasive behaviour of P-cadherin expressing breast tumours. Oncogene (2010) 29, 392-402; doi:10.1038/onc.2009.338; published online 9 November 2009	[Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Seruca, R.; Schmitt, F. C.; Paredes, J.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal; [Albergaria, A.] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Bracke, M.] Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Lab Expt Canc Res, Ghent, Belgium; [Schmitt, F. C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Minho; Ghent University; Ghent University Hospital; Universidade do Porto	Paredes, J (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	jparedes@ipatimup.pt	Schmitt, Fernando/A-5270-2008; Correia, Ana Luisa/E-9738-2012; Albergaria, André/J-6162-2013; Paredes, Joana/F-8224-2011; Sousa, Bárbara/K-8854-2014; Ribeiro, Ana/J-7334-2013; seruca, raquel/F-8187-2011	Schmitt, Fernando/0000-0002-3711-8681; Albergaria, André/0000-0002-2315-2360; Paredes, Joana/0000-0002-1076-1343; Sousa, Bárbara/0000-0002-0990-022X; Ribeiro, Ana/0000-0002-9698-9233; Seruca, Raquel/0000-0002-8851-4166; Schmitt, Fernando/0000-0003-1006-6946; Correia, Ana Luisa/0000-0003-2414-0131	Portuguese Science and Technology Foundation (FCT) [POCI/BIA-BCM/59252/2004, SFRH/BD/36096/2007, SFRH/BD/15316/2005]	Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology)	The work presented was mainly supported by a scientific project (POCI/BIA-BCM/59252/2004) financed by the Portuguese Science and Technology Foundation (FCT). FCT also provided research grants as follows: Programa Ciencia 2007 (FCT) for Joana Paredes, and PhD research grants for Ana Sofia Ribeiro (SFRH/BD/36096/2007) and Andre Albergaria (SFRH/BD/15316/2005).	Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chen HY, 1997, J CELL SCI, V110, P345; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; De Paul AL, 2005, J ANDROL, V26, P44; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujimoto D, 2008, ANTICANCER RES, V28, P847; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ito T, 1999, MODERN PATHOL, V12, P669; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Longatto Filho A, 2005, CYTOPATHOLOGY, V16, P88, DOI 10.1111/j.1365-2303.2004.00226.x; Mannello F, 2008, CANCER SCI, V99, P2160, DOI 10.1111/j.1349-7006.2008.00921.x; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; Murray GI, 1998, J PATHOL, V185, P256; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noe V, 2001, J CELL SCI, V114, P111; Okuyama N, 2008, ONCOL REP, V20, P1497, DOI 10.3892/or_00000171; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Paredes J, 2002, PATHOL RES PRACT, V198, P795, DOI 10.1078/0344-0338-00338; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774; Paredes J, 2007, CELL ONCOL, V29, P467; Remacle AG, 1998, BRIT J CANCER, V77, P926, DOI 10.1038/bjc.1998.153; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Soler AP, 2002, J CELL BIOCHEM, V85, P180, DOI 10.1002/jcb.10126; Stefansson IM, 2004, J CLIN ONCOL, V22, P1242, DOI 10.1200/JCO.2004.09.034; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Marck V, 2005, CANCER RES, V65, P8774, DOI 10.1158/0008-5472.CAN-04-4414; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	42	84	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					392	402		10.1038/onc.2009.338	http://dx.doi.org/10.1038/onc.2009.338			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901964	Green Published			2022-12-28	WOS:000273793200008
J	Puri, C; Chibalina, MV; Arden, SD; Kruppa, AJ; Kendrick-Jones, J; Buss, F				Puri, C.; Chibalina, M. V.; Arden, S. D.; Kruppa, A. J.; Kendrick-Jones, J.; Buss, F.			Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis	ONCOGENE			English	Article						myosin VI; prostate cancer; PSA; VEGF	EPITHELIAL-MESENCHYMAL TRANSITION; UNCONVENTIONAL MYOSIN; MEDIATED ENDOCYTOSIS; SERINE PROTEASES; GOLGI-COMPLEX; MDCK CELLS; E-CADHERIN; PROTEIN; DISABLED-2; MEMBRANE	Tissue expression microarrays, employed to determine the players and mechanisms leading to prostate cancer development, have consistently shown that myosin VI, a unique actin-based motor, is upregulated in medium-grade human prostate cancers. Thus, to understand the role of myosin VI in prostate cancer development, we have characterized its intracellular localization and function in the prostate cancer cell line LNCaP. Using light and electron microscopy, we identified myosin VI on Rab5-positive early endosomes, as well as on recycling endosomes and the trans-Golgi network. Intracellular targeting seems to involve two myosin VI-interacting proteins, GIPC and LMTK2, both of which can be co-immunoprecipitated with myosin VI from LNCaP cells. The absence of Disabled-2 (Dab2), a tumour suppressor and myosin VI-binding partner, inhibits recruitment of myosin VI to endocytic structures at the plasma membrane in LNCaP cells, but interestingly has no effect on endocytosis. Small interfering RNA-mediated down-regulation of myosin VI expression results in a significant reduction in prostate-specific antigen (PSA) and vascular endothelial growth factor (VEGF) secretion in LNCaP cells. Our results suggest that in prostate cancer cells, myosin VI regulates protein secretion, but the overexpression of myosin VI has no major impact on clathrin-mediated endocytosis. Oncogene (2010) 29, 188-200; doi:10.1038/onc.2009.328; published online 26 October 2009	[Puri, C.; Chibalina, M. V.; Arden, S. D.; Kruppa, A. J.; Buss, F.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; [Kendrick-Jones, J.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology	Buss, F (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	fb1@mole.bio.cam.ac.uk		Buss, Folma/0000-0003-4457-3479	Cancer Research UK; Wellcome Trust; Medical Research Council; MRC [MC_U105184323] Funding Source: UKRI; Medical Research Council [MC_U105184323] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank A Peden for help with transferrin uptake assays and JP Luzio for helpful discussions. This work was funded by the Cancer Research UK project grant (CP), the Wellcome Trust Senior Fellowship (to FB), the Wellcome Trust PhD studentship (AJK) and was supported by the Medical Research Council. CIMR is in receipt of a strategic award from the Wellcome Trust.	Ameen N, 2007, TRAFFIC, V8, P998, DOI 10.1111/j.1600-0854.2007.00587.x; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; Au JSY, 2007, J CELL BIOL, V177, P103, DOI 10.1083/jcb.200608126; Balk SP, 2003, J CLIN ONCOL, V21, P383, DOI 10.1200/JCO.2003.02.083; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Buss F, 2008, BIOCHEM BIOPH RES CO, V369, P165, DOI 10.1016/j.bbrc.2007.11.150; Chibalina MV, 2007, J CELL SCI, V120, P4278, DOI 10.1242/jcs.014217; Clements JA, 2004, CRIT REV CL LAB SCI, V41, P265, DOI 10.1080/10408360490471931; Dance AL, 2004, TRAFFIC, V5, P798, DOI 10.1111/j.1600-0854.2004.00224.x; Dunn TA, 2006, AM J PATHOL, V169, P1843, DOI 10.2353/ajpath.2006.060316; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; Lawrence MG, 2007, CELLS TISSUES ORGANS, V185, P111, DOI 10.1159/000101311; Maddugoda MP, 2007, J CELL BIOL, V178, P529, DOI 10.1083/jcb.200612042; Martin DB, 2004, CANCER RES, V64, P347, DOI 10.1158/0008-5472.CAN-03-2062; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Morriswood B, 2007, J CELL SCI, V120, P2574, DOI 10.1242/jcs.007005; Peden AA, 2004, MOL BIOL CELL, V15, P3530, DOI 10.1091/mbc.E03-12-0918; Puri C, 2005, MOL BIOL CELL, V16, P2704, DOI 10.1091/mbc.e04-07-0596; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Spudich G, 2007, NAT CELL BIOL, V9, P176, DOI 10.1038/ncb1531; Su AI, 2001, CANCER RES, V61, P7388; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Veveris-Lowe TL, 2005, ENDOCR-RELAT CANCER, V12, P631, DOI 10.1677/erc.1.00958; Warner CL, 2003, EMBO J, V22, P569, DOI 10.1093/emboj/cdg055; Wei SZ, 2008, PROSTATE, V68, P1387, DOI 10.1002/pros.20806; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; Whitbread AK, 2006, BIOL CHEM, V387, P707, DOI 10.1515/BC.2006.089; Yoshida H, 2004, P NATL ACAD SCI USA, V101, P8144, DOI 10.1073/pnas.0400400101	41	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	2010	29	2					188	200		10.1038/onc.2009.328	http://dx.doi.org/10.1038/onc.2009.328			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855435	Green Accepted, Green Submitted			2022-12-28	WOS:000273650000003
J	Lin, KBL; Tan, P; Freeman, SA; Lam, M; McNagny, KM; Gold, MR				Lin, K. B. L.; Tan, P.; Freeman, S. A.; Lam, M.; McNagny, K. M.; Gold, M. R.			The Rap GTPases regulate the migration, invasiveness and in vivo dissemination of B-cell lymphomas	ONCOGENE			English	Article						B cells; lymphoma; Rap GTPase; cell migrationl extravasation	PYK2 TYROSINE PHOSPHORYLATION; CHEMOKINE; ACTIVATION; ADHESION; LYMPHOCYTES; RECEPTOR; POLARIZATION; MOTILITY	B-cell lymphomas are common malignancies in which transformed B cells enter the circulation, extravasate into tissues and form tumors in multiple organs. Lymphoma cells are thought to exit the vasculature and enter tissues through the same chemokine- and adhesion molecule-dependent mechanisms as normal B cells. We have previously shown that activation of the Rap GTPases, proteins that control cytoskeletal organization and integrin activation, is critical for chemokine-induced migration and adhesion in B-lymphoma cell lines. Using the A20 murine B-lymphoma cell line as a model, we now show that Rap activation is important for circulating lymphoma cells to enter tissues and form tumors in vivo. In vitro assays showed that Rap activation is required for A20 cells to efficiently adhere to vascular endothelial cells and undergo transendothelial migration. These findings suggest that Rap or its effectors could be novel targets for treating B-cell lymphomas. Oncogene (2010) 29, 608-615; doi: 10.1038/onc.2009.345; published online 19 October 2009	[Gold, M. R.] Univ British Columbia, Dept Microbiol & Immunol, Life Sci Ctr, Vancouver, BC V6T 1Z3, Canada; [Lin, K. B. L.; Freeman, S. A.; Gold, M. R.] Univ British Columbia, I3 Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; [Lin, K. B. L.; Freeman, S. A.; Gold, M. R.] Univ British Columbia, CELL Res Grp, Inst Life Sci, Vancouver, BC V6T 1Z3, Canada; [Tan, P.; Lam, M.; McNagny, K. M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Gold, MR (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Life Sci Ctr, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mgold@interchange.ubc.ca	McNagny, Kelly/P-5239-2014; Gold, Michael/AAF-2081-2021	McNagny, Kelly/0000-0003-4737-3499; Gold, Michael/0000-0003-1222-3191	Canadian Institutes of Health Research [MOP-68865]; KMM [MOP-15477]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); KMM	We thank Andy Johnson of the UBC Flow Cytometry Facility and Goran Mansson of the LSI Imaging facility for technical assistance. This work was supported by grants from the Canadian Institutes of Health Research to MRG (GRANT MOP-68865) and KMM (GRANT MOP-15477). KMM is a Michael Smith Foundation for Health Research senior scholar.	Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Durand CA, 2006, EUR J IMMUNOL, V36, P2235, DOI 10.1002/eji.200535004; Gerard A, 2007, J CELL BIOL, V176, P863, DOI 10.1083/jcb.200608161; Goddard S, 2001, TRANSPLANTATION, V72, P1957, DOI 10.1097/00007890-200112270-00016; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Jeon TJ, 2007, J CELL BIOL, V179, P833, DOI 10.1083/jcb.200705068; KIM KJ, 1979, J IMMUNOL, V122, P549; Krebs Danielle L., 1999, Methods in Cell Science, V21, P57, DOI 10.1023/A:1009843325770; Lin KBL, 2008, IMMUNITY, V28, P75, DOI 10.1016/j.immuni.2007.11.019; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SIKORSKI EE, 1993, J IMMUNOL, V151, P5239; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Thelen M, 2008, NAT IMMUNOL, V9, P953, DOI 10.1038/ni.f.207; Till KJ, 2008, CANCER RES, V68, P8429, DOI 10.1158/0008-5472.CAN-08-1758	20	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					608	615		10.1038/onc.2009.345	http://dx.doi.org/10.1038/onc.2009.345			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19838206				2022-12-28	WOS:000274084600013
J	Zhang, J; Li, Y; Liu, Q; Lu, W; Bu, G				Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.			Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis	ONCOGENE			English	Article						LRP6; Wnt signaling; mammary gland; breast cancer	BETA-CATENIN; C-MYC; MATRIX METALLOPROTEINASES; FIBROBLASTIC CELLS; TUMOR VIRUS; HUMAN COLON; EXPRESSION; PROTEIN; GENE; PATHWAY	Although Wnt signaling activation is frequently observed in human breast cancer, mutations in genes encoding intracellular components of the Wnt signaling pathway are rare. We found that the expression of Wnt signaling co-receptor, LRP6, is upregulated in a subset of human breast cancer tissues and cell lines. To examine whether the overexpression of LRP6 in mammary epithelial cells is sufficient to activate Wnt signaling and promote cell proliferation, we generated transgenic mice overexpressing LRP6 in mammary epithelial cells driven by the mouse mammary tumor virus (MMTV) promoter. We found that mammary glands from MMTV-LRP6 mice exhibit significant Wnt activation evidenced by the translocation of beta-catenin from membrane to cytoplasmic/nuclear fractions. The expression of several Wnt target genes including Axin2, Cyclin D1 and c-Myc was also increased in MMTV-LRP6 mice. More importantly, mammary glands from virgin MMTV-LRP6 mice exhibit significant hyperplasia, a precursor to breast cancer, when compared with wild-type littermate controls. Several matrix metalloproteinases are upregulated in MMTV-LRP6 mice that could contribute to the hyperplasia phenotype. Our results suggest that Wnt signaling activation at the cell-surface receptor level can contribute to breast cancer tumorigenesis. Oncogene (2010) 29, 539-549; doi: 10.1038/onc.2009.339; published online 2 November 2009	[Zhang, J.; Li, Y.; Liu, Q.; Lu, W.; Bu, G.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Bu, G.] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Li, Y.; Lu, W.] So Res Inst, Dept Biochem & Mol Biol, Drug Discovery Div, Birmingham, AL 35255 USA	Washington University (WUSTL); Washington University (WUSTL)	Bu, G (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave, St Louis, MO 63110 USA.	bu@wustl.edu	Liu, Qiang/E-9245-2011		National Institutes of Health [R01CA100520, RO1CA124531]; NATIONAL CANCER INSTITUTE [R01CA100520, R01CA124531] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Christof Niehrs (German Cancer Research Center) for providing LRP6 cDNA, Dr Philip Leder (Harvard Medical School) for providing the MMTV-SV40-Bssk vector, Dr Gail VW Johnson (University of Rochester) for providing the GST-E-cadherin construct, and Dr Jin-Moo Lee for providing rat brain sections subjected to hypoxia-ischemia as positive controls for apoptosis. We also thank Dr Taj King for critical reading of the manuscript. This work was supported by grants from the National Institutes of Health R01CA100520 (to GB) and RO1CA124531 (to YL).	Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Blavier L, 2006, CANCER RES, V66, P2691, DOI 10.1158/0008-5472.CAN-05-2919; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chenard MP, 1999, INT J CANCER, V82, P208; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GILLETT C, 1994, CANCER RES, V54, P1812; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heppner KJ, 1996, AM J PATHOL, V149, P273; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klopocki E, 2004, INT J ONCOL, V25, P641; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; Lu WY, 2008, FEBS LETT, V582, P643, DOI 10.1016/j.febslet.2008.01.035; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Nielsen BS, 1997, LAB INVEST, V77, P345; Nielsen BS, 2001, CANCER RES, V61, P7091; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tamamura Y, 2005, J BIOL CHEM, V280, P19185, DOI 10.1074/jbc.M414275200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	52	74	76	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					539	549		10.1038/onc.2009.339	http://dx.doi.org/10.1038/onc.2009.339			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881541	Green Accepted			2022-12-28	WOS:000274084600007
J	Blackburn, JS; Liu, I; Coon, CI; Brinckerhoff, CE				Blackburn, J. S.; Liu, I.; Coon, C. I.; Brinckerhoff, C. E.			A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis	ONCOGENE			English	Article						MMP-1; PAR-1; angiogenesis; superarray; xenograft	THROMBIN RECEPTOR; CELLS; EXPRESSION; PAR-1; GROWTH; PROGRESSION; INHIBITION; MECHANISMS; PROGNOSIS; SYSTEM	Hallmarks of malignant melanoma are its propensity to metastasize and its resistance to treatment, giving patients with advanced disease a poor prognosis. The transition of melanoma from non-invasive radial growth phase (RGP) to invasive and metastatically competent vertical growth phase (VGP) is a major step in tumor progression, yet the mechanisms governing this transformation are unknown. Matrix metalloproteinase-1 (MMP-1) is highly expressed by VGP melanomas, and is thought to contribute to melanoma progression by degrading type I collagen within the skin to facilitate melanoma invasion. Protease activated receptor-1 (PAR-1) is activated by MMP-1, and is also expressed by VGP melanomas. However, the effects of MMP-1 signaling through PAR-1 have not been examined in melanoma. Here, we demonstrate that an MMP-1/PAR-1 signaling axis exists in VGP melanoma, and is necessary for melanoma invasion. Introduction of MMP-1 into RGP melanoma cells induced gene expression associated with tumor progression and promoted invasion in vitro, and enhanced tumor growth and conferred metastatic capability in vivo. This study demonstrates that both the type I collagenase and PAR-1 activating functions of MMP-1 are required for melanoma progression, and suggests that MMP-1 may be a major contributor to the transformation of melanoma from non-invasive to malignant disease. Oncogene (2009) 28, 4237-4248; doi: 10.1038/onc.2009.272; published online 7 September 2009	[Blackburn, J. S.; Coon, C. I.; Brinckerhoff, C. E.] Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA; [Liu, I.; Brinckerhoff, C. E.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Dept Med, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Brinckerhoff, CE (corresponding author), Dartmouth Med Sch, Dept Med, 1 Med Ctr Dr,Rubin Bldg,HB 7936, Lebanon, NH 03756 USA.	brinckerhoff@dartmouth.edu		Blackburn, Jessica/0000-0001-9464-3784	NIH [CA-77267, AR-26599, T32-AI07363]; Friends of the Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA077267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR026599, R01AR026599] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Friends of the Norris Cotton Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Shaun Coughlin (University of California, San Francisco, CA, USA) for his generous gift of the AP-PAR-1 construct. This work was supported by NIH grants CA-77267 and AR-26599 (to CEB), NIH grant T32-AI07363 (to JSB) and the Prouty Pilot Grant by the Friends of the Norris Cotton Cancer Center (to CEB).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Berwick M, 2009, DERMATOL CLIN, V27, P205, DOI 10.1016/j.det.2008.12.002; Blackburn JS, 2007, CANCER RES, V67, P10849, DOI 10.1158/0008-5472.CAN-07-1791; Blackburn JS, 2008, AM J PATHOL, V173, P1736, DOI 10.2353/ajpath.2008.080512; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Clark W H Jr, 1975, Semin Oncol, V2, P83; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Depasquale I, 2008, HISTOPATHOLOGY, V52, P500, DOI 10.1111/j.1365-2559.2008.02978.x; DURKO M, 1998, BIOCHIM BIOPHYS ACTA, V1356, P271; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haluska Frank G, 2006, Curr Oncol Rep, V8, P400, DOI 10.1007/s11912-006-0065-x; Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Leiter U, 2004, J SURG ONCOL, V86, P172, DOI 10.1002/jso.20079; Loffek S, 2005, J INVEST DERMATOL, V124, P638, DOI 10.1111/j.0022-202X.2005.23629.x; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; Tellez CS, 2007, J INVEST DERMATOL, V127, P387, DOI 10.1038/sj.jid.5700539; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Villares GJ, 2008, CANCER RES, V68, P9078, DOI 10.1158/0008-5472.CAN-08-2397; Wyatt CA, 2005, CANCER RES, V65, P11101, DOI 10.1158/0008-5472.CAN-05-2446	41	72	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4237	4248		10.1038/onc.2009.272	http://dx.doi.org/10.1038/onc.2009.272			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19734937	Green Accepted			2022-12-28	WOS:000272876300002
J	Soeda, A; Park, M; Lee, D; Mintz, A; Androutsellis-Theotokis, A; McKay, RD; Engh, J; Iwama, T; Kunisada, T; Kassam, AB; Pollack, IF; Park, DM				Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R. D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A. B.; Pollack, I. F.; Park, D. M.			Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha	ONCOGENE			English	Article						glioma; cancer stem cell; HIF-1 alpha; hypoxia; CD133	INDUCIBLE FACTOR 1-ALPHA; TUMOR ANGIOGENESIS; FACTOR-I; EXPRESSION; CANCER; GROWTH; PRECURSORS; PROLIFERATION; PATHWAY; FACTOR-1-ALPHA	Hypoxia contributes to the progression of a variety of cancers by activating adaptive transcriptional programs that promote cell survival, motility and tumor angiogenesis. Although the importance of hypoxia and subsequent hypoxia-inducible factor-1 alpha (HIF-1 alpha) activation in tumor angiogenesis is well known, their role in the regulation of glioma-derived stem cells is unclear. In this study, we show that hypoxia (1% oxygen) promotes the self-renewal capacity of CD133-positive human glioma-derived cancer stem cells (CSCs). Propagation of the glioma-derived CSCs in a hypoxic environment also led to the expansion of cells bearing CXCR4 (CD184), CD44(low) and A2B5 surface markers. The enhanced self-renewal activity of the CD133-positive CSCs in hypoxia was preceded by upregulation of HIF-1 alpha. Knockdown of HIF-1 alpha abrogated the hypoxia-mediated CD133-positive CSC expansion. Inhibition of the phosphatidylinositol 3-kinase (PI3K)-Akt or ERK1/2 pathway reduced the hypoxia-driven CD133 expansion, suggesting that these signaling cascades may modulate the hypoxic response. Finally, CSCs propagated at hypoxia robustly retained the undifferentiated phenotype, whereas CSCs cultured at normoxia did not. These results suggest that response to hypoxia by CSCs involves the activation of HIF-1a to enhance the self-renewal activity of CD133-positive cells and to inhibit the induction of CSC differentiation. This study illustrates the importance of the tumor microenvironment in determining cellular behavior. Oncogene (2009) 28, 3949-3959; doi:10.1038/onc.2009.252; published online 31 August 2009	[Park, D. M.] Univ Pittsburgh, Inst Canc, UPMC Canc Pavil, Brain Tumor Program, Pittsburgh, PA 15232 USA; [Mintz, A.; Engh, J.; Kassam, A. B.; Pollack, I. F.; Park, D. M.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15232 USA; [Androutsellis-Theotokis, A.; McKay, R. D.] NIH, Mol Biol Lab, Bethesda, MD 20892 USA; [Iwama, T.] Gifu Univ, Sch Med, Dept Neurosurg, Gifu 500, Japan; [Kunisada, T.] Gifu Univ, Sch Med, Dept Tissue & Organ Dev Regenerat & Adv Med Sci, Gifu 500, Japan; [Park, D. M.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; Gifu University; Gifu University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Park, DM (corresponding author), Univ Pittsburgh, Inst Canc, UPMC Canc Pavil, Brain Tumor Program, 5th Floor,5150 Ctr Ave, Pittsburgh, PA 15232 USA.	parkdm@upmc.edu	Park, Deric/C-5675-2013	Androutsellis-Theotokis, Andreas/0000-0002-1985-4589; Kunisada, Takahiro/0000-0003-1651-2716; Iwama, Toru/0000-0002-9426-284X	Uehara Memorial Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002981] Funding Source: NIH RePORTER	Uehara Memorial Foundation(Uehara Memorial Foundation); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Akio Soeda is in part supported by the Uehara Memorial Foundation.	Aebersold DM, 2001, CANCER RES, V61, P2911; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Birner P, 2000, CANCER RES, V60, P4693; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen HL, 2007, STEM CELLS, V25, P2291, DOI 10.1634/stemcells.2006-0609; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Ehtesham M, 2004, NEOPLASIA, V6, P287, DOI 10.1593/neo.03427; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Nieoullon V, 2005, MOL CELL NEUROSCI, V28, P462, DOI 10.1016/j.mcn.2004.10.007; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Oka N, 2007, BIOCHEM BIOPH RES CO, V360, P553, DOI 10.1016/j.bbrc.2007.06.094; Oka N, 2009, NEUROL MED-CHIR, V49, P146, DOI 10.2176/nmc.49.146; Panchision DM, 2007, STEM CELLS, V25, P1560, DOI 10.1634/stemcells.2006-0260; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park DM, 2007, CELL CYCLE, V6, P467, DOI 10.4161/cc.6.4.3856; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shimogai R, 2008, INT J GYNECOL CANCER, V18, P499, DOI 10.1111/j.1525-1438.2007.01055.x; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wurmser AE, 2004, SCIENCE, V304, P1253, DOI 10.1126/science.1099344; Xu L, 2004, CLIN CANCER RES, V10, P701, DOI 10.1158/1078-0432.CCR-0953-03; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhong H, 2000, CANCER RES, V60, P1541	49	495	520	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3949	3959		10.1038/onc.2009.252	http://dx.doi.org/10.1038/onc.2009.252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718046				2022-12-28	WOS:000272560300001
J	Solyakov, L; Sayan, E; Riley, J; Pointon, A; Tobin, AB				Solyakov, L.; Sayan, E.; Riley, J.; Pointon, A.; Tobin, A. B.			Regulation of p53 expression, phosphorylation and subcellular localization by a G-protein-coupled receptor	ONCOGENE			English	Article						apoptosis; p53; G-protein-coupled receptor; M-3-muscarinic; mitochondria; SH-SY5Y	DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; INDUCED APOPTOSIS; CELL-DEATH; M-3-MUSCARINIC RECEPTOR; RHO-KINASE; IN-VIVO; ACTIVATION; MITOCHONDRIA; CANCER	G-protein-coupled receptors (GPCRs) have been extremely successful drug targets for a multitude of diseases from heart failure to depression. This superfamily of cell surface receptors have not, however, been widely considered as a viable target in cancer treatment. In this study we show that a classical G(q/11)-coupled GPCR, the M-3-muscarinic receptor, was able to regulate apoptosis through receptors that are endogenously expressed in the human neuroblastoma cell line, SH-SY5Y, and when ectopically expressed in Chinese hamster ovary (CHO) cells. Stimulation of the M-3-muscarinic receptor was shown to inhibit the ability of the DNA-damaging chemotherapeutic agent, etoposide, from mediating apoptosis. This protective response in CHO cells correlated with the ability of the receptor to regulate the expression levels of p53. In contrast, stimulation of endogenous muscarinic receptors in SH-SY5Y cells did not regulate p53 expression but rather was able to inhibit p53 translocation to the mitochondria and p53 phosphorylation at serine 15 and 37. This study suggests the possibility that a GPCR can regulate the apoptotic properties of a chemotherapeutic DNA-damaging agent by regulating the expression, subcellular traf. cking and modi. cation of p53 in a manner that is, in part, dependent on the cell type. Oncogene (2009) 28, 3619-3630; doi:10.1038/onc.2009.225; published online 3 August 2009	[Solyakov, L.; Tobin, A. B.] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; [Sayan, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Riley, J.; Pointon, A.] MRC Toxicol Unit, Leicester, Leics, England	University of Leicester; University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	tba@le.ac.uk	SAYAN, A. EMRE/H-7330-2012	SAYAN, A. EMRE/0000-0002-5291-1485	Wellcome Trust [073480, 047600]	Wellcome Trust(Wellcome TrustEuropean Commission)	We thank the Wellcome Trust for their support (Grants 073480 and 047600).	Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Budd DC, 2004, BIOCHEM J, V381, P43, DOI 10.1042/BJ20031705; Budd DC, 2003, J BIOL CHEM, V278, P19565, DOI 10.1074/jbc.M211670200; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; De Sarno L, 2005, BRAIN RES, V1041, P112, DOI 10.1016/j.brainres.2005.01.081; De Sarno P, 2003, J BIOL CHEM, V278, P11086, DOI 10.1074/jbc.M212157200; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Diao CTM, 2000, BBA-MOL CELL RES, V1499, P49, DOI 10.1016/S0167-4889(00)00107-5; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Haupt S, 2006, ANTI-CANCER DRUG, V17, P725, DOI 10.1097/01.cad.0000217422.52208.fa; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murph MM, 2007, MOL CANCER RES, V5, P1201, DOI 10.1158/1541-7786.MCR-06-0338; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park BS, 2005, APOPTOSIS, V10, P193, DOI 10.1007/s10495-005-6074-7; Paulsen MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-25; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Song P, 2007, CANCER RES, V67, P3936, DOI 10.1158/0008-5472.CAN-06-2484; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tobin AB, 2003, BIOCHEM SOC T, V31, P1182; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; van Koppen CJ, 2003, PHARMACOL THERAPEUT, V98, P197, DOI 10.1016/S0163-7258(03)00032-9; Vichalkovski A, 2005, CELL SIGNAL, V17, P447, DOI 10.1016/j.cellsig.2004.09.010; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; YAN GM, 1995, MOL PHARMACOL, V47, P248; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	62	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3619	3630		10.1038/onc.2009.225	http://dx.doi.org/10.1038/onc.2009.225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648965	Green Accepted			2022-12-28	WOS:000270851800003
J	Herynk, MH; Lewis, MT; Hopp, TA; Medina, D; Corona-Rodriguez, A; Cui, Y; Beyer, AR; Fuqua, SAW				Herynk, M. H.; Lewis, M. T.; Hopp, T. A.; Medina, D.; Corona-Rodriguez, A.; Cui, Y.; Beyer, A. R.; Fuqua, S. A. W.			Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ER alpha transgenic mice	ONCOGENE			English	Article						breast cancer; estrogen receptor; K303R ER mutation; HER2/neu	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; GLAND DEVELOPMENT; HINGE REGION; MUTATION; TUMORS; TRANSACTIVATION; OVEREXPRESSION; ACETYLATION; EXPRESSION	We identified a somatic mutation in estrogen receptor-alpha (ER alpha) in breast cancer causing a lysine to arginine transition (K303R) resulting in hypersensitivity to estrogen, altered associations with coactivators and corepressors and altered posttranslational modifications of ER alpha. We have developed a transgenic mouse expressing the K303R mutant ER alpha under control of the mouse mammary tumor virus (MMTV) promoter. At 4 months of age, K303R ER alpha transgenic animals demonstrate precocious alveolar budding compared with wild-type ER alpha transgenic mice or nontransgenic littermates. Despite these morphologic differences, K303R ER alpha transgenic mice displayed no differences in levels of ER alpha, progesterone receptor or proliferation at this time-point. Pregnancy or chronic estrogen plus progesterone exposure in K303R ER alpha transgenic mice also resulted in significantly more alveolar budding, increased beta-casein production and dilated ducts when compared with nontransgenic littermates. To examine the effects of mutant expression on tumorigenesis, mutant ER alpha mice were crossed with FVB-MMTVneu mice and significantly delayed time to neu-mediated tumorigenesis in bigenic animals. In contrast, mutant expression did not affect carcinogen-induced tumorigenesis. Collectively, these data demonstrate that aberrant estrogenic signaling through the K303R ER alpha mutation may lead to precocious alveolar budding in virgin mice, and to an expedited maturation and differentiation phenotype in the mammary glands of hormonally stimulated animals. Oncogene (2009) 28, 3177-3187; doi: 10.1038/onc.2009.174; published online 29 June 2009	[Herynk, M. H.; Lewis, M. T.; Hopp, T. A.; Medina, D.; Corona-Rodriguez, A.; Cui, Y.; Beyer, A. R.; Fuqua, S. A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, 1 Baylor Plaza,MS 600,N1200 Alkek, Houston, TX 77030 USA.	sfuqua@bcm.edu	Lewis, Michael T/A-9572-2009		NIH/NCI [CA72038, DAMD17-03-1-0417]; NATIONAL CANCER INSTITUTE [R01CA072038] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gary Chamness for editorial assistance and Ms Robin Sample for administrative assistance. This work was supported by NIH/NCI CA72038 to SAWF, and by DAMD17-03-1-0417 to MHH.	Bershtein LM, 2003, B EXP BIOL MED+, V135, P580, DOI 10.1023/A:1025437620749; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; Conway K, 2005, BREAST CANCER RES, V7, pR871, DOI 10.1186/bcr1315; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Cui YK, 2006, MOL ENDOCRINOL, V20, P2020, DOI 10.1210/me.2005-0063; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Davies MPA, 2005, BREAST CANCER RES, V7, pR113, DOI 10.1186/bcr965; DURBAN EM, 1985, DEV BIOL, V109, P288, DOI 10.1016/0012-1606(85)90456-7; Frech MS, 2005, CANCER RES, V65, P681; Fuqua SAW, 2000, CANCER RES, V60, P4026; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; Herynk MH, 2007, CLIN CANCER RES, V13, P3235, DOI 10.1158/1078-0432.CCR-06-2608; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; IP MM, 2000, METHODS MAMMARY GLAN, V16; Jin ZM, 2002, J NUTR, V132, P3186, DOI 10.1093/jn/131.10.3186; Lavrovsky Y, 1998, TRANSGENIC RES, V7, P319, DOI 10.1023/A:1008838616203; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Rajkumar L, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1645; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Tekmal RR, 2007, J STEROID BIOCHEM, V106, P111, DOI 10.1016/j.jsbmb.2007.05.009; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Tokunaga E, 2004, BREAST CANCER RES TR, V84, P289, DOI 10.1023/B:BREA.0000019963.67754.93; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Yang XH, 2003, CANCER RES, V63, P2425	30	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3177	3187		10.1038/onc.2009.174	http://dx.doi.org/10.1038/onc.2009.174			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561644	Green Accepted			2022-12-28	WOS:000269673400001
J	Sullivan, NJ; Sasser, AK; Axel, AE; Vesuna, F; Raman, V; Ramirez, N; Oberyszyn, TM; Hall, BM				Sullivan, N. J.; Sasser, A. K.; Axel, A. E.; Vesuna, F.; Raman, V.; Ramirez, N.; Oberyszyn, T. M.; Hall, B. M.			Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells	ONCOGENE			English	Article						interleukin-6; epithelial-mesenchymal transition; breast cancer; tumor microenvironment; metastasis	GROWTH-FACTOR; TUMOR PROGRESSION; CARCINOMA CELLS; E-CADHERIN; METASTASIS; ACTIVATION; EXPRESSION; APOPTOSIS; CYTOKINE; SERUM	Breast tumor interleukin-6 (IL-6) levels increase with tumor grade, and elevated serum IL-6 correlates with poor breast cancer patient survival. Epithelial-mesenchymal transition (EMT) phenotypes such as impaired E-cadherin expression or aberrant Vimentin induction are associated with enhanced metastasis and unfavorable clinical outcome in breast cancer. Despite this fact, few tumor microenvironment-derived extracellular signaling factors capable of provoking such a phenotypic transition have been identified. In this study, we showed that IL-6 promoted E-cadherin repression among a panel of estrogen receptor-alpha-positive human breast cancer cells. Furthermore, ectopic stable IL-6 expressing MCF-7 breast adenocarcinoma cells (MCF-7(IL-6)) exhibited an EMT phenotype characterized by impaired E-cadherin expression and induction of Vimentin, N-cadherin, Snail and Twist. MCF-7(IL-6) cells formed xenograft tumors that displayed loss of E-cadherin, robust Vimentin induction, increased proliferative indices, advanced tumor grade and undifferentiated histology. Finally, we showed aberrant IL-6 production and STAT3 activation in MCF-7 cells that constitutively express Twist, a metastatic regulator and direct transcriptional repressor of E-cadherin. To our knowledge, this is the first study that shows IL-6 as an inducer of an EMT phenotype in breast cancer cells and implicates its potential to promote breast cancer metastasis. Oncogene (2009) 28, 2940-2947; doi:10.1038/onc.2009.180; published online 6 July 2009	[Ramirez, N.; Oberyszyn, T. M.] Ohio State Univ, Dept Pathol, Coll Med, Columbus, OH 43210 USA; [Sullivan, N. J.; Sasser, A. K.; Hall, B. M.] Ohio State Univ, Integrated Biomed Sci Grad Program, Coll Med, Columbus, OH 43210 USA; [Sullivan, N. J.; Sasser, A. K.; Axel, A. E.; Ramirez, N.; Hall, B. M.] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc, Columbus, OH USA; [Vesuna, F.; Raman, V.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Johns Hopkins University	Oberyszyn, TM (corresponding author), Ohio State Univ, Dept Pathol, Coll Med, 1645 Neil Ave,129 Hamilton Hall, Columbus, OH 43210 USA.	oberyszyn.1@osu.edu	Oberyszyn, Tatiana/E-3774-2011; Vesuna, Farhad/G-3179-2010	Vesuna, Farhad/0000-0002-0356-5096; Oberyszyn, Tatiana/0000-0002-5308-0855	Elsa U Pardee Foundation; American Cancer Society-Ohio Division; Research Institute at Nationwide Children's Hospital; NATIONAL CANCER INSTITUTE [R01CA097226] Funding Source: NIH RePORTER	Elsa U Pardee Foundation; American Cancer Society-Ohio Division(American Cancer Society); Research Institute at Nationwide Children's Hospital(Ohio State University); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the generous support of the Elsa U Pardee Foundation (BH), the American Cancer Society-Ohio Division (BH) and The Research Institute at Nationwide Children's Hospital (BH).	Bachelot T, 2003, BRIT J CANCER, V88, P1721, DOI 10.1038/sj.bjc.6600956; Barton BE, 2004, MOL CANCER THER, V3, P11; Blaskovich MA, 2003, CANCER RES, V63, P1270; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Conze D, 2001, CANCER RES, V61, P8851; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Heimann R, 2000, EUR J CANCER, V36, P1631, DOI 10.1016/S0959-8049(00)00151-9; Jiang XP, 2000, CYTOKINE, V12, P458, DOI 10.1006/cyto.1999.0591; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kishimoto T, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1916; Kozlowski L, 2003, Rocz Akad Med Bialymst, V48, P82; Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656; Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; OKA H, 1993, CANCER RES, V53, P1696; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Pedersen KB, 2002, BRIT J CANCER, V87, P1281, DOI 10.1038/sj.bjc.6600624; Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sasser AK, 2007, FASEB J, V21, P3763, DOI 10.1096/fj.07-8832com; Sasser AK, 2007, CANCER LETT, V254, P255, DOI 10.1016/j.canlet.2007.03.012; Singh A, 1999, ENDOCR-RELAT CANCER, V6, P139, DOI 10.1677/erc.0.0060139; Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Waerner T, 2006, CANCER CELL, V10, P227, DOI 10.1016/j.ccr.2006.07.020; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang GJ, 1999, ANTICANCER RES, V19, P1427	37	537	566	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2940	2947		10.1038/onc.2009.180	http://dx.doi.org/10.1038/onc.2009.180			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19581928	Green Accepted			2022-12-28	WOS:000269142800002
J	Perez-Soler, R				Perez-Soler, R.			Individualized therapy in non-small-cell lung cancer: future versus current clinical practice	ONCOGENE			English	Review						EGFR; biomarker; genomics; proteomics	GROWTH-FACTOR RECEPTOR; MESSENGER-RNA EXPRESSION; BETA-TUBULIN GENE; ACQUIRED-RESISTANCE; ACTIVATING MUTATIONS; PROLONGED SURVIVAL; ERCC1 EXPRESSION; PREDICTIVE-VALUE; PHASE-III; GEFITINIB	Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers. Oncogene (2009) 28, S38-S45; doi:10.1038/onc.2009.200	Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Div Med Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Perez-Soler, R (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Div Med Oncol, 111 E 210th St,Hofheimer Room 100A, Bronx, NY 10467 USA.	rperezso@montefiore.org			Boehringer Ingelheim Pharmaceuticals Inc.	Boehringer Ingelheim Pharmaceuticals Inc.(Boehringer Ingelheim)	I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Atkins D, 2004, J HISTOCHEM CYTOCHEM, V52, P893, DOI 10.1369/jhc.3A6195.2004; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bonomi PD, 2007, CLIN CANCER RES, V13, p4606S, DOI 10.1158/1078-0432.CCR-07-0332; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Chiappori A, 2005, ONCOLOGY-BASEL, V68, P382, DOI 10.1159/000086979; CLARK GM, 2006, P AM SOC CLIN ONCO S, V24, P7166; Conrad DH, 2008, J GEN INTERN MED, V23, P78, DOI 10.1007/s11606-007-0411-1; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; de Reynies A, 2008, J CLIN ONCOL, V26, P228, DOI 10.1200/JCO.2007.15.9186; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Douillard J, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8001; Dowlati A, 2006, J CLIN ONCOL, V24, p370S; DZIADZIUSZKO R, 2007, J CLIN ONCOL, V25, pS403; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858; EISMANN U, 2006, J CLIN ONCOL S, V24, P13058; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; GANDARA DR, 2007, J CLIN ONCOL S, V25; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290; Guney N, 2008, MED ONCOL, V25, P194, DOI 10.1007/s12032-007-9026-y; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hasegawa S, 2002, INT J CANCER, V101, P46, DOI 10.1002/ijc.10575; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Hirsch J, 2004, AM J PHYSIOL-LUNG C, V287, pL1, DOI 10.1152/ajplung.00301.2003; Huang Cheng-Long, 2006, Future Oncol, V2, P289, DOI 10.2217/14796694.2.2.289; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Kikuchi T, 2007, RESPIROLOGY, V12, P22, DOI 10.1111/j.1440-1843.2006.00957.x; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAHESWARAN S, 2008, NEW ENGL J MED, V359, P1; Marchetti A, 2006, NEW ENGL J MED, V354, P526; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok T, 2008, ANN ONCOL, V19, P1; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; *NCCN, 2008, CLIN PRACT GUID NONS; Okano T, 2007, CLIN CANCER RES, V13, P799, DOI 10.1158/1078-0432.CCR-06-1654; Oldenhuis CNAM, 2008, EUR J CANCER, V44, P946, DOI 10.1016/j.ejca.2008.03.006; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Patterson SD, 2003, NAT BIOTECHNOL, V21, P221, DOI 10.1038/nbt0303-221; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Reckamp KL, 2008, J THORAC ONCOL, V3, P117, DOI 10.1097/JTO.0b013e3181622bef; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Simon GR, 2005, CHEST, V127, P978, DOI 10.1378/chest.127.3.978; Solan Merrill J, 2003, Semin Surg Oncol, V21, P64, DOI 10.1002/ssu.10023; Solomon BJ, 2007, J CLIN ONCOL, V25; Stinchcombe TE, 2008, ONCOLOGIST, V13, P28, DOI 10.1634/theoncologist.13-S1-28; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Tsao MS, 2008, J CLIN ONCOL, V26; Van Cutsem E, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2; Webster J, 2005, METH MOL B, V310, P227; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Yanagisawa K, 2003, LANCET, V362, P433, DOI 10.1016/S0140-6736(03)14068-8; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	72	23	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S38	S45		10.1038/onc.2009.200	http://dx.doi.org/10.1038/onc.2009.200			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680295				2022-12-28	WOS:000269515400006
J	Wright, TM; Brannon, AR; Gordan, JD; Mikels, AJ; Mitchell, C; Chen, S; Espinosa, I; van de Rijn, M; Pruthi, R; Wallen, E; Edwards, L; Nusse, R; Rathmell, WK				Wright, T. M.; Brannon, A. R.; Gordan, J. D.; Mikels, A. J.; Mitchell, C.; Chen, S.; Espinosa, I.; van de Rijn, M.; Pruthi, R.; Wallen, E.; Edwards, L.; Nusse, R.; Rathmell, W. K.			Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; Ror2; tyrosine kinase; cancer; cell signaling	RECEPTOR TYROSINE KINASE; KIDNEY; CANCER; GENES; MOUSE; MICROENVIRONMENT; ANGIOGENESIS; EXPRESSION; FAMILY; TUBULE	Inappropriate kinase expression and subsequent promiscuous activity defines the transformation of many solid tumors including renal cell carcinoma (RCC). Thus, the expression of novel tumor-associated kinases has the potential to dramatically shape tumor cell behavior. Further, identifying tumor-associated kinases can lend insight into patterns of tumor growth and characteristics. Here, we report the identification of the RTK-like orphan receptor 2 (Ror2), a new tumor-associated kinase in RCC cell lines and primary tumors. Ror2 is an orphan receptor tyrosine kinase with physiological expression normally seen in the embryonic kidney. However, in RCC, Ror2 expression correlated with expression of genes involved at the extracellular matrix, including Twist and matrix metalloprotease-2 (MMP2). Expression of MMP2 in RCC cells was suppressed by Ror2 knockdown, placing Ror2 as a mediator of MMP2 regulation in RCC and a potential regulator of extracellular matrix remodeling. The suppression of Ror2 not only inhibited cell migration, but also inhibited anchorage-independent growth in soft agar and growth in an orthotopic xenograft model. These findings suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of renal carcinomas, with significant implications for unraveling the tumorigenesis of RCC. Oncogene ( 2009) 28, 2513-2523; doi: 10.1038/onc.2009.116; published online 18 May 2009	[Wright, T. M.; Brannon, A. R.; Rathmell, W. K.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Wright, T. M.; Brannon, A. R.; Chen, S.; Pruthi, R.; Wallen, E.; Rathmell, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Gordan, J. D.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Mitchell, C.; Edwards, L.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Espinosa, I.; van de Rijn, M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Pruthi, R.; Wallen, E.] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA; [Rathmell, W. K.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; Stanford University; Howard Hughes Medical Institute; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rathmell, WK (corresponding author), Univ N Carolina, Lineberger Canc Ctr, 450 W Dr CB 7295, Chapel Hill, NC 27599 USA.	rathmell@med.unc.edu	Edwards, Lloyd/N-2759-2019; Ariel, Pablo/AGJ-4118-2022	Edwards, Lloyd/0000-0002-7788-4575; van de Rijn, Matt/0000-0002-1909-9739	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training [NIH-R25GM055336, NCI-F31CA132543]; MSTP [T32]; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [F31CA132543, K08CA098410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055336] Funding Source: NIH RePORTER	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training; MSTP; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Rathmell Lab members and the Lineberger Cancer Center community for thoughtful insights/advice. Additional thanks to the Microscopy Services Laboratory for use of their facilities, the Lineberger Animal Core Studies Facility and the Baldwin Lab for use of reagents. We also thank Dr H Shelton Earp, Dr Ian Davis and Dr Jon Serody for paper critiques. Funding for this project was provided in part by the Doris Duke Charitable Fund and the V foundation (WKR), Initiative for Maximizing Student Diversity Training Grant NIH-R25GM055336 (TMW and CM) and NCI-F31CA132543 ( TMW). Funding for JDG was provided by a MSTP grant and a T32 grant in hemostasis and thrombosis. Human tumor samples were collected by the UNC Tumor Procurement Facility, supported by the UNC Lineberger Comprehensive Cancer Center.	*AM CANC SOC INC, 2008, CANC FACTS FIG; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; Coombs GS, 2008, CURR DRUG TARGETS, V9, P513, DOI 10.2174/138945008784911796; Cowey CL, 2008, EXPERT OPIN DRUG DIS, V3, P311, DOI 10.1517/17460441.3.3.311; Davies JA, 1996, ACTA ANAT, V156, P187; de Castro-Carpeno J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Rathmell WK, 2005, EXPERT REV ANTICANC, V5, P1031, DOI 10.1586/14737140.5.6.1031; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757; Zhang XH, 2002, INT J UROL, V9, P509, DOI 10.1046/j.1442-2042.2002.00511.x	29	83	85	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2513	2523		10.1038/onc.2009.116	http://dx.doi.org/10.1038/onc.2009.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448672	Green Submitted, Green Accepted			2022-12-28	WOS:000267806800004
J	Somanath, PR; Vijai, J; Kichina, JV; Byzova, T; Kandel, ES				Somanath, P. R.; Vijai, J.; Kichina, J. V.; Byzova, T.; Kandel, E. S.			The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt	ONCOGENE			English	Article						extracellular signal-regulated MAP kinases; protein kinase B; neoplastic cell transformation; p21-activated kinases	PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; PLASMA-MEMBRANE; SERINE 338; RAF; PHOSPHORYLATION; AKT/PKB; CANCER; CYCLE; DEPENDENCE	The activity of protein kinase B, also known as Akt, is commonly elevated in human malignancies and plays a crucial role in oncogenic transformation. The relationship between Akt and the mitogen-activated protein kinase cascade, which is also frequently associated with oncogenesis, remains controversial. We report here examples of cooperation between Akt and cRaf in oncogenic transformation, which was accompanied by elevated activity of extracellular signal-regulated mitogen-activated protein kinases. The effect of Akt on extracellular signal-regulated kinases depended on the status of p21-activated kinase (PAK). Importantly, disruption of the function of PAK not only uncoupled the activation of Akt from that of extracellular signal-regulated kinases, but also greatly reduced the capacity of Akt to act as a transforming oncogene. For the malignancies with hyperactive Akt, our observations support the role for PAK-1 as a potential target for therapeutic intervention. Oncogene (2009) 28, 2365 2369; doi:10.1038/onc.2009.114; published online 4 May 2009	[Vijai, J.; Kichina, J. V.; Kandel, E. S.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Somanath, P. R.; Byzova, T.] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Cleveland Clinic Foundation	Kandel, ES (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-318,Elm & Carlton St, Buffalo, NY 14263 USA.	eugene.kandel@RoswellPark.org	Joseph, Vijai/J-9158-2013	Joseph, Vijai/0000-0002-7933-151X; Byzova, Tatiana/0000-0002-2615-875X; Rammohan Shenoy, Somanath/0000-0003-3017-0230	Howard Temin Award to ESK; NIH [HL071625]; American Heart Association [0830326N]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071625] Funding Source: NIH RePORTER	Howard Temin Award to ESK; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Nikolay Neznanov for the Ets-reporter construct, Dr Channing Der for RIE-1 cells, Dr George Stark for the MEF cells and Dr Nissim Hay for various Akt-expressing constructs. This work was supported by the Howard Temin Award to ESK, NIH Grant HL071625 to TB and American Heart Association grant 0830326N to PRS.	Bereiter-Hahn J, 1998, CELL STRUCT FUNCT, V23, P85, DOI 10.1247/csf.23.85; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gartel AL, 2006, BIOMOL ENG, V23, P17, DOI 10.1016/j.bioeng.2006.01.002; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nheu T, 2004, CELL CYCLE, V3, P71; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shelton JG, 2004, CELL CYCLE, V3, P503; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Somanath PR, 2009, J CELL PHYSIOL, V218, P394, DOI 10.1002/jcp.21612; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Weinberg RA, 2007, BIOL CANC; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	28	50	53	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2365	2369		10.1038/onc.2009.114	http://dx.doi.org/10.1038/onc.2009.114			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19421139	Green Accepted			2022-12-28	WOS:000267342400001
J	Zhou, J; Huang, W; Tao, R; Ibaragi, S; Lan, F; Ido, Y; Wu, X; Alekseyev, YO; Lenburg, ME; Hu, GF; Luo, Z				Zhou, J.; Huang, W.; Tao, R.; Ibaragi, S.; Lan, F.; Ido, Y.; Wu, X.; Alekseyev, Y. O.; Lenburg, M. E.; Hu, G-F; Luo, Z.			Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells	ONCOGENE			English	Article						AMPK; LKB1; cell proliferation; cell cycle; tumor suppressor	ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHASE; METABOLIC CHECKPOINT; SOMATIC MUTATIONS; DIABETIC-PATIENTS; METFORMIN; LKB1; PHOSPHORYLATION; APOPTOSIS; TUMORIGENESIS	AMP-activated protein kinase (AMPK) serves as a fuel-sensing enzyme that is activated by binding of AMP and subsequent phophorylation by upstream kinases such as the tumor suppressor LKB1, when cells sense an increase in the ratio of AMP to ATP. Acute activation of AMPK stimulates fatty acid oxidation to generate more ATP and simultaneously inhibits ATP-consuming processes including fatty acid and protein syntheses, thereby preserving energy for acute cell-surviving program, whereas chronic activation leads to inhibition of cell growth. The goal of the present study is to explore the mechanisms by which AMPK regulates cell growth. Toward this end, we established stable cell lines by introducing a dominant-negative mutant of AMPK alpha 1 subunit or its shRNA into the prostate cancer C4-2 cells and other cells, or wild type LKB1 into the lung adenocarcinoma A549 and breast MB-MDA-231 cancer cells, both of which lack functional LKB1. Our results showed that the inhibition of AMPK accelerated cell proliferation and promoted malignant behavior such as increased cell migration and anchorage-independent growth. This was associated with decreased G1 population, downregulation of p53 and p21, and upregulation of S6K, IGF-1 and IGF1R. Conversely, treatment of the C4-2 cells with 5-aminoimidazole-4-carboxamide 1-D-ribonucleoside (AICAR), a prototypical AMPK activator, caused opposite changes. In addition, our study using microarray and RT-PCR revealed that AMPK regulated gene expression involved in tumor cell growth and survival. Thus, our study provides novel insights into the mechanisms of AMPK action in cancer cells and presents AMPK as an ideal drug target for cancer therapy. Oncogene (2009) 28, 1993-2002; doi:10.1038/onc.2009.63; published online 6 April 2009	[Zhou, J.; Huang, W.; Luo, Z.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Ibaragi, S.; Alekseyev, Y. O.; Hu, G-F] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Tao, R.; Lan, F.; Ido, Y.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Wu, X.] ADV Biosci LLC, Birmingham, AL USA; [Lenburg, M. E.; Luo, Z.] Boston Univ, Sch Med, Genome Sci Inst, Boston, MA 02118 USA; [Lenburg, M. E.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA	Boston University; Harvard University; Harvard Medical School; Boston University; Boston University; Boston University	Luo, Z (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,E645, Boston, MA 02118 USA.	zluo@bu.edu	Luo, Zhijun/AAE-9302-2019; Lenburg, Marc/B-8027-2008	Luo, Zhijun/0000-0001-8105-5289; Lenburg, Marc/0000-0002-5760-4708; Ido, Yasuo/0000-0002-3036-9971; Alekseyev, Yuriy/0000-0001-6105-8861	NIH [R01 CA118918, GM 057959]; NATIONAL CANCER INSTITUTE [R01CA118918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project is supported by NIH R01 Grants, CA118918 and GM 057959 (to Z Luo). We thank Dr David Carling for providing us thecDNA construct for the dominant- negative mutant of AMPKa1 subunit.	Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Barb D, 2007, AM J CLIN NUTR, V86, p858S, DOI 10.1093/ajcn/86.3.858S; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5; De Schrijver E, 2003, CANCER RES, V63, P3799; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; GONG YF, 1993, MOL PHARMACOL, V44, P30; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haheim LL, 2006, AM J EPIDEMIOL, V164, P769, DOI 10.1093/aje/kwj284; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; He GB, 2006, CANCER RES, V66, P1873, DOI 10.1158/0008-5472.CAN-05-3111; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jimenez AI, 2003, CANCER RES, V63, P1382; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; KLIPPERAURBACH Y, 1995, MED HYPOTHESES, V45, P486, DOI 10.1016/0306-9877(95)90228-7; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Lee IM, 2003, MED SCI SPORT EXER, V35, P1823, DOI 10.1249/01.MSS.0000093620.27893.23; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Ngo TH, 2003, ENDOCRINOLOGY, V144, P2319, DOI 10.1210/en.2003-221028; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Singh AP, 2008, CANCER LETT, V259, P28, DOI 10.1016/j.canlet.2007.09.018; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133	41	88	93	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1993	2002		10.1038/onc.2009.63	http://dx.doi.org/10.1038/onc.2009.63			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347029	Green Accepted			2022-12-28	WOS:000265820900006
J	Lomonosova, E; Chinnadurai, G				Lomonosova, E.; Chinnadurai, G.			BH3-only proteins in apoptosis and beyond: an overview	ONCOGENE			English	Review						BH3-only; apoptosis; autophagy; non-apoptotic functions; cancer	BCL-2 FAMILY-MEMBER; PROGRAMMED CELL-DEATH; BREAST-CANCER CELLS; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; BECLIN 1-DEPENDENT AUTOPHAGY; CHRONIC LYMPHOCYTIC-LEUKEMIA; SURVIVAL-PROMOTING PROTEINS; SMALL-MOLECULE INHIBITORS; CYTOCHROME-C RELEASE; DNA-DAMAGE RESPONSE	BH3-only BCL-2 family proteins are effectors of canonical mitochondrial apoptosis. They discharge their pro-apoptotic functions through BH1-3 pro-apoptotic proteins such as BAX and BAK, while their activity is suppressed by BH1-4 anti-apoptotic BCL-2 family members. The precise mechanism by which BH3-only proteins mediate apoptosis remains unresolved. The existing data are consistent with three mutually nonexclusive models (1) displacement of BH1-3 proteins from complexes with BH1-4 proteins; (2) direct interaction with and conformational activation of BH1-3 proteins; and (3) membrane insertion and membrane remodeling. The BH3-only proteins appear to play critical roles in restraining cancer and inflammatory diseases such as rheumatoid arthritis. Molecules that mimic the effect of BH3-only proteins are being used in treatments against these diseases. The cell death activity of a subclass of BH3-only members (BNIP3 and BNIP3L) is linked to cardiomyocyte loss during heart failure. In addition to their established role in apoptosis, several BH3-only members also regulate diverse cellular functions in cell-cycle regulation, DNA repair and metabolism. Several members are implicated in the induction of autophagy and autophagic cell death, possibly through unleashing of the BH3-only autophagic effector Beclin 1 from complexes with BCL-2/BCL-xL. The Chapters included in the current Oncogene Review issues provide in-depth discussions on various aspects of major BH3-only proteins. Oncogene (2009) 27, S2-S19; doi:10.1038/onc.2009.39	[Lomonosova, E.; Chinnadurai, G.] St Louis Univ, Inst Mol Virol, Sch Med, Doisy Res Ctr, St Louis, MO 63104 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Inst Mol Virol, Sch Med, Doisy Res Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu			National Cancer Institute [CA-33616, CA-116262, CA-73803]; NATIONAL CANCER INSTITUTE [R21CA116262, R01CA033616, R01CA073803] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	GC received grant support from the National Cancer Institute Grants CA-33616, CA-116262 and CA-73803. We thank John Tavis, Ling-jun Zhao and Carolyn Mulhall for reading the paper.	Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245; Bachmann PS, 2005, BLOOD, V105, P2519, DOI 10.1182/blood-2004-05-2023; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Bouillet P, 2002, J CELL SCI, V115, P1567; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Broustas CG, 2004, J BIOL CHEM, V279, P26780, DOI 10.1074/jbc.M400159200; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chen GG, 2001, CANCER LETT, V172, P75, DOI 10.1016/S0304-3835(01)00630-9; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Claveria C, 2003, BIOCHEM BIOPH RES CO, V304, P531, DOI 10.1016/S0006-291X(03)00626-0; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Day CL, 2008, J MOL BIOL, V380, P958, DOI 10.1016/j.jmb.2008.05.071; Denisov AY, 2006, BIOCHEMISTRY-US, V45, P2250, DOI 10.1021/bi052332s; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104; Dorn GW, 2008, J MOL MED, V86, P1085, DOI 10.1007/s00109-008-0362-y; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Fennell DA, 2008, FRONT BIOSCI-LANDMRK, V13, P6682, DOI 10.2741/3181; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fernandez-Luna JL, 2008, CELL SIGNAL, V20, P1921, DOI 10.1016/j.cellsig.2008.04.015; Fleischer A, 2002, ONCOGENE, V21, P3181, DOI 10.1038/sj.onc.1205464; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Garcia-Saez AJ, 2004, BIOCHEMISTRY-US, V43, P10930, DOI 10.1021/bi036044c; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Haker G, 2007, ARCH BIOCHEM BIOPHYS, V462, P150, DOI 10.1016/j.abb.2006.12.022; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hinds MG, 2005, CURR OPIN STRUC BIOL, V15, P690, DOI 10.1016/j.sbi.2005.10.003; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kammouni W, 2007, ARTHRITIS RHEUM, V56, P2854, DOI 10.1002/art.22853; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karst AM, 2007, CELL MOL LIFE SCI, V64, P318, DOI 10.1007/s00018-006-6364-4; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lama D, 2008, PROTEINS, V73, P492, DOI 10.1002/prot.22075; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Lee JH, 2004, J PATHOL, V202, P439, DOI 10.1002/path.1532; Lee SH, 2003, APMIS, V111, P599, DOI 10.1034/j.1600-0463.2003.1110602.x; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Liu HT, 2006, ARTHRITIS RHEUM-US, V54, P3174, DOI 10.1002/art.22132; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Liu ZH, 2005, MOL CANCER RES, V3, P21; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ma C, 2007, J BIOL CHEM, V282, P30901, DOI 10.1074/jbc.M608694200; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Morales AA, 2004, LEUKEMIA, V18, P41, DOI 10.1038/sj.leu.2403183; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Nakajima K, 2004, EMBO J, V23, P3216, DOI 10.1038/sj.emboj.7600333; Nakamura M, 2005, ACTA NEUROPATHOL, V110, P402, DOI 10.1007/s00401-005-1065-x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Nikrad M, 2005, MOL CANCER THER, V4, P443; O'Brien SM, 2009, BLOOD, V113, P299, DOI 10.1182/blood-2008-02-137943; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Obata T, 2003, CLIN CANCER RES, V9, P6410; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970; Ponassi R, 2008, CELL CYCLE, V7, P3211, DOI 10.4161/cc.7.20.6830; Porzio O, 2007, Hum Mutat, V28, P1150, DOI 10.1002/humu.9511; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Rashmi R, 2008, ONCOGENE, V27, P1366, DOI 10.1038/sj.onc.1210783; Real PJ, 2006, FEBS LETT, V580, P5905, DOI 10.1016/j.febslet.2006.08.088; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; Renshaw SA, 2004, J BIOL CHEM, V279, P2846, DOI 10.1074/jbc.M309769200; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sanz C, 2001, EMBO J, V20, P2286, DOI 10.1093/emboj/20.9.2286; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scatizzi JC, 2006, ARTHRITIS RHEUM, V54, P3182, DOI 10.1002/art.22133; Scatizzi JC, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2204; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schmitz R, 2006, INT J CANCER, V119, P1738, DOI 10.1002/ijc.22010; Schmutte C, 1999, CANCER RES, V59, P4564; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shaw J, 2008, AUTOPHAGY, V4, P427, DOI 10.4161/auto.5901; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Shibue T, 2006, INT J CANCER, V119, P2036, DOI 10.1002/ijc.21751; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Shore Gordon C, 2005, Hematology Am Soc Hematol Educ Program, P226; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Sowter HM, 2001, CANCER RES, V61, P6669; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Subramanian T, 2007, J VIROL, V81, P10486, DOI 10.1128/JVI.00808-07; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tang GZ, 2007, J MED CHEM, V50, P3163, DOI 10.1021/jm070383c; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang Z, 2008, ANTICANCER RES, V28, P1667; Wang ZQ, 2003, J BIOL CHEM, V278, P23861, DOI 10.1074/jbc.M301843200; Weber A, 2007, J CELL BIOL, V177, P625, DOI 10.1083/jcb.200610148; Wick W, 1996, ONCOGENE, V12, P973; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yussman MG, 2002, NAT MED, V8, P725, DOI 10.1038/nm719; Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang H, 1999, FEBS LETT, V448, P23, DOI 10.1016/S0014-5793(99)00335-X; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	226	286	301	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S2	S19		10.1038/onc.2009.39	http://dx.doi.org/10.1038/onc.2009.39			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641503	Green Accepted			2022-12-28	WOS:000268566800001
J	Liu, DP; Song, H; Xu, Y				Liu, D. P.; Song, H.; Xu, Y.			A common gain of function of p53 cancer mutants in inducing genetic instability	ONCOGENE			English	Article						p53; tumorigenesis; gain of function; genetic instability	LI-FRAUMENI-SYNDROME; DNA-DAMAGE; COMPLEX; ATM; SUPPRESSOR; MUTATIONS; REVEALS; GENOME; SITES; MODEL	The critical tumor suppressor p53 is mutated in over half of all human cancers. The majority of p53 cancer mutations are missense mutations, which can be classified into contact mutations that directly disrupt the DNA-binding of p53 but have modest impact on p53 conformation and structural mutations that greatly disrupt p53 conformation. Many p53 cancer mutants, including the hot spot mutations (R175H, R248W and R273H), not only lose p53-dependent tumor-suppressor activities, but also acquire new oncogenic activities to promote cancer. Therefore, it is critical to elucidate the gain of oncogenic function of p53 cancer mutants. Using humanized p53-mutant knock-in mouse models, we have identified a gain of oncogenic function shared by the most common p53 contact mutants (R273H and R248W) and structural mutant (R175H). This gain of function inactivates Mre11/ATM-dependent DNA damage responses, leading to chromosomal translocation and defective G(2)/M checkpoint. Considering the critical roles of ATM in maintaining genetic stability and therapeutic responses to many cancer treatments, the identification of this common gain of function of p53 cancer mutants will have important implication on the drug resistance of a significant portion of human cancers that express either the contact or structural p53 cancer mutants. Oncogene (2010) 29, 949-956; doi:10.1038/onc.2009.376; published online 2 November 2009	[Liu, D. P.; Song, H.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu		Xu, Yang/0000-0001-5574-921X; Song, Hoseok/0000-0001-5723-3057	NIH [R01 CA94254]; DOD Breast Cancer Research Program [W81XWH-08-10381]; NATIONAL CANCER INSTITUTE [R01CA094254] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Program(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr M Hollstein for the HUPKI construct. This work was supported by Grants from the NIH (R01 CA94254) and DOD Breast Cancer Research Program (W81XWH-08-10381) to YX.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hainaut P, 2000, ADV CANCER RES, V77, P81; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lavin MF, 2007, ONCOGENE, V26, P7749, DOI 10.1038/sj.onc.1210880; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Lista F, 1997, CANCER RES, V57, P4408; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Sigal A, 2000, CANCER RES, V60, P6788; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xu Y, 2006, NAT REV IMMUNOL, V6, P261, DOI 10.1038/nri1804	20	139	143	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					949	956		10.1038/onc.2009.376	http://dx.doi.org/10.1038/onc.2009.376			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19881536	Green Accepted, Bronze			2022-12-28	WOS:000274604400002
J	Khodarev, N; Ahmad, R; Rajabi, H; Pitroda, S; Kufe, T; McClary, C; Joshi, MD; MacDermed, D; Weichselbaum, R; Kufe, D				Khodarev, N.; Ahmad, R.; Rajabi, H.; Pitroda, S.; Kufe, T.; McClary, C.; Joshi, M. D.; MacDermed, D.; Weichselbaum, R.; Kufe, D.			Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer	ONCOGENE			English	Article						MUC1; STAT1; breast cancer; IFN gamma; auto-inductive loop; inflammation	CARCINOMA-ASSOCIATED ANTIGEN; BETA-CATENIN; TRANSCRIPTION FACTOR; C-SRC; APOPTOTIC RESPONSE; GENE-TRANSCRIPTION; DNA-DAMAGE; CELLS; ACTIVATION; EXPRESSION	Signal transducer and activator of transcription 1 (STAT1) is activated in the inflammatory response to interferons. The MUC1 oncoprotein is overexpressed in human breast cancers. Analysis of genes differentially expressed in MUC1-transformed cells has identified a network linking MUC1 and STAT1 that is associated with cellular growth and inflammation. The results further show that the MUC1-C subunit associates with STAT1 in cells and the MUC1-C cytoplasmic domain binds directly to the STAT1 DNA-binding domain. The interaction between MUC1-C and STAT1 is inducible by IFN gamma in non-malignant epithelial cells and constitutive in breast cancer cells. Moreover, the MUC1-STAT1 interaction contributes to the activation of STAT1 target genes, including MUC1 itself. Analysis of two independent databases showed that MUC1 and STAT1 are coexpressed in about 15% of primary human breast tumors. Coexpression of MUC1 and the STAT1 pathway was found to be significantly associated with decreased recurrence-free and overall survival. These findings indicate that (i) MUC1 and STAT1 function in an auto-inductive loop, and (ii) activation of both MUC1 and the STAT1 pathway in breast tumors confers a poor prognosis for patients. Oncogene (2010) 29, 920 -929; doi:10.1038/onc.2009.391; published online 16 November 2009	[Ahmad, R.; Rajabi, H.; Kufe, T.; McClary, C.; Joshi, M. D.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Khodarev, N.; Pitroda, S.; MacDermed, D.; Weichselbaum, R.] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute [CA97098, CA111423]; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA111423] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA97098 and CA111423 awarded by the National Cancer Institute.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang L, 2003, CANCER BIOL THER, V2, P702; Khodarev NN, 2007, CANCER RES, V67, P9214, DOI 10.1158/0008-5472.CAN-07-1019; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Khodarev NN, 2003, GENOMICS, V81, P202, DOI 10.1016/S0888-7543(02)00042-3; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Lagow EL, 2002, J CELL BIOCHEM, V86, P759, DOI 10.1002/jcb.10261; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Pitroda SP, 2009, P NATL ACAD SCI USA, V106, P5837, DOI 10.1073/pnas.0812029106; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Raina D, 2009, CANCER RES, V69, P5133, DOI 10.1158/0008-5472.CAN-09-0854; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	46	71	81	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					920	929		10.1038/onc.2009.391	http://dx.doi.org/10.1038/onc.2009.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19915608	Green Accepted			2022-12-28	WOS:000274397800014
J	Bocanegra, M; Bergamaschi, A; Kim, YH; Miller, MA; Rajput, AB; Kao, J; Langerod, A; Han, W; Noh, DY; Jeffrey, SS; Huntsman, DG; Borresen-Dale, AL; Pollack, JR				Bocanegra, M.; Bergamaschi, A.; Kim, Y. H.; Miller, M. A.; Rajput, A. B.; Kao, J.; Langerod, A.; Han, W.; Noh, D-Y; Jeffrey, S. S.; Huntsman, D. G.; Borresen-Dale, A-L; Pollack, J. R.			Focal amplification and oncogene dependency of GAB2 in breast cancer	ONCOGENE			English	Article						GAB2; DNA amplification; genomic profiling; array-based comparative genomic hybridization; breast cancer; oncogene dependency	DOCKING PROTEIN; TRANSFORMATION; PATTERNS	DNA amplifications in breast cancer are frequent on chromosome 11q, in which multiple driver oncogenes likely reside in addition to cyclin D1 (CCND1). One such candidate, the scaffolding adapter protein, GRB2-associated binding protein 2 (GAB2), functions in ErbB signaling and was recently shown to enhance mammary epithelial cell proliferation, and metastasis of ERBB2 (HER2/neu)-driven murine breast cancer. However, the amplification status and function of GAB2 in the context of amplification remain undefined. In this study, by genomic profiling of 172 breast tumors, and fluorescence in situ hybridization validation in an independent set of 210 scorable cases, we observed focal amplification spanning GAB2 (11q14.1) independent of CCND1 (11q13.2) amplification, consistent with a driver role. Further, small interfering RNA (siRNA)-mediated knockdown of GAB2 in breast cancer lines (SUM52, SUM44PE and MDA468) with GAB2 amplification revealed a dependency on GAB2 for cell proliferation, cell-cycle progression, survival and invasion, likely mediated through altered phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling. GAB2 knockdown also reduced proliferation and survival in a cell line (BT474) with ERBB2 amplification, consistent with the possibility that GAB2 can function downstream of ERBB2. Our studies implicate focal amplification of GAB2 in breast carcinogenesis, and underscore an oncogenic role of scaffolding adapter proteins, and a potential new point of therapeutic intervention. Oncogene (2010) 29, 774-779; doi: 10.1038/onc.2009.364; published online 2 November 2009	[Pollack, J. R.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Bergamaschi, A.; Langerod, A.; Borresen-Dale, A-L] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Miller, M. A.; Rajput, A. B.; Huntsman, D. G.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Han, W.; Noh, D-Y] Seoul Natl Univ, Coll Med, Dept Surg, Seoul, South Korea; [Jeffrey, S. S.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA; [Borresen-Dale, A-L] Univ Oslo, Fac Div, Norwegian Radium Hosp, Fac Med, Oslo, Norway	Stanford University; University of Oslo; University of British Columbia; British Columbia Cancer Agency; Seoul National University (SNU); Seoul National University (SNU); Stanford University; University of Oslo	Pollack, JR (corresponding author), Stanford Univ, Dept Pathol, Sch Med, CCSR-3245A,269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Huntsman, David/ABE-6082-2020; Han, Wonshik/B-3699-2008; Noh, Dong-Young/G-5531-2011; Bergamaschi, Anna/D-2022-2009	Han, Wonshik/0000-0001-7310-0764; Bergamaschi, Anna/0000-0001-8709-1766; Jeffrey, Stefanie/0000-0003-4478-2764	National Institutes of Health [CA97139, CA09302, CA130172]; Department of Defense Breast Cancer Research Program [BC073467]; California Breast Cancer Research Program [8KB-0135, 11IB-0175]; Norwegian Research Council, NFR [155218/300]; Korea Health 21 R&D Project, Ministry of Health Welfare ROK [01-PJ3-PG601GN07-0004]; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE [F31CA130172, R01CA097139, T32CA009302] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); California Breast Cancer Research Program; Norwegian Research Council, NFR(Research Council of Norway); Korea Health 21 R&D Project, Ministry of Health Welfare ROK; Sanofi-aventis, Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Stanford Functional Genomics Facility for microarray manufacture, the Stanford Microarray Database for database support and members of the Pollack lab for helpful discussion. This work was supported in part by grants from the National Institutes of Health, CA97139 (JRP), CA09302 and CA130172 (MB); the Department of Defense Breast Cancer Research Program, BC073467 (MB); the California Breast Cancer Research Program, 8KB-0135 (JRP) and 11IB-0175 (SSJ); the Norwegian Research Council, NFR, 155218/300 (ALBD); and the Korea Health 21 R&D Project, Ministry of Health & Welfare ROK, 01-PJ3-PG601GN07-0004 (WH and D-YN). AB was during this work a fellow of The Norwegian Cancer Society. DGH is a Michael Smith Foundation for Health Research Scholar. Funding for the thermomechanical analysis was provided in part by an unrestricted educational grant from Sanofi-aventis, Canada.	Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bergamaschi A, 2008, MOL ONCOL, V2, P327, DOI 10.1016/j.molonc.2008.09.004; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; Jemal A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1672; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Sarmay G, 2006, IMMUNOL LETT, V104, P76, DOI 10.1016/j.imlet.2005.11.017; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tibshirani R, 2008, BIOSTATISTICS, V9, P18, DOI 10.1093/biostatistics/kxm013	19	55	61	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					774	779		10.1038/onc.2009.364	http://dx.doi.org/10.1038/onc.2009.364			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19881546				2022-12-28	WOS:000274223700013
J	Liu, X; Wang, X; Zhang, J; Lam, EKY; Shin, VY; Cheng, ASL; Yu, J; Chan, FKL; Sung, JJY; Jin, HC				Liu, X.; Wang, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Yu, J.; Chan, F. K. L.; Sung, J. J. Y.; Jin, H. C.			Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis	ONCOGENE			English	Article						methylation; gastric cancer; glucose metabolism; ras	NF-KAPPA-B; PYRUVATE-KINASE; GLUCOSE-METABOLISM; II HEXOKINASE; CANCER; RAS; P53; TRANSFORMATION; TRANSCRIPTION; REPRESSION	In cancer cells, glucose is often converted into lactic acid, which is known as the 'Warburg effect'. The reason that cancer cells have a higher rate of aerobic glycolysis, but not oxidative phosphorylation, remains largely unclear. Herein, we proposed an epigenetic mechanism of the Warburg effect. Fructose-1,6-bisphosphatase-1 (FBP1), which functions to antagonize glycolysis was downregulated through NF-kappaB pathway in Ras-transformed NIH3T3 cells. Restoration of FBP1 expression suppressed anchorage-independent growth, indicating the relevance of FBP1 downregulation in carcinogenesis. Indeed, FBP1 was downregulated in gastric carcinomas (P < 0.01, n = 22) and gastric cancer cell lines (57%, 4/7). Restoration of FBP1 expression reduced growth and glycolysis in gastric cancer cells. Moreover, FBP1 downregulation was reversed by pharmacological demethylation. Its promoter was hypermethylated in gastric cancer cell lines (57%, 4/7) and gastric carcinomas (33%, 33/101). Inhibition of NF-kappaB restored FBP1 expression, partially through demethylation of FBP1 promoter. Notably, Cox regression analysis revealed FBP1 promoter methylation as an independent prognosis predicator for gastric cancer (hazard ratio: 3.60, P = 0.010). In summary, we found that NF-kappaB functions downstream of Ras to promote epigenetic downregulation of FBP1. Promoter methylation of FBP1 can be used as a new biomarker for prognosis prediction of gastric cancer. Such an important epigenetic link between glycolysis and carcinogenesis partly explains the Warburg effect. Oncogene (2010) 29, 442-450; doi:10.1038/onc.2009.332; published online 2 November 2009	[Jin, H. C.] Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Liu, X.; Zhang, J.; Lam, E. K. Y.; Shin, V. Y.; Cheng, A. S. L.; Jin, H. C.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, J.; Chan, F. K. L.; Sung, J. J. Y.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Zhejiang Univ, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Zhejiang University	Jin, HC (corresponding author), Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Runrun Shaw Hosp,Dept Med Oncol, Hangzhou 310003, Zhejiang, Peoples R China.	jinhc@srrsh.com	Cheng, Alfred SL/C-3327-2014; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Jin, Hongchuan/C-3686-2009; Chan, Francis K. L./F-4851-2010	Cheng, Alfred SL/0000-0003-2345-6951; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Chan, Francis K. L./0000-0001-7388-2436; Shin, Vivian Yvonne/0000-0003-1282-7593; Jin, Hongchuan/0000-0002-6697-3097; Wang, Xian/0000-0003-0041-7589	RGC-GRF [465808]; Institute of Digestive Disease, the Chinese University of Hong Kong	RGC-GRF(Hong Kong Research Grants Council); Institute of Digestive Disease, the Chinese University of Hong Kong(Chinese University of Hong Kong)	The project was supported by RGC-GRF ( Project No. 465808) granted to HJ, and Research Funding from the Institute of Digestive Disease, the Chinese University of Hong Kong.	Aarenstrup L, 2008, J INVEST DERMATOL, V128, P1095, DOI 10.1038/sj.jid.5701146; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhat KP, 2008, FEBS LETT, V582, P3193, DOI 10.1016/j.febslet.2008.08.010; Cheng YY, 2008, BRIT J CANCER, V99, P2083, DOI 10.1038/sj.bjc.6604760; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Garber K, 2004, J NATL CANCER I, V96, P1805, DOI 10.1093/jnci/96.24.1805; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kondoh H, 2005, CANCER RES, V65, P177; KOSHIBA M, 1993, JPN J CANCER RES, V84, P163, DOI 10.1111/j.1349-7006.1993.tb02850.x; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Peng SY, 2008, ONCOL REP, V19, P1045; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; TANNOCK IF, 1968, BRIT J CANCER, V22, P258, DOI 10.1038/bjc.1968.34; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang LJ, 2009, BIOCHEM BIOPH RES CO, V379, P959, DOI 10.1016/j.bbrc.2008.12.180; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309	36	150	162	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					442	450		10.1038/onc.2009.332	http://dx.doi.org/10.1038/onc.2009.332			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19881551				2022-12-28	WOS:000273793200013
J	Sowalsky, AG; Alt-Holland, A; Shamis, Y; Garlick, JA; Feig, LA				Sowalsky, A. G.; Alt-Holland, A.; Shamis, Y.; Garlick, J. A.; Feig, L. A.			RalA suppresses early stages of Ras-induced squamous cell carcinoma progression	ONCOGENE			English	Article						Ral; Ras; squamous cell carcinoma; E-cadherin; tumor progression	EXOCYST COMPLEX; CANCER; GTPASES; RAIA; SKIN; ACTIVATION; EXPRESSION; GROWTH; IDENTIFICATION; PROLIFERATION	Ras proteins activate Raf and PI-3 kinases, as well as exchange factors for RalA and RalB GTPases. Many previous studies have reported that the Ral-signaling cascade contributes positively to Ras-mediated oncogenesis. Here, using a bioengineered tissue model of early steps in Ras-induced human squamous cell carcinoma of the skin, we found the opposite. Conversion of Ras-expressing keratinocytes from a premalignant to malignant state induced by decreasing E-cadherin function was associated with and required an approximately two to threefold decrease in RalA expression. Moreover, direct knockdown of RalA to a similar degree by shRNA expression in these cells reduced E-cadherin levels and also induced progression to a malignant phenotype. Knockdown of the Ral effector, Exo84, mimicked the effects of decreasing RalA levels in these engineered tissues. These phenomena can be explained by our finding that the stability of E-cadherin in Ras-expressing keratinocytes depends upon this RalA signaling cascade. These results imply that an important component of the early stages in squamous carcinoma progression may be a modest decrease in RalA gene expression that magnifies the effects of decreased E-cadherin expression by promoting its degradation.	[Sowalsky, A. G.; Feig, L. A.] Tufts Univ, Dept Biochem, Sch Med, Boston, MA 02111 USA; [Sowalsky, A. G.; Shamis, Y.; Feig, L. A.] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Boston, MA 02111 USA; [Alt-Holland, A.] Tufts Univ, Dept Endodont, Sch Dent Med, Boston, MA 02111 USA; [Garlick, J. A.] Tufts Univ, Dept Oral & Maxillofacial Pathol, Sch Dent Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Tufts University	Feig, LA (corresponding author), Tufts Univ, Dept Biochem, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.	larry.feig@tufts.edu	Sowalsky, Adam/K-1485-2013	Sowalsky, Adam/0000-0003-2760-1853	NIGMS; NIDCR; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047717, R56GM047717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH083324] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank MW Carlson, Y Szwec-Levin, S Ezell, T DesRochers and S Dong for excellent technical assistance. This work was supported by grants to LAF from NIGMS and to JAG from NIDCR. We thank N Fusenig for HaCaT cells and their derivatives and F Watt for the H-2K<SUP>d</SUP>-Ecad vectors.	BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Carlson Mark W, 2008, Curr Protoc Cell Biol, VChapter 19, DOI 10.1002/0471143030.cb1909s41; Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166; Chen XW, 2006, J BIOL CHEM, V281, P38609, DOI 10.1074/jbc.M512847200; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dlugosz A, 2002, J INVEST DERM SYMP P, V7, P17, DOI 10.1046/j.1523-1747.2002.19631.x; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; FENWICK R, 2009, BIOCHEMISTRY; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Garlick JA, 2007, ADV BIOCHEM ENG BIOT, V103, P207; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Greenberg S, 2004, METH MOL B, V289, P425; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hao YS, 2008, MOL CELL BIOL, V28, P2851, DOI 10.1128/MCB.01917-07; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kudo Y, 2003, ORAL ONCOL, V39, P515, DOI 10.1016/S1368-8375(03)00015-0; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Margulis A, 2004, METH MOL B, V289, P61; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Panner A, 2006, MOL CELL BIOL, V26, P7345, DOI 10.1128/MCB.00126-06; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Pons M, 2006, Clin Transl Oncol, V8, P466, DOI 10.1007/s12094-006-0046-4; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Singhal SS, 2005, BIOCHEM PHARMACOL, V70, P481, DOI 10.1016/j.bcp.2005.05.005; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Sugita S, 2008, ACTA PHYSIOL, V192, P185, DOI 10.1111/j.1748-1716.2007.01803.x; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Zhu AJ, 1996, J CELL SCI, V109, P3013	47	16	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					45	55		10.1038/onc.2009.307	http://dx.doi.org/10.1038/onc.2009.307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802010	Green Accepted			2022-12-28	WOS:000273373500005
J	Ashley, N; Poulton, J				Ashley, N.; Poulton, J.			Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling	ONCOGENE			English	Article						anthracyclines; mtDNA; mitochondria; nucleoids; doxorubicin; mitofusin	HUMAN-CELLS; DOXORUBICIN; P53; ADRIAMYCIN; MUTATIONS; DEPLETION; FUSION; DRUGS; OPA1; CARDIOMYOPATHY	Many anticancer drugs, such as doxorubicin (DXR), intercalate into nuclear DNA of cancer cells, thereby inhibiting their growth. However, it is not well understood how such drugs interact with mitochondrial DNA (mtDNA). Using cell and molecular studies of cultured cells, we show that DXR and other DNA intercalators, such as ethidium bromide, can rapidly intercalate into mtDNA within living cells, causing aggregation of mtDNA nucleoids and altering the distribution of nucleoid proteins. Remodelled nucleoids excluded DXR and maintained mtDNA synthesis, whereas non-remodelled nucleoids became heavily intercalated with DXR, which inhibited their replication, thus leading to mtDNA depletion. Remodelling was accompanied by extensive mitochondrial elongation or interconnection, and was suppressed in cells lacking mitofusin 1 and optic atrophy 1 (OPA1), the key proteins for mitochondrial fusion. In contrast, remodelling was significantly increased by p53 or ataxia telangiectasia mutated inhibition (ATM), indicating a link between nucleoid dynamics and the genomic DNA damage response. Collectively, our results show that DNA intercalators can trigger a common mitochondrial response, which likely contributes to the marked clinical toxicity associated with these drugs. Oncogene (2009) 28, 3880-3891; doi:10.1038/onc.2009.242; published online 17 August 2009	[Ashley, N.; Poulton, J.] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England	University of Oxford	Ashley, N (corresponding author), Univ Oxford, Nuffield Dept Obstet & Gynaecol, Womens Ctr, John Radcliffe Hosp, Level 3, Oxford OX3 9DU, England.	Neil.Ashley@clin-pharm.ox.ac.uk; Joanna.Poulton@obs-gyn.ox.ac.uk	Poulton, Joanna/AAB-4828-2021	Poulton, Joanna/0000-0002-2460-5587; Ashley, Neil/0000-0002-1655-5137	MRC/Wellcome Trust; MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695] Funding Source: researchfish	MRC/Wellcome Trust(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank I Sargent for providing the equipment; E Brampton, M Zeviani, I Holt, B Roques, A Trifunovic, P Cook and D Chan for materials; and K Morten and F Brook for technical support. This work was funded by the MRC/Wellcome Trust.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013; Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150; Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090; Ashley N, 2009, BIOCHEM BIOPH RES CO, V378, P450, DOI 10.1016/j.bbrc.2008.11.059; Bakhanashvili M, 2008, CELL DEATH DIFFER, V15, P1865, DOI 10.1038/cdd.2008.122; Bakhanashvili M, 2009, AIDS, V23, P779, DOI 10.1097/QAD.0b013e328329c74e; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen XJ, 2005, SCIENCE, V307, P714, DOI 10.1126/science.1106391; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; Conklin Kenneth A, 2005, Integr Cancer Ther, V4, P110, DOI 10.1177/1534735405276191; Cullinane C, 2000, NUCLEIC ACIDS RES, V28, P1019, DOI 10.1093/nar/28.4.1019; ELLIS CN, 1987, BIOCHEM J, V245, P309, DOI 10.1042/bj2450309; Emmerson CF, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.2.e1; FELIX CA, 1992, CANCER RES, V52, P2243; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; Griparic L, 2007, J CELL BIOL, V178, P757, DOI 10.1083/jcb.200704112; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158; HIXON SC, 1981, J MOL CELL CARDIOL, V13, P855, DOI 10.1016/0022-2828(81)90242-X; Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kucej M, 2008, J CELL SCI, V121, P1861, DOI 10.1242/jcs.028605; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lebrecht D, 2005, J PATHOL, V207, P436, DOI 10.1002/path.1863; Lebrecht D, 2004, NEPHROL DIAL TRANSPL, V19, P329, DOI 10.1093/ndt/gfg564; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; McKenzie PP, 2002, MOL CANCER THER, V1, P1097; Nithipongvanitch R, 2007, J HISTOCHEM CYTOCHEM, V55, P629, DOI 10.1369/jhc.6A7146.2007; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; STEINHERZ L, 1991, Pediatrician, V18, P49; Suliman HB, 2007, J CLIN INVEST, V117, P3730, DOI 10.1172/JCI32967; Tokarska-Schlattner M, 2006, CR BIOL, V329, P657, DOI 10.1016/j.crvi.2005.08.007; Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; von Wurmb-Schwark N, 2006, MUTAT RES-FUND MOL M, V596, P57, DOI 10.1016/j.mrfmmm.2005.12.003; Wallace KB, 2003, PHARMACOL TOXICOL, V93, P105, DOI 10.1034/j.1600-0773.2003.930301.x; Zhou SY, 2001, TOXICOL LETT, V121, P151, DOI 10.1016/S0378-4274(01)00329-0	45	42	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3880	3891		10.1038/onc.2009.242	http://dx.doi.org/10.1038/onc.2009.242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19684617	Green Accepted			2022-12-28	WOS:000271471900003
J	Harris, CR; DeWan, A; Zupnick, A; Normart, R; Gabriel, A; Prives, C; Levine, AJ; Hoh, J				Harris, C. R.; DeWan, A.; Zupnick, A.; Normart, R.; Gabriel, A.; Prives, C.; Levine, A. J.; Hoh, J.			p53 responsive elements in human retrotransposons	ONCOGENE			English	Article						p53; LINE-1; genome stability	SUPPRESSOR PROTEIN P53; DNA-BINDING; GENE-EXPRESSION; L1 RETROTRANSPOSITION; ACTIVATION; CELLS; APOPTOSIS; LINE-1; IDENTIFICATION; METHYLATION	Long interspersed nuclear elements-1 (L1s) are highly repetitive DNA elements that are capable of altering the human genome through retrotransposition. To protect against L1 retroposition, the cell downregulates the expression of L1 proteins by various mechanisms, including high-density cytosine methylation of L1 promoters and DICER-dependent destruction of L1 mRNAs. In this report, a large number of p53 responsive elements, or p53 DNA binding sites, were detected in L1 elements within the human genome. At least some of these p53 responsive elements are functional and can act to increase the levels of L1 mRNA expression. The p53 protein can directly bind to a short 15-nucleotide sequence within the L1 promoter. This p53 responsive element within L1 is a recent addition to evolution, appearing B20 million years ago. This suggests an interplay between L1 elements, which have a rich history of causing changes in the genome, and the p53 protein, the function of which is to protect against genomic changes. To understand these observations, a model is proposed in which the increased expression of L1 mRNAs by p53 actually increases, rather than decreases, the genomic stability through amplification of p53-dependent processes for genomic protection. Oncogene (2009) 28, 3857 -3865; doi:10.1038/onc.2009.246; published online 31 August 2009	[Harris, C. R.; Normart, R.] Raymond & Beverly Sackler Fdn, New Brunswick, NJ USA; [Harris, C. R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA; [Harris, C. R.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08903 USA; [DeWan, A.; Hoh, J.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Zupnick, A.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; [Gabriel, A.] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA; [Levine, A. J.] Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University; Columbia University; Rutgers State University New Brunswick; Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu		DeWan, Andrew/0000-0002-7679-8704	Verto Institute; NIH [K25HG00060, R01EY015771, R01MH44292, P01CA87497]; NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY015771] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K25HG000060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044292] Funding Source: NIH RePORTER	Verto Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was primarily supported by the Verto Institute, with additional support provided by NIH Grant nos K25HG00060, R01EY015771, R01MH44292 and P01CA87497.	Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Donehower LA, 2005, EXP GERONTOL, V40, P7, DOI 10.1016/j.exger.2004.10.007; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Haoudi A, 2004, J BIOMED BIOTECHNOL, P185, DOI 10.1155/S1110724304403131; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu WW, 2007, NATURE, V450, P721, DOI 10.1038/nature05993; Jin SK, 2001, J CELL SCI, V114, P4139; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; Jurka J, 2000, TRENDS GENET, V16, P418, DOI 10.1016/S0168-9525(00)02093-X; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan H, 2006, GENOME RES, V16, P78, DOI 10.1101/gr.4001406; Kwon HS, 2006, BBA-GENE STRUCT EXPR, V1759, P141, DOI 10.1016/j.bbaexp.2006.04.005; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LANE DP, 1992, NATURE, V358, P16; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Ostertag EM, 2002, NAT GENET, V32, P655, DOI 10.1038/ng1022; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Tchenio T, 2000, NUCLEIC ACIDS RES, V28, P411, DOI 10.1093/nar/28.2.411; Wang T, 2007, P NATL ACAD SCI USA, V104, P18613, DOI 10.1073/pnas.0703637104; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Zhao RB, 2000, GENE DEV, V14, P981	39	68	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3857	3865		10.1038/onc.2009.246	http://dx.doi.org/10.1038/onc.2009.246			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718052	Green Accepted			2022-12-28	WOS:000271471900001
J	Sher, YP; Tzeng, TF; Kan, SF; Hsu, J; Xie, X; Han, Z; Lin, WC; Li, LY; Hung, MC				Sher, Y-P; Tzeng, T-F; Kan, S-F; Hsu, J.; Xie, X.; Han, Z.; Lin, W-C; Li, L-Y; Hung, M-C			Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival	ONCOGENE			English	Article						targeted gene therapy; lung cancer; BiKDD; VISA; survivin	CELL-DIVISION; EXPRESSION; APOPTOSIS; PROMOTER; CARCINOMA; PULMONARY; MODELS; TUMORS	Lung cancer is a leading cause of cancer death due to the high incidence of metastasis; therefore, novel and effective treatments are urgently needed. A current strategy is cancer-specific targeted gene therapy. Although many identified that cancer-specific promoters are highly specific, they tend to have low activity compared with the ubiquitous cytomegalovirus (CMV) promoter, limiting their application. We developed a targeted gene therapy expression system for lung cancer that is highly specific with strong activity. Our expression vector uses the survivin promoter, highly expressed in many cancers but not normal adult tissues. We enhanced the survivin promoter activity comparable to the CMV promoter in lung cancer cell lines using an established platform technology, whereas the survivin promoter remained weak in normal cells. In mouse models, the transgene was specifically expressed in the lung tumor tissue, compared with the CMV promoter that was expressed in both normal and tumor tissues. In addition, the therapeutic gene BikDD, a mutant form of pro-apoptotic Bcl2 interacting killer, induced cell killing in vitro, and inhibited cell growth and prolonged mouse survival in vivo. Importantly, there was virtually no toxicity when BikDD was expressed with our expression system. Thus, the current report provides a therapeutic efficacy and safe strategy worthy of development in clinical trials treating lung cancer. Oncogene (2009) 28, 3286-3295; doi:10.1038/onc.2009.187; published online 13 July 2009	[Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 079, Houston, TX 77030 USA; [Sher, Y-P; Tzeng, T-F; Kan, S-F; Li, L-Y; Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Sher, Y-P; Tzeng, T-F; Kan, S-F; Li, L-Y; Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Lin, W-C] China Med Univ, Dept Pharmacol, Sch Med, Taichung, Taiwan; [Li, L-Y; Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 079, 1515 Holcombe Blvd, Houston, TX 77030 USA.	lyl@mail.cmu.edu.tw; mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Sher, Yuh-Pyng/0000-0002-6062-7556; Li, Long-Yuan/0000-0001-7472-8318	NRPGM [DOH97-TD-G-111-041]; MDACC SPORE [P20 CA101936, 1P50 CA116199, DOH97-TD-111-TM003]; National Health Research Institutes, Taiwan [PD9602]; NATIONAL CANCER INSTITUTE [R01CA109311, P50CA116199, P01CA099031, P20CA101936] Funding Source: NIH RePORTER	NRPGM; MDACC SPORE; National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from NRPGM in DOH97-TD-G-111-041 and MDACC SPORE grants in pancreatic (P20 CA101936) and breast (1P50 CA116199) cancer ( to M-C Hung) and DOH97-TD-111-TM003 ( to L-Y Li). YP Sher was also supported by a postdoctoral fellowship award from the National Health Research Institutes, Taiwan (PD9602). In memory of Mr Nan-Tu Huang, the late Chairman of Wei-Chuan Group in Taiwan for his courageous battle in lung cancer.	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; Day CP, 2006, CANCER GENE THER, V13, P706, DOI 10.1038/sj.cgt.7700945; Fitzsimons HL, 2002, METHODS, V28, P227, DOI 10.1016/S1046-2023(02)00227-X; Fukazawa T, 2007, MOL CANCER THER, V6, P244, DOI 10.1158/1535-7163.MCT-06-0408; Gunther Michael, 2005, Curr Med Chem Anticancer Agents, V5, P157, DOI 10.2174/1568011053174855; Hay RJ, 1996, J CELL BIOCHEM, P107; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang L., 2005, NONVIRAL VECTORS G 1; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li YM, 2003, CANCER RES, V63, P7630; MCLEMORE TL, 1988, CANCER RES, V48, P2880; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Oshikiri T, 2006, CANCER GENE THER, V13, P856, DOI 10.1038/sj.cgt.7700953; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Retzer-Lidl M, 2007, INT J CANCER, V121, P66, DOI 10.1002/ijc.22619; Russ V, 2007, PHARM RES-DORDR, V24, P1047, DOI 10.1007/s11095-006-9233-9; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x	25	36	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3286	3295		10.1038/onc.2009.187	http://dx.doi.org/10.1038/onc.2009.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597463	Green Accepted			2022-12-28	WOS:000269893700003
J	Guha, M; Xia, F; Raskett, CM; Altieri, DC				Guha, M.; Xia, F.; Raskett, C. M.; Altieri, D. C.			Caspase 2-mediated tumor suppression involves survivin gene silencing	ONCOGENE			English	Article						caspase-2; survivin; NF kappa B; RIP1; tumor growth; gene expression	NF-KAPPA-B; WILD-TYPE P53; INDUCED APOPTOSIS; DRUG DISCOVERY; MELANOMA-CELLS; ACTIVATION; CANCER; PATHWAY; PHOSPHORYLATION; EXPRESSION	One of the pivotal functions of endogenous tumor suppression is to oppose aberrant cell survival, but the molecular requirements of this process are not completely understood. Here, we show that caspase 2, a death effector with largely unknown functions, represses transcription of the survivin gene, a general regulator of cell division and cytoprotection in tumors. This pathway involves caspase 2 proteolytic cleavage of the nuclear factor kappa B (NF kappa B) activator, RIP1. In turn, loss of RIP1 abolishes transcription of NF kappa B target genes, including survivin, resulting in deregulated mitotic transitions, enhanced apoptosis and suppression of tumorigenicity in vivo. Therefore, caspase 2 functions as an endogenous inhibitor of NF kappa B-dependent cell survival and this mechanism may contribute to tumor suppression in humans. Oncogene (2010) 29, 1280-1292; doi: 10.1038/onc.2009.428; published online 23 November 2009	[Guha, M.; Xia, F.; Raskett, C. M.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01609 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01609 USA.	dario.altieri@umassmed.edu			National Institutes of Health [CA78810, CA90917, CA118005]; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810, R01CA118005] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Bert Vogelstein, Michelle Kelliher and Neal Silverman for reagents. This work was supported by the National Institutes of Health grants CA78810, CA90917 and CA118005.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Anand P, 2008, CANCER RES, V68, P8861, DOI 10.1158/0008-5472.CAN-08-1902; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Ghosh JC, 2008, J BIOL CHEM, V283, P5188, DOI 10.1074/jbc.M705904200; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Kang BH, 2006, J BIOL CHEM, V281, P24721, DOI 10.1074/jbc.M603175200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; Lamkanfi M, 2005, J BIOL CHEM, V280, P6923, DOI 10.1074/jbc.M411180200; Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Makishi S, 2008, BRIT J HAEMATOL, V142, P583, DOI 10.1111/j.1365-2141.2008.07229.x; Mhaidat NM, 2007, MOL CANCER THER, V6, P752, DOI 10.1158/1535-7163.MCT-06-0564; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Shi MG, 2009, CELL, V136, P508, DOI 10.1016/j.cell.2008.12.021; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Soung YH, 2004, HUM GENET, V115, P112, DOI 10.1007/s00439-004-1129-3; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Upton JP, 2008, MOL CELL BIOL, V28, P3943, DOI 10.1128/MCB.00013-08; Vaira V, 2007, ONCOGENE, V26, P2678, DOI 10.1038/sj.onc.1210094; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wheatley SP, 2007, CELL CYCLE, V6, P1220, DOI 10.4161/cc.6.10.4179; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Zhou JB, 2009, BLOOD, V113, P4052, DOI 10.1182/blood-2008-05-156422	57	25	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1280	1292		10.1038/onc.2009.428	http://dx.doi.org/10.1038/onc.2009.428			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19935698	Green Accepted			2022-12-28	WOS:000275170600004
J	Bourke, E; Brown, JAL; Takeda, S; Hochegger, H; Morrison, CG				Bourke, E.; Brown, J. A. L.; Takeda, S.; Hochegger, H.; Morrison, C. G.			DNA damage induces Chk1-dependent threonine-160 phosphorylation and activation of Cdk2	ONCOGENE			English	Article						centrosome; DNA damage response; Chk1; Cdk2; Cdk1	INDUCED CENTROSOME OVERDUPLICATION; CYCLIN-E OVEREXPRESSION; CELL-CYCLE; CHROMOSOME INSTABILITY; TUMOR-CELLS; AMPLIFICATION; PHASE; DUPLICATION; CHECKPOINT; CDC25A	Abnormal centrosome numbers arise in tumours and can cause multipolar mitoses and genome instability. Cdk2 controls normal centrosome duplication, but Chk1-dependent centrosome amplification also occurs after DNA damage. We investigated the involvement of cyclin-dependent kinases (Cdks) in DNA damage-induced centrosome amplification using cells lacking either Cdk2, or both Cdk1 and Cdk2 activity. Cdk2(-/-) DT40 cells showed robust centrosome amplification after ionizing radiation (IR), whereas Cdk1-deficient Cdk2(-/-) cells showed no centrosome amplification, demonstrating that Cdk1 can substitute for Cdk2 in this pathway. Surprisingly, we found that Cdk2 activity was upregulated by IR in wild-type but not in Chk1(-/-) DT40 cells. Cdk2 upregulation also occurred in HeLa cells after IR treatment. Chk1-dependent Cdk2 induction was not accompanied by increased levels of Cdk1, Cdk2, cyclin A or cyclin E, but activating T160 phosphorylation of Cdk2 increased after IR. Moreover, Cdk2 overexpression restored IR-induced centrosome amplification in Cdk1-deficient Cdk2(-/-) cells, but T160A mutation blocked this rescue. Our data suggest that Chk1 signalling causes centrosome amplification after IR by upregulating Cdk2 activity through activating phosphorylation. Oncogene (2010) 29, 616-624; doi: 10.1038/onc.2009.340; published online 19 October 2009	[Bourke, E.; Brown, J. A. L.; Morrison, C. G.] Natl Univ Ireland Galway, Ctr Chromosome Biol, Sch Nat Sci, Galway, Ireland; [Takeda, S.] Kyoto Univ, Sch Med, Dept Radiat Genet, Kyoto 606, Japan; [Hochegger, H.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England	Ollscoil na Gaillimhe-University of Galway; Kyoto University; University of Sussex	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Ctr Chromosome Biol, Sch Nat Sci, Univ Rd, Galway, Ireland.	ciaran.morrison@nuigalway.ie	Morrison, Ciaran/B-6568-2008; Brown, James/H-3437-2019; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Brown, James/0000-0002-3155-0334; Morrison, Ciaran/0000-0003-2401-7029; Hochegger, Helfrid/0000-0001-8366-6198; Takeda, Shunichi/0000-0002-7924-7991; Bourke, Emer/0000-0002-2218-3114	Science Foundation Ireland [08/IN.1/B1029]; Health Research Board [RP/2006/36]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board	This work was supported by Science Foundation Ireland Principal Investigator award 08/IN.1/B1029 and by Health Research Board project grant RP/2006/36. We thank Helen Dodson for helping us with the initial Cdk kinase assays and Corrado Santocanale for critical reading of the paper.	Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Balczon R, 2001, CHROMOSOMA, V110, P381, DOI 10.1007/s004120100157; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bettencourt-Dias M, 2007, NAT REV MOL CELL BIO, V8, P451, DOI 10.1038/nrm2180; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Dodson H, 2007, CELL CYCLE, V6, P364, DOI 10.4161/cc.6.3.3834; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Saladino C, 2009, ENVIRON MOL MUTAGEN, V50, P725, DOI 10.1002/em.20477; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Shreeram S, 2008, MOL CELL BIOL, V28, P7442, DOI 10.1128/MCB.00138-08; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Uto K, 2004, EMBO J, V23, P3386, DOI 10.1038/sj.emboj.7600328; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	47	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					616	624		10.1038/onc.2009.340	http://dx.doi.org/10.1038/onc.2009.340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19838212				2022-12-28	WOS:000274084600014
J	Hassan, S; Biswas, MHU; Zhang, C; Du, C; Balaji, KC				Hassan, S.; Biswas, M. H. U.; Zhang, C.; Du, C.; Balaji, K. C.			Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells	ONCOGENE			English	Article						PKD1; Hsp27; AR; p38; prostate cancer	BETA-CATENIN; MAPKAP KINASE-2; SERINE-82 PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; E-CADHERIN; C-MU; HSP27; NEUROTENSIN; ACTIVATION; GROWTH	We have previously shown that protein kinase D1 (PKD1), charter member of PKD protein family, is downregulated in advanced prostate cancer ( PC) and influences androgen receptor (AR) function in PC cells. Other independent studies showed that serine 82 residue in heat shock protein 27 (Hsp27) undergoes substrate phosphorylation by PKD1 and is associated with nuclear transport of AR resulting in increased AR transcriptional activity. In this study, we show that PKD1 interacts and phosphorylates Hsp27 at Ser82 in PC cells, which is mediated by p38-dependent mitogen-activated protein kinase pathway and is necessary for PKD1 repression of AR transcriptional activity and androgen-dependent proliferation of PC cells. The study provides first in vivo evidence that Hsp27 is a mediator of repression of AR function by PKD1 in PC cells, thereby linking the data in the published literature. Oncogene (2009) 28, 4386-4396; doi: 10.1038/onc.2009.291; published online 21 September 2009	[Hassan, S.; Biswas, M. H. U.; Zhang, C.; Du, C.; Balaji, K. C.] Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Balaji, KC (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Div Urol, 55 Lake Ave N,Room S4-868, Worcester, MA 01655 USA.	Balajik@ummhc.org	Du, Cheng/F-1569-2013	Du, Cheng/0000-0002-8882-2513	Department of Surgery, University of Massachusetts Medical School	Department of Surgery, University of Massachusetts Medical School	We thank Dr FJ Johannes, Fraunhofer Institute for Interfacial Engineering, Stuttgart, Germany for providing the PKD1 expression vector. This study was supported by an institutional grant from the Department of Surgery, University of Massachusetts Medical School.	BELKA C, 1995, LEUKEMIA, V9, P288; CARRAWAY R, 1976, J BIOL CHEM, V251, P7045; Carraway RE, 2007, REGUL PEPTIDES, V141, P140, DOI 10.1016/j.regpep.2006.12.027; Cornford PA, 2000, CANCER RES, V60, P7099; Doppler H, 2005, J BIOL CHEM, V280, P15013, DOI 10.1074/jbc.C400575200; Du C, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-28; Du C, 2009, CANCER RES, V69, P1117, DOI 10.1158/0008-5472.CAN-07-6270; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Edwards J, 2005, BJU INT, V95, P1327, DOI 10.1111/j.1464-410X.2005.05527.x; Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002; Fanelli MA, 2008, CELL STRESS CHAPERON, V13, P207, DOI 10.1007/s12192-007-0007-z; Geum D, 2002, J BIOL CHEM, V277, P19913, DOI 10.1074/jbc.M104396200; Gomase VS, 2008, CURR DRUG METAB, V9, P255, DOI 10.2174/138920008783884803; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; Jaggi M, 2005, CANCER RES, V65, P483; Jaggi M, 2003, BIOCHEM BIOPH RES CO, V307, P254, DOI 10.1016/S0006-291X(03)01161-6; Jaggi M, 2008, MOL CANCER THER, V7, P2703, DOI 10.1158/1535-7163.MCT-08-0119; Jaggi M, 2007, FRONT BIOSCI-LANDMRK, V12, P3757, DOI 10.2741/2349; Ku GY, 2008, CANCER CHEMOTH PHARM, V62, P875, DOI 10.1007/s00280-008-0677-y; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li J, 2008, J BIOL CHEM, V283, P2614, DOI 10.1074/jbc.M707513200; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Mak P, 2008, BIOCHEM BIOPH RES CO, V373, P618, DOI 10.1016/j.bbrc.2008.06.097; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martinez V, 2000, PEPTIDES, V21, P1617, DOI 10.1016/S0196-9781(00)00293-X; Moody TW, 2003, CURR PHARM DESIGN, V9, P495, DOI 10.2174/1381612033391621; Mosca A, 2005, J Endocrinol Invest, V28, P141; Neckers L, 2003, CURR MED CHEM, V10, P733, DOI 10.2174/0929867033457818; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Roberts JD, 2006, CLIN CANCER RES, V12, P5809, DOI 10.1158/1078-0432.CCR-05-2730; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rybin VO, 2009, J BIOL CHEM, V284, P2332, DOI 10.1074/jbc.M806381200; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; So A, 2007, CURR GENOMICS, V8, P252; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Syed V, 2008, J CELL BIOCHEM, V104, P82, DOI 10.1002/jcb.21603; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yuan J, 2008, J CELL BIOCHEM, V103, P648, DOI 10.1002/jcb.21439; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	46	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4386	4396		10.1038/onc.2009.291	http://dx.doi.org/10.1038/onc.2009.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767773				2022-12-28	WOS:000272876400007
J	Du, XL; Yang, H; Liu, SG; Luo, ML; Hao, JJ; Zhang, Y; Lin, DC; Xu, X; Cai, Y; Zhan, QM; Wang, MR				Du, X-L; Yang, H.; Liu, S-G; Luo, M-L; Hao, J-J; Zhang, Y.; Lin, D-C; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R			Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma	ONCOGENE			English	Article						Calreticulin; Cortactin; anoikis; motility; STAT3	2-DIMENSIONAL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM; PROTEOMIC ANALYSIS; INDUCED APOPTOSIS; DUCTAL CARCINOMA; CORTACTIN; EXPRESSION; GENE; OVEREXPRESSION; PROTEIN	We have shown earlier that overexpression of Calreticulin (CRT) contributed to a poor prognosis for patients with esophageal squamous cell carcinoma (ESCC). Here, we have shown an important role of CRT in tumorigenesis through enhancing cell motility and anoikis resistance. SiRNA-mediated knockdown of CRT caused impaired cell migration, invasion and resistance to anoikis. Notably, CRT downregulation decreased the expression of Cortactin (CTTN), which has been previously reported as a candidate oncogene associated with anoikis through the PI3K-Akt pathway. In addition, Akt phosphorylation was abolished after CRT downregulation and its activation can be refreshed by CRT upregulation, suggesting that CRT-enhanced cell resistance to anoikis through the CRT-CTTN-PI3K-Akt pathway. Moreover, the CTTN mRNA level was decreased in CRT-siRNA cells, coupled with the inactivation of STAT3. Expression of both CTTN and p-STAT3 was reduced in tumor cells following incubation with the JAK-specific inhibitor, AG490. Chromatin immunoprecipitation assay showed direct binding of p-STAT3 to the conservative STAT3-binding sequences in CTTN promoter. Furthermore, overexpression of CTTN in CRT-downregulated ESCC cells restored its motility and resistance to anoikis. This study not only reveals a role of CRT in motility promotion and anoikis resistance in ESCC cells, but also identifies CRT as an upstream regulator in the CRT-STAT3-CTTN Akt pathway. Oncogene (2009) 28, 3714-3722; doi: 10.1038/onc.2009.237; published online 17 August 2009	[Wang, M-R] Chinese Acad Med Sci, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Wang, MR (corresponding author), Chinese Acad Med Sci, Canc Inst Hosp, State Key Lab Mol Oncol, 17 Pan Jia Yuan, Beijing 100021, Peoples R China.	wangmr04@126.com	Luo, Man/GWQ-4789-2022; luo, man/HGC-7868-2022; LIN, DECHEN/K-9457-2014		National Basic Research Program of China [2004CB518705]; National High-tech R&D Program of China [2006AA02A403]; National Key Technologies R&D Program of China [2006BAI02A14]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20060023003]; National Natural Science Foundation [30872936, 30721001]	National Basic Research Program of China(National Basic Research Program of China); National High-tech R&D Program of China(National High Technology Research and Development Program of China); National Key Technologies R&D Program of China(National Key Technology R&D Program); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	We thank Professor Simon J Harris for the English revision of the article. This study was supported by National Basic Research Program of China (2004CB518705), National High-tech R&D Program of China (2006AA02A403), National Key Technologies R&D Program of China (2006BAI02A14), Specialized Research Fund for the Doctoral Program of Higher Education of China (20060023003) and National Natural Science Foundation (30872936, 30721001).	Alaiya A, 2000, ANAL CELL PATHOL, V21, P1, DOI 10.1155/2000/351963; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chahed K, 2005, INT J ONCOL, V27, P1425; Chen DQ, 2005, J BIOL CHEM, V280, P22425, DOI 10.1074/jbc.M413380200; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Clark ES, 2009, ONCOGENE, V28, P431, DOI 10.1038/onc.2008.389; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Du XL, 2007, J MOL MED, V85, P863, DOI 10.1007/s00109-007-0159-4; Eric A, 2009, PATHOL ONCOL RES, V15, P89, DOI 10.1007/s12253-008-9112-2; Gold LI, 2006, J INVEST DERM SYMP P, V11, P57, DOI 10.1038/sj.jidsymp.5650011; Hayashida Y, 2006, J BIOL CHEM, V281, P32469, DOI 10.1074/jbc.M607240200; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kim YM, 2004, MOL CELL BIOCHEM, V259, P23, DOI 10.1023/B:MCBI.0000021341.38630.52; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Li YS, 2001, CANCER RES, V61, P6906; Lim S, 2008, MOL CELLS, V25, P390; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; Mesaeli N, 2004, MOL BIOL CELL, V15, P1862, DOI 10.1091/mbc.E03-04-0251; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Nishimori T, 2006, PROTEOMICS, V6, P1011, DOI 10.1002/pmic.200500262; Okunaga T, 2006, CANCER RES, V66, P8662, DOI 10.1158/0008-5472.CAN-05-4256; Pallero MA, 2008, FASEB J, V22, P3968, DOI 10.1096/fj.07-104802; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Shago M, 1997, EXP CELL RES, V230, P50, DOI 10.1006/excr.1996.3408; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Vougas K, 2008, J BUON, V13, P101; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	37	60	69	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3714	3722		10.1038/onc.2009.237	http://dx.doi.org/10.1038/onc.2009.237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19684620				2022-12-28	WOS:000271023200004
J	Kang, BH; Altieri, DC				Kang, B. H.; Altieri, D. C.			Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones	ONCOGENE			English	Review						Hsp90; mitochondrial permeability transition; CypD; protein folding; cancer therapy	PERMEABILITY TRANSITION; CYCLOPHILIN-D; MOLECULAR CHAPERONE; OXIDATIVE STRESS; PROTEIN-1 TRAP-1; PROTECTS CELLS; HUMAN BREAST; APOPTOSIS; PEPTIDES; DISEASE	There is a plethora of attractive drug targets in cancer, but their therapeutic exploitation proved more difficult than expected, and only rarely truly successful. One possibility not often considered in drug discovery is that cancer signaling pathways are not randomly arranged in cells, but orchestrated in specialized subcellular compartments. The identification of heat shock protein-90 (Hsp90) chaperones in mitochondria of tumors, but not most normal tissues, provides an example of a compartmentalized network of cell survival, opening fresh prospects for novel, subcellularly targeted cancer drug discovery. Oncogene (2009) 28, 3681-3688; doi: 10.1038/onc.2009.227; published online 3 August 2009	[Kang, B. H.; Altieri, D. C.] Univ Massachusetts, Sch Med, Dept Canc Biol, Prostate Canc Discovery & Dev Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Prostate Canc Discovery & Dev Program, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Kang, Byoung Heon/E-6165-2010	Kang, Byoung Heon/0000-0001-5902-0549	National Institutes of Health [CA78810, CA90917, CA118005]; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810, R01CA118005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We apologize to all the colleagues, whose work could not be cited due to space limitations. This work was supported by National Institutes of Health grants CA78810, CA90917 and CA118005.	Armstrong JS, 2007, BRIT J PHARMACOL, V151, P1154, DOI 10.1038/sj.bjp.0707288; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Butcher EC, 2005, NAT REV DRUG DISCOV, V4, P461, DOI 10.1038/nrd1754; Cechetto JD, 2000, EXP CELL RES, V260, P30, DOI 10.1006/excr.2000.4983; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cowen LE, 2005, SCIENCE, V309, P2185, DOI 10.1126/science.1118370; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Gesualdi NM, 2007, STRESS, V10, P342, DOI 10.1080/10253890701314863; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gyurkocza B, 2006, J NATL CANCER I, V98, P1068, DOI 10.1093/jnci/djj300; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Henchcliffe C, 2008, NAT CLIN PRACT NEURO, V4, P600, DOI 10.1038/ncpneuro0924; Hua GQ, 2007, J BIOL CHEM, V282, P20553, DOI 10.1074/jbc.M703196200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028; Kang BH, 2009, J CLIN INVEST, V119, P454, DOI 10.1172/JCI37613; Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kolata G., 2009, NY TIMES        0424; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Leaf C, 2004, FORTUNE, V149, P76; Li RX, 2007, NEOPLASIA, V9, P801, DOI 10.1593/neo.07394; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Masuda Y, 2004, J BIOL CHEM, V279, P42503, DOI 10.1074/jbc.M404256200; McClellan AJ, 2007, CELL, V131, P121, DOI 10.1016/j.cell.2007.07.036; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Murphy MP, 2008, BBA-BIOENERGETICS, V1777, P1028, DOI 10.1016/j.bbabio.2008.03.029; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Petit A, 2005, J BIOL CHEM, V280, P34025, DOI 10.1074/jbc.M505143200; Pilkington GJ, 2008, SEMIN CANCER BIOL, V18, P226, DOI 10.1016/j.semcancer.2007.12.006; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Price JT, 2005, CANCER RES, V65, P4929, DOI 10.1158/0008-5472.CAN-04-4458; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rajasethupathy P, 2005, CURR OPIN CHEM BIOL, V9, P400, DOI 10.1016/j.cbpa.2005.06.008; Rodina A, 2007, NAT CHEM BIOL, V3, P498, DOI 10.1038/nchembio.2007.10; Ross MF, 2004, BIOCHEM J, V383, P457, DOI 10.1042/BJ20041095; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Schein PS, 2006, CLIN CANCER RES, V12, P3243, DOI 10.1158/1078-0432.CCR-06-0329; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Solit DB, 2008, DRUG DISCOV TODAY, V13, P38, DOI 10.1016/j.drudis.2007.10.007; Steensma DP, 2009, J CLIN ONCOL, V27, P1737, DOI 10.1200/JCO.2008.20.6292; Szeto HH, 2008, ANN NY ACAD SCI, V1147, P112, DOI 10.1196/annals.1427.013; Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; van der Greef J, 2005, NAT REV DRUG DISCOV, V4, P961, DOI 10.1038/nrd1904; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Wright GL, 2008, FASEB J, V22, P3264, DOI 10.1096/fj.08-106468; XU LJ, 2009, J CEREBR BLOOD F MET, V29, P365, DOI DOI 10.1038/JCBFM.2008.125; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zeitlin BD, 2008, J CLIN ONCOL, V26, P4180, DOI 10.1200/JCO.2007.15.7693; Zhao RM, 2007, ADV EXP MED BIOL, V594, P27	81	49	50	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3681	3688		10.1038/onc.2009.227	http://dx.doi.org/10.1038/onc.2009.227			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19648961	Green Accepted			2022-12-28	WOS:000271023200001
J	Farrall, AL; Whitelaw, ML				Farrall, A. L.; Whitelaw, M. L.			The HIF1 alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element	ONCOGENE			English	Article						SIM2; BNIP3; HIF1 alpha; hypoxia; cell death; cancer	DRUG-THERAPY TARGET; SINGLE-MINDED GENE; PANCREATIC-CANCER; PROSTATE-CANCER; COLORECTAL-CANCER; UP-REGULATION; EXPRESSION; AUTOPHAGY; PROTEIN; APOPTOSIS	The short isoform of single-minded 2 (SIM2s), a basic helix-loop-helix/PAS (bHLH/PAS) transcription factor, is upregulated in pancreatic and prostate tumours; however, a mechanistic role for SIM2s in these cancers is unknown. Microarray studies in prostate DU145 cells identified the pro-cell death gene, BNIP3 (Bcl-2/adenovirus E1B 19 kDa interacting protein 3), as a novel putative target of SIM2s repression. Further validation showed BNIP3 repression in several prostate and pancreatic carcinoma-derived cell lines with ectopic expression of human SIM2s. BNIP3 levels are enhanced in prostate carcinoma cells upon short interfering (si) RNA-mediated knockdown of endogenous SIM2s. Chromatin immunoprecipitation and promoter studies show that SIM2s represses BNIP3 through its activities at the proximal promoter hypoxia response element (HRE), the site through which the bHLH/PAS family member, hypoxia-inducible factor 1 alpha (HIF1 alpha), induces BNIP3. SIM2s attenuates BNIP3 hypoxic induction via the HRE, and increased hypoxic induction of BNIP3 occurs with siRNA knockdown of endogenous SIM2s in prostate PC3AR+ cells. BNIP3 is implicated in hypoxia-induced cell death processes. Prolonged treatment of PC3AR+ cells with hypoxia mimetics, DP and DMOG, confers hypoxia-induced autophagy, measured by enhanced LC3-II levels and SQSTM1/p62 turnover. We show that PC3AR+ cells expressing ectopic SIM2s have enhanced survival in these conditions. Induction of LC3-II and turnover of SQSTM1/p62 are attenuated in PC3AR+/SIM2s DMOG and hypoxia-treated cells, suggesting that SIM2s may attenuate autophagic cell death processes, perhaps through BNIP3 repression. These data show, for the first time, SIM2s cross-talk on an endogenous HRE. SIM2s' functional interference with HIF1 alpha activities on BNIP3 may indicate a novel role for SIM2s in promoting tumourigenesis. Oncogene (2009) 28, 3671-3680; doi: 10.1038/onc.2009.228; published online 10 August 2009	[Farrall, A. L.; Whitelaw, M. L.] Univ Adelaide, Discipline Biochem, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; [Farrall, A. L.; Whitelaw, M. L.] Ctr Mol Genet Dev, Adelaide, SA, Australia	University of Adelaide	Farrall, AL (corresponding author), Univ Adelaide, Discipline Biochem, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	alexandra.farrall@adelaide.edu.au	Farrall, Alexandra/ABD-2079-2020	Farrall, Alexandra/0000-0002-0909-8978	Australian Cancer Research Foundation; Australian Research Council; Cancer Council South Australia	Australian Cancer Research Foundation; Australian Research Council(Australian Research Council); Cancer Council South Australia(Cancer Council South Australia)	We thank M van Bekkum and C Bindloss for their kind technical assistance, and Dr S Woods for reagents and critical reading of the manuscript. PC3AR+ cells were a kind gift from Prof W Tilley, Hanson Research Institute, Adelaide, Australia. Tet-inducible lentiviral vectors were a kind gift from Dr S Barry, Children's Health Research Institute, SA, Australia (Drabsch et al., 2007). Anti-HIF1 alpha-CAD antibody was obtained from the laboratory of Prof J Pouyssegur, CNRS UMR6543, University of Nice, France (Richard et al., 1999). We acknowledge the contribution of the Australian Cancer Research Foundation for their support of the Adelaide Microarray Facility, Adelaide, Australia, which supplied, processed and analysed the microarrays. This work was supported by grants from the Australian Research Council and the Cancer Council South Australia.	Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1; Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45; Chrast R, 1997, GENOME RES, V7, P615, DOI 10.1101/gr.7.6.615; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; De Angelis PM, 2004, INT J ONCOL, V24, P1279; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Ema M, 1996, MOL CELL BIOL, V16, P5865; Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642; Goshu E, 2002, MOL CELL BIOL, V22, P4147, DOI 10.1128/MCB.22.12.4147-4157.2002; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Ishiguro M, 2007, ANN SURG ONCOL, V14, P1752, DOI 10.1245/s10434-006-9285-4; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lee H, 2006, MOL CELLS, V21, P1; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Semenza GL, 2000, GENE DEV, V14, P1983; Shamblott MJ, 2002, DEV DYNAM, V224, P373, DOI 10.1002/dvdy.10116; Sowter HM, 2001, CANCER RES, V61, P6669; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Woods S, 2008, NUCLEIC ACIDS RES, V36, P3716, DOI 10.1093/nar/gkn247; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028	51	36	38	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3671	3680		10.1038/onc.2009.228	http://dx.doi.org/10.1038/onc.2009.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19668230				2022-12-28	WOS:000270851800008
J	Yamagata, H; Shimizu, S; Nishida, Y; Watanabe, Y; Craigen, WJ; Tsujimoto, Y				Yamagata, H.; Shimizu, S.; Nishida, Y.; Watanabe, Y.; Craigen, W. J.; Tsujimoto, Y.			Requirement of voltage-dependent anion channel 2 for pro-apoptotic activity of Bax	ONCOGENE			English	Article						apoptosis; Bax; VDAC; mitochondria	OUTER MITOCHONDRIAL-MEMBRANE; CYTOCHROME-C RELEASE; CELL-DEATH; PROTEINS; FAMILY; VDAC; LIFE; OLIGOMERIZATION; ACTIVATION; MICE	Mitochondrial membrane permeabilization is central to apoptotic signaling and is directly regulated by the Bcl-2 family of proteins, consisting of anti-apoptotic members and pro-apoptotic members, although the precise mechanisms involved remain elusive. When cells are deficient in both pro-apoptotic multidomain members of this family (Bax and Bak), mitochondrial membrane permeabilization does not occur in response to various apoptotic stimuli. We have previously reported that the voltage-dependent anion channel (VDAC or porin) plays a role in apoptotic mitochondrial membrane permeabilization by interacting with Bcl-2 family members. Here, we have provided additional evidence that VDAC2 is required for pro-apoptotic activity of Bax in the absence of Bak. In the absence of Bak, VDAC2-deficient cells showed strong resistance to various apoptotic stimuli, whereas reintroduction of the Vdac2 gene restored their apoptotic response. Consistently, silencing of VDAC2 in Bak-deficient cells, but not Bax-deficient cells, also conferred resistance to various apoptotic stimuli. In the absence of VDAC2 and Bak, the activation of Bax (assessed by mitochondrial membrane integration, conformational changes and oligomerization) was markedly impaired. Taken together, these findings indicate that VDAC2 is required for pro-apoptotic activity of Bax in the absence of Bak. Oncogene (2009) 28, 3563-3572; doi: 10.1038/onc.2009.213; published online 20 July 2009	[Yamagata, H.; Shimizu, S.; Nishida, Y.; Tsujimoto, Y.] Osaka Univ, Dept Med Genet, Sch Med, Suita, Osaka 5650871, Japan; [Yamagata, H.; Watanabe, Y.] Yamaguchi Univ, Sch Med, Dept Neuropsychiat, Yamaguchi, Japan; [Shimizu, S.; Nishida, Y.] Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Tokyo, Japan; [Craigen, W. J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Craigen, W. J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Osaka University; Yamaguchi University; Tokyo Medical & Dental University (TMDU); Baylor College of Medicine; Baylor College of Medicine	Tsujimoto, Y (corresponding author), Osaka Univ, Dept Med Genet, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp			SORST of the Japan Science and Technology Corporation (JST); Japan Society for the Promotion of Science; Ministry of Education, Science, Sports and Culture; Ministry of Health, Labor and Welfare, Japan	SORST of the Japan Science and Technology Corporation (JST)(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We are grateful to Dr Kitamura for providing of Plat-E cells. This study was supported in part by SORST of the Japan Science and Technology Corporation (JST), a grant for Creative Scientific Research from Japan Society for the Promotion of Science, a grant for the 21st Century COE Program from the Ministry of Education, Science, Sports and Culture, and a grant for Comprehensive Research on Aging and Health from the Ministry of Health, Labor and Welfare, Japan.	Abu-Hamad S, 2006, P NATL ACAD SCI USA, V103, P5787, DOI 10.1073/pnas.0600103103; Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Bellot G, 2007, CELL DEATH DIFFER, V14, P785, DOI 10.1038/sj.cdd.4402055; Blachly-Dyson E, 2001, IUBMB LIFE, V52, P113; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ott M, 2007, J BIOL CHEM, V282, P27633, DOI 10.1074/jbc.M703155200; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; Sampson MJ, 1997, J BIOL CHEM, V272, P18966, DOI 10.1074/jbc.272.30.18966; Sampson MJ, 1996, GENOMICS, V33, P283, DOI 10.1006/geno.1996.0193; Setoguchi K, 2006, EMBO J, V25, P5635, DOI 10.1038/sj.emboj.7601438; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shoshan-Barmatz V, 2006, CURR PHARM DESIGN, V12, P2249, DOI 10.2174/138161206777585111; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	32	45	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3563	3572		10.1038/onc.2009.213	http://dx.doi.org/10.1038/onc.2009.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19617898	Bronze			2022-12-28	WOS:000270851700005
J	Haan, S; Wuller, S; Kaczor, J; Rolvering, C; Nocker, T; Behrmann, I; Haan, C				Haan, S.; Wueller, S.; Kaczor, J.; Rolvering, C.; Noecker, T.; Behrmann, I.; Haan, C.			SOCS-mediated downregulation of mutant Jak2 ( V617F, T875N and K539L) counteracts cytokine-independent signaling	ONCOGENE			English	Article						SOCS; Janus kinases; proteasomal degradation; myeloproliferative disorders	CHRONIC MYELOPROLIFERATIVE DISORDERS; ACUTE MYELOID-LEUKEMIA; JANUS TYROSINE KINASE; POLYCYTHEMIA-VERA; WILD-TYPE; ESSENTIAL THROMBOCYTHEMIA; CONSTITUTIVE ACTIVATION; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR; LYMPHOMA LINE	Recently, mutations in the gene of Janus kinase 2 (Jak2) were discovered in patients suffering from chronic myeloproliferative disorders (MPD) and leukemia. As suppressors of cytokine signaling (SOCS) proteins are potent feedback inhibitors of Jak-mediated signaling, we investigated their role in signal transduction through constitutively active Jak2 mutants. We selected two mutants, Jak2-V617F and Jak2-K539L, found in patients with MPDs and Jak2-T875N identified in acute mega-karyoblastic leukemia. We found SOCS family members to be induced through Jak2-V617F in human leukemia cell lines expressing the mutant allele and in stable HEK transfectants inducibly expressing constitutively active Jak2 mutants. SOCS proteins were recruited to the membrane and bound to the constitutively active Jaks. In contrast to wild-type Jak2, the mutant proteins were constitutively ubiquitinated and degraded through the proteasome. Taken together, we show a SOCS-mediated downregulation of the constitutively active, disease-associated mutant Jak2 proteins. Furthermore, a threshold level of mutant Jak expression has to be overcome to allow full cytokine-independent constitutive activation of signaling proteins, which may explain progression to homozygocity in MPDs as well as gene amplification in severe phenotypes and leukemia. Oncogene (2009) 28, 3069-3080; doi:10.1038/onc.2009.155; published online 22 June 2009	[Haan, S.; Kaczor, J.; Rolvering, C.; Behrmann, I.; Haan, C.] Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg; [Wueller, S.; Noecker, T.] Rhein Westfal TH Aachen, Dept Biochem, Aachen, Germany; [Wueller, S.] Rhein Westfal TH Aachen, Dept Pediat, Aachen, Germany	University of Luxembourg; RWTH Aachen University; RWTH Aachen University	Haan, S (corresponding author), Univ Luxembourg, Life Sci Res Unit, Campus Limpertsberg,162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	serge.haan@uni.lu; claude.haan@uni.lu		Behrmann, Iris/0000-0003-3688-3645	UL [R1F105L01, R1F107L01]; Marie Curie Research Training Network ReceptEUR; Serono GmbH (Unterschleissheim, Germany)	UL; Marie Curie Research Training Network ReceptEUR(European Commission); Serono GmbH (Unterschleissheim, Germany)	This work was supported by the UL Grant nos. R1F105L01 and R1F107L01, the Marie Curie Research Training Network ReceptEUR, and by Serono GmbH (Unterschleissheim, Germany).	Andrieux Joris Loup, 2005, Curr Hematol Rep, V4, P224; Bacher U, 2005, CANCER GENET CYTOGEN, V160, P179, DOI 10.1016/j.cancergencyto.2004.12.015; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Behrmann I, 2004, J BIOL CHEM, V279, P35486, DOI 10.1074/jbc.M404202200; Bock O, 2006, J MOL DIAGN, V8, P170, DOI 10.2353/jmoldx.2006.050064; Bock O, 2007, LEUKEMIA RES, V31, P799, DOI 10.1016/j.leukres.2006.08.022; Bumm TGP, 2006, CANCER RES, V66, P11156, DOI 10.1158/0008-5472.CAN-06-2210; Capello D, 2008, BRIT J HAEMATOL, V141, P504, DOI 10.1111/j.1365-2141.2008.07072.x; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Ekmekci CG, 2004, AM J HEMATOL, V77, P233, DOI 10.1002/ajh.20186; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Garcon L, 2006, BLOOD, V108, P1551, DOI 10.1182/blood-2005-10-009514; Grandage VL, 2006, BRIT J HAEMATOL, V135, P303, DOI 10.1111/j.1365-2141.2006.06291.x; Hookham MB, 2007, BLOOD, V109, P4924, DOI 10.1182/blood-2006-08-039735; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kralovics R, 2005, BLOOD, V106, P3374, DOI 10.1182/blood-2005-05-1889; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kratz CP, 2006, LEUKEMIA, V20, P381, DOI 10.1038/sj.leu.2404060; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lu XH, 2005, P NATL ACAD SCI USA, V102, P18962, DOI 10.1073/pnas.0509714102; Lu XH, 2008, J BIOL CHEM, V283, P5258, DOI 10.1074/jbc.M707125200; Melzner I, 2006, INT J CANCER, V118, P1941, DOI 10.1002/ijc.21485; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Mercher T, 2006, BLOOD, V108, P2770, DOI 10.1182/blood-2006-04-014712; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Reilly JT, 2005, SEMIN ONCOL, V32, P359, DOI 10.1053/j.seminoncol.2005.04.007; Roder S, 2001, EXP HEMATOL, V29, P694, DOI 10.1016/S0301-472X(01)00637-3; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Scott LM, 2007, NEW ENGL J MED, V356, P459, DOI 10.1056/NEJMoa065202; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tefferi A, 2006, CANCER-AM CANCER SOC, V106, P631, DOI 10.1002/cncr.21645; Teofili L, 2008, INT J CANCER, V123, P1586, DOI 10.1002/ijc.23694; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Vannucchi AM, 2007, BLOOD, V110, P840, DOI 10.1182/blood-2006-12-064287; Vuong BQ, 2004, MOL CELL BIOL, V24, P9092, DOI 10.1128/MCB.24.20.9092-9101.2004; Walz C, 2006, J BIOL CHEM, V281, P18177, DOI 10.1074/jbc.M600064200; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zaleskas VM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000018; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	51	29	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	2009	28	34					3069	3080		10.1038/onc.2009.155	http://dx.doi.org/10.1038/onc.2009.155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543316				2022-12-28	WOS:000269319000006
J	Gazdar, AF				Gazdar, A. F.			Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors	ONCOGENE			English	Review						epidermal growth factor receptor; mutation; non-small-cell lung cancer; tyrosine kinase inhibitor; tyrosine kinase	GROWTH-FACTOR-RECEPTOR; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; ACQUIRED-RESISTANCE; GEFITINIB SENSITIVITY; PROLONGED SURVIVAL; GENE-MUTATIONS; ADENOCARCINOMAS; ERLOTINIB; TRANSFORMATION	The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, are reversible competitive inhibitors of the tyrosine kinase domain of EGFR that bind to its adenosine-50 triphosphate-binding site. Somatic activating mutations of the EGFR gene, increased gene copy number and certain clinical and pathological features have been associated with dramatic tumor responses and favorable clinical outcomes with these agents in patients with non-small-cell lung cancer (NSCLC). The specific types of activating mutations that confer sensitivity to EGFR TKIs are present in the tyrosine kinase (TK) domain of the EGFR gene. Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations. The NSCLC tumors insensitive to EGFR TKIs include those driven by the KRAS and MET oncogenes. Most patients who initially respond to gefitinib and erlotinib eventually become resistant and experience progressive disease. The point mutation T790M accounts for about one half of these cases of acquired resistance. Various second-generation EGFR TKIs are currently being evaluated and may have the potential to overcome T790M-mediated resistance by virtue of their irreversible inhibition of the receptor TK domain. Oncogene (2009) 28, S24-S31; doi:10.1038/onc.2009.198	[Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Gazdar, A. F.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu			Boehringer Ingelheim Pharmaceuticals Inc.; National Cancer Institute, Bethesda, MD, USA [P50CA70907]; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	Boehringer Ingelheim Pharmaceuticals Inc.(Boehringer Ingelheim); National Cancer Institute, Bethesda, MD, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc. Supported by grant P50CA70907 from the Specialized Programme for Research Excellence in Lung Cancer from the National Cancer Institute, Bethesda, MD, USA.	Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269; Bonomi PD, 2007, CLIN CANCER RES, V13, p4606S, DOI 10.1158/1078-0432.CCR-07-0332; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Douillard J, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8001; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gazdar AF, 2008, CANCER PREV RES, V1, P156, DOI 10.1158/1940-6207.CAPR-08-0080; Gazdar AF, 2005, PLOS MED, V2, P1085, DOI 10.1371/journal.pmed.0020377; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hirsch FR, 2006, J CLIN ONCOL, V24, p382S; Ikeda K, 2008, ANN THORAC SURG, V85, P1430, DOI 10.1016/j.athoracsur.2007.10.012; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Janne PA, 2006, CLIN CANCER RES, V12, p4416S, DOI 10.1158/1078-0432.CCR-06-0555; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kancha RK, 2009, CLIN CANCER RES, V15, P460, DOI 10.1158/1078-0432.CCR-08-1757; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAHESWARAN S, 2008, NEW ENGL J MED, V359, P1; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok T, 2008, ANN ONCOL, V19, P1; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Paz-Ares L, 2006, J CLIN ONCOL, V24, p369S; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Yung TKF, 2009, CLIN CANCER RES, V15, P2076, DOI 10.1158/1078-0432.CCR-08-2622; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	53	637	691	5	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S24	S31		10.1038/onc.2009.198	http://dx.doi.org/10.1038/onc.2009.198			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680293	Green Accepted			2022-12-28	WOS:000269515400004
J	Bouteille, N; Driouch, K; El Hage, P; Sin, S; Formstecher, E; Camonis, J; Lidereau, R; Lallemand, F				Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Formstecher, E.; Camonis, J.; Lidereau, R.; Lallemand, F.			Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein	ONCOGENE			English	Article						WWOX; dishevelled; Wnt; beta-catenin; signaling pathway	CHROMOSOMAL FRAGILE SITE; WNT SIGNALING PATHWAY; KINASE-I-EPSILON; CANCER CELL-GROWTH; BREAST-CANCER; BETA-CATENIN; BINDING PROTEIN; GENE WWOX; C-JUN; EXPRESSION	The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/beta-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/beta-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on beta-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/beta-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins. Oncogene (2009) 28, 2569-2580; doi: 10.1038/onc.2009.120; published online 25 May 2009	[Lallemand, F.] Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, F-92210 St Cloud, France; [Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Lidereau, R.; Lallemand, F.] INSERM, U735, St Cloud, France; [Formstecher, E.] Hybrigenics, Paris, France; [Camonis, J.] Inst Curie, INSERM, U528, Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lallemand, F (corresponding author), Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, 35 Rue Dailly, F-92210 St Cloud, France.	f.lallemand@stcloud-huguenin.org		FORMSTECHER, Etienne/0000-0002-6410-4365	GenHomme Network [02490-6088]; Institut Curie	GenHomme Network; Institut Curie	We are grateful to Dr Trevor Dale for donating HA-Dvl-2 (mouse) expression vector, Dr Akira Kikuchi for donating pCCN/Dvl-1 (human) and pEF-BOS-myc/Dvl-3 (human) plasmids, Dr Howe PH for donating pCDNA3-myc/Axin (human) and Dr Shinji Takada for donating mouse. broblast L cells producing Wnt-3a and Lcells stably transfected with the pGKneo plasmid. We thank Ivan Bieche and Christian Gespash for useful comments, Florence Copigny and Cedrick Lefol for excellent technical assistance, and Philippe Leclerc (IFR 93, kremelin Bicetre, France) for immunofluorescence analysis. This work was supported by a GenHomme Network Grant (02490-6088) to Hybrigenics and Institut Curie. We thank all the Hybrigenics staff for their contribution and the staff of the Drosoman laboratory, headed by Jacques Camonis and supported by Institut Curie.	Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; HERBER B, 1994, ONCOGENE, V9, P1295; Hezova Renata, 2007, Biomedical Papers (Olomouc), V151, P11; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Ishii H, 2003, MOL CANCER RES, V1, P940; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Klimowski LK, 2006, FEBS J, V273, P4594, DOI 10.1111/j.1742-4658.2006.05462.x; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Lallemand F, 2005, J BIOL CHEM, V280, P27645, DOI 10.1074/jbc.M500188200; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Ludes-Meyers JH, 2007, GENE CHROMOSOME CANC, V46, P1129, DOI 10.1002/gcc.20497; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Pimenta FJ, 2006, INT J CANCER, V118, P1154, DOI 10.1002/ijc.21446; Pluciennik E, 2006, EJSO-EUR J SURG ONC, V32, P153, DOI 10.1016/j.ejso.2005.11.002; Polakis P, 2000, GENE DEV, V14, P1837; Qin HR, 2007, MOL CANCER RES, V5, P957, DOI 10.1158/1541-7786.MCR-07-0211; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang X, 2009, TUMOR BIOL, V30, P8, DOI 10.1159/000197911; Watanabe A, 2003, CANCER RES, V63, P8629; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750-2187-2-11; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	63	82	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2569	2580		10.1038/onc.2009.120	http://dx.doi.org/10.1038/onc.2009.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465938				2022-12-28	WOS:000268058900003
J	Foltz, G; Yoon, JG; Lee, H; Ryken, TC; Sibenaller, Z; Ehrich, M; Hood, L; Madan, A				Foltz, G.; Yoon, J-G; Lee, H.; Ryken, T. C.; Sibenaller, Z.; Ehrich, M.; Hood, L.; Madan, A.			DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis	ONCOGENE			English	Article						epigenetics; histone modifications; methylation; glioblastoma	TUMOR-SUPPRESSOR GENES; CANCER-CELL-LINES; COLON-CARCINOMA CELLS; POLYMERASE-CHAIN-REACTION; DOWN-REGULATION; BRAIN-TUMORS; SYNDECAN-2 EXPRESSION; TUMORIGENIC ACTIVITY; COLORECTAL-CANCER; INITIATING CELLS	Epigenetic inactivation of tumor suppressor genes is a common feature in human cancer. Promoter hypermethylation and histone deacetylation are reversible epigenetic mechanisms associated with transcriptional regulation. DNA methyltransferases (DNMT1 and DNMT3b) regulate and maintain promoter methylation and are over-expressed in human cancer. We performed whole-genome microarray analysis to identify genes with altered expression after RNAi-induced suppression of DNMT in a glioblastoma multiforme (GBM) cell line. We then identified genes with both decreased expression and evidence of promoter CpG island hypermethylation in GBM tissue samples using a combined whole-genome microarray transcriptome analysis in conjunction with a promoter array analysis after DNA immunoprecipitation with anti-5-methylcytidine. DNMT1 and 3b knockdown resulted in the restored expression of 308 genes that also contained promoter region hypermethylation. Of these, 43 were also found to be downregulated in GBM tissue samples. Three downregulated genes with hypermethylated promoters and restored expression in response to acute DNMT suppression were assayed for methylation changes using bisulfite sequence analysis of the promoter region after chronic DNMT suppression. Restoration of gene expression was not associated with changes in promoter region methylation, but rather with changes in histone methylation and chromatin conformation. Two of the identified genes exhibited growth suppressive activity in in vitro assays. Combining targeted genetic manipulations with comprehensive genomic and expression analyses provides a potentially powerful new approach for identifying epigenetically regulated genes in GBM. Oncogene (2009) 28, 2667-2677; doi: 10.1038/onc.2009.122; published online 25 May 2009	[Foltz, G.; Yoon, J-G; Lee, H.; Madan, A.] Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, Seattle, WA 98122 USA; [Foltz, G.; Hood, L.; Madan, A.] Inst Syst Biol, Seattle, WA USA; [Ryken, T. C.; Sibenaller, Z.] Univ Iowa, Dept Neurosurg, Iowa City, IA USA; [Ehrich, M.] Sequenome Inc, San Diego, CA USA	Swedish Medical Center; Institute for Systems Biology (ISB); University of Iowa; Sequenom	Madan, A (corresponding author), Swedish Neurosci Inst, Ctr Adv Brain Tumor Treatment, James Tower Suite 570,500 17th Ave, Seattle, WA 98122 USA.	anup.madan@swedish.org						Abdullah JM, 2007, NEUROL RES, V29, P239, DOI 10.1179/016164107X158965; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Arai E, 2006, INT J CANCER, V119, P288, DOI 10.1002/ijc.21807; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Choe G, 2003, CANCER RES, V63, P2742; Costello JF, 1996, CANCER RES, V56, P2405; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Essner JJ, 2006, INT J BIOCHEM CELL B, V38, P152, DOI 10.1016/j.biocel.2005.08.012; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fang JY, 2004, WORLD J GASTROENTERO, V10, P3394; Fears CY, 2006, J BIOL CHEM, V281, P14533, DOI 10.1074/jbc.C600075200; Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453; Fontijn D, 2007, MOL CANCER THER, V6, P2807, DOI 10.1158/1535-7163.MCT-07-0044; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Han I, 2004, J MOL HISTOL, V35, P319; Hayashi H, 2007, HUM GENET, V120, P701, DOI 10.1007/s00439-006-0254-6; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2007, CURR OPIN MOL THER, V9, P231; Kim HJ, 2006, CANCER, V107, P1042, DOI 10.1002/cncr.22087; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kusano Y, 2004, J BIOCHEM, V135, P129, DOI 10.1093/jb/mvh015; LORENTE A, 2008, BRAIN PATHOL; Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Modrowski D, 2005, BONE, V37, P180, DOI 10.1016/j.bone.2005.04.010; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Park HJ, 2006, CANCER LETT, V233, P271, DOI 10.1016/j.canlet.2005.03.017; Paz MF, 2003, HUM MOL GENET, V12, P2209, DOI 10.1093/hmg/ddg226; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Shi HD, 2003, CANCER RES, V63, P2164; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shostak KO, 2003, J SURG ONCOL, V82, P57, DOI 10.1002/jso.10180; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tan SH, 2007, ONCOL REP, V18, P1225; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Zhang W, 2007, DIS COLON RECTUM, V50, P1618, DOI 10.1007/s10350-007-0286-6	70	40	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2667	2677		10.1038/onc.2009.122	http://dx.doi.org/10.1038/onc.2009.122			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19465937				2022-12-28	WOS:000268211200005
J	Thomas, WD; Chen, J; Gao, YR; Cheung, B; Koach, J; Sekyere, E; Norris, MD; Haber, M; Ellis, T; Wainwright, B; Marshall, GM				Thomas, W. D.; Chen, J.; Gao, Y. R.; Cheung, B.; Koach, J.; Sekyere, E.; Norris, M. D.; Haber, M.; Ellis, T.; Wainwright, B.; Marshall, G. M.			Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression	ONCOGENE			English	Article						N-Myc; PP2A-B56; Sonic Hedgehog; medulloblastoma; initiation; Myc	HEDGEHOG-INDUCED MEDULLOBLASTOMA; EXTERNAL GRANULAR LAYER; C-MYC; SONIC HEDGEHOG; GENE-EXPRESSION; NEURONAL PRECURSORS; MICE; PROLIFERATION; CEREBELLUM; PATHWAY	Medulloblastoma tumorigenesis caused by inactivating mutations in the PATCHED1 (PTCH1) gene is initiated by persistently activated Sonic Hedgehog (Shh) signaling in granule neuron precursors (GNPs) during the late stages of cerebellar development. Both normal cerebellar development and Shh-driven medulloblastoma tumorigenesis require N-Myc expression. However, the mechanisms by which N-Myc affects the stages of medulloblastoma initiation and progression are unknown. Here we used a mouse model of Ptch1 heterozygosity and medulloblastoma to show that increased N-Myc expression characterized the earliest selection of focal GNP hyperplasia destined for later tumor progression. Step-wise loss of Ptch1 expression, from tumor initiation to progression, led to incremental increases in N-Myc protein, rather than mRNA, expression. Increased N-Myc resulted in enhanced proliferation and death resistance of perinatal GNPs at tumor initiation. Sequential N-Myc protein phosphorylation at serine-62 and serine-62/threonine-58 characterized the early and late stages of medulloblastoma tumorigenesis, respectively. Shh pathway activation led to increased Myc protein stability and reduced expression of key regulatory factors. Taken together our data identify N-Myc protein stability as the result of loss of Ptch1, which distinguishes normal cerebellar development from medulloblastoma tumorigenesis.	[Marshall, G. M.] Childrens Canc Inst Australia Med Res, Mol Carcinogenesis Program, Randwick, NSW 2031, Australia; [Ellis, T.; Wainwright, B.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Marshall, G. M.] Prince Wales Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of Queensland	Marshall, GM (corresponding author), Childrens Canc Inst Australia Med Res, Mol Carcinogenesis Program, POB 81, Randwick, NSW 2031, Australia.	Glenn.Marshall@SESIAHS.HEALTH.NSW.GOV.AU	Chen, Jinbiao/J-5868-2013; Chen, Jinbiao/N-9905-2019	Chen, Jinbiao/0000-0003-0339-5880; Chen, Jinbiao/0000-0003-0339-5880; Haber, Michelle/0000-0003-2036-8817; Wainwright, Brandon/0000-0003-0406-2092; Norris, Murray/0000-0002-0632-4589; Cheung, Belamy/0000-0001-8784-860X	Cure For Life Foundation; Cure Cancer Australia Foundation; National Health and Medical Research Council; Cancer Institute New South Wales; John Trivett Foundation; The Children's Cancer Institute Australia; University of New South Wales; Sydney Children's Hospital	Cure For Life Foundation; Cure Cancer Australia Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; John Trivett Foundation; The Children's Cancer Institute Australia; University of New South Wales; Sydney Children's Hospital	This work was supported by funds from the Cure For Life Foundation (WT), the Cure Cancer Australia Foundation (WT), the National Health and Medical Research Council (Australia; GMM, MDN, BW and MH), the Cancer Institute New South Wales (Australia; GMM, MDN and MH) and John Trivett Foundation (TE). The Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barnes EA, 2005, ONCOGENE, V24, P902, DOI 10.1038/sj.onc.1208240; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Browd SR, 2006, CANCER RES, V66, P2666, DOI 10.1158/0008-5472.CAN-05-2198; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhart CG, 2004, J NEUROPATH EXP NEUR, V63, P441, DOI 10.1093/jnen/63.5.441; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2008, CANCER RES, V68, P3081, DOI 10.1158/0008-5472.CAN-07-5832; FERRER I, 1992, PROG NEUROBIOL, V39, P1, DOI 10.1016/0301-0082(92)90029-E; Fogarty MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166; GARSON JA, 1989, BRIT J CANCER, V59, P889, DOI 10.1038/bjc.1989.188; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOPPEL H, 1983, NEUROPATH APPL NEURO, V9, P207, DOI 10.1111/j.1365-2990.1983.tb00108.x; Lelievre V, 2008, DEV BIOL, V313, P359, DOI 10.1016/j.ydbio.2007.10.031; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Moriuchi S, 1996, ANTICANCER RES, V16, P2687; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pizzo P.A., 2002, PRINCIPLES PRACTICE, V4th; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Pritchard JI, 2008, CANCER GENET CYTOGEN, V180, P47, DOI 10.1016/j.cancergencyto.2007.09.008; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; RUIZ IAA, 2004, CANC LETT, V204, P145; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Smith DP, 2006, BLOOD, V108, P653, DOI 10.1182/blood-2006-01-0172; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wechsler-Reya RJ, 2003, RECENT PROG HORM RES, V58, P227, DOI 10.1210/rp.58.1.227; Wetmore C, 2000, CANCER RES, V60, P2239; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; ZAKHARY R, 2001, BRAIN TUMORS ENCY AP, P605	57	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1605	1615		10.1038/onc.2009.3	http://dx.doi.org/10.1038/onc.2009.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234491				2022-12-28	WOS:000264780500005
J	McCabe, N; Cerone, MA; Ohishi, T; Seimiya, H; Lord, CJ; Ashworth, A				McCabe, N.; Cerone, M. A.; Ohishi, T.; Seimiya, H.; Lord, C. J.; Ashworth, A.			Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer	ONCOGENE			English	Article						BRCA1/2; Tankyrase 1; synthetic lethality; anticancer therapy	DNA-REPAIR DEFECT; POLY(ADP-RIBOSE) POLYMERASE; CENTROSOME AMPLIFICATION; HUMAN TELOMERES; MUTANT-CELLS; TRF1; PARP; INSTABILITY; PROGRESSION; SUBSTRATE	The BRCA1 and BRCA2 proteins are involved in the maintenance of genome stability and germ-line loss-of-function mutations in either BRCA1 or BRCA2 strongly predispose carriers to cancers of the breast and other organs. It has been demonstrated previously that inhibiting elements of the cellular DNA maintenance pathways represents a novel therapeutic approach to treating tumors in these individuals. Here, we show that inhibition of the telomere-associated protein, Tankyrase 1, is also selectively lethal with BRCA deficiency. We also demonstrate that the selectivity caused by inhibition of Tankyrase 1 is associated with an exacerbation of the centrosome amplification phenotype associated with BRCA deficiency. We propose that inhibition of Tankyrase 1 could be therapeutically exploited in BRCA-associated cancers.	[McCabe, N.; Cerone, M. A.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [McCabe, N.; Ashworth, A.] Inst Canc Res, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England; [Ohishi, T.; Seimiya, H.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Biotherapy, Tokyo 170, Japan	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Japanese Foundation for Cancer Research	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Alan.Ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; Ohishi, Tomokazu/0000-0002-9039-4474; Seimiya, Hiroyuki/0000-0003-3314-9736	Breakthrough Breast Cancer; Cancer Research UK	Breakthrough Breast Cancer; Cancer Research UK(Cancer Research UK)	This work was funded by Breakthrough Breast Cancer and Cancer Research UK. We thank Jill Williamson and Dave Robertson for assistance with karyotyping and microscopy, respectively.	Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chang W, 2005, BIOCHEM J, V391, P177, DOI 10.1042/BJ20050885; Chang W, 2003, GENE DEV, V17, P1328, DOI 10.1101/gad.1077103; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DelloRusso C, 2007, MOL CANCER RES, V5, P35, DOI 10.1158/1541-7786.MCR-06-0234; Dynek JN, 2004, SCIENCE, V304, P97, DOI 10.1126/science.1094754; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kleine H, 2008, MOL CELL, V32, P57, DOI 10.1016/j.molcel.2008.08.009; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Seimiya H, 2006, BRIT J CANCER, V94, P341, DOI 10.1038/sj.bjc.6602951; Seimiya H, 2005, CANCER CELL, V7, P25, DOI 10.1016/j.ccr.2004.11.021; Seimiya H, 2004, MOL CELL BIOL, V24, P1944, DOI 10.1128/MCB.24.5.1944-1955.2004; Seimiya H, 2002, J BIOL CHEM, V277, P14116, DOI 10.1074/jbc.M112266200; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Smith S, 1999, J CELL SCI, V112, P3649; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	26	60	66	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1465	1470		10.1038/onc.2008.483	http://dx.doi.org/10.1038/onc.2008.483			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19182824				2022-12-28	WOS:000264354400007
J	Tchougounova, E; Jiang, Y; Brasater, D; Lindberg, N; Kastemar, M; Asplund, A; Westermark, B; Uhrbom, L				Tchougounova, E.; Jiang, Y.; Brasater, D.; Lindberg, Nanna; Kastemar, M.; Asplund, A.; Westermark, B.; Uhrbom, L.			Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence	ONCOGENE			English	Article						Sox5; glioma; PDGF; p27(Kip1); senescence	NEURAL PROGENITORS; IN-VIVO; INHIBITOR P27(KIP1); CYCLE PROGRESSION; BRAIN-TUMORS; PROTEIN; EXPRESSION; CANCER; GENES; CELLS	SOX5 is a member of the high-mobility group superfamily of architectural non-histone proteins involved in gene regulation and maintenance of chromatin structure in a wide variety of developmental processes. Sox5 was identified as a brain tumor locus in a retroviral insertional mutagenesis screen of platelet-derived growth factor B (PDGFB)-induced mouse gliomas. Here we have investigated the role of Sox5 in PDGFB-induced gliomagenesis in mice. We show that Sox5 can suppress PDGFB-induced glioma development predominantly upon Ink4a-loss. In human glioma cell lines and tissues, we found very low levels of SOX5 compared with normal brain. Overexpression of Sox5 in human glioma cells led to a reduction in clone formation and inhibition of proliferation. Combined expression of Sox5 and PDGFB in primary brain cell cultures caused decreased proliferation and an increased number of senescent cells in the Ink4a(-/-) cells only. Protein analyses showed a reduction in the amount and activation of Akt and increased levels of p27(Kip1) upon Sox5 expression that was dominant to PDGFB signaling and specific to Ink4a(-/-) cells. Upon inhibition of p27(Kip1), the effects of Sox5 on proliferation and senescence could be reversed. Our data suggest a novel pathway, where Sox5 may suppress the oncogenic effects of PDGFB signaling during glioma development by regulating p27(Kip1) in a p19(Arf)-dependent manner, leading to acute cellular senescence.	[Tchougounova, E.; Jiang, Y.; Brasater, D.; Lindberg, Nanna; Kastemar, M.; Asplund, A.; Westermark, B.; Uhrbom, L.] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden	Uppsala University	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	lene.uhrbom@genpat.uu.se		Westermark, Bengt/0000-0001-7153-5545	Swedish Cancer Society; Swedish Research Council; Association for International Cancer Research; Swedish Society for Medical Research	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research; Swedish Society for Medical Research	We thank Veronique Lefebvre for the Sox5 cDNA, Fredrik Ponten for supplying the normal and tumor tissue microarrays, and Umashankar Singh for advice on siRNA. This work has been supported by grants from the Swedish Cancer Society, the Swedish Research Council and Association for International Cancer Research, and by donations in the memory of Joacim Bonnevier. ET has been supported by postdoctoral grants from the Swedish Research Council, the Swedish Society for Medical Research and the Swedish Cancer Society.	Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Huang DY, 2008, J PATHOL, V214, P445, DOI 10.1002/path.2299; JEN J, 1994, CANCER RES, V54, P6353; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; KAMB A, 1994, SCIENCE, V264, P440; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Schlierf B, 2007, NEUROPATH APPL NEURO, V33, P621, DOI 10.1111/j.1365-2990.2007.00881.x; Schultz C, 2002, CANCER RES, V62, P6270; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stolt CC, 2006, DEV CELL, V11, P697, DOI 10.1016/j.devcel.2006.08.011; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tchougounova E, 2007, ONCOGENE, V26, P6289, DOI 10.1038/sj.onc.1210455; The WHO, 2020, CLASSIFICATION TUMOU; Ueda R, 2007, INT J CANCER, V120, P1704, DOI 10.1002/ijc.22472; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P384, DOI 10.1074/mcp.R500009-MCP200; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Xia Y, 2000, CANCER RES, V60, P6303; Zafarana G, 2002, CANCER RES, V62, P1822	42	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1537	1548		10.1038/onc.2009.9	http://dx.doi.org/10.1038/onc.2009.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19219070				2022-12-28	WOS:000264537400006
J	Martin, D; Galisteo, R; Ji, Y; Montaner, S; Gutkind, JS				Martin, D.; Galisteo, R.; Ji, Y.; Montaner, S.; Gutkind, J. S.			An NF-kappa B gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia	ONCOGENE			English	Article						G proteins; signal transduction; G protein coupled receptors; angiosarcoma; endothelial cell; angiogenesis	PROTEIN-COUPLED-RECEPTOR; HERPESVIRUS; KSHV; CELL; CANCER; ANGIOGENESIS; SURVIVAL; PROMOTE	Kaposi's sarcoma (KS) is the most frequent AIDS-associated malignancy, etiologically linked to the infection with the human herpesvirus 8 (HHV-8/KSHV). This member of the gamma-herpesviridae family encodes 81 open reading frames, several bearing oncogenic potential. A constitutively active virally encoded G protein-coupled receptor (vGPCR) readily induces KS-like lesions when expressed in endothelial cells in vivo, and unmasks the oncogenic potential of other HHV-8 genes in a paracrine fashion. How vGPCR causes endothelial cell transformation is still not fully understood. Using full-genome microarray analysis we show here that the expression of nuclear factor-kappa B (NF-kappa B)regulated genes is a prominent feature triggered by vGPCR in cells expressing this viral oncogene and in cells exposed to vGPCR-induced secretions, thus mimicking its paracrine effect. Indeed, vGPCR activates the NF-kappa B pathway potently, and NF-kappa B activation is a hallmark of both human and experimental KS. Of interest, whereas constitutive NF-kappa B signaling is not sufficient to promote endothelial cells transformation, NF-kappa B function is strictly required for vGPCR-induced direct and paracrine neoplasia. Taken together, these results strongly support the role of NF-kappa B regulated genes in KS pathogenesis, thus providing the rationale for the development of novel mechanism-based therapies for this angioproliferative disease.	[Martin, D.; Galisteo, R.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Dept Diagnost Sci & Pathol, Baltimore, MD 21201 USA; [Ji, Y.; Montaner, S.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, NIH, Oral & Pharyngeal Canc Branch, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Abrams, William R/A-5782-2008; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Basile JR, 2004, CANCER RES, V64, P5212, DOI 10.1158/0008-5472.CAN-04-0126; Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13; Cesarman E, 2007, CURR TOP MICROBIOL, V312, P263; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hamilton TA, 2002, IMMUNOL RES, V25, P229, DOI 10.1385/IR:25:3:229; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Kanegane H, 1997, J INFECT DIS, V176, P254, DOI 10.1086/517260; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Montaner S, 2006, CANCER RES, V66, P168, DOI 10.1158/0008-5472.CAN-05-1026; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Rezza G, 1999, J NATL CANCER I, V91, P1468, DOI 10.1093/jnci/91.17.1468; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SCIACCA FL, 1994, J IMMUNOL, V153, P4816; Sodhi A, 2004, NAT REV MOL CELL BIO, V5, P998, DOI 10.1038/nrm1529; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	27	162	167	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1844	1852		10.1038/sj.onc.1210817	http://dx.doi.org/10.1038/sj.onc.1210817			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17934524				2022-12-28	WOS:000254150600004
